<SEC-DOCUMENT>0000950170-23-009046.txt : 20230322
<SEC-HEADER>0000950170-23-009046.hdr.sgml : 20230322
<ACCEPTANCE-DATETIME>20230322072103
ACCESSION NUMBER:		0000950170-23-009046
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		114
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230322
DATE AS OF CHANGE:		20230322

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Pyxis Oncology, Inc.
		CENTRAL INDEX KEY:			0001782223
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				831160910
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40881
		FILM NUMBER:		23751286

	BUSINESS ADDRESS:	
		STREET 1:		35 CAMBRIDGE PARK DRIVE
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02140
		BUSINESS PHONE:		(617) 221-9059

	MAIL ADDRESS:	
		STREET 1:		35 CAMBRIDGE PARK DRIVE
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02140
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>pyxs-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2023-03-22T07:17:54.3575+00:00 --><!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:pyxs="http://pyxisoncology.com/20221231" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt="http://fasb.org/srt/2022" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_26aa710e-2ffa-4cd0-bc6a-fe75f8ecd043" name="dei:DocumentFiscalPeriodFocus" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3">FY</ix:nonNumeric><ix:nonFraction id="F_21fd044a-b819-46e1-b788-a6db20d760e8" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_375ab7b5-f3d4-409a-a33f-662272797faf" unitRef="U_pure" decimals="8" scale="0" format="ixt:numdotdecimal">0.15725743</ix:nonFraction><ix:nonFraction id="F_75a80392-2b27-400f-a0cf-7ce4dabe8391" name="us-gaap:CommitmentsAndContingencies" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_75c9cf87-9bea-4479-b9a0-51fd354b8283" name="dei:EntityCentralIndexKey" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3">0001782223</ix:nonNumeric><ix:nonFraction id="F_2c1f21b5-66b1-456a-be0d-8b2e18d9a8f1" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_e41e2b33-e797-4eaf-ab2c-e21d506eef7d" unitRef="U_pure" decimals="8" scale="0" format="ixt:numdotdecimal">0.15725743</ix:nonFraction><ix:nonFraction id="F_00af17d6-813e-4e14-882a-ed1d6e7ac76a" name="us-gaap:PreferredStockValue" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_41c663ee-99b7-4ec5-8325-a97c8245ffa8" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="C_39ee5c29-3e12-49e2-946c-de8d95e7af1a" format="ixt-sec:duryear">10</ix:nonNumeric><ix:nonNumeric id="F_2078513f-c53f-43d5-970f-e0c43d587906" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="C_f1ffa94f-ab1a-4b1c-85bc-689829d80a9f" format="ixt-sec:duryear">10</ix:nonNumeric><ix:nonFraction id="F_b428182c-65cb-436d-ad3d-3dafc7163ff1" name="us-gaap:CommitmentsAndContingencies" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_41e41108-0a2f-4aeb-862b-b3c3f3023412" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="C_f4ce7ade-74e0-45ba-8c22-a5ba47efa398" format="ixt-sec:duryear">10</ix:nonNumeric><ix:nonNumeric id="F_d611e941-4710-44ff-876f-7ae06b2a44a8" name="dei:AmendmentFlag" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonFraction id="F_a2ce678e-6dad-403a-8b9e-c365b9d6f501" name="us-gaap:PreferredStockValue" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" unitRef="U_USD" xsi:nil="true"></ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="pyxs-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_bbf8f5ff-a294-4a9f-8e73-2626887266b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pyxs:StockOptionsAvailableForIssuanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a4a72a0d-ee7f-4589-88fb-129aff57c90e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_580efdd7-1697-4746-bb08-330be421f077"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_47830253-f4d4-4397-a12e-e52eed550ec3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d17eff6a-c465-4999-9b00-c89ab59f6085"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1f74468d-690d-401f-99d9-cb0dfb69f6d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_63b19c56-1b8a-44d0-841a-bbbe8b23192a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pyxs:UniversityLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_08e26df7-c143-4cfe-8ad0-f01a4ebe0f85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesAConvertiblePreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_47b0f4dc-1f2b-43a4-82d0-e3339f869c87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e7d9bbba-b0b8-45c6-b0a7-dd4392b30f05"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pyxs:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a299bf89-0287-4625-8850-fb9123db63e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7dd94bc0-72fc-44a2-b88d-da7188b1ce64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_97a1de80-f534-45ad-9ae5-0bf704ac27f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dd3f048c-500a-44b0-97cc-8865eadc0230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesAConvertiblePreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7f69dc96-1c3c-4d15-bee7-ceb32b6a4546"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:BiosionLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3ade2bd0-ad16-4bf4-a99d-4a51299354f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_57e97640-061e-4d91-86fa-37e25ab50455"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2af509fb-9702-480c-8cbd-911f991087fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_38547283-6d39-4795-b0d3-95f75e72293e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_606b0303-5274-48c3-af42-6ee3a9b3c452"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SubleaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5e6b169a-61c1-4460-b0cf-4abc20516158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_98625906-14f2-47a1-9eb9-724228999619"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ea786617-a1e9-4846-aa80-4f080345af40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_056d4eec-ac13-4d48-b518-557aadce6575"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:LegoChemLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3f691b8c-c469-4e4a-96b6-9103063b1982"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ab715df4-cb33-446f-9bc3-90688e948155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pyxs:VoxallMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_52660871-d822-4029-a359-773d492fbb93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aae7c872-143d-4e13-980e-a4b7733afaf6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-08</xbrli:startDate><xbrli:endDate>2021-10-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3437eb60-7ead-49e1-af88-52c11bcf8430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_93a31468-e176-4adc-8cfc-d60e8d2102f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4e8c269f-db1b-4dbe-9107-8e90b43b9fa4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_878945eb-02c9-42de-ab14-20785d15bab1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwothousandtwentytwoequityinducementplanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_23f0eeb1-4ec3-40f7-8427-0bbf70cd0d1c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-06</xbrli:startDate><xbrli:endDate>2022-10-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c0ed8f27-3a4c-4474-9fee-718c5b4c9f5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dadd6f97-7a5c-4e8e-b808-bf02287c4b0a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_de8208ab-bcfc-47b0-b387-5579dfad9705"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_21e45814-d1c9-49d0-b212-624324f81c19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_570474f3-f0f4-4608-961a-97edb7e8318e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pyxs:UnvestedRestrictedStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6eb028fe-0dfc-4fcc-8cfd-de5ca6f2a851"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pyxs:VoxallMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a1592c2f-78e9-4a1b-b7a3-b5e832dfc0e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pyxs:StockOptionsAvailableForIssuanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_afca8c75-429e-4247-b930-08b342481fcc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:LegoChemLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_915e850b-ae03-438e-afb7-244101692549"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5fa06219-1252-449b-973f-3a4c942c0ae4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-10-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d9e659d3-c4ff-4e05-bb19-5b5effadffa3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2b2bc485-3a60-4ce8-850d-05c0692602e2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6c431810-e959-4b5a-b476-c39c7b79b09c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pyxs:UniversityLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_22898140-752b-4c56-a019-59406d30b9a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f2ddafed-be8d-4bfb-afe6-eafef4a6d2bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pyxs:UniversityLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_382dcedb-c053-467b-83f2-217ce9a3521e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f891bb1b-8647-4939-8740-f3d10c242ed2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1f7d801f-7c91-43b6-b20d-6c5b26ad7c1b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4595b0e9-9dcf-4916-9f78-cc4f6d5b5648"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pyxs:UniversityLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4f7769e8-70e6-4d06-bdc0-89e5d970d334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:StockOptionsTwoThousandTwentyTwoTwoThousandTwentyOneAndTwoThousandNineteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e31029d2-1718-44fb-bbfe-596a8f71bb1d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9d0748e3-ecbb-419d-b1da-43ca99f6d64d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_72ee8eff-e4a6-4e5c-8e34-b16da25e910f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b7d0661d-e805-4887-84a1-6ba122628999"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_18591516-6c3d-465a-804c-40424d183530"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_772490ef-27c8-4a53-a78c-52e1650134c4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pyxs:UniversityLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7df0d474-6f80-47b5-b237-25bf19a5fb4c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6d15f333-7588-4ef5-8888-a6b87820dd75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_07d0bbc1-f9a2-43f9-8983-bf7982db0cbd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dbf80555-08a0-4969-b239-4e3694866a9d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9188f657-2f90-466d-b42f-29e1c97321d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:BiosionLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-28</xbrli:startDate><xbrli:endDate>2022-03-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d4e409b9-f87d-4dfd-8ff7-0b2a843ec39f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:LegoChemLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5c8d1870-c7a8-4c74-97ca-d9e6a13f9efc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ffecffd1-fb25-4239-b101-0b9e9224e3c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0ca7fd08-59a5-40fc-a0ec-73b51bc9fbd9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fa5ee9fe-cc4b-4842-b6f4-396be31d8300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3bcaea08-ed4d-45f4-8fc4-c0510f776740"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ac6c23d7-b491-43cb-a347-d0c5845136d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-08</xbrli:startDate><xbrli:endDate>2021-10-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_375ab7b5-f3d4-409a-a33f-662272797faf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesAConvertiblePreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d753a366-cbec-4a3f-8e6d-a172249fde7b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4311203d-759e-4680-a158-b189b0b27135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e79d7fea-f750-4f59-be70-803b9b5030d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SubleaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-02</xbrli:startDate><xbrli:endDate>2023-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d2032e34-dd12-44a0-9706-073c354f8dbb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5f32f318-d7b3-49c5-87d5-d8693945f998"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d6d15861-ed2b-4844-b8f3-06bd9a409de9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_10356595-90e4-4664-b68b-60f5a32b9285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_403332e3-9bcb-4fd2-8dda-17c8ccb33760"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pyxs:VoxallMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_83982012-10a6-4487-8dce-be863732bf86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b7382cca-33a6-4f4e-9ad5-9ec9267d027f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5e0e5fda-24f4-4956-a238-9aa47842953a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1bfa7a44-4da1-4bfe-8679-1f28fa3b517b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cf314be8-48e6-4158-ba0a-296598f0c1fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9ea37f53-ac68-4a4e-aac4-357a7fa13f64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_163b85b6-849f-484c-908c-c506a40b598b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5c8c8e6c-dc1c-4e3b-9625-ec421e4f99d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:AgreementsWithPfizerIncAndLegochemBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a7460a4a-43b1-45a4-98f8-5736508db488"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:LegoChemLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_38e9b9ce-48eb-4a5a-a998-eeab38167e13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c48b4d06-4690-4a44-ad08-1d47a45d7069"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3389ea65-f351-4b62-b0ce-6e94188e7981"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_466cd526-a6e1-4fea-9b6a-9ed2473eda8d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SubleaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">pyxs:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a1de02fe-e0e6-413a-b471-0f1518c7ea8a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b0e457cc-4ee1-4962-882e-7cdda5c5a1d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwothousandtwentytwoequityinducementplanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3d815e67-ceab-4431-bce9-20d33a91f2dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pyxs:UniversityLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0aaf1ee4-befe-4b18-b335-1a09ea9d6b96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5e26e7a4-9894-40ab-9e05-0b5c0cf9ee51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fe914f5c-2d5d-4dbc-9ba9-aab3f109118d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_da4afd79-994b-493e-8986-8748cbb9b1f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4fe8a1ab-50a0-48b5-951b-24bf559a7115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c0722afc-490f-4a94-9fc9-f07e63c7ee4d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_db0b438d-a530-4514-b2e4-b58d0c1167a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pyxs:UniversityLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_85b71da5-c5ad-4ef2-b3fa-15ed03b03ade"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5478d9a9-32de-4b14-a7d9-c5a5e108dfa0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_967897c5-c155-4f05-933c-68db3867f01a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_84cf517c-82fd-437e-b63e-4d987372dee8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:LegoChemLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_53e9aeb6-174d-402f-8c2f-b1df11873669"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a5dd394e-5224-4d6a-bf00-62f63373e448"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f6a77c26-5d28-4ad5-be66-8947787249a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4460d945-b64a-45f5-af82-5ed6de882504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e407da6f-df2b-430d-8ab8-23f237d727f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6f4aa2e1-b13f-4cc9-a66d-bd0c94991ce0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_adc6355e-17ce-4144-a867-ae971f7735e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesAConvertiblePreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_53f21008-ad1c-494d-bca3-09d4d9bb06f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_671ff9d5-4324-4bce-bc54-ecdc38e8840f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_43213977-374c-49b1-8370-aa4e647874fe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:BiosionLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_00119c4b-52cf-4804-ac21-c9c54ee69b67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_39ee5c29-3e12-49e2-946c-de8d95e7af1a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1d6dfd74-4dd3-4d8d-ade5-27835ecdb4ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6da87304-fe59-4975-99b3-27f5fd2ceb69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4a91be42-9646-464e-a10b-8cf7d387c4f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pyxs:AlloyTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pyxs:VoxallMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6adee125-dbcb-4f6a-b664-d9891421fd72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_706b851a-18a8-416b-8796-5d143cc0bd07"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9194297f-b13d-4587-9fe5-fcc007d82f0e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2caa6904-2924-4060-8a2d-3b3cec935236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:LegoChemLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-31</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fb9e3219-0355-4d5e-8d21-c73eefcac6c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_09c28f97-719c-42ef-a251-1140fcd23e11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pyxs:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_efd5ca4b-dd20-4280-870e-b98268ab08eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3722df37-e565-465f-bb4b-034fdf13c6ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pyxs:UnvestedRestrictedStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6378744b-423a-4a6b-972a-85f28e55d021"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2e52bce4-48fd-4d5c-8c03-b3c7a4ce8258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesAConvertiblePreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_39d48607-26ba-431a-ac8a-d3b4ffb3641d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_48de2a5c-eadc-4299-a519-18facbfa1720"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a7b2c38b-0a9d-45f4-9d96-7571430846e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e311d53d-fcab-422f-9f96-6793c81e2f3c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_08a1f0a8-28d8-47d4-a0dd-966a0c736ac3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f4712df5-2590-48af-9284-6195c97975a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pyxs:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e54e83a0-b25b-418c-b85c-d5c2ca67e4c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7f8a7acb-6ab0-451e-8b00-67975a1ecf54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pyxs:StockOptionsAvailableForIssuanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bae164c2-2642-4b70-85fd-0d414f578d75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5f97b551-d4c5-4d8c-95ef-8c2b79aac91a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:AgreementsWithPfizerIncAndLegochemBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1c996d2e-def1-46a6-a4e5-dd50cc8ddbfa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e41e2b33-e797-4eaf-ab2c-e21d506eef7d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_df8cfd51-bc03-4a95-b0a5-24677e60cdc1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4673806d-5b9d-43ee-aed1-9c1f8ab9e297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:BiosionLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-28</xbrli:startDate><xbrli:endDate>2022-03-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5779ffa7-ef54-4318-b0b8-ed0b0cb8c6b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ccb57e6f-0f25-4bfd-96c2-4d333afebc0b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesAConvertiblePreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_96ed1430-e72f-4da1-9065-31aa0a3ed55e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f1ffa94f-ab1a-4b1c-85bc-689829d80a9f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwothousandtwentytwoequityinducementplanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_98ff73fd-5dca-4046-abbc-fee18b4eea2d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2c0f07bf-9ab0-42b4-921b-a98e8aea7faf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:NonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:LegoChemLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_de5078e1-9398-411e-9b9d-a3b0e59ba4db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_453b4504-5d6b-406e-8878-c49bf593ff1e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pyxs:StockOptionsAvailableForIssuanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8e2d7745-07cf-4ad1-90b5-7d195c47708c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_622e53e6-f8fa-4c10-a051-8ba806014c88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f4ce7ade-74e0-45ba-8c22-a5ba47efa398"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2ae41d03-8671-4c50-80d0-d05659459fdb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwothousandtwentytwoequityinducementplanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a8379558-2ae3-4803-896a-b59ad651d3b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pyxs:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4881d8cf-3758-45cf-9629-35b8395ed61a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pyxs:VoxallMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_Days"><xbrli:measure>pyxs:Days</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>pyxs:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U_Lease"><xbrli:measure>pyxs:Lease</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="border-top:2.25pt double;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">UNITED STATES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Washington, D.C. 20549</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FORM </span><span style="font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d7b842f6-e1d7-477d-97b9-5e30a063be5b" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Mark One)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.998%;"></td>
    <td style="width:96.002%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9c1a1456-6ebe-4eba-9c89-267e70c63d60" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_360eebb6-513d-4d44-bec4-c939bc0c3121" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f6475505-b154-4299-82a5-f715333ebd74" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="dei:CurrentFiscalYearEndDate" format="ixt:datemonthdayen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5acbaa35-3dcb-4be4-84b7-6748dda7b920" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="dei:DocumentFiscalYearFocus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">OR</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.998%;"></td>
    <td style="width:96.002%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e7ea0f11-893b-49c0-b35d-91bf41d5ee55" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">                     </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commission File Number </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_edd1796a-1b47-4d70-95e7-065988a8776f" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-40881</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:20.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1f7d7b59-516d-41bc-aeaf-f9ebf8a36ff0" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:20.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pyxis Oncology, Inc.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exact name of Registrant as specified in its Charter)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f4dafdad-484e-4eb1-92fa-c3516392de48" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6c9a37b6-b0ca-42fd-9b27-ef039ebbae76" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83-1160910</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(I.R.S. Employer</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ba20a7c7-9153-4b68-adc3-c8f4fb687441" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">150 Cambridgepark Drive</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br /></span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7614f85d-6c19-4937-a711-13e6d224b397" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cambridge</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3bc8a45c-a599-49fe-8249-b7cae1b03917" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Massachusetts</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b65f61f9-0831-4e9b-a440-0017ab3b3a54" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">02140</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registrant&#x2019;s telephone number, including area code: (</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4db554cc-355e-4938-81d9-829216b65297" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">617</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_037e4f96-c311-47a0-946a-d74c99314a57" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">221-9059</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:37.996%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:15.0%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:45.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trading</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9e3c39af-ce9d-4cdd-a03b-f2ed9c0173a4" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock, par value $0.001 per share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f704e9a6-7819-4d68-b5cf-ad59cd80d16d" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PYXS</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_dc1aaf07-d223-4c48-9beb-d29b612f0e76" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: None</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9744;     </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c270360d-a487-4912-80e4-cc73b58764da" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="dei:EntityWellKnownSeasonedIssuer"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.  </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9744;     </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6517539a-9ccd-485b-8221-99608b8c518e" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="dei:EntityVoluntaryFilers"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_de3b6bdf-3935-4558-ba46-82fc308ad0d3" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="dei:EntityCurrentReportingStatus"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9746;     </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).  </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ed7e0fda-3e9c-48e6-b77e-a989e37cee0f" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="dei:EntityInteractiveDataCurrent"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9746;     </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:19.107%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:55.665%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:20.317%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:1.905%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4e024beb-4ab2-4a2d-a681-0770e5b30231" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1befa643-62db-4a92-96aa-df6020cebece" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_51d04845-666d-494f-8d63-1529e72e6c0d" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7ed8902f-d741-47e9-8012-fac4f641f011" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#x2019;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit re</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">port.  </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1318667a-6179-48b6-8eb5-6bff4565b345" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#x2019;s executive o&#xfb03;cers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9744;     </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_35f2d4c4-ba93-4c29-a03f-df1d54919bfd" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="dei:EntityShellCompany" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate market value of the Registrant&#x2019;s common stock held by non-affiliates as of June 30, 2022 the last business day of the Registrant&#x2019;s most recently completed second fiscal quarter, was approximately $</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9b2b6008-003a-404d-99d4-d37086b35aef" contextRef="C_00119c4b-52cf-4804-ac21-c9c54ee69b67" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">76.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, as computed by reference to the closing price of the common stock on the Nasdaq Global Select Market on that date.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 21, 2023, the Registrant had </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_def12a5a-5a9d-4c92-af9a-d19a50b9c542" contextRef="C_38e9b9ce-48eb-4a5a-a998-eeab38167e13" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">36,980,621</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, $0.0001 par value per share, outstanding.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_079d766f-af96-40dd-bea5-f0e0a8165165" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Portions of the Registrant&#x2019;s Proxy Statement for its 2023 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein. Such Proxy Statement will be filed with the Securities and Exchange Commission within 120 days of the registrant&#x2019;s fiscal year ended December 31, 2022.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.992%;"></td>
    <td style="width:82.004%;"></td>
    <td style="width:7.004%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_i"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART I</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Business</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">118</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 2.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Properties</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">118</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 3.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">118</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 4.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">118</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_ii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART II</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 5.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_5_market_for_registrants_common"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">119</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 6.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_6_selected_financial_data"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[Reserved]</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">121</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7_managements_discussion"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">122</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7a_quantitative_and_qualitative"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">136</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 8.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_8_financial_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">136</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9_changes_in_and_disagreements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">136</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9a_controls_and_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">136</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9b_other_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">137</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9b_other_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">137</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART III</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 10.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_10_directors_executive_officers"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">138</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 11.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_11_executive_compensati"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">138</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 12.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_12_security_ownership_of_certa"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">138</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 13.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_13_certain_relationship"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">138</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 14.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_14_principal_accounting_fees"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Principal Accounting Fees and Services</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">138</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_iv"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART IV</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 15.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_15_exhibits_financial"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibits, Financial Statement Schedules</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">139</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 16.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_16_form"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">140</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Signatures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">141</span></p></td>
   </tr>
  </table>
  <p style="margin-left:13.6%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">i</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Annual Report on Form 10-K contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. These statements involve known and unknown risks and other important factors that are in some cases beyond our control and may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unless the context requires otherwise, references in this Annual Report on Form 10-K to &#x201c;Pyxis Oncology,&#x201d; the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; and &#x201c;our&#x201d; refer to Pyxis Oncology, Inc. and its subsidiary. In some cases, you can identify forward-looking statements by terms such as &#x201c;may,&#x201d; &#x201c;would,&#x201d; &#x201c;should,&#x201d; &#x201c;expects,&#x201d; &#x201c;plans,&#x201d; &#x201c;anticipates,&#x201d; &#x201c;could,&#x201d; &#x201c;intends,&#x201d; &#x201c;target,&#x201d; &#x201c;projects,&#x201d; &#x201c;contemplates,&#x201d; &#x201c;believes,&#x201d; &#x201c;estimates,&#x201d; &#x201c;predicts,&#x201d; &#x201c;outlook,&#x201d; &#x201c;potential&#x201d; or &#x201c;continue&#x201d; or the negative of these terms or other similar expressions. The forward-looking statements in this Annual Report on Form 10-K are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Annual Report on Form 10-K and are subject to a number of risks, uncertainties and assumptions described in the section titled &#x201c;Risk Factors&#x201d; and elsewhere in this Annual Report on Form 10-K. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Some of the key factors that could cause actual results to differ from our expectations include:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to develop and advance our current or future product candidates and programs, and to successfully initiate and complete clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the ability of our clinical trials to demonstrate the safety, purity and potency of our product candidates and other positive results;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the size of the market opportunity for our product candidates, including our estimates of the number of patients who suffer from the cancers we are targeting;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our manufacturing, commercialization and marketing capabilities and strategy;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our plans to expand our pipeline of product candidates and further develop the FACT Platform;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing or likelihood of regulatory filings and approvals for our product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory developments in the United States and Europe and other foreign countries:</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our expectations and plans to obtain funding for our operations, including from our existing and potential future collaboration and licensing agreements;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates:</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our continued reliance on third parties to manufacture our product candidates for preclinical studies, and, in the future, to conduct clinical trials and manufacture product candidates for such clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, statements such as &#x201c;we believe&#x201d; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Annual Report on Form 10-K and, although we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted a thorough inquiry into, or review of, all potentially available relevant information. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events or otherwise.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SUMMARY RISK FACTORS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">You should consider carefully the risks described under &#x201c;Risk Factors&#x201d; in Part II, Item 1A of this Annual Report on Form 10-K. References to &#x201c;Pyxis Oncology,&#x201d; the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; and &#x201c;our&#x201d; in this section titled &#x201c;Summary Risk Factors&#x201d; refer to Pyxis Oncology, Inc. and its wholly owned subsidiary. A summary of the risks that could materially and adversely affect our business, financial condition, operating results and prospects include the following:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a clinical stage biopharmaceutical company with a limited operating history and have incurred significant losses since our inception. We expect to incur losses over at least the next several years and may never achieve or maintain profitability.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will require substantial additional capital to finance our operations, obtain regulatory approval for our product candidates, and commercialize our product candidates. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce or eliminate one or more of our research and product development programs or future commercialization efforts.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are heavily dependent on the success of PYX-201 and PYX-106, which are in the early stages of development, and if PYX-201 and/or PYX-106 are not successful in clinical trials or do not receive regulatory approval or licensure or are not successfully commercialized, our business will be materially and adversely affected.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product candidates may fail in development or suffer delays that materially and adversely affect their commercial viability. If we or our existing or future collaborators are unable to initiate and complete clinical development of, obtain regulatory approval or licensure for or commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our preclinical studies and clinical trials may fail to demonstrate adequately the safety, purity and potency of any of our product candidates, which would prevent or delay development, regulatory approval or licensure and commercialization.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our preclinical programs may experience delays or may never advance to clinical trials, which would adversely affect our ability to obtain regulatory approval or licensure or commercialize these programs on a timely basis or at all.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We face competition from entities that have developed or may develop product candidates for cancer, including companies developing novel treatments and technology platforms. If these companies develop technologies or product candidates more rapidly than we do or if their technologies are more effective, our ability to develop and successfully commercialize product candidates may be adversely affected.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical testing and product development is a lengthy and expensive process with an uncertain outcome. We may incur unexpected costs or experience delays in completing, or ultimately be unable to complete, the clinical testing and the development and commercialization of our product candidates.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The regulatory licensure and approval processes of the FDA and other comparable regulatory authorities are lengthy, time-consuming and inherently unpredictable and, if we are ultimately unable to obtain marketing licensure or approval for our product candidates, our business will be substantially harmed.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we fail to attract and retain qualified senior management and key scientific personnel, our business may be materially and adversely affected.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We face risks related to health epidemics and outbreaks, including the COVID-19 pandemic, which could significantly disrupt our preclinical studies and clinical trials, and therefore our receipt of necessary regulatory licensure or approvals could be delayed or prevented.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely on third parties to manufacture our product candidates. Any failure by a third party manufacturer to produce acceptable raw materials or product candidates for us or to obtain authorization from the FDA or comparable foreign regulatory authorities relating thereto may delay or impair our ability to initiate or complete our clinical trials, obtain regulatory licensure or approvals or commercialize approved products.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are unable to obtain and maintain patent protection for our product candidates, or if the scope of the patent protection obtained is not sufficiently broad, or if our patents are insufficient to protect our product candidates for an adequate amount of time, or if we are unable to obtain adequate protection for our proprietary know-how, we may not be able to compete effectively in our markets.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we fail to comply with our obligations under any license, collaboration or other agreements, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our product candidates or we could lose certain rights to grant sublicenses.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues. If we breach our University of Chicago, Pfizer, or Biosion license agreements or any of the other agreements under which we acquired, or will acquire, intellectual property rights covering our product candidates, we could lose the ability to continue the development and commercialization of the related product candidate(s).</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to stringent and changing obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions, litigation, fines and penalties, a disruption of our business operations, including our clinical trials, harm to our reputation, and other adverse effects on our business or prospects.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our internal computer systems, or those of any of our existing or future CROs, manufacturers, other contractors, consultants, or collaborators, may fail or suffer security or data privacy breaches or other unauthorized or improper access to, use of or destruction of our proprietary and confidential data, employee data or personal data, which could result in additional costs, significant liabilities, harm to our reputation and material disruption of our operations.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the market opportunities for any product that we develop are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_i"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">T I</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1. Business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a clinical-stage oncology company focused on developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. We develop our product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. We consider multi-modality as a variety of technologies, either stand-alone or in combination with others, to build effective cancer therapeutics for patients. Since our launch in 2019, we have developed a broad portfolio that includes novel antibody drug conjugate, or ADC, product candidates, immuno-oncology, or IO, product candidates, and monoclonal antibody, or mAb, preclinical discovery programs that we are developing as monotherapies and in combination with other therapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have assembled a team with deep experience and proficiency in oncology research and development and plan to leverage our team&#x2019;s decades of experience in drug development to bring a variety of innovative therapies through the clinic. The collective experience across our team spans the spectrum of both pharmaceuticals and biotechnology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that the diversification of a multi-modality approach optimizes our ability to effectively progress multiple assets for the benefit of patients. By leveraging our expert knowledge of the tumor microenvironment, or TME, and our established business development record, we are developing cancer therapies and technologies through multiple avenues (see Figure 1) including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Platform Development: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are capitalizing on years of industry innovation and advancement in ADC platforms to develop and design our product candidates. For example, our PYX-201 product candidate is built utilizing the Flexible Antibody Conjugation Technology, or FACT, platform technology in-licensed from Pfizer Inc., or Pfizer. The FACT Platform leverages over a decade of investment refining the technical components of ADCs to improve the clinical properties of ADCs. Using our expertise in site-specific antibody conjugation, we are developing next-generation ADCs with customized linker-payload combinations aimed at increasing stability and, consequently, a reduced off target side-effect profile potentially enhancing the therapeutic index, or TI. We are leveraging our FACT ADC Platform to further build our pipeline while we consider expansion opportunities into adjacent modalities.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Target Catalog</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: We have a large proprietary target catalog that is based on our own discovery activities and the in-licensed intellectual property, or IP, which formed the founding of the company from the University of Chicago out of the work of Dr. Thomas Gajewski&#x2019;s laboratory. We believe that our target catalog will enable us to identify new ways to exploit multiple components of the TME for tumor targeting, either as new IO, or ADC targets. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forging Creative Business Models and Alliances: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are continuously evaluating business development and alliance opportunities with a variety of third parties. We aim to be unconstrained by conventional ideas and practices to overcome the many and complex challenges of cancer treatment. We are creating development optionality by engaging in creative business models to further expand the pipeline such as our joint venture with Alloy Therapeutics, known as Voxall Therapeutics, LLC, or Voxall. See &#x201c;Licensing and Collaboration Agreements&#x201d; in Item 1. Business in this Annual Report on Form 10-K. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Product In-Licensing and Acquisitions: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We selectively seek to in-license product candidates to expand our product pipeline. For example, our PYX-106 (Anti-Siglec-15) product candidate was in-licensed from Biosion USA, Inc. Additionally, we also in-licensed PYX-201 (EDB ADC) from Pfizer. We are actively evaluating opportunities to acquire product candidates which we believe could enable us to add to our portfolio as we build a durable, multi-asset, multi-modality diversified oncology company. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 1</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img30600998_0.jpg" alt="img30600998_0.jpg" style="width:672px;height:369px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Portfolio</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our portfolio consists of both ADC and IO product candidates. Our pipeline is balanced across programs with an emphasis on solid tumors. We in-licensed two ADC programs in March 2021 from Pfizer and one IO program from Biosion USA, Inc. in March 2022. We have additional preclinical mAb discovery programs derived from work at the laboratory of Dr. Thomas Gajewski. We retain full worldwide development and commercialization rights to all our product candidates, with the exception of PYX-106 in Greater China (mainland China, Hong Kong, Macau and Taiwan). In December 2022, we announced clearance of our investigation new drug applications, or IND, by the U.S. Food and Drug Administration, or FDA, for PYX-201 and PYX-106. We are enthusiastic to have transitioned to a clinical stage oncology company and look forward to leveraging our team&#x2019;s experience to execute our clinical trials with the aim of providing patients with safer and more efficacious treatment options.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following is our current clinical development pipeline:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img30600998_1.jpg" alt="img30600998_1.jpg" style="width:672px;height:144px;" /><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">PYX-201</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our lead ADC product candidate is PYX-201, an investigational, novel ADC consisting of an Immunoglobulin G1, or IgG1, anti-fibronectin Extradomain-B, or EDB, mAb site-specifically conjugated to an auristatin derivative via a cathepsin B-cleavable linker. Fibronectin is a glycoprotein found in the extracellular matrix. Fibronectin EDB regulates blood vessel morphogenesis, which provides the tumor access to nutrition and oxygen, a means to remove waste, and a pathway for metastasizing cells. EDB is overexpressed in many malignancies and is minimally expressed in most normal adult tissues, making it a potentially attractive means to target tumors while sparing healthy cells. In preclinical models of patient-derived xenograft, or PDX models, we observed tumor regression with single agent PYX-201. In addition, we observed that the treatment of preclinical syngeneic tumor models with PYX-201 resulted in enhanced T-cell infiltration into the TME, which is a hallmark of immunogenic cell death, or ICD, enabling synergistic activity in combination with a checkpoint inhibitor.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2022, we announced clearance of our IND by the FDA for PYX-201 to initiate a Phase 1 clinical trial. During the first quarter of 2023, we announced dosing of the first subject in a Phase 1 trial of PYX-201, referred to as PYX-201-101. PYX-201-101 is an open-label, multicenter, dose-escalation trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of PYX-201 and identify recommended doses for further study. Patients with relapsed or refractory solid tumors, including non-small cell lung cancer, or NSCLC, hormone receptor positive breast cancer, ovarian cancer, thyroid cancer, pancreatic ductal adenocarcinoma, or PDAC, soft tissue sarcoma, or STS, hepatocellular carcinoma, or HCC, and kidney cancer are eligible to enroll. We anticipate reporting preliminary data from this Phase 1 clinical trial, including biomarker results and early signs of potential clinical activity, in early 2024.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">PYX-106</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our lead IO product candidate is PYX-106, an investigational, fully human IgG1 isotype Siglec-15-targeting antibody designed to block Siglec-15 mediated suppression of T-cell proliferation and function. We plan to initially develop this asset for the treatment of solid tumors. We licensed worldwide rights, other than in Greater China (mainland China, Hong Kong, Macau and Taiwan), to PYX-106 from Biosion USA, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2022, we announced clearance of our IND by the FDA for PYX-106 to initiate a Phase 1 clinical trial. During the first quarter of 2023, we began activating clinical trial sites and are currently screening patients for enrollment in the Phase 1 trial, referred to as PYX-106-101. PYX-106-101 is a first-in-human, Phase 1, multicenter, open-label dose escalation trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PYX-106 in patients with relapsed or refractory solid tumors. This Phase 1 dose escalation trial includes patients who have developed solid tumors and disease progression through standard therapy and patients for whom standard of care therapy that prolongs survival is unavailable or unsuitable. This trial will enroll patients with solid tumors including non-small cell lung cancer without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma, or HNSCC. We anticipate dosing patients in early second quarter of 2023. We anticipate reporting preliminary data from this Phase 1 clinical trial, including biomarker results and early signs of potential clinical activity, in late 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Paused / terminated programs</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2022, we paused preclinical development of our anti-CD123 ADC, PYX-203, and anti-KLRG1 IO program, PYX-102. Although these programs remain important to our diversified portfolio of therapeutic candidates, pausing preclinical development efforts currently will allow us to increase the resources available to advance clinical development of PYX-201 and PYX-106. Further, we elected to pause the continued development of our anti-DLK1 ADC, PYX-202, based upon review and analysis of data from preclinical toxicity studies, and the anticipated clinical use and commercial prospects of PYX-202 if approved.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Discovery</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to the programs identified above, we are conducting research and development activities on various targets, leveraging our expertise in monoclonal antibodies, ADC conjugation, linker and payload selection, and understanding of immuno-oncology.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Strategy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our goal is to improve the lives of patients with difficult-to-treat cancers by building a superior portfolio of biological products, including ADCs and monoclonal antibody immunotherapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Elements of our strategy to achieve our short and long-term goals include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Develop multi-asset, multi-modality, durable portfolio aimed at defeating difficult-to-treat cancers. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that the diversification of a multi-modality approach optimizes our ability to effectively progress multiple assets for the benefit of patients.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Progress our product candidates, PYX-201 and PYX-106, through clinical development. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We began activating clinical trial sites and patient enrollment is ongoing for the PYX-106-101 Phase 1 clinical trial. During the first quarter of 2023, we announced dosing of the first subject in a Phase 1 trial of PYX-201, referred to as PYX-201-101. We expect preliminary data from Phase 1 clinical trials of PYX-106-101 and PYX-201-101, including biomarker results and early signs of potential clinical activity, in late 2023 and early 2024, respectively. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursue a multi-modality approach to cancer therapy addressing various key components of the TME.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Our approach is to leverage our capabilities to develop investigational products that directly target tumor cells and stromal components of the TME with ADCs as well as enhance effector cell function and overcome key mechanisms of immune-suppression with immunotherapeutic mAbs to improve response rates and/or deliver durable responses for more patients.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Efficiently progress our preclinical IO programs.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> We plan to continue the preclinical development of our pipeline of immunotherapies. If approved, we believe these monoclonal antibody programs have the potential to overcome several of the mechanisms responsible for suppressing immune function and effector cell activity, thus enhancing the anti-tumor immune response in the TME. We also plan to leverage the potential ability of certain ADCs to induce immunogenic cell death to support synergistic combinations with IO agents, including those derived through our own programs. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Continue to leverage the FACT Platform and our Target Catalog to expand our pipeline of product candidates.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> We plan to continue to mine our target catalog to identify new ways to exploit multiple components of the TME for tumor targeting. Our target catalog may help identify critical immunomodulatory pathways within the TME that can be addressed with monoclonal antibodies. We plan to use our target catalog and the FACT Platform to develop differentiated ADCs with potentially superior clinical activity relative to the current standards of care including monoclonal antibodies. Additionally, we intend to use the FACT Platform to develop ADCs for attractive targets beyond our target catalog. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Selectively forge alliances to enhance and expand our product pipeline to further leverage our intellectual property</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. We believe that the potential for single agent anti-tumor activity of our current and future products could be enhanced by incorporating potential collaborator technologies. We intend to selectively form alliances with partners to gain access to complementary technologies and expertise to develop and commercialize product candidates with increased potential for anti-tumor activity and the potential for a strong safety profile. We seek to further leverage our intellectual property portfolio through the formation of these alliances. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leverage our team&#x2019;s deep experience and proficiency in oncology research and development to discover and advance novel ADC and immuno-oncology treatments for patients suffering from difficult-to-treat cancers.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> We believe our team, which brings deep scientific TME knowledge, functional biology expertise, ADC and IO modality experience, and biologics development capabilities, position us to build a leading oncology company focused on developing product candidates for cancers with high unmet need.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unmet Need in Oncology</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Despite the meaningful advances made in oncology with the approval of several new classes of drugs, there remains significant unmet medical need for novel treatments. According to the World Health Organization, cancer is the second leading cause of death globally, accounting for nearly 10 million deaths in 2020. The key limitations of existing oncology treatments include high toxicity, low or limited response rates, and relapse or recurrence.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chemotherapy remains one of the most common treatments for cancer, often combined with surgery and radiotherapy depending on the stage and type of tumor. A major challenge in the development of cancer treatments has been the overall complexity and heterogeneity not only of tumors, but of their dynamic surrounding microenvironments. While recent advances in treatment approaches, such as targeting specific tumor mutations that contribute to carcinogenesis or redirecting a patient&#x2019;s immune system to eliminate tumors, have begun to address these challenges, their focus has largely been on tumor cells. We believe that targeting the TME, which has been shown to play a key role in driving tumor progression, growth and multidrug resistance, represents a novel approach for addressing unmet needs in oncology. For example, while the development of immune checkpoint inhibitors has transformed the treatment paradigm for numerous cancers, many patients who respond to these therapies ultimately develop resistance and experience disease progression. Many features of the TME have been shown to influence response and resistance to immune checkpoint inhibitors and targeting the TME has potential to overcome these limitations. Our development efforts aim to leverage our deep understanding of the TME biology with the goal of designing and developing next-generation ADCs, with site-specific conjugation and customized linker-payload combinations, and immunotherapies that target key modulators of the adaptive and innate immune system found within the TME.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ADC Product Candidate</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PYX-201: Site-Specific Investigational ADC Targeting Onco-Fetal Fibronectin EDB</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ADC PYX-201 is an investigational human IgG1 isotype site-specifically conjugated with an auristatin toxin targeting EDB that we plan to initially develop for solid tumors, including NSCLC, hormone receptor-positive breast cancer, ovarian cancer, thyroid cancer, PDAC, STS, HCC, and kidney cancer. We licensed worldwide rights to PYX-201, built on the FACT Platform, from Pfizer. In December 2022, we announced clearance of our IND by the FDA for PYX-201 to initiate a Phase 1 clinical trial. During the first quarter of 2023, we announced dosing of the first subject in a Phase 1 trial of PYX-201, referred to as PYX-201-101. PYX-201-101 is an open-label, multicenter, dose-escalation trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of PYX-201 and identify recommended doses for further study. Patients with relapsed or refractory solid tumors, including NSCLC, hormone receptor positive breast cancer, ovarian cancer, thyroid cancer, PDAC, STS, HCC, and kidney cancer are eligible to enroll.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Rationale for Targeting EDB and Mechanism of Action for PYX-201</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fibronectin is a component of the extracellular matrix and its downstream signaling pathways regulate cell adhesion, migration, differentiation, and wound healing. EDB is an alternatively spliced form of fibronectin, which occurs when RNA is re-arranged to produce multiple variants of the same protein. EDB is typically only spliced during embryogenesis and is rarely found in healthy adult tissues. However, cancer cells take advantage of EDB&#x2019;s ability to promote neo-vasculature structures, which are critical to feeding and supporting the uncontrolled growth of a tumor.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EDB is overexpressed in a variety of cancers, including, but not limited to, cancers of the lung, breast, ovary, pancreas, head and neck, thyroid, and brain (refer to Figures 2 and 3). </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">In vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> studies have shown that down regulation of EDB resulted in a significant reduction in cancer motility. Furthermore, EDB expression is maintained in distal metastasis in human cancer. EDB meets our criteria of a highly desirable ADC target due to its strict preferential expression in tumor tissue and its role as a driver of the poor prognosis in many cancers.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 2</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img30600998_2.jpg" alt="img30600998_2.jpg" style="width:618px;height:489px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">EDB is highly expressed in a variety of solid tumors with restricted normal tissue expression (IHC: Immunohistochemistry; mRNA: Messenger RNA; TCGA: The Cancer Genome Atlas portal; GTEX: Genotype-Tissue Expression portal).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 3</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img30600998_3.jpg" alt="img30600998_3.jpg" style="width:672px;height:358px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comparison of tumor versus matched normal samples for indications where statistical significance of the differential expression exceeds a threshold.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PYX-201 was developed using the FACT Platform to produce an ADC designed to be highly stable and target a predictable drug-to-antibody ratio, or DAR, of four. The complementarity-determining regions, or CDRs, of the EDB antibody used in PYX-201, which is the part of the antibody responsible for binding to EDB, is well characterized and has been tested clinically in the form of a radio-conjugated antibody for tumor imaging&#x2014;demonstrating a high degree of tumor-directed specificity. Furthermore, PYX-201 is designed to optimize linker stability to enable delivery of the auristatin payload without internalization of the ADC into the cancer cell. Unlike currently approved ADCs which bind to the tumor cell surface, PYX-201 is designed to deliver the auristatin payload to the TME consisting of tumor cells, stromal cells and the surrounding blood vessels. PYX-201 is designed to exhibit anti-tumor activity through three distinct modes of action, as illustrated in Figure 4 below. PYX-201 may be internalized prior to extracellular cleavage of the linker due to fibronectin turnover, resulting in the release of the payload in the tumor cell.</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Direct killing activity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: After binding to EDB locally expressed in the TME, cathepsin B, a protease which is aberrantly overexpressed in and secreted by invasive and metastatic cancers, cleaves the linker enabling the cell-permeable auristatin toxin to kill both the tumor and stromal cells, and thus may remodel the TME and may enhance T cell activity. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">2.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Bystander effect</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: Releasing the payload extracellularly within the TME may also confer added cytotoxicity via bystander activity, which may enable killing of cancer cells that do not express EDB. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">3.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Immunogenic cell death</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: Lastly, auristatin has been shown in preclinical models to drive immunogenic cell death by causing the release of tumor antigens and damage-associated molecular patterns, or DAMPs, and promoting dendritic cell maturation and activation, which together initiate an adaptive immune response.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Taken together, we believe that PYX-201 may generate a multi- pronged attack on difficult-to-treat cancers by directly killing cancer cells, modulating the TME, and mobilizing an anti-tumor immune response.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 4</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img30600998_4.jpg" alt="img30600998_4.jpg" style="width:544px;height:391px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">PYX-201 is designed to bind Fibronectin EDB in the surrounding stroma to kill tumor cells and the supporting infrastructure through direct payload-induced cell death, bystander effect and triggering immunogenic cell death based on data from preclinical models.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Preclinical Development</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PYX-201 has shown promising preclinical results. In preclinical studies, we have observed strong </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in-vivo </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">activity in NSCLC PDX and in the EMT-6 syngeneic mouse breast cancer models. While PDX mouse models are generated by grafting patient derived cells to immune deficient mice, syngeneic mouse models are grafted with tumors derived from mice which allow the immune system to remain intact. As a result, while PDX models provide the most clinically translatable signals of efficacy in a preclinical setting, syngeneic models allow us to assess the ability of PYX- 201 to generate an immune response. In these syngeneic models, we have been able to show that PYX-201 effectively localizes to cancers and can generate not only significant reductions in tumor burden but can also mobilize an anti-tumor immune response.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For example, in a PDX model of NSCLC, PYX-201 was intravenously administered four days apart for twelve days and a dose-dependent regression in tumor burden and a durable response at 3 mg/kg was observed (Figure 5).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 5</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><img src="img30600998_5.jpg" alt="img30600998_5.jpg" style="width:609px;height:325px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">PYX-201 has been shown to be highly active in a PDX model of NSCLC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The anti-EDB human mAb used in PYX-201 is cross-reactive with mouse EDB-fibronectin. As a result, in syngeneic tumor models conducted in immune competent mice, PYX-201 achieved a durable response with a single dose of 9 mg/kg (Figure 6). In preclinical studies, we observed increased infiltration in CD3 T cells and upregulation of PD-L1, which suggests that PYX-201 may be capable of inducing immunogenic cell death. Combining sub-optimal doses of PYX-201 with checkpoint therapy resulted in synergistic inhibition of tumor growth in the EMT-6 model. Consequently, we believe PYX-201 may synergize with checkpoint inhibitors, as shown in Figure 7. PYX-201 was also well-tolerated in our mouse models and toxicology studies conducted in rat and cynomolgus monkeys. In an exploratory toxicology study in cynomolgus monkeys the highest non-severely toxic dose, or HNSTD, was found to be greater than 12 mg/kg with three doses of PYX-201 administered every three weeks. There was no differential in body weight or food consumption detected and based on the types of toxicities observed (i.e., no fibrosis, neuropathology etc.), all toxicities are reversible, or are expected to be reversible. PYX-201 was observed to have a preclinical relevant therapeutic index of 16 (the HNSTD in monkeys was 144 mg/m</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and was 16 times greater than the dose required for a complete response in mice of 9 mg/m</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">), which we believe is promising based on our experience investigating the relative therapeutic index among different ADC constructs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 6</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img30600998_6.jpg" alt="img30600998_6.jpg" style="width:618px;height:187px;" /><img src="img30600998_7.jpg" alt="img30600998_7.jpg" style="width:431px;height:221px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">PYX-201 treatment in vivo of syngeneic cell-derived tumor models has been associated with enhanced T cell infiltration based on increased CD3 positivity. (CR: complete response; rcEDB: Reverse Chimeric EDB)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 7</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img30600998_8.jpg" alt="img30600998_8.jpg" style="width:672px;height:358px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">EDB vc0101 ADC combines with anti-PD-L1 to synergistically reduce tumor growth in EMT6 mouse syngeneic model.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Clinical Development Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the first quarter of 2023, we initiated a Phase 1, multicenter, open-label dose escalation trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PYX-201 in patients with relapsed or refractory solid tumors and identify the recommended doses for further study. This Phase 1 dose escalation trial includes patients who have developed solid tumors and have disease progression through standard therapy and patients for whom standard of care therapy that prolongs survival is unavailable or unsuitable. The trial will enroll patients with solid tumors including NSCLC, hormone receptor positive breast cancer, ovarian cancer, thyroid cancer, PDAC, STS, HCC, and kidney cancer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As illustrated below in Figure 8, the trial is designed as a Phase 1 monotherapy dose escalation trial to investigate the safety and tolerability of PYX-201, to identify a biologically active doses for cohort expansion, and to identify a maximum tolerated dose. We plan to initially enroll patients with NSCLC, breast cancer and other tumor types with a high frequency of EDB expression to identify a recommended dose to evaluate in separate expansion cohorts in select tumor types. We may pursue the development of PYX-201 as a combination therapy with the standard of care as appropriate in future studies. For example, in NSCLC and breast cancer, where immunotherapy is widely used in both first- and second-line settings, PYX-201 may provide a synergistic treatment benefit since the auristatin payload has been observed in preclinical studies to trigger hallmarks of immunogenic cell death. Information on this clinical trial is available on ClinicalTrials.gov (NCT05720117).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 8</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img30600998_9.jpg" alt="img30600998_9.jpg" style="width:672px;height:287px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We anticipate reporting preliminary data from this Phase 1 clinical trial, including biomarker results and early signs of potential clinical activity, in early 2024.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Immuno-Oncology Programs and Target Catalog Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Background on Current Immuno-Oncology Therapeutics</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The advent of immuno-oncology therapeutics, particularly immune checkpoint inhibitors, has shifted the treatment paradigm for oncology. The immune system has the capability to recognize and eliminate cancer, but tumor cells take advantage of immune checkpoint pathways, which normally prevent autoimmunity, to suppress and evade immune effector cell activity. The first generation of drugs that interrupt these pathways, including PD-L1 and cytotoxic T-lymphocyte associated protein 4, or CTLA-4, inhibitors, has generated significant enthusiasm due to their ability to achieve durable responses in some patients. While these drugs provide significant therapeutic benefit for durable responders, response rates remain low for most patients, particularly for tumors with low levels of T-cells infiltrating the tumor. These non-inflamed (i.e., &#x201c;cold&#x201d;) tumors can suppress the adaptive immune response through a variety of mechanisms within the TME.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Target Catalog Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have a large proprietary target catalog that we have assembled through both our own discovery activities and through an exclusive license from the University of Chicago for the work on immunotherapy targets out of Dr. Thomas Gajewski&#x2019;s laboratory. We are also building a large &#x201c;cold&#x201d; tumor target discovery database leveraging several human tumor databases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The target catalog is based upon findings from an </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> mouse model system which examined tumor tissue for functional and dysfunctional T cells based on the ability of the T cells to produce the cytokine IL-2. Furthermore, since 4-1BB and LAG3 positive T cells do not secrete IL-2, the CD8+ T cells were sorted based on cell surface marker expression i.e., 4-1BB and LAG3, which further defined functional or dysfunctional T cells. Gene expression analysis identified upregulated cell surface molecules in dysfunctional cells which included well established markers such as PD1, CTLA4, and TIM3, while many other novel targets were identified of which we have prioritized a select subset for discovery research based on bioinformatics and deep biological rationale.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our cold tumor target discovery database used RNA-seq transcriptome analysis of human tumor databases to identify potential novel targets involved in regulation of T cell function and/or infiltration leading to cold tumors. We have supplemented this database with additional resources which we continue to mine to identify additional novel targets for immunomodulation. These cold tumor targets are potentially dominant immune suppressors that are expressed across a variety of tumor associated cells, including immune cells, tumors cells, and stroma, offering the potential to uncover not only novel IO mechanisms, but additional novel targets for our ADC platform.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Immuno-Oncology Programs Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have initiated multiple monoclonal antibody programs that address critical immunomodulatory pathways within the TME and are exploring additional potential targets. Our programs address critically important tumor infiltrating immune cell populations, such as macrophages, T cells, and natural killer, or NK, cells, which may play crucial roles in limiting tumor growth and metastasis. In addition to singling out specific cell types, we believe our IO programs also address mechanisms responsible for T cell exhaustion and the immunosuppressive effects of the TME on T and NK cells. These effects can occur due to chronic exposure to tumor antigens within the TME and direct exposure to immunosuppressive cytokines and other signaling molecules. Though PD-L1 therapies can help reinvigorate T cells, they are often not sufficient to overcome T cell exhaustion and many patients do not respond to standard checkpoint therapy. Several immunosuppressive pathways can also directly limit T cell activity and other critical components of the anti-tumor immune response, such as direct tumor killing by NK cells. Therapies that target both T cell and NK cells to counteract these pathways have the promise to restore immune effector function, either alone or in combination with checkpoint inhibitors. Furthermore, MDSCs/TAMs are another major component of the TME with significant immunosuppressive activity. These cells represent a mixed population of immature myeloid cells and are actively recruited to the TME where they broadly suppress immune activity. MDSCs and tumor-associated macrophages, or TAMs, support tumor growth by depriving other immune cells of key amino acids essential for immune function, producing signaling molecules that block immune effector function, and enhancing activation of regulatory T cells. Furthermore, MDSCs and TAMS promote tumor angiogenesis and growth and are a marker associated with poor outcomes and linked to poor response to PD-L1 therapy. We believe our IO programs represent potential novel therapies that have the potential to overcome multiple protumor mechanisms by enhancing T and NK cell activity, or by inhibiting immune suppressive functions of MDSCs and TAMs within the TME.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PYX-106: Investigational IgG1 isotype anti-Siglec-15 Targeting Antibody</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PYX-106 is an investigational fully human IgG1 isotype antibody that is designed to block Siglec-15 mediated suppression of T-cell proliferation and function. PYX-106 aims to address critically important tumor infiltrating immune cell populations, such as macrophages, T cells, and NK cells, which may play crucial roles in limiting tumor growth and metastasis. In addition to singling out specific cell types, we believe PYX-106 may also address mechanisms responsible for T cell exhaustion and the immunosuppressive effects of the TME on T and NK cells. We believe that our in-licensed anti-Siglec-15 mAb PYX-106 has the potential to provide additional benefit to cancer patients either alone or in combination with other therapies, including other immuno-therapies. We licensed worldwide rights other than in Greater China (mainland China, Hong Kong, Macau and Taiwan) to PYX-106 from Biosion USA, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2022, we announced clearance of our IND by the FDA for PYX-106 to initiate a Phase 1 clinical trial. During the first quarter of 2023, we began activating clinical trial sites and are currently screening patients for enrollment in the Phase 1 trial, referred to as PYX-106-101. PYX-106-101 is a first-in-human, Phase 1, multicenter, open-label dose escalation trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PYX-106 in patients with relapsed or refractory solid tumors. This Phase 1 dose escalation trial includes patients who have developed solid tumors and disease progression through standard therapy and patients for whom standard of care therapy that prolongs survival is unavailable or unsuitable. This trial will enroll patients with solid tumors including non-small cell lung cancer without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Rationale for Targeting Siglec-15 and Mechanism of Action for our Siglec-15 targeting antibody</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Siglec-15 is a member of the Siglec family (Sialic acid-binding ImmunoGlobulin Lectins), a distinct subgroup of immunoglobulin, or Ig, superfamily proteins involved in immune regulation. Siglec recognize and bind to sialic acid on the surface of cells and this binding can affect cell signaling on immune cells. Siglec-15 is a single-pass type I membrane protein that has been shown to associate with the activating adaptor proteins DNAX activation protein (DAP)12 and DAP10 via its lysine residue in the transmembrane domain, implying that it functions as an activating signaling molecule. While Siglec-15 is minimally expressed on normal tissues, it is highly expressed on both tumor cells and M2 macrophages in the TME across multiple tumor types, including thyroid cancer, HNSCC, lung cancer, breast cancer and cholangiocarcinoma. The increased presence of highly immunosuppressive M2 macrophages within tumors leads to impaired T cell proliferation and function, causing a decreased anti-tumor immune response. Additionally, Siglec-15 may exacerbate this immunosuppressive effect by interacting with tumor associated myeloid cells to promote their survival and differentiation to drive a tumor-promoting environment. Interestingly, Siglec-15 appears to function independently from the PD-L1 pathway with largely non-overlapping expression in select tumor samples. Therefore, targeting Siglec-15 in the TME may be a promising therapeutic option for patients less likely to respond to a PD-1/PD-L1 targeted therapy.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">An overview of the role of Siglec-15 in regulating the immune system and driving anti-tumor immune dysfunction is depicted in Figure 9 below.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 9</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img30600998_10.jpg" alt="img30600998_10.jpg" style="width:616px;height:493px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Source: American Association for Cancer Research Journal - Cancer Clinical Research Review - Siglec-15 as an Emerging Target for Next-generation Cancer Immunotherapy by Jingwei Sun, Qiao Lu, Miguel F. Sanmamed and Jun Wang</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Siglec-15 targeting antibody is a fully human monoclonal antibody and is engineered with high affinity to block Siglec-15 induced immune suppression and therefore restore T cell proliferation, function and anti-tumor immunity in the TME. Overall, by binding and blocking Siglec-15 activity on myeloid cells and tumors, our Siglec-15 targeting antibody is designed to enhance immune cell mediated tumor cell kill. Given the broad tumor expression profile of Siglec-15, our Siglec-15 targeting antibody has the potential to treat multiple oncology indications including those where PD-1/PD-L1 directed cancer therapies are ineffective.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expression data for Siglec-15 in tissues where tumor expression was significantly higher than normal tissue expression are depicted in Figure 10. Of the indications tested, NSCLC, breast cancer, uterine cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and sarcoma all show higher expression of Siglec-15 in tumor compared to normal samples. The low expression of Siglec-15 across the range of normal tissues tested suggests limited potential for effects in nontumor tissues of therapies targeting Siglec-15. Significantly higher expression in most tumor types indicates that patients with such tumors may respond to anti-Siglec-15 antibody treatment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 10</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img30600998_11.jpg" alt="img30600998_11.jpg" style="width:609px;height:446px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Siglec-15 is broadly expressed across a range of solid tumors with higher expressing tumors, with kidney and thyroid cancer where the difference is substantial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Preclinical Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Blocking Siglec-15 with an antibody such as PYX-106 may overcome the immunosuppressive TME and enhance the antitumor activity of other immune checkpoint inhibitors. We have conducted a preclinical study in various animal models to evaluate the effect of blocking Siglec-15 and our observed results provide sufficient scientific rationale in both </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">ex vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> studies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In an </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> mouse syngeneic tumor model, PYX-106 demonstrated significant inhibition of tumor growth when administered at 15 mg/kg twice weekly for 6 weeks compared to the control group. PYX-106 resulted in an approximately 60% decrease in tumor volume at doses of 5 mg/kg and 15 mg/kg, with the decrease reaching statistical significance in the latter dose group. Moreover, the inhibition of tumor growth was not accompanied by any changes in behavior, body weight, or spleen weight within the mice.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In an </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">ex vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> study using normal human peripheral blood mononuclear cells, or PBMCs, which are blood cells that are considered critical components in the immune system, PYX-106 was able to reverse Siglec-15-mediated suppression of T cell proliferation and interferon-gamma, or IFN-&#x3b3;, secretion. The numbers of CD4+ and CD8+ T cells and secretion of IFF-&#x3b3; were increased substantially while the negative control antibody had no effect on the suppression of proliferation. The effects of a single concentration of anti-Siglec-15 antibodies on T-cell proliferation using PBMCs are shown in Figure 11. The addition of the anti-CD3 antibody led to proliferation of both CD4+ and CD8+ T cells, which was reduced by addition of Siglec-15. The addition of the negative control antibody had no effect on this suppression of proliferation. PYX-106 reversed this suppression.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 11</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img30600998_12.jpg" alt="img30600998_12.jpg" style="width:617px;height:321px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Illustrates an ex vivo assay using PBMCs, from normal healthy donors. In preclinical studies, PYX-106 reverses Siglec-15 mediated T cell suppression, upregulating the immune system to fight the cancer cells and prevent tumor growth.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Clinical Development Plan</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2022, we announced clearance of our IND by the FDA for PYX-106 to initiate a Phase 1 clinical trial. During the first quarter of 2023, we began activating clinical trial sites and are currently screening patients for enrollment in the Phase 1 trial, referred to as PYX-106-101. PYX-106-101 is a first-in-human, Phase 1, multicenter, open-label dose escalation trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PYX-106 in patients with relapsed or refractory solid tumors. This Phase 1 dose escalation trial includes patients who have developed solid tumors and disease progression through standard therapy and patients for whom standard of care therapy that prolongs survival is unavailable or unsuitable. This trial will enroll patients with solid tumors including non-small cell lung cancer without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As illustrated below in Figure 12, this trial is designed as a Phase 1 monotherapy dose escalation trial to investigate the safety and tolerability of PYX-106, to identify a biologically active dose for cohort expansion and to identify a maximum tolerated dose. As part of the trial, tumor samples will be collected from participants to enable biomarker analysis. Patients with relapsed or refractory solid tumors known to have significant infiltration of M2 macrophages and expression of Siglec-15, including non-small cell lung cancer, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma, are eligible to enroll. Information on this clinical trial is available on ClinicalTrials.gov (NCT05718557).</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 12</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img30600998_13.jpg" alt="img30600998_13.jpg" style="width:672px;height:257px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We anticipate dosing patients in early second quarter 2023. We anticipate reporting preliminary data from this Phase 1 clinical trial, including biomarker results and early signs of potential clinical activity, in late 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Overview of Antibody Drug Conjugates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ADCs are a therapeutic class in which cytotoxic chemotherapy molecules are linked to a targeting mAb to effectively deliver the tumor killing effect into tumor lesions while limiting systemic toxicity. Systemic toxicity limits the efficacy of chemotherapy, a highly cytotoxic class of anti-tumor medicines. ADCs can significantly improve the therapeutic window of toxic payloads even more cytotoxic than traditional chemotherapies by targeting their delivery to tumorous cells and their local environment and sparing healthy tissue. ADCs achieve this level of precision by pairing payloads with monoclonal antibodies, proteins that can recognize their target antigens with great specificity. ADCs are an established and fast-growing class of biological products. To date, thirteen ADCs have been FDA approved, of which nine have entered the market since 2019.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 13</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img30600998_14.jpg" alt="img30600998_14.jpg" style="width:279px;height:275px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Schematic representation of an ADC, highlighting the three key components; targeted antibody, linker, and payload or cytotoxic agent (dark blue: mAb heavy chain; pink: mAb light chain).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The clinical properties of ADCs are a function of three components (as show in Figure 13 above):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.796%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.9288834417523018%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A monoclonal antibody that selectively targets a distinct antigen preferentially expressed on tumor cells or other cells in the tumor microenvironment; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.796%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.9288834417523018%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A linker that joins together the antibody and the payload; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.796%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.9288834417523018%;">(3)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A payload that can effectively kill the targeted cell. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ideal ADC targets typically have highly tumor restricted expression to spare healthy tissues, are accessible to circulating antibodies, and have well-defined internalization kinetics or can be effectively bound within the TME. Once administered, an ADC will travel in the bloodstream until it encounters its target antigen followed by release of the toxic payload.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A measure of drug tolerability for ADCs is the preclinical therapeutic index, which is calculated from data to estimate the safety profile (refer to Figure 14). This measure is the preclinical ratio of the HNSTD in monkeys versus the minimally effective dose, or MED, in mouse tumor models. The therapeutic index is defined formulaically as HNSTD (mg/m</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:5.36pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) in monkeys / mouse minimal tumor regression dose (mg/m</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:5.36pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">). As further illustrated in Figure 14 below, a wider therapeutic index is a key attribute of an ADC&#x2019;s potential clinical success.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 14</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img30600998_15.jpg" alt="img30600998_15.jpg" style="width:589px;height:324px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The therapeutic index is a measure to estimate the clinical tolerability profile of ADCs based upon the ratio of maximum tolerated dose, or MTD, in monkeys versus the MED in rodents from preclinical studies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Key Areas of Innovation for Engineering the Next-Generation ADCs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Optimizing the Linker</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The linker that joins the payload to the antibody should prevent the payload&#x2019;s premature release while in circulation and ensure efficient release of the payload into the target cell(s) and/or the TME. There are two general classes of linkers:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.796%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.9288834417523018%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cleavable linkers are designed to conditionally unload cytotoxic agents within the tumor cell or TME in response to the presence of tumor-associated factors such as proteases or highly acidic conditions. Typically, cleavable linkers carry uncharged payloads, allowing the drug to diffuse out of the target cell to kill surrounding &#x201c;bystander cells.&#x201d; Bystander killing can also occur when the uncharged payload is unleashed within the TME. </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.796%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.9288834417523018%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In contrast, non-cleavable linkers remain intact upon internalization and rely on lysosomal degradation of the entire construct to achieve sufficient payload release. Non-cleavable ADCs typically release their payloads as charged catabolites, which traps the toxin within the cell where it was internalized. As a result, non-cleavable ADCs are naturally well suited to address cancers with a high and uniform expression of the target antigen since cells lacking the target antigen will not be directly affected. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe our toolbox of cleavable and non-cleavable linkers allows us to select the optimal linker tailored to each program. We select our linkers based on several factors, including but not limited to the level and distribution of the target antigen and rates of antigen turnover, internalization, lysosomal processing, and degradation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Site-Specific Conjugation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Site-specific conjugation chemistry enables the engineering of next-generation ADCs with predictable DAR with improved ADC pharmacokinetics, or PK, observed preclinically. This improved PK results in minimizing premature payload release and less off-target toxicity and as a result improves the overall TI of the ADC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DAR is defined as the number of payload moieties attached to each antibody, which typically range from zero to    eight. Ideally, there is limited variability in DAR to allow for ADCs with predictable PK and more predictable efficacy. Variability in DAR and stability are primarily a consequence of the technology used to conjugate the linker to the antibody. The two conventional conjugation approaches employed in conventional ADC conjugation technology utilize either lysine residues or the interchain disulfides located on an antibody. These approaches result in a stochastic mixture of conjugates consisting of a heterogeneous pool of synthesized ADCs, as shown in Figure 15 below. Each bar in the graph consists of an ADC with the number of payloads indicated on the X-axis. Each one of these parts of the mixture of conjugates contributes to the efficacy and toxicity making it difficult to optimize for either property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to DAR, research has shown conjugate stability and the resulting rate of payload release can vary significantly between specific conjugation sites. Hence, conventional conjugation suffers from unpredictable and premature payload release outside of the tumor resulting in off target toxicities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Together with our extensive toolbox of linkers, we believe our site-specific conjugation chemistry offers us the advantage of fine-tuning and optimizing the cleavage of the drug in the TME while limiting off-tumor release and allowing for predictable DAR distribution. Site-specific conjugation technologies have led to improved ADC predictability with narrow distribution of DAR to facilitate CMC manufacture and consistent potency (refer to Figure 15).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 15</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img30600998_16.jpg" alt="img30600998_16.jpg" style="width:672px;height:265px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Depicted above is an illustrative example of DAR distribution for a DAR 4 ADC using different conjugation chemistries which highlights how our site-specific conjugation technology allows for linker/payload to be precisely conjugated, leading to more predictable DAR ADCs. This also improves CMC characteristics and enhances stability of ADCs to maximize tumor delivery of the payload.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The Selection of Cytotoxic Payload</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The chemotherapeutic payload is a highly potent toxin that would otherwise carry devastating side effects as a systemically delivered monotherapy. There are several potential payloads, including antineoplastic auristatins, which act on microtubules to inhibit cell division, and alkylating or intercalating agents, which damage DNA.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While an ADC&#x2019;s primary mode of action is to induce direct cell death through the payload, ADCs can exploit multiple avenues of anti-tumor action beyond direct cytotoxicity. For example, a growing area of interest is applying ADCs to induce ICD allowing for synergy with immunotherapy modalities including checkpoint inhibitors. Rapid cancer cell death caused by ADCs results in the release of damage-associated molecular patterns and tumor antigens, stimulating a tumor-specific immune response and recruitment of T cells into the TME (Figure 16). An emerging area of interest is utilizing ADCs to disrupt various aspects of the TME, such as angiogenesis or tumor-associated fibroblasts. Furthermore, certain payloads, such as auristatins, have been shown to engender the maturation and activation of dendritic cells, a critical compartment of the immune system responsible for initiating and regulating the innate and adaptive immune response.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 16</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img30600998_17.jpg" alt="img30600998_17.jpg" style="width:617px;height:457px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Overview of the process by which ADCs, particularly those with certain payloads, can potentially trigger hallmarks of immunogenic cell death to enhance tumor cell killing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ADCs have and may continue to revolutionize the treatment paradigm for several cancers. Despite the improvements that have been seen with currently marketed ADCs, these ADCs still have limitations that impact dosing, and are associated with significant adverse events. We have designed our product candidates to overcome the limitations of ADCs that use conventional conjugation with the aim of providing patients with safer and more efficacious treatment options. We believe that our combined expertise in ADC design and insights into TME biology have the potential to yield a holistic treatment spanning multiple mechanisms for patients with difficult-to-treat cancers that will overcome the current limitation of ADCs and result in better outcomes for patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FACT Platform</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are developing next-generation ADCs using customized linker-payload combinations that are novel and supported by the preclinical data and site-specific conjugation techniques derived from the FACT Platform. We believe that these payloads and linkers could be readily applied to any IgG1 antibodies using our site-specific conjugation techniques to efficiently develop novel product candidates. We initially licensed the FACT Platform from Pfizer in December 2020, before securing an exclusive license to the FACT Platform in October 2022, and benefit from over a decade of research and investment by Pfizer. See &#x201c;Licensing and Collaboration Agreements&#x201d; in Item 1. Business in this Annual Report on Form 10-K. We believe that the site-specific conjugation techniques and ADC technology which underpin the FACT Platform enable us to develop next-generation ADCs with more favorable drug properties than traditional technologies based on preclinical studies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Despite the clinical successes of ADCs as a therapeutic class, many ADCs still utilize conventional non-site-specific conjugation techniques that result in a heterogeneous mixture of ADCs with varying DAR. Recently, preclinical research carried out by Pfizer to empirically assess the impact of conjugation sites on ADC stability and activity in rodent models has indicated that site-specific conjugation techniques may enable enhanced pharmacologic properties and predictable DAR to potentially improve the therapeutic index.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Though multiple reports have shown that site-specific conjugation techniques often result in ADCs with a wider therapeutic index, greater stability, and better efficacy in preclinical </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vivo </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">models than traditional non-specific, conventional ADC conjugates, less is understood about how to optimize these sites, as optimization relies upon empirical data generation for each specific linker-payload combination. We believe that the FACT Platform has demonstrated that there are multiple biochemical parameters of ADCs impacting performance </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vivo </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and established a framework for optimized conjugation sites for a variety of linker-payload combinations (Figure 17).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 17</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img30600998_18.jpg" alt="img30600998_18.jpg" style="width:512px;height:269px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The FACT Platform technology is designed to empirically define optimal conjugation sites for linker-payloads to generate highly stable and predictable ADCs with potential for improved therapeutic indices.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pfizer optimized sites for linker-payload conjugation through empirical research</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that the FACT Platform provides a toolkit of novel and validated payloads, cleavable and non-cleavable linkers, and a strong understanding of optimized conjugation sites. The FACT Platform provides the basis for our ADC product candidate, PYX-201, and preclinical program, PYX-203, and will underpin our development of future ADCs that we believe are optimized for, and guided by the following design elements:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ADC cytotoxicity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Target tumor cells require delivery of a certain threshold of payload molecules based on the payload&#x2019;s biochemical properties to induce cell killing at specific dose levels. Our ADC programs are designed to provide anti-tumor cytotoxicity and, as applicable, immunogenic cell death based on data from preclinical models. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Plasma stability and maintenance of the linker-payload</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. ADCs must be optimized for systemic circulation to prevent premature linker cleavage or release of the linker-payload construct in the blood plasma that can result in off-target toxicity. We are designing our ADC candidates to optimize for stability when in circulation </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vivo </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to avoid premature cleavage and support maximal payload delivery to the target site. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Efficient proteolytic cleavage of the linker for payload release</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The timing and rate of linker cleavage is important for achieving optimal delivery and release of a specific payload at the target site. We believe that we have the capability to utilize both cleavable and non-cleavable linkers to achieve potential therapeutic effects that are optimized for individual payloads and targets.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">High target specificity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ADC programs are founded on the identification of promising tumor targets and developing highly specific antibodies against these tumor targets. We draw upon our empirical understanding of site-specific conjugation sites and linker-payload toolkit to select combinations that we believe are well-suited for individual targets. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Defined and target specific DAR. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intrinsic to the FACT Platform and conjugation techniques is the development of products with a consistent DAR, which we believe may enable us to develop a product with optimized stability, tolerability, and cytotoxicity. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that the FACT Platform conveys several distinct advantages and flexibility in the development of our ADC candidates, including the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Improved anti-tumor activity in preclinical models with optimized conjugation sites for linker-payload combinations</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The FACT Platform is designed to select for optimal conjugation sites that are specific to each linker-payload combination. We employ site-specific conjugation techniques to conserved regions found within the antibody backbones that do not affect antigen binding or other normal antibody functional properties, such as Fc binding when appropriate, which we believe makes our conjugation technology broadly applicable to a wide variety of IgG monoclonal antibodies. Leveraging our diverse toolkit of improved and novel payloads, cleavable and non-cleavable linkers, and deep understanding of optimized site-specific conjugation sites, we have developed payload and linker combinations that can readily be applied to other antibodies in the same class. For example, our auristatin analogues, a potent microtubule inhibitor, and CPI, a highly potent DNA-cross-linking agent, have site-specific conjugation engineering with several linkers alongside IgG1 antibodies. These payloads and linkers could be readily applied to other IgG1 antibodies to efficiently develop novel product candidates. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Potential for improved therapeutic index and ADC stability</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that our site-specific conjugation technology has potential to mitigate off-target liabilities of ADCs contributing to an enhanced plasma stability and enhanced therapeutic index. As shown in Figures 18 and 19, applying the FACT Platform to a well-established antibody, NG-HER2-ADC, to generate a model ADC was observed to mitigate toxicity and increase the TI and PK exposure and half-life of the ADC </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The rate of linker cleavage and release of the linker/payload construct has been observed to be heavily dependent on the conjugation location and we optimize our linkers for both specific targets and payloads. As a result, we believe the FACT Platform and our empirical understanding of optimal site-specific conjugation may allow us to generate candidates against a broad set of targets that result in superior cell killing. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 18</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img30600998_19.jpg" alt="img30600998_19.jpg" style="width:620px;height:396px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Schematic illustration of how the therapeutic index of a model ADC generated using the FACT Platform can potentially mitigate toxicity while maximizing PK exposure in vivo. (NHP: non-human primates)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 19</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img30600998_20.jpg" alt="img30600998_20.jpg" style="width:618px;height:306px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comparison of stability and exposure in cynomolgus monkeys of Pfizer&#x2019;s NG-HER2-ADC using the same linker-payload and conjugation site chemistry as our PYX-201 ADC was observed to improve the stability and tolerability over conventional ADCs conjugated with the same linker-payload in preclinical studies (NG: next generation).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Enhanced anti-tumor activity through bystander activity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As depicted in Figure 20 below, bystander activity occurs when payloads that are delivered to target cells diffuse into and kill neighboring cells in the tumor microenvironment and is of particular importance if the target is not uniformly expressed on all tumor cells. Bystander activity also has the potential to overcome resistance that may occur over time to treatment with ADCs, carrying non-bystander active payloads, as anti-tumor activity is not directly tied to antigen expression at the target site and destruction of a single target cell. We believe our toolkit of novel and validated payloads, linkers and site-specific conjugation techniques will allow us to further develop ADC candidates with bystander activity that may result in greater clinical activity, especially in cases with heterogeneous target expression. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 20</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img30600998_21.jpg" alt="img30600998_21.jpg" style="width:618px;height:304px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the potential advantages of our next-generation ADC platform that utilizes preclinically optimized payloads and site-specific conjugation compared to the currently approved ADCs using conventional conjugation:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:23.036%;"></td>
    <td style="width:38.601%;"></td>
    <td style="width:38.363%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pyxis Oncology's Next-Generation ADCs</span></p><p style="border-top:1pt solid;padding-top:1.0pt;text-indent:0.0pt;font-size:4.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Conventional ADCs</span></p><p style="border-top:1pt solid;padding-top:1.0pt;text-indent:0.0pt;font-size:4.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Potential Therapeutic Index</span></p></td>
    <td style="background-color:rgba(204,238,255,1);text-indent:12.25pt;word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><div style="text-indent:0.0pt;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.1701388888888889in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8 &#x2013; 16</span></div></div></td>
    <td style="background-color:rgba(204,238,255,1);text-indent:12.25pt;word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><div style="text-indent:0.0pt;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.1701388888888889in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 &#x2013; 5</span></div></div></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Linker</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:12.25pt;word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;"><div style="text-indent:0.0pt;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.1701388888888889in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Site-specific conjugated linkers designed to target a specific DAR and high therapeutic index</span></div></div><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><div style="text-indent:0.0pt;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.1701388888888889in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Highly stable linkers designed to prevent premature release of payload</span></div></div></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:12.25pt;word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;"><div style="text-indent:0.0pt;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.1701388888888889in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-site-specific conjugation results in heterogenous DAR</span></div></div><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><div style="text-indent:0.0pt;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.1701388888888889in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many linkers are labile, resulting in premature release of payload and systemic toxicity</span></div></div></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payload</span></p></td>
    <td style="background-color:rgba(204,238,255,1);text-indent:12.25pt;word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;"><div style="text-indent:0.0pt;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.1701388888888889in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Extensive array of payloads available to match tumor biology for optimal tumor killing</span></div></div><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><div style="text-indent:0.0pt;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.1701388888888889in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payloads include microtubule inhibitors and DNA damaging agents whose potential mechanism of action has been shown to induce immunogenic cell death in preclinical models for combination with immunotherapy</span></div></div></td>
    <td style="background-color:rgba(204,238,255,1);text-indent:12.25pt;word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><div style="text-indent:0.0pt;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.1701388888888889in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Due to the labile nature of linkers, some conventional ADCs are built with less potent payloads</span></div></div></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forging Creative Business Models and Alliances</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We continuously evaluate a robust set of business development opportunities to build alliances with partners. The set of opportunities include, but are not limited to, joint ventures, spin-offs, discovery partnerships and licenses. Furthermore, we intend to retain the optionality to explore the potential for creative business models.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The Voxall Joint Venture</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">One such endeavor is Voxall Therapeutics, LLC, or Voxall, which is a 50:50 co-owned joint venture formed by us and Alloy Therapeutics, Inc., or Alloy, to accelerate the discovery and development of drugs to address cancer and autoimmune diseases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We bring to Voxall targets from our target catalog and expertise in stromal and immune biology while Alloy contributes its ATX-Gx transgenic mouse and other discovery services which accelerate antibody drug discovery. Both parties provide full-time employees and project execution and project oversight. Under the collaboration agreement, the parties will conduct research under a mutually agreed research plan for up to six research programs focused on mutually selected targets. With this initial wave of targets, we retain an exclusive option to obtain an exclusive license to further develop and commercialize development candidates at our discretion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional Discovery Efforts</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe our broad expertise enables us to pioneer our scientific understanding in immune biology of the TME and beyond. We have a flexible pathway to do so via platform development, forging creative business models and alliance building, in-licensing and leveraging target catalogs to expand our portfolio of differentiated therapeutics for difficult-to-treat cancers. The realization of this vision will necessitate rapid innovation and operational excellence from a scientific and business perspective. As such, our mission is to take the next step towards creating an oncology company of the future &#x2014; an oncology company unconstrained by conventional ideas and conventional practices, an oncology company that will rise to meet the many and complex challenges of difficult-to-treat cancers, and an oncology company that will have a significant impact on the lives of patients with limited effective treatment options.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Competition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The biotechnology and pharmaceutical industries, including the oncology subsector, are characterized by rapidly evolving technologies, intense competition, and a strong defense of intellectual property and proprietary technologies. Any product candidates that we successfully commercialize may be competitive with currently marketed therapies and any new therapies commercialized in the future. While we believe our technology, drug development expertise, leadership team and strong scientific understanding of cancer targets and biology provides us with certain competitive advantages, we face potential competition from many sources, including major pharmaceutical companies, biotechnology companies, academic institutions, and other public and private research institutions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many companies are active across various stages of development in the oncology subsector and are marketing and developing products that employ similar ADC and immunotherapy approaches. As of February 2023, we estimate that there are more than 500 industry-sponsored active clinical trials involving more than 140 unique ADCs, which may result in continued interest and subsequent transactions in the space. Additionally, there are several large and small companies working on various immunotherapy approaches for treatment of cancer. Multiple companies are also involved in the development of ADC therapeutics and immunotherapies, including, but not limited to, ADC Therapeutics SA, Astellas Pharma, Inc., AstraZeneca plc, Daiichi Sankyo Company, Ltd., Genentech, Inc., Gilead Sciences, Inc, GlaxoSmithKline, plc, Pfizer Inc., Rakuten Medical, Inc., Seagen, Inc., Nextcure, Inc. and Abcure, Inc.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ADC and immunotherapy candidates may face substantial competition from alternative therapeutic modalities, such as CAR-T therapies, bispecific antibodies, and small molecules that are being developed for the same cancer types that we are targeting with our pipeline candidates. These approaches could prove to be more effective, safer, or convey other advantages over any products resulting from our technology. In addition, we also face competition on specific targets, including the target of our PYX-201 candidate, EDB, from Philogen S.p.A., and the target of our PYX-106 product candidate, BSI-060T, from Nextcure, Inc.'s lead program - NC318. In November 2022, Nextcure announced that NC318 would not move forward in the Phase 2 monotherapy clinical trial, although NC318 has been observed to be safe and well-tolerated in patients. Additionally, there is a wide array of activity in the development of immunotherapies for oncology which may be competitive with our preclinical discovery programs. Furthermore, if any of our product candidates are approved in oncology indications such as lung, hematological and other cancers, they may compete with existing approaches to treating cancer including surgery, radiation, and drug therapy, including conventional chemotherapy, biological products, and targeted drug small molecule therapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our competitors may possess greater scientific, research and development capabilities, as well as greater financial, technical, manufacturing, marketing, sales and supply resources or experience than we do. These competitors compete with us on the basis of establishing clinical trial sites and patient registration, recruiting and retaining qualified scientific and management personnel, and acquiring new technologies that may be complementary to, or necessary for, our programs. Our commercial opportunity for our product candidates may be dependent on the ability of our competitors to develop new products that may be more effective, safer, or less expensive than any products that we may develop. Our competitors may succeed in developing competing products before we do, obtaining marketing approval for products and gaining acceptance for such products in the same markets that we are targeting. Smaller or earlier-stage companies that seek collaborative arrangements with large and established companies, may prove to be significant competitors. In addition, our ability to compete may be affected by the availability of reimbursement from government and other third-party payors. Competitive factors affecting the success of our programs, if approved, will likely be based on their safety and effectiveness, the timing and scope of marketing approvals, the availability and cost of supply, the depth of marketing and sales capabilities, and reimbursement coverage.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chemistry, Manufacturing and Controls</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe the manufacturing of our ADCs and monoclonal antibodies requires considerable expertise, know-how, and resources. We do not own or operate and currently have no plans to establish any cGMP compliant manufacturing facilities. We currently rely, and expect to continue to rely, on external contract manufacturing organizations, or CMOs, for the manufacture of product to support non-clinical and clinical testing, as well as for commercial manufacture if our product candidates receive marketing approval. Furthermore, the raw materials and intermediates for our product candidates may be sourced, in some cases, from a single-source supplier. As part of the manufacture and design process for our product candidates, we rely on internal scientific and manufacturing know-how and trade secrets and the know-how and trade secrets of third party manufacturers. We believe that this strategy allows us to maintain a more efficient infrastructure by eliminating the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to focus our expertise and resources on the development of our current product candidates. We maintain agreements with our CMOs that include confidentiality and intellectual property provisions to protect our proprietary rights related to our product candidates. We have personnel with significant technical, manufacturing, analytical, quality, including Current Good Manufacturing Practices, or cGMP, and project management experience to oversee our CMOs and to manage manufacturing and quality data and information for regulatory compliance purposes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercialization Plans</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We retain full commercialization rights for all our product candidates, including those obtained through exclusive collaboration agreements, with the exception of PYX-106 in Greater China (mainland China, Hong Kong, Macau and Taiwan) and the right of first negotiation granted to Pfizer for PYX-201. We have not yet established our own commercial organization or distribution capabilities because our product candidates are still in preclinical or clinical development. Should any of our candidates receive marketing approval or licensure in the United States or elsewhere, we will need to develop a plan to realize the commercial value of the approved product candidate. At the appropriate time, we plan to build our own specialized sales and marketing organization to support the sales commercialization of approved candidates in the United States. We may also pursue collaboration, co-promotion, distribution and/or other marketing arrangements with one or more third parties to commercialize our product candidates in markets outside the United States. We may also pursue these arrangements for situations in which a larger sales and marketing organization is necessary to realize the full commercial value of any approved wholly owned or collaboration product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Licensing and Collaboration Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">License Agreement with Pfizer Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2020, we entered into a license agreement, as amended, or the Pfizer License Agreement, with Pfizer Inc., or Pfizer, for worldwide development and commercialization rights to two of Pfizer&#x2019;s proprietary ADC product candidates (now referred to as PYX-201 and PYX-203), as well as other ADC product candidates directed to the licensed targets. The Pfizer License Agreement became effective for the Company in March 2021. The initial exclusively licensed targets are extra domain B (EDB of fibronectin) and CD123 and we have the option to expand the scope of our license to add other licensed targets. Pfizer also granted us a non-exclusive license to use Pfizer&#x2019;s FACT Platform technology to develop and commercialize the licensed ADCs. In March 2021, we entered into an amendment to the Pfizer License Agreement to include additional know-how within the scope of our license. Pursuant to the Pfizer License Agreement, we incurred a combined $25.0 million for license fee, consisting of an upfront fee of $5.0 million and issued 12,152,145 shares of Series B convertible preferred stock in 2021 to Pfizer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On October 6, 2022, we entered into an amended and restated license agreement, or the A&amp;R License Agreement, with Pfizer, which amends and restates the Pfizer License Agreement. Pursuant to the A&amp;R License Agreement, Pfizer granted us exclusive worldwide rights under Pfizer&#x2019;s FACT Platform technology to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates. Additional ADC targets may be licensed for a nominal upfront payment and milestones. Further, we granted the right of first negotiation to Pfizer, on an exclusive basis, to purchase or to develop, manufacture and commercialize licensed ADCs and licensed products in one or more countries directed to EDB and CD123. In accordance with the terms of the A&amp;R License Agreement, we agreed to pay $8.0 million to Pfizer and issued 2,229,654 shares of our common stock. Additionally, we will issue such number of shares of common stock 180 days following the effective date, or the Issuance Date, equivalent to $5.0 million at a per share price equal to the closing price of our common stock on the business day prior to the Issuance Date, such that Pfizer&#x2019;s ownership interest in us shall not exceed nineteen and a half percent (19.5%) with any difference in value between the value of shares and $5.0 million being payable in cash.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are also obligated to pay future contingent payments and royalties, including up to an aggregate of $665 million in milestones for the first four licensed ADCs. In addition, we are required to pay future contingent payments including development, regulatory and commercial milestones for ADCs for each additional licensed target beyond the first four licensed ADC targets developed and commercialized via the FACT Platform. Additionally, if ADC licensed products are launched, we will pay Pfizer tiered royalties on net sales of licensed products in varying royalty rates ranging from low single digits to mid-teens. Our royalty obligations apply on a licensed product-by-licensed product and country-by-country basis from first commercial sale until the latest to occur of: (1) 12 years from first commercial sale; (2) the expiration of all regulatory or data exclusivity; and (3) the expiration of the last valid claim of a licensed patent covering the licensed product in a country. We are also obligated to pay Pfizer a percentage of certain sublicensing revenue ranging from twenty percent to low-double digits based on the stage of development of the licensed product at the time of entering into the applicable sublicense.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Pfizer License Agreement, we are obligated to use commercially reasonable efforts to nominate a clinical candidate within four years of a target becoming a licensed target. We are also required to use commercially reasonable efforts to develop and seek regulatory approval for at least one licensed product directed to each licensed target in the United States and at least one other major market country (France, Germany, Italy, Japan, Spain and the United Kingdom), and to commercialize any licensed product in each such country after receiving regulatory approval. We control prosecution and enforcement with respect to any exclusively licensed patents, and Pfizer has prosecution and enforcement rights if we elect not to exercise such rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Pfizer License Agreement will remain in effect until the expiration of the last to expire royalty term, unless terminated in accordance with the following: (1) by either party for the other party&#x2019;s material breach if such party fails to cure such breach within the specified cure period; (2) by either party upon certain insolvency events of the other party; or (3) prior to receipt of the first regulatory approval for a licensed product, by us for any reason upon 90 days&#x2019; prior written notice, or after receipt of the first regulatory approval for a licensed product, by us for any reason upon one years&#x2019; prior written notice.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">License Agreement with the University of Chicago</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2020, we entered into a license agreement, or the University License Agreement, with the University of Chicago, or the University, to obtain an exclusive license under certain patents resulting from research performed, in-part, by our scientific founder, Dr. Thomas Gajewski, as well as a non-exclusive license to certain know-how and materials. Under the terms of the license, we have the exclusive global right to develop and commercialize products that are covered by a valid claim of a licensed patent, incorporate or use the licensed know-how and materials or are known to assess, modulate or utilize the activity of certain specified biological targets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In partial consideration for the license from the University, we issued to the University 48,919 shares of our common stock in 2020. Pursuant to the University License Agreement, we are obligated to pay to the University an annual maintenance fee of $10,000 commencing on the third anniversary of the effective date, potential development and commercial milestones of up to an aggregate of $7.7 million as well as running royalties on net sales of licensed products at varying rates ranging from less than one percent to the low single digits, subject to a minimum annual royalty ranging from $1.0 million to $3.0 million during certain years following the first commercial sale of a licensed product. Our royalty obligations apply on a licensed product-by-licensed product and country-by-country basis until: (1) for licensed products covered by a valid claim of a licensed patent in a given country, the expiration of such valid claims; and (2) for all other licensed products, 10 years from the first commercial sale of a licensed product in a given country. We are also obligated to pay the University a percentage of certain sublicensing revenue ranging from low- to mid-teens based on the date of entering into the applicable sublicense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the University License Agreement, we are obligated to use commercially reasonable efforts to develop and bring licensed products to market, meet certain preclinical and clinical development milestones by specific dates, and promote and sell licensed products after receipt of regulatory approval, subject to certain free and payment-based extensions. The University controls prosecution of the licensed patents at our cost and we have the first right to enforce the licensed patents subject to the University&#x2019;s backup enforcement rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The University License Agreement will remain in effect on a licensed product-by-licensed product basis until the expiration of all royalty obligations with respect to a licensed product, unless terminated in accordance with the following: (1) by the University upon 30 days&#x2019; prior written notice for any uncured payment breaches or 90 days prior written notice for all other uncured breaches; (2) by the University upon certain insolvency events or dissolution by us or any affiliate; or (3) by us in full or with respect to a particular licensed product at the end of the calendar quarter following the calendar quarter when we provide written notice of termination.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The Voxall Joint Venture with Alloy Therapeutics, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2021, we entered into definitive transaction agreements with Alloy to finance and operate Voxall, a joint venture company formed in collaboration with Alloy to leverage Pyxis Oncology&#x2019;s site-specific target catalog and Alloy&#x2019;s ATX-Gx</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:5.36pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#153;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> platform and antibody discovery services.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Voxall granted to both Pyxis Oncology and Alloy 50% of the voting membership units of Voxall in exchange for certain initial contributions. Our initial contribution included $50,000 and a non-exclusive fully paid-up license to certain intellectual property owned or controlled by us to enable the collaboration with Voxall as further described below. Alloy&#x2019;s initial contribution included $50,000 and the execution of a license agreement and a services agreement to enable the collaboration with Voxall as further described below. Voxall is governed by a board of directors consisting of an equal number of our representatives and Alloy&#x2019;s representatives. We have designated our CEO, Lara Sullivan M.D., as our board representative. The protective provisions under Voxall&#x2019;s operating agreement require the approval of both Pyxis Oncology and Alloy before Voxall may take certain actions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the formation of Voxall, we entered into a three-year research collaboration with Alloy and Voxall to identify and select certain biological targets and create development candidate antibodies directed to those targets for further preclinical development, clinical development and commercialization. Under the collaboration agreement, the parties will conduct research under a mutually agreed research plan and budget for up to six research programs focused on mutually selected targets. Each of us and Alloy will provide research support for the collaboration through separate services agreements with Voxall, which services will be paid in the form of promissory notes issued by Voxall. Voxall will own all intellectual property arising from the collaboration, subject to certain exceptions for intellectual property relating to Alloy&#x2019;s ATX-Gx</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#153;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> platform.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If a development candidate antibody under a research program meets certain mutually agreed selection criteria, we will have the exclusive option to obtain an exclusive license from Voxall to further develop and commercialize all the development candidate antibodies discovered under that research program. We may in-license one research program on certain pre-agreed financial terms. For all other in-licensed research programs, we will be obligated to pay fair market value as determined by a third-party valuation. Any research program that we do not in-license may be licensed by Voxall to a third party.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Agreements with LegoChem Biosciences, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2020, we entered into a license agreement, or the LegoChem License Agreement, and an opt-in, investment and additional consideration agreement, or the Opt-In Agreement, with LegoChem Biosciences, Inc., or LegoChem. Pursuant to the LegoChem License Agreement, we obtained worldwide (other than Korea) development and commercialization rights for LCB67, an ADC product candidate targeting DLK-1, and products containing the licensed compound. We paid $9.0 million in March 2021 to LegoChem, which was recorded as research and development expenses. Additionally, we may purchase certain initial quantities of licensed products from LegoChem for an estimated cost of $7.0 million and are also obligated to make future contingent payments including development, regulatory and commercial milestones as well as running royalties on net sales of licensed products at varying rates. In the third quarter of the calendar year 2022, we stopped the continued development of LCB67, based on review and analysis of data from the toxicity studies, and anticipated clinical use and commercial prospects of anti-DLK1 ADC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, as part of the Opt-in Agreement, LegoChem exercised an option to pay $8.0 million to us, in exchange for the right to receive a milestone payment, or the Extra Milestone Payment, of $9.6 million upon the earliest to occur of certain events, including the date of pricing or offer of the first public offering of its common stock or if we are the subject of a change in control transaction. Upon our IPO in October 2021, the extra milestone payment event triggered, and we paid $9.6 million in January 2022 to LegoChem.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">License Agreement with Biosion USA, Inc.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 28, 2022, we entered into a license agreement, or the Biosion License Agreement, with Biosion USA, Inc., or Biosion, pursuant to which we obtained an exclusive, worldwide (other than Greater China (mainland China, Hong Kong, Macau and Taiwan)) license for development, manufacture and commercialization rights for BSI-060T, a Siglec-15 targeting antibody, an IO product candidate (now referred to as PYX-106), and products containing the licensed compound. Under the terms of the Biosion License Agreement, each party granted to the other party a right of first offer to obtain an exclusive license in the other party&#x2019;s territory (Greater China for Biosion, and the rest of the world for Pyxis) to develop, manufacture and commercialize any bi-specific or multi-specific antibody any antibody-drug conjugate controlled by a party or its affiliate that inhibits, modulates or binds to Siglec-15 as an intended mechanism of action.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the Biosion License Agreement, we agreed to pay an upfront fee of $10 million and are obligated to pay future contingent payments including development, regulatory and commercial milestones up to an aggregate of $217.5 million in case of normal approval and $222.5 million in case of accelerated approval. Additionally, if products are launched, we will pay Biosion tiered royalties on net sales of licensed products in varying royalty rates ranging from low single digits to low teens. Our royalty obligations apply on a licensed product-by-licensed product and country-by-country basis from first commercial sale until the latest to occur of: (1) 12 years from first commercial sale; (2) the expiration of all regulatory or data exclusivity; and (3) the expiration of the last valid claim of a licensed patent covering the licensed product in a country. We are also obligated to pay Biosion a percentage of certain sublicensing revenue ranging from mid-double to low-double digits based on the stage of development of the licensed product at the time of entering into the applicable sublicense.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Biosion License Agreement, we are obligated to use commercially reasonable efforts to clinically develop and seek regulatory approval for at least one licensed product in the licensed territory, and to commercialize such licensed product following receipt of regulatory approval. We control prosecution and enforcement with respect to the licensed patents in the licensed territory.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Biosion License Agreement will remain in effect on a licensed product-by-licensed product and country-by-country basis until the expiration of the applicable royalty term, unless terminated in accordance with the following: (1) by either party for the other party&#x2019;s material breach if such party fails to cure such breach within the specified cure period; (2) by either party upon certain insolvency events of the other party; (3) by us for scientific or safety reasons; (4) any time following completion of our first clinical trial for a licensed product, by us for convenience; or (5) by Biosion if we cease development and commercialization activities for licensed products for a specified period of time, subject to certain exceptions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intellectual Property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our intellectual property is critical to our business, and we strive to protect it, including by obtaining and maintaining patent protection in the United States and internationally for our product candidates, new therapeutic approaches and potential indications, and other inventions that are important to our business. We also rely on trade secrets and proprietary know-how to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our patent portfolio includes patents and patent applications that are exclusively licensed from the University of Chicago, Pfizer, and Biosion, and patent applications that are owned by us. Our patent portfolio includes patents and patent applications that cover our product candidates PYX-201, PYX-203, PYX-106 and PYX-102 and the use of these candidates for therapeutic purposes in certain territories. Our proprietary technology has been developed primarily through relationships with academic institutions, Pfizer, Biosion and contract research organizations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For our product candidates, we will, in general, initially pursue patent protection covering compositions of matter and methods of use. Throughout the development of our product candidates, we seek to identify additional means of obtaining patent protection that would potentially enhance commercial success, including through additional methods of use, process of making, formulation and dosing regimen-related claims.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For all patent applications, we determine claiming strategy on a case-by-case basis. Advice of counsel and our business model and needs are always considered. We file patent applications containing claims for protection of useful applications of our proprietary technologies and any products, as well as new applications and/or uses we discover for existing technologies and products, assuming these are strategically valuable. We continuously reassess the number and type of patent applications, as well as the existing patent claims to ensure that maximum coverage and value are obtained for our processes and compositions, given existing patent office rules and regulations. Further, claims may be modified during patent prosecution to meet our intellectual property and business needs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We recognize that the ability to obtain patent protection and the degree of such protection depends on a number of factors, including the extent of the prior art, the novelty and non-obviousness of the invention and the ability to satisfy the enablement requirement of the patent laws. The patent positions of immuno-oncology companies like ours are generally uncertain and involve complex legal, scientific and factual questions. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted or further altered even after patent issuance. Consequently, we may not obtain or maintain adequate patent protection for any of our future product candidates or for our platform technology. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Any patents that we hold may be challenged, circumvented or invalidated by third parties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Regardless of the coverage we seek under our existing patent applications, there is always a risk that an alteration to the product or process may provide sufficient basis for a competitor to avoid infringement claims. In addition, the coverage claimed in a patent application can be significantly reduced before a patent is issued, and courts can reinterpret patent scope after issuance. Moreover, many jurisdictions, including the United States, permit third parties to challenge allowed or issued patents in administrative proceedings, which may result in further narrowing or even cancellation of patent claims. Moreover, we cannot provide any assurance that any patents will be issued from our pending or any future applications or that any current or future issued patents will adequately protect our products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In total, our patent portfolio, including patents licensed from the University of Chicago, Pfizer and Biosion, and patents owned by us, comprises 26 different patent families, filed in various jurisdictions worldwide, including families directed to composition of matter for antibodies and antibody drug conjugates, families directed towards the manufacture, use, and compositions of antibodies and antibody drug conjugates generally, and families directed to methods of treating cancer and identifying potential targets. Our patent portfolio as of December 31, 2022, is outlined below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Composition of Matter Patents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">PYX-201 Anti-EDB Antibody-Drug Conjugate.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> We have exclusively licensed from Pfizer a patent family for antibodies and antibody-drug conjugates that bind to the extra domain B splice variant of fibronectin, that includes four issued patents, one each in Australia, Japan, Russia, and South Korea, and pending applications in Australia, Brazil, Canada, China, Europe, Hong Kong, India, Israel, Japan, Mexico, Singapore, South Africa, and the United States that claim the composition of matter and certain methods of use with respect to PYX-201. The 20-year term of the patents in this family runs through 2037, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">PYX-203 Anti-CD123 Antibody-Drug Conjugate.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> We have exclusively licensed from Pfizer a patent family for antibodies and antibody-drug conjugates that specifically bind to CD123, that includes two issued patents in South Korea and Taiwan, and pending applications in Australia, Brazil, Canada, China, Colombia, Europe, Hong Kong, India, Indonesia, Israel, Japan, South Korea, Malaysia, Mexico, New Zealand, Peru, Philippines, Russia, Saudi Arabia, Singapore, South Africa, Taiwan, and the United States that claim the composition of matter and certain methods of use with respect to PYX-203. The 20-year term of the patents in this family runs through 2038, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">PYX-106 Anti-Siglec-15 Antibody.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> We have exclusively licensed from Biosion USA, Inc. a patent family for monoclonal antibodies that specifically bind human Siglec15, that recently entered the PCT national stage and now has pending applications in Australia, Brazil, Canada, Egypt, Europe, India, Indonesia, Israel, Japan, Malaysia, Mexico, New Zealand, Philippines, Russia, Saudi Arabia, Singapore, South Africa, South Korea, United Arab Emirates, and the United States. The 20-year term of the patent in this family runs through 2041, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GPNMB Antibodies and Methods of Use</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. We own a pending PCT application directed to compositions with binding specificity for glycoprotein nonmetastatic melanoma protein B. The 20-year term for patents in this family runs through 2042, excluding any extension of patent term that may be available. If we elect to do so, we are able to file national stage entry applications for this patent family through 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">ADC Patent Rights</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Spliceostatin analogs. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have exclusively licensed from Pfizer, subject to certain reservations, a patent family for compositions, methods of use, and/or methods of manufacture useful in antibody-drug conjugates generally, directed toward novel cytotoxic spliceostatin analogs and derivatives, to antibody drug conjugates that includes twenty-seven issued patents in Australia, Belgium, Brazil, Canada, China, Germany, Denmark, Spain, Finland, France, United Kingdom, Hong Kong, Ireland, India, Italy, Japan, South Korea, Mexico, Netherlands, Russia, Sweden, Turkey, and the United States, and no pending applications. The 20-year term of the patents in this family runs through 2033, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Tubulysin analogs and methods for their preparation. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have exclusively licensed from Pfizer, subject to certain reservations, a patent family for compositions, methods of use, and/or methods of manufacture useful in antibody-drug conjugates generally, directed toward cytotoxic tubulysin analogs and derivatives, to antibody drug conjugates thereof, that includes one issued patent in the United States, and no pending applications. The 20-year term of the patent in this family runs through 2037, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Heteroaryl Sulfone-based Conjugation Handles, Methods for Their Preparation, and Their Use in Synthesizing Antibody Drug Conjugates. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have exclusively licensed from Pfizer, subject to certain reservations, a patent family for compositions, methods of use, and/or methods of manufacture useful in antibody-drug conjugates generally, directed toward heteroaryl sulfone-based conjugation handles for use in synthesizing antibody-drug conjugates, that includes one issued patent in Canada, and pending applications in the United States, Europe and Japan. The 20-year term of the patents in this family runs through 2037, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Purification of Antibody Drug Conjugates Using a Sodium Phosphate Gradient. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have exclusively licensed from Pfizer, subject to certain reservations, a patent family for compositions, methods of use, and/or methods of manufacture useful in antibody-drug conjugates generally, directed toward methods of removing high molecular weight species, in particular aggregates, from antibody drug conjugate preparations, by contacting preparations of the antibody drug conjugate reaction mixture with a hydroxyapatite resin and selectively eluting the ADC from the resin using a gradient comprising sodium phosphate, that includes six issued patents in France, Germany, Ireland, Italy, Spain, and the United Kingdom, and a pending application in the United States. The 20-year term of the patents in this family runs through 2036, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Bifunctional Cytotoxic Agents Containing the CTI Pharmacophore. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have exclusively licensed from Pfizer, subject to certain reservations, a patent family for compositions, methods of use, and/or methods of manufacture useful in antibody-drug conjugates generally, directed toward bifunctional CTI-CTI and CBI-CTI dimers that can function as stand-alone drugs, payloads in ADCs, and linker-payload compounds useful in connection with the production or administration of such ADCs, that includes twenty-seven issued patents in Australia, Belgium, China, Denmark, Germany, Finland, France, Hong Kong, Ireland, Israel, India, Italy, Japan, Mexico, Netherlands, Norway, Russia, Singapore, South Korea, Spain, Sweden, Turkey, Taiwan, the United Kingdom, the United States and pending applications in Brazil and Canada. The 20-year term of the patents in this family runs through 2036, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Calicheamicin derivatives and antibody drug conjugates thereof. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have exclusively licensed from Pfizer, subject to certain reservations, a patent family for compositions, methods of use, and/or methods of manufacture useful in antibody-drug conjugates generally, directed toward calicheamicin derivatives useful as payloads in antibody-drug-conjugates, that includes two issued patents in Canada and Japan, and pending applications in the United States and Europe. The 20-year term of the patents in this family runs through 2038, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cysteine Engineered Antibody Drug Conjugate. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have exclusively licensed from Pfizer, subject to certain reservations, a patent family for compositions, methods of use, and/or methods of manufacture useful in antibody-drug conjugates generally, directed toward anti-CD33 antibody-drug conjugates with an engineered cysteine residue, that includes one issued patent in the United States, and no pending applications. The 20-year term of the patent in this family runs through 2038, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> Platform Patent Rights (Pyxis Oncology Managed)</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Antibodies Specific for Trop-2 and Their Uses. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have exclusively licensed from Pfizer, subject to certain reservations, a patent family for compositions, methods of use, and/or methods of manufacture related to Pfizer&#x2019;s FACT Platform, directed toward antibodies and antibodies conjugates specific for Trop-2 in treating cancer, that includes four issued patents in the United States and Japan, and no pending applications. The 20-year term of the patents in this family runs through 2032, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Engineered Polypeptide Conjugates Using Transglutaminase. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have exclusively licensed from Pfizer, subject to certain reservations, a patent family for compositions, methods of use, and/or methods of manufacture related to Pfizer&#x2019;s FACT Platform, directed toward engineered polypeptide conjugates comprising specific acyl donor glutamine-containing tags and amine donor agents, that includes twelve issued patents in Canada, France, Germany, Ireland, Italy, Japan, Spain, the United Kingdom, and the United States, and a pending application in the United States. The 20-year term of the patents in this family runs through 2034, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stability-Modulating Linkers For Use With Antibody Drug Conjugates. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have exclusively licensed from Pfizer, subject to certain reservations, a patent family for compositions, methods of use, and/or methods of manufacture related to Pfizer&#x2019;s FACT Platform, directed toward stability-modulating linker components used to make these stability-modulated antibody-drug conjugates, that includes thirty-five issued patents in Australia, Austria, Belgium, Bulgaria, Canada, China, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Luxembourg, Mexico, Netherlands, Poland, Portugal, Romania, Russia, Slovakia, Slovenia, South Korea, Spain, Sweden, Switzerland, Turkey, the United Kingdom, the United States, and pending applications in Brazil, Mexico, Russia, and the United States. The 20-year term of the patents in this family runs through 2035, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Synergistic Auristatin Combinations. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have exclusively licensed from Pfizer, subject to certain reservations, a patent family for compositions, methods of use, and/or methods of manufacture related to Pfizer&#x2019;s FACT Platform, directed toward combinations of an auristatin or an auristatin-based ADC with second active agents including PI3K/mTOR inhibitors, MEK inhibitors, taxanes, or other anti-cancer agents, that includes two issued patents in the United States and Japan, and pending applications in Canada and Europe. The 20-year term of the patents in this family runs through 2035, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Capped and Uncapped Antibody Cysteines, and Their Use in Antibody-Drug Conjugation. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have exclusively licensed from Pfizer, subject to certain reservations, a patent family for compositions, methods of use, and/or methods of manufacture related to Pfizer&#x2019;s FACT Platform, directed toward antibody production process in which engineered unpaired cysteine residues are post-translationally modified and capped with particular chemical entities, which capped antibodies are well suited to further site-specific conjugation steps to form antibody-drug conjugates, that includes thirty-six issued patents in Australia, Austria, Belgium, Bulgaria, China, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Luxembourg, Mexico, Netherlands, Poland, Portugal, Romania, Russia, Slovakia, Slovenia, South Korea, Spain, Sweden, Switzerland, Turkey, the United Kingdom, the United States, and pending applications in Brazil, Mexico, Russia, and the United States, and pending applications in Brazil, Canada, Europe, Russia and the United States. The 20-year term of the patents in this family runs through 2036, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Large Scale Production Process for Capped and Un-capped Antibody Cysteines and Their Use in Therapeutic Protein Conjugation. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have exclusively licensed from Pfizer, subject to certain reservations, a patent family for compositions, methods of use, and/or methods of manufacture related to Pfizer&#x2019;s FACT Platform, directed toward optimizing production of selectively capped, and uncapped, cysteines on antibodies by manipulation of cell growth conditions, that includes four issued patents in Canada, Japan, Russia, and South Korea, and pending applications in Australia, Brazil, China, Europe, Hong Kong, India, Israel, Mexico, and the United States. The 20-year term of the patents in this family runs through 2038, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Platform Patent Rights (Pfizer Managed)</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cytotoxic Peptides and Antibody Drug Conjugates Thereof. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have exclusively licensed from Pfizer, subject to certain reservations, a patent family currently managed by Pfizer for compositions, methods of use, and/or methods of manufacture related to Pfizer&#x2019;s FACT Platform, directed toward cytotoxic pentapeptides, to antibody drug conjugates thereof, that includes seventy-six issued patents in Australia, Austria, Belgium, Bulgaria, Canada, China, Colombia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, Iceland, Indonesia, Ireland, Israel, Italy, Japan, Luxembourg, Malaysia, Mexico, Netherlands, New Zealand, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, Slovak Republic, Slovenia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Turkey, the United Kingdom, and the United States, and pending applications in Argentina, Brazil, India, Peru, and Venezuela. The 20-year term of the patents in this family runs through 2032, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Bifunctional Cytotoxic Agents. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have exclusively licensed from Pfizer, subject to certain reservations, a patent family currently managed by Pfizer for compositions, methods of use, and/or methods of manufacture related to Pfizer&#x2019;s FACT Platform, directed toward cytotoxic dimers comprising CBI-based and/or CPI-based sub-units, antibody drug conjugates comprising such dimers, that includes forty-nine issued patents in Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Colombia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, Iceland, India, Indonesia, Ireland, Israel, Italy, Japan, Luxembourg, Malaysia, Mexico, Netherlands, New Zealand, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, Slovak Republic, Slovenia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Turkey, the United Kingdom, and the United States, and pending applications in Argentina and Venezuela. The 20-year term of the patents in this family runs through 2035, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Antibodies and Antibody Fragments for Site-Specific Conjugation.  </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have exclusively licensed from Pfizer, subject to certain reservations, a patent family currently managed by Pfizer for compositions, methods of use, and/or methods of manufacture related to Pfizer&#x2019;s FACT Platform, directed toward polypeptides, antibodies, and antigen-binding fragments thereof, that comprise a substituted cysteine for site-specific conjugation, that includes eight issued patents in China, Colombia, Japan, Russia, South Africa, South Korea, and Russia, and pending applications in Argentina, Australia, Brazil, Canada, Europe, Hong Kong, India, Indonesia, Israel, Malaysia, Mexico, New Zealand, Peru, Philippines, Saudi Arabia, Singapore, Taiwan, the United States, and Venezuela. The 20-year term of the patents in this family runs through 2036, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Engineered Antibody Constant Regions for Site-Specific Conjugation and Methods and Uses Therefor. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have exclusively licensed from Pfizer, subject to certain reservations, a patent family currently managed by Pfizer for compositions, methods of use, and/or methods of manufacture related to Pfizer&#x2019;s FACT Platform, directed toward antibodies, and antigen-binding portions thereof, engineered to introduce amino acids for site-specific conjugation, that includes issued nine issued patents in Canada, France, Germany, Ireland, Italy, Japan, Spain, the United Kingdom, and the United States, and pending applications in Canada, Europe and Japan. The 20-year term of the patents in this family runs through 2032, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Engineered Polypeptide Conjugates and Methods for Making Thereof Using Transglutaminase. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have exclusively licensed from Pfizer, subject to certain reservations, a patent family currently managed by Pfizer for compositions, methods of use, and/or methods of manufacture related to Pfizer&#x2019;s FACT Platform, directed toward engineered polypeptide conjugates comprising acyl donor glutamine-containing tags and amine donor agents, that includes six issued patents in Canada, Japan, and the United States, and pending applications in Europe and the United States. The 20-year term of the patents in this family runs through 2031, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Antibody-Drug Conjugates with High Drug Loading.  </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have exclusively licensed from Pfizer, subject to certain reservations, a patent family currently managed by Pfizer for compositions, methods of use, and/or methods of manufacture related to Pfizer&#x2019;s FACT Platform, directed toward transglutaminase-mediated antibody-drug conjugates with high anti-body-drug ratio, that includes thirty-six issued patents in Australia, Austria, Belgium, Bulgaria, Canada, China, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Luxembourg, Mexico, Netherlands, Poland, Portugal, Romania, Russia, Slovak Republic, Slovenia, South Korea, Spain, Sweden, Switzerland, Turkey, the United Kingdom, and the United States, and pending applications in Brazil, South Korea, and the United States. The 20-year term of the patents in this family runs through 2035, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Methods in Immuno-Oncology</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Methods and compositions related to T-cell activity. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have exclusively licensed from the University of Chicago a patent family that includes two issued patents in the United States and pending applications in Europe and the United States that claim methods for treating patients with immunotherapy based on the identification of the patient as having non-anergic T cells after measuring expression levels of various genes. The 20-year term for patents in this family runs through March 2034, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Beta-catenin inhibitors in cancer immunotherapy. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have exclusively licensed from the University of Chicago a patent family that includes one issued patent and one pending application in the United States that claim methods for treating solid tumor cancers. The 20-year term for patents in this family runs through March 2036, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have exclusively licensed from the University of Chicago a patent family that includes six pending applications in Canada, China, Europe, Japan, Hong Kong, and the United States that claim methods of treating cancer comprising administering an agent that specifically targets dysfunctional tumor antigen-specific CD8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">+</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> T cells. The 20-year term for patents in this family runs through January 2038, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Patent Term and Term Extensions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Individual patents have terms for varying periods depending on the date of filing of the patent application or the date of patent issuance and the legal term of patents in the countries in which they are obtained. Generally, utility patents issued for applications filed in the United States are granted a term of 20 years from the earliest effective filing date of a non-provisional patent application. In addition, in certain instances, the term of a U.S. patent can be extended to recapture a portion of the United States Patent and Trademark Office, or the USPTO, delay in issuing the patent as well as a portion of the term effectively lost as a result of the FDA regulatory review period. However, as to the FDA component, the restoration period cannot be longer than five years and the restoration period cannot extend the patent term beyond 14 years from FDA approval. In addition, only one patent applicable to an approved drug is eligible for the extension, and only those claims covering the approved drug, a method for using it, or a method of manufacturing may be extended. Similar provisions are available in Europe and other foreign jurisdictions to extend the term of a patent that covers an approved drug. We will, in general, pursue available patent term extensions in the U.S. and in foreign jurisdictions that provide for patent term extensions, however, there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment of whether such extensions should be granted, and if granted, the length of such extensions. All taxes, annuities or maintenance fees for a patent, as required by the USPTO and various foreign jurisdictions, must be timely paid in order for the patent to remain in force during this period of time.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The actual protection afforded by a patent may vary on a product-by-product basis, from country to country, and can depend upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions and the availability of legal remedies in a particular country and the validity and enforceability of the patent.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our patents and patent applications may be subject to procedural or legal challenges by others. We may be unable to obtain, maintain and protect the intellectual property rights necessary to conduct our business, and we may be subject to claims that we infringe or otherwise violate the intellectual property rights of others, which could materially harm our business. For more information, see the section titled &#x201c;Risk Factors&#x2014;Risks Related to Our Intellectual Property.&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Trademarks and Know-How</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the ongoing development and advancement of our product candidates in the United States and various international jurisdictions, we seek to create protection for our marks and enhance their value by pursuing trademarks where available and when appropriate. In addition to patent and trademark protection, we rely upon trade secrets and know-how and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, using confidentiality agreements with our commercial partners, collaborators, employees and consultants and invention assignment agreements with our employees and selected consultants. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and our trade secrets and other proprietary information may be disclosed. We may not have adequate remedies for any breach and could lose our trade secrets and other proprietary information through such a breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our consultants, contractors or collaborators use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting trade secrets, know-how and inventions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our commercial success will also depend in part on not infringing the proprietary rights of third parties. In addition, we have licensed rights under proprietary technologies of third parties to develop, manufacture and commercialize specific aspects of our future products and services. It is uncertain whether the issuance of any third-party patent would require us to alter our development or commercial strategies, alter our processes, obtain licenses or cease certain activities. The expiration of patents or patent applications licensed from third parties or our breach of any license agreements or failure to obtain a license to proprietary rights that we may require to develop or commercialize our future technology may have a material adverse impact on us. If third parties prepare and file patent applications in the United States that also claim technology to which we have rights, we may have to participate in interference proceedings in the USPTO to determine priority of invention.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For more information regarding the risks related to our intellectual property, please see &#x201c;Risk Factors&#x2014;Risks Related to Our Intellectual Property.&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, recordkeeping, serialization and tracking, promotion, advertising, distribution and marketing, post-approval or licensure monitoring and reporting, and export and import, among other things, of our product candidates are extensively regulated by governmental authorities in the United States and other countries. In the United States, the FDA regulates biological products under the Federal Food, Drug, and Cosmetic Act, or the FDCA, and its implementing regulations, and the Public Health Service Act, or the PHSA, and its implementing regulations. Failure to comply with the applicable U.S. requirements may subject us to administrative or judicial sanctions, such as the FDA&#x2019;s refusal to approve a Biologics License Application or BLA, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions and/or criminal prosecution.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Approval and Licensure Process for Biological Products</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Biological products such as ours may not be commercially marketed without prior licensure from the FDA and approval or licensure from comparable regulatory agencies in other countries. In the United States, the process for receiving such licensure is long, expensive and risky, and includes the following steps:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">preclinical laboratory tests, animal studies, and formulation studies; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">submission to the FDA of an IND application for human clinical testing, which must become effective before human clinical trials may begin; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">approval by an Institutional Review Board, or IRB, at each clinical site before each trial may be initiated; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">adequate and well-controlled human clinical trials to establish the safety, purity, and potency of the drug for each indication; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">submission to the FDA of a BLA; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">satisfactory completion of an FDA advisory committee review, if applicable; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the biological product is produced to assess compliance with cGMP; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a potential FDA audit of the preclinical and clinical trial sites that generated the data in support of the BLA; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the ability to obtain clearance or approval of companion diagnostic tests, if required, on a timely basis, or at all; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FDA review and approval of the BLA prior to any commercial marketing or sale of the drug in the United States; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">compliance with any post-approval requirements and/or commitments, including the potential requirement to implement a REMS, and the potential requirement to conduct post-approval studies. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In guidance, FDA has stated that it considers antibody-drug conjugates to be combination biological product-drug products for which a BLA should be submitted. FDA has also stated in guidance that it regulates monoclonal antibodies as biological products which require a BLA. FDA has issued guidance on product development considerations for antibody-drug conjugates, including dosing and clinical pharmacology testing recommendations.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Regulation by U.S. and foreign governmental authorities is a significant factor affecting our ability to commercialize any of our products, as well as the timing of such commercialization and our ongoing research and development activities. The commercialization of drug products requires regulatory approval by governmental agencies prior to commercialization. Various laws and regulations govern or influence the research and development, non-clinical and clinical testing, manufacturing, processing, packaging, validation, safety, labeling, storage, record keeping, registration, listing, distribution, advertising, sale, marketing and post-marketing requirements and/or commitments of our products. The lengthy process of seeking these approvals, and the subsequent compliance with applicable laws and regulations, require expending substantial resources.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The results of preclinical testing, which include laboratory evaluation of product chemistry, formulation, toxicity and carcinogenicity, animal studies to assess the potential safety, purity and potency of the product and its formulations, details concerning the drug manufacturing process and its controls, and a proposed clinical trial protocol and other information must be submitted to the FDA as part of an IND that must be reviewed and become effective before clinical testing can begin. The study protocol and informed consent information for patients in clinical trials must also be submitted to an independent IRB for approval covering each institution at which the clinical trial will be conducted. Once a sponsor submits an IND, the sponsor must wait 30 calendar days before initiating any clinical trials. If the FDA has comments or questions within this 30-day period, the issue(s) must be resolved to the satisfaction of the FDA before a clinical trial can begin. In addition, the FDA or an IRB may impose a clinical hold on ongoing clinical trials if, among other things, it believes that a clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable and significant risk to clinical trial patients. If the FDA imposes a clinical hold, clinical trials can only proceed under terms authorized by the FDA. If applicable, our preclinical and clinical studies must conform to the FDA&#x2019;s Good Laboratory Practice, or GLP, and Good Clinical Practice, or GCP, requirements, respectively, which are designed to ensure the quality and integrity of submitted data and protect the rights and well-being of study patients. Information for certain clinical trials also must be publicly disclosed within certain time limits on the clinical trial registry and results databank maintained by the National Institutes of Health, or NIH.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Typically, clinical testing involves a three-phase process; however, the phases may overlap or be combined:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 1 clinical trials typically are conducted in a small number of volunteers or patients to assess the early tolerability and safety profile, the pattern of drug absorption, distribution and metabolism, the mechanism of action in humans, and may include studies where investigational drugs are used as research to explore biological phenomena or disease processes; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 2 clinical trials typically are conducted in a limited patient population with a specific disease in order to assess appropriate dosages and dose regimens, expand evidence of the safety profile and evaluate preliminary efficacy; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 3 clinical trials typically are larger scale, multicenter, well-controlled trials conducted on patients with a specific disease to generate enough data to statistically evaluate the efficacy and safety of the product, to establish the overall benefit-risk relationship of the drug and to provide adequate information for the labeling of the drug. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A therapeutic product candidate being studied in clinical trials may be made available for treatment of individual patients, intermediate-size patient populations, or for widespread treatment use under an expanded access protocol, under certain circumstances. Pursuant to the 21st Century Cures Act, or Cures Act, which was signed into law in December 2016, the manufacturer of one or more investigational products for the diagnosis, monitoring, or treatment of one or more serious diseases or conditions is required to make available, such as by posting on its website, its policy on evaluating and responding to requests for individual patient access to such investigational product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, on May 30, 2018, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017 was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA authorization under an FDA expanded access program; however, manufacturers are not obligated to provide investigational new drug products under the current federal right to try law.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Disclosure of Clinical Trial Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sponsors of certain clinical trials of FDA-regulated products are required to register and disclose certain clinical trial information. Information related to the product, patient population, phase of investigation, trial sites and investigators, and other aspects of the clinical trial are then made public as part of the registration. Sponsors are also obligated to disclose the results of their clinical trials after completion. Competitors may use this publicly available information to gain knowledge regarding the progress of development programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Orphan Drugs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Orphan Drug Act, the FDA may grant orphan drug designation to therapeutic candidates (drugs or biological products) intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the U.S. or more than 200,000 individuals in the U.S. and for which there is no reasonable expectation that the cost of developing and making available in the U.S. a therapeutic candidate for this type of disease or condition will be recovered from sales in the U.S. for that therapeutic candidate. Orphan drug designation must be requested before submitting a marketing application for the therapeutic candidate for that particular disease or condition. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. Among the other benefits of orphan drug designation are tax credits for certain research and an exemption from the BLA application fee. The FDA may revoke orphan drug designation, and if it does, it will publicly disclose that the product is no longer designated as an orphan drug.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications, including a full BLA, to market the same biological product for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or if the FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the biological product was designated. Orphan drug exclusivity does not prevent the FDA from approving a different biological product for the same disease or condition, or the same biological product for a different disease or condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A designated orphan drug may not receive orphan drug exclusivity if it is licensed for a use that is broader than the indication for which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expedited Development and Review Programs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA has a number of programs intended to expedite the development and review of product candidates. These programs include Fast Track designation, Breakthrough Therapy designation, priority review designation, and accelerated approval. Fast Track designation is intended to expedite or facilitate the process for reviewing new biological products that meet certain criteria. Specifically, new biological products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a new biological product may request the FDA to designate the biological product as a Fast Track product at any time during the clinical development of the product. Unique to a Fast Track product, the FDA may consider for review sections of the marketing application on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the application, the FDA agrees to accept sections of the application and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the application. FDA may revoke the Fast Track designation if it believes that the designation is no longer supported by data emerging in the clinical trial process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Breakthrough Therapy program, products intended to treat a serious or life-threatening disease or condition may be eligible for Breakthrough Therapy designation, which includes eligibility for the benefits of the Fast Track program, when preliminary clinical evidence demonstrates that such product may have substantial improvement on one or more clinically significant endpoints over existing therapies. Additionally, FDA will seek to ensure the sponsor of a Breakthrough Therapy product receives timely advice and interactive communications to help the sponsor design and conduct a development program as efficiently as possible.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A product is eligible for priority review if it is intended to treat a serious condition and, if approved or licensed, it would provide a significant improvement in safety or effectiveness. FDA intends to take action on a priority review marketing application within six months of receipt, compared to 10 months of receipt for regular review submissions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, a product may be eligible for accelerated approval if it is intended to treat a serious or life-threatening disease or condition and would provide meaningful therapeutic benefit over existing treatments. Accelerated approval may be granted on the basis of adequate and well-controlled clinical studies establishing that the product has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality and is reasonably likely to predict an effect on irreversible morbidity, mortality, or other clinical benefit. As a condition of approval, the FDA may require that a sponsor of a biological product receiving accelerated approval diligently perform adequate and well-controlled clinical studies demonstrating clinical benefit, and may require that these studies by underway prior to approval under the Food and Drug Omnibus Reform Act of 2022, or FDORA. In addition, the FDA requires as a condition for accelerated approval the submission of promotional materials in advance, which could adversely impact the timing of the commercial launch of the product. Fast Track designation, Breakthrough Therapy designation, priority review and accelerated approval do not change the standards for licensure but may expedite the review process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Pediatric studies and exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Pediatric Research Equity Act of 2003, a BLA or supplement thereto must contain data that are adequate to assess the safety and effectiveness of the biological product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. With enactment of the Food and Drug Administration Safety and Innovation Act of 2012, or FDASIA, sponsors must also submit pediatric study plans prior to the assessment data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Those pediatric study plans must contain an outline of the proposed pediatric study or studies the applicant plans to conduct, including study objectives and design, any deferral or waiver requests, and other information required by regulation. The applicant, the FDA and the FDA&#x2019;s internal review committee must then review the information submitted, consult with each other and agree upon a final plan. The FDA or the applicant may request an amendment to the plan at any time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after licensure of the product for use in adults, or full or partial waivers from the pediatric data requirements. Additional requirements and procedures relating to deferral requests and requests for extension of deferrals are contained in FDASIA. Unless otherwise required by law or regulation, the pediatric data requirements do not apply to products with orphan designation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pediatric exclusivity is a type of non-patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity. This six-month exclusivity may be granted if a BLA sponsor submits pediatric data that respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#x2019;s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or patent protection cover the product are extended by six months. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot approve another application.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">FDA Review of BLAs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">After completion of the required clinical testing, a BLA is prepared and submitted to the FDA. FDA approval of the BLA is required before marketing of the product may begin in the United States. The BLA must include the results of all preclinical, clinical and other testing and a compilation of data relating to the product&#x2019;s pharmacology, chemistry, manufacture and controls. The cost of preparing and submitting a BLA is substantial. The submission of most BLAs is additionally subject to a substantial application user fee, currently $3,242,026 for BLAs requiring clinical data for fiscal year 2023, and the manufacturer and sponsor under an approved BLA are also subject to annual program fees, currently $393,933 for each prescription product. These fees are typically increased annually. Sponsors of applications for drugs granted Orphan Drug Designation are exempt from these user fees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA has 60 days from its receipt of a BLA to determine whether the application will be accepted for filing based on the agency&#x2019;s threshold determination that it is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept a BLA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth review. The FDA has agreed to certain performance goals in the review of BLAs to encourage timeliness. Applications for standard review biological products are meant to be reviewed within ten months; applications for priority review drugs are meant to be reviewed in six. Priority review can be applied to biological products that the FDA determines offer major advances in treatment or provide a treatment where no adequate therapy exists. The review process for both standard and priority review may be extended by the FDA for three additional months (&#x201c;major amendment&#x201d;) to consider certain late-submitted information, or information intended to clarify information already provided in the submission.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA is required to refer an application for a novel biological product to an advisory committee or explain why such referral was not made. An advisory committee is typically a panel that includes clinicians and other experts&#x2014;for review, evaluation and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA will inspect the facility or the facilities at which the drug is manufactured. The FDA will not license the product unless compliance with cGMPs is satisfactory, and the application meets the appropriate standard. A BLA must include data that demonstrate that the biological product is safe, pure, and potent.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">After the FDA evaluates the BLA and accompanying information and the manufacturing facilities, it issues either an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing, or information, in order for the FDA to reconsider the application. If, or when, those deficiencies have been addressed to the FDA&#x2019;s satisfaction in a resubmission of the BLA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">An approval or licensure letter authorizes commercial marketing of the biological products with specific prescribing information for specific indications. As a condition of BLA licensure, the FDA may require a risk evaluation and mitigation strategy, or REMS, to help ensure that the benefits of the biological product outweigh the potential risks. REMS can include medication guides, communication plans for healthcare professionals and elements to assure safe use, or ETASU. ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring and the use of patient registries. The requirement for a REMS can materially affect the potential market and profitability of the drug. Moreover, product licensure may require substantial post-approval testing and surveillance to monitor the drug&#x2019;s safety or efficacy. Once granted, product licenses may be withdrawn if compliance with regulatory standards is not maintained, or problems are identified following initial marketing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the FDA approves a product, it may limit the approved indications for use for the product; require that contraindications, warnings or precautions be included in the product labeling; require that post-marketing studies, including Phase 4 clinical trials, be conducted to further assess the drug&#x2019;s safety after licensure; require testing and surveillance programs to monitor the product after commercialization; or impose other conditions, including distribution restrictions or other risk management mechanisms, including REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. Changes to some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes or facilities, require submission and FDA approval, as applicable, of a new BLA or supplement before the change can be implemented. A BLA supplement for a new indication typically requires similar non-clinical and CMC data to that in the original application, and the FDA uses the same procedures and actions in reviewing supplements as it does in reviewing BLAs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Biosimilars and Reference Product Exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Biologics Price Competition and Innovation Act of 2009, or BPCIA, created an abbreviated approval pathway for biological product candidates shown to be highly similar, or &#x201c;biosimilar,&#x201d; to or interchangeable with an FDA licensed reference biological product. Biosimilarity, which requires that a product is highly similar to the reference product notwithstanding minor differences in clinically inactive components, and that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can generally be shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the interchangeable biosimilar and the reference biological product may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biological product. A product shown to be biosimilar or interchangeable with an FDA-approved reference biological product may rely in part on the FDA&#x2019;s previous determination of safety and effectiveness for the reference product for approval, which can potentially reduce the cost and time required to obtain approval to market the product. Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles and have slowed implementation of the BPCIA by the FDA.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of reference product exclusivity, another company may obtain FDA licensure and market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#x2019;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#x201c;interchangeable&#x201d; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A biological product can also obtain pediatric market exclusivity in the United States. As stated above, pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued &#x201c;Written Request&#x201d; for such a study.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, there has been discussion of whether Congress should reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate implementation of the BPCIA is subject to significant uncertainty.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Post-Licensure FDA Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Biological products manufactured or distributed pursuant to FDA licenses are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion with the product. After licensure, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and licensure. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with clinical data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Often times, even after a biological product has been licensed by the FDA for sale, the FDA may require that certain post-licensure requirements be satisfied, including the conduct of additional clinical studies. If such post-approval requirements are not satisfied, the FDA may withdraw its licensure of the biological product. In addition, holders of a biological product license are required to report certain adverse reactions to the FDA, comply with certain requirements concerning advertising and promotional labeling for their products, and continue to have quality control and manufacturing procedures conform to cGMP after approval. In addition, biological product manufacturers and their subcontractors are required to register their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements and other aspects of regulatory compliance. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Among the conditions for BLA licensure is the requirement that the manufacturing operations conform on an ongoing basis with cGMP. In complying with cGMP, we must expend time, money and effort in the areas of training, production and quality control within our own organization and at our contract manufacturing facilities. A successful inspection of the manufacturing facility by the FDA is usually a prerequisite for final licensure of a biological product. Following licensure of the BLA, we and our manufacturers will remain subject to periodic inspections by the FDA to assess continued compliance with cGMP requirements and the conditions of licensure. We will also face similar inspections coordinated by foreign regulatory authorities. The FDA periodically inspects the sponsor&#x2019;s records related to safety reporting and/or manufacturing facilities; this latter effort includes assessment of compliance with cGMP. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Once licensure is granted, the FDA may withdraw licensure if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restrictions on the marketing or manufacturing of the product, including total or partial suspension of production, complete withdrawal of the product from the market or product recalls; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fines, warning letters or holds on post-licensure clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Refusal of the FDA to license pending BLAs or supplements, or suspension or revocation of product licensure; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Product seizure or detention, or refusal to permit the import or export of products; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Mandated modification of promotional materials and labeling and the issuance of corrective information; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA closely regulates marketing, labeling, advertising and promotion of products that are placed on the market. Biological products may be promoted only for the licensed indications and in accordance with the provisions of the approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off label uses may be subject to significant liability. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#x2019;s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#x2019;s communications on the subject of off-label use of their products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the distribution of prescription drug products, including most biological products that require a prescription, are subject to the Prescription Drug Marketing Act, or the PDMA, which regulates the distribution of drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription drug product samples and impose requirements to ensure accountability in distribution.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Patent term extension</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, after BLA licensure, owners of relevant drug patents may apply for up to a five-year patent extension, which permits patent term restoration as compensation for the patent term lost during the FDA regulatory process. The allowable patent term extension is typically calculated as one-half the time between, the latter of the effective date of an IND and issue date of the patent for which extension is sought, and the submission date of a BLA, plus the time between BLA submission date and the BLA approval date up to a maximum of five years. The time can be shortened if the FDA determines that the applicant did not pursue licensure with due diligence. The total patent term after the extension may not exceed 14 years from the date of product licensure. Only one patent applicable to a licensed biological product is eligible for extension and only those claims covering the product, a method for using it, or a method for manufacturing it may be extended and the application for the extension must be submitted prior to the expiration of the patent in question. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Some, but not all, foreign jurisdictions possess patent term extension or other additional patent exclusivity mechanisms that may be more or less stringent and comprehensive than those of the United States.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">FDA approval and regulation of companion diagnostics</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A therapeutic product may rely upon an</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> companion diagnostic for use in selecting the patients that will be more likely to respond to that therapy. If safe and effective use of a therapeutic depends on an</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> diagnostic, then the FDA generally will require approval or clearance of that diagnostic, known as a companion diagnostic, at the same time that the FDA approves the therapeutic product. In August 2014, the FDA issued final guidance clarifying the requirements that will apply to approval of therapeutic products and</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> companion diagnostics. According to the guidance, for novel drugs, a companion diagnostic device and its corresponding therapeutic should be approved or cleared contemporaneously by the FDA for the use indicated in the therapeutic product&#x2019;s labeling. In July 2016, the FDA issued a draft guidance intended to assist sponsors of the drug therapeutic and</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> companion diagnostic device on issues related to co-development of the products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If FDA determines that a companion diagnostic device is essential to the safe and effective use of a novel therapeutic product or indication, FDA generally will not approve the therapeutic product or new therapeutic product indication if the companion diagnostic device is not approved or cleared for that indication contemporaneously, except for the high unmet medical need. Approval or clearance of the companion diagnostic device will ensure that the device has been adequately evaluated and has adequate performance characteristics in the intended population. The review of</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> companion diagnostics in conjunction with the review of our therapeutic product candidates will, therefore, likely involve coordination of review by the FDA&#x2019;s Center for Biologics Evaluation and Research and the FDA&#x2019;s Center for Devices and Radiological Health.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the FDCA,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> diagnostics, including companion diagnostics, are regulated as medical devices. In the United States, the FDCA and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. Unless an exemption applies, diagnostic tests require marketing clearance or approval from the FDA prior to commercial distribution. The three primary types of FDA marketing authorization applicable to a medical device include premarket notification, also called 510(k) clearance, premarket approval, or PMA, and De Novo classification requests. The FDA has generally required</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> companion diagnostics intended to select the patients who will respond to cancer treatment to obtain a PMA for that diagnostic simultaneously with approval of the drug.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The PMA process, including the gathering of clinical and preclinical data and the submission to and review by the FDA, can take several years or longer. It involves a rigorous premarket review during which the applicant must prepare and provide the FDA with reasonable assurance of the device&#x2019;s safety and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing and labeling. PMA applications are subject to an application fee of $441,547 for most PMAs for fiscal year 2023. Medical device establishments are also subject to annual registration fees, currently $6,493, and class III devices are subject to annual fees for periodic reporting, currently $15,454. FDA requires lower fee amounts for businesses certified by the Center for Devices and Radiological Health as a small business. In addition, PMAs for certain devices must generally include the results from extensive preclinical and adequate and well-controlled clinical trials to establish the safety and effectiveness of the device for each indication for which FDA approval is sought. In particular, for a diagnostic, a PMA application typically requires data regarding analytical and clinical validation studies. As part of the PMA review, the FDA will typically inspect the manufacturer&#x2019;s facilities for compliance with the Quality System Regulation, or QSR, which imposes elaborate testing, control, documentation and other quality assurance requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PMA approval is not guaranteed, and the FDA may ultimately respond to a PMA submission with a not approvable determination based on deficiencies in the application and require additional clinical trial or other data that may be expensive and time-consuming to generate and that can substantially delay approval. If the FDA&#x2019;s evaluation of the PMA application is favorable, the FDA typically issues an approvable letter requiring the applicant&#x2019;s agreement to specific conditions, such as changes in labeling, or specific additional information, such as submission of final labeling, in order to secure final approval of the PMA. If the FDA&#x2019;s evaluation of the PMA or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue a not approvable letter. A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the PMA approvable. The FDA may also determine that additional clinical trials are necessary, in which case the PMA approval may be delayed for several months or years while the trials are conducted and then the data submitted in an amendment to the PMA. If the FDA concludes that the applicable criteria have been met, the FDA will issue a PMA for the approved indications, which can be more limited than those originally sought by the applicant. The PMA can include post-approval conditions that the FDA believes necessary to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling, promotion, sale and distribution, and the requirement for post approval studies as well as post-marketing surveillance. Once granted, PMA approval may be withdrawn by the FDA if compliance with post approval requirements, conditions of approval or other regulatory standards are not maintained, or problems are identified following initial marketing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">After a device is placed on the market, it remains subject to significant regulatory requirements. Medical devices may be marketed only for the uses and indications for which they are cleared or approved. Device manufacturers must also establish registration and device listings with the FDA. A medical device manufacturer&#x2019;s manufacturing processes and those of its suppliers are required to comply with the applicable portions of the QSR, which cover the methods and documentation of the design, testing, production, processes, controls, quality assurance, labeling, packaging and shipping of medical devices. Manufacturers are also subject to medical device reporting requirements as well as reporting certain requirements related to device corrections and removals. Domestic facility records and manufacturing processes are subject to periodic unscheduled inspections by the FDA. The FDA also may inspect foreign facilities that export products to the U.S.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Foreign Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to regulations in the United States, we will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our product candidates to the extent we choose to sell any products outside of the United States. Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities and, if required, from independent ethics committees in foreign countries before we can commence clinical trials as well as regulatory approvals prior to marketing the product candidates in those countries. The approval processes vary from country to country and the time may be longer or shorter than that required for FDA approval. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country. As in the United States, post-approval regulatory requirements, such as those regarding product manufacture, marketing, or distribution would apply to any product that is approved outside the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Healthcare Laws</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Among others, the FDA, U.S. Department of Health and Human Services, or HHS, Office of Inspector General, the Centers for Medicare and Medicaid Services, or CMS, and comparable regulatory authorities in state and local jurisdictions and in other countries impose substantial and burdensome requirements upon companies involved in the preclinical and clinical development, manufacture, marketing, and distribution of drugs such as those we are developing. These agencies and other federal, state, and local entities regulate, among other activities, the research and development, testing, manufacture, quality control, safety, effectiveness, labeling, storage, record keeping, approval, sales, commercialization, marketing, advertising and promotion, distribution, post-approval monitoring and reporting, sampling, and export and import of our product candidates. Any drug candidates that we develop must be approved by the FDA before they may be legally marketed in the United States and by the appropriate foreign regulatory agency before they may be legally marketed in those foreign countries. Generally, our activities in other countries will be subject to regulation that is similar in nature and scope as that imposed in the United States, although there can be important differences. Additionally, some significant aspects of regulation in the European Union, or EU, are addressed in a centralized way, but country-specific regulation remains essential in many respects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although we do not currently have any products on the market, in addition to FDA restrictions on marketing of pharmaceutical products, we are also subject to healthcare statutory and regulatory requirements and enforcement by the U.S. federal and state governments. Pharmaceutical companies like us are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Such regulation may constrain the financial arrangements and relationships through which we research, develop, and, ultimately, sell, market, and distribute any products for which we obtain marketing approval. Such laws include, without limitation:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal Anti-Kickback Statute, an intent-based criminal statute that prohibits, among other activities, persons and entities from knowingly and willfully soliciting, offering, paying, receiving, or providing any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order, or recommendation of, any item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as Medicare or Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. A conviction for violation of the federal Anti-Kickback Statute can result in criminal fines and/or imprisonment and requires mandatory exclusion from participation in federal health care programs. Exclusion may also be imposed if the government determines that an entity has committed acts that are prohibited by the federal Anti-Kickback Statute.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal civil and criminal false claims laws, including the civil False Claims Act, or FCA, which prohibit individuals or entities from, among other activities, knowingly presenting, or causing to be presented, to the federal government claims for payment or approval that are false, fictitious, or fraudulent; knowingly making, using, or causing to be made or used, a false statement or record material to a false or fraudulent claim or obligation to pay or transmit money or property to the federal government; or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay money to the federal government. In addition, the government may assert that a claim that includes items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. Moreover, pharmaceutical manufacturers can be<br />held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to<br />&#x201c;cause&#x201d; the submission of false or fraudulent claims. The FCA also permits a private individual acting as a &#x201c;whistleblower&#x201d; to bring </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">qui tam </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery or settlement. FCA liability is potentially significant in the healthcare industry<br />because the statute provides for treble damages and significant mandatory penalties per false or fraudulent claim or<br />statement for violations. Criminal penalties, including imprisonment and criminal fines, are also possible for making<br />or presenting a false, fictitious or fraudulent claim to the federal government.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal civil monetary penalties laws, which prohibit, among other activities (1) arranging for or contracting with an individual or entity that is excluded from participation in federal healthcare programs to provide items or services reimbursable by a federal healthcare program, (2) failing to report and return a known overpayment, or (3) offering or transferring any remuneration to a Medicare or Medicaid beneficiary if the person knows or should know it is likely to influence the beneficiary&#x2019;s selection of a particular provider, practitioner, or supplier of items or services reimbursable by Medicare or Medicaid, unless an exception applies. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal criminal statutes enacted under the Health Insurance Portability and Accountability Act of 1996, or HIPAA, which impose criminal liability for knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program; knowingly and willfully embezzling or stealing from a healthcare benefit program; willfully preventing, obstructing, misleading, or delaying a criminal investigation of a healthcare offense; and knowingly and willfully falsifying, concealing, or covering up a material fact or making any materially false statements in connection with the delivery of or payment for healthcare benefits, items, or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal Physician Payments Sunshine Act, enacted as part of the Patient Protection and Affordable Care Act, which imposes annual reporting requirements for &#x201c;applicable manufacturers,&#x201d; meaning certain manufacturers of drugs, devices, biological products, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#x2019;s Health Insurance Program. The law requires applicable manufacturers to disclose certain payments and other &#x201c;transfers of value&#x201d; provided to &#x201c;covered recipients,&#x201d; which include U.S.-licensed physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, anesthesiologist assistants, certified nurse midwives, and U.S. teaching hospitals. The law also requires applicable manufacturers to disclose certain ownership and investment interests held by U.S.-licensed physicians and their immediate family members.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDCA and PHSA, which regulate licensure of biological products and prohibit the misbranding and adulteration of biological products. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply with respect to healthcare items or services reimbursed by non-governmental third-party payors and may be broader than their federal equivalents; state and foreign laws requiring pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and/or the relevant compliance guidance promulgated by the federal government or otherwise restricting payments that may be made to healthcare providers; state laws and regulations requiring drug manufacturer disclosures to state agencies and/or commercial purchasers with respect to certain price increases; state and foreign laws requiring drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers and restricting marketing practices or requiring disclosure of marketing expenditures and pricing information; and state and local laws that requiring registration of pharmaceutical sales representatives. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Violations of any of these laws or any other applicable laws or regulations may result in significant penalties, including, without limitation, administrative, civil, and criminal penalties, damages, fines, disgorgement, the curtailment or restructuring of operations, integrity oversight and reporting obligations to resolve allegations of noncompliance; exclusion from participation in federal and state healthcare programs, such as Medicare and Medicaid; and imprisonment. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming and can divert a company&#x2019;s attention from its business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Coverage and Reimbursement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales of any pharmaceutical product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a payor-by-payor basis. These third-party payors are increasingly reducing coverage and reimbursement for healthcare items (including drugs) and services. Moreover, for products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself may or may not be available. Instead, the hospital or administering physician may be reimbursed only for providing the treatment or procedure in which our product is used.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the U.S. government, states, and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement, and requirements for substitution of lower-cost or generic products. Adoption of price controls and cost-containment measures and adoption of more restrictive policies in jurisdictions with existing controls and measures could further limit sales of any drug product. Decreases in third-party reimbursement for any drug product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the product and also have a material adverse effect on sales.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, as a condition of participating in, and having products covered under, certain federal healthcare programs, such as Medicare and Medicaid, we may become subject to federal laws and regulations that require pharmaceutical manufacturers to calculate and report certain pricing metrics to the government, including the Average Manufacturer Price, or AMP, and Best Price under the Medicaid Drug Rebate Program, the Medicare Average Sales Price, the 340B Ceiling Price, and Non-Federal AMP reported to the Department of Veteran Affairs, and with respect to Medicaid, pay statutory rebates on utilization of manufacturers&#x2019; products by Medicaid beneficiaries. Compliance with these laws and regulations will require significant resources and may have a material adverse effect on our revenues.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">56</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Healthcare Reform</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively the ACA, was enacted in the United States, which made a number of substantial changes in the way healthcare is financed by both governmental and private insurers. Among other ways in which it may affect our business, the ACA established a new Patient-Centered Outcomes Research Institute to oversee and identify priorities in comparative clinical effectiveness research in an effort to coordinate and develop such research; implemented payment system reforms including a national pilot program on payment bundling to encourage hospitals, physicians and other healthcare providers to improve the coordination, quality and efficiency of certain healthcare services through bundled payment models; implemented the federal Physician Payments Sunshine Act; and expanded the eligibility criteria and rebates for Medicaid programs.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since its enactment, there have been executive, judicial and legislative branch challenges to certain aspects of the ACA. For example, while Congress has not passed comprehensive repeal legislation, two bills affecting the implementation of certain taxes under the ACA have been signed into law, including the repeal, effective January 1, 2019, of the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#x201c;individual mandate.&#x201d; Additionally, on June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#x2019;s decision, President Biden had issued an executive order that instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, policies that create barriers to obtaining access to health insurance coverage through the ACA marketplaces. It is unclear how healthcare reform measures enacted by Congress or implemented by the Biden administration or other efforts to challenge, repeal or replace the ACA, if any, will impact the ACA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other legislative changes have been proposed and adopted in the U.S. since the ACA was enacted. These changes include the Budget Control Act of 2011, which, among other changes, led to aggregate reductions in Medicare payments to providers of up to 2% per fiscal year that started in April 2013 and, due to subsequent legislation, will continue into 2031 (with the exception of a temporary suspension instituted during the COVID-19 pandemic that halted the sequestration from May 1, 2020 to March 31, 2022, and later reduced the reductions to 1% from April 1, 2022 until July 1, 2022). To offset the temporary suspension during the COVID-19 pandemic, in 2030, reductions in Medicare payments will be 2.25% for the first half of the year, and 3% in the second half of the year. In addition, the American Rescue Plan Act of 2021 eliminated the statutory cap on drug manufacturers&#x2019; MDRP rebate liability effective January 1, 2024. Under current law, enacted as part of the ACA, drug manufacturers&#x2019; MDRP rebate liability is capped at 100% of AMP for a covered outpatient drug. However, beginning in 2024, drug manufacturers&#x2019; MDRP rebate liability may exceed 100% of AMP if the price of a covered outpatient increases faster than the rate of inflation.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, in August 2022, President Biden signed into law the Inflation Reduction Act of 2022, or the IRA, which implements substantial changes to the Medicare program, including drug pricing reforms and the creation of new Medicare inflation rebates. Namely, the IRA (1) imposes inflation rebates on drug manufacturers for products reimbursed under Medicare Parts B and D if the prices of those products increase faster than inflation; (2) implements changes to the Medicare Part D benefit that, beginning in 2025, will cap beneficiary annual out-of-pocket spending at $2,000, while imposing new discount obligations for pharmaceutical manufacturers; and, (3) beginning in 2026, establishes a &#x201c;maximum fair price&#x201d; for a fixed number of high expenditure pharmaceutical and biological products covered under Medicare Parts B and D following a price negotiation process with CMS.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On February 2, 2022, the Biden Administration signaled its continued commitment to the Cancer Moonshot initiative, which was initially launched in 2016. In its announcement, the administration noted that its new goals under the initiative include addressing inequities in order to ensure broader access to cutting-edge cancer therapeutics and investing in a robust pipeline for new treatments. Additionally, on October 14, 2022, President Biden also issued an Executive Order on Lowering Prescription Drug Costs for Americans, which instructed the Secretary of the HHS to consider whether to select for testing by the CMS Innovation Center new health care payment and delivery models that would lower drug costs and promote access to innovative drug therapies for beneficiaries enrolled in the Medicare and Medicaid programs. Most recently, on February 14, 2023, the HHS issued a report in response to the October 14, 2022 Executive Order, which, among other things, selects three potential drug affordability and accessibility models to be tested by the CMS Innovation Center. Specifically, the report addresses: (1) a model that would allow Part D Sponsors to establish a &#x201c;high-value drug list&#x201d; setting the maximum co-payment amount for certain common generic drugs at $2; (2) a Medicaid-focused model that would establish a partnership between CMS, manufacturers, and state Medicaid agencies that would result in multi-state outcomes-based agreements or certain cell and gene therapy drugs; and (3) a model that would adjust Medicare Part B payment amounts for Accelerated Approval Program drugs to advance the developments of novel treatments.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Meanwhile, individual states in the U.S. have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures. In some cases, states have also encouraged importation of pharmaceutical and biological products from other countries and employed bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could adversely affect our business prospects, financial condition, and results of operations. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates or put pressure on our product pricing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect that additional state and federal healthcare reform and/or drug pricing measures will be adopted in the future, any of which could affect the pricing and/or availability of drug products, the amounts that federal and state governments and other third-party payors will pay for healthcare products and services, and/or our ability to generate revenue, attain or maintain profitability, or commercialize products for which we may receive regulatory approval in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Data Privacy &amp; Security</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Numerous state, federal and foreign laws and regulations govern the collection, dissemination, use, access to, privacy and security of personal information (including health-related information). Such laws and regulations that could apply to our operations or the operations of our partners include health information privacy and security laws (e.g., HIPAA), federal and state consumer protection laws and regulations (e.g., Section 5 of the Federal Trade Commission Act), state privacy laws (e.g., the California Consumer Privacy Act, or CCPA, as modified by the California Consumer Privacy Rights Act, or CPRA, in 2023; the Virginia Consumer Data Protection Act which went into effect in 2023), data breach notification laws, and the EU General Data Protection Regulation. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employees and Human Capital Management</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We view our values of &#x201c;Be Clever,&#x201d; &#x201c;Be of Service,&#x201d; &#x201c;Be Gutsy,&#x201d; &#x201c;Be Tenacious,&#x201d; and &#x201c;Be You,&#x201d; as a mandate for excellence and the foundation for our success. These values create a culture that focuses on science and patients and promotes trust, teamwork, and celebration. As of March 22, 2023, we employed 75 full-time permanent employees. Of these employees, approximately 49% have advanced degrees including Ph.D., M.D., M.B.A., J.D. and approximately 69% were engaged in research and development activities. More than half of our workforce and our executive leadership is comprised of women. None of our employees are represented by a labor union or covered by a collective bargaining agreement. We consider our relationship with our employees to be good.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We consider the intellectual capital of our employees to be an essential driver of our business. Our workforce expanded during fiscal year 2022; new employees were hired to support our clinical and preclinical work, with additions in our research, clinical development, clinical operations and general and administrative functions. We continually evaluate our business needs and opportunities and strive to balance inhouse expertise and capacity with outsourced expertise and capacity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Strategy</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our human capital resource objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our employees. We believe that our continued success is directly due to the commitment, engagement and performance of our employees. We strive to attract and retain experienced operators, oncology experts, clinicians, and biopharma veterans with deep market knowledge and insights with an uncompromising vision of delivering solutions for patients. In order to achieve this, we provide an inclusive and empowering work environment, foster a culture built on diversity, equity and inclusion, reward performance and leadership skills, and by offering competitive compensation and benefits programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Culture and Employee Engagement</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also place a high value on the diversity of our team, including gender, background and expertise, to foster our culture of innovation. Our employees are guided by our Code of Conduct, which sets basic requirements for business conduct and serves as a foundation for our policies, procedures and guidelines, all of which provide additional guidance on expected employee behaviors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> Compensation and Benefits</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Drug development is a complex endeavor which requires deep expertise and experience across a broad array of disciplines. Biotechnology and pharmaceutical companies both large and small compete for a limited number of qualified applicants to fill specialized positions. As part of our total rewards philosophy, we offer competitive compensation and benefits to attract and retain top talent. We are committed to fair and equitable treatment in our compensation and benefits for employees at all levels. Our total rewards offerings include an array of programs to support our employees' financial well-being, including annual performance incentive opportunities, retirement savings programs, health and welfare benefits, paid time off and flexible work schedules. We also allow our employees to participate in equity incentive plans. The principal purposes of our equity incentive plans are to align the interests of our stockholders and those eligible for awards, to retain and incentivize officers, directors, employees, and other service providers and to encourage them to act in our long-term best interests.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Ongoing Professional Development</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We focus on attracting, retaining and cultivating talented individuals. We provide reimbursement and time for employees to attend professional development courses ranging from technical training, competency-based workshops, and leadership development programs. Direct managers also take an active role in identifying individualized development plans to assist their employees in realizing their full potential and creating opportunities for promotions and added responsibilities that enhance the engagement and retention of our workforce. We are committed to maintaining and increasing our investment in our workforce as we grow, including improvements in the way we hire, develop, motivate and retain employees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Safety and Well-Being</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee health and safety in the workplace is one of our main priorities. As a result of the new challenges the COVID-19 pandemic brought, we took various steps to support our employees, including transitioning to remote work and offering flexible schedules. At the same time, we protected our facility-dependent employees, including those needed to maintain our research and development activities, by instituting strict protocols designed to ensure a healthy environment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">     </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Board of Directors Oversight</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Board of Directors, or the Board, recognizes the critical importance of our team and the necessity to ensure a diverse, inclusive, and innovative work environment that is centered around a values-based culture. Our Board meets regularly with management to discuss issues impacting our employees, and to focus on ways to support our workforce. Our focus on culture comes from our Board and flows throughout our company. In evaluating our Chief Executive Officer and management team, significant emphasis is place on their contributions to our overall culture.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Board&#x2019;s Compensation Committee is responsible for reviewing with management our human resources activities, which include, among other things, matters relating to employee development, management and engagement, pay equity, and our demographics, diversity and inclusion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Board&#x2019;s Nominating and Corporate Governance Committee is responsible for developing and recommending to the Board any company program relating to corporate responsibility and sustainability, including environmental, social and governance matters.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate Information</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We were incorporated in the state of Delaware on June 11, 2018 and launched with our first employee and Series A funding in July 2019. Our principal executive offices are located at 150 Cambridgepark Drive, Cambridge, Massachusetts 02140, and our telephone number is (617) 221-9059. Our website address is www.pyxisoncology.com.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information in, or that can be accessed through, our website is not a part of this Annual Report on Form 10-K. Our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 12(a) or 15(d) of the Exchange Act are available, free of charge, on or through our website as soon as reasonably practicable after such reports and amendments are electronically filed with or furnished to the SEC. The SEC maintains an Internet site that contains, reports, proxy and information statements and other information regarding our filings at sec.gov. The contents of these websites are not incorporated into this filing. Further, references to the URLs for these websites are intended to be inactive textual references only.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1A. Ris</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">k Factors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business involves a high degree of risk. You should consider and read carefully all of the risks and uncertainties described below, as well as other information included in this Annual Report on Form 10-K, including our financial statements and related notes appearing at the end of this Annual Report on Form 10-K. The risks described below are not the only ones facing us. The occurrence of any of the following risks or additional risks and uncertainties not presently known to us or that we currently believe to be immaterial could materially and adversely affect our business, financial condition or results of operations. In such case, the trading price of our common stock could decline, and you may lose all or part of your investment. This Annual Report on Form 10-K also contains forward-looking statements and estimates that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of specific factors, including the risks and uncertainties described below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Financial Position and Need for Additional Capital</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a clinical stage biopharmaceutical company with a limited operating history and have incurred significant losses since our inception. We expect to incur losses over at least the next several years and may never achieve or maintain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a clinical stage biopharmaceutical company with a limited operating history. Since our inception, we have incurred significant operating losses. We reported net losses of $120.7 million and $76.0 million for the years ended December 31, 2022 and 2021, respectively. As of December 31, 2022, we had an accumulated deficit of $212.4 million. To date, we have not generated any revenue from product sales and have financed our operations primarily through sales of our equity interests. As such, we expect that it will be several years, if ever, before we have a product candidate ready for regulatory licensure and commercialization. We may never succeed in these activities and, even if we do, may never generate revenues that are significant enough to achieve profitability. To become and remain profitable, we must succeed in developing, obtaining marketing licensure for and commercializing products that generate significant revenue. This will require us to be successful in a range of challenging activities, including, without limitation, procuring clinical- and commercial-scale manufacturing, successfully completing preclinical studies and clinical trials of our product candidates, establishing arrangements with third parties for the conduct of our clinical trials, obtaining marketing licensure for our product candidates, manufacturing, marketing and selling any products for which we may obtain marketing licensure, discovering or obtaining rights to additional product candidates, identifying collaborators to develop product candidates we identify or additional uses of existing product candidates and successfully completing development of product candidates for our collaboration partners.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect to continue to incur significant expenses and increasing operating losses for at least the next several years. We anticipate that our expenses will increase substantially if and as we:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">manufacture product candidates and continue to develop and conduct clinical trials for our ADC product candidate, PYX-201, and our IO product candidate, PYX-106;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">select antibody programs to take into development, manufacture product candidates, conduct IND enabling studies and submit INDs and initiate Phase 1 clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">initiate, conduct and successfully complete later-stage clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">scale up external manufacturing capabilities for later stage trials and to commercialize our products; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seek marketing licenses for any product candidates that successfully complete clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ultimately establish a sales, marketing and distribution infrastructure for which we may obtain marketing licensure; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">leverage the FACT Platform to identify and then advance additional product candidates into preclinical and clinical development; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expand, maintain and protect our intellectual property portfolio;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">hire additional clinical, regulatory, scientific, operational, financial and management information personnel; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">continue to operate as a public company. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our expenses could increase beyond our expectations if we are required by the U.S. Food and Drug Administration, or FDA, the European Medicines Agency, or EMA, or other comparable regulatory authorities to perform trials in addition to those that we currently expect to perform, or if we experience any delays in establishing appropriate manufacturing arrangements for completing our planned clinical trials or the clinical development of any of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses we will incur or when, if ever, we will be able to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts or continue operations. A decline in the value of our company, or in the value of our common stock, could also cause investors to lose all or part of their investment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing those approved product candidates. Even if we are able to generate revenues from the sale of any approved products, we may not become profitable and may need to obtain additional funding to continue operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce or eliminate one or more of our research and product development programs or future commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The development of biopharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive and uncertain process that takes years to complete. Our operations have consumed substantial amounts of cash since inception, and we expect our expenses to increase in connection with our ongoing activities, particularly as we continue our clinical trials of our product candidates PYX-201 and PYX-106 and advance our other preclinical research and development programs. For example, to refocus development efforts and spending towards our two most advanced programs, PYX-201 and PYX-106, we have elected to pause preclinical development of PYX-203 and PYX-102. Even if one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with sales, marketing, manufacturing and distribution activities. Our expenses could increase beyond expectations if we are required by the FDA, the EMA or other comparable regulatory authorities to perform clinical trials or preclinical studies in addition to those that we currently anticipate. Other unanticipated costs may also arise. Because the design and outcome of our planned and anticipated clinical trials are highly uncertain, we cannot reasonably estimate the actual amount of resources and funding that will be necessary to successfully complete the development and commercialization of any product candidate we develop. Accordingly, we will need to obtain substantial additional funding in order to continue our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we had approximately $179.3 million in cash and cash equivalents. Based on our current operating plan, we estimate that our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements into the first half of the calendar year 2025. Our estimate as to how long we expect to be able to continue to fund our operations is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We intend to use our cash and cash equivalents for development and regulatory activities relating to our product candidates, discovery programs, business development activities and other general corporate purposes. Advancing the development of our product candidates will require a significant amount of capital. Our cash and cash equivalents will not be sufficient to fund any of our product candidates through regulatory licensure. Because the length of time and activities associated with successful research and development of any individual product candidate are highly uncertain, we are unable to estimate the actual funds we will require for development, marketing licensure and commercialization activities. The timing and amount of our operating expenditures will depend largely on:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the manufacture of product candidates and conduct of Phase 1 clinical trials for PYX-201 and PYX-106;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing and progress of our other preclinical and clinical development activities; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the number and scope of other preclinical and clinical programs we decide to pursue; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the progress of the development efforts of parties with whom we have entered or may in the future enter into in-licensing, collaborations and research and development agreements; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing licensure; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to maintain our current licenses and research and development programs and to establish new collaboration arrangements; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs involved in prosecuting, maintaining and enforcing patent and other intellectual property rights; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any delays or interruptions that we experience in our preclinical studies, future clinical trials and/or supply chain; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost and timing of regulatory licenses; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our efforts to hire additional clinical, regulatory, scientific, operational, financial and management personnel. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are unable to obtain funding on a timely basis or on acceptable terms, we may have to delay, reduce or terminate our research and development programs and preclinical studies or clinical trials, if any, limit strategic opportunities or undergo reductions in our workforce or other corporate restructuring activities. We also could be required to seek funds through arrangements with collaborators or others that may require us to relinquish rights to some of our technologies or product candidates that we would otherwise pursue on our own. We do not expect to realize revenue from sales of products or royalties from licensed products in the foreseeable future, if at all, and not until our product candidates are clinically tested, licensed for commercialization and successfully marketed. To date, we have primarily financed our operations through the sale of equity securities. We will be required to seek additional funding in the future and our ability to raise additional funds will depend on financial, economic and other factors, many of which are beyond our control. Additional funds may not be available to us on acceptable terms or at all. For example, market volatility resulting from global economic developments, political unrest, high inflation, the COVID-19 pandemic and other factors could adversely impact our ability to access capital as and when needed. If we raise additional funds by issuing equity securities, our stockholders will suffer dilution and the terms of any financing may adversely affect the rights of our stockholders. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adverse developments affecting the financial services industry, including events or concerns involving liquidity, defaults or non-performance by financial institutions or transactional counterparties, could adversely affect our business, financial condition or results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. Most recently, on March 10, 2023, Silicon Valley Bank (&#x201c;SVB&#x201d;) was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) as receiver. Similarly, on March 12, 2023, Signature Bank and Silvergate Capital Corp. were each swept into receivership. Although we assess our banking and customer relationships as we believe necessary or appropriate, our access to funding sources and other credit arrangements in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that affect us, the financial services industry or economy in general. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all. Any decline in available funding or access to our cash and liquidity resources could, among other risks, adversely impact our ability to meet our operating expenses, financial obligations or fulfill our other obligations, result in breaches of our contractual obligations or result in violations of federal or state wage and hour laws. Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors not described above, could have material adverse impacts on our liquidity and our business, financial condition or results of operations</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We incorporated in 2018 and staffing and meaningful operations commenced in mid-2019 and our operations to date have been focused on developing and conducting preclinical and, since the first quarter of 2023, initiating Phase 1 clinical trials of our product candidates. To date, we have not yet demonstrated our ability to successfully complete a clinical trial, obtain marketing licenses, manufacture a commercial scale product directly or through a third party, or conduct sales, marketing, and distribution activities necessary for successful product commercialization. Consequently, any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history or if we had already successfully completed some or all of these types of activities</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, as a clinical stage biopharmaceutical company, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown challenges. We will need to transition at some point from a company with a research and development focus to a company capable of supporting commercial activities and we may not be successful in making that transition.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect our financial condition and operating results to continue to fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any quarterly or annual periods as indications of future operating performance.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to the Discovery and Development of our Product Candidates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are heavily dependent on the success of PYX-201 and PYX-106, which are in the early stages of development, and if PYX-201 and/or PYX-106 are not successful in clinical trials or do not receive regulatory approval or licensure or are not successfully commercialized, our business will be materially and adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To date, we have invested a significant portion of our efforts and financial resources in the development of PYX-201 and PYX-106. Our future success is substantially dependent on our ability to successfully initiate and complete clinical development for, obtain regulatory licensure for, and successfully commercialize PYX-201 and PYX-106 which may never occur. We currently have no products that are approved or licensed for commercial sale and may never be able to develop a marketable product. We expect that a substantial portion of our efforts and expenditures over the next few years will be devoted to PYX-201 and PYX-106 which will require clinical development, management of clinical and manufacturing activities, regulatory licensure, establishing commercial scale manufacturing, and significant sales, marketing, and distribution efforts before we can generate any revenues from any commercial sales. We cannot be certain that we will be able to successfully complete any of these activities or that, even if PYX-201 and PYX-106 receive regulatory licensure, such products will be able to successfully compete against therapies and technologies offered by other companies.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The research, testing, manufacturing, labeling, licensure, sale, packaging, marketing, and distribution of biological products are subject to extensive regulation by the FDA and comparable regulatory authorities in other countries. We are not permitted to market PYX-201 and PYX-106 in the United States until we receive licensure of a Biologics License Application, or BLA, from the FDA for such product candidates, as appropriate. Further, we are not permitted to market PYX-201 and PYX-106 in any foreign countries until we receive the requisite licensure or approvals from such countries. We have not submitted a BLA to the FDA or comparable applications to any other comparable regulatory authorities for PYX-201 and PYX-106. We will not be in a position to do so for several years, if ever. If we are unable to obtain the necessary regulatory licensure or approvals for PYX-201 and PYX-106 in a country, we will not be able to commercialize such product candidate in that country. As a result, our financial position will be materially adversely affected, and we may not be able to generate sufficient revenue to continue our business.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product candidates may fail in development or suffer delays that materially and adversely affect their commercial viability. If we or our existing or future collaborators are unable to initiate and complete clinical development of, obtain regulatory approval or licensure for or commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have no products on the market and only two of our product candidates are currently in early stages of clinical development. As a result, their risk of failure is high. Our ability to achieve and sustain profitability depends on obtaining regulatory licensure for and successfully commercializing our product candidates, either alone or with third parties. Before obtaining regulatory licensure for the commercial distribution of our product candidates, we or an existing or future collaborator must conduct extensive preclinical studies and clinical trials to demonstrate the safety, purity and potency in humans of our product candidates. In addition, the development of novel antibodies is complex and difficult. Although our discovery and preclinical programs may initially show promise in identifying potential product candidates, they may not translate into product candidates for clinical development for a number of reasons, including that the target selection methodology we use may not be successful due to our inability to generate an applicable antibody candidate. In addition, several of our product candidates are in-licensed and we continue to look for additional product candidates to in-license or acquire. Our preclinical studies or clinical trials may not replicate or advance the results of the research programs and pre-clinical studies that were completed prior to our in-licensing or acquisition of product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not have the financial resources to continue development of, or to modify existing or enter into new collaborations for, a product candidate if we experience any issues that delay or prevent regulatory licensure of, or our ability to commercialize, product candidates, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">negative or inconclusive results from preclinical studies or clinical trials leading to a decision or requirement to conduct additional preclinical studies or clinical trials or abandon a program; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product-related side effects experienced by participants in our clinical trials or by individuals using therapeutic biological products similar to our product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure in obtaining the necessary approvals from regulators to commence a clinical trial, or a suspension or termination of a clinical trial once commenced; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">conditions imposed by the FDA, EMA or other comparable authorities regarding the scope or design of our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in enrolling patients in clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">high drop-out rates of patients; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">inadequate supply or quality of product candidate components or materials or other supplies necessary for the conduct of our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">greater than anticipated clinical trial costs; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">poor effectiveness of our product candidates during clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">unfavorable FDA or other comparable regulatory agency inspection and review of a clinical trial site; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure of our third party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight around clinical testing generally or with respect to our technology in particular; or </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">varying interpretations of data by the FDA, the EMA and other comparable foreign regulatory authorities. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If any of the foregoing circumstances occur, we could experience significant delays or an inability to successfully commercialize our product candidates, which could materially harm our business. Moreover, if we do not receive regulatory approvals, we may not be able to continue our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have no experience as a company completing a clinical trial or submitting a BLA or NDA and may be unable to successfully do so for PYX-201 and PYX-106.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The conduct of a clinical trial is a long, expensive, complicated and highly regulated process. Although our employees have conducted successful clinical trials and made regulatory submissions in the past across many therapeutic areas while employed at other companies, we, as a company, have not completed any clinical trials, or submitted a BLA or New Drug Application, or NDA, and as a result may require more time and incur greater costs than we anticipate. Failure to commence or complete, or delays in, our clinical trials or planned regulatory submissions would prevent us from, or delay us in, obtaining regulatory approval of and commercializing PYX-201 and PYX-106, which would adversely impact our financial performance. Large-scale clinical trials would require significant additional financial and management resources and reliance on third-party clinical investigators and consultants. Relying on third-party clinical investigators, contract research organizations, or CROs, and consultants may cause us to encounter delays that are outside of our control. In addition, relying on third parties in the conduct of our preclinical studies or clinical trials exposes us to a risk that they may not adequately comply with good laboratory practice, or GLP, or good clinical practice, or GCP, as required for any studies or trials we plan to submit to a regulatory authority. We may be unable to identify and contract with sufficient investigators, CROs and consultants on terms that are acceptable to us on a timely basis or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not be able to submit INDs to commence additional clinical trials on the timelines we expect and, even if we are able to, the FDA may not permit us to proceed.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may submit additional INDs in the future. We may experience manufacturing delays or other delays with IND-enabling studies. Moreover, we cannot be sure that submission of an IND will result in the FDA allowing us to commence clinical trials or that, once begun, issues will not arise that lead to the suspension or termination of our clinical trials. Additionally, even if the applicable regulatory authorities agree with the design and implementation of the clinical trials set forth in our INDs, we cannot guarantee that those regulatory authorities will not change their requirements in the future, or that circumstances will not arise under which FDA or other regulatory authorities may place our clinical trials on partial or full clinical hold. These considerations apply to the INDs described above and also to new clinical trials we may submit as amendments to existing INDs or as part of new INDs in the future. Any failure to submit INDs on the timelines we expect or to obtain authorization to proceed with our trials may prevent us from completing our clinical trials or commercializing our products on a timely basis, if at all.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our preclinical studies and clinical trials may fail to demonstrate adequately the safety, purity and potency of any of our product candidates, which would prevent or delay development, regulatory approval or licensure and commercialization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Before obtaining regulatory licensure for the commercial sale of any of our product candidates, including PYX-201 and PYX-106, we must demonstrate through lengthy, complex and expensive preclinical studies and clinical trials that our product candidates are safe, pure, and potent, as required under a BLA. Preclinical and clinical testing is expensive and can take many years to complete and the outcome of these activities is inherently uncertain. Failure can occur at any time during the preclinical study and clinical trial processes and, because our product candidates are in an early stage of development and have never been tested in humans, there is a high risk of failure. In addition, any failures or adverse outcomes in preclinical or clinical testing seen by other developers of similar product candidates could materially impact the success of our programs. We may never succeed in developing marketable products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">It is also possible that the results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. Although product candidates may demonstrate promising results in preclinical studies and early clinical trials, they may not prove to be effective in subsequent clinical trials. For example, testing on animals occurs under different conditions than testing in humans and, therefore, the results of animal studies may not accurately predict human experience. There is typically an extremely high rate of attrition from the failure of product candidates proceeding through preclinical studies and clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety, purity, and potency profile despite having progressed successfully through preclinical studies and/or initial clinical trials. Likewise, early, smaller-scale clinical trials may not be predictive of eventual safety, purity and potency in large-scale pivotal clinical trials. Many companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of potency, insufficient durability of potency or unacceptable safety issues, notwithstanding promising results in earlier trials. Most product candidates that commence preclinical studies and clinical trials are never approved or licensed for commercialization. In addition, preclinical studies or clinical trials we conduct may contradict, undermine or otherwise not replicate or advance the results of the research programs and pre-clinical studies that were completed prior to our in-licensing or acquisition of product candidates, which may materially and adversely affect our business, results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, we expect that the first clinical trials for our product candidates may be open-label studies, where both the patient and investigator know whether the patient is receiving the investigational product candidate or an existing licensed biological product. Most typically, open-label clinical trials test only the investigational product candidate and sometimes do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. In addition, open-label clinical trials may be subject to an &#x201c;investigator bias&#x201d; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. FDA may also not consider open-label clinical trials to be adequate and well controlled trials sufficient to support BLA licensure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any preclinical studies or clinical trials that we may conduct may not demonstrate the safety, purity, and potency necessary to obtain regulatory licensure to market our product candidates. If the results of our ongoing or future preclinical studies and clinical trials are inconclusive with respect to the safety, purity, and potency of our product candidates, if we do not meet the clinical endpoints with statistical and clinically meaningful significance or if there are safety concerns associated with our product candidates, we may be prevented or delayed in obtaining marketing licensure for those product candidates. In some instances, there can be significant variability in safety, purity, and potency results between different preclinical studies and clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical trial protocols and the rate of dropout among clinical trial participants. Results of our trials could reveal a high and unacceptable severity and prevalence of these or other side effects. If that were to occur, or if other developers of similar products were to find an unacceptable severity or prevalence of side effects with their candidates, our trials could be suspended or terminated, and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny licensure of our product candidates for any or all targeted indications. Product-related side effects could also affect patient recruitment or the ability of enrolled patients to complete an ongoing trial or result in potential product liability claims. Any of these occurrences may significantly harm our business, financial condition and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, our product candidates could cause undesirable side effects in clinical trials related to on-target toxicity. If on-target toxicity is observed or if our product candidates have characteristics that are unexpected, we may need to abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Many compounds that initially showed promise in early-stage testing for treating cancer have later been found to cause side effects that prevented further development of the compound.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our preclinical programs may experience delays or may never advance to clinical trials, which would adversely affect our ability to obtain regulatory approval or licensure or commercialize these programs on a timely basis or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In order to obtain FDA, European Commission (based on the opinion of the EMA&#x2019;s Committee for Human Medicinal Products, or CHMP) or other comparable licensure to market a new biological product we must demonstrate proof of safety, purity and potency or efficacy in humans. To meet these requirements, we will have to conduct adequate and well-controlled clinical trials. Before we can commence clinical trials for a product candidate, we must complete extensive preclinical studies that support our planned INDs or similar applications in foreign countries. We cannot be certain of the timely completion or outcome of our preclinical studies and cannot predict if the FDA or other comparable foreign authorities and independent ethics committees will accept our proposed clinical programs or if the outcome of our preclinical studies will ultimately support the further development of our programs. As a result, we cannot be sure that we will be able to submit INDs or similar applications for our preclinical programs on the timelines we expect, if at all, and we cannot be sure that submission of INDs or similar applications will result in the FDA or other regulatory authorities or independent ethics committees allowing clinical trials to begin.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Conducting preclinical studies is a lengthy, time-consuming and expensive process. The length of time may vary substantially according to the type, complexity and novelty of the program, and often can be several years or more per program. Any delays in preclinical studies conducted by us or potential future partners may cause us to incur additional operating expenses. The commencement and rate of completion of preclinical studies for a product candidate may be delayed by many factors, including, for example:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">inability to generate sufficient preclinical or other </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> or </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> data to support the initiation of clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the COVID-19 pandemic, which may result in delays; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in reaching a consensus with regulatory agencies on study design. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, because standards for preclinical assessment are evolving and may change rapidly, even if we reach an agreement with the FDA on a pre-IND proposal, the FDA may not accept the IND submission as presented. Even if clinical trials do begin for our preclinical programs, our clinical trials or development efforts may not be successful.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">68</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical testing and product development is a lengthy and expensive process with an uncertain outcome. We may incur unexpected costs or experience delays in completing, or ultimately be unable to complete, the clinical testing and the development and commercialization of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to the timing and outcome. A failure of one or more clinical trials can occur at any stage of the process. We may experience numerous unforeseen events during or as a result of clinical trials, which could delay or prevent our ability to receive marketing licensure or commercialize our product candidates, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in reaching, or the failure to reach, a consensus with regulators on clinical trial design; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate, including as a result of delays in the testing, validation, manufacturing and delivery of product candidates to the clinical sites by us or by third parties with whom we have contracted to perform certain of those functions; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in reaching, or the failure to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the failure of regulators or institutional review boards to authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">difficulty in designing clinical trials and in selecting endpoints for diseases that have not been well studied and for which the natural history and course of the disease is poorly understood; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the selection of certain clinical endpoints that may require prolonged periods of clinical observation or analysis of the resulting data; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may receive feedback from regulatory authorities that requires us to modify the design of our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, participants may drop out of these clinical trials at a higher rate than we anticipate or fail to return for post-treatment follow-up or the failure to recruit suitable patients to participate in our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators or institutional review boards to suspend or terminate our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may have to suspend or terminate clinical trials of our product candidates for various reasons, including a finding that the participants are being exposed to unacceptable health risks; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the third parties with whom we contract may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the requirement from regulators or institutional review boards that we or our investigators suspend or terminate clinical trials for various reasons, including noncompliance with regulatory requirements or unacceptable safety risks; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clinical trials of our product candidates may produce negative or inconclusive results and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product candidate development and discovery programs; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of clinical trials of our product candidates may be greater than we anticipate; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">imposition of a clinical hold by regulatory authorities as a result of a serious adverse event, concerns with a class of product candidates or after an inspection of our clinical trial operations, trial sites or manufacturing facilities; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">occurrence of serious adverse events associated with the product candidate that are viewed to outweigh its potential benefits; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulators may revise the requirements for approving our product candidates, or such requirements may not be as we anticipate; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in developing and validating any companion diagnostic to be used in the trial, to the extent we are required to do so.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">be delayed in obtaining marketing licenses for our product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">not obtain marketing licensure at all; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtain licensure for indications or patient populations that are not as broad as intended or desired; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtain licensure with labeling that includes significant use or distribution restrictions or safety warnings; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">be required to perform additional clinical trials to support marketing licensure; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">have regulatory authorities withdraw or suspend their license, or impose restrictions on distribution of a product candidate in the form of a modified risk evaluation and mitigation strategy, or REMS; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">be subject to additional post-marketing testing requirements or changes in the way the product is administered; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may fail to approve any companion diagnostics that may be required in connection with approval of our therapeutic product candidates; or </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">have our product removed from the market after obtaining marketing licensure. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For example, the FDA launched </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Project</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Optimus</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in 2021 as an initiative to reform the dose optimization and dose selection paradigm in oncology drug development, which was driven by the FDA&#x2019;s concerns that the current paradigm for dose selection may result in doses and schedules of molecularly targeted therapies that are inadequately characterized before initiating pivotal trials. Through collaboration with the biopharmaceutical industry, academia and other stakeholders, the FDA&#x2019;s goal for this initiative is to advance an oncology dose-finding and dose optimization paradigm that emphasizes dose selections that maximize efficacy as well as safety and tolerability. In support of this initiative, the FDA may request sponsors of oncology product candidates to conduct dose optimization studies pre- or post-approval. The FDA also continues to develop and finalize guidance documents and implement initiatives regarding the development and clinical research of oncology product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product development costs also will increase if we experience delays in preclinical studies or clinical trials or in obtaining marketing licenses. We do not know whether any of our preclinical studies or clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant preclinical study or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates, or could allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates, which may harm our business, results of operations, financial condition and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, cancer therapies sometimes are characterized as first-line, second-line or third-line. The FDA often approves or licenses new oncology therapies initially only for third-line or later use, meaning for use after two or more other treatments have failed. When cancer is detected early enough, first-line therapy, usually hormone therapy, surgery, radiation therapy, immunotherapy or a combination of these, is sometimes adequate to cure the cancer or prolong life without a cure. Second-line and third-line therapies are administered to patients when prior therapy is not effective. Our clinical trials will be with patients who have received one or more prior treatments and we expect that we would initially seek regulatory licensure for use of these product candidates as second-line or third-line therapy. Subsequently, for those products that prove to be sufficiently beneficial, if any, we would expect to seek licensure potentially as a first-line therapy, but any product candidates we develop, even if approved for second-line or third-line therapy, may not be approved for first-line therapy and, prior to seeking and/or receiving any licensures for first-line therapy, we may have to conduct additional clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any failures or setbacks involving the FACT Platform, including adverse events, could have a detrimental impact on our research pipeline and future success.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We use the FACT Platform in our ADC product candidate, PYX-201. Any failures or setbacks involving the FACT Platform, including adverse events, could have a detrimental impact on our research pipeline and future success. For example, we may uncover a previously unknown risk associated with the FACT Platform or other issues that may be more problematic than we currently believe, which may prolong the period of observation required for obtaining regulatory approval, necessitate additional clinical testing or result in the failure to obtain regulatory licensure. If the FACT Platform or any of its components that is used in our ADC product candidate is not safe, we would be required to abandon or redesign other product candidates we develop via the FACT Platform, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not be successful in our efforts to use and expand the FACT Platform to continue to build a pipeline of product candidates and develop marketable products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are using the FACT Platform to develop PYX-201, as well as continuing to build our pipeline of product candidates. Our business depends not only on our ability to successfully develop, obtain regulatory licensure for, and commercialize our product candidates, but to continue to generate new product candidates through our platform. Even if we are successful in continuing to build our pipeline and further progress the development of our current product candidates, any additional product candidates may not be suitable for clinical development, including as a result of harmful side effects, manufacturing issues, limited potency or other characteristics that indicate that they are unlikely to be products that will succeed in clinical development, receive marketing licensure or achieve market acceptance. If we cannot validate our technology platform by successfully commercializing product candidates, we may not be able to obtain product, licensing or collaboration revenue in future periods, which would adversely affect our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may expend our resources to pursue particular product candidates and fail to capitalize on product candidates that may be more profitable or for which there is a greater likelihood of success.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of our limited financial and managerial resources, we must make strategic decisions as to which targets and product candidates to pursue and may forego or delay pursuit of opportunities with other targets or product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Failure to properly assess potential product candidates could result in our focus on product candidates with low market potential, which would harm our business, financial condition, results of operations and prospects. Our spending on current and future research, product candidates and discovery programs for specific targets or indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the market opportunities for any product candidate that we develop are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The potentially addressable patient population for our current programs or future product candidates may be limited and the number of patients who have the cancers we are targeting may turn out to be lower than expected. Potentially addressable patient populations for our product candidates are only estimates. These estimates could prove to be incorrect, and the estimated number of potential patients in the United States and elsewhere could be lower than expected. It may also be that such patients may not be otherwise amenable to treatment with our product candidates, or patients could become increasingly difficult to identify and access, any of which could materially adversely affect our business, financial condition, results of operations and growth prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our estimated addressable markets and market opportunities for our product candidates are based on a variety of inputs, including data published by third parties, our own market insights and internal market intelligence, and internally generated data and assumptions. We have not independently verified any third-party information and cannot be assured of its accuracy or completeness. Market opportunity estimates, whether obtained or derived from third-party sources or developed internally, are subject to significant uncertainty and are based on assumptions and estimates that may prove not to be accurate. Although we believe our market opportunity estimates are reasonable, such information is inherently imprecise. In addition, our assumptions and estimates of market opportunities are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including but not limited to those described in this Annual Report on Form 10-K. If this third-party or internally generated data prove to be inaccurate or if we make errors in our assumptions based on that data, our actual market may be more limited than we estimate it to be. In addition, these inaccuracies or errors may cause us to misallocate capital and other critical business resources, which could harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The market may not be receptive to our product candidates because they are based on our novel therapeutic modality, and we may not generate any future revenue from the sale or licensing of product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if regulatory licensure is obtained for a product candidate, we may not generate or sustain revenue from sales of the product due to factors such as whether the product can be sold at a competitive cost and whether the product is otherwise accepted in the market. Some product candidates that we are developing are based on the FACT Platform, which is a new technology and therapeutic approach. Our future success depends on the successful development of this novel therapeutic approach. Additionally, the regulatory licensure process for novel product candidates such as ours can be more expensive and take longer than for other, better-known or extensively-studied product candidates. No regulatory authority has granted licensure for any therapeutic using the FACT Platform. As a result of these factors, it is more difficult for us to predict the time and cost of product candidate development, and we cannot predict whether the FACT Platform will result in the development and marketing licensure of any products. Any development problems we experience in the future related to any of our programs may cause significant delays or unanticipated costs or may prevent the development of a commercially viable product. Advancing our products creates significant challenges for us, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">educating medical personnel regarding the potential potency and safety benefits, as well as the challenges, of incorporating our product candidates, if approved, into treatment regimens; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establishing the sales and marketing capabilities to gain market acceptance, if approved. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any of these factors may prevent us from commercializing any of our product candidates we may develop on a timely or profitable basis, if at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market participants with significant influence over acceptance of new treatments, such as physicians and third-party payors, may not adopt a product or treatment based on the FACT Platform and technologies, and we may not be able to convince the medical community and third-party payors to accept and use, or to provide favorable reimbursement for, any product candidates developed by us or our existing or future collaborators. Market acceptance of our product candidates will depend on, among other factors:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing of our receipt of any marketing and commercialization licensures; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the terms of any licensures and the countries in which licensures are obtained; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the safety, purity, and potency of our product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the prevalence and severity of any adverse side effects associated with our product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">limitations or warnings contained in any labeling approved by the FDA, or other comparable foreign regulatory authorities; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">relative convenience and ease of administration of our product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the willingness of patients to accept any new methods of administration; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the success of our physician education programs; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the availability of adequate government and third-party payor reimbursement; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the pricing of our products, particularly as compared to alternative treatments; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">availability of alternative effective treatments for the disease indications our product candidates are intended to treat and the relative risks, benefits and costs of those treatments. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If any product candidate we commercialize fails to achieve market acceptance, it could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are early in our development efforts. Our lead product candidates, PYX-201 and PYX-106, are in the early stages of clinical development. The results of preclinical studies and early-stage clinical trials may not be predictive of future results in later studies or trials. Initial success in clinical trials may not be indicative of results obtained when these trials are completed or in later-stage clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The results of preclinical studies may not be predictive of the results of clinical trials, and the results of any early-stage clinical trials that are continuing may not be predictive of the results of the later-stage clinical trials. In addition, initial success in clinical trials may not be indicative of results obtained when such trials are completed on in later stage clinical trials. In particular, the small number of patients in our planned early clinical trials may make the results of these trials less predictive of the outcome of later clinical trials. For example, even if successful, the results of our Phase 1 clinical trials of our product candidates PYX-201 and PYX-106 and other product candidates may not be predictive of the results of further clinical trials of these product candidates or any of our other product candidates. Moreover, preclinical and clinical data often are susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless have failed to obtain marketing licensure of their products. Our future clinical trials may not ultimately be successful or support further clinical development of any of our product candidates. There is a high failure rate for product candidates proceeding through clinical trials. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving encouraging results in earlier studies. Any such setbacks in our clinical development could materially harm our business, results of operations, financial condition and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, from time to time, we may publish interim, top-line or preliminary data from our planned clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or top-line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously announced or published. As a result, interim, top-line and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary, top-line or interim data and final data could significantly harm our reputation and business prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we experience delays or difficulties in the enrollment of patients in our clinical trials, our timelines for submitting applications for and receiving necessary marketing authorizations, if any, could be delayed or prevented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not be able to initiate clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials, as required by the FDA or similar regulatory authorities outside of the United States. While we believe that we will be able to enroll a sufficient number of patients into each of these clinical trials, we cannot predict with certainty how difficult it will be to enroll patients for trials in these rare indications generally and during the COVID-19 pandemic, specifically. Our ability to identify and enroll eligible patients for clinical trials may turn out to be limited or we may be slower in enrolling these trials than we anticipate. In addition, some of our competitors have ongoing clinical trials for product candidates that treat the same indications as our product candidates and, as a result, patients who would otherwise be eligible for our clinical trials may instead elect to enroll in clinical trials of our competitors&#x2019; product candidates. Patient enrollment in clinical trials is also affected by other factors including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the severity of the disease under investigation; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the size and nature of the patient population; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the eligibility criteria for the trial in question; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">competing clinical trials or approved therapies which present an attractive alternative to patients and their physicians; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">perceived risks and benefits of the product candidate under study, including as a result of adverse effects observed in similar or competing therapies; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the efforts to facilitate timely enrollment in clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the patient referral practices of physicians; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the burden on patients due to the scope and invasiveness of required procedures under clinical trial protocols, some of which may be inconvenient and/or uncomfortable; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the ability to monitor patients adequately during and after treatment; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the proximity and availability of clinical trial sites for prospective patients; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the impact of the current COVID-19 pandemic, which may affect the conduct of a clinical trial, including by slowing potential enrollment or reducing the number of eligible patients for clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the risk that enrolled subjects will drop out or die before completion of the trial; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">patients failing to complete a clinical trial or returning for post-treatment follow-up; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to manufacture the requisite materials for a patient and clinical trial. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our inability to enroll a sufficient number of patients for our planned clinical trials, or our inability to do so on a timely basis, would result in significant delays and could require us to abandon one or more clinical trials altogether. Enrollment delays in our planned clinical trials may result in increased development costs for our product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product candidates may cause undesirable and unforeseen side effects or have other properties impacting safety that could halt their clinical development, delay or prevent their regulatory licensure, limit their commercial potential or result in significant negative consequences.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Undesirable side effects caused by our product candidates could cause regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory licensure or approval by the FDA or other regulatory authorities. As is the case with oncology drugs, it is likely that there may be side effects associated with their use. Results of our trials could reveal a high and unacceptable severity and prevalence of these or other side effects. In such an event, our trials could be suspended or terminated, and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny licensure or approval of our product candidates for any or all targeted indications. Such side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may materially and adversely affect our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of patients and limited duration of exposure, rare and severe side effects of our product candidates may only be uncovered with a significantly larger number of patients exposed to the product candidate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the event that any of our product candidates receive regulatory licensure or approval and we or others identify undesirable side effects caused by one of our products, any of the following adverse events could occur, which could result in the loss of significant revenue to us and materially and adversely affect our results of operations and business:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory authorities may withdraw their licensure or approval of the product or seize the product; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be required to recall the product or change the way the product is administered to patients; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be subject to fines, injunctions or the imposition of civil or criminal penalties; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory authorities may require the addition of labeling statements, such as a &#x201c;black box&#x201d; warning or a contraindication; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we could be sued and held liable for harm caused to patients; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the product may become less competitive; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our reputation may suffer. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we do not achieve our projected development goals in the timeframes we announce and expect, the commercialization of our products may be delayed and, as a result, our stock price may decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, we estimate the timing of the anticipated accomplishment of various scientific, clinical, regulatory and other product development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of preclinical studies and clinical trials and the submission of regulatory filings and may be associated with payments from collaborators. From time to time, we may publicly announce the expected timing of some of these milestones. All of these milestones are and will be based on numerous assumptions. The actual timing of these milestones may vary dramatically compared to our estimates, in some cases for reasons beyond our control. If we do not meet these milestones as publicly announced, or at all, our revenue may be lower than expected, the commercialization of our products may be delayed or never achieved and, as a result, our stock price may decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We face competition from entities that have developed or may develop product candidates for cancer, including companies developing novel treatments and technology platforms. If these companies develop technologies or product candidates more rapidly than we do or their technologies are more effective, our ability to develop and successfully commercialize product candidates may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The development and commercialization of therapeutic biological products is highly competitive. We compete with a variety of multinational biopharmaceutical companies and specialized biotechnology companies, as well as technology being developed at universities and other research institutions. Our competitors have developed, are developing or will develop product candidates and processes competitive with our product candidates. Competitive therapeutic treatments include those that have already been approved or licensed and accepted by the medical community and any new treatments that enter the market. We believe that a significant number of products are currently under development, and may become commercially available in the future, for the treatment of conditions for which we may try to develop product candidates. The biotechnology and pharmaceutical industries, including the oncology subsector, are characterized by rapidly evolving technologies, intense competition, and a strong defense of intellectual property and proprietary technologies. Any product candidates that we successfully commercialize may not be competitive with currently marketed therapies and any new therapies commercialized in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are aware of several companies that are developing cancer immunotherapies and ADCs. Many of these companies are well-capitalized and, in contrast to us, have significant clinical experience, and may include our existing or future collaborators. In addition, these companies compete with us in recruiting scientific and managerial talent and the patient pool available for participation in clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our success will partially depend on our ability to develop and protect therapeutics that are more safe, pure, and potent than competing products. Our commercial opportunity and success will be reduced or eliminated if competing products that are safer, more effective, or less expensive than the therapeutics we develop are commercialized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If our product candidates are licensed, they will compete with a range of therapeutic treatments that are either in development or currently marketed. Many companies are active across various stages of development in the oncology subsector and are marketing and developing products that employ similar ADC and immunotherapy approaches. As of April 2021, there were approximately 275 ADCs in clinical or preclinical development worldwide, of which the vast majority are being developed for the treatment of various cancer indications. Additionally, there are several large and small companies working on various immunotherapy approaches for treatment of cancer. Multiple companies are also involved in the marketing of ADC therapeutics and Immunotherapy which include, but are not limited to, ADC Therapeutics SA, Astellas Pharma, Inc., AstraZeneca plc, Daiichi Sankyo Company, Ltd., Genentech, Inc., Gilead Sciences, Inc, GlaxoSmithKline, plc, Pfizer Inc., Rakuten Medical, Inc., Seagen, Inc., Nextcure, Inc. and Abcure, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our preclinical ADC and immunotherapy candidates may face substantial competition from alternative therapeutic modalities, such as CAR-T therapies, bispecific antibodies, and small molecules that are being developed for the same cancer types that we are targeting with our pipeline candidates. These approaches could prove to be more effective, safer, or convey other advantages over any products resulting from our technology. In addition, we also face competition on specific targets, including the target of our PYX-201 candidate, EDB, from Philogen S.p.A., the target of our PYX-203 product candidate, CD123, from ImmunoGen, Inc., Vincerx Pharma, Inc., Macrogenics and Byondis B.V., the target of our PYX-106 product candidate, BSI-060T, from Nextcure, Inc. lead program - NC318 and the target of our PYX-102 product candidate, Anti-KLRG1, from Abcuro, Inc. Additionally, there is a wide array of activity in the development of immunotherapies for oncology which may be competitive with our preclinical discovery programs. Furthermore, if any of our product candidates are approved in oncology indications such as lung, hematological and other cancers, they may compete with existing approaches to treating cancer including surgery, radiation, and drug therapy, including conventional chemotherapy, biological products, and targeted drug small molecule therapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many of our competitors have significantly greater scientific, research and development capabilities, as well as greater financial, technical, manufacturing, marketing, sales and supply resources or experience than we do. If we successfully obtain licensure for any product candidate, we will face competition based on many different factors, including the safety, purity and potency of our products, the ease with which our products can be administered and the extent to which patients accept relatively new routes of administration, the timing and scope of regulatory licenses for these products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing products could present superior treatment alternatives, including by being more effective, safer, less expensive or marketed and sold more effectively than any products we may develop. Competitive products may make any products we develop obsolete or noncompetitive before we recover the expense of developing and commercializing our product candidates. Such competitors could also recruit our employees, which could negatively impact our level of expertise and our ability to execute our business plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our biological product candidates for which we intend to seek licensure may face competition sooner than anticipated.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Affordable Care Act, or ACA, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated licensure pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the licensure of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#x2019;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have an adverse effect on the future commercial prospects for our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There is a risk that any product candidates we may develop that are licensed as a biological product under a BLA would not qualify for the 12-year period of exclusivity or that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider any product candidates we may develop to be reference products for competing products, potentially creating the opportunity for competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation, including litigation challenging the constitutionality of the ACA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For example, in December 2018, a federal district court ruled that the ACA, without the &#x201c;individual mandate&#x201d; penalty (which was repealed by Congress as part of the Tax Cuts and Jobs Act), is unconstitutional in its entirety. In December 2019, the U.S. Court of Appeals for the 5th Circuit upheld the district court ruling that the individual mandate provisions are unconstitutional and remanded the case back to the district court for further analysis of whether such provisions could be severed from the remainder of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the case without specifically ruling on the constitutionality of the ACA. There may, however, be other efforts to challenge, repeal, or replace the ACA in the future. We continue to evaluate the effect that the ACA and its possible repeal and replacement has (or may have) on our business and exclusivity under the BPCIA. It is uncertain the extent to which any such changes may impact our business or financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business entails a significant risk of product liability, and if we are unable to obtain sufficient insurance coverage, such failure could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect to be exposed to significant product liability risks inherent in the development, testing and manufacturing of our product candidates and products, if approved. Product liability claims could delay or prevent completion of product candidate development programs. If we succeed in marketing products, such claims could result in an FDA investigation of the safety and effectiveness of our products, our third-party manufacturer&#x2019;s manufacturing processes and facilities or our marketing programs and potentially a recall of our products or more serious enforcement action, including limitations on the approved indications for which our product candidates may be used or suspension or withdrawal of licenses. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of management&#x2019;s time and our resources, substantial monetary awards to trial participants or patients and a decline in our stock price. In addition, we may be subject to liability based on the actions of our existing or future collaborators in connection with their development of products using the FACT Platform. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to maintain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Regulatory Licensure or Approval and Other Legal Compliance Matters</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The regulatory licensure and approval processes of the FDA and other comparable regulatory authorities are lengthy, time-consuming and inherently unpredictable and, if we are ultimately unable to obtain marketing licensure or approval for our product candidates, our business will be substantially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The time required to obtain approval or licensure by the FDA and other comparable regulatory authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval and licensure policies, regulations or the type and amount of clinical data necessary to gain approval or licensure may change during the course of a product candidate&#x2019;s clinical development and may vary among jurisdictions. We have not obtained marketing approval or licensure for any product candidate, and it is possible that none of our existing product candidates, or any product candidates we may seek to develop in the future, will ever obtain marketing approval or licensure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product candidates could fail to receive marketing licensure in the United States for many reasons, including the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA may disagree with the design or implementation of our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be unable to demonstrate to the satisfaction of the FDA that a product candidate is safe, pure, and potent; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">results of clinical trials may not meet the level of statistical significance required by the FDA for licensure; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be unable to demonstrate that a product candidate&#x2019;s clinical and other benefits outweigh its safety risks; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA may disagree with our interpretation of data from preclinical studies or clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">data collected from clinical trials of our product candidates may not be sufficient to support the submission of a BLA to the FDA or other submission or to obtain marketing licensure in the United States; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA may find deficiencies with or fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the licensure policies or regulations of the FDA may significantly change in a manner rendering our clinical data insufficient for licensure. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This lengthy licensure process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory licensure to market any of our product candidates, which would significantly harm our business, results of operations, financial condition and prospects. The FDA has substantial discretion in the licensure process and determining when or whether regulatory licensure will be obtained for any of our product candidates. Even if we believe the data collected from clinical trials of our product candidates are promising, such data may not be sufficient to support licensure by the FDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, even if we were to obtain licensure, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, may grant a license contingent on the performance of costly post-marketing clinical trials, or may approve or license a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we obtain FDA licensure for any of our product candidates in the United States, we may never obtain approval or licensure for or commercialize any of them in any other jurisdiction, which would limit our ability to realize their full market potential.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In order to market any products in any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a country-by-country basis regarding safety, purity, potency and efficacy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Licensure by the FDA in the United States does not ensure approval or licensure by regulatory authorities in other countries or jurisdictions. However, the failure to obtain approval or licensure in one jurisdiction may negatively impact our ability to obtain approval or licensure elsewhere. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval or licensure in one country does not guarantee regulatory approval or licensure in any other country.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Approval or licensure processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval or licensure could result in difficulties and increased costs for us and require additional preclinical studies or clinical trials which could be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved or licensed for sale in any jurisdiction, including in international markets, and we do not have experience in obtaining regulatory approval or licensure in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals or licensures, or if regulatory approvals or licensures in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of any product we develop will be unrealized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we receive regulatory licensure of any product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If any of our product candidates are licensed or approved by regulatory authorities, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies, track and trace, serialization, post-market adverse event reporting, and submission of safety, purity, potency, efficacy and other post-market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities. In addition, we will be subject to continued compliance with cGMP and GCP requirements for any clinical trials that we conduct post-licensure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacturers and manufacturers&#x2019; facilities are required to comply with extensive FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any BLA or other marketing application and previous responses to inspection observations. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any regulatory licenses that we receive for our product candidates may be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of licensure, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials and surveillance to monitor the safety, purity, and potency of the product candidate. The FDA may also require a REMS program as a condition of licensure of our product candidates, which could entail requirements for long-term patient follow-up, a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Comparable foreign regulatory authorities may also have programs similar to REMS. In addition, if the FDA or a comparable foreign regulatory authority licenses or approves our product candidates, we will have to comply with requirements including submissions of safety and other post-marketing information and reports and registration.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical trials of our product candidates must be conducted in carefully defined subsets of patients who have agreed to enter into clinical trials. Consequently, it is possible that our clinical trials, or those of any future collaborator, may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable side effects. If one or more of our product candidates receive marketing licensure and we, or others, discover that the biological product is less effective than previously believed or causes undesirable side effects that were not previously identified, a number of potentially significant negative consequences could result, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory authorities may withdraw their licensure of the biological product or seize the biological product; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we, or any future collaborators, may be required to recall the biological product, change the way the biological product is administered or conduct additional clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">additional restrictions may be imposed on the marketing of, or the manufacturing processes for, the particular biological product; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be subject to fines, injunctions or the imposition of civil or criminal penalties; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory authorities may require the addition of labeling statements, such as a &#x201c;black box&#x201d; warning or a contraindication; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we, or any future collaborators, may be required to create a medication guide outlining the risks of the previously unidentified side effects for distribution to patients; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we, or any future collaborators, could be sued and held liable for harm caused to patients; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the biological product may become less competitive in the marketplace; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our reputation may suffer. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any of these events could have a material and adverse effect on our operations and business and could adversely impact our stock price.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">80</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety, purity, or potency of the product, including the adoption and implementation of REMS. The FDA and other agencies, including the United States Department of Justice, or DOJ, closely regulate and monitor the post-licensure marketing and promotion of biological products to ensure they are marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA and DOJ impose stringent restrictions on manufacturers&#x2019; communications regarding off-label use, and if we do not market our products only for the approved indications, we may be subject to enforcement action for off-label marketing. Violations of the Federal Food, Drug and Cosmetic Act, or FDCA, and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription drugs may lead to investigations and enforcement actions alleging violations of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We, and any collaborators, must comply with requirements concerning advertising and promotion for any of our product candidates for which we or they obtain marketing licensure. Promotional communications with respect to prescription biological products are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#x2019;s approved labeling. Thus, we, and any collaborators, will not be able to promote any products we develop for indications or uses for which the biological product is not licensed. The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Products may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses and a company that is found to have improperly promoted off-label uses may be subject to significant liability. However, physicians may, in their independent medical judgment, prescribe legally available products for off-label uses. The FDA does not regulate the behavior of physicians in their choice of treatments, but the FDA does restrict manufacturer&#x2019;s communications on the subject of off-label use of their products. The policies of the FDA and of comparable foreign regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory licensure of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing licensure that we may have obtained and we may not achieve or sustain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, later discovery of previously unknown side effects or other problems with our products or their manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">restrictions on such products, manufacturers or manufacturing processes; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">restrictions and warnings on the labeling or marketing of a product; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">restrictions on product distribution or use; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">requirements to conduct post-marketing studies or clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">warning letters or untitled letters; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">withdrawal of the products from the market; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">refusal to approve pending applications or supplements to approved applications that we submit; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">recall of products; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fines, restitution or disgorgement of profits or revenues; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">suspension or withdrawal of marketing licenses; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">suspension of any ongoing clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">damage to relationships with any potential collaborators; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">unfavorable press coverage and damage to our reputation; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">refusal to permit the import or export of our products; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product seizure; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties; or </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">litigation involving patients using our products. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA and similar foreign authorities may impose consent decrees or withdraw licensure if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or voluntary or mandatory product recalls; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fines, warning letters or holds on clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">refusal by the FDA and similar foreign authorities to approve pending applications or supplements to approved applications filed by us or suspension or revocation of licenses; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product seizure or detention or refusal to permit the import or export of our product candidates; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-compliance with European Union requirements regarding safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population (as explained further below), also can result in significant financial penalties, and non-compliance with pediatric requirements may prevent regulatory approvals from being granted. Similarly, failure to comply with the European Union and United Kingdom's, or UK, requirements regarding the protection of personal information can lead to significant penalties and sanctions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A Breakthrough Therapy designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or licensure process and it does not increase the likelihood that our product candidates will receive marketing licensure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may seek Breakthrough Therapy designation for our product candidates and some or all of our future product candidates. A Breakthrough Therapy is defined as a drug that is intended, alone or in combination with one or more other drugs or biological products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug or biological products may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For product candidates that have been designated as Breakthrough Therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as Breakthrough Therapies by the FDA may also be eligible for other expedited approval programs, including accelerated approval, if they meet requirements for those other programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designation as a Breakthrough Therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a Breakthrough Therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a Breakthrough Therapy designation for a product candidate may not result in a faster development process, review or licensure compared to candidate products considered for licensure under non-expedited FDA review procedures and does not assure ultimate licensure by the FDA. In addition, even if one or more of our product candidates qualify as Breakthrough Therapies, the FDA may later decide that the product no longer meets the conditions for qualification. For example, in June 2022, FDA published a draft guidance document outlining considerations for the FDA in rescinding Breakthrough Therapy designation for products that no longer meet the requirements for that designation. Thus, even though we intend to seek Breakthrough Therapy designation for some or all of our future product candidates for the treatment of various cancers, there can be no assurance that we will receive Breakthrough Therapy designation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fast Track designation by the FDA, even if granted for other current or future product candidates, may not lead to a faster development or regulatory review, licensure process and does not increase the likelihood that our product candidates will receive marketing licensure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may seek Fast Track designation for one or more of our future product candidates. If a drug or biological product is intended for the treatment of a serious or life-threatening disease or condition and it demonstrates the potential to address unmet medical needs for such a disease or condition, the drug sponsor may apply for FDA Fast Track designation for a particular indication. We may seek Fast Track designation for our product candidates, but there is no assurance that the FDA will grant this designation to any of our proposed product candidates. Marketing applications submitted by sponsors of products in Fast Track development may qualify for priority review under the policies and procedures offered by the FDA, but the Fast Track designation does not assure any such qualification or ultimate marketing licensure by the FDA. The FDA has broad discretion whether or not to grant Fast Track designation, so even if we believe a particular product candidate is eligible for this designation, there can be no assurance that the FDA would decide to grant it. Even if we do receive Fast Track designation, we may not experience a faster development process, review or licensure compared to conventional FDA procedures or pathways and receiving a Fast Track designation does not provide assurance of ultimate FDA licensure. In addition, the FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program. In addition, the FDA may withdraw any Fast Track designation at any time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we decide to seek Orphan Drug Designation for any of our current or future product candidates, we may be unsuccessful or may be unable to maintain the benefits associated with Orphan Drug Designation, including the potential for supplemental market exclusivity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may seek Orphan Drug Designation for one or more of our current or future product candidates. Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs or biological products for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States when there is no reasonable expectation that the cost of developing and making available the drug in the United States will be recovered from sales in the United States for that drug or biological product. In the United States, Orphan Drug Designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. After the FDA grants Orphan Drug Designation, the identity of the drug or biological product and its potential orphan use are disclosed publicly by the FDA. Orphan Drug Designation does not convey any advantage in, or shorten the duration of, the regulatory review and licensure process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If a product that has Orphan Drug Designation subsequently receives the first FDA approval or licensure for a particular active ingredient for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including an NDA or BLA, to market the same drug or biological product for the same indication for seven years, except in limited circumstances such as a showing of clinical superiority to the product with orphan drug exclusivity or if the FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the biological product was designated. As a result, even if one of our product candidates receives orphan exclusivity, the FDA can still approve or license other drugs or biological products that have a different active ingredient for use in treating the same indication or disease. Further, the FDA can waive orphan exclusivity if we are unable to manufacture sufficient supply of our product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may seek Orphan Drug Designation for our product candidates in additional orphan indications in which there is a medically plausible basis for the use of these product candidates. Even if we obtain Orphan Drug Designation, exclusive marketing rights in the United States may be limited if we seek licensure for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective or if we, through our manufacturer, are unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. In addition, although we intend to seek Orphan Drug Designation for other product candidates, we may never receive these designations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Congress is also considering updates to the orphan drug provisions of the FDCA in response to a recent 11th Circuit decision. Any changes to the orphan drug provisions could change our opportunities for, or likelihood of success in obtaining, orphan drug exclusivity and would materially adversely affect our business, financial condition, results of operations, cash flows and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accelerated approval by the FDA, even if granted, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing licensure. If we are unable to obtain licensure of our products through the Accelerated Approval Program in the United States, we may be required to conduct additional nonclinical and clinical studies and trials beyond those that we currently contemplate, which could increase the expense of obtaining, reduce the likelihood of obtaining and/or delay the timing of obtaining, necessary marketing licensure. Even if we receive accelerated approval from the FDA through the Accelerated Approval Program, if our confirmatory post-marketing trial does not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA may seek to withdraw accelerated approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We plan to seek accelerated approval of PYX-201 and PYX-106 and may seek approval of future product candidates using the FDA&#x2019;s accelerated approval pathway. For any licensure to market a biological product, we must provide the FDA and foreign regulatory agencies with clinical data that adequately demonstrate the safety, purity, and potency of the product for the indication applied for in the NDA or BLA or other respective regulatory filings. The Accelerated Approval Program is one of several approaches used by the FDA to make prescription drugs or biological products more rapidly available for the treatment of serious or life-threatening diseases. Section 506(c) of the FDCA provides that the FDA may grant accelerated approval to &#x201c;a product for a serious or life-threatening condition upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments.&#x201d; Licensure through the Accelerated Approval Program is subject, however, to the requirement that a sponsor perform adequate and well controlled post-marketing clinical trials to verify and describe the drug&#x2019;s clinical benefit, where there is uncertainty as to the relationship of the surrogate endpoint to the clinical benefit, or of the observed clinical endpoint to ultimate outcome. Typically, clinical benefit is verified when post-marketing clinical trials show that the biological products provide a clinically meaningful positive therapeutic effect, that is, an effect on how a patient feels, functions, or survives. These confirmatory trials must be completed with due diligence and may require that such studies be underway prior to approval under FDORA. If such confirmatory post-marketing trial fails to confirm the product&#x2019;s clinical profile or risks and benefits, the FDA may withdraw accelerated approval of the product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA has broad discretion with regard to licensure through the Accelerated Approval Program, and even if we believe that the Accelerated Approval Program is appropriate for one of our products, we cannot assure you that the FDA will ultimately agree. Furthermore, even if we do obtain licensure through the Accelerated Approval Program, we may not experience a faster development process, review, or licensure compared to conventional FDA procedures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if the FDA reviews a BLA seeking accelerated approval, there can be no assurance that licensure will be granted on a timely basis, or at all. The FDA may disagree that the design of, or results from, our studies support accelerated approval. Additionally, the FDA could require us to conduct further studies or trials prior to granting licensure of any type, including by determining that licensure through the Accelerated Approval Program is not appropriate and that our clinical trials may not be used to support licensure through the conventional pathway. We might not be able to fulfill the FDA&#x2019;s requirements in a timely manner, which would cause delays, or licensure might not be granted because our submission is deemed incomplete by the FDA. There also can be no assurance that after subsequent FDA feedback we will continue to pursue licensure through the Accelerated Approval Program. A failure to obtain licensure through the Accelerated Approval Program could result in a longer time period to obtain licensure of our products, could increase the cost of its development, could delay our ability to commercialize our products and could significantly harm our financial position and competitive position in the marketplace.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we receive licensure for one of our products through the Accelerated Approval Program, we will be subject to rigorous post-marketing requirements, including the completion of one or more confirmatory post-marketing trials as the FDA may require, to verify the clinical benefit of the product, and submission to the FDA of all promotional materials prior to their dissemination. These requirements could adversely impact the timing of the commercial launch of the product. Even if we do receive accelerated approval, we may not experience a faster development or regulatory review or licensure process. Further, receiving accelerated approval does not provide assurance of ultimate full FDA licensure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA could seek to withdraw accelerated approval for multiple reasons, including if we fail to conduct any required confirmatory post-marketing trial with due diligence, our confirmatory post-marketing trial does not confirm the predicted clinical benefit, other evidence shows that the product is not safe, pure, or potent under the conditions of use, or we disseminate promotional materials that are found by the FDA to be false and misleading.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any delay in obtaining, or inability to obtain, licensure through the Accelerated Approval Program, or any issues in maintaining approval granted under the Accelerated Approval Program, would delay or prevent commercialization of our products, and would materially adversely affect our business, financial condition, results of operations, cash flows and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If foreign regulatory authorities approve biosimilar versions of any of our product candidates that receive marketing approval, or such authorities do not grant our product candidates appropriate periods of data or market exclusivity before approving generic versions of our product candidates, the sales of our product candidates could be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the European Union and the UK, innovative medicinal products are authorized based on a full marketing authorization application and conditional authorization (as opposed to an application for marketing authorization that relies on data in the marketing authorization dossier for another, previously approved medicinal product). Applications for marketing authorization for innovative medicinal products must contain, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">inter alia</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the results of pharmaceutical tests, preclinical tests and clinical trials conducted with the medicinal product for which marketing authorization is sought (and where applicable the results of the pediatric studies unless a waiver or a deferral has been obtained&#x2014; as described further below).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A marketing authorization can be obtained via the centralized procedure or the national procedure. The centralized procedure results in a single marketing authorization, issued by the European Commission (based on the opinion of the EMA), which is valid across the entire European Economic Area, or EEA, which comprises the EU, Iceland, Liechtenstein and Norway. The centralized procedure is compulsory for human drugs that are (i) derived from biotechnology processes, such as genetic engineering; (ii) contain a new active substance indicated for the treatment of certain diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative diseases, autoimmune and other immune dysfunctions and viral diseases; (iii) designated orphan medicines; and (iv) advanced-therapy medicines, such as gene therapy, somatic cell therapy or tissue-engineered medicines. The centralized procedure may at the request of the applicant also be used in certain other cases. Therefore, the centralized procedure would be mandatory for the product candidates we are developing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Where an applicant for a marketing authorization submits a full dossier containing its own pharmaceutical, preclinical tests and clinical trials data, and where the application does not fall within the &#x2018;global marketing authorization&#x2019; of an existing medicinal product, reference product candidates may receive eight years of data exclusivity and an additional two years of market exclusivity, upon grant of the marketing authorization. If granted, during the data exclusivity period, applicants for approval of biosimilars cannot rely on data contained in the marketing authorization dossier submitted for the already authorized, or reference product candidate, to support their application. The market exclusivity period prevents a successful biosimilar applicant from commercializing its product in the EU until 10 years have elapsed from the initial marketing authorization of the reference product in the EU, but a biosimilar marketing authorization application can be submitted during this time. The overall 10-year market exclusivity period can further be extended by one more year if, during the first eight years of those 10 years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. However, even if a compound is considered to be a new active substance and the innovator is able to gain the period of data and market exclusivity, provided that no other IP or regulatory exclusivities apply, another unrelated company could also apply for a marketing authorization and market another competing medicinal product for the same therapeutic indication if such company obtained its own marketing authorization based on a separate marketing authorization application based on a full self-standing scientific data package supporting the application.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the EU, there is a special regime for biosimilars, or biological medicinal products that are similar to a reference medicinal product but that do not meet the definition of a generic medicinal product, for example, because of differences in raw materials or manufacturing processes. For such products, the results of appropriate preclinical testing or clinical trials must be provided, and guidelines from the EMA detail the type of quantity of supplementary data to be provided for different types of biological products. There are currently no such guidelines for complex biological products such as gene or cell therapy medicinal products, and so in the short term it is unlikely that biosimilars of those products will be approved in the EU. However, guidance from the EMA states that they will be considered in the future in light of the scientific knowledge and regulatory experience gained at the time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the EU, marking authorization applications for new medicinal products must include the results of clinical trials conducted in pediatric population, in compliance with a pediatric investigation plan, or PIP, agreed with the EMA&#x2019;s Pediatric Committee, or PDCO. The PDCO can grant waivers or deferrals to these requirements in certain circumstances (for example, a waiver may be obtained if the condition only occurs in adult populations). Where required, pediatric studies must cover all sub-sets of the pediatric population for both existing and new indications, pharmacological forms and route of administrations. Limited further exclusions apply, including in relation to biosimilar applications. Certain incentives may be available for completion of pediatric studies. For example, once the marketing authorization is obtained in all European Union Member States and study results are included in the product information, even when negative, the product is eligible for a six-months supplementary protection certificate extension (if any is in effect at the time of approval) or, in the case of orphan pharmaceutical products, a two year extension of the orphan market exclusivity is granted.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the EU, the criteria for designating an &#x201c;orphan medicinal product&#x201d; are similar in principle to those in the United States. A medicinal product may be designated as orphan if (1) it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition (2) either (a) such condition affects no more than five in 10,000 persons in the EU when the application is made or (b) the product, without the benefits derived from orphan status, would not generate sufficient return in the EU to justify investment and (3) there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU, or if such a method exists, the product will be of significant benefit to those affected by the condition. The application for Orphan Drug Designation must be submitted before the marketing authorization application. Orphan Drug Designations entitle a party to financial incentives such as reduction of fees or fee waivers and are, upon grant of a marketing authorization, entitled to 10 years of market exclusivity. During the 10-year market exclusivity period, the EMA cannot accept another marketing authorization application, or grant a marketing authorization or accept an application to extend an existing marketing authorization, for the same therapeutic indication, in respect of a similar medicinal product. An orphan medicinal product can also obtain an additional two years of market exclusivity in the European Union for pediatric studies. No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications. Orphan Drug Designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ten-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for Orphan Drug Designation, for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. At any time, a marketing authorization may be granted to a similar product for the same indication if:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">2.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the holder of the marketing authorization for the original orphan medicinal product has given his consent to the second applicant; or </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">3.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the holder of the marketing authorization for the original orphan medicinal product is unable to supply sufficient quantities of the medicinal product. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although the UK has left the EU, its regulatory legal framework provides for similar periods of protection (namely regulatory data exclusivity, marketing protection and market exclusivity).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Competition that our product candidates may face from biosimilar versions of our product candidates could materially and adversely impact our future revenue, profitability and cash flows and substantially limit our ability to obtain a return on the investments we have made in those product candidates. Our future revenues, profitability and cash flows could also be materially and adversely affected and our ability to obtain a return on the investments we have made in those product candidates may be substantially limited if our product candidates, if and when approved, are not afforded the appropriate periods of non-patent exclusivity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The failure to obtain required regulatory clearances or approvals for any companion diagnostic tests that we may pursue may prevent or delay approval of any of our product candidates. Moreover, the commercial success of any of our product candidates that require a companion diagnostic will be tied to the receipt of any required regulatory clearances or approvals and the continued availability of such tests.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the clinical development of our product candidates for certain indications, we may work with collaborators to develop or obtain access to companion diagnostic tests to identify appropriate patients for our product candidates. We may rely on third parties for the development, testing and manufacturing of these companion diagnostics, the application for and receipt of any required regulatory clearances or approvals, and the commercial supply of these companion diagnostics. The FDA and foreign regulatory authorities regulate companion diagnostics as medical devices that will likely be subject to clinical trials in conjunction with the clinical trials for product candidates, and which will require separate regulatory clearance or approval prior to commercialization. This process could include additional meetings with health authorities, such as a pre-submission meeting and the requirement to submit an investigational device exemption, or IDE. In the case of a companion diagnostic that is designated as &#x201c;significant risk device,&#x201d; approval of an IDE by the FDA and IRB is required before such diagnostic is used in conjunction with the clinical trials for a corresponding product candidate. We or our third-party collaborators may fail to obtain the required regulatory clearances or approvals, which could prevent or delay approval of our product candidates. In addition, the commercial success of any of our product candidates that requires a companion diagnostic will be tied to and dependent upon the receipt of required regulatory clearances or approvals and the continued ability of such third parties to make the companion diagnostic commercially available to us on reasonable terms in the relevant geographies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are required to in the future and if we are unable to successfully develop companion diagnostic tests for our product candidates that require such tests, or experience significant delays in doing so, we may not realize the full commercial potential of these product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may be required by the FDA to develop, either by ourselves or with collaborators, companion diagnostic tests for our product candidates for certain indications. To be successful, we or our collaborators will need to address a number of scientific, technical, regulatory and logistical challenges. We have no prior experience with medical device or diagnostic test development. If we choose to develop and seek FDA clearance or approval for companion diagnostic tests on our own, we will require additional personnel with medical device knowledge and expertise. We may rely on third parties for the design, development and manufacture of companion diagnostic tests for our therapeutic product candidates that require such tests. If these parties are unable to successfully develop companion diagnostics for these therapeutic product candidates, or experience delays in doing so, we may be unable to enroll enough patients for our current and planned clinical trials, the development of these therapeutic product candidates may be adversely affected, these therapeutic product candidates may not obtain marketing approval, and we may not realize the full commercial potential of any of these therapeutics that obtain marketing approval. Any failure to successfully develop this companion diagnostic may cause or contribute to delayed enrollment of this trial and may prevent us from initiating or completing further clinical trials to support marketing approval for our product candidates. As a result, our business, results of operations and financial condition could be materially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our relationships with customers, physicians and third-party payors are subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, and other healthcare laws and regulations. If we are unable to comply or have not fully complied with these laws, we could face substantial penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Healthcare providers, physicians and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing licensure. Our current and future arrangements with healthcare professionals, principal investigators, consultants, customers and third-party payors subject us to various federal and state fraud and abuse laws and other healthcare laws that may constrain the business or financial arrangements and relationships through which we research, develop, sell, market and distribute our product candidates, if we obtain marketing licensure. In particular, the research of our product candidates, as well as the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other business or financial arrangements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ensuring that our business arrangements with third parties comply with applicable healthcare laws and regulations will likely be costly. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations, or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, or exclusion from participating in government-funded healthcare programs, such as Medicare and Medicaid; additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws; contractual damages; reputational harm; and/or the curtailment or restructuring of our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the physicians or other providers or entities with whom we expect to do business are found not to be in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusion from government-funded healthcare programs. Even if resolved in our favor, litigation or other legal proceedings relating to healthcare laws and regulations may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development, manufacturing, sales, marketing or distribution activities. Uncertainties resulting from the initiation and continuation of litigation or other proceedings relating to applicable healthcare laws and regulations could have an adverse effect on our ability to compete in the marketplace.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The successful commercialization of our product candidates in the United States and elsewhere will depend in part on the extent to which third-party payors, including governmental authorities and private health insurers, provide coverage and adequate reimbursement levels, as well as implement pricing policies favorable for our product candidates. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant uncertainty exists as to the coverage and reimbursement status of any products for which we may obtain regulatory licensure. In the United States and in other countries, patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. The availability of coverage and adequacy of reimbursement for our products by third-party payors, including government health care programs (e.g., Medicare, Medicaid or TRICARE), managed care providers, private health insurers, health maintenance organizations and other organizations is essential for most patients to be able to afford medical services and pharmaceutical products such as our product candidates. Third-party payors decide which medications they will pay for and establish reimbursement levels.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to successfully commercialize our product candidates will depend, in part, on the extent to which coverage and adequate reimbursement for any products for which we obtain marketing authorization will be available from third-party payors. In the United States, no uniform policy for coverage and reimbursement for pharmaceutical products exists among third-party payors. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting reimbursement policies, but also have their own methods and approval processes apart from Medicare coverage and reimbursement determinations. Therefore, coverage and reimbursement for products for which we may obtain marketing authorization could differ significantly from payor to payor. One payor&#x2019;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product. Payors consider a number of factors when determining whether to cover a new product, including, for example, whether the product is a covered benefit under its health plan; safe, effective and medically necessary; appropriate for the specific patient; cost-effective; and neither experimental nor investigational. Third-party payors may also limit coverage to specific products on an approved list, or formulary, which might not include all of the FDA-approved products for a particular indication.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, a payor&#x2019;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the reimbursement rate that the payor will pay for the product. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment. A decision by a third-party payor not to cover or not to separately reimburse for any products for which we may obtain marketing authorization could reduce physician utilization of such products. If coverage and adequate reimbursement are not available, or are available only to limited levels, we may not be able to successfully commercialize our product candidates. We cannot be sure that coverage and reimbursement in the United States will be available for our current or future product candidates or for any procedures using our current or future product candidates, and any reimbursement that may become available may not be adequate or may be decreased or eliminated in the future. Moreover, for products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself may or may not be available. Instead, the hospital or administering physician may be reimbursed only for providing the treatment or procedure in which our product is used.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, increasing efforts by third-party payors in the United States and abroad to cap or reduce healthcare costs may cause payor organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. In order to secure coverage and reimbursement for any product that might be approved for sale, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain FDA or comparable marketing authorizations or approvals. Additionally, we may also need to provide permissible discounts to purchasers, private health plans or government healthcare programs. Our product candidates may nonetheless not be considered medically necessary or cost-effective. If third-party payors do not consider a product to be cost-effective compared to other available therapies, they may not cover the product after marketing authorization or approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to sell its products at a profit. We expect to experience pricing pressures from third-party payors in connection with the potential sale of any of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lastly, in some foreign countries, the proposed pricing for a drug must be approved before the drug may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, countries in the European Union Member States can restrict the range of medicinal products for which their national health insurance systems provide reimbursement and they can control the prices of medicinal products for human use. To obtain reimbursement or pricing approval, some of these Member States may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies. A European Union Member State may approve a specific price for the medicinal product, or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Approaches between European Union Member States are diverging. For example, in France, effective market access will be supported by agreements with hospitals and products may be reimbursed by the Social Security Fund. The price of medicines is negotiated with the Economic Committee for Health Products, or CEPs. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our product candidates. Historically, products launched in the European Union do not follow price structures of the United States and generally prices in the European Union tend to be significantly lower than prices in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Enacted and future healthcare legislation may increase the difficulty and cost for us to progress our clinical programs and obtain marketing licensure or approval of and commercialize our product candidates and may affect the prices we may set.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> In the United States and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect results of our future operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. See Part I, Item 1, Government Regulation &#x2013; Other Healthcare Laws - Healthcare Reform for additional detail on recent healthcare reform efforts that could affect our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the extent to which state and federal governments cover particular healthcare products and services and could limit the amounts that federal and state governments will pay for healthcare items and services. This could result in reduced demand for any product candidate we develop or could result in additional pricing pressures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In markets outside of the United States, reimbursement and healthcare payment systems vary significantly by country and many countries have instituted price ceilings on specific products and therapies. The price control regulations outside of the United States can have a significant impact on the profitability of a given market, and further uncertainty is introduced if and when these laws change. For example, in Canada, price control legislation for patented medicines is currently undergoing significant change that may have significant effects on profitability for companies selling products in Canada.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action in the United States or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or these third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory licensure or approval that may have been obtained and we may not achieve or sustain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, operations, and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The global data protection landscape is rapidly evolving, and we may be or become subject to or affected by numerous federal, state and foreign laws and regulations, as well as regulatory guidance, governing the collection, use, disclosure, transfer, security and processing of personal information, such as information that we collect about participants and healthcare providers in connection with clinical trials. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, which may create uncertainty in our business, affect our or our service providers&#x2019; ability to operate in certain jurisdictions or to collect, store, transfer use and share personal data, result in liability or impose additional compliance or other costs on us. Any failure or perceived failure by us to comply with federal, state or foreign laws or self-regulatory standards could result in negative publicity, diversion of management time and effort and proceedings against us by governmental entities or others.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As our operations and business grow, we may become subject to or affected by new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities. In the United States, most healthcare providers, including certain research institutions from which we may obtain patient health information, are subject to privacy and security regulations promulgated under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act, which we collectively refer to as HIPAA. We are not currently acting as a covered entity or business associate under HIPAA and therefore are not directly regulated under HIPAA. However, any person may be prosecuted under HIPAA&#x2019;s criminal provisions either directly or under aiding-and-abetting or conspiracy principles. Consequently, depending on the facts and circumstances, we could face substantial criminal penalties if we knowingly receive individually identifiable health information from a HIPAA-covered healthcare provider or research institution that has disclosed individually identifiable health information in a manner that is not authorized or permitted under HIPAA. In addition, in the future, we may maintain sensitive personal information, including health-related information, that we receive throughout the clinical trial process, in the course of our research collaborations and/or directly from individuals (or their healthcare providers) who may enroll in patient assistance programs if we choose to implement these types of programs. As a result, we may be subject to data privacy and security laws protection such information, including state laws requiring notification of affected individuals and state regulators in the event of a breach of personal information, which is a broader class of information than the health information protected by HIPAA.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Federal Trade Commission, or the FTC and many state attorney generals are interpreting existing federal and state consumer protection laws to impose evolving standards for the collection, use, dissemination and security of health-related and other personal information. Privacy laws require us to publish statements that describe how we handle personal information and choices individuals may have about the way we handle their personal information. Violating individuals&#x2019; privacy rights, publishing false or misleading information about security practices, or failing to take appropriate steps to keep individuals&#x2019; personal information secure may constitute unfair or deceptive acts or practices in violation of Section 5 of the FTC Act. Additionally, the FTC recently published an advance notice of proposed rule making on &#x201c;commercial surveillance&#x201d; and data security, and is seeking comment on whether it should implement new trade regulation rules or other regulatory alternatives concerning the ways in which companies (2) collect, aggregate, protect, use, analyze, and retain consumer data, as well as (2) transfer, share, sell, or otherwise monetize that data in ways that are unfair or deceptive. Federal regulators, state attorneys general and plaintiffs&#x2019; attorneys have been and will likely continue to be active in this space, and if we do not comply with existing or new laws and regulations related to patient health information, we could be subject to criminal or civil sanctions. Further, the California Consumer Privacy Act of 2018, or the CCPA, went into effect in January 2020, which creates individual data privacy rights for consumers and operational requirements for companies, including placing increased privacy and security obligations on entities handling certain personal information of consumers or households. These requirements could increase our compliance costs and potential liability. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. While there is currently an exception for protected health information maintained by a business associate or covered entity as well as an exception for clinical trial data, as currently written, the CCPA may impact certain of our business activities. Further, the California Privacy Rights Act, or CPRA, recently passed in California and modifies the CCPA. The CCPA (as modified by the CPRA) imposes additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It also creates a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. The majority of the provisions went into effect on January 1, 2023, and additional compliance investment and potential business process changes may be required. Similar laws have been adopted in other states or proposed in other states and at the federal level, and if passed, such laws may have potentially conflicting requirements that would make compliance challenging. For example, on March 2, 2021, the Nevada Privacy of Information Collected on the Internet from Consumers Act went into effect on October 1, 2021, the Virginia Consumer Data Protection Act went into effect on January 1, 2023, the Colorado Privacy Act goes into effect on July 1, 2023, the Connecticut Data Privacy Act goes into effect July 1, 2023, and the Utah Consumer Privacy Act goes into effect December 31, 2023. In the event that we are subject to or affected by HIPAA, the CCPA and CPRA, or other privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the European Union General Data Protection Regulation, or EU GDPR, went into effect on May 2018 and imposes strict requirements for processing the personal data (i.e., data which identifies an individual or from which an individual is identifiable) of individuals within the EEA and grants individuals various data protection rights (e.g., the right to erasure of personal data).</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Companies that must comply with the EU GDPR face increased compliance obligations including </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">inter alia</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: (i) accountability and transparency requirements, and enhanced requirements for obtaining valid consent; (ii) obligations to consider data protection as any new products or services are developed, including to limit the amount of personal data processed; (iii) obligations to implement appropriate technical and organizational measures to safeguard personal data and to report certain personal data breaches to the relevant supervisory authority without undue delay (and, in any event, no later than 72 hours, where feasible); and (iv) additional more onerous requirements around the processing of special categories of personal data (including health data and genetic data).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The EU GDPR also prohibits transfers of personal data subject to the EU GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States, unless specific safeguards are implemented. Historically of the primary safeguards allowing U.S. companies to import personal data from the EEA was certification to the EU-U.S. Privacy Shield framework. However, the Court of Justice of the European Union, or the CJEU, issued a decision in July 2020 invalidating the EU-U.S. Privacy Shield framework as a data transfer mechanism (</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Schrems II</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) and imposing further restrictions on the use of standard contractual clauses, or SCCs, including a requirement for companies to carry out a transfer privacy impact assessment, which, among other things, assesses laws governing access to personal data in the recipient country and considers whether supplementary measures that provide privacy protections additional to those provided under the SCCs will need to be implemented to ensure an &#x201c;essentially equivalent&#x201d; level of data protection to that afforded in the EU. Subsequently, the European Commission published new EU SCCs in June 2022 to account for the decision in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Schrems II</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and which place onerous obligations on the contracting parties. At present, there are few, if any, viable alternatives to the SCCs. However, on October 7, 2022, the U.S. President introduced an Executive Order to facilitate a new U.S.-EU Data Privacy Framework which will act as a successor to the invalidated Privacy Shield. On December 13, 2022, the European Commission also published its draft adequacy decision to reflect its view that the new executive order and U.S.-EU Data Privacy Framework, is able to meet the concerns raised in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Schrems II</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. If the draft adequacy decision is approved and implemented, the agreement will facilitate the transatlantic flow of personal data and provide additional safeguards to data transfer mechanisms (including EU SCCs and Binding Corporate Rules) for companies transferring personal data from the EU to the U.S. However, before parties rely on the new framework, there are still legislative and regulatory steps that must be undertaken both in the U.S. and in the EU.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Companies subject to the EU GDPR may be subject to robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#x20ac;20 million or 4% of the annual global turnover of the noncompliant company, whichever is greater. In addition, the EU GDPR confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting from violations of the EU GDPR.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, from January 1, 2021, companies may have to comply with the EU GDPR and also the United Kingdom GDPR, or the UK GDPR, which, together with the amended United Kingdom Data Protection Act 2018, retains the EU GDPR in United Kingdom national law. The UK GDPR mirrors the fines under the EU GDPR, i.e., fines up to the greater of &#x20ac;20 million (&#163;17.5 million) or 4% of annual global turnover. The European Commission has adopted an adequacy decision in favor of the UK, enabling data transfers from EU Member States to the UK without additional safeguards. However, the UK adequacy decision will automatically expire in June 2025 unless the European Commission re-assesses and renews/extends that decision, and remains under review by the Commission during this period. These changes may lead to additional costs and increase our overall risk exposure. It should also be noted that the UK Government published its own form of SCCs, known as the International Data Transfer Agreement and International Data Transfer Addendum to the new EU SCCs. The UK Information Commissioner&#x2019;s Office has also published its version of the transfer impact assessment and revised guidance on international transfers, although entities may choose to adopt either the EU or UK style transfer impact assessment. In terms of international data transfers between the UK and U.S., it is understood that the UK and the U.S. are negotiating an adequacy agreement to be known as a &#x201c;Data Bridge&#x201d;.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although we work to comply with applicable laws, regulations and standards, our contractual obligations and other legal obligations, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another, and may conflict with one another or other legal obligations with which we must comply. Any failure or perceived failure by us or our employees, representatives, contractors, consultants, collaborators, or other third parties to comply with such requirements or adequately address privacy and security concerns, even if unfounded, could result in additional cost and liability to us, damage our reputation, and adversely affect our business and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we or our third-party manufacturers and suppliers fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have an adverse effect on the success of our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our research and development activities involve the use of biological and hazardous materials and produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by our third-party manufacturers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. Upon an event of this nature, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Further, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of any changes of this nature and cannot be certain of our future compliance. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although we maintain workers&#x2019; compensation insurance to cover us for costs and expenses, we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. We do not carry specific biological waste or hazardous waste insurance coverage, workers compensation or property and casualty and general liability insurance policies that include coverage for damages and fines arising from biological or hazardous waste exposure or contamination.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations, which can harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#x2019;s Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act of 2001 and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors and other collaborators from authorizing, promising, offering or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties for clinical trials outside of the United States, to sell our products abroad once we enter a commercialization phase and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals. We may also have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors and other collaborators, even if we do not explicitly authorize or have actual knowledge of these activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">93</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Employee Matters, Managing Our Growth and Other Risks Related to Our Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we fail to attract and retain qualified senior management and key scientific personnel, our business may be materially and adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our success depends in part on our continued ability to attract, retain and motivate highly qualified management and clinical and scientific personnel. We are highly dependent upon members of our senior management, including Lara Sullivan, M.D., our President and Chief Executive Officer, Pamela Connealy, our Chief Financial Officer and Chief Operating Officer, and Jay Feingold M.D., Ph.D., our Chief Medical Officer, as well as our senior scientists and other members of our senior management team. The loss of services of any of these individuals could delay or prevent the successful development of our product pipeline, the initiation and completion of our planned clinical trials or the commercialization of product candidates or any future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Competition for qualified personnel in the pharmaceutical, biopharmaceutical and biotechnology field is intense due to the limited number of individuals who possess the skills and experience required by our industry. We will need to hire additional personnel as we expand our clinical development and if we initiate commercial activities. We may not be able to attract and retain quality personnel on acceptable terms, or at all. In addition, to the extent we hire personnel from competitors, we may be subject to allegations that they have been improperly solicited or that they have divulged proprietary or other confidential information, or that their former employers own their research output.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If our product candidates advance into clinical trials, we may experience difficulties in managing our growth and expanding our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 22, 2023, we had 75 full-time employees. As our development and commercialization plans and strategies develop, and as we continue to operate as a public company, we expect to expand our employee base for managerial, operational, financial and other resources. In addition, we have limited experience in product development. As our product candidates enter and advance through preclinical studies and clinical trials, we will need to expand our development, regulatory and manufacturing capabilities or contract with other organizations to provide these capabilities for us. In the future, we expect to have to manage additional relationships with collaborators or partners, suppliers and other organizations. Our ability to manage our operations and future growth will require us to continue to improve our operational, financial and management controls, reporting systems and procedures. We may not be able to implement improvements to our management information and control systems in an efficient or timely manner and may discover deficiencies in existing systems and controls. Our inability to successfully manage our growth and expand our operations could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently have no marketing, sales, or distribution infrastructure and we intend to either establish a sales and marketing infrastructure or outsource this function to a third party. Either of these commercialization strategies carries substantial risks to us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently have no marketing, sales, and distribution capabilities because all our product candidates are still in preclinical development. If any of our product candidates complete clinical development and are approved, we intend to either establish a sales and marketing organization with technical expertise and supporting distribution capabilities to commercialize our product candidates in a legally compliant manner, or to outsource this function to a third party. There are risks involved if we decide to establish our own sales and marketing capabilities or enter into arrangements with third parties to perform these services. To the extent that we enter into collaboration agreements with respect to marketing, sales or distribution, our product revenue may be lower than if we directly marketed or sold any approved products. Such collaborative arrangements with partners may place the commercialization of our products outside of our control and would make us subject to a number of risks, including that we may not be able to control the amount or timing of resources that our collaborative partner devotes to our products or that our collaborator&#x2019;s willingness or ability to complete its obligations, and our obligations under our arrangements may be adversely affected by business combinations or significant changes in our collaborator&#x2019;s business strategy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are unable to enter into these arrangements on acceptable terms or at all, we may not be able to successfully commercialize any approved products. If we are not successful in commercializing any approved products, either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we may incur significant additional losses, which would have a material adverse effect on our business, financial condition, and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our internal computer systems, or those of any of our existing or future CROs, manufacturers, other contractors, consultants, or collaborators, may fail or suffer security or data privacy breaches or other unauthorized or improper access to, use of or destruction of our proprietary and confidential data, employee data or personal data, which could result in additional costs, significant liabilities, harm to our reputation and material disruption of our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the ordinary course of our business, we collect, process, and store proprietary, confidential, and sensitive information, including personal information (including health information), intellectual property, trade secrets, and proprietary business information owned or controlled by ourselves or other parties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Despite the implementation of security measures, our internal computer systems and those of our current and any future CROs, manufacturers, other contractors, consultants, existing or future collaborators and other third-party service providers are vulnerable to damage from various methods, including cybersecurity attacks, breaches, intentional or accidental mistakes or errors, or other technological failures, which can include, among other things, computer viruses, unauthorized access attempts, including third parties gaining access to systems using stolen or inferred credentials, ransomware attacks, denial-of-service attacks, phishing attempts, service disruptions, natural disasters, fire, terrorism, war and telecommunication and electrical failures. As the cyber-threat landscape evolves, these attacks are growing in frequency, sophistication and intensity, and are becoming increasingly difficult to detect. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If such an event were to occur and cause interruptions in our operations or result in the unauthorized acquisition of or access to personally identifiable information or individually identifiable health information, it could result in a material disruption of our product candidate development programs and our business operations including without limitation, disruptions of our drug development programs, delays in our regulatory approval efforts, regulatory investigations or enforcement actions, litigation, indemnity obligations, negative publicity, and financial loss and significant liabilities. In addition, system failures could cause the loss, theft, exposure, or unauthorized access or use of valuable clinical trial data as a result of accidents, errors or malfeasance by our employees, independent contractors or others working with us or on our behalf or otherwise disrupt our clinical activities and be expensive and time-consuming to remedy. Some of the federal, state and foreign government legal requirements include obligations of companies to notify individuals of security breaches involving particular personally identifiable information, which could result from breaches experienced by us or by our vendors, contractors or organizations with which we have formed strategic relationships. Notifications and follow-up actions related to a security breach could impact our reputation and cause us to incur significant costs, including legal expenses and remediation costs. For example, the loss of clinical trial data from completed, ongoing or future clinical trials involving our product candidates could result in delays in our regulatory licensure efforts and significantly increase our costs to recover or reproduce the lost data. Any breach of our computer systems may result in a loss of data or compromised data integrity across many of our programs in various stages of development.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may be required to expend resources, modify our business activities and practices, or modify our operations (including our development program activities) or information technology in an effort to comply with applicable data protection laws, privacy policies and data protection obligations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While we have implemented security measures designed to protect against security breaches, there can be no assurance that our security measures or those of our service providers, partners and other third parties, will be effective in protecting against all security breaches and material adverse effects on our business that may arise from such breaches. The recovery systems, security protocols, network protection mechanisms and other security measures that we (and our third parties) have integrated into our platform, systems, networks and physical facilities, which are designed to protect against, detect and minimize security breaches, may not be adequate to prevent or detect service interruption, system failure, or data loss.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will also rely on third parties to manufacture our product candidates, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data, or inappropriate disclosure of confidential or proprietary information, we could be exposed to litigation and governmental investigations, the further development and commercialization of our product candidates could be delayed and we could be subject to significant fines or penalties for any noncompliance with certain state, federal or international privacy and security laws.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our insurance policies may not be adequate to compensate us for the potential losses arising from any such disruption, failure or security breach. In addition, such insurance may not be available to us in the future on economically reasonable terms, or at all. Further, our insurance may not cover all claims made against us and could have high deductibles in any event, and defending a suit, regardless of its merit, could be costly and divert management attention.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">95</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We or the third parties upon whom we depend on may be adversely affected by earthquakes, wildfires or other natural disasters, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any unplanned event, such as flood, fire, explosion, earthquake, extreme weather condition, medical epidemics or pandemics, power shortage, telecommunication failure or other natural or manmade accidents or incidents that result in us being unable to fully utilize our facilities, or the manufacturing facilities of our third-party contract manufacturers, may have a material and adverse effect on our ability to operate our business, particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of our product candidates or interruption of our business operations. Earthquakes, wildfires or other natural disasters could further disrupt our operations, and have a material and adverse effect on our business, financial condition, results of operations and prospects. If a natural disaster, power outage or other event prevented us from using all or a significant portion of our headquarters, damaged critical infrastructure, such as our research facilities or the manufacturing facilities of our third-party contract manufacturers, or otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, we cannot assure you that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities, or the manufacturing facilities of our third-party contract manufacturers, are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development and discovery programs may be harmed. Any business interruption may have a material and adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business is subject to economic, political, regulatory and other risks associated with conducting business internationally.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may seek regulatory approval or licensure of our product candidates outside of the United States. Accordingly, we expect that we will be subject to additional risks related to operating in foreign countries if we obtain the necessary approvals or licenses, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">differing regulatory requirements and reimbursement regimes in foreign countries; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">economic weakness, including inflation, or political instability in particular foreign economies and markets; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">foreign taxes, including withholding of payroll taxes; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">difficulties staffing and managing foreign operations; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">workforce uncertainty in countries where labor unrest is more common than in the United States; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">potential liability under the Foreign Corrupt Practices Act, or FCPA, or comparable foreign regulations; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">business interruptions resulting from geo-political actions, including war and terrorism. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These and other risks associated with our international operations may materially adversely affect our ability to attain or maintain profitable operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We face risks related to health epidemics and outbreaks, including the COVID-19 pandemic, which could significantly disrupt our preclinical studies and clinical trials, and therefore our receipt of necessary regulatory licensure or approvals could be delayed or prevented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2019, the coronavirus disease, COVID-19, was identified in Wuhan, China. Since then, COVID-19 has spread globally. In March 2020, the World Health Organization declared COVID-19 a global pandemic and the United States declared a national emergency with respect to COVID-19. In response to the COVID-19 pandemic, &#x201c;shelter in place&#x201d; orders and other public health guidance measures have been implemented across much of the United States, including in the locations of our offices and those of key vendors and partners. As a result of the COVID-19 pandemic, or similar pandemics, and related &#x201c;shelter in place&#x201d; orders and other public health guidance measures, we may in the future experience disruptions that could materially and adversely impact our preclinical studies and development, any clinical trials we subsequently commence, and our business, financial condition, and results of operations. Potential disruptions to our preclinical development efforts include, but are not limited to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays or disruptions in preclinical experiments and IND-enabling studies due to restrictions of on-site staff, limited or no access to animal facilities, and unforeseen circumstances at CROs and vendors; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">limitations on employee or other resources that would otherwise be focused on the conduct of our preclinical work and any clinical trials we subsequently commence, including because of sickness of employees or their families, the desire of employees to avoid travel or contact with large groups of people, an increased reliance on working from home, school closures, or mass transit disruptions; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in necessary interactions with regulators, ethics committees, and other important agencies and contractors due to limitations in employee resources or forced furlough of government or contractor personnel; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">limitations in maintaining our corporate culture that facilitates the transfer of institutional knowledge within our organization and fosters innovation, teamwork, and a focus on execution. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Potential disruptions of clinical activities as a result of COVID-19 or similar pandemics including, but are not limited to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">interruption of key clinical trial activities, such as clinical trial site data monitoring and efficacy, safety and translational data collection, processing and analyses, due to limitations on travel imposed or recommended by federal, state, or local governments, employers and others or interruption of clinical trial subject visits, which may impact the collection and integrity of subject data and preclinical study endpoints; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays or difficulties in initiating or expanding clinical trials, including delays or difficulties with clinical site initiation and recruiting clinical site investigators and clinical site staff; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays or difficulties in enrolling and retaining patients in our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">increased rates of patients withdrawing from our clinical trials following enrollment as a result of contracting COVID-19 or other health conditions or being forced to quarantine; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns, or stoppages and disruptions in materials and reagents; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">interruption or delays in the operations of the FDA and comparable foreign regulatory agencies; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in regulations as part of a response to the COVID-19 pandemic which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in receiving approval from local regulatory authorities to initiate our planned clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">limitations on employee resources that would otherwise be focused on the conduct of our preclinical studies and clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">refusal of the FDA or comparable regulatory authorities to accept data from clinical trials in affected geographies; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">additional delays, difficulties or interruptions as a result of current or future shutdowns due to the COVID-19 pandemic in countries where we or our third-party service providers operate. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The COVID-19 global pandemic continues to rapidly evolve. Although many countries, including certain countries in Europe and the United States, have re-opened, rises in new cases have caused certain countries to re-initiate restrictions. The extent to which the outbreak may affect our preclinical studies, clinical trials, business, financial condition, and results of operations will depend on future developments, which are highly uncertain and cannot be predicted at this time, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions, and actions to contain the outbreak or treat its impact, such as social distancing and quarantines or lock-downs in the United States and other countries, business closures, or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. Additionally, we are unable to predict if a different pandemic could have similar or different impacts on our business, financial condition, or share price. Future developments in these and other areas present material uncertainty and risk with respect to our clinical trials, business, financial condition, and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disruptions at the FDA, the SEC and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the Securities and Exchange Commission, or the SEC, and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, in recent years, including in 2018 and 2019, the U.S. government shut down several times and certain regulatory agencies, such as the FDA and the SEC, had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Separately, in response to the COVID-19 pandemic, on March 10, 2020, the FDA announced its intention to postpone most inspections of foreign manufacturing facilities, and on March 18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. On July 10, 2020, the FDA announced its intention to resume certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA intends to use this risk-based assessment system to identify the categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities. Additionally, on April 15, 2021, the FDA issued a guidance document in which the FDA described its plans to conduct voluntary remote interactive evaluations of certain drug manufacturing facilities and clinical research sites. According to the guidance, the FDA intends to request such remote interactive evaluations in situations where an in-person inspection would not be prioritized, deemed mission-critical, or where direct inspection is otherwise limited by travel restrictions, but where the FDA determines that remote evaluation would still be appropriate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FDA has since adjusted its inspection activities in response to the ongoing COVID-19 pandemic. On December 29, 2021, the agency implemented temporary changes to its inspectional activities to ensure the safety of its employees and regulated firms. On February 2, 2022, FDA announced that it would resume domestic surveillance inspections across all product areas on February 7, 2022. We cannot predict whether, and when, FDA will decide to pause or resume inspections due to the COVID-19 pandemic.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">98</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Dependence on Third Parties</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we fail to comply with our obligations under any license, collaboration or other agreements, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our product candidates or we could lose certain rights to grant sublicenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a party to license agreements with Pfizer Inc., or Pfizer, Biosion USA, Inc., or Biosion, and the University of Chicago, pursuant to which we in-license patents and technology for certain of our product candidates, and we are also party to a collaboration agreement with Alloy Therapeutics, Inc., or Alloy, and Voxall Therapeutics, LLC, or Voxall, pursuant to which we may license patents and technology for future product candidates. Our current license agreements and our collaboration agreement impose, and any future license agreements or collaboration agreements we enter into are likely to impose, various development, commercialization, funding, milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement and/or other obligations on us. If we breach any of these obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and the licensor may have the right to terminate the license, which could result in us being unable to develop, manufacture and sell products that are covered by the licensed technology or enable a competitor to gain access to the licensed technology. Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor&#x2019;s rights. In addition, while we cannot currently determine the amount of the royalty obligations we would be required to pay on sales of future products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in products that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have already entered into collaborations with third parties for the research, development and commercialization of certain of the product candidates we may develop. We may form or seek additional collaborations or strategic alliances or enter into additional licensing arrangements in the future. If any of these collaborations, strategic alliances or additional licensing arrangements are not successful, we may not be able to capitalize on the market potential of those product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We entered into a three-year collaboration with Alloy to finance and operate Voxall, a joint venture company formed in collaboration with Alloy to leverage our site-specific target catalog and Alloy&#x2019;s ATX-Gx platform and antibody discovery services. We additionally may seek other third-party collaborators for the research, development and commercialization of our current or future product candidates. The collaboration with Alloy and Voxall and any other collaboration agreements we enter into will likely limit our control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of any product candidates we may seek to develop with them. Our ability to generate revenues from these arrangements will depend on our collaborators&#x2019; abilities to successfully perform the functions assigned to them in these arrangements. We cannot predict the success of any collaboration in which we have entered or may enter.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may in the future form or seek strategic alliances, create joint ventures or collaborations or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our product candidates and any future product candidates that we may develop. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process for these sorts of transactions is time-consuming, complex and expensive. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate safety, potency, purity and efficacy and obtain marketing approval. Additionally, our existing partners may decide to acquire or partner with other companies developing oncology therapeutics, which may have an adverse impact on our business prospects, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result, if we enter into additional collaboration agreements and strategic partnerships or license our product candidates, we may not be able to realize the benefit of those transactions if we are unable to successfully integrate them with our existing operations and company culture, which could delay our timelines or otherwise adversely affect our business prospects, financial condition and results of operations. We also cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies the entry into the transaction in the first place. Any delays in entering into new collaborations or strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates in certain geographies for certain indications, which would harm our business prospects, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely on third parties to manufacture our product candidates. Any failure by a third party manufacturer to produce acceptable raw materials or product candidates for us or to obtain authorization from the FDA or comparable foreign regulatory authorities relating thereto may delay or impair our ability to initiate or complete our clinical trials, obtain regulatory licensure or approvals or commercialize approved products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely on third-party contract manufacturers to manufacture our preclinical trial product supplies and clinical product supplies, and if we receive authorization to market our product candidates, for commercial supplies. We do not own or operate manufacturing facilities for producing such supplies. There can be no assurance that our preclinical and clinical development product supplies will not be limited, interrupted, or of satisfactory quality or continue to be available at acceptable prices. In particular, any replacement of our manufacturer could require significant effort and expertise because there may be a limited number of qualified replacements and could take a significant amount of time to complete.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The manufacturing process for a product candidate is subject to FDA and foreign regulatory authority review. Suppliers and manufacturers must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory standards, such as cGMPs. In the event that any of our manufacturers fail to comply with such requirements or to perform its obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third party, which we may not be able to do on reasonable terms, if at all. In some cases, the technical skills or technology required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty transferring such skills or technology to another third party and a feasible alternative may not exist. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third party manufacture our product candidates. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates in a timely manner or within budget.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect to continue to rely on third party manufacturers if we receive regulatory licensure for any product candidate. To the extent that we have existing, or enter into future, manufacturing arrangements with third parties, we will depend on these third parties to perform their obligations in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance. If we are unable to obtain or maintain third party manufacturing for product candidates, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our product candidates successfully. Our or a third party&#x2019;s failure to execute on our manufacturing requirements and comply with cGMP or similar foreign requirements could adversely affect our business in a number of ways, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">an inability to initiate or continue clinical trials of product candidates under development; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delay in submitting regulatory applications, or receiving regulatory licenses, for product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">loss of the cooperation of an existing or future collaborators; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">subjecting third party manufacturing facilities or our manufacturing facilities to additional inspections by regulatory authorities; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">requirements to cease distribution or to recall batches of our product candidates; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the inability to commercialize a product candidate, and an inability to meet commercial demands for such products. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may be unable to establish agreements with third party contract manufacturing organizations, or CMO, or to do so on acceptable terms. Even if we are able to establish agreements with CMOs, reliance on them entails additional risks, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reliance on the CMO for regulatory, compliance and quality assurance; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the possible breach of the manufacturing agreement by the CMO; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the possible misappropriation of our proprietary information, including our trade secrets and know-how; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the possible termination or nonrenewal of the agreement by the CMO at a time that is costly or inconvenient for us. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have only limited technology transfer agreements in place with respect to our product candidates, and these arrangements do not extend to commercial supply and, in some instances, to clinical supply. We acquire many key materials on a purchase order basis. As a result, we do not have long-term committed arrangements with respect to our product candidates and other materials. If we receive marketing licensure for any of our product candidates, we will need to establish an agreement for commercial manufacture with a third party.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The CMOs we retain may not be able to comply with cGMP regulations or similar regulatory requirements outside of the United States. Our failure, or the failure of our CMOs, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of license, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The facilities used by our contract manufacturers to manufacture our product candidates must be approved by the FDA or the European Union Member States in coordination with the EMA pursuant to inspections that will be conducted after we submit our BLA to the FDA or our marketing authorization application to the EMA. We do not have complete control over all aspects of the manufacturing process of, and are dependent on, our contract manufacturing partners for compliance with cGMP regulations for manufacturing. Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside of the United States. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or comparable foreign regulatory bodies, they will not be able to secure and/or maintain marketing licensure for their manufacturing facilities. In addition, we do not have complete control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA, European Union Member States and the EMA or other comparable regulatory authorities does not approve these facilities for the manufacture of our product candidates or if it withdraws any such licensure in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain marketing licensure for or market our product candidates, if approved or licensed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of licensure, license revocation, seizures or recalls of products or product candidate, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates and harm our business and results of operations. Our product candidates and any products that we may develop may compete with other product candidates and products for access to suitable manufacturing facilities. As a result, we may not obtain access to these facilities on a priority basis or at all. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing licensure. We do not currently have arrangements in place for redundant supply or a second source for bulk drug substance. If our current CMOs cannot perform as agreed, we may be required to replace such manufacturers. Although we believe that there are several potential alternative manufacturers who could manufacture our product candidates, we may incur added costs and delays in identifying and qualifying any such replacement manufacturer or be able to reach agreement with any alternative manufacturer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our current and anticipated future dependence upon others for the manufacture of our product candidates or products may adversely affect our future profit margins and our ability to commercialize any products that receive marketing licensure on a timely and competitive basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A portion of our manufacturing of our product candidates takes place in China, through third-party manufacturers. A significant disruption in the operation of those manufacturers could materially adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently contract manufacturing operations to third parties, and large quantities of our product candidates are manufactured by these third parties outside the U.S., including in China. Any disruption in production or inability of our manufacturers to produce adequate quantities to meet our needs could impair our ability to operate our business on a day-to-day basis and to continue our development of our product candidates. Furthermore, since certain of these manufacturers are located in China, we are exposed to the possibility of product supply disruption and increased costs in the event of changes in the policies of the U.S. or Chinese governments, political unrest or unstable economic conditions in China. For example, a trade war could lead to tariffs on the chemical intermediates we use that are manufactured in China. Any of these matters could materially and adversely affect our business and results of operations. Any recall of the manufacturing lots or similar action regarding our product candidates used in clinical trials could delay the trials or detract from the integrity of the trial data and its potential use in future regulatory filings.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our CMOs may be unable to successfully scale-up manufacturing of our product candidates in sufficient quality and quantity, which would delay or prevent us from developing our product candidates and commercializing approved products, if any.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In order to conduct clinical trials of our product candidates, we will need to manufacture them in large quantities. Quality issues may arise during scale-up activities. Our reliance on a limited number of CMOs, the complexity of drug manufacturing and the difficulty of scaling up a manufacturing process could cause the delay of clinical trials, regulatory submissions, required licensure, or commercialization of our product candidates, cause us to incur higher costs and prevent us from commercializing our product candidates successfully. Furthermore, if our CMOs fail to deliver the required commercial quality and quantities of materials on a timely basis and at commercially reasonable prices, and we are unable to secure one or more replacement CMOs capable of production in a timely manner at a substantially equivalent cost, then testing and clinical trials of that product candidate may be delayed or infeasible, and regulatory licensure or commercial launch of any resulting product may be delayed or not obtained, which could significantly harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Some of our suppliers may experience disruption to their respective supply chain due to the effects of the COVID-19 pandemic, which could delay, prevent or impair our development or commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We obtain certain chemical or biological intermediates in the synthesis of our product candidates in countries affected by the COVID-19 pandemic. If we are unable to obtain these chemical or biological intermediates in sufficient quantity and in a timely manner, the development, testing and clinical trials of that product candidate may be delayed or infeasible, and regulatory licensure or commercial launch of any resulting product may be delayed or not obtained, which could significantly harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are unable to obtain sufficient raw and intermediate materials on a timely basis or if we experience other manufacturing or supply difficulties, our business may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The manufacture of certain of our product candidates requires the timely delivery of sufficient amounts of raw and intermediate materials. We work closely with our suppliers to ensure the continuity of supply but cannot guarantee these efforts will always be successful. Further, while efforts are made to diversify our sources of raw and intermediate materials, in certain instances we acquire raw and intermediate materials from a sole supplier. While we believe that alternative sources of supply exist where we rely on sole supplier relationships, there can be no assurance that we will be able to quickly establish additional or replacement sources for some materials. A reduction or interruption in supply, and an inability to develop alternative sources for such supply, could adversely affect our ability to manufacture our product candidates in a timely or cost-effective manner.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect to rely on third parties to conduct our clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for completing such trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will rely on third-party CROs, to conduct clinical trials for our biological product candidates. We currently do not plan to conduct any clinical trials independently. Agreements with these CROs might terminate for a variety of reasons, including for their failure to perform. Entry into alternative arrangements, if necessary, could significantly delay our product development activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our reliance on these CROs for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols in the applicable IND. Moreover, the FDA requires compliance with standards, commonly referred to as GCPs for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If these CROs do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing licenses for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">102</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Intellectual Property</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are unable to obtain and maintain patent protection for our product candidates, or if the scope of the patent protection obtained is not sufficiently broad, or if our patents are insufficient to protect our product candidates for an adequate amount of time, or if we are unable to obtain adequate protection for our proprietary know-how, we may not be able to compete effectively in our markets.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely upon a combination of patents, proprietary know-how, trade secret protection and confidentiality agreements to protect the intellectual property related to our product candidates and discovery programs. Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our current and any future product candidates. We seek to protect our proprietary position by, among other methods, licensing and filing patent applications in the United States and abroad related to our current and future product candidates and discovery programs. The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. We may also rely on trade secrets, know-how and continuing technological innovation to develop and maintain our proprietary and intellectual property position.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We in-license and file patent applications directed to our product candidates in an effort to establish intellectual property positions directed to their compositions of matter as well as uses of these product candidates in the treatment of diseases. Our intellectual property includes patents and patent applications that we own, as well as patents and patent applications that we in-license. For example, our license agreements with Pfizer and Biosion grant us exclusive rights to certain patents and patent applications relating to our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We or our licensors have not pursued or maintained, and may not pursue or maintain in the future, patent protection for our product candidates in every country or territory in which we may sell our products, if approved. In addition, we cannot be sure that any of our pending patent applications will issue or that, if issued, they have or will issue in a form that will be advantageous to us. The United States Patent and Trademark Office, or the USPTO, international patent offices or judicial bodies may deny, or significantly narrow claims made under our patent applications and our issued patents may be successfully challenged, may be designed around, or may otherwise be of insufficient scope to provide us with protection for our commercial products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">It is possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, patent prosecution is a lengthy process, during which the scope of the claims initially submitted for examination by the USPTO may be significantly narrowed by the time they issue, or claims may not issue at all. The claims of our issued patents or patent applications when issued may not cover our current or future product candidates, or even if such patents provide coverage, the coverage obtained may not provide any competitive advantage. The patent applications that we own, or in-license may fail to result in issued patents with claims that cover our current or any future product candidates in the United States or in other foreign countries. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue and even if such patents cover our current or any future product candidates, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed, invalidated, or held unenforceable. Any successful opposition to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. Further, if we encounter delays in regulatory licensure or approvals, the period of time during which we could market a product candidate under patent protection could be reduced.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the patent applications we own or have in-licensed with respect to our product candidates and discovery programs fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for our current or any future product candidates, it could dissuade companies from collaborating with us to develop and commercialize product candidates and future drugs and threaten our ability to commercialize future drugs. Any such outcome could have a negative effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">103</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. In addition, the laws of foreign countries may not protect our intellectual property rights to the same extent as the laws of the United States. For example, European patent law restricts the patentability of methods of treatment of the human body more than United States law does. Furthermore, other parties may have developed or may develop technologies that may be related to, or competitive with, our technologies, and such parties may have filed, or may file, patent applications, or may have received, or may receive, patents, claiming inventions that may overlap or conflict with those claimed in our patent applications or issued patents, and that we may rely upon to establish exclusivity for our products in the market. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or drugs, in whole or in part, or which effectively prevent others from commercializing competitive technologies and drugs. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may be subject to a third-party submission of prior art to the USPTO, or other patent offices, in our pending patent applications. Such a submission may preclude the granting of any of our pending patent applications, or may result in patents granting with narrow claims, which could limit our ability to stop others from using or commercializing similar or identical technology and products. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patent rights may be challenged in the courts or patent offices in the United States and abroad. For example, we may become involved in opposition, derivation, reexamination, inter partes review, post-grant review, or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such proceeding, or in litigation, could reduce the scope of our patent claims, result in our patent rights being held invalid, in whole or in part, or unenforceable, or limit the duration of the patent protection of our technology and products, and allow third parties to commercialize our technology or products and compete directly with us without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize our current or any future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, patents have a limited lifespan. In the United States, a patent generally expires 20 years after the earliest filing date of a non-provisional patent application. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Without patent protection for our current or any future product candidates, we may be open to competition from generic and/or biosimilar versions of such products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent rights may not provide us with sufficient rights to exclude others from commercializing drugs similar or identical to ours.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if our patent rights are unchallenged, our issued patents and our pending patent applications, if issued, may not provide us with any meaningful protection or prevent competitors from designing around our patent claims to circumvent our owned patent rights by developing similar or alternative technologies or products in a non-infringing manner. For example, a third-party may develop a competitive product that provides benefits similar to one or more of our product candidates, but that has a different composition that falls outside the scope of our patent protection. If the protection provided by our patent rights with respect to our product candidates is not sufficiently broad to impede such competition, or if the breadth, strength or term (including any extensions or adjustments) of protection provided by our patent rights with respect to our product candidates or any future product candidates is successfully challenged, our ability to successfully commercialize our product candidates could be negatively affected, which would harm our business. Further, if we encounter delays in our clinical trials, the period of time during which we could market our product candidates or any future product candidates under patent protection would be reduced.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Obtaining and maintaining our patent rights depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In addition, periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and/or patent applications will have to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our owned and licensed patents and/or applications and any patent rights we may own or license in the future. We rely on our service providers or our licensors to pay these fees. The USPTO and various non-U.S. government patent agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and we are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our licensors fail to maintain the patents and patent applications covering our products or technologies, we may not be able to stop a competitor from marketing products that are the same as, or similar to, our product candidates, which would have a material adverse effect on our business. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market and this circumstance could harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, if we fail to apply for applicable patent term extensions or adjustments, we will have a more limited time during which we can enforce our granted patent rights. In addition, if we are responsible for patent prosecution and maintenance of patent rights in-licensed to us, any of the foregoing could expose us to liability to the applicable patent owner.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Given the amount of time required for the development, testing and regulatory review of new product candidates such as PYX-201 and PYX-106, patents protecting such candidates might expire before or shortly after such candidates are commercialized. We expect to seek extensions of patent terms in the United States and, if available, in other countries where we have or will obtain patent rights. In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years beyond the normal expiration of the patent, provided that the patent is not enforceable for more than 14 years from the date of licensure, which is limited to the approved indication (or any additional indications approved during the period of extension). However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If this occurs, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their drug earlier than might otherwise be the case.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">105</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats to our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business. The following examples are illustrative:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">others may be able to make compounds or formulations that are similar to our product candidates but that are not covered by the claims of any patents, should they issue, that we own or license; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we or our licensors might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own or license; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we or our licensors might not have been the first to file patent applications covering certain of our inventions; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">it is possible that our pending patent applications will not lead to issued patents; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">issued patents that we own or license may not provide us with any competitive advantages, or may be held invalid or unenforceable as a result of legal challenges; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights and then use the information learned from such activities to develop competitive drugs for sale in our major commercial markets; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may not develop additional proprietary technologies that are patentable; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the patents of others may have an adverse effect on our business.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a negative impact on the success of our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our commercial success depends, in part, upon our ability and the ability of others with whom we may collaborate to develop, manufacture, market and sell our current and any future product candidates and use our proprietary technologies without infringing the proprietary rights and intellectual property of third parties. The biotechnology and pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual property rights. We may in the future become party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our current and any future product candidates and technology, including interference proceedings, post grant review and inter partes review before the USPTO. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their merit. There is a risk that third parties may choose to engage in litigation with us to enforce or to otherwise assert their patent rights against us. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, which could have a negative impact on our ability to commercialize our current and any future product candidates. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. Moreover, given the vast number of patents in our field of technology, we cannot be certain that we do not infringe existing patents or that we will not infringe patents that may be granted in the future. Other companies and research institutions have filed, and may file in the future, patent applications related to antibodies or antibody-drug conjugates and their therapeutic use. Some of these patent applications have already been allowed or issued, and others may issue in the future. While we may decide to initiate proceedings to challenge the validity of these or other patents in the future, we may be unsuccessful, and courts or patent offices in the United States and abroad could uphold the validity of any such patent. Furthermore, because patent applications can take many years to issue and may be confidential for 18 months or more after filing, and because pending patent claims can be revised before issuance, there may be applications now pending which may later result in issued patents that may be infringed by the manufacture, use or sale of our product candidates. Regardless of when filed, we may fail to identify relevant third-party patents or patent applications, or we may incorrectly conclude that a third-party patent is invalid or not infringed by our product candidates or activities. If a patent holder believes our product candidate infringes its patent, the patent holder may sue us even if we have received patent protection for our technology. Moreover, we may face patent infringement claims from non-practicing entities that have no relevant drug revenue and against whom our own patent portfolio may thus have no deterrent effect. If a patent infringement suit were threatened or brought against us, we could be forced to stop or delay research, development, manufacturing or sales of the therapeutic or product candidate that is the subject of the actual or threatened suit.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are found to infringe a third party&#x2019;s valid and enforceable intellectual property rights, we could be required to obtain a license from such third party to continue developing, manufacturing and marketing our product candidate(s) and technology. Under any such license, we would most likely be required to pay various types of fees, milestones, royalties or other amounts. Moreover, we may not be able to obtain any required license on commercially reasonable terms or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The licensing or acquisition of third-party intellectual property rights is a competitive area, and more established companies may also pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate(s), which could have a material adverse effect on our business, financial condition, results of operations and prospects. Furthermore, even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or product candidate. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#x2019; fees, if we are found to have willfully infringed a patent or other intellectual property right. We may be required to indemnify collaborators or contractors against such claims. A finding of infringement could prevent us from manufacturing and commercializing our current or any future product candidates or force us to cease some or all of our business operations, which could materially harm our business. Even if we are successful in defending against such claims, litigation can be expensive and time consuming and would divert management&#x2019;s attention from our core business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain of our employees, consultants or advisors are currently, or were previously, employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#x2019;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we may in the future be subject to claims by our former employees or consultants asserting an ownership right in our patents or patent applications, as a result of the work they performed on our behalf. Although it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own, and we cannot be certain that our agreements with such parties will be upheld in the face of a potential challenge or that they will not be breached, for which we may not have an adequate remedy. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">107</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues. If we breach our University of Chicago, Pfizer, or Biosion license agreements or any of the other agreements under which we acquired, or will acquire, intellectual property rights covering our product candidates, we could lose the ability to continue the development and commercialization of the related product candidates(s).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The licensing of intellectual property is of critical importance to our business and to our current and future product candidates, and we expect to enter into additional such agreements in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In particular, the rights to the intellectual property covering PYX-201 are in-licensed from Pfizer and the rights to the intellectual property covering our product candidate PYX-106 are in-licensed from Biosion. We may acquire the rights to the intellectual property covering future product candidates from other third-party licensors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we fail to meet our obligations under any of our in-license agreements, including the Pfizer License Agreement (as amended and restated by the A&amp;R License Agreement), or the Biosion License Agreement, then the licensor may terminate the license agreement. If one of our material in-license agreements is terminated, we will lose the right to continue to develop and commercialize the product candidate(s) covered by such in-license agreement. While we would expect to exercise all rights and remedies available to us, including seeking to cure any breach by us, and otherwise seek to preserve our rights under our in-license agreements, we may not be able to do so in a timely manner, at an acceptable cost or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may be involved in lawsuits to protect or enforce our patents, the patents of our licensors or our other intellectual property rights, which could be expensive, time consuming and unsuccessful.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Competitors may infringe or otherwise violate our patents, the patents of our licensors or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to file legal claims, which can be expensive and time consuming and is likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our owned or licensed patents at risk of being invalidated or interpreted narrowly and could put our owned or licensed patent applications at risk of not issuing. The initiation of a claim against a third party might also cause the third party to bring counter claims against us, such as claims asserting that our patent rights are invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, non-enablement or lack of statutory subject matter. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant material information from the USPTO, or made a materially misleading statement, during prosecution. Third parties may also raise similar validity claims before the USPTO in post-grant proceedings such as ex parte reexaminations, inter partes review, or post-grant review, or oppositions or similar proceedings outside the United States, in parallel with litigation or even outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. We cannot be certain that there is or will be no invalidating prior art, of which we and the patent examiner were unaware during prosecution. For the patents and patent applications that we have licensed, we may have limited or no right to participate in the defense of any licensed patents against challenge by a third party. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of any future patent protection on our current or future product candidates. Such a loss of patent protection could harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. Our business could be harmed if in litigation the prevailing party does not offer us a license, and such a license may not be on commercially reasonable terms. Any litigation or other proceedings to enforce our intellectual property rights may fail, and even if successful, may result in substantial costs and distract our management and other employees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have an adverse effect on the price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating or from successfully challenging our intellectual property rights. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our current and any future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The United States has recently enacted and implemented wide ranging patent reform legislation. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce patents that we own, have licensed or that we might obtain in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions, changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we own or have licensed or that we may obtain in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world, which could negatively impact our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filing, prosecuting and defending patents covering our current and any future product candidates in all countries throughout the world would be prohibitively expensive. Competitors may use our technologies in jurisdictions where we or our licensors have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we may obtain patent protection but where patent enforcement is not as strong as that in the United States. These products may compete with our products in jurisdictions where we do not have any issued or licensed patents and any future patent claims, or other intellectual property rights may not be effective or sufficient to prevent them from so competing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to seeking patent and trademark protection for our product candidates, we may also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect our trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees, advisors and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets. Monitoring unauthorized uses and disclosures of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property will be effective. In addition, we may not be able to obtain adequate remedies for any such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, our competitors may independently develop knowledge, methods and know-how equivalent to our trade secrets. Competitors could purchase our products and replicate some or all of the competitive advantages we derive from our development efforts for technologies on which we do not have patent protection. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also seek to preserve the integrity and confidentiality of our data and other confidential information by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached and detecting the disclosure or misappropriation of confidential information and enforcing a claim that a party illegally disclosed or misappropriated confidential information is difficult, expensive and time-consuming, and the outcome is unpredictable. Further, we may not be able to obtain adequate remedies for any breach. In addition, our confidential information may otherwise become known or be independently discovered by competitors, in which case we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since we rely on third parties to help us discover, develop, manufacture or commercialize our current and any future product candidates, or if we collaborate with third parties for the development, manufacturing or commercialization of our current or any future product candidates, we must, at times, share trade secrets with them. We may also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development partnerships or similar agreements. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#x2019;s discovery of our trade secrets or other unauthorized use or disclosure could have an adverse effect on our business and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets. Despite our efforts to protect our trade secrets, we may not be able to prevent the unauthorized disclosure or use of our technical know-how or other trade secrets by the parties to these agreements. Moreover, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our confidential information or proprietary technology and processes. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. If any of the collaborators, scientific advisors, employees, contractors and consultants who are parties to these agreements breaches or violates the terms of any of these agreements, we may not have adequate remedies for any such breach or violation, and we could lose our trade secrets as a result. Moreover, if confidential information that is licensed or disclosed to us by our partners, collaborators, or others is inadvertently disclosed or subject to a breach or violation, we may be exposed to liability to the owner of that confidential information. Enforcing a claim that a third-party illegally or unlawfully obtained and is using our trade secrets, like patent litigation, is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any trademarks we may obtain may be infringed or successfully challenged, resulting in harm to our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect to rely on trademarks as one means to distinguish any of our product candidates that are approved for marketing from the products of our competitors. We have not yet selected trademarks for our product candidates and have not yet begun the process of applying to register trademarks for our current or any future product candidate. Once we select trademarks and apply to register them, our trademark applications may not be approved. Third parties may oppose our trademark applications or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we could be forced to rebrand our products, which could result in loss of brand recognition and could require us to devote resources to advertising and marketing new brands. Our competitors may infringe our trademarks, and we may not have adequate resources to enforce our trademarks.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, any proprietary name we propose to use with our current or any other product candidate in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of the potential for confusion with other product names. If the FDA objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable proprietary product name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">110</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect our operating results to be subject to annual and quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">results of preclinical studies, IND submissions, clinical trials, or the addition or termination of clinical trials or funding support by us, or existing or future collaborators or licensing partners; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">variations in the level of expense related to the ongoing development of the FACT Platform, our product candidates or future development programs; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our execution of any additional collaboration, licensing or similar arrangements, and the timing of payments we may make or receive under existing or future arrangements or the termination or modification of any such existing or future arrangements; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any intellectual property infringement lawsuit or opposition, interference or cancellation proceeding in which we may become involved; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">additions and departures of key personnel; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">if any of our product candidates receive regulatory licensure, the terms of such licensure and market acceptance and demand for such product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory developments affecting our product candidates or those of our competitors; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in general market and economic conditions. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If our operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our stock price is volatile, and you could lose all or part of your investment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our stock price is highly volatile. As a result of this volatility, investors may not be able to sell their common stock at or above the price they purchased their common stock. The market price for our common stock may be influenced by many factors, including the other risks described in this section of the Annual Report on Form 10-K titled &#x201c;Risk Factors&#x201d; and the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">results of our preclinical studies, IND submissions and clinical trials, if any, of our product candidates, or those of our competitors or our existing or future collaborators; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory or legal developments in the U.S. and other countries, especially changes in laws or regulations applicable to our products; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the success of competitive products or technologies; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">introductions and announcements of new products by us, our future commercialization partners, or our competitors, and the timing of these introductions or announcements; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">actions taken by regulatory agencies with respect to our products, preclinical studies, clinical trials, manufacturing process or sales and marketing terms; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">actual or anticipated variations in our financial results or those of companies that are perceived to be similar to us; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the success of our efforts to acquire or in-license additional technologies, products or product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">developments concerning any future collaborations, including but not limited to those with our sources of manufacturing supply and our commercialization partners; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">market conditions in the pharmaceutical and biotechnology sectors; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures or capital commitments; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">developments or disputes concerning patents or other proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our products; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability or inability to raise additional capital and the terms on which we raise it; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the recruitment or departure of key personnel; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in the structure of healthcare payment systems; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">actual or anticipated changes in earnings estimates or changes in stock market analyst recommendations regarding our common stock, other comparable companies or our industry generally; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our failure or the failure of our competitors to meet analysts&#x2019; projections or guidance that we or our competitors may give to the market; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fluctuations in the valuation of companies perceived by investors to be comparable to us; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">announcement and expectation of additional financing efforts; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">speculation in the press or investment community; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">trading volume of our common stock; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">sales of our common stock by us, our insiders or our other stockholders; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the concentrated ownership of our common stock; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in accounting principles; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">terrorist acts, acts of war or periods of widespread civil unrest; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the impact of any natural disasters or public health emergencies, such as the COVID-19 pandemic, and other calamities; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">general economic, industry and market conditions. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the stock markets in general, and the markets for pharmaceutical, biopharmaceutical and biotechnology stocks in particular, have experienced extreme volatility that has been often unrelated to the operating performance of the issuer. These broad market and industry factors may seriously harm the market price of our common stock, regardless of our operating performance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The future issuance of equity or of debt securities that are convertible into equity will dilute our share capital.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will need to raise additional capital in the future. To the extent we raise additional capital through the issuance of equity or convertible debt securities in the future, there will be dilution to our existing investors and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#x2019; rights. Future issuances of our common stock or other equity securities, or the perception that such sales may occur, could adversely affect the trading price of our common stock and impair our ability to raise capital through future offerings of shares or equity securities. We may choose to raise additional capital through the issuance of equity or convertible debt securities due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. No prediction can be made as to the effect, if any, that future sales of common stock or the availability of common stock for future sales will have on the trading price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If securities or industry analysts do not publish research or reports about our business, or if they issue adverse or misleading research or reports regarding us, our business or our market, our stock price and trading volume could decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The trading market for our common stock is influenced by the research and reports that industry or securities analysts publish about us, our business or our market. If no or few securities or industry analysts commence or maintain coverage of us, the trading price for our stock would be negatively impacted. If any of the analysts who cover us issue adverse or misleading research or reports regarding us, our business model, our intellectual property, our stock performance or our market, or if our operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">112</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval and their interests may conflict with your interests as an owner of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 22, 2023, our executive officers and directors, together with holders of five percent or more of our outstanding common stock and their respective affiliates, beneficially own approximately 56.2% of our outstanding common stock. As a result, these stockholders, if acting together, have significant influence over the outcome of corporate actions requiring stockholder approval, including the election of directors, any merger, consolidation or sale of all or substantially all of our assets and any other significant corporate transaction. The interests of these stockholders may not be the same as or may even conflict with interests of our other stockholders. For example, these stockholders could delay or prevent a change of control of our company, even if such a change of control would benefit our other stockholders, which could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of our company or our assets and might affect the prevailing market price of our common stock. The significant concentration of stock ownership may adversely affect the trading price of our common stock due to investors&#x2019; perception that conflicts of interest may exist or arise.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our common stock price could decline as a result of sales of a large number of shares of common stock or the perception that these sales could occur. These sales, or the possibility that these sales may occur, might also make it more difficult for us to sell equity securities in the future at a time and price that we deem appropriate.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares issued upon the exercise of stock options and warrants outstanding under our equity incentive plans or pursuant to future awards granted under those plans will become available for sale in the public market to the extent permitted by the provisions of applicable vesting schedules, market stand-off agreements and/or lock-up agreements, as well as Rules 144 and 701 under the Securities Act.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are an &#x201c;emerging growth company&#x201d; and a &#x201c;smaller reporting company,&#x201d; and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are an &#x201c;emerging growth company,&#x201d; as defined in the JOBS Act. We will remain an emerging growth company until the earlier of (i) the last day of the fiscal year (a) following the fifth anniversary of the completion of our IPO, (b) in which we have total annual gross revenue of at least $1.235 billion or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeded $700 million as of the prior June 30th and (ii) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">An emerging growth company may take advantage of specified reduced reporting requirements and other burdens that are otherwise applicable generally to public companies. These provisions include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">being permitted to present only two years of audited financial statements and only two years of related management&#x2019;s discussion and analysis of financial condition and results of operations in this Annual Report on Form 10-K; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">an exemption from compliance with any new requirements adopted by the Public Company Accounting Oversight Board, or PCAOB, regarding mandatory audit firm rotations; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">exemptions from the requirement to hold a nonbinding advisory vote on executive compensation and to obtain stockholder approval of any golden parachute payments not previously approved. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">113</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have elected to take advantage of certain reduced disclosure obligations and may elect to take advantage of other reduced reporting requirements in future filings. As a result, the information that we provide to our investors may be different from the information you might receive from other public reporting companies that are not emerging growth companies in which you hold equity interests. The JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have irrevocably elected not to avail itself of this extended transition period, and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are also a &#x201c;smaller reporting company,&#x201d; and will continue to be a smaller reporting company as long as (i) the market value of our shares held by non-affiliates is less than $250 million or (ii) our annual revenue was less than $100 million during the most recently completed fiscal year and the market value of our shares held by non-affiliates is less than $700 million. If we are a smaller reporting company at the time, we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and have reduced disclosure obligations regarding executive compensation, and, similar to emerging growth companies, if we are a smaller reporting company with less than $100 million in annual revenue, we would not be required to obtain an attestation report on internal control over financial reporting issued by our independent registered public accounting firm.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Anti-takeover provisions in our charter documents and under Delaware law would make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Provisions in the amended and restated certificate of incorporation and our amended and restated bylaws may delay or prevent an acquisition of us or a change in our management. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Because our board of directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. These provisions include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a prohibition on actions by our stockholders by written consent; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a requirement that special meetings of stockholders be called only by the chairman of our board of directors, our chief executive officer, or our board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">advance notice requirements for election to our board of directors and for proposing matters that can be acted upon at stockholder meetings; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a requirement that directors may only be removed &#x201c;for cause&#x201d; and only with 66 2/3% voting stock of our stockholders; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a requirement that only the board of directors may change the number of directors and fill vacancies on the board; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">division of our board of directors into three classes, serving staggered terms of three years each; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the authority of the board of directors to issue preferred stock with such terms as the board of directors may determine. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, as amended, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. These provisions would apply even if the proposed merger or acquisition could be considered beneficial by some stockholders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">114</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices. Additionally, if we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a public company, and particularly after we are no longer an emerging growth company or a smaller reporting company, we will incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of Nasdaq and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Also, the Exchange Act requires, among other things, that we file annual, quarterly and current reports with respect to our business and operating results. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations have increased and will continue to increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or to incur substantial costs to maintain the same or similar coverage. These rules and regulations could also make it more difficult for us to attract and retain qualified members of our board of directors or our board committees or as executive officers. However, these rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, as a public company, we will incur additional costs and obligations in order to comply with SEC rules that implement Section 404 of the Sarbanes-Oxley Act. Under these rules, we are required to make a formal assessment of the effectiveness of our internal control over financial reporting, and once we cease to be an emerging growth company or a smaller reporting company, we will be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section 404 within the prescribed period, we are engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of our internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are designed and operating effectively, and implement a continuous reporting and improvement process for internal control over financial reporting.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation to meet the detailed standards under the rules. During the course of its testing, our management may identify material weaknesses or deficiencies which may not be remedied in time to meet the deadline imposed by the Sarbanes-Oxley Act. Our internal control over financial reporting will not prevent or detect all errors and all fraud.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner, or if we are unable to maintain proper and effective internal controls, we may not be able to produce timely and accurate financial statements. If that were to happen, the market price of our stock could decline and we could be subject to sanctions or investigations by the stock exchange on which our common stock is listed, the SEC or other regulatory authorities. In addition, if we are not able to continue to meet these requirements, we may not be able to remain listed on Nasdaq.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These inherent limitations include the facts that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">115</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, your ability to achieve a return on your investment will depend on appreciation of the value of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to any appreciation in the value of our common stock, which is not certain.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may be subject to securities litigation, which is expensive and could divert our management&#x2019;s attention.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the past, companies that have experienced volatility in the market price of their securities have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Regardless of the merits or the ultimate results of such litigation, securities litigation brought against us could result in substantial costs and divert our management&#x2019;s attention from other business concerns.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our certificate of incorporation and bylaws designate the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#x2019; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery of the State of Delaware does not have jurisdiction, another state court located within the State of Delaware, or the federal district court for the District of Delaware) shall be the sole and exclusive forum for the following types of proceedings: (1) any derivative action or proceeding brought on our behalf under Delaware law, (2) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (3) any action arising pursuant to any provision of the Delaware General Corporation Law or our amended and restated certificate of incorporation or bylaws, (4) any other action asserting a claim that is governed by the internal affairs doctrine or (5) any other action asserting an &#x201c;internal corporate claim,&#x201d; as defined in Section 115 of the Delaware General Corporation Law. This provision would not apply to suits brought to enforce a duty or liability created by the Securities Act, the Exchange Act or any other claim for which the U.S. federal courts have exclusive jurisdiction. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. Our amended and restated bylaws further provide that the federal district courts of the United States of America will be the exclusive forum to the fullest extent permitted by law, for resolving any complaint asserting a cause of action arising under the Securities Act or the Exchange Act. This choice of forum provision may limit a stockholder&#x2019;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and employees. Alternatively, if a court were to find these provisions of our amended and restated certificate of incorporation and amended and restated bylaws inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business and financial condition. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and to have consented to the provisions of our amended and restated certificate of incorporation and amended and restated bylaws described above.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">116</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to use net operating loss carryforwards and other tax attributes may be subject to limitations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have incurred substantial losses during our history, do not expect to become profitable in the near future and may never achieve profitability. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, subject to certain limitations (including the limitations described below) until such unused losses expire (if at all). As of December 31, 2022, our federal and state net operating losses, or NOL, in the United States were $10.1 million ($48.0 million before tax) and $3.0 million ($48.1 million before tax) respectively. The federal net operating loss carryforwards in the United States can be carried forward indefinitely but may be subject to annual usage limitations to the extent certain substantial changes our ownership occur. The state net operating loss carryforwards begin expiring in 2039. In addition, as of December 31, 2022, we had $2.5 million and $1.2 million of federal and state credit carryovers which begin to expire in 2039. These loss and credit carryforwards are subject to review and possible adjustment by the appropriate taxing authorities.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our NOL and credit carryforwards are subject to review and possible adjustment by the IRS, and state tax authorities. Under Section 382 of the Internal Revenue Code of 1986, as amended, or the Code, our federal NOL and credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership of our company. An &#x201c;ownership change&#x201d; pursuant to Section 382 of the Code generally occurs if one or more stockholders or groups of stockholders who own at least 5% of a company&#x2019;s stock increase their ownership by more than 50 percentage points over their lowest ownership percentage within a rolling three-year period. Our ability to utilize our NOL carryforwards and other tax attributes to offset future taxable income or tax liabilities may be limited as a result of ownership changes, including potential changes in connection with our IPO. Similar rules may apply under state tax laws. We have not yet determined the amount of the cumulative change in our ownership resulting from our IPO or other transactions, or any resulting limitations on our ability to utilize our NOL carryforwards and other tax attributes. In addition, we may experience ownership changes in the future due to subsequent shifts in our stock, some of which are outside of our control. If we earn taxable income, such limitations could result in increased future income tax liability to us, and our future cash flows could be adversely affected. We have recorded a full valuation allowance related to our NOL carryforwards and other deferred tax assets due to the uncertainty of the ultimate realization of the future benefits of those assets.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">117</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1B. Unresolved S</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">taff Comments.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> 2. Properties.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our headquarters are located at 150 Cambridgepark Drive, Cambridge, MA 02140, where we lease approximately 8,955 rentable square feet of office and laboratory space under a lease that terminates on March 31, 2023. On September 29, 2021, we entered into a new lease agreement for approximately 31,659 square feet of an office and laboratory space at 321 Harrison Avenue, Boston, MA 02118. The lease will end on December 31, 2032, with an additional five-year option to extend the lease beyond December 31, 2032. We believe that our existing facilities are adequate to meet our current needs, and that suitable additional alternative spaces will be available in the future on commercially reasonable terms.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">tem 3. Legal P</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">roceedings.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. As of the date of this Annual Report on Form 10-K, we were not a party to any material legal matters or claims and we are not aware of any pending or threatened legal proceeding against us that we believe could have a material adverse effect on our business, operating results or financial condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Mine Safety Disclosures.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not Applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">118</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_ii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RT II</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_5_market_for_registrants_common"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 5. Market for Registrant&#x2019;s C</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ommon Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market Information</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our common stock is trading on The Nasdaq Global Select Market under the symbol &#x201c;PYXS&#x201d;.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Holders of Our Common Stock</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Broadridge Corporate Issuer Solutions, Inc is our transfer agent and registrar for our common stock. As of the close of business on March 21, 2023, there were approximately 34 holders of record of shares of our common stock. These numbers were derived from our stockholder records and do not include beneficial owners of our common stock whose shares are held in &#x201c;street&#x201d; name with various dealers, clearing agencies, banks, brokers and other fiduciaries.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividends</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all available funds and future earnings, if any, for use in the operation of our business and do not anticipate paying any cash dividends on our common stock in the foreseeable future. Any future determination to declare and pay dividends will be made at the discretion of our board of directors and will depend on various factors, including applicable laws, our results of operations, our financial condition, our capital requirements, general business conditions, our future prospects and other factors that our board of directors may deem relevant. Our ability to pay cash dividends on our capital stock in the future may also be limited by the terms of any preferred securities we may issue or agreements governing any additional indebtedness we may incur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recent Sales of Unregistered Equity Securities</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 16, 2023, or the Effective Date, we entered into the first amendment, or Amendment No. 1, to the Amended and Restated License Agreement, or the A&amp;R License Agreement, dated October 14, 2022 between Pfizer Inc. or Pfizer, and the Company, which amends and restates certain terms of the A&amp;R License Agreement. The A&amp;R License Agreement amends and restates the previously executed license agreement dated December 8, 2020, effective as of March 12, 2021 between Pfizer and the Company, as amended to date. Pursuant to Amendment No. 1, we agreed to issue such number of shares of common stock equivalent to $5.0 million at a per share price equal to the closing price of our common stock on the business day when the closing price of our common stock on the Nasdaq Global Select Market is at or above $2.46 per share on any day from the Effective Date to a date that is within 180 days following October 6, 2022, or the A&amp;R Effective Date. If, within 180 days following the A&amp;R Effective Date, the share price for our common stock has not closed at or above $2.46 per share, then we agreed to issue such number of shares of common stock 180 days following the effective date, or the Issuance Date, equivalent to $5.0 million at a per share price equal to the closing price of our common stock on the business day prior to the Issuance Date, such that Pfizer&#x2019;s ownership interest in us shall not exceed nineteen and a half percent (19.5%) with any difference in value between the value of shares and $5.0 million being payable in cash.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 17, 2023, the closing price of our common stock on the Nasdaq Global Select Market was $2.76 per share. In accordance with the terms of Amendment No. 1, we issued 1,811,594 shares of our common stock to Pfizer, which is an amount equivalent to $5.0 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The shares of common stock issued pursuant to Amendment No. 1 are not registered under the Securities Act of 1933, as amended, or the Securities Act, in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A copy of Amendment No. 1 is filed as Exhibit 10.24 to this Annual Report on Form 10-K. The foregoing description of the terms of Amendment No. 1 is qualified in its entirety by reference to the full text of Amendment No. 1.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">119</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Proceeds from Initial Public Offering</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our initial public offering of common stock, or the IPO, was affected through a Registration Statement on Form S-1 (File No. 333-259627) that was declared effective by the SEC on October 7, 2021. We issued and sold in aggregate 10,500,000 shares of common stock, at a public offering price of $16.00 per share, for net proceeds of $152.3 million after deducting underwriting discounts, commissions and other offering costs of $15.7 million. BofA Securities, Inc., Jefferies LLC, Credit Suisse Securities (USA) LLC and William Blair &amp; Company, L.L.C. and LifeSci Capital LLC acted as underwriters for the offering. None of the underwriting discounts and commissions or offering expenses were incurred or paid to directors or officers of ours or their associates or to persons owning 10% or more of our common stock or to any of our affiliates. We have invested the net proceeds from the IPO in a money market fund. There has been no material change in our planned use of the net proceeds from the IPO as described in our final prospectus filed pursuant to Rule 424(b)(4) under the Securities Act with the SEC on October 8, 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities authorized for issuance under equity incentive plans</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes information about our equity incentive plans as of December 31, 2022. All outstanding awards relate to our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:46.319%;"></td>
    <td style="width:0.982%;"></td>
    <td style="width:0.982%;"></td>
    <td style="width:14.772%;"></td>
    <td style="width:0.992%;"></td>
    <td style="width:0.992%;"></td>
    <td style="width:1.141%;"></td>
    <td style="width:12.292%;"></td>
    <td style="width:0.992%;"></td>
    <td style="width:0.992%;"></td>
    <td style="width:0.992%;"></td>
    <td style="width:18.552%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of Securities</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to be Issued Upon</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise of</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options, Warrants</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and Rights</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(a)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Average Exercise</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Price of</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options,</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrants and</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Rights</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(b)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of Securities</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Remaining Available</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for Future Issuance</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under Equity</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Compensation Plans</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Excluding Securities</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reflected in Column (a))</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(c)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity compensation plans approved by security holders:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021 Equity Incentive Plan(1)(3)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,117,872</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.28</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">360,924</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2019 Equity Incentive Plan(1)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,745,402</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.22</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">657,484</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021 Employee Stock Purchase Plan(4)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">752,524</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted Common Stock pursuant to Separate Agreements(5)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">151,286</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.01</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity compensation plans not approved by security holders:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022 Inducement Plan(1)(2)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">721,242</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.95</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">678,758</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,735,802</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.43</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,449,690</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted Stock Units issued under the 2022 Inducement Plan, 2021 Equity Incentive Plan and 2019 Equity Incentive Plan, which do not have an exercise price, are excluded in the calculation of weighted-average exercise price.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(2) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On July 1, 2022, the Company&#x2019;s board of directors approved the 2022 Equity Inducement Plan (the &#x201c;2022 Plan&#x201d;), which became effective on that date.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(3) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The number of shares of common stock reserved for issuance under the 2021 Equity Incentive Plan will automatically increase annually on the first day of each fiscal year, beginning with the fiscal year ending December 31, 2021, and continuing until (and including) the fiscal year ending December 31, 2031 by the lesser of (i) 5% of the total number of shares of common stock outstanding on December 31st of the immediately preceding fiscal year and (ii) the number of shares as may be determined by our board of directors. As a result of the evergreen provision of the 2021 Plan, the Company added an additional 1,639,643 shares of common stock to the 2021 Plan as of January 1, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(4) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On September 27, 2021, our board of directors and stockholders approved the 2021 Employee Stock Purchase Plan (the &#x201c;2021 ESPP&#x201d;), which became effective on the date immediately preceding the date on which our registration statement declared effective by the SEC. The 2021 ESPP initially reserved and authorized the issuance of up to a total of 424,595 shares of common stock to participating employees. The number of shares of common stock reserved for issuance under the ESPP will automatically increase annually on the first day of each fiscal year, beginning with the fiscal year ending December 31, 2022, and continuing until (and including) the fiscal year ending December 31, 2031 by the lesser of (i) 1% of the total number of shares of common stock outstanding on December 31st of the immediately preceding fiscal year and (ii) the number of shares as may be determined by the board of directors. As a result of the evergreen provision of the 2021 ESPP, the Company added an additional 327,929 shares of common stock to the 2021 ESPP as of January 1, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(5) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2019, we issued certain shares of restricted common stock to the employee co-founders and certain non-employee consultants. The shares of restricted common stock were issued pursuant to standalone restricted stock purchase agreements that are independent of the 2019 Plan. The shares of restricted common stock carried a purchase price equivalent of $0.01 per share.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuer Purchases of Equity Securities</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_6_selected_financial_data"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> 6. [Reserved].</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">121</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7_managements_discussion"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7. Management&#x2019;s Discussion and</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Analysis of Financial Condition and Results of Operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">You should read the following discussion and analysis of our financial condition and results of operations together with our audited consolidated financial statements and related notes thereto included elsewhere in this Annual Report on Form 10-K. Unless the context requires otherwise, references in this Annual Report on Form 10-K to &#x201c;Pyxis Oncology,&#x201d; the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; and &#x201c;our&#x201d; refer to Pyxis Oncology, Inc. and its subsidiary.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a clinical-stage oncology company focused on developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. We develop our product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. We consider multi-modality as a variety of technologies, either stand-alone or in combination with others, to build effective cancer therapeutics for patients. Since our launch in 2019, we have developed a broad portfolio that includes novel antibody drug conjugate, or ADC, product candidates, immuno-oncology, or IO, product candidates, and monoclonal antibody, or mAb, preclinical discovery programs that we are developing as monotherapies and in combination with other therapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have assembled a team with deep experience and proficiency in oncology research and development and plan to leverage our team&#x2019;s decades of experience in drug development to bring a variety of innovative therapies through the clinic. The collective experience across our team spans the spectrum of both pharmaceuticals and biotechnology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our portfolio consists of both ADC and IO product candidates. Our pipeline is balanced across programs with an emphasis on solid tumors. We in-licensed two ADC programs in March 2021 from Pfizer and one IO program from Biosion USA, Inc. in March 2022. We have additional preclinical mAb discovery programs derived from work at the laboratory of Dr. Thomas Gajewski. We retain full worldwide development and commercialization rights to all our product candidates, with the exception of PYX-106 in Greater China (mainland China, Hong Kong, Macau and Taiwan). In December 2022, we announced clearance of our investigation new drug applications, or IND, by the U.S. Food and Drug Administration, or FDA, for PYX-201 and PYX-106. We are enthusiastic to have transitioned to a clinical stage oncology company and look forward to leveraging our team&#x2019;s experience to execute our clinical trials with the aim of providing patients with safer and more efficacious treatment options.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following is our current clinical development pipeline:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img30600998_22.jpg" alt="img30600998_22.jpg" style="width:672px;height:144px;" /><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">122</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">PYX-201</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our lead ADC product candidate is PYX-201, an investigational, novel ADC consisting of an Immunoglobulin G1, or IgG1, anti-fibronectin Extradomain-B, or EDB, mAb site-specifically conjugated to an auristatin derivative via a cathepsin B-cleavable linker. Fibronectin is a glycoprotein found in the extracellular matrix. Fibronectin EDB regulates blood vessel morphogenesis, which provides the tumor access to nutrition and oxygen, a means to remove waste, and a pathway for metastasizing cells. EDB is overexpressed in many malignancies and is minimally expressed in most normal adult tissues, making it a potentially attractive means to target tumors while sparing healthy cells. In preclinical models of patient-derived xenograft, or PDX models, we observed tumor regression with single agent PYX-201. In addition, we observed that the treatment of preclinical syngeneic tumor models with PYX-201 resulted in enhanced T-cell infiltration into the TME, which is a hallmark of immunogenic cell death, or ICD, enabling synergistic activity in combination with a checkpoint inhibitor.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2022, we announced clearance of our IND by the FDA for PYX-201 to initiate a Phase 1 clinical trial. During the first quarter of 2023, we announced dosing of the first subject in a Phase 1 trial of PYX-201, referred to as PYX-201-101. PYX-201-101 is an open-label, multicenter, dose-escalation trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of PYX-201 and identify recommended doses for further study. Patients with relapsed or refractory solid tumors, including non-small cell lung cancer, or NSCLC, hormone receptor positive breast cancer, ovarian cancer, thyroid cancer, pancreatic ductal adenocarcinoma, or PDAC, soft tissue sarcoma, or STS, hepatocellular carcinoma, or HCC, and kidney cancer are eligible to enroll. We anticipate reporting preliminary data from this Phase 1 clinical trial, including biomarker results and early signs of potential clinical activity, in early 2024.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">PYX-106</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our lead IO product candidate is PYX-106, an investigational, fully human IgG1 isotype Siglec-15-targeting antibody designed to block Siglec-15 mediated suppression of T-cell proliferation and function. We plan to initially develop this asset for the treatment of solid tumors. We licensed worldwide rights, other than in Greater China (mainland China, Hong Kong, Macau and Taiwan), to PYX-106 from Biosion USA, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2022, we announced clearance of our IND by the FDA for PYX-106 to initiate a Phase 1 clinical trial. During the first quarter of 2023, we began activating clinical trial sites and are currently screening patients for enrollment in the Phase 1 trial, referred to as PYX-106-101. PYX-106-101 is a first-in-human, Phase 1, multicenter, open-label dose escalation trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PYX-106 in patients with relapsed or refractory solid tumors. This Phase 1 dose escalation trial includes patients who have developed solid tumors and disease progression through standard therapy and patients for whom standard of care therapy that prolongs survival is unavailable or unsuitable. This trial will enroll patients with solid tumors including non-small cell lung cancer without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma, or HNSCC. We anticipate dosing patients in early second quarter of 2023. We anticipate reporting preliminary data from this Phase 1 clinical trial, including biomarker results and early signs of potential clinical activity, in late 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Paused / terminated programs</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2022, we paused preclinical development of our anti-CD123 ADC, PYX-203, and anti-KLRG1 IO program, PYX-102. Although these programs remain important to our diversified portfolio of therapeutic candidates, pausing preclinical development efforts currently will allow us to increase the resources available to advance clinical development of PYX-201 and PYX-106. Further, we elected to pause the continued development of our anti-DLK1 ADC, PYX-202, based upon review and analysis of data from preclinical toxicity studies, and the anticipated clinical use and commercial prospects of PYX-202 if approved.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Discovery</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to the programs identified above, we are conducting research and development activities on various targets, leveraging our expertise in monoclonal antibodies, ADC conjugation, linker and payload selection, and understanding of immuno-oncology.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">123</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since our inception, we have focused substantially all of our resources on conducting research and development activities, undertaking preclinical studies and clinical trials, organizing and staffing our company, business planning, raising capital, establishing and maintaining our intellectual property portfolio and identifying potential product candidates. We do not have any products approved for sale and have not generated any revenue from product sales or from any other sources. We have incurred significant operating losses since our inception. We reported net losses of $120.7 million and $76.0 million for the years ended December 31, 2022 and 2021, respectively. As of December 31, 2022, we had an accumulated deficit of $212.4 million, net equity of $160.8 million, and cash and cash equivalents of $179.3 million. We expect to continue to incur significant expenses and operating losses for the foreseeable future. We expect that our expenses and capital expenditures will increase substantially in connection with our ongoing activities. Our operations to date have been financed primarily through sales of convertible preferred stock and sale of equity securities and additional funding may be necessary to fund future clinical and preclinical activities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Licensing and Collaboration Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">License Agreement with Pfizer Inc.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2020, we entered into a license agreement, as amended, or the Pfizer License Agreement, with Pfizer Inc., or Pfizer, for worldwide development and commercialization rights to antibody drug conjugate product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates. Our rights are exclusive with respect to certain patents owned or controlled by Pfizer covering the licensed ADCs. Pfizer has also granted us a non-exclusive license to use Pfizer&#x2019;s ADC technology, or FACT, platform. The initial licensed targets include CD123 and extra domain B (EDB of fibronectin) and we have the option to expand the scope of its license to add additional licensed targets that have not been licensed to a third party or are not the subject of a Pfizer ADC development program. The Pfizer License Agreement became effective in March 2021 and we paid a combined $25.0 million for the license fee, consisting of an upfront cash payment of $5.0 million and issued 12,152,145 shares of Series B convertible preferred stock, which was converted into 1,911,015 shares of its common stock upon the initial public offering in October 2021, with a value of $20.0 million to Pfizer.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On October 6, 2022, we entered into an amended and restated license agreement, or the A&amp;R License Agreement, with Pfizer, which amends and restates the Pfizer License Agreement. Pursuant to the A&amp;R License Agreement, Pfizer granted us exclusive worldwide rights under Pfizer&#x2019;s FACT Platform technology to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates. Additional ADC targets may be licensed for a nominal upfront payment and milestones. Further, we granted the right of first negotiation to Pfizer, on an exclusive basis, to purchase or to develop, manufacture and commercialize licensed ADCs and licensed products in one or more countries directed to EDB and CD123. In accordance with the terms of the A&amp;R License Agreement, we agreed to pay $8.0 million to Pfizer (which was paid in January 2023) and issued 2,229,654 shares of our common stock. Additionally, we will issue such number of shares of common stock 180 days following the effective date, or the Issuance Date, equivalent to $5.0 million at a per share price equal to the closing price of our common stock on the business day prior to the Issuance Date, such that Pfizer&#x2019;s ownership interest in us shall not exceed nineteen and a half percent (19.5%) with any difference in value between the value of shares and $5.0 million being payable in cash.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are also obligated to pay future contingent payments including development, regulatory and commercial milestones up to an aggregate of $665 million for the first four licensed ADCs. In addition, we are required to pay future contingent payments including development, regulatory and commercial milestones for ADCs to each additional licensed target beyond the first four licensed ADCs developed and commercialized via the FACT Platform. Additionally, if ADC licensed products are launched, we will pay Pfizer tiered royalties on net sales of licensed products in varying royalty rates ranging from low single digits to mid-teens. Our royalty obligations apply on a licensed product-by-licensed product and country-by-country basis from first commercial sale until the latest to occur of: (1) 12 years from first commercial sale; (2) the expiration of all regulatory or data exclusivity; and (3) the expiration of the last valid claim of a licensed patent covering the licensed product in a country. We are also obligated to pay Pfizer a percentage of certain sublicensing revenue ranging from twenty percent to low-double digits based on the stage of development of the licensed product at the time of entering into the applicable sublicense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">124</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">License Agreement with the University of Chicago</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2020, we entered into a license agreement, or the University License Agreement, as well as a sponsored research agreement, with the University of Chicago, or the University. Under the terms of the license, we have the exclusive global right to develop and commercialize products that are covered by a valid claim of a licensed patent, incorporate or use the licensed know-how and materials or are known to assess, modulate or utilize the activity of certain specified biological targets.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In partial consideration for the license from the University, we issued to the University 48,919 shares of our common stock in 2020. Pursuant to the University License Agreement, we are obligated to pay potential development and commercial milestones of up to an aggregate of $7.7 million as well as running royalties on net sales of licensed products at varying rates ranging from less than one percent to the low single digits, subject to a minimum annual royalty of up to $3.0 million during certain years following the first commercial sale of a licensed product. We are also obligated to pay the University a percentage of certain sublicensing revenue ranging from low- to mid-teens based on the date of entering into the applicable sublicense.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Agreements with LegoChem Biosciences, Inc.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2020, we entered into a license agreement, or the LegoChem License Agreement, and an opt-in, investment and additional consideration agreement, or the Opt-In Agreement, with LegoChem Biosciences, Inc., or LegoChem. Pursuant to the LegoChem License Agreement, we obtained worldwide (other than Korea) development and commercialization rights for LCB67, an ADC product candidate targeting DLK-1, and products containing the licensed compound. We paid $9.0 million in March 2021 to LegoChem, which was recorded as research and development expenses. Additionally, we may purchase certain initial quantities of licensed products from LegoChem for an estimated cost of $7.0 million and are also obligated to make future contingent payments including development, regulatory and commercial milestones as well as running royalties on net sales of licensed products at varying rates. In the third quarter of the calendar year 2022, we stopped the continued development of LCB67, based on review and analysis of data from the toxicity studies, and anticipated clinical use and commercial prospects of anti-DLK1 ADC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, as part of the Opt-in Agreement, LegoChem exercised an option to pay $8.0 million to us, in exchange for the right to receive a milestone payment, or the Extra Milestone Payment, of $9.6 million upon the earliest to occur of certain events, including the date of pricing or offer of the first public offering of its common stock or if we are the subject of a change in control transaction. Upon our IPO in October 2021, the extra milestone payment event triggered, and we paid $9.6 million in January 2022 to LegoChem. We have no further obligations under the Opt-In Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">License Agreement with Biosion USA, Inc.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 28, 2022, we entered into a license agreement, or the Biosion License Agreement, with Biosion USA, Inc., or Biosion, pursuant to which we obtained an exclusive, worldwide (other than Greater China (mainland China, Hong Kong, Macau and Taiwan)) license for development, manufacture and commercialization rights for BSI-060T, a Siglec-15 targeting antibody, an IO product candidate (now referred to as PYX-106), and products containing the licensed compound. Under the terms of the Biosion License Agreement, each party granted to the other party a right of first offer to obtain an exclusive license in the other party&#x2019;s territory (Greater China for Biosion, and the rest of the world for Pyxis) to develop, manufacture and commercialize any bi-specific or multi-specific antibody any antibody-drug conjugate controlled by a party or its affiliate that inhibits, modulates or binds to Siglec-15 as an intended mechanism of action.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the Biosion License Agreement, we paid an upfront fee of $10.0 million and are also obligated to pay future contingent payments including development, regulatory and commercial milestones up to an aggregate of $217.5 million in case of normal approval and $222.5 million in case of accelerated approval. Additionally, if products are launched, we will pay Biosion tiered royalties on net sales of licensed products in varying royalty rates ranging from low single digits to low teens. Our royalty obligations apply on a licensed product-by-licensed product and country-by-country basis from first commercial sale until the latest to occur of: (1) 12 years from first commercial sale; (2) the expiration of all regulatory or data exclusivity; and (3) the expiration of the last valid claim of a licensed patent covering the licensed product in a country. We are also obligated to pay Biosion a percentage of certain sublicensing revenue ranging from mid-double to low-double digits based on the stage of development of the licensed product at the time of entering into the applicable sublicense.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">125</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The Voxall Joint Venture with Alloy Therapeutics, Inc.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2021, we entered into definitive transaction agreements with Alloy to finance and operate Voxall, a joint venture company formed in collaboration with Alloy to leverage Pyxis Oncology&#x2019;s site-specific target catalog and Alloy&#x2019;s ATX-Gx</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#153;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">platform and antibody discovery services. Voxall granted to both Pyxis Oncology and Alloy 50% of the voting membership units of Voxall in exchange for certain initial contributions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the formation of Voxall, we entered into a three-year research collaboration with Alloy and Voxall to identify and select certain biological targets and create development candidate antibodies directed to those targets for further preclinical development, clinical development and commercialization. Under the collaboration agreement, the parties will conduct research under a mutually agreed research plan and budget for up to six research programs focused on mutually selected targets. Each of us and Alloy will provide research support for the collaboration through separate services agreements with Voxall, which services will be paid in the form of promissory notes issued by Voxall. Voxall will own all intellectual property arising from the collaboration, subject to certain exceptions for intellectual property relating to Alloy&#x2019;s ATX-Gx</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#153;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> platform.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If a development candidate antibody under a research program meets certain mutually agreed selection criteria, we will have the exclusive option to obtain an exclusive license from Voxall to further develop and commercialize all the development candidate antibodies discovered under that research program. We may in-license one research program on certain pre-agreed financial terms. For all other in-licensed research programs, we will be obligated to pay fair market value as determined by a third-party valuation. Any research program that we do not in-license may be licensed by Voxall to a third party.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">126</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Components of Our Results of Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses consist of costs incurred for our research activities, including our discovery efforts, and the development of our programs. These expenses include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">employee-related expenses, including salaries, payroll taxes, related benefits, severance and stock-based compensation expense for employees engaged in research and development activities; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expenses incurred under agreements with clinical research organizations, or CROs, investigative sites that conduct our clinical trials, and other clinical trial-related vendors, and consultants;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs of acquiring, developing, and manufacturing and testing clinical and preclinical materials, including costs incurred under agreements with contract manufacturing organizations, or CMOs;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">costs associated with preclinical activities and regulatory operations;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">license fees and milestone payments related to the acquisition and retention of certain licensed technology and intellectual property rights; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">facilities, depreciation, market research, and other expenses, which include allocated expenses for rent and maintenance of facilities, depreciation of leasehold improvements and equipment, and laboratory supplies.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expense research and development costs as incurred. Non-refundable advance payments that we make for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed, or when it is no longer expected that the goods will be delivered, or the services rendered.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our direct external research and development expenses consist of costs that include fees, reimbursed materials and other costs paid to consultants, contractors, CMOs and CROs in connection with our preclinical and clinical activities. We do not allocate employee costs, costs associated with our discovery efforts, laboratory supplies, and facilities expenses, including depreciation or other indirect costs, to specific product development programs because these costs are deployed across multiple programs and our platform and, as such, are not separately classified.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development expenses will increase substantially in connection with our ongoing and planned preclinical and clinical development activities in the near term and in the future. The successful development of our product candidates is highly uncertain. At this time, we cannot accurately estimate or know the nature, timing and costs of the efforts that will be necessary to complete the preclinical and clinical development of any of our product candidates and we may never succeed in obtaining regulatory approval for any of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative expenses consist primarily of salaries and personnel-related costs, including stock-based compensation, and severance for our personnel in executive, legal, finance and accounting, human resources and other administrative functions. General and administrative expenses also include professional fees for auditing, tax, and legal services, as well as insurance, board of director compensation, consulting, other administrative expenses and facility costs not otherwise included in research and development expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Income (Expense)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest income consists primarily of interest earned on our invested cash and cash equivalent balances.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The change in fair value of derivative liability represents the increase in the fair value of the derivative liability recorded as a result of an opt-in, investment and additional consideration agreement with LegoChem.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">127</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since our inception, we have not recognized any income tax benefits for the net losses we have incurred or for the research and development tax credits earned in each year and interim period, as we believe, based upon the weight of available evidence, that it is more likely than not that all of our net operating losses, or NOLs, carryforwards and tax credit carryforwards will not be realized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, our federal and state net operating losses in the United States were $10.1 million ($48.0 million before tax) and $3.0 million ($48.1 million before tax) respectively. The federal net operating loss carryforwards in the United States can be carried forward indefinitely but may be subject to annual usage limitations to the extent certain substantial changes our ownership occur. The state net operating loss carryforwards begin expiring in 2039. In addition, as of December 31, 2022, we had $2.5 million and $1.2 million of federal and state credit carryovers which begin to expire in 2039. These loss and credit carryforwards are subject to review and possible adjustment by the appropriate taxing authorities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Results of Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comparison of the Years Ended December 31, 2022 and 2021</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes our results of operations for the years ended December 31, 2022 and 2021 (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:59.191%;"></td>
    <td style="width:1.302%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.162%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.312%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.301%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.312%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.42%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86,129</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51,054</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,075</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37,352</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,663</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,689</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating expenses:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">123,481</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69,717</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53,764</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(123,481</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(69,717</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(53,764</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense):</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest income</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,764</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,741</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Service fee income from related party</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">181</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(181</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in fair value of derivative liability</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(6,231</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,231</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total other income (expense)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,764</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(6,027</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,791</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from equity method investment in joint venture</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(231</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">231</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(120,717</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(75,975</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(44,742</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes our research and development expenses for the years ended December 31, 2022 and 2021 (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:58.732%;"></td>
    <td style="width:1.316%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.91%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.305%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.228%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.305%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.203%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year  Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development program expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60,967</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,363</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,604</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Personnel-related expenses including stock-based compensation</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,975</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,836</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,139</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other research and development expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,187</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,855</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,332</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total research and development expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86,129</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51,054</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,075</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses increased by $35.1 million, from $51.0 million for the year ended December 31, 2021, to $86.1 million for the year ended December 31, 2022. The program expenses increased by $20.6 million, which was primarily due to increases in contract manufacturing costs of $13.7 million, preclinical costs of $6.2 million primarily related to toxicity studies and preclinical work towards IND filings related to PYX-201 and PYX-106, and clinical trial costs of $3.0 million, offset by a decrease in licensing fees of $2.3 million. The increases in both personnel-related expenses by $8.6 million and stock-based compensation by $2.5 million were primarily due to an increase in headcount to support our research and development activities. Other research and development expenses increased by $3.3 million which was primarily related to the increase in laboratory supplies, allocated cost for laboratory space and higher professional and consulting costs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">128</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes our general and administrative expenses for the years ended December 31, 2022 and 2021 (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:58.732%;"></td>
    <td style="width:1.316%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.91%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.305%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.228%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.305%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.203%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Personnel-related expenses including stock-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,732</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,622</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,110</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Professional and consultant fees</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,061</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,606</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,455</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Facilities, insurance and other costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,559</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,435</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,124</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total general and administrative expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37,352</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,663</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,689</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative expenses increased by $18.7 million, from $18.7 million for the year ended December 31, 2021, to $37.4 million for the year ended December 31, 2022. Personnel-related expenses including stock-based compensation increased by $10.1 million primarily due to higher personnel-related expenses of $3.3 million and higher stock-based compensation of $6.8 million, both of which were due to an increase in headcount. Professional and consultant fees increased by $5.4 million primarily due to an overall increase in legal, professional, and consulting fees to support our growth and operations. Facilities, insurance and other costs increased by $3.1 million mainly due to an increase in rent expense by $1.6 million and directors and officers insurance expense of $1.5 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Income (Expense)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest income for the years ended December 31, 2022 and 2021 was $2.8 million and $23 thousand, respectively, consisting of interest earned on invested cash and cash equivalent balances. The increase during the year ended December 31, 2022 was primarily due to higher interest rates on our deposits and money market funds.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other expense consists of change in fair value of the derivative liability of $6.2 million for the year ended December 31, 2021 as a result of the Opt-In Agreement. Service fee income from related party consists of income from services provided to the Voxall joint venture of $0.2 million for the year ended December 31, 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">129</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liquidity and Capital Resources</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We had cash and cash equivalents of $179.3 million as of December 31, 2022. For the years ended December 31, 2022 and 2021, we had net losses of $120.7 million and $76.0 million, respectively. As of December 31, 2022, we had an accumulated deficit of $212.4 million.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the clinical trials for our product candidates in development. The timing and amount of our funding requirements will depend on many factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost associated with Phase 1 clinical trials for PYX-201 and PYX-106;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the manufacture of product candidates for PYX-201 and PYX-106;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing and progress of our other preclinical and clinical development activities; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the number and scope of other preclinical and clinical programs we decide to pursue; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the progress of the development efforts of parties with whom we have entered or may in the future enter into in-licensing, collaborations and research and development agreements; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing licensure; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to maintain our current licenses and research and development programs and to establish new collaboration arrangements; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs involved in prosecuting, maintaining and enforcing patent and other intellectual property rights;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs of maintaining, expanding and protecting our intellectual property portfolio;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost and timing of regulatory licenses; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our efforts to hire additional clinical, regulatory, scientific, operational, financial and management personnel; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">incur insurance, legal and other regulatory compliance expenses to operate as a public company. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Until such time, if ever, we can generate substantial product revenue, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions, engaging in acquisition, merger or collaboration transactions, selling or licensing our assets, making capital expenditures, redeeming our stock, making certain investments or declaring dividends.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Shelf Registration Statement and &#x201c;At-the-Market&#x201d; Program</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On November 1, 2022, we filed a registration statement on Form S-3 with the SEC for the issuance of common stock, preferred stock, warrants, debt securities, rights and units up to an aggregate of $250.0 million. On November 14, 2022, the registration statement was declared effective by the SEC. The registration statement includes an at-the-market, or ATM, offering program for the sale of up to $125.0 million of shares of our common stock. We have not sold any shares of our common stock or received any proceeds from the ATM offering program as of the date of this report.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">130</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Flows</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table provides information regarding our cash flows for the years ended December 31, 2022 and 2021 (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.108%;"></td>
    <td style="width:1.493%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.883000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.493%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.022%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(89,335</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(35,326</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(6,399</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(590</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">183</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">304,044</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net (decrease) increase in cash, cash equivalents and restricted cash</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(95,551</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">268,128</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in operating activities was $89.3 million for the year ended December 31, 2022 and consisted of our net loss of $120.7 million, partially offset by non-cash charges of $26.9 million and a net change in our operating assets and liabilities of $4.6 million. The non-cash charges primarily consisted of $9.3 million related to license fees for Pfizer FACT Platform settled and payable in common stock, stock-based compensation expenses of $15.8 million, and amortization of operating lease right-of-use assets of $1.1 million. The change in our operating assets and liabilities was primarily due an increase in operating lease liabilities of $4.3 million as a result of the operating lease for our new headquarters and an increase in prepaid expenses and other current assets of $3.4 million primarily related to prepayment of clinical and contract manufacturing costs and directors and officers insurance policy costs, offset by an increase in accrued expenses and other current liabilities of $12.0 million and a decrease in accounts payable of $8.3 million related to timing of routine vendor payments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in operating activities was $35.3 million for the year ended December 31, 2021 and consisted of our net loss of $76.0 million, partially offset by non-cash charges of $34.0 million and a net change in our operating assets and liabilities of $6.7 million. The non-cash charges of $34.0 million was primarily due to the $20.0 million of research and development license fees for Pfizer settled in Series B convertible preferred stock, the $6.2 million change in the fair value of derivative liability and $6.4 million in stock-based compensation. The change in our operating assets and liabilities was primarily due to an increase of $9.7 million in accounts payable and accrued expenses and other current liabilities, partially offset by changes in prepaid and other current assets and lease payments of $3.0 million, all of which were due to growth in our business, the advancement of our research programs, and the timing of vendor invoicing and payments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Investing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in investing activities for the years ended December 31, 2022 and 2021 was $6.4 million and $0.6 million, respectively, primarily due to purchases of property and equipment. The purchases of property and equipment consists of laboratory equipment, furniture and fixtures and leasehold improvements for our new headquarters. During the year ended December 31, 2021, we also made an investment in our joint venture, Voxall Therapeutics, LLC, for $0.1 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Financing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by financing activities was $0.2 million for the year ended December 31, 2022 and consisted primarily of net proceeds from stock option exercises.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by financing activities was $304.0 million for the year ended December 31, 2021 and consisted primarily of net proceeds of $152.3 million from the sale of our common stock in the initial public offering and net proceeds of $151.6 million from the sale of our Series B convertible preferred stock.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on our existing cash balance as of December 31, 2022 of $179.3 million and our research and development and business development plans, we expect to be able to fund our operating expenses and capital expenditure requirements into the first half of the calendar year 2025. However, we have based this estimate on assumptions that may prove to be wrong, and our operating plan may change as a result of many factors currently unknown to us. In addition, we could utilize our available capital resources sooner than we expect.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">131</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contractual Obligations and Commitments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following summarizes our contractual obligations as of December 31, 2022, and the effects that such obligations are expected to have on our liquidity and cash flows in future periods.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We lease an office and laboratory space in Boston, Massachusetts. The lease payments on from December 22, 2022 and will continue through December 31, 2032, and have scheduled rent increases each year of 3%. The remaining contractual fixed lease payments over the term of the lease net of tenant improvement allowance aggregate to $31.8 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we entered into licensing and related agreements in the normal course of business. In accordance with the agreements, we are obligated to pay, among other items, future contingent payments, royalties, and sublicensing revenue in the future, as applicable. We have not included potential future payments due under these licensing and collaboration agreements in contractual obligations because the payment obligations under the agreements are contingent upon future events.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the A&amp;R License Agreement with Pfizer, we are obligated to pay future contingent payments including development, regulatory and commercial milestones up to an aggregate of $665 million for the first four licensed ADCs. In addition, we are required to pay future contingent payments including development, regulatory and commercial milestones for ADCs to each additional licensed target beyond the first four licensed ADCs developed and commercialized via the FACT Platform. Additionally, if products are launched, we will pay Pfizer tiered royalties on net sales of licensed products in varying royalty rates ranging from low single digits to mid-teens. Our royalty obligations apply on a licensed product-by-licensed product and country-by-country basis from first commercial sale until the latest to occur of: (1) 12 years from first commercial sale; (2) the expiration of all regulatory or data exclusivity; and (3) the expiration of the last valid claim of a licensed patent covering the licensed product in a country. We are also obligated to pay Pfizer a percentage of certain sublicensing revenue ranging from twenty percent to low-double digits based on the stage of development of the licensed product at the time of entering into the applicable sublicense.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, pursuant to the A&amp;R License Agreement with Pfizer, we agreed to issue such number of shares of common stock in April 2023, equivalent to $5.0 million at a per share price equal to the closing price of our common stock on the business day prior to the date of issuance, such that Pfizer&#x2019;s ownership interest in us shall not exceed nineteen and a half percent (19.5%) with any difference in value between the value of shares and $5.0 million being payable in cash.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the LegoChem License Agreement, we are obligated to pay up to an aggregate of $284.5 million to LegoChem if certain development, regulatory and sales milestones are achieved, as well as tiered royalties on net sales of licensed products ranging from mid-single digit to high single digit royalty rates. As part of our pipeline reprioritization, we have elected to stop the continued development of the PYX-202, which was licensed from LegoChem.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the University License Agreement with the University of Chicago, or the University, we are obligated to pay potential development and commercial milestones of up to an aggregate of $7.7 million as well as running royalties on net sales of licensed products at varying rates ranging from less than one percent to the low single digits, subject to a minimum annual royalty ranging up to $3.0 million during certain years following the first commercial sale of a licensed product. We are also obligated to pay the University a percentage of certain sublicensing revenue ranging from low- to mid-teens based on the date of entering into the applicable sublicense.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the Biosion License Agreement, we are obligated to pay future contingent payments including development, regulatory and commercial milestones up to an aggregate of $217.5 million in case of normal approval and $222.5 million in case of accelerated approval. Additionally, if products are launched, we will pay Biosion tiered royalties on net sales of licensed products in varying royalty rates ranging from low single digits to low teens. Our royalty obligations apply on a licensed product-by-licensed product and country-by-country basis from first commercial sale until the latest to occur of: (1) 12 years from first commercial sale; (2) the expiration of all regulatory or data exclusivity; and (3) the expiration of the last valid claim of a licensed patent covering the licensed product in a country. We are also obligated to pay Biosion a percentage of certain sublicensing revenue ranging from mid-double to low-double digits based on the stage of development of the licensed product at the time of entering into the applicable sublicense.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also enter into contracts in the normal course of business with CMOs, CROs, and other third parties for preclinical work and clinical development related work. These contracts do not contain minimum purchase commitments and are cancelable by us upon prior written notice. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including non-cancelable obligations of our service providers, up to the date of cancellation. These payments are not included in the contractual obligations above as the amount and timing of such payments are not known.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">132</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Off-Balance Sheet Arrangements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We did not have during the years presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the Securities and Exchange Commission.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Critical Accounting Policies and Significant Judgments and Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events, and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While our significant accounting policies are described in more detail in Note 2 to our audited consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K, we believe that the following accounting policies are the critical accounting policies used in the preparation of our consolidated financial statements that require significant estimates and judgments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development expenses. This process involves estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. The majority of our service providers invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met; however, some require advance payments. We make estimates of our accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to us at that time. At each period end, we corroborate the accuracy of these estimates with the service providers and make adjustments, if necessary. Examples of estimated accrued research and development expenses include those related to fees paid to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CROs in connection with performing research and development services on our behalf;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CMOs in connection with manufacturing of drug substance and drug products to be used in clinical trials on our behalf;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">other providers in connection with clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">vendors in connection with non-clinical development activities; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">vendors related to product manufacturing, development and distribution of clinical supplies.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We record the expense and accrual related to contract research and manufacturing based on our estimates of the services received and efforts expended considering a number of factors, including our knowledge of the progress towards completion of the research, development and manufacturing activities; invoicing to date under contracts; communication from the CROs, CMOs and other companies of any actual costs incurred during the period that have not yet been invoiced; and the costs included in the contracts and purchase orders. In accruing service fees, we estimate the period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or the amount of prepaid expense accordingly. There have not been any material adjustments to our prior estimates of accrued research and development expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">133</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We maintain equity incentive plans as a long-term incentive for employees, consultants, and directors. We account for all stock-based awards granted to employees and non-employees based on their fair value on the date of the grant and recognize compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. The grant date fair value of the stock-based awards with graded vesting is recognized on a straight-line basis over the requisite service period. We recognize forfeitures related to stock-based compensation awards as they occur and reverse any previously recognized compensation cost associated with forfeited awards in the period the forfeiture occurs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We value stock options with service conditions using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model uses various inputs and we make certain assumptions regarding the fair value of our common stock, the expected volatility of our common stock, the expected term of stock options, the risk-free interest rate for a period that approximates the expected term of our common stock options and our expected dividend yield. The following summarizes the inputs used and assumptions made:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected Volatility&#x2014;We lack company-specific historical and implied volatility information. Therefore, we estimate the expected stock volatility based on the historical volatility of a publicly traded set of peer companies and expect to continue to do so until we have adequate historical data regarding the volatility of our traded stock price.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected Term&#x2014;We use the simplified method described in the SEC&#x2019;s Staff Accounting Bulletin No. 107, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Share-Based Payment </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(&#x201c;SAB 107&#x201d;), to determine the expected life of the option grants.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-Free Interest Rate&#x2014;The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividends&#x2014;Expected dividend yield is zero because we have not paid cash dividends on shares of common stock and do not expect to pay any cash dividends in the foreseeable future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Determination of Fair Value of Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to the our IPO on October 8, 2021, the estimated fair value of our common stock has been determined by our board of directors as of the date of grant of each option award, with input from management, considering our most recently available third-party valuations of common stock and our board of directors&#x2019; assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#x2019; Accounting and Valuation Guide,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> Valuation of Privately-Held-Company Equity Securities Issued as Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Our common stock valuations were prepared using either an option pricing method, or OPM, or a hybrid method, both of which used market approaches to estimate our enterprise value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The assumptions underlying these valuations represented management&#x2019;s best estimate, which involved inherent uncertainties and the application of management&#x2019;s judgment. As a result, if we had used significantly different assumptions or estimates, the fair value of our common stock and our stock-based compensation expense could have been materially different.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Following our IPO, we determined the fair value of our common stock based on the quoted market price of our common stock on the Nasdaq Global Select Market.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">134</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For information with respect to recently issued accounting standards and the impact of these standards on our consolidated financial statements, refer to &#x201c;Note 2 &#x2014; Summary of Significant Accounting Policies&#x201d; in our consolidated financial statements in Part II, Item 8 of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Jumpstart Our Business Startups Act</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Jumpstart Our Business Startups Act of 2012, or the JOBS Act, permits an &#x201c;emerging growth company&#x201d; to take advantage of an extended transition period to comply with new or revised accounting standards. We are an &#x201c;emerging growth company,&#x201d; as defined in the JOBS Act. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this extended transition period, and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are also a &#x201c;smaller reporting company,&#x201d; meaning that the market value of our shares held by non-affiliates is less than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year. We may rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and have reduced disclosure obligations regarding executive compensation, and, similar to emerging growth companies, if we are a smaller reporting company with less than $100 million in annual revenue, we would not be required to obtain an attestation report on internal control over financial reporting issued by our independent registered public accounting firm.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">135</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7a_quantitative_and_qualitative"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7A. Quantita</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">tive and Qualitative Disclosures About Market Risk.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under SEC rules and regulations, because we are considered to be a &#x201c;smaller reporting company&#x201d;, we are not required to provide the information required by this item in this report.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_8_financial_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 8. Financial</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Statements and Supplementary Data.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The financial information required by Item 8 is located beginning on page F-1 of this report.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9_changes_in_and_disagreements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9. Changes in and Dis</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">agreements With Accountants on Accounting and Financial Disclosure.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9a_controls_and_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9A. Co</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ntrols and Procedures.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We maintain &#x201c;disclosure controls and procedures&#x201d; (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act), that are designed to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#x2019;s rules and forms.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosure controls and procedures include, without limitation, controls and procedures designed to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2022, the end of the period covered by this Annual Report. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of December 31, 2022, at the reasonable assurance level.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management&#x2019;s Report on Internal Control over Financial Reporting.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over our financial reporting. Internal control over financial reporting is defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, our principal executive and principal financial officers and effected by our board of directors, management, and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with United States GAAP. Our internal control over financial reporting includes those policies and procedures that:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">pertain to the maintenance of records that, in reasonable detail, accurately, and fairly reflect our transactions and dispositions of our assets;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with United States GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2022. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission, or COSO, in its 2013 Internal Control - Integrated Framework. Based on our assessment, our management has concluded that, as of December 31, 2022, our internal control over financial reporting is effective based on those criteria.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">136</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in Internal Control Over Financial Reporting.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the fiscal quarter ended December 31, 2022, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inherent Limitation on the Effectiveness of Internal Control.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures, or our internal controls, will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Attestation Report of the Registered Public Accounting Firm.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Annual Report does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting due to an exemption established by the JOBS Act for &#x201c;emerging growth companies.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9b_other_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9B. O</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ther Information.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 16, 2023, or the Effective Date, we entered into the first amendment, or Amendment No. 1, to the Amended and Restated License Agreement, or the A&amp;R License Agreement, dated October 14, 2022 between Pfizer Inc. or Pfizer, and the Company, which amends and restates certain terms of the A&amp;R License Agreement. The A&amp;R License Agreement amends and restates the previously executed license agreement dated December 8, 2020, effective as of March 12, 2021 between Pfizer and the Company, as amended to date. Pursuant to Amendment No. 1, we agreed to issue such number of shares of common stock equivalent to $5.0 million at a per share price equal to the closing price of our common stock on the business day when the closing price of our common stock on the Nasdaq Global Select Market is at or above $2.46 per share on any day from the Effective Date to a date that is within 180 days following October 6, 2022, or the A&amp;R Effective Date. If, within 180 days following the A&amp;R Effective Date, the share price for our common stock has not closed at or above $2.46 per share, then we agreed to issue such number of shares of common stock 180 days following the effective date, or the Issuance Date, equivalent to $5.0 million at a per share price equal to the closing price of our common stock on the business day prior to the Issuance Date, such that Pfizer&#x2019;s ownership interest in us shall not exceed nineteen and a half percent (19.5%) with any difference in value between the value of shares and $5.0 million being payable in cash.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 17, 2023, the closing price of our common stock on the Nasdaq Global Select Market was $2.76 per share. In accordance with the terms of Amendment No. 1, we issued 1,811,594 shares of our common stock to Pfizer, which is an amount equivalent to $5.0 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The shares of common stock issued pursuant to Amendment No. 1 are not registered under the Securities Act of 1933, as amended, or the Securities Act, in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">137</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">T III</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_10_directors_executive_officers"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 10. Directors, Executive </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Officers and Corporate Governance.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this Item will be included in our definitive proxy statement to be filed with the SEC, with respect to our 2023 Annual Meeting of Stockholders and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_11_executive_compensati"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 11. E</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">xecutive Compensation.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this Item will be included in our definitive proxy statement to be filed with the SEC, with respect to our 2023 Annual Meeting of Stockholders and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_12_security_ownership_of_certa"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 12. Security Ownership of Certai</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">n Beneficial Owners and Management and Related Stockholder Matters.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this Item will be included in our definitive proxy statement to be filed with the SEC, with respect to our 2023 Annual Meeting of Stockholders and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_13_certain_relationship"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 13. Certain Relationshi</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ps and Related Transactions, and Director Independence.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this Item will be included in our definitive proxy statement to be filed with the SEC, with respect to our 2023 Annual Meeting of Stockholders and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_14_principal_accounting_fees"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 14. Principal Accou</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">nting Fees and Services.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this Item will be included in our definitive proxy statement to be filed with the SEC, with respect to our 2023 Annual Meeting of Stockholders and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">138</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iv"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RT IV</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_15_exhibits_financial"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 15. Exhibits, Fi</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">nancial Statement Schedules.</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For a list of the financial statements included herein and report of independent registered public accounting firm (PCAOB ID: </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d4aa8cb6-3198-4dcc-a420-320c219c7d99" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="dei:AuditorFirmId"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">), see </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Index to the Consolidated Financial Statements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> on page F-1 of this Annual Report on Form 10-K, incorporated into this Item by reference.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial statement schedules have been omitted because they are either not required or not applicable or the information is included in the consolidated financial statements or the notes thereto.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(3)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibits:</span></div></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:7.688%;"></td>
    <td style="width:0.734%;"></td>
    <td style="width:52.728%;"></td>
    <td style="width:5.734%;"></td>
    <td style="width:9.732%;"></td>
    <td style="width:6.736%;"></td>
    <td style="width:10.159%;"></td>
    <td style="width:6.488%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">File No.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filing Date</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filed Herewith</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1782223/000095017021004476/pyxs-ex3_1.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Certificate of Incorporation of Pyxis Oncology, Inc.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;001-40881</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;3.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">November 15, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1782223/000095017021004476/pyxs-ex3_2.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Bylaws of Pyxis Oncology, Inc.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;001-40881</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;3.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;November 15, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="pyxs-ex4_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description of registrant&#x2019;s securities</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-40881</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 22, 2023</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1782223/000119312521288350/d156228dex101.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Investor Rights Agreement, dated March 5, 2021</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-259627</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 1, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1782223/000119312521290298/d156228dex102.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Indemnification Agreement</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-259627</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 4, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.3+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1782223/000119312521290298/d156228dex103.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employment Agreement between Pyxis Oncology, Inc. and Lara Sullivan, M.D.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-259627</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 4, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1782223/000119312521305462/d248391dex43.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pyxis Oncology, Inc. 2019 Equity Incentive Plan</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-8</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-260441</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 22, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.5+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1782223/000119312521305462/d248391dex44.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pyxis Oncology, Inc. 2021 Equity Incentive Plan</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-8</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-260441</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 22, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.6+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1782223/000119312521305462/d248391dex45.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pyxis Oncology, Inc. Employee Stock Purchase Plan</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-8</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-260441</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.5</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 22, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.7&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1782223/000119312521276227/d156228dex107.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">License Agreement by and between Pyxis Oncology, Inc. and Pfizer Inc., dated December 8, 2020</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-259627</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.7</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 17, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.8&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1782223/000119312521276227/d156228dex108.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment No. 1 to License Agreement by and between Pyxis Oncology, Inc. and Pfizer Inc., dated March 22, 2021</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-259627</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.8</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 17, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.9&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1782223/000119312521276227/d156228dex109.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exclusive License Agreement between the University of Chicago and Pyxis Oncology for Cancer Immunotherapy Technology, dated April 16, 2020</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-259627</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.9</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 17, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.10&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1782223/000119312521276227/d156228dex1010.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">License Agreement between Pyxis Oncology, Inc. and LegoChem Biosciences Inc., dated December 1, 2020</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-259627</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.10</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 17, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:3.25pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.11&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1782223/000119312521276227/d156228dex1011.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">First Amendment to License Agreement between Pyxis Oncology, Inc. and LegoChem Biosciences Inc., dated February 25, 2021</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-259627</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.11</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 17, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.12&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1782223/000119312521276227/d156228dex1012.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Opt-In, Investment and Additional Consideration Agreement between Pyxis Oncology, Inc. and LegoChem Biosciences, Inc., dated December 1, 2020</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-259627</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.12</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 17, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.13</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1782223/000119312521288350/d156228dex1013.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment to Opt-In, Investment and Additional Consideration Agreement between Pyxis Oncology, Inc. and LegoChem Biosciences, Inc., dated August 2, 2021</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-259627</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.13</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 1, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.14&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1782223/000119312521288350/d156228dex1014.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration Agreement by and among Pyxis Oncology, Inc., Alloy Therapeutics, Inc. and Voxall Therapeutics, LLC., dated March 30, 2021</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-259627</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.14</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 1, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.15</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1782223/000119312521288350/d156228dex1015.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease by and between B9 LS Harrison &amp; Washington LLC and Pyxis Oncology, Inc., dated September 29, 2021.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-259627</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.15</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 1, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.16+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1782223/000119312521290298/d156228dex1016.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employment Agreement between Pyxis Oncology, Inc. and Pamela Connealy.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-259627</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.16</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 4, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.17+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1782223/000119312521290298/d156228dex1017.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employment Agreement between Pyxis Oncology, Inc. and Jay Feingold, M.D.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-259627</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.17</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 4, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.18&#134;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1782223/000095017022009807/pyxs-ex10_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">License Agreement, dated March 28, 2022 between the registrant and Biosion USA, Inc.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-40881</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">May 13, 2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.19&#134;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1782223/000095017022020701/pyxs-ex10_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated License Agreement by and between Pyxis Oncology, Inc. and Pfizer Inc., dated October 6, 2022</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-40881</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">November 1, 2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.20&#134;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1782223/000095017022020701/pyxs-ex10_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Letter Agreement by and between Pyxis Oncology, Inc. and Pfizer Inc., dated October 14, 2022</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-40881</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">November 1, 2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">139</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:7.688%;"></td>
    <td style="width:0.734%;"></td>
    <td style="width:52.728%;"></td>
    <td style="width:5.734%;"></td>
    <td style="width:9.732%;"></td>
    <td style="width:6.736%;"></td>
    <td style="width:10.159%;"></td>
    <td style="width:6.488%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.21+</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="pyxs-ex10_21.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended Employment Agreement between Pyxis Oncology, Inc. and Lara Sullivan, M.D.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.22+</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="pyxs-ex10_22.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended Employment Agreement between Pyxis Oncology, Inc. and Pamela Connealy</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.23+</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="pyxs-ex10_23.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended Employment Agreement between Pyxis Oncology, Inc. and Jitu Wadhane</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.24</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="pyxs-ex10_24.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment No. 1 dated March 16, 2023 to Amended and Restated License Agreement by and between Pyxis Oncology, Inc. and Pfizer Inc., dated October 14, 2022</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.25&#134;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="pyxs-ex10_25.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment No. 1 to License Agreement, dated March 28, 2022 between the registrant and Biosion USA, Inc.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.26&#134;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="pyxs-ex10_26.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment No. 2 to License Agreement, dated March 28, 2022 between the registrant and Biosion USA, Inc.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.27&#134;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="pyxs-ex10_27.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment No. 3 to License Agreement, dated March 28, 2022 between the registrant and Biosion USA, Inc.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="pyxs-ex21_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">List of Subsidiaries</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="pyxs-ex23_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consent of Ernst &amp; Young LLP, independent registered public accounting firm.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Power of Attorney (included on signature page to this Annual Report on Form 10-K)</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="pyxs-ex31_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="pyxs-ex31_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32.1*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="pyxs-ex32_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32.2*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="pyxs-ex32_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.INS</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Instance Document &#x2013; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.SCH</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.CAL</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.DEF</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.LAB</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:3.25pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.PRE</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;margin-right:80.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*  The certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Annual Report on Form 10-K and are not deemed &#x201c;filed&#x201d; for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act, irrespective of any general incorporation language contained in such filing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">+  Indicates management contract or compensatory plan.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#134;  Certain confidential information contained in this exhibit, marked by [***], has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_16_form"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 16. For</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">m 10-K Summary</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">140</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIGNATURES</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.387%;"></td>
    <td style="width:2.698%;"></td>
    <td style="width:5.536%;"></td>
    <td style="width:46.379%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pyxis Oncology, Inc.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 22, 2023</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Lara Sullivan</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lara Sullivan, M.D.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">POWER OF ATTORNEY</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Lara Sullivan, M.D. and Pamela Connealy and each of them, as such person&#x2019;s true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for such person and in such person&#x2019;s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Annual Report on Form 10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or such person&#x2019;s substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:32.976%;"></td>
    <td style="width:1.042%;"></td>
    <td style="width:43.304%;"></td>
    <td style="width:1.042%;"></td>
    <td style="width:21.637%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Lara Sullivan</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President, Chief Executive Officer and Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 22, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lara Sullivan, M.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Executive Officer)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Pamela Connealy</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Financial Officer and Chief Operating Officer</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 22, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pamela Connealy</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Financial Officer)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Jitendra Wadhane</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Accounting Officer</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 22, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Jitendra Wadhane</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Accounting Officer)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ John Flavin</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chairman of the Board of Directors</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 22, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">John Flavin</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Thomas Civik</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 22, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thomas Civik</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Darren Cline</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Director</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 22, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Darren Cline</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Freda Lewis-Hall, M.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Director</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 22, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Freda Lewis-Hall, M.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Rachel Humphrey, M.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Director</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 22, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Rachel Humphrey, M.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">141</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PYXIS ONCOLOGY, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:92.0%;"></td>
    <td style="width:8.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Page</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#report_of_independent"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Balance Sheets as of December 31, 2022 and 2021</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_of_operations"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2022 and 2021</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_of_convertible"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Convertible Preferred Stock and Stockholders&#x2019; Equity (Deficit) for the Years Ended December 31, 2022 and 2021</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_of_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Cash Flows for the Years Ended December 31, 2022 and 2021</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#notes_to_consolidated_financial"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="report_of_independent"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Report of Independent Reg</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">istered Public Accounting Firm</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the Stockholders and the Board of Directors of Pyxis Oncology, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Opinion on the Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Pyxis Oncology, Inc. (the Company) as of December 31, 2022 and 2021, the related consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders&#x2019; equity (deficit) and cash flows for the years then ended, and the related notes (collectively referred to as the &#x201c;consolidated financial statements&#x201d;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2022 and 2021, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basis for Opinion</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These financial statements are the responsibility of the Company&#x2019;s management. Our responsibility is to express an opinion on the Company&#x2019;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#x2019;s internal control over financial reporting. Accordingly, we express no such opinion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6e6db33c-c670-49b0-bea4-9b92995a52e4" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="dei:AuditorName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ernst &amp; Young LLP</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have served as the Company&#x2019;s auditor since 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9ab248d6-8a29-4ffe-a80f-0da91cddb6cb" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="dei:AuditorLocation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Boston, Massachusetts</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 22, 2023</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PYXIS ONCOLOGY, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance Sheets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands, except share and per share amounts)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:61.845%;"></td>
    <td style="width:1.514%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:15.494%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.514%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:15.633%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current assets:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f77df0be-b36e-4eb0-9fb4-304a93701b1a" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">179,293</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dbb1fae5-7206-482c-a0e1-56ba5d943102" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">274,735</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1ba6b95b-dc5f-4cb1-8be9-97964a23973b" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:RestrictedCashCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,472</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f0b04946-033d-4bbb-ab58-147e170c9c0f" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:RestrictedCashCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,472</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6e2a0a02-281f-48ba-ac2d-fd5156df618e" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:PrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,847</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c47c72ca-15a2-473a-acd3-90e23967329c" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:PrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,466</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_91efea23-c023-4aad-ad13-7a8002959032" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">186,612</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_067a4cf7-fa5a-4a96-8c5a-595e20e547b1" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">278,673</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8ee0e6f7-5949-4918-8a99-4f1db4d40866" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,165</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7346dd59-6309-480f-9978-9a8f5f3ed2e1" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,007</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_000c0ab5-975f-43f5-8387-6283b2ea1cd4" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,602</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2518903d-d9a1-4aad-a07f-911f272a5943" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">232</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other assets, noncurrent</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_61a35903-aabb-4792-ac29-31e8f2180739" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">109</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6320e7bb-d155-426d-9b36-66c065376b78" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">211,379</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ac6a8f46-7e40-4abe-8876-ffca2b22ec1d" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">280,021</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liabilities and Stockholders&#x2019; Equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1613405a-b409-4fb5-84aa-d543b051d547" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,097</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_560a1372-d552-4ddb-856b-67adc92f0b95" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,951</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c5835064-a2ea-4fa0-afd7-f63062813d3f" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,537</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_25720e36-8501-4bd7-a2a1-690474ddab7d" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,592</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, current portion</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f09da2fa-1f70-4a80-bece-e7c8344a6738" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">165</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9df3f90c-9499-4087-b0eb-b7d1fc34e2f0" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">31,634</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ebc7d8b5-0cd8-4739-abc0-d0571402fb9b" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,708</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, net of current portion</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cc8a478f-53e2-4d87-ad4f-7e7a4e81121d" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,921</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_34033721-78db-4b26-b55e-f55d7361997d" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">50,555</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c22c6d56-0d96-4469-b964-6efb7bfe4081" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,708</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_b428182c-65cb-436d-ad3d-3dafc7163ff1;"><span style="-sec-ix-hidden:F_75a80392-2b27-400f-a0cf-7ce4dabe8391;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commitments and contingencies (Note 16)</span></span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stockholders&#x2019; equity:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preferred stock, par value $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7a979be3-8efb-4609-919a-518da8b737bc" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_b3aef1db-1617-4d6d-b134-82b5083860c6" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;per share, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d45a208a-1379-42b0-8f1a-c56dc23ee2ab" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_73ecc630-75b1-4301-b905-de9a610d1ca7" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares authorized; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4bf55630-1a02-48ac-81c6-afd188116887" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_61fac355-b3c5-41c7-b4da-0dcbc9ebd90f" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_9c3570cb-3cc7-49f2-b9c6-3e5113d24ffe" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_df515620-3083-48b7-8a65-c7752d9e5670" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">zero</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares issued and outstanding</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_a2ce678e-6dad-403a-8b9e-c365b9d6f501;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_00af17d6-813e-4e14-882a-ed1d6e7ac76a;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0bf11c4b-0180-4565-85de-fcbe3603bd56" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_07110ba9-1b37-40f2-a960-0cb7839adce8" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;par value per share; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eb3fda72-3c51-468f-8ce1-5a3f47268989" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_3877c111-9db1-476d-aed0-31774bfd3f70" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">190,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3c5c4569-3958-466f-bfa6-c8ca800f2b8e" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">35,110,016</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_31d31057-244f-45ee-9098-9b165f395234" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">32,792,867</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares issued as of December 31, 2022 and 2021, respectively, and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_757c2f76-716a-4e51-84b4-6a73302815e9" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">34,958,730</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1ee4b183-a2ce-4eed-b58d-14e337eaa4c1" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">32,222,881</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares outstanding as of December 31, 2022 and 2021, respectively</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_00b6712f-b0e8-4b5d-b47a-da5bc07db260" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">34</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e911c4ef-0914-4927-a9c1-69f4c908a164" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_be0a2518-572b-4447-8622-1ab450dd40ef" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">373,225</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fa6706dc-a97b-4f3f-8bb5-ed77b0591495" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">352,999</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4d89fb4c-2d90-4053-a2f0-56ce921f2437" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">212,435</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fd18533d-89f6-4f66-b36e-44a1da9f21bd" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">91,718</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stockholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d4408e7e-7efb-4edc-8dd2-3db29d8ee514" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">160,824</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c223880a-0234-4a73-b3b2-82e4d00152a9" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">261,313</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities and stockholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e88f6638-d0a4-4c78-8bc2-e96b3c23194b" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">211,379</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ca3c5581-4f3c-4e6f-b299-7441c9b0cb03" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">280,021</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PYXIS ONCOLOGY, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_of_operations"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Op</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">erations and Comprehensive Loss</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands, except share and per share amounts)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.217%;"></td>
    <td style="width:2.044%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:19.367%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:2.035%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:19.561%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:2.775%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f7b6b5a8-cf1e-4d39-a327-0f29c879c2c3" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">86,129</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_31224bd2-40bf-49a8-8a6e-ca56fd15bbb1" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">51,054</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7905669c-da59-4b80-b0d8-df93757d75a8" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">37,352</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_14915534-ca76-47b7-9317-ca7ed7dc04c7" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,663</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_88421dfa-26e5-48be-8ea2-f9a5a1e80e02" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">123,481</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0930ef4d-0412-4e4f-8bfb-233c4ea53a8b" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">69,717</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9ef3833f-ced3-4c96-9960-95939a769b6f" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">123,481</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_15262f68-6ed6-42bb-8576-a02a4070f953" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">69,717</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense):</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest income</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d896adde-1cbe-46b9-84a2-20b322b836fe" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,764</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ac6634bb-7bb9-4889-8cda-b72aa846959f" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Service fee income from related party</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_84868a23-e73a-43ab-9752-dfa257eb3063" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="pyxs:ServiceFeeIncomeFromRelatedParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">181</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in fair value of derivative liability</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a9dd97b3-c268-40e4-a145-86b59246727c" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:DerivativeGainLossOnDerivativeNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">6,231</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total other income (expense)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_07f0bb50-dbe7-4b26-a6a6-9714df9485e5" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,764</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_69af4052-7e13-4e60-b865-904799839d6e" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">6,027</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from equity method investment in joint venture</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ccab80d8-e272-443d-8ef0-311d4bfe32c4" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_99e7cca8-cf16-49c9-b934-c164a6045630" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">231</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss and comprehensive loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_24dafaa2-2f1b-417f-af82-7d232995c71c" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">120,717</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_26d6ba2e-a116-401c-9a47-8b24f72f92a1" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">75,975</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per common share - basic and diluted</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_23217c58-cbb3-4d24-9ad3-ba93769a2e14" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_04b142d3-ff0f-4f68-a740-7a5309aa1ee5" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">3.65</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ee7d5069-e7bd-441c-8817-99723d5db99f" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_51c23966-0d91-4af0-80c3-75840b587608" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">8.95</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average shares of common stock outstanding - basic and diluted</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a4772deb-5f59-45e1-8704-0d0a0a3af0b6" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_181f5ba5-dbe3-4201-8895-d5339e769ac9" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">33,033,081</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e3faed05-1937-4115-bf7a-d6066eda6057" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_f978ad06-40af-4bb2-9b2e-c12c544f7a03" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">8,493,273</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PYXIS ONCOL OGY, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_of_convertible"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Convertible Pre</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ferred Stock and Stockholders&#x2019; Equity (Deficit)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands, except share data)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:29.042%;"></td>
    <td style="width:0.946%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.739000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.015%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.141%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.946%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.302%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.015%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.393000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.174%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.67%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.026%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.795%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.958%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.840999999999999%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Convertible Preferred Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional<br />Paid-in</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total<br />Stockholders&#x2019;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity (Deficit)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2020</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6c4aabeb-608b-4ff6-aaa9-553c3bca4682" contextRef="C_b7382cca-33a6-4f4e-9ad5-9ec9267d027f" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">22,724,925</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2a61c7f9-433c-4e9e-ab1b-a897d5ebc573" contextRef="C_b7382cca-33a6-4f4e-9ad5-9ec9267d027f" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,942</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d92d99de-b8ec-4ac9-a361-363d1089de16" contextRef="C_d17eff6a-c465-4999-9b00-c89ab59f6085" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,289,342</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b8ffdb6b-6d87-4a27-8b15-76e583264d3b" contextRef="C_d17eff6a-c465-4999-9b00-c89ab59f6085" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2cab8aa7-0788-4300-a8d5-c1e756f3fcbe" contextRef="C_07d0bbc1-f9a2-43f9-8983-bf7982db0cbd" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">97</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bffb2274-d1b4-4683-9d6d-bfdea5529262" contextRef="C_21e45814-d1c9-49d0-b212-624324f81c19" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">15,743</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5240999c-2c45-448e-9bfd-3d1f048fa882" contextRef="C_4460d945-b64a-45f5-af82-5ed6de882504" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">15,645</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of Series B convertible preferred stock to Pfizer Inc. (Refer to Note 3)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e1d2f84e-4568-4626-879d-32674fb2ab11" contextRef="C_a5dd394e-5224-4d6a-bf00-62f63373e448" name="pyxs:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">12,152,145</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0db3b881-54b5-4968-b16f-2da5ff54abd2" contextRef="C_a5dd394e-5224-4d6a-bf00-62f63373e448" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of Series B convertible preferred stock, net of issuance costs of $</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3fe2b1c5-1148-41a6-82d5-4db19fa98202" contextRef="C_83982012-10a6-4487-8dce-be863732bf86" name="pyxs:TemporaryEquityIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">419</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_60525367-a49f-435c-b5cb-e03b95201efc" contextRef="C_ffecffd1-fb25-4239-b101-0b9e9224e3c5" name="pyxs:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">92,660,103</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3879eb03-832e-479b-8a67-bc1ce67ad9b7" contextRef="C_ffecffd1-fb25-4239-b101-0b9e9224e3c5" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">152,081</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of shares of common stock through initial public offering, net of underwriting commission and issuance costs of $</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_35a314d6-9e3a-4b7e-9122-cfd17d94eccc" contextRef="C_2b2bc485-3a60-4ce8-850d-05c0692602e2" name="us-gaap:DeferredFinanceCostsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,704</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_53b0a928-b8b0-471d-b6aa-525e974242b6" contextRef="C_de8208ab-bcfc-47b0-b387-5579dfad9705" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,500,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_013767bc-9dc7-4f20-b7d4-40262e501a23" contextRef="C_de8208ab-bcfc-47b0-b387-5579dfad9705" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d2ce6306-5850-402c-bac3-ccf3a7bf4ec3" contextRef="C_d753a366-cbec-4a3f-8e6d-a172249fde7b" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">152,285</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5571f57e-467f-490e-aa36-b5f424c53796" contextRef="C_22898140-752b-4c56-a019-59406d30b9a2" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">152,296</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Conversion of Series A and Series B convertible preferred stock into shares of common stock</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4f2eaccc-b84a-4205-9a49-89bd2cb2c918" contextRef="C_ffecffd1-fb25-4239-b101-0b9e9224e3c5" name="pyxs:TemporaryEquityConvertiblePreferredStockConvertedIntoSharesOfCommonStock" unitRef="U_shares" decimals="INF" sign="-" format="ixt:numdotdecimal">127,537,173</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_40952fb5-4595-4bc2-9f51-d6680d666f02" contextRef="C_ffecffd1-fb25-4239-b101-0b9e9224e3c5" name="pyxs:TemporaryEquityConvertiblePreferredStockConvertedIntoCommonStockValue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">194,023</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_07f97213-13d6-460c-ba28-2ac865be3033" contextRef="C_5e26e7a4-9894-40ab-9e05-0b5c0cf9ee51" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">20,056,145</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9d19b788-04bb-4885-a4b6-3e929099a9d2" contextRef="C_5e26e7a4-9894-40ab-9e05-0b5c0cf9ee51" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_02fd240b-ac24-4638-b5bb-1421c368370d" contextRef="C_8e2d7745-07cf-4ad1-90b5-7d195c47708c" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">194,003</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_48507914-14d2-47ee-ae93-0766fe65c8ee" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">194,023</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options exercised</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3402c8f5-d786-41e1-b821-c19293beec91" contextRef="C_5e26e7a4-9894-40ab-9e05-0b5c0cf9ee51" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">70,396</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_44c08c25-1674-4888-bc8f-6878aa239d34" contextRef="C_8e2d7745-07cf-4ad1-90b5-7d195c47708c" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">170</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3795117f-ce3d-453d-b244-de7e86ca82b4" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">170</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vesting of restricted common stock</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_04ec58c0-c989-494c-8569-84e1b2245828" contextRef="C_5e26e7a4-9894-40ab-9e05-0b5c0cf9ee51" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">306,998</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a5374442-f165-4f0d-90a8-3f8e3b0ce6aa" contextRef="C_8e2d7745-07cf-4ad1-90b5-7d195c47708c" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ab159ef6-c2e0-47c8-8569-2ebf31c34bc4" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7bf31454-b931-46cd-a985-1c3390b4df04" contextRef="C_8e2d7745-07cf-4ad1-90b5-7d195c47708c" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,441</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5119ebf4-719a-4322-aef0-f0e0d9bba694" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,441</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ec8d38ac-a3e6-4c7b-aded-3380c9e33e5f" contextRef="C_e311d53d-fcab-422f-9f96-6793c81e2f3c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">75,975</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a2dd9dae-4fee-4090-8ada-97d17b7b9a6c" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">75,975</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c414eb1a-7bac-4dda-b744-555edb91c2b7" contextRef="C_85b71da5-c5ad-4ef2-b3fa-15ed03b03ade" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">32,222,881</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9f2933d7-fdf8-4682-abda-f38832df364d" contextRef="C_85b71da5-c5ad-4ef2-b3fa-15ed03b03ade" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_84aff777-7ed7-48bb-b1a0-8a1d293cbdec" contextRef="C_1f7d801f-7c91-43b6-b20d-6c5b26ad7c1b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">352,999</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_089fb919-036c-4a93-8bae-c362cf50c8f5" contextRef="C_4fe8a1ab-50a0-48b5-951b-24bf559a7115" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">91,718</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4d3284a3-e624-4189-98d7-4236e18f0689" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">261,313</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock to Pfizer Inc. (Refer to Note 3)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7153999a-5f65-409a-bf59-0624740ae63b" contextRef="C_e31029d2-1718-44fb-bbfe-596a8f71bb1d" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,229,654</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dd06894d-7177-49a9-9820-1db2126f3c13" contextRef="C_e31029d2-1718-44fb-bbfe-596a8f71bb1d" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_59172ff2-bcb9-48ba-a212-0e89a67cc4b5" contextRef="C_706b851a-18a8-416b-8796-5d143cc0bd07" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,279</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4a9a9421-1635-4017-9563-e9cbaf488e24" contextRef="C_f891bb1b-8647-4939-8740-f3d10c242ed2" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,281</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options exercised</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_01817c59-0a4f-4d92-9453-018244aafcbc" contextRef="C_c0ed8f27-3a4c-4474-9fee-718c5b4c9f5f" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">73,841</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c36ec260-17eb-4790-890e-74098b59da4b" contextRef="C_3f691b8c-c469-4e4a-96b6-9103063b1982" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">183</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8e834ee1-0430-4747-bb35-9a278bbd87be" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">183</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vesting of restricted common stock</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_adb11212-427d-47e4-bb81-84b325e72b63" contextRef="C_c0ed8f27-3a4c-4474-9fee-718c5b4c9f5f" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">432,354</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1f161f04-25f1-47b3-8eeb-270eefc8bd56" contextRef="C_3f691b8c-c469-4e4a-96b6-9103063b1982" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,764</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fba64715-7849-4893-9178-4191729043bb" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,764</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ed8900dd-92f4-4fd1-b744-8bfa93ccf4c3" contextRef="C_dadd6f97-7a5c-4e8e-b808-bf02287c4b0a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">120,717</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8e41995a-d1ea-4bb4-9863-f1a22c91b086" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">120,717</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5d0f120c-b367-415f-8735-9e3c503abf9e" contextRef="C_39d48607-26ba-431a-ac8a-d3b4ffb3641d" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">34,958,730</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_98701ff7-3fef-48b5-8665-277a9db21428" contextRef="C_39d48607-26ba-431a-ac8a-d3b4ffb3641d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">34</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4c6db28e-adeb-4d2b-ac8b-c6deff5c39af" contextRef="C_93a31468-e176-4adc-8cfc-d60e8d2102f2" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">373,225</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6ab88177-cfb9-435f-b67a-495f2081ca54" contextRef="C_c0722afc-490f-4a94-9fc9-f07e63c7ee4d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">212,435</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8eec8cb5-9415-4140-a67b-508b64ffa862" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">160,824</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PYXIS ONCOLOGY, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_of_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statem</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ents of Cash Flows</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:68.908%;"></td>
    <td style="width:1.415%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.034%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.415%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.228%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_799e58b5-d38f-4308-9547-73e2ec379197" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">120,717</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_50c7e9b8-58db-4c5e-9f16-5c2439a285c0" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">75,975</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation and amortization</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fb80a35b-b99f-4aa5-b153-e99c28c6c49e" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">709</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b8d3b1a1-8823-4c5a-81e0-de4ef880a3df" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">647</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1f7c07db-4462-4c00-acbe-7d603f44b597" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,764</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_abe1f05b-f91d-4f43-b15c-f153f4e3ca69" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,441</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-cash research and development expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ddead4c3-99a8-4162-80f7-376eafd4203e" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="pyxs:NonCashResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,281</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e30ef7b1-2b66-462e-b71e-02583e060888" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="pyxs:NonCashResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-cash lease expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7806ad03-9173-4dde-ad97-383a3ad00144" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,127</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c8cd4cfa-474a-41fd-923f-2e8b8bb538fd" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">604</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-cash loss from equity method investment in joint venture</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_36468cc6-2548-4375-9df8-22f5650de6e2" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="pyxs:NonCashGainLossFromEquityMethodInvestmentInJointVenture" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">50</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in fair value of derivative liability</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0079618c-53cc-4bd8-8c31-f0639449dc5e" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:UnrealizedGainLossOnDerivatives" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">6,231</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fd608f0b-fc5f-4cd3-99a1-08a7e585e86e" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,381</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_71169218-f757-4b92-9f79-a8dfb3ef6879" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,444</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_97977d15-710e-44b9-9dad-68f51372eceb" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">8,328</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_233544e3-ebc7-43ed-abec-4be57c8fb6e6" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,643</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e8a2024f-9806-488d-b3ad-8c7309e17da7" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,951</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c9aff77c-87a1-4a20-ab05-04e9cc6749ea" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,092</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bd7a31a5-63d0-418b-8500-f647ec6acbb7" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,259</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_10bc9711-d718-4b5d-a6bb-af68eae1fb45" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">615</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c8128bbd-153d-4981-bb32-01addd217a36" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">89,335</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ae2158a3-935a-4e81-bbc6-661f8f8ed226" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">35,326</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchase of property and equipment</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_214a1fd1-f1fe-4c0f-9f07-f7faa4ee0140" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,399</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_204cfee0-d3a2-4a98-ac8d-65b8391169f0" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">540</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investment in joint venture</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c5118153-11a6-4f00-b317-77f84be8a44f" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:PaymentsToAcquireInterestInJointVenture" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">50</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_509acf03-ff2c-4f03-bdbd-050ccde011cc" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">6,399</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_48a70272-5807-43ca-b2e9-80822fbaa70c" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">590</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from issuance of Series B convertible preferred stock, net of issuance costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_495ba30e-6f9a-4931-ada7-5f1fc3e78b98" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">151,581</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from issuance of common stock in initial public offering, net of issuance costs</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_12ece6f4-7f91-4e22-bf89-81ccc9746041" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">152,296</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from the exercise of stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_682597bd-2f81-439c-a5cd-1c4fa8d9f325" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">183</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a219fb88-cd97-41b6-be63-124e7917a4a3" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">167</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_665d2a55-d2db-4ca7-9626-518239c01f14" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">183</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1d9e0471-aa12-40f9-999f-7a879c1e59a3" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">304,044</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net (decrease) increase in cash, cash equivalents, and restricted cash</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e2f4e1ce-56c4-4b37-b2ad-8fd45fe7fe38" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">95,551</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_14d2e1f2-4b81-4903-b3de-f063500aec52" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">268,128</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash, cash equivalents and restricted cash at beginning of year</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_788e0265-ce73-48ec-979a-d2a6f07aad2f" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">276,316</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2c4d5beb-2c48-4f6c-a658-eb14dd6ee645" contextRef="C_4460d945-b64a-45f5-af82-5ed6de882504" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,188</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash, cash equivalents and restricted cash at end of period</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b0bbeaaa-31e7-4a0a-b5f5-dda27211b565" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">180,765</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9165d944-712f-4f9d-b47c-7c3a78b31767" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">276,316</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supplemental cash flow information:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash received for interest</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0260926a-bc3e-4c86-bc83-ac30085e03b9" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="pyxs:CashReceivedForInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,166</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash paid for taxes</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b0ae8ce8-3936-41f7-b899-3ca8ab78003b" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:IncomeTaxesPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Noncash investing and financing activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment in accounts payable and accrued expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c32c81ca-d8e7-4787-bb34-032d9face39a" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,479</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_84f3342b-320b-4b17-8869-81df75339eed" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease right-of-use asset obtained in exchange for operating lease liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cf12b3ea-5117-4009-9b97-50302b3c878a" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,497</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reconciliation of cash, cash equivalents and restricted cash:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f6c654ad-e66f-4e73-9cbe-721f064cfbd5" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">179,293</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a48ee119-1b49-492e-8ffc-297f0c86960c" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">274,735</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_074f6ec1-a2db-4aec-a994-dd4d8f1846c6" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,472</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2a9410a3-aa7d-482e-88c7-692e2ab4e80e" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,581</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash, cash equivalents and restricted cash shown in the statement of<br />&#160;&#160;&#160;cash flows</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_22340cd5-8536-47c2-ada7-a462e10eec2a" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">180,765</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4431c01d-1775-47ea-8df5-e332cdeb9576" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">276,316</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PYXIS ONCOLOGY, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="notes_to_consolidated_financial"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">d Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2f0147dd-67d9-455d-90af-56590913ee7c" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. Description </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7f15c21e-ce1a-472c-a32e-e659514af919" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="pyxs:NatureOfBusinessPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Nature of Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pyxis Oncology, Inc. (the &#x201c;Company&#x201d;), a Delaware corporation, was founded in June 2018 and launched its operations in July 2019. The Company is a clinical stage company focused on defeating difficult-to-treat cancers. The company is efficiently building next-generation therapeutics that hold the potential for mono and combination therapies. The Company's therapeutic candidates are designed to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. The Company's antibody-drug conjugates (&#34;ADCs&#34;) and immuno-oncology (&#34;IO&#34;) programs employ novel and emerging strategies to target a broad range of solid tumors resistant to current standards of care.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_30698667-058f-4f1a-82bb-630824ebf859" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> operating segment. The Company&#x2019;s chief operating decision maker, its Chief Executive Officer, manages the Company&#x2019;s operations on a consolidated basis for the purposes of assessing performance and allocating resources.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_72a18483-4508-4611-afbc-d74d75300057" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2. Basis of Presentation and Summary of Significant Accounting Policies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b1be25a6-d5da-44ee-a06e-429adee7993f" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s fiscal year ends on December 31 and its first three quarters end on March 31, June 30 and September 30. The accompanying consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). The consolidated financial statements include the Company and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated upon consolidation.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is an &#x201c;emerging growth company,&#x201d; as defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). Section 107(b) of the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company has irrevocably elected not to avail itself of this extended transition period, and, as a result, the Company will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1d992552-0430-4b69-9e79-32fa234bebed" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="pyxs:LiquidityPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liquidity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the Company had an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b3ef92ad-08ee-4c5e-a6ff-d5ab7c9dacb3" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">212.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The Company has incurred losses and negative cash flows from operations since inception, including net losses of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_78a4f0e6-903d-43af-ba0b-fb7b707bedc2" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">120.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7bd00b07-6887-47e6-ae8d-136c1f8fadfc" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">76.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended December 31, 2022 and 2021, respectively.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has not generated any revenue to date and does not anticipate generating any revenues unless and until it successfully completes development and obtains regulatory approval for its current or any future product candidates. The Company expects that its operating losses and negative cash flows will continue for the foreseeable future as the Company continues to expand its research and development programs and develop its product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company currently expects that its existing cash and cash equivalents of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6b2bf50b-2930-45c3-b77d-8564896a8060" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">179.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of December 31, 2022 will fund its operating expenses and capital requirements at least twelve months from the date these audited consolidated financial statements are issued. Additional funding may be necessary to fund future clinical and preclinical activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company plans to continue to fund its losses from operations and capital funding needs through public or private equity, convertible or debt financing or other sources. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, or suspend or curtail planned programs. Any of these actions could materially harm the Company&#x2019;s business, results of operations and future prospects.</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d4a2545b-86ff-482a-ac89-4bff2e556fc8" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:UseOfEstimates" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expense, and related disclosures. The Company regularly evaluates estimates and assumptions related to assets, liabilities, stock-based compensation, operating leases, assessment of the useful lives of property and equipment, valuation of deferred tax assets and liabilities, impairment of investment in joint venture, and research and development costs. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Actual results could differ from those estimates and there may be changes to management&#x2019;s estimates in future periods.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_99478180-13b6-4157-8e59-95e9f6d4f209" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="pyxs:RisksAndUncertaintiesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is subject to risks common to early-stage companies in the biopharmaceutical industry including, but not limited to, uncertainties related to commercialization of products, regulatory approvals, dependence on key suppliers for active ingredients and third-party service providers such as contract research and manufacturing organizations, protection of intellectual property rights and the ability to make milestone, royalty or other payments due under any license, collaboration or supply agreements.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3c8d2bc5-76e9-4726-88a0-f461f2446bb7" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risks</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company&#x2019;s cash and cash equivalents are held at an accredited financial institution and the Company has not experienced any losses in such accounts. The Company maintains its cash in bank deposit accounts, which at times may exceed federally insured limits. The Company&#x2019;s cash equivalents consist primarily of short-term money market funds held in accredited financial institutions. The Company believes it is not exposed to any significant risk in cash and cash equivalents.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_966977eb-49e0-47a6-8b69-66a0a7ebd866" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers all short term, highly liquid investments with original maturities of 90 days or less to be cash equivalents. Cash equivalents consist primarily of money market funds as of December 31, 2022 and 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9c457ab0-1eb2-4044-b4b8-9ce4f83cf489" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value Measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principle or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, the first two are considered observable and the last is considered unobservable:</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> 1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> 2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;Quoted prices in markets that are not considered to be active or financial instrument valuations for which all significant inputs are observable, either directly or indirectly; and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> 3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_111182bd-d681-4cb2-8da9-031ccf676799" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment, net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9562f89a-1b00-4343-b82a-a4b6cb36878d" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="pyxs:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment are recorded at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful lives of the related assets as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:73.0%;"></td>
          <td style="width:2.037%;"></td>
          <td style="width:24.963%;"></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated Useful<br />Life (Years)</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f99bc6e4-dde6-4783-b40a-747263583873" contextRef="C_cf314be8-48e6-4158-ba0a-296598f0c1fa" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></ix:nonNumeric></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and office equipment</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7b054131-23b0-4568-8a5b-e44bacd03e3c" contextRef="C_98ff73fd-5dca-4046-abbc-fee18b4eea2d" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></ix:nonNumeric></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_265cfcd7-4e38-4e59-ad89-9f1914edd5dc" contextRef="C_915e850b-ae03-438e-afb7-244101692549" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shorter of remaining life<br />of lease or useful life</span></ix:nonNumeric></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Construction in process</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">N/A</span></p></td>
         </tr>
        </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and amortization expense is included in research and development and general and administrative expenses. Major additions and upgrades are capitalized; maintenance and repairs, which do not improve or extend the life of the respective assets, are expensed as incurred. Upon retirement or sale, the cost of assets disposed of, and the related accumulated depreciation and amortization are removed from the respective accounts and any resulting gain or loss is included in income (loss) from operations.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8e9770fa-8077-4908-bd79-c300d55ba66d" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company evaluates the long-lived assets, which consist of property and equipment and operating lease right-of-use assets, for impairment at least annually and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. Management then determines whether the remaining useful life continues to be appropriate, or whether there has been an impairment of long-lived assets based primarily upon whether expected future undiscounted cash flows are sufficient to support the assets&#x2019; recovery. Recoverability of these assets is measured by comparison of the carrying amount of the asset to the future undiscounted cash flows the asset is expected to generate. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. The Company recognized </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_196f33b4-994a-4b12-8c6a-4fa5b5611a7e" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_9d7355fb-8f33-4041-af31-e5ddfde587a9" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> impairment losses for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c0411a81-dbb0-4dc9-bdfc-f0e6c49cdf7e" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">lease right-of-use (&#x201c;ROU&#x201d;) assets represent the Company&#x2019;s right to use an underlying asset during the lease term, and operating lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease ROU assets and lease liabilities are initially recognized and measured based on the present value of the future fixed lease payments over the expected lease term at the commencement date calculated using the Company&#x2019;s incremental borrowing rate applicable to the lease asset, unless the implicit rate is readily determinable. The Company determines the lease term as the non-cancelable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease ROU assets also include any initial direct costs incurred and any lease payments made on or before the lease commencement date, less lease incentives received. Operating lease ROU assets are subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Leases with a term of 12 months or less are not recognized on the consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Variable lease costs such as common area costs and other operating costs are expensed as incurred. The Company accounts for lease and non-lease components as a single lease component for all its facilities leases. The Company had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d4d9cdc4-f0b0-470e-89b8-7c5a2408706b" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="pyxs:NumberOfFinanceLease" unitRef="U_Lease" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_12d369cc-4250-4257-8746-326d0e03ef02" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="pyxs:NumberOfFinanceLease" unitRef="U_Lease" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> finance leases as of December 31, 2022 and 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_13832a71-ea80-4758-ba3e-cdb2814b492d" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:InvestmentPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Investment in Joint Venture</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investment in the Company&#x2019;s joint venture is accounted for using the equity method of accounting. The Company applies the equity method of accounting to investments when the Company has significant influence, but not controlling interest in the investee. Judgment regarding the level of influence over equity method investment includes considering key factors such as ownership interest, representation on the board of directors, participation in policy-making decisions and material intercompany transactions. Under the equity method, investments are initially recorded at cost and are adjusted for dividends, distributed and undistributed earnings and losses, and additional investments. In the event the Company&#x2019;s share of a joint venture&#x2019;s cumulative losses exceeds the Company&#x2019;s investment balance, the balance is reported at zero value until proportionate income exceeds the losses. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company assesses investments for impairment whenever events or changes in circumstances indicate that the carrying value of an investment may not be recoverable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5029a56d-0cd6-43f1-8395-387cab3e93c4" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Contingencies</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company, from time to time, may be a party to various disputes and claims arising from normal business activities. The Company continually assesses disputes and claims including resulting litigation to determine if an unfavorable outcome would lead to a probable loss or reasonably possible loss which could be estimated. The Company accrues for all contingencies at the earliest date at which the Company deems it probable that a liability has been incurred and the amount of such liability can be reasonably estimated. If the estimate of a probable loss is a range and no amount within the range is more likely than another, the Company accrues the minimum of the range. In the cases where the Company believes that a reasonably possible loss exists, the Company discloses the facts and circumstances of the contingencies, including an estimable range, if possible.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fbfa1981-5160-4aea-83bb-33ee39b4d520" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company expenses research and development costs as incurred. The Company&#x2019;s research and development expenses consist primarily of license fees to acquire intellectual property which does not meet the definition of intangible assets and costs incurred in performing research and development activities, including personnel-related expenses such as salaries, stock-based compensation and benefits, facilities costs, depreciation as well as external costs from third parties who conduct research and development activities (including manufacturing) on behalf of the Company. The Company accrues expenses related to development activities performed by third parties based on an evaluation of services received and efforts expended pursuant to the terms of the contractual arrangements. Payments under some of these contracts depend on preclinical and/or clinical trial milestones. There may be instances in which payments made to the Company&#x2019;s vendors will exceed the level of services provided and result in a prepayment of expenses. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company adjusts the accrual or prepaid expense accordingly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1e653a7f-06c6-4c64-a08c-a2784045e811" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company maintains an equity incentive plan as a long-term incentive for employees, consultants, and directors. The Company accounts for all stock-based awards granted to employees and non-employees based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. The grant date fair value of the stock-based awards with graded vesting is recognized on a straight-line basis over the requisite service period. The Company recognizes forfeitures related to stock-based compensation awards as they occur and reverses any previously recognized compensation cost associated with forfeited awards in the period the forfeiture occurs. The Company classifies stock-based compensation expense in the statement of operations in the same manner in which the award recipients&#x2019; payroll costs are classified or in which the award recipients&#x2019; service payments are classified.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company values its stock options with service conditions using the Black-Scholes option-pricing model. The Company uses certain assumptions to determine fair value of the stock options pursuant to the Black-Scholes option-pricing model, including the expected life of the award, volatility of the underlying shares, the risk-free interest rate, expected dividend yield and the fair value of the Company&#x2019;s common stock. Since the Company lacks sufficient historical option exercise data to provide a reasonable basis upon which to estimate the expected term, the Company uses the simplified method described in the SEC&#x2019;s Staff Accounting Bulletin No. 107, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Share-Based Payment </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(&#x201c;SAB 107&#x201d;), to determine the expected life of the option grants. The Company lacks sufficient company-specific historical and implied volatility information. Therefore, the Company estimates the expected stock volatility based on the historical volatility of a publicly traded set of peer companies. The risk-free interest rate is based on the rates paid on securities issued by the U.S. Treasury with a term approximating the expected life of the equity award. As the Company has never paid and does not anticipate paying cash dividends on its common stock, the expected dividend yield is considered as zero.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to the completion of the Company&#x2019;s initial public offering (&#34;IPO&#34;) of common stock, the fair value of the Company's common stock which is one of the key inputs in Black-Scholes option-pricing model, was determined by the board of directors with input from management and based on certain assumptions including probability weighting of events, business and market conditions, volatility, time to liquidation, a risk-free interest rate and an assumption for a discount for lack of marketability. The Company used 409A valuations to determine the fair value of the shares of common stock. The 409A valuations were performed using methodologies, approaches, and assumptions consistent with the American Institute of Certified Public Accountants </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. After completion of the IPO on October 8, 2021, the Company uses the fair value of its publicly traded common stock to determine grant date fair value.</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_da88ec1f-82e2-4d39-830a-e2ff267bbf32" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for income taxes in accordance with FASB ASC 740, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (&#x201c;ASC 740&#x201d;), which requires the use of the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between amounts in the consolidated financial statements and the tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income tax (benefit) expense in the consolidated statements of operations and comprehensive loss in the period that includes the enactment date.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes deferred tax assets to the extent that it believes these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_51ea7f9f-b80b-4e67-9da4-b5c43bcb1de1" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Loss per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net income (loss) per share attributable to common stockholders is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the diluted weighted average number of common shares outstanding for the period, including potential dilutive common shares.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In periods in which the Company reports a net loss, all common stock equivalents are deemed anti-dilutive such that basic net loss per common share and diluted net loss per common share are equivalent. Potentially dilutive common stock has been excluded from the diluted net loss per common share computations in all periods presented because such securities have an anti-dilutive effect on net loss per common share due to the Company&#x2019;s net loss. There are no reconciling items used to calculate the weighted-average number of total common stock outstanding for basic and diluted net loss per common share data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_daaef799-6e7f-4f40-af72-7cb486393590" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="pyxs:RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recently Issued Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2016, the FASB issued ASU 2016-13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (&#x201c;ASU 2016-13&#x201d;), which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss model that requires the use of forward-looking information to calculate credit loss estimates. It also eliminates the concept of other-than-temporary impairment and requires credit losses on available-for-sale debt securities to be recorded through an allowance for credit losses instead of as a reduction in the amortized cost basis of the securities. For &#34;emerging growth companies&#34;, ASU 2016-13 is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. The Company is currently evaluating the new standard and expects it to have no material impact on the Company's consolidated financial statements and related disclosures.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2020, the FASB issued ASU 2020-06, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt &#x2013; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(&#x201c;ASU 2020-06&#x201d;). ASU 2020-06 revises the guidance on calculating earnings per share, requiring use of the if-converted method for all convertible instruments and rescinding an entity&#x2019;s ability to rebut the presumption of share settlement for instruments that may be settled in cash or other assets. As an &#34;emerging growth company&#34;, ASU 2020-06 will become effective for the Company for fiscal years beginning after December 15, 2023, and early adoption is permitted. The Company is currently evaluating the new standard and expects it to have no material impact on the Company's consolidated financial statements and related disclosures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recent authoritative guidance issued by the FASB (including technical corrections to the ASC), the American Institute of Certified Public Accountants, and the SEC did not, or are not expected to, have a material impact on the Company&#x2019;s audited consolidated financial statements and related disclosures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5dc4c4ae-ddca-4502-a93d-0b06fad33284" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="pyxs:LicensingAgreementsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3. Licensing Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The University of Chicago Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2020, the Company entered into a license agreement (the &#x201c;University License Agreement&#x201d;), as well as a sponsored research agreement, with the University of Chicago (the &#x201c;University&#x201d;). Under the terms of the license, the Company has the global right to develop and commercialize products that are covered by a valid claim of a licensed patent, incorporate or use the licensed know-how and materials or are known to assess, modulate or utilize the activity of certain specified biological targets. In partial consideration for the license from the University, the Company issued to the University </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_90cdbb3b-93c9-463b-b0a8-70143f163c1f" contextRef="C_6c431810-e959-4b5a-b476-c39c7b79b09c" name="pyxs:CommonStockIssuedToUniversity" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">48,919</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock in 2020.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursua</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">nt to the University License Agreement, the Company is obligated to pay potential development and commercial milestones of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_03d80a2c-f84e-40e2-90dc-0e1e49081153" contextRef="C_772490ef-27c8-4a53-a78c-52e1650134c4" name="pyxs:PotentialDevelopmentAndCommercialMilestonePayment" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">7.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as well as running royalties on net sales of licensed products at varying rates ranging from less than a percent to the low single digits, subject to a minimum annual royalty of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_02503f1c-a5ec-443c-8ebb-fca26d412de0" contextRef="C_63b19c56-1b8a-44d0-841a-bbbe8b23192a" name="pyxs:MinimumAnnualRoyaltyFees" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during certain years following the effective date. The Company is also obligated to pay the University a percentage of certain sublicensing revenue ranging from low- to mid-teens based on the date of entering into the applicable sublicense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company assessed the milestone and royalty events under University License Agreement as of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and 2021, and determined that </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_31b10035-1daa-42a2-b71a-376724b96eb0" contextRef="C_3d815e67-ceab-4431-bce9-20d33a91f2dd" name="pyxs:MilestoneAndRoyaltiesIncurred" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_44a58517-2f85-48d4-b3c6-5f0b07b7091d" contextRef="C_4595b0e9-9dcf-4916-9f78-cc4f6d5b5648" name="pyxs:MilestoneAndRoyaltiesIncurred" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> such amounts were required.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Pfizer Inc. Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2020, the Company entered into a license agreement (as amended, the &#x201c;Pfizer License Agreement&#x201d;) with Pfizer Inc. (&#x201c;Pfizer&#x201d;) for worldwide development and commercialization rights to ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates. The Company&#x2019;s rights are exclusive with respect to certain patents owned or controlled by Pfizer covering the licensed ADCs. Pfizer has also granted the Company a non-exclusive license to use Pfizer&#x2019;s ADC technology (&#x201c;FACT&#x201d;) platform. The initial licensed targets include CD123 and extra domain B (EDB of fibronectin) and the Company has the option to expand the scope of its license to add additional licensed targets that have not been licensed to a third party or are not the subject of a Pfizer ADC development program. The Pfizer License Agreement became effective in March 2021 and the Company paid a combined $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fff135e4-9536-431b-8b18-f63e32877ccb" contextRef="C_9ea37f53-ac68-4a4e-aac4-357a7fa13f64" name="pyxs:PaymentForLicenseFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">25.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the license fee, consisting of an upfront cash payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2faa6396-e30b-4f62-b531-f28b0fd7838f" contextRef="C_9ea37f53-ac68-4a4e-aac4-357a7fa13f64" name="pyxs:UpfrontPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_75d54e83-b35d-4ad6-a779-46b902f0586e" contextRef="C_1d6dfd74-4dd3-4d8d-ade5-27835ecdb4ee" name="pyxs:IssuanceOfConvertiblePreferredStockShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">12,152,145</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Series B convertible preferred stock, which was converted into </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_48d8e0da-a21a-4d0f-ad00-8a13396dbeaf" contextRef="C_72ee8eff-e4a6-4e5c-8e34-b16da25e910f" name="pyxs:NumberOfCommonSharesIssuedUponConversionOfPreferredStock" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,911,015</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock upon the IPO in October 2021, with a value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_21cb963d-0e16-4ae5-8e6a-e3fbf8511938" contextRef="C_5e0e5fda-24f4-4956-a238-9aa47842953a" name="pyxs:ConvertiblePreferredStockSharesIssuedValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to Pfizer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On October 6, 2022, the Company entered into an amended and restated license agreement (the &#x201c;A&amp;R License Agreement&#x201d;) with Pfizer, which amends and restates the Pfizer License Agreement. Pursuant to the A&amp;R License Agreement, Pfizer granted to the Company exclusive worldwide rights under Pfizer&#x2019;s FACT Platform technology to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates. Additional ADC targets may be licensed for a nominal upfront payment and milestones. Further, the Company granted the right of first negotiation to Pfizer, on an exclusive basis, to purchase or to develop, manufacture and commercialize licensed ADCs and licensed products in one or more countries directed to EDB and CD123. In accordance with the terms of the A&amp;R License Agreement, the Company agreed to pay $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5ebe9d37-5467-4b41-8469-3cf2473e16da" contextRef="C_23f0eeb1-4ec3-40f7-8427-0bbf70cd0d1c" name="pyxs:UpfrontPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to Pfizer (which was paid in January 2023) and issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c79ecf32-274f-4f12-884c-0b6ad026c4a6" contextRef="C_2af509fb-9702-480c-8cbd-911f991087fa" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,229,654</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock. Additionally, the Company will issue such number of shares of common stock </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_21e26427-7937-4fcb-8ecf-96d45031d438" contextRef="C_23f0eeb1-4ec3-40f7-8427-0bbf70cd0d1c" name="pyxs:NumberOfDaysCommonStockIssuedFromEffectiveDate" unitRef="U_Days" decimals="INF" format="ixt:numdotdecimal">180</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> days following the effective date (the &#x201c;Issuance Date&#x201d;), equivalent to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_37527caf-f176-4693-ab3a-fd8ef5a87e16" contextRef="C_2af509fb-9702-480c-8cbd-911f991087fa" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million at a per share price equal to the closing price of the Company&#x2019;s common stock on the business day prior to the Issuance Date, such that Pfizer&#x2019;s ownership interest in the Company shall not exceed nineteen and a half percent (</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fb3a160e-7be8-428e-91eb-59d45e084214" contextRef="C_23f0eeb1-4ec3-40f7-8427-0bbf70cd0d1c" name="pyxs:MaximumPercentageOfOwnershipInterest" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">19.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%) with any difference in value between the value of shares and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_81c29a35-b828-4b25-b159-9d87ac746d87" contextRef="C_2af509fb-9702-480c-8cbd-911f991087fa" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million being payable in cash. The Company recorded $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3eb106b7-faae-4353-88ce-a4189496b95c" contextRef="C_f891bb1b-8647-4939-8740-f3d10c242ed2" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">17.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as research and development expenses for the A&amp;R License Agreement during fourth quarter of the calendar year 2022.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is also obligated to pay future contingent payments including development, regulatory and commercial milestones up to an aggregate of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_35b0c421-a735-4630-9348-c772618523c4" contextRef="C_18591516-6c3d-465a-804c-40424d183530" name="pyxs:AggregateMilestonePayments" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">665</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the first four licensed ADCs. In addition, the Company is required to pay future contingent payments including development, regulatory and commercial milestones for ADCs to each additional licensed target beyond the first four licensed ADC targets developed and commercialized via the FACT Platform. Additionally, if ADC licensed products are launched, the Company will pay Pfizer tiered royalties on net sales of licensed products in varying royalty rates ranging from low single digits to mid-teens. The Company&#x2019;s royalty obligations apply on a licensed product-by-licensed product and country-by-country basis from first commercial sale until the latest to occur of: (1) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_82920f91-cb9e-4c6f-a396-d7bf5782b842" contextRef="C_6da87304-fe59-4975-99b3-27f5fd2ceb69" name="pyxs:RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years from first commercial sale; (2) the expiration of all regulatory or data exclusivity; and (3) the expiration of the last valid claim of a licensed patent covering the licensed product in a country. The Company is also obligated to pay Pfizer a percentage of certain sublicensing revenue ranging from twenty percent to low-double digits based on the stage of development of the licensed product at the time of entering into the applicable sublicense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company assessed the milestone and royalty events under A&amp;R License Agreement as of December 31, 2022 and 2021, and determined that </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f057a6eb-0551-48fa-9b2a-811e1f82fcff" contextRef="C_e54e83a0-b25b-418c-b85c-d5c2ca67e4c7" name="pyxs:MilestoneAndRoyaltiesIncurred" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_4d98d585-c37d-4b0d-8e4e-dc51e0600f7c" contextRef="C_fa5ee9fe-cc4b-4842-b6f4-396be31d8300" name="pyxs:MilestoneAndRoyaltiesIncurred" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> such amounts were required.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">LegoChem Biosciences, Inc. Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2020, the Company entered into a license agreement (the &#x201c;LegoChem License Agreement&#x201d;) and an opt-in, investment and additional consideration agreement (the &#x201c;Opt-In Agreement&#x201d;) with LegoChem Biosciences, Inc. (&#x201c;LegoChem&#x201d;). Pursuant to the LegoChem License Agreement, the Company obtained worldwide (other than Korea) license for development and commercialization rights for LCB67, an ADC product candidate targeting DLK-1, and products containing the licensed compound. The Company paid $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_77c3f490-131b-4e2b-80cf-2b411b2d20d1" contextRef="C_84cf517c-82fd-437e-b63e-4d987372dee8" name="pyxs:UpfrontFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">9.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in March 2021 to LegoChem, which was recorded as research and development expenses. Additionally, the Company may purchase certain initial quantities of licensed products from LegoChem for an estimated cost of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_416f443d-3f4f-435a-9c2c-100f2207a78a" contextRef="C_d4e409b9-f87d-4dfd-8ff7-0b2a843ec39f" name="pyxs:EstimatedCostToPurchaseLicensedProducts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is obligated to make future contingent payments including development, regulatory and commercial milestones as well as running royalties on net sales of licensed products at varying rates. During the year ended December 31, 2022, the Company stopped the continued development of LCB67, based on review and analysis of data from the toxicity studies, and anticipated clinical use and commercial prospects of anti-DLK1 ADC. Due to stoppage of clinical development of LCB67, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_700cfb69-c305-4eb6-b0f7-b1aea0c8873d" contextRef="C_056d4eec-ac13-4d48-b518-557aadce6575" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> amounts were due and payable related to the manufacturing of the initial quantities of licensed product as well as the milestones and royalties related to LCB67 ADC of December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, as part of the Opt-in Agreement, LegoChem had an option to pay $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3803ab40-4267-4f68-809a-7ffb74182694" contextRef="C_a7460a4a-43b1-45a4-98f8-5736508db488" name="pyxs:OptionUpfrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to the Company, in exchange for the right to receive a milestone payment (the &#x201c;Extra Milestone Payment&#x201d;) of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8a90ae72-7c52-40ef-a4b4-652243a29a43" contextRef="C_a7460a4a-43b1-45a4-98f8-5736508db488" name="pyxs:ExtraMilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">9.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million upon the earliest to occur of certain events, including the date of pricing or offer of the first public offering of its common stock or if the Company is the subject of a change in control transaction. The Company determined that the Extra Milestone Payment met the definition and recognition condition of derivative under ASC 815, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#x201c;Derivatives and Hedging&#x201d; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for which there was a binding contract and firm commitment in January 2021. An initial derivative liability was recognized for $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_40868468-6926-4235-9c8c-0090b5581a84" contextRef="C_afca8c75-429e-4247-b930-08b342481fcc" name="pyxs:DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million with an offset to research and development expenses in January 2021. The derivative liability was re-measured at each reporting date, and as a result, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_835e9cda-d1bf-4086-b784-ff8621fbc2c2" contextRef="C_2c0f07bf-9ab0-42b4-921b-a98e8aea7faf" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was recorded in &#x201c;Other income (expense)&#x201d; in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2021. The liability was realized upon the IPO of the Company and Extra Milestone Payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8899686a-6911-4007-998b-1c69dd75f290" contextRef="C_2caa6904-2924-4060-8a2d-3b3cec935236" name="pyxs:ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">9.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was paid to LegoChem in January 2022. The Company has no further obligations under the Opt-In Agreement as of December 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">License Agreement with Biosion USA, Inc.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 28, 2022, the Company entered into a license agreement (the &#x201c;Biosion License Agreement&#x201d;) with Biosion USA, Inc. (&#34;Biosion&#34;), pursuant to which the Company obtained an exclusive, worldwide (other than Greater China (mainland China, Hong Kong, Macau and Taiwan)) license for development, manufacture and commercialization rights for BSI-060T, a Siglec-15 targeting antibody, an IO product candidate (now referred to as PYX-106), and products containing the licensed compound. Under the terms of the Biosion License Agreement, each party granted to the other party a right of first offer to obtain an exclusive license in the other party&#x2019;s territory (Greater China for Biosion, and the rest of the world for Pyxis) to develop, manufacture and commercialize any bi-specific or multi-specific antibody any antibody-drug conjugate controlled by a party or its affiliate that inhibits, modulates or binds to Siglec-15 as an intended mechanism of action.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the Biosion License Agreement, the Company paid an upfront license fee of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d115b6b8-b967-4530-aed9-d2414a145984" contextRef="C_9188f657-2f90-466d-b42f-29e1c97321d0" name="pyxs:UpfrontFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which was recorded as research and development expenses. The Company is also obligated to pay future contingent payments including development, regulatory and commercial milestones up to an aggregate of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_489505e1-f0c2-4526-a244-a9efbe78bcec" contextRef="C_7f69dc96-1c3c-4d15-bee7-ceb32b6a4546" name="pyxs:AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">217.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in case of normal approval and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_632989bd-0f53-4666-b8f7-5bce7ea254d0" contextRef="C_7f69dc96-1c3c-4d15-bee7-ceb32b6a4546" name="pyxs:AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">222.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in case of accelerated approval. Additionally, if products are launched, the Company will pay Biosion tiered royalties on net sales of licensed products in varying royalty rates ranging from low single digits to low teens. The Company&#x2019;s royalty obligations apply on a licensed product-by-licensed product and country-by-country basis from first commercial sale until the latest to occur of: (1) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ba94c6ed-e590-4e5e-9ada-851012eb0876" contextRef="C_4673806d-5b9d-43ee-aed1-9c1f8ab9e297" name="pyxs:RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years from first commercial sale; (2) the expiration of all regulatory or data exclusivity; and (3) the expiration of the last valid claim of a licensed patent covering the licensed product in a country. The Company is also obligated to pay Biosion a percentage of certain sublicensing revenue ranging from mid-double to low-double digits based on the stage of development of the licensed product at the time of entering into the applicable sublicense.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company assessed the milestone and royalty events involving Biosion as of December 31, 2022 and determined that </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_15adc3c5-ef55-4237-b833-370e05e67d88" contextRef="C_43213977-374c-49b1-8370-aa4e647874fe" name="pyxs:MilestoneAndRoyaltiesIncurred" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> such amounts were required.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b8370498-dd90-4576-aaab-022ffa37f120" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4. Joint Venture</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2021, the Company entered into definitive transaction agreements with Alloy Therapeutics, Inc. (&#x201c;Alloy&#x201d;) and Voxall Therapeutics, LLC (&#x201c;Voxall&#x201d;), to finance and operate Voxall, a joint venture company formed in collaboration with Alloy to leverage the Company&#x2019;s technology and Alloy&#x2019;s ATX-Gx</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:5.025pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#153; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">platform and antibody discovery services. Voxall granted to the Company and Alloy, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_72352eb9-fd04-4e60-aa64-a362674ab6ab" contextRef="C_4a91be42-9646-464e-a10b-8cf7d387c4f2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the voting membership units of Voxall in exchange for certain initial contributions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounted for investment in Voxall under the equity method of accounting. Voxall has incurred losses since inception and the Company&#x2019;s share in the losses of Voxall aggregated to</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8eb431cb-b2db-4da9-8d85-3c826cb56fda" contextRef="C_6eb028fe-0dfc-4fcc-8cfd-de5ca6f2a851" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ce1efa4e-1b22-42ec-a629-9a6581bf0020" contextRef="C_403332e3-9bcb-4fd2-8dda-17c8ccb33760" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">million for the years ended December 31, 2022 and 2021, respectively. The Company recognized its share of losses of Voxall only to the extent of the carrying value of its</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">investment in Voxall and the promissory note issued by Voxall, which aggregated to</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b41d1a03-6d6d-463f-959a-c952cd3f4c65" contextRef="C_403332e3-9bcb-4fd2-8dda-17c8ccb33760" name="pyxs:ProceedsFromPromissoryNoteIssued" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">million for the year ended December 31, 2021. The remaining unabsorbed loss will be offset against future income, if any. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_79f58cea-d603-412a-ae07-d0cdf8f935ad" contextRef="C_6eb028fe-0dfc-4fcc-8cfd-de5ca6f2a851" name="us-gaap:EquityMethodInvestmentDescriptionOfPrincipalActivities"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As the Company has no commitment to fund the losses of the equity method investment, the carrying value of the equity method investment has not been reduced below zero</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f38e5861-0152-42e8-a598-e670d91b79df" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5. Fair Value Measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0a351edc-586b-4e4c-a7f6-bbf94e990db7" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:4.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables present the financial instruments carried at fair value on a recurring basis as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, respectively, in accordance with the FASB ASC 820 hierarchy (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:4.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.699%;"></td>
        <td style="width:1.23%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.995000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.23%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.995000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.23%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.995000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.23%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.395000000000001%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements at<br />December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c45fa535-d680-45fb-8844-e5a7ac64d38d" contextRef="C_671ff9d5-4324-4bce-bc54-ecdc38e8840f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">177,279</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_34ad4de3-eedd-426f-8839-bf82a3e013ba" contextRef="C_3bcaea08-ed4d-45f4-8fc4-c0510f776740" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">177,279</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements at<br />December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f4acd167-83ce-4a01-b57f-450474b01d3e" contextRef="C_f6a77c26-5d28-4ad5-be66-8947787249a5" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">272,210</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c6ca1977-8979-423b-a8a8-b52c95b60a28" contextRef="C_47b0f4dc-1f2b-43a4-82d0-e3339f869c87" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">272,210</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s cash equivalents represent deposits in a short-term United States Treasury money market fund quoted in an active market and classified as a Level 1 asset. There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_66ea34cc-c061-49ad-a85e-6553cb651550" contextRef="C_d6d15861-ed2b-4844-b8f3-06bd9a409de9" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_49827f0d-1e04-40b2-8cdf-e439235c6660" contextRef="C_a1de02fe-e0e6-413a-b471-0f1518c7ea8a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_642d07c8-5d5a-4b10-91c4-cac82285f2ac" contextRef="C_d6d15861-ed2b-4844-b8f3-06bd9a409de9" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_31e13251-461f-4f3d-a9b5-f8178131ec0d" contextRef="C_a1de02fe-e0e6-413a-b471-0f1518c7ea8a" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> assets or liabilities measured at fair value on a nonrecurring basis at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021. There were no transfers between Level 1 and Level 2 of the fair value hierarchy during the years ended December 31, 2022 and 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recorded the derivative liability of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0c8ffba3-bc10-4779-b668-96fdd00c15ac" contextRef="C_afca8c75-429e-4247-b930-08b342481fcc" name="pyxs:DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in January 2021 for Extra Milestone Payment due under the Opt-in Agreement with LegoChem. The fair value of the derivative liability was initially determined using a probability-weighted income approach and revalued at each reporting date. Changes in the fair value of the derivative liability of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4428407c-c57f-4148-b507-73add8808e8e" contextRef="C_2c0f07bf-9ab0-42b4-921b-a98e8aea7faf" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million were recorded as expense within other (expense) income in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2021. The significant unobservable inputs used in the fair value measurement of the derivative liability include probability of payment factors and the discount rate. The liability was realized upon the IPO of the Company and Extra Milestone Payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c1fab83d-f681-40a0-a715-5ca6d1af734a" contextRef="C_2caa6904-2924-4060-8a2d-3b3cec935236" name="pyxs:ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">9.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was paid to LegoChem in January 2022. Refer to Note 3, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Licensing Agreements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, for additional information on the derivative liability.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2a217c20-88a3-4414-9885-05a7fe771d3c" contextRef="C_0ca7fd08-59a5-40fc-a0ec-73b51bc9fbd9" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_7beeddea-aa1e-4e48-8f53-72e775271b46" contextRef="C_0ca7fd08-59a5-40fc-a0ec-73b51bc9fbd9" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_16f52d25-9d41-4442-96e5-00bfbd32f533" contextRef="C_6378744b-423a-4a6b-972a-85f28e55d021" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_739ab674-e945-4a5b-a92c-84b2819b5d88" contextRef="C_6378744b-423a-4a6b-972a-85f28e55d021" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Level 3 assets or liabilities as of December 31, 2022 and 2021.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f8b52a7a-f591-41b3-8546-b38730f850f2" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:OtherCurrentAssetsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6. Prepaid Expenses and Other Current Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_bcb14799-b364-4006-9932-f80606195e78" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.065%;"></td>
        <td style="width:1.622%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.645999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.622%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.043999999999999%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a88e8313-c1cb-4351-a3d9-682c7a27d2b0" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="pyxs:PrepaidResearchAndDevelopmentCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,560</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2b47c7ff-6abc-4ded-bf6d-75dde3b9a689" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="pyxs:PrepaidResearchAndDevelopmentCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">619</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Insurance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c86c2478-04df-4483-9b52-e386aee72c5d" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,308</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ab7f79f3-fa87-4f2f-8707-6c2ee1b9c936" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,763</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued interest receivable</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_de3ef799-1102-4f56-a4f7-87b4d2f2fd4a" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:InterestReceivableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">598</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b9654815-bf92-4895-8fa8-10acf1aa0af9" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">381</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_46d77d70-7f36-4a39-8b6b-27921fdd174b" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">84</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_de03580e-f838-4a3b-80cf-82ca4a1732e9" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,847</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_82401c02-298e-4b01-aa2f-b05b4d5a9a21" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,466</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_bed7a128-98ff-4bce-9cfe-6129b4410f1e" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7. Property and Equipment, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9e21224c-9c55-40cb-81e4-9d8ed8dd498c" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net, consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.932%;"></td>
        <td style="width:1.619%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.818%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.619%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.012%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5320ffbd-e53c-4aea-9f1a-c290ccdc7da8" contextRef="C_a8379558-2ae3-4803-896a-b59ad651d3b9" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,247</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3d17b76e-e578-4ae5-b5d5-245c10b0f20a" contextRef="C_f4712df5-2590-48af-9284-6195c97975a9" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,804</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and office equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b76a0ab0-ba16-4a1a-9f11-751c05b5ad65" contextRef="C_e7d9bbba-b0b8-45c6-b0a7-dd4392b30f05" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,036</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bc52b881-2db2-478a-adec-f484339cc2e9" contextRef="C_09c28f97-719c-42ef-a251-1140fcd23e11" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">94</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f58576d5-d5db-4257-8a3c-383c44b0ba48" contextRef="C_622e53e6-f8fa-4c10-a051-8ba806014c88" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">530</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_14197e04-2fcf-407b-936e-f339783d5801" contextRef="C_5478d9a9-32de-4b14-a7d9-c5a5e108dfa0" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">225</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Construction in process</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ff417fdb-58db-4b19-a856-ecb6fee75fc9" contextRef="C_163b85b6-849f-484c-908c-c506a40b598b" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,177</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1db3e7aa-c581-4a05-8d2a-c94dfc433bbe" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,990</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_02edc6e8-21ee-47bb-8cb0-2dfb353403b9" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,123</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: accumulated depreciation and amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ebd741cd-4279-46b9-9e05-3cdeb729e5f8" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,825</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_01fee292-1d77-448d-a036-b082ba7668ae" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,116</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5c234500-45da-474b-8e3e-fb6ca3b54d0c" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,165</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_94092326-d9ca-4e35-8406-789f16d78e7a" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,007</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation and amortization expense for the years ended December 31, 2022 and 2021 was</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_89ece6b3-740b-414c-8bb8-3e843f1bea47" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_de99a5a9-86d7-400f-afae-3ba0c9bcd0dc" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">million, respectively.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c5107091-45ea-441b-8752-d295c92ad6cc" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8. Accrued Expenses and Other Current Liabilities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_57987ba0-39ce-4c1d-bae6-24143faa9795" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="pyxs:SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses and other current liabilities consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.065%;"></td>
        <td style="width:1.622%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.645999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.622%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.043999999999999%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6ae336ab-434f-481d-942f-57ed0f71b22c" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="pyxs:AccruedResearchAndDevelopmentExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,414</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0a52ac59-3107-4848-949d-cee8f082274f" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="pyxs:AccruedResearchAndDevelopmentExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,381</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee compensation and benefits</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_424f155e-5d38-4ba5-b135-bc28a69f7c47" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,238</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b0215c36-69a9-4b04-9eb5-564fca6ad77d" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,963</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Legal and professional fees</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_095d8a5f-f7d6-4ca4-80a5-71e45654efc5" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,794</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f68b1d17-4164-428f-bdde-81df1a992765" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">982</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_08b279ee-689f-489c-86e3-7beacf232fc3" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,091</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d826441d-33d9-40c8-a9c4-941bf62a0072" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">266</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ee18e940-e1a0-403e-81ba-3a73bd96f1de" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,537</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0d99c4dd-9ee0-43ee-b49f-70643ce709e9" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,592</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_caa98c84-a6c7-40d5-9723-99e88d6b0754" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9. Operating Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2021, the Company entered into an operating lease agreement, with a lease term commencement date of April 1, 2022, the date the Company took control of the property, for an office and laboratory space in Boston, Massachusetts. The lease payments began on December 21, 2022 and will continue through </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_46c43839-b12c-4f18-9ad8-c2d3ee1c6d88" contextRef="C_53f21008-ad1c-494d-bca3-09d4d9bb06f6" name="us-gaap:LeaseExpirationDate1" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2032</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and with scheduled rent increases each year of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_570c7dc8-1bb7-4502-ad22-b8c5406d589e" contextRef="C_53f21008-ad1c-494d-bca3-09d4d9bb06f6" name="pyxs:RentIncreasePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%. In addition to the rent, the Company bears the costs of certain insurance, property taxes and maintenance, which represent the Company&#x2019;s proportionate share of the actual expenses incurred by the landlord. There is an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_78d12bde-cc34-416f-9024-0eeaf30c048d" contextRef="C_47830253-f4d4-4397-a12e-e52eed550ec3" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_81fa43d3-b564-417f-965e-a15f574ab549" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">option to extend the lease beyond December 31, 2032.</span></ix:nonNumeric></span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At the lease commencement date, the operating lease ROU assets of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1c2c8412-02c3-4b94-bb3d-d582ab4619f5" contextRef="C_fe914f5c-2d5d-4dbc-9ba9-aab3f109118d" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and lease liabilities of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_112ec353-49c3-47d1-acc5-fcc846f69820" contextRef="C_fe914f5c-2d5d-4dbc-9ba9-aab3f109118d" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million were recognized based on the present value of remaining fixed lease payments over the expected lease term using an incremental borrowing rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_406290d7-48c3-47c3-9b39-1eeba5e37354" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="pyxs:IncrementalBorrowingRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">9.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%. As the Company&#x2019;s operating lease does not provide an implicit rate, an estimated incremental borrowing rate based on the information available at the time of lease commencement date was used in determining the present value of lease payments. Under the lease agreement the landlord provided for a tenant improvement allowance of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_867f7bba-9c89-4ec7-b987-5e0d2b054c51" contextRef="C_fe914f5c-2d5d-4dbc-9ba9-aab3f109118d" name="pyxs:TenantImprovementAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to be applied to the costs of the construction of the leasehold improvements, of which $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a9c173f6-c331-4d18-ab26-d82eb2d865ba" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="pyxs:ProceedsFromTenantImprovementAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was received by the Company during the year ended December 31, 2022. The tenant improvement allowance is recognized as a reduction in operating lease ROU assets and lease liabilities on the lease commencement date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c9610c48-f326-403d-9de1-810ff34e1ff6" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of lease expense were as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.492%;"></td>
        <td style="width:1.608%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.151%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.608%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.142%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_216dd1c6-97fb-42e5-a174-ebaa4bc91f73" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,978</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f25d87b2-f1ab-462d-9630-6089ac657747" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">650</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b7505076-2bd5-4908-a03d-74af7cb58b94" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,681</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cda23bb6-58f8-4c38-9cc5-269a04354278" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Variable lease cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c1d26570-04e3-4422-9ee3-7c477d1e6ae8" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">121</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_91ec74d0-bdef-4da2-8f41-5796ae9a1fa5" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">75</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_46eced01-add7-4219-97c4-f28057553fd4" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,780</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a79724cf-3dde-415f-892c-16ef1df8dd8e" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">730</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other information</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease right-of-use asset obtained in exchange for new operating<br />&#160;&#160;&#160;lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_26e088aa-8d6a-4f95-97e6-e012955e2617" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,497</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities, included<br />&#160;&#160;&#160;in operating cash flows</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_70efcbf0-305f-4b2f-a9fc-64a1dd155fda" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">663</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average remaining lease term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_40e15558-cfa1-4c7a-bae0-06bb727c4e94" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.00</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e4a81cd7-53e2-40e4-a896-851a5d21c8af" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.25</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_912e2c9f-adaf-4dfb-a81d-e2f85e433fd8" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">9.40</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_97968d3a-e253-4de2-81f2-830f9d1ca27b" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">10.00</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Variable lease costs primarily relate to common area costs and other operating costs</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which are assessed based on the Company&#x2019;s proportionate share of such costs for the leased premises. Total lease costs are included as operating expenses in the Company&#x2019;s consolidated statements of operations and comprehensive loss.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_428a292a-e24c-4709-91d6-4d258be86e01" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturities of lease liabilities as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, were as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:75.252%;"></td>
        <td style="width:2.082%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:20.667%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ending December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating Leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0f454f63-2617-43c9-a899-283209abcf06" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,557</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_629f4c84-2879-4a3d-9ca9-9f3f6e3b5a0a" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,208</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3e37d128-b423-492f-b20a-86a40897838e" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,302</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_38c2e3d5-081d-4b01-8745-b5b799ea0f43" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,399</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_18f4baf0-3339-4af0-9fd7-70a872166a6d" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,499</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_18d93da9-a51b-43e3-9d8e-5a973081692f" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,750</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total undiscounted payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_01dbae9e-1be6-4c36-a8b2-e6891c8477f7" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">34,715</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: tenant improvement allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f4461769-bbdd-49e5-8905-9caa6cc6405f" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="pyxs:TenantImprovementAllowanceReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,026</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: present value adjustment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2e12b9ee-705a-4ae0-8f7c-f51ec8f7766f" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,768</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Present value of future payments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7b1c5ef6-2b35-4591-938b-b05a55dd21ad" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,921</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: current portion of operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, net of current portion</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5179b652-1a0d-4699-a7ff-fafccdf09ad7" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,921</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e4c7d106-be07-49eb-a7f7-9a0b084551c8" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:PreferredStockTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10. Convertible Preferred Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Series A Convertible Preferred Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2019, the Company entered into a securities purchase agreement (as amended, &#x201c;Series A Agreement&#x201d;) with certain investors to sell shares of Series A convertible preferred stock (&#x201c;Series A&#x201d;) at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_86d6e817-eb50-4951-b088-d1c965203ab1" contextRef="C_ccb57e6f-0f25-4bfd-96c2-4d333afebc0b" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">0.9681</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. In June and July 2019, the Company issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fe4a647f-9320-417b-af88-e81b57d2a981" contextRef="C_ccb57e6f-0f25-4bfd-96c2-4d333afebc0b" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_63d9bea8-8731-4dd3-a755-8e14c31ec3fa" contextRef="C_2e52bce4-48fd-4d5c-8c03-b3c7a4ce8258" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">22,724,925</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Series A to institutional investors at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_24eb2f9c-790f-4578-baa4-81c48314cf4c" contextRef="C_ccb57e6f-0f25-4bfd-96c2-4d333afebc0b" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_c2a292c4-3ea4-48d2-af11-31fcfd525bc5" contextRef="C_2e52bce4-48fd-4d5c-8c03-b3c7a4ce8258" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">0.9681</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share for gross cash proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8437c418-74b7-45d5-9552-55f8df00eaa4" contextRef="C_08e26df7-c143-4cfe-8ad0-f01a4ebe0f85" name="pyxs:GrossProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">22.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, less issuance costs of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f624d656-9d43-4579-b66b-f35e7ce20e91" contextRef="C_08e26df7-c143-4cfe-8ad0-f01a4ebe0f85" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, resulting in net proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d0113c2d-2f45-43c2-9737-d841b1172736" contextRef="C_08e26df7-c143-4cfe-8ad0-f01a4ebe0f85" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">21.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. On October 1, 2021, the Company effected a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4407aca1-3d5e-44ea-a1d0-74473f5cb1a1" contextRef="C_375ab7b5-f3d4-409a-a33f-662272797faf" name="us-gaap:StockholdersEquityReverseStockSplit"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_21fd044a-b819-46e1-b788-a6db20d760e8;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1-for-6.359</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> reverse stock split</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Upon completion of the IPO, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_80d780cd-8cea-4154-a9d6-7b460d269854" contextRef="C_dd3f048c-500a-44b0-97cc-8865eadc0230" name="us-gaap:ConversionOfStockSharesConverted1" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">22,724,925</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Series A were converted to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1aebff4f-06de-4f93-8b2b-a1cc847b1349" contextRef="C_adc6355e-17ce-4144-a867-ae971f7735e9" name="us-gaap:PreferredStockConvertibleSharesIssuable" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,573,659</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Series B Convertible Preferred Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 5, 2021, the Company entered into a securities purchase agreement (as amended, &#x201c;Series B Agreement&#x201d;) with certain investors to sell shares of Series B convertible preferred stock (&#x201c;Series B&#x201d;) at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d920fa75-2f62-425e-9b27-a18dcfbc5359" contextRef="C_6adee125-dbcb-4f6a-b664-d9891421fd72" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">1.6458</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. In March 2021, the Company issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_058abee8-ea0f-4125-aded-a9c4060cd11c" contextRef="C_4e8c269f-db1b-4dbe-9107-8e90b43b9fa4" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">92,356,299</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Series B to institutional investors at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_231c7c1b-7917-445d-a95e-20aded6d2f13" contextRef="C_4e8c269f-db1b-4dbe-9107-8e90b43b9fa4" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">1.6458</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share for gross cash proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_78717fea-6647-4784-b1d6-1b635dade365" contextRef="C_08a1f0a8-28d8-47d4-a0dd-966a0c736ac3" name="pyxs:GrossProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">152.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, less issuance costs of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8f4f4498-8e02-4b44-9b8c-18be5440f0e8" contextRef="C_08a1f0a8-28d8-47d4-a0dd-966a0c736ac3" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, resulting in net proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_483cfa52-6e0e-4113-9a19-4c80ea0f5ee0" contextRef="C_08a1f0a8-28d8-47d4-a0dd-966a0c736ac3" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">151.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. In addition, the Company granted </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_04304815-ef0a-4e66-aa17-06c7bf80bb7f" contextRef="C_5c8c8e6c-dc1c-4e3b-9625-ec421e4f99d1" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">12,455,949</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares, or $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9106f9d2-1c9a-43bd-9f70-5370cde1e33a" contextRef="C_5f97b551-d4c5-4d8c-95ef-8c2b79aac91a" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, of Series B convertible preferred stock through separate agreements with Pfizer and LegoChem. On October 1, 2021, the Company effected a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_20a3ebc9-d486-479c-b78a-4c6c6088528d" contextRef="C_e41e2b33-e797-4eaf-ab2c-e21d506eef7d" name="us-gaap:StockholdersEquityReverseStockSplit"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_2c1f21b5-66b1-456a-be0d-8b2e18d9a8f1;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1-for-6.359</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> reverse stock split</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Upon completion of the IPO, the entire outstanding shares of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5fc76690-cd8d-446c-94c0-fb711f6cc6a3" contextRef="C_38547283-6d39-4795-b0d3-95f75e72293e" name="us-gaap:ConversionOfStockSharesConverted1" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">104,812,248</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of Series B were converted to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_95195a4c-e8ea-4c5e-bf7a-54641d952712" contextRef="C_a7b2c38b-0a9d-45f4-9d96-7571430846e6" name="us-gaap:PreferredStockConvertibleSharesIssuable" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">16,482,486</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_567f3fb5-f824-4076-8bbb-e7774016837a" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stockholders&#x2019; Equity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Preferred Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the closing of the IPO, the Company filed an Amended Certificate of Incorporation and authorized </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b9386fc4-c5e2-4e0f-96bb-2ddb45f9383a" contextRef="C_5fa06219-1252-449b-973f-3a4c942c0ae4" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of preferred stock, with a par value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5653226b-dbd6-4295-9fd9-4fd9b486d2a5" contextRef="C_5fa06219-1252-449b-973f-3a4c942c0ae4" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">0.001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. The board of directors has the authority, without further action by the stockholders to issue such shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, and to fix the dividend, dividend rights, conversion rights, voting, redemption terms, liquidation preference and other rights, preferences and privileges of the shares. There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9f58c56b-c86e-4089-8925-9a97aa2f30b6" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_c879b3e0-18bf-4541-9e83-d44149ba821b" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> issued and outstanding shares of preferred stock as of December 31, 2022 and 2021, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Initial Public Offering</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On October 8, 2021, the Company completed an IPO in which the Company issued and sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3fe88f82-5993-4cf4-a782-9165f44a4082" contextRef="C_aae7c872-143d-4e13-980e-a4b7733afaf6" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,500,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock at a public offering price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6a503739-712e-4640-a776-7b9c6d9a88a1" contextRef="C_3437eb60-7ead-49e1-af88-52c11bcf8430" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">16.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, for aggregate gross proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7849ef11-b876-496b-ad0a-f1e06db66ec3" contextRef="C_ac6c23d7-b491-43cb-a347-d0c5845136d5" name="pyxs:GrossProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">168.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The Company raised approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8c142ee5-b3bf-4388-b26a-e8d259a728a9" contextRef="C_ac6c23d7-b491-43cb-a347-d0c5845136d5" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">152.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in net proceeds after deducting underwriting discounts and commissions of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3f89a586-2e6e-424c-8239-35f80fd08061" contextRef="C_aae7c872-143d-4e13-980e-a4b7733afaf6" name="pyxs:UnderwritingDiscountsAndCommissions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">11.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and offering expenses of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d06ff37d-05af-4490-ae47-ee9d162b9a97" contextRef="C_aae7c872-143d-4e13-980e-a4b7733afaf6" name="pyxs:StockIssuanceExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company was authorized to issue up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b28c0699-97ba-4a4e-b755-61b75da58696" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_fb9dcda7-b505-4e47-bf45-780f17ed2faf" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">190,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock as of December 31, 2022 and 2021, respectively, of which </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3ace31da-96a1-4b63-8ba6-0788368d4b32" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">35,110,016</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b36bb458-50ea-4140-b877-454be93d7e0d" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">32,792,867</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares were issued as of December 31, 2022 and 2021, respectively, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3a301ad4-37fc-4bfb-a425-105c779cc22e" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">34,958,730</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bbe73c82-3fbb-48a0-8c96-d7ee65d5190e" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">32,222,881</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares were outstanding at December 31, 2022 and 2021, respectively.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Voting, dividend and liquidation rights of the holders of the common stock are subject to and qualified by the rights, powers and preferences of the holders of the preferred stock.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Voting</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;Each holder of outstanding shares of common stock shall be entitled to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_cd9b3ae9-aa07-4256-9a02-ab10dea60d5c" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:CommonStockVotingRights"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> vote in respect of each share.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Reserved Shares</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_938201ee-0af4-4453-9634-ad747fc1e1fa" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="pyxs:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" escape="true" continuedAt="F_938201ee-0af4-4453-9634-ad747fc1e1fa_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company reserved the following shares of common stock for issuance:</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:continuation id="F_938201ee-0af4-4453-9634-ad747fc1e1fa_1"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:94.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60.207%;"></td>
        <td style="width:1.205%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.502%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.215%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.871%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d26db75c-8849-48be-a778-a0644290d274" contextRef="C_dbf80555-08a0-4969-b239-4e3694866a9d" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,720,415</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_31a62249-2fde-4e5d-8399-edda3c4f270a" contextRef="C_de5078e1-9398-411e-9b9d-a3b0e59ba4db" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,926,969</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted stock awards</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7ab4590a-19ac-4dde-979a-9b1035a20184" contextRef="C_9194297f-b13d-4587-9fe5-fcc007d82f0e" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,015,387</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0d0d20e5-dcac-4d7c-906c-d0d456929b9e" contextRef="C_382dcedb-c053-467b-83f2-217ce9a3521e" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">618,494</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options available for issuance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b2c76ba4-3c85-4a74-90b6-c07d366b376d" contextRef="C_7f8a7acb-6ab0-451e-8b00-67975a1ecf54" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,697,166</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_146959d5-dcf6-467f-8ea2-99852a205ffa" contextRef="C_bbf8f5ff-a294-4a9f-8e73-2626887266b2" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,289,259</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee stock purchase plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0563b703-8cb2-47bf-bd99-adafd38db950" contextRef="C_a4a72a0d-ee7f-4589-88fb-129aff57c90e" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">752,524</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1cdf87e8-883d-47d6-b5d7-44e27fb5747e" contextRef="C_97a1de80-f534-45ad-9ae5-0bf704ac27f6" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">424,595</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7658e2ff-9f8e-4952-81d6-4c5287fc9598" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">11,185,492</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_06ab3faf-f754-4cd8-b011-39a1f90c97e8" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">8,259,317</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_505d1ee4-8c28-4056-96d5-67ae0f3684ce" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12. Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2022 Equity Inducement Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On July 1, 2022, the Company&#x2019;s board of directors approved the 2022 Equity Inducement Plan (the &#x201c;2022 Plan&#x201d;), which became effective on that date. The 2022 Plan allows the Company to make equity-based incentive awards to its officers and employees without stockholder approval pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules, or any successor rule relating to inducement awards. Unless earlier terminated by the Board, 2022 Plan will terminate on the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_2078513f-c53f-43d5-970f-e0c43d587906;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ten</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">th anniversary of the effective date. The Company has initially reserved </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f822de35-f504-42c1-9e9c-f43cb1bb50ff" contextRef="C_878945eb-02c9-42de-ab14-20785d15bab1" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,400,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock for the issuance of awards under the 2022 Plan. As of December 31, 2022, options to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2fcc706e-a2dd-4df5-b3ea-1436f5adeecc" contextRef="C_2ae41d03-8671-4c50-80d0-d05659459fdb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">400,692</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c76a5c38-a92c-40af-85df-edcb448167aa" contextRef="C_b0e457cc-4ee1-4962-882e-7cdda5c5a1d8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">320,550</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> restricted stock units were outstanding under the 2022 Plan and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4e4cf2fa-3b1e-40f9-bde2-088d4776efc2" contextRef="C_2ae41d03-8671-4c50-80d0-d05659459fdb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">678,758</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares remained available for future issuance under the 2022 Plan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2021 Equity Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On September 27, 2021, the Company&#x2019;s board of directors and stockholders approved the 2021 Equity Incentive Plan (the &#x201c;2021 Plan&#x201d;), which became effective on October 7, 2021, when the Company&#x2019;s registration statement was declared effective by the SEC. The 2021 Plan allows the Company to make equity-based and cash-based incentive awards to its officers, employees, directors and consultants. The Company has initially reserved </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1c000a38-c2b9-4f10-bff9-c35a88235629" contextRef="C_52660871-d822-4029-a359-773d492fbb93" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,852,807</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock for the issuance of awards under the 2021 Plan. The number of shares of common stock reserved for issuance under the 2021 Plan will automatically increase annually on the first day of each fiscal year, beginning with the fiscal year ending December 31, 2022, and continuing until (and including) the fiscal year ending December 31, 2031 by the lesser of (i) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_51127572-821c-4e2b-98e1-ccb599a22da1" contextRef="C_10356595-90e4-4664-b68b-60f5a32b9285" name="pyxs:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesReservedAndAvailableForIssuancePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the total number of shares of common stock outstanding on December 31st of the immediately preceding fiscal year and (ii) the number of shares as may be determined by the board of directors. As a result of the evergreen provision of the 2021 Plan, the Company added an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cd7d0022-b59d-44b3-95af-db9defa40649" contextRef="C_da4afd79-994b-493e-8986-8748cbb9b1f6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,639,643</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock to the 2021 Plan as of January 1, 2022. The maximum number of shares of common stock that may be issued pursuant to the exercise of incentive options under the 2021 Plan is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_16b945ea-5d31-462c-9ab8-43beda251a87" contextRef="C_57e97640-061e-4d91-86fa-37e25ab50455" name="pyxs:MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,705,614</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unless earlier terminated by the Board, 2021 Plan will terminate on the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_41e41108-0a2f-4aeb-862b-b3c3f3023412;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ten</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">th anniversary of the effective date. As of December 31, 2022, options to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0206ba68-98a0-4c2a-a28e-e79da52166e1" contextRef="C_57e97640-061e-4d91-86fa-37e25ab50455" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,668,700</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_87e22e1e-c2dc-4b9c-ab50-1120877dea07" contextRef="C_1f74468d-690d-401f-99d9-cb0dfb69f6d0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,449,172</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> restricted stock units were outstanding under the 2021 plan and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bb107d6c-2c22-42bf-85dc-7358bd31170c" contextRef="C_57e97640-061e-4d91-86fa-37e25ab50455" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">360,924</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares remained available for future issuance under the 2021 plan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2019 Equity Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2019, the Company established the 2019 Equity Incentive Plan (the &#34;2019 Plan&#34;), under which the Company is allowed to grant options and restricted stock to its employees and non-employees. The maximum number of shares of common stock reserved for issuance under the 2019 Plan is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_db50b4e7-7dcd-45e3-80ee-7ff0668dd1cf" contextRef="C_fb9e3219-0355-4d5e-8d21-c73eefcac6c3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,042,408</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares. Options granted under the 2019 Plan include incentive stock options that can be granted only to the Company&#x2019;s employees and non-statutory stock options that can be granted to the Company&#x2019;s employees, consultants, advisors and directors. The 2019 Plan also permits the Company to issue restricted stock awards. Unless earlier terminated by the Board, the 2019 Plan will terminate on the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_41c663ee-99b7-4ec5-8325-a97c8245ffa8;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ten</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">th anniversary of the effective date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to the IPO, the exercise prices, vesting and other restrictions of the awards granted under the 2019 Plan were determined by the board of directors, except that no stock option may be issued with an exercise price less than the fair market value of the common stock at the date of the grant or have a term in excess of ten years. Options granted under the 2019 Plan are exercisable in whole or in part at any time subsequent to vesting. As of December 31, 2022, options to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cd067478-d2ad-40a2-8880-651025a9ba35" contextRef="C_9d0748e3-ecbb-419d-b1da-43ca99f6d64d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,651,023</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fa085fab-fba1-4587-be5a-faccd9d4d21e" contextRef="C_3389ea65-f351-4b62-b0ce-6e94188e7981" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">94,379</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> restricted stock units were outstanding under the 2019 Plan and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_76dc511c-a214-4045-8f3a-a3afd75a16a1" contextRef="C_9d0748e3-ecbb-419d-b1da-43ca99f6d64d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">657,484</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares remained available for future issuance under the 2019 Plan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2021 Employee Stock Purchase Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On September 27, 2021, the Company&#x2019;s board of directors and stockholders approved the 2021 Employee Stock Purchase Plan (the &#x201c;2021 ESPP&#x201d;), which became effective on October 7, 2021, when the Company&#x2019;s registration statement was declared effective by the SEC. The 2021 ESPP initially reserved and authorized the issuance of up to a total of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4939c241-f372-428a-b63f-36dca40a4471" contextRef="C_6d15f333-7588-4ef5-8888-a6b87820dd75" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">424,595</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock to participating employees. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The number of shares of common stock reserved for issuance under the ESPP will automatically increase annually on the first day of each fiscal year, beginning with the fiscal year ending December 31, 2022, and continuing until (and including) the fiscal year ending December 31, 2031 by the lesser</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of (1) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_77a4ff6b-04a0-42b6-b235-e1600341d6bc" contextRef="C_0aaf1ee4-befe-4b18-b335-1a09ea9d6b96" name="pyxs:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesReservedAndAvailableForIssuancePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the total number of shares of common stock outstanding on December 31st of the immediately preceding fiscal year and (ii) the number of shares as may be determined by the board of directors.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> As a result of the evergreen provision of the 2021 ESPP, the Company added an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fb773912-192f-432c-b363-8190251614f0" contextRef="C_df8cfd51-bc03-4a95-b0a5-24677e60cdc1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">327,929</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock to the 2021 ESPP as of January 1, 2022. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_29e3d1d2-e3f9-43d7-8462-b2a5ab27db65" contextRef="C_0aaf1ee4-befe-4b18-b335-1a09ea9d6b96" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares are issued under 2021 ESPP plan as of the date of issuance of these consolidated financial statements.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the authorized number of shares and shares available for issuance under the 2021 ESPP is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_80c0e824-2827-4835-8563-bc5b0bd2a1f3" contextRef="C_1bfa7a44-4da1-4bfe-8679-1f28fa3b517b" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">752,524</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock Options</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options granted under the 2022 Plan, 2021 Plan and 2019 Plan (together, the &#x201c;Plans&#x201d;) to employees generally vest over </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4e94d74e-d773-4d95-b932-5dafdd5edfd2" contextRef="C_4f7769e8-70e6-4d06-bdc0-89e5d970d334" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and expire after </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1e90e4ba-e229-47c7-a2d1-4b805217420d" contextRef="C_4f7769e8-70e6-4d06-bdc0-89e5d970d334" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10 years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ac7f8dca-c384-4e6f-8288-64f433252c62" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes stock option activity for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 (in thousands, except share and per share amounts):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.137%;"></td>
        <td style="width:0.069%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.744000000000002%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.069%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:5.943%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.069%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.295%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.208%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:7.465%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br />Options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br />Average<br />Exercise<br />Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br />Average<br />Remaining<br />Contractual<br />Term (Years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br />Intrinsic<br />Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at January 1, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c2d594d3-937c-4721-b63b-ad4a5aadc22c" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,926,969</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_318c00cc-1f37-493c-aeeb-19acf16317e6" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">10.03</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_97bc0266-cae7-4cdd-846a-bf42b735fe6e" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.5</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7a1bee7a-a17b-4a9e-8d3a-f661dc34e86e" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,414</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cd364b96-cec9-4be6-9cc3-70c9c9f6d574" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,178,280</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7a62e176-cdc5-4f5b-8e83-430ce5620b79" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">4.06</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_11807cf3-e992-46fa-b644-0a2d28b35495" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">73,841</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3e7321fc-6149-4839-a385-10ebff1db88f" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">2.48</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_64b2549c-a21d-42ed-a7ce-81c29131b247" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">834,095</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e7d79e48-c5f0-4e48-9bcc-f21c2c11e49a" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">7.24</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expired</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d96e0a08-3262-47f6-a2d1-be62e99db932" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">476,898</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8492f507-2bde-4092-8add-8ba7d333bd78" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">5.51</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1fd0560e-a276-4823-b7f6-ec2ca45f92e0" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,720,415</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1018a87b-9e35-4443-a7c6-c76902bcc061" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">9.68</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_421d5667-55dc-4691-9c77-5db7a1e835dc" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.8</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6837add3-1b72-42cc-8d54-2a1bbacd1218" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">72</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercisable at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8010e802-f645-496d-bf74-a872ccf11246" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,037,934</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6c5dd3c2-1cb4-4476-a1d8-e39fb4d33a24" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">9.34</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0d92c3aa-9b4e-4d03-9bf5-994da8bfea2d" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.5</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_87800b2b-ba1a-428f-bfdc-941c2c717976" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">59</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted-average grant-date fair value of options granted during the years ended December 31, 2022 and 2021, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1b18feb7-9aeb-4ad9-880e-2141cb6d4e22" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.06</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5b2027af-cb5a-4c9e-8797-ba4ba6a5a917" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">7.57</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">per share, respectively. The aggregate intrinsic value is calculated as the difference between the exercise price of all </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">outstanding and exercisable stock options and the fair value of the Company&#x2019;s common stock of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0f774c72-da39-459d-999b-480afebe885b" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="pyxs:FairValueOfCommonStockPerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">1.34</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share as of December 31, 2022. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2022 and 2021 was less than $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c3335331-251c-4cd0-8bc0-f2785e52cdd8" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cf99a92e-78b9-4511-a98f-177cb9a90edb" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_d33eae78-9df5-45bf-8181-bcd0f6944a9c" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company estimated the fair value of each option on the date of grant using the Black-Scholes option-pricing model applying the range of assumptions in the following table:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.065%;"></td>
        <td style="width:2.019%;"></td>
        <td style="width:27.843%;"></td>
        <td style="width:2.019%;"></td>
        <td style="width:19.037%;"></td>
        <td style="width:2.019%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_41a85512-88ef-48a1-bd22-285603bafbf7" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">96.09</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_18b033f8-a929-4fc4-82e4-e610b2552a58" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">101.66</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c48b76c6-663b-4c69-94b4-6f4a57690bec" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">72.88</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ec57d48d-1db9-4e0b-b703-f54af0561377" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">103.41</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_440b066e-fe2a-4a49-9ad9-0bd6dde1ac70" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">1.60</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f44cb382-3369-4fb4-8bcf-ce63c633f710" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">4.02</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bef07b45-9a3c-425d-8a9d-751afeb3d193" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.81</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a08cf75c-e63f-4456-9b3d-1316809f4b3d" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">1.36</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bbf97932-aabb-4cf4-887c-9e76fd68b045" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_38a12b4d-0b6e-48d0-8d48-f36057a8abd7" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2a32dc7c-d293-4a11-aaa7-b524c14481c3" contextRef="C_48de2a5c-eadc-4299-a519-18facbfa1720" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.00</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3ad0758b-c516-4462-967a-c221df4a4681" contextRef="C_7dd94bc0-72fc-44a2-b88d-da7188b1ce64" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.11</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_49fe1eb9-88eb-42c9-99a9-be5a4a386802" contextRef="C_3ade2bd0-ad16-4bf4-a99d-4a51299354f9" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.25</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3bc8634e-9103-4c1e-be1c-772e02ecbeca" contextRef="C_5779ffa7-ef54-4318-b0b8-ed0b0cb8c6b5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.00</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3cae245e-411e-4fe0-a0f0-0c0ccf8b4ce8" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense related to stock options recorded in the statements of operations is as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.847%;"></td>
        <td style="width:2.298%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:21.929%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:2.298%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:22.328%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:2.298%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e1b9bc96-1af2-4d12-a4ef-8c13e4553ec4" contextRef="C_98625906-14f2-47a1-9eb9-724228999619" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,330</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_10ebe9e6-cad4-415c-b43f-eba8e048fc3a" contextRef="C_efd5ca4b-dd20-4280-870e-b98268ab08eb" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,396</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_262077bd-3dab-429f-a138-720d7f5c89c0" contextRef="C_e407da6f-df2b-430d-8ab8-23f237d727f3" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,617</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_99bc3e9a-2cc3-4776-a680-d081d83fdced" contextRef="C_d2032e34-dd12-44a0-9706-073c354f8dbb" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,976</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0daa00a2-1ba7-42a4-bfb2-3f546bdf82b5" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,947</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c4680745-9c6b-410c-86cd-0d4a63332bde" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,372</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has an aggregate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_47831aea-524e-407b-a41f-2778f1614456" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">25.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">million of gross unrecognized stock-based compensation expense as of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, remaining to be amortized over a weighted average period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4ee6c8a5-5099-45e2-80c0-35e5c147a41d" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.29</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years. The Company has not recognized and does not expect to recognize in the near future, any tax benefit related to employee stock-based compensation expense as a result of the full valuation allowance related to its net deferred tax assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Stock Awards</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the 2019 Plan, 2021 Plan and 2022 Inducement Plan, the Company issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9a4929af-7b2d-4602-88c0-a0927df92829" contextRef="C_5e6b169a-61c1-4460-b0cf-4abc20516158" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,174,656</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> restricted stock units (&#34;RSU&#34;) to employees and non-employees. Compensation costs related to these RSUs were recorded based on the Company's stock price on the date of issuance and amortized over the service period.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, the Company issued certain shares of restricted common stock (&#34;RSA&#34;) to the employee co-founders and certain non-employee consultants in 2019. The shares of restricted common stock were issued pursuant to standalone restricted stock purchase agreements that are independent of the 2019 Plan, 2021 Plan and 2022 Inducement Plan. The shares of restricted common stock pursuant to standalone restricted stock purchase agreements carried a purchase price equivalent of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4a030434-bf67-4090-9f9f-5c7a4a99e89a" contextRef="C_9194297f-b13d-4587-9fe5-fcc007d82f0e" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">0.01</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. As of December 31, 2022, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7322e7c2-d27f-4c51-90e6-05f192ecb683" contextRef="C_9194297f-b13d-4587-9fe5-fcc007d82f0e" name="pyxs:RestrictedStockSharesUnvestedAndOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">151,286</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> RSAs were unvested and outstanding</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of the restricted stock purchase agreements, the Company has a repurchase option whereby it has the right to repurchase any unvested shares upon termination at a price per share equal to the lesser of (i) the fair market value of the Company&#x2019;s common stock on the date of repurchase and (ii) the original purchase price. The shares of restricted common stock issued to the Company&#x2019;s co-founders and non-employee consultants vest based on a predefined number of shares.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognized an associated deposit liability for restricted stock awards issued pursuant to standalone restricted stock purchase agreements upon issuance based on the purchase price of the awards as the unvested shares are subject to repurchase upon termination. As the awards of restricted stock vest, the Company reclassifies the deposit liability to additional paid-in capital. The compensation cost was measured based on the fair value of the underlying common stock less the purchase price of the restricted common stock and the Company recognizes compensation costs over the requisite service period.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d9ddb626-2b89-4813-a6c8-c19e4a7cd660" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes restricted stock activity for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:70.57%;"></td>
        <td style="width:1.081%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.265%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.724%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.359%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br />Average<br />Grant Date Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-vested at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cfc96860-824c-4929-8c2d-ccbcd7b066bd" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">618,494</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bfbd468c-ed38-4582-b72d-acd39e02a1c0" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">3.04</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a83427ab-f39f-4a2d-9fdd-85fd895ae802" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,174,656</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3603034a-ef03-4e41-b25c-f30593b540d1" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">3.69</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and settled</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b5508971-c9f4-4bf5-998c-e66cad952cb5" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="pyxs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">432,354</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8af3a2c0-f7ca-4cd3-9e3a-32c55d036455" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="pyxs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">0.55</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8b492ed3-003c-410c-91f9-515a5f1f7d77" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">345,409</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bd69e674-4d0c-4ffe-9b2e-3e2702871238" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.74</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-vested and unsettled at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_105ebe99-5d0d-48c9-aabf-700934eda7c8" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,015,387</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_12289d2b-57ad-42f2-9c33-1702f76687ed" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">3.64</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has recorded stock-based compensation expense related to the restricted stock of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c3962b90-14ad-49a2-bf79-f2a6b918e0ee" contextRef="C_ea786617-a1e9-4846-aa80-4f080345af40" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0b204ce6-4937-4ecd-acd8-24474d53915f" contextRef="C_5f32f318-d7b3-49c5-87d5-d8693945f998" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended December 31, 2022, and 2021, respectively. The Company has an aggregate $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c590b1a7-932f-4685-ac31-0c5f9f662b8b" contextRef="C_9194297f-b13d-4587-9fe5-fcc007d82f0e" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of gross unrecognized restricted stock-based compensation expense as of December 31, 2022, remaining to be amortized over a weighted average period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_21e0edbb-c723-42af-81fc-29240529adb8" contextRef="C_ea786617-a1e9-4846-aa80-4f080345af40" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.26</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years.</span></p></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div><ix:nonNumeric id="F_5e2f8ec2-e86b-4db8-9b11-53e0082e27aa" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13. Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company recorded </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f28ee4a4-cf70-479a-8689-15f7287e2d44" contextRef="C_c48b4d06-4690-4a44-ad08-1d47a45d7069" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_b84d8acb-2c7f-41fc-aa85-e9088fcf12d1" contextRef="C_a299bf89-0287-4625-8850-fb9123db63e0" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_a4eb101b-f682-41d7-ad6d-6fe2e711474a" contextRef="C_c48b4d06-4690-4a44-ad08-1d47a45d7069" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_03e3127e-bb9e-46b5-a4db-67b668bc02f7" contextRef="C_a299bf89-0287-4625-8850-fb9123db63e0" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> current or deferred income tax expenses or benefits as the Company has incurred losses since inception and has provided a full valuation allowance against its deferred tax assets.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d730a093-f729-4575-ac61-3127becabe42" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation of the expected income tax benefit computed using the federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.205%;"></td>
        <td style="width:1.161%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.241%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.161%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.232%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax computed at federal statutory rate %</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fb9ca2ab-c5cd-4bca-832a-a3ea57a950a7" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5c03ec70-227c-4ca7-a334-3f042b6ed85e" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State taxes, net of federal benefit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_588bc660-a999-4c6a-8aa8-63620db29a53" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">5.6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_48155b6f-5a4c-414d-904c-b4aecc0b6cf2" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">5.7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_94f4cf33-f554-4cae-9051-69edad7308be" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">26.6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b87b8c51-968a-48b4-b65d-0f75ba6e97be" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">27.7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development credit carryovers</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c5410b17-494a-46d5-aff1-aa0f9f6480c4" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c8b76a7e-68f1-4485-863b-ea5736e50202" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Permanent differences</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bc4bd1f5-dcf2-45ea-8a26-459720803dfa" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="pyxs:EffectiveIncomeTaxRateReconciliationPermanentDifferences" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">1.7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_75049c6d-c405-4cfc-9a2e-fed4ca949035" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="pyxs:EffectiveIncomeTaxRateReconciliationPermanentDifferences" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective income tax rate %</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a91c9ca4-2a36-4865-a8aa-2944100a9cc6" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f9e5bae3-03d1-4b08-b28a-c56739eafd45" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company's effective tax rate was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9bd92f94-7c40-4e8a-a5b7-b933801e05a0" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal"><ix:nonFraction id="F_69d4a0ca-62be-4060-8ade-4a1277831108" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">0</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% for the years ended December 31, 2022 and 2021, as a result of the valuation allowance that eliminates the company's net deferred tax assets.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9e5a41fe-1854-4fa5-82d2-40cc74978bca" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true" continuedAt="F_9e5a41fe-1854-4fa5-82d2-40cc74978bca_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Significant components of the Company&#x2019;s net deferred tax assets as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 are as follows (in thousands): </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_9e5a41fe-1854-4fa5-82d2-40cc74978bca_1"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.458%;"></td>
        <td style="width:1.526%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.049%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.517%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.449%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_34a20ddd-ef8a-4fc9-bbd8-842a91454658" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,108</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bddd8984-a00f-4ed1-9cfc-603dc88503ee" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,918</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangibles</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fd0dfd93-d996-4c06-8fc6-e418921ed9f2" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">69</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d9f0ce8d-006b-4a31-ae80-a8b2a89cec27" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">75</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax credit carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f5e31051-3781-4279-9cab-2616aecfc5a0" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,674</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cb9a678b-89f0-4f77-9b43-58532a48b6c2" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,648</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Derivative</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6e3ff422-d70a-4c2c-a9bd-51ef96f04eca" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:DeferredTaxAssetsDerivativeInstruments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,455</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e089720e-1e5a-4496-9f2d-fd0e4a6753d2" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:DeferredTaxAssetsDerivativeInstruments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,577</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bd3bcccb-51ec-43e0-b673-b24f264402fd" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,645</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e4e846c3-955c-431d-9e6b-4aa334d176be" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,003</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reserves and accruals</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c3e87f63-3f46-4612-b062-5cec0749ab5b" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,105</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6ab8c8d0-477d-4c9a-9eec-c80bcf8d808f" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">804</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capitalized research expenditures</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_50b51b0a-2179-42e6-842f-c720b088fdfc" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="pyxs:DeferredTaxAssetsCapitalizedResearchExpenditures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,059</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">License fees</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c70cae85-64bd-4c07-9d9b-c4ce9eef5dac" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="pyxs:DeferredTaxAssetsLicenseFee" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,235</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_948619c6-2b01-4f02-9525-3f87501575c9" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="pyxs:DeferredTaxAssetsLicenseFee" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,716</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liability</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d669f803-3118-4835-8997-2ba61bd46d1d" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="pyxs:DeferredTaxAssetsOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,107</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f3963af9-fd00-4382-bb35-ea8bd5c4a9f4" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="pyxs:DeferredTaxAssetsOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">45</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0af0a78f-854d-477f-bb7c-634edc65a0f5" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4cd73d7e-dbbc-49eb-877b-5d724bf36428" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets before valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_99addee9-e777-4dc0-b09c-348f3c0f0069" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61,486</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2e319832-350c-4d67-ad3f-26b97acc51dd" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,811</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f4fff1b1-4cdd-46f3-8d8d-0afbb74e07a9" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">57,812</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1e18345c-043e-49f7-8de1-345d37347375" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,748</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_64ceaeb5-73a5-4418-8a5d-fcb188cbf3bf" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,674</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_259e0526-f3f4-44b3-a67c-4a44b97a970c" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">63</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease ROU assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_edfbae06-9691-4886-a151-68c932ae1509" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="pyxs:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,674</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e8aa8390-ba09-4f9c-9ffe-aa5fe9cb4f8a" contextRef="C_4311203d-759e-4680-a158-b189b0b27135" name="pyxs:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">63</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the Company's federal and state net operating losses (&#34;NOL&#34;) in the United States were $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d34e19ec-cb64-47b3-9a3c-147ff4696790" contextRef="C_d9e659d3-c4ff-4e05-bb19-5b5effadffa3" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million ($</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9a0ef27d-a439-4414-b597-6ba4d814c901" contextRef="C_d9e659d3-c4ff-4e05-bb19-5b5effadffa3" name="pyxs:OperatingLossCarryforwardsBeforeTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">48.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million before tax) and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f610826a-b100-4722-a209-ad3ec73a1859" contextRef="C_96ed1430-e72f-4da1-9065-31aa0a3ed55e" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million ($</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a59e1615-ea07-4ae4-b328-900eeb41ae4f" contextRef="C_96ed1430-e72f-4da1-9065-31aa0a3ed55e" name="pyxs:OperatingLossCarryforwardsBeforeTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">48.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million before tax) respectively. The federal net operating loss carryforwards in the United States can be carried forward indefinitely but may be subject to annual usage limitations to the extent certain substantial changes in the entity's ownership occur. The state net operating loss carryforwards begin expiring in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0220035b-df26-4708-af71-fd505575d02d" contextRef="C_bae164c2-2642-4b70-85fd-0d414f578d75" name="pyxs:OperatingLossCarryforwardsExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2039</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In addition, as of December 31, 2022, the Company had $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_51ce342e-2b34-4fd5-94a4-a24fb795feb5" contextRef="C_d9e659d3-c4ff-4e05-bb19-5b5effadffa3" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9acb2f25-7174-4996-aa59-17368ad39618" contextRef="C_96ed1430-e72f-4da1-9065-31aa0a3ed55e" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of federal and state credit carryovers which begin to expire in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2398856f-241c-441c-968f-3562c8628276" contextRef="C_a299bf89-0287-4625-8850-fb9123db63e0" name="pyxs:TaxCreditCarryforwardExpirationYear"><ix:nonNumeric id="F_62d88d67-ee5a-4f6a-a06a-09e51e958d12" contextRef="C_bae164c2-2642-4b70-85fd-0d414f578d75" name="pyxs:TaxCreditCarryforwardExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2039</span></ix:nonNumeric></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. These loss and credit </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">carryforwards are subject to review and possible adjustment by the appropriate taxing authorities.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company assesses the realizability of the deferred tax assets at each balance sheet date based on the available positive and negative evidence in order to determine the amount which is more likely than not to be realized and records a valuation allowance as necessary. Due to the Company's cumulative loss position which provides significant negative evidence, which is difficult to overcome, the Company has recorded a valuation allowance of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0ae6feed-e39b-49a3-92ff-515d9c706581" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">57.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of December 31, 2022, representing the portion of the deferred tax asset that is not more likely than not to be realized. For the years ended December 31, 2022 and 2021, the valuation allowance for deferred tax assets increased by $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ddcd673b-f043-4fcb-a605-05d3d2da096d" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">32.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f908fca8-848e-47c4-8524-c59f7517713a" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">21.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. The amount of the deferred tax asset considered realizable, could be adjusted for future factors that would impact the assessment of the objective and subjective evidence. The Company will continue to assess the realizability of deferred tax assets at each balance sheet date in order to determine the proper amount, if any, required for a valuation allowance.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Tax Cuts and Jobs Act contained a provision which requires the capitalization of Section 174 costs incurred in the years beginning on or after January 1, 2022. Section 174 costs are expenditures which represent research and development costs that are incident to the development or improvement of a product, process, formula, invention, computer software or technique. This provision changes the treatment of Section 174 costs such that the expenditures are no longer allowed as an immediate deduction but rather must be capitalized and amortized. We have included the impact of this provision, which results in a deferred tax asset of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b52f6b90-6c32-4b09-91eb-3badaccd9e3d" contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999" name="pyxs:TaxCutsAndJobsActDeferredTaxAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of December 31, 2022.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The U.S. tax attributes may be subject to an annual limitation under Section 382 of the Internal Revenue Code of 1986 (the &#x201c;Code&#x201d;), and similar state provisions if the Company experiences one or more ownership changes, which would limit the amount of the tax attributes that can be utilized to offset future taxable income. In general, an ownership change as defined by Section 382, results from the transactions increasing ownership of certain stockholders or public groups in the stock of the corporation of more than fifty percentage points over a three-year period. If a change in ownership occurs in the future, the net operating loss and research and development credit carryforwards could be eliminated or restricted. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. Due to the existence of the valuation allowance, limitations created by future ownership changes, if any, will not impact the Company&#x2019;s effective tax rate.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is subject to tax and will continue to file federal income tax returns in the United States as well as in certain state and local jurisdictions. The Company is subject to tax examinations for tax years ended December 31, 2019 and forward in all applicable income tax jurisdictions. Tax audits and examinations can involve complex issues, interpretations and judgements. The resolution of matters may span multiple years particularly if subject to litigation or negotiation. The Company believes that it has appropriately recorded its tax position using reasonable estimates and assumptions, however the potential tax benefits may impact the results of operations or cashflows in the period of resolution, settlement, or when the statutes of limitations expire. The Company does not currently have any reserves related to unrecognized tax benefits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d25bae70-0f3f-43de-92f4-bb39f1dc4d4c" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14. Net Loss per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3414c14e-e6a6-48ee-8d91-35278061a044" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic and diluted net loss per share was calculated as follows (in thousands, except share and per share amounts):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:45.492%;"></td>
        <td style="width:2.562%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:21.324%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:2.552%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:21.518%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:2.552%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Numerator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_384cd0f3-44fd-4765-84af-18a7235eb100" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">120,717</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9a79e128-0693-46ce-8bc5-4f7852d0fe98" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">75,975</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Denominator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average common shares outstanding, basic and diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e41927a8-1681-401a-ad28-05fd5cbaaab1" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_1ef819f1-61cc-4647-95f8-6ed0d0c9c45b" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">33,033,081</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_67ee1d1b-7a7f-4d68-8247-a244f868913d" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_51e1154f-47a2-492f-a801-a1cc6c8b9ddb" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">8,493,273</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9bfde924-78dc-496e-971f-ddca67a981c0" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_35bd5c57-886e-44b3-9322-26e5660a6583" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">3.65</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e9a3db6b-f35b-4f33-b6cd-a803c80e6a20" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_7880aa09-b153-4e66-86ac-b1f3473b7b49" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">8.95</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s potentially dilutive securities, which include restricted stock, and stock options, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9aa801ee-cb59-45fd-9320-fb4f098bad86" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following potentially dilutive securities have been excluded from the calculation of diluted net loss per common share due to their anti-dilutive effect:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.822%;"></td>
        <td style="width:1.434%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.953%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.434%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.356%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options outstanding</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fab05c60-a73a-4589-86a4-9de8965ec47a" contextRef="C_5c8d1870-c7a8-4c74-97ca-d9e6a13f9efc" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,720,415</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_981d11b6-be4d-4fc1-814d-06b4986f60c3" contextRef="C_967897c5-c155-4f05-933c-68db3867f01a" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,929,969</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted stock awards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a052e83d-f3d8-4eb9-96a5-1b9e831ccf47" contextRef="C_570474f3-f0f4-4608-961a-97edb7e8318e" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,015,387</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_674345b7-3414-4e2b-8c1b-b867a1370021" contextRef="C_3722df37-e565-465f-bb4b-034fdf13c6ee" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">618,494</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options available for issuance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b5b6cad9-a7e3-42c5-aaf3-696d7a152f29" contextRef="C_a1592c2f-78e9-4a1b-b7a3-b5e832dfc0e6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,697,166</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1364f5c2-a632-4260-af89-d781e6ba0f4e" contextRef="C_453b4504-5d6b-406e-8878-c49bf593ff1e" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,289,259</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee stock purchase plan</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0f4bb719-366a-45b5-ade3-0c85d39f48f4" contextRef="C_6f4aa2e1-b13f-4cc9-a66d-bd0c94991ce0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">752,524</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d1ab0541-d6d7-4b6d-8bc8-e60bd663671d" contextRef="C_580efdd7-1697-4746-bb08-330be421f077" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">424,595</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_59f55c86-bee6-4fdf-a0dc-8c7e9ec68e68" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">11,185,492</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d780bf48-b5df-42d5-90f4-9a23cafd4997" contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">8,262,317</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_02584dfb-fa7c-4a9e-89bf-96e5bace1cf5" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15. Related Parties</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company was founded out of Dr. Thomas Gajewski&#x2019;s laboratory at the University of Chicago. In 2020, the Company entered into the License Agreement with the University of Chicago, as well as a sponsored research agreement. The Company incurred $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_96ab4562-bdd5-424c-a50e-621696007943" contextRef="C_f2ddafed-be8d-4bfb-afe6-eafef4a6d2bd" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6e3f4de5-d809-4eae-a17d-161687abcc85" contextRef="C_db0b438d-a530-4514-b2e4-b58d0c1167a0" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for the years ended December 31, 2022 and 2021, respectively, with regards to the University License Agreement. Refer to Note 3 for additional discussion.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pfizer owns more than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bd30312c-429d-4768-ae0b-42a0b4750610" contextRef="C_53e9aeb6-174d-402f-8c2f-b1df11873669" name="pyxs:RelatedPartyTransactionOwnership" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">10</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the Company and is considered the principal owner of the Company. On October 6, 2022, the Company entered into the A&amp;R License Agreement with Pfizer, which amends and restates the previously executed license agreement between Pfizer and the Company. During the year ended December 31, 2022, the Company incurred $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_819939f4-430b-4adf-b871-ce7fafd75ba7" contextRef="C_7df0d474-6f80-47b5-b237-25bf19a5fb4c" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">17.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of research and development expenses for the A&amp;R License Agreement. During the year ended December 31, 2021, the Company incurred $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_46957378-6fa2-4993-b9aa-b61df41a83b4" contextRef="C_1c996d2e-def1-46a6-a4e5-dd50cc8ddbfa" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">25.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of research and development expenses towards license fee. Refer to Note 3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for additional discussion.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company and Alloy formed a joint venture company, Voxall Therapeutics, LLC (&#x201c;Voxall&#x201d;) to leverage the Company&#x2019;s technology and Alloy&#x2019;s ATX-Gx&#153; platform and antibody discovery services. The Company and Alloy contributed $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4f70e6d4-215b-437d-a1f6-b7de093bdd77" contextRef="C_ab715df4-cb33-446f-9bc3-90688e948155" name="pyxs:ContributedAmountToJointVentureByEachEntity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> thousand each to Voxall along with certain license in 2021. During the year ended December 31, 2022, the Company has not incurred expenses related to Voxall. During the year ended December 31, 2021, the Company provided services to Voxall for which it recognized service fee other income of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_90273f4b-57bc-433e-ade1-964c93937249" contextRef="C_4881d8cf-3758-45cf-9629-35b8395ed61a" name="pyxs:RelatedPartyTransactionServiceFeeOtherIncomeFromTransactionsWithRelatedParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">181</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> thousand. Refer to Note 4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for additional discussion.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e6145700-e6e9-499a-8d3e-a5f34e2f7883" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16. Commitments and Contingencies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Legal Proceedings</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, the Company may become involved in various legal proceedings that arise in the ordinary course of business. The Company is not currently a party to any material legal proceedings and is not aware of any pending or threatened legal proceeding against it that the Company believes could have an adverse effect on its business, operating results or financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Commitments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the normal course of business, the Company enters into agreements with various third parties for clinical trials, preclinical research studies and testing, manufacturing and other services and products for operating purposes, which are generally cancellable by the Company at any time, subject to payment of remaining obligations under binding purchase orders and, in certain cases, nominal early-termination fees. These commitments are not deemed significant.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fde93abe-3dcb-43d8-8134-d5f43756c314" contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3" name="us-gaap:SubsequentEventsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17. Subsequent Event</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On February 2, 2023, the Company entered into a sublease agreement for approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c29fbc97-ef5a-4c8e-abab-e84faf2a781c" contextRef="C_466cd526-a6e1-4fea-9b6a-9ed2473eda8d" name="us-gaap:AreaOfLand" unitRef="U_sqft" decimals="INF" format="ixt:numdotdecimal">17,729</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet of office and laboratory space in the building located at 321 Harrison Avenue, Boston, Massachusetts. The sublease is for the fixed period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7171b917-5c36-4e61-8a11-cf4488f36df4" contextRef="C_606b0303-5274-48c3-af42-6ee3a9b3c452" name="pyxs:SubleaseTerm" format="ixt-sec:durmonth"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> months and will expire on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_59f706a8-4070-45e6-9b2e-e5fdfb2964e1" contextRef="C_e79d7fea-f750-4f59-be70-803b9b5030d4" name="pyxs:SubleaseExpirationDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 1, 2025</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company will receive approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_108b8b03-f924-4b27-8394-cf99fe12f524" contextRef="C_e79d7fea-f750-4f59-be70-803b9b5030d4" name="us-gaap:SubleaseIncome" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in base rent payments over the sublease term. The subtenant will also be responsible for certain other costs under the sublease, such as operating expenses, taxes, insurance, property management fee and utilities.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4
<SEQUENCE>2
<FILENAME>pyxs-ex4_1.htm
<DESCRIPTION>EX-4.1
<TEXT>
<html>
 <head>
  <title>EX-4</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 4.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DESCRIPTION OF REGISTRANT&#x2019;S SECURITIES</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">REGISTERED PURSUANT TO SECTION 12 OF THE</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECURITIES EXCHANGE ACT OF 1934</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Pyxis Oncology, Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;): its common stock, par value $0.001 per share (the &#x201c;common stock&#x201d;). For purposes of this exhibit, unless the context otherwise requires, the words &#x201c;we,&#x201d; &#x201c;our,&#x201d; &#x201c;us&#x201d; and &#x201c;our company&#x201d; refer to Pyxis Oncology, Inc., a Delaware corporation.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description of Common Stock</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following summary sets forth some of the general terms of our common stock. Because this is a summary, it does not contain all of the information that may be important to you. For a more detailed description of our common stock, you should read our amended and restated certificate of incorporation and the amended and restated bylaws, each of which is an exhibit to our Annual Report on Form 10-K to which this summary is also an exhibit, and the applicable provisions of the Delaware General Corporation Law (the &#x201c;DGCL&#x201d;).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our amended and restated certificate of incorporation authorizes 190,000,000 shares of common stock, $0.001 par value per share, and 10,000,000 shares of undesignated preferred stock, $0.001 par value per share, the rights, preferences and privileges of which may be designated from time to time by our board of directors.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend Rights</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subject to preferences that may apply to shares of preferred stock outstanding at the time, the holders of outstanding shares of our common stock are entitled to receive dividends out of funds legally available if our board of directors, in its discretion, determines to issue dividends and only then at the times and in the amounts that our board of directors may determine.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Voting Rights</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The holders of our common stock are entitled to one vote per share. Stockholders do not have the ability to cumulate votes for the election of directors. We have a classified board of directors consisting of three classes of approximately equal size, each serving staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No Preemptive or Similar Rights</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our common stock is not entitled to preemptive rights and is not subject to redemption or sinking fund provisions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right to Receive Liquidation Distributions</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upon our liquidation, dissolution or winding-up, the assets legally available for distribution to our stockholders would be distributable ratably among the holders of our common stock and any participating preferred stock outstanding at that time, subject to prior satisfaction of all outstanding debt and liabilities and the preferential rights of and the payment of liquidation preferences, if any, on any outstanding shares of preferred stock.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preferred Stock</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our board of directors is authorized, subject to limitations prescribed by Delaware law, to issue preferred stock in one or more series, to establish from time to time the number of shares to be included in each series and to fix the</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">designation, powers, preferences and rights of the shares of each series and any of its qualifications, limitations or restrictions, in each case without further vote or action by our stockholders. Our board of directors can also increase or decrease the number of shares of any series of preferred stock, but not below the number of shares of that series then outstanding, without any further vote or action by our stockholders. Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of our common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in our control and might adversely affect the market price of our common stock and the voting and other rights of the holders of our common stock.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Anti-Takeover Provisions</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The provisions of the Delaware General Corporation Law, or the DGCL, our amended and restated certificate of incorporation and our bylaws could have the effect of delaying, deferring or discouraging another person from acquiring control of our company. These provisions, which are summarized below, are expected to discourage certain types of coercive takeover practices and inadequate takeover bids and encourage persons seeking to acquire control of our company to first negotiate with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the disadvantages of discouraging a proposal to acquire us because negotiation of these proposals could result in an improvement of their terms.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Section 203 of the DGCL</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:4.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to the provisions of Section 203 of the DGCL regulating corporate takeovers. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a &#x201c;business combination&#x201d; with an &#x201c;interested stockholder&#x201d; for a three-year period following the date that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. Under Section 203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions:</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:4.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">before the stockholder became interested, our board of directors approved either the business combination or the transaction, which resulted in the stockholder becoming an interested stockholder;</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:4.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">upon consummation of the transaction, which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans in some instances, but not the outstanding voting stock owned by the interested stockholder; or</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:4.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">at or after the time the stockholder became interested, the business combination was approved by our board and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least two-thirds of the outstanding voting stock, which is not owned by the interested stockholder.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:4.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 203 defines a business combination to include:</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:4.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any merger or consolidation involving the corporation and the interested stockholder;</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:4.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any sale, transfer, lease, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:4.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">subject to exceptions, any transaction that results in the issuance of transfer by the corporation of any stock of the corporation to the interested stockholder;</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:4.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; and</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:4.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.</font></div></div>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In general, Section 203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Amended and Restated Certificate of Incorporation and Bylaw Provisions</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our amended and restated certificate of incorporation and our bylaws include a number of provisions that may have the effect of deterring hostile takeovers, or delaying or preventing changes in control of our management team or changes in our board of directors or our governance or policy, including the following:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Board Vacancies</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our amended and restated certificate of incorporation and bylaws authorize generally only our board of directors to fill vacant directorships resulting from any cause or created by the expansion of our board of directors. In addition, the number of directors constituting our board of directors may be set only by resolution adopted by a majority vote of our entire board of directors. These provisions prevent a stockholder from increasing the size of our board of directors and gaining control of our board of directors by filling the resulting vacancies with its own nominees.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Classified Board</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our amended and restated certificate of incorporation and bylaws provide that our board of directors is classified into three classes of directors. The existence of a classified board of directors could delay a successful tender offeror from obtaining majority control of our board of directors, and the prospect of that delay might deter a potential offeror..</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Directors Removed Only for Cause</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our amended and restated certificate of incorporation provides that stockholders may remove directors only for cause.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Supermajority Requirements for Amendments of Our Amended and Restated Certificate of Incorporation and Bylaws</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our amended and restated certificate of incorporation further provides that the affirmative vote of holders of at least two-thirds of the voting power of our outstanding common stock is required to amend certain provisions of our amended and restated certificate of incorporation, including provisions relating to the classified board, the size of the board of directors, removal of directors, special meetings, actions by written consent and designation of our preferred stock. The affirmative vote of holders of at least two-thirds of the voting power of our outstanding common stock is required to amend or repeal certain provisions of our bylaws, although our bylaws may be amended by a simple majority vote of our board of directors.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stockholder Action; Special Meetings of Stockholders</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our amended and restated certificate of incorporation provides that our stockholders may not take action by written consent, but may only take action at annual or special meetings of our stockholders. As a result, holders of our capital stock are not able to amend our bylaws or remove directors without holding a meeting of our stockholders called in accordance with our bylaws. Our amended and restated certificate of incorporation and our bylaws provide that special meetings of our stockholders may be called only by a majority of our board of directors, the chairperson of our board of directors or our chief executive officer, thus prohibiting a stockholder from calling a special meeting. These provisions might delay the ability of our stockholders to force consideration of a proposal or for stockholders to take any action, including the removal of directors.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Advance Notice Requirements for Stockholder Proposals and Director Nominations</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:4.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our bylaws provide advance notice procedures for stockholders seeking to bring business before our annual meeting of stockholders or to nominate candidates for election as directors at our annual meeting of stockholders. To be timely, a stockholder&#x2019;s notice generally must be delivered to us not later than the close of business on the 90th day nor earlier than the close of business on the 120th day prior to the first anniversary of the preceding year&#x2019;s annual meeting of stockholders. Our bylaws also specify certain requirements regarding the form and content of a stockholder&#x2019;s notice. With respect to nominations of persons for election to our board of directors, the notice shall provide information about the nominee, including, among other things, name, age, address, principal occupation, ownership of our capital stock and whether they meet applicable independence requirements. With respect to the proposal of other business to be considered by our stockholders at an annual meeting, the notice shall provide a brief description of the business desired to be brought before the meeting, the text of the proposal or business, the reasons for conducting such business at the meeting and any material interest in such business by such stockholder and any beneficial owners and associated persons on whose behalf the notice is made, or the proposing persons. In addition, a stockholder&#x2019;s notice must set forth certain information related to the proposing persons, including, among other things:</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:4.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the name and address of the proposing persons;</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:4.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">information as to the ownership by the proposing persons of our capital stock and any derivative interest or short interest in any of our securities held by the proposing persons;	</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:4.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">information as to any material relationships and interest between the proposing persons and us, any of our affiliates and any of our principal competitors;</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:4.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a representation that the stockholder is a holder of record of our stock entitled to vote at that meeting and that the stockholder intends to appear in person or by proxy at the meeting to propose such nomination or business; and</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:4.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a representation whether the proposing persons intend or are part of a group which intends to deliver a proxy statement or form of proxy to holders of at least the percentage of our outstanding capital stock required to elect the nominee or carry the proposal.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These provisions may preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting of stockholders. We expect that these provisions might also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#x2019;s own slate of directors or otherwise attempting to obtain control of our company.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">No Cumulative Voting</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The DGCL provides that stockholders are not entitled to the right to cumulate votes in the election of directors unless a corporation&#x2019;s certificate of incorporation provides otherwise. Our amended and restated certificate of incorporation and bylaws do not provide for cumulative voting.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Issuance of Undesignated Preferred Stock</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our board of directors has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of undesignated preferred stock with rights and preferences, including voting rights, designated from time to time by our board of directors. The existence of authorized but unissued shares of preferred stock enables our board of directors to render more difficult or to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Exclusive Forum</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the sole and exclusive forum for (1) any derivative action or proceeding brought on our behalf under Delaware law, (2) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (3) any action arising pursuant to any provision of the Delaware General Corporation Law or our amended and restated certificate of incorporation or bylaws, (4) any other action asserting a claim that is governed by the internal affairs doctrine or (5)</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any other action asserting an &#x201c;internal corporate claim,&#x201d; as defined in Section 115 of the Delaware General Corporation Law, shall be the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another state court located within the State of Delaware, or the federal district court for the District of Delaware) in all cases subject to the court having jurisdiction over indispensable parties named as defendants. These exclusive-forum provisions do not apply to claims under the Securities Act or the Exchange Act. Our amended and restated certificate of incorporation also provides that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act or the Exchange Act. Any person or entity purchasing or otherwise acquiring any interest in our securities shall be deemed to have notice of and consented to this provision. Although we believe these provisions benefit us by providing increased consistency in the application of Delaware law for the specified types of actions and proceedings, the provisions may have the effect of discouraging lawsuits against us or our directors and officers.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Transfer Agent and Registrar</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The transfer agent and registrar for our common stock is Broadridge Corporate Issuer Solutions, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exchange Listing</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#x201c;PYXS.&#x201d;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>3
<FILENAME>pyxs-ex10_21.htm
<DESCRIPTION>EX-10.21
<TEXT>
<html>
 <head>
  <title>EX-10</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 10.21</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pyxis Oncology, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 18, 2022</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Via Email Only</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:39.389%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lara S. Sullivan, M.D., MBA</font><font style="color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:39.389%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">lsullivan@pyxisoncology.com</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:39.389%;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RE:	AMENDED AND RESTATED OFFER LETTER</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dear Dr. Sullivan:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.046%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Amended and Restated Offer Letter (this &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Letter</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) memorializes the amended and restated employment terms offered to you by Pyxis Oncology, Inc. (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Pyxis</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; or the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;). This Letter (including all amended and restated terms herein) will supersede and replace in full the prior Offer Letter, entered into by and between you and the Company dated October 21, 2019 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Prior Letter</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), and it will become effective as of the closing of the Company&#x2019;s initial public offering. This Letter is intended to summarize the terms and conditions of your employment.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3643897564274687%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Position</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. You will continue to serve as the Company&#x2019;s President and Chief Executive Officer, and you will continue to report to the Company&#x2019;s Board of Directors (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Board</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;). You will also continue to serve as a member of the Board. During your employment with Pyxis, you will devote your full time and best efforts to the business of Pyxis, except that you may engage in the business activities described on </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Appendix A</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of this Letter, and other activities that may be approved in advance in writing by the Board.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:7.602%;text-indent:0.0%;display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.607220935518085%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Location</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Your primary place of employment will be Pyxis&#x2019;s corporate headquarters,</font></div></div>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">located in the Boston-metropolitan area.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:7.602%;text-indent:0.0%;display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.607220935518085%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Compensation</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:10.204%;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.065%;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3643897564274687%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Base Salary</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Your annualized base salary rate will be $565,000, less standard deductions and withholding and payable bi-weekly in accordance with Pyxis&#x2019;s regular payroll practices. Your salary shall be reviewed annually and may be </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">adjusted </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in connection with any such review</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:10.204%;font-size:0;margin-top:4.5pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.065%;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3643897564274687%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Bonus Program</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. You will be eligible for an annual target bonus of 55% of your then-current base salary, as determined by the Board in its sole discretion based upon, among other things, the achievement of pre-determined performance milestones. Any annual bonus, if earned, shall be paid no later than March 15</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:8.040000000000001pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of the year immediately following the year to which the applicable annual bonus relates.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:10.204%;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.065%;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3643897564274687%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity Compensation. </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">You currently are the holder of certain equity under the Company&#x2019;s equity incentive plans, including, without limitation to the Company&#x2019;s 2021 Equity Incentive Plan (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity Grants</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), which Equity Grants will continue to vest based upon your</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.84%;text-indent:0.0%;font-size:10.0pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">continued service, pursuant to the applicable award agreements, and are subject to the accelerated vesting set forth in Section 5(b)(ii)(2).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:10.204%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.065%;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3643897564274687%;">d.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Withholding. </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pyxis shall withhold from any compensation or benefits payable to you by Pyxis any federal, state and/or local income, employment and/or other similar taxes as may be required to be withheld pursuant to any applicable law or regulation.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:7.602%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.607220935518085%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Benefits</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:10.204%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.065%;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3643897564274687%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Generally</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. You will be eligible to participate in the benefits to be offered by Pyxis on the same terms and conditions as it will make such benefits available to employees in positions similar to your position. The benefits are currently expected to include health insurance and such other benefits provided by similar companies of a similar stage, as approved by the Board.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:10.204%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.065%;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3643897564274687%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expenses</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Pyxis shall reimburse you for all reasonable business expenses incurred by you in the performance of your duties under this Letter, all in accordance with the Company&#x2019;s reimbursement policies.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:10.204%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.065%;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3643897564274687%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Terms</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. As is the case of all employee benefits, such benefits will be governed by the terms and conditions of applicable Pyxis plans or policies, which are subject to change or discontinuation at any time.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:7.602%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.607220935518085%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Severance</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10.935%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7422107449615454%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Definitions. </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For purposes of this Letter:</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:12.381%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.065%;min-width:12.13%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.575691198885603%;">i.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accrued Benefits</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means: (i) any unpaid base salary for services rendered prior to the date of termination of employment; (ii) any earned but unpaid annual bonus for any completed fiscal year prior to the year in which termination of employment occurs; (iii) reimbursement of any unreimbursed business expenses incurred as of the date of termination of employment in accordance with Pyxis&#x2019;s reimbursement policies; (iv) accrued but unused vacation (if applicable) earned through the date of termination of employment; and (v) all other payments, benefits or fringe benefits to which you shall be entitled under the terms of any applicable compensation arrangement or benefit, equity or fringe benefit plan or program or grant with or by Pyxis or this Letter.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:11.701%;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.065%;min-width:11.463%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.575691198885603%;">ii.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cause</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means conduct involving one or more of the following by you: (i) material failure to perform a substantial portion of your duties and responsibilities in accordance with the terms or requirements of this Letter and your position, except in the case of your physical or mental illness; (ii) disloyalty, gross negligence, willful misconduct, or dishonesty that materially injures Pyxis or a breach of fiduciary duty to Pyxis; (iii) the conviction of (x) a felony or (y) a misdemeanor involving moral turpitude or fraud that materially injures Pyxis; (iv) the commission of an act of embezzlement or fraud; or (v) your material breach of this Letter or any other written agreement between Pyxis and you; provided, in </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">case </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of clauses (i), (ii) and (v)</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, that the Company provides you with written notice that specifically identifies the conduct that the Board believes to constitute Cause, and you fail to remedy such conduct within </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15 </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">days following your receipt of such notice. Notwithstanding the foregoing, &#x201c;Cause&#x201d; shall not include or be predicated upon any act or omission by you which is taken or made either at the direction of the Board.</font></div></div>
  <p style="margin-left:0.933%;text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.065%;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:11.87%;text-indent:0.0%;display:flex;margin-top:3.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:5.731%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.502893452853739%;">iii.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Change in Control</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; shall mean the occurrence of any of the following events:</font></div></div>
  <div style="margin-left:0.935%;text-indent:0.0%;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.065%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.171924051399558%;">(A)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the consummation of merger, consolidation or similar transaction involving (directly or indirectly) the Company and, immediately after the consummation of such transaction, the stockholders of the Company immediately prior thereto do not hold, directly or indirectly, voting securities representing more than 50% of the outstanding voting power of the surviving entity; or</font></div></div>
  <div style="margin-left:0.935%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.463%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.495684651491445%;">(B)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the sale of all or substantially all of the Company&#x2019;s stock or assets.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:11.293%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.065%;min-width:11.065%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.575691198885603%;">iv.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Good Reason</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means, without your express written consent, (i) any reduction in your annual base salary as in effect immediately prior to such reduction other than a reduction which is proportional to general reductions affecting other senior executive officers of Pyxis generally, (ii) any diminution in title or position or a material reduction in your duties or responsibilities, or (iii) a material breach by the Company of this Letter; provided, in each case, that (a) you provide the Company with written notice that specifically identifies the event that you believe to constitute Good Reason within </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0 days after you first have knowledge of such event,</font></div></div>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.046%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(b) the Company fails to remedy such event within 30 days following the Company&#x2019;s receipt of such notice and (c) you actually resign your employment with the Company within </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0 days following the end of such 30-day remedy period.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10.935%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7422107449615454%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Severance Benefits and Payment</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:12.399%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.204%;min-width:12.13%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.575691198885603%;">i.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Generally</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. If your employment with Pyxis is terminated (x) by Pyxis for any reason other than Cause, or (y) by you for Good Reason, Pyxis will pay you (1) the Accrued Benefits; and (2) subject to your compliance with </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 5(c)</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> below, after the execution and delivery by you of a general release of all claims that you may have against the Company or persons affiliated with the Company, in a form prescribed by the Company, without alterations (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Release</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), and the expiration of any revocation period without the release being revoked,</font></div></div>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.065%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(A) twelve (12) months&#x2019; base salary, less standard deductions, payable in bi-weekly installments in accordance with the Company&#x2019;s regular payroll policies over the twelve (12) month period following such termination of employment, commencing within 60 days following such termination of employment and with the first payment to include the amounts that would have been paid following such termination of employment but were delayed subject to the effectiveness of the Release, and (B) if you elect to continue your health insurance coverage pursuant to your rights under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">COBRA</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), following the termination of your employment, your monthly premium under COBRA on a monthly basis until the earlier of (1) twelve (12) months following the effective termination date, or (2) the date upon which you commence employment that provides you with eligibility for healthcare benefits substantially comparable to those provided by Pyxis. A termination of your employment by Pyxis due to physical or mental illness which is not a Disability (as defined herein) shall be treated as an involuntary termination other than for Cause. The term &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Disability</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; shall mean that you have not been able to materially engage in your duties and responsibilities after reasonable accommodation by reason of any medically determinable physical or mental impairment for a period of not less than 90 consecutive days or not less than 120 days during any one-year period.</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.065%;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:12.398%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:5.204%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.940503641469372%;">ii.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">In connection with the Change in Control Period.</font></div></div>
  <div style="margin-left:0.935%;text-indent:17.007%;font-size:0;margin-top:3.95pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.065%;min-width:16.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3643897564274687%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If your employment with Pyxis is terminated (x) by Pyxis for any reason other than Cause, or (y) by you for Good Reason during the period commencing three (3) months prior to a Change in Control and continuing until the twelve (12) month anniversary of a Change in Control (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Change in Control Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), in lieu of the benefits set forth in Section 5(b)(i), Pyxis will pay you (1) the Accrued Benefits and (2) subject to your compliance with </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 5(c)</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> below, after the execution and delivery of the Release and the expiration of any revocation period without the release being revoked, (A) eighteen (18) months&#x2019; base salary plus your annual bonus at one hundred percent (100%) of target, payable in a single lump sum on the 60</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:8.040000000000001pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> day following the termination of your employment (or, if later, on the 60th day following the Change in Control less the base salary continuation previously paid under Section 5(b)(i)(2)(A)); provided, however, that if the termination of employment occurs within three (3) months prior to the Change in Control and the eighteen (18) months&#x2019; of base salary under this clause (2)(A) constitutes non-qualified deferred compensation within the meaning of Section 409A of the Code, then such base salary shall be payable in bi-weekly installments in accordance with the Company&#x2019;s regular payroll policies over the twelve (12) month period following such termination of employment in accordance with Section 5(b)(i)(2) to the extent required to comply with Section 409A of the Code, and (B) if you elect to continue your health insurance coverage pursuant to your rights under COBRA following the termination of your employment, your monthly premium under COBRA on a monthly basis until the earlier of (1) twelve (12) months following the effective termination date, or (2) the date upon which you commence employment that provides you with eligibility for healthcare benefits substantially comparable to those provided by Pyxis. A termination of your employment by Pyxis due to physical or mental illness which is not a Disability shall be treated as an involuntary termination other than for Cause.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:17.007%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.065%;min-width:16.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3643897564274687%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to the severance benefits and payments set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5(b)(ii)(1)</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, if your employment with Pyxis is terminated during the Change in Control Period (x) by Pyxis for any reason other than Cause or (y) by you for Good Reason, then the Equity Grants shall immediately vest with respect to 100% of the shares subject to the Equity Grants and become exercisable; provided, however, that if the Company or its successor entity (if applicable) does not assume, substitute or continue the unvested portion of any Equity Grants in connection with the Change in Control, then 100% of the unvested portion of the applicable Equity Grants will vest and the applicable Equity Grants will become exercisable immediately prior to the date of the Change in Control, contingent on the consummation of the Change in Control.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:10.204%;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.065%;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3643897564274687%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Eligibility for Severance</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Eligibility for receipt of the items in </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 5(b)</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> above, shall be conditioned on your (i) returning to Pyxis promptly upon termination of your employment all of its property, including confidential information and all electronically stored information, and</font></div></div>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(ii) signing and not revoking the Release.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:10.204%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.065%;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3643897564274687%;">d.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accrued Benefits</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Accrued Benefits shall be paid to you (or your estate in the event of your death) upon termination of employment regardless of the circumstances giving rise to such termination. </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:6.667%;font-size:0;margin-top:4.5pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.065%;min-width:6.537%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3643897564274687%;">6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At-Will Employment.</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Your employment with Pyxis is at will, meaning it may be terminated by you or Pyxis at any time, subject to </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 5</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> above, for any reason with or without Cause. You understand that this Letter is not a contract for employment for a definite term.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3643897564274687%;">7.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proprietary Rights Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. You acknowledge and reaffirm your continuing obligations owed to the Company, pursuant to that certain Proprietary Information and Inventions Agreement, dated as of October 12, 2020 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Proprietary Information Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;). For the avoidance of doubt, nothing in the Proprietary Information Agreement or otherwise will prohibit or restrict you from responding to any inquiry, or otherwise communicating with, any federal, state or local administrative or regulatory agency or authority or participating in an investigation conducted by any governmental agency or authority. You cannot be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that is made (A) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney, and (B) solely for the purpose of reporting or investigating a suspected violation of law; or that is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. As a result, the Company and you shall have the right to disclose trade secrets in confidence to Federal, State, and local government officials, or to an attorney, for the sole purpose of reporting or investigating a suspected violation of law. Each of the Company and you also have the right to disclose trade secrets in a document filed in a lawsuit or other proceeding, but only if the filing is made under seal and protected from public disclosure. Nothing in the Proprietary Information Agreement is intended to conflict with that right or to create liability for disclosures of trade secrets that are expressly allowed by the foregoing.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3643897564274687%;">8.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No Inconsistent Obligations</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. By accepting this offer of continued employment, you represent and warrant to Pyxis that you are under no obligations or commitments, whether contractual or otherwise, that are inconsistent with your obligations set forth in this Letter or that would be violated by your employment by Pyxis. You agree that you will not take any action on behalf of Pyxis or cause Pyxis to take any action that will violate any agreement that you have with a prior employer.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:7.602%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.607220935518085%;">9.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delayed Commencement Date for Payments and Benefits</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:10.204%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.065%;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3643897564274687%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The intent of the parties hereto is that payments and benefits under this Letter comply with, or be exempt from, Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations and guidance promulgated thereunder (collectively &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Code Section 409A</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) and, accordingly, to the maximum extent permitted, this Letter shall be interpreted to be in compliance therewith or exempt therefrom. If you notify Pyxis (with specificity as to the reason therefor) that you believe that any provision of this Letter (or of any award of compensation, including equity compensation or benefits) would cause you to incur any additional tax or interest under Code Section 409A and Pyxis concurs with such belief or Pyxis independently makes such determination, Pyxis shall, after consulting with you, reform such provision to try to comply with Code Section 409A through good faith modifications to the minimum extent reasonably appropriate to conform with Code Section 409A. To the extent that any provision hereof is modified in order to comply with Code Section 409A, such modification shall be made in good faith and shall, to the maximum extent reasonably possible, maintain the original intent and economic benefit to you and Pyxis of the applicable provision without violating the provisions of Code Section 409A.</font></div></div>
  <p style="margin-left:10.933%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.065%;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:10.068%;font-size:0;margin-top:4.5pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.065%;min-width:9.87%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3643897564274687%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A termination of employment shall not be deemed to have occurred for purposes of any provision of this Letter providing for the payment of any amounts or benefits upon or following a termination of employment that are considered &#x201c;nonqualified deferred compensation&#x201d; under Code Section 409A unless such termination is also a &#x201c;separation from service&#x201d; within the meaning of Code Section 409A and, for purposes of any such provision of this Letter, references to a &#x201c;termination,&#x201d; &#x201c;termination of employment&#x201d; or like terms shall mean &#x201c;separation from service.&#x201d; Notwithstanding any provision to the contrary in this Letter, no payments or benefits that are considered &#x201c;nonqualified deferred compensation&#x201d; under Code Section 409A, then (i) each such payment which is conditioned upon your execution and non-revocation of the Release and which is to be paid or provided during a designated period that begins in one taxable year and ends in a second taxable year, shall be paid or provided in the later of the two taxable years and (ii) each such payment to which you become entitled under this Letter in connection with your termination of employment, shall be made or provided to you prior to the earlier of (x) the expiration of the six (6) month period measured from the date of your &#x201c;separation from service&#x201d; with Pyxis (as such term is defined in Code Section 409A) or (y) the date of your death, if you are deemed at the time of such separation from service to be a &#x201c;specified employee&#x201d; under Code Section 409A and if, in the absence of such delay, the payments would be subject to additional tax under Code Section 409A. Upon the expiration of the applicable Code Section 409A(a)(2) deferral period, all payments and benefits deferred pursuant to this </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 8(b)</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (whether they would have otherwise been payable in a single sum or in installments in the absence of such deferral) shall be paid or reimbursed to you in a lump sum, and any remaining payments and benefits due under this Letter shall be paid or provided in accordance with the normal payment dates specified for them herein. For clarity, a Change in Control shall not be deemed to have occurred for purposes of any provision of this Letter unless such Change in Control also constitutes a &#x201c;change in control event&#x201d; within the meaning of Code Section 409A.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:10.204%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.065%;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3643897564274687%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For purposes of Code Section 409A, your right to receive any installment payment pursuant to this Letter shall be treated as a right to receive a series of separate and distinct payments. Whenever a payment under this Letter specifies a payment period with reference to a number of days (</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">e.g.</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, &#x201c;payment shall be made within 30 days following the date of termination&#x201d;), the actual date of payment within the specified period shall be within the sole discretion of Pyxis. Notwithstanding any other provision of this Letter to the contrary, in no event shall any payment under this Letter that constitutes &#x201c;nonqualified deferred compensation&#x201d; for purposes of Code Section 409A be subject to offset, counterclaim or recoupment by any other amount payable to you unless otherwise permitted by Code Section 409A.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:10.204%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.065%;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3643897564274687%;">d.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All in-kind benefits provided and expenses eligible for reimbursement under this Letter shall be provided by Pyxis or incurred by you during the time periods set forth in this Letter. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year. Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:10.204%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.065%;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3643897564274687%;">e.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If under this Letter an amount is to be paid in installments, each installment shall be treated as a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2)(iii).</font></div></div>
  <p style="margin-left:10.933%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.065%;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:10.068%;font-size:0;margin-top:4.5pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.065%;min-width:9.87%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3643897564274687%;">f.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A termination of employment shall not be deemed to have occurred for purposes of any provision of this Letter providing for the payment of any amounts or benefits upon or following a termination of employment that are considered &#x201c;nonqualified deferred compensation&#x201d; under Code Section 409A unless such termination is also a &#x201c;separation from service&#x201d; within the meaning of Code Section 409A and, for purposes of any such provision of this Letter, references to a &#x201c;termination,&#x201d; &#x201c;termination of employment&#x201d; or like terms shall mean &#x201c;separation from service.&#x201d; Notwithstanding any provision to the contrary in this Letter, no payments or benefits that are considered &#x201c;nonqualified deferred compensation&#x201d; under Code Section 409A, then (i) each such payment which is conditioned upon your execution and non-revocation of the Release and which is to be paid or provided during a designated period that begins in one taxable year and ends in a second taxable year, shall be paid or provided in the later of the two taxable years and (ii) each such payment to which you become entitled under this Letter in connection with your termination of employment, shall be made or provided to you prior to the earlier of (x) the expiration of the six (6) month period measured from the date of your &#x201c;separation from service&#x201d; with Pyxis (as such term is defined in Code Section 409A) or (y) the date of your death, if you are deemed at the time of such separation from service to be a &#x201c;specified employee&#x201d; under Code Section 409A and if, in the absence of such delay, the payments would be subject to additional tax under Code Section 409A. Upon the expiration of the applicable Code Section 409A(a)(2) deferral period, all payments and benefits deferred pursuant to this </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 8(b)</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (whether they would have otherwise been payable in a single sum or in installments in the absence of such deferral) shall be paid or reimbursed to you in a lump sum, and any remaining payments and benefits due under this Letter shall be paid or provided in accordance with the normal payment dates specified for them herein. For clarity, a Change in Control shall not be deemed to have occurred for purposes of any provision of this Letter unless such Change in Control also constitutes a &#x201c;change in control event&#x201d; within the meaning of Code Section 409A.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:10.204%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.065%;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3643897564274687%;">g.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For purposes of Code Section 409A, your right to receive any installment payment pursuant to this Letter shall be treated as a right to receive a series of separate and distinct payments. Whenever a payment under this Letter specifies a payment period with reference to a number of days (</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">e.g.</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, &#x201c;payment shall be made within 30 days following the date of termination&#x201d;), the actual date of payment within the specified period shall be within the sole discretion of Pyxis. Notwithstanding any other provision of this Letter to the contrary, in no event shall any payment under this Letter that constitutes &#x201c;nonqualified deferred compensation&#x201d; for purposes of Code Section 409A be subject to offset, counterclaim or recoupment by any other amount payable to you unless otherwise permitted by Code Section 409A.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:10.204%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.065%;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3643897564274687%;">h.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All in-kind benefits provided and expenses eligible for reimbursement under this Letter shall be provided by Pyxis or incurred by you during the time periods set forth in this Letter. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year. Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:10.204%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.065%;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3643897564274687%;">i.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If under this Letter an amount is to be paid in installments, each installment shall be treated as a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2)(iii).</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.065%;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:10.884%;font-size:0;margin-top:4.5pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.065%;min-width:10.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3643897564274687%;">j.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A termination of employment shall not be deemed to have occurred for purposes of any provision of this Letter providing for the payment of any amounts or benefits upon or following a termination of employment that are considered &#x201c;nonqualified deferred compensation&#x201d; under Code Section 409A unless such termination is also a &#x201c;separation from service&#x201d; within the meaning of Code Section 409A and, for purposes of any such provision of this Letter, references to a &#x201c;termination,&#x201d; &#x201c;termination of employment&#x201d; or like terms shall mean &#x201c;separation from service.&#x201d; Notwithstanding any provision to the contrary in this Letter, no payments or benefits that are considered &#x201c;nonqualified deferred compensation&#x201d; under Code Section 409A, then (i) each such payment which is conditioned upon your execution and non-revocation of the Release and which is to be paid or provided during a designated period that begins in one taxable year and ends in a second taxable year, shall be paid or provided in the later of the two taxable years and (ii) each such payment to which you become entitled under this Letter in connection with your termination of employment, shall be made or provided to you prior to the earlier of (x) the expiration of the six (6) month period measured from the date of your &#x201c;separation from service&#x201d; with Pyxis (as such term is defined in Code Section 409A) or (y) the date of your death, if you are deemed at the time of such separation from service to be a &#x201c;specified employee&#x201d; under Code Section 409A and if, in the absence of such delay, the payments would be subject to additional tax under Code Section 409A. Upon the expiration of the applicable Code Section 409A(a)(2) deferral period, all payments and benefits deferred pursuant to this </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 8(b)</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (whether they would have otherwise been payable in a single sum or in installments in the absence of such deferral) shall be paid or reimbursed to you in a lump sum, and any remaining payments and benefits due under this Letter shall be paid or provided in accordance with the normal payment dates specified for them herein. For clarity, a Change in Control shall not be deemed to have occurred for purposes of any provision of this Letter unless such Change in Control also constitutes a &#x201c;change in control event&#x201d; within the meaning of Code Section 409A.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:10.204%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.065%;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3643897564274687%;">k.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For purposes of Code Section 409A, your right to receive any installment payment pursuant to this Letter shall be treated as a right to receive a series of separate and distinct payments. Whenever a payment under this Letter specifies a payment period with reference to a number of days (</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">e.g.</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, &#x201c;payment shall be made within 30 days following the date of termination&#x201d;), the actual date of payment within the specified period shall be within the sole discretion of Pyxis. Notwithstanding any other provision of this Letter to the contrary, in no event shall any payment under this Letter that constitutes &#x201c;nonqualified deferred compensation&#x201d; for purposes of Code Section 409A be subject to offset, counterclaim or recoupment by any other amount payable to you unless otherwise permitted by Code Section 409A.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:10.204%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.065%;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3643897564274687%;">l.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All in-kind benefits provided and expenses eligible for reimbursement under this Letter shall be provided by Pyxis or incurred by you during the time periods set forth in this Letter. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year. Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:10.204%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.065%;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3643897564274687%;">m.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If under this Letter an amount is to be paid in installments, each installment shall be treated as a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2)(iii).</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:6.667%;font-size:0;margin-top:4.5pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.065%;min-width:6.537%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3643897564274687%;">10.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">280G</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">. </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the event that the amount of any compensation, payment or distribution by Pyxis or its affiliates to or for your benefit, whether paid or payable or distributed or distributable pursuant to the terms of this Letter or otherwise, calculated in a manner consistent with Section 280G of the Code and the applicable regulations thereunder (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Aggregate Payments</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) would be subject to the excise tax imposed by Section 4999 of the Code, then the Aggregate Payments shall be reduced (but not below zero) so that the sum of all of the Aggregate Payments shall be $1.00 less than the amount at which you become subject to the excise tax imposed by Section 4999 of the Code; provided that such reduction shall only occur if it would result in you receiving a higher After Tax Amount (as defined below) than you would receive if the Aggregate Payments were not subject to such reduction. In such event, the Aggregate Payments shall be reduced in the following order, in each case, in reverse chronological order beginning with the Aggregate Payments that are to be paid the furthest in time from consummation of the transaction that is subject to Section 280G of the Code: (i) cash payments not subject to Section 409A of the Code; (ii) cash payments subject to Section 409A of the Code; (iii) equity-based payments and acceleration not subject to Section 409A of the Code; (iv) equity-based payments and acceleration subject to Section 409A of the Code; and (v) non-cash forms of benefits; provided that in the case of all the foregoing Aggregate Payments all amounts or payments that are not subject to calculation under Treas. Reg. &#167; 1.280G-1, Q&amp;A-24(b) or (c) shall be reduced before any amounts that are subject to calculation under Treasury Regulation &#167;1.280G-1, Q&amp;A- 24(b) or (c). For purposes of this Section 9, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">After Tax Amount</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means the amount of the Aggregate Payments less all federal, state, and local income, excise and employment taxes imposed on you as a result of your receipt of the Aggregate Payments. For purposes of determining the After Tax Amount, you shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination is to be made, and state and local income taxes at the highest marginal rates of individual taxation in each applicable state and locality, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes. The determination as to whether a reduction in the Aggregate Payments shall be made pursuant to this Section 9 shall be made by a nationally recognized accounting firm or a firm specializing in Section 280G calculations selected by Pyxis, which shall provide detailed supporting calculations both to Pyxis and you. The costs of obtaining such determination and all related fees and expenses (including related fees and expenses incurred in any later audit) shall be borne by Pyxis. Notwithstanding the foregoing, if (i) Pyxis is not publicly traded prior to the occurrence of a change in control such that the private company exception pursuant to Q &amp; A #7 of the regulations promulgated under Section 280G of the Code is applicable and (ii) you request that Pyxis seek shareholder approval of the portion of any payments to be made to you which are parachute payments under Section 280G and exceed 2.99 times your &#x201c;base amount&#x201d; (as such term is defined in Section 280G) in order that, upon obtaining such approval, all of the payments will be exempt from the excise taxes imposed under Sections 280G and 4999 of the Code, Pyxis shall use its reasonable best efforts to obtain such approval.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:7.602%;text-indent:0.0%;display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.607220935518085%;">11.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Miscellaneous.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Letter, along with the Proprietary Information Agreement and the equity documents referenced in Section 3(c) above (which are separate agreements and governed in full by their own terms and conditions), forms the complete and exclusive statement of your agreement with the Company regarding the subject matter herein. This Letter supersedes, extinguishes, and replaces in their entirety all other prior agreements and/or representations, whether oral or written, with</font><font style="color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">respect to your employment compensation, benefits and terms with the Company (including the Prior Letter).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:10.068%;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.065%;min-width:9.87%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3643897564274687%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Your employment with Pyxis is subject to all written Company policies and procedures, and Pyxis retains the right to change its policies or procedures at any time. Such policies may include, without limitation, stock ownership guidelines, clawback policies, insider trading policies and policies regarding hedging or pledging of Pyxis Common Stock.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:10.204%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.065%;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3643897564274687%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Letter may be executed in several counterparts, each of which shall be deemed to be an original but all of which together will constitute one and the same instrument.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:10.204%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.065%;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3643897564274687%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Neither this Letter nor any of your rights or obligations hereunder shall be assignable by you. Pyxis may assign this Letter or any of its obligations hereunder to any subsidiary of Pyxis, or to any successor (whether by merger, purchase or otherwise) to all or substantially all of the equity, assets or businesses of Pyxis. This Letter is intended to bind and inure to the benefit of and be enforceable to you and Pyxis and Pyxis&#x2019;s permitted successors and assigns.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:10.204%;font-size:0;margin-top:4.5pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.065%;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3643897564274687%;">d.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No provision of this Letter may be modified, waived or discharged unless such waiver, modification or discharge is agreed to in writing and signed by you and such officer or director as may be designated by the Board. No waiver by either party hereto at any time of any breach by the other party hereto of, or compliance with, any condition or provision of this Letter to be performed by such other party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same or at any prior or subsequent time.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:10.204%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.065%;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3643897564274687%;">e.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The validity, interpretation, construction and performance of this Letter shall be governed by the laws of the Commonwealth of Massachusetts without regard to the choice of law principles thereof.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:24.933%;text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:25.065%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">remainder of page intentionally left blank</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">]</font></p>
  <p style="margin-left:10.933%;text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.065%;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.791%;font-size:10.0pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.111%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the foregoing is acceptable, please indicate your agreement by signing below and returning the original signed Letter (keeping a copy for your own records) to me. If you have any further questions or require additional information, please feel free to contact me.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sincerely,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PYXIS ONCOLOGY, INC.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:13.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:-12.988%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:41.083%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By: </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ John Flavin</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">                                              </font><font style="color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">		</font><font style="color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:0.933%;text-indent:-12.987%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:41.065%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">John Flavin</font></p>
  <p style="margin-left:0.933%;text-indent:-12.987%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:41.065%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chairman of the Board of Directors</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:13.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:13.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:11.55pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ACCEPTED AND AGREED</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:14.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.933%;text-indent:-12.987%;padding-left:6.667%;font-size:10.0pt;margin-top:0.3pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:41.065%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Lara Sullivan                                               </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font></p>
  <p style="margin-left:0.933%;text-indent:-12.987%;padding-left:6.667%;font-size:10.0pt;margin-top:0.65pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:41.065%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lara S. Sullivan, M.D., MBA</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 18, 2022	</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Appendices:	Appendix A &#x2014; Approved Activities</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">	&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.074%;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Appendix A</font></p>
  <p style="margin-left:30.2%;text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:32.38%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">APPROVED ACTIVITIES</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:22.893%;text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:25.065%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None</font></p>
  <p style="margin-left:22.893%;text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:25.065%;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>4
<FILENAME>pyxs-ex10_22.htm
<DESCRIPTION>EX-10.22
<TEXT>
<html>
 <head>
  <title>EX-10</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 10.22</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pyxis Oncology, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">November 21, 2022</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Via Email Only</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">pconnealy@pyxisoncology.com</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ms. Pamela Connealy</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RE:	AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dear Ms. Connealy:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On behalf of Pyxis Oncology, Inc. (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Pyxis</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;, or the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), it is my pleasure to confirm the terms and conditions of your employment as Pyxis&#x2019;s Chief Financial Officer, reporting to the Company&#x2019;s Chief Executive Officer (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">CEO</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), commencing on July 19, 2021 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Start Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).  During your employment with Pyxis, you will devote substantially all of your professional efforts to the business of Pyxis, except that you may engage in the business activities described on </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Appendix A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of this employment agreement (this &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), and other activities that may be approved in advance by the Company&#x2019;s Chief Executive Officer, with advice from the Board (which together with the activities set forth on </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Appendix A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> may include one for-profit board membership(s)), in each case, so long as these activities do not interfere or conflict with your obligations to the Company. Your employment under the terms of this Agreement shall continue until it terminates in accordance with </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> below.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Agreement supersedes, amends and restates in all respects all prior agreements and understandings between you and the Company regarding the subject matter herein.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Agreement is intended to summarize some of the terms and conditions of your employment.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Location</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Your primary place of employment will be remote from a location you select.  From time to time you will be required to travel to Pyxis&#x2019;s principal offices in the Boston-metropolitan area or other locations as determined by the CEO. You will be reimbursed for any travel expenses from your place of residence to Pyxis offices and Pyxis meetings when work activities necessitate in-person presence.  If permanent or semi-permanent relocation to or near the Company&#x2019;s principal offices is required, then the Company will provide a customary relocation package to the extent any such expenses are not able to be reimbursed by the Company under its travel and entertainment policies.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">    &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">    &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Compensation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.8457544394060026%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Base Salary</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Your initial annualized base salary rate will be $430,000, less standard deductions and withholding and payable bi-weekly in accordance with Pyxis&#x2019;s regular payroll practices.  Your salary shall be reviewed annually and may be adjusted in connection with any such review.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.8457544394060026%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Bonus Program</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. You will be eligible for an annual target bonus of 45% of your annual base salary, as determined by the Board in its sole discretion based upon, among other things, the achievement of pre-determined performance milestones.  Any annual bonus, if earned, shall be paid no later than March 15</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:8.040000000000001pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of the year immediately following the year to which the applicable annual bonus relates.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.8457544394060026%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Option Grants.  </font></div></div>
  <div style="text-indent:21.733%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:21.731%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.0%;">i.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On the earliest to occur of the commencement of your service to the Company as a consultant or an employee, you will be granted an option to purchase 1.25% of shares of Pyxis&#x2019;s common stock (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Initial Option Grant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), vesting 25% on the first anniversary of your Start Date, and thereafter in 36 equal, monthly installments until fully-vested, on the fourth anniversary of your Start Date.</font></div></div>
  <div style="text-indent:21.733%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:21.731%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.0%;">ii.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On the 60th day following the first to occur of the date on which (x) the Company has registered a class of securities pursuant to Section 12(b) or subject to Section 15(d) of the Securities Exchange Act of 1934 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Exchange Act</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), or (y) the Company is subject to the periodic and current reporting requirements of Section 13 or 15(d) of the Exchange Act (each such date, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Measurement Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), you will be granted an additional option to purchase the number of shares of Pyxis common stock such that the number of shares subject to this option </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">plus</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> the number of shares of the Initial Option Grant will equal 1% of the total outstanding shares of the Company on the Measurement Date (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Additional Option Grant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), subject to the Market Cap Limitation (as defined below).  The term &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Market Cap Limitation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means, if the Measurement Date is on or before the nine-month anniversary of the Start Date, a Market Cap (as defined below) of $1,000,000,000, or if the Measurement Date is after the nine-month anniversary of the Start Date, a Market Cap of  $2,000,000,000. The term &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Market Cap</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means, as calculated on a daily basis during the 60-day period ending on the Measurement Date, the averages of the closing per share price of the Company&#x2019;s common stock </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">multiplied by</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> the number of outstanding shares of the Company as of such day.  The Market Cap Limitation shall be applied in the following manner: If the Company exceeds the applicable Market Cap Limitation, then the Additional Option Grant shall be reduced (if any) so that the Black-Scholes value of the Initial Option Grant and the Additional Option Grant is equal to 1% of the applicable Market Cap Limitation.  Any Additional Option Grant shall vest on the same basis as the Initial Option Grant.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">    &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:21.733%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:21.731%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.0%;">iii.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The option grant is subject to the terms of Pyxis&#x2019;s equity incentive arrangements, including its customary Incentive Stock Option (ISO) Grant Agreement.         </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.8457544394060026%;">d.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Withholding.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pyxis shall withhold from any compensation or benefits payable to you by Pyxis any federal, state and/or local income, employment and/or other similar taxes as may be required to be withheld pursuant to any applicable law or regulation.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Benefits</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.8457544394060026%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. You will be eligible to participate in the benefits to be offered by Pyxis on the same terms and conditions as it will make such benefits available to similarly situated senior executives of the Company.  The benefits are currently expected to include health insurance and such other benefits provided by similar companies of a similar stage, as approved by the Board.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.8457544394060026%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expenses</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pyxis shall reimburse you for all reasonable expenses of the type authorized by Pyxis and incurred by you in the performance of your duties under this Agreement, all in accordance with the Company&#x2019;s reimbursement policies.  </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As is the case of all employee benefits, such benefits will be governed by the terms and conditions of applicable Pyxis plans or policies, which are subject to change or discontinuation at any time.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Severance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.8457544394060026%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Definitions.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  For purposes of this Agreement:  </font></div></div>
  <div style="text-indent:21.733%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:21.731%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.0%;">i.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accrued Benefits</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means: (i) any unpaid base salary for services rendered prior to the date of termination of employment; (ii) any earned but unpaid annual bonus for any completed fiscal year prior to the year in which termination of employment occurs; (iii) reimbursement of any unreimbursed business expenses incurred as of the date of termination of employment in accordance with Pyxis&#x2019;s reimbursement policy, (iv) accrued but unused vacation (if applicable), earned through the date of termination of employment; and (v) all other payments, benefits or fringe benefits to which you shall be entitled under the terms of any applicable compensation arrangement or benefit, equity or fringe benefit plan or program or grant with or by Pyxis or this Agreement. </font></div></div>
  <div style="text-indent:20.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:20.0%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.0%;">ii.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cause</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means conduct involving one or more of the following by you: (i) failure to perform a substantial portion of your duties and responsibilities in accordance with the terms or requirements of this Agreement and your position, which failure continues for, or is not permanently cured within, a period of 30 days after written notice given to you by Pyxis, except in the case of your physical or mental illness; (ii) disloyalty, gross negligence, willful misconduct, or dishonesty that materially injures Pyxis or a breach of fiduciary duty to Pyxis; (iii) the conviction of (x) a felony or (y) a misdemeanor involving moral turpitude, or fraud;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(iv) the commission of an act of embezzlement or fraud; or (v) the material breach of any agreement between Pyxis and you. </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">    &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:20.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:20.0%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.0%;">iii.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Change in Control</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; shall mean the occurrence of any of the following events: (A) the consummation of merger, consolidation or similar transaction involving (directly or indirectly) the Company and, immediately after the consummation of such transaction, the stockholders of the Company immediately prior thereto do not hold, directly or indirectly, voting securities representing more than 50% of the outstanding voting power of the surviving entity; or (B) the sale of all or substantially all of the Company&#x2019;s stock or assets.</font></div></div>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:20.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:20.0%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.0%;">iv.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Good Reason</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means, without your express written consent, (i) any reduction in your annual base salary other than a reduction which is proportional to general reductions affecting other senior executive officers of Pyxis generally, or (ii) any material reduction in your title or scope of responsibilities without your consent.</font></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Severance Benefits and Payment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  </font></div></div>
  <div style="text-indent:18.4%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:18.398%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.0%;">i.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Generally</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  If your employment with Pyxis is terminated (x) by Pyxis for any reason other than Cause, or (y) by you for Good Reason, Pyxis will pay you (1) the Accrued Benefits; (2) subject to your compliance with </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 4(c)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> below, after the execution and delivery of the Separation Agreement and General Release in the form attached hereto as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Appendix B</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Separation Agreement and General Release</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) and the expiration of any revocation period without the release being revoked, nine (9) months&#x2019; base salary, less standard deductions, payable in bi-weekly installments in accordance with the Company&#x2019;s regular payroll policies; and (3) if you elect to continue your health insurance coverage pursuant to your rights under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">COBRA</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), following the termination of your employment, your monthly premium under COBRA (plus tax gross-up) on a monthly basis until the earlier of (x) nine (9) months following the effective termination date, or (y) the date upon which you commence full-time employment (or employment that provides you with eligibility for healthcare benefits substantially comparable to those provided by Pyxis).  A termination of your employment by Pyxis due to physical or mental illness which is not a Disability (as defined herein) shall be treated as an involuntary termination other than for Cause.  The term &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Disability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; shall mean that you have not been able to materially engage in your duties and responsibilities by reason of any medically determinable physical or mental impairment for a period of not less than 120 consecutive days or not less than 180 days during any one-year period.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">    &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:18.4%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:18.398%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.0%;">ii.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">In connection with the Change in Control Period.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></div></div>
  <div style="text-indent:23.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:23.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.545020659184814%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If your employment with Pyxis is terminated (x) by Pyxis for any reason other than Cause, or (y) by you for Good Reason during the Change in Control Period, Pyxis will pay you (1) the Accrued Benefits; (2) subject to your compliance with </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 4(c)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> below, after the execution and delivery of the Separation Agreement and General Release and the expiration of any revocation period without the release being revoked, twelve (12) months&#x2019; base salary plus your annual bonus at one hundred percent (100%) of target, less standard deductions, payable in a single lump sum on the 60</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:8.040000000000001pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> day following the termination of your employment; and (3) if you elect to continue your health insurance coverage pursuant to your rights under COBRA following the termination of your employment, your monthly premium under COBRA (plus a tax gross-up) on a monthly basis until the earlier of (x) twelve (12) months following the effective termination date, or (y) the date upon which you commence full-time employment (or employment that provides you with eligibility for healthcare benefits substantially comparable to those provided by Pyxis).  A termination of your employment by Pyxis due to physical or mental illness which is not a Disability shall be treated as an involuntary termination other than for Cause.</font></div></div>
  <div style="text-indent:23.585%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.065%;min-width:23.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.545020659184814%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to the severance benefits and payments set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5(b)(ii)(1)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, if your employment with Pyxis is terminated during the Change in Control Period (x) by Pyxis for any reason other than Cause or (y) by you for Good Reason, then the Equity Grants shall immediately vest with respect to 100% of the shares subject to the Equity Grants and become exercisable; provided, however, that if the Company or its successor entity (if applicable) does not assume, substitute or continue the unvested portion of any Equity Grants in connection with the Change in Control, then 100% of the unvested portion of the applicable Equity Grants will vest and the applicable Equity Grants will become exercisable immediately prior to the date of the Change in Control, contingent on the consummation of the Change in Control.</font></div></div>
  <p style="margin-left:23.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.8457544394060026%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Eligibility for Severance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Eligibility for receipt of the items in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 4(b)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  above, shall be conditioned on your (i) returning to Pyxis promptly upon termination of your employment all of its property, including confidential information and all electronically stored information, and (ii) signing and not revoking the Separation Agreement and General Release.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.8457544394060026%;">d.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accrued Benefits</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Accrued Benefits shall be paid to you (or your estate in the event of your death) upon termination of employment regardless of the circumstances giving rise to such termination.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At-Will Employment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Your employment with Pyxis is at will, meaning it may be terminated by you or Pyxis at any time, subject to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> above, for any reason with or without Cause. You understand that this Agreement is not a contract for employment for a definite term.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Confidentiality and Proprietary Rights Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  This offer of employment is subject to the Confidentiality and Proprietary Rights Agreement attached as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Appendix C</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which shall be effective as of the date set forth therein.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">    &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">7.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No Inconsistent Obligations</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  By accepting this offer of employment, you represent and warrant to Pyxis that you are under no obligations or commitments, whether contractual or otherwise, that are inconsistent with your obligations set forth in this Agreement or that would be violated by your employment by Pyxis.  You agree that you will not take any action on behalf of Pyxis or cause Pyxis to take any action that will violate any agreement that you have with a prior employer.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">8.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delayed Commencement Date for Payments and Benefits</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The intent of the parties hereto is that payments and benefits under this Agreement comply with, or be exempt from, Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations and guidance promulgated thereunder (collectively &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Code Section 409A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted to be in compliance therewith or exempt therefrom.  If you notify Pyxis (with specificity as to the reason therefor) that you believe that any provision of this Agreement (or of any award of compensation, including equity compensation or benefits) would cause you to incur any additional tax or interest under Code Section 409A and Pyxis concurs with such belief or Pyxis independently makes such determination, Pyxis shall, after consulting with you, reform such provision to try to comply with Code Section 409A through good faith modifications to the minimum extent reasonably appropriate to conform with Code Section 409A. To the extent that any provision hereof is modified in order to comply with Code Section 409A, such modification shall be made in good faith and shall, to the maximum extent reasonably possible, maintain the original intent and economic benefit to you and Pyxis of the applicable provision without violating the provisions of Code Section 409A.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits upon or following a termination of employment that are considered &#x201c;nonqualified deferred compensation&#x201d; under Code Section 409A unless such termination is also a &#x201c;separation from service&#x201d; within the meaning of Code Section 409A and, for purposes of any such provision of this Agreement, references to a &#x201c;termination,&#x201d; &#x201c;termination of employment&#x201d; or like terms shall mean &#x201c;separation from service.&#x201d; Notwithstanding any provision to the contrary in this Agreement, no payments or benefits that are considered &#x201c;nonqualified deferred compensation&#x201d; under Code Section 409A to which you otherwise become entitled under this Agreement in connection with your termination of employment, shall be made or provided to you prior to the earlier of (i) the expiration of the 6 month period measured from the date of your &#x201c;separation from service&#x201d; with Pyxis (as such term is defined in Code Section 409A) or (ii) the date of your death, if you are deemed at the time of such separation from service to be a &#x201c;specified employee&#x201d; under Code Section 409A and if, in the absence of such delay, the payments would be subject to additional tax under Code Section 409A. Upon the expiration of the applicable Code Section 409A(a)(2) deferral period, all payments and benefits deferred pursuant to this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 8(b)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (whether they would have otherwise been payable in a single sum or in installments in the absence of such deferral) shall be paid or reimbursed to you in a lump sum, and any remaining payments and benefits due under this Agreement shall be paid or provided in accordance with the normal payment dates specified for them herein.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">    &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For purposes of Code Section 409A, your right to receive any installment<br>payment pursuant to this Agreement shall be treated as a right to receive a series of separate and distinct payments.  Whenever a payment under this Agreement specifies a payment period with reference to a number of days (</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">e.g.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, &#x201c;payment shall be made within 30 days following the date of termination&#x201d;), the actual date of payment within the specified period shall be within the sole discretion of Pyxis.  Notwithstanding any other provision of this Agreement to the contrary, in no event shall any payment under this Agreement that constitutes &#x201c;nonqualified deferred compensation&#x201d; for purposes of Code Section 409A be subject to offset, counterclaim or recoupment by any other amount payable to you unless otherwise permitted by Code Section 409A.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">d.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by Pyxis or incurred by you during the time periods set forth in this Agreement.  All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred.  The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year.  Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">e.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If under this Agreement an amount is to be paid in installments, each installment shall be treated as a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2)(iii).  </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">    &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">280G</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the event that the amount of any compensation, payment or distribution by Pyxis or its affiliates to or for your benefit, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with Section 280G of the Code and the applicable regulations thereunder (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Aggregate Payments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) would be subject to the excise tax imposed by Section 4999 of the Code, then the Aggregate Payments shall be reduced (but not below zero) so that the sum of all of the Aggregate Payments shall be $1.00 less than the amount at which you become subject to the excise tax imposed by Section 4999 of the Code; provided that such reduction shall only occur if it would result in you receiving a higher After Tax Amount (as defined below) than you would receive if the Aggregate Payments were not subject to such reduction.  In such event, the Aggregate Payments shall be reduced in the following order, in each case, in reverse chronological order beginning with the Aggregate Payments that are to be paid the furthest in time from consummation of the transaction that is subject to Section 280G of the Code: (i) cash payments not subject to Section 409A of the Code; (ii) cash payments subject to Section 409A of the Code; (iii) equity-based payments and acceleration; and (iv) non-cash forms of benefits; provided that in the case of all the foregoing Aggregate Payments all amounts or payments that are not subject to calculation under Treas. Reg. &#167; 1.280G-1, Q&amp;A-24(b) or (c) shall be reduced before any amounts that are subject to calculation under Treasury Regulation &#167;1.280G-1, Q&amp;A- 24(b) or (c).  For purposes of this Section 9, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">After Tax Amount</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means the amount of the Aggregate Payments less all federal, state, and local income, excise and employment taxes imposed on you as a result of your receipt of the Aggregate Payments.  For purposes of determining the After Tax Amount, you shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination is to be made, and state and local income taxes at the highest marginal rates of individual taxation in each applicable state and locality, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes.  The determination as to whether a reduction in the Aggregate Payments shall be made pursuant to this Section 9 shall be made by a nationally recognized accounting firm or a firm specializing in Section 280G calculations selected by Pyxis, which shall provide detailed supporting calculations both to Pyxis and you.  The costs of obtaining such determination and all related fees and expenses (including related fees and expenses incurred in any later audit) shall be borne by Pyxis.  Notwithstanding the foregoing, if (i) Pyxis is not publicly traded prior to the occurrence of a change in control such that the private company exception pursuant to Q &amp; A #7 of the regulations promulgated under Section 280G of the Code is applicable and (ii) you request that Pyxis seek shareholder approval of the portion of any payments to be made to you which are parachute payments under Section 280G and exceed 2.99 times your &#x201c;base amount&#x201d; (as such term is defined in Section 280G) in order that, upon obtaining such approval, all of the payments will be exempt from the excise taxes imposed under Sections 280G and 4999 of the Code, Pyxis shall use its reasonable best efforts to obtain such approval.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">    &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;text-indent:0.0%;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">10.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Miscellaneous</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This offer of employment is made subject to you having the legal right to work in the United States.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Your employment with Pyxis is subject to all Company policies and procedures, and Pyxis retains the right to change its policies or procedures at any time.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Agreement may be executed in several counterparts, each of which shall be deemed to be an original but all of which together will constitute one and the same instrument.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">d.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Neither this Agreement nor any of your rights or obligations hereunder shall be assignable by you.  Pyxis may assign this Agreement or any of its obligations hereunder to any subsidiary of Pyxis, or to any successor (whether by merger, purchase or otherwise) to all or substantially all of the equity, assets or businesses of Pyxis.  This Agreement is intended to bind and inure to the benefit of and be enforceable to you and Pyxis and Pyxis&#x2019;s permitted successors and assigns.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">e.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No provision of this Agreement may be modified, waived or discharged unless such waiver, modification or discharge is agreed to in writing and signed by you and such officer or director as may be designated by the Board.  No waiver by either party hereto at any time of any breach by the other party hereto of, or compliance with, any condition or provision of this Agreement to be performed by such other party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same or at any prior or subsequent time.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">f.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the Commonwealth of Massachusetts without regard to the choice of law principles thereof.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">remainder of page intentionally left blank</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">    &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the foregoing is acceptable, please indicate your agreement by signing below and returning the original signed Agreement (keeping a copy for your own records) to me on or before June 20, 2021.  If you have any further questions or require additional information, please feel free to contact me.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sincerely,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PYXIS ONCOLOGY, INC.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.933%;text-indent:-12.987%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:41.065%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Lara Sullivan					</font></p>
  <p style="margin-left:0.933%;text-indent:-12.987%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:41.065%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lara S. Sullivan, M.D.</font></p>
  <p style="margin-left:0.933%;text-indent:-12.987%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:41.065%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President &amp; Chief Executive Officer</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ACCEPTED AND AGREED</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.933%;text-indent:-12.987%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:41.065%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Pam Connealy							</font></p>
  <p style="margin-left:0.933%;text-indent:-12.987%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:41.065%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pam Connealy</font></p>
  <p style="margin-left:0.933%;text-indent:-12.987%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:41.065%;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.933%;text-indent:-12.987%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:41.065%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">November 21, 2022					</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Appendices:	Appendix A &#x2014; Approved Activities</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	                Appendix B &#x2014; Separation Agreement and General Release</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	                Appendix C &#x2014; Confidentiality and Proprietary Rights Agreement</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">    &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.0%;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Appendix A</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.0%;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.0%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">APPROVED ACTIVITIES</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.0%;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Board Director &amp; Audit Committee Chair of Orchestra Biomed</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Advisor Perfuse Therapeutics</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Appendix B</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.0%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SEPARATION AGREEMENT AND GENERAL RELEASE</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Note: This form is not to be signed until the termination of Employee&#x2019;s employment.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">THIS SEPARATION AGREEMENT AND GENERAL RELEASE </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(this &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) is made and entered into as of ______________ ___, 20__ (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) by and between </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PYXIS ONCOLOGY, INC.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, having an address at [company address] (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Pyxis</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), and [employee], residing at [address] (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Employee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WHEREAS, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the parties desire to set forth in this Agreement the terms upon which they have mutually agreed to an orderly termination of Employee&#x2019;s employment with Pyxis;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOW THEREFORE, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in consideration of the mutual agreements and other consideration contained in this Agreement, the parties agree as follows:</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Severance and Other Benefits</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  In accordance with the terms of the executive employment agreement between Pyxis and Employee, dated [date], 2021 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Employment Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), which is attached hereto and incorporated herein as Attachment A, Pyxis agrees to pay Employee the severance benefits set forth in Section 4 of the Employment Agreement in accordance with the terms thereof.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Release</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  In consideration for the payments made pursuant to Section 1 above, Employee, on behalf of Employee, Employee&#x2019;s heirs, executors, administrators, successors and assigns, hereby releases, acquits and forever discharges Pyxis and any and all of its current or former subsidiaries and other affiliated entities and benefit plans, as well as its and/or their officers, directors, representatives, attorneys, agents, servants, employees, stockholders, successors, predecessors and affiliates, each in their respective capacities from any and all claims, liabilities, demands, causes of action, costs, expenses, attorneys&#x2019; fees, damages, indemnities and obligations of every kind and nature, in law, in equity or otherwise, known or unknown, suspected and unsuspected, disclosed and undisclosed, arising out of or in any way related to agreements, acts or conduct at any time as of or prior to the Effective Date, including, but not limited to: all such claims or demands arising from Employee&#x2019;s employment or the termination of Employee&#x2019;s employment; all such claims and demands related to salary, bonuses, commissions, stock, stock options (except as provided in Section 4 of the Employment Agreement), expense reimbursements, or any form of compensation; claims pursuant to any federal, state or local law or cause of action including, but not limited to, the Federal Civil Rights Acts of 1964, as amended, the Age Discrimination in Employment Act of 1967, as amended, or any law or legal principle of similar effect in any other relevant jurisdiction; contract claims; tort claims; or claims of wrongful discharge, discrimination, fraud, defamation, and emotional distress.  Employee further agrees not to sue or otherwise institute or cause to be instituted or in any way voluntarily participate in the prosecution of any complaints or charges against any persons or entities released herein in any federal, state or other court, administrative agency or other forum concerning any claims released herein.  Notwithstanding the foregoing, this release by Employee excludes (i) any rights to payment under Section 4 of the Employment Agreement, (ii) any rights to vested accrued benefits and compensation under the Company&#x2019;s applicable plans and arrangements (including with respect to equity awards), (iii) any right to indemnification by the Company or its affiliates and (iv) any right to coverage under applicable directors&#x2019; and officers&#x2019; or other third party liability insurance policies.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Noncompetition and Nonsolicitation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Employee agrees and acknowledges that the non-solicitation restrictions set forth in the Confidentiality and Proprietary Rights Agreement between Pyxis and Employee, dated [date] (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Confidentiality and Proprietary Rights Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), remain in full force and effect until the one-year anniversary of the date of Employee&#x2019;s termination (i.e., until [date]).  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional Covenants</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The parties covenant and agree that for a one-year period following the Effective Date, each shall refrain from making any defamatory, derogatory or other unfavorable statements regarding the other or, in the case of Employee, Pyxis&#x2019;s business, officers, directors, employees and agents.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Confidentiality</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Except for his own attorney, his tax advisor and his immediate family, Employee agrees that the existence and the terms of this Agreement shall be confidential, and that he, his attorney, his tax advisor and his immediate family will not disclose any information concerning the terms of this Agreement to anyone, including but not limited to past, present or future employees of Pyxis.  In addition, Employee is party to and bound by the provisions of the Confidentiality and Proprietary Rights Agreement, including with respect to confidentiality. </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No Admission</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Employee understands and agrees that nothing contained in this Agreement is to be considered an admission by Pyxis of any wrongdoing under any federal, state or local statute, regulation, public policy, tort law, contract law, common law.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">7.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Acknowledgement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  Employee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">acknowledges that he has read and understands this Agreement and executes it knowingly, voluntarily and without coercion.  Employee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">acknowledges that he is being advised herein in writing to consult with an attorney prior to executing this Agreement, that he has consulted with an attorney, and he has been given a period of at least 21 days within which to consider and execute this Agreement, unless he voluntarily chooses to execute this Agreement before the end of the 21 day period by executing the attached Election to Execute Prior to Expiration of 21 Day Consideration Period.  Employee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">understands that he has 7 days following his execution of this Agreement to revoke his execution of this Agreement.  The Effective Date of this Agreement shall be the 8th day after it is executed and has not been revoked.  For any revocation to be effective, written notice of revocation must be delivered to Pyxis, attention: Chairman of the Board, no later than 5:00 p.m. on the 7th calendar day after Employee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">signs this Agreement.  If Employee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">revokes this Agreement, it shall not be effective or enforceable and he shall not receive the benefits described herein.  No payments shall be made under the terms of this Agreement until the 7-day revocation period described in this paragraph has expired without revocation by Employee.</font></div></div>
  <div style="text-indent:7.467%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:7.463%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">8.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Modifications</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  This Agreement may not be modified in any way except in a written agreement signed by both Employee and an authorized representative of Pyxis.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">9.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Governing Law</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. This Agreement shall be governed by, and construed in accordance with, the laws of the Commonwealth of Massachusetts without giving effect to its conflict of law provisions.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">10.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Entire Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  This Agreement constitutes the entire agreement and understanding between the parties relating to Employee&#x2019;s separation from Pyxis.  Employee acknowledges and agrees that in executing this Agreement, Employee has not relied on any promises or representations other than those set forth in this Agreement.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[For the avoidance of doubt, this Agreement does not alter, amend or otherwise change the rights or obligations of Employee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">or Pyxis in respect of grants of any stock options or other equity compensation provided to Employee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">on ______, ______ and _____</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">]</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IN WITNESS THEREOF, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee and Pyxis, after carefully reading the provisions of this Agreement, herein declare that they understand such provisions and willingly accept and agree thereto by executing this Agreement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pyxis Oncology, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	 	By:	</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">		Title:	</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">		Date:	</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Form agreement not to be signed</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">			&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">                [Employee]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	             Date:	</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ELECTION TO EXECUTE PRIOR TO EXPIRATION<br>OF 21 DAY CONSIDERATION PERIOD</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, [name], understand that I have at least 21 days within which to consider and execute the foregoing Separation Agreement and General Release.  However, after having an opportunity consult counsel, I have freely and voluntarily elected to execute the Separation Agreement and General Release before the 21 day period has expired.</font></p>
  <p style="text-indent:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">						&#160;</font></p>
  <p style="margin-left:13.333%;text-indent:38.461%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[employee name]</font></p>
  <p style="margin-left:13.333%;text-indent:38.461%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date:</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">						</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.0%;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Appendix C</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.0%;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.0%;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Confidentiality and Proprietary Rights Agreement</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[on file with Company]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>5
<FILENAME>pyxs-ex10_23.htm
<DESCRIPTION>EX-10.23
<TEXT>
<html>
 <head>
  <title>EX-10</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 10.23</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pyxis Oncology, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">November 21, 2022</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Via Email Only</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">jwadhane@pyxisoncology.com</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RE:	EXECUTIVE EMPLOYMENT AGREEMENT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dear Mr. Wadhane:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Employment Agreement (this &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) memorializes the employment terms offered to you by Pyxis Oncology, Inc. (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Pyxis</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; or the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).  This Agreement (including all amended and restated terms herein) will supersede and replace in full the prior Offer Letter, entered into by and between you and the Company dated August 10</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:8.040000000000001pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, 2021 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Prior Letter</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), and it will become effective as of November 21</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:8.040000000000001pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, 2022.  This Agreement is intended to summarize the terms and conditions of your continued employment with Pyxis.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Position</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  You will continue to serve as the Company&#x2019;s SVP, Chief Accounting Officer, and you will continue to report to the Company&#x2019;s Chief Financial Officer (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">CFO</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).  During your employment with Pyxis, you will devote your full time and best efforts to the business of Pyxis, except that you may engage in the business activities described on </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Appendix A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of this Agreement, and other activities that may be approved in advance in writing by the Board of Directors of the Company (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Board</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Location</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Your primary place of employment will be remote from a location you select.  From time to time you will be required to travel to Pyxis&#x2019;s principal offices in the Boston-metropolitan area or other locations as determined by the CFO. You will be reimbursed for any travel expenses from your place of residence to Pyxis offices and Pyxis meetings when work activities necessitate in-person presence.  If permanent or semi-permanent relocation to or near the Company&#x2019;s principal offices is required, then the Company will provide a customary relocation package to the extent any such expenses are not able to be reimbursed by the Company under its travel and entertainment policies.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Compensation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.8457544394060026%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Base Salary</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Your annualized base salary rate will be $362,010, less standard deductions and withholding and payable bi-weekly in accordance with Pyxis&#x2019;s regular payroll practices.  Your salary shall be reviewed annually and may be adjusted in connection with any such review.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.8457544394060026%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Bonus Program</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. You will be eligible for an annual target bonus of 40% of your then-current base salary, as determined by the Board in its sole discretion based upon, among other things, the achievement of pre-determined performance milestones.  Any annual bonus, if earned, shall be paid no later than March 15</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:8.040000000000001pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of the year immediately following the year to which the applicable annual bonus relates.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.8457544394060026%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Withholding. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pyxis shall withhold from any compensation or benefits payable to you by Pyxis any federal, state and/or local income, employment and/or other similar taxes as may be required to be withheld pursuant to any applicable law or regulation.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Benefits</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.8457544394060026%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Generally</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  You will be eligible to participate in the benefits to be offered by Pyxis on the same terms and conditions as it will make such benefits available to similarly situated senior executives of the Company.  The benefits are currently expected to include health insurance and such other benefits provided by similar companies of a similar stage, as approved by the Board.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.8457544394060026%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expenses</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pyxis shall reimburse you for all reasonable business expenses incurred by you in the performance of your duties under this Agreement, all in accordance with the Company&#x2019;s reimbursement policies.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.8457544394060026%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Terms</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  As is the case of all employee benefits, such benefits will be governed by the terms and conditions of applicable Pyxis plans or policies, which are subject to change or discontinuation at any time.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Severance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.8457544394060026%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Definitions.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  For purposes of this Agreement:  </font></div></div>
  <div style="text-indent:21.733%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:21.731%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.0%;">i.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accrued Benefits</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means: (i) any unpaid base salary for services rendered prior to the date of termination of employment; (ii) any earned but unpaid annual bonus for any completed fiscal year prior to the year in which termination of employment occurs; (iii) reimbursement of any unreimbursed business expenses incurred as of the date of termination of employment in accordance with Pyxis&#x2019;s reimbursement policies; (iv) accrued but unused vacation (if applicable), earned through the date of termination of employment; and (v) all other payments, benefits or fringe benefits to which you shall be entitled under the terms of any applicable compensation arrangement or benefit, equity or fringe benefit plan or program or grant with or by Pyxis or this Agreement. </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:20.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:20.0%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.0%;">ii.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cause</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means conduct involving one or more of the following by you: (i) material failure to perform a substantial portion of your duties and responsibilities in accordance with the terms or requirements of this Agreement and your position, except in the case of your physical or mental illness; (ii) disloyalty, gross negligence, willful misconduct, or dishonesty that materially injures Pyxis or a breach of fiduciary duty to Pyxis; (iii) the conviction of (x) a felony or (y) a misdemeanor involving moral turpitude or fraud that materially injures Pyxis;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(iv) the commission of an act of embezzlement or fraud; or (v) your material breach of this Agreement or any other written agreement between Pyxis and you; provided, in the case of clauses (i), (ii) and (v), that the Company provides you with written notice that specifically identifies the conduct that the Company believes to constitute Cause, and you fail to remedy such conduct within 15 days following your receipt of such notice.  Notwithstanding the foregoing, &#x201c;Cause&#x201d; shall not include or be predicated upon any act or omission by you which is taken or made either at the direction of the Board or the CEO. </font></div></div>
  <div style="text-indent:20.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:20.0%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.0%;">iii.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Change in Control</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means the occurrence of any of the following events: (A) the consummation of a merger, consolidation or similar transaction involving (directly or indirectly) the Company and, immediately after the consummation of such transaction, the stockholders of the Company immediately prior thereto do not hold, directly or indirectly, voting securities representing more than 50% of the outstanding voting power of the surviving entity; or (B) the sale of all or substantially all of the Company&#x2019;s stock or assets.</font></div></div>
  <div style="text-indent:20.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:20.0%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.0%;">iv.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Good Reason</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means, without your express written consent, (i) any reduction in your annual base salary as in effect immediately prior to such reduction other than a reduction which is proportional to general reductions affecting other senior executive officers of Pyxis generally, (ii) any diminution in title or position or a material reduction in your duties or responsibilities, or (iii) a material breach by the Company of this Agreement; provided, in each case, that (a) you provide the Company with written notice that specifically identifies the event that you believe to constitute Good Reason within 30 days after you first have knowledge of such event, (b) the Company fails to remedy such event within 30 days following the Company&#x2019;s receipt of such notice and (c) you actually resign your employment with the Company within 30 days following the end of such 30-day remedy period.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Severance Benefits and Payment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  </font></div></div>
  <div style="text-indent:18.4%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:18.398%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.0%;">i.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Generally</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  If your employment with Pyxis is terminated (x) by Pyxis for any reason other than Cause, or (y) by you for Good Reason, Pyxis will pay you (1) the Accrued Benefits; and (2) subject to your compliance with </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 4(c)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> below, after the execution and delivery of the Separation Agreement and General Release in the form attached hereto as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Appendix B</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Separation Agreement and General Release</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) and the expiration of any revocation period without the release being revoked, (A) nine (9) months&#x2019; base salary, less standard deductions, payable in bi-weekly installments in accordance with the Company&#x2019;s regular payroll policies over the nine (9) month period following such termination of employment, commencing within 60 days following such termination of employment and with the first payment to include the amounts that would have been paid following such termination of employment but were delayed subject to the effectiveness of the Separation Agreement and General Release; and (B) if you elect to continue your health insurance coverage pursuant to your rights under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">COBRA</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), following the termination of your employment, your monthly premium under COBRA (plus tax gross-up) on a monthly basis until the earlier of (1) nine (9) months following the effective termination date, or (2) the date upon which you commence full-time employment (or employment that provides you with eligibility for healthcare benefits substantially comparable to those provided by Pyxis).  A termination of your employment by Pyxis due to physical or mental illness which is not a Disability (as defined herein) shall be treated as an involuntary termination other than for Cause.  The term &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Disability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; shall mean that you have not been able to materially engage in your duties and responsibilities after reasonable accommodation by reason of any medically determinable physical or mental impairment for a period of not less than 90 consecutive days or not less than 120 days during any one-year period.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:18.4%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:18.398%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.0%;">ii.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">In connection with the Change in Control Period.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></div></div>
  <div style="text-indent:20.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:20.0%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.545020659184814%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If your employment with Pyxis is terminated (x) by Pyxis for any reason other than Cause, or (y) by you for Good Reason during the period commencing three (3) months prior to a Change in Control and continuing until the twelve (12) month anniversary of a Change in Control (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Change in Control Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), in lieu of the benefits set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 5(b)(i)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, Pyxis will pay you (1) the Accrued Benefits; (2) subject to your compliance with </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 5(c)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> below, after the execution and delivery of the Separation Agreement and General Release and the expiration of any revocation period without the release being revoked, (A) twelve (12) months&#x2019; base salary plus your annual bonus at one hundred percent (100%) of target, payable in a single lump sum on the 60</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:8.040000000000001pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> day following the termination of your employment (or, if later, on the 60th day following the Change in Control less the base salary continuation previously paid under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 5(b)(i)(2)(A)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">); provided, however, that if the termination of employment occurs within three (3) months prior to the Change in Control and the twelve (12) months&#x2019; of base salary under this clause (2)(A) constitutes non-qualified deferred compensation within the meaning of Section 409A of the Code, then such base salary shall be payable in bi-weekly installments in accordance with the Company&#x2019;s regular payroll practices over the twelve (12) month period following such termination of employment in accordance with </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 5(b)(i)(2)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to the extent required to comply with Section 409A of the Code, and (B) if you elect to continue your health insurance coverage pursuant to your rights under COBRA following the termination of your employment, your monthly premium under COBRA (plus a tax gross-up) on a monthly basis until the earlier of (1) twelve (12) months following the effective termination date, or (2) the date upon which you commence full-time employment (or employment that provides you with eligibility for healthcare benefits substantially comparable to those provided by Pyxis).  A termination of your employment by Pyxis due to physical or mental illness which is not a Disability shall be treated as an involuntary termination other than for Cause.</font></div></div>
  <div style="text-indent:20.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:20.0%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.545020659184814%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to the severance benefits and payments set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 5(b)(ii)(1)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, if your employment with Pyxis is terminated during the Change in Control Period (x) by Pyxis for any reason other than Cause or (y) by you for Good Reason, then the Equity Grants shall immediately vest with respect to 100% of the shares subject to the applicable Equity Grants and become exercisable; provided, however, that if the Company or its successor entity (if applicable) does not assume, substitute or continue the unvested portion of any applicable Equity Grant in connection with the Change in Control, then 100% of the unvested portion of the applicable Equity Grant will vest and become exercisable immediately prior to the date of the Change in Control, contingent on the consummation of the Change in Control.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.8457544394060026%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Eligibility for Severance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Eligibility for receipt of the items in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 5(b)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> above, shall be conditioned on your (i) returning to Pyxis promptly upon termination of your employment all of its property, including confidential information and all electronically stored information, and (ii) signing and not revoking the Separation Agreement and General Release.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.8457544394060026%;">d.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accrued Benefits</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Accrued Benefits shall be paid to you (or your estate in the event of your death) upon termination of employment regardless of the circumstances giving rise to such termination.  </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At-Will Employment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Your employment with Pyxis is at will, meaning it may be terminated by you or Pyxis at any time, subject to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> above, for any reason with or without Cause. You understand that this Agreement is not a contract for employment for a definite term.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">7.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Confidentiality and Proprietary Rights Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  You acknowledge and reaffirm your continuing obligations owed to the Company, pursuant to that certain Proprietary Information and Inventions Agreement, dated as of August 23, 2021 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Proprietary Information Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).  For the avoidance of doubt,  nothing in the Proprietary Information Agreement or otherwise will prohibit or restrict you from responding to any inquiry, or otherwise communicating with, any federal, state or local administrative or regulatory agency or authority or participating in an investigation conducted by any governmental agency or authority.  You cannot be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that is made (A) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney, and (B) solely for the purpose of reporting or investigating a suspected violation of law; or that is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.  As a result, the Company and you shall have the right to disclose trade secrets in confidence to Federal, State, and local government officials, or to an attorney, for the sole purpose of reporting or investigating a suspected violation of law.  Each of the Company and you also have the right to disclose trade secrets in a document filed in a lawsuit or other proceeding, but only if the filing is made under seal and protected from public disclosure.  Nothing in the Proprietary Information Agreement is intended to conflict with that right or to create liability for disclosures of trade secrets that are expressly allowed by the foregoing.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">8.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No Inconsistent Obligations</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  By accepting this offer of continued employment, you represent and warrant to Pyxis that you are under no obligations or commitments, whether contractual or otherwise, that are inconsistent with your obligations set forth in this Agreement or that would be violated by your employment by Pyxis.  You agree that you will not take any action on behalf of Pyxis or cause Pyxis to take any action that will violate any agreement that you have with a prior employer.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">9.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delayed Commencement Date for Payments and Benefits</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.333%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The intent of the parties hereto is that payments and benefits under this Agreement comply with, or be exempt from, Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations and guidance promulgated thereunder (collectively &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Code Section 409A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted to be in compliance therewith or exempt therefrom.  If you notify Pyxis (with specificity as to the reason therefor) that you believe that any provision of this Agreement (or of any award of compensation, including equity compensation or benefits) would cause you to incur any additional tax or interest under Code Section 409A and Pyxis concurs with such belief or Pyxis independently makes such determination, Pyxis shall, after consulting with you, reform such provision to try to comply with Code Section 409A through good faith modifications to the minimum extent reasonably appropriate to conform with Code Section 409A. To the extent that any provision hereof is modified in order to comply with Code Section 409A, such modification shall be made in good faith and shall, to the maximum extent reasonably possible, maintain the original intent and economic benefit to you and Pyxis of the applicable provision without violating the provisions of Code Section 409A.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.333%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits upon or following a termination of employment that are considered &#x201c;nonqualified deferred compensation&#x201d; under Code Section 409A unless such termination is also a &#x201c;separation from service&#x201d; within the meaning of Code Section 409A and, for purposes of any such provision of this Agreement, references to a &#x201c;termination,&#x201d; &#x201c;termination of employment&#x201d; or like terms shall mean &#x201c;separation from service.&#x201d; Notwithstanding any provision to the contrary in this Agreement, no payments or benefits that are considered &#x201c;nonqualified deferred compensation&#x201d; under Code Section 409A, then (i) each such payment which is conditioned upon your execution and non-revocation of the Release and which is to be paid or provided during a designated period that begins in one taxable year and ends in a second taxable year, shall be paid or provided in the later of the two taxable years and (ii) each such payment to which you become entitled under this Agreement in connection with your termination of employment, shall be made or provided to you prior to the earlier of (x) the expiration of the 6 month period measured from the date of your &#x201c;separation from service&#x201d; with Pyxis (as such term is defined in Code Section 409A) or (y) the date of your death, if you are deemed at the time of such separation from service to be a &#x201c;specified employee&#x201d; under Code Section 409A and if, in the absence of such delay, the payments would be subject to additional tax under Code Section 409A. Upon the expiration of the applicable Code Section 409A(a)(2) deferral period, all payments and benefits deferred pursuant to this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 8(b)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (whether they would have otherwise been payable in a single sum or in installments in the absence of such deferral) shall be paid or reimbursed to you in a lump sum, and any remaining payments and benefits due under this Agreement shall be paid or provided in accordance with the normal payment dates specified for them herein. For clarity, a Change in Control shall not be deemed to have occurred for purposes of any provision of this Agreement unless such Change in Control also constitutes a &#x201c;change in control event&#x201d; within the meaning of Code Section 409A.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.333%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For purposes of Code Section 409A, your right to receive any installment<br>payment pursuant to this Agreement shall be treated as a right to receive a series of separate and distinct payments.  Whenever a payment under this Agreement specifies a payment period with reference to a number of days (</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">e.g.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, &#x201c;payment shall be made within 30 days following the date of termination&#x201d;), the actual date of payment within the specified period shall be within the sole discretion of Pyxis.  Notwithstanding any other provision of this Agreement to the contrary, in no event shall any payment under this Agreement that constitutes &#x201c;nonqualified deferred compensation&#x201d; for purposes of Code Section 409A be subject to offset, counterclaim or recoupment by any other amount payable to you unless otherwise permitted by Code Section 409A.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.333%;">d.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by Pyxis or incurred by you during the time periods set forth in this Agreement.  All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred.  The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year.  Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.333%;">e.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If under this Agreement an amount is to be paid in installments, each installment shall be treated as a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2)(iii).  </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">280G</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the event that the amount of any compensation, payment or distribution by Pyxis or its affiliates to or for your benefit, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with Section 280G of the Code and the applicable regulations thereunder (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Aggregate Payments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) would be subject to the excise tax imposed by Section 4999 of the Code, then the Aggregate Payments shall be reduced (but not below zero) so that the sum of all of the Aggregate Payments shall be $1.00 less than the amount at which you become subject to the excise tax imposed by Section 4999 of the Code; provided that such reduction shall only occur if it would result in you receiving a higher After Tax Amount (as defined below) than you would receive if the Aggregate Payments were not subject to such reduction.  In such event, the Aggregate Payments shall be reduced in the following order, in each case, in reverse chronological order beginning with the Aggregate Payments that are to be paid the furthest in time from consummation of the transaction that is subject to Section 280G of the Code: (i) cash payments not subject to Section 409A of the Code; (ii) cash payments subject to Section 409A of the Code; (iii) equity-based payments and acceleration not subject to Section 409A of the Code; (iv) equity-based payments and acceleration subject to Section 409A of the Code; and (v) non-cash forms of benefits; provided that in the case of all the foregoing Aggregate Payments all amounts or payments that are not subject to calculation under Treas. Reg. &#167; 1.280G-1, Q&amp;A-24(b) or (c) shall be reduced before any amounts that are subject to calculation under Treasury Regulation &#167;1.280G-1, Q&amp;A- 24(b) or (c).  For purposes of this Section 9, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">After Tax Amount</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means the amount of the Aggregate Payments less all federal, state, and local income, excise and employment taxes imposed on you as a result of your receipt of the Aggregate Payments.  For purposes of determining the After Tax Amount, you shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination is to be made, and state and local income taxes at the highest marginal rates of individual taxation in each applicable state and locality, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes.  The determination as to whether a reduction in the Aggregate Payments shall be made pursuant to this Section 9 shall be made by a nationally recognized accounting firm or a firm specializing in Section 280G calculations selected by Pyxis, which shall provide detailed supporting calculations both to Pyxis and you.  The costs of obtaining such determination and all related fees and expenses (including related fees and expenses incurred in any later audit) shall be borne by Pyxis.  Notwithstanding the foregoing, if (i) Pyxis is not publicly traded prior to the occurrence of a change in control such that the private company exception pursuant to Q &amp; A #7 of the regulations promulgated under Section 280G of the Code is applicable and (ii) you request that Pyxis seek shareholder approval of the portion of any payments to be made to you which are parachute payments under Section 280G and exceed 2.99 times your &#x201c;base amount&#x201d; (as such term is defined in Section 280G) in order that, upon obtaining such approval, all of the payments will be exempt from the excise taxes imposed under Sections 280G and 4999 of the Code, Pyxis shall use its reasonable best efforts to obtain such approval.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;text-indent:0.0%;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">10.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Miscellaneous</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.333%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Agreement, along with the Proprietary Information Agreement and the equity documents referenced in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 3(c)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> above (which are separate agreements and governed in full by their own terms and conditions), forms the complete and exclusive statement of your agreement with the Company regarding the subject matter herein.  This Agreement supersedes, extinguishes and replaces in their entirety all other prior agreements and/or representations, whether oral or written, with respect to your employment compensation, benefits and terms with the Company (including the Prior Letter).  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.333%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Your employment with Pyxis is subject to all written Company policies and procedures, and Pyxis retains the right to change its policies or procedures at any time.  Such policies may include, without limitation, stock ownership guidelines, clawback policies, insider trading policies and policies regarding hedging or pledging of Pyxis&#x2019;s common stock.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.333%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Agreement may be executed in several counterparts, each of which shall be deemed to be an original but all of which together will constitute one and the same instrument.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.333%;">d.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Neither this Agreement nor any of your rights or obligations hereunder shall be assignable by you.  Pyxis may assign this Agreement or any of its obligations hereunder to any subsidiary of Pyxis, or to any successor (whether by merger, purchase or otherwise) to all or substantially all of the equity, assets or businesses of Pyxis.  This Agreement is intended to bind and inure to the benefit of and be enforceable to you and Pyxis and Pyxis&#x2019;s permitted successors and assigns.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.333%;">e.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No provision of this Agreement may be modified, waived or discharged unless such waiver, modification or discharge is agreed to in writing and signed by you and such officer or director as may be designated by the Board.  No waiver by either party hereto at any time of any breach by the other party hereto of, or compliance with, any condition or provision of this Agreement to be performed by such other party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same or at any prior or subsequent time.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.333%;">f.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the Commonwealth of Massachusetts without regard to the choice of law principles thereof.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">remainder of page intentionally left blank</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the foregoing is acceptable, please indicate your agreement by signing below and returning the original signed Agreement (keeping a copy for your own records) to me.  If you have any further questions or require additional information, please feel free to contact me.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sincerely,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PYXIS ONCOLOGY, INC.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.933%;text-indent:-12.987%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:41.065%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Lara Sullivan					</font></p>
  <p style="margin-left:0.933%;text-indent:-12.987%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:41.065%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lara S. Sullivan, M.D.</font></p>
  <p style="margin-left:0.933%;text-indent:-12.987%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:41.065%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President &amp; Chief Executive Officer</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ACCEPTED AND AGREED</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.933%;text-indent:-12.987%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:41.065%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Jitu Wadhane						</font></p>
  <p style="margin-left:0.933%;text-indent:-12.987%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:41.065%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Jitendra Wadhane</font></p>
  <p style="margin-left:0.933%;text-indent:-12.987%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:41.065%;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.933%;text-indent:-12.987%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:41.065%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">November 22, 2022						</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Appendices:	Appendix A &#x2014; Approved Activities</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">                        Appendix B &#x2014; Separation Agreement and General Release</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.0%;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.0%;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Appendix A</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.0%;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.0%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">APPROVED ACTIVITIES</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.0%;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Business advisor for accounting advisory, CyberSecurity and ESG consulting firm set up in NY. </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Appendix B</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.0%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SEPARATION AGREEMENT AND GENERAL RELEASE</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Note: This form is not to be signed until the termination of Employee&#x2019;s employment.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">THIS SEPARATION AGREEMENT AND GENERAL RELEASE </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(this &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) is made and entered into as of ______________ ___, 20__ (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) by and between </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PYXIS ONCOLOGY, INC.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, having an address at [company address] (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Pyxis</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), and [employee], residing at [address] (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Employee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WHEREAS, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the parties desire to set forth in this Agreement the terms upon which they have mutually agreed to an orderly termination of Employee&#x2019;s employment with Pyxis;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOW THEREFORE, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in consideration of the mutual agreements and other consideration contained in this Agreement, the parties agree as follows:</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Severance and Other Benefits</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  In accordance with the terms of the executive employment agreement between Pyxis and Employee, dated [date], 2021 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Employment Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), which is attached hereto and incorporated herein as Attachment A, Pyxis agrees to pay Employee the severance benefits set forth in Section 4 of the Employment Agreement in accordance with the terms thereof.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Release</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  In consideration for the payments made pursuant to Section 1 above, Employee, on behalf of Employee, Employee&#x2019;s heirs, executors, administrators, successors and assigns, hereby releases, acquits and forever discharges Pyxis and any and all of its current or former subsidiaries and other affiliated entities and benefit plans, as well as its and/or their officers, directors, representatives, attorneys, agents, servants, employees, stockholders, successors, predecessors and affiliates, each in their respective capacities from any and all claims, liabilities, demands, causes of action, costs, expenses, attorneys&#x2019; fees, damages, indemnities and obligations of every kind and nature, in law, in equity or otherwise, known or unknown, suspected and unsuspected, disclosed and undisclosed, arising out of or in any way related to agreements, acts or conduct at any time as of or prior to the Effective Date, including, but not limited to: all such claims or demands arising from Employee&#x2019;s employment or the termination of Employee&#x2019;s employment; all such claims and demands related to salary, bonuses, commissions, stock, stock options (except as provided in Section 4 of the Employment Agreement), expense reimbursements, or any form of compensation; claims pursuant to any federal, state or local law or cause of action including, but not limited to, the Federal Civil Rights Acts of 1964, as amended, the Age Discrimination in Employment Act of 1967, as amended, or any law or legal principle of similar effect in any other relevant jurisdiction; contract claims; tort claims; or claims of wrongful discharge, discrimination, fraud, defamation, and emotional distress.  Employee further agrees not to sue or otherwise institute or cause to be instituted or in any way voluntarily participate in the prosecution of any complaints or charges against any persons or entities released herein in any federal, state or other court, administrative agency or other forum concerning any claims released herein.  Notwithstanding the foregoing, this release by Employee excludes (i) any rights to payment under Section 4 of the Employment Agreement, (ii) any rights to vested accrued benefits and compensation under the Company&#x2019;s applicable plans and arrangements (including with respect to equity awards), (iii) any right to indemnification by the Company or its affiliates and (iv) any right to coverage under applicable directors&#x2019; and officers&#x2019; or other third party liability insurance policies.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Noncompetition and Nonsolicitation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Employee agrees and acknowledges that the non-solicitation restrictions set forth in the Confidentiality and Proprietary Rights Agreement between Pyxis and Employee, dated [date] (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Confidentiality and Proprietary Rights Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), remain in full force and effect until the one-year anniversary of the date of Employee&#x2019;s termination (i.e., until [date]).  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional Covenants</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The parties covenant and agree that for a one-year period following the Effective Date, each shall refrain from making any defamatory, derogatory or other unfavorable statements regarding the other or, in the case of Employee, Pyxis&#x2019;s business, officers, directors, employees and agents.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Confidentiality</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Except for his own attorney, his tax advisor and his immediate family, Employee agrees that the existence and the terms of this Agreement shall be confidential, and that he, his attorney, his tax advisor and his immediate family will not disclose any information concerning the terms of this Agreement to anyone, including but not limited to past, present or future employees of Pyxis.  In addition, Employee is party to and bound by the provisions of the Confidentiality and Proprietary Rights Agreement, including with respect to confidentiality. </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No Admission</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Employee understands and agrees that nothing contained in this Agreement is to be considered an admission by Pyxis of any wrongdoing under any federal, state or local statute, regulation, public policy, tort law, contract law, common law.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">7.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Acknowledgement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  Employee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">acknowledges that he has read and understands this Agreement and executes it knowingly, voluntarily and without coercion.  Employee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">acknowledges that he is being advised herein in writing to consult with an attorney prior to executing this Agreement, that he has consulted with an attorney, and he has been given a period of at least 21 days within which to consider and execute this Agreement, unless he voluntarily chooses to execute this Agreement before the end of the 21 day period by executing the attached Election to Execute Prior to Expiration of 21 Day Consideration Period.  Employee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">understands that he has 7 days following his execution of this Agreement to revoke his execution of this Agreement.  The Effective Date of this Agreement shall be the 8th day after it is executed and has not been revoked.  For any revocation to be effective, written notice of revocation must be delivered to Pyxis, attention: Chairman of the Board, no later than 5:00 p.m. on the 7th calendar day after Employee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">signs this Agreement.  If Employee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">revokes this Agreement, it shall not be effective or enforceable and he shall not receive the benefits described herein.  No payments shall be made under the terms of this Agreement until the 7-day revocation period described in this paragraph has expired without revocation by Employee.</font></div></div>
  <div style="text-indent:7.467%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:7.463%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">8.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Modifications</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  This Agreement may not be modified in any way except in a written agreement signed by both Employee and an authorized representative of Pyxis.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">9.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Governing Law</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. This Agreement shall be governed by, and construed in accordance with, the laws of the Commonwealth of Massachusetts without giving effect to its conflict of law provisions.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">10.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Entire Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  This Agreement constitutes the entire agreement and understanding between the parties relating to Employee&#x2019;s separation from Pyxis.  Employee acknowledges and agrees that in executing this Agreement, Employee has not relied on any promises or representations other than those set forth in this Agreement.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[For the avoidance of doubt, this Agreement does not alter, amend or otherwise change the rights or obligations of Employee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">or Pyxis in respect of grants of any stock options or other equity compensation provided to Employee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">on ______, ______ and _____</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">]</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IN WITNESS THEREOF, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee and Pyxis, after carefully reading the provisions of this Agreement, herein declare that they understand such provisions and willingly accept and agree thereto by executing this Agreement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pyxis Oncology, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	 	By:	</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">		Title:	</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">		Date:	</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Form agreement not to be signed</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">			&#160;</font></p>
  <p style="margin-left:40.0%;text-indent:11.111%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[Employee]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">		Date:	</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ELECTION TO EXECUTE PRIOR TO EXPIRATION<br>OF 21 DAY CONSIDERATION PERIOD</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, [name], understand that I have at least 21 days within which to consider and execute the foregoing Separation Agreement and General Release.  However, after having an opportunity consult counsel, I have freely and voluntarily elected to execute the Separation Agreement and General Release before the 21 day period has expired.</font></p>
  <p style="text-indent:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">						&#160;</font></p>
  <p style="margin-left:13.333%;text-indent:38.461%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[employee name]</font></p>
  <p style="margin-left:13.333%;text-indent:38.461%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date:</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">						</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.0%;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Appendix C</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.0%;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.0%;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Confidentiality and Proprietary Rights Agreement</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[on file with Company]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>6
<FILENAME>pyxs-ex10_24.htm
<DESCRIPTION>EX-10.24
<TEXT>
<html>
 <head>
  <title>EX-10</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:33.267%;text-indent:-1.189%;padding-left:0.773%;font-size:10.0pt;margin-top:8.55pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.926%;text-align:right;" id="amendment_no__1_to_amended_and_restated_"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 10.24</font></p>
  <p style="margin-left:33.267%;text-indent:-1.189%;padding-left:0.773%;font-size:10.0pt;margin-top:8.55pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.926%;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.55pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.093%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment No. 1 to Amended and Restated License Agreement (&#x201c;Amendment No. 1&#x201d;)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.55pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.093%;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:3.5%;border-spacing:0;table-layout:fixed;width:92.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:37.039%;"></td>
    <td style="width:7.404%;"></td>
    <td style="width:55.558%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.5pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment No. 1 Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.5pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.5pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.44583333333333336in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 16, 2023</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.5pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name of Original Agreement:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.5pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.5pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.44583333333333336in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated License Agreement, as by that certain Letter Agreement, dated October 14, 2022, between the Parties (the &#x201c;Agreement&#x201d;)</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.5pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Execution Date of the Agreement:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.5pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.5pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.44583333333333336in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 6, 2022 (&#x201c;A&amp;R Effective Date&#x201d;)</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.5pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Parties:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.5pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.5pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.44583333333333336in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pfizer Inc. (&#x201c;Pfizer&#x201d;) and Pyxis Oncology Inc. (&#x201c;Pyxis&#x201d;)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:2.04%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:7.694%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WHEREAS, the parties hereto desire to amend and restate certain terms of the Agreement relating to equity issuance terms pursuant to Section 5.1.2(b) of the Agreement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:2.04%;text-indent:-3.834%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:7.694%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOW, THEREFORE, in order to accommodate the desired amendment, the parties hereby agree as follows:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:2.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:5.87%;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.401020408163266%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Defined Terms</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Capitalized terms used herein but not otherwise defined shall have the meanings ascribed to such terms in the Agreement.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:2.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:11.204%;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.401020408163266%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment and Restatement of Section 5.1.2(b) of the Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Section 5.1.2 (b) of the Agreement is hereby deleted, and amended and restated in its entirety as set forth below:</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.773%;text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:6.759%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;(b) such number of shares of Pyxis&#x2019;s Common Stock as is the equivalent to five million dollars (US$5,000,000) at a per share price equal to the closing price on the Business Day when Pyxis&#x2019;s closing share price of Common Stock is at or above $2.46 per share on the Nasdaq Global Select Market on any day from the date of this Amendment No. 1 to a date that is within one hundred eighty (180) days following the A&amp;R Effective Date.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:6.759%;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.773%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:6.759%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If within one hundred eighty (180) days </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">following the A&amp;R Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, Pyxis&#x2019;s share price for its Common Stock has not closed at or above $2.46 per share, then Pyxis will issue to Pfizer such number of shares of Pyxis&#x2019;s Common Stock as is equivalent to five million dollars (US$5,000,000) at a per share price equal to the closing price of Pyxis&#x2019;s Common Stock on the one hundred eightieth (180th) day after the A&amp;R Effective Date. Notwithstanding anything to the contrary herein, the number of shares of Common Stock to be issued by Pyxis to Pfizer pursuant to this Section 5.1.2(b) shall be adjusted to keep Pfizer&#x2019;s ownership interest in Pyxis not to exceed nineteen and a half percent (19.5%) with any difference in value between the value of shares and $5,000,000 being payable in cash to Pfizer in order to comply with NASDAQ Listing Rule Section 5635, including, without limitation, in order not to require approval by shareholders. For example, if the value of the stock that Pyxis can issue is worth three-million five hundred thousand ($3,500,000), Pyxis shall pay Pfizer one-million five hundred ($1,500,000) in cash on the Issuance Date.&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:2.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:8.398%;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.401020408163266%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Termination of Letter Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Letter Agreement dated October 14, 2022, by and between the Parties is hereby terminated and shall be of no further force and effect as of the time of execution of this Amendment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <p style="margin-left:5.373%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:8.426%;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:2.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:8.398%;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.401020408163266%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ratification of the Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Except as expressly set forth in Article 2 above, the Agreement shall remain unmodified and in full force and effect. The execution, delivery and effectiveness of this Amendment No. 1 shall not, except as expressly provided herein, operate as a waiver of any right, power or remedy of the parties to the Agreement, nor constitute a waiver of any provision of the Agreement. In the event of a conflict between the terms of this Amendment No. 1 and the Agreement, the terms of this Amendment No. 1 shall control.</font></div></div>
  <p style="margin-left:5.373%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:8.426%;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:2.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:8.398%;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.401020408163266%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Miscellaneous</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. This Amendment No. 1, together with the Agreement, constitutes the entire agreement and understanding between the Parties with respect to the subject matter hereof and supersedes all negotiations, representations, prior discussions and preliminary agreements between the Parties relating to the subject matter of this Amendment No. 1 and the Agreement.</font></div></div>
  <p style="margin-left:5.373%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:8.426%;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:2.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:8.398%;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.401020408163266%;">6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Counterparts</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. This Amendment No. 1 may be executed in any number of counterparts, each of which shall be an original instrument and all of which, when taken together, shall constitute one and the same agreement. Transmission by e-mail or other form of electronic transmission of an executed counterpart of this Amendment No. 1 shall be deemed to constitute due and sufficient delivery of such counterpart.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:13.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:15.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIGNATURES IMMEDIATELY FOLLOWING ON NEXT PAGE</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.84%;text-indent:0.0%;font-size:10.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:10.37%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IN WITNESS WHEREOF, the duly authorized representatives of Pfizer and Pyxis have executed this Amendment No. 1 as of the date first above written.</font></p>
  <p style="margin-left:0.84%;text-indent:0.0%;font-size:10.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:10.37%;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.833%;border-spacing:0;table-layout:fixed;width:97.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:18.562%;"></td>
    <td style="width:20.616%;"></td>
    <td style="width:4.117%;"></td>
    <td style="width:18.905%;"></td>
    <td style="width:37.8%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pyxis Oncology, Inc.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pfizer Inc.</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.11319444444444444in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Pam Connealy</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Uwe Schoenbeck</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.2604166666666667in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Print Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.2013888888888889in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pam Connealy</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.3451388888888889in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Print Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.050694444444444445in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Uwe Schoenbeck</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CFO</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CSO, SVP Ext Science &amp; Innovation</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.17916666666666667in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 16, 2023</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.30069444444444443in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 16, 2023</font></p></td>
   </tr>
  </table>
  <p style="margin-left:1.107%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>7
<FILENAME>pyxs-ex10_25.htm
<DESCRIPTION>EX-10.25
<TEXT>
<html>
 <head>
  <title>EX-10</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.84%;text-indent:0.852%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.556%;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 10.25</font></p>
  <p style="margin-left:0.84%;text-indent:0.852%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.556%;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.84%;text-indent:0.852%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.556%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p>
  <p style="margin-left:0.84%;text-indent:0.852%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.556%;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:33.747%;text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:33.759%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AMENDMENT NO. 1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.065%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">THIS AMENDMENT NO. 1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(&#x201c;Amendment No. 1&#x201d;) is made and entered into on June 28, 2022 (the &#x201c;Amendment Effective Date&#x201d;), by and between </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pyxis Oncology, Inc.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, a corporation, organized under the laws of Delaware, with its registered office at 35 Cambridgepark Drive, Suite 100-R, Cambridge, MA 02140 (hereinafter referred to as &#x201c;Pyxis&#x201d; or &#x201c;Client&#x201d;) and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Biosion USA, Inc.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, a Delaware corporation, having an address at 1 Innovation Way, Suite 300, Newark, Delaware 19711 (hereinafter referred to as &#x201c;Biosion&#x201d;) and amends that certain March 28, 2022 License Agreement entered into by and between Pyxis and Biosion (the &#x201c;Agreement&#x201d;).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;text-indent:6.817%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.102%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WHEREAS, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">under the terms of the Agreement, Biosion granted certain exclusive license rights to Pyxis under certain technology, materials and other proprietary materials of Biosion;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;text-indent:6.816%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.083%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WHEREAS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, subject to the terms of the Agreement, the Parties agreed to enter into a Clinical Supply Agreement within [***] of the Effective Date; and</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;text-indent:6.815%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.065%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WHEREAS, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Parties hereto have entered into an agreement to extend the time period by which to enter into such Clinical Supply Agreement, and of which they desire to memorialize in this Amendment No. 1;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;text-indent:6.817%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.093%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOW, THEREFORE, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in consideration of the premises and of the following mutual promises, covenants and conditions hereinafter set forth, the Parties hereto agree as follows:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:1.065%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.065%;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.368878556628089%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Defined Terms</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.	Capitalized terms used but not defined herein shall have the respective meanings ascribed to such terms in the Agreement.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:1.065%;text-indent:0.0%;display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.368878556628089%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment(s) to the Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:4.44%;text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 3.5.1 shall be deleted in its entirety and shall be replaced with the following:</font></p>
  <p style="margin-left:1.107%;text-indent:-7.312%;padding-left:6.667%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.056%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#x201c;3.5.1. Upon execution of the Clinical Supply Agreement, notwithstanding the provisions of Section 2.2 and Section 2.10 (but subject to the terms of the Clinical Supply Agreement), as between the Parties, Licensee shall have the first and primary right to have Manufactured by a Third Party contract manufacturer the Compound and Products for Development in the Field within the Licensed Territory and the Retained Territory. Within </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">after the Effective Date (or such later date mutually agreed by the Parties based on timing of identification of a Third Party contract manufacturer meeting the requirements set forth in this Section 3.5.1), the Parties shall negotiate in good faith the terms and conditions of a clinical supply agreement and corresponding quality agreement on customary terms, pursuant to which Licensee would Manufacture and supply, itself or through an Affiliate or one (1) or more Third Party contract manufacturers, the Compound and Products to Licensor to support Licensor&#x2019;s Development of the Compound and Products in the Field in the Retained Territory (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Clinical Supply Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#x201d;). The Clinical Supply Agreement shall include terms and conditions providing that the Compound and Products supplied thereunder must meet the requirements of Regulatory Authorities in the Retained Territory, and backup Manufacturing rights (including technology transfer at Licensee&#x2019;s cost and expense) for Licensor in the event that Licensee is unable or unwilling to meet its supply obligations thereunder. Any Third Party contract manufacturer engaged by Licensee or any of its Affiliates for the Manufacture of Compound or Product to be supplied under the Clinical Supply Agreement shall have the capability to Manufacture such Compound or Product in conformance with the same specifications, in both the United States and China and with world class quality, and Licensor shall have the right under the Clinical Supply Agreement to designate the site of the Third Party contract manufacturer to be used to provide supply to Licensor thereunder.&#x201d;</font></p>
  <p style="margin-left:1.107%;text-indent:-7.312%;padding-left:6.667%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.056%;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:1.065%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.065%;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.368878556628089%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ratification of the Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Except as expressly set forth in Article 2 above, the Agreement shall remain unmodified and in full force and effect. The execution, delivery, and effectiveness of this Amendment No. 1 shall not, except as expressly provided herein, operate as a waiver of any right, power or remedy of the parties to the Agreement, nor constitute a waiver of any provision of the Agreement. In the event of a conflict between the terms of this Amendment No. 1 and the Agreement, the terms of this Amendment No. 1 shall control.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:1.065%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.065%;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.368878556628089%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Miscellaneous</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. This Amendment No. 1, together with the Agreement, constitutes the entire agreement and understanding between the Parties with respect to the subject matter hereof and supersedes all negotiations, representations, prior discussions and preliminary agreements between the Parties relating to the subject matter of this Amendment No. 1 and the Agreement.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:1.065%;text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.065%;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.368878556628089%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Counterparts</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. This Amendment No. 1 may be executed in any number of counterparts, each of which shall be an original instrument and all of which, when taken together, shall constitute one and the same agreement. Transmission by e-mail or other form of electronic transmission of an executed counterpart of this Amendment No. 1 shall be deemed to constitute due and sufficient delivery of such counterpart.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.056%;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:4.173%;text-indent:0.0%;font-size:10.0pt;margin-top:7.85pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IN WITNESS WHEREOF</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Parties hereto, each by a duly authorized representative, have executed this Amendment No. 1 as of the Amendment Effective Date.</font></p>
  <p style="margin-left:1.107%;text-indent:0.0%;font-size:10.0pt;margin-top:7.85pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:3.5%;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:21.79%;"></td>
    <td style="width:33.25%;"></td>
    <td style="width:2.411%;"></td>
    <td style="width:20.758%;"></td>
    <td style="width:21.79%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Biosion USA, Inc.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pyxis Oncology, Inc.</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.11319444444444444in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Hugh Davis</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Pam Connealy</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.2604166666666667in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Print Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.2013888888888889in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Hugh Davis</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.3451388888888889in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Print Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.050694444444444445in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pam Connealy</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">COO, Biosion Inc, &amp; President, Biosion USA, Inc.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CFO</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.17916666666666667in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 28, 2022</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.30069444444444443in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 28, 2022</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>8
<FILENAME>pyxs-ex10_26.htm
<DESCRIPTION>EX-10.26
<TEXT>
<html>
 <head>
  <title>EX-10</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="margin-left:0.84%;text-indent:0.852%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.556%;text-align:right;" id="amendment__2_to_license_agreement"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 10.26</font></p>
  <p style="margin-left:0.84%;text-indent:0.852%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.556%;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.84%;text-indent:0.852%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.556%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p>
  <p style="margin-left:0.84%;text-indent:-0.841%;padding-left:0.84%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.833%;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:19.213%;text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:19.444%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AMENDMENT #2 TO LICENSE AGREEMENT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;text-indent:6.815%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.065%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This AMENDMENT #2 TO LICENSE AGREEMENT (this &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) is made effective as of July 1, 2022 (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), by and between Pyxis Oncology, Inc., a Delaware corporation, having an address at 35 Cambridge Park Drive, Cambridge, Massachusetts 02140 (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Licensee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), and Biosion USA, Inc., a Delaware corporation, having an address at 1 Innovation Way, Suite 300, Newark, Delaware 19711 (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Licensor</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;). Licensee and Licensor may, from time-to-time, be individually referred to as a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; and collectively referred to as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Parties</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;.</font></p>
  <p style="margin-left:19.213%;text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:19.426%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RECITALS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;text-indent:6.834%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.343%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WHEREAS, the Parties entered into that certain License Agreement effective as of March 28, 2022 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), pursuant to which Licensee obtained from the Licensor certain exclusive rights to exploit certain anti-Siglec-15 compounds in the Field in the Licensed Territory (each as defined in the Agreement);</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;text-indent:6.833%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WHEREAS, Section 2.7 of the Agreement requires the Parties to execute an amendment to the Agreement within [***] following the Effective Date setting forth terms and conditions for a right of first offer to be granted by each Party to the other Party to obtain an exclusive, sublicensable (through multiple tiers), transferable, and royalty-bearing license under the ROFO Product Technology Controlled by such Party or any of its Affiliates to Develop, Manufacture, and Commercialize each ROFO Compound and any corresponding ROFO Products in the Field within the other Party&#x2019;s territory (i.e., the Licensed Territory for Licensee and the Retained Territory for Licensor); and</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;text-indent:6.833%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WHEREAS, the Parties hereto desire to amend the Agreement to more particularly set forth the terms of the ROFO as provided below.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;text-indent:6.834%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.343%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOW, THEREFORE, in consideration of the mutual agreements and covenants set forth herein and other good and valuable consideration, the receipt and sufficiency of which the Parties hereby acknowledge, the Parties, intending to be legally bound hereby, agree to the foregoing as follows:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:1.065%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.333%;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.7387678778996305%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Definitions. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capitalized terms used herein which are not otherwise defined shall have the meanings ascribed to such terms in the Agreement.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <div style="margin-left:1.065%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.333%;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.7387678778996305%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment to Agreement. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 2.7 of the Agreement is hereby deleted and replaced in its entirety with the following:</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:7.731%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.333%;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.225612069058946%;">2.7</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right of First Offer. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Each Party hereby grants to the other Party, for each ROFO Compound Controlled by such Party or any of its Affiliates, a right of first offer (each, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ROFO</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) to obtain on commercially reasonable terms an exclusive, sublicensable (through multiple tiers), transferable, and royalty-bearing license under the ROFO Product Technology Controlled by such Party or any of its Affiliates to Develop, Manufacture, and Commercialize such ROFO Compound and any corresponding ROFO Products in the Field within the other Party&#x2019;s territory (i.e., the Licensed Territory for Licensee and the Retained Territory for Licensor) (each, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ROFO License</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), subject to the terms of this Section 2.7.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:14.398%;text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.333%;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.788369430620779%;">2.7.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Beginning on the Amendment Effective Date and continuing during the Term, on a ROFO Compound-by-ROFO Compound basis, each Party (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granting Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) shall notify the other Party (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Offering Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) in writing [***] before the estimated date of IND Readiness with respect to any ROFO Compound or any corresponding ROFO Products Controlled by such Party or any of its Affiliates. Within [***] after IND Readiness with respect to any ROFO Compound or any corresponding ROFO Products, the Granting Party shall deliver to the Offering Party a Data Package for such ROFO Compound and ROFO Products. As used herein, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IND Readiness</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means, with respect to a particular ROFO Compound and any corresponding ROFO Products, such time when the Granting Party or its Affiliate has obtained possession of data, final drafts of all reports (except clinical protocols), and other information (including with respect to pre-clinical toxicology, cGLP and non-cGLP toxicology, and chemistry, manufacturing and controls (CMC)) that are necessary to support the filing of an IND with the FDA for such ROFO Compound and ROFO Products. &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Data Package</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means, with respect to a ROFO Compound and any corresponding ROFO Products, the following, to the extent available: (a) final drafts of all reports (except clinical protocols), including with respect to pre-clinical toxicology, cGLP, non-cGLP toxicology and CMC, expected to be included as part of an IND filing with the FDA for such ROFO Compound and ROFO Products; (b) a reasonably detailed analysis of the key data related to such ROFO Compound and ROFO Products; (c) the protein amino acid and nucleotide sequence information for such ROFO Compound and ROFO Products, as applicable; (d) a reasonably detailed summary of any other material research and development activities, or diligence and the findings thereof, conducted with respect to such ROFO Compound and ROFO Products; and (e) any Patent Rights and Regulatory Materials Controlled by the applicable Party or any of its Affiliates relating to such ROFO Compound and ROFO Products.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:21.107%;text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.315%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Following the Offering Party&#x2019;s receipt of a Data Package with respect to any ROFO Compound and any corresponding ROFO Products, the Offering Party shall have [***] (each, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ROFO Review Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) to exercise its ROFO with respect to such ROFO Compound and ROFO Products by providing the Granting Party a bona fide written offer to obtain a ROFO License with respect to such ROFO Compound and ROFO Products (each, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ROFO Offer</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;). Upon receipt of a ROFO Offer with respect to any ROFO Compound and any corresponding ROFO Products within the applicable ROFO Review Period, the Parties shall negotiate in good faith for a period of [***] (each, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ROFO Negotiation Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">,&#x201d; and together with the applicable ROFO Review Period, each, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ROFO Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) regarding the ROFO License for such ROFO Compound and ROFO Products. During the ROFO Period for any ROFO Compound and any corresponding ROFO Products, the Offering Party may reasonably request the Granting Party to clarify any information contained in the applicable Data Package, or supplement the Data Package with additional information, data or results. Within [***] of receiving such request, the Granting Party shall use commercially reasonable efforts to provide such clarification, additional information, data or results to the extent then in existence and available to the Granting Party.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:14.398%;text-indent:0.0%;display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.333%;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.788369430620779%;">2.7.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On a ROFO Compound-by-ROFO Compound basis, the Offering Party&#x2019;s ROFO shall expire, and this Section 2.7 shall no longer apply with respect to such ROFO Compound and ROFO Products, upon the earlier of (a) if the Offering Party does not provide the ROFO Offer to the Granting Party within the applicable ROFO Review Period, the expiration of such ROFO Review Period, and (b) if the Offering Party provides the ROFO Offer to the Granting Party within the applicable ROFO Review Period and the Parties do not consummate or agree to consummate a definitive agreement for a ROFO License with respect to such ROFO Compound and ROFO Products within the applicable ROFO Negotiation Period, the expiration of such ROFO Negotiation Period (each, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ROFO Expiration Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:14.398%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.333%;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.788369430620779%;">2.7.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notwithstanding the foregoing, the obligations set forth in this Section 2.7 will not restrict the Granting Party or its Affiliates from entering into any agreement with any contract research organization, contract manufacturing organization, or other Third Party under which such Third Party performs contract services on behalf of the Granting Party or its Affiliates that would grant such Third Party a non-exclusive license to Develop or Manufacture a ROFO Compound or any corresponding ROFO Product in all or any portion of the other Party&#x2019;s territory solely for the purpose of providing such services.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <div style="margin-left:14.398%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.333%;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.788369430620779%;">2.7.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For purposes of clarity, unless otherwise agreed upon in writing between the Parties, (a) the Granting Party shall not be prohibited during the ROFO Period or any other time from engaging in negotiations with Third Parties,</font></div></div>
  <p style="margin-left:21.107%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.278%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(b) the Granting Party shall not be obligated to share with the Offering Party any details regarding offer(s) from any Third Party, (c) except as permitted by Section 2.7.4, the Granting Party shall not, and shall cause its Affiliates not to, directly or indirectly license, transfer, sell or otherwise grant to any Third Party any right to Develop, Manufacture, or Commercialize a ROFO Compound or any corresponding ROFO Product in the Field in the other Party&#x2019;s territory without first complying with its obligations under this Section 2.7, and (d) upon expiration of the ROFO Negotiation Period with respect to any ROFO Compound and any corresponding ROFO Products, the Granting Party and its Affiliates shall not have any further obligation to the Offering Party with respect to such ROFO Compound and ROFO Products.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:1.065%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.333%;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.7387678778996305%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further Amendments to the Agreement. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Schedule 1.121 of the Agreement is hereby amended to replace &#x201c;License Agreement, dated as of March 28, 2022, between </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and Biosion, Inc.&#x201d; with &#x201c;None.&#x201d;</font></div></div>
  <p style="margin-left:7.773%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.287%;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:1.065%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.333%;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.7387678778996305%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ratification of the Agreement. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Except as expressly set forth in Section 2 above, the Agreement shall remain unmodified and in full force and effect. The execution, delivery, and effectiveness of this Amendment shall not, except as expressly provided herein, operate as a waiver of any right, power or remedy of the Parties to the Agreement, nor constitute a waiver of any provision of the Agreement. In the event of a conflict between the terms of this Amendment and the Agreement, the terms of this Amendment shall control.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:1.065%;text-indent:0.0%;display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.333%;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.7387678778996305%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Miscellaneous. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Amendment, together with the Agreement, constitutes the entire agreement and understanding between the Parties with respect to the subject matter hereof and supersedes all negotiations, representations, prior discussions and preliminary agreements between the Parties relating to the subject matter of this Amendment and the Agreement.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:1.065%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.204%;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.7387678778996305%;">6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Counterparts. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Amendment may be executed in two (2) or more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument. If any signature is delivered by email delivery of a &#x201c;pdf&#x201d; format data file, such signature will create a valid and binding obligation of the Party executing (or on whose behalf such signature is executed) with the same force and effect as if such &#x201c;pdf&#x201d; signature page were an original thereof.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:19.213%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:19.38%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Signature Page Follows</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;text-indent:6.832%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.315%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IN WITNESS WHEREOF, the Parties intending to be bound have caused this Amendment to be executed by their duly authorized representatives as of the Amendment Effective Date.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:1.833%;border-spacing:0;table-layout:fixed;width:97.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:21.623%;"></td>
    <td style="width:30.197%;"></td>
    <td style="width:3.719%;"></td>
    <td style="width:20.621%;"></td>
    <td style="width:23.839%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pyxis Oncology, Inc.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Biosion USA, Inc.</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.11319444444444444in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Pam Connealy</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Hugh Davis</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.2604166666666667in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.2013888888888889in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pam Connealy</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.3451388888888889in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.050694444444444445in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Hugh Davis</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CFO</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:19.222%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">                                     Signature Page to Amendment #2 to License Agreement</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>9
<FILENAME>pyxs-ex10_27.htm
<DESCRIPTION>EX-10.27
<TEXT>
<html>
 <head>
  <title>EX-10</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="margin-left:0.84%;text-indent:0.852%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.556%;text-align:right;" id="amendment__2_to_license_agreement"><font id="amendment_no__3_to_license_agreement"></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 10.27</font></p>
  <p style="margin-left:0.84%;text-indent:0.852%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.556%;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.84%;text-indent:0.852%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.556%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p>
  <p style="margin-left:2.653%;text-indent:0.0%;font-size:10.0pt;margin-top:4.2pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.241%;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:2.653%;text-indent:0.0%;font-size:10.0pt;margin-top:4.2pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.241%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AMENDMENT NO. 3 TO LICENSE AGREEMENT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:2.653%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.287%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">THIS AMENDMENT NO. 3 TO LICENSE AGREEMENT (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment No. 3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) is made and</font></p>
  <p style="margin-left:2.413%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">entered into on November 22, 2022 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), by and between Pyxis Oncology, Inc., a corporation, organized under the laws of Delaware, with its registered office at 150 Cambridgepark Drive, 8th Floor, Suite 2, Cambridge, MA 02140 (hereinafter referred to as &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pyxis</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) and Biosion USA, Inc., a Delaware corporation, having an address at 1 Innovation Way, Suite 300, Newark, Delaware 19711 (hereinafter referred to as &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Biosion</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;). Pyxis and Biosion may, from time-to-time, be individually referred to as a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; and collectively referred to as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Parties</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:2.413%;text-indent:6.893%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.065%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WHEREAS, Pyxis and Biosion entered into that certain License Agreement effective as of March 28, 2022, as further amended by Amendment No. 1 on June 28, 2022, and Amendment No. 2 on July 1, 2022 (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), pursuant to which Pyxis obtained from Biosion exclusive rights to certain anti-Siglec-15 patents, technology, know-how, and other proprietary materials in the Field in the Licensed Territory (each defined in the Agreement);</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:2.413%;text-indent:6.89%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.019%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WHEREAS, Section 3.4 of the Agreement requires that the Parties enter into a Pharmacovigilance Agreement within </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">after the Effective Date of the Agreement, and Section 3.2.2 of the Agreement requires that Pyxis provide Biosion its development plan for the Development of the Biomarker Test within </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">after the Effective Date of the Agreement (each defined in the Agreement); and</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:2.413%;text-indent:6.892%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.046%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WHEREAS, the Parties wish to extend the time periods in Sections 3.2.2 and 3.4 referenced above, and now desire to memorialize these extensions in this Amendment No. 3.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:2.413%;text-indent:6.894%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.074%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOW, THEREFORE, in consideration of the premises and of the following mutual promises, covenants and conditions hereinafter set forth, the Parties hereto agree as follows:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:2.398%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.065%;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.414889039159034%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Defined Terms</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.	Capitalized terms used but not defined herein shall have the respective meanings ascribed to such terms in the Agreement.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:2.398%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.414889039159034%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendments to the Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:9.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 3.2.2 shall be deleted in its entirety and shall be replaced with the following:</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:2.413%;text-indent:-7.414%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">3.2.2. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Licensee will provide Licensor its development plan for Development of the Product within </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">after the Effective Date, and its development plan for the Development of the Biomarker Test within </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">after the Effective Date, to the extent applicable, in the Licensed Territory (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Licensee Development Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#x201d;). The Parties shall thereafter, through the JSC, discuss the Licensee Development Plan and Licensee shall consider in good faith any comments from Licensor with respect thereto, including with respect to the activities and timelines in the Licensee Development Plan. At least </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">prior to the end of each Calendar Year during the Term when Development activities of Products or the Biomarker Test are ongoing, or from time to time if a material amendment to the Licensee Development Plan is required, Licensee shall provide the JSC an updated version of the Licensee Development Plan.&#x201d;</font></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:4.5pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 3.4 shall be deleted in entirety and shall be replaced with the following:</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:2.96%;text-indent:-6.79%;padding-left:6.107%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.991%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">3.4. Complaints; Adverse Event Reporting Procedures. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Each Party will maintain a record of any and all complaints it receives with respect to each Product and the Biomarker Test. Each Party will notify the other Party in reasonable detail of any complaint received by it with respect to each Product or the Biomarker Test within sufficient time to allow the other Party to comply with any and all Applicable Law in any jurisdiction in which each Product or the Biomarker Test is being marketed or tested in clinical trials. Licensee will maintain a global adverse event database for each Product and the Biomarker Test, at its cost and expense, and Licensor will have access thereto. Each Party will provide the other Party with all adverse event information and safety data relating to each Product or Biomarker Test in its control within sufficient time to allow the other Party to comply with any and all Applicable Law in any jurisdiction in which each Product or the Biomarker Test is being marketed or tested in clinical trials. Following entry into the Pharmacovigilance Agreement, each Party will report to the other Party the details around any adverse events and serious adverse events relating to each Product or Biomarker Test in its control within the time periods for such reporting as specified in the Pharmacovigilance Agreement. Each Party shall be responsible, at its own expense, for submitting adverse event reports with respect to a Product and the Biomarker Test to the applicable Regulatory Authorities in its respective territory. By the first to occur of the following: (1) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">after the Effective Date, or (2) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">before prospective FPFD in any human clinical study by either Party, the Parties will develop and agree in writing upon a pharmacovigilance agreement (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Pharmacovigilance Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#x201d;) that will include safety data exchange procedures governing the coordination of collection, investigation, reporting, and exchange of information concerning any adverse experiences, and any product quality and product complaints involving adverse experiences, related to each Product and the Biomarker Test, sufficient to enable each Party to comply with its respective legal and regulatory obligations. The Pharmacovigilance Agreement may supersede the reporting provisions of this Section 3.4.&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <div style="margin-left:2.398%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.065%;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.414889039159034%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ratification of the Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Except as expressly set forth in Article 2 above, the Agreement shall remain unmodified and in full force and effect. The execution, delivery, and effectiveness of this Amendment No. 3 shall not, except as expressly provided herein, operate as a waiver of any right, power, or remedy of the parties to the Agreement, nor constitute a waiver of any provision of the Agreement. In the event of a conflict between the terms of this Amendment No. 3 and the Agreement, the terms of this Amendment No. 3 shall control.</font></div></div>
  <p style="margin-left:5.747%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.037%;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:2.398%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.065%;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.414889039159034%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Miscellaneous</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. This Amendment No. 3, together with the Agreement, constitutes the entire agreement and understanding between the Parties with respect to the subject matter hereof and supersedes all negotiations, representations, prior discussions, and preliminary agreements between the Parties relating to the subject matter of this Amendment No. 3 and the Agreement. </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.065%;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:2.398%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.065%;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.414889039159034%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Counterparts</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. This Amendment No. 3 may be executed in any number of counterparts, each of which shall be an original instrument and all of which, when taken together, shall constitute one and the same agreement. Transmission by e-mail or other form of electronic transmission of an executed counterpart of this Amendment No. 3 shall be deemed to constitute due and sufficient delivery of such counterpart.</font></div></div>
  <p style="margin-left:5.747%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:2.413%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IN WITNESS WHEREOF</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Parties hereto, each by a duly authorized representative, have executed this Amendment No. 3 as of the Amendment Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:3.5%;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:20.846%;"></td>
    <td style="width:28.135%;"></td>
    <td style="width:3.124%;"></td>
    <td style="width:21.175%;"></td>
    <td style="width:26.721%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Biosion USA, Inc.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pyxis Oncology, Inc.</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.11319444444444444in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Hugh Davis</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Pam Connealy</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.2604166666666667in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Print Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.2013888888888889in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Hugh Davis</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.3451388888888889in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Print Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.050694444444444445in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pam Connealy</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">COO, Biosion Inc, &amp; President, Biosion USA, Inc.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CFO</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.17916666666666667in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">November 22, 2022</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.7777777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.30069444444444443in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">November 28, 2022</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>10
<FILENAME>pyxs-ex21_1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html>
 <head>
  <title>EX-21</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 21.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">List of Subsidiaries</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:84.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subsidiary</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Jurisdiction</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pyxis Securities Corporation</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Massachusetts</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>11
<FILENAME>pyxs-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 23.1</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We consent to the incorporation by reference in the following Registration Statements:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registration Statement (Form S-8 No. 333-260441) pertaining to the Pyxis Oncology, Inc. 2019 Stock Plan, Pyxis Oncology, Inc., 2021 Equity and Incentive Plan, Pyxis Oncology, Inc. 2021 Employee Stock Purchase Plan,</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registration Statement (Form S-8 No. 333-263950) pertaining to the Pyxis Oncology, Inc. 2021 Equity and Incentive Plan,</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(3)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registration Statement (Form S-8 No. 333-266005) pertaining to the Pyxis Oncology, Inc. 2022 Inducement Plan, and</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(4)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registration Statement (Form S-3 No. 333-268100) of Pyxis Oncology, Inc.; </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of our report dated March 22, 2023, with respect to the consolidated financial statements of Pyxis Oncology, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2022.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Ernst &amp; Young LLP				</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Boston, Massachusetts</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 22, 2023</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>12
<FILENAME>pyxs-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, Lara Sullivan, M.D., certify that:</font></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Pyxis Oncology, Inc.;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[Reserved]</font></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">d.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any fraud, whether or not material, which involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:45.463%;"></td>
    <td style="width:5.056%;"></td>
    <td style="width:3.037%;"></td>
    <td style="width:46.444%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 22, 2023</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;/s/ Lara Sullivan</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lara Sullivan, M.D.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President and Chief Executive Officer</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>13
<FILENAME>pyxs-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, Pamela Connealy, certify that:</font></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Pyxis Oncology, Inc.;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[Reserved]</font></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">d.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any fraud, whether or not material, which involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:25.019%;"></td>
    <td style="width:25.019%;"></td>
    <td style="width:25.019%;"></td>
    <td style="width:24.944%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 22, 2023</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;/s/ Pamela Connealy</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pamela Connealy</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Financial Officer and Chief Operating Officer</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>14
<FILENAME>pyxs-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the Annual Report of Pyxis Oncology, Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the fiscal year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:45.463%;"></td>
    <td style="width:5.056%;"></td>
    <td style="width:3.037%;"></td>
    <td style="width:46.444%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 22, 2023</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;/s/ Lara Sullivan</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lara Sullivan, M.D.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President and Chief Executive Officer</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>15
<FILENAME>pyxs-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 32.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the Annual Report of Pyxis Oncology, Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the fiscal year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:25.019%;"></td>
    <td style="width:25.019%;"></td>
    <td style="width:25.019%;"></td>
    <td style="width:24.944%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 22, 2023</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;/s/ Pamela Connealy</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pamela Connealy</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Financial Officer and Chief Operating Officer</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font>&#160;</p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img30600998_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img30600998_0.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#X17AI9@  34T *@    @ ! $[  (
M   /   (2H=I  0    !   (6IR=  $    >   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $YI8V]L92!3
M96ET=&5R    !9 #  (    4   0J) $  (    4   0O)*1  (    #.38
M )*2  (    #.38  .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                         #(P,C,Z,#,Z,3D@,3,Z-3$Z,3$ ,C R,SHP
M,SHQ.2 Q,SHU,3HQ,0   $X :0!C &\ ; !E "  4P!E &D = !T &4 <@
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" +-!1D# 2(  A$! Q$!_\0 'P
M 04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0
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MN:K]*49'3CWI .<'I0  9S1CY<TN<*1ZTWZ4 &:7WHSS12  -V .M-[TY>7
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M7O\ DF.H_P#88E_]$PU[/6,MS1;!1114C"BBB@ HHHH **** "BBB@ HHHH
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M7_\ DF.H_P#88E_]$PU[/6,MS1;!1114C"BBB@ HHHH **** "BBB@ HHHH
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MP<4!*$X?$K"?SHSWJ>.UN98B\-O*Z]V6,D?G706%I;MX4EEDMXVE$<IWL@W
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M3#7L]8RW-%L%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[:/H+:R1PW<<D\?FQJ<E,]:Z7^V[ZYE3^S]/9H<<F12,_0]!61X>BBEU=!.
M<*64'N:W=1AU>:\"64JQ6Y ^8$ CUSW_ "HC>QODM/$PP4JU.4K.5K0BG+YM
M[(K^*XD-C#,5PXDVYQS@@G^E6-)DCB\+I+*H9(U=ROKAB:B\4C_B3Q8)(\U>
M?^ FDM/^1+;'_/*3^9JOM'MR?L\YKSBM?9-_D/T;7'U*ZDAFB1,+N7;GIZ'\
MZRI;"*3Q<UK@",ON*CTV[B*3PM_R%V_ZY'^8JQ<SQVOC(S2MA0R@Y[90#/ZU
M.ZU/)>(>,R_#U<6[_O4FWVUN7=8UMM*ECMK:%"=H8[AP!T  'TJQ]J2]\-SW
M")LWP2%E'8X.:I:_H]S?7,<]H%?Y0K*6 QSUY^M6TLS8^&)K=R"RP2%L>I!-
M5K<]R,L>\9B(U4_9*+Y=-/*S]+W.*[T?3CTHQG.*!UK$_+3JO"7_ !YW'_70
M?RK M[?[9JZV_0/*03[9Y_2M_P )?\>=Q_UT'\JPK*X6UUR.9SA5E.3Z \&K
M>R/KL2H/ X!5/AN[^EU<ZC4;JYTU(8=,L3*N.=J$A1Z<=Z@U: :CH/VN6 PW
M$:[L,,$8/(^E6-575&\N32905(^9,+S[@FLK4!KT-@[7=Q&867#J-H//;I_*
MJ9]!F%5P]O3J0G*'+HN5<JTT:=^A;T2"+3M#>_=-\C*6SWP.@%167BB.9I4U
M*-$3'R[%)S[$5/I#+J/AI[16"R*K1GVST-9]CX6G>5_MY\I /E*,"2?\*-=+
M'&I8^G2PJRZ-X..NFE^O-_6Y!I!A/BJ/[*&$)9R@88(&T\5LZWK#:7<1K;PQ
MM)(,LS^@[<5D:7!';>+(X89/-1"P#XZ_(<TGBO/]L+_UR'\S4W:B<-'$5\)E
M-6=-\LO:M:6TT5[?UL:^MLMWX;6\"X8*CKZC) (_6CPV$.@OYH#)O;<",Y&*
M9>?\B2O_ %RC_P#0EI?#W_(NR_5_Y57VCV8.^;0J/=TKOS=QNE>(GO\ 5/LS
MPI'&P/EXSD8&>?PK-UNQ#^)4AB&W[1M)QV)."?TS5?PZ,:_;8_VO_035[79Q
M:^)[:9ONQJC'Z9.:F]XZGC/$RQN5*IBW>U1*_E97_-FAJ>H1^'[2&WLH5W,#
M@-T '<^IHT^\B\1V$T-Y"JNF,[??H1Z=*;K^ER:M#!/9%9"H.!NQN!]#2Z)I
M[:+9SW%^RQE@"1G.T#^O-5KS>1[E\9_:3I2C_LUNRY;<O?U_#R*/A:(P:M>0
MMR8U*G\&Q49L5O\ QA-%*/W:L78>H '%3^&W:76KV5U*&12^#[MFF0W26OC2
M<RG"R$ID]L@8_E4Z61Y%*-!X'#1G\'M7OVN]RUJ_B!M,NA:6<,9\L#?NZ#V
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MHHH **** "BBB@#\_N >*&.6) Q[4.?3UZ^M23PFW8(S*Y90W';VKU#SR/\
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MV"BBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBDH
M***2F(***2@!:2BDS0 M)FBDIB"BBB@ HI** "BBB@ HI**8A:2BB@ HHHH
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M%X(T2XNYM8UW4K[[;J6HW#,6=(\': 2<+PWY5]*4 +1244 +124M "TM-HH
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M<=@U@,/0K:\L[R5GMK\GZ7-:XN8]/U 6EAIB&3C#LO7/IWQ^-2>*3_Q+XO\
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M[#$O_HF&O9JPEN:K8****D84444 %%%% !1110 4444 %%%% !1110 4444
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M\=J;GYLTH!/ Z]!6U:^&;B:,/<2+!GD#;N(I6[';A,#B<9)QP\'*W];O0Q
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MK&W^R>(XX&=7,;XRO3I2./#K&U(8=5]:/.DKVMOKYVW\C9ET328&\R<+''@
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M*N:\?^) "$V<H=O]WVIGIUL-AZF%Q$)TZ<94U=*-[K_%*RN6K'[%_99^S?\
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MQMIHGJE_705-+T2"Y^RW#B2X8\*788ST'']:R]>TJ/39XV@)\J4' )SM(_\
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MOXDOL_:-8NMIZJDA4'\!UK>.%GU/8I<+XN7QR4?Q_K[SZ9DFBB7=+(B#IEF
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MJ-1Q&?[P'H>]=%*I]EGV&1YJ[K"UGZ/]/\ON,OX8>,SH&K#3KZ3&GW;8R?\
MED_9OH>AKWL&OD>O>OA9XN_MW1?[.O9,WMD ,L>9$YP?PZ?E16A]I#S_ "__
M )BJ:_Q?Y_YF_P".?#G_  EW@C5-#63RGNX2L;G^%@<C]17DL>H-XR\*V7@C
M4K"ZT;QSH,8GT]I(\(TD ^4H_<,H&:]XKBOBIXGO_!WA6'6=*BMVF2\AAE>>
M/=MB9L-CD8/2N1GR".+^'W]L7?C"[^(OQ'\G05^R+IUI#=/Y6<$;F^;'!()_
M'VKVBWN(;J!)[:5)HG&5>-@RL/8BO&OBOI%EJ_Q7\!+KJ"ZT>[,L#1;CL,F
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M .,F@8T]:4@8YXI2H$A4G.#CBD]012&&<=>:3K_]:CCTQZT$]*  ?>Z_6E7
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MC:Q492'*]3G%/-O)MSC\,T0-NN<MU-7:J4FB8Q3,WI1FGSX,[;?6I!:,5R6
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MWP_\1Z3H?QFM==U*Z^SZ:D]R[3>6S8#QR*IVJ"W)8=N]3RNS]"KJZ&'3K/\
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MYX8N=)TN)T9V).WRU.T'!8ACD\#.,]Z-;!H/TB_T7XB>"?%T5UX4T72;G2+
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M]HWA3Q]XM\%6EU-<:5IYAN+032;C")!DH#_GI7KE "TM)12&+2TE+2&%%%%
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MY5W9:1,7P!\*;#PO''?:JJ7NJ$9RR@I ?11Z^]>AT45RRDY.[.J,5%60E%%
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M9AL V1[CWIU1>Y=K"TM-I:0"TM-I:!BTM)10,6IH[AXUP,$>]0U/:QB1SNY
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M"HPYI;GF5)NM/ECL=M\&OA[_ &;:IXDU>(B[G7_18G'^K0_QX]3V]OK7KE
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M?\4Z[=>(M>DU#4(!!=%$CF0 CYD4*3@].G3M7U!H]G'9:?''$NQ%0(BCLH&
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MBTM)2BN<Z#S&%?M_Q\E;JMK#GV&(P/YM7J%>;>!$^W_$;Q/J?54D,*GZM_\
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M!VP9)(VGN>".*]8H 44M)2T +2TE+2&+111BD,^"&"[< 8;M30"5/'3KBG(
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M']K]OL%C_P!^?_KTG]K?]0^Q_P"_/_UZS^:,XZ=>]+4?U_$_S?@O\C0_M?\
MZA]C_P!^?_KT?VM_U#['_OQ_]>L\C/:@X_"B[#Z_B?YOP7^1?.K_ /3A8_\
M?G_Z]']K?]0^Q_[\?_7K/XI223FE</K^)_F_!?Y%_P#M;C_D'V/_ 'Y_^O5.
M:7SYFDV)'G^&,8442"-501DLV,L?0TP]*3=S*KB:M9<LW="=^:*!QUYI>*#
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MU.6)-8L?PV\)Q:PNJQZ5B]2X%RLOVF7B0-NW8W8Z\XQBA5ES2;Z@Z+Y8I=#
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MO]*TU+5DB;S)=[R-L')&6)/:N%^(/Q4\.:EX/N],T69K^>\01\PNBQ#.23N
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MZDYD'*SSGN/UI<^E/EAD@D,<R;6QD@U'5"%XYYQ_6DI!]*7IVH&(,_\ UJ,
M^U6YTMDL8?+;=.QRYS]T>E5/\YI 'ZTA-%*!2 =&JLX#MM7N::>IQT[4>N*5
MF!"A5 P/SH&,Z4HX.<4F*<.GI2& ..:7WI#1C(_E0!]3_LQ_\DSU#_L+R?\
MHF&O8Z\;_9C&/AGJ'_87D_\ 1,->R5RS^)F\=@HHHJ1A1110 4444 %%%)0
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M#L,DXQ<7C-=3_P"_(=WZ @?A2^(U^V6]KI8_Y?IU20#_ )YK\S_H,?C6R!@
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M>)?A<ND$Y9[*-H<]I%4%?U&/H37D/P=ULZ/XX.GW!*1:@A@93QB1>5_'J/\
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M^(?!^JZ1"X1[ZTDA5CV++BF(\.\1_$+XG:CX5E\;:+)9Z'X?,RQV-M*@>XN
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MKBT\,ZS/!,@DCEBT^5E=2,@@A<$$<YKJ_C+80W&MZ;XNT]-ECXELTN@O]R8
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M%)YGQ2U3_9\M?_(:U]3U\I?%DY^*&L?]=%'_ (XM=F$^-^AQXOX%ZG'5ZA\
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MA$-I:1B.)!Z#N?4GJ36A0(*6DI: "EHHI#%%+12TAA2TE+0 M%%%(9\%28&
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M_D4X XYH'/4#\*0#?4&@+QGMZT\)NR>F!S32?2@8Y1'M;<3N[>],-%'0^HI
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M9W(KMD9SSD]?QJKX&\$_"SQ#;Q>)O"VAVTR&0A3,CD(Z]MC\ CV%>G@   #
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MRD'U+_I[#_P+_@&>,Y&>M'T%:'_$I_Z??_'*3&D#I]N_\<I#^H_]/8??_P
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M_P"?W_QR@?U/_IY'[RCU/]*7D=\5=/\ 9*GK>=?]BD_XE.<#[;GT^2@/J?\
MT\C]Y1ZBDSSD]:O_ /$IY_X_>.OW*JS^6TI-ON,?;?C/Z4C*K0]G&_,GZ.Y'
MRV2>34S)M;;N#<9)';VJ(97"]*7D$\X H,!P.U<8'--QSG.?6C(Q\W2E7#+C
MGB@#Z@_9G_Y)KJ'_ &%Y/_1,->PUX_\ LT\?#;4,?]!:3_T3#7L%<-3XF=$=
M@HHHJ"@HHHH **** "BBB@ I*6DH 2O#O@H=+7QWXU&M-&/$[ZG(=L^/,\CJ
M-N?KSCV[5Z_K7B/1O#D,<NNZI:Z>DI(C-Q*$WD=0,]?PKQ7XBCX,>,-2_M.[
M\5QZ?JB@;[S3G+,X'3< I!(P.G-,1;^-S:6?&7@Q='$1\2MJD6TP8\SR<X(8
MCM]?>O;J\.^$^F_";3/$0GT/Q)_;.OR_+'+J!PX)_P">8*CD_4FO<C0A"5\S
M?'.'ROB5*^/];;1-G\,?TKZ9KYY_:#MO+\7Z?<8QYMGCZ[6/^/\ *NO"O]X<
MN*7[L\FJ:SG:VOH)T.&BD5P?0@YJ&BO5/*/M:TG6ZL8)T^[+&KC\1FI:YOX=
MZA_:?P\T:X)RXMEC?ZK\O],_C72UX<E9M'N1=TF-HI:2@8E)3J::!"4U_NGZ
M=Z=13$> ?"*;R/BE=PG*F6*9.>IPP./T_2O?:^<O!\W]E_&I$/RK]NF@8?4L
M/T./RKZ-KIQ'Q)FE3<*2EI*YS(=&P212>@-7=R[<Y&*H4Y(GD'RCBI:3*3:&
MRL&D8CH33*>Z,APPQ3:M$#:2G4E,!*2EHH$)24M1W$ODPL_<#CZTP*%[=-YQ
M1,;5&/QJC3CR<GK5^SL20)IEX_A!%7HC/5C;.RZ2S#W53_.K].I*DJPE%+24
M )4MNZQSJTG0?I4=%&Z!:%F]ECDVA#DCJ:J4ZBDE96&W=W&TN/ESG\***8A*
M6EIVP^7OXQG'6@#(O[?RY/,4?*W7V-5*W9(UEC*,.#68^GSJV%4,/4&J3)L5
M:*L?8;C_ )Y_^/"E^PW/_//_ ,>%.XBO15C[!<_\\_\ QX4?8+C_ )Y_^/"E
M<+%VPG\V'8WWD_45<JI96K0;FDQN88P.U6ZEEH*6BE RP'K2*$IR+N<+ZG%7
M/L:;.IW>M4^5;CJ#4J5]BG%K<O?98MN,<^M4R#'(0#RIZU/]L;;]T9]:KYR<
MFIBGU'*W0E-S(RXS^51TE+56L*]PI:2EH 6BBN&\=_$FS\+Q/9V!6YU0C 3J
ML7NW^%$8N3LC2G2G5ERP6IH>-_'-EX0T\Y(FOY5_<0#_ -";T%>"Q0ZUXY\2
MG;NN[ZY;+,>%4?T45?T/PYKWQ"UR6X9F<.^9[N;.U?;Z^@KWOPOX3TWPGIHM
M=.C)=L&69^6D/J?\*Z;QHK3<]CFI8"'*M9LI>"? ]EX/T_$>)KZ4?O[@]_8>
M@KJ:**Y6VW=GCSG*I)RD]3S[XB?$F/P-J^F6NKZ1/)HFH!X[G4$8XB)& H [
MXR>HXZ5SNH3)\&/"MMJ7@72I-:T.^NVNKZ?[09/+B8?*%]!S][VYZU:\;^++
MCQ?XFO?AYX9T&UUEHHLZE-?.4AM\^A'.X9'([_0UQOAO4?$OP-U&'0O'<,=Y
MX4U%MJ7$1,L=NQZCD=/52/4C-9L$=/XTGTSQ+\$]5U/X:VZSIJ%PESJ,-L")
M)!D&174<@X&"![U23QA'\7=2\/>'?#6AW5MI.GW45UJ<EW$ D2QCB)><'/3^
ME4]:\,7_ ,/+U_'OP@N8[[0Y!YFH:9%)OC*#DE<=L'ZK7L?@OQ+8>+_"=GKF
ME1^5!=*28R "C D,#CW!H U=/TZRTJS6TTRT@L[9,[88(PBKGT XJU24M,!:
M***0"TM)2TAA2BBEH *6BBD,6EI*6@84444@/@DGT'6@>AHSS_\ 6H!^7!&:
M]P\D&X;_ !H(^;GH?UHR>,G'O03@^HH$'^SU]A2#CIP?6GRH8U7(^\,CWIO1
MN0* &8QG.>M!!/6G9'KBCY3G(.>V*!C1TZ4<YS2G')'Y4[[I&ZD!&2<<_AF@
M!B.1P.^*>02">H]#2!OE(SP>PH ;P.G:E&68=?\ "E R,8]Z3H<TAB$=EZ9I
M79G/)SCH:" %&&Y]Z0G)H&'.>O/<TW&?NU8M8H)9MMQ+Y2 $[L=3Z4D\JRR$
MHJH,8 4?K0*^I'%&9) JX'&>32'[I7WY-)GIBEZ_A2&-VYI1P>#@BE(!&<Y[
M8H)Z ]!04(P[FC XQ^M!]Z>5]^U(",CKG-*1G';Z4[''7CW[T8/?OVH&-92@
M'3GWI",C)Z>@I2.OUHP <GFD W (-!&32COBCL><4 -Z]>*7&3[4=.^11G Z
MX/K0 F,G I3[4;B,C\/K2X[8S].](8F.GK12J0#@\ TH&5P!0 WITHVYZ=33
MP.G%.Z]L4#(G4KA3ZTA&>:D9,<DG\*85(_PI -4 MR<#O2;#TQGTI^W(_K0!
MUH ;M;./S%)MXIW)Z_G1GH=O% R9X[8:<CB3-PS<KV JMC\J<V">ASWI,[AS
MZ<4@&D<4N<KCJ!Z48SQ03C@&D WKVHQBESCI1CYN.30 !3R2,#UI/P_^O4GG
M/]G\G^#=G&.],QZ4 )[&E/';Z4;2:%4G% ">U&/EXZT[:-WTZTNS(SP,4BAN
MTGITI.>>*>#_ '>!ZT;3DT -"$#/./6E'RMP?H:<SEE"DDJO2F'&?Z4 #<].
M/7WI00FP[@?]G'2FGKQT-"C\:0Q222>@YS5ARDD$4<,)WC)=C_$:K 8;@_A4
ML<A1A\VWW':@9&<ID%>>G-(1\H.>M.EP9#@Y'J>YIJ@$@,3COB@#ZB_9G)/P
MUU#/_07D_P#1,->PUX_^S1_R3;4,=/[7DQ_WYAKV"N&I\3.B.P4445!04444
M %%%% !1110 4444 <[XM\"^'O'$-K%XFL?MB6CL\(\QEVDC!Z$9Z#@UCVWP
M9^'MKCR_"UBV/^>@9\_]]$UW-)3$>#_'3X>^%?#O@!O$&A:7;Z5J5C<Q&&6U
M&S<2XX('7V]*]HT.:>Y\/:=/=Y\^2UC>3<,'<5!.?QJU<VEO>P^5>013QYSL
ME0,,^N#4F,# X H 2O$_VB;/-OHMX!D!I(B?3(!'YX/Y5[::\R^/%C]I^'JW
M"C+6MTC$^BG*G]2*Z*#M41SUU>FSYLHHHKV#QSZ+^ FI_:_!-Q9,?GLKDC'^
MRPR#^>?RKU&OGW]G[4'A\4ZA89^2XM?,(]T8<_\ CQ_.OH*O)Q$;5&>MAY7I
MH2DI:*P.@2D-+24Q"4E*:2@1\Q^+&;0_BW>3H,>1?B=1ZC(;']*^F(I%FA26
M,[D=0RGU!KYY^-5B;7X@-< 82Z@1\^X&T_R'YU['\.]5&K^ ],GW;G2(1/\
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M:]?KQ_\ 9I_Y)M?_ /86DX]/W,->P5PU/C9TQV"BBBH*"BBB@ HHHH ****
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M^@Z7)J&IZ'+#9Q &1UFCE,?NP1B5'U%>VWD6WXY+-"#)=0^$S):M,!YAEW,
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MO;K0)EMXU\R3$D;R*OJ4#%@/PK0^#-I _P 6M$^VX _>R1*1D%Q$Q7Z=,CW
MKIM%U[PAI7Q(;5K;_A-[W7FGE6:U:&"1IFY#HRJV2!CIVVCTHG)IV0HQ35V>
M6+X9U:3PLWB**U$FE)-Y$EPDJ-Y;^C*#N7J.2 .1ZBMGP[\-M=U;4]!^UV!B
ML-7E#(WVF))'@5AYCJK-NX7D$CG(QG(SV/PRD^T>,/%D%Q;"W\'31SOJEO>
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MNB7[VPMI&E8J6"*<Y!XSC P.]5I-8>XT?P1!:^$FT#1?[=AFM)YM1\\O\_S
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M(.P_6NSHHK@E)R=V>=*3D[L*6BBI)"EHHI#%I:2EH *6BEI#"BBEH&%%%%(
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MIQC\<@D8/4'%5>>,<>E&>,=Z+(5V=I)\7O',\\,S:_(LD+&1-D$2 G!'S*%
M;@G[P-9.B>.?$7AU;V+1]1^S1WQW7$7DQO&Q]0K*0O7L!V]!6"O/7BFGC/OT
MI<D=K%<TNYN1^,=>C\)OX96_/]CN<FV>)& .[?PQ7<OS#/!'-5=7\0ZKK>OO
MK6IW;RZC(R.;E%$;;D "D;0 " HY'I6;N_'/%!! &[/THLK["NSL+GXN^.KJ
M%8IO$$VU2IRD,:,2IR 6502..A.#WK*C\:^(8?%,GB.#4GAU6;F2XB14#\ '
M*@;2.!QC&1GK6&,YX'/K2 =?;K2Y(K9!S2[G0^(O&GB7Q;!%'KNHR74,#;DC
M6-(XU)[[4 &?<C/)JX_Q-\7R3Z=-)K!DFTPG[)(]O$S1Y4H<L5RWRDCYL^O6
MN<^V.FG_ &55&QFW$XY^E5]W&.^:?+':P^:6]S6TKQ!JFC:P=;TNX\F_C=G%
MQY:MM9@0W!!'()XQWJE>7US>:I-?W$S&[GF,\DH&"SL=Q;CH<G/%5]QR1DX;
MTZ&DR2,'UXIV6X79V<GQ:\<2Z8;1O$$PC9/++K'&)-O_ %T"[\^^<UQO!;U_
MI30<'&*7. 2/RI**6R!MO<]8U;X@7_AWP'X,A\*ZY%%.MG,E[#$8YMAWJ5#H
MP(4]<9&>M<%)XQ\0GQ9'XCDU.235HCF.XD57*\$8"D;<8)XQBL4GH2*!D-S4
MQA%%.39J:=XCU33?$@U^SNO)U(2O*)_+1OF<$,=I&WG<>W>I=%\8:]X;U*XO
MM%U*2UGNL^?A599,G/S(05/)/;C)K&R60 XP#GCO29Y)/<TW%,5V;.M^+]?\
M27\%[K>IRW,]N,0-Q&(N<_*% "G@<@=AZ5KW/Q:\<W.GO92Z_/Y+IL9DCC60
MC_KH%#?K7(;LC QCKFFD$DD8QZ4G&/8:DS<\.>-_$?A*.>/P_J<EK%.<R1;$
MD1CTSM<$9]\>E0>(O%&L^*KR.ZU_4)+R6-=B;@%5!Z*J@ ?@*R1R>.:0@?CZ
M4<JO<=W:Q;TS4KG1M0AU#3KF2VO8&#PRQG!0_P!1VQW'%=+??%CQKJ-K<6UY
MKCR0W%O);31BWB571QAL@(.2/XNHYP1DUQQ(YH^\<+RU)Q3W07:.C\/?$/Q/
MX6L7LM"U=[:V=M_E-$DJAO4!U.#],4L_Q&\57&HZ;J%SJ[RW>EM(UI*\,;&,
MO]XG*_-G_:SCM7,CKTZ4GK2Y8WO8.9FIIWB/5=+\2?\ "06-UY6IB1Y?M'EH
MWSOD,=I&WG<>W>G-XFU=]#N=':[_ - NKK[9-#Y:?/+C&[.,CIT!Q[5DK[\4
M?C3L@NS3CUR]&@)H4UPQT?[:+UX$1-WF;=A8,1G.WC&<>U>U6>H7=M<6<>E?
M%;31X2C5&,=[/']O6( %H\; ^>PP1@?2O \XY/0T]9&C! '48S[5$H)E*5C=
M^(.OP>*?'^KZS:!EM[B;]R6&"450BG';(7./>HO#WC;Q#X6M;JVT+46MH+O'
MGPF))4?C&<.I /N.?RK"V[1[T=,L<>U5RJUA7=[FGJGB#5=:T_3[/4;GS[;2
MXO)M5\M5\I#CC( )Z#DYJ^OCGQ#;ZAHU[!J6VXT:W^SV+^1&?)CVE<8VX;@G
MELFN=#'IG@\D4I&?NGBCE5AW9T.A>/O$_AJ2[?1-7DMQ=R&6X0QHZ.QZG:RE
M0?<#T]*I^(?%.M>*[Y+OQ!J$E[,B;8]P"K&/154 #\!61USW%&".W..":FRO
M<+O84 =^U"@'&?\ (HXQSS2].HZ>], /RJ4QC/K3.C?2G,<MDCFAB!C^M(!N
M"<\=.] [$XH(^;)Z#MZTTGGCKUH&.S\W3Z4G!!/?-!!SP2?ZT@ZXZ^U(#Z@_
M9JS_ ,*VO\_]!:3_ -$PUZ_7D'[-7_)-K_\ ["TG_HF&O7ZX*GQLZH_"%%%%
M04%%%% !1110 4444 %%%% !1110 4444 %%%% "44M)3$)24ZDH 2DI:0TQ
M"4E+10 E)2T4P/,?CUK&B6/PUN;#68OM5UJ!$=A;)_K&E!!##OP<9_+O4?PA
M\ S>%M(E\2>+97E\1:C&'N9KE^;>(#A,GH< 9_+M7=:WX<TG6;FQOM4L%O)]
M+D,]KGJKX[>O0=>X%>(+J7B;X^^(KW2([@^'?#6GR;+RUWC[3+ST(Q[=.@]Z
M0&SXQ^-6I:CJ%QH_PHTYM8N;-3+=WHCW1HB\D)SSTQG\LUZ)X \;67CSPI;Z
MK9X2;&RZMR?FAE'53_3VJ_X7\):-X.T9-,T"S2W@4?,V 7E/]YF[FO+/AUY-
MC^T9XVT_0L?V6\*RS(GW$GRN?;JSC_\ 53$>RWEG!?V<MK=Q++!,I1T89# U
M\P_$'P3<>#==,8#/83DM;2^V?NGW%?4E97B3P[8^*-%FTW4DS')RKC[T;#HP
MK>C5Y'Y%1E9GR'7L'PP^*GV7RM#\2S9AX2VNG/W.P5CZ=,'M7G'BGPQ?^$]:
MDT_44Y',4@'RRIGAA6-7HRC&I$U:4D?9P(905((/(([T5X#\./BO+H9BTGQ"
M[3:=G$<YY:#_ !7^5>]6US!>VL=S:2I-!*H9)$.0P/<5YM2G*F[,PE%H?13L
M4F*S)$HHHIB$HI:* $HHHH 2N/\ &GPYTSQ;&TZ@6FI!?DN4'WO9AW^O6NQH
MJHR<7=%1E*#O$\/M/%GBSX:7RZ;XEMWO[#I&[-GY?5'_ *']*]1\.^,]$\40
MAM+O%,V,M;R';(OX=_J*U=0TVSU6R>TU&VCN8)!ADD&1_P#6/O7D7B?X-7=E
M.;_P=<NVT[A;.^UT/^RW?\:VO"IOHSIO2J_%H_P/9J*\"TGXJ^*/#-T;'Q!
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M#>Z=:\OU'XLZI?ZI>6?P]\)W'B2*PD\NXO1,(HMXZHN1\Q]ZE\&_%[2/B/\
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M/L)05M44OB)HV@6GPO\ "CV&L*TD4$K6J+8-']NW.F]R<_(5_P!K)->=>'M
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M!H)&WOG-&,GCCZT%,<@_C3 7&[C/09I">/4TO!'XTO\ "1_%ZB@!F?J!VQ0
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ME0J#EAGU%- YP/\ ]5(9]._LUG/PWO\ '_06D_\ 1,->OUY!^S6-OPWU ?\
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M#['\ZX*E!QUCL8R@UL>C8I*4'(R.E%<QF)24[%)B@!**7%% "4444Q!24M%
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M:QCSMS\NZD"D+DGI28SC'.:DH^G?V:O^2;:A_P!A>3_T3#7K]>0_LVC'PXU
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MMC_JM=E'^];@_P#LU>O*0RAE(((R".]+6GMJBZFBQ%5=3QD_ +GC7N/>V_\
MLJ<GP"7^/7C^%M^GWOUKV2BG[>IW*^LU>YY+%\!-.&//UJY;UV1*O\\UIVWP
M0\,P\SRWLY[YD"C]!7H]%)UJCZDNO5?4Y&S^%_A"RQLTA)3ZS.S_ ,S706>B
MZ9IZA;'3[6W Z"*%5Q^0J]BEK-RD]V9N4I;L2EHH) QD@9Z>]22%+7+2_$GP
MC#KD&DMK=NUY/,8%522H<=BW0>G7K5;XI^,;OP-X(DU?3K>*>Y,\<*+,2%&X
MXR<4AF[XH?5(_"NI2>'R@U..V=[;>NX%P,@8]^E>%?#SP4?C)HO_  D7CKQ1
MJ6H+%</$^FHPCCA9<'!Z\$$'@#K7T/;LSVT32??9 6XQSCTKYI;P3);?'34O
M!3Z[?Z+HNKDWT,5DX3SB<D)GMT(_"DQH]LTW3=%TWPSJ'A_X>75E9W5O$Q58
M)!*89&'#,"3R3ZUY+\--'/Q@U;4+SXEL]]-H<2:>EB[E0'YWRL!C#$CJ/Z"O
M3])\/>!/A%I\MPDL&F><H$UU>7),DWU+'U]!7()87GA;]H&QUKP_9SWN@^+;
M??<26L9=4?&?,8@8 ^93D]B: ,#0O#\7AKQQXD^$NHRR+HOB&V:?2VD.=C8)
M!SZC9^:BK7ACQSXM^%6G+X1\3^$=1U5;,E+&]L5++)'GY1G&,<^N1TQ7J'B_
MX>6/B[7M#U>:[FLKO1Y_-26 #=(O782>@S_6K'C2V\8SVMJW@6^TZUN(W)F6
M_C+)*N.!P,B@#P[5[3Q'X8\<^&OB)JR_9-6U[5#!/IBG(C@8!%7CJ=O7WQWK
MZ/M].L[2YGN+:UAAGN6W32(@#2'&,L>_ KSS0/AIK%]XIM?$_P 2=9CUC4++
MFRL[>+R[>U;^\!_$?K_2O3* "EHI: "EHHI#"EHHH *6BBD,**** "BBB@ H
MHHH **** "BBB@ HHHH ^&"  ".>?RJ3?^Y6+@!#D'')J(@E<GN><TH)Y Z^
MM?0GC#E8>2ZE1DG[V>E)C.>.G:D7/?A1V(HVYR%!P!R*!@0#VP>O%"\<X^F:
M%X<!>>^/2GE/D#%AENJCM2 (YE24&2/>O=::1\VY<9S^5-(7=W!_I2[N !SC
MJ:86ZCYXHHI5$<OG$@%B!T/I49'=?_U4HR0=V..<T ,S!$&2Q^4>M(!5BFE@
M+J04CZD\5&0-Q/7UYIQRNZ-^QY [4@7=@T$J_4;CG^M &!Z48PW.>O>E.<YS
MDGH*18^&WEN&*VZ,Y49.#V]:B*C;G.WZ=ZGCGEM=_DL4WC:VWN*A! )VCCTZ
MT"&LIX/MTH!.,*OZ4H'!]/7-'0]C[BG8!#R<=.*4@ALG.,<'-&/H/?TIQR/3
M_&D P E,8YIN/F^4]NM/^;@'CCK2 ;>_/TH*%8*, +SW)[5&."VTYYYP.E2'
M)SN.::/E4'@X]#UI"&YZX/3H*4#@#.3U(I0 3V!_E1U7C%(:$^ZQ(&<],TF<
M<'K2\;N>N./:D(.<'!'J*!B#C';/'%(!G///KZTX E@N,#Z4A !('X>](D5
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MR=D>V-F!<_..U(9],_LU?\DWU Y)SJ\G7_KC#7K]>0_LV#'PWU#(Q_Q-I/\
MT3#7KU>?4^-G7#X4%%%%9E!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !24M% "4E.I*8A*2EHH 2DIU)0 VBEHIB,W6- TKQ!;Q0:U86]
M]%#*LT:SH&"N.AYJS>6-K?V,ME>V\<]K*FR2&1059?0BK%% 'BOC:S\!?!^%
M+W0/#=K+XEOF*Z;!@R,KGC> Q.T ^G?BM'X<^!T\&6-WXV^(=Y$_B"^'F7-W
M<OE;16_@!/ /(!Q]!Q65#X4UK2OVC;WQ)XBTIM4TJ:%Y+/42P9+!57.-IZ$
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ML5$BH3W;D8'ZUS?P5\'>'#\(].G;3[2]EU*)I+N6:)79V)(*DD9P.F/K7(^
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M&>E'? ^M(!,8IG^?I3F'S=:4 -U(SWH&-^O7UHXI2N%&!]": ,CONST I#$
MSC!R<]*!UZ^PI> "<8:A49C@<D^E( 0@D;N!GGVI"%R<9(SQFG$88KT(X.:3
M"[2Q;!STQ0 @'/'/TIX7YFX^;'7TJ,8&1^7%*#S\V>G04#!20<CL*#SU!W>E
M(V"ORYSGFD^HJ1GT[^S7Q\.-0YS_ ,3:3_T3#7KU>0_LV?\ )-[_ !_T%I,_
M]^8:]>KSZGQLZX_"@HHHK,H**** "BBB@ HHHH **** "BBB@ HHHH ****
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MA@"P)Q]:D=?+9U+9*G;D"F8Z8Y[]* $.,9[=O>@'@XX^M*0..Q[4#)!SZ=J
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MSZTO^]^&.U)CGCGWI /PH4@\GMGM3 N!C&!3@ 2#C@C\J0$ECD#GCK3 0XW
MG)(]*0Y(!ZCJ<TO5N<X%!_W>!2 ;][@8)]#0%." <^WI2CGJ:".>/6D,0@#K
MCCJ#29&WH<"G.?GS_.D"G/.>.AH&)@;<DC/I0!\IQ_\ KI2!D],GO1@X^7]:
M  GICK1'&9&VJ"2Q]:,_NPOO^=*N5)VG![XI"(V&&(/7T[4<K_G@4'IC/&:7
MDD8[]:!@OOSWH'7TQU]Z.%48ZT,,X'?VH& Y/&?SZ4(P5SP.E R.G%(OW?7G
MBD @ [COG'K2G[O''-*,X&128)_&@$"J7.%.#CD4T@8!"]_2EQV[GOZTH4[N
M:0Q,D1X7\SUII&<#O[4\#YCCIBDV$<\]: &<CC/(['M1T].M.(_N\TA'&3D4
MAB>_)YHZ @D ^G:G$]CC &:;G+9'\J $'(.>AI N&.#Q3N2.W'7CI1UY_,4@
M&A1T_6DP,G^HHQ_]?FE R><^U QHQZ<T$<9&,^]+C/W>#3@@9>.M(8T<=OPQ
M3<] !@YI>XQ0>Y'&/6@!&X8]J0@XV]1UYI2>>1S2'TX+=^>E(8F>NWFDQGJ>
MOI3@.,]0*0<]N :0#Q'(6V(R],\<4U(G>)I%&Y4^\1VINXG.>AI0S")E5OE/
M51WI#&@$=>G:C )..>*7#,!G-)MQDYSS2&(<CZ'C- 7*D#D]Z4]\?_JI!GMR
M:!B$$XSUIK#'4_04_<2:L22P-8+&(C]H!R[GTI,9])?LV?\ )-[_ /["TG_H
MF&O7J\A_9K_Y)O?_ /86D_\ 1,->O5YU3XV=4/A04445F6%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% "44M%,!*2EHH$)12T4 )12TE "44M% "8HI:* $Q12T8H ;BC
M%.Q24 )BC%.HI@-Q12T4@$Q2XI<44 )12T4 )12T4 &**** "BEHH 2EHHH
M**6B@8E+112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !24M% "44M%,!**6B@0E)2T4 )12T4 )12T4 )1
M2T4 )12T4 )12T4 )2T44 %%+24 %%+10,2EHHI %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
'%%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img30600998_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img30600998_1.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#X17AI9@  34T *@    @ ! $[  (
M   /   (2H=I  0    !   (6IR=  $    >   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $YI8V]L92!3
M96ET=&5R    !9 #  (    4   0J) $  (    4   0O)*1  (    #-#8
M )*2  (    #-#8  .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                         #(P,C,Z,#,Z,C$@,C(Z-38Z,3  ,C R,SHP
M,SHR,2 R,CHU-CHQ,    $X :0!C &\ ; !E "  4P!E &D = !T &4 <@
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" $3!0<# 2(  A$! Q$!_\0 'P
M 04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0
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M]?\ UZNT4 4O[2_Z<KS_ +]?_7H_M+_IRO/^_7_UZNT4 4O[2_Z<KS_OU_\
M7H_M+_IRO/\ OU_]>KM% %+^TO\ IRO/^_7_ ->C^TO^G*\_[]?_ %ZNT4 4
MO[2_Z<KS_OU_]>C^TO\ IRO/^_7_ ->KM% %+^TO^G*\_P"_7_UZ/[2_Z<KS
M_OU_]>KM% %+^TO^G*\_[]?_ %Z/[2_Z<KS_ +]?_7J[10!2_M+_ *<KS_OU
M_P#7H_M+_IRO/^_7_P!>KM% %+^TO^G*\_[]?_7H_M+_ *<KS_OU_P#7J[10
M!2_M+_IRO/\ OU_]>C^TO^G*\_[]?_7J[10!2_M+_IRO/^_7_P!>C^TO^G*\
M_P"_7_UZNT4 4O[2_P"G*\_[]?\ UZ/[2_Z<KS_OU_\ 7J[10!2_M+_IRO/^
M_7_UZ/[2_P"G*\_[]?\ UZNT4 4O[2_Z<KS_ +]?_7H_M+_IRO/^_7_UZNT4
M 4O[2_Z<KS_OU_\ 7H_M+_IRO/\ OU_]>KM&: *7]I?].5Y_WZ_^O1_:7_3E
M>?\ ?K_Z]7:* *7]I?\ 3E>?]^O_ *]']I?].5Y_WZ_^O5VB@"E_:7_3E>?]
M^O\ Z]']I?\ 3E>?]^O_ *]7:* *7]I?].5Y_P!^O_KT?VE_TY7G_?K_ .O5
MVB@"E_:7_3E>?]^O_KT?VE_TY7G_ 'Z_^O5VB@"E_:7_ $Y7G_?K_P"O1_:7
M_3E>?]^O_KU=HH I?VE_TY7G_?K_ .O1_:7_ $Y7G_?K_P"O5VB@"E_:7_3E
M>?\ ?K_Z]']I?].5Y_WZ_P#KU=HH I?VE_TY7G_?K_Z]']I?].5Y_P!^O_KU
M=HH I?VE_P!.5Y_WZ_\ KT?VE_TY7G_?K_Z]7:* *7]I?].5Y_WZ_P#KT?VE
M_P!.5Y_WZ_\ KU=HH I?VE_TY7G_ 'Z_^O1_:7_3E>?]^O\ Z]7:* *7]I?]
M.5Y_WZ_^O1_:7_3E>?\ ?K_Z]7:* *7]I?\ 3E>?]^O_ *]']I?].5Y_WZ_^
MO5VB@"E_:7_3E>?]^O\ Z]']I?\ 3E>?]^O_ *]7:* *7]I?].5Y_P!^O_KT
M?VE_TY7G_?K_ .O5VB@"E_:7_3E>?]^O_KT?VE_TY7G_ 'Z_^O5VB@"E_:7_
M $Y7G_?K_P"O1_:7_3E>?]^O_KU=HH I?VE_TY7G_?K_ .O1_:7_ $Y7G_?K
M_P"O5VB@"E_:7_3E>?\ ?K_Z]']I?].5Y_WZ_P#KU=HH I?VE_TY7G_?K_Z]
M']I?].5Y_P!^O_KU=HH I?VE_P!.5Y_WZ_\ KT?VE_TY7G_?K_Z]7:* *7]I
M?].5Y_WZ_P#KT?VE_P!.5Y_WZ_\ KU=HH I?VE_TY7G_ 'Z_^O1_:7_3E>?]
M^O\ Z]7:* *7]I?].5Y_WZ_^O1_:7_3E>?\ ?K_Z]7:* *7]I?\ 3E>?]^O_
M *]']I?].5Y_WZ_^O5VB@"E_:7_3E>?]^O\ Z]']I?\ 3E>?]^O_ *]7:* *
M7]I?].5Y_P!^O_KT?VE_TY7G_?K_ .O5VB@"E_:7_3E>?]^O_KT?VE_TY7G_
M 'Z_^O5VB@"E_:7_ $Y7G_?K_P"O1_:7_3E>?]^O_KU=HH I?VE_TY7G_?K_
M .O1_:7_ $Y7G_?K_P"O5VL[Q!K5OX;\.W^LWR2R6UA \\JP@%RJC) !(&?J
M10!)_:7_ $Y7G_?K_P"O1_:7_3E>?]^O_KURWAWXK^'?$O@'4O%UFMW#I^F>
M9]ICG11*NQ0QPJL1R",<\U=^'_Q TKXCZ!/J^AV]Y!;PW36K+>(JN6"JQ("L
MPQAQW]: -S^TO^G*\_[]?_7H_M+_ *<KS_OU_P#7J[10!2_M+_IRO/\ OU_]
M>C^TO^G*\_[]?_7JAI'B[2M=\2ZUH>G/+)=:(8EO&:/:@:3?A03R2-ASQCD8
M)YQE^-OB3I_@?4M+T^[TG6-4N]5$GV:#2K99G;R]I8;2P/1L\9Z&@#H_[2_Z
M<KS_ +]?_7H_M+_IRO/^_7_UZY7PQ\4]*\2>)#H$VD:YH.J-!]HAMM:LOL[7
M" D$I\QSC!ZX[XS@X[>@"E_:7_3E>?\ ?K_Z]']I?].5Y_WZ_P#KU=HH I?V
ME_TY7G_?K_Z]']I?].5Y_P!^O_KU=J*ZNH;*SFNKI]D,$;22-@G:JC).!ST%
M %?^TO\ IRO/^_7_ ->C^TO^G*\_[]?_ %ZK>%_$MAXO\-VVN:1YOV*Z+^49
M4VLP5V3..P)4D=\$9QTK6H I?VE_TY7G_?K_ .O1_:7_ $Y7G_?K_P"O5VB@
M"E_:7_3E>?\ ?K_Z]']I?].5Y_WZ_P#KU=HH I?VE_TY7G_?K_Z]']I?].5Y
M_P!^O_KU=HH I?VE_P!.5Y_WZ_\ KT?VE_TY7G_?K_Z]7:* *7]I?].5Y_WZ
M_P#KT?VE_P!.5Y_WZ_\ KU=HH I?VE_TY7G_ 'Z_^O1_:7_3E>?]^O\ Z]7:
M* *7]I?].5Y_WZ_^O1_:7_3E>?\ ?K_Z]7:* *7]I?\ 3E>?]^O_ *]']I?]
M.5Y_WZ_^O5VB@"E_:7_3E>?]^O\ Z]']I?\ 3E>?]^O_ *]7:* *7]I?].5Y
M_P!^O_KT?VE_TY7G_?K_ .O5VB@"E_:7_3E>?]^O_KT?VE_TY7G_ 'Z_^O5V
MB@"E_:7_ $Y7G_?K_P"O1_:7_3E>?]^O_KU=HH I?VE_TY7G_?K_ .O1_:7_
M $Y7G_?K_P"O5VB@"*UN$N[9)HPP5LX##!ZXHJOH_P#R"H?^!?\ H1HH -2_
MY=/^OE/ZU=JEJ7_+I_U\I_6KM !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ",<"D!I)3A
M1]::IH DI::*<* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y+XJ_\DC\
M4?\ 8+G_ /0#76U%=VEO?V<MK?6\5S;3*4EAF0.DBGJ"IX(]C0!\H65C?6]K
MHG@RSC<V'CZQTJ>1D/$/E<3X[Y*QAC[&K9O+K3?@[XBAM+B>PTJX\=S6NJ3V
M@PT-FR(& QT!^48P<YQT.*^FH]!TB&6QDBTJR1]-1H[)EMD!M58;2L9Q\@(X
M(&.*6WT/2;2SNK.UTNR@MKQW>Z@CMT5)V<8<NH&&+#@D]>] 'B'A^/P]X=^,
M"Z;\+-38Z!-HT\^KI87+WL%NX!V2CELR9"C .>PZX/$>!Y--\+^,O#.H+?6.
MMW6I:CY(U/0M7E6ZE\QR"+RUG4L0<@_*J?=Y))!KZDTG0-'T"&2+0M)L=,CE
M;=(EG;)"'/3)"@9-16WA7P]9ZP^K6>A:9!J4C,[WL5G&LS,V=Q+@;B3DY.><
MT >-_"O0/#6E?'[QQ#L@M[^SGC&EQ/=-O*2)(TVU2WS\;2<@[>.F:T_C!9ZC
M?_%WX=6NB:I_9%](;T0WOV=9_).Q"3L;ALC(Y]:]6_L'1_[;_MG^RK'^U-NW
M[=]F3S\8QCS,;L8XZ]*EN-*T^\O[6^N["VGN[/=]FN)85:2#<,-L8C*Y'7'6
M@#Q#P<-5A^-6I6WQ$U2?4/%^GZ>ZZ$_EQQ6US;L&)9411\_7OTW#G;D>9^%!
MJ=WJ6B^(O^$B\/6GB6XU<)))-=WS:I,^\J8984#H$88'W ,;02.17US<Z+I=
M[J5MJ%YIMG<7MI_Q[W,L"M)#_N,1E?PJ&+PUH4&M-K$.BZ='JCDEKY+1!.V1
M@YDQNY''6@#P?4K3P=K_ ,1/'DGQ;UB2QN]-F1=*\R]>%[:W"$J]N@X=CPV
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M<TC$%^I&0, GC QTH ^B]4\2Z-H]REIJ&JV-O?3)NM[2>Z2.6?L JDY.2,<
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M0HV_*W3/\.1Z=\ +U[WP'>NNC6NF6G]I3?9GLO/%O=+A<R1+,Q8+G(P,#@C
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M_P#LXER&Y<;3DC''U- '40_&^WN?"NC:M#H4RSWVNIH=W9S3[&LYB,L<[3O
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M_P#Q%?*E%'U.GW8?7*G9'U7_ ,+F\ _]![_R3G_^(H_X7-X!_P"@]_Y)S_\
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M7/U?_P!%25\JU]5?&#_DGUS]7_\ 14E?*JC<P QDG')Q7J8/X&>7C/C1Z?\
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M]:QJ2;:MM_7Y&4J<4D[[_P!?F6?#'PQ\1Z__ &=?MI5P-&N;B-9;A)$5Q$7
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MW?\ 4U?^4[_[;1]9I=_S#ZM5[?D>&T5[E_PS=_U-7_E._P#MM'_#-W_4U?\
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M ,0:I+J6KSBXNY@HDE\M4W8  R% '0"J->Y?\,W?]35_Y3O_ +;1_P ,W?\
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M >JFLOQ'X/NOB#KFCJ-)OO"]C=6NJ/(]O$%+%WB,;7 V84RD;VC;YC@@G.<
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M^.4?\+S\2?\ /CI7_?J3_P".4?V5B?+[P_M;#>?W'O5%>"_\+S\2?\^.E?\
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M?4@R31%"\4DK .,CD%3D'Z8H [.;5[&WUFUTJ6;%]=QR2PPA&;*1[=S$@84
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M<><:I8:S?_#];>[T_P 4-KT-VGF:1::>]MI]BJ7@=WC$4:QW"X4;?FE;Y@P
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MM97A:X\6^(_#^D>*[?6X_P#B82)<2:1-#&MJEJQP45U0R^8%PVXL5+ C !X
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 9'B/_D'Q?]=A_P"@FJ-GT%7O$?\ R#XO^NP_]!-4;/H*
M ->'I5M:J0]*MK0 \44"B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH I:/_ ,@J'_@7_H1H
MHT?_ )!4/_ O_0C10!D>.]6GT3PZ+^T2-Y89=ZB4$J2$9AG!'<5Y9_PO#Q)_
MSY:5_P!^I/\ XY7HGQ3_ .1)F_WF_P#1;U\YUUT(1E'5'VW#V!PV)H2E6@F[
MGI'_  O#Q)_SY:5_WZD_^.4?\+P\2?\ /EI7_?J3_P".5YO171[*'8^E_L?+
M_P#GTCTC_A>'B3_GRTK_ +]2?_'*/^%X>)/^?+2O^_4G_P <KS>BCV4.P?V/
ME_\ SZ1Z1_PO#Q)_SY:5_P!^I/\ XY1_PO#Q)_SY:5_WZD_^.5YO11[*'8/[
M'R__ )](](_X7AXD_P"?+2O^_4G_ ,<H_P"%X>)/^?+2O^_4G_QRO-Z*/90[
M!_8^7_\ /I'I'_"\/$G_ #Y:5_WZD_\ CE'_  O#Q)_SY:5_WZD_^.5YO11[
M*'8/['R__GTCTC_A>'B3_GRTK_OU)_\ '*/^%X>)/^?+2O\ OU)_\<KS>BCV
M4.P?V/E__/I'I'_"\/$G_/EI7_?J3_XY1_PO#Q)_SY:5_P!^I/\ XY7F]%'L
MH=@_L?+_ /GTCTC_ (7AXD_Y\M*_[]2?_'*/^%X>)/\ GRTK_OU)_P#'*\WH
MH]E#L']CY?\ \^D>D?\ "\/$G_/EI7_?J3_XY1_PO#Q)_P ^6E?]^I/_ (Y7
MF]%'LH=@_L?+_P#GTCTC_A>'B3_GRTK_ +]2?_'*/^%X>)/^?+2O^_4G_P <
MKS>BCV4.P?V/E_\ SZ1Z1_PO#Q)_SY:5_P!^I/\ XY1_PO#Q)_SY:5_WZD_^
M.5YO11[*'8/['R__ )](](_X7AXD_P"?+2O^_4G_ ,<H_P"%X>)/^?+2O^_4
MG_QRO-Z*/90[!_8^7_\ /I'I'_"\/$G_ #Y:5_WZD_\ CE'_  O#Q)_SY:5_
MWZD_^.5YO11[*'8/['R__GTCTC_A>'B3_GRTK_OU)_\ '*/^%X>)/^?+2O\
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M)'I/_"\/$G_/EI7_ 'ZD_P#CE'_"\/$G_/EI7_?J3_XY7F]%/V4.Q7]CY?\
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MWZD_^.5YO11[*'8/['R__GTCTC_A>'B3_GRTK_OU)_\ '*/^%X>)/^?+2O\
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MCTC_ (7AXD_Y\M*_[]2?_'*/^%X>)/\ GRTK_OU)_P#'*\WHH]E#L']CY?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-'UE=@_UKH_\^W]Z/EBBOJ?_ (1'PW_T+VE?^ 4?_P 31_PB/AO_ *%[2O\
MP"C_ /B:/K*[!_K71_Y]O[T?+%%?4_\ PB/AO_H7M*_\ H__ (FC_A$?#?\
MT+VE?^ 4?_Q-'UE=@_UKH_\ /M_>CY8HKZG_ .$1\-_]"]I7_@%'_P#$T?\
M"(^&_P#H7M*_\ H__B:/K*[!_K71_P"?;^]'RQ17U/\ \(CX;_Z%[2O_  "C
M_P#B:/\ A$?#?_0O:5_X!1__ !-'UE=@_P!:Z/\ S[?WH^6**^I_^$1\-_\
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M -"]I7_@%'_\31_PB/AO_H7M*_\  */_ .)H^LKL'^M='_GV_O1\L45]3_\
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M-'UE=@_UKH_\^W]Z/EBBOJ?_ (1'PW_T+VE?^ 4?_P 31_PB/AO_ *%[2O\
MP"C_ /B:/K*[!_K71_Y]O[T?+%%?4_\ PB/AO_H7M*_\ H__ (FC_A$?#?\
MT+VE?^ 4?_Q-'UE=@_UKH_\ /M_>CY8HKZG_ .$1\-_]"]I7_@%'_P#$T?\
M"(^&_P#H7M*_\ H__B:/K*[!_K71_P"?;^]'RQ17U/\ \(CX;_Z%[2O_  "C
M_P#B:/\ A$?#?_0O:5_X!1__ !-'UE=@_P!:Z/\ S[?WH^6**^I_^$1\-_\
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M -"]I7_@%'_\31_PB/AO_H7M*_\  */_ .)H^LKL'^M='_GV_O1\L45]3_\
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MP\2?\^6E?]^I/_CE'L)C_P!6\P[+[SW>BO"/^%X>)/\ GRTK_OU)_P#'*/\
MA>'B3_GRTK_OU)_\<H]A,/\ 5O,.R^\]WHKPC_A>'B3_ )\M*_[]2?\ QRC_
M (7AXD_Y\M*_[]2?_'*/83#_ %;S#LOO/=Z*\(_X7AXD_P"?+2O^_4G_ ,<H
M_P"%X>)/^?+2O^_4G_QRCV$P_P!6\P[+[SW>BO"/^%X>)/\ GRTK_OU)_P#'
M*/\ A>'B3_GRTK_OU)_\<H]A,/\ 5O,.R^\]WHKPC_A>'B3_ )\M*_[]2?\
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M+2O^_4G_ ,<H_P"%X>)/^?+2O^_4G_QRCV$P_P!6\P[+[SW>BO"/^%X>)/\
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M.!CH.!T'H_PIUBXU[X4^'M0O69[B2S5)'8Y+LA*%C[G;G\: .NHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** (+R]M=.LY;O4+F&UMH5W233R!$0>
MI8\ 56M=?T>^TB35;+5K&XTZ)6:2\BN4>% HRQ+@[0 .O/%<O\1]L-YX6U#4
M5SHMCJXFU!F7*1#RI!%*_HJR%#N/"G!/3(YKQ=KGANZLM2U+P_8P7D,NJZ8M
M_K,K/+IH97!$Q$<BB7RAMW<JN2@8G;@ 'I-AXGT#5+*YO-,US3;RUM 6N)[>
M[CD2$ 9)=@2%X!//84V/Q7X=EM+RZBU_2WM[!@MW,MY&4MR3@"0YPISQSBO&
M+O4!>>*_%<@\2)XB,W@B]+WUO;QQ6S,)"1%"4SN"*X!R[D%N6SD#IKB*VTWP
M[\,-0OXTCT'3UA:[=E_=6[FU*P2R=E59&^^>%+ DCK0!W[^);"?3K*_TC4=)
MO+6ZNX[99VU!5C<LVTB-E#!Y,\!.,GC(I9?%WAN"^CLI_$&E1W4DQ@2![V,2
M-(&VE I.2P;C'7/%>;>*;_P_JD]G?>&86DCF\7Z2;C4(GW6UY*' )B(8ABH
M5F  )P,D@XI2V=L?A'\69#!&7DU;4V=B@)8K@KGZ'D>AH ]<U?Q%HGA]8CKV
ML6&F";(B-[=)#YF,9V[B,XR.GJ*74?$&C:/&DFKZM8V"2(9$:ZN4B#*"H+ L
M1D NO/\ M#U%>?6NKZ9X=^)6M7WC:\M[.+4-(LQIUW?L%CDA16\Z%7;@MYC!
MBF<D,IQWK%\(:5+#XB^'*:G:21>5%K<]E!<(0]O"TL?DC!Y7$;# /(! XQB@
M#U)?&'AEVLE3Q%I+-J!Q9@7T9-R=VS]W\WS_ #?+QGGBIM7\2Z%H#1+KVM:=
MIC3 F(7MVD)<#KC<1G&1T]:\BU6SMK?X0_%26"WCCD;6KQRRH 2RM&5/U!Y'
MH>:U=<UF&W^)7B2UN-9L_"Y\BTW2-;>??:O%L<[;82L8R-VZ/8D3DMGN10!Z
MTCK)&KQL'1@"K*<@CU%,N;F"SM9;J\FC@MX4,DLLKA4C4#)9B>  !DDUP?P>
MU*UA^$_A.TO+R&.[N+9XH()) LDIC+;E53R2H'('3'-6_BC'G0M*N+F)I=+L
M]7MKG5%"%U%LA)9G4=45MCMZ!23P* .FTW7M(UFQDO='U6RO[6)BDD]K<)+&
MC  D%E) (!!^A%5[7Q3HNJ:=>7>@ZK8:LMG&7D%E=)*%."0"5)QG!KSGQQ=Z
M'XHTO7KGPC;R:LX2P&KWNFMYL%U;QW 9H 48AY%C+D@ G8P4GD+5K4]3TOQ-
MX^TW4/!UW;WUO9:)>IJ=W8L'C6)U7R87<<;MX9@G48)P : .NTKQQI-SX(TC
MQ)KEW9Z'!J<$<J+>7:(JLZ[M@=MH8XSV[=*U;GQ!HUGIT&H7>K6,%E<KO@N9
M;E%CE787RK$X8;06R.P)Z5Y!X%OK/0+SP9J_B>YALM+D\(PVMA>W3A((KC?N
ME0NWRJ[($(R1D(0.E0VUHLO_  C<RP%=(O/'LEYI,;Q[5^SF%V1T4]$:0.Z\
M#A@1P10!ZY=^,/#-A9VEW?>(M)MK:]4M:S37T:).!C)1BV& R.GJ*NZCJ^FZ
M/8_;=7U"UL+3('GW4ZQ1Y/0;F('->6:M=S:!\6/$MUJ^M:%H4%_9VZV,^MV#
M3)<VZ)^]CC?SXU!$C,6CY)WJ>F*K^'XX_#,_@:_\332PZ+:V-_%;W6I6PM4M
M)GE4P[U+N(LPAD0LV<84X8XH [S7OB+X?T$Z$TNI6,L&M7/E0W O(UC6/:S&
M7=G!4$!<CC+#FM;4/%/A_2=0CL-5UW3;*\E ,=M<WD<<C@G (5B"<D$#Z5YM
MJ^I>'8YO#^LZ1&=/T5?%LDUQ?W$FRVF<V\JM/&Q8J(V?@-\JLV2,[LG$\3ZM
M'+9_$"Q;5[30I6N;I6T:&U\[4-5/V=5C<F5GS$W!Q'&-JC(88)H ]<A\2^=X
M_N_#/V3'V;3HK[[3YGWM\CILVXXQLSG/?I6[7D_@F_@C\<IJ%Y<Q1P+X(TZ>
M6XD<*BKND8N6/ &.<]*]5AFBN;>.>WD26&50\<D;!E=2,@@CJ".] &:?%/A\
M:W_8QUW31JF[;]A^V1^?G&<>7G=G'/3I3;WQ=X;TRY^SZEX@TJTF\PQ>5/>Q
MQMO 4E<%LYPZ''7##U%>!ZKKD=S\,4"ZU::=+%J*2'PQ96VZXLY%O@TCW;RL
M\H*X.7_=#<P!R& /?6-E;2W?Q<DEMXG>63RI&9 =Z"R4A3ZC+'CW- 'HVK:]
MI&@P)-KNJV6FQ2-L22\N$A5FQG +$9.*I>%/$@\4:9=7BVPMU@O[FS $N\.(
MI63?G Z[<X[9ZFO//"VIVF@Z[H&K^++J&SLKKPE8P6&H7L@2))0"TT>]N%=@
M4;DY8+WV\=#\'#9MX+O#I<'V>Q.LWYMH3$8_+C^T/M780"N!@8(XZ4 =]111
M0!Y?\?3CP'8_]A./_P!%2UX#&U>^?M G'@&Q_P"PI'_Z*EKY]C:NRC\)][D$
MK81>K+JO4@>JJM3P]=%SZF-0L;Z-]0;Z-].Y?M"??1OJ#?1OHN'M"??1OJ#?
M1OHN'M"??1OJ#?1OHN'M"??1OJ#?1OHN'M"??1OJ#?1OHN'M"??1OJ#?1OHN
M'M"??1OJ#?1OHN'M"??1OJ#?1OHN'M"??1OJ#?1OHN'M"??1OJ#?1OHN'M"?
M?1OJ#?1OHN'M"??1OJ#?1OHN'M"??1OJ#?1OHN'M"??1OJ#?1OHN'M"??1OJ
M#?1OHN'M"??5K3=5N](U&&^TZ=H+F%MR.IZ?XCL1WK.WT;Z!2DI)QEJF?3G@
M/QY9^,M.P=L&I0K_ *1;YZ_[:^J_RZ'L3UM?(FC7VH6.LVMQHKRK?+(!#Y0R
MQ8\8QWSTQWKZOTB6_FT>UDU>".WOFC!GBB;<JMW /_Z\>IZUP5::B[H_-LZR
MV&#J*=)^[+IU7_ +E%%%8G@!1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %<=X_^(=M\/WT9[^QDN+74+HPS31L<VR*NYI-H!+  $D<8 )]J[&N"
M\>11S^/O ,,\:R127]TKHZY5@;20$$'J* -[5_%*:9KWAS3XK=;J/79Y(EG6
M; C"PM*& P=P.W'4=<U<;Q)H::X-%?6=/753C%@;I!.<KN_U>=W3GITYKR%;
M._\ "GQ9\%>#;A))M)MKVYN=%O&;<?LYMI T#D\[HV( /.49>G2H6NK)/@WJ
MWA*Z93XWDOKC-ATO)KYIS(EPB_>(P4<2CY0HSNP* /;H=2L;B.YD@O;>5+21
MHKADE4B%U&65R#\I (R#TJC>^+/#FFV=K=ZCK^EVEM>KOM9I[V-$G7 .48G#
M#!!R/45YKXXM]2TOQ/=>'['>5\?6\5L9HUXAGCVQW+\=-ULV[ZQT:@[>%OBG
MK+WNK:'X>LIM+M;?2YM9L7FBEM8U(DAB?SXU4JYRT?)(93C% 'J.H^(-&T>-
M)-7U:QL$D0R(UU<I$&4%06!8C(!=>?\ :'J*K+XP\,NUDJ>(M)9M0.+,"^C)
MN3NV?N_F^?YOEXSSQ7F/A;2E@\1?#6*Z6:58+;6)K7[59_9FC0M%LQ$7<HH5
ML*"V0N,@'@5M5L[:W^$/Q4E@MXXY&UJ\<LJ $LK1E3]0>1Z'F@#T:3X@:/8>
M*-7TC7;RQTB/3EMS'<WEZD0N#*K-@!L8*[/4YSVK=U'6=,T>P%[JVI6EC:$@
M"XNIUBC)/0;F('->=)K?A;0OC'XRG\3W=G8RR6%G&DUZ0JO%L<O&K'@D_*2G
M5L# .#CE].M]7\/R^";[6;FST/3[>QOH[2YUFS>6&SDDGW0HX$D?DN;?"@LW
M&&3&30![4VOZ.FEPZF^K6*V$^/*NS<H(I,]-KYP>AZ'M4MEJEAJ>FKJ&EWD%
M]9N&*3VD@F1]I(.TKG.""..XQ7B5S:I<:-'/]J34+#4?'5A(LD-A]FM)B719
M6@!ED+QLP)+9 9MQ&0<U[I++%:V\DTSK%%&I=W8X"@<DG^= '&KXZU:UATS4
M-=\,MINDZG=1VT3/=EKN RMMB,\!C 3)V@A78J6&1UPNH>/+Z*36KK2=!74-
M'T&0Q7]R;SRYF9%#S""+81)L5A]YTRP91G&3RVF^,O#_ ,1?$MCJ6K>)-)L-
M&T^[$FE:1)?Q+<WMPIPD\RELJ ?N1XR3AF["G)K5CX6T;QWX?U:?R]8N]0O+
MBPL6_P!=?K=#,/D+UDRS%/ESM*G.,4 =M=>)=7NM0%OX4T*/4H!:)=-?7MVU
MI;R"3E$B812>8V 2W "@KDY; JVOCFZUK1='N_#6@W%Y/JC3*5NI#!#9F%BL
M@FE57VG>"J@*=QZ< D<IJ7C$>'--T3X?0:WINBZM#I4":AJ=]<QHE@@C"_(&
M8>9*<':.@X8\=;NI^-_#7P]\#Z+I7@^_TR]>\+6VF2W&H(+;*DF6>>?.-JDD
MMCYF8[0,G( .P\,^)7UV74[*^L?L&J:3<BWO+=9?-CRR!T=),+N5D8'E5(.0
M1T)WJX_X=P:)!IEZVD^([3Q'J%U<?:=4O[>X23S)F '1"0B@* J=@O?DUV%
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M!_A'JWJ?P'<GT2BBN.4G)W9\#B,14Q-1U*KNV%%%%2<X4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** ,CQ'_P @^+_KL/\ T$U1L^@HHH U
MX>E6UHHH >**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img30600998_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img30600998_2.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1_(4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'ZR^@0@X0DE-! 0      !\< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<<
M @   @   #A"24T$)0      $-/)GTL]C>HHA4@U:H05G"LX0DE-!#H
M 1D    0     0      "W!R:6YT3W5T<'5T    !@    !#;')396YU;0
M  !#;')3     %)'0D,     26YT965N=6T     26YT90    !#;')M
M $UP0FQB;V]L      ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R
M3F%M951%6%0    - %( 90!A &P ( !P '( :0!N '0 90!R       /<')I
M;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P
M   *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M    "7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT
M3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L
M  !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS
M8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M    0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M          !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M    0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M        4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!
M     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M              !4;W @56YT1B-2;'0               !38VP@56YT1B-0
M<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E
M8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC
M<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X
M0DE- ^T      ! #O_XU  (  0.__C4  @ !.$))300F       .
M     #^    X0DE-! T       0   !:.$))3009       $    'CA"24T#
M\P      "0           0 X0DE-)Q        H  0         !.$))30/U
M      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(
M   ! %H    &       ! #4    ! "T    &       !.$))30/X      !P
M  #_____________________________ ^@     ____________________
M_________P/H     /____________________________\#Z     #_____
M________________________ ^@  #A"24T$"       $     $   )    "
M0      X0DE-!!X       0     .$))300:      ,U    !@
M   %V@  !V0          0                         !
M  =D   %V@                     !                         !
M   !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL
M;VYG   %V@    !29VAT;&]N9P  !V0    &<VQI8V5S5FQ,<P    %/8FIC
M     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O
M=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M#6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !)
M;6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P  !=H     4F=H
M=&QO;F<   =D     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M    37-G951%6%0    !       &86QT5&%G5$585     $       YC96QL
M5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z
M06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E
M<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +
M8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4
M   )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M#&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M.$))300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
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M24D?CXKV;'TU
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 1$  A$! Q$!_\0 'P !  (" @,! 0            8'" D!"@($!0L#_\0
M:!    4# @$$"@L-!0,)! @' @,$!08  0<($2$)$C%!$Q05%A=15F%VEC=7
M<8&1E)6VTM35(C4V4U15H;&UP=/6\ HCM]'Q)3+A&"0F-$)$1E)B&45F<C-'
M9&6"A::R.%AC=YBBP__$ !P! 0 !!0$!               ! P0%!@<""/_$
M $D1  (" @$" P8$!0 &!P4)   ! @,$$1(%(1,Q408B07&1\!1AL=$C,H&A
MP0<(%20S0A8E-%*2X?$7-39UTC=69'2#E+.TPO_:  P# 0 "$0,1 #\ [_%
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MIU<.3/Y2,&:Y!&72;QK&W@EQ\&72.$LZ]<V+9>S,@\GV7+8\4L;5I0G(LJY
M1)S0B%80!6M&WW[??T_3??ML$V=^6S9S,VY>P+C/D_M?6<)O@@<"2Y6!BG&4
M%D2>%.N0HBCEK.S/Y?A&3K&QQ(*.<6I24K3%!&YL3N!*-0G3A/,D&4;ARG>
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M.<.UK!L(TDLP5@VO>]@V$,-[VM:][WM;?;>][]=ZAI/S2?S &C2&!+ 8E3F
M*#S"@C(*$$L'"W-+"(-[ #L$-N:&UK<+<.%JD']A  (%RQ "(L0;@$ 0;7!<
M%[;7#<-[<VX;VX7#>VU[<-MJ \"DY">U[$$$DV%>UQ6*+ 785[<+7O8 0VO>
MUN%M^B@/(198[@$, !B+%SB[B"$5P"VO;G O>U[A%M>]MP[7VO>V^UZ \;D$
M7L;:Y)5['7W.M<L%['7VL'<VU[;&7YMK6^[WX6M;HM0'E8HJP^R6++L98%BK
M#L -AV+M?>Q?.M;G<RU^-@;\VU^-K;T!X63D6Z"";?WMS^!8+?WXK7L([@'_
M .EO:][7,_W[VO?>] >0BBA#"8(LL1@0B $P0 W&$ O]X(17MSK!%_V@VOM?
MKM0'(2RP L4 L "[6N&Q80A""P;[[AL"UK!M:^]][;;<;T  6 H 2R@ ++#;
M8( !L  ;;[[!"&UK6MO>]]K6MQH  LLNX[@  %S!7&9< 0AN,=[6M<8[VM;G
M"O:UK7$+>][6M;?A0'P"HA$R9$?+R8O'298J2A0J904R-I<B4(@6"$*,][ F
MLY')0V"&P4YBD15K!#:P+6M;8#^<@A4-EAS:IE42C$F4,RCMIG/D#"U/)S4J
ML( [*6TUQ2*1H5%A%@%V9*(HSG !?G;AM>P$CL458?9+%EV,L"Q5AV &P[%V
MOO8OG6MSN9:_&P-^;:_&UMZ Q<U@:0,3ZWL/FX+S4?+ 8Z<)A!Y=(VJ'O")C
M/EQ<"D:.5-44DBI6TNPU<07O;<WJWAL2A1+%0D*6Z9R1F%\^X&49999)99))
M8"BB@!+**+"$!998 V" L  VL$  !M8(0AM8(0VM:UK6M0$;;X3#&E]<I0U1
M&,-DF>;;.\B;V!J1/KK;>U]G)W3)"W!=;<(;[*E!MMPVOU6H"27++N98VX 7
M-"&X+&7"'LE@7O:]P6'MSK!O>UKW#:^U[VM>]M[4!_$Q$C-&(PU(F-,%MSAF
M$%#&+FVM:W.$(%Q7VM:UK;WX6M:UNBFEZ _L$HL AC 6  C+VN8(( A$9>UM
MK7'>UK7%>UN%KBO>]K<+4 +**)#S"BRR@;W%S2P! 'G"ON(7-#:UM[WXWOMO
M>_30&.MKBM+<D[7%;>9IMK6OM_X%A.W"W&^_N^?AT4!]"PA</N[[WOT6O?W+
M>;WK[;6H!SKVVZ;WO;KO>_3_ %O;;:_GOOP <X7#C?CPO;>]]^/GWZ?U]71>
MX"UQ?^:^VU^B][;VM?KZ.GC;CO?S=% <<X6_2*^_GOQ_?>W#;JH#FPK[_P"]
M?;KM>][_  ^.]NGS^[0#G"O_ -H6_NWZN-KWXWMP]WAMY][ <<\5^&XK\+]=
M_/TWX]&_FWM^@#GG"_\ ,*_7QO?SVX[[\=OAZ-K\* ;B_P#-?CPO]U>_1X^/
MP<=O/:@.-Q=&XM^C;>^_P=- +BO?I%?H\=^''HV_5;A;;Q4!S>XN-M[]/1OO
MU=/^?B\5N% -Q6Z[WO?SWX[^/CQOQM?;H\=NF@%A"VZ;VOMTVO>W"W#CU>:V
MW'>WCO0#G"Z>=?COQM>^W'S<.G;COU=7"@'.%:_ 0O-QVOS>-^/N]/[MKVH!
M:XKWVM<6][\;[W^'JOT\>GQ;VH#CG"X[BOP\][WWWM;I]ZU <\\6^^]_>%>W
M3[M[^[[NU_%:@*]R@,5X@=O>]]Y#![=/BG$<O^[]] 6%SA;6^ZO?JO;>_O6M
MU[^?HMO:W10'%[BOPYPKVM_ZKWMT7OPZ-N'5TT W%O\ [U^KCO?HO???Q^?_
M (WM0'/.O;:^XK\.L77M;HZ>CAY^CWP%A7YW3>]O=Z/<OO:UMK\+7M>UO%T[
M4 L(7CO;CT[W\][[<.%]MNCQ=%Z <X71>XN'5SK[>;KWX<.'ZMM[@<<Z_COU
M<=[]?3P_1?:W5MQWX@.=?QBOTWZ;^+CX_?OUV\5 .<+QBZ[[[WZ?A\WNWZ/<
M YYU[[;7OOYM_'OO:UK<+VZ+_HH#C<7#C>_#QWX\=]NKIWM?;IZ_< <X76(7
M1?KO\'&_N;[=5_=H#GG7M;IOY[7WZ=K[7Z[;<>'1OXNN@.><+CN+JM;C>]^G
MKX<.&V_^=Z \><+QWOM;KO>^W^75_5]J 7$+;B*][^[>_G\?N\./7PMMQ <X
M5M]A"Z>-][[<?T;\+]=Z YYPMK;W%T;;;WM:]M]]^G?AQVZNC?>@'.%PW&+X
M;^>^_BOQX6OOU=% .<+AQ'OOT<[>_#S=5_=\_"@..=?K%?S_ *;\./#S<-M^
MGA0#<7_FO:W7?>^WGZ.GI_3MOM0"XKWZ[\/%^C?WM]M[WOPO0#G"W_WK\//?
MAM;CT_IZO>H#GG"Z[WWX<=^BUMO%OQZO';;;CT4!QSA7_P"U?X>GJ]RVW5T;
M>.@.>=?HN*]NG;I\W#;IWX6X[WX<* F^*_P2%Z53[Y]2*@+&H!0%=Y?G?@MQ
M-E')O:-W/P<X[FT[[FV$(%W#O0C3G(.T;"!:X@W5]S^U["#:X@]DWM:][6H#
MJ,8=Y5#+F.=)N;-1>1LS:TWG6+DC0I*]26,X+GK%V/8KHV=#U\IB3<GE^EUA
M860Q\4M>'C92V(AVE+U9).8[=7)5[>XIU:(\@"29TU4:W]%^2Y%HQ;-8>4\P
M.&HO%.@&4QC/N2VJ!/TXP/,]2VH1;A;,;C"3F^*-;,3''-G;%KM!660-[NGA
MRHY!=K.,4DJ5RZ/V\_7Z??H#<CR961LQI<P\H;I+ROF"<Y]:=(6>L?,&,,KY
M1$Q*\DN4%RQB*/Y')B\Q>XXR1YND;A$7-4N3EO9C6G7*"%X230E)$Z%*FG[^
M_O\ 4&R&,YPQ',5CPWQK(,:=EL?5#1/*4AP+ <@4EF&$C*/ =V*]KA-*,+%<
M/.#88;AO??:HVO5#?WIO]"8=^43\I&3Y22?Q:;7JB-_/_P +_87F<2MQO)&6
MW_YBE\__ /5\U_<ZZ;7JAOY_1GB";0\T-AER=B&"^^P@.:,0;[7VOM>QM[7V
MOPOXK\.FIVO7\OZ^@W\_Z)O]$>??C$_*1E^4DGN?C?'PJ-KU7U_K^G<;7Y_1
M_L<=^43\I&7Y22_Q?]>'CM3:]4-_/Z/]CGOQB?E&R_*27^+3:]5]1M?G]'^Q
MQWY1/RD9?E)+_%IM>J&U^?T?['/?C$_*-E^4DO\ %IM>J^HVOS^C_8X[\HGQ
MOWR,NUO_ +R2_P 7STVO5#?S^C_8=^43\HV7Q??%+[GXSQW_ *VO3:]5]4-_
M/Z/]OOMZH=^43X_])&7A_P#>*7;Q]/9?%3:]5]1OY_1_L<]^,3\HV7Y22_Q:
M;7JOJ-K\_H_V.._*)^4C+X_ODEV^'LNU3M>HW\_H_P!CGOQB?3WQLOO.26__
M /UJ-KU7U&U^?T?[''?E$_*1E^4DOZ/[WC[EO-X[5.UZC?S^C_8=^<2YQ8.^
M5DYQII1!=NZ:3<9QY@2B2@_WO$PTT82RP6^Z&,00AM<5[6H-[]?ZIK]22T)%
M 8X_^+LD]?\ TR3?H@L)]WHVX]'7Y]P/?M;JZ./&_BMT<;?\: >[PMTVWM?C
M_7];;T OOT?!:VVU[]'N?!U\* 7X;V]Z_P /^GBZ* 7WZ]]^CC?]_P#7N^,!
M>_Z?\^GS=&W#AMPH!T?!X]OW==NKC^Z@'3O[WN^Y;?I_X;6\X'/3U\>-^CA>
M_3;AUWWWM^J@./ZXVMY_'TT \5[]?'CUV_7QXT _5QX</%?W/A^#CM0"WCW\
M=K;^;CT='7Y[^*UZ <;7OOMTWW\_C^'^MJ YZ-^-^.UN&VWBVOX[[>YO?HZ=
MZ XO;;JM;?CPZN/';CT^.U^O>@&W1_G[OP;[=?N]% +<+WMMYMM_/[^_]7ZJ
M <>G?J\?3OOPOY^GI\7N;@+VZ^&^_'JOX]K]'1??S[W]S<"O\GW_ .AYUNBW
M?!"/%OMW\1SAOPWX?#T;4!8/ZN/3PX7VMOU[\>.W'HX4!QU>YP^'>_\ 5K[]
M-Z >?W?]>C:UO^.WF X_K_6@/+Q\.GHOT7X\/'M:W3OPOXM^N@.+6Z/'XMM_
MZX<?/>VW70'-OT7Z?>OOO;H^&_1QWZJ XOT^]T\+VOM;S<+\>'ZZ >*WN[</
M/[U[\?=V^&U <\>-K^+K^';QVZ=_=Z: XO\ !;;>W1?IVX_Z6ZMO'0#^NBWN
M^+X?-PZ* YMO?CT[7Z^/B]_CPM\/GH#CHZ/%>V_CMQ_K_C0#W_\ 3Q?#QMPZ
M;[[VVH!X][VX</=]R^W1;;S<.CIH!QXVX\>FW7T^+IO[W10#X/%[_CMT<-O'
MT<>CA0'/N7MPWZ-^/#?H\VW3:UMN%Z X_7;]/3OQ_K?JOU4 OPZO'MT[7\_5
MU;?!;>@&]_W;]/NVM?Q?NOY[[@.'N?UU?Z_Y4 OYO/\ !?\ UOOU>[TW YOU
M^+S7X<?<Z-]NB_5[F] <?Z=5OA_SOT^.@'3Q_5U=/[K='BH!T?U[NWFV\?N7
MMU4!.<5_@D+TJGWSZD5 6-0"@/G/#0UR!H=6![0IG1E?&U<T.[8M*"<C<6MR
M2FHEZ%62+[DU,K2'FISRA?<F%&##?A>@-4V*>18T6XP;9DP.7AHS%%I+@^6Z
M:HO$\X9<?L@1_#F!YNO YR+&F&4II#<?"FA4K3MXR':ZISE2 #4W$HI 042,
M!H'\&+D6-(*'%N6,:2R0ZALKN66V?%$=6Y>RIFAYE&:8-'<$.I;_ (78\7SD
ME V6@[=C5^!W982VUK&:M7#'>2'/J?FD! S%TG:/,6Z/8M-V+'SQD:;R/*4\
M<,FY5RIF*9JL@Y5R9-U[<VLW=N7RM4F0@4W0,K.V-#4W-K<V-+:B26LE0%GJ
M%AZD"YRF=I3Y$%<AK;B;G1 XPVY2),7<TR[V1N89<!0>>.^]]Q"W%?>_'C0$
MZ[00_D23XL3]"@/Y*&IM4$')S4*:Y9Y1A)E@D%!%<!@+@%S1!#801<T5^:(-
M[7#?:]KVO:@->Z+(SVU7(P+ICQTL;YK'IFJ-?S,UMD@LTD0HU["H?92TOP['
MDO5E9JM62TH;N)1Y8B>8%,$@)=[X]6S]['Q8.-E=BY_B(SX^"Y-2LA+RFVUJ
M,>2>N[26C:Y8%.J^K]<R:[L/,Q9*A=)LQ97?CH45NG#R*%PEBJN#4KK/"E#D
MN$9RFY\=A1;>D[&7V5$BN;S ]DN!,58%S.;;GW!:X+WL'G;\VU[WOMMOQK(?
M,U3Y'GV@A_(DGQ8GZ% .T$/Y$D^+$_0H!V@A_(DGQ8GZ% .T$/Y$D^+$_0H!
MV@A_(DGQ8GZ% .T$/Y$D^+$_0H!V@A_(DGQ8GZ% .T$/Y$D^+$_0H!V@A_(D
MGQ8GZ% .T$/Y$D^+$_0H!V@A_(DGQ8GZ% 5#G)&D*Q\<86E3EF!E$#N 99!8
M!AOW[Q_B$00V%:^V]N%^B][== 730"@,<;[VEN2?%>9)?=_ 6$_JWZ+>[QO0
M'T..]^/'Q]'N>+S;<-NOAM0''_#X/=W\5]MK=73T4 Z+^+CX][V_3U>]QW]X
M!MQVZ^B_O?UQ^'>@&^W1X][</\[WZ[6\?"VV]N- -NC]?#S6\WO[WZ[>[<#G
MAPWX\?/PMU>]QOO:WBX>.@&_3;I_1:]N&W#_ "X[;;;6M?<#C:W'C;AO[_'S
M_P!;>.] +VX[>]Q\W#Q='#X.&] <]5MK].]^'5T=/1>VW3?JX6Z=N "_BVOP
MO>_1\'3QM;HZ?=X]0'%K7O?;?CQVX]/CMO;AQM_E0'/5:W#A;Q].]^B_5U[_
M *_,!QMPX>>^WBV_X;>[[UJ >+_A^K;X>G>@.>%M^NW"W7T^[XM^/&W':W#Q
M <>*_P"^WNWM[_'Q].W3O0'-[]-O/>_5^F_7>W'W=_<H#CW+>]??AY^GS<=^
M'FVM0%?Y/M_T//\ 2"$?/F.?KVX6H"P-NCWM^BW3[]_AZNN@.?<X=?3OM?AQ
MX='3U]'';C0''P=75T^?C[GZ?%PH!;;JX7WX7Z-O-[GGX]'1TT!S:U^CA_K[
ME][VVOO;IWZK<;T \7N\>OC[ENFUNKQ\>FU +V\]M_UVMPZ;WVZM^GAQ\6U
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MI4XRMM,:U*$N/.*=]7-Y:5$2K/*<@GICAF".3@+,*%:]A@ ZS?)Z:D]7[7I
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MR-GG.,W[RD^\D]ONR1U)3% * 4 H!0"@% * 4 H"GLZ^QXH])X'\]X_0%PT
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M$H>7Q6DNM):&XH+<A4)FI(6E %$A36$9SP+]MXM[VZ_'X]^CS=/"_1??:V]
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MN'N<>KHMPOY^KQT O;;IOOU6O;CQM^[]'BWZ* 7Z?<WMYO%OU>];:VUK6Z:
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M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H"L,P_@*?Z3X]_Q"BU 6?0"@%
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M!0"@% * 4 H"L,P_@*?Z3X]_Q"BU 6?0"@% * 4 H!0"@% * 4 H!0"@% *
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M-Y0TDS#4V@QKB9F="\?0_&6,3%!.IUM-D2(E2P/4U;PK.Z"MD;6\Y/&QE&V
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MG Q'+'LYE5P=+D7(\M-(@BX<3)/?WZS;*&LD*!Q1,*82SM@NR^Q)-CQE^_\
M=@_OJ"Y''.NH!'RT;*IF6.XLGUXSG3)D'3J[]U7IQLWO& $B)V-09-;BF H3
M(WOCXV$LG9V@V2&I42TUY"D4FH2FY6!*(CHHY0O59JSQ?JKUMQ'3_@T[2_IC
MS9AG$<(Q#D!ZR =DK*&:X*\0&13Z3.BAC1)HE!@-+N<H:XZ6-V>V]:4G ;=4
M7=0>(":X_P"3^S/BSD<,!Z&,A::M/&L6:0@2MKRQAV9Y9?\ 'D)>6%PG60I<
M6]8WRPGA*UU8)_'U3[%U+2[F,;.(@L,@)2NB919$<I??WY REY(O2KJ(T?Z6
MG7%VHR7!=WAQR_/YIC?'Q.0Y%EI'@3$+\)J+A.$T62I2C;W:7DQ(I M5&.5D
M*5!92[GDH2Q%@$<:!M'H!0"@% * 4 H!0%89A_ 4_P!)\>_XA1:@+/H!0"@%
M * 4 H!0"@% * 4!5V:UV8FS%<U7Z?V"!RG,J9I[) (_DY[>(Y G1Z[;3!NG
MDSVP-[H\-Z"R(2LT)J! H-$I+()O8LLP9I8'6_TQ<EMR@Q^G;E'=(6IUKTP0
M_%NN^89^S^GR%C/(,[FLL@V=LIJH&HBT>M''>'1YO78X8ED4$XK5PW#OA,N4
M6G+Y]S^<6!-L#<G#KRSQF+1<Z\H&S8/Q]BCD]M-N3L%8^1XCG+I/Y)GB79.Q
M@@PPZ9$>K+F)E20UH3PQF9W<EM4]L.(9(WBL6A A>5 &<"I,+<E'RAB^'Z&]
M"6H(K3\FT8Z"=4=]1#=G2(3-^<LFYV9XA)II*<:0@>-U+*23$% 54W=&V3JU
MSM=*2U7270'."UD[+) .UM0"@% * 4 H!0"@% * 4 H"&03[SN7IGD+Y]R*@
M)G0"@% * 4 H"%W]D,'H:=^VD] 32@/EOB<"MF=4IBE8C+4-RPD:MN$("],
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MCPP8F]M#'GKI&_M*@VOS^C_8>&#$OMH8\]=(Y]I4&_G]'^P\,&)O;0QYU_\
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M%ROH4 [11?D:7XN5]"@':*+\C2_%ROH4 [11?D:7XN5]"@':*+\C2_%ROH4
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M<V%O;HS(5*MV,='MX"7(P =D2@% * 4 H!0"@*PS#^ I_I/CW_$*+4!9] *
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MIRE^/>8X.P+PR1*S376-W Y+@B:52405)H;V'<"V* 4 H"%W]D,'H:=^VD]
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M>!_/>/T!<- * @4,^_&3/3TOYB0>@)[0"@% * 4 H!0"@% * 4 H!0"@% *
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M]/@<URK+[<F^S*ME?D2ML=]TIJR5MO)J<W8FU/E)-\DVI>:[,F5>RW% * 4
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MY:1/UC9_KE ._P!@OEI$_6-G^N4 [_8-Y:1/UB9_KE ._P!@WEI$_6-G^N4
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M7U2@/F8[3)D; M2HTY"1,1,,@EDITQ19!!)89W(N: HDH("RP6Z@@#8-NJU
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MEI K4:<I.<6"P$_H!0"@(7?V0P>AIW[:3T!-* _D?<82#A%%6/,L49<L@0K
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M>_XA1:@+/H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M[)R>Y3D_C*3>V_BV22O13% * 4 H!0"@% * 4 H"GL[>QXH])X'\]X_0%PT
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MGFK&.&<E:8<K$8]B,80,QEI-*(TVNF.)FI1FH92N8A/9#0V1H1:5!83NG47
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MTGH":4!&IFB7N,0D[>UDA4.2]@=D2$@1X4P352I">00"Z@99H"=S# _W@RS
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M;L?+N7CW8N3?C9%$L:^BV==N/--2HG&34JI*3<DX/W7MM]N[V3FO9;B@% *
M4 H!0"@% * 4!3V=O8\4>D\#^>\?^#^K== 7#0"@(%#/OQDST]+^8D'H">T
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MXE .Z;;^<4/QM/\ Q* =TVW\XH?C:?\ B4!&(",!C(X&%C"8 <RR"( P"L,
M@WG<BVN$0;WL*U^J]KWM0'P<Z."%HPEF)U=&=+(FULQ9D%P<8^N.4ID3ZA11
M)W4JV=8H1&%+"$KFG*,1*#DAI:DHD\8R# &A *P'3+Q= ?[/U,6K'Z&4::]+
M,7?Y/R=;+J]?W4W6YD5*P1[.J\:!$MTKFLCAE<M:GF",]4>NNB62 N7%(4PD
MIT3L.PUP6UZ_E_7T!VJM$L]BZODY]*F3H_C6\1AIVC?#,X9L0P,#W,1QR-WP
MW'GU#CR'%O*I;(I28V-O8HZP%NBQ6\O0R4@%BD]:I,-$7Y_?_J#K-.+7E_E
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M 4 H"L,P_@*?Z3X]_P 0HM0%GT H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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MC@>3':/('#+#,@?\<1^63A!#E$*A$HE[4Z-ZAJC$P?V1][(M3(U2!,M.+3B
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M)-7@\E/9U]CQ1Z3P/Y[Q^@+AH!0$#AGWYR9Z>E_,2#_KH0O\O]?\$\H2* 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * K#,/X"G^D^/?\0HM0%GT H!0"@% *
M 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@(9!/O.Y>F>0OGW(J F=
M * _@I/"E3*%(RSC0IR#3Q%)B3%"@P))8C+EITY01&GG#L&X2B2@B,-,N$
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M!0"@% * 4 H!0"@% * 4 H"L,P_@*?Z3X]_Q"BU 6?0"@% * 4 H!0"@% *
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MU[D^Z\U[K[K\UYESA[_&8NHJ;_$T:@]:F_%AJ+WVU+R>^VGW/R+UBC_GAIX
MJ+6$XE!4".MS0D%F%J3!\RU^>0/8 K]C+)+N;8)>X; YQEJYA"OE7X;E5/\
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M?.Z'<-8J2+DJ)4-J>^Y#KW&>4Y)S2[7;5UF]:HNE/Y@&3] * 4!6&8?P%/\
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MJ'4DYNJEJRQ12I;<N,7K7??D?GK@+LD)V[;[($LBYAP5)P2A]K6/!;L)5R0
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M<3"/8VS=AC3-&<69&?(^YMT(G#LU8=)8'Q-&I$H3 ;GH; Z\]&] ;CU VX\
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MCM.;9 V2^0-H!A67-LWG]KN8T+>!V"Z 4 H"L,P_@*?Z3X]_Q"BU 6?0"@%
M* 4 H!0"@% * 4 H!0&B'E;,/9KUMY_T,Z"F#&V13=*\GR:5J!UD9;1Q]V+Q
MIWA8J$N<(AAUTEQ9%V<;S-GML<QJ& U2%P1KQ01Y G,('V8@"*\KOC32RHRY
MAS(&0M)G*/Y(S7&,6/L<QEEGD]67(#>:;'375Q#;!,ZF^.WY$?&D#FN6JW!.
M!P:4Y"1I?7,U$\<Q2N;Q@9'\AUI R-HMY/N!8WR\Q&1')\WFN0LRS&"FN0GE
M1 5.0GSMACARUX&J6F.3LS1)NCP'X\Y2><6_&N:0U0J&FNJ/ V\T H!0"@%
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M@V"$SN']P(5[[6'_ -F][7ZJQ*Z%B;7_ !'_ /K6_P#U&D_^S7H7QC=KL_\
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M;;>]>226W/1E'>5ZC^J/$LCU XFR;&\+LJ]].GHR<VK<B <4*AA7)6]$;%W
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M* >#>*?BW_USF?\ ,% /!O%/Q;_ZYS/^8* >#>*?BW_USF?\P4 \&\4_%O\
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M&\4_%O\ ZYS/^8* >#>*?BW_ -<YG_,% /!O%/Q;_P"N<S_F"@'@WBGXM_\
M7.9_S!0#P;Q3\6_^NDS_ )@H!X-XI^+?_7.9_P P4 \&\4_%O_KG,_Y@H!X-
MXI^+?_7.9_S!0$G9F9M8&\MK:2!IT11JL\)9BE4L,$>N5G+EAQJE:<H5'FJ%
M:@]0:8<<8,1AHKW%T6L!]2@% * 4 H!0"@% * Z>VH601I%RA.39,]Q_3>#4
MTR:S,=Q;$NB5\Y-"#3:=ZB,5+I7CE&7GX&K!1!E<Y)?U\<<Y1D,G(;?+"H]
MUL-"U/*,P:0X(P.X30"@% * ZU/*\174\#-SU-8KJ?R5C."-,$Q63B[#F*=;
MV*M(CK.@NC1J'8LMN7:L]D\6*>Y3$LBK].DT*?)$J%'W#'S/,8@RGVD)MR*
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M\%2&'XN7MK A2*(/'GT@1A+PVQT95VXEQ+4+ K+D"/[?<+CNM/ O^@% * 4
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@.G[ES >3#<49(Q&ZZ)L(:N8+@N8<H$SX>UK/VIK3DGTN8]1ZC<F.LMR9D[
M4]&YN:MFD.S3IO<$?:<F,:"!.2!TCKP0WN2=0H&H1@=J#3O!"\6Z?\&8R*E!
M,W*QSAW&4$+FB<P)Q$O+B$*9(^"4$&@.4@-)?PM]G8LP*@\(P*PB"<;:]AB
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3YP.:9>XJ M?HZ* 4 H!0"@/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img30600998_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img30600998_3.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#X17AI9@  34T *@    @ ! $[  (
M   /   (2H=I  0    !   (6IR=  $    >   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $YI8V]L92!3
M96ET=&5R    !9 #  (    4   0J) $  (    4   0O)*1  (    #,C0
M )*2  (    #,C0  .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                         #(P,C,Z,#,Z,30@,38Z-3DZ,34 ,C R,SHP
M,SHQ-" Q-CHU.3HQ-0   $X :0!C &\ ; !E "  4P!E &D = !T &4 <@
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" +T!8H# 2(  A$! Q$!_\0 'P
M 04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0
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MV0@X8?J.XKOJ\DL?V?=&TKXE#Q9I&JW6G)%<K<6]A:1*J1<#<FXY^1OFX &
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M<X&,8YJ?2OC_ .._!'BF\TGXDVW]HO K+)!Y<4,L4FW<F&C 4J<C/7@Y![$
M^J:*^6?%'Q1^-WAU+7Q'K%E'I.D7C@06S6L31\@D*_6520#U*DXKWKP/XZB\
M7_#6U\5-:R1EH)&N+>%#(P>,D.$ Y;)7('4Y ZT =917S*?B7\:_'>O7T'@C
M2&TN*T8%H&MXE:-3G:'>XX+'!Z8Z=*M_#_XV>-++XE6_@WXCP1R2SW M&=HD
MBEAE;&S[F%922!P/X@0>Q /1OBY\7/\ A5?]D?\ $D_M7^TO._Y>_(\OR_+_
M -ALY\SVQCWKM_#FK_\ "0>%=*UGR/L_]HV4-WY._?Y?F('V[L#.,XS@5\__
M +7/_,H_]OO_ +0KV[X<?\DL\*?]@6S_ /1"4 =)7SG=?M9?9KR:#_A"]WE2
M,F[^U<9P<9_U-?1E?%?PA\4Z-X.^,5QJOB.\^QV2I<1F7RGD^9CP,("?TH ]
M"_X:Y_ZDG_RK?_::]3^$WQ0_X6AI-_>_V1_9?V.=8=GVGSM^5SG.Q<55_P"&
M@_AC_P!#-_Y(7/\ \;KK=%\1Z9XW\,R:AX4U1VMY@\,5XD!5HW'&X+*O)!YY
M!!H W**^:_#?QA\9^$/B\_ACXI:DMS9>9]F:4VT4(B+$&.8%%&4/&<] V>U)
MJ/Q<\;>._C$/#OPRU5;+2_,\E9A:Q2JR*?WEP2ZD[?09&0%[F@#Z5HKR/X^>
M,?$?@+P/I%UX;U5K>\DO%@FN'@B<RKY;$DAE*@D@'@"O/=.^)?QJ\=Z)%/X(
MT\BWLH4CNKX00;KF8*-Y'F *>?X47(X]: /IZBO"/@W\<-5\1^)F\(^.84CU
M0[U@N!'Y3-(F=T4B= W#=,=,8S61\9/B]XM\$?%N/3])U+9I,44$TMG]GA/F
M G+KO9"PR!C.>* /HZBOGOX7>._BUXP^(-G-J]I-;>&KD/,[/I>R 1[3M$<I
M4%B3@#YCW/:HO&7QM\7>(/'<WA/X26:R/;NT9NQ$LKS,O#,-_P B(#D9.<\'
M(SB@#Z)HKYJTOXU_$#P!XMMM'^+M@KVTY!><Q(LD:$XWJ8OD=1W &>.N:]0^
M,7Q0_P"%<>$;>\TZ&*[U#4)/+LQ(<Q@ 9+G!Y !' /.10!Z+17SY9/\ M ZM
MX7@\46&NZ4UO=6ZW<&G)!$97C9=R@#RB,D=B^>U>D_"SQ%XRU_0ICX^\/-I-
MY"R^7-M"+<*<_P#+,DLK#'.>#D8H [JBOGK4?BQX[\>?$Z\\)?#&6QTN*S:1
M?M=VBLSB-MK.=RL N2, *3CGZ6X]8^/7A/Q+:6NJV%KXNM)OF=[2%$3;GE?,
M"IL;TW#'UYH ]1^(WC3_ (0#P1=>(?L']H?9WC7[/YWE;M[A?O;6QC.>E5_A
M?X__ .%D>$6US^S?[-VW+V_D>?YWW0ISNVK_ 'NF.U4OC-XFU?PK\*;[6= N
M#8ZA$\ 1VC20IND4$$,&4\$CO5'X%>,-8\7_  VEU?Q3?BZNDO98S.T:1!45
M5/(0 <9/- 'IE%?-6M_'7QOXV\7RZ#\([!1$A;R[CR5>655ZR'S/D1/3([C)
MR<"*T^-7Q(^'7B6WT[XKZ9]HMIN6?R8TD"YY:-HOW;X[CZ<B@#Z:HK@OBKXM
MN]&^#&H^)O"=^L<XCMI;2[1%D!22:,9 8$'*L>H[UXOX3^+OQ>\::*^D^%;-
M=3U2%VDN=3>&%/+0_<0 A8UZ,<MDGMTH ^I:*^:_AQ\;_&5O\28/"/Q%"3-<
MW/V-G>!(IK>8G"#Y %92<#IW!!]?I2@ HK)\4^)+#PAX8OM=U=RMK9Q[V"_>
M<]%5?<D@#ZU\Z6?Q4^,WQ*O;J?X?:?'9V5N^"L,4+!>X5I)^&;']W'TH ^H:
MY;XA>/M,^'/AG^V-7268/*((((0-TLA!..> ,*23[>N!7E'PZ^.VNIXT7P?\
M3[);6^DE$$=SY7E,DIQM61>F&R,,,=1U!R.<_:>_X3'^UD^W_P#(I>=']A_U
M/^O\H[NG[S^_][C]* .S\#_M(1^,_&ECX?'A:2T:]D*1S+?"3: "Q)7RQV'K
M7N%?/7[/,7Q&6/2O[011X)^S3-:X%M]\L<'C][G=NZU]"T >+_$?]H3_ (5_
MXVN?#W_",?VAY$<;_:/[0\K=O4-C;Y;8QGUKE?\ AKG_ *DG_P JW_VFN/\
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M9[N:9/*B'5R(%.![G'%>K?LS?$8W^FR>"M6F)N;-3+I[.>7B_BC^JGD>Q/\
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MYS[8KZF\1FU/A353?[3:?8IO.SC&S8=W7CIFOE;]H.S&H_'R"R9RBW,-K$6
MSMW'&?UK?UWX=?'-M-/A"+5/[4\/8$2S+<PQAHAT#EL2XP!E?F';F@"I^RK.
MUMXB\23RMLLXM/5YF.>"'R#^6^M_3/BS\1/BOXHO=,^&T>G:+96R[S=7BAY
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M*(6\N?G3#LN4;)X'9B.,"@#=_:N_Y)_H_P#V%!_Z*>NQ^ C6[?!'P_\ 92I
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M9_:2[]O3/DOFH/AU\"==;QHOC'XGWJW5]'*)X[7S?-9Y1]UI'Z87 PHR.!T
MP>H_:#\%>(/''@_3;'PO8?;KB"_$TB>=''M3RV&<NP'4B@#9^!O_ "1/PW_U
MP?\ ]&O7?UR'PIT/4?#7PNT32-:M_LU]:Q,LT6]7VDR,1RI(/!'0UU] 'Q[\
M<;:*\_:.-M<IOAF>RCD7)&Y2J C(YZ&O>?\ AGSX8_\ 0L_^3]S_ /'*\Q^,
M/PJ\>^(?BY<>(?"NC?:+<+ T%Q]J@3YT1?X7<'@CN*E_XR=_S_9E 'M7A+X;
M>$_ UU<7'A;2OL,MR@25OM,LFY0<@8=CCGTKYJ_:%_Y+U#_UPM?YUZA\/O\
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M_P#Y-7E_[ MG_P"TJ\9^"WP=T3XF>'=6N]6OM0M+BTN%BA-LR;,%<Y8,I)_
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M^$DMC:ZLMLB7<1=7Q(HPQRI(.2,]>];% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X?\1_@MXB\8?%
MJT\4:9>Z7%90_9]T=Q+(LA\MLG "$?3FO<*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** /-?C;\.M6^)/A>PTW0[BRMYK:\
M\]VO'=5*[&7 VJQSEAVKH_AQX:O/!_P[TG0=3D@ENK*-DD>W8LA)=FX) /0^
M@KIZ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN(#YDF$X+[O]7\Q^:JWC;XL:[X/^#/A_Q++::>VN:L8<V[Q/Y*!T:0_+OW<
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ME55CF/?SU4CJ1R#G!H ]%J&\O+73[.6[U"YAM;:%=TDT\@1$'J6/ %>!:?\
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MF2V!:.0 @,%&3\P)7@$Y# BL?4_B)\45T35_$MKX4TK2-%TMF)M=9\Y;R9%
M)9<$+T/Y\#.* /9J*\E\0_&::S^ ]CX[TJR@BO;^1(8;6[W/&)/,97'RE21B
M-R#D=OI7):O\=OB%I?AO2O$LO@RS@T.Y$<<ES<,RM<2E<L8UW[D0X;:6#9 !
MSSB@#Z')"J2QP!R2>U4[G6-,LM*.J7FHVEOIZJ&-W+.JQ $@ [R<8)('7O7@
M?[17B/Q%>:%H.GZ<]K;Z/X@$;Q0JTBWDKX^97'W?+_>1\<G</PI?C1)KFA_
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MR1Y\MF4 [DSSC##N><BNWH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M49(>0N%5&]<F,?\  =]=QXN4>,?VLO#NC.!)::#;+<S)UVN 903]2817O5%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB^Q/M/DEPN9.G\()_*K-EXBU#5)H+*$6]G?BUD>Z21"XBE1H^ .ZLKY!]"*
M/4O[>L?[[?\ ?!H_MZQ_OM_WP:\?3Q/K"V.ARW=W:1'5;9[EG2T9_+ 6,A=H
M.3]\\^PHN/'DMMI^AW$R6R&[3[1>@L?E@\P1AD]R6W8/0*U 'L']O6/]]O\
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MCUKA1]X?6NY'W1]* *#:Y9(Y5G;*G!^4TW^WK'^^W_?!KFY_^/F7_?/\ZCH
MZC^WK'^^W_?!H_MZQ_OM_P!\&N7HH ZC^WK'^^W_ 'P:/[>L?[[?]\&N7HH
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MI[E5,AGDA>,'=#(\PE1Q[KC\?QK8T#3YM)\/65A<RI+-;Q!))(P0K-W(![4
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MW\1XQCZT )16I_8C_P!Z3_OV:/[$?^])_P!^S0!ET5J?V(_]Z3_OV:/[$?\
MO2?]^S0!ET5J?V(_]Z3_ +]FC^Q'_O2?]^S0!ET5J?V(_P#>D_[]FC^Q'_O2
M?]^S0!EUK>'?^0A)_P!<S_,4W^Q'_O2?]^S5[2=.:TNF=BQRF.4QW% $NO\
M_(+/^^*YBNNU2V-U9>6"0=P/ S6+_8C_ -Z3_OV: ,NH;JT@O81%=1B1 Z2
M'^\K!E/X$ UM?V(_]Z3_ +]FC^Q'_O2?]^S0!S5UH.FWLLDMQ;9EDD$IE1V5
M@P78""#D?+Q4,GA;1I$C0V0543R\)(R[UR20V#\PR2><]3ZUU?\ 8C_WI/\
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M0\5W%(6?Y7!YC([T ;MQ_P >LO\ N'^5<2.E=O*N^%U_O*1^E<Y_8C_WI/\
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M?^])_P!^S1_8C_WI/^_9H RZ*U/[$?\ O2?]^S1_8C_WI/\ OV: ,NM'0?\
MD*K_ +AI_P#8C_WI/^_9JYIFF-:WPD+.1M(Y3% &U1110 4444 %%%% !4%_
M9IJ&G7%G,TB1W$31,T3E74,,9!'0\]:GHH YG0?"$NF:LNJ:OK-SK-Y#;&TM
MI)T5/)B)!;@=68JN6[[153XB=?"O_8QVG_L]=C7'?$3KX5_[&.T_]GH [&BB
MB@!@GB:=H%D4RJH9D!Y .<''X'\J?7,6(_XNGK![_P!E6G_HR>NGH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH ***PM3\:^'M'UZWT;4M4A@O[G'EPL>>>!GTSVS0!NT
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !112%U#
M!2P#'H,\F@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHKF-4\67R7TMCX<\/WFKW$+;))=RPP(WIYC\$^PS0!T]%<9%X
MI\663;]=\&2BWS\TFG727#(/]SAC^%=98WL.HV,-W:L6AF0.A*D''N#TH GK
MCOB)U\*_]C':?^SUV-<;\1/^96Q_T,=I_P"ST =E13,R^B_G1F7T7\Z .;L?
M^2I:Q_V"[3_T9/73URUB9/\ A:.L<+G^R[3O_P!-)JZ;,OHOYT /HIF9?1?S
MHS+Z+^= #Z*9F7T7\Z,R^B_G0 ^BF9E]%_.E7?GY@N/8T .HI&SCY<9]Z;F7
MT7\Z 'T4S,OHOYT9E]%_.@!]%,S+Z+^=&9?1?SH ?13,R^B_G1F7T7\Z 'T4
MS,OHOYT9E]%_.@!]%-7?_& /H:5MV/EQGWH 6BF9E]%_.C,OHOYT /HIF9?1
M?SHS+Z+^= #Z*9F7T7\Z,R^B_G0!YW\5?B;>> )=-AL=-2Z:[#.TDS%5 4CY
M1CN<UW>D7_\ :NB66H&%X#=6Z3>4_P!Y-R@X/TS2W=A!J"HM_9VURJ-N43('
M"GU&15@>8!@*@'UH ?13,R^B_G1F7T7\Z &W;3)93M:('G6-C$K' 9L< _C7
MEWPDUWQWJNNZK%XP@F%I&F5::'R_+EW?<7U&,_D*]3S+Z+^=&9?1?SH ?13,
MR^B_G1F7T7\Z 'T4S,OHOYUQ?CKXGZ9X"NK.VU*VFN9KI3)L@Q\B XW'/OV]
MJ .WHJM9W@O[&"\M2KP7$:RQMR,JPR#^1J;,OHOYT /HIF9?1?SHS+Z+^= #
MZ*9F7T7\Z,R^B_G0 ^BF9D]%_.GT %%,S+Z+^=&9?1?SH ?13,R^B_G1F7T7
M\Z 'T4S,OHOYT9E]%_.@!]%,S+Z+^=&9?1?SH ?13,R^B_G0#)GD+CZT /HH
M^E,S+Z+^= #ZX'Q-\(]'\4>-(?$-W=7$;J8S- F-LVS[O/4< "N[S+Z+^=&9
M?1?SH ?13,R^B_G1F7T7\Z 'T4S,OHOYT9E]%_.@!]%,S+Z+^=&9?1?SH ?1
M3 9,\A<>QIYSCCK0 44S,OHOYT9E]%_.@!INK=;E;=IXQ.PR(BXW$>N.M2U\
MU^(TO?\ AI>(A+O?_:-OLQG.S"9V_P"SU_#-?2.9?1?SH ?13,R^B_G1F7T7
M\Z 'T4S,OHOYT9E]%_.@!]%,S+Z+^=*N_/S!<>QH =12'./EZ^]-S+Z+^= #
MZ*9F7T7\ZRD\3Z0^OMHB:G9MJ:C)M1)\XXST]<=J -BBF9E]%_.C,OHOYT /
MHIF9?1?SHS+Z+^= #Z*9F7T7\Z,R^B_G0 ^BF9E]%_.C,OHOYT /HIF9?1?S
MHS+Z+^= #Z*9F7T7\Z>,XYZT %%-)DSP%Q[FDS+Z+^= #Z*9F7T7\Z,R^B_G
M0 ^BF9E]%_.C,OHOYT /HIF9?1?SHS+Z+^= #Z*9F7T7\Z,R^B_G0 ^BCZTP
MF3/ 7'UH ?13,R^B_G4<T_V=-\[Q1J6"[F; R3@#\2<4 3T4S,OHOYT9E]%_
M.@!]%,S+Z+^=&9?1?SH ?13,R^B_G1F7T7\Z 'T4S,OHOYT^@ HIF9/1?SHS
M+Z+^= #Z*9F7T7\Z,R^B_G0 ^BF9E]%_.C,OHOYT /HIF9?1?SHS+Z+^= #Z
M*9F7T7\Z 9.X7\Z 'T44S,OHOYT /HIF9?1?SHS+Z+^= #Z*9F7T7\Z,R^B_
MG0 ^BF9E]%_.C,OHOYT /HIF9?1?SHS+Z+^= #Z*9F7T7\Z,R^B_G0 ^BF9E
M]%_.C,OHOYT /HIF9?1?SIR[L?-C/M0 M%-;?GY0,>YI,R^B_G0!F^)_$-KX
M5\-WFLWZN\-JH)2,?,Q)  'U)%97@'Q[9>/M(GO+*VEM7MY?*EAEP2#@$$$<
M$8-;NI6=OJ.F7%IJL,$UG*A69)3\I7WJCX9T;1M$TG[/X8M[6*S9RY,#[@S=
MR3W- &W13,R^B_G1F7T7\Z 'UY+XG^'WB[5/B]::]IVI^7IB21.&\\J857&Y
M-G?.#_WUS7J^9?1?SJC-K=A;:I%IMQ?6D=[,,QV[2@.WT% &C13,R^B_G1F7
MT7\Z 'T4S,OHOYT9E]%_.@!]%,S+Z+^=&9?1?SH ?1309,_,%Q[&G'...M !
M13,R^B_G1F7T7\Z 'T4S,OHOYT9E]%_.@!]%,S+Z+^=&9?1?SH ?13,R^B_G
M1F7T7\Z 'T4S,OHOYTJ[\_,%Q[&@!U%%% !1110 5P6O^*O&EAXVCT/1_#EA
M>07,#W%M=2WC1@JA4,&&WALN/J*[VDP"P) R.AH Y31-2\<W&KPQZ]H&F6=@
MV[S9H+XR.O!QA=HSS@5UE10W,%R91!*DAA<QR;3G8P )!]#R/SJ6@ KCOB)U
M\*_]C':?^SUV-<=\1.OA7_L8[3_V>@#L:*Y+XCZQJ.B^&H)M(N!;7$U[# 92
M@?:K$YX/TK@_^$C\7?\ 0Q?^2:?XUY^*S+#8.2C6=F_)G;AL#7Q,7*DKI>9Z
M%8_\E2UC_L%VG_HR>NGKPR/4O$L6K3:DFOD74\20R-]E7!1"Q48SZNU6O^$C
M\7?]#%_Y)I_C7'_;V _F?W,ZO[&QG\OXH]IHKGO >J7>M>!M,U#4I!+=31DR
M.J[0Q#$9Q^%=#7MIW5SR'H%%%%, HHHH **** "LC3=8EO?$FM::\:K'IY@"
M.#RV]-QS]*UZYC0?^1^\6?[UI_Z)H Z>BBB@ HHHH **** "BBB@ HHHH R=
M%UB35+_68)(EC&GWOV9"ISO'EH^3^+D?A6M7,>$O^0UXK_["_P#[;PUT] !1
M110!Q/Q ^)VG_#^6RAO+.>\FNPSA(2!M0$ DD_7I76Z;J$.JZ5:ZA:$F"ZA2
M:,L,':P!'\ZS_$'A+0_%*P#7].BO/L[;HB^05SU&1V..E:T44<$*0PHL<<:A
M411@*!P * 'T444 %%%% !1110 5@^)/!.@>+7MGU[3TNGMC^[8D@@'J..H]
MJWJ\W^)_Q4E\ :C86=KIJWDEQ&9I#))M"H#C QWZT >C11)!"D4*!(XU"HJC
M 4#@ 4ZJNF7R:GI-I?Q*R)=0),JMU 900#^=6J "BBB@ HHHH **** "BBB@
M HJM=:A:V=Q:PW,H22\E,4"G^-]I;'Y*3^%6: "BBB@ HHHH **** "BBB@
MJM-J%K;W]M932JMQ=!S"AZOM&6_(&K-<QKG_ "4+PK_NWG_HM: .GHHHH **
M** "BBB@ HHHH **** (S;0-<+<-#&9E&T2%!N ],]:DK#N-3N8_'MCI:LOV
M6;3IYW7;R762-0<_1C6Y0 4444 %%%% !1110 4444 %?..GZ3>#]IEW.EW(
MC74Y9\X. I5L2;O3G/XXKZ.J/S8OM)B#IYP0,4S\VW/7Z9S0!)1110 4444
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M?,HZ8&?T- 'J=%%% !1110 4444 %%%% !1110!Y+-\3/$J?&E?#"Z2ITTW
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M_P"^17-:%#*?'GBH"=@0UID[1S^YH ZVBJ_D3?\ /RW_ 'R*/(F_Y^6_[Y%
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ML=2@2XM9TVR1/T85S_PWL=,M? ]C/I&FQ:='>()Y(HV+?,?<\GI70M!-M/\
MI+=/[HKG/AY#*WP[T4K<,H^RKQM% '6457\B;_GY;_OD4>1-_P _+?\ ?(H
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M?I9AD>,MK%FC%&(RIF4$?0BNDKF/'7_(-TK_ +#5E_Z.6NGH **** "BBB@
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MQ\0?^19A_P"PE9?^E,= '3T444 %%%% !1110 4444 %%%% '+^-_P#F7O\
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M-1_PG>C>MS_WX:NA\F+_ )Y1_P#?(H\F+_GE'_WR*_-O:8+_ )]R_P# E_\
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MA_,T /HIGDIZ'\S1Y*>A_,T /HIGDIZ'\S1Y*>A_,T /HIGDIZ'\S3P,# H
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M4H;N:)-[HA.0N<9_.O),#T%;?P\4-\1+H$?\PH?^C:Z<OSQXS$*BZ=KWZ_\
M .?&Y0L+1=7GO;R_X)ZS13/)3T/YFCR4]#^9KZ4\$?13/)3T/YFCR4]#^9H
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M I_]'5U->5-\0-#/CY-4\G4/L@TTV^[[(^=_F[L8^E;G_"T_#/\ SSU+_P
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MCQW^Z5?\+_(Z<)_O-/\ Q+\SC:***_*#])(Y_P#CVE_W#_*O6/ ?_)//#_\
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M.WE^2"C-%<SH<CMX^\4(SL47[)M4L2%S$<X':O8/+.FHHHH **** /G[1_\
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M;-&!FC-:.N>"-=T6WM93K5I+]HO(+7'V4C;YCA=W7MG-:7_"L->_Z&"T_P#
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M &15K[7!_P ]5_.H=+1/['L_E7_4)V_V15KRT_NK^5 $?VN#_GJOYT?:X/\
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M_GVON0OPWT;3M!^)5L;)/)$MA<;RS9SAH\?S->V?:X/^>J_G7DO@H _$RRR
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M_P# 4_\ Q54M,\>^*M)6Y6UN;#%U<R74F^V)^=SDXYZ5A45^D_V+@?Y/Q?\
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M)%D7=&P8>HH\M/[J_E2@ = !]* &O-'$<2.%/O7C_B^17^)6I%&R/LEMR/\
M@=>Q%5;J ?J*\P\8>%O$-SXVNM1TG3$N[6>VA0-]H2,JR[L\'ZBO+S:C4KX.
M=.FKMV_-'H9;5A1Q49U'9*_Y,YS)HR:N?\(OXP_Z%Y?_  -C_P :JZ7I/B?6
M-+M]0L-!WV]P@>-FNXU)!]LU\-_8V/\ ^??XK_,^O_M7!?S_ (/_ "(=VW6=
M$+' &JVQ)/\ OUZ3\2IX9?AKKB+(I+6V.#_M"N*M/!_BJ;6M*>ZT9+>"WOH9
MY9#=(V%5LG@=:[GXE(H^&VMX4#_1_3_:%?8Y+AZN&PCA55G=O\$?+YK7IXC$
MJ=-W5D>'CP1:X'_$RU#_ +_FE_X0>U_Z"6H?]_S72C[H^E+7Q']I8O\ G9];
M]0PW\AS/_"#VO_02U#_O^:]2^#:0Z;X4O[7SV81:G, TC98\+U-<G7;?"95.
M@:KE0?\ B:S=1[+7T608NO7KSC4E=6_5'AYUAJ-&C%TXVU_0XKXB:[JZ?$*^
MMK'6;RVMHH82D=O(%4$KDGI7-G6M>92#XAU0@C!'GC_"KGQ7O)K/XH:@(+.2
MX#6\&=G\/R5R']LWG_0)GK]@R]8#ZK'VL+RU^RWU[V/R?,7C_K4_93M'2WO)
M=%TN;UMJ6L65K';6FNZE#!$H2.-)AA5'0#BM3P]K^N)XOT19M>U"6&6^2.2.
M64%64@Y!&*XW^V;S_H$SUJ^$]0N+KQWX?CFL)8%_M",[WZ=#Q6F,67_5Y^SA
M9VT]UK]#+!O,/K$/:3NKZ^\G^I]0+<1.P5)%)/0 T]F"*68X ZDT!%!R% /T
MI2,C!YKXP^U.'^*[V]U\.;V!G5UDFMU90>H,R9KR/_A!M _Y\S_WV:]B^*:*
M/A_=84#_ $BV[?\ 3=*\^Q7R'$.)K4:E-4IN-T]G8^FR3#TJL)NI%/5;HY[_
M (0;0/\ GS/_ 'V:/^$&T#_GS/\ WV:Z&@=:^8_M#&?\_9?>SZ#ZCA?^?:^Y
M';_"0VUG\/8+=&5%BNKE54GH!,^*\D^(6J&U^)>NK':RW"M-&=T8R!^Z3BO8
MOA2BGP(F5!/VRZ[?]-WKRSQKQ\1_$ ' ^T1]/^N25^T9"IU*T.65G;??IYGY
M-GLH0H3YHW5]MNOD<=_;TG_0,NORH_MZ3_H&77Y5L9-&37W7U?$_\_O_ "5'
MPOUC#?\ /G_R9EKX>:I]J^)N@B6UEMU664[I!@']T_%?2:3Q2-M216/H#7SW
MX)Y^)/A\'D>?+U_ZXO7T.%4'(4 ^PKXK.(SCBVIRYG9:['VV3RA+")PCRJ[T
MW%HHHKR#UPHHHH *\@USPKX[?3_&&AZ5IFESZ=X@NYYDNIKPI)&)$5?NXQQM
M]:]?JGJJZB^F2KHLEO'>G'E/<J2@Y&<@<],T <QX;U+QQ-J<%MK>B:1;Z?&#
M'--:WYED0A>!MV]<X_.NSKS7X>VWBV/7->:]N--^Q_VW,;I4A<.[>5'RA/&/
MN]?0UZ50 5QWQ$Z^%?\ L8[3_P!GKL:X[XB=?"O_ &,=I_[/0!V-%%% ',6/
M_)4M8_[!=I_Z,GKIZYBQ_P"2I:Q_V"[3_P!&3UT] !1110!SGQ"_Y)QK_P#U
MXR_^@UOP?\>\?^X/Y5@?$+_DG&O_ /7C+_Z#6_!_Q[Q_[@_E0!)1110 5Y]\
M6?\ CV\/_P#82/\ Z)DKT&O/OBS_ ,>WA_\ ["1_]$R5QX[_ '2K_A?Y'3A/
M]YI_XE^9QM%%%?E!^DD<_P#Q[2_[A_E7K'@/_DGGA_\ [!T'_H KR>?_ (]I
M?]P_RKUCP'_R3SP__P!@Z#_T 5]GPQM5^7ZGRO$&]/Y_H;]>2_'OPSJNO:1I
M5SI<*S1V<KB9=P##?M"GGMD8_$5ZU7,?$7GP+>9_Y[6W_I1'7V!\N3> M(N]
M!\!:1IFI!5NK:W"RJAR%.2<?AFNAHHH **** "BBB@#F/"7_ "&O%?\ V%__
M &WAKIZYCPE_R&O%?_87_P#;>&NGH **** .8\=?\@W2O^PU9?\ HY:Z>N8\
M=?\ (-TK_L-67_HY:Z>@ KR_XMV\5WKGAV&X3S(S'=$H2<9'E\UZA7DWQH@O
MKG5O#L>F72VL^RZ/F,N1C$>17'CM<+4]ZVCU[?<=6#_WB&E]=NYRO]AZ9_SY
MQ_F?\:/["TL=+*,>N,_XUD?V3XJ_Z#T/_?K_ .M1_9/BK_H/0_\ ?K_ZU?G_
M "2_Z"5]\O\ (^TYH_\ 0._NC_F6]9T?3X=#OI(K5$=+=V5@3D':>>M?0M@V
M-)MF;M A/_?(KYEU32_$L>D7;W.M0R0K"Y=!%C<N.17TQ9_\@2#_ *]U_P#0
M:^KR)-4YWJ<^OG^J1\YG#3J1M#ET\OT.'B^,.G7$*RP:)JLD;C*N(AAAZ]:R
MO$7Q$BU=-,%OHFIK]DU&"Z?=&!E4)) YZUR?A[_D7;'_ *XK6E7DUN(L33J2
M@HK1M=?\STJ61T)TXR<GJEV_R.R_X6W9_P#0!U;_ +]+_C6WX5\;VGBJ\N[6
MWL[NTFM421UN$ RK%@"/^^37F5='\,?^1QUS_KRMO_0Y:[LKSFMC,1[*<4E9
M[7_S./,,JI86A[2$FW<]0HJEJ&L:=I7E_P!IWT%KYF=GG2!=V.N,_6J?_"8>
M'/\ H-V/_?\ 7_&OJ3YXH>".GB'_ +#ES_[+745P?@[Q/H=N-=\_5K./S-9N
M)$W3 ;E.W!'M71CQ?X=)P-;L?^_Z_P"- &S10#D9%% !1110!S'BK_D8?"7_
M &%&_P#2::NGKF/%7_(P^$O^PHW_ *335T] !1110!G>(-*.N>'-0TM9VMC>
M6[PB5.J;AC-<=\*?AO=_#^WU'[=J$=T]XR82$$(@7///<Y_05Z%7.^![F>[\
M.2274KS.+^\3<YR=JW$@ _  "@#HJ*** "FRQ1SPO%,BR1N"K(XR&![$=Z=1
M0!E_\(OH'_0$T[_P%3_"N;UKP]HL?CSPQ$FD6*QR+=[T%L@#8C7&1CG%=Q7,
M:Y_R4+PK_NWG_HM: -/_ (1?0/\ H":=_P" J?X5=L[&TT^$Q6%K#:QD[BD,
M80$^N!4]% !1110!S'PX_P"2=:/_ -<3_P"A&NGKF/AQ_P DZT?_ *XG_P!"
M-=/0 4444 %%%% ',7?_ "5;3/\ L$77_HV&NGKF+O\ Y*MIG_8(NO\ T;#7
M3T %%%% %35O^0+>_P#7O)_Z":SO!7_(@Z!_V#K?_P!%K6CJW_(%O?\ KWD_
M]!-9W@K_ )$'0/\ L'6__HM: -RBBB@ IDT,5Q$8YXTE0]5=00?P-/HH I_V
M/IG_ $#K3_OPO^%<U'I>G_\ "U+F/[#;>7_8T+;?)7&?.DYQBNQKF(O^2L7/
M_8%A_P#1\M &W_8^F?\ 0.M/^_"_X59BBC@C6.&-8T7HJ+@#\*?10 9 ZFL+
MQL1_P@.O\C_D&W'_ *+:O)M;MQ>^,_$#7$]T2E^44+<R*%4(G  ..]4WT>UE
MC9)&N71AAE:ZD((]"-U?/XC/L/AZLJ4HNZTZ?YGM4,FKUJ:J1DK/U_R/=]+(
M_L>SY'^H3O\ [(JWD'H:^?AI-NJ@+)= #@ 7<O'_ (]6KX/@^Q_$;0U@FN=L
MOV@.KW#N& B)&021UJL+GN'Q-:-&$7=^G^8L1D];#TG5E)67K_D>V4445[QX
MQS%G_P E4U7_ +!-K_Z-GKIZYBS_ .2J:K_V";7_ -&SUT] !1110 5\_7%_
M;V6MZS#=%XY/[3N6VF-NAE8@]*^@:0JIZJ/RKAQV"AC:7LIMI7OH=F#Q<\)4
M]I!7=K:GSXVNZ<BEGN"JCJ6C8 ?I3O[;L/\ GLW_ 'Z;_"O6OB,JCX>ZMA1_
MJU[?[:UTRHNT?*.GI7B_ZM8;^>7X?Y'J_P!OU_Y5^/\ F>.?#^ZBO?B3:O;;
MW2.PN [;" N6CQU'L:]'\6^+;+P?IT%WJ$4\RSS"%$@3<Q;:6_DIK="@= !]
M!7FWQL_Y &C_ /82'_HJ2OI,MP4**IX5-VO;SU?_  3P,QQ<ZBJ8EK6U_+1?
M\ =_PNO1?^@7JG_?D?XUC:;\5-,L_%.MZE)IFHF&_P#(\H"(9&Q-ISSZUY_1
M7W7^KN'_ )W^'^1\+_K%B/Y(_C_F>LGXUZ* 2=+U3 _Z8#_&N\TC4X=9T:SU
M.T#""[A6:,.,$!AD9%?-$G^J?_=/\J^@OA__ ,DY\/\ _8/A_P#0!7B9KEU/
M N'(V[WW\K'NY3F-3'*?.DK6V\[G0T445XA[9\P6]_XBA66.PTF&>W6>79(T
MN"P\QNU2_P!J>*_^@'!_W^K9T?\ Y!__ &VE_P#1C5>K\UQ>*IQQ%1.C%ZO^
M;OZGWN&PTW0@U5DM%V[>AS']J>*_^@'!_P!_J[+X1W&I7/CZ^;5[-+20:: B
MH^[</-ZU4K;^'7_)1;K_ +!0_P#1M=^2XB%3&1BJ48Z/57[>;9Q9K0G#"N3J
M-[:.W?T/6*9+O,+^20)-IV%N@/:GU%=3?9K2:<C=Y2,^/7 S7W9\>>5_"S3_
M (A6GB[5)/&$MPU@R,#Y[AE>7<,&/';&?;I7K->.?"GXJZWXQ\8W>F:Q%;"!
MH&GA\I-IBVLHVY[\-U]J]CH **** &R()(V0]&!!KS>#X/\ V:W2"#Q+>+%&
MNU%\A#@"O2J*RJT:596J13]5<TIU:E)WIR:]#R+7_A_<:/\ V9Y7B*ZD^V7\
M5HVZ!/E5@V2/?BM?_A4TO_0SWG_?A*WO&_\ S+W_ &&[?^3UU%<_U#"?\^H_
M<C;ZYB?^?C^]G+>$?!*>%;R^NCJ4U]->)&C&5 NT)NQC'^\:X;XT?\C+H?\
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MQ?\ XNCK!VM_R"[3M_TTFKIO,_V'_*N;L?\ DJ6L?]@NT_\ 1D]=/0 SS/\
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M6UZF(PL:E7=W_,1CM&<$_2O/?BNVZV\/_*P_XF1ZC_IC)7H=>??%G_CV\/\
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M#$8#%RK3:IRW?1]SZ>AC<,J44ZBV74Z*NA^&3;?&.M\$_P"A6W0?[<M>>?\
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M\6?]A4?^D\5=/0 SS/\ 8?\ *GT44 ,\S_8;\J/,_P!A_P J?10!RGC9\_\
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M2,Z::LK:GT.4X&I@J<H5&G=WT%K'\429\(:P-K?\>$_;_IFU;%9?B@$^$-8
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M/1?\:_5<+@J^+;5%7L?F^*QM#").L[7/6O$3Y\:^$CM;_CXN>W_3!JZ?S/\
M8?\ *OG:Y\7^*KR^L[R?6$,UDS/ PM5&TLNTYYYX-6O^%@^,_P#H-Q_^ B_X
MUV_V)COY?Q1P_P!N8'^;\&>_^9_L/^5.5MPS@CZBN#^%7B35O$6G:H=;N4N9
M+6[$<;K&$^4QJW0>Y-=[7DU*<J<W"6ZT/7IU(U(*<=GJ-9]I^ZQ^@I/,_P!A
M_P J?14%D;2?*?D?IZ5S7PZDQ\.M$^5C_HJ]!74-]T_2N:^'/_).=$_Z]5H
MZ/S/]A_RH\S_ &'_ "I]% #/,_V'_*N8U1_^+F>'SM;_ (\;WM_M0UU5<QJG
M_)3?#_\ UXWO_H4- '2>9_L/^5'F?[#_ )4^B@!GF?[#_E45U)_HDWR-_JV[
M>U6*BNO^/.;_ *YM_*@#G_ $F/AWH(V-_P >,7;_ &171>9_L/\ E6!\/_\
MDG>@_P#7C%_Z"*Z*@!H?)QM8?44XG SU^E%% #/,_P!A_P J/,_V'_*GT4 <
MH[_\79C.UO\ D"GC'_3:NH\S_8?\JYE_^2MQ_P#8%/\ Z.KJ: &>9_L/^595
MYX;T+4;I[F^T6UN)WQNDDMU9FP,<FMBB@#CO$?A/PY#X5U:6'0;..1+*9D<6
MR@J1&2#TIV@>$O#DWAO39)= LG=[6-F8VRDDE1S6UXI_Y$[6?^O"?_T6U.\-
M?\BKI?\ UYQ?^@"@"*S\.:%IUVEU8Z+:V\Z9VR1VZJRY&#@UK*^XXVL/J*=1
M0 4444 %%%% !7E>C^(;WPCX@\517?A+7KUKW69+F.YM+,R))$8T5?F]MIKU
M2O,+SQ+J]O\ #_XCW\=_(+K2[^\2RD."8%2*,J!QT!)Z^M  VMWGBOXD>$[B
M#POK>GQZ=-<M<7-[:&-51[=E S[MMX]A7I]<;KVI7<7C#P-##<ND5Y<7 N$4
M\2@6KL ?HP!KLB<#)X% !7'?$3KX5_[&.T_]GKHM-UW2M8>9-*U"WNV@;;*(
M9 VP^^*YWXB=?"O_ &,=I_[/0!V-%%% ',6/_)4M8_[!=I_Z,GKIZYBQ_P"2
MI:Q_V"[3_P!&3UT] !7R_P"*M)LKWQUXAEN8=[_VE*,Y[9%?4%>0ZU\)]?O?
M$>IW]EJ&G+!>73SHLH?<H;L<"O2RVIAZ5?FQ*O&W:YYN94L15H<N&=I7[VT/
M*?\ A'M,_P"?;_QXT?\ "/:9_P ^W_CQKN];^&GB/0]"O=4N+W3)(K.%IF1-
M^6 &<#(JZGPA\3NBL-0TK# '_EI_A7T?U[)_Y5_X#_P#YOZCG'\S_P# O^"8
MOPITVUL/BAIYM8MA>VN W.<_**^AJ\P\&?#36M \7VVKZE>V,D,$,J;( ^XE
MP!W'M7I]?,8^I1J8B4J"M'2VENA]1E].O3PT8UW>6M];]>X5Y[\7 ZZ=HDPB
MED2'4=TAC0MM'DR#.![D5Z%17FU::JTY4WLTU]YZ5.;IS4UNG<^?_P"U8/\
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MD0_9;?\ Y]XO^_8KI_A=&D?C#7!&BH/L5MPHQ_'+7/5T?PQ_Y'+7/^O*V_\
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M.F?\^B?F:^YRIXKZG#V:C;7=N^[\CX7-EA?KD_:.5]-DK;+S+/VZT_Y^8O\
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MN;C1+^TM[;SS)+<1;5&Z,@<_6O5]+_Y ]G_UP3_T$5:IX?)<+AZJJPO=>?\
MP!5\UQ->FZ<[6?D>>?&T2-\/E$#!93?0;">@.37A/V?7O^?NW_[YKWKXS?\
M(BP_]A"#^9KQVOT7(L/&K2FW)K7HVNA^?9[B)4JT$HIZ=4GU,?[/KW_/W;_]
M\T"WU[/_ !]V_P#WS6Q0.HKZ#ZC#^>7_ ($SY[Z]/^2/_@*/</A-D?"S1-W+
M>4V?KO:NQKC_ (4_\DOT;_KF_P#Z&U=A7YM+XF?I<?A04445)1S'Q'_Y)YJW
M_7-?_0UKIE^Z/I7,_$?_ ))YJW_7-?\ T-:Z9?NCZ4 +7GGQCL+V^\/:9_9]
MG/=M#?AW2!"[!?+<9P/<BO0Z*TIU'3FIQW3O]QG4IJI!PELU;[SYG_LG6?\
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M+_DG&O\ _7C+_P"@UOP?\>\?^X/Y4 ,W7?\ <B_[Z-.C,Y;]ZJ 8_A.:EHH
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MK77EMT[GMD1F)/G*@';:<TLAD"CR@I.>=QQ3Z*^//L2#==_W(O\ OHT;KO\
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M 'UKI5:ZVCY(NG]XU@?$?_DGFK?]<U_]#6NF7[H^E $.Z[_N1?\ ?1HW7?\
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M4 @?2@";==_W(O\ OHT;KO\ N1?]]&IZ* (-UW_<B_[Z-<SX)-QY.N;$C/\
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MX/AW6EV*"+Q27!Y/R#@_3^M 'K^Z[_N1?]]&C==_W(O^^C4]% $&Z[_N1?\
M?1KRSQ+\2+#3/C!IFGW%M(TMFC6DDJ'Y TYC(]^-H_/VKUJO"/&?@S6+_P"/
M-G?6[V(AFGMYD+RJ"%CV[LH>2?E./7B@#V_==?W(O^^C2[KO^Y%_WT:GHH @
MW7?]R+_OHU%<0R7=N]O=6UO-#(-KQR<JP]""*N44 9]A8#2[1;73;*UM8%Y$
M<0VJ/P JSNN_[D7_ 'T:GHH A0W!<>8D87N03FI7W;3L +=LTM% $&Z[_N1?
M]]&C==_W(O\ OHU/10!Y#+\2+9/CLFFFS<L(O[+,F>/-+[LXZXSQ^M>K[KO^
MY%_WT:\WE\7>!%^,2V#Z3G7/-^S_ -H^5\HEQC;]>V<5Z?0!!NN_[D7_ 'T:
M-UW_ '(O^^C4]% &'XG:Y_X1#6-R1@?8)\X8_P#/-J=X<:Y_X1?2]J1X^R1=
M6/\ <%2^*?\ D3M9_P"O"?\ ]%M3O#7_ "*NE_\ 7G%_Z * +FZ[_N1?]]&G
M1F<O^]5 O^R34M% !1110 4444 %<=\1[J-]*L=$&CVVL7>LW0M[:WNV*Q*R
MHTC2,PY&U4)XYSTKL:\X\<:@^LN^EW'@_P 1S?8KD2VNHZ>%5DD4<21MGT)'
M(Y!- &/HGAA?"GB.TTOQ/X>TB:#Q LMBE]9SS2,A\MG,3"4Y"LJ-ROIS7K<$
M$5K;QV]M&L4,2A(XT&%50,  =A7EO@ZSNIO&5E=Z[IGBV\N85D6VN]9\L0VN
M5.2%3^(CY<\]:]6H *X[XB=?"O\ V,=I_P"SUV-<=\1.OA7_ +&.T_\ 9Z .
MQHHHH YBQ_Y*EK'_ &"[3_T9/73US%C_ ,E2UC_L%VG_ *,GKIZ "BBB@#G/
MB%_R3C7_ /KQE_\ 0:WX/^/>/_<'\JCO[&VU/3Y[*^B$UM<(8Y8ST93U%3J
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MV2[B2Q4GYAC'KTQ7KT0=8D$C!G"@,0.I[T .HHHH *YCX?\ _(KR?]A&]_\
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M0IA=!CUY85NTQY8XV59)%5G.%#-@M]* #8__ #T/Y4;'_P">A_*GT4 ,V/\
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M;N4C/ZTNG6!T_3+:S68N+>)8@Q7&=HQG]*N44 ,V/_ST/Y4JJP/+D^V*=10
M4444 %%%% !1110 4444 %<=\1.OA7_L8[3_ -GKL:XWXD1WG]GZ'=6.GW6H
M&QUJWN98;2/>_EJ&R0/Q% '945QG_"PIO^A.\2_^ !_QH_X6%-_T)WB7_P
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M^ !_QH [.BN$MOBC'>2W,5IX6\12O:2^3.JV))C?:&VGGKAE/XBK'_"PIO\
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M4\]* .QHJO?W1L=/GNEMYKDPH7$,"[G?'91W-<I_PL*;_H3O$O\ X '_ !H
M[.BN,_X6%-_T)WB7_P  #_C5>;XI16]];6<_A;Q$ES=AS!$UB=TFP9;'/8$4
M =W17&?\+"F_Z$[Q+_X '_&C_A84W_0G>)?_   /^- '9U@>.-)U'7?!.IZ;
MHMQ]FO;B+;$^XKW!*Y'3(!&?>LO_ (6%-_T)WB7_ , #_C1_PL*;_H3O$O\
MX '_ !H H?!_PEK_ (1\/WEOXCGRTTX>&W$OF>4 ,$Y]SV]J]"KA+#XHQ:I8
M17NG>%O$5S;3#='+'8DJPSCCGVJQ_P +"F_Z$[Q+_P" !_QH [.BN2L_'4MW
M?06Y\*>(8!+(J&66R*HF3C+'/ %=%JM^=,TN:\6TN+PQ $06J;Y'Y ^4=^M
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MBDN;39Y\2V)S'N&5SSW'- '=T5QG_"PIO^A.\2_^ !_QH_X6%-_T)WB7_P
M#_C0!V=%5["Z-]I\%TUO-;&9 YAG7:Z9'1AV-<O+X_FCE=/^$0\2/M8C<MB2
M#[CF@#L*H:QI$&M6*VMTSJBSQ3@H<'=&X<?AE17-_P#"PIO^A.\2_P#@ ?\
M&J][\48]-MQ/?^%O$5O$9$B#O8D L[!5'7J6('XT =W17&?\+"F_Z$[Q+_X
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MS_A84W_0G>)?_  _XT?\+"F_Z$[Q+_X '_&@#LZ*XS_A84W_ $)WB7_P /\
MC1_PL*;_ *$[Q+_X '_&@#I]*TJVT:P%G9!A$)'DPS9.7<N?U8U<KA+'XI1:
MG:BYT_PMXBN("[()$L21N5BK#KV((_"K'_"PIO\ H3O$O_@ ?\: .SHKC/\
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M3K9G$,A20J74# ()7(;&<&NMH *Y>^UGPGX3\17MQJ6HPV6HZDD4DPD8_.J
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MH_ASP2>!F@#'\&:A87?BC=;^-X];N)(6W0"Q2)W48Y+@9P/2O1*Y3P\/$/\
M:BG5M7T2[M_+/[NRB*R$]CG)XKJZ "BBB@ HHIKNL4;22,$1069F.  .] 'D
ME[J8\,ZEXATJ-/#>I)J5Y+/++?7R1.N\Y\N=&&6"9P,?P@5W_@J.UM?!NF6-
MEJ<6IK96T=NUS$X8,RJ ?I^-><&>R2]UY+33?"_B&._OIW-]=WD,;(6./+D#
M?,0GW05Z@#O74?#/P^=-MSJ-O-:RV-SI]G#!+:KM%V8T):X9<  MOQZX09H
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MC+Q%);^.)M+U'Q7#X>LULHY;=1:+,9]S,'W$]/NJ-O?K7IE>=ZREXOQ*O?[
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M&VA\N& #/"]S]3Z#BM6LGPKJ$FK>$-(U">99Y;JSBF>54V!V9 20O;D]*UJ
M"N0^(SM+I-AI@L-/NUU*]6 OJ3%8(,(SAB5Y#93"XQR:Z^N&^(<;2Z2T6KQZ
M+-9RWL"645\)3O<J000@R6W<C'&,D]* '^ _#EQH%W=^9#H:),@RVGO*\K$'
MC<TA)V@9P,UVU>>> M/ATCQ9JFG26VB6E]!;IYD5@9_,*L00?WG!7W'?BO0Z
M "LOQ'I?]LZ#<6(AMYS)M(BN2PC?# X)7D=.HK4HH \F;PM8QRK%<?"R26X
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MOL(1Z$A0WZT =6DB2+F-U<9(RISR*=5>PL+73+*.TL(5@@C&%1>W^)]S5B@
MKSCQIIG_  E/CA-'M--T=[JSL$N7O-41G(5W=0D:J1GE&+'MD5Z/7D7CV+55
M2*Z\5VWAF25"8[,13W2W4F3]Q!& S9XXZ4 ==\.'CCT?4-.6PL[*;3;][:<6
M#$P2OL1MZYY&0R@CL0177URGPXMM0M/!L$>JZ%:Z%*9&9;*V<OM4X(9B>=Y.
M<YYKJZ "BBB@ K"\:V%YJ_@O5=.TO8UY<6S+&C/MWCN >Q(R >Q(K=K+UKP_
M9ZXL9N'G@GASY5Q;2F.2//7!'7IT((H \HD\(Z7J-UIPT?P'J]A]B9I;UKF2
M2,21"-LQH=_SN6VX(Z'G->I>$+?4+7P=I<&LR&2^CMD69B^\[@.A;N1T)[D5
MF)X&FD;;J/BG7+RWS_J&G5 P]"54$_F*Z:TM(+&TBM;2,10Q*%1!V% $U'7K
M110!S%_\/_#=Y<-.;62SD<Y8V=S) &^JHP'Z5HZ%H&B:-&_]BVT2$DK)*',C
ML1U#.22>>V:\_P#&GA6^U'Q5J.HWFFWVHP0R6D]JMO=.JO;KA)X BL/GY9_?
MCGBNK^&VFR:5X-2W>PEL(S=7$D$$Y)E$32LR&3))WE2,YYH ZNBBB@# \<ZA
M!I?@C4[J[LTOHEB"&WD;:DA9@H#'LN6&3V&:X;2-!;P;XIT*;4-)\/,FH7!M
MH'TQ'22V<QNP(!.&3"D$\8R*[?Q7#KMQ:F'28M&EL9(F6[756<*0>WR@C&,Y
MS7G7P_MKE_'4<FD^'M'GTVW#I-K%M<7$B0G!^2#S>"<X!V\ 9YH ]FHHHH *
M*** &3Q>?;R1;W3>I7>APRY'4'L:Y:72O&MHWEZ9X@L;F#^$W]H?,4>[(<-]
M<"NLKS#7_%WB0>*[NTT_5-,TNSM=2BT]UNK<R.HD@\Q9F.X *SG8* .VT;2M
M3M9FNM:UA[^X=-HCCB$4,8]EY)/'4FMFN;\ :C=ZMX*L[O4KL7MVSS+-.B!4
M=EE93L _@XPI[C!KI* "N7^(EU#;^$7AN+"WU#[;<P6B0W;%8=\D@56D(_A!
M.3],=ZZBN3\:6^MW5K-!!#H$NBM!_I(U:21><DG[HP!T.<YS0!SGAK1SX0\<
MZ;9:AIFAF74H9A;W.F(\;PE &(96)RI'<=P!WKT^O)/A=!=R>)[BZL_#^FKI
M2PF,:S#/.YE.?N1>=R4XY(XX%>MT %%%% !5;48)KG3;B"V:)99$*KYT>]#[
M,O<'I5FB@#S6/09=-:2'_A5^CW;22,YFMI(/+9B<DXD 8#VQ79: FL+ 3J\%
ME91A56"RM,L(0/5N!Z< 8&*PH_'MS8ZIJ=CK6@ZLQMKMTM[BRL))8YH>JG([
MCH?IQ77VERMY9PW*))&LR!PDJ%64$9P0>A]J )J*** .2^(\T/\ PCMM8S:?
M9W[ZE?16D27Q(@1VR=[X[ *>.YP.]87A'2SX4\=0Z7?:;HPN+^REEAN],1T9
M%1DW(Z,3P=RD'V-:_CFWUFZM+F)XO#KZ%Y8:7^U994((YSE1@8.""#FN=^%$
M-ZVM7MW#X>L+;2GAV1ZM'-.\ETP(P$\[YO+Z\\ G'6@#U6BBB@ HHHH CN+B
M&UA,MS*D48(!=S@#)P.?J:\CN? 6MWBW\5[I=KJEI"][<VQ>[S_:-Q<.!'(^
M?N>5'D?RKURXMX;NW>"ZB2:&08>.10RL/0@URTOPW\/&4O']NMHNK0PW\J1_
MENX'TQ0!L^'E^RZ+9Z;/>I>7EC;117+J^XEPN"3]2":U*HZ1I6FZ39+%H]M%
M! WS9CYW^Y;JWU)-7J "N*^(XCODT?0_[.L+VXU*Z986U+/D0E(RQ8@<LV!@
M#_"NUK@/'\&KSVMR=3C\,G08F62-]2FFCD0@?>R@X;.<;3F@!G@6R_X1WQ=?
MZ#=:=I45XUG'="[TQ657CWLNQU8G:01D>H/M7H5>;?"6"_5-0N9O#MII=C,5
M^SW:22M->8S\Q$OSA<'C/J:])H **** "@G HJGJC:BED7T=()+E6!\NX8JK
MCN,CH?0T >+R:?))H\GQ!.G: MNK&].CMYFXX;.#\VSSO;;C=Q7N,4BRQ*Z]
MP#C/3VKR67PKH\EP\4_PKOGGDD\QMMZ#$SYSNW>9C.><]:[[P=HK:)I$D+6$
M&G^;*91;PSO-LR .68G)X[<4 ;]%%% '+ZLGB>VOO.M=.TW7+=93) LC>3-!
MD$8!(*G@D9R#5;P[IVN6\V(=$TGPU9--YL\5MB268]_N@*,],Y)IWC?QC?>&
MY([?1]+34;G[%<7\JRS^4JPP[=V#W8[Q@?6G^$/$>LZSJVIVNNVEG9FVBMY8
M([:8R[TD#'S-V ,'& /]DT =91110 CML1F.2%&>!7AHTQ!X7_X3H>'O#(TI
ME%X;$!_M!C)S_K,X,N.=N.O%>QZW_;']GC_A'19&[WC/VUF";><_=!.>E>,2
MV%[_ ,)I':Z5X:\-ZOJ*W FNH[.YN?L]H<Y,D@/[L-GG&,Y[4 >[(P:-6 P"
M 0*6@=!FB@ HHHH *\TU^W\0^*+YC%HL<T-K(\<<EIKIAW#/\2J.O'0]*]+K
MGM5\#Z'JURUU+;RVURYR\]G.\#-]=I /U(H S_!&G+X=L[B+4K"+2[N\N0?G
MOS<R7)V@ EFYX P!V KL:P-&\(Z%HUT9K*$S7B#!GN9FGE7/NQ.W\,5OT %<
MUXVGN+?387AU6;2X=Y$]PED+E0I'\8/W5]ZZ6D9E1"SD*JC)). !0!Y/8R:1
MIUY;W_\ PGNC.D4@8I#I,".XSRH*_,,CCCUKT[3-0CU2Q2[ABFBCDSL$\91B
M.QP><'J*Y5?&?P\AODDM;_2'O9)EB0V\:M*SLP  P,DY/Y<UVM !1110!YYX
MZL1XD\7V.@VVFZ3-=QV;79N]45G"(7V[8U!&6R"2>PQZU?\ ASLLX]8T8Z?8
MVESIMXJ3OIY;R9RT:.& /(." 1V(KGOB!%JGDBZ\3P^&#;PR,+)FGN5N3D\*
MGEC<6.!D#BNC^%]MJ5MX48:IX?M=!+SL\5M [,SH0/GD+?-O)SUYQB@#LJ**
M* "BBB@#+\3:A/I/A35=0L[;[5/:VDLL<&,^8RJ2!CTKRK0]>DLM4M(;?5M)
MU=HM7@A@B@LHTW1W$*-(T07E-A+,3W (->KZS%K#QQR:%<6R31D[H;I"4F'H
M6'*_4 ]:Y&QTWQ#;:DT]AX+\.Z9=OD-?K*._4@*N[^5 'H%%5M/BNH+&./4+
ME;FX _>2K'L#'/8=AVJS0 5YIXMTK_A+?'<VF6.F:*;G3K.*26\U1&D=A(7P
MD:J1P-IR?4XKTLYP<=>V:\>\=PZLOD77BFS\,SWF#%:1V\]TMU-D_<01@,PS
MVZ"@#M/AS/$WAZYLX["UL9-/O9K69+)B87=3RZ$\X.1P>AR.U=;7,_#ZVO[3
MP9:1:KHMIH<XW$6-HY=8U)R,D\ECU.>]=-0 4444 %%%% !1110 4444 %%%
M% !1110!@>.;34K[P1J=OHGF?;7B&Q87V.Z[@756[,5W 'U->=Z3X4;3_'VG
M?9M#U8F/4OMD5Q=322016CVYRK%F($B2$@#K7=_$F=[?X<ZQ)#/- XA 5H,B
M1R74;%(Y!;.W/;=FN<\*:=8P^(;*6+P9X@TV09(N+N\=XXSM/W@9"#Z=.IH
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MD2&8-(Q5D52 !M([>_>O9;4 6<(574"-<"3[PX[^] $M%%% '!>)/AYJ>O\
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M$8EW..1N*CNP7) ]<5NUSWCZ_N=,\ ZQ>V-V+.>"W++/@93D9VY_BQD#W(H
M\XL!=0^.=,M)-;\0ZB_]IQSV]K<L1'+9O;[Q*Q"C[CD@@GJ,$5[17F7A74--
MN->L1!K?C*XE<DB+48F6%CM)^?\ =C'Y]<5Z;0 4444 >2Z];1:A\2=<2Z\.
M:KXCCACMPC6UVT,=H3'DQ@;U!)R'SS][':O0O"D$=MX;MHH-+GTI%+8M+B7S
M'C^8]6R<YZ]>]</XHLWU/QU?_P#".V.MW=];PQ)?/9ZFEI"F5W(GS#YGVG/L
M"*Z_P->07OA2 V[7Q,4LL,R:@X>>.5'971B.#A@1QVQ0!T-%%% ''^.O!-]X
MR-G'#K\NGV<!+368@$D=R>V_Y@2!Z9P>]3Z)X>\2:9>6WVKQ-;W%A",&SBTM
M(01@@ $-\N#@].U=310 4444 %%%% !7EGB+59;_ ,5ZYI=]J_AS288C%#]G
MU&S$TEU%L5P[$L/EW,P [%37J=>3>)YH/#7C35)9SX2D34GCN%75W8SH1&J'
MHC83Y.!]?6@#T3PPJ)X9L4BN+.Y18\++91".%@#QL4$@#M6K6;X>+-X?LV>.
MQC+1[MNGG,&#R-AP.,5I4 %<3XU\!7_B[5[2Y7Q UK96J#&G26HF@DDR3O<;
MANZC@\<5VU% '.Z'HOB+3[Y7U3Q)%?VBH5%LFG+!@]B"&.,>F*Z*BB@ HHHH
M **** /'M5?31K6M#QG-XB35OM<O]GK8M,%\C/[GR0GRDXQG.?FSFO3/"QU,
M^$M*.O\ _(3^R1_:L]?,VC=G'?->8M?0WVOZZ-4N_&-U)!J4T*/HZN;94#?*
MB[1U4?*W^T#7J^DA!HMGY7VC9Y";?M0/FXVC[^>=WK[T 7**** .&\7?#_4?
M%'B*WU$>(S#:6RCRM-GLUF@#C_EH5+#<?KD"MK0M(\0V%ZSZSXBCU*V\LJL"
M6"P;6R,'(8]LC'O6_10 4444 %%%% !7A^M>$KYC=7NMZ5KU_-)/?VUPUE<R
M,9"[![66-%8 (%^3IP3S7N%>)V-M;ZA-J5Q?>&/$>NN=0N5748+QXXYU$K ;
M5#KM"XVXQ_#0!ZWX=MYK3PQIEO=P1V\\5I$DD,?W8V" %1[ \5HU!9*%T^W5
M8GB41J!'(<LG'0GU%3T %<#K_P .]4UOQ@=<'B;"18^R65S8K/#;$  LJE@"
MQ.3D@D9XKOJ* ,30=,UVPFF;7->354=0(U6R6#RSW.0QSFMNBB@ HHHH *"<
M D\ 44$@ YZ=Z /,[CXNW;V,]SIGA&^FA%F+V&>6>-$:!F*K*1G(7C)XR!S7
MI4;%XD8XR5!.#D5XQ#I,6OZ-9G1?"GB%-)D21(9(M1AC\^UE8,8BK'(C..!U
M ..]>SHH2-54;54  >E #J*** .*\;3LWB'1K.RT&VU/4#'<3137=QY,<* *
MCKG^(L''R\C SVI_P]\//H,%]YVD6^G/,R8,-\]T6500%RWW57H![FJ'Q)T?
M[=K&BWUUHLVMV%JDZR6T=T+<1.VS;)N++DX#+C/\1K4\!6MI;V=VUCX=N-$2
M1U.)KL3B;@\@AVQB@#K:*** ,+QAH-]XE\/2:;INM3Z+)*PWW-N@9RG.5&2,
M9]1S6!H_@?Q'H-G%9Z7XJM;:TC.?*CT=!N]23OR2?4Y-=Y10 "BBB@ HHHH
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M(V\ET"IC(QSU%>X5Y=X/DUQM/T;?J'@Z2#9%D6X(D*\<*.F['ZUZC0 4444
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M$P8*$:1?O[P7;!Y!!]:[ZN<\+>(="U.26ST&RFM!&OF,C6+6Z')QQD $UT=
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M\#C/J*];KQ.&,V/AW3O&#P^$YX9W@E_LNWTV-742.H"QRYR9%W#MR1VKVR@
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MB#P%=:C)]LE?[1;7BPPW<>XE'>'S N=N <CG&3UKUZUD6:SAEC4*CQJRJ""
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M=VXU)+J!;V61H?L;6^2S]@Z2$C!YS@8YKV>@ HHILCK%&TDC!44%F8] !WH
MY;Q5:>";W5;.W\5KI[7\HVVZS-ME<>@P<D9SP>*V-(L-%C@AO=$M[01/;K%%
M-;*N#$"2J@C^'))Q7E'BO4;/_A+9M6T34- U-;JZM+EOM%^D4L'D<% 6ZHV,
M\="6KT+X=V2V?@^,I<6DXN;B>YQ8MN@B,DK.8XS_ '5SC\* .HHHHH ****
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MPG)((Y&>E 'KE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#: K90!HS&1&N4)SMXZ9[U-0 4444 %%%% !1110 5EZ\FM/9(/#LMC'/O\
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M<:Y\1+"_L-(U#1XK*S>&_P#MK[#.A'[J,19.<-EM^/;/->A4 %%%% !1110
M4444 %%%% 'G7C_21;7<FLWEYH\4$K1PQ13Z$EW<228P%4YW,3@X'84WX;RV
M<FJ.T%[ILDD]BEPD-OHJV,IC9N&R#\P!&".QQ6S\0_)CTW2[I;U[34;?4$;3
MBEN9S).R.FPQCD@HSYQT'/:L/P'H\VC^+1INOZDMQJ>EZ:8;2&*V:*)H))%9
MY%8_?.X(IQ]W'O0!Z51110!F>))I[?P[>2V<MQ#.J91[:V\^13D?=C_B/M7F
MW]N^)<<:OXE]O^*6_P#LJ]<KQ#6I9K+QM<_V]#XA>\N9;Z(FS\TH]NP'V80[
M?E!X'/4,#F@#V;37DDTFT>9I'D:!"[2Q^6Q.T9)7^$^H[59K,\-KJ2^%M+77
M3NU,6D0NSZR[1N_7-:= !7*>/;J:*STJUMK*PN);O4$1)M1)$-LRJTBN2.=V
M4P,=S75UQOQ(6&\TW3-(?3;/4)]3OUAMUOG98(G".^]MO)P%.!W)% #?!GAV
MXTK7-0O[NVT&.6[7+R:89"[,6R<[N "23@8R>:[2O,?AI-9PZM:1QZ+964^I
M:,MZ)K25ST=5D1E8G W,"I[C/I7IU !63XGU231O#MQ?03V5N\6W$E\S+",L
M!\Q4$]^..N*UJ:Z+(I61593U##(H \K/Q.U( G^V_!O_ ($W'_Q%>HVTAFM(
M96*,716)0_*<CM[5XC=^++F'4]0>]\21Z?>&"_QIIM4*V<D,T8@4*1ERZ9YS
M\P8XKVC29[BYT6RGO8/L]S+;QO-#_P \W*@LOX'(H MT444 %%%% !1110 4
M444 %>/2W.HQ^#[SP[=6/B*3Q;+<23QW,6_RVN-QV2K+G:(1\IV]  01FO8:
M\.FTT#1+NVO-%\12^.V>3R[Z+SMAGW'9(L@/EB(<'&,!>",T >VP"06\8N"&
ME"#>5Z%L<_K4E1P"46T8N"&E"#>5Z%L<_K4E !1110 4444 %%%% !575$$F
MCWB-"TX:!P8E;!?Y3\H/;/2K5(P4J0^-I'.>F* /)?!-UKG_  CNAHFM^$OL
MXAA41!?WJKP-G7[X'&?45ZW7!P77PN%_&ELOAW[3YH$?EPQ[M^>,$#KFN\H
M**** "BBB@ HHHH **** (YX(KJWD@N(UDBE0HZ,,AE(P0?PKD=/^'NA6U];
M,NHZA>06,H>WL+B],D,#KRN%ZG;U ).,"NCUZ.YE\.:E'87"VMT]I*L$[G B
M<H=K$^@.#7C7A_1[U]2CMM&\-:IITIN["X2]D<F&,QY%RYEW$2;UW+CG=N![
M4 >Z4444 %%%% !1110 4444 %<YXON8&T^?3+^RM[JTO+24,LUXD&]AC"#<
M0<G).X=,5T=<I\18+&+P=J&JW.F6=]=6-NS6[75LLPC)(&2#_"."?84 <CX7
MM)I?%6FG4XKV]2W<FV%YK]O<+;'81N$:8+M@D9.<9->LUXI+I^H>'M1T2XL-
M4\'/<7DQC$EKI"*T1\MF\P$-D( I!/8&O5?"NL2>(/">FZM-"(9+N!9&13D
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MUMO$'@?6+J=[UVCO=.2?R[F/C:2%<?,!P3C!QQ7J6E+$FCV:VT$MM"($"0S
M[XUVC"MGG(Z'- %NBBB@ HHHH **** "BBB@ KQC4=%F\1'5O$VFZ%IITN*X
MN/-M)M0FB:]\EV5V=%^122AX/7C/6O9Z\?D\-W7BJ_U#4M/\,6*6DMY-')#/
MJTT(N&1RA>6%!MRQ4G'<'GK0!ZGHU]!J>A6-]9QF*WN;>.:*,C&U64$#';@U
M=J*U1H[.%'CCB944%(_NJ<=![5+0 4444 %%%% !1110 4'IZ44C?=/4<=J
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MVMM(D5Y"W;<3A>#NSZ<T >LT444 %%%% !1110 4444 %%%% !1110 4444
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M [B0!DG' KN:Y+PIXV?Q!<6EM>:<UE+>::NH0,) Z2+D+(OJ"K,HYZ@@UUM
M!115/5=0_LK39;S[)=7GEX_<VD1DD;) X4=>N: /*;S7K-=)UI=?U.:U\7K=
MRM:1)9*TT.USY"0_(=R,H4YSSN/(KUC2Y+N71[.34HUBO'@1KA%Z+(5&X#\<
MUS)\>KN#GPGXD+*.#_9C9%=;#()H(Y0"H=0P##D9'>@!]%%% !1110 4444
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MJ%GX762VNA?7$<G]K312W4EM*B2LRJ=J [FVY]!G&:]DU66_ATR5](MXKF\
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M44 %%%% !1110 4444 %%%% !1110 4V57>%UC?RW92%?&=I]<4ZB@#@M0\
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MF021NO1E(R#^5>/:OKNMS:_=M/XEM=$M5U*ZL6633T9;4HI:!G9NHD52V?<
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M:=).)Y(R[R2*FU6=V+MA>PRQP.PQ6O110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% &=K7A_2?$5F+77-/M[Z$'*K/&&VGU![?A3+/POH.GW2W
M5AHFGVUPF=LL-JB,N?0@9%:E% !1110 4444 %%%% !1110 5Q/Q+\(VOB#0
MC=)HUKJ-W;RPO(D@59)K=) TD2N?NY7=W[^]=M7+?$2SFO\ PDUO %E!NH&E
MM#-Y7VR,2J6A#9&"XX]^G>@#EO"NEV5]X\TW5_#?A0Z!:6EK-'=SRHB&X# !
M4503G#*26]L=Z]2KR3P-IUW#XJTQAH<_AZ&WDU %;EEC^T12RM)%"B \[ =Q
M/;&.]>MT %%%% !1110 4444 %%%% '$_%&YM;+0]-NKYKBW2+48]M]:G][9
ML5<"15P=PYVE?[K'TK,^&EGX=BU C3?$=QKM[:VAAB,T?EBW@+AF"C &2VW)
MZ\#TKTFB@ HHHH JZG8+J>FS63SSVZS+M,MN^R1>>Q[5YC:Z)<:CIFNW>DW>
MO2)IUS);6RRZUL^U-$Q64GY?D ((&>O7@5ZK++'!$TDTBQQKRS.V /QKC-3\
M)>"]5U&>\GO5B-TVZYAM]2,45P>A+JK8)(Z],]Z .C\-7\&J>%-*OK,S&"YL
MXI(S.<R;2@(W'N?4UIU%:QP0VD,5FJ);HBK$L?W0H' &.V*EH *X[XC&U;3M
M,A:#49M2DO1_9ITQE6>.81N2P+?* $#YSP1Q78UYY\1=)C-S9W<FJ:_+=7%V
MB:=INFRQI^^",=REE^4;5<L2<8S0!/X%TZ_37;J_URRUIKXVPB2\U2:)@$W9
M,:+'PN3@D]\"N\K@? ]U?6_B2YTO7Y=<BU VOGQ6^I7$4T3QA@"Z-& ,@D @
M_P!X5WU !1110!X/?ZA=6^OWL>I3^(?[;NH+^-EM?,9#)YT9L_(Q\F-J]?\
M>S7MNE?;/[&LO[4V_;?LZ?:-O3S-HW8]LYKDK3P9XFTJ2[CT;Q>MM93W,MQ%
M;2:<LOD;V+%0Q?.,DG\:[:)76%%E?>X4!F QN/<X[4 .HHHH **** "BBB@
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M#Z)<AT<36$+YCC\M>4'1>P]JVJK:;";?2K2%A"ICA12+<8C&% ^4=E]/:K-
M!7%_$U86T;3@+G4(+_[>AL!IL:O<22A'^5=W &W<23Q@&NTKCOB,UFFG:8TL
MNH0ZDMZ#ICZ;#YLWG>6^<)T*^7OR#VH Y/P]I&IZGXPF-_XA\0Z9K:6@(BOH
M(2'MMXSY97*XW8W=_N^U>NUP'@:&[NO$=SJ6MC7)[];7R8Y]1L5M8HXRP)1%
M!/)(!)S_  BN_H **** /*[S6O$EMK]U'X"FU#7L7++-:ZC;;;:([CN5;@XP
M!S@8:NX\-ZY?ZK]KMM9TF33+^R=5E3>)(Y RY#(XZC]01S7F\OBVY\*WFIV$
M7CKP^((;J>5(+M)99;=2Y8H6'7!./;I7KFGW/VS3+6YSGSH4DR5*]0#T/(Z]
M#0!8HHHH **** "BBB@ HHHH *\(N6TZZTZ?['I^M6FB6]E=7,,UO=Q^9<:>
MTRK.@0C*QC[Z@_-@<=:]WKP>R@\,W$TG]LMXBTX@S6UQI5M'(]JT9EW,J-LS
MY3$!L9[D4 >YVOD_8X?LN/(\M?+Q_=QQ^E2TU JQJ$&U0   ,8%.H **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y_QUI^F:AX*U,:Z+AK
M&WMI+B46TK(Y"HQ."#SQG@\&O+K:'1K&^TT/X=FEM;$Z>U^TVKR2?9IIY (5
M5-VV0J=C'TR,5[#K]]!IGAO4K^[A^T06MI+-+#C/F*J$E<>X&*\<L6N;+[-;
MIX6T+3[.RU*PNI)%O99O+-P55)0I^_C[@R<*1D<"@#W.BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O,==TR[\4>(O
M$%MH.A:?M@E@BO+N[NY89)YD19$,80':5#J-_?IR!7IU>/>*+.VU;XB71L]-
MO&6:Z33+NZCU5[??/]F,J(J+U 4*"Q_O''2@#O?A_-9S>!=/.G6#:?"@>-K=
MGWE)%=E?YOXLN&.[OG/>NDKA_AGHFD6V@P:GHRZA;+)&]NUG<W9E6!D<JZ@=
M.&0C(Z_C7<4 %%%% !1110 4444 %5M0N9K33YI[6TDO)8URMO&P5I#Z GBK
M-1W$"75M+!,"8Y4*. 2"01@\CD4 >6:MIVKC6]3'AVT\16]C<7,C7":?=VWE
MR2'[[)O.Z,DYS[Y->B^'(;6W\,:;#I\ MK6.VC6*$.'\M0HPNX<''K7CW]D:
M%#=7-AH'A][B[N=7NK>W6[UB:-6$()GD?:V54,-HSR=P)ZUZQX,N;&]\#Z-<
MZ1:?8K*6RB:"V'_+)"HPOOCIF@#;HHHH **** "BBB@ HHHH AN[2&^LYK2Z
M3?#,A210Q7*D8(R.1^%>%&PT".Q>#0O"]O-++=:A*J7FJS*!;6[XD=]K?*6D
M;:H/;!)ZU[W7A]_>76I7FJS:7X;\-)%JZWP8W4L@EG^RR@,DFW@,Q^?'?'-
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M]KN]3NXY=S2O,V$MAW*QJ$Y/'RC'>O2: "BBB@ HHHH **** "BBB@ HHHH
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MWE>A;'./QJ2D3&Q<=,<4M !1110 4444 %%%% !1110 4444 %%%% !1110
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M-<I!&+>P.4=HU(:8\#!;(&.P44 =E1110 4444 %%%% !1110 4444 %%%%
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MN.2 ,HK''4CTKT2B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8GB;P_+KD-E
M-87IL-1TZX^TVEQY8D56V,A#*>JE78'ZUMT4 <QH/AO58->?7/$NJQ7]\+8V
MD"6T'E10QE@S<9)))5>3TVUT]%% !1110!X9?V5JNFZZFJ^#O$6I^(C<W/D:
ME#!)^\)=O*>-P<(J@J,?[/>O5?"&L3:KHD27=KJ$-U:Q1QSR7MJT!F?:-S*#
MU!.:WJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *#R/2BD/W3SCCK0!XGHOARUT^**Q
MU/P%<7FHI(3+<C5D#7#;LF4IY@(+=2,5[:.@[5X9;Z']L\)BPMO"-W=^)9@3
M'XBB<-$\Q/%T+C.=N?FV_P# <5[C&&6) YW,% 8^IH =1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %4-6T+2]=ACBUFP@O8XVW(LR!@I]15^B@#
MG[?P'X5M;F*XMM L(IH7#QNL(!5@<@C\:Z"BB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MTJBO*1XE\<:M-JNHZ#I^K3FTU*>UM;.(:>ME(D,IC(E,D@GWMM8Y!4*2N%8
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %!.
M2>E%!.!D]* /#FM ^C/K\>A:I_PA'-VUD-5 5H,[C)Y&,[,?-LW=.W:O;XV5
MXD:/[A4%<>E>%))ILMO=SG3-<7PLEN-4CT]=17RIK7S2&?RL9" #=LW<K^5>
MZQLKQ(T?W"H*X]* '4444 %%%% !1110 45D:]XIT;PTD1UF]2W:<D11X+/)
MCKA1R<5/HNNZ9XAL/MFC7D=U &*,R'E6'52#R#[&@#0HHHH ***JWNI6>G&W
M%]<)#]JF$$.X_?D()"CWP#^5 %JBBF331V\32SR+'&OWG=L ?C0 ^BCKTHH
M**** "BH[BY@M8O,NIHX8\XWR.%'YFLB;Q=HT.LVNG&^MV>YBDD$@F78H3;P
M3G@G=Q]#0!MT5!;7UK>!OL=S#/M^]Y4@;'UQ3Y[B&UA::ZFCAB7[SR,%4?B:
M )**IP:QIES,L-MJ-I-*WW4CG5F/T -7* "BBB@ HHILDB0QM),ZQHHRS,<
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M984=BL0. ,(%& !TXK>HHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
<0 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img30600998_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img30600998_4.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2<\4&AO=&]S:&]P(#,N,  X0DE-! 0
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MYT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M  "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@
M    EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN=$
M]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M  4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V
M)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M   $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M          1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M   $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M       %)S;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0
M    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M              5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4'
M)C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296
M-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W
M)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$
M))30/M       0 2P    !  (!+     $  CA"24T$)@      #@
M     _@   .$))300-       $    'CA"24T$&0      !    !XX0DE- _
M,       D           $ .$))32<0       *  $          CA"24T#]0
M      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M   0!:    !@       0 U     0 M    !@       3A"24T#^       <
M  _____________________________P/H     /____________________
M________\#Z     #_____________________________ ^@     ______
M_______________________P/H   X0DE-! @      !     !   "0    D
M      .$))300>       $     #A"24T$&@     #-0    8
M  !5    =D          $                          0
M '9   !5                       0                         0
M   0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0
M    0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&
M]N9P  !5      4F=H=&QO;F<   =D    !G-L:6-E<U9L3',    !3V)J8P
M    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W
M5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@
MUA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26
MUG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;V
MYG          !,969T;&]N9P          0G1O;6QO;F<   50     %)G:'
M1L;VYG   '9     -U<FQ415A4     0       &YU;&Q415A4     0
M   $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L;%
M1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D
M%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97
M)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V
M)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M  "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
MQB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #
MA"24T$*       #     (_\        #A"24T$$0       0$ .$))3004
M     $     SA"24T$#      <HP    $   "@    <P   >   ->@   <AP
M 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_; (0 # @("
MD(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,#
MP,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0
MP,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@ <P"@ P
M$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,  0($!08'"
MD*"P$  04! 0$! 0$          0 " P0%!@<("0H+$  !! $# @0"!0<&"
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MT(;8T[?=N%MS?L^S_PTVBS?_
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(T)2L<'1\ HDX1@E,V)CDO$94R9#1'*"-&2BTN+_Q  = 0$  @(# 0$
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ME%8YPY(PGX"215CYF'=&2D(MZDHU>MT%R&("E9%I2L"FLJXPK=@E*I8LBT:
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M2&,CX5.<KK24:P5E6@8M27:+M'UK96>?MN)M7M-&N-"M[@1V-S([R84^>JR
M":&.7F_AP3$9E0+EBSX90[AI&+5+V&RDL(Y.6WE9F; /F , 'C5\^[&^,NH&
M22=P&8&-=AFY;>]GC=IOLAL_8AKE(VS8WNL7C+;59*5.P5F@E[%C&4G8C+T9
M.V%)PWL<U;7[FPU4911:OQ57@I:L6*HPBCR1KTZ\=0%1U;*,DX@Q/F2)9P&7
M<8X^RG!Q[].480V1:;7;K%L9)$.$Y!FPLD=)-6SPI>2 Y12(L*8F3$XD,8H\
MXY)(FYHI'C;#+S1LR-RL"&7*D'# D,,X()!VKDK,ARC,IP1E25.",$9!!P1L
M1W%2 @@@U01;-D4F[9NDF@W;H)D10001(":2**28%32223*4B:9"E(0A0*4
M* !KA7&L6OM]I>+:5:,C9%LT/3*+2820LEKM5@>I1\- P<4W.Z?R,@[6$")(
M((D,/ =2BIQ(BBFHLHFF93IUK4Q>MYVX_<6*L3MDK;_;;B%T*J*FX',=127S
M1;H]4@&0E,-8'L"2C2C,7).3L[=N!9$G$1, FP8[:F;RIK#8</7-R%EN2;:$
MX(##^,X/]*'[&>Q??T4@UK_7O$#3=-+VVG :E>J2I*DBSB<9R'F7>5@<>Y#D
M'H9%(Q445?;+CV-N$;DVWK7#-.7XM-4C#+F=;=,Y3O<0=P4Q72E06L:ZU?QH
M@Z*=1->*Q;7Z3 ^4JJDE%)HJJ)GM=KIMA98,,"F0#_?2$O)G W!.0N?10HW(
MP*U5JG$NNZT'CN[QUMW.]K /(@(ZA61/?D '_>N_J=^EAR1P\ /3QV^W?CO[
M??MQ^FL[S#G8Y!^&V_;(SC[Z@UMSUY<CY ?0XW_+XU]!CA^WZ<\^GY>_W]_U
MU],A^/3OD]3V],?@.O:N1MSZ=,].N_ID?E]37'4CQ !#I#TY]/O[\?[^_IP6
M3X[Y^1 ^6QS\3\*ZC!\/CTZ#?N/]*@.S1LCBS<+MXW-TR+>IOZK>&V-,[.H'
MX5!Y9MM^08J?@Y1M:"K.6+>7KV,,E2-%RXFN^655J476;;(Q(HI2DVVDH'B&
MT]JM1<1QAIX&RS#',8 IYP3L6"$J^_3#8!R35]\/=7.FZFVGW%P8[*^0K%&Y
M)C%]S((BH&R-*I:(X #L4!.RUL.O'B*[+L9Y/RAB/(.?:73+9A>NTZQY1<6)
M=W&56F)7V99PE9AIBY.&I:RE:G:\E$OW56)**3D5!RT=/2C)G$. >%H>#ML=
M\XVZXZX]<=_2MZ\R[CF7( )W&P8D*3OL&((!/4@XZ5<*$G8.S13*=K<S%6"#
MDT2N8Z9A)%I+14@W,(@5PRD6"SAH[1,)3 55!91,1 0 W(#KY7*NUTI32E-*
M4TI32E-*4TI32E-*5KT5*"?BNL3E'N\\/25*L #VXC=R,,+43!QVY^:NP((C
MWX/P'8W*E9YNF\.[9+O7=PDGNCVW8XR].5QK\OA+/-,'T3;X^,!=1R$.E<*P
M_@[0>%*Y56<DA5I92*(Y7<.",RK.%CG4J8\#;<,%;7,=M<4[=,54C#5!9KN'
MR-<HT$TB6:\JZ221<34LHF47D[-N$T&R;J8FG3^4=I-FZ3AXHFBD4BE:2<=^
M(3GW;IE/++3=;FB#S1CJ#WRVS8[7)![3\<X&B*FXK^U1CNA895LUCC64BF_>
MS2[23QFVJ2CJ-CQ5EXZ;1D5WC,8QVI7UC/'/OEP;XX=X]V7,IMKDBOX6/'+3
MFY!E7O@;KG':'8MW]?KCA-/#DLHI#0=1I%RKLY9"E354E6M?7CH1P2:?-H%2
MNXA_'FJMBD:@]A]NK\:;:JUCX01D<LP[++;:\Y)V7R>]6$!IB="G/EY/#,74
M([]AK'F=.RMTF%N4<*LZ;(1;!9=12I W$;MMW%RV8[,=U^)[%%;3Y'<3F?:[
M37^.W,'2MP0N,;;N<M8UIM*M+VR3</6V\5:*W2;<>SK5^*CUF/SN2-!R$H]1
MC"/EE*A[)WCC3>WG%TU:\@X(AK6-%S3N"P4@[<9?=P5[S8QV>W-;'6>\R5FH
M5G!]@I-.34EA@):'I-RNU2;.7UD4@8J<<IL&+N34JC&X#Q-/$CKV9<V33&TQ
M]?P;1,Z[YCH53']QQ5"VLF*-@6(Z=?Y:H5^4ONT?*)H^5N[*],[%:9BPO;8Y
MMTLDRJ-4<8;B8B0G;6Z_K]?C2KI[DO&3OS:EV#(V***C5:3@O?!A;!M_@H*X
MPF1-Q^5HMG9H$V6*?$;?S8\>K5JH7F*F?D..[^6Y)6:<=@SD&L-6V<HW?I/U
M^OU]U*RIOXP>0AR'&-Z=B6%RX\S7';(XG%^/XS.57C\75*?W+8%W6YQ<2K'*
M[/!X6F>9(-<#,X"TGF8N032>N"N:O%Q@Q[Z.GU*[_$_CH5O,.3]M='KN VT1
M#Y^<;2H)VO:LVP<1D.O6;==C2S94C7E4QBE2GKS(V-\?P54D(.S7]">K0.+D
MZ80C6!21))R$:I6_'2E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-
M*5K/M;,-GF].JY"AR&C]O>_*UL<:Y8AVR8%AJ)O";P*G]$V6BI$$21S;/=5K
M:V&;PLBD1&2R-"X7=*<2-@G7KM2MF&E*:4II2FE*:4JAOB">(]MC\-/$+/+F
MY&Q2Z)+%)+P5 Q_3HU"=R'D>>:H)NGT=589T^BH\K>*:*I.YJ<G9>&K\2DNR
M;NY,LE*0["14K6KLF_XDO9/N_P Y5W;K8Z3F+;-DF^/&D?C0<T15?;U2[RLH
M8@0=>;6&"FWYX6Q6'K L WG(QE"S#H48N.L#F9?1D:^4K?.3)6.5;HMC=._T
MI3(C=N#MQ0B6J"/=$&AF:4@5TM5BOQG$FYF"R+X%CL2IBS52<@;R5"G%2LUT
MI7\*8I@Y*8#!R(<E$!#D!$!#D.W(" @/T$! >X:4K^Z4K'JM;JI>(@+!2[-
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M;MQ[B/I_OZ=_7OJX,^>_3KZ*-_3KVVZG\:T_#!GH/KU[]OCZ'[N^,C;1W/\
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MJ:EB]T$=&4'&QQD X^1R/3T^%88_;@)3E$/8?8>>._ \!QZ#Z<\?;TUF1/\
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M1LB*GE1!4@*J8\<T87WL^1;J1S<O+;Q*% #!\MK"(,) &&$Y/+#8BY<(N&C
M"G*QQ+G?"Q(HPO,&EHD0BB#.+C6J#9 @(,6+1JBF@V;I% J""#=!(A$D4$2
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ME.E*G\XE;%)D2:1;V4+;V*Y8=BV8QX1Z9WGQ6COE^OSK<?S_ %^56LK?AQ[
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M^@4749&>F29W!^@['<5!V8L)9OS':*9?\JV?:7N#NV.$?(I$_N(V:-[%,0"
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MD_9C*F-T!*@5K+5=T,S7V:K%G?*S3)Q0T,EM33=8L]1CC2(B*=$ :V? 90
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MJS2=8J242K9[!!UY.>L$+4H(TU)LXP)FTV1\G&P%=BOBUDOF$W,/U4VL;%M
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MKCZU'\37"7VJW]Q%_N1,8[7 V%K;J+> #&P40Q(3O@'IWS,:Q>E0?OW]./\
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MD>@6*IS[("Q\H9@N\CVI$==WMK#=W'FQ2S1JDO-$K$@>7SY7*AV,;E,9*R.
M?YFQS5L'3M1GTRUFMFM;>5)HV$KA%\P2.A!RS*5FC5CD(\>",[*/=$JR/AT;
M6G'4,G6,I3AC"/4>R;FMT-E,81]?,^?YDD>KGU'J 0$1$?0=9D=K;]&$K'.<
MFXGR1_\ A,'XCKCO4)<:IJ2@F-[= ,8"V-D ,=" ;<X[[]C^&!2'AQ;-TQ'S
M<*LGO'K\SNF29?JY^OS2XO.K_P W/5R///;6;'861 _@*V,8+/(=\CKE_GO\
MP>F3 7.OZVFRWK)C^B&W3MM]F(=<GIL,[>M1;<_#0V1V*OSM==;>J,U1G8F1
MB3R;9J\&8C3/VJK4DE%2#IXNJSE6!E0=QSU,?-:/$47"8@=,HZR_W5ITJ,K6
MR>\I4D%B1D$<P]XC(SD'H&'PJ(/%?$5M/',FI3'RY$DY2L05PC \C\L8)1P.
M5]\$':J!;#]H6WS(<%N(;YMVQ8?7R%CG<?)8GGBKTF)/'KR5!PKA"'GK%7FR
MA5@8UC(%K)8<EP#$I@!NPN20="9Q,0N!H.EVRVUS%=VT,L]O?3PEG0,2JI"5
MQG^4\Q9=ALWKTF>/^*M2_>.EW6CZE=VMG?Z):7:QPRE%\R26Y$F0-O,7E$;D
M$[I@$BM@K+P^-DB9TE$MKV&FRJ9B'34:4R-:*$.00$IBJM4T3E, EYY*8!$>
M.?34S)I6G#!%G I!&ZH%.WRY>X[]MCWJHP<5<2.6#:S?,.0YYY>?.<#'O*3^
M6/ATJ?,X;?*SN"H+*AS\I+0+6-EXZ:BW\0*"AVCUBBLR$56SHITG931+Z19)
MD6.!45'978E5.@0AK'P]Q'=<,:BVH6D,-PS6\EK)%-S -"Y1\*RGF4K-'%(2
M 2P0ID!B:PY+-;Z$Q3,PRXD+*1GG&?>(^(8C'3)SOC%31@K$D!A;'T!CFM.9
M![%P)7?0\E7!EWSM=\[6=KN5P 0:H&4.J(G08(M&0*=:J+1$55 &&X@UFYUW
M4KG5+I(DFN"A*0J%C01H(T1=RS 8/O2,\F"%9SRBI_3K1+>&*!,E8P0.8@G<
MD[GUW;I@9WP <"2Y@@FD" /8J39,"AQVZCG4,(]^W/< 'G^Z'Z0(;"DCU(SG
M&XVZY[;]L9(.:SKI?XRC<!8UQM_46)/S V(^_!KH)2X4FIH%=6FWU>MMA>)Q
MWQ$_/14.B:06;*/48\JD@[;D%ZJS24=)M -YZC9(ZQ4Q3(8P1US>VML"]Q<0
M0J'6/,LR1J'?'(F79<,^1R+U;*A1D[Y<$2@9)  ";L0N"[*J;D@#F9E"_P!3
M$8W(J2&J2"K=-R15$6JB)%R.04(+<Z!R H1<JP&\LR)B"!P5 PD$@@8#<#K@
MTR<O/SJ4*\_.&'(4(!#<V0O*5P02<<N^<8J8B@!7)P01D'(Y<8^T,[<N-P>G
M?I5/,-R<OES.]KS'7(P"XN2J3NAL)6=<I+3OSF-GR"NVB(8IFLM5&,Y',(.T
MN(B?:G<(H/&;WX5J_GW@-ZGIDLU]K=[J?LIB@\A+1)9IB\CHF'C*1^SH(A(K
M), ;JX5(Y&*QV\MQ/Y@6I,\CO R85%61I>8,N6.5B$*\O.O(X)GE"J3RK$TT
MIDV,U]F92 1$P?\ A+.4B\@/[H+&/ZASSP)Q+SQSS[#QVLKO[YQU(4^F^!^8
M&Q]>Y'2>M(";1,C[+.HZ;CG)/_S?'TWQFNJDVH !AX[@/?MP/IV'L/OWY[??
M\LJ)\]\YQ]^-OOZ?,8&U8%S%@DX^8]/UU'WYWK 7Z'8X<=NX@/U]^/R^_?M]
M-9L3;[]MOH?[=_\ TJOWD6Q.,]?]>F#TZ=>F]:Y]XZ?])5LV][6&B1'K?+F2
M&^1\J-P-V9X(V\OH7(5E.\*F85TV-OR<.'\7N2"3RG\7>9E 3@FBN).5T?.>
MWMA_VTHEE'_L;<AVZ'.'D$4?3H[;^G5IRBSBU+5VV-G:O;6AQGFOKU6MX\ [
M9B@-Q/GL44[[5:&0)^(P]A$>>1^O/?Z\]N_/?GGGOWU.Q'88'3!'YX^GPJB7
M"[Y/KO\ (_W.PZ=O2JI[J;/-U#"]DD*]94Z,^EY['5$<Y#61*NEC*!R9DNH8
MYM&5%$SD42Z,85JT2U]ZW*2K%$:\"\BF+!-R(=.KW,MKIEW/ #YJ1CD(WY?,
M=$,@'3W%8R ]/=R<C:LOA#3;35.)M*L;X@6TEP[2*2 )3#%),D!/7$SQK&0#
MDAB!O@UOTQ%BJBX-QA0\/XRA4J]0,<5>(J54B$E5'!FT1#M4VR"CIXN8[F1D
M7@E.]E91XHL^E9)R[D7RZ[MTLJ?4))))))).23N23U)/<FO70 4!5 "@
M  #   V  V &P%2+KY7VFE*AS<1C.-S1@+-N()=!-S&90Q-D3'[U%4@'(9"W
M5*6@3")1 WXDQ? H00*(E.0IB_B -*5'>QK*$CFO9AM0RW,G%2=R+MUPW;K"
M<3"8PV*:H$ \L &,(B83$F5'Q#=0B8!*(&'JYTI5I]*4TI32E-*4TI32E-*4
MTI32E-*55/>7@.;W!X2D(.A2S*K9LQ]8*_F#;U=WJ8G0IV;L=.S3-+?/3$$%
MOV=L7_>%#O39$>J4Q_;;5$& R<@<HJ5EFUW/T+N:PA2LNQ<0^JLI,(2,)?*#
M,&)^T6,,HU"4>57)N,+.D3_P;!0;O$3E:D1Z2I.S1Y)%F*K!ZT754JP&E*TH
M[T\8Y.PEN(O6[F/I,QE/"&2,>8VJV5GM)CG5ARC@L^)CW,6%D&FLR*S%ZPL\
M96]]*S3.D-9:ZT2S*V"Q#6+%6[%*/JE9>'=8@TV26*X3$5PR$SJ,M&RY #CJ
MT7O$^[EE)) ;)QK?Q#X1ON);>TN=.F!NM/68+92N$BN$EY&;RF/NI< Q@*7(
M1QA69.7)ZZJ6B!MD#"VFK3,98:W8HMA-P$]#/6\C$3,/)MDWD?)QK]HHHV>L
MGK19)PU<H*G2704(<AA*8!'8N4E198V61'4,K*0RLI (92-B".^3MTKSL%FM
M9I+6XCDAG@D:-XI%97C=3AHW4[J0PQC WP<],R"S=_NB ]_0?M_'T_/^/H(!
MC2*?IGZ=>AQ^NF^VTG#-T^X@[8^?W_3Y8SE3-]QTCU=_M[]_?]?7Z#Q^N*R]
ML=#C!ZCMM\O38&I2&<X SC?J>WSWZ9^&^^<=:R5M(AP &'V^O;V[ /\ D/V^
M^L9H@<XQ\=MN_4=1T^52<-T1WV^?8_'T.^QV/QKMDWX>H'_F/'/'J/'<>?H'
M;^>N@PYSL1\C^/K^6/A6>EYTR?SZXV)/^/IUK[#(=A_&'''?@1]_3@?3_'G^
M.N(A.>_U/^3C\/7XUV&]&.OKW)Z>@Q\-LY[5UCM=JJHBLLD@LLV$QVRJJ:9U
M$#&XY,B<Q1.F8>"@8R0E$>  1'C7<D; $ D<VS $^\-]B!L?\5T/?,,\K,H/
MH2H._0X.3CUZ^NU=2[D>KG\7 <#R(B//L(]ON/Y^H?<-=Z1 =MQ@8!W_  S@
M? ;_ ';QDUSS9R>_<[GUZ9]3G^P-8N[>@;D.K@ Y_7Z_;[>OUY'MK(5">@]-
M^F/3 SG/H/CG&^:C)ILGTVZ?XWZ]_0?7-5BHU/=;IKVYR#:V""^W7#&7'N/,
M18[E2"+?<QNLQ_9UZ\]LUU: FN!L$;>\@QKAO'1;@J)[;E:G3%CD&YX.DTY.
MVTO7]4:>5[&$E8(7*S'H994.ZG?/)&PQ@X+."2" IK<_ 7"\=E:PZW>*LE[>
M1"2T!]Y;:VF4,K@$;3S(<LP)Y8F"#!:3.VG]D:+BZ 5F<L7Q\YD94WQ,P\++
MRT$E-R1$"B\,G$UI9K,6A82@!SA*?.CMD"D;QK6(AT&<4SK-;*KJ5,;,LH,T
M1KE25Q75'*@'<6EZQ%CDJ>9!TG*-?8J*KJ5=H]#L,Q9/,GQ1%0J-=8&.A)"I
M4H1V"L90D86.KU?-7%"-T6Y9:%D'[.:4^&1!!!1]("X4/+]!"@!V\T618N"]
M23IHN@<Z1E*Z5CC"<KDL1[76&-5G@ ?X6W/JXK#3L8HNF=L\?/*_6TV=>LDL
MY:'.W"3:K4U1)%=PW%%9JLLBJI6FS=UB:GX8S'<E\IMI;,41E9@KD3'0W*1?
MV-25OZ0)QDSBLE854_9)M*RTR5I,8]1:0;,KN.EIF#9I SI8FUH3]H+A[]HK
MB>Y\,T\!_$+B;@_2M5UW3>!_$+3N%I8=%DT*/4KN22Q\1[G5],@M=<;1X[ 7
M=EQ$K:DT.GSZ9I<L">9K91.>@S\#:1+Q%)QSH=IK<@LKC6.&I]3:>]2ZN((E
M6?AF*SN)Y+-;E[AHKC3BMNAGBN;J-G(LLUSLIX<G,+[--M3F?1AHR-H&X]Q+
M9&KU:BF#.J-Y6U5C-U0GYX#,$W"CMQ(Y)ML-7H4S1VWA&5:4C:]$M%FJIW,E
MZCTZ>WN-9L[;VK4;NPL=.BT72[C6KZYU'5IM.TG318Z=)JE_<22W.H:I<V]L
MDVHW4\DDM]J$]S/(9)9SS=?"=C#8>1!+%:PR7'M=W=I:0I;6@O[L275RMM!"
ML:1VRSLT%I JA4MUAA"X4+6>XLSJV8Y<BV[YBVC8V2JD"XB@6D$2N&\<V^8,
MDR_ HHG:$+\8S7ZVR,@=5H5RW,HD'6H5&Q7.FW$NGGD@Y%6:5'RW\120C*6C
M"8'NE0")&]"-B!<IK.5[4<D6 LD@._OC(!&8^4A<C &'/IR^Z<;50S!61A0<
M?&H<BAS^^7TZ?7U].>?;TU23IMP)<<C8YO3J<].N<?'Z>AJM>Q2\^,'&1UV.
M,X^7U_ 5Y^O$YSC 2L(\KK!T@X>R2HH$2(8#&X.H;S#B "(\$)U&[\>GW#G<
M' VE31S1RL&"Q^^Q(Q@#&/\ S$ 8[YVR 35\T"TDB'F,.48(WSD[ =/7X^F.
MM4Q\+5C+V;Q"=N+A@FX73J37(DU-&1*)RLJ]'X.OU3%X[X'^K9%G[-7HGS!#
MI![*,$NPK .I#Q/>.#AI(B</<ZK#R*,')"W$[D[@A0JG) .&*@C#5]XL=5TQ
M4.S27484#&_*LCDG?.,#J.Y .,U[/M>>ZUM32E-*4TI32E-*4TI32E-*4TI3
M2E-*4TI6L?Q6YY%?;]C?# @917<CN6PCBYTV3-P=W4JK85\^9,8G* \BTE\8
MX7N$ \.("0J4QTFX,<FI'2(/:=3LH<9#7",P]5C/FN#\.5#GX57^*KXZ;PYK
M-XK<KQV,R1-L")IQ[/"1GN)95(V._8]*A>/3Y$O/U^X\=O?]>>>1]PUMJ5MR
M?K\B3_Z?XKR9:*"<^IWSTP!V^_\ 6*_*8BY=JJ#R("H8"@/J!"#TD* ?8H%]
M XY$>P"/.L20[ 9]!GXG<G(^_/Z.;&.>0MZG"]_=!Y1^NY%9G&))B8$^HICD
M #&(!@Y* CVY+SU !AX$.0X]..=1TK@DXV/IG<8WWZ^N^>W7J,SEO%@#[_KM
MC[AGI]1VK$\WS];KF,YIE8BG<*W@O]'U:BV\(RLKV7MEK;.&$(S9U^1.FQF5
M$'',DI'NC@FY08JHID7<&0;+5GB&[CM]+N^=+F8W$36L4-I$LUR\UTK1)Y:R
M/%$"K'G+RRQQJ%W=25J>@A*H7"2N0O+RQ)SR#GPF<<R# YL^\Z(=\L"5!RO:
M?!3E9PWB]"?K!J=*-(]9=W6CG<>;'-9*7D7J2*[9T8Z\4LYCWB;D\&JH<]?.
MX"''RS,/*2Q-&#1:/:1-!+;GRG813B-9U$DLDBF5(F=(W/,&$2.RQ@B,-@5.
MZ= (3;R(LB*I#%9!&KA'8\ZL(F>)25<CE1G53@*S8R+OR<("93<%X$.?;_/U
M'V[>O/U'URHYL@;XZ';OMCM\ 1ZCU/0VRYLBH(Y=\=@-MS@9[_GWS48R[$"@
M;@O EY ?;W]>WL ?Q]NX]Y*)\@#N,X/Q&QQ]Q]-\]:K5W!RYV^!_61OC;[CM
M48RS<.!$?;D!Y_/@?0>/<.?R[>HZDX&SCXCN._W''O8/2JG?1 $XZ'(STS_?
MTR?AUJ,91'CK]N.>>WO_ # .P#P/Y]N^I.%NV_IO\L^G;T/3/6JM=IL?7^_0
M?<<]\5JSR?DEIM8WJT;YY'F:XDWRGB*2ZL#</^5JFY^C1Z,)474T')2I,\OX
M]-7J.DX3*LJE.X[KYEBHL'$F];XTDXL=0AYQBWU/EB+#&$O8@$0MTVGBY$)W
M(:)>V2)&+3VU[ARZ$+!M1X7,EPD6Q:XT:Z;S9E3 R397'F3 ="DSJ"6* ['V
M??G]!_@)A#_#Z>^I:0Y^N3]0/]?]1UJJ6P&3\P/O(_ C([_#&]9K'!P(?3G@
M/T_V&L";[7W_ )#]"IZWW ^6?P _O4@Q90X > ]^?T ./</\!X]_76!)T^07
M\L_F<[]ZL%J-QTZ;?09S\]S^>_2OQ:D7;5BK*,&9I%RW9.2H,"J%1%X[0167
M9-?./_5HB\5 6_FJ?@3$2F-V]<!W=8YA&H=T61HT9BJLP3*JS!68!FP"55B,
MD@'H<^[A.8IE .PC.<A0WVE+$!MFRP)Y3C V)(%:_P#:IA;#N2::I<+ $K=+
M9%3]SKT[\[?62,?P[^66+*+QUF:$=LVTU<6L?+Q,B]L*@R"L;8DVKF&>L9."
M9JLJ+H6E:=?6\MW<(DMX6EMKN.-FC\B5S!/)%-'#=7,:77F"*[D6.ZGBM;UF
MDMY%G,DTO9:HDCN75%<H898X'PJ<_)(RND<TBQ3%PLTB)(PBF9WA?WV>2;6^
MR6KI/X!A WVWQ..6UHAKC;Z&\>24R%[FH)^[69)R\NM--$4(XT6X:Q#HB<,M
M*.@A825=2R\PQ*]-]?AF*-H(8;N:/38HH(6L 9%1_9B!"R202P")D1$"2+&9
M00[EW>0-',Q67,T2B9A;QQPP>1[X+"')1A*DB,D@(C/F*O.2C,S,S!DN75*#
M4L>5MG6*;#M8."9'=+(,&QUU?^8?.5GKYTX=.UG+QZ[=NUUEW#MZX7<K',/F
M*F I0"7L;6"QA6VM(5@AC)Y408!+$LS-W=V)RS$DDD;U*I;0P1!(46.,$X1>
MA).68]RQ)YF9B6).223FIRCXWX""8-U"]"ID#.%2B'!B&<G.OTG ?0Q"*%3'
MW 2<#Z:[0_/*Q'3FP-OZ1CK],_<=]L320""TB0C#%69LX!!<\P!^*AL$? C:
ML)DREY5#@/01]/U_W^>I")M_N/?;H?S)Z5"7:C<?#.?3(/X_$Y_M56]QV8ZU
MMWPIEG.MP:OWU8Q)0;3?YJ.BOAAE9-C68MU)*1<65ZLV:&DY(6Y6,>1TY00.
M\<(E6723,8Y<MY5@CDE?)6-&<@=3R[X&2!D]!D]_2H5;5[ZZ@LXRJO<2K$K,
M-E+X',V-\*"2<;X%:[=C66:+O(L>9=\U2FF$Q 7)\QP3AZ)^,:GL5&P_B]PX
MD7H7&$;O'2U4N63,D3UENDC#/R-Y ]$;8J.Z3,+=(YNS394NWFO000Q$,2Y!
M,<49YB'4'*O([%\$@E G3%87$UO+I4%EHS(RF,->W4G*1'/=3^X#&Q $D<$*
M+$K#(\QI>_6Y=X<2:+1BUB5Q:OI20.R2>>6BK\,=.+DY)$1(X(J@)7+B/0CS
M^8F;^K=FZ!*J"9BS;M(%5(SR,[E ^ <<J2NN>8$>\R",DC^; WP:IUO%;M+-
M)=)YL-O")&CYF7G#7$$#$E&1@8TE:488#,8YLKD5&MW6@+'3/@IN,93M8N3%
MQ$SM=DV!G[:<KLM"OS6*)=M!*8@@$(616=M7)!*[(T7B^GXAVD&N^25&MXV8
M!XYU"O&4+<\;1,\JX[,D2NY!W;RS&!S.*C+6SG34[J-':&YL6:2"Y25$%O=)
M<PQVDG,=GCEN)(H 4/N+.)R?*B>K>>&1DZVO*3DW;5>YI];I?:S8:M5Z3?)-
M\I*S5RP9=ZT2PXC<6V46.99]=ZFT9V#'-@D' ?%V)M2XBZO#JN[6L;6KM7L1
MI]_-;HP:+W9(CD,?*D',H)'==USW ##8UZ@X2UM^(-"L]1FC,5R>>WNTY2JB
MYMV\N5D!W".0' _EYBO\M;.M1E62FE*_@\<#SQQP///IQ[\\]N/KI2M>OA/=
MO#AV?=/_ (/]#<$+/^[\O%T_&-Z/_3^ %MY0!V!/I .W&E*V%Z4II2FE*:4I
MI2FE*:4J+<U9MQ1MSQ?;\T9OO4#C;%U#C?FUKN-D<'0C(MH=PBS;$ B"3AZ_
M?R#YRUCHJ)C6KR4EI)TUCHQF[?.4&ZBE:5\+_P#$O^%)FO+[/#[#*=]Q^YF9
M=*#K%_RGCM]4,9V22=.0;,$TK&$A)/JRV?J&**,A?H6H1R '(5^Z9JF*F*E;
M^2F*8H&*(&*8 ,4Q1 2F*(<@("'80$.X"'80[AI2O[I2J:TC UXQ%NZR5DC'
M*L$7;_N/JY;AF2F.7J[&1JFY:GDK]8B<G4J.19+LWZ&8<<)M8#)[-9Q& UFL
M6U&S-#/)*QV/XE2KE:4II2O/@[I8[7=S.5MM;Q 8ZA7Z5M&X_;(N#<C6'6HU
MXG_F>8L6Q!R=*(R>'LN3LG+IP[<B2,5C+*&-&L<BHWBY/X+8/"FH"6W?3Y&'
MFP%GA!ZO QRRCU\IR21V5QC(4X\_>*^@/:W\/$%O&?9[T)!>%02(KN-2(Y'P
M,*L\*JN>GF1-S8+C,V-W7'3P/?V]/?CL _7_ !]AY[ZM3)U[_#'3]??6K(9R
M#@G#>N?M =CVR,?KI7?-GWIR/ _3D/OW]/;Z?8.![!SCO&#N/N[_ .OUWZXW
M-2<5QV)/Q^_K\>_P^(KO$7X@'8W/MQS_ "]?IP(\#[\\^NL<Q'_!W!^.W7.=
MMMML=ZS8Y^F_R_ ]/[CZ5V!)'[^GN \<#]..?]?7OKK*;;XSC^89.-_3!'S)
M'PWS60+G'7!^GTWV)S]:^HR7;CK$0X].H?\ ,=?.49SM]Q_SC\*Y&Y..V!_Q
M9_"N,K(^O \?F/H'UYY]/KWX#O\ 3G7()GITQ]"=MC@#?MOM]#D];7!P=^WZ
MS_Z=,^N_4+R & W!P-TCP/2;GI$/4![]A]!X]>_</77<L>?D-ML==]B>VVV!
MWQOT-8LDV,9)W&1G.X/3KVP>V=\_3%9JPQL0S6?RTDQBF#<ACN'LB[08M$4R
ME$QCJN7)TTDRE* F,8YPX .H> #G7:3'$I>1T103NS!%&?BQ &W7)^_&:Q5$
M]T_E6T,L\AZ)#&TCGKG"(&8_0'.VYZ5@GAWVF0EL>2Q*^9K*LF.Z;<7,XG=N
MD'ZU<>5C+FYO-EE>V=X]8(J$"O.;.XBI.NJG7:A:&3:'=0+I5E*M9(-4ZDT;
MZA>M$ZR1M<S,KH04<,[-E2-B"2<$;$;@D5ZIX>2XCT+2([J)X;B/3K2.6*0%
M9(VCA1 LBM[RN%4<ZM[RMD$ @BMJ-,J$*^D'^4[0_-+M(PSXT+.SRK<XOVL.
MJY!U='8E*1@PB?-3>*TR&CBI0L/""6PD34FYUVZ;X53-<5/)5SR"!EJ-"6)O
M5U5%D4Y:$C8,; LFFH9,CD)*]2$-5(GS3%'S6+!C>99B00;2S6!FDW<>P4J/
M,SY-I>WVE'OF7FEU8Q2CUG$QS=/,MID;7:[%)K$;Q==K=0A)EJ2<GY5T<B36
M&K[94@=1U1209(JJI<D1I&5$5G=R%55!9F8G "@9)).P &2:ZY98X(Y)II$B
MBB1I)99&"1QH@+,[NQ"JJJ"68D  $DUK-L&Y+=8^L3&YXYP%4Z56#*+*JUJR
M9XL57O*S,JZ@L_GQZ!CO)17#A5H<%'GGV2XJK+"F*=8B''Q#=.PIPMJC1B1U
MBC)&?++EY%^+K&'Z#<B,R..@0[XU]+XH<+K=-;0S7%P%;E]H6'R;:4^D,MPT
M0SGHUP+>''O&8+O7/<;R*%-*1C[<+M:SY$.(RT0$G(9EB7L%NCC* G4W#J9C
M'='A\;."Y?K\LPDUE$F$F\PA&3<>C*OGRY9!1(6FN"6.N:6+F:T:1$FMI[&Z
MDLYE/F6UPO)<6TT8*RA)%P'CDC7?EV# 8E$XGX6U>2UMKJ54N%GAO+2WU"WD
MB/GP-SPW%O,RM;2E&SR203R*1S$,4.3;=MEO9KOZK%WV\5C.5#1AF$$ZI\!B
MR,L[2J9=A)V/2!*!R&ZQK8%(JX1@4U^R925"BYRN_"C)1QYB<8KJ$CFL?#Q2
M7%C<Q3H'AN+>5)HRZE2KQL'4LK8)&0.93LPR#L35PM;I"T5S:3QR<C))'+"Z
MR)S*>92&0LK#([$@CX&O/WFU3+6 +B;">=4G=-R715',A2+Y$H.%JS<*\LN#
M0EEKRBQS*2M,LOPK95PV,K\WKDFB2+EP:3<:_C5?07#MU8:];F[L_*D>1%74
M]+9PLUM*,X>/."R LWL\X!1T9D<+(&6/:NEW=MJ4/G0E!(5 NK4G='&W,O1N
M4G)C<#E(8@D,"JX$[WHYN8QQHGYS%.B 7RB2#-Z99-8H!T^85(RB:Y -QR!%
MTD% _M$*'X=3B<+Z6\@EY)DSN4= "/AS8(^XL#V)K._=UIGF\K?.1WP?3;M]
M?K53;;<K!<I-69LLFO(O5E"D(*AC& #KJ@1)NV1+U")UEE")(I)@=5=4Z:9
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MGTLF9!HD(*)M52\+.CAP) 42'ND@40Y.!P ZH ! 3%,XG#!E8+E4R6)P6 R
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MI=EBZ!)V$K<! D(E-NY"-(N\_P"2)89:OHC_ ,^XC]*5XKMQ.:J/DW8)X?\
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M0%P)55"K!"<$J>8G*]0#G.,'UKLU#PXT=K*X%@;J.]$3&V>2XYT:502JR+R
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MUSMZ_#O\]^O^*JEV^Q]?D=CO_?/]]NL#6^SK0$T91TFN>'3KZ[CEN45E#O\
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MDQY<<;/$[H2LK%.;..85L:VGX_-M\PW:TI.?@;=G_,=OMEWEEH%H9.0GK*\
MT%68UE$/EU92/I5/81+6/BB31FZ4#7VRKFPJI3*LVX<4NYN)+JXFN92#)-(S
MMC(49.RJ"20J+A5!)PH%;DTVPM]+L+33K52(+2!((^;!=@@P9'( !DD;,DA
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M^TV:37.K37TB!&NKV73[A9;A2MQ8W-L%5)&X-E>02Q7K+/!,G*T3.Q1LG)&
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M@'KZ=_N/Z?;4C))U'3U)&_4[=3N<?>,G;8URW@SC QZGO\!V^OW#M6<LHL.
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M$$"F(@BDB0ZBBQRI)D3*=58XJ+*F*0"@9150QCJ'$!,<YA,81,(CI2NM+7H
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M8L69Y)&)DE=F9F9Y&9V9B2Q)-<G*WAGL7\=9LVP,A.XJR"[<FO\ >$:$[J#
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M;L99!E)E:*(G>,6:YCM4^BPO[;4;9+RSD\ZVD:18I@00_ER-$S#!)Y2ZL%)
M;;)4 @UQ2>.X '-$Q9>9'AD62&5<;M&ZD[@@@C)!Y25)&*[F4: ('X .0_+V
MY]/S^P?KR&I>%\['X@_=O]_7YU$WL&"2!C.?Q[?B-^GQ-1I*M^.KMV[B';ZA
MZ^O_ ,"'KR'.I*)L=]\[C/IUP,=_GGH:JUU']H8]1WQ\-^O_ *5Q_#_B#/MV
MV]ZZ&_&E&4+:9B5N;D!!)S76V<LFR28#W'E1OEZ#4, B'8I#<?BYU1N*'Y]3
M"_\ =6T2?'<O)^3CX8 K>GAC!Y/#(8C!N-0NY=^X410_G">N^<[D8K;OJN5L
M.FE*:4II2FE*:4II2FE*:4II2FE*:4II2O+SD?",%:6K@BS%$%#E-R84PZ3#
MQS]/PB(CQZ\!]M>.[[1XY@1R?'![==U.Y4[D]OF0!7ZO:'Q=<6;1YE)4$;YW
M'IW_ "'Q(Q77X1W0[E]E;MK!QRR^5L+-52D5QI:GSD58-B!P,J-!LABNGE:4
M*4!%*,61DJV8RBQ@ADG2PODY7ASCGB+A!DMI6?5]&4A397+GVBVC!W-G.06C
MP-Q&W/"1DB-20PA^/?!_P^\78IM0Y(^&.+Y5++K^FP1^5>S8P/WUIZ&**_!.
MS7*-!J&%4>U-&GE/O[VU[N<*[IZ^I*8TL!TK!&H)*6C'UA32BKS5%5.DO3*0
M_GKINF(J&!-"<AG4G!N5!%%&1%TFNW1]%\.<6:)Q3:^T:5=!Y$53<6<H$=Y:
MD_RS0DG;.PEC:2%CLLA(('@#Q$\*N,O#'4!:<2Z=_L<[LNG:Y8LUSHVJ*N3F
MUNPB&.; )>SNX[:]C YWMQ&4D>QLG&1LU&R$-,Q[&6B)9DZC92*DVB#^.DHY
M\@=L]8/V+I-5L\9/&RJC=TU<)*(.$%#I*IG3.8HV2M<5HZS)MFO6Q91[<\*P
MEER;LP2,J\L>)H9"0M&3]JS,W4J[F\5QJ!',WD7;Y%))F6D,8,B2V0L7M3*+
MX\0LU):H4NJV?1M?>T*6MX2]K]E)#EG@S]Y:(=U&2HW7(]VM9\9<!Q:L)-2T
MA4M]4 YY81RQPWV 22=@L=R=@LA(1R,2%3_$&15&]UR[5R$MU.GXBTU:R1K6
M8@+# R#:4AYB+>IE6:OX^09J*M7;99,P&(HB<Q?4HB!@,4+ZHCF5)8V#HZAD
M=-U96&05..^=\8WSG?-:'D>>TGDMKA'@N(7:.6&12DL;J<,I5NA!SODYZC(-
M9$[L+:/;*O'KA-LV1* J+*CP4HF,4A"DX'J.JHH8J:*1 .JJJ<B:9#',4H\&
M18U+,P51N2<@;X '4YST WR<  DUWP2S7,B0PH\DKG"HF6)P"2<YP%4#F9B0
MJJ"S$ $U6M]NZILA-6FH8PJ60<Z7NHI(J35.P]&0-E<PIEW;=F1.[6=_98>@
M8J42.Z;N'*66[=17#=B8[LR!BI*$"'N=:T^U+B4R,XW5$5&=OFHD)B./Y9Q$
MW3;.15PT_@O7]46-[=8%A<^_-.T\4<>V>96>#EN5[![,W"$[A^4\U6"I^TC=
MMG"/3L&8\O4S:MC%^S2D4ZE@!]$92S,ZBS$*NH%@SE=X!3%E-!1N"A))E0L:
M71=F!S*P.50,DF]-6[OB:[FYDM46U0Y'/GS)B/\ F(Y5)[\JY!QAMLUL72?#
M72;7DEU.634YAN8CF"T!SG'EH?,D _XY.4[YC .!9? VVO"&,C3,OM/QS!1=
MFFRA%6[=3DPT[DO)5P30$R3M-C?+Q)2V0L@%;."F.B60L,9CN/7,)8-"1226
MC4*]+)+,YDF=Y';<O(Q9C]6)./3L.U;!M[:WM(E@M88K>%-EBA18T7U 50 #
MZ[9SUJ=@CL786*\L=LL\C<[J0',PH[F7#:9M3EW\$5NY>14"Q3;MXXQFJ(,1
MF%VZ/R^,\J,>3C>%;((H===]=GC[%!%)5ADVYH&/<7S^=LB$.Y1:G)536%9R
MM$Q7Q!2&56DJQ%2DK%KNBK"BY=RCXP =NPA"L%*FZ:C2S,-+1!U!2)*QC^-.
MJ <BF5\U5:F4 .W(D!43 '(<B&E*T\)5&YX@EANE> 6_R!Y'X_L<4DT2L16D
M 8BR(-YVMO2C\\KC%. L<$\<QDK&/+([@&]E(Q&5=1[Z:4KAR6SN$L<\XO>T
M&[4K;!E.VI/9^X8:D*N[N.U7,3\')4Y:_5^EPDQ19^B7=9R06EBL%(DJ]+H.
M^H<K8TLTJG%R8R>GZO>:<2(6#Q-GFADRT>3_ #+@@HWQ4X/\P:JQQ!PEI'$2
MJU[$T5R@ CO+<JEP%&2(W+*RRQY)/*ZDC?D9,FH=MF2\L[> ?([N<'VO%<+#
MD3,[SGCM.7S1MI?M!,1(\R[OU7@F]QQ7&)'$QY-SG+'F-X.( Q2I6:8; $BI
M<+/B6QN0$N0UI)L,MEXB3Z2*I*]-^=5 '\QWK4NK>&^N:>7DTYX]5M0"W*A6
M&[4>C0NP60X_[J1F;?W!TJ?8V<9R+-G(1[QJ_8/VS=XQ?,G"3IF]:.DDUVKM
MHZ;G.W<M7""A%FZZ*ATEDE"*IG,0P&&>\L, RL"#N"#LP/?(R-_4=1WJA><T
M;F.12CHS*Z."KJRG#*RG!# C!!4';%=R20'@/QB >G(#Z_7\O\.>VNLQXS\>
MF1@[?+(SZY'QSZ]RW'7??X=?P./IM\Z^OS#MV./V'D?M[=OS[\?X!KYY>#G"
M[]<9'7?TS\>_UKE[0?4_C_GZ_+XUQE'_ !W$WL/KQP(=_P _7GT_3WYUR$1/
M8XZ[=?D">HW]-_I76UP-QGOVV_N2!\Q74.Y1-%,ZBBI$DB!R=14Q4R$#G]XY
MSB4H!WX$3" #V^H:[0BJ.9B !U).P'Q).V#\<??6.97D8+&K.S;*%!8DX.VV
M2=AT_P#AJN$WFA]=+58<18#QG8MQ&38HR45:(R#5C:UBF@KR;(CI,F6<RVQ:
M/HU=23CW!'TG5JXXNV3PC%D7+#'<F1VU\Z)U#7;"Q#PDFXF QY,0RHYAL)9,
M\JC?+ <SX.X&0:MG#_ ^NZVT-WR#3[$NKK=W.5=@C EK>W'\20[$([B.(D;/
MU%78PF@?!^W7 6VR9LL1D>H[7,!T>.SSDB*EHJ(QVY/CJL)0[2(>V.TR3)%A
M1(MQ7WDK-KJ#(RBL# LXI['+_$3S1+6+LJAG8JB@%B2<*JC))))V51U).P&2
M:]+Q1R.8X45YI7*1(J*7DED8A%544%F>1B JJ"S,0 "2!4+V')&R_P 4BQPV
M'D,BPUHR54'<M:J')U&$R-BFXX<6C$D&DI?\6Y/N-7HUTMUS:-71F[%M11:T
MYPS67<WZM3E;:>1(Q&G:_HNKRS0:;J5I>S6XYI(X) S! 0ID4''F1<Q"^;'S
MQY91S>\N;KQ1X;\=\%6=CJ'%?"NLZ%9:DWEV=SJ%HT4,DQ1I1;2."PMKLQI)
M(+.Y\FZ*1R.(N6-R)II&=<F[))6O87WJR3*PX>F)5O7L/;YHV+0A*Q,2TS(>
M5%4;=A#,>(W%&6IR1=&^!RHS08X8R=*NR(BO0+I(,ZA)S%4FM@>,<JXXS14&
M]_Q/=*_D&DO)BTP#.TU>02E81[+4JT3%,M#5G(-Q,W=A$V> EXE5PW.JU759
M'6:+N&JB*ZJE2!I2FE*K1;MWNW^B[G\4[.K1?H^+S]FF@W3)&/J8L404EJ]1
MW+5!^11UR";:4ET0L4A7&)RB:784:Z+)J)J0R:+Q2K+Z4II2FE*:4II2FE*:
M4II2OFL<Y$53IIF54(DH=-(@$$ZARE$2ID!15!,3', %*"BZ)!$0ZU4R\G#Z
MH!902 "0"3G !.Y.%8X WV5CZ*3M7QB0"0"2 2 ,9) V R5&3T&6 ]2.M:J-
M@&X7>EF++6>Z[N6QJ:H5.HN!4KKH*L:KLHF<-89.ON*K"O%Y"7+<HIL-;ESC
M)Q4U/)1+YNZ3D)R01EX,&^W?$7AO@;1-&X>N>%M5%[>7B@72>UB[>: 6T=RM
MW.BQP^Q2M[3"/*E@MS-&R&*"-H;@MK;@G7>+=5U/6[?B#3Q:VMJY]F<6YMU2
M3SY(3!&6DD-Q&/(D(=9)?+8,'E8/%C33XD&]^YP.[JY#@2PY_P &W2CSTI0\
MNQDE/0AL<7%[CIV#7'EW85P\_)D>1T[6WB\D6MVVI/*RZA7L#86K%I(SEG7F
M_'_'G&]WI6H06>C7=]8ZCI]PHN[6>RMGLK^WGBCFBEBF8RRL!M$0ODEEEDY2
MDL*EOTM_9T\ ='XOX<OM<XYT;0-=X7XETV5M&UC3M?U2WU_AO4M.N[BSN[6Z
MM(_9+*%I/>N>:7VX1/:6QDCFM+QPNQ^'\4S*]GN6"=MT)@Z,@LTY?Q%A5W.S
M]DD)..K]!R!E#';2Z3TBUHU61L5GDZS6HR:C)-K RTG2)]%=A+1<V]A8WR+4
MAZNTCPXN=2\-VX^GU*WM)U@DNSI4B2!0D4T%O+#-=3"$)=).+Q$2)+F&X(MH
MTG21Y%3\[=;XUL-#\3)N";*U;6+"UU.2U@U9>417T,<L[VUREK&79K2\MEM9
M)&=K>2!))V:)E5"?+UX@F*K;5(!*!LL$\+=L*94OD#D-\)%G*Z,?;T*JSAWK
MIP/F+*P 3]5D%F4J<I(_XRY1YRN%'-E9@M(^'UY$LU[9M(%]IB@FMXB<!FA\
MU9@G8L$:+*C)Y4+ 85C7K?\ ;XT>WXDT_P */%OAJS]HX>U;0)='GU2UC CM
M%61-2T>SNU1<6\F+S4H8T)#1RV=S;NJM"JUMI\"'Q5+O,VZ)V0;B;6_MC.>C
MG:&WV\S[E9]/1,I$1JKM3%DW+N53KR,,^BF3A:C.'QE'T7(M351-R\82E=8P
MG5QUPM#'"^M:=$L7(0;^WC 5"K-@7,:C 5@[ 3*H"L"),*5<OXKX+XFFGD72
M-0D:5R#['.YRY"J28)&.[$*,QL26V*'/NUO0W1W)WMF\/_+V8R%?KW&M8OI=
MEB8Y=L"3\+=!1E-B*53V[98"J)%4L3)BS!JMTF"3E9%<Z9%7*I=:H52S*HW+
M$*!ZDG _&MDNZQH\CG"1JSL?15!8GZ 50/;+C)CB7"V.<=1ZXO4*C5X6MEDC
M&$YY@E<C6E<:32ZH@ JN)=A$M9!PN;DZZ[DZQQ$YQ'6WK"%;>RBB7T(YNS*F
M(XV&.S1)&<]QOWKR3Q#=R:CKEU/("".7W"-XI)3[3<1D=C'<W$X([8P-A5@'
M:YNHK)(>  I1<" B F$P=0)#W#@H (&/_>$P%$.Q@'FYZL?IWP!G?;U]>G7M
MBL/)!$2[;9<_$C89[C&_J>AZ8/;1S0! !$.?X#S^7Z^_;D._/MK#E<@X W/W
M@?K;KM\.TA;0]#C/0 '\_P"Y^/4=Q][E$S3RBW)I69-*#L3JJS[>$FUU%44X
MB66BG:<?)G6;L9)= L>Z,DZ\Y&-D54?)!0C!X8I6RT/J,DQM+I;:9;>8V\HB
MG9"XBD*'EE* $OR'#! &YB "K?9,W;PY((P#UYF0R ?$H""X'7D!&0,9WK];
M2K=/67$M'>65-<7)FBD$O)+O'DHC/?)G:T2PMK*3DG3V1D&]@;-6[]R]D%OB
M7+M=VLH!BD255A='OGO]*M[AO,>0(8S-,8B]QY1*"<M SPLTH7F<PL85EYUB
M)0*38=+8&3HWD32.%Y@@ 8L0LBB,^6%8D<PB+0@'W&(4$VZ>0HD*(&3]N>0#
MV#_'Z^PA]=9Z3G;<8^>PW^._UP/3.:GYK' Z8.V^/S'4X^/?K6$24;T=0]/;
MV$ Y[?0?L'W[_KW'-C?N/AG^Q']OT:A+FV&X('0X_6.@[]B-QBH\EF0%Y'@
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MQZC[<_QX[=OOZ^_=*<?$COGMD]"?B2?C6#:@#E^_Z'.!Z;;YS@?&I3BDPY(
M![!P/\O?T[ZBICOC]; ?Y-6ZP7&-AGU^ ^\]NY^=<V:7%5ZBT*8 2:HIB).0
MX%=8 .)QX]_*%(I?<H]7''4/.(3L3@98GYX!SCX[G.>GY5GSGFF2+<K&JD@=
MW89)QW]T*!GID^N:[6-9E4*7L'(_XCV_@ CZCZ_GSK#E?!/KOWSL._\ ?'KD
MU)6T2N!D].GW=3Z[;=O0XKB6AY$UB&E)Z;>H1L1"1[J4DY!P)@19,6*!W3ER
MH)"&.)4D4SGZ"$,H80Z4R&.)2FZ3<1Q1R32NJ10HTDDC;*B(.9RQ] -_7&:[
M+F-(E9RRJB@LS,0JJHR2S,2 H4#/,3L-R?2A6TM.-;I9F4J\*O%5,<K2+FK2
M3-5RA6Y2-%LF6*) 0\@U;R,*O#5]&NL99J'Q$210&32-7!RPE&S:)X3ECGCU
M*:"5I[>6]D,$H\P0&,%UCBA$A93Y5N(58VQ]E$301KS3I<N]8E()DFCN#,3+
MS*X+\L94D*B,X*,44("8?X('*,&X%Q(]X72@.FR+C@ ^(0*J8/8IC$ QB@/K
MP4PB >_;G5QC.'QZ8)^AQ\O6NVY;S(4? R\8;;ME<D9ZG!V'RJ-9<@ )N [\
MF /3TY$ ]1#V'M[\ZE(CN/D.Q],?GGX8&?0U5+M=S\=AU[9&?QQOCIZFN=X8
MR1G\IOQM*@%'YIO))7FB@=Q-'T;:[MIKYB ;C]Q*:).$ H#P53S1X QC<Z_U
MYR^JW77"F-!G<X6)/PSG'P].@] <#0B'A;2P  9$GE.-AF2YF(_^'ES\:VFZ
MAZMM-*4TI32E-*4TI32E-*4TI32E-*4TI32E:&%4$U2B E 0$/\ '^.O,K*K
M###(K]$UD9""IP1^OUZ]ZPJ>J3*31427;IJD,40Z3E >.0X_"/'8>._ <^_;
MOJ.N;)9%.0&'8@88>F/3\O@*G-/U>:V=2'*D$=_EN=_7O\>_2JA6[$5BIED8
M9'Q9.R]*NM><"]AK'77:D=*L5NDQ3D\U$ *NU<)F.@\9N"JLWK515J\06;JJ
MI&K3VE]I5VFHZ5<S65Y W-'<0,R,,;E95&0ZM]EE8,KKD,&#$'9=KK>E<0Z9
M<:!Q+8VFKZ3?Q^3=6%_$)X)5."& 8Y26,@/%-&4FAD59(W215(VU;+O$JC<F
M/XO#.X\(VB9E,9..@+4!"1E)R:L E1;I(&44\BM7%T8.%(18R<5+N1 :^LBX
M<HP#;>O _B;;:VT>D:]Y6GZV,)')]BSU$X&#$2<0W#;YA8\CD$Q,"PA7QCXS
M?LX7O"<=UQ9P$+G7.#QS3WMADW.K\.H<LS2A5Y]0TJ,?9O4#7%LFU\C)&][)
MMOUMNO*=:O<M>'/5VUUMF5<"YNE]JL?<%).RY8I\54:E<<2SMI<+_'R.2XRI
MV@[)KCZZ2G]?^V4G67[.!N!S$F+!7G5F*M/N)2PUB^TY62WD'EL<^7(O.BMW
M9 2.4GO@X/<$@&JQKO!^A<1213:C:L;B(<HN+=S!,Z=HY74'S$4[J'!*[\I
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M?E>(R!8TJW18O]F*P[J=>D)Z-N\FQH=O&4AW;P#C$V9V?X2Q-##Y_P#&R_\
MVC;KQ;\(>'O"?B+2^#_#'Q)NX=$UO5=(X-X7N]7X+U/AVQFU;C::\U_6=)U?
M5UB?A33[WBW0Y8KNT%R$U#2(Q)-I+32\M!M^#[70.+IN*HM3UOB+1(VO=)LK
MK6]3@LM<M=3N$L]%BCT^PN;.T:2+5KF'2K]&BDY%]GO.18[KD&V#"NV-7$F(
MJ%BQO1,6NUJK7F4;*V>4L%BL 3<XH!W=@L#JMA4:^V6-,33E_)!'A,MTFI'!
M6:2_E(D-KTIK>IR:QJEYJ+AP+B0"%)9&EDCMH46"UADE;+2O%;111O*Q+2NK
M2-[S$F+T?3DTG3;/3T(;V>+$C@<HDGD9I;B0+D\JR3R2.J9(0,%&P%6 K.(J
M["*(.WY&LBZ;NT9!K'Q\6SKE1BWS?@R#B+J42!&!W#58!<,Y*?6L$XT<&%1"
M7)TIE3BZDJE?2E-*54'/5&D&K^8LD(U:+-+FPCXZ6:N>E)B_L<:NR/"M95RH
MJ@V:!,'C(1I#2#Y9O'$D(]U6'CID6^?,V"E1D]K8Y?J<78*6_=,\G5PS:5E8
M=P)8B1N9(4YHIO:6Y!<1QX/)$0JW&OV.0;KQZ[.?83%0G?,C"0RY5*R^M9PM
ML)!BCD48]9HBJM"OGUFAIQ2$?N@+Y;EHYMU3@)92O."E.""E5R3CJK6,1/T
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MR3B30>,D-?$EB68DLQ)))R22<DD]R3N36_D18U5$4(B*J(J@!550 JJ!L H
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MNXBL>VKXH2F((1U7OG]%639-4PF(WC,?O51(/'(<;W^'[->#_P"SS>7+C/\
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M057F!  RRJIYW',0#RJQ3[3A59"T-+8O/ UQ'-;CWN4HTGELKY?W7=U6&)B
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M!_WS_/\ +V'W#656#N#\1^NWZ[UU$A%I.B&*8A>1 0].P\_[Y$/M]-8\L"R
MX !/PV/^/UT))K+MKMX67WC@';X?']?YS5[*F"XBWMEP,T3*N<!$! H%Y,(C
MP8I@X$H\CU=QY 0#I'MWJ^HZ.LH)488$E<95D;L4;&1Z@?/X5LOA[B^:S90S
MDKTWW&.AY@<[=L8 /?<XKO<7;P=ZVVINWKZ,W'YEHL<1-NRKN44G\E+1K%$
M(1M#W-BZ:6%(I$2D1;)32\^Q9I$(FU8I)ATC/Z+XA<8\/*MM-)%K=E'A$BU
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MF*2<-6#8H>4J8[IVQ:$7>H8]W=6]C;37=W*(;:WC,LTK!BL<:_:=@@9L#J<
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M(*_U&WLX"EMRM-( V00>4E6 9VY=V SRIV."<+@5:Z26  $I0*!0_"4I0
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M<:2HY6L]>;().',A'9.SK=8%TT2\I]$JMP.B?XS*BL[L%5069F(5551DLQ.
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M/SS4VQNWL[R"Z&28Y S#NZ-E9%.>I9&8;]SFMS:UI<6KZ1?:6P"+<VS11$
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MK%<I)C) ST((QZ^I_,_$"JU<V$L!.0=AN"#MT]?T>W2NY I#E'@ $!Y]>_\
MOCZ:R:P=P?0BL0L%;;2R"J*R15$U"B!B& !YY]!+SZ#SVY_00]M8%U:+*I'+
MD'L!N.N_TV^8R#4SIVJ26CJRL58=#\ON^[UWSG.:GWC;+6Y]4RQ&B2:I3>80
MW0!#D.!N0,10H=A*/<H\E$!X$.! !U5KG0D9N=,JX.SJ3'(".GO@[GIN2?3;
M&:V9I7'<\$81WYE8$%3[RLN#D$'.1OW!&-MQ7QKI=U>($TD\69^RI7X]D'+2
M%/:7U@K:!2CR!$JW8S3$"1,. #H".Z.GJ 2CU#SFVFK<8:. +#7]3CC7[,,T
MQNK< =/X4_F1_,!.IZU@ZIHOA7Q8SOQ%P/PU>SS'^)>1Z=!8:@Y.=VU#3Q:7
MA/Q,W78; 8LI1_$ZWB8Q5:MLKTFCYH@D#%(\?-6:N/[HX(' &5+(PR;NJ=92
M\G\DM.0\T_X?.1+W"WZ;XN<46!1-8TVSU: 8#RVP-G=D#&6PH: DC^46Z@G;
MF'2M5Z_^RUX6Z^DLO"NM:QPE>."8;>:9==TA#V4PW9AU/&=N<ZI)RC)*L:V<
M8!\2C:]G>0A*F>V_T4Y-GGY(>)QOE15A69F?F3MUG)(VGRIGBU>MSQPBT>KL
MXJ'DU+$LT9N':\$U23/T[AX6XZT+BPM!I\D\-_%$TT^GW412XCB5E1Y0R<\,
MD0=U7F63F!9>9%YA7DWQ-\#^-?"V.*_UA+#4= N;E;2TU[2KI9;26YDCEFCM
MIK:<07]M<M##)(5DMC 0CB*XE*,1?W5SK3M-*5HYSYXO,9_VZ[+X5&!(^N57
M=L^D*-$U[,67Y*-/@^LQUMQRADB?E/D326B[7><EP$0]C8FEXGC?@VETLDRP
M4D;="1,9-H$4JZ6._#BVRUY\%VS!46V['.+] Q;)GG=#&P66KY)+KB)W+>L1
M\]%JTO%57*8PI1U(Q36*;58]H4J81J[H[MZZ4J2\1;-,$[?<G6#(^!ZZZPW'
MW"!>1=QQ#CEVE6<$V.=7DHR0:9#5Q,Q:EJT%D6/18NHG]J:BVKKB;B9A\VM:
M-@5:P;B(4JU.E*:4II2FE*Z9C7*]&/GTG&P,-'R4HNHZDY!C%L6CZ1=*\ JY
M?.VZ";AVNH  "BSA110_ =1AX#2E=SI2FE*CG+>**-G+'%KQ/DJ+<S=%NT>G
M%66)9S,S7W#]@F\;/@;DF*^_C)ED4[AHCYIV+]LHJD!T#G,BJH0W3<6\-U!-
M:W""6"XBD@FC)91)%*I21"4*L R,5)5@<'8@UFZ;J-[H^HV.K:;.UKJ&F7EM
M?V-RJ1NUO>6DR3VTZI*DD3-%-&DBB1'0LHYE(VKS[;0/">SCC_>RAFNXUFJX
M:PSC;(D_;J95H'),KDB3FF2;20C:77ZW,2KZ3L!85!!1B\MTY=5(*5E_*DF3
M*I-$[$H>O:XT?@6?3^+Y-?(TVRTVV%Q'IEAIS3L[)+;26BM=^=;Q*KM%+)/+
MR2SGV@B-&\E%9O4?&_[0UCQ+X*6OAP6XIX@XIU5].N>*N)>)TT^*&*>TU2WU
MAX-&6RO[N26&.YL[>PM6FMK!?W<))YHC>W$B1^D_6S:\GTTI32E-*4TI32E-
M*4TI32E-*4TI32E-*4TI32E:Z]UAS89W3[,=TB1$FM9D[+9]FN:I(1*FDUI>
MXL\'*8AG)-4YB)BE";BZ!CRFQRJ@C\"GER;,0 ([7,52N@\4+>(OM4PB"='R
MI!8VSC;F\I,8V9SV-K9?_P!L8BF.H0MVAJ^XB*_/5:NV@J%DA?D[Z\-7$$Y<
MN21CANS2?J62OU[B76%T?3)I4O=/LKZ1'_=YU,2&UGGCY7:%A$\;\SQY5&#X
M1V5W5T5E.R_"K@>;CCBNQLI]!XEUW0+6>!^)%X4-LNK6.GW)DMX[V-KJWNH?
M+@N3'+-&8"\\$<MO#)#/+%*M7?"ZWD;B-T]:RA77P54]QH\O%S,W87\(XAZG
M(1ES"360>,&\2#A"'O3^:AIYQ-LXZ*-4'"+II/(5Z+E EDK-&<#<37/%&DRW
M=Y!%!=6UV]I*;<.L$H$4,R2(LCR,C8EY9$YW *AU($@1+;^T)X3Z9X1<9V>C
M:)J-WJ&DZMHT.LV:ZDT+ZC9\]Y>V4MK<26\%M%/&)+,RV]PMO"S)(T$B-);M
M/-,VZC 3/*%B0OP6B[X^W,XMJTDRJ^98: J%XHD5!2(_,#T+-<=C^!KEPL^*
M91YQ*A 6B/0<5J0Z;M5%X^6:+NG-]M+RXLI1-;2&-P,'8%64]5=3D,#Z$;'<
M8(!KSKJNDV&LVC6>HVZSPL0RY)5XW'V9(I%(>-QZJ1D95@5)!K+BK*;EQD+(
M>(;O!J47+E)3AYRWTE9V60CU49Q(Z"%TQ]/D209W+&-M39M)BNV5DDFY^->R
MT78F$-.LG<6AL'2]1@U(2!/<D*I++"Q^Q(0$EY,=8F*HX;KS.P;!VK07%7#U
MYP][,9B9K99)+6WNU!Y9;93YUKYW7DN55Y8'391'!$8N92";--Y40XX-VY#L
M/?W'W]OXAS]/;4FT6.WJ,],[# VV/?T]=R*J\=T,;-_K\/@,]>G8]J[1.7'C
M]X?;T$?MP/Y>O ?Z:ZC%\,^NP![^G?8;_3N<Y0NSV.?EMCK\?K^B*^:LL(@/
MXN>WN/?W]AX^@=P#^??7T1=-L;[XQ\._7'7;)].E<6NR1CFQ\,Y(&QZDD_Y^
M&U0KEK<!BC"\>RD<H7Z!J)99P#2"C7SE1U8[,_$Q2EC:E4XQ)]:+;*G,/"<5
M6H>5D5>_EM3<:XS36UJG/<S1PKVYV]YNOV5^VYP1T'85W6=EJ6K2^3IUG<7D
MF=S&A,: Y&9)&Q'&.QYV7<;=A460TUNSW"*.TL&8ACL.4AJ(J2>:MSI5&!F$
M4!%#KS$5A&O3L=9&A4DNA0\?E^Z8=M[#DKLN/IUB5;HKUWQ3&@*6$)=MQYTP
M*KMT*1@ACZCF*8[@UL#2O"Z>8K+KMX(4V)L[(AY3OGEDN64QH=B,1)(/1Q5U
M]M&P/#;:28Y4S:VL>Y;+-?E4I.JY$S:]5L=2@'JB!% EL0XF4H>.L8X^!HKU
M$C+-!4%_;W#,R'Q61+ !"KEJMW?W=ZW-<SO+@DJA.(TS_1&N$7Y@9/<FMI:5
MH6DZ)'Y>FV4-MS "24+S3RX_[V=^:5_7!;E'\J@;5M%UAU+UXC__ *HF4\F9
MHG\DHY]F\,Y896YS7U,+V.R3K.FMC1TB>,2AJR9\T4QI)54PHID>Q=W7@IM.
M36=D<-[ 9 UH?; O^"[ZTC#VL)U"R>(3K<0\OG(K('Q)%GG+*"2K0^8K+CW5
M8\I]1^"_CQ^S;JO!5KX<^*/"6F\-:O#+)I]SKDVDM>0:K<23-&FJG7+2*36M
M)OR6"RER+:U5%,5S%:_[-!/^U?-Q*.P##]A9P] K,A=;0UP=(RJ+Z/IL"S6\
M^US&WQ [DY?A[+C [N13QM6).8:O)K#)*^E&R,U.T&^)L?NAZJ$B339I(XY(
MA_L\\Y'EO;C<* &7FECW 3GC!CP0^5*MX^_:F_9^N?"KQ!O+BR]LU?AK6X(M
M5T6XLD26XO;2Z=XXI9YDC-O')$R&&^FA@D#SK'=);QV]_$4V ,K:Z(J8C>1A
MK,F0G6HUBU",9U(A?_$41CUG3EO)%*'XQ*"L:H! .5$':PD1/8Q*2=GAN1L>
M6(A)P,98K&799 ,Y YHCC(4.V ?+;62*H,EO?:2Y;"R72M<6#MORK)<)%');
M$D<@)2X!8J7,2!G7\W3-6+\:UQ&W9#R'3Z16W)4Q:2]LGXZ :/%%>D$FK(91
MRT.\?JG.5)..;)K/E%Q! C8RP^7KE)/:Q1":6>..)EY@[N$!!].?!)^ '-G8
MC.16/;V.JW-T]E:V%Q<W4;E'B@@DF96!P26C#(%WR'YN0@A@Q&#7356^YPS0
M+4NVS:[ES(\._ #(9.R:S-MNPP@0PB4KP\]E=FSR?98TY@#R)3&&&LBQSE(1
M50=&2 IQKUUQ/ID)(MUENY ".9%\N/Y&210Q&>ZQLOQK86E>&7$5\%;4)+;2
MH3@E)']INL>HAA8Q ^HDG5A_3Z9M6]D&9,A1MNR?N.W#/L<,*RZG:TYH6U!@
MC$&LA*T\59*0K3,N1Z[8KZ=J^L1G=?2<T&FXQM4I+M3+LGK-)XC%)U:YX@OY
MYGFB*VI9%C7RAET0$GE$CY(+,2690I.PV&QVEIG 6B6-G#:7*RZDL4K3O[2W
M+%+.P5?,>"+D1PB*%2.0R( ,E2V"+48"Q#MWQ74',EBW9E<Z_/3LJHE:KJ_,
ME;<FS%EB1,R<O;=ENTW"6SI/*QZQG#8).7!R^;F^*0;,DS^<WU"N[R.TDCM(
M['+.[%F8^I8DD_4U<888;>)(;>*."&,82*%%CC0>BH@55'R JP-7QS,6:9DY
M*9@'\%'RZ+6,EG<W+S<R_/56JJCH]/K:]G>.;,"=A=J"2[3LPPK:3B'30@X*
M .<QIYKQKMJUNE*:4II2FE*T._\ $#^)QD/PU-H5>F,()L$,[YWNCC'./K-+
MQ[66CJ!&QL*O-V^])Q#Y-:/F)N+:?+(NNQTF@XBB2LXC+R3229Q"T1(J5Y3L
MA;L_&<\."I;?=Y=WWM9?S<ZRD\Q_/Y#Q#>%U<BX'J#3*5$#*U*QC?7$O<3N*
M[?;703GE#0M5QY36<0Q)(FI>19.0@)-M'J5[(:5XQ.W>488TLV0XN?QM0LC;
M.=MFZY"XF8V*\K,)#<OE-]ARIXC3I]$JL]:92QM;TU0B1F(UFX8O5WR( U;(
M$.Z%2I"@/&"\/*SP,M9(;.LNXC8=&@++)+X0W!1\S)!D^]2&+J:E6JY(XK:V
M"WNGV3(J1QW(LZK&3+JN7AFO5;(C$SB9F(*5WF-O%?V#9</%)43.;B16G;!A
MNL0:,IBC--57FI?/MXDL9XN)#HVO'4(I*,)K(D-,4B8FF!7$+2K3$R<)=Y"N
MOV#I%)2OTP\5W8/)VS'5*99U56G<JN:DTIAAQ7F=&"<+7W)MUPS3/GUK7QVG
M5J8E9<I8]M=(B%[E,0"+N<8M$4U/*F85:04KYQ_BQ[!)6&L4[&9T<2#.ON*4
M@T:L\49J<3E_2R/=);'5#D\,5I+'1K%G6!MMW@9JMP=BPU%WJ"?2$6]\N1\A
M ZP*5R(3Q6M@MCD<9Q4+GUL^=9>CT9*D&+CS+*+)=!]9[Q2X-"R2+FB(Q]$D
M[7:\;7> I4->G-<E[K)0"[>JLI<SEA\4I6%PWBZ;-<@DQP\Q!E&$MT1<<L8R
MQY8)&ZP67L0_LY7\M8FRQEZEWV';77$*9K5"SE<Q%95HN164K='<-XVP'>9
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MCBMX)IWR0^H:.0EC<@N2\DEN+*[E;=KPYQ5M:ED;PR=Y[].'RMB*H8FS!+*
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M!(WND$$Y!&#M_?\ #[]LC*)3]P'D!]A^O'J'Z?K]=9E19!!P1@U^#MDC_O%
M?S !_P!/Y\ZXE%/51^7Y5R61UZ,1]:X*L2V4Y_ 7[=N__3U'\N??74UO&W8C
MY8_QG\?B:R$O)DQOG'ZZ?K[JQF4J#%Z0Q%FR2I1 P<*$ >1]Q ?7GCG@>?TU
MB3:>C@^ZK?0 _?L?EN?O&\I:ZU/"1RR.N,="<#<9V^O;U(STKSH>+_M>?7^W
MT8(N449-(.J+3$%%L5C-UF$ZXF'Z4A+G!,P&%RX08Q:#1T/3Y9&:J:) ,5PH
MK<N!V_<J7D]M"#)-,D=PSH"7B1 T<?/A2O(Q=L9ZMEL9%9_%/AF?&3A7S[B>
M\\[1+JXAL3'(_DPS2V\$LDJQG^%)*RE$E4\SK&$ (5AF6M@'CO[W=O&*;3MW
MW$*Q69']3:0\=AW,%\&4>7:M,PD6H'C<@O4SB?)$$G#-)-C&/WCIE;HEXJS5
MDYN<BP1;QWK[P=X(M/$B>\NY]1DMM.TEXHM1T]()!>,]W#,UJUK?$F!$\R)V
MECDCED5$7E"I(H'YL>,O#G%'AE'+IG[KCN-=ES/IESYZ):7EG!(J77F6C*'-
MVBM&(RLT$<G,_.))L,WKJ\/[?C";XJ7;YX8"OT2T5.<:L5*8PN86F4>5YQ"0
M[I"X]*D+!JH0LE-.Y6,8F11?(IC'>4N^,X, '>(OA_-P'>V4"W5QJ-G>V[2I
M?O9>RP+.)YE-F&6>X5IHX$BE?+1LWF<RQA.FLN"^,4XLM[UI;5-.O;&X\B:P
M:<RW"H(X\S.CQ0NBM,9(P.5N0IR,Q89-J*K@#!U(R'=LN5+$F.Z_E;)#Y.1O
MV3(VI0B%_M[I%DTC6_S^X S&PR+9I'L6;%DQ<2!V3)HV1;M6Z*1 +K7-7:I>
MTI32E-*4TI32E1W?,N8MQ<YJ;/(^0Z;1WM\L3"HTEC:;%%PKZW6>4=M6+"!K
M;)\Y1=34HY=O6;<C2/2<*E4<H H4@*D$>#RQ1E!))'&9'$<8=U0R2-GECC#$
M%W;!PBY8X) V-9$%I=70G:VMKBY6U@>ZN6MX)9A;6T6/,N;@QHPAMXRRAYI>
M6)"RAF&1F1-<ZQZ:4II2FE*:4JL6ZC=OB/9Y2(6^Y?&V#$V.QI52#;5.L/;
M[?3BL>^E_A%774R@8CIBXN1?)GG9J+!ZFQ<(QOQKPGPPQVJZMI^B6C7^ISFV
MM$=(VF$%S<!7D/*@9+6&:10S>Z'9 G,54L&90;1PAP9Q)Q[K47#O"FGQZIK,
M\%Q<PV3ZCI>FM+#:H)+@Q3:M>V%M(\<>9#"DS3&-9)%C*1R,F=X)SYBK<ICF
M+RIARTHVJGRCATP%Q\(]C)**EV IED8.>AI-NTDX:88^:BHJR?-DC+-'+*29
MF=1C]@]<]UC?V>IVD-]87"75I<*6AFCYN5P&*,"&"NC(ZLCHZJZ.K(ZJRD#
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MO.RI2\A8XD[/3]AN [&ZL&/)Z/DY:#F=[&;&OQK-;)+U^DLA*3VVVBNG;UY
M/I!0B6=\F==M63D,>52 =73.J KD[BMC\-F"3&OM+A*XUN\3+2MRP+D&$(FG
M+UIV?SW\A6ZM+G5.VB@9"\?L)JGS4%8JS:*,NW;+QLK%,IV)B^V&>6WE6:"1
MHY4.5=>H^!'0@]"#L1L:Q;VRM=0MI;.]A2XMIUY9(I!D,.H((P593@JZD,K
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MGKM'XBI[K&6.9B:<XF,ZRWEVRT/&3^3J.-4LJ&B6\9&R"K65EXM5=P\(I7K
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M<50AP[" _;GG\M=H(.X((]0<UCD%3@@CYU2_=+MMD,JJI7&L'1=3D;#%CG<
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M.'\Y<3!]V<.'#?:()WKD\6F:E:FT(M;JUY0GE1O&Z(J@!0HC;^&4 '+R\I7
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M_"$+%H-S]I9C Q.3R*%0Y[&,%E W[ ; C?K5MO/$#2'?EN-.2XCQCF20QRX
MZEF#K(>N<A2QW+=JR,U!W45'@S2*@[HV( F,I7K$@T<E3+VY4:64($QE.._D
MM%'@\\ 0Q]9'[KUZ'WH_(NE&<<K^4V.O\W*">FPSOTR-ZCQQ%P%?Y\Z6ZTUR
M< 75H\J9WZ261N<#XR+'\0-Q7'#<#<:0[0:9(J5DJ1E#E*FM/Q+QFR<#S_\
MI9 Z?P;H#" ])FSE0IN.0'N&NLZCJ%DP%[:W, _J=3)&<C^M1C!ZG';H1O7<
M.%M&UF-I-%U&PU# )*VMQ&\J[C_>0@B6,C;(9!C/2K44#+$/:FR*[1VF85"@
M)4Q4 1, @' EY'U,/?@1Y /4>>0U.V&JI.%*L,M@@YR&'W@@YR"#],'!%!UO
MAB>Q9U:,X!()Y<8^[J!C&1OZC;:<&CY-P0H@8!$?7ZAZ_;Z^WK_AJP1RK(-C
MOZ?X_6?SJCS0/$Q!!P/UOO\ Y].F]0O9]M>'+8$PL^JH-9&<?N)-[+QTE(H/
M@?NUU'#A=N19RYCT2JJ*JB9J#$67X^H&P'(F<DI%JE[%Y8$W,D:JBQNJ%"JC
M"AL!7)&![Q;GVW;&0;YI/BGQOH_L4=OJ_GVEA;16D%C=6MK);&WAC6**.4I%
M%<R%%1,2FX$YY<&0JSJV/US:IA:FN4)*&I4>[F6RHK-IN=$\U)M5NDQ 78J/
M1.WC5RD,=,%XQLR6%,YR'4,4Y@'!U"XO+]2DLQ,;;-$F(T(]&Y2I<?!V(]!7
M1JWB!K_$$PDU.XA"*PD2WM+:&VMT< CG 53([;YS)))@G*@;U_;=A*N3R9RK
MQZ("8H@(@F0Q?0?;CGU]  1].0#MVJEWHT4H*\@P,[,,C<]ML@G/7?&?NS-,
MXPN[8C^*QWWP<'KU.?\ \7/IZP2VV_V>B2IY[%UQME F1$3!)TFR3%6D# /J
M4[B'=LECD$ *4R9S&(<H" E$O;4?!8ZEIDAETN^O;"0;A[*ZEB.1V(5E/PQB
MK1<\2Z'Q!;"RXCT?2=;M2 #!J^GVNH0['J$NXIE!&Y#+@J=\]ZE"-S=X@5,\
MI6&W(7=^1M^$B-HC:K<$UDT^Q2.5+/7Y9PN8X=CJF7\\W<PJ]8@8)R'C'Q L
M\&/7YY0G:\MK>X# #^9I(79L]"2<[Y!SO5.NO#'P)U?F%SP#I-N9,DOIMSJ6
ME%6;_NUT^^MTCP2"%6/E[<O+D5.%<\4C>;42HMKOB[$^1&S;@JSUBVL=+FWA
M2B'4=9RVEIJ$35$.>!;5Y!+G@?* .VK):>,'%-L M_H^F7P&Q>W>:UE;XD%Y
M8P3M@+&N_P Q5 U/]E3PKU,O)HG$_$VA2/DK#<OI^KV</7"JCVUG>,H.Q\R]
MD; W;J38BK^,Y10%)/)NWG*U14-P55Q4).LWQBB;T,=0TBXHK[R0$!$?(8N5
M@#@ 2./?5GL_&O1F(&I:+JM@3L6B\F\C'Q+9MFY>NX0GX'?&M]5_8XXE3F;A
MWC?AG5E&2J:G;ZCHDSCT40QZQ#S>A>9$.Y+ "K6TOQ.-DUT\E$N:&%1?J](*
M,,@U^STKX4YN/ZMQ+3D0VK@B41X,HWFET0'GA40#G5PL?$K@J_Y1'KMO Y_[
M.]2:S*[XP7GC2+YXD..^*U1K/[.'C+HO.S\&76I0IDK/H=YIVL"0#/O);65U
M+?#.-A):(QR,+DXJXE1R-CZ_M"/J+>J?<V9R@<KJJV6&L" E,'(#YL4]=D#M
M["("'N :N%M?65ZH>SO+6[0C(:VN(IUP>^8G85J35- UW0Y##K6BZKI$H)4Q
MZGI]W8OD'!'+=0Q$[^@K,]951--*4TI32E-*4TI32E-*4TI32E-*4TI32E-*
M4TI32E-*4TI32E-*4TI32E-*4TI32E-*5\$FK5 QSH-D$3JCRH=)%-,R@_4Y
MB%*)Q^YA'2E??2E-*4TI6NCQ/MPV1MO.VM61Q!:(VCY+OUI842M7:6K VQG4
MBO(N7EI2=2BSN$VAI)NQB3MXM9ZTF6[=VZ*[/!2A&QT2R>D"Q]MC?489KBTC
M!=X()%C>0C'*I9BON9^T%96(V#*,D7S@'PKXP\6KW5-"X*O-#L=5T_2I-5>?
M7I[J"V,"7-M:&.#V2SO9'NFDNHS&)(DMU57:652$23P>9LP#NQON1).VV^6L
M&XF3L)?F+O,K2?GK3!.RB<2JMYVRW5O"25-7CE>I 8:XLZT=NU*V=1K5: =Q
M;]YO/2^(>&UL0;>6WTV*'W#:2K';RH0,[11EO-Y@,AXC(&(.6+ @:8XT\ ?&
MWAWBO_HSK'!?$>KZQ<<KVDVD6=UK=E?Q.Q59;*\L8YH'CSGG7F1X,E9XXG#(
MNSGPU\(UK#^7,66*>BH!V2-L=95W Y0LT0:Q4"BUZPRZ,86FJ3:3>1KU=@'3
MM>,KKBYN%6S2<N3LX)6)2D(LW#K7/%?$4FLR/:P,ZV"R*MK"JE9+J4'"SR C
MGW8D11G 5<,R^80%]@:%^SKP;X*^"&N<7>+:*OB9Q1ITMMPYI)O#YF@W+<D]
MG##%;.8Y;R(Q^UZW=2O+:VMD/8!R3RR+<WR\8&U[C:7CJM95V(V09K:-&C/U
MC+,I2V=7RBPBK2]:5,Z;QVZFXBU2++'!X%A7X%LZ1??(XF2B3Q"X1\8Y@$'7
M=PGI&FQW]UI_$EC<6FJY1K."_%Q9,0CR))Y2DPN9UF0X8DD\A\K=)*\8<3ZG
MJ365O>\/W4%S8CG%Y):>3=_:1&3G(\U/*,;Y90.8<RL^Q7&@[8]6]BV<\KKU
M'>W8;A@J$<Q4C.1F3\86&MU6ENI"$9K2LA W:MSU.MZ44I8FK9PWKSJ@#!,T
MY4K.O,ZJ=>6:/F.Q=:?7-.M%ET18[\ADC-M=)+/<*K>XLD,JS1M*$)!D$_F,
M1F0RX4JU!T==$U*Z9-84V+8:7VBVD6"V<K[S)-$R.L18 \I@,:YRH0'!';VO
M-F[W;WFFS3>VO>/E;+E(K$J)*9DO'F1[?;8"2I#)0K:J)76@2[EZ2N%;1I&<
M8YJ5YJR,0B[:K-H4LO")L9%UPALM'U&RBBU+2+:SN)4_C6UQ;QP2+,03*T$Z
MA?,RW,XEAE+X(Y^5LJ.RXNM9L;R2;3-4N+^V1OX4\$S7*&$'"1SPDL4*KA")
M$"G&4..GN(\,?<_E7=WM"H.8LTT)S0\A.7TU6YGJB'L%$W,*^NDW;7VN1;\H
M+M(>PI*@55),RC).;93"4:?Y<1J0NE>)-,M=)U:XL[.X%Q;J$D0AE=HO,&3!
M(RG#/'Z['E*\PYLUMS0;^YU+3+>ZN[=K>X?F61"I0.4.!*BMNJR#< ]#G&V*
MV Z@:F*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*AC,VW
MG#&X*$)!9=Q] W%NW(H6-D7:"C.Q0AE?WU8"S1RC.>A53" &4&-D&Q%^D"N"
M+)\D&'UC0-'U^W]FU?3[>]C (1I4Q-$3_-!.A6:%N^8W7)QG-6_A#CWB_@.]
M-_PIKU]I$KLIGAAD$EC>!>BWVGSK+97B@9 %Q!(4!/(5.]:?<M^%[F3%RCJQ
M[7,@'R%!MRF7#&>17S**MY"@(B+: N*2+"N3!AY B#:P-ZT**)#>;-/W!B@?
M2^N>$6H69>YX5U W,:Y8:7J,@28=?<M[T!8VZ@*EPL:J![TK$U[!X._:GX:U
MY8M.\3-"&C73X3_I%H$,MSIK'&TE]I+M-?6H!R7DL9+\,Q'+:0H":ITRS9/T
M6R*43+]4L6.;FR$"NH2U1;J(>B3GH*Y; Y(5&18K&_$@_CU7#)T3@Z#A4@@8
M==27NH:3=&QUFSN-/ND./+NHS$6&2.>.3_=2H=^5T;#=5/<[V7A_2.)-.76N
M%-5T_7=+FR4N]-N([F(-C)CD"'S()ER \$Z)-&=GC5@15D8"\14R@15J[06(
M8I3 *9RF'@>_<O/)>P^O''/8!U-P:C%,!A@3WQL>O3'P]/Q]:1?Z%=6CL'C9
M<$]0<?>>GUW)-9JDX17* E,4P#]P]^W^_I]=2"NKC*D'\_NJ$>-XSAE*D?V^
M/P]:_"C1NJ/)DP$1_M< /K]P[AZ_;_#7PQQMU4'\/OQU^M?5FD3[+'_TKZ%;
MH)_ND*4/8.P!_EKZ$5>B@?'O]_6N)D=NK$_K\*'51( \F*';UY#V^H_I]^="
MRKU('S._W5\".W12?I7229H609NHR5;LI*/>I';O(]^W1>,G;<X<*(N6K@BJ
M#A$X=CIK)G(8.P@/IKJ>:$J5;#J=F4J&!'H5;8_+!K,MX;R*6.:!I8)48/%-
M"[1RQN-PT<D95D8=0RL".QJAF1<'R>.7ZMTP<HZ>Q!#G<2^.S+J.'30O6)U7
M%064,*KEN4O)CP#I51V3I,$4NYZV\6C3;_21!(UUI)Y23F6R+>X^<Y,'HW?E
MSU^SG.*W%H7%8U2%=+XK11*5"VVM+&%5L* $U%5 56)Z7<:A3D>>B!6G;-L3
M;@HFQH)-G;GR'J1O(736 4ED5B#T'272/TG*HF;DIRF #E,42B'("&N6GZPK
M8CDRKK@,C9$B$;;@XR >A'W@D"L7B+@V2 M)"@>-P75DPRNIWYE89!##<,/=
M-6VBK V>IIF(J0Q3% 0,!@$H\AR(]A^GY"''IQJU07:2*"2"#C!'QVQZY'H=
M^O4]=77>FRP,V5*X)V(/TZ_KU.362$6(< $!#O\ K_AK,#!MP0>]1C(RG!&/
MR].OSK]&(0_J #^7&OI .Q&1Z&O@)'0D=ZXBC!!3U(7U^GM^?\_\.-=30QMU
M'W?ZY&U=R7$J=&/W[_\ I\L5PCPC8P" )E#GZ ''K^G'Y 'VUUFV0^O^G?I@
M;_*N];Z93G)^_?Z?7_.QKI7538K\];=(_/;\29! ?S$Q>?3ZB'IV^V.]@C;E
M4)]2!G?KV'YUG1:S/'@AW7&,X)[9QMGX_CZUB,AB^#>%-YL<W-SSW A0]?7L
M(#].W8/7C6')I4;#[!'Q!R<^N!S#_.?K4M;\3W41&)CUV'4G'QVVZU&4UM[J
ML@!P-&I@)NH>123, "/ <>@"(=N/0>W8/O&S:'#)_(N_7*+GYY&^,?3;XFK#
M:\<7D9'\4GUPQZ?7Z' /TVJ'I3:?"D< ^B@-'O4S=23MDHJR=(F >0,DN@*2
MB8@/!N2'*/(!]AU@'0GA;GMY)874[-!,\; ]B,$8SU[_ $WJQ1<?&:,PW2I<
M1,,-%.B31,#UYDD#HW<'(/4C&"0<NAPW9T B:%(W&YHBF;8 *VCE;]/344B0
M.>@B45-/)*.*0.>R96P$+W "ZE+?5>,M. 6TXBUA47'+')</<1   !0DK.O;
ML,8^9Q 7NB^$^O,SZMP!PC<32$F2>/1K.TN7)SDFXLX[:<DGJ2^<XSDXQRH7
MQ%]Z-,FG$ KN'K%N=,'2C!6.O./ZD9LF[;J>4L@K.1$!75U52*%,D<33*@>8
M!BE'K >-B6UWXV6VGQ:H+5-2L)(%N(Q+:V$MPT#*'27V6U=-1PZ$, 8\\N&Y
M0#DQE]^S7X/:M:K>Q\%:GI,<R+,L^CZ[J8<QNO,K)9W=YJ$:J5/,N+8$@@G;
M%6+CO%9WBUTS5.VXHPA94E5"HHGCD[A4WSY3H,H)$UG%IL#,RQDDU% *A']D
MR'/Y9BD,.L6R\5^,B)S-PW97Z6D7GW3627J-;P>8D)FN#YDZPQ^=+%%SNB)Y
MDL<9/.Z@ZQU3]ESP@YH%MN-^)-$FO)O9[2/4KK0[R.:X\N2;V>VC:RTV>XF$
M,,LQA25I#'%(^ B,PF&&\9M^U%%&];6+#'J&Y(=>JY'C)HRYB$,=0S:.F*O7
MC!P0AS^4,BJ(%*(F4  ,(3%KXS\\<DEWPIJ2) JM/-:7"W,42L\<2O)S01>4
MK2RQQJ7<AG=%!+.JFH:C^Q]$DL<6E>*&CR2W+,MI:ZMHTMA+,R123/'&]OJ=
M\T[I#%)*WE6X(BCED*!(V:IC@/&2VRR!TTK)1\Z4DP\ LYEZ7 RS!$WN(*5>
MWS;Y5,/8Q8TJ@_\ V@$0 9:V\9N$9B%N(]7LF/4SV2N@^.8)Y6(SM]@'/;&]
M5/4/V0/$ZV#/8:GP;K"C=$M-8O+:=A\4U+2[.%&Z9'M!&^S$;U.,#XGVQR?$
MA$\XLXA8_ &2LU-R%6@2,/\ 95=3539L X]U"NSI>X*"'?4_;>)? ]U@)K]M
M&Q_EN(;NW(.,X+36Z)]S$9VS5'O_ -FSQJT_)DX(N;E!N'T[4]#U'G&^ZQV>
MIS3]NAB5AT(!J>*ONPVQ77H"K;@L-S*I^.ELVR+5"O>1]"F8KRB+PA^X<IG0
M*</<H:G[7B;AV]_ZKKFE3G^E+^V+>N.4R!@<;X(SC>J/J7ACXC:/G]Y<"\6V
MBKG,DF@:F8L XR)DMFB*[;,'(/8U.$=+Q,P@5S$2D=*-CAU$<1SUL^0,4?0Q
M56RJJ9@'Z@80U,I+'* T4B2*1D,CJX(]05)&*IEQ:W5JYCNK:>VD!P4N(9(7
M!]"LBJP/P(KL=<ZZ*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4I
MI2FE*:4II2FE*C_)N*\>YEJ+^B9/JD7<:I)'16<1,H17I(Y;&$S9ZR=M56[^
M-D&PF/\ #R$<Z:O42J*$37*110IN2LR$,I((Z$?K\*G^&>*>(.#M7M]>X9U6
MZT?5K972*[M63)BD $D$T4J207-O( /,M[B*6%RJEHR54BCL=X3NR=A*_,E,
M>V*20*H*B</(Y N"D4G^+J*3AM+-9!9(G8 (ZD' ' H KY@";GO-W,0!S 8W
MR!N?GU'TQC[A6[[G]JWQJN+3V9>(=/MG*\K7EOH&CK=MM@G,MI+;HQZYBMXR
M#NO+@8L;>MJV*[)M\O>W&G0<5BNE7J"<0KL]*@XMLLS4<';*'E1060%*2E1%
MJEUOI(SAVH)2J'<"J0ARR.@:W-H.MZ=K<<274VG7"W"P3.ZQRD*R\CLGO!2&
M.<=1D$$$UYYXYU+7?$2/43Q1KVJ:I>ZC;FV?4+VYDN[B"+FYUCMQ*Q2"*,Y,
M<$(CAC))1%J&MH^UPFPS;7=JR-A?97F$R6'(\PBDVEHZ.?2C6H,2N:S7X7XF
MQE;M73R'<I(OV,.$I*)OFP/XQ\Y9H)&M7&?%A\0^*+&Z-K'I$#&VTN$LT,LB
M0O>2<MU<SE;7F98YU+123^3$8W\N9%=VJ@\+<-KP3P_=VXN)-2E43W\NTL:-
M(ELF;>&+FG"J7B8"1(A)('7GC9D5:U4;3\%88\3#&6^FL9/VXT[#+W)N18.9
MBLE8VHU3KM@HSEK#5IE"56,F%4T9]\X@Y?'K2TV>.4B&L#8YJQ6YS(J,7DZ5
M@QM/'6B-X;WW#TVF\17.L>?!)+)9WL\DB!4AAA>6..-3 EM<>9(8<SM-'F,(
MKK&97KW"6J+QU9:W#J&APZ8(YDB6XM8DC=F:21U$CN1*T\7)'SCRO*;E8NP+
M+&NN6O> ;XDNWK<%3+E@#)V*5352U,Y:JYFBKC*U)Q!-D'/0+NT5!]%+2X$=
M,3+-YNLPJMQBY*.<N8AP]D6CIP4W3+QWP[J.GSPZA:W0,L3)):-"DH=B.D4R
ML%!#8*2.(F5E#84@$\(>"M=T[4(9["[M^2.56%P)'B94#9(EBY27!79D4L&S
MC8;CVU%Z@*4#B43](=0E*)2B;C\0E*)C"4HCR(%$QA .PF$>XZ8K;7S_ %^=
M?W2E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI4:9
M2PWBS-E=/5,KT2N7J#,8RB+6>CTW"\>X,04_C8>1)Y4G"R!2&,5.1B'C)\F4
MQ@3<% 1YCM3TG3-9MFM-4L;:^MV_[.XC5^4XQS1ML\3XZ/&R..S"K%PUQ;Q+
MP=J"ZIPOK>H:)? !6FL;AHEF0$,(KJ \UO=P<P!,%U%-"Q +1G%:ALO>%+;:
M<LZLNT_)*PH)BLZ#%>3Y!99#@!%0K*LWMLW4<H 4I0;L65I8/144,!W]J13
MQPTWKGA \1>YX4U PX);]UZD[20^O+;WB@RQ],*LRR#IS3*-Z]=<%_M76E\L
M6F^*&@))D+$>)>'8%28 X!EU'1I)%BDR<O--IL\&!D0Z:YP*HG)9.R+A:P)4
MS/M!LN-;$(F*W+/LO+CY0J0]"CB#GF:CF"GVH" @+N'D7S<! 2BJ4P"4-87<
MFL\/W M=>T^YT^3HKS+S02@;9AND+P2KG.X8XZ=:]#Z?I_"_&]@VK<$Z[IVO
M6> 9!92_[3;LPYA'>6$HBO;*0C<I=6\+=#@@@F5(S.-1>HD53EVO!@ 0ZSE
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M E8DO8S:8\THO]*0,R6RO#=6\=J1;7$2! \UD<&147DK$D7E;-,G,U7'^'F
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M%UI96SDSU]Z)5:V??<EX"V>C#)SO7@_]I'Q6X1Y(7UW_ *4:<N =-XL675T
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MK71>"^+]*NWN(XM1DT33KP/)!*T$ZEKBT%Q$Z2(0RN(W(Y9!S)(C--47G#Q
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MX#Q!E4'CLF/M8+7QGX5E*K=6^KV+'JTMHDD8._\ -#.[GZ1=QVR11=1_8_\
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M.U"S8K>6-Y:,.JW-K/ P^8E1"/J*[O7=6'32E-*4TI32E-*5_#&*4!,8P%*
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M3MM#UJ\Q['H^J7>>GLVGW<^?EY4+Y^E8"\W+;<X]3R7V?,+M%NX"DXRA2$E
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M60SE5U5QS^R%POXR<03\3:WXD:G[)%;VEEH6D\-1:7/9Z=90I')>E[F66_\
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MSI+)'_?1D<M7EP@?GUZFZD\*1N0^J?'';C6))<<57&1/Q#KDH;JKZC<A3O\
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M!V..HR#FI$C=R52>=(A() (_W5BB _?N'/;\Q[AS[=\N/7X&&.="/_> =.N
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M+MV'_'C[ZX^6G](KF)9!T<[?';TSO\=]^]?,6;4?4I?_ &_]-?##&?Y?Q/\
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M""J2YDP'C\)G/7Q_^8(]]0T_@OH_*R66N:Y:HQYN226"X3F[$H(H P VW][
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MXZD0$>>. ]L)O#_Q$BR?W1;R8&QCU.R.?D&N0V?F!4O'XV?L_7 __C)X&/\
M+/PWQ*F,]BZZ2Z#&2/M'OCUKK5,"^(<S,/G;;K<<   'X:TX_> /''/'PUQ6
M,(#[<!R(>G(^G2>#/$)3_P#F"3;NM[:'UW&)]_H/S%9:>*G@++]GC_35)/\
MVFF:['U^#Z2N,=3D^H.-B>.;#V_\.X[:<@\ ' @1]5S=^_\ <L!OY<_GQWUQ
M_P"B/B /_P"7[L^G^TVQ_*:NX>)7@5__ '!T7UWMM3&VV/\ [GC?KD;'[L5^
M0P[X@!N>G;5D+GGC\3VL$#T]NNP%_/O^7VT_Z(^('_\ 3]V/_P#:M?F1_OOI
ML>WSI_\ 25X$C.?$'1<==K;4S]-K#.?IMZ'MRD\$>(:Z+PEMMN)>?_OV:@-0
M[C[_ !%P2_@/M]-?1P9XA-_]P)!GNU[:#\YA\_G\-JZ7\4_ 6/=N/M,._P#)
MIVN2'_\ 5Z41^(^%<I/:_P") \$/)V\2"7/ <NLDXG:\<ASS_7WTG ?4> X'
M@!#G7:O ?B(__P!Q8UZXY]1L5ZCXW/3Z@^IKI;QE_9^BW;CB-L#/\/A[B67[
MO+T?<_#N#TKM$-FOB0OQ*"N(8>*Y'N:0RICDY2\CSU&^5V:2,/;L/20P\\\=
MM=R^''B$_P!K3K&+X2:E;,?_ -7,XSOV/;[\.7QW\ (<E.)KZYVZ0<-:ZI/P
M!N+"W'IU(V]*RV.\.;Q 9\Q22$CABJ)G_>4E[U./3HAP(CRE7ZE,@<WL'2KP
M)O4P!^(,V'PHXWF($MUHML&^USW%Q+R_2*"3)^ VZ;C&:A[G]IGP1L@3;V?%
MVIE<X6VT:RA5_0!K[5;8J,[G*YQOU !DF+\(7<%+%(-LW/4N $P@*J=<H,_:
M0)R =14EI.R5 3=^0*8Z!?[W0 _AU,0^"VJ/@W?$\,1(W]EL'E .V /,F@)
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M"<;Y8&MR49XC^T1XV(*%NR-'E2$&XLY#;=N2BEVATP H-56SO$: H*D  *"
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M3MF"Q4R3%4F0-\IM-8D_,;N&3SY9)_&-G3=ZKL!-)MM3M%M+W_:;"Z)2&X
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MK[=Y43@9Z?)%DHDHT@*P@0Y0*VC83'60#3TJN4'!IB1ML&@V<1IJK*MIC8W
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M3,NT@8I],/DY)9G'-SNG"41#3%ADSI)\=0,H2 8R<U)+]^2M8Y@[<G#D2(F
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M!\LLWW_=.>TVXQ5CA$IQZX16D9A163>J")!$[Q^H+IR8?<O]:J;@/[( !0X
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MJ2^9DGWQRLS^_P!<. ^3AE#9%;&Z3>J5DJL1-VQW;JW>J?.M_BH6T5&;CK#
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M[CE%_P =6#7.N6.L3;?[1K%[.)M;TUG;?RKI9K"%B>2>./&+]>%M:(F9QON
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M*K33K;7EN94NH-/N%CMYGC+/8ZOI(:YNKNS5K>?R$%Y(\LDD5TLOM%K,IG]
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M+VSDCDC\P /SC.2%(YT51AF9@Q4==OM*V[8/Q]BMCA.M8PIB6+V<7\J7J$E
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MTRYD,+QVUXUOS+R7ME(RRV]Q$R.>0V\WFVLLT#S)4*35:%#(0%1A&<)%MRD
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M.8W+G&<K2T<9Q^:[=M?F]QS?%,PWE[V^L^.4;%'56?;U@UU5^8&9F82 C(P
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M:E6LO'@N;P)!#-CBL7/#B=@S%?-H65LA69/)]HCK%FDV*<!Q>.,[8:R"K<\
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MT%<:YD8[#(.2H6VQ4\WMT3B>KV)T]BF:E6H\/OPV\[[8L]8KRYD.R0BU;J&
M-S^,7U.5RNCE&0JT_FW-F!LE0,3C]W7-MNVVF0^,6#/&%I??LQ&T:$3JLS8D
MHV'1EXQ<[B-4K>7I2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*
M:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II
M2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*
D:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img30600998_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img30600998_5.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %% F$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "OC3Q/^V#\5M0^/'Q!\ ?#[X<Z3XE3P?&D]PUS?M#-+&0.
M5R0,DYX]J^RZ_-/PYX5^(_C']N[]H+3_ (;^+M/\'7SVT*WUY?V NR\+$ ",
M9&U@<G- 'J-__P %$KR7X0>&?B1IW@T#14U[^PO%=I<S$S:4^0!(C# 92<C)
M'7BO4_$'[4%]J/[2?A/X5^!M+LM=BO-,_MG6-6FD;R[.V8;HRNWJ6'K_ 'E]
M:J^"/V./"_PY_9A\3_#/4+J77TUF&YNM4U*90KSW+J6\Q1SMVD CG\:\@_X)
M.>#+1?A?XK\=7MQ)?^(;_5&TF2[N&W%+:V1 B*3T'S#(_P!E?2@#M?"'[><5
MCX=^+<?Q&T>V\->+? #OOTN"4[;]"=L1CW<_,^T?1U->Z?L\^//$_P 3OA+H
M7BKQ9HMOX>U35HS=)I]NS,(X6.8BV[G<5P2/>OS/_:BT/4/VDOBO\3/BWX+T
M6UO/"GP\:UL[PE"1K30OF5CCAE4 Y_V%4U]P3?$KXL_&+P3X-\6_ M_!Z^&-
M1TQ7N(=?,HEAN 2&B7RP1A<;?J#0!)^T3\</C1X#US58/AY\++?Q#H6CV0O;
MS7-3O!''(-F]TB0,K,54'/7I7->'_P#@H'I.H?LDS?&*]\/2Q:A'>?V2NBPR
MY$UZ6VHJN1PK=>F16!^V)^T_J&FV^F_!#0=2TJR^(OB*T2#6]6N)Q#8Z/!(G
M[QMSD9+*6P/0^IX\I_:6^'O@SX8_L0^$-'\!:[9^*=%\+>)K&ZUF^TZX6X#S
M,X:263:3MR>W88H ]Q\ ?M>?$31_C%X,\#_%WP-IOAM/&MOYVB7ND732A7P"
M(I0Q/S<@'&,9[U+\1/VW=;\-_'SPCX%TOP#>1:!JVN+HLOB#6%:!9Y P#FV3
MJRKG[YX->=?'SQAHGQ@_:O\ V8+3P?J=KKDMI/\ VK=?V;*LPMK<!22^TG:<
M9X//%7OVX?'7AN7]H?\ 9Z5/$&EO_97B7=J 6\C/V,!DR9>?W?3^+% 'W=7R
MG^V;^V;JO[-NM:%HOAGPU!XIU6ZM)M2OXII&7[+:HP4/\OJ=W7IBOJ+3-7L=
M:TZ'4-.O+>_L)EWQ75M*LD3KZJRD@CZ5^:%KXL\8?&3]H#XV>-/#WPJOOB7X
M>O;6;P59W-OJ$-M':0JH60KYGWBV%<8Z9]Z /T5\">/M+\>_#W1?%]G/&FE:
MG81WZRNP541D#')/3'.<^E8 _:$^'-UHNO:EI_C70=2BT6!Y[Q;;4H6,:J#U
M^;C)& >F3BOS1L?B+XKLO^">/Q,^&\Z7.G>(/!.LIIVHVN[]_!822EB&QV5\
MIQQP*^KO!_PY_9HU+X>VUEX4TOPGJ&OWWA*XQ;6822>YA$*M(9U7.6#A3F3D
M'I0!V_@']KK3?CE\"?$7BSP--I.E>*;*VN7ATCQ#?QKY)B.U99]K K$>/F.!
M[UZ#\'?BB?$?A'PI:^+-<\-_\)YJFG_;)=/T2^66*5<MEX!N+,F!U&1D'TKX
M"_9JT?P1'_P3W^*5_:V^C+X^?3=6@O98_+_M VJR?(L@^_Y8XQGBC5+7_A5?
MP+_90^.EM&^SPULTW5?*&"UE+(YP3]05_P"!T ??WQ;^*']A>$O%UOX1UOPV
M_CC1[#[6+'6+Y8XK<$C#S@,"B\]3CJ/6O,O$7[9FD_"?2_A38>.9=*N_$OBX
M0I?2:)?QM9V ?:/M!+,3Y)W<-G'RMSQ7RWI&GM\0OV;?VIOC9>1$R^,)I[33
MI'&#]A@950CV8;/Q2LGXQ>#_  DW@/\ 8UU?6])TT6]^;*RU>^NXE"S6BB ^
M7,QX,8#/P>.30!^E^B_$CPIXDU8:7I/B72=3U%K=;P6MG>QRR&%L;9 JDDJ<
MCYNG(JYI7C#0M=U;4M+T[6+&_P!2TQPE[:6]PCRVS'H)%!RI^M?#/[3T>@_L
MP_%SX0_'3P79V:>"DMV\.ZE%HH7[.UJ4)AV%/E(],?\ /,5Z5_P3G\'74?PM
MU_XC:N#)KGC_ %FXUB6:1?F,&\K#SZ%1N_X%0!ZC=?$+QE;_ +3$'A4W/A1/
M IT=KR2.2]QK F ^\(MW^KSWQT[UTUY\>/AOIZ:>]QX[\/0IJ$C16K-J4.)F
M!VD+\W8\?6OE#QJH_P"'FTAQS_P@%U_Z+-?._P -?@=X(\0?\$[_ (L^/-1T
M&WO/%MG>ZC]DU2;+2VHAD78(C_ /F.0,9[T ?KBCK(JNC!E89#*<@CUKXT^%
M/_!08^,/VFM5^%_B+P];Z)IIU*ZTK2]6CF8^=<0N0$?/&6 XQW('>OH+]F>^
MGU+]GSX=W%Q(TLSZ%:;G8Y)Q$HY/T%?G]HOP*N/C/\.OV@;W0@T7C7PKX^NM
M9T6XAXD\R-F9XP>OS <#^\%H ^P[7]JXV?Q*^..B:QI$<.B_#C3[>_6YMW)F
MNQ)$SE2#P#E0!]:Y3X&?M)?&[XP?\(QXK'PRT5/AOKUR46XM=3+7]I!E@)I%
M)VL,CD 9YZ5X1^Q?\7M ^+?CG]H'QKX]6"PT34M"TJ'7!<@B(8C>&;..0I;/
MTS6-J$:_L>_%SX=K\$/BG_PF/A'Q9K$=K/X*%XEZL<;LH9QL)Q\K'#$!AMZG
MF@#Z:^+O[7GBB/XSR_"?X/\ @N'QMXNL81<:K=7UQY-G8J?X6((R>F>1R< &
ML[XA?M<?$OX1_ N]\5>,_AO:Z'XHL]>M-(-DUV9+6ZAF;'GQ.I)P.F">M>8_
M WQKHOP,_;_^.FG>.[Z#P])XHD2\TF^U%A%%/'NW!=[?*!@^N,C%;O\ P46^
M*/A/XD?LU7;>%]?LM=BTGQ3IMO>S64GF1Q2%]P7>/E/ SP30!]>^+OB9I/@'
MX8WOCC7Y/LFE6.GB_N-O) V!MJ^I).!7RYX/_:T^/GQ$T>'QQX;^"-M>?#ZX
MES;QOJ.W4I[<-M,J*3@]#QM[<9JU^UQX@T;XS_L9^*?#_@CQ%IOB'6[+2K6_
MGL-,O$GF$,+1M)E$)/0&NE_9M_:O^$]O^S3X-O+WQAH^B?V5I-O8WEC<7"K/
M%+$@C8>5]YMQ7<, YW4 >Y_%7QU+\._A7XF\6Q68NI])TR:_6UD;:'9$+!21
MTY%?'.E_\%!OB3X>^'_AGXE>-OA;8P?#76ITA_M;2=0+30;B0&:-LG^%N.,X
MZBOJ#]J&9)_V:?B/*AW1OX>NV5O4&(D5\5?L[_LK>._VD/V</AMIOBKX@VMO
M\*(66]3P[8:<%NI0CMA'GSSR6YP>#0![;\1/VN_B-_PT3<?"_P"&G@C2?$TL
M>C6^LI/J%XUNTD4D:N>^!C<!70_!W]KS6/B)XH\4?#KQ%X+;P5\6='LGNX-'
MO+@2VUZ N5*2+VZ=,C!SFO(H->T#X>_\%1-=EU;5+'0M*M_!MO;QS7]PL,8Q
M%'M7<Q S@=/:HO#_ (ST?XV_\%&O^$V\)727GA#P7X=F@U;7X@?L[.5/RA^A
MQ_($]* .MT7_ (**6P_9Y\6>+=>T&'3?B#X?U+^Q9?"RRG,MXS;8@N?FVG!S
MC.-I]17U9\,]8U[Q!X T'4_$^G0Z3K]Y:)<7=A;LQ2W=ANV9;G(! /OFOR3\
M=17_ (O^)&N_M6:9X:MKGX<Z7XP@C;3G0_Z;#'A&NF'0C(7)Q_$/0U^OGA/Q
M1IOC?PQI7B#1[A;K2]2MH[JVF7^)'4$?0\\CL: /CSX>_P#!0K4?$?[3-Q\.
M=;\)VVF^'I-;N]!L]:BG8M]HB)"!P>/GP!@8Y85VG[:7[95Y^S+-H6E^'] M
M_$FOW\$M_<07$K(EK:(0OF-CGEB0/I7QQ)\/KOQ;\-_VDO$.D93Q#X-^()U^
MQDC'SCRII/, /H%);_@ K2U+Q%=_M)?"K]HGX\ZE9M;6J:':^'-&@EY,*J\+
MSD?4[#QW)H _1?P?\9M&U#X.>&_'WB:^L/"]EJFGP7DC7MRL<432(&V!F(S_
M #KH?!?Q$\,?$;3WOO"_B#3O$%I&VUY=/N4F"'T;:>#]:_.3Q4-%U;QQ^R!H
M_P 0'B_X5O)X8CE>'4&"V,E[Y9 $N[Y2,!.O'2M32;73?#/[8'QD@^"R6L/A
MF/P%-)=0Z"0;)+WRB4V[/EW;O3O0!]*?M7?M7:7\-?@_XQU#P)XK\/ZAXUT7
MR@=/^TQSO'F0*VZ,-DX&<^G>O5M)^+&C:-\*/#'BSQGKFFZ"FHZ;:W,UQ>3K
M!$99(5=@NX^I/ K\IM6T'X+?\.Z+#6-VDM\69KG,UP9!_:CW/G?O$?G>8]G.
M&^7\:]8^+\VK:A\?OV?M-NX_#=SHR>!;:;3;?QLSKI#W)M_WA;! +C$>,]]M
M 'V]\;/C;#HO[.7B_P"('@/5]-UF33[!Y[2\MY%N8/,!'!VG!QGI70?L]^-]
M2^)/P/\  _BG6#$=5U?28+RY,*[$,CJ"<#L,U\1+\*-0^''[/G[3=_+K_A&Z
MT_6[**Z70O!MT9K339?FW84D^6&ZX]O:OK[]CS_DUOX6_P#8 M?_ $ 4 >PT
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7,:+\,O"GAOQAK/BK2] L;'Q'K*JFH
M:G#"%GNE7E0[=\5T]% #)H4N(7BD4/&ZE65NA!X(KFO!GPO\)_#OP[<Z!X9\
M/V&AZ-<R2336-C"(XG>0 .Q [D 9^E=110!RO@_X5^$/ 'A6?PUX<\.:=H^@
M3F0S:=:P*L,F\8?<O?<.#FIO /PW\,?"W0SHWA+0[/P_I7FM-]CL8Q''O;[S
M8'<UTE% 'F/C?]F3X4?$KQ!<:[XI^'WA_7]9N%1)KZ_LDDE<*-J@L1S@#%:'
MA?X!_#CP3X7U;PYH/@G1=*T'5CNO].M;-%@N3MVY=<8/'%=]10!YW\-?V>?A
MK\'K^YOO!?@K1_#E[<KLEN+&V"2,N<[=W7'L*R/$'[)/P8\5:U?:OK'PS\-Z
MCJ=](9KJ[N+!&DF<]68XY->MT4 9'AOPCHO@_P -VGA_1-,MM+T2TB,,%A:Q
MA(HD.<JJCH.3^=4_ GPZ\,_#'1#H_A/0[+P_I9E:<VMC$(T,C?>8@=SCK71T
M4 <9;_!GP+:ZUXDU>+PII2:EXDB\G6+G[,NZ_3^[+_>'/>LWX<_L[?#/X1ZG
M=ZCX-\$:-X=O[I#'-<6-L$=T)R5SZ>W2O1:* /,]'_9I^%>@7'B&?3O 6AV<
MOB&![756AM5'VR)SN9''=2>2*V[SX/\ @G4/A[%X$N?"^F3^#HHUBCT62W!M
ME56W* G08/-=C10!R5O\)O!MK\/3X$A\-:=%X.,+6YT18 +8QL2S+LZ8))/X
MU2\2? WX?^,/!.G^#]:\(Z5J7AC3@BV>EW%N##;A1M4(/X<#CBNZHH ^;?VM
MOV<=5^*7[/NF_"_X=V.CZ-IR7ELC)<?NXK.TCS_J5 /S#(Q[9]:]W\$^%;/P
M-X/T7P]I\2PV6EVD5I$B# "HH7^E;=% '+W'PO\ "=YXV_X3"?P]82^*/LC6
M']K-"#<?9VX,>[^Z?2J.G?!/P'I/@34O!=EX4TNV\)ZDTCWFCQVX%O.TA!D+
M+WW$#/TKMJ* *.AZ'8>&='L]*TJTBL--LXE@M[6!=J11J,*JCL *R_"?P]\-
M>!9M6E\/:)9Z/)JUTU[?M:1!#<SM]Z1\=6/K7144 <+H?P+^'OAG_A(?[)\&
MZ+IX\0C;JRV]FBB^&6.)1CYOO-U]361X$_9?^$WPQ\0?VYX5^'^A:'JXR%O+
M2T59$SUVG^'\*]1HH X7XE? WX?_ !B2W7QMX1TGQ+]GR(7U"W5VCSV#=1^=
M4U_9S^&"> SX)7P)H8\)F=;DZ/\ 8T^SF5>CE<<L/4UZ-10!YW\/OV=_AE\*
M-4N=2\'>!M#\-W]U ;::XTZS2)Y(B02C$#D9 ./:L?\ X9'^#/\ PE'_  D7
M_"M/#G]M>;Y_VO["F[S,YW8Z9SWQ7KE% %#6]"T_Q)HMYI&J6<-_IEY"UO<6
MDZAHY8V&&5AW!%5O"?A'1? ?AZRT'P]IEMH^C62>7;65H@2*)>N% Z5L44 >
M:^._V:_A7\4-??6_%O@'0?$.KNBQM>ZA9)+*5484$D= *W=+^$W@S0_!]WX4
MT[PQIEAX<NXVAN--M;98X9488(8 #.176T4 <K8_"OP?IO@ ^![7PWIL'A P
M-;'14MU%L8F)++LZ8))K0\'^#=$^'_ANRT#PYI=OHVBV2E+>QM$V11 DL0H[
M<DG\:VJ* .3T'X3^#O#$?B&/2?#>G6$?B&62?5EA@"B^D<$.TH_B)#'.?4U4
MT_X)> M+^']UX&L_"6E6W@^ZW>?HL=NHMI-S!FW)WR0#^%=O10!P_B?X(> ?
M&G@VP\)ZYX1TG5/#E@JI::;<VRM%;JHPH0?PX''%3_#GX0>"?A%I<^F^#/#&
MF^'+*=M\T5A $\UL=6/4_C78T4 >2?\ #)/P:^W:O>'X:^'3<ZLC)>R&Q4F9
M6.6!],GKC%='XU^"/@'XC>'-/T'Q-X2TK6M(TY%CL[6[MPRVZJH50G=<  <>
ME=Q10!YYX=_9Z^&OA'PCJ_A;1_!6CZ?X>UA=NH:?#; 1W8Z?O/[WXUV7AWP[
MIGA+0['1=&L8=-TJQA6WM;.W3;'#&HPJJ.P K1HH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JO=:
MA:V4D"7%S# ]P_EPK*X4R/\ W5!ZGV%6*^+_ -J#P+J6G_M/? 7Q1J'B>^U2
MWO/&<=K8Z*RJEI81BW=F( Y>1F'WST'% 'V!J'B'2M)E$5]J=G92L-P2XN$C
M8CUP32W>O:98-;"YU&TMC<X\@33JOFY_NY/S?A7P9^UM\*-4U;XP>/?BC?Z!
MX+\<>%O"^@6ZS:)K-_(+J..,M)*42(CRW8$X+\'M7(?$.S\-_&36/C%KNIZ=
MY=KX;^&-EJ'A.SN)&!TP&W\Y'BYX8.%7=WQB@#])-0UK3M):%+Z_M;)IFVQ+
M<3+&9#Z+D\GZ5=K\Q-3LXOC7>>,;WXAQ'4+WP_\ !NUU/2/M;D&"Y-OYIN4&
M?]89 /FZ]J^G? /Q'^,?_#._PAU3PAX*L?'6H:CX?MIM4N-5UA;%T?RDVM\P
M.\MR30!]/45\V_#/]HOXC:G\>K'X9_$+X>Z;X1N[[19]:@N+'6!>[HXY%CP=
MJ@#))[]J^DJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?4% !1110 4444 %%%% !1110 4444 %%%% !1110 5\QZI_RD9T3_LG<_\
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M& (I]1S31VT,DTTBQ11J7>1R JJ!DDD] !0!%_9UI_SZP_\ ?L?X5850JA5
M51T '%>;>&OVE/A9XQ\5/X:T7Q]H6I:ZK%/L,%XID+#L.S'Z9KTJ@ HHKD(?
MBQX6G^)]S\/1JL:^+K>P34VTY^&:W9BH=3_%R#D#I0!U]%8&D^.='UKQ9KGA
MNTN?,U?18X)+V#:1Y:S!C&<]\A&_*MZ@!:**2@!:*2L_Q!X@TWPIH=[K&L7L
M6G:791-/<74[;4C0#))- &C17"?#GXV>$OBI<WEKH-_*]]:(LTME=V\EO.(F
MX24(X!*-V85K:;\1O#NL>.-4\(V.J0W?B#2[>.ZO;2$[C;HY(7>1T)VGCKC%
M '2T5YI:_M&> +SQL/"\6N Z@UTU@DWD2"UDNESNMUGQL,@P?ESV(ZUTOBOX
MD>'/!.K:!IFLZI#9ZCKUV+'3K1FS+<2D$X5>N  <GH* .FHJ"^OK?3;.>[NY
MH[>U@1I99I&VJB@9+$]@!7GW@/\ :%\"_$K7!I&A:NTU[+$T]JL]M)"+R%?O
M20%U D4>H^O2@#TBBN>\=>/M"^&_A^36?$-\MA8JZQ*=I=Y9&.$C1%!+NQX"
M@9JM\/?B=X=^*6EW%]X>O3<K:S&WNK>:)HI[:4 '9)&P#*<$'D<@\4 =5111
M0 445PWB[XS^%? ^L2Z9J]\]O<Q1V\DFV(LJ^?,(8@2.[.>GIS0!W-%)2T %
M%)SZ44 >)_MB:_I'AOX'WMYK^E:;K&A?VC817]OJT;/;B![F-9'8 YRJDL#V
M(KY$B^)G[/"ZU<OX.\*>"Y?$MIXOL-.T+RO.DDO+1Y(MUTH)'S*6?'8;:^R_
MVIM5UW0_A%<W^A6$FH_9[^SDU""WLUNYOL(G0W!CB8$,P3/8]Z^5?MOCGQ%K
M,'Q@TJQ/AGPS)XHL=&\.>"Y/#T"F_LVD"2W,V8_,C8C>X.1MV?2@#]!Z^,OV
MHOAO9:-^TQ\ _%\FH:CJ&JZGXTCMECNKDM;VD"VSGRX8^BY89+=37V;6%XB\
M#Z#XLU#1+[6-+M]0N]%NOMVG33 EK:?:5\Q/?!(_&@#XR_:XL? /BCXA:]\-
M/#&D:+=?$[QE;P'7O$6L3((M"L4(Q+O<_+)@?(B<Y(-<-\7-!\-6?C;X_P"F
M^)I[/5)=(^&-G!X<NM497D9$@(26$G^-I0IRO))K[+\7_LH_"+Q]X@OM<\1>
M =(U?5KY_,N;NZC9GD8 #)Y] !6GXJ_9W^&OC:30GUWP9I6IOH<,=OIS3PY-
MO&F-B#GE1@8!R* /@6:.TUB[\=-\2DM;C4(/@G:R:1_;&TLK_9\EHM__ "T\
MW'(YS7T[\.X?C9J'[-_P>E\#ZCX?M;X^';4ZH?$\,TDKL84V$;>^,YS7LWQ
M^!/P_P#BG>:9=>+/">FZY<::,6DEU%DQ#.=HQC*Y'W3Q[5W,,*6\*11(L<2*
M%5$& H'  '84 ?$W@2W^(]M^W]X97XF7FA7FK'P/>FU?0(I(XA#]I3(</SNW
M9_"OMROE_P 3?\I&_!?_ &3Z^_\ 2Q:^H* "BBB@ HHHH **** "BBDH ^0_
MVV;'XG_#?PCXE^)7A?XL:GH]A:O:1P^'([&%H4\R6.%CYA&[JY;]*]M^!_P\
M\8^!;._D\6?$>_\ 'YOEB>W^W6<5O]EP#N"[.N<CK_=KY?\ VE/C3XN_:0\
M?$+X<^"/A-X@U9;#65TN76XI8C;^=;7$<CC;G=R%'_?0KV_X+_M.:AX\^)TG
MPZU_X=ZUX&UNUT<:H/[4FB821!UCX"$GDD_E0!] TE+10!R/B;XHZ%X1U%[+
M47NDE1!(S1V[,@!Z?,!BK/A7X@Z3XRFFBTTW#-$@=C- T8P?0D<US7QV\5:;
MHW@F_P!/GD!OK^(QPPKRQ_VCZ"LR&_F\9>";75?#WBBXTH:=9;)[2&)&)D51
M][/(Z?K7S]3'5*>*E24E*RORK?[VSVZ>#A4PT:KBXW=N9[?<EUV/7"P526.
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MB,IGOC%>A77P<\%WOA.]\,3^'K630KRZ>]GLVW8:=WWM*#G<K;N<J00>E7_
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MI>,M+MKO3]8EGBN95:YB5SEI&8(RG'##H:Z+XL?#'1OV;7\(^-/ $FH:+/\
M\)#8Z7J&G'49[BVU"VN91$Z-'*[#<NX,K#!&#0!]2>?%NV^8N[IMW#-25^>,
MD/AB_P#%'QLNM<^'GCSQAK5MXIU*.TU3P[)/Y=NHQY:*4F7:5//W3CWZ5]-_
M!/XS^&=$^#'P]3QA\1=#FUR_TR,BYO=02*2[8-L) D*LS!OD/&=P- 'N=%>
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M.>:^H/ G@#XPZE^SO\(+3PAX\M? =_9>';6/5(=3T5+^29_)3:/G(*%><^M
M#?$W_*1OP7_V3Z^_]+%KZ@KXC\!^&_'WAG]OWPQ;_$/QE9^-=4D\#WKVUY9:
M6E@L,/VE!Y9120QW9.[WQ7VY0 4444 %%%% !1110!6U+C3[HC_GDW\C7P9^
MRW^Q[\-?CI\)1XG\9V.J:KJ\^L7X>3^U[E%^2X<+A%< 8'H*^][J'[1;RQ9Q
MYB%<^F1BOS]^$/@/XT>'?BYXQ^$7@'XMV-AX9\-1_P!I7-])X?BG$-U=2M(+
M7YCDL%.[.?PH ]*_9#^'6B?"']HSXY>#?#$5Q:>'=.CTAK6SFN'F$1>&1WP7
M)/+$FOKVO"?V>_@#XJ^%WCCQSXM\8^-(/&6N>*!:++/!IRV:H(%95^56(Y##
MIZ5[M0 UE# J1D'J#7C/@7X>Z+JWQ'\3:O\ 9$%OIU[Y%O;@?N_, !9\?4]*
M]BNIEM;:69N%C0N?H!FN&^"MO(?![W\W,NH7<UT6]0SG;^F*\G%4:>(Q-&$U
M>UW_ %\ST\-6J4*%64&U>R_7\D=]17R'^WM^SWX1UCX7>/OBC,=6B\7:;HV;
M:>VU6XBA4QG"'R58(?O'.1S7I'[+_P"SKX.^$/ARP\0^'DU0:GKFDVK7C7VI
MSW2,2BN2JR,0OS'MBO6/,,W]O37IM,_9KU[2[-O^)AXBN+70[>//,AGF5& _
MX!O_ "KW'PEX?M_"?A71]$M!MMM-LX;.(?[,:!1^@KYZ_:8V>-/VA/@#X$(\
MR/\ MBX\27*=1LLX24W>Q9S^(KZ;H \,^+G_ "<5\&_]_4/_ $2*]SKPSXN?
M\G%?!O\ W]0_]$BO<ZPI_%/U_1'?B?X='_#_ .W,****W. **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HGM89%*O$C!A@@J#FI:
M*32>X[M;'"Z!\'?#_AWQ1<ZW;P;I9#F&%\%(">I4>_Z5VZPHARJ*I]0*=2US
MT</1PZ<:44EN;5J]6N^:K)M[:A7AWB[X*^.6^,NK^/?!?C/3-"?5-+MM-N+/
M4=)-V,0N[!E82KC._P!.U>XT5TF!X1XV^"GQ"^)'PYET/Q%XXTF76H=6L]4L
M-1M-&,<4)MY1(%>+S3OR5'.14L/P+\8^,O$^@ZC\2O'-OXBTO0[Q-1L]%TG2
MQ90/=(#Y<LQ+NS[,DA<@9YKW*B@#YZTWX$_$[P?K_C2?PE\1M)TK2O$FM7.L
M&&ZT(W$UL\Q&0KF4 XP,97\*[GX;_L^^$OA]X'T3P[+I]MX@?3 [#4-4MHY)
MGE>0R2/R/ERY)P, 5Z910!XYKW[.=EKG[06C?$IM3>*ULX,W&B>7F.YO$4I;
MW);/#1H6 &.]8]S^S[XOT>\\2:7X/\=KX;\'^(M0;4KN%+-FU&RDDP9A:3AP
M$#D9RRL5).*][HH ^>_$7[-7B*9O%FA>'?&46C^!?%UQ]IU>QGLC->QLZ*EP
M+>;> HE5!G>K$$DCK7H7Q6^$L'Q"^$\W@BQNET:V/V1891%Y@B2":.0+MR.H
MCV]>]>A44 >6?$CX3ZWK7B[0?&?@[7+70_%6EVDNFLVHVAN;2[M9"K%)$5E8
M%64,K!AU.<YK7^$/PO\ ^%8>$[G3Y]1;6-8U*\GU+5-4>,1FYNIF+2.%'W5Z
M +DX %=Y10!P_P %/ANWPC^&>C^%&OQJ;:>)0;H1^6'WRN_W<G&-V.O:N*\;
M? _Q3+XQ\3:WX%\6VGAN/Q7:Q6NM07VGFY(:-2BSVY#KLDV,5^;<O0XXKVVB
M@#SWPW\+[OP7IOA;PYH6L?8_!VDZ7)I]S8- #<73E0$F$V<HP.YC@<ENU>?V
M?[._C'5%\-^'_%GCR/Q!X*\/:A%J%M$;(KJ5XT+[X%NIRY5@AVDE5!;:,U]!
M44 <)\7OAFWQ1TG0;-;\:?\ V9K=GK!<Q;_,$#[O+ZC&[IGM69)\&WD\<_$/
MQ#_:@ \6:3!I@M_)_P"/;RXG3?G/S9WYQQTKTZB@#XQU[03^SKXITJVT_P 2
M:KX<U'_A&+;2[S5E\-S:E9:NL!98_*$1)BN4!(&[Y2".#7=_LD_!G7/"_A?P
MCK_B:>9+RVT:XMH=-O(=MQ"\]TT[RR$' =EV@@#C)%?21 /49I: /GOP_P#L
MIGPG9^&+O2-=CM?$VB:Q>WQU!;3Y+VSNYWDGLYD#992K !LY!4$>E?/WBC3=
M8U?PJ?A3X5UC7X;4^(X_LWA&\\.2QW%I&+WS9/-OL>4;5?FD4@[B"HR>E?H+
M28&<XYH B\GZ45-10 V0E8V(*@@'!;I^-?F_\)?BX/%OBS2[CQ'\:O&::^^N
M-!-I6A>'8VT:1EN2JI%,(3F)@%RV1C)Z8K[M^)WQ@\)?!^TTFZ\8:HFCV&J7
M?V"*ZG0F%9"C.!(W1 0A&3QD@=Z^/_AOKGAWX8M8Z?I'[6&AP^&;:^:Z&BKI
M]L(Q&TID>%6SE5.2!W&: /O6BN:^'7Q"T7XJ>#]/\3^'9Y+K1[\,UO-)$8RZ
MABN<'G&1Q72T 8.I> O#>LZ_::Y?Z#IM[K-H,07]Q:H\T0_V7(R*=KW@7P[X
MJO;*\UG0M/U6[LFWVTUY;)*\)]5+#BMRB@##\0^!_#OBVXLY];T/3]6FLW\R
MVDO;9)6B;U4L#BML#' X%+10!\O^)O\ E(WX+_[)]??^EBU]05\O^)O^4C?@
MO_LGU]_Z6+7U!0 4444 %%%% !65XD\5:/X/TTZCKNJ6FD6 =8S<WLRQ1[CT
M&YB!DUJUS_CCP!X<^)6AMHWBG1K/7M*:19C9WT8DCWK]UL'N* .5UK]H_P"&
MFBZ/?:@_CG0)$M8'GV)J$19MJDX !Y)QVKSO]A?PW>_\*IU'Q[K*,NO^/]4G
M\07'F+ATA=BMO$?]V,#'LU?$_B#X3^"=2\0?$7P!H_A71X_$7B'XE0:!I,GV
M<%M.L5B66=D[JH56&?5J_5G1-'MO#^C6&EV4?E6=E!';0QC^%$4*H_("@"[1
M110!R_Q.U4Z+X!UNZ'WA;,B_5OE_K5OP/I?]B^#M'L?^>-JBG\JX[X_:]8Z)
MX1LQJ5[!IUA-?0_:;FY;;''"K;G9CV' K/7]K3X*PVZG_A9WAA8E& W]HQXX
M'UKSH>_BYO\ E27WZG=+W<+!?S-O[M/\SS+]N;XN:5<_#OQ1\(-#L=2\3_$+
MQ%I+K;Z/H]L9G@C8C$LQZ1J<'&>M<OIO[37CO6_ L=I\,M,T6WO_  5HBCQ-
MH7C(36FHVTD40PT:+P\;!6PW0G%1>&?C)X-_9[_:P^)TGC_5K:PM?'$%EK6A
M>(YCO@-FL6SR"XR4 ;YAG@YKR[XJ?M0^ /%G[26OZWX?>^O+.7P3=:!;SZ=I
M\DCZ]=2MA$C4#+)'G.\\#GTKT3A.M_8Y^(WC;]I#]J+4_B!XFL-'@M]$\+PZ
M?Y>G.[+;M<MYR$;OXRH(;T&*^^Z_/S_@EVT'A_X<>-_"%S>-HGQ3GN6N9-/U
M2W:.:.W6-4@EVL!O4$MG'2O69M0^-\/Q=M_ 9\?:*;F726U;[9_9/R!1)LV8
MSU[YK*=3DMI<Z\/A_;W]Y*W>_P#D=Q\7/^3BO@W_ +^H?^B17N=?GK\3OVL'
MM?C!X-O!;+K0\&F2"]O-A@^W3.H29D0_< QE<_RK[O\ !?B_3_'GA?3M?TII
M'L+Z(31>:A1@#V(/0UA0JPJ3FHOJ>AF&$K8>C1E46EOU;_)FW11178>(%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !44EQ%"C/)(
MB(HRS,P  ]34AY!%>):W^R'X&UR2_FEN=?CFO"[.R:O-M#-G)"YQCGITJ).2
M^%7-Z,:4G^]DU\K_ *HT/!7[4?@7QY\1-2\'Z;J'^FVIVP7$F%AO"/OB)NY!
M_/M7KBR*W 8$^QKX3^'O[ >JVWQ.O%\1Z@R^$[!]]K=64OEW%YG[H&.8\=S^
M5?3_ (#_ &=_"GPY\21ZWI,NL/>QQO$!>:E+/'M;&?E8XSQ7-1G6DOWD;'J8
M^A@:32PU1O1=.OJ>GU\Y>.?B9\0M0^/VN^"/#/B/PSX:TS2]&L]0\[7+8R/,
M\SR*0N'7@;!^=?1M?'_Q:\#V9_:@\1>(/%'PGUSQ_H%WH%C;6-UIMD;A(YDD
ME,BG##!PRUV'B':_$+XA_$CX<?""/49/$/AK7O$E]K]CI=K?65HPM(8YYDC.
M] Q+,-Q/!JQJGQ#^*/P8UKPY-X^F\/>)/">LZG#I,U]H]O+;7-A/,=L+LC,5
M>,MA3W&17$>/M(_M;X$Q6?@7X4>(_#L6E>*=,U-]#DL/*GN%2X1Y9(D+'=A4
M]>U;_CS4_%7[2%]X7\,6G@#7_"F@6>M6FL:KJ_B*%;<>5;OYBPQ)N+.[N%&>
M@ - &7#\9/B?X@UKXD7>G>+? ^B:9X7UR]TZWTW6H6$LT<&""[AQ@,#C(%>_
M_!_QS<_$SX8>&?%-YIKZ/=:M91W,MC)G,3$<CGG'<9[$5\C1_#K0['QA\55\
M;? /Q!XWNM6\3WUY9:A;:=YD5Q:N1Y8$F\8'!Y]Z]5^%?P'^($WPN\#6^O?$
M/Q'X2U32[=DFTO3)HI%,1F+Q13.RDLR1[8R0>@H ]?\ ^%R>#_\ A"]6\5G6
M8ET+2KB6TO;EE8>3-&X1XRN,[@Q QCN*P_$'[2_P[\+^()=&U+7A!=6[QQ7<
MGD2-#9R2 %$GD"[8V.1P3QGG%>2>*O@SXGN/VA(]!M-,DD^&&OZI;^+=4O.L
M45W;* ;<KG_EO($<]OEI_A^;Q5\([#XA>$7^&^H>,]8UKQ!<ZEIEW]F$FF:A
M'<,I4W,QR(O+P0P8$X48H U/$7QR^(.H6OC_ ,8>%+71)/!W@J]FLY+&\#FZ
MU3R$5[ETD!Q'@,0G!R5.:U_CU^TAJW@/P/I.L>#_  S=:VFHPV=X^JSKLL;*
MVGE1%9VSEI#OX0>N3Q7 WFE>,?A_X-^*OPWMO!.K:QJ/BK4+NYT;4M-@W:=L
MO(T5_-E/^J$3;\AN2 N.M>C_ !R^&NJ?\,NIX,T.TFUG4+&'2K6.*W7+RB"X
MM]S >RHS?04 :GQ(^(GBN;XD>'_A]X*.G6>KWVF2ZS>ZIJD;2QVUNCK&BK&I
M&YG<D<G "FJ'A?X_:U>_#35[Z[\*7&L^-M&UB;P]=:-H(+I+>1L0'5F/R0L,
M,6;[H/>J_P 1K35_ /QT\-_$.'P]JGB+1)- ET&_BT6W-Q=6KB4312>4.60D
MNIQTXK5_9R\(:OHOAWQ;KNN:=-H^I>+-=O-;&ESD&6UBD($4;XZ/L4$CL3B@
M#9_9S^(NJ_%CX,^'/%>MVT%GJNHQR/<6]MDQQLLKIM!/7&W&>]<G^T=\?-?^
M%+:79^'O"]SJ+3WUG#>ZQ=)ML;.*:81@ YR\ASPH''4UN?LI^&=5\'? ;PQI
M&MV$VF:G;BX\VUN!ATS/(PR/<$'\:K_M5>%=7\8?#&TL-$T^;4[Q=<TVX:&W
M&6$<=TC.WT"@D_2@#UC5-0ATC3;N^N#M@M87FD/HJ@D_H*^</#?QZ\?KI'@?
MQ]K]IHT?@7QAJ$%G'IMNL@O-.CN&*VLK2$[7+'9O&!C?QTKVSQE>3:G=CPF-
M'OY[76M/NDDU:% ;:T(3:%D.<AFW<8'8U\VZ)H?B_P 5?#SX7_"2]\&ZSIE]
MX9U.P;6-9N(-NG"WL'#*\,V<2F7RX\ <C<<]* /IKQ_\1O#GPNT)=9\4:I%I
M&F-.EL+B8$KYCYVKP"<G!KSV3]K[X6PVMY*^O3":R;%U9_8)_M%NF WFO'LW
M+'M(.XC&*F_:<\(ZGXR\,^$+73-,DU5K;Q9I=Y<11H&V01S;GD8'^%1R:P)_
M >L-\8OC=JPT:4VNL>&K2SL;ORQBZD6"56C4]R"P&/>@#NO%'[0G@/PB^E)>
MZVLTFIVHO[=;*&2X/V4_\MV" [8^?O&L?Q/\<+37?!OA'5/ &HVVJ_\ "3ZS
M;Z=9700LAB,A\^4*<9"HK&O$O@]IWB7X(^(;34+_ ,'ZEXC.J>#M+T^6RTY4
MDNM,N+=74PSQELI%)G=O^Z"#FI_V0=$U'Q9IWPUU&YT:73]%T&QU6_BD4 P?
M;+FZDC\I6'#;(MW(X]* /6?A#^T):>)?"VC2^)[JWM=?UK6=0TW3["U1F>=8
M+F2,,%&2 %0%F/ K1U;]JKX8Z)JMW8WGB18?LUU]A>Z^SRFV-SNVF!90NTN"
M>0#7S]\$_@OXQ^#>O:?XW71]5U%M=U74M*US2[@"2;3;6:[D:VN[5?X(UR&=
M1]Y7SVKG_'&I:SX+_997X=7O@R[O);+7(8O^$CB,<FFW"-J8=+B.4'YI&+!2
M@&X-NSTH ^^=Z^M%5]K>_P"5% $6L:'IGB"U$&JZ?::E;JV\17D"RH&'?# C
M/O7@7A_XV? +Q/=:W%I^DZ;)#I-S;6L]XWA\+ [3S&&)HW,>'0R*5W#C/>OH
MIT61&1AE6&"/45^8_@N\^&FK:I;WMO\ %7Q&_AB#4M/TR+P!>:7!!>O!'>E[
M55F+CS8$F?<60$X&#0!^F5AI]KI=G%:65M#9VL0VQP6\81$'H%' JQ110 45
MXS\4_P!K+P)\(_%,F@:LVJ7M]:P1W>HMI6GR74>FP.VU9;AE&$4G\:A^)?[7
MWP[^%NN6FEZG=7]]++91ZG<3:7927,5E9R$!)YV4?(A)&#0![917B_Q2_:X^
M'WPFU6QL-3N;_49;BQ7596TBR>Z2ULF("W,Q0?+&2>M>NZ3JMIKFEVFHZ?<1
MW=C=Q+/!<1'*2(P!5@?0@B@#YJ\3?\I&_!?_ &3Z^_\ 2Q:^H*^7_$W_ "D;
M\%_]D^OO_2Q:^H* "BBB@ HHHH *^8?VR/$7C2'QI\%O"?@_QE?>"&\5:[<6
M%YJ%C!',_EK;EU^60$'!'MUK'_:\C\1?$;XK>#/AEX?\0ZIX;N[K3KC6(IM'
MNWMI9RC['1V! V@8.#W-?,^I?"3QS\'IO"/Q2U7QKK'C>;0?$"VNF6&N7;R0
M3WDK&%(N78Q\DYD [5Q3Q=.G55%IW?D=D,+.=-U4U9>9U_QI_8U\2?L\Z/XC
M^-NF?&76]1\8:<S7C33:9 AG>5E20DY(!93C(6OT)\)W<U_X5T:YG<RSS64,
MDCGJS%%)/YFODOXSZ7^TM\:?AOK/@R]^'?A33+35%6*2\AU[>\:APQ(4KSTK
MZW\,V,NE^&]*LIP!-;6D,,FTY&Y4 /ZBNTXRIJ7CSP[HUX]I?:S9VMU'C=#+
M*%89&>15>;QM;ZII=U/X8>V\07D&W-O#.HZGN>W&?RKS+]H7Q-H5E:OI,=C;
MSZY<%'DG$:[XD!!&6QG)QC'I6IX;^,W@O3?#JW4-LFGWK1_O;2WML,S =,J,
M'V)]:^<EF:^LSP\YQ2BO._\ E<]Y9=+ZM#$0IR?,_E_G9G+^(_$6H_$7QQI^
MB:GX5M[A=-WR7>FW$R/%(C* 2V1M( .<5\S:UXV_9]\"_M2_$C4;^S\(ZAX<
ML/"=NEIIEO;PRQ3WZ2-O@A0*5,Q^4$#GGFND^.GCW6->\&?$"ZTMO[,O-:M!
M#)<PRE'MK4.IFVM_>,885ZG\0/A=\!;/]DB]F73/#EKX5AT,SV6K6ZQ"82B/
M,<B3CYS(7QSG)/%3DE=8B%6KS\S<OPZ&F<X>6&G3I\G*N5??U_$T/V6_@9+>
MZ1JOQ'^).C6=WXR\8B.4Z;=0))#I&GJ/]&LHT8$*%7!..YKD_%6KZ!\ /VVD
M\3^-(K?0_!FM>%XM*T'5GB"66GW4<I::)B!MA+J0<\9Z5[?^RIJ'B'5OV<?A
MU>>*O._X2";1H&NS.,2%MO!;W*[37HNO>'=*\5:;)IVM:99ZO82??M;Z!9HF
M],JP(KZ4^=/D_5?'/ASX\?ME?#*[^&]S#KH\)VM]-K_B+3OGMH[>6+;';&4<
M.S-_""=N<UZ5??\ )Z6G?]B?)_Z4BO8/#/A#0O!>GFQ\/Z-8:)9D[C;Z?;)
MA/J0@ )]Z^?OBAXM@\"?M-7?B"X*B/3_  )<3@,<!F$_RK^)P/QK"L[)-]T=
M^#BYSE&.[BSGX?@EX;^/G[2OB[7[RV1/#_AV>&SD@MT"KJ%VJYD\P_[)P#CK
M7UG;6\5G;QP01K##&H1(T&%50,  =A7EW[,OA.X\+_"/2I;\$ZMJQ?5;UV&&
M,DS%\-[@$#\*]5I48*,>:VKU+QU>=2:I\UXPT7R_S%HHHKH/-"BBB@ HHHH
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M\#;CBO.?CU^QIX=^!'P\O/BWX5U_6)O'7A-X];DOM=O#=1:G*A ;SD?@$AB
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M/[0/@&QM_P!E32M:UG2H)?%VGZ9HEB;ZX3=-!BZMMZJ3]TEB<XY->^Z]\&_
MWBCQ5:^)=7\*:3J.OVNWRM0N+57E7:<KR1S@],].U=%KWA_3/%&ERZ;J]A;Z
ME82LK/;748>-BK!E)!XX901[@4 >)ZI-%IO[8WA:>^D6"&\\%3VUB\I"AYDN
ME>5%)_BV%#CT%9'P#\'Z)\0]'^)EQJNGVNN>&KCQW?ZCIBSJ)+>1HVV^:HZ,
M-X8CMGFO;_&_PW\+?$G2X=.\4:#8Z[90OYD4-["'$;8QE>X./2M70]!TWPUH
M]KI.DV-OIVF6L8B@M+6,1Q1H.BJHX H \@_8N 7]FOP> ,*%N0 .@_TF6J_Q
MHN=+\?:#\0/#'AKQI;^"O$.FVHEUZ8V:!Y('A;8)&< F,KD;U.1R 0:]FT'P
M_IGA?2H-,TBPM]-T^#/E6MK&(XTR23A1P,DD_C7-^-/@QX%^(FJ6NI>)O"FE
M:W?VPVQ7%Y;*[A0<A<GJ,]CQ0!P_PE\5)XL_9A\-K:6<'A[4[_PT\=CI"R_,
M!'$8U,8;YF7 5@?1AFO'(]2L-3_93_9^TK2IHSK$FLZ'!!;1L/-6:"4&Z&WJ
M"H27=Z<YZU]<OX3T635].U5M+M#J.FPO;V=UY*^9;QN &1#_  J0!D#T%8>D
M?!OP-H'B^X\4Z=X4TJR\17!9I-2AME68EOO'..">Y'7O0!YW^V"UW)X!\+6=
MIJ=[I)O_ !9I=E-<:?.T,OE22E74,#D9!(KR2Z^#^D'XC?&CPQ_:FOCPYH>A
MVVJZ;IHUJZVVMY);R,\ZMYFXME%."2 <G'-?8&M>'=,\1PV\6J6%OJ$5O<1W
M4*7,8<1S(<I(,]&4\@]JB/A/16U#4[\Z7:&]U2%;>^N/*&^YB4%51S_$ "1@
M^M 'Q[\,[Z'XR>)M.M?B7X@OH++3_ ^F:EI8&I262S22*WVF\RC+O=&4+DY
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M3:FE[=:_;:)Y6N7<,<PE2W>0-L'W54N%R57U- 'TUS14^Q?2B@ ;(4E1N;'
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M4444 %%%% !1110 4444 %%%% !1110 4444 %%%)0 M%)2T %%%% !1110
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MK:PJ6DFE8*JCU)-*]M6-)R=D</\ '3Q?I/A'X;ZN=5NA;?;8'M8%VEB\C*<
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MAZ[YGBMNB.GB#,<OA[..4VO;65M5Z=F^HEG9P:?;1V]M#';P1J%2.-0JJ!V
M%2T;AZBC</6OH#\\;;=V+12;AZBC</44"%HI-P]11N!Z'- "T444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 ?#W[1'A?QAX(^,OQ4U72O!>L^+=/^(O
M@O\ L&QGT>$2BVO=ABV3<_*NT[MW3BO5-%_8]\/>*_@K\,?#'CIM3.I>%=&A
MLF.DZI-:KYGEJ),^6PW#*\9KZ-HH _/'6_V//AY9_MJ>&?!$9U_^Q+SP==:G
M*6UNX,_G)<J@Q+NW!=I/R@X)YKW;_AWI\)?7Q3_X4EW_ /%U[5=>%O!LWQ-L
MO$EQ;Z>?'%O8/I]M<M,!=+:LV]D";ONEAGI774 ?,_\ P[T^$OKXI_\ "DN_
M_BZ\4T[]D7P)<_MC:O\ #Y[GQ*?#-MX+AUF.W_X2"ZWBZ:\,1;=OSC9QBOT#
MKD8?#G@R+XG7'B.*+3AXYFTY=-EN%F'VIK17\P1E-WW0WS=* /%?^'>GPE]?
M%/\ X4EW_P#%T?\ #O3X2^OBG_PI+O\ ^+KZ8IDTR6\3RRNL<: LSL<!0.22
M>PH ^ ?"7[(?@/5OVL/'W@6YN?$K>'=(T'3[^T@'B"Z#+-*S!R6WY(.!Q7M/
M_#O7X2_WO%/_ (4EW_\ %U[=9^%_".E^)-2\>V]O8P:KJ=G%;W>MB48FMX\F
M,%L[=HR<'WKH[&^MM2M4N;.XBNK>092:!PZ-]".#0!\W?\.]?A+Z^*?_  I+
MO_XNO$/AC^R3X%\4?M)_%CP??W7B:30_#\-@]A"OB"Z5D,L9+Y8/DY/KTK[\
MU+5K'1K?S]0O;>Q@SM\RYE6-<^F20*Q-"\"^%]'\2ZQXMTK3K6'6-<2/[?J4
M+$FZ6,83)SC 'I0!X;_P[U^$H[^*?_"DO/\ XNC_ (=Z_";U\4_^%)=__%U]
M(6-_;:G:I<V=Q#=V[_=F@<.C8..".#4>I:Q8:-&DFH7UM8QNVU7N95C!/H"Q
M'- 'P%\%?V,OAMXK^-/QBT"^CUW[!X;U"VMM.$.M7$;QQO"&<%@V6RWK7T7-
M^Q#\,;C2SI[0:P("@CRNIR!\#_:'.?>O4K#PSX/\!:IK?B2"#3]&O->ECFU'
M4))@@NG5=J%BQQG;P,5U$$\=S"DL,BRQ.-RR(P96![@CK6,J-.5N:*T.RGC,
M32O[.HU??5GSWH_["/PMT.X>:!/$$KNNP_:M;N)^,YXWL<?A7CW[/_[-O@WQ
MU\6?C(-7_M6=/#?B :7IT8U"0)'!Y"M@J."<D_-C-?<EU=0V-O)<7,T=O!&I
M9Y96"JH'4DG@"N7T7P[X-^'UQK&MV$6GZ,_B*Z6]OKTS!%O)RH"N69L$E0,8
MI2H4I-N45=EPQ^*IQ4(59)+5*[T/)M:_82^%NO7*3SQZ] ZIL'V/6IX 1[A&
M&?QJ9/V)?AW'"MNIU86JIY8C-ZQ;;C'WNN?>O?E99%#*0RL,A@<@BHKR]M]/
MM9+F[GCM;>,9>:9PB*/4D\"IEAJ,DHR@K(UIYICJ4Y5(5I)RW=]SX7_9I_9Q
M\/\ Q#A\?6]W?:A!:^&_%E]HEE&LN]OLT3#8&<\L<-C/M7J<O_!/[X<::E]<
M^'I-5TO5KK[UU<7TEPG7)RC''Y5[;H'A_P %_"^'4)=,33= BUR_DU*Y<SA%
MN[J3!>3+-RS8'2NN5@R@@Y!Y!%1]3P]I+D6NYM_;68.5.3K2]S;78^:_#O[$
M/AVT67^V=7O=18D;/((A"CN#CK7C7[+7[+_@SXY>#_%'B#Q1-KK:C:^*=4TJ
M/^S]8N+2,06\WEQ#9&P&=HY/4FONO4->TS29%2^U&TLG8;E6XG6,D>H!-<_X
M5\.>"_A-H\EKHL>G>'M-U&]EORHG")/<3-ND<%FY+'GBBC@Z%!WIP28L9G./
MQZY<35<EVZ?<>1:;^P3\+-+O$NHAXBED4$ 7.NW,R\C'W78BG:Y^PA\+-:D%
MQ<)K\;QIM'V76IX!CKSL(S^-?1*L&4$'(/((JG?:SIVG30P7E]:VLMP=L4<\
MRHTA]%!//X5O[*'-S\NO<X/K5?V7L.=\G:^GW'P1^QW^R-X%^,7P-L/$OB:Z
M\2W6K2W]];O)%X@NHU*17,D:# ?'"J*]CG_X)P_!BZF\V>SU^>7C]Y+KMRS<
M=.2V:]Y\)>#_  I\'_"BZ5H=E9^&] @EDF$(?9$CR.6<Y8]69B>O4UTZL& (
M.0>016C2>YSQE*.L78^6->_X)_?"?3=!U*[@_P"$G2:"VDD0CQ%=\%4)'\?M
M7FG[*'['7P_^*WP#\*>*?$-QXFN-9OXI&N)8_$-TBL5E=1A0_' %?;6H^(=
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^6OC2UCN-'\?\
MQ2D\P?$C3OBU:Z=::CYK>?!;B5$%JO/$94D;?>OU'A9GA1G7:Y4$KZ''2O']
M4_9)^&NL?$QO'-SH\[:M)>)J4ULMW(+*:\086X> '8T@_O$5['0 F<<GI7Y7
MZ;9K#\4+/Q[_ &:1X57XKRQM\0Q<?\3>0[MGV)H-W_'OO^3=D_+_  U^J->)
M1_L<_#"'QZOBM=(NA<+J)U==-^W2_P!GB])R;C[/NV;\\YQ^% 'MM>%_MD>!
M=4\<?!'Q&EIXIO\ PYIMAIEY>7UOIZJ'U!4A9DA:0\HFX?-CJ.*]TK,\3>';
M'Q=X=U/0]3C:;3M2MI+2YC5BI:-U*L 1TX)H _/+XAW6J:E^S7^R#X3L[*'4
M],\0?8X;S2KJX:WM;PI:HT4<SKSY>XDD<YVXKZ,_8CU#2;7P_P"/?"=EX?7P
MOJ7ACQ'/8ZGIMG>/<V*3LJOFU9P"L9# [<<'->B>(/V;? ?B;X5Z'\/K[2Y&
M\/Z&D*:88[ATN+,Q#$;QR@[@P ZYK<^%7PA\,_!GP[)HWABSD@@GG:ZN;BYF
M:>XNIF^])+(Q+,Q]Z /'?VR]#^&%M8Z%XK^(\-]XCEL/.L]%\'PSEH=6O)EP
MH\@<O(.S9 4$DUX'K7C#6?V=OV;_  3\(?$7B!_"FO\ BX7ES=:@S/,N@::2
M6:WC<9W2898U&>"Q/:OKGXS?LO\ @3X]:UHVK>+;6^N+[1T9+*2TOI+?R=Q!
M+#81\W YZUO>!_@KX5^'_A'_ (1O3[.6\TT-(X.J3-=RCS,;@)),MCCIF@#Q
M;_@FQXBTK5_V4?#%AIUTL\VE27%M=1@',3F9W /J=K*?QK7_ &M?@_H?Q2L9
M9(]*L?%_CJQTFX72/#>JZJ+:V"R'#W7E]W3LW3MQUKV'X7_"_P ._!WP;9>%
M_"]E]AT>T+F.-G+MEF+$ECR>2>M<Y\7OV<O!7QLOM.O_ !#;7D.J6$;P0:CI
M=[):7 A?[\1="-R-W4T ?)-C)\)-6_91^$WC#QW<:YXY;1[2;2=)\+W4I_XF
MNH;FB:,P#)D9&&U7W8"@&OI;]C3X;^(_A3^S]H&@^*96_M4//<_8S+YOV".6
M1GCM0V3GRU(7\*@\6?L4_"GQAIWA6PNM&NK.R\,6[6^E0Z??RP"W#$EF!4Y+
MDGEB<GUKTKX9?#/1OA+X5C\/:";PZ?'+),/MUT]S)N<Y;YW).,]NU 'Q?_P4
M@^.%IJEGX@^$*:VWAV&#0WU?4YRC;]0<C_1K&,@8PY!9SV  K+A_X1;]H+Q[
M\%_#VL&/7?!=I\-Y[F*SD9D@:]CA2-WQD9>/;P>U?=/CSX;^'?B5X;U;0]?T
MV&\L=4MFM+D[0LK1L,$!QR/PKB/'G[*OP\^(>@^&]*U'3;FU3P];?8M.NM-N
MY+6XB@*!'B,B$$JP W ]: .;_8(US4?$'[)_@.ZU.XEN[A8)H$N)F+/)''/(
MB$D]<* /PKYL_P""DOQRM?$R^(_A9'K9T.RT2QBU"_C*,'U:Z=E,-HAQC8JG
MS&/0D*.U??O@_P (Z1X!\+Z;X>T&RCT[1]-A6WM;6+.V-!VYZ^N3U)K)^(WP
MI\,?%;POJF@>(]+AO+#4HQ%<%0$E9001AQ\PZ#O0!\ ?&VXL_C9XL\(_\(=H
M]G\2FM?AM-)-I>K7!MK/3P,*+N%C]Z8,"-N.@'(K[1_9+U2SU?\ 9M^'L]CJ
M=YK$"Z3#";S4%VSR,@VMO&3R"".IZ5#\0OV3OAW\2'TF:_T^\T^[TVQ_LR*Z
MTB]DLY7M.\$C(1O0]P:]*\(^$=(\!^&=-\/:#8QZ;H^G0K;VMK%G;&BC '/)
M^IH ^(_VOO@]K'C#XQ^*O'EWH/@_QKX8\+^&HC_8FN:C)'. &:2;:D1RC,.C
M/Q7FWCJ^D^.WQ;DCL/!6FZ]X3TGX96>K:9X?UW49+6+3X7!\QH2H):;"!%<]
M, U]N?$[]D_X=_%SQ5+XAUW3[U-2N;=+2^;3[^6V34(%.5BN%1@)%'H:7XD?
MLG_#CXHR:3+JFDW%C-IEE_9D,FDW<EFS6> /LSE"-\>!]TT ;7[.OBG2_&OP
M-\$:UHD-U;Z5=:7";>&^E,LT:J-NUG/+$%2-W?&:^$?C?'?>-/CW^T#J^O>$
M['QCH_@B#3F5=0U22SN=.M/+$A^Q;00)&(+ECZ8[U^D?AWP_IWA/0=/T72+2
M.PTNP@2WMK:$86.-1A0/P%>7_$S]D[X<?%KQ8?$6OZ7='49HH[>]^QWLMO'?
MQ(<I'<(A D4'U]* /A?]N+]H[2/BYX3E\*:9KMQH^@:#IVGZBMG=*WVC6KN4
MQLL;'&-D,19F)ZN?:OTI\ >(M.\6^"=#UC2+E;S3;RSBE@N%! =2HP>:Q?B#
M\$_!GQ.\%W/A77-$MY-'N%C1H[=1$X6-E9 '49 !4?A79V-G#IUG!:VT:PV\
M*"..-1@*H& !0!\2?M&?LY_#?XC?M+>#_!NG>$K6W\0:_/)XG\3ZY&\GG&TA
M8#8/FVJTKX!XZ XK+_:X^$O@75/&U[X6\+Z?>^*OC3XL2U73S-=EH_"]I"0!
M<(1@01@*2 <EC7V5#\,/#]O\2[GQZMJY\2W&GKICW#2$J(%;<%"] <]Z\P\9
M?L2_##QUXZUCQAJ5MK":_JS W5U::O/ 6   4!6&%&.G2@#VKPWI]QI/A[2[
M&[NVO[JVM8H9;INLSJ@#.?<D$_C7Y@?$2UCN?B9XZ\>QZ=]I\*:5\1K2"]^(
M/VC&K::T;1QR6L$&?FA#L%SZ'H:_472=-AT72[/3[??]GM(4@C\QR[;54*,L
M>2<#J:\=UK]CGX8>(/'<_BJ[TBZ-Q<WJ:E=:;'>RK87-TOW9I+<'8SY&>G/>
M@#XR^-.FVNMZ7^TE\2;W>_CWPGXJTZV\/WYE836<*21+&D0SP&5F) '-?I;H
ML\MUH]C-.-LTD$;N/1BH)_6O*?%W[)?PV\<?$+_A,M5TB>35))8+BZMXKN2.
MTO)8?]4\T(.UV7 QD?7->Q !0 !@#H* /RN^S1P?$1/B =-SX2/Q36W'Q&^T
M'^V"Y?RA9^1N_P!1O^3=Z?PTGQ.L5N?BEX\\<1:;YWAFR^(]E'<>/EN,:KII
M5D1K6WAW?-#N(7.1PQXK[E;]C?X7MX\_X2K^Q[KS_P"T!JW]F?;I?[.^VCD7
M'V;.S?GG.,9[4NN?L<_##Q%XZN/%-YI%TUQ=7R:G=:<E_*MA<W:8VSR6X;8S
MC YQ0![/<;I[.3R9 CNAV2=@2.#7Y;Z?H>M?"GQU\*;B7PEJ5A\0V^(+V>K^
M-A.'MM=MYY'S$KASY@*8RN/DV$=Z_4TC=D'D>E>->%?V1OAKX-^("^+].TFY
M_M&*ZFO;6UN+V66TL[B4DR2PPL=J,V3R!QVQ0!\*^%=3>3Q%XA^*GC3PG;ZW
M#9_$UM.F\01ZK+#K%DXD"111(!M\B,$ ID%LGTK]3D8.JL.A&17C6H?LA?#'
M5/B,_C.?19CJ$EZNIS62WDBV,UXOW;A[<'89!ZXKV:@!:*** "BBB@ HHHH
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M77?#%S)-:PW4ME/#<1^7-!-&Q5T=,_*<C\17;T %%%% !1110 4444 %%%%
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M,<9QZX]* +/[.=])\/?V]OCEX#MVV:/K$,'B&*V486.=@-Q [94BOM:OB_\
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M:]0;1*$"X5SR/FP<U>\1?%W7?&7@?X&6UQ=:YX?^'U^FHQ7EQX@\126C7-U
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M@YV[F)(&>P]*^![YOB;I7[4_PY\9>-/AOJ7_  F>JZ]<M'_IT31-:+&5BMH
M&.Q8T)=BV-Q)-?I%X,^(&@?$*#4YO#^HQZE'IM]+IMVT8(\JXCQOC.1U&1^=
M ' ZE^UI\+])^(Y\$7/B/9K:WBZ>["WD-M'=-]V!IPNQ9"3C:3G->NR1B:-T
M.=K J<'!YK\L/&FL+'\1?%[_ -L+9SK\4K><?"9K?+ZG('11?"7_ %@W??\
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M=:BT(-IY2^25Z;,#;^F*LT %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2444 9-
MOX/T&SO!=P:)IT-T&W">.TC5P?7<!G-6-8\/Z7XAA2'5--M-2A1MZQWD"RJK
M>H# X-%% #-6\-Z1KUG'::EI=EJ%K&04@NK=)$7'3"L"!2WWAS2=3TQ=-O-+
ML[K3E "VDUNCQ#'3"$8X^E%% "W?A[2M0TM=-NM,L[C3E "V<L"-",=,(1CC
MZ5-9:79Z;YAM+2"U,A!?R8E3<0, G YP.*** *4G@_09KTWDFB:<]V6WFX:T
MC,A;UW8SFK&J:#IFN>1_:.G6E_\ 9W\R'[5 LGEM_>7<#@^XHHH \L^-'[-N
MG?&I='TR_P!;O-)\)6MRMW?>'=-ABC@U*17WKYK;=P&>H'6O7X84MX8XHU"1
MQJ%51T  P!110!2M_#^EVFJ3ZE!IMG#J,XVRWD<"K-(/1G R?Q-9O@?P)I'P
M]TF?3M'A:*&XNIKZ9G;<TDTK;G<^Y/IZ"BB@#:GT^UNKB">:VAEF@),4DD89
MHR>"5)Z?A6-X-\"Z3X%AU1-*A9&U.^EU*[D=LM+/)C+'\%4#'91110!?E\-Z
M3-J\>K2:79/JD8VI?-;H9E'H'QN _&J'A;P+I/@^_P!>OM/A9;S7+TW]],[9
M,DFT*/8 *H ^E%% &S<:?:WDUO+<6T,\MNV^&22,,T;8QE2>AQW%9MQX)\.W
M5P\\V@Z9-.[;FDDLXV9CZDE>3110!LJHC4*H"J!@ #  I:** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
=HHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img30600998_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img30600998_6.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "[ FH# 2(  A$! Q$!_\0
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MIEP\<DMLMJH5V081CQU4< ]: / ]>_;,UJ/0/"LFBZ3INH:E?Z;=ZC>R%9Q
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M*P4^+=6#$%@#K+9P!DGKTQS3V\):<HMRWBK6%%P<0YU=OWI_V>>?PKYTU/\
M99O/$_CJ[UW4-+TZ&TN=?TZZ6T_M!CY.G1V@CGM_E8#!<#@?>Q6#+^ROXPV>
M&+:\E^W:;96,UD+>QU98I+!_M\DT<J,YY'EM&/E^8;,=* /I_4M%T/1[.\N[
MSQCJUO;V<+W%Q(^L-^ZC7[S-SP!@UF:G=>$M'\$GQ?=>.=5C\-^2LXU$:L[1
MLK8V[<<DDD  <YKPF/\ 9/UB1KB:7[!]NU!M>COKF2]9S-%< ?8U89P0K '
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MU_PKZ+_H/>(/_!G)1_PKZ+_H/>(/_!G)72_:X/\ GM'_ -]"C[7!_P ]H_\
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MQ^-(?B-J4VEW]GI5M_PCL-FQ5[G=&2S *#YLGF_*(SV['K7U%\)CJG_"L_#
MUJT%CJBZ?"L]N$V;&"@8*_PG&,CL<B@#K**** "BBB@ HHHH **** "BBB@
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M:S=AY(851F_T"X/) YYKUZO+?BK_ ,E,^$7_ &&;K_T@N* /4J*** "BBB@
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MS9?!.TTB/0UTO7=4TW^SK*/3I6@:/==VZ2&14<E?E^8M\R;3AB*]$@F\^%)
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MG?6,&J64]I=1+/;3HT<D;=&4C!!_"LWPYX2T?P;;SQZ9:BU69_,FDDE>1W;
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M42(VIB5F!,*H6#+R2X.<\&@#Z9\1>#]#\7);IK>DVFJK;L7B%U$)-A/7&?7
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MYYZ\UBZ/'K/B#3XK_3/&]I?V<OW)[?3XW1NQY#U=_L'Q1_T-<?\ X*T_^+H
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M^8YK/_@7_P#6H_X04?\ 0=UG_P "_P#ZU 'SOX/\#ZI#KVA0:GX5U19-%O\
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MPKJ& .<$9H ZZO)/C#\=M)^&OBOPGH!@M;_5]4O8D=9IE3[' [%/..><DC:
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M1OEW$<!B""1VKT2L'P?X&T/P#I]Q8Z!I\6FVMQ<274D4(P#(YRQK>H ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MDCN&NKAB5W$QF-.0P"XY'->WS^"=%NO%UEX@ELA)JUC T5K,TC[85;AMJ9V
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? **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>img30600998_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img30600998_7.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #= :\# 2(  A$! Q$!_\0
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MOO=&[5O:I^U=\.=+T^^N3JMQ=O;:S-H"VMG:233W-[$ 98X8U&9-H/)' ]:
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ME\<O!VI:QX+TNSU3[5>>+[)]1TE(8V82VZH',C'^ 88=>_% '?4444 %%%%
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M[#6? 'C+1[:PU"\DO526S,43(4\D\R!LXXZ!J\G_ &!/AIJ%M\2O'NJ:C?\
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M\Z +%%%>>^*/CYX'\&^-K3PIJVL-;ZS<-"A5;:5XH&E)$*RRJI2,N0=H8C-
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M)0G)'S,?2N\K^>3_ (7M\2_^BA^*O_!U<?\ Q='_  O;XE_]%#\5?^#JX_\
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M0 4444 %%<S\1OB3X<^$_A2Y\2^*]232=$MF1);J1&<*68*HPH)Y)':O'?\
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MIF@RWRW4=J+^ 7UHT O+0OL%Q"3]^/=@9XZCCFL'X'?\E>^.O_8PVG_INMJ
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M7_(F_#;_ +"=S_Z)K]$Z_.S_ (+%?\B;\-O^PG<_^B:!K<_+^BBB@T"BBB@
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MZ]M[7Q#;!9]2NGN;AMUA;L=TCDLW)XR>!@5]!5XK\#_^2N_'7_L8;3_TW6U
M&G^U=_R;;\2/^P)<_P#H!K\ (?\ 5)_NBOW_ /VKO^3;?B1_V!+G_P! -?@!
M#_JD_P!T4%Q'T444%!1110 5]4_\$S/^3M-!_P"O&[_] KY6KZI_X)F?\G::
M#_UXW?\ Z!0)['[54444&9\L_P#!2_\ Y-%\4?\ 7S9_^CUK\4J_:W_@I?\
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M\.Q_@-_T+U]_X'O05S'XLT5^S]U_P3-^ [13Q6^A7GVH1DHAU%L@X."1Z9K
M^&O_  3'^%*^"=,3Q?HDTWB5$87S6NH,8]V]L8Q_L[: YC\?Z*_:1?\ @F;\
M I&=5T*\9E.& U%R0??TIW_#L?X#?]"_??\ @>] <Q\U?\$<\_\ "7?$X]OL
M-C_Z,FK]0J^;_"O[ ?PI\#R7$OAU-?T*2X 69M/UB6$R 9P&*]<9/YUT/_#(
M_A/_ *&#QE_X45Q_C02SV^OSM_X+% _\(;\-CCC^T[D9_P"V-?4?_#(_A/\
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M\'QPQ(,M))>R*H^I+5;T;]@_X&>&W34](T6;29'78MY8ZO/ S*>P='&0?3-
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>img30600998_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img30600998_8.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#X17AI9@  34T *@    @ ! $[  (
M   /   (2H=I  0    !   (6IR=  $    >   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $YI8V]L92!3
M96ET=&5R    !9 #  (    4   0J) $  (    4   0O)*1  (    #-#8
M )*2  (    #-#8  .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                         #(P,C,Z,#,Z,30@,3(Z-#@Z-34 ,C R,SHP
M,SHQ-" Q,CHT.#HU-0   $X :0!C &\ ; !E "  4P!E &D = !T &4 <@
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" *W!1@# 2(  A$! Q$!_\0 'P
M 04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0
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MO/%FAP7$+F.6*74H5>-@<%6!;(((P0:?9^.?">H7 @L/%&BW4S=(X-0B=C^
M;- &[1163)XL\.Q:R-(EU_2TU,N(Q9->1B;<>B[,[LG(XQWH UJ*** "BBB@
M HK-M?$FAWVKS:59:SI]QJ,&[S;.*Z1YH]IPVY <C!.#D<5I4 %%17=W;V%G
M+=7UQ%;6T*EY9IG")&HZDL> /<U@?\+'\$?]#EX?_P#!I!_\50!TE%<W_P +
M'\$?]#EX?_\ !I!_\570PS17-O'/;R)+#*H>.2-@RNI&001U!'>@!]%%% !1
M110 445E+XJ\/MK7]CKKNF'5-Q3["+R/S]P&2/+SNSCG&* -6BLK5O%7A[0;
MA(-=UW3--FD7>D=Y>1PLRYQD!B,C(ZUJT %%%% !1110 44R:>*V@>>XD2**
M-2SR2,%50.I)/04^@ HHHH ***H:MKNDZ#;I/KFJ66FPR-L22\N$A5FQG +$
M G /% %^BH+.]M=1LXKO3[F&ZMIEW1S02!T<>H8<$4^YN8+.UENKR:."WA0R
M2RRN%2-0,EF)X  &230!)17-_P#"Q_!'_0Y>'_\ P:0?_%4?\+'\$?\ 0Y>'
M_P#P:0?_ !5 '2455TW5+#6+%+W2+ZVO[5R0L]K,LJ,0<'#*2#@\5:H ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'Q%A\#?$H-+)-*+99)U4302L/D!9>'5L@9Y/S @XXK#_ &K_ /D?-%_[!O\
M[5>@#Z5U_P 26?AWPG=^(;V.>2TM8//=(5!D*\< $@9Y]:Q_A[\2M'^)6G7E
MYH5M?6\=I*(I!>1HI)(SQM9N*H?%+_DA&N?]@L?R%>?_ +)W_(I:_P#]?R?^
MBZ /-?V??&&B>"/$.N:KXCO!;6XT\(@ W/*YD7"JHY)X/\S7O/A3]H+P1XMU
MN+2H);W3KF=]D']H0JBRMV 968 GMG&3QUKP/]G?P;I'B_XA7 U^V2\M=/LS
M<+;2#*2/O51N'<#)..YQ73?M+^ ]#\,G1=:\.6%OIAN7D@GAM4$:,0 RL%'
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M\;9K_4ED31[<B29<\06RGY(0?[S'K]7;M7U[##%;6\<%O&L442A$1!A54#
M'8 5X+^RQX@T:3PQJ&@00K;ZQ#,;F9B<FYC. &'^[PI'3D'N:]@\6>-?#_@?
M3X;[Q1?_ &&WGE\F-_)DDW/@G&$4GH#0!MNVR-FVLVT$[5ZGV%?*WA_X5>*_
MBI\2M2U#XFP:OI-ML,NXQ[2<MA88F8%0%&>QX'3G->Z^'OC%X$\5:];Z-H.N
M_:]0N=WE0_8YTW;5+GYF0 ?*I/)[5+\2/B3I'PW\/F^U$^=>3 K9V2G#3N/Y
M*,C+=O<X% 'S=J>C7'P3^/FEV7AK4KB>WF:W8K*<&2*1]K1R;<!NAYP.QQD5
MWG[4GB^^M8=)\):9,\8OD:XNUC)!E7=MC3Z$AR1WP*I_"KP#X@^(7CU?B9X]
M0QV_FK<6<#+M\]E_U953RL:X!&>N!U&2<7]I<?\ %ZM!/;^S;?\ ]*)J &_$
M?X"P?#[X=0>)M+U>\EU*Q>$WF[:$!9@H:/: 5PY7J3]17MGPR\>R:]\%[?Q+
MJY>>YL;:47A0#=(T.<GL,LH![#)J#]H/_DA/B'_MV_\ 2F*L/]F6%)O@W-%<
M1K)%+J$ZLCKE74J@((/4=10!X[\4_B1XK^)F@MJ$6ES:9X0M;E8TYXFE.=NY
MOXR #\J\+WYP:]^_9\_Y(3X>_P"WG_TIEK"_::ACM_@Y#%!&D4::C"JHB@*H
MVOP .E;O[/G_ "0GP]_V\_\ I3+0!Z37S+^UM_R%/"__ %QN?_0HZ^FJ^9?V
MMO\ D*>%_P#KC<_^A1T =!I_[+O@^_T*TNAJVN1SW%O'(3YT)4%E!/'E@XY]
M:\]TB[UG]GWXS1Z-=7YN=&N7C,_\,<\#G EVY.UU(/\ WR1G!KZK\/?\BSI?
M_7G%_P"@"OF#]JUHC\1-)5=OFC2EWX'./-DQ_6@#ZEU75K#0]+GU'5[N*SL[
M==TLTK851_GC'>O)Y_VG_ ,6H?9XX]7GBSC[5':J(_KAG#?^.UQ7[4FLWT5E
MX8T$LR6S0M=3)G[\@ 5<_3+?]]5ZEX?^"W@:U\$6NEW?A^RO))+9?/O)8@9W
M<C+,)/O+R> ",4 =AX;\3Z/XNT:/5?#M]'>VCG;O3(*L.JLIY4^QKBO%_P >
M_!/@W5IM,NI[O4+V!MLT6GPA_+;^Z69E7([@$XZ=:\A^ ]Q<^$OCWK7A&&=Y
M;)I+JU<'HS0,VU_KA6'_  *LV./QG\"OB+JNLW'AP:K9SM(/MLL3-&\9?<'$
MJY\MCQD'\1T- 'N'A#X]^"?&.JPZ9:W%W87MPVV&*_A">8W90RLRY/8$\_6N
MX\0^(])\*Z+-JVOWL=E90_>D?)R>R@#EB?0<UX1X>^*OPJ\;^,K?4/%7A2/2
M]<E*1I=W&)H=P/REF& &R?O%/3)X%8_[5^MW#^)M$T(2,+:&S-X4'1G=V0$^
MI C./3<?6@#T*T_:<\ 7.I"UE_M2UB+8^US6H\KZ_*Q;'_ :]:M+NWO[.&[L
MIX[BWG0212QL&5U(R"".HKY(\4^-?@YJ7P_ET30?"6HV6HQ0C[)?FT@63S .
M#)()"S ]\YZ\#.*]/_99UBXOOAS?:?<.733[XK#G^%'4-M_[ZW'_ (%0![=7
MS]X?_P"%??\ #3TOV'_A)O\ A)_MUWN\[[/]B\SRI-^,?/MV[L=\XS7T#7RG
MX4_Y/3G_ .PE?_\ HB:@#V[Q5\8O#G@_QQ8^%]8AOENKP1%;E$C\B(2.5#.S
M." ,$DX.!7/7G[37@"UU4V<9U.ZB#;3>0VH\H>_S,&(^BUY5^T;9C4?CGIMD
MS%!<V=M$6 ^[NE<9_6N_^-WPR\):%\%;N[T30[2RN=+: Q7$48$KAI4C(=^K
MY#Y^;/- 'M.D:O8Z]I%MJFD7*75E=()(9DZ,/Z'MCL:N5Y!^S)/)-\'E21B5
MAOYT0>@^5L?FQ_.O7Z /E+QSX@U[XU_& ^"M!O6MM%MYVA &=A$>?,G<#[W(
M.T'_ &1P2376:I^RCHO]A2#1M=U#^U5C)1KGRS"[>A4*"H/3.XXZ\]*XG]F8
MF#XS7\6H BZ;3ITPQY$@EC+?H&KZWH \5_9\3Q_I5G=Z+XSTJ^ATR) ]C<7A
M :(@X,0!.[:1R.,#!]17H?C3XA^&_ %E'/XDOQ"\V?)MXU+RRXZ[5';W.![U
MN66JZ?J6_P#LZ_M;O82K^1,K[2."#@\5\J&P3XH?M77NG>(V:2RM[ZX@,(8X
M,5L&"H/0,4R<?WF[T >MZ-^TKX!U;4%M)GU#3-[!5FOK=1&23W*,V![G KT;
MQ%XBL_#7A:\U^\62>SLX?/<6P#,Z_P"SD@'KZUY7\:_A5X37X7ZCJ>CZ+8Z7
M?:7$)HI;2%8MZ@@,KA0-V03R><XYZUR/@C7KO6/V2?%-I>NTG]EB6VA9CD^5
MA'"_@68?3 H [W_AI/P$/#ZZF[:@DCR,B6'DH;@A<?-@.553GC+#.#Z5J^'?
MCIX&\1:)?ZDFHR:>FGQB6XAOHPDBH2 " I8-DD#"DG) [C/E?[-'@+PYX@T'
M6-8U_2[74YDN1:Q)=Q"1(U"!B0IXR=W7&1CBN)\(>"=)UC]I6Y\-3VX.D6NJ
MW@-N6.#'"TA5/<?*H/MF@#WG0?VC/ FO:]'I:27]B\SB.*>\@58I&)P!E6)&
M?5@!5+]J#_DD4?\ V$H?_07KR_\ ::\):)X:U_0IM TVVTY;NVD66*UB$:$H
MRX;:.,_-R>^*]"_:%F>X^ >ES2G+R7-J['U)B8F@#'^&_P :O"/P_P#@WX>T
M[5IKF[U "X:2UL8P[Q W,I!8LR@9!!QG."#BO7_ WQ'\.?$.QEN/#MTS20$"
M>VG39+%GH2O.0?4$CWKS/X"?#+PIJ/PIM=8UK1;/4[S5'F+O=PB3RU21HPJ9
M^[]S.1SSUZ5P'@VR'@#]K(Z+I+,+)KN6U\L$G]S)'O5">^TE/^^: .U^)7_"
MOO\ A?6E_P#"0?\ "3?V]YEGY/V'[/\ 9<[QY>[=\_7KCMTKT;XB?%K0OAG/
M81:]::C<-?*[1&RC1@ A .=SK_>'3->'?&+_ ).CT3_KMI__ *,%:/[6W_(4
M\+_]<;G_ -"CH ]"U_\ :/\  >A:L]@LE_J;1MLDFL(5>)2.OS,R[OJN17H/
MA?Q3I'C'08M7\/W8NK20E=V"K(PZJP/((]*\KUCX3>$;#]GV\,.C6AO[?16O
M?[0,0\]IDB\PMO\ O8)'W<XP<8K'_9,GD;P]XCMRQ\J.ZA=5]"R,"?\ QT?E
M0!W'C#X^>"O!NL2Z7=37>H7D!VS1Z?$KB)O[I9F5<CN 3CH>:L>"?C?X.\=Z
MHNF:9/<V=_("8K:^B"-+CDA2K,I.!G&<UYC?7GP-\%^+[V2WTZ[\4:G(S1O9
MB+[;$DF26P9>&;/4Y;';O7G-I>V\O[1FA7FD:!-X9MI]8LC'I\J["BLZ*2%P
M,!ADX''S<4 >@?M*?$V1KYO!6C7%_9RVC_\ $RV[4BN%>-'10P;<0 QR" /K
M78?#;XE>'?%OPLN?#HMM4B_L/PZD6H/Y<8WJL&Q_*.XY/RG&X#MFN4_:OTO3
M[:'0M0M[&VBO;N:87%RD*K),%1 N]@,M@<#/2O1/#V@:/IG[/ZWVFZ38VEW>
M>%5:YN(+9(Y)R;7)+L!ECDD\]Z ,#]G3_A"/^*C_ .$#_P"$@_Y=?M?]M>1_
MTUV;/*_X%G/MCO7;>./B[X2^'\XM=;O9);XJ'%E:1^9*%/0GD!?Q(S7D'[)T
MOV>U\9S;=WEI:-C.,X$YKG/@;X=L_B=\4-9UGQE&NHF%#=O!+RDDKOQN'=0,
M_+TZ=AB@#VSPE\?_  /XNU2+3H+BZTV[G;9#'J$002,>@#*S+D]@2,UU_C7Q
MA8>!/"UQK^KPW,UK;LBLEJJLY+,%& S =3ZUX=^TC\./#NB^%;+Q'X>TRVTN
MY2[6VFCM(Q%'(C*Q!V*,!@5'( R"<YXJSXLUZZ\2_L:VNIW[M)<N(8I';JYC
MN?+W'W.S/XT =;<_M(> [70++4F?4'DO%9EL(X4:>,*[)E_GV+DJ2!NS@@XY
MKI_ 7Q3\-?$:.;_A'YYDN;=0TMI=1A)44G&[ )!&>X)KR[]G?X<^%]7^',NL
MZ[H]IJEW>7,D6Z[B$@B1< !0> <Y.1SS[5QWP;LU\/\ [3U_H]B2MM;SW]F!
MDG,<9;:/?[B_E0!]:5P.M_&#0/#_ ,1K7P9J=GJ4=]=20QQ7(BC\AO-P%.[?
MNQDX/R]0?K7?5\Y?M4Z');3>'O%ME^[EAD-G)*HY##]Y%^1$E 'L'Q"^(^C?
M#;2;6_UV*[G2ZG\F..S16?.TL3AF48&/7N*N>%_&NE>+/!47BC3_ #H;!TD=
MA<*%>,1DAMP!('W2>O3%?.WQDUF7XI^,/ N@Z*ZEKVPBN.ORQR7&"=P_V50&
ML[P9XX?1/V;_ !IHDKE+N.Z6VA1^"%N1L=?P$<I^IH ]AC^+'A3XF?#_ ,6J
MMCKL&F6&GL;Z0Q0K(4=6XC^=ANPIZ\5A_"7Q+X#\'_#7Q+KWAB/Q%+IME<1O
M=IJ*P-,6("CRPA"XY'4BLSP#X=_L7]DOQ)?2H5GU>TNKD[AR$"%$'TPI;_@5
M/_9<L+/5/ OB.SU.T@O+66]C$D%Q&)$<; >5.0>10!YYX)^,::5\7[_Q=XME
MU/4;>>":"!8PKR1JSJ44*6"J %Z ]:Z7]J*_BU5/!FHVZNL-W92SQK( &"MY
M3 '&><&LGX)Z%I&J_'?6=/U32K*]LHXKLI;7-NDD:$3*!A6! P.!6[^U?#%;
M7GA2"WC2*&*WN$CCC4*J*#&  !T ':@#NYOVA? WA>TT_2Y9;W4)X;:*.9["
M%72)@@R"S,N<=]N:],\,^*-(\8:%%J_AZ\6[LY25W %2K#JK*>01Z'Z]#7EF
MK?"?PAI_[/MX8M%LS?V^B->?V@809VF6+S-V_P"\ 6'3.,<8K%_9,N)&\.^(
M[<G]W'=0NH]"R,#_ .@B@#Z#KY"^)FB6WB7]K"XT6^>6.VO[RR@E>$@.%:WB
M!()!&?J#7U[7QY\5]0U+2OVI+V_T*T^VZC;7-G);6WE-)YL@MXL+M4ACD]AS
M0!W_ (I_9=\/6?AF_N_#^L:HM];0/-&MZ\;QN5&=IVHI&<8SGCT-5_V5O%E_
M=KJWAB\G::UM8ENK17)/E MAU'L25./7/K63K?Q"^.7BK29]'7P7<Z<EW&T4
MDMMI%Q$Q5A@C?(Q"\<9&#S7H?P#^%5_\/])OM0\0A(]5U+8OD(X;R(EY )'&
MXD\XR.!SUH \3TWP=I_CO]I?7]!U>:YAM9]5U%V>U95<%9)&&"RL.H]*]&\3
M_LJZ3'HEQ-X3U?43J$<9>*&^,;I,P&=F55=N>F><5S'PX_Y/ UC_ +"6J?\
MH4E?5E 'S]^S-\0[_5X[WPAK=P]Q)8Q?:+*25B7$8(5HR3U"DJ1W )'0#'&:
M[_R>5%_V&+7_ - CI/@'MD_:&U![7!@\N\8;.!LWC'X<BEUW_D\J+_L,6O\
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MBXB8J<]QG%?5-% '%>)O^2"ZO_V+4W_I*:\M_9*_Y!'B;_KO;_\ H+U]#T4
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MGI6;IOBKP]K-TUMH^NZ9?SI]Z*UO(Y6'U"DF@#5HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#&Z/L-Q_T%;O\ [XA_^-U=HH I?8;C_H*W?_?$/_QNC[#<?]!6[_[XA_\
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M?]!6[_[XA_\ C=7:* *7V&X_Z"MW_P!\0_\ QNC[#<?]!6[_ .^(?_C=7:*
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M?_C=7:* *7V&X_Z"MW_WQ#_\;H^PW'_05N_^^(?_ (W5VB@"E]AN/^@K=_\
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MHH I?8;C_H*W?_?$/_QNC[#<?]!6[_[XA_\ C=7:* *7V&X_Z"MW_P!\0_\
MQNC[#<?]!6[_ .^(?_C=7:* *7V&X_Z"MW_WQ#_\;H^PW'_05N_^^(?_ (W5
MVB@"E]AN/^@K=_\ ?$/_ ,;H^PW'_05N_P#OB'_XW5VB@"E]AN/^@K=_]\0_
M_&Z/L-Q_T%;O_OB'_P"-U=HH I?8;C_H*W?_ 'Q#_P#&Z/L-Q_T%;O\ [XA_
M^-U=HH I?8;C_H*W?_?$/_QNC[#<?]!6[_[XA_\ C=7:* *7V&X_Z"MW_P!\
M0_\ QNF1B>WU:&%[R:XCD@D<B54&"K(!C:H_O&M"J4O_ "'K7_KVF_\ 0HJ
M+M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%)/]GE62,N5!8JR$J5SG!!(Q6K0 4444 %%%% !1110 4444 %%%% !1110
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MI!=7D<3NI) (5B"02",^H-6-1UG3-'$)U;4;2Q%Q((H3=3K%YCGHJ[B,GV%
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M)5VJ6J_\><?_ %\P?^CDH NT444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5%<VT-Y:36MU&LL$Z-'(C=&4C!!^H-2T4 96F>&-%T?PS'X>L
M-.@32(XFB%FX\Q&1B2P8-G=DDYSG.3FJVB^"M"\/W27.G6T[3Q0BWADN[V:Z
M,$?]R/S7;8O R%QG ST%;U% &'#X-T&#P[8:%%8;=-T^6.:U@\Z0^6\;[T.[
M=N.&&>2<]Z)?!N@3VNI6\VGJ\>J7/VNZS(^6FPH$BG.48;%P5(P1D8/-;E%
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M8/Y1!8 D%,$\G-=110 BJJ*%0!548  P *6BB@ HHHH **** "BBB@ HHHH
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M4 'T'('H *^A]?\ A)X&\4:Y_;&N>'H+B^( >59)(O,P<@NJ, Y[98$D #H
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MU.> #[#0 52U7_CSC_Z^8/\ T<E7:I:K_P ><?\ U\P?^CDH NT444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@"&XNX+5H5N)5C,\@BB!_C8@G _
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MRZ>_@WVIF$NS]PG\0 !SUKT:N'\%_P#)0/'?_7_!_P"DZ5W% !1110 4444
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M_P !0@?\#/I0!KZ1IL6CZ/;6$!++ FTN>KMU9C[DDD^YJ[17(>(?%J32'0]
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MP\A_VB<@>Y)[5T5A8V^FV$-G9QB."! B*.P%9GAK39[>";4M4 _M/4&$L_\
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M)]97.YOR)P/8"J.N_P#$U\2:7HJ\Q1M]ONA_LQD;%/U<KQW -='0 5SFD_\
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M]:]&KA_!?_)0/'?_ %_P?^DZ5W% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKX?T>3[1(LHP]S<#_5JR_P (7._:>>%R!D [^KWMQK&I/H&C3-%M .H7J?\
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MC$<$*!$4=@*Q_#-C<%9]:U1-FH:B0Q0\^1$/N1#Z#D^I)-;U !1110 4444
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MJ(HP%%1Z;IMKI.GQ6=C'Y<,8P!U)/<D]R>YJU0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4UUW1LIZ$$<TZFR*K
M1,KG"D$$Y[4 >#^&_$FIZ#K">&=+\;Z0UDM_)%#YVD7#1AFD+&$7&0I89(Y)
MYXS7O5?.:ZOI6Z'P1)XWTF7PW;ZCO7R=.N&NVQ-O$6\*8_O<;Q7T90 4444
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M-.\,:9IMS]K$3W5]C!O;MS+,?HS?='LN![5HWEY!I]E-=WDBQ00H7D=CPH%
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MT\)_#W2?"%Y-<V$MW<2O$MO&UW.9/(A4DK$F>B@FJ/Q,_P"94_[&&W_] DH
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M69F^192I)4YZD\9KZ*KP'5?$P_M9(?#7Q#\3:GJ)U!(_[,_L\A67S,.H8Q
M 9YR>E>_4 4]8OO[+T2]OL;OLT#R@8SG )KQC2OBWXB7PA>ZAJ%[IUQJQBMA
M!IS:=-:M \T@17;>?WB#/5>OK7M=_:+?Z?/:/+-")XRAD@<HZ9&,JPY!]ZX
M_!^"^M+X>(/$.HZK?7%M':P7TJHDEM'&X=,8&&;< 2S9)Q0!D'XA^*S>CPJC
M:9_PD(UC^SVOC _V?R_)\WS/+W9SCC&[WKH]!^)^E?\ "$6.L>,+ZTTJ>:>6
MU?)(C>6)RK;>^#MSSZU7;X3(;$2_\)!>C7QJ']HG61#'O,NSR\>7C;MV<8KJ
M_#'AFS\+^'+;2+5GG2#<S2S8+R.S%F8]LDDT <;X*U_2O$OQ>\2ZAH-]%?6G
M]FV<?G0G*[@TF1^HKTJN%T50OQO\3!0 /[*LN /]J6NZH ***QM6\0K9W0T[
M38&U'577<MK&V!&O]^1NB+[GD]@30!>U/5++1[%KO49U@A4XR>2Q/10!R2>P
M')K#2QOO%-Q%<:W;FRTF-Q)#ITG,EP1T:;L .HCY_P!K^[5K3/#SK>KJFO7"
MZAJ@'[MMN(;4'JL2=O0L?F/J!Q6[0 5D>)O$=IX8T62^O&7.=D,98 RN>B_X
MGL*PO$WQ1T/0-072+$2ZWKLC;(],TX>9)N_VST0>N3G':N1\0:%=^(=6L]0\
M3:G&-91&^S:797.+72U_CFFD^\S*,<@KDX ZYH H3WTFN:P^EZGJ,MK'=%9]
M56V5FO+U?X($1072,C@+@';EFQNP>UL'N-+P+2QC37M40)9V) ":?:)PF_'W
M5 .2!U8A><"G^'FM]/TQ-/\  6EB[&/WNKW68XIG[NTA&^9B>?ER.VX4EA;7
M5W=WECH]XTMS+)C5]>V@88?\L81R,@' '(3.3ECR 36R2V\D^A^&IS/J#OOU
M7695#>4Y'/L9,?=3HHQGWL+,NE9\.>#X5FO@=]U=3$NEN6ZR3-U>0]0O4^RB
MH[=S<QG0?!>+2QMF*7>IJ-P1OXEC)_UDI/5CD \G)XKI-*TJTT:P6TT^+RXP
M2S$DEG8]69CRS'N30!#HNAV^C0R;'>XNKAM]S=S',D[>I/H.RC@#I6E15>^O
M[73+*2[U"XCM[>(9>21L 4 6*Y6YD3Q/K3QR,HT/29-UPS'Y;F=>=ONB=3ZG
M [&G[M6\5_<\_1M&;^+[EU=#V'6)#Z_?/^SUJLMG;ZY.-!TN)8/#NFMLNO*X
M6YD'/D@]U!Y<]SQW. "SIL;^*-4BUN[0KIEL<Z9 X_UIZ?:&'_H ]/F[C'3T
MBJ%4*H  &  .E+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 445'<7$-I;27%U*D,,2EY)';"JHZDGL* / ?$?AA?^$T\07&J>$(M=-S
M>-)%<OXC6U8)CA"F> .@]J]WTI!'H]HB0^0JPJ!$)-^SCIN[X]:\@\;>$9O$
MEUJO]F?#/2[R2^#>1KC7ZJ6+#Y9<!<^^,UZ_I-K)8Z-9VLVSS(8$C?RQA<A0
M#CVH S?'%S<VO@369;"6.&Y%G(L4LDHC5&(P"6/ P3UKQ&+4M1T;3I/#%Q<:
MA9ZE<:EIT%_=KJKW*FWF#',;G'EEL8./7BOH6\L[?4+*:TOH$N+>="DL4BY5
MU/4$5@6OP[\)V6AW6CV^AVB6-XP:>+9GS".A)Z\=O2@#R.#4-2U/5+;PE=Z[
MJ,6E6VHZI%'>)=LLLRP*#&IESD[<D]><<UW/A?QGXC;X<>';Y?#U[XAN;JUS
M//#-'&00<!CO(R6'/%='<?#SPI=>'[;1)]#M7T^U8O##LX1CU(/7)[^M=!:V
ML%C:16MG$D,$*!(XT&%11T % 'G_ ,,[VZU'Q7XUN;_3I=,G>_AW6LSJ[)^X
M3J5XYZUZ+7#^"_\ DH'CO_K_ (/_ $G2NXH **** "BBB@ HHHH **** "BB
MB@ HHKF-0N[CQ+J$NC:3*T5C"VS4+Z,X.>\,9_O?WF_AZ=>@ VZGE\7WDNG6
M$C1Z-"Q2]NT.#<L.L,9_N_WF_ =ZZ6WMXK6W2"VC6**-0J(@P%'H*JO)IWA[
M1P7:&QL;5 HS\JJ.P'O[=2:X[6M<U'6Y(K*U@GMX;I<P62MY=Q=K_?D/6&'_
M ,>;IQR* +OB3QR;:3^SO#</]H:C(QB5EYC5^X']YAW[+W/8N\)^!QIE\^O>
M(9CJ7B&X7#W,AW"!?^><?H/IUK1\->%H-"C\Z7RYKYT"-(B;4C7M'&O\*#TZ
MGJ<FM#5]9M=%M!-=EF=VV0P1C=),_957N?Y=3Q0!)J>IVFD6#WFH3"*%.^,E
MB>B@=23V ZUA)IFH>*?W^O[[/3&.8]+5L-(.QF8=?]P<#OFI]-T:ZO\ 4$UG
MQ(%-RG-K9*=T=F#_ .A2>K?@,"NAH 9##%;PI#!&L<:#"H@P /84^BB@ HHH
MH **** "BBB@ HHHH **** "BBB@ JE+_P AZU_Z]IO_ $**KM4I?^0]:_\
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M:WC;X?\ @?36#ZW:HC-NEF1VN))G[L[*"68^_P#*O)&\&_&+XA-&->CCT;3
M ([1IU@C11T C0,1CW&?>NFT;]FVP,@F\7:_=ZJX&%A082,>@,A8_CQ0!5\4
M?M,Z=#<"U\+6$DRL.;ZX*JJ_1,Y_[Z(^AKSS6?$VM^+[.6^O[N]%N""+F*WG
M>./_ 'YL(J+Z^6OYU]$Z7\(O 6D0".V\+:?)ZO=1>>Q_%\FMN'PAX;MV5H-
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_"ZO#G_0.\0?^"B;_"M;P=X;O]#\1>++V^\KR=6U(7-ML;)V>6J_-Z'(KK:
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M2VUN&:[\J% %A .XMZCIQ78?V#H__0*L?_ 9/\* .?\ ^%L^ ?\ H;M)_P#
ME:/^%L^ ?^ANTG_P)6N@_L'1_P#H%6/_ (#)_A1_8.C_ /0*L?\ P&3_  H
MY_\ X6SX!_Z&[2?_  )6C_A;/@'_ *&[2?\ P)6M75O#NF2Z+>QVVD69F>!U
M0+;IDL5..U8OPZ\*0:=\.-#L]:T:VCOX;14G26!&8-WR>: )?^%L^ ?^ANTG
M_P "5H_X6SX!_P"ANTG_ ,"5KH/[!T?_ *!5C_X#)_A1_8.C_P#0*L?_  &3
M_"@#G_\ A;/@'_H;M)_\"5H_X6SX!_Z&[2?_  )6N@_L'1_^@58_^ R?X5Q_
MASP@MM\2/%MY>Z+;KI]T+7[&[P(5;:C!]H[<D4 :'_"V? /_ $-VD_\ @2M'
M_"V? /\ T-VD_P#@2M=!_8.C_P#0*L?_  &3_"C^P='_ .@58_\ @,G^% '/
M_P#"V? /_0W:3_X$K1_PMGP#_P!#=I/_ ($K70?V#H__ $"K'_P&3_"N.\<^
M$%OM=\(2Z3HMN\-KK"S7ABA0!(O+89;U&2.* -'_ (6SX!_Z&[2?_ E:/^%L
M^ ?^ANTG_P "5KH/[!T?_H%6/_@,G^%']@Z/_P! JQ_\!D_PH Y__A;/@'_H
M;M)_\"5H_P"%L^ ?^ANTG_P)6N@_L'1_^@58_P#@,G^%9OB/PWI]QX8U*&RT
MBS:XDM9%B5+= 2Q4XQQZT 4?^%L^ ?\ H;M)_P# E:/^%L^ ?^ANTG_P)6K/
MA+PS96G@O1;;4='M$NX;"".=7MT+!Q& P)QUSFM?^P='_P"@58_^ R?X4 <_
M_P +9\ _]#=I/_@2M'_"V? /_0W:3_X$K70?V#H__0*L?_ 9/\*/[!T?_H%6
M/_@,G^% '/\ _"V? /\ T-VD_P#@2M'_  MGP#_T-VD_^!*U4\+>$H[7QCXM
MN+_1;=;2ZNX7LV>!"KJ(@&*CMS75_P!@Z/\ ] JQ_P# 9/\ "@#G_P#A;/@'
M_H;M)_\  E:/^%L^ ?\ H;M)_P# E:Z#^P='_P"@58_^ R?X4?V#H_\ T"K'
M_P !D_PH R=-^(W@[6-1BL-*\2:==W<QQ'#%.&9S["NFK@O%?A9I/&7@Z\T7
M28EALM0>2[E@B5/+0Q, 3C'&2*[V@ HHHH **** "BBB@ HHHH **** /-OB
M5-=7WBSP]X?&IW>F6-W!=W$TMI.87D>) 4&X<X!.['M3/#OCGQ&OPY\.7Z>&
MK_Q'<WEKF>:VEC3!!P&;<1DL.>*[7Q%X4T3Q99QVWB#3XKV*)]\8D'*'H<$<
MC(X-:-I:06-G%:V<*06\*!(XT&%11T % 'BWAGQ?KL'C?Q;>1?#O4[JYGNX3
M)&L\&^VQ"H"DD\YZ\>M=;_PL/Q5_T3#6_P#P*@_^*KI-#\./I'B+7]3:Y65=
M7N(YEC"8\K;&J8SGG[N:WJ //?\ A8?BK_HF&M_^!4'_ ,51_P +#\5?]$PU
MO_P*@_\ BJ]"HH \QN_BOK=G?6=C>?#G6([B_9DMHFN8,RE1E@.>P]:S;R_U
M"\FDE_X51KUN\O\ K/LM_%$']R%< UZ#KGAM]7\3>']56Y$2Z/++(T93/F[T
MVXSGC'6M^@#YQOO UK>W9N1\+/$\,S?>*ZC RM]58D'\:P=4^%=Y>DFT\!Z]
M;?W<?8UQ_P!\%:^K** /C.X\ _$'PI:W&IV&GZY9VULAEE:66,!% R3\LF>G
MI6U8Z#\2+J&*YOOAY'K"RJ'62[NF;>#R#_K17T]XGT=O$'A74](280-?6LD
ME*[@FY2,X[]:MZ;:&PTJUM"^\V\*1E@,;L #/Z4 ?/VFVWBFTQY_P-T]L?\
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MIX([FWD@G4/%*A1U/<$8(KC;'X3^&K*VOH&%[=+>6_V3-S=N[00@[A'&2<J
M>>* *OPLUO4-1AU&TU[5+^YU2U:,S6M_9I!);AER,;.&4]0:] K \+^#=-\)
MK<M8O<W%S=L&GNKR8RRR;1A06/8#@"M^@ HHHH **** "BBB@ HHHH ****
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M;O+8CAL<9QZ5YKI7P>O;?PWJFA:QXJ.H6.HHSL5TY(IA<%@PF:3<6<@CH>*
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M#SPF/#IT,:':?V<9?.,.S_EI_?SUW>];6E:38:)IL.GZ3:Q6EI",1PQ+A5H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MK-U_Q!I?A?1Y=5UVZ6TLH2H>9E9@"3@< $]36E7G/QX!_P"%2WQ"LVVYMF(5
M23@3(3P* .D\->/O"_B^>:#P[J\-Y-"NZ2(*R.J^NU@#CWKHLUXAJ_B*S\6_
M$*U\1>#;:_O;31=&O?MUS;6[P-*63$<2,ZC+YY'!QUKD/"EMJ.OWFKV&C7=S
M9)=Z!]IMQ%>73_Z7'(K M)*%S)V;8 O.* /I[-%?/#ZGJOC;P'KWC"\OM0TN
M&X>ULH8XTED1%BP9MZ1$,$9R067D 5W?P2OI;GP_J4/V62.VM[S;#<)<SS6\
MX*\F'SAO51Z'/- 'IE%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?_B:3^W;'UN/_ 67_P")H T:*SO[=L?6X_\  67_ .)H_MZP_O3_ /@++_\
M$T 7Y(UEC:.10R."K*>A![55TS2=/T6S%II-E!9VX);RX$"KD]3@5#_;]A_>
MG_\  67_ .)H_M_3_P"_/_X"R_\ Q- &E16;_P )!I_]^;_P%E_^)H_X2#3O
M^>DW_@-+_P#$T :5%9G_  D.G?\ /2;_ ,!I?_B:/^$ATW_GI-_X#2?_ !-
M&G169_PD6F_\]9O_  &D_P#B:/\ A(M-_P">LW_@-)_\30!IT5F?\)%IO_/6
M7_P&D_\ B:/^$BTW_GK+_P" TG_Q- &G169_PD6F_P#/67_P&D_^)H_X2+3?
M^>LO_@-)_P#$T :=%9G_  D6F_\ /67_ ,!I/_B:/^$BTW_GK+_X#2?_ !-
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MM-_YZR_^ TG_ ,30!IT5F?\ "1:;_P ]9?\ P&D_^)H_X2+3?^>LO_@-)_\
M$T :=%9G_"1:;_SUE_\  :3_ .)H_P"$BTW_ )ZR_P#@-)_\30!IT5F?\)%I
MO_/67_P&D_\ B:/^$BTW_GK+_P" TG_Q- &G169_PD6F_P#/67_P&D_^)H_X
M2+3?^>LO_@-)_P#$T :=%9G_  D6F_\ /67_ ,!I/_B:/^$BTW_GK+_X#2?_
M !- &G169_PD6F_\]9?_  &D_P#B:/\ A(M-_P">LO\ X#2?_$T :=%9G_"1
M:;_SUE_\!I/_ (FC_A(M-_YZR_\ @-)_\30!IT5F?\)%IO\ SUE_\!I/_B:/
M^$BTW_GK+_X#2?\ Q- &G5'6=*BUO29]/GGN;>.==K26DQBD ]F'(J+_ (2+
M3?\ GK+_ . TG_Q-'_"1:;_SUE_\!I/_ (F@!^A:'I_AO1+;2='@\BSMEVQI
MDD]<DDGDDDDYK0K,_P"$BTW_ )ZR_P#@-)_\31_PD6F_\]9?_ :3_P")H TZ
M*S/^$BTW_GK+_P" TG_Q-'_"1:;_ ,]9?_ :3_XF@#3HK,_X2+3?^>LO_@-)
M_P#$T?\ "1:;_P ]9?\ P&D_^)H TZ*S/^$BTW_GK+_X#2?_ !-'_"1:;_SU
ME_\  :3_ .)H TZ*S/\ A(M-_P">LO\ X#2?_$T?\)%IO_/67_P&D_\ B: -
M.BLS_A(M-_YZR_\ @-)_\31_PD6F_P#/67_P&D_^)H TZ*S/^$BTW_GK+_X#
M2?\ Q-'_  D6F_\ /67_ ,!I/_B: -.BLS_A(M-_YZR_^ TG_P 31_PD6F_\
M]9?_  &D_P#B: -.BLS_ (2+3?\ GK+_ . TG_Q-'_"1:;_SUE_\!I/_ (F@
M#3HK,_X2+3?^>LO_ (#2?_$T?\)%IO\ SUE_\!I/_B: -.BLS_A(M-_YZR_^
M TG_ ,31_P )%IO_ #UE_P# :3_XF@#3HK,_X2+3?^>LO_@-)_\ $T?\)%IO
M_/67_P !I/\ XF@#3HK,_P"$BTW_ )ZR_P#@-)_\31_PD6F_\]9?_ :3_P")
MH TZ*S/^$BTW_GK+_P" TG_Q-'_"1:;_ ,]9?_ :3_XF@#3HK,_X2+3?^>LO
M_@-)_P#$T?\ "1:;_P ]9?\ P&D_^)H TZ*S/^$BTW_GK+_X#2?_ !-'_"1:
M;_SUE_\  :3_ .)H TZ*S/\ A(M-_P">LW_@-)_\31_PD.F_\])O_ :3_P")
MH TZ*S/^$AT[_GI-_P" TG_Q-'_"0:=_STF_\!I?_B: -.BLW_A(-._OS?\
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M_P \[O\ \ IO_B: +M%4O[5M_P#GG=_^ 4W_ ,31_:MO_P \[O\ \ IO_B:
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ME:NT4;10!E?V<O\ =_2C^SE_N_I6KM%&T4 97]G+_=_2C^SE_N_I6KM%&T4
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M_P#SSN__  "F_P#B:/[5M_\ GG=_^ 4W_P 35VB@"E_:MO\ \\[O_P  IO\
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M7]JV_P#SSN__  "F_P#B:/[5M_\ GG=_^ 4W_P 35VB@"E_:MO\ \\[O_P
MIO\ XFC^U;?_ )YW?_@%-_\ $U=HH I?VK;_ //.[_\  *;_ .)H_M6W_P">
M=W_X!3?_ !-7:* *7]JV_P#SSN__  "F_P#B:/[5M_\ GG=_^ 4W_P 35VB@
M"E_:MO\ \\[O_P  IO\ XFC^U;?_ )YW?_@%-_\ $U=HH I?VK;_ //.[_\
M *;_ .)H_M6W_P">=W_X!3?_ !-7:* *7]JV_P#SSN__  "F_P#B:/[5M_\
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MM_\ GG=_^ 4W_P 35VB@"E_:MO\ \\[O_P  IO\ XFC^U;?_ )YW?_@%-_\
M$U=HH I?VK;_ //.[_\  *;_ .)H_M6W_P">=W_X!3?_ !-7:* *7]JV_P#S
MSN__  "F_P#B:/[5M_\ GG=_^ 4W_P 35VB@"E_:MO\ \\[O_P  IO\ XFC^
MU;?_ )YW?_@%-_\ $U=HH I?VK;_ //.[_\  *;_ .)H_M6W_P">=W_X!3?_
M !-7:* *7]JV_P#SSN__  "F_P#B:/[5M_\ GG=_^ 4W_P 35VB@"E_:MO\
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M_P#SSN__  "F_P#B:/[5M_\ GG=_^ 4W_P 35VB@"E_:MO\ \\[O_P  IO\
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M7]JV_P#SSN__  "F_P#B:/[5M_\ GG=_^ 4W_P 35VB@"E_:MO\ \\[O_P
MIO\ XFC^U;?_ )YW?_@%-_\ $U=HH I?VK;_ //.[_\  *;_ .)H_M6W_P">
M=W_X!3?_ !-7:* *7]JV_P#SSN__  "F_P#B:/[5M_\ GG=_^ 4W_P 35VB@
M"E_:MO\ \\[O_P  IO\ XFC^U;?_ )YW?_@%-_\ $U=HH I?VK;_ //.[_\
M *;_ .)J2#4(+B?R4\Y9"I<"6!X\@$ XW 9ZC\ZLU2E_Y#UK_P!>TW_H45 %
MVBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *I:K_ ,><?_7S!_Z.2KM4M5_X\X_^OF#_ -')0!=HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MISC'7C/H* /++;P_<-:_#72/&%C]HB?4[TI8ZB!.8[?R96ACDW9!*KMX.<8
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M E9_)R-L1/E84J,KGOBC0/'&O^#+'XHZ?/J]YK:^&V4Z;/J3^=*I=F0;V/+
M?(<=.#@#.* /H2BOE[P[XG\:V\WA[7='3XB:O=74J/JL>HV32Z;-#(06-N%S
MM _A('3I@?*>KNX]?\4?M,>(?#,7BW6M)TB/2XYI(;&Z*D#9!Q'N!$;%V!+
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXW8SC.*])\ ^%M4\(^'I-/UOQ+=^)+A[AIA>78;>JE5 3YG<X!4GKWZ5T]%
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M-G#'=ZY)S75T4 %4M5_X\X_^OF#_ -')5VJ6J_\ 'G'_ -?,'_HY* +M%%%
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M@4 76947+L%'J3BD21)!F-U<>JG->/75S9>.?%FE#Q7HFNVMAJ2>3:P/J*I
MT@0R;A'$VYU*X^?)7/%=?8_"S0-&U&WO?#TFHZ3)#(',=O>R-'* >5='+ @_
M@: .THHHH **** .%^*[I_PCNF)N7=_;=@=N>?\ 7K7=5YG\6/#FE$:5KYM<
MZHFK6,*W'F/PGG@8VYV]SVKTR@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHJC9ZK%?:G>VENCD615))<?*7(R4'N!@G_>% %ZBBB@ HHHH **** "BBB@
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M7\+Z=I.HZ+82P74>LV2*[7<L@ ,R@\,Q'2O8Z "BBB@ HHHH **** "BBB@
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M34/!-[JS:A?P-8PKBV@N"L,W[Q?OIT:@#T*Q_P"0?;_]<E_D*GJ"Q_Y!]O\
M]<E_D*GH **** "BBB@ HHHH **** "BBB@".XGCM;:2>=@D42%W8]@!DFL/
MPI!)-;W&MW:E;C5'\T*W6.$<1K^7/XTSQ.QU.[LO#L)/^F-YMV1_#;H<D?\
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M!5'4DX J-;J!X?-2:-H_[P88_.@=F2T4R.:*7/E2(^.NU@:?0+8**0L%4EB
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M NT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3CYN2=IYQ746_@_1K:TGM4MV:"X4*Z22LPP.F,GC\*LVN@6%AI4NGV4;00S
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M^,9I_A+XFZ?XMU9;*'3[VR%Q ]U8S72@+>0J^UG3!..<<'!P<URD?PSU]_$
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M6=H@C@@C$<:CLH&!6'X<!U?4;OQ',#LGS;V(/\,"GEO^!L,_15KHZ "BBB@
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M<N9IW8RW$YZRRMRS'\?TQ5'1=-N[N_.O:XGEW;J5M;7.1:1'M[N?XC^%=!0
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MGZ%1L^KBNAKG=-/]J>--2U#[T&G(-/MSGC></,1^/EK]4- '1    < 4444
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M4AJ_AJ/2&$<B#[),".7R?N]>1GI5.[\"^);74KS0(=,EN;?5+[3KH:HLB^7
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M23W)IFCZ1;:+IXM;7<V6+RRR'+S.?O.Q[DFKU !1110 4444 %%%% !1110
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M>[A?QQ-!X1U'6=2\._8M]U)JGFE8[G=P$:0 Y(SN XKUJ@ HHHH *XWXM_\
M)*=<_P"N2?\ HQ:[*O-?C7H,E]X*O-436-1M4LH5W64$VV"X_>+_ *Q<<T >
MAV/_ "#[?_KDO\A4]06/_(/M_P#KDO\ (5/0 4444 %%%% !117/7GB*:\NY
M-.\+Q)>72';-=.?]'MC_ +1'WF_V1^)% &EK&M:?H.FRWNJ745O%&I;]XX4O
M@=!GJ?:O/].\5W36TT/A[3[C4/$FKC[4[R1-%#;H>%W,X'"KP, Y-5]3BM+G
M7+6WMU;Q!J'G;I;J8 B>9?NQ+V6)#\S;>!@#.:]"T+1?[)@DDN9?M6H73>9=
M7)&/,;T [*.@'84 8>C^'?$%M8BW;4+?3$=B\S6R>=/,YZLTC\$GV48K3@\&
MZ2DRSWL<NI7"\B:_E,Q!]@W _ 5O44   4  8 Z 445SVL:E=7^H'0="D\NY
M*@WEV.1:1GT_Z:'L.W6@!M[JM_JVHS:5X<=(A =MYJ+#<(3_ '$'1G^O"]\]
M*CN4MO"5@MKH\!NM7U!RL1E;=)/)WDD8\[5ZD_@*TC_9GA'PZ<#R;2V7@#EG
M8_\ H3,?S)JMX?TRY>XEUS6DQJ-TNU(B<BUBZB,>_=CW/TH MZ%HR:-8&-I#
M/=3,9;JX;[TTAZD^W8#L*LZGJ$6E:7<7UQ_JX(RY'KZ#ZD\5:KF]=_XF_B'3
M]#7YH8S]MO!_L*?D4_5OY4 6_"VGRV6BK)>?\?MXYN;DG^^_./P&!^%;-%%
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MJX()YP2 >0#6=\*[)[?6-;FT?3M1TGPQ*L(LK/4=X;S1N\QT5R65#\HP>I%
M'I=%%% !1110!PWQ7(_X1K3!W_MNP_\ 1ZUW->7_ !9\,V+3Z5XB,EW]M35;
M&$(+EO)V^>!_J\[<\GFO4* "BBB@ HHHH **** "N:\0'^V]8M?#L9S <7.H
MX[0@_+&?]]N,?W0U7=?UI].6*TT^(7.J7A*VMOGCW=O1%ZD_AU-&CZ=:Z!:O
M]JNTEO;AO-N[J5@K3/Z^RCH!V'XF@#8HK)N/%6@VIQ<:O9QGT,PJI_PG&A,V
M+:YDNSZ6L#R_^@B@#H:;)(D,;22NJ(HRS,< #ZU@-XL9^++0=8N&/W0UHT(/
MXO@"F1:!>:U(MSXLD22,$-'I<)S G_70_P#+0_7Y?8]: $;6[_Q QA\+(L=K
MG#ZK.F8_?RE_Y:'WX7W[5IZ1H5IHXD>(R3W4_,]W.VZ64^Y[#T P!Z5HJH10
MJ *JC  & !2T %9FN:U'HUJFV-KF\N&\NUM8_O3/Z#T ZD] .:9XD\2:?X5T
M:34=5E"1J0L: _-*YZ(H[DUPD7VF^9]=\6W3:5#=+L2)21<21GI#$.J*>Y'S
M.?08H AU&XU2[NGM-'NEEUS47^RSZJ@REN.K16^?X4'+/Z]>2%KT;0-#M/#F
MAVVEZ>I$-NF-S'+2-U9V/=B<DGU-9?A/1C!OU2ZM/LDDJ>3:6F,?9+<'*ICL
MS'YF]\#M72T %%%8OB;4I[.PCM-.P=1U!_L]J#_"2.7/LJY8_2@"G;?\5#XL
M>\/S:?H[&*#TEN",._T4':/<GTKIJJ:5IL&D:5;V%KGRX$V@MU8]2Q]R22?<
MU;H **** "BBB@ HHHH **** "BBB@ HHHH *BN+:"[A,-U#'-$2"4D4,"0<
MC@^XJ6B@".!H7A4VS1M'T!C(*_I4E?/^B:WJ.@ZP-$T?QQ+#H_\ :3Q13OH&
M^T61Y23")R?[Q*@],U] #I0 4444 %%%4-<M+^^T:>VT?4/[-O'QY=T(A)Y?
M()^4\'(R/QH Y;X7?\@[Q%_V,FH_^CC7<5Y_\'H;BW\.:U#?7/VNYCU^^66X
MV!?-<2G+8' R><5Z!0 4444 %%%% !1110 4444 %%%% !1110 445%<W,-G
M:RW-U(L4,*%Y)'. J@9)- %'7M871M/$B1&XNYG$-K;*<&:4]%]AU)/8 GM3
M= T=M)LW:ZE^T:A=/YUY<8QYDA'0>B@851V %4="MIM7U ^)-2B>/>A33K:0
M8,$)_C([.^ 3Z# ]:Z.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "J4O_ "'K7_KVF_\ 0HJNU2E_Y#UK_P!>TW_H45 %VBBB@ HHHH ****
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MI4WSCHS \B,=@?O'GI0 MI!+XMO8M2OXVCT>!M]E:N,&X8=)G'I_=4_4UU-
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MOB"Y?5KQ#N0S#$,)_P!B,<#ZG)]ZWP,# X%%% !1110 4444 %%%% !1110
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MTFST:R%M81;%SN=F.YY&/5F8\L3ZFK<44<,2Q0HL<: *J(,!1Z 4Z@ HHHH
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MJ6J_\><?_7S!_P"CDJ[5+5?^/./_ *^8/_1R4 7:*** "BBB@ HHHH ****
M.<T[Q]X<U7Q)-H5CJ DOHBR[?+8([+]]5<C:Q7N >*SOC 6'PC\0&/E_LXV
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M>N?]%+\3_P#?47_Q%'_"L]<_Z*7XG_[ZB_\ B* /0J*\]_X5GKG_ $4OQ/\
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MMYSG5=2U/43Z2W1C7\H]OZYJ_8^'M'TQ@]AIEK!(/^6BQ#>?^!=3^=>1^&_
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MK#7(_&FG6JWB%Q"=(5MF&(ZYYZ5M?\(Y\4/^A\TW_P $R_\ Q5 'H5%>>_\
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M6N))K:1%B23RR^5(VAL'!/K0!D>"/%/AO7X[F/PK;301!OM#EK-X$D+GEP2
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M)!!<)O02QE&Q[J>1^-6ZY[P'!K5KX&TN'Q.[/JBPXF+MN8<G 8CJ0,9-=#0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M44 %%%% !1110 8QTHHHH **** #'.>]%%% !1110 8&<XYHQCI110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %<GXU\"GQ=?:/?0:S>:/>:1)*]O/:*I;,BA3]X'L/UKK
M** /-YO@SIMSH5U:W6LZC<:G=WT-]/JLQ5I9)(@0@*D;2H!(VXQ6-XJ^&=[I
MG@75=#\.0W6M7FNZBEW]IEE2+[#,-G[W( X^3H/7%>PT4 <+=_#&&;PSHVD6
M&L7FFKI=K]F_<*CQS J Q='!4G.3GKS71^%?#EGX1\+V.A:89&MK*/8C2MEF
MR222?<DUKT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 52E_Y
M#UK_ ->TW_H457:I2_\ (>M?^O:;_P!"BH NT444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %1"[MS>-9B>(W*QB5H XWA"2 Q7K@D$
M9]C4M<G!_P EDO\ _L 6W_I1/0!TRW=L]Y):)<1-<Q(LDD(<%T5B0K%>H!*M
M@]\'TJ:O*_'FHZFFN^(;2RU6]LE%OH8B:WF*F$RZ@Z2,HZ LN >.0 #D54U[
M4M2\.W'B/1-)OKO[&+O2T$U]J<Q:V2Y+))_I+B1XU;8J[N=I<E<'F@#U^BO*
MWLO$D$&HZ0^MZ79;[JR,&G2>)KB:?YF;S(C=/&)H_-" I@,<JX'!XZCX>:@;
MK1+RTFAU.WNM/O&@N;;4KQ;Q[>0HDAC2<$F1 )!@L2W.#C   .LHKQQ[O5+;
MP7<:E#J=[+<ZCXDN-.EENM5FBBM[;[;(@56PXASM5!(J[AOX(P,2ZD-;TO3[
MK3]1UZ/3+=M6TQ%CM-=FO;FS227$@>:5$<*X *AMP^]V % 'KU0W=L+NW,3.
M\?S*X=,9!5@PZ@CJ!VKRK5&NX-<NO#=AK6J#38]:TZ+S?[0E>:,3(YF@\XL9
M,85&Y8E?,R"/EQ'J@\07FM>)[?3K^.R3P^(8[.XOO$ES;?8XQ KK/+'Y;K<*
M7WDM,S!@C*<8)(!ZE]AN/^@K=_\ ?$/_ ,;H^PW'_05N_P#OB'_XW7F^IWNH
M6/B.37-2OY[_ $U+ZVB:XT/6B!I[,L2^1+:-B.1'=R=WS2;9!@#"D5;2[\3:
MI=WFN+?V5C)::]):M+>>(9XHX8TN/+%N]GY7DDO$5P2VXF17# [0 #U+[#<?
M]!6[_P"^(?\ XW45NGVM7:TUR:=8Y&B<Q&!@KJ<,IPG!!&".QKS19;ZU']NG
M5]4ENO\ A-#IZ1O?2^0ML]YY)B\G=L( 8D$J6!Q@@* .G^&&G0V&FZYY#W+[
MM=OE/GW4DW"SN!C>QP?4]2>3DT =3]AN/^@K=_\ ?$/_ ,;H^PW'_05N_P#O
MB'_XW7E+W>J6W@NXU*'4[V6YU'Q)<:=++=:K-%%;VWVV1 JMAQ#G:J"15W#?
MP1@8OM9>(XK>_P!'DUO3+0M>V?D:<_B:XEG(8.7A-TT8GC\S8&7 8_*X&%Z
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M_P")H\%1WLGA*U_M:_L]1ND:6-KFSN//C8+(RJ/,VKN90 K' ^96K=^SKZ4
M8/F:O_T$9?\ OU'_ /$TGFZQ_P!!&7_OU'_\36_]F7TI/LR^E &!YNL_]!&3
M_OU'_P#$TGG:S_T$)/\ OU'_ /$UT'V9?2C[*OI0!S_G:U_T$)/^_4?_ ,31
MYVM?]!"3_OU'_P#$UT'V5?2C[*OI0!S_ )VM?]!"3_OU'_\ $T>=K7_00D_[
M]1__ !-=!]E7TH^RKZ4 <_YVM?\ 00D_[]1__$T>=K7_ $$)/^_4?_Q-=!]E
M7TH^RKZ4 <_YVM?]!"3_ +]1_P#Q-'G:U_T$)/\ OU'_ /$UT'V5?2C[*OI0
M!S_G:U_T$)/^_4?_ ,31YVM?]!"3_OU'_P#$UT'V5?2C[*OI0!S_ )VM?]!"
M3_OU'_\ $T>=K7_00D_[]1__ !-=!]E7TH^RKZ4 <_YVM?\ 00D_[]1__$T>
M=K7_ $$)/^_4?_Q-=!]E7TH^RKZ4 <_YVM?]!"3_ +]1_P#Q-'G:U_T$)/\
MOU'_ /$UT'V5?2C[*OI0!S_G:U_T$)/^_4?_ ,31YVM?]!"3_OU'_P#$UT'V
M5?2C[*OI0!S_ )VM?]!"3_OU'_\ $T>=K7_00D_[]1__ !-=!]E7TH^RKZ4
M<_YVM?\ 00D_[]1__$T>=K7_ $$)/^_4?_Q-=!]E7TH^RKZ4 <_YVM?]!"3_
M +]1_P#Q-'G:U_T$)/\ OU'_ /$UT'V5?2C[*OI0!S_G:U_T$)/^_4?_ ,31
MYVM?]!"3_OU'_P#$UT'V5?2C[*OI0!S_ )VM?]!"3_OU'_\ $T>=K7_00D_[
M]1__ !-=!]E7TH^RKZ4 <_YVM?\ 00D_[]1__$T>=K7_ $$)/^_4?_Q-=!]E
M7TH^RKZ4 <_YVM?]!"3_ +]1_P#Q-'G:U_T$)/\ OU'_ /$UT'V5?2C[*OI0
M!S_G:U_T$)/^_4?_ ,31YVM?]!"3_OU'_P#$UT'V5?2C[*OI0!S_ )VM?]!"
M3_OU'_\ $T>=K7_00D_[]1__ !-=!]E7TH^RKZ4 <_YVM?\ 00D_[]1__$T>
M=K7_ $$)/^_4?_Q-=!]E7TH^RKZ4 <_YVM?]!"3_ +]1_P#Q-'G:U_T$)/\
MOU'_ /$UT'V5?2C[*OI0!S_G:U_T$)/^_4?_ ,31YVM?]!"3_OU'_P#$UT'V
M5?2C[*OI0!S_ )VM?]!"3_OU'_\ $T>=K7_00D_[]1__ !-=!]E7TH^RKZ4
M<_YVM?\ 00D_[]1__$T>=K7_ $$)/^_4?_Q-=!]E7TH^RKZ4 <_YVM?]!"3_
M +]1_P#Q-'G:U_T$)/\ OU'_ /$UT'V5?2C[*OI0!S_G:U_T$)/^_4?_ ,31
MYVM?]!"3_OU'_P#$UT'V5?2C[*OI0!S_ )VM?]!"3_OU'_\ $T>=K7_00D_[
M]1__ !-=!]E7TH^RKZ4 <_YVM?\ 00D_[]1__$T>=K7_ $$)/^_4?_Q-=!]E
M7TH^RKZ4 <_YVM?]!"3_ +]1_P#Q-'G:U_T$)/\ OU'_ /$UT'V5?2C[*OI0
M!S_G:U_T$)/^_4?_ ,31YVM?]!"3_OU'_P#$UT'V5?2C[*OI0!S_ )VM?]!"
M3_OU'_\ $T>=K7_00D_[]1__ !-=!]E7TH^RKZ4 <_YVM?\ 00D_[]1__$T>
M=K7_ $$)/^_4?_Q-=!]E7TH^RKZ4 <_YVM?]!"3_ +]1_P#Q-'G:U_T$)/\
MOU'_ /$UT'V5?2C[*OI0!S_G:U_T$)/^_4?_ ,31YVM?]!"3_OU'_P#$UT'V
M5?2C[*OI0!S_ )VM?]!"3_OU'_\ $T>=K7_00D_[]1__ !-=!]E7TH^RKZ4
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M]\0__$5=Q10!2^PW'_05N_\ OB'_ .-T?8;C_H*W?_?$/_QNKM% %+[#<?\
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/ 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>img30600998_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img30600998_9.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#X17AI9@  34T *@    @ ! $[  (
M   /   (2H=I  0    !   (6IR=  $    >   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $YI8V]L92!3
M96ET=&5R    !9 #  (    4   0J) $  (    4   0O)*1  (    #,S@
M )*2  (    #,S@  .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                         #(P,C,Z,#,Z,30@,3(Z-3$Z,38 ,C R,SHP
M,SHQ-" Q,CHU,3HQ-@   $X :0!C &\ ; !E "  4P!E &D = !T &4 <@
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" (T!2<# 2(  A$! Q$!_\0 'P
M 04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0
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M>G3IGG(H [ZBBO.OBS\7K#X8V-M']E.H:I> M!:A]BJHX+NV#@9X [\],9H
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M\H+QV\?<OM8$$] ,^_U /6**YCX<>);SQA\.])U[4XX(KJ]C9Y$MU*H"'9>
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M:3XR\9^*M8FU2]\BZN;*!6;9!]YDW,3EMH(P. ,=ZM_LG?\ (I:__P!?R?\
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M<B(?+&/IC+?\#KP?2=!NYOC[J^BR^*KGPI>R7UU&FHQ;@SL7)"Y#I@..G//
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MGIUY_;W]E_8H6BV?8_.WY;.<[UQ^M>HT4 1V\7V>UBASN\M N<8S@8J2BB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJP27<BX6:0[LA!U(&T<G'4<53^&/B;Q5XJT_5+SQ=HG]C+'>&&R@>TEMY'B
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M<A%D!" _*@P0>6KN* "BBN,^*/Q#M_AKX/.KRVQO+B:86]M;[MH>0@G).#@
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M"$*]?6O8?"?AZ'PIX1TS0K>3SDL+9(3+LV^8P'S-C)QDY.,GK7/_ !#^'/\
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M##/N.IZ@U%X,^&3>'/$MYXEUWQ!=^(==O$\M[J:,0QHO PL2D@< #V'3&3D
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M]5RO_"C?&_\ T6CQ!_WS/_\ )% &5\9+/6/#VA_#OQ-XEO4O=6T74T6^NX$
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M=P& 22 RMBO6=!T+3O#.A6FCZ+;K;V5HFR*,<^Y)/<DDDGN30!XKH>DZ=?\
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M%/"^F?%CXZ^/-4UN2>;3M/D6S%O#.\0G&3&N64@[<0$XSR2/2O2_A_\ "E?
MFO\ B#5_[;FU6ZUA@4ENH?WD0W,QW-N/F$D@DX7[O09XYK0?@-JWA2WFE\,_
M$&]T_4[PL+ZZ6P1TN%)RO[MG.UAD_-NSR<8H Y3X=ZW<>"8/BMI]C>37&B^'
MQ*;'S'+"*7=(B*#[E0#Z[<UCIJVK_#_]F#1(= :6VU+Q/J$CM+"#YBH<@;<<
MAF5(P".Q..<&MCXDZ9X<\ _"B?P#X6U%-3\0:QJ4$=ZGG*]U(^1(&=0<J,A
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *I-HNEOK*:N^FV;:G&GEI>F!3,J<
M_*'QN Y/&>YJ[10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2,H92K $$8((Z
MTM% &?I7A_1M"$HT/2+'31,<R?8[9(=Y]3M S6A110 4444 %%%% !1110 4
M444 %%%% !1110 5CZGX1\-ZU<_:-9\/:5J$^,>;=V4<K?FRDUL44 16MI;V
M-LEO9016\$8PD42!%4>P' J6BB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH S!X9T$:T=8&B:<-3)R;W[)'YQ.,9\S&[I[UIT44
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:G,-R6.GP>=+CUQD#\,YKS+Q;X@MOBG\0/#>D^%/-N+6RF,T]R8BB@%E+'#
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M^R*/[;##O3:#G#J2><\BOJ*OEWX=?\*W_LF[_P"%@?\ 'YY_[C_CY_U>T?\
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M (JWP(>_VV3_ -&05Z_6%2,5&,EU.BG*3E*+Z!1116)J%%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHIDD@C'/)["@!]%53<.>AQ^%)Y\G][]*KE9/,BW5>^T^RU.W,&I6<
M%W">L=Q$LBG\",4SSY/[WZ4>?)_>_2GRL7,AFG:)I6D;O[)TRSL=WWOLUNL>
M?KM HU'0])UC9_:VF6=]L^[]IMTDV_3<#BG^?)_>_2CSY/[WZ4[2O>XKQM:P
M]M/LGT\V#V<#6;)L-N8E,97TVXQCVIL&EV%KIHT^VL;:&R (%M'"JQX)R1M
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M<PK(H/T8&CSY/[WZ4>?)_>_2CEE>X<T;6)+.QM-.M5MM/M8;6!?NQ01A%'T
MXJE<^&-!O+PW=WHFFSW).3-+:1LY/KN(S5GSY/[WZ4>?)_>_2G:7<5X]B>:V
M@N+=K>>&.6%EVM&Z@J1Z$'C%5=.T/2=(+G2=,L[$R??^S6Z1[OKM S3_ #Y/
M[WZ4>?)_>_2ERO8?,BW6'_PA'A3_ *%C1O\ P7Q?_$UH^?)_>_2CSY/[WZ4T
MI+9B;B]T1:=X?T;1Y'DTC2;&P>0;7:UMDB+#T)4#-1+X7T!+W[8NAZ:MUNW>
M>+2/?GUW8SFK7GR?WOTH\^3^]^E%I=PO'L2W5I;7UL]O>V\5Q _#13('5OJ#
MP:@T[1=+TA6&DZ;9V(?[PMH%CW?7:!FG>?)_>_2CSY/[WZ4N5VL/F5[D#>'=
M$:^DO6T?3S=2Y\R<VJ;WSURV,G-(?#6A'31IQT73C8A_,%K]D3R@_P#>V8QG
MWJQY\G][]*//D_O?I3M+N*\>PR]T32M2MXH-1TRSNX8>(HY[='6/M\H(P.@Z
M4D&A:1;7R7MMI=E%=(GEI/';HKJN,;0P&0,=JD\^3^]^E'GR?WOTHM+N%X]B
M/^P=(_M3^T_[*L?M^<_:_LR>;GI]_&?UI^GZ1INDK(NE:?:V0E;=(+:!8]Y]
M3M R:7SY/[WZ4>?)_>_2BTNX7CV($\.:)'J/V^/1]/6]W;OM*VJ"3/KNQG-3
M7^D:;JC0MJ>GVMX8&W1&X@63RSZKD'!X'3TI?/D_O?I1Y\G][]*+2[A>/82]
MTC3=3F@EU+3[6[DMFW0// LAB/!RI(^4\#IZ"KE5//D_O?I1Y\G][]*7*Q\R
M+=%5//D_O?I1Y\G][]*.5AS(MT54\^3^]^E'GR?WOTHY6',BW153SY/[WZ4>
M?)_>_2CE8<R+=%5//D_O?I1Y\G][]*.5AS(MT54\^3^]^E'GR?WOTHY6',BW
M153SY/[WZ4HN''7!_"ERL?,BU134<2+D?B*=4E!1110 4444 %%%% !14#W&
M#A/SJ/SY/[WZ57*R>9%NBJGGR?WOTH\^3^]^E/E8N9%NBJGGR?WOTH\^3^]^
ME'*PYD6Z*J>?)_>_2CSY/[WZ4<K#F1;H(R,'D54\^3^]^E'GR?WOTHY6',A-
M.T?3-'C>/2-.M+!)#N=;6!8@Q]2% S2:CHVF:NL8U;3;2^$1)C%S LFPGJ1N
M!QTIWGR?WOTH\^3^]^E%I7N%XVL)#I&FV^I2ZC;Z?:Q7TR[9;I(%660<<,X&
M2.!U/840:1IMKJ$U_:Z?:PWEP,37$<"K))W^9@,GH.M+Y\G][]*//D_O?I1R
MR#FB5AX7T!9)W&AZ:'N 5F86D>90>H8XYS[TZ7PWH<^GPV$^C:?+9P$M#;/:
MH8XR<Y*J1@=3T]:G\^3^]^E'GR?WOTIVEW%>/8X#XG:-XL\8E/#FEZ1!%I33
MQRR:I)=)T Y'E_>&"3TSG%=_I>G0:1I%IIUH,0VL*PIQV48S]>*//D_O?I1Y
M\G][]*I\SBH]B5RJ3EU96D\+Z!+??;)=#TU[K=N\]K2,OGUW8SFK&H:1INK+
M&NJZ?:WHB;=&+F!9-A]1N!P:7SY/[WZ4>?)_>_2IM+N5>/8-0TC3=7B6+5M/
MM;Z-3E4N85D /L&!IUCIUEI=O]GTVSM[.'.?+MXEC7/T  IOGR?WOTH\^3^]
M^E+EE:P^97N6Z*J>?)_>_2CSY/[WZ4<K#F1;HJIY\G][]*//D_O?I1RL.9%N
MBJGGR?WOTH\^3^]^E'*PYD6Z*J>?)_>_2CSY/[WZ4<K#F1;HJJ)Y!WS^%31R
MB3V/I2<6AJ29)1114E!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 53F;=*?;BKE4I/\
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M:7_G\F_)/_B:/LTO_/Y-^2?_ !-6**+L+(K_ &>8=+R7/^TJ$?RIT$KEVAG
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M\*?\\=1_[\K_ /%4?\+V\*?\\=1_[\K_ /%4>RJ=@]O3[GI5%>:_\+V\*?\
M/'4?^_*__%4?\+V\*?\ /'4?^_*__%4>RJ=@]O3[GI5%>:_\+V\*?\\=1_[\
MK_\ %4?\+V\*?\\=1_[\K_\ %4>RJ=@]O3[GI5%>:_\ "]O"G_/'4?\ ORO_
M ,51_P +V\*?\\=1_P"_*_\ Q5'LJG8/;T^YZ517FO\ PO;PI_SQU'_ORO\
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MG_/'4?\ ORO_ ,55JG-JZ1DZU-.S9Z517FO_  O;PI_SQU'_ +\K_P#%4?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV^T_Y^H?^_@H^WVG_/U#_P!_!7*=1/14'V^T_P"?J'_OX*3[?:=KF(^P<&@
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M^S_86$[$+)KJPN4/.#*0<9I>WCT'["74\=HKU&[^&6C6_P :K'P@ES?'3[B
MR/*9$\T$1._!V8ZJ.WK57PYX%\/ZCJ6MVUZVO7LUEJ!M(+/2K8-($WE5DDE9
M?+4'!ZE?NL:KVT;7)]C*]CSBBO=]!^&WAWPU\8+?3;S[3J"2V?VNQCN%1EC8
M;@PEQPQ&,K@8YY'&:QD\ :%XCUKQ)KL?]NR:58W3Q/;6L*27<]R6RX0 $;!N
M&,C.#R1BH^L1N7]7E8\AHKMOB%X#C\)Q:;J.G->?V=J<>Z.'4(A'<6[@#*2
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MEC#"!P24SC/0#(SU/<&I?$'@/Q)XQOM!MO$NHV9T>QBC>^2!V\R[N OSMC8
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M:'\1?] O3?\ OF3_ .*H^JU0^N4_,^B:*^=O^&A_$7_0+TW_ +YD_P#BJ/\
MAH?Q%_T"]-_[YD_^*H^JU0^N4_,^B:*^=O\ AH?Q%_T"]-_[YD_^*H_X:'\1
M?] O3?\ OF3_ .*H^JU0^N4_,^B:*^=U_:(\0[OFTK32/99/_BJZ/0?VA+&Y
ME2+7],:UW'!F@;<H_P" GM^-)X:JEL4L72;/9:*IZ7JUAK5@E[I5U'=6[])(
MS^A'4'V-7*YMCI335T%%%% PHHHH **** "J4G^L;ZFKM4I/]8WU-7 B8PG
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M^G!&3SM]%J/CGXA>';H:A#:-J&E"XA26PCN$M< [E"OPV64D,>1D>E>A:O\
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MF_.O#*]3"4TH\[W9Y.*J.4^7H@HHHKM.0**** "BBB@ HHHH **** "BBB@
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MQ]:EJ*Y_U8^M1'<\F6Q5HHHK8Q"C%%% !BC%%% !BC%%% !BC%%% !BC%%%
M!BC%%% !BN3^)X_XMQJG_;+_ -')765PGQ9U&2T\(36K6[/!>E$693_JW5U?
M##T*J<'U'OQ4/B1Z650<\=12_F3^YW.E\*#_ (HW1?\ KP@_]%K6MBN9\ :C
M+J7@^Q=K<P00P1V\18_-)L4*S>PW @?2NFI2W.?&0<,3.,M[L,48HHI'*&*,
M444 &*,444 &*,444 &**** "BBB@ HHHH OT445@;A3)#@4^HY?NF@#YU^/
M[%O%^G_]>0_]#:O*:]3^/G_(WV'_ %YC_P!#:O+*]NA_"1X=;^)+U"BBBMC(
M**** "O3?@'_ ,E*;_KQE_FM>95W/PB\1Z5X7\;G4-=NOLMK]EDC\SRV?YB5
MP,*">QK*LFZ;2-:+2J)L]IT^?Q9K2:K9_$O0-*M/#PM7<S"13]T@@G]XV, %
ML\8(!S7%7,'AV7X$^$F\6W-]#9K.X5;!5,C,6D'5N  ,D\$^E>5ZMXJUW51<
M6UYKFI7=G(Y/DSW<CHP!R/E)QZ5TOB/Q-I%_\'?#>AVEWYFHV,[O<0>6XV E
M\?,1M/WAT)KG5&46O7IZ'1[:,D_3KZHO:E\-=%TCXI+X?OM1OVTZ6T^U0"VM
MFGN9>O[L!%//RL=VW&%[5;\3?"6PM-&T/4='DU2P_M*^BLWMM86,RQ^:<*Y$
M?W<8Y4\\]B,5T=Q\3_";?$>>[34)%L[S1%LAJ<,#A[60.[$;2N[!RIR >0ON
M1@:[XE\'2_#>'P\FNWVJRV^J+<W,S0/'+>*Q+2.A8$ _O#]\Y)4^H)%*K=;C
M<:5GL)XK^&WA3P]9ZC#+<^(K&ZM8E,.H7EIYEC<2$ [0T:$C/3DC!]<8,7A[
MX6:8WAG2=3\1Q^(+J75V!BCT:V$BVT9Z/*Q5L @@^O7 .#CH=/\ B/H.@6%V
M_P#PFFI>(K)[4K;Z-?6),XD;;]^X( 8#Y@1TP>,X&<C2_&^C:UX)T/3=2\7:
MGX4O-(Q#*;))BMW"  /]7T. .6Z'/!S2O5MU_KY!:E?I_7S//?&?A6?P;XHN
M='N)A<>4%:.<+M$B,,@XR<=QC/:O5O@M<>%X9#9:5;37&MS:=)<7M[+]V'#*
MODH,#CG<3].3T7R3Q5J,&I^([F>ROM2O[482"?5)O,G90/XCZ9S@=@171_"+
MQ)I7A?Q9>7FNW7V6WDT^2%'\MWRY="!A03T!K:I&4J6NYC3E&-738X2BBBN@
MYPHHHH **** "O>?V<3_ *!K_P#UT@_D]>#5[Q^SC_QX:_\ ]=(/Y/7/BOX3
M-\-_&C_71GME%%%>,>T%%%% !1110 52D_UC?4U=JE)_K&^IJX$3(Y/NUE7#
MM!<),@R5/(]1W%:S#(JE<P;P:MZD(1=9LRH+LR'T*$X_*E_MFQ_Y['_OVW^%
M9,L42L0TD8/H6%1>7#_SUC_[Z%1RHOF9M_VS8_\ /8_]^V_PH_MFQ_Y['_OV
MW^%8GEP_\]8_^^A1Y</_ #UC_P"^A1RH.9FW_;-C_P ]C_W[;_"C^V;'_GL?
M^_;?X5B>7#_SUC_[Z%'EP_\ /6/_ +Z%'*@YF;?]LV/_ #V/_?MO\*/[9L?^
M>Q_[]M_A6)Y</_/6/_OH4>7#_P ]8_\ OH4<J#F9M_VS8_\ /8_]^V_PH_MF
MQ_Y['_OVW^%8GEP_\]8_^^A1Y</_ #UC_P"^A1RH.9FW_;-C_P ]C_W[;_"C
M^V;'_GL?^_;?X5B>7#_SUC_[Z%'EP_\ /6/_ +Z%'*@YF;G]L6)Z2G_OVW^%
M.&I6[?ZOS'/H(F_PK$1( >9H_P#OL5HVLELI $\6?3>*.5!S,NP*\DQN)1L)
M7:J9^Z/?WJ:3[M*O3BAAD5:T(;N9-P[07"3(,E3R/4=Q5A=9LRH+LR'T*$X_
M*EN8-X-9,L42L0TD8/H6%2TBD[&M_;-C_P ]C_W[;_"C^V;'_GL?^_;?X5B>
M7#_SUC_[Z%'EP_\ /6/_ +Z%+E0^9FW_ &S8_P#/8_\ ?MO\*/[9L?\ GL?^
M_;?X5B>7#_SUC_[Z%'EP_P#/6/\ [Z%'*@YF;?\ ;-C_ ,]C_P!^V_PH_MFQ
M_P">Q_[]M_A6)Y</_/6/_OH4>7#_ ,]8_P#OH4<J#F9M_P!LV/\ SV/_ '[;
M_"C^V;'_ )['_OVW^%8GEP_\]8_^^A1Y</\ SUC_ .^A1RH.9FW_ &S8_P#/
M8_\ ?MO\*/[9L?\ GL?^_;?X5B>7#_SUC_[Z%'EP_P#/6/\ [Z%'*@YF;?\
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MJ>B@"#[./2C[./2IZ* (/LX]*/LX]*GHH @^SCTH^SCTJ>B@"#R!2B "IJ*
M&*@%/HHH **** "BBB@"2#_7+5NJD'^N6K=9RW-([!1114%GFMA(-!^.VH07
M/R1:S;!H&/ 9L X_-7'Y5Z57*^//!Z^*-,CEM9EM=3LF\VUN#Q@]=I/8< Y[
M$9KDM ^+TD%S'I/B6S\Z[240&ZLI$=7.<9(SC\0?PK9Q<U='O3P\\QHQK4-9
M124EUTT37>Z_$]7J*Y_U8^M2U%<_ZL?6LH[G@2V*M,ED6*-G<A549)/84^L;
MQ3*8_"^J,O46<I'_ 'P:V6K,).R;/F+QKX@F\2^*[R^F8[3(5C7^ZHX _2L"
ME8[F)/<YI*]E*RLCQM>H4J(TDBI&I=V.%51DD^@I*N:1J3Z/K-IJ,4,,\EI,
MLR1S@E"RG(R 02,@=Z;!;GU%H?A?6] L?"=AI<UI'8:=&YU.-V8/,[KSMPI'
M#,S<D=JXKP1X='A;]H#6[&.+;;-82SVX P/+=XR /8'*_P# :\;\3>([[Q7X
M@N-8U3RQ<3[04B!"(   %!)(''KZUU2?&+7UURUU=K+3)+VWL6L?-:%\RQDJ
MV6P_)!4D8P/F;BN'V%1)Z[H[O;TVUY,ZJWUFX\:_ OQ+-K4=NPTZX4V*1P*B
MVJ*$VH@4#  )4'K@D<UV?AV9M!UW1O".K:E;B2:PVC0]-TX+;QKM=FDEED+,
M^<$<$9;!(Y)/@FE>--1TCPAJ?ARVAM6L]2;=,\B,9%. /E(8 ?='4&NC@^-G
MB2&:VN38Z/+?01" WTEH3/+&.=C,&^Z3SA<<TYT9.Z6PH5HJS>YT]I<-X?\
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M(#N4<J&Y&3G.>^:NZ-\4=8TG1K33+BPTG5X+%]UFVIVIF>W] C!AC';N.@.
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MV\5H81A8Y/-!88]PH_[X(P,<ZO\ 8OB2/]I!M6:.Y_LC[-DW)SY(A\G'EYZ
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M_P"^S1]MNO\ GXE_[[-'U7S#ZV_Y?Q_X!]G;AZC\Z-P]1^=?&/VVZ_Y^)?\
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MJG41*,8+9 5F/'=:/;P#V$SR2BO8;+P-I^C>./!&H^&=2U**RUM'DC>=8C/
M1'NZ[2G(<#!4]#R>R/X#T35[CQOK7B/4]2!TG4) TL7E;I5')RNT#>W08VC)
M'%'MX_UZV#V$OZ]+GC]%>G:M\,--O;/PQ?\ @N[O9+779_(VZ@%,D1Y)8[0!
M@!6R/;@G-:>H_!W3)+35;71/^$@34]+A\SS[^U"6EZ57YEB; [],G\QR'[>
MO83/'J*Z'P'H%KXH\;Z=HVH231V]TSAV@8!QA&88)!'4#M7?P_#'P3>KXC@M
M-<U:*?P[(3>7$L2-$(P6)"J!N9@J%2<C+#(&#BG*K&#LQ1I2FKH\?HKT3Q'X
M%\.0^&_#_B'P_J=]#I>JW)MI6U",220\L"VV,<XV-P,YXP:W]1^$F@R>%-;U
M+2/^$BM)-+A>5)=5@2*.YV)O8+&563&!C) &3WP:7MH(?L9L\<HKUCPM\*M#
M\8>']'U?3-4N88E=H]:CGD3="57),?R_*"1QNSPX/8@GANQLI/!GQ!?PWJFH
MQ:5;QJ(HY!"3<J$?ER8\@'!("[2 >>:'6CK;H"HRTOU/)Z*]H/PL\%6E_P"'
M;&_U#6_M6NP;HEA:(JC!0Q))3@<X P35*7X5>')+;Q'ING:MJ,^N:#!YTDCQ
M(MO)D%@@49;.T;2<]3D9'%+V\!^PF>245WOB'P+IFD^&O!^H6T]VTNN!3<K(
MZE4R$/R848^\>N:ZR/X.>'6\<:OHTFH:E%:6-A'=),9$+!F+9W?)R!CH,'WI
MNM!*XE1FW8\6HKU67P)X%_X0JU\81ZEKT>D^8T4]L\<+7$K[MJA",*F""QSN
MR/0US/Q+\&VW@KQ-%9:=<37%G<VJ7,+3@;U!)4J2  3E<]!P13C5C)V0I4I1
M5V<A17LVDZ;X0A_9_NM0N+;4 9Y52[GB$?G-,&7"J3QY6[''7KWK*B^'GA;0
MK31(/'&I:G#JFM /''9+&([53@#S"P)/)ZCW&.,E>VCKH5[&6FIY=17M7AKP
MO<^#]-^)FC7DBS&'2@T<RK@2H8Y2K8[<=1S@@C)ZU1T7X2::-'T5_$*>()KS
M65\Q6TNU#062MMV><2I(/S9/3'([9*]O'7^NEP]A+3^NMCR.BO6-)^%&D6\?
MBD^*M0O5'A^529++:/-BV;\[6!^8KC S@$]ZI^'/!O@[Q$UW<6"^*;V'STAM
MK.UMT,R KR\TI7R5!.<#<, 9).>'[:(O8RT/,Z*]Y\,?#KP]X:^,C:7<_:-0
M9;%;[3Q.J%8_F96\SIN8$ J0,<],@&N>LOA]H>OW&O\ B%%U^;1K6Y,$5I:0
MI)>3S9&\@ %=@+<>W4C'*]O&X_82L>3T5ZCJ'P>)\9:'I^EW-U%IVLPM.K7L
M.VXM0B@NLB\#(W*.W+8[9/7^!]-\):</&$'A*^U&XDM[*2"X6^"$/@-AXRH'
M&01R/2B5>*5UJ$:$F[/0^?Z*U/#.@S>)O$UCHUM(L4EW+L\QAD(,99L=\ $X
MKV_X=:)X.T3XC:I8>'=1U.?4K"TDAN!=JABE^9-QC*@$%6&"#USQD#-54JJ"
M)ITG-GSY17?Z1X*T"P\!P>*O'%WJ4<%]-Y5E:Z:J>:P&<LQ<8Q\IXXX .3G%
M;=E\&K6Y\>V]@NJ2W&A7FGMJ5K<Q*JR2Q[E C&>-WSH=V,$'H.@'6@MP5&;V
M/):*[[Q-X-T&"/2X?#SZW9:K>W A&F:]:-%(X9MJNK*@7&>V3U[8P>JD^"NE
M/<SZ':2Z\-7BMA*-1FM -.DDX.P-C.2#ZG'/4C;2=:"5V-49MV1XO0"0<C@T
MZ6-X9GBE4JZ,593V(ZBFUL8GU)\*M:DUOX?V4L[%I;<FW=CWVXQ^A _"NQKS
M;X$_\D\D_P"OZ3_T%*])KR:BM-H]6B[TT20?ZY:MU4@_URU;KGEN=,=@HHHJ
M"SS?P9_R5WQ=_P !_F*](KS?P9_R5WQ=_P !_F*](K2I\7W'JYK_ !X_X8?^
MDH*BN?\ 5CZU+45S_JQ]:B.YY,MBJ>E<_P"+O^17U3_KTE_] -= >E<_XN_Y
M%?5/^O27_P! -;K='//X&?)1ZT4'K17LGCA1110 5Z9X-UWPK_PJ;5_#'B75
MI;">^OA)&T5N\I0 1[7.!@@%#D9R0#CG%>9T5$XJ:L7";@[GK_\ PFWA;1Y/
M!N@:1J$EWIFCW?VN[U%[=T#,=V<(1NZNQQCC@<\T#Q_X<OM<\8:/JEU(NB:_
M)YD&H1PLWDN$ #,A&XC*KT&<CT.1Y!16?L(_U]YI[>7]?<>N0^)M"T^T\+>"
M_"E[+JD7]L07-YJ$D!A5F\T854;D=L^F!R<G'1>(K_P7X>^,E[XDU/5;J+4[
M"-0VF):LWVB0P *ZR#Y0-C@;3M^92<XZ^#V=W/87T%Y:/Y<]O(LL3X!VLIR#
M@\'D=ZL:UK5_XAU>;5-8G^T7D^WS)=BINVJ%'"@ < #I2=#7?O\ B4J^FVIZ
M+X9\7:5_IVH1^,=4\*:M=7DMQ<1-:_;+.42,Q^2(+PP&P%F_#KQNP?$[PQ/\
M7[S6I+E[;3UT=K%+EX')N)!(&W;5!(!'3('"\XZ5X?13="+=R57DDD>M:#XY
MTK4_A]IVA:IXHU'PK>Z7* MS9I*PNH3GY?W?((&!S[$9R<9MEXA\//XYO;A_
M%?BFS18A#I^L33^>PVY8^:@7<T9;;A!_P+&?E\WHI^QCK;J+VTM/(]1^)GCG
M3M=\'Z7HL&L/XAOX+@W$^IFR^RKC#@($P.<,.G'RCOTH_"WQ1H_ARR\21ZS>
M?9FOK+RK<>4[[VP_'R@XZCKBO/**?LH\G(+VLN?G.[U+Q)I5Q\#=(\/PW6[5
M+;4FGEM_+<;4/F\[L;3]]> <\UI0Z_X4\8^!=%T7Q7JLVAWNAML2X6T:=;B$
M\%5VY*MA4R3QQP#G \RHH]DOQN'M7^%CW6Q^+'AV?QAJ<T]Q)9:7#I0L+%I8
MF9IB&)+$*I*YSW[ '@DBN-_X2C1_^%#?\([]L_XFOVWS?L_E/]W?G.[&WI[U
MYY14JA%;>7X%.O)[^?XGH?Q;\4:/XGO=&DT.\^U+:V0BF/E.FUL]/F S^%:6
MA^*/#5[\*+'PWJVOWFB2V=T\EU';P2/]OB)=C'E>!D,!\W *]#UKRJBJ]DN5
M1[$^U?,Y=SO/B_XCTGQ3XP@U+0KO[3;FR2-LQ.A1@S$@A@.Q'3(K@Z**N,5"
M*BB)2<Y.3"BBBJ)"IK+_ (_X/^NB_P ZAJ:R_P"/^#_KHO\ .@3V/L^BBBO%
M/;+]%%%8&X5'+]TU)4<OW30!\Y?'O_D;K#_KS'_H;5Y97J?Q[_Y&ZP_Z\Q_Z
M&U>65[=#^$CPZW\27J%=5X-\;MX7M=2TZ]TY-6TG4X]ES9R2F/) (#*P!VGG
MJ!G@=, URM%:RBI*S,XR<7='<ZG\3IGUC0[SPYH]IHT>AILMH\^<S*005>0@
M$J02,<'YF.<G(N:A\5;<6NJMX;\,6^C:CK VWU\MTTK,I!W;%P A).<C\B<$
M>=45'LH=C3VL^YV&L>/?[6T'PSIO]F^3_8./WGG[O/\ N]MHV_=]3UK5O/C!
M?2?$1/%%AIR6ZFU6TN+*27S5FCR206VC!Y!!QP1W&0?.J*/90[?TQ>UGW_I'
M<:W\1+>X\,3Z!X6\/P^'[&\E\V\"7#3O,>, ,0-J\=/P&!D&EXV\<OXO\366
ML16(L7M+>.%8S+YN2C,P;.T?WNGM7*44U3BM4#J2>C.Q\?>.++QQ<07O]A#3
M]10!9KE;MI!*H' V%0%P>?6JMGXR^R?#._\ "/V#?]LO!=?:_.QLQY?R[-O/
M^KZY[^U<Q10J<4DNPG4DVWW/0-2^*/\ :'Q'TGQ7_8_E_P!G6ZP_9?M6?,QO
MYW[./O\ H>E<GXFUK_A(O$U_J_V?[-]LF,OE;]^S/;.!G\JRZ*(PC'8)5)2T
M9Z+I?Q-T;3KFSU,^!M/&MV<92.\L[AK:(G# ,8%7:3AN3W]N *FE_$UQ8ZMI
MWBG2(]=T_5+HWCP&X: QS%@Q*L,D+QT'Y]0>%HI>R@/VLSO],^)UMI/CN/7[
M#PQ96EK#:M;16%HPBX/\3R!/G;W(]/J8M+^(]LF@W.A^)?#T6MZ8]TUU;PM=
M- ]NS$D@.H)(Y/H>6Z@XKA:*/90[![6?<[2R^)$^E^/?^$ATG1M/L+<QFW?3
M;:(1QR0$YVL0.6Z'?CJ!QCY:DUWXA65WH,&D>'/#%GHMK'=_;')E-PYDR,%6
M8#;TP?; &!P>'HH]G"][![2=K7.Q\?>.++QQ<07O]A#3]10!9KE;MI!*H' V
M%0%P>?6N.HHJHQ459$RDY.["O>/V<?\ CPU__KI!_)Z\'KWC]G'_ (\-?_ZZ
M0?R>L<5_"9KAOXT?ZZ,]LHHHKQCV@HHHH **** "J4G^L;ZFKM4I/]8WU-7
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M4]92W-8[!1114E!5:Y_U@^E6:K7/^L'TJH[DRV(3TKG_ !:?^*6U3_KTE_\
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MM"^*TVEE#;M*V&0?*SB,AR/7+;CGOUKY_I4I2E)MCK1C&*2"BBBN@YPHHHH
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MXKJ33X5CW2QY\N##DR[CT7<A Y^]TYQ3'>/5H?BI:Z,ANI&**L=NNXN_DE2
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MQGM2+X$\1LND$:=QK0S8?OX_WW ;^]\O!'WL4E[._-<;]I;DL4'\1:W)I?\
M9KZQ?M8;0GV4W3F+:.@V9Q@8Z8I-.\0ZUH\+Q:3J]_8QNVYDM;EXPQZ9(4C)
MJQ=>$M<L?$T?AZ[L&BU25T2.!G7YBWW<-G:0?7.*EN?!?B"T756GT\C^QR@O
M@LR.8-WW20&)(]QD#GTJKP\B;3\S/M]:U6TEN9;34KR"2[!%P\4[*9L]=Y!^
M;.3U]:DMO$.M6=@+&TUB_@M =PMXKIUC!SG.T''7GZUG5=T;1K_Q!JT&F:1!
M]HO)\^7%O5=V%+'EB . >]4U&UV2G+9$LGB/6Y7NFEUC4':]01W1:Z<F=0"
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M\'HKWC_A2_A_^]>_]_1_\31_PI?P_P#WKW_OZ/\ XFCZS3#ZO4['@]%>\?\
M"E_#_P#>O?\ OZ/_ (FC_A2_A_\ O7O_ ']'_P 31]9IA]7J=CP>BO>/^%+^
M'_[U[_W]'_Q-'_"E_#_]Z]_[^C_XFCZS3#ZO4['@]%>\?\*7\/\ ]Z]_[^C_
M .)H_P"%+^'_ .]>_P#?T?\ Q-'UFF'U>IV/!Z*]X_X4OX?_ +U[_P!_1_\
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MUW=NWTKQS4H+6UU*X@T^\%]:QN1%<B(Q^:O9MIY'T->[?\*1\.?W[[_OZ/\
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MG/1;'52H<CYI;A1117.=)?HHHK W"BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+^2&[T[PW;PPVHCC:W%[>[@5PREMH9(&^]GH#D$@]QJW@#PWK<D[:C8R,MS
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD[)"N,#C/// !+<^*I9]<_LRUMY(X_[4AL([J.49E=8C<3#:R$; B!"1R2S
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MP:95< X6.8HK#Y6#OC. : -[Q'K3:!H<E_Y,#E&56-S=K;019.-\DK?=0=R
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M#4/"S74FL26U[]F>_P!)73;?$.X6FWS?G R-V3*../\ 5CFJMSX1O[767O\
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M^!&SKDC86P64,,C  ZZ\=7">/YO#-EIEK-+;B!G6>_\ (N)XY.6D@B9-LJ(
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MFQXU5/MS2%_+$GV7;GR_,XR7#;?FVXK4TCQU<:SXROM%MM,M?+L+M[:X!O\
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MX2=F=EFC$H+N&;<'#+T^[UR =%X?U*YU?18;V]M8+9Y<E?LUVMS#*F?DDCD
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M,84<DY4WA75H-=U.[T+Q FFVNK2QSW<9L1-,DBHL9:&1FVKE$08>.0 @GO@
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M@!;=C &%'.Z?Q'X%3Q)=ZO-<WQC^WZ7'I\*B$,( LC2,QR?G#$H"O'"8SSD
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MWC$S,5V%RQ_U>X X##@@ ZJBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
=HHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>img30600998_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img30600998_10.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" /U!/(# 2(  A$! Q$!_\0
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M[#_P)'UQ]H3^]1]H3^]7R2OQ4^/?_0L:3^('_P =I?\ A:7Q\_Z%C2?P _\
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M  -'U5NHW5\J_P#"ROVAO^A1TC\A_P#':</B1^T0>1X1TC'T7_X[1_:5 /\
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M']I4$;+@G,91YE.'+_B1]>_:$_O4?:$_O5\B_P#"VOCP>?\ A&M)_P"^1_\
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M3]H+_H5-&_[Y'_QVG_:5 7^IN/ZU8?\ @:/J[=1NKY4_X6C^T%_T*>D?DO\
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MDG\!_P#':/[2H!_J;CO^?D/_  -'U7NHW5\J_P#"S/VAO^A1TC\A_P#':/\
MA9G[0Y_YE'2/R'_QVC^TJ ?ZFX[_ )^0_P# T?56ZC=7RNOQ*_:'SQX1TC\A
M_P#':7_A9'[1)_YE'2/R'_QVC^TJ ?ZG8[_GY3^<T?4^ZC=7RR/B-^T2>GA#
M2#^"_P#QVE_X6)^T5_T)^C_DO_QVC^T:/0/]3L;_ ,_*7_@:/J7=1NKY;7XA
M?M%M_P R?H_Y+_\ ':7_ (6!^T7_ -"?I'Y#_P".T?VC1%_J?C?^?E+_ ,"1
M]1[J-U?+G_"?_M%_]"?I!_ ?_':!X^_:-;IX.T?\E_\ CM/^T:7F+_4_&_\
M/RE_X&CZCW4;J^7O^$\_:._Z$[1__'/_ ([1_P )U^T>?^9-T<_0)_\ ':?]
MH4G_ #?<'^I^,ZU:7_@2/J'=1NKY?'CC]I!O^9,TG_QS_P".T?\ ";?M(_\
M0EZ3_P".?_':/[0I?WON#_4_&?\ /ZE_X$CZ@W4;J^85\;?M(G_F3-)_\<_^
M.T[_ (3+]I%O^9+TD_\ ?'_QVC^T*/\ >^X/]4<9_P _J7_@2/IS=1NKYC'C
M+]I(<_\ "%:3CZI_\=JO;?&+XR>'?&GA'2_&.@Z3I6GZYJ,=F)(TWN5)^;:5
MD.#@]Z<<=3;LNO<F7".,LVJE-^DDWIJ?4H.:*GL]+%PPVW:D9QG'N:UX?"9D
MY%VO_?&:](^)<7=W,&BND_X1!_\ GZ7_ +]T?\(@_P#S]+_WQ0+E.;HKI/\
MA$'_ .?I?^^*/^$0?_GZ7_OB@.4YNBND_P"$0?\ Y^E_[XH_X1!_^?I?^^*
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MB@ I'^Z3SZ\'%+39 6C8=L4GL!\8_M:V=K:_M$?"K46.R>XMYH)'9OD(5AL
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M"WV)5J1>M1+STY[>W/'6N&T/XTZ+KWQ5U/P!;VMZ-5TV)IIII% A95VYP?\
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MD^.&_L72/ NGNPU#6)%N+I8S_J[=#PK?[S ?]\FJ'PH\-+#]FA1,1Q@*H/8
M<"O1P-/FJ^T[%YK6^IY2J2^.L[_]N1_SE^1]"?#/3/*MH21CBO9-.CVQ+[5P
M_@O3/*MXP1C&*[^W7;&!7N'YN39S2444P"BBB@ HHHH **** "BBB@ HHHH
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M<MDW*D95ER?TK@/A+JEMJ/[9'B_4+:3S[.:SN)D:)L[UV*?IG'ZYJW\.=?\
MB5^T?KGB'4K+QS+X-T'3+GR+:SL8@S'.2N<_[/.3W.*RE1C&HY))1LG]X1KU
M'25";?/S-*UD].]ST/X!_'Z]^)VL:MX9\2Z0FA>+-+0M)#&2%F53AOE/W6!P
M?QKB/AWC_AN3QL>QLY^/0_NJQ_@IIFI:3^V!XHM-9UE?$.K164HN=22/RQ,V
M$Y*]B!@'WK9^'/\ R?'XVR/^7*;'UQ#5<BIRGR]OD9TZTZL:+J[^T:U/H3XC
M>-+?X=>!M;\27!^2PMBZ*3P\A&$7ZDXKQCX _9O@_P# O6/B+XI:07VL.VJW
M3'_6NK$B",>I8L3_ ,"%1_M+74WQ*^('@CX4V$C%;VX74=79. D*YQD>F Y_
M$>M:G[:&ER0?L_M#81&*RL[VU#I'PJPKE%!'IG;]*YZ,5&$:;^T=&(JRDYUH
MJ_LU9?XNIR,7Q\^-NK^'9O'6E^!]+_X0R/=*D$GS2R1*VTMG.YQZD <CTKUN
MS^.EOXF^ .J_$+084%S9V<DIL[@[A%.F-R/CJ#D8([&O,OAWX;^-_B3X;Z)+
MH7COPLOAV?3TAMXOL&XQP[=IC8X^\O(/N#4FA_!_5_@S^S)\3--U35-/U1;V
M&2Z@DTUBR ;-K<GCKZ5U5*='F45O=')2JXA7:;:Y6W?O8I^$_P!I#XN?%;PK
M$_@?P997NH6H9M2OW&+<,6RD42L<,Q7K7HG[./[1-S\5M0U3PUXBTQ-%\7:2
M<RV\*E%G4-@X5N48$\BJG[#US97GP)LK6R*O>VM].EW'']Y9&(*EA[CI]*\_
M\ SV^L?M]^(;K1V62RA@E%P\?W=PC56R1_M=Z)4X2<X<MN7J32J58>PJ>TOS
M6T^1Z-\*_BO=^*OVBO'/@^;1=(L[+28Y&BO;2W"W4Q# 8D8=>O/TKYXU#Q%\
M3(_VN[G4[3PY8R^/%61+;2MV(7A\O"L<GJ4 ;KWKT[X$?\GE_%?T^SS?^AK3
M0I;_ (**Q  EOLC8&/\ IV%;0Y85)65[Q.6HY5*,')[3)OVP;S7=2_9E\+W'
MB:RAT[7I-2C-[:0_<C?8PP/:JFL?M ?&/P_X%TSQ/H7@>UMO 5E:01+<WZ;Y
MYT"A?-< Y5&QV'&0:ZC]OU2OP5TY2"K?VQ&1D?\ 3-L_I7H?Q!14_99U1%4"
M)?#$?&,8'EK@5C3DO8TTX;NWXF]2$O;5&IVM%?J:?A/X[:+KWP13XDWBMIVF
M16LDMU!]YHI$.UT4]\M\J_6O#[7]H?XZ>*_#]WXY\->!-+7P3;L[I!-EIY8T
M^^PYRV/4<=<9KB;>UNKG_@G:YM22L>JM)/MSQ$+A@<^V2*[KX.>'?CKX@^%?
MA^;PKX\\+0>'FLA!;VLFG[Y($ *M#(P'W@,Y-:*C3CS/L[&3Q%6;A'5^[?0]
M2TWXO6'QL_9I\3>(M/B:UE_LNZ@N[)B";>=8CD ]U/4>Q%<7^Q7?'2?V5-2O
MDCCE>UN-0F$<J[D;;&A 8=U)&"*3X:_!#6_@G\#_ (J6^KZOIFL)JEK-=0OI
M9/E(1$ZOG\<=/2H/V/\ _DT'71_MZE_Z*2I<8J,U#:Z'S3E./M'KRL[G]EGX
ML:I\4OA#K'B.70=)T_4;6\GBBL=*B\B&;9$K ,,?>);%>?:I\;OVE;#1Y_$3
M_#'3K'1(%\Z2T<;Y5B_B8C=NQP<]Q7-_LP_$:;X3_L<>,_%%O;K<WMCJDGD1
MR?<WLD:J6_V03DUT_P /?!WQE^)GPU7QWJ'QDN-*.J6DUU'IHM5>W\D!LA^P
M! /T!YK3V<>:7-U:,_:RG3C!-MV>Q[+\)/C+8_'3X-ZAXCL[;[!<K;W%M>6>
M_>(9A$W0]P0<@^]>3_\ !.#_ ))=XP[8UW'_ )#K*_8'"CX&_$/;@J+J?E>F
M/L[<_2M7_@G""WPQ\6C'_,=X/UBQ2J14(U%$JG4=:5*?5H[#]MCQY=Z#\+[?
MPGHS,?$7C&\33+58S\PCR/,;Z'(7\ZSOVA? =I\+OV)-0\+62A(]-M;6)R!]
MZ3S 7?ZEJQ_![?\ "_\ ]L;6/$G_ !\>%_A_#]@L"W^KENSD%OKDLWY5Z!^V
ML3_PS/XM!SMW6PR?^NHI1_=RIP^8YM3C5K=+-(\(\"_&KXRZ3\"?#T_P_P#
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MQ7:Q7HOW<US5J5*"DGT.VC4Q3E3JSNE.][VM9[6]#EO#7[2OQ&\:ZMXD\/\
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M\*>&-('B3QKJ@!@LF)*PJ3A-ZC[S,<X'3')KRS]IZ:+4?VIOA79::ROK%N\
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MG^V5[>JMQ11A3BZ=/D^*YY]:I6:K5%4MR-&#XM_:(^+5EI \::9X*M;/P,S
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MAD1B0"K#!''M7S)\/_V(G^&WCZUUG1OB'JEOX?M[U;S^Q1'M\X*3M20J<'C
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M!YIYF$EW?S\RSN.A/8*!G"CI^-=L.E/2MI8FI42CW,*>#HTI*<8Z]#S'X)_
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M-P_B?P2K SZ9<OB>U3(Y!]NQ'_ LUU7@/XEZ%\0K-6TVY'VI5#364PVS1_\
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M=;++*DOB=CCGGV4T]*=*=3YJ/_!,?4/VK_$>JN@\.>!_)3(/G:C*2<$<\
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M/\57'!8CI"QA+$Y5#XL4GZ1;/K6]US3--CE>[U&SM4B&7,TZKM'ODUQVN?M
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M^%=!:Z2L:@;1^5=)\X<MHWA.*W"_NP/PKJK/3$A4845=CMU0=*E&!T% #%C
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MJ*C\Y?[U.5P>]*S0#J*6DH&%%%% !1110 4444 %%%% !1110 4444 %%%%
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MVW1[_!<B51@U8KDO#^K"XB4[NHKJHFW(*^V/D1]%%%, HHHH **** "BBB@
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MHD>V-C&/O*OZ5]!>$O'_ ,.OC_X-=-"U/1/&.@74)26Q79)B(C!22'[RX!]
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 DG^K?_=;^5<-7<R?ZM_]UOY5PU0*04444&0[:*TO#JG^
MTA_NM6=4VGZM9:7J5L+R\M[/SRT4/VB58_,?^ZN3R?84F[:LVC&4GRQ5V=C1
M4$ERL8RPVCL2>#]/6E2XSC/ [58;.S)J*0.#T-+36NP@HHHH&%%%% !1110
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MKRGXA3'3]5L77 8W!7\-N:]6O"!U]:\4^+ETJZKI\1SYGGLW'3  !KBRZ_\
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MJ")!M%%%%!D&?6OEK]L[2HO$'B+X7Z9.TB6]U?W$;-&^UTRJ#*D#C']:^IF
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFO(/VGM$NO$7P<\06UFNZ>)$NE0#EEC;+#\B?RKTC3]42X08.:35X!<V\BL
MR.N&![Y['VKBI2Y)JIV/.P]3V<XU>Q\1?#_7(;K3K2=6SE I'H17I<WBB-K$
M1EU'OFN,^)'P1U7P=KUUJGA 1OI\S;Y-,D;'E'//ED\8/O7 W'B/Q.B^2^@S
MQ2],R9"U]1STZZ4^9(^RYZ6)2FI)?,T?B?K4<>ESHAS)<'RT7N>>M=_\&9I+
M33[*WYQ'&JX_"O(M,\,:GKFI)=:D2SJ<K&O1:^A?AKX8>U\HD=Z\W'5XR2IQ
MZ'BYEB:=2*HTWMN?G;^TCXRUOP'^UWXWU[P[JEUHVKVNJK)%=6<A1P1&F0<<
M$''(8$'/(K"^$/C3P[XE_:$TCQ=\8M8O;W27U :EJ=YY)N#<2*0460*1MBW!
M<X!^50 M6/VQ$\G]J#XC(WR[=3!Y_P"N25VW[//[ _Q#^.R0:K>Q?\(7X7+;
MAJ6K0,)KE/6"$\M_O$A:\4\QV2/V$\.^)M)\8:/!K&A:I::SIEQ\\-Y8SK-$
M_'(RIP..W;O6C7F/P%_9T\&_LX^&I]'\(07:BZ82WEU?7+327,@& [#[BG_=
M45Z=31S/<****8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ ;_5O_
M +I_E7#^M=PW^K;_ '3_ "KB=M01(;13MM%!D(WW:^8OVK/^2A?"3_L*3?R2
MOIUONU\Q?M6<?$#X2'_J*3?R2O.S#_=F?:<)?\C>GZ3_ /26:L??ZU:CJK'W
M^M6HZ^-1^CR+4=6X25*D''K@_P"?UJI'5N'JM6<KYD^9,X+QQ\"="\8W"ZC8
M,_AOQ#&V^+5-.&QMW^V!C//<8/OVJIX2_:"\6?!O4+;0OB?:/>Z:[;+7Q+:)
MO5U!_CQU/JW##N#UKU2/C_ZU1ZKH=AXCTNXT_5+2&]L;@8EMYAE6YX./7Z8K
MLHUJE)\T'IV*J5*6,I_5\?'G@NNTH^C_ $V/7O"WC:QU[3[:]L;N*[M+E!)#
M/$VY74C((-=?:WBS+U!.<<5\"&Q\2?LM:JVKZ1<7.N?#JXE*WFGR,2^G@MD.
MN/\ T,<'H1FOJ[P!\2-.\7:39ZCI]TMU:7(WQR#J>.5/H1Z&OJL+BXUU;J?G
M.<Y+/+I*O3?/2EM+]&NC7XGK'6BL^QOA,@S_ #J^.>0:[#YKR%HHHI@%%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJH&,5MJ JXKA.![Z;!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH.O1FYTJY2,83:O6(\G..OM7):M^S[\:?CY=:7IOQF\5^';+P-8W<=Y/X?\
M"EO(DFI/&=R"61^B9YP*ZSYM%C]JZ\BU7XF?LLWD(;R+KQ4;A%/&%:UWCGV!
MKK?C3\9O&B_&/1_A+\+K;2T\4WVGR:OJ.M:T&DMM-M V WE@@N['H.E;7QN^
M">H?$[QI\(=5TJ]L;"S\%ZXVIW-O<!@TL/D^6J1X!&X<=<<5C?&_X&^+]8^*
MVB?%?X7ZSI^D^-]-LWTNZLM8B9K/4K-FW"-BOS*0>A%(#PC]K?P]\7]#\,>
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M]_W:\U9J*S@^RV-M 2':*&.(LO"G:H'3\*EH,^H4444 %%%% !1110 4444
M%%%% !1110 4444 %(PRII:*0MCSKXF0-_9B3+_RQF5^F>]4?-$\,<B]'4-^
M8KJO&.GF]TNYB R64@#WKA/#]U]ITE%/,D)*-]!TK\]SZG[/%1G_ #K\C[C*
MY>TPKA_(_P R6X^96&,C^5?&/[4VD_V?X^T;4%0 7-H\#R#.7>-OEX^AK[.N
M.,C\:^5/VPM/3=X;OB[!X[N:V"X^7YDW9/OQ7S5"5L0DO,^JP,FDS8_95O5:
M^OK8CE9H9=V< =5Q7UG>99W/O7Q!^SGK TWQ4(78JMU!A?\ :D4[A^E?;37
MNH$F7[LB!OS%>A;EJU%W9EFR_>0J=# \1+OT^9,XW8_F*_.OQ-?KK'Q4\47B
MQF)9=2EPA.<8./Z5^A/C;4HM+TB6>:01PJ&D>3. %4%CGVX%?G)H<[ZMK5W?
MNJ[[JYDG.P8'S,3Q6>"C>K.7DOS.G 75./J>FZ&A\GCCIGW'I7EWBCX\3> _
MB?J>BZG:?:]%C,926$8G@#1J3C/##J<=>:]?T:';"#M[5\C_ +0RD?%[7,''
MRP^W_+)>M>[E]&G7JRC4V.O.L=7P.%A5H2L[GUAX?\0:7XLTU+[1[V*_M6P-
MT39VGT8'E3]0*O-&"IY(!&,BO@_PUXJU7P?J27VD7LMA=*=Q"GY7QU#@\-V_
M.OL;X6>*=>\8>'5N]>T*71[E<!)C\J7&?XE0\C\?PHQV6RPMVI:'1DN?1S']
MU.%I_@-U*Z?P7\1-'\1KB.SN6^RW9SQ@C&[^OX5]L?#/6A/!%\XPPS\IXKY"
M\7Z -=\/WUD,"1DWQ<9^9>:]._9E\?'7/#-DLK_Z5:_Z-*O<%>%S]0!7K9+B
M+Q=%]#RN-,O^L8>EF%-:Q]R7YIGVWIDP:->>U:-<EX9U!;BW4AN,<&NJC8,H
MKZ@_&UM<=11N SVQUR,5&TR+RQQ3"Z)**B^T)UW8'UI1,A]3ZX&:-ADGX=B?
MRK\R?^"KWQ;&N>+_  S\-;"1+B#2D&I7\2$EC<RX6*,CL0F&]?G'2OO#X]?'
M+0OV?_AGJ?B_69#(L(\FRM8UW-=W+ ^5&H]">6/90?I7YH?L7_"+6?VK?VB[
M[QUXRDDO=,TN\&L:M<,N8[NZW;HK<>@X!([(@'\5(N.FY^B_[)GPINO@O^SS
MX0\+7X*ZK';&ZO8RQ/ES3,9&09Z!<A<=.#7KYZFC<6Y)R3S24R/-A2,P7)/3
MUQ1(P502< ]Z^2/BY^TAKOB7Q%>>'_ <RZ?IUL7M[G6=@:61P<,L9YVKP>>O
M%;T:$\0[0.S#86IBI-0Z;GUFTVW) /'7BH&G27 8KSZ\5^?G_".^(9KX:F_B
MC5VU%0 +AKERXP,=2<UV_@3X_>)_ .K0V'C"^EUC0YB(TU!^9;9O[S$]1[5Z
M$\NDE=2N>E4RF<8\T)7MT/L62SCFYZ#TI$TB+.0*P=$\4PZ@L;QR*Z. 59>A
M!Y!^E=3:W E4>E>/9J]SPKR=^;H)#8K$.*9JVH0Z/IUQ>7#>7:V\332D]E4%
MC_*KNT5RGQ,L9M4\#^(+"W4//<V$\,:MT+-&0*N"O))[%T[<ZN?#MUJ5Y\7O
M'%_XLU;,HEE*6D)'R0Q*<(H'L,?4UW5MX1_T;(C 4#GBN&^%MZG]DP1,NV2%
MC&Z=PV>_N:]JL=9MH[!D(4DCK7U=2\+*&BL?<5OW5HPT2V/$O&GA5["2/4['
M=;ZC92":*6/CD?U_QKZ(^$WQ+'C/PWI]_,0+B5<3J !\ZX!X[9/.*\A\=:E!
M!;7,K$;%4YR>.1P*J_ 6^EL].B3&P23M*%_$5Q8V*G03>YYV8^]AE)[H^RM-
MC2X7. 3ZUM0V*+7*^$[DRVZ9-=G'RM?/GRGH*JA.@I:** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@04OO2'Y>O%9FK:Y::/;FXN;A88U_B8_R]:<8NH^6.X.2AK/8T
MFD5 #GKP*RM6\166DQEKNYC@] YY_*N%OO&^K>(G:/1+9H+=N#>3=3[CTJ"S
M\(P^89]0F?4+D?Q2G('T%>O3R_K5?R/$K9I]FDK_ )%^\^)[7;>7I%A/>GIY
MCC:M4))/%>K-^_O(M-C8?ZN%>16['&L2A40(HXVJ,"GJ#]!Z#I7H0HT:?P0/
M*J8BO5^.>G8YD>"HYGWWNH7=VV3]Y\"K,/@O1XXPIM=_J68D_P ZWMHHVBM_
M:R[G,J4;:HRD\,Z5&H4:?"0/[R@T2>&=+D4J;"$?[J[?Y5J[11M%)5)?S,?L
MH=(HP)?!>E/MVV[1D=TD8'^=5O\ A"1;G=9ZC<VS9R,G=74;101Z4<[>^HU!
M+;3T.7"^)M+^9)X]00=CPU3VOQ":U=8]0MI;-\X)896N@YJ.XMXKI-DT:R1G
M^%@#64Z-*IK*.O=&]/$5J7PRNNS+VG>*[>\53',CKZ@UNVNI)(N=PQ7F5[X+
MCW&;39FLI^H7/RFJT?B34M!F5-2A;:./.'0UYM; 2^*B[GJT,RC)\M96/9%F
M5\<T[@]ZXG2/%$5U&C+("#WS73VM^LP!S]*\F5T[2W/;332<=F7Z*:KA@,<T
MZD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1_N-_NG^5
M<;TKLG^XWT/\JY"I8AM%.HI (WW:^8/VL/\ DH/PD_["DW\DKZ??[M?,'[6'
M_)0/A)_V%)OY)7F9A_NTCZ[A/_D;T_2?_I+-&/O]:M1U5C[_ %JU'GMUKX]'
MZ/(\"_:9\7>*+SQ9X-^&7A343H][XD<O<:@K[7V#@(#U QDX')Q7+_!_X5I\
M'/VN-.T,:Q=:WYWAN>[FN[KY69VP#CD_SS7J7Q\^!MS\6+/2M3T'4CHOBS1'
M:2QO>0",Y*LP!*\\AL?I7A\GP_\ VD9/B1%XH^S6:^((M/.E)K*S6X40'^+K
M][_:Q7NX>4'2M%I;[GQ^,4X8CVLHMM235MK=CUC]GOQ7KUC\=_BAX$U?6+CQ
M!;6<PU"VN+EMSQEC@J/08(&.G%?2T=>(_LY_ 2?X.V.JZGK>H_VOXMUQQ-?W
M2Y** <[%8\MR<EN_IBO;HZY*SBZGN;'?AU-4_P!YOJ_OZ%J.KB=*IQU<7[M3
M$TD5[KQ-I&FZM!IMWJ-O:WTR;XX9GV%E)P"">.2#6]'SM*],<8YS]/6O&/BA
M\$[WQQK$FK6&IQFY9!&+2Y3:JJH^55<?CU'>O.8]2^(GPC;]Y]NM;;.T+/F:
MV/TSD#\"*V@?#8K.<3@:TUB*+<%M)=2/XF0KH'[5=ZRQRQ1ZII\<VXGY9) N
M"WT 0"OISX8W>ZVBY["OC_QGXVOO'OQ \.^)IX[>SDL+7[+<1VV<2(6)W*.Q
MYZ5]-?!GQ)8:M%&MK>13-T,88!Q]5ZU[6732I.+[BSG-,%F-2C6PTTWR)279
MH^C=/DW1)GT^HJ[QC&/E]!69I+;HEYY]ZT^V>H]J]8\.PG/X?2ESZBF&15SS
MG;C.WD5C^(O%VD^%;,WFL:C;Z;;#^*YD"D_0=32NMR)24-9,VOQ^O/7WH/XG
MZFN?\,^-M)\8Z/!JNCW:WEC/NV2JI'0X(((R/QK<CN!)QFDFFKH(R4E='GOC
M+]G/X9_$3Q;%XG\3>"]+UO78P@%[=QLS'9]P,,X8#MD5Z(D:QQJBJJ*H 55&
M%4 8P!Z<#\J?2510?YZ4444 'Z4?F?QHHH 7_/2DHHH **** "BBB@ HHHH
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M:&*W0$<UV4?RC'M6;I=D(% Q6F!7"<'2PM%%% !1110 4444 %%%% !1110
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MBC\&=6\0R^++?PI$FH:#K$]P)9GT^9"!')("=Q4X&:!\I]1D *6+ (N=S,0
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MSN$:YTQG+(V?FCS_ $KU>ZA\U>/2N%\4>'1>J<KEATXKS,9@5C(KD?+);/\
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M/FSQ7PYX7NY[KQC%>6<#I;N!'*S=_0_RKZY^'MTYMX\\XX->[A9.5/WMSZ7
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MQU?3]8AW6U[!>*1@[9%?J.F,^E9^K> = U9B;K2H!(?XXQY;_F,5Y7J7PO\
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M,O\ O) >Q!.*];^&-OY=O#CIBL,PO]8MV/:RY6PR?<]DTT$P]/X6_D:^#/\
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M2&)\M3\QSG@ <T#DU?0^;/\ @H(/^,(O@V/^P;_Z1K7WAX$_Y$;PU_V"K/\
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MRKANM6;B7KS6=-)P:U1T)%.X;K67<'K5ZXDZUF7#]JWCN;Q1A^)+P6>FSO\
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M 4444 %+244 )M![4TQ*>WZ4^B@!@B4=A^5+LQ3J*  #%%%% !1110 4444
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M/N>!.FUNC;CN /K4Z7 /?;DCYL<5C)-[Y]Q4JS].AY!YJ>5^ACROH>(?$/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MRY;:BT5D:]XNT7PQ>Z/::IJ5O8W.L7:V&GQ3-@W-PRLPC7WPC?E6O0(****
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M.@J &T4^B@ JWI__ !\#W6JE6]/_ ./@?[M &CMHVBEHJP# ]**** "BBB@
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MZ?H?Y5AU+ ****0!5O3_ /CX'^[52K>G_P#'P/\ =H TJ***L HHHH ****
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MDTI4:1K]9U, 0?>;?G&!W.<5YW8?M0?"S4=4M;&/QA:1F\E,%I=7,<D-K=2
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MNR_]\J3^%!?-?0\7^ '[/-M^TMI,7QD^-MO)XJU'Q$6N=&\.7DC"PTNQ)/E
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M"@8P*ECM5B (4D=C@G^E3I<QJQ ;=C]?P[4 6%7;2TR.56XS3]P/2@ HHI:
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M!_NT :%%%%6 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)2VBX["O5+11Y>*\]\"P;;6/CL*]$MUQ'7Z<=:):***!A1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 #?=;Z&L/;6XWW3_NF
ML>H CVT5)10 58L/^/A?]VJ]6+#_ (^%_P!V@#0HHHJP"BBB@ HHHH ****
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M.*<@9CB::1F4'L"0*86/5OCM^V/K'P3\!^!-+7PU_;OQ?\46,4@T/852VD;
M9G1>22QPJ#&<'M7F>M?M=?M%?L]WFEZO\9_AYI\G@V^E6*2XTL!)+?)YY0L
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MKHE^48Q00,GA$BGBN<U?04NE.5!)ZFNHIC(#VH$>1:E\/8;B3<4!/KBF:?\
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M+1O!&CV/BW5H-<\2V\.R^U&UA$4<\FXG<J#[HP1Q714""BBB@ HHHH ****
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M>=I!X9,X.T]^17A/AK_@FRE]X@TR\^)7Q0UKX@:/I;@VNDSATB;&/OEG8@'
M! P3]*S_ /AZGX._Z)_XP_[]Q?\ Q5)_P]1\&_\ 1/\ QA_W[B_^*HNNX^65
MK'HG_!2"."Q_8[\1VUO&EK!;W%C''%'@)$@<A5&.@ '3%>-^ /V#%^(WP7\&
MZ]X/^(VM>!(?$.C6\VM:5;LTEI=2%<-( K+M)_ND'-:NJ_\ !3KX?Z[9M9ZE
M\,?$^HV3$%K:[M8)8B1R#M8D5-9_\%1O VG6L5M:_#CQ9;6T2[(X8H(51%]
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M]-Z?X;$EN&V[L<CV^E?,W[+EXWAG7OB%X+U)%@UO2/$-U-+&2<LKR,-XXY'
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MX)61&0[<YP00<>AP>M<5\&?@_H/P+\#IX5\-RWDVEI=SW@>^F$LA>5R[_,%
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MW_!1;4;[17CGLO"W@X:=JUU#R@N)9 4AR#@D#J.V*F_9?@1?VF/VFIM@$O\
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MODQ_\\H_^^!_A1Y,?_/*/_O@?X4ZBCF8#?)C_P">4?\ WP/\*/)C_P">4?\
MWP/\*=11S,!OE1_\\H_^^!_A2>5'_P \H_\ OV/\*><X..M>)?M#>.OC+X'D
MAO/AOX0T#Q'H5O82W>I7.L7I@>%DRV$4=1L&?K37,W8+GM?DQ_\ /*/_ +X'
M^%'DQ_\ /*/_ +X'^%?,/[+7QU^-7QS_ + \2Z]X*\.:7\.=5@FE75+&\8W0
M9"55?*/(!=2.>U?35U=0V-K-<W4R6UO#&9)9IG")&H'))/0 4>]>P7N2>3'_
M ,\H_P#O@?X4>3'_ ,\H_P#O@?X5R?@SXO>!OB->W-GX5\7Z-XBO+;F6WTZ\
M2611GKM![<#(J,?&7P&WC#_A$U\::&WB?=L&D_;HQ.6_N;<\M[4>\*YV'DQ_
M\\H_^^!_A1Y,?_/*/_O@?X5XC8_&CQ#<?MC:M\+GBLAX:M/"L>LHWDM]I^T,
MY4@OG!7 Z8S3OV1_C-K_ ,<OA[K^M^(X[**\L/$=_I,0L(FC0PPOM7()/S>]
M4U-*X<Q[9Y,?_/*/_O@?X4>3'_SRC_[X'^%.HJ.9C&^3'_SRC_[X'^%'DQ_\
M\H_^^!_A3J*.9@-\F/\ YY1_]\#_  H\F/\ YY1_]\#_  IU%%V WR8_^>4?
M_? _PH\F/_GE'_WP/\*=11=@-\F/_GE'_P!\#_"CR8_^>4?_ 'P/\*=11S,!
MODQ_\\H_^^!_A1Y,?_/*/_O@?X4ZBCF8#?)C_P">4?\ WP/\*/)C_P">4?\
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MV2ZOKZ6Y,$+'+1QASA4/H!6+J/[$/P9U/Q=+XAD\+2K+-="^ET^WOYH]/DN
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M;FQ2,AA;)<O)(4*0F7G9C[S9Q\O0_A7 ?!:WLK?P'X9BM!&EJNG0",1'( V
MG'XYH-(Z'-W'[,/P^N=+:S?P?I@@V;=T<1#\=/GS7E<&I>(_V(?&&EZIH>IW
M>H?"_4KM;?4=&O&+I8ECPR>C8R0P],&OMB:&U_L_( W8Z5\Y?M91VI^"OB[S
MO+*_9AM\SKN,BX(]^M!=[[GU]X5\8P:U;0W%O.LL$RJZ2*=VY2,@_B"*[VSN
MA*J\YKXJ_90\0:A_PJOP?%J#?Z3'I\<1Z<+CY<XX^YBOKWP[=>=#'SF@PZG2
M44B]*6@ HHHH **** "BBBD 444F\>M%UT'9]4+12;O<4;J9(M%%% PHHHH
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M]TUFU+ ,FBBBIN ZI;7_ %W2HJEM?]=1<=BW1116@BK??=;_ '6_]!-?+/\
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MO5^3/H"WGWKG.14U<QH6L)<1J0>#720R"1>*^::L?2(?1112&%%%% !1110
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M>(M&E\-7BW5F6^S2-T_N_P"S75^#O%R7<84MAAP0>WM7R..P;PLO=^%]3[/
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M^CUK]2>@P.E!4Y.X;<8!.XCK[>U%'I13,@HHHH **** "BBB@ HHHH ****
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M=(\3+@13DPS+P=U?FV;4WA<PE5GM(^[P+>*P$(4]XWNNNIW6H+%Y/RFO,OB
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MN2T?Q$EXJD."*Z:UN!(N<YKZH^:)Z*** "BBB@ HHHH **** "BBB@ HHHH
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M--/D?NL]BI.&'P_+AJC7.O>0^BBBO92Y=#QV[ZA1113$%%%% !1110 4444
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M'M6;?,="TJ\GL+$32X,AAA&TR-W)]1CM[5S'PU\5:GX@^UQ7T)DBA8LMT!M
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M+PEI'B0H-J&_M@SKCT<<_AFNQI:0[LY'X>_"/P3\)[&:S\'>%=,\.03#$O\
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MKQP_Q+^$O@_Q7( )M8TNWNYL=#(R#?\ AN!Q]:[&@E[A1110(**** "BBB@
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MTXU;X+>!/$FL2:AJW@S0=3U"X=?.N[O3H999,<9+%23@ #\*_-3]DSP-X?\
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M,_\ E(U\0O\ KIKG_H\UT4_A9$MS]1NQ^M)2]C]:2N8H****8PHHHH ****
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M.E:ZAE,C32*BB95_U#%6+X;CY2.M'*PN?0N1NVY&[^[GG\J/;O7BNCWGV?\
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M-,DC.(XT&%7(&/I7T%UY]>:&K.P!1112&%%%% !7Y]_MR?\ )Y'PP_[%J?\
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MHH ****@J(4444%BT4ZAN]*Y,AE%%%:$%6^^ZW^ZW_H)KY9_X)F_\D5\8?\
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MZ:>L4=M:QX0#VJ;I4</RJ!4E:FP4444#"BBB@04444#"BBB@ HHHH *_/O\
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M2/X'\;:MX6E=EBEF-U:;N <C+#WX_E7NY+B6[0J/<UX@P:QV4>VC%>TI6?\
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M.)2['&> ,G^5'+S:#2O<^.?VKO%[^*/B58>&87SI^BPBXG4?Q32#.#]%V_\
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M8OXTF/;\NM%% !1110 4444 %%%% !1110 4444 %'5@.]%-E;8N><G]<=J
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M8U.>3S6XC;AUKO7F? =&UL.HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^^ZW^ZW_ *":^6?^"9O_ "17QA_V.>I_^C#7-B/X9M2^(^N****\T[0HHHH
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M4LKBPE'!++\OYU[DN7$+FIZGY[4HU,+)QJ*R[GMG]L[K?;GM7,:Q?!LUQO\
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M>DI:2@H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*(HX%78[=4[5-^Q-S)L='2!5&T"M:.!8NV:D*CM12#<6DHHH$%%%% !1110
M4444 %%%% !1110 J_?7ZUH5GK]]?K6A4%1$HHHH+"H[DX@-6=M07:CR?QH!
MZ%&BBBK,BK??=;_=;_T$U\L_\$S?^2*^,/\ L<]3_P#1AKZFOONM_NM_Z":^
M6?\ @F;_ ,D5\8?]CGJ?_HPUS8C^&;4OB/KBBBBO-.T**** "BBB@ HHHH @
MNHPRGZ5XS\9/A'X=^)FG^1KNEI>M&#Y5Q]R:+V5QR!GG' KVUE##WK+OM/\
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M$LL$R%'1AD,I&"OX@UUU4[R .A&.M5%M.Z#7='P#\1OA3JGPUU*YN-(MWO\
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MB.O)E(YD2(NT<4ZEI*S*"BBB@ K\^_VY/^3R/AA_V+4__HZ6OT$K\^_VY/\
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M>U8'P)_;D^&7QZ\3+X:L6O\ P_XCER8--UB$1FX(&<1L"1G'\).: UW/4_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *_/S]IGY?^"EWP:SQ^XM/_0Y:_0.
MOC[XZ? 'QYXR_;@^&GQ"TC0ENO".CQ6Z7M^UU&IC*,Y;"$[CPPZ"D7!ZZDW_
M  52_P"35Y_^P]9C@_[,U>C3\?L.R$X7_B@R<DXX^R=:T?VOO@;=_M#?!'6O
M"6F7$5MJZSQW]@9VQ')-'NQ&Q[!E9AGL2*^5/"W@/]KCQ1\&;SX2ZKH^G>'?
M#5GILEG_ &M<.AO+J%%_=VL;!]K%L*N\C &<F@$SLOV#\M^P+XFY(;&L'/I^
MY]*K_P#!*?P/H%[\#_$.K7>DVEWJ&H:R]G//<0+(QMUB3;%EA]WYF)'JQKT'
M]D[X*^,_AC^R+KW@GQ+H_P#9WB:Z_M(0V/VA)-PECVQ?.I(Y/7GBM#_@GQ\&
M_%_P+^#%WH'C;2QHVK2:Q)=K;K<).#$40!MR$CJIXIE71\\?\$^O 'A]/VI/
MC8QTNVE&@W%Q:Z;')&'6W0W;*=@8''RJ%^F:OZ?HUCX1_P""MD5MI%I#86UW
M:>9-#;Q!$8R6IWG:.!G:#7J7['_P%\<_"OX\?&?Q'XGT8:=HWB.]EETRY^TQ
MR>>IN6D&54Y4[2#S46H?L_\ CRX_X**V7Q070P? \=HD;:F;J/(=8&3'EYW?
M>([4!='F7[*.CV7QC_;K^,_B?Q7!%J>J:%+*FGP7RB00E9O*5PK# VH/EXXW
M$U8_X*C^$]+\&M\-OB)H=I#I?BN'5Q;B\M$$;RA 'C+$8)*D$ ]<$BNI^-7[
M,_Q1^%_Q]NOC3\"5M-1N]24C5O#MTP4R,P DP"0'1L X!W C(K#L?V??C=^U
MM\4_#7B/XXZ=9^#O!_AR036^A6K#?.P8,5"AB1N(&6;L,"@+HR?^"I7G^)M!
M^".[=!=ZE.X=E.-CRI&&/URV?P[5]E?!SX#>"O@?X=L=.\,Z#:V-U';1Q7&I
M*F;JY.T,[/(22V6R<9P,\5X;^WI\!_&WQLOOA:_@S15U6/0]5-Q>C[3' +>'
M<A7 8C=PIZ>E?6N?N9&#M'!Z]!0-R5CGOB+K%UX=^'?BK5K+F^L=(N[F# _Y
M:)"[+^.:^,/^"5G@70]4^&GBCQW?6EOJ7BC4=8EM9[RYC665(PH8JI;IN+$G
MN:^Z[NUBOK6>UN(UEMIXVBEC;HRL-K#'H02/QK\_M)^!G[0?['/C;Q)_PIW3
M+/QWX"UJ;SXM/NW!:V;^#<FY6#J#MW+D, ,T$1:L>Y_MAZ;I_P (_P!E'XFW
MG@W2K30+C5?+-V^G0B+S&GE2*20[>C%,CCCDU\V?LQ_&JZ^'_P"SUI?A6Q_9
MN\5>+=)U"WD-]J]E;I);ZIO)#,"5.5X"@=MOK7TG\*OAO\6?BM\*_'VB?M 2
MV"0^* RVFF6"+YVG1LO8J2H"D*RKDD$'+<UXK\/_  _^UI^RKI<_@/PGX7TK
MXB>%X9I'TC4Y)N(58YZ;P54DDE&X!)YI%W#]A'POXS\#_"WXY:-XA\+:WX6T
M26"2_P!+MM8MGBV[H90RKD $A5CR1UX/>M?_ ()?X_X93\<#O_:U[Q_VYI7O
MWPI\/?%N;X&>(;'XIW]AJOC+4H+P6T%B0%@21"$@9A\I()P".@QDFO/?V$/@
M?XV^"_[/_BKPSXQTC^RM:O;^YN+>U%Q'-O1[9(U.Y20,L#P:+"NC@?\ @DQ_
MR2SX@_\ 8Q+_ .BFK[G6OE/_ ()Z? WQK\"? 7C#3/&^CC1[S4-9%W;(+F.<
M21>65W90D#GL:^K101)W84444R0HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH 4=5_WJU:RAU7_>K5J65$****FQ8[:*K7PQ;G_>JS5>__ -0?]ZE<)&?1
M116ID5;[[K?[K?\ H)KY9_X)F_\ )%?&'_8YZG_Z,-?4U]]UO]UO_037RS_P
M3-_Y(KXP_P"QSU/_ -&&N;$?PS:E\1]<4445YIVA1110 4444 %%%% !1110
M 444^'_71_[P_G0(B2:.4L(Y$D*G#!&#;3Z''0T-(@D$1D02$9"%QN(]0.N*
M_,3X#_&35/@%^T/\0?%'B&YG?X7:YXJO- U*Y:1Y5L;M 9892#G:""5XXYQV
MK9^!/C;Q5\4?V\_"?Q UWSK+1O%>F:A-H-@TC!8M/A)BC;9T^?:6R1GO6WLR
M;GZ+:E#NA8=\8ZXY],^M>!?%;]G[P=XXU:?5=2\.VUWJ3#]Y<89&?C@MM89(
M]3ZUC_%W]I;XM_">[U_6M1^$%E+X T>X*SWD6NH=1EM0P47*0?W<'.#ZUH?&
M']H]=%F\":'X \-MXY\9>-K1=1TO3&G^SPQ6A7<T\[X^5>P'L:CV:E\2.FAB
MJ^%ESX>;C+75>9YXGP1T_10L6FZ;#9Q#./+CY.#ZG)KH= ^%860$H#D^G7Z?
MRJCX^^.7CGX5_ GQ'XZ\;_#&WT/6M)U.WL4LEU 26U['(5!GCD'S87=T(YQ4
M,?[6&JZ'\.7\7:U\,KW3I=<U&WT[P;HQFQ=:XTB$^:PQ^[0<'Z,*U245:*,J
MM6IB'S5I.3\SV;P_\/X[11NB V]1BNVM?#$4:$!!QQTKQ3X=?M$^+--^+6A?
M#KXM^ +7P-JWB*%I=$OM/OOM=K=,@R\#MCY7 X^IKE=!_; ^)WQ"UKX@Z5X
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M\-Z5KFES"XT[4K9+NWEQ@M&ZA@<=CSS]*TZS]1A1110,**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ***.F.],"*:\M[=MLMQ#$V,XDE53
M^IHCO+>9ML5Q#*^,[8Y58_D#7S;^V1^S;X-^(W@WQ3X^U@:I_P )#H7AZ?[$
MUIJ$D,(\H/(FZ-3ACN8\FO$OA/X;\,_LL?LGZ#^T+I.EZCKOC&ZT>UBN[>^U
M64VTHN9TC<[>0I QCZ5I&*:N3?4_00XYYZ<4'"X#<9.!GN?2O%OBM^T%=_#?
M6/A!8P:-!?#QUJ<&G3R-,5^QJ\:MO3CYCSWKB/%W[5'Q _X7KX\^%_@3X:6O
MBG5/#MG!>17,^I&WC:-U5G\W(XZX4#))Q4\C87/J!6#=AGT- ^;HN?48Z?6O
MB6W_ &\_B%XB^%>H>//#WP;6YT/PVSP>)I+O4@ABF1L2I;+C+A1R2>AXKTWQ
MW^UU(L?P^T;X<^%9/&GC7QMIRZO9:7/.((+2TV@M+<2=@#D<=<4>SD%SZ-_
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M$1/X3U_X2_ZF/\*^A]&_U*U\\?"7_4Q_A7T/HW^I6O3ZL\U&O24M)04%%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(S_\71_P]$^"O_/#Q=_X(S_\71[.?\H<R/KFBOD;_AZ)\%?^>'B[_P $9_\
MBZ/^'HGP5_YX>+O_  1G_P"+H]G/^4?,?7-%?(W_  ]$^"O_ #P\7?\ @C/_
M ,71_P /1/@K_P \/%W_ ((S_P#%T_9S["YD?7-%?(W_  ]$^"O_ #P\7?\
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M%W_@C/\ \71[.?8.9'US17R-_P /1/@K_P \/%W_ ((S_P#%T?\ #T3X*_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?\*?'_/!?^^!_A1_PI\?\\%_[X'^%?3_ /PCT']RC_A'H/[E :GS!_PI\?\
M/!?^^!_A1_PI\?\ /!?^^!_A7T__ ,(]!_<H_P"$>@_N4!J?,'_"GQ_SP7_O
M@?X4?\*?'_/!?^^!_A7T_P#\(]!_<H_X1Z#^Y0&I\P?\*?'_ #P7_O@?X4?\
M*?'_ #P7_O@5]/\ _"/0?W*/^$>@_N4!J?,'_"GQ_P \%_[X%'_"GQ_SP7_O
M@5]/_P#"/0?W*/\ A'H/[E :GS!_PI\?\\%_[X%'_"GQ_P \%_[X'^%?3_\
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M?\*?'_/!?^^!_A1_PI\?\\%_[X'^%?3_ /PCT']RC_A'H/[E :GS!_PI\?\
M/!?^^!_A1_PI\?\ /!?^^!_A7T__ ,(]!_<H_P"$>@_N4!J?,'_"GQ_SP7_O
M@4?\*?'_ #P7_O@5]/\ _"/0?W*/^$>@_N4!J?,'_"GQ_P \%_[X%'_"GQ_S
MP7_O@5]/_P#"/0?W*/\ A'H/[E :GS!_PI\?\\%_[X'^%'_"GQ_SP7_O@?X5
M]/\ _"/0?W*/^$>@_N4!J?,'_"GQ_P \%_[X'^%'_"GQ_P \%_[X'^%?3_\
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M]GB_YY+^5%% !]GB_P">2_E1]GB_YY+^5%% !]GB_P">2_E1]GB_YY+^5%%
M!]GB_P">2_E1]GB_YY+^5%% !]GB_P">2_E1]GB_YY+^5%% !]GB_P">2_E1
M]GB_YY+^5%% !]GB_P">2_E1]GB_YY+^5%% !]GB_P">2_E1]GB_YY+^5%%
M!]GB_P">2_E1]GB_YY+^5%% !]GB_P">2_E1]GB_YY+^5%% !]GB_P">2_E1
M]GB_YY+^5%% !]GB_P">2_E1]GB_YY+^5%% !]GB_P">2_E1]GB_YY+^5%%
M!]GB_P">2_E1]GB_YY+^5%% !]GB_P">2_E1]GB_YY+^5%% !]GB_P">2_E1
M]GB_YY+^5%% !]GB_P">2_E1]GB_YY+^5%% !]GB_P">2_E1]GB_YY+^5%%
M!]GB_P">2_E1]GB_YY+^5%% !]GB_P">2_E1]GB_YY+^5%% !]GB_P">2_E1
M]GB_YY+^5%% !]GB_P">2_E1]GB_YY+^5%% !]GB_P">2_E1]GB_YY+^5%%
M!]GB_P">2_E1]GB_YY+^5%% !]GB_P">2_E1]GB_YY+^5%% !]GB_P">2_E1
M]GB_YY+^5%% !]GB_P">2_E1]GB_YY+^5%% !]GB_P">2_E1]GB_YY+^5%%
M!]GB_P">2_E1]GB_YY+^5%% !]GB_P">2_E1]GB_YY+^5%% !]GB_P">2_E1
M]GB_YY+^5%% !]GB_P">2_E1]GB_YY+^5%% !]GB_P">2_E1]GB_YY+^5%%
M!]GB_P">2_E1]GB_YY+^5%% !]GB_P">2_E1]GB_YY+^5%% "K;Q?\\U'X5-
,TXHHJ6-!1112*/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>img30600998_11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img30600998_11.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#X17AI9@  34T *@    @ ! $[  (
M   /   (2H=I  0    !   (6IR=  $    >   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $YI8V]L92!3
M96ET=&5R    !9 #  (    4   0J) $  (    4   0O)*1  (    #,#@
M )*2  (    #,#@  .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                         #(P,C,Z,#,Z,30@,3(Z-30Z-#D ,C R,SHP
M,SHQ-" Q,CHU-#HT.0   $X :0!C &\ ; !E "  4P!E &D = !T &4 <@
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" ,'!"$# 2(  A$! Q$!_\0 'P
M 04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0
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MB]T/3%T+QI8^$I%N6,D]YJKV(F&W[H9?O$=<5Z?7@/[6/_(I:!_U_/\ ^BZ
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M_P#(^:+_ -@W_P!JO0![5\2?B3%X!^'YO;>YL9M;:")K:RN;@!Y-Q"E]F=S
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M^S(M?TM]0SM^R+>QF7/ILSG]*\O_ &EO&E[X:\$6>EZ5.UM<:S,Z22HV&$*
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M^(6B>$IM7T3Q+>IIPO'2:">X.V,.H(96;^$XQC/'!Z'KVG[0'Q-\+7GPSN]
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MJ&-$2TF67RT#J[,^/N\+C!YR?:L/X<Z'<:5^R=XKN[N-HSJ<-U<1!AC,8B"
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M=.N-6>XM)1+#'+<J8T8?1 2/8F@#Q_0O^3RI?^PQ=?\ H$E:7[67_(S>'O\
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M;;LM;/4KB2XY/>/S05QU.['3UP*]-^$EOX&'A>>]^&UG-:Z=<SGS?-\[+2*
M./-)SC.,KQG/<5R]M^R]X"@OA/+-K%S'G/V>6Z0)],J@;_QZO6].TZSTC38-
M/TNVCM;2W0)%#$NU4'H!0!9KYPOOCIXI\*?&N;1O&I@AT.VNWBECMK;!,+ ^
M5+DY8\%6(!Z9KZ/KE/&GPU\+>/HT_P"$CTX2SQKMBNHF,<J#T##J.3P<CVH
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M(HHD"JBC@  < 5P'@KX*^'? GBN?Q!I%[JDUW-$\3)=2QM& [!C@*BG.0.]
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MMSC3IE1&/^ZRL!^ % 'B_P 9O$,'Q8^+.E:-X-;[?'$BV<4R*=LDC,2[#_8
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MT\ ('B<;2>!L)_#BKUQIUM\0?VN[B&_A6ZL/#MDI,<@!1R@! ([XDF)Q_LT
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M7GB2=X=R ^6%4RN%],EU'_ <4 >Q>"OB;X=\=^';O6=)FEM[>Q)^UI>*(V@
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M3$BCS)77/3)8C/\ L_GH?LQ6#W&B^)/%%Q$L<NK:CM 48 " L<>@W2D?\!H
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M=\-[?4/MD?A6V,N<[9)97C_[]LQ7\,5WD44<,*10HL<:*%1$& H'0 =A3J*
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M"^G&...G%<_X@\%:5X*\!^+[OP+HMQ'J6J6<BM#:--,99&#!2L62 07)^4#
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MW1]AN/\ H*W?_?$/_P ;J[10!2^PW'_05N_^^(?_ (W1]AN/^@K=_P#?$/\
M\;J[10!2^PW'_05N_P#OB'_XW1]AN/\ H*W?_?$/_P ;J[10!2^PW'_05N_^
M^(?_ (W1]AN/^@K=_P#?$/\ \;J[10!2^PW'_05N_P#OB'_XW1]AN/\ H*W?
M_?$/_P ;J[10!2^PW'_05N_^^(?_ (W1]AN/^@K=_P#?$/\ \;J[10!2^PW'
M_05N_P#OB'_XW1]AN/\ H*W?_?$/_P ;J[10!2^PW'_05N_^^(?_ (W1]AN/
M^@K=_P#?$/\ \;J[10!2^PW'_05N_P#OB'_XW1]AN/\ H*W?_?$/_P ;J[10
M!2^PW'_05N_^^(?_ (W1]AN/^@K=_P#?$/\ \;J[10!2^PW'_05N_P#OB'_X
MW1]AN/\ H*W?_?$/_P ;J[10!2^PW'_05N_^^(?_ (W1]AN/^@K=_P#?$/\
M\;J[10!2^PW'_05N_P#OB'_XW1]AN/\ H*W?_?$/_P ;J[10!2^PW'_05N_^
M^(?_ (W1]AN/^@K=_P#?$/\ \;J[10!2^PW'_05N_P#OB'_XW1]AN/\ H*W?
M_?$/_P ;J[10!2^PW'_05N_^^(?_ (W1]AN/^@K=_P#?$/\ \;J[10!2^PW'
M_05N_P#OB'_XW1]AN/\ H*W?_?$/_P ;J[10!2^PW'_05N_^^(?_ (W1]AN/
M^@K=_P#?$/\ \;J[10!2^PW'_05N_P#OB'_XW1]AN/\ H*W?_?$/_P ;J[10
M!2^PW'_05N_^^(?_ (W1]AN/^@K=_P#?$/\ \;J[10!2^PW'_05N_P#OB'_X
MW1]AN/\ H*W?_?$/_P ;J[10!2^PW'_05N_^^(?_ (W1]AN/^@K=_P#?$/\
M\;J[10!2^PW'_05N_P#OB'_XW1]AN/\ H*W?_?$/_P ;J[10!2^PW'_05N_^
M^(?_ (W1]AN/^@K=_P#?$/\ \;J[10!2^PW'_05N_P#OB'_XW1]AN/\ H*W?
M_?$/_P ;J[10!2^PW'_05N_^^(?_ (W1]AN/^@K=_P#?$/\ \;J[10!2^PW'
M_05N_P#OB'_XW1]AN/\ H*W?_?$/_P ;J[10!2^PW'_05N_^^(?_ (W1]AN/
M^@K=_P#?$/\ \;J[10!2^PW'_05N_P#OB'_XW1]AN/\ H*W?_?$/_P ;J[10
M!2^PW'_05N_^^(?_ (W1]AN/^@K=_P#?$/\ \;J[10!2^PW'_05N_P#OB'_X
MW1]AN/\ H*W?_?$/_P ;J[10!2^PW'_05N_^^(?_ (W1]AN/^@K=_P#?$/\
M\;J[10!2^PW'_05N_P#OB'_XW1]AN/\ H*W?_?$/_P ;J[10!2^PW'_05N_^
M^(?_ (W1]AN/^@K=_P#?$/\ \;J[10!2^PW'_05N_P#OB'_XW1]AN/\ H*W?
M_?$/_P ;J[10!2^PW'_05N_^^(?_ (W1]AN/^@K=_P#?$/\ \;J[10!2^PW'
M_05N_P#OB'_XW1]AN/\ H*W?_?$/_P ;J[10!2^PW'_05N_^^(?_ (W1]AN/
M^@K=_P#?$/\ \;J[10!2^PW'_05N_P#OB'_XW1]AN/\ H*W?_?$/_P ;J[10
M!2^PW'_05N_^^(?_ (W1]AN/^@K=_P#?$/\ \;J[10!2^PW'_05N_P#OB'_X
MW1]AN/\ H*W?_?$/_P ;J[10!2^PW'_05N_^^(?_ (W1]AN/^@K=_P#?$/\
M\;J[10!2^PW'_05N_P#OB'_XW1]AN/\ H*W?_?$/_P ;J[10!2^PW'_05N_^
M^(?_ (W1]AN/^@K=_P#?$/\ \;J[10!2^PW'_05N_P#OB'_XW1]AN/\ H*W?
M_?$/_P ;J[10!2^PW'_05N_^^(?_ (W1]AN/^@K=_P#?$/\ \;J[10!2^PW'
M_05N_P#OB'_XW1]AN/\ H*W?_?$/_P ;J[10!2^PW'_05N_^^(?_ (W1]AN/
M^@K=_P#?$/\ \;J[10!2^PW'_05N_P#OB'_XW1]AN/\ H*W?_?$/_P ;J[10
M!2^PW'_05N_^^(?_ (W4-U%<VD<<JZC<2?OXD*.D6"&D53T0'H3WK3JEJO\
MQYQ_]?,'_HY* +M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !5+6?^0#?_P#7M)_Z":NU2UG_ ) -_P#]>TG_ *": +M%%% !1110
M!R_Q"\7MX(\)/JT=LES*9X[>,2R>7&C.VT-(V#M4=2:Y2^^)GB/1/"&M:MJ>
MDZ5=_8! ]M>:;>F6TN1)(J%<_>5ESGWKMO&.G:QJ?AR2W\/36<=YO5O+OX1)
M!.@/S1N"#@,.X&17EEW\'M=U:S\0RQ6>B^''U.U@MX].T^5V@9HYUD:9SM #
M87: %[\T ==?>./$VI^(M5TWP1HVGW<6BE$O;G4+IHEDF9=WE1A0>0,9)XR:
MMVWCR^G\3^%-*N=&:P;7+2YGN(KA_P!Y;/$!\O'!!/?TQ6)K'@+Q%:ZQKZZ#
M;Z/JFC^)'2:[M-3DD3[/.H +C8/G4[0=O!R*S].^&7B_P[#X0FT.XT>XO?#\
M-[#(+MY5CE$\A*D;1GA>WKZT =%X[\?:IX;\6Z3H>DP:3NU"VEG:XU6[-O&F
MP@8W 'DYJO<>/_$6=%T?3-.T>_\ $.K+-,#;WK/90P1G!D,@7+9/& .N:H^)
MO WB_P 1ZWH6N7MCX6O+RQMIX+BSO/->V8NPVLH*DD@#OWJ5O!?BNSO-$\0Z
M39^'K75]+CGM'TRU,D=I-;2$-A6VY1PV3TP<T :<WQ!UC1/!NIZGXG\)WT=]
MILCQO%8J989E52PF5SC$?')(X]ZA\0_%"71]+\-36UA8M<:Y:&Z*WNHK:QP*
M$1L;V&"<R #ITJ['X=\5ZKX#\1V/B;4;234]8BFCMX(<_9[)7C*J@;&YN3DD
MBJ&L>$O$4>AZ%;:7IWA[57L]+_L^X34HR"C%%7?')M)V\<K@9XH [%-<CL_"
MJZUX@:WT^-+<3W)6<21Q#&>' ^8>A YK'A^)WA2;3Y;TZB\,,$\5O/Y]M)&T
M+2?ZLNK*"JMV8C'O69>_#>XN/@:G@9=05KJ.TCB6Y8$(SHX<#U"Y&/4"L%?A
MGKUWH>N0M:Z9I]UK:06<\DE_<7KK;+]]MTN06_N# QG)- '87/Q1\(VEJEQ+
MJA,,MU+9Q.EO(XFFC^\J84[O0$<$\"DF^*?@^WT>QU.75U%M?M(EN1#(69XQ
M\Z%0N0PZ;2 <UYWJ/AKQ%X5G^'NBVB:?>SZ9J=VM@Y#(DL B)7S2%^1R,C(!
M&<'GFM[0?AEK5KKFAZSJ=Q8_:(=9OM6OH(2Q1&N(PBI'D<XP"2<=Z .OB^(G
MAB;Q"NBIJ/\ IC2^0I,+B,S8SY7F8V[\?PYS4>G_ !+\)ZGJ4EE::J-Z)*ZR
M20ND4JQ?ZPI(P"OMP<X)Z5Q5E\*-3M?%C^=#9W6F?VVVK)=S7]QN3+;@HMU(
M3>&_C)QCJ#TJ+1/AEXHT_P 1-)"NEZ;I_E72W%M#=336EZTBD+_HS_ZH9.6V
MMSVH ZFY^*^@7/AW5+[0;Z)[BQM/M:I?0S0H\18*)!\F63)QN4'M5[4?B9X7
MT6]BL=7U-8;HQQR3;(I'CMQ)C:9'"X0'/&[%>>6GPE\5-HFN:8);/2[*]THV
M<5@NH374'G;U/F)O7=$F 1M!/6M76_AUXI=O$FGZ.VERZ?XHAMTN;BY=Q)9E
M(Q&Y50I#@@97D8- '6:K\4_"&BZM/INHZJ8KFVD2.<"WD982X!4LP4@ Y').
M*TO%?B!O#UA8W$;6H^U7\%KFX9PI$C8XV@_-Z9X]2*XG5/A=J=UHOC6PM;NU
M_P")ZMDEH\C-E1 B*?,XZG;VS74>-_"]YXET72;.REAC>RU.UO)#*2 4B;+
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MF,LV,#JK87:6R<=,D5,NKZM;:@\IDNKNT:(!"=/9<G]_AMH&<EEB';J#@9H
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M.T' &Z3GC[O7@Y /5/\ A(++_II_WS1_PD%E_P!-/^^:\:FUWQ%<6=Y'LN8
M8G,4J6+&3>4.V/ ''S C(S@C[W.:V-:U75K'4+**PAEDC,:&4>07#%B0?F /
M(X/;KWZ  ]-_X2"R_P"FG_?-'_"067_33_OFO(;_ %#Q(+5X)&G1GB5HY8+,
MEGD*Q$Q\?= +2?-_L]>#G5UN^UVVO+E]*@$T42J(H?)SYA,<A)W>S*@X]?<4
M >D_\)!9?]-/^^:NQW,<EI]H7/E[2W(YP*\6&K>()K5TE,J[HW$#Q63EISR,
M$X785Z@X&??&*]2\//>OX)MVU2-(KOR'\Q$8L!R<<GKQB@"U_P )!9?]-/\
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MA;_]=%_G0!U=Y>Q62*\^[#' VC-5/^$@LO\ II_WS47B/_CUB_WC7.T =/\
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M&)!N3/DXR.HK2G\3:#;2>7<ZWIT+C^&2[C4_D33LV7&$YNT5<?\ V%9^C_\
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MQ&*OK^EJPZ@WL8Q^M.S>Q<*<Y_ FR;^PK/T?_OJC^PK/T?\ [ZJ#_A+O#?\
MT,.E?^!L?_Q5'_"7>&_^AATK_P #8_\ XJCE?8OZO6_D?W,F_L*R]'_[ZH_L
M*R]'_P"^JA_X2[PW_P!##I7_ (&Q_P#Q56K37-)U!L6&J65R?2&X1_Y&BS)E
M0JQ5Y1:^18MK:.TA\J'.W.>353^PK/T?_OJM ,&&5((]C5>YU*QLH_,O+VWM
MT_O2RJH_,FD9I-NR*_\ 85GZ/_WU1_85GZ/^=0?\)=X;_P"AATK_ ,#8_P#X
MJC_A+O#?_0PZ5_X&Q_\ Q5/E?8V^KUOY']S)_P"PK/T?\Z3^PK+T?_OJH?\
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MT?\ [ZJ]YT?_ #T3_OH4>='_ ,]$_P"^A0!0_L*R]'_[ZH_L*R]'_P"^JO\
MG1_\]$_[Z%'G1_\ /1/^^A0!5M])M;:=98@VY>F34EWI\%ZRF<,2HP,&IQ(C
M'"NI/H#2LZK]Y@OU- &:?#]@75BA++G:21D9ZT[^PK/T?_OJKWG1_P#/1/\
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M.R*QE:I3J>RA)J,4K)/R6OJS'_X1'PW_ -"]I7_@%'_\31_PB/AO_H7M*_\
M */_ .)K8HJ.9]SC^L5OYW][,?\ X1'PW_T+VE?^ 4?_ ,35#5?A]H-] 38V
M46EWB?-!=6*"%HW['Y<9^E=/13YI+J5#%XB$N:,W]YRWA;Q%-<^#+B\U8*+K
M2S+!=E3PSQ#D^V1@_C69X7\+VWB.SC\2>*H5O[N^!EA@E):&VB)RJJIXZ8.3
M_P#KJ:9_R)/Q$_[".I_^BQ77^$?^1)T/_L'6_P#Z+6M)>[>QZF(?U:-25'W6
MY6TZ*U[+RU_ /^$1\-_]"]I7_@%'_P#$T?\ "(^&_P#H7M*_\ H__B:V**RY
MGW/)^L5OYW][,?\ X1'PW_T+VE?^ 4?_ ,31_P (CX;_ .A>TK_P"C_^)K8H
MHYGW#ZQ6_G?WLX/Q1X7MO#EG)XD\*PK87=B!+-!$2L-S$#EE91QTR<C_ /58
M\0:S>:T^D:%X>G:TFU: 74UTG6WML9)'N2< UN>+O^1)US_L'7'_ *+:N0\(
M\^-M"SV\&V^/^_BUK'57?0]?#R=6A[>I[TH7M?7II?O9ZK_(Z&#P5X3T737>
MXTNR>*)2\MS?1K*Q Y+,S?G4NG:%X.U:QCO=,TC1;JVE&4EBM(F5OQQ6S?V-
MMJFGW%C?1":VN(S'+&?XE(P15;0M!T[PUH\6F:-!Y%K$253<6.2<DDGD\UGS
M2[GDRQ6(D[N;^]D'_"(^&_\ H7M*_P# */\ ^)H_X1'PW_T+VE?^ 4?_ ,36
MQ12YGW%]8K?SO[V8_P#PB/AO_H7M*_\  */_ .)JK?\ @+PSJ%L8FT:UMC_#
M+:1+"Z'L05 YKHJ*?-+N..*Q$7=3?WLXKP_K-WHKZOH7B&=KR728#=0W3];B
MVQD$^X(P34'A?PO;>([./Q)XJA6_N[X&6&"4EH;:(G*JJGCI@Y/_ .NIXNX\
M;:[COX-N,_\ ?QJZ_P (_P#(DZ'_ -@ZW_\ 1:UI+1774];$2=*A[>G[LIVO
M;3IK;M=ZO_(/^$1\-_\ 0O:5_P" 4?\ \31_PB/AO_H7M*_\ H__ (FM?<-V
MW(SC.*6LN9]SR/K%;^=_>S'_ .$1\-_]"]I7_@%'_P#$T?\ "(^&_P#H7M*_
M\ H__B:V**.9]P^L5OYW][.#\4>%[;PY9R>)/"L*V%W8@2S01$K#<Q Y964<
M=,G(_P#U:?BGQ%-;>#+>\TD*;K5#%!:%CPKRC@^^!D_A6CXN_P"1)US_ +!U
MQ_Z+:N0U/_D2?AW_ -A'3/\ T6:UC[UKGK8=_68TY5O>:E;7JK7L_+3\3H-*
M^'V@V, -]91:I>/\T]U?()FD?N?FSCZ5?_X1'PW_ -"]I7_@%'_\36Q16?-)
M]3RY8O$3?-*;^\Q_^$1\-_\ 0O:5_P" 4?\ \31_PB/AO_H7M*_\ H__ (FM
MBBES/N3]8K?SO[V8S>#_  TZE3X?TO!]+.,'\P*YQM/3P+XLTS^RRRZ-J\YM
MI+1W)6"8\JZ9Z9QC'_UL=Y7'_$+_ )E?_L8;3_V:KBVW9G9@ZU2I5]E.3<9)
MW3?D]?5'7D!NH!^HI/+3^ZOY4ZBLSS!OEI_=7\J/+3^ZOY4ZB@!OEI_=7\J/
M+3^ZOY4ZB@! B@Y"@'Z4%0W4 _44M% #?+3^ZOY4>6G]U?RIU% #?+3^ZOY4
M>6G]U?RIU% #?+3^ZOY4H55Z #Z"EHH X[Q8]SK/B73O"MI.]K#<1-=7TT38
MD\E3MV ]MQXS6G:^!_"]G;K%%H-@ZJ,9FMUD8_5F!-9O_-;?^Y>_]N:W_$%E
M>ZEX?O;/2KTV%Y-$5AN0,F-O6M)-I)(].O5J4:=.G3;2Y4W;JW?5_D0?\(CX
M;_Z%[2O_  "C_P#B:/\ A$?#?_0O:5_X!1__ !-.\+Z=J.D^&K.QUK4#J5]"
MA$MT<_.<DCKR<# R?2M:HYGW./ZQ6_G?WLQ_^$1\-_\ 0O:5_P" 4?\ \34-
MUX'\+WENT,N@V"*P(S#;K&P^C* :WJ*?-+N-8JNG=3?WLX[PG)<Z-XDU'PK=
M3O=0V\2W=C-*V9/)8[=A/?:> :[ HI.2H/X5R'_-;?\ N7O_ &YKL*<][FV-
MUG&?644WZ]?OW&^6G]U?RH\M/[J_E3J*@X1OEI_=7\J/+3^ZOY4ZB@!OEI_=
M7\J4 #H /I2T4 )L4]5'Y4GEI_=7\J=10 WRT_NK^5'EI_=7\J=10 WRT_NK
M^5'EI_=7\J=10   # &!3=B?W5_*G44 -\M/[J_E1Y:?W5_*G44 -\M/[J_E
M1Y:?W5_*G44 -\M/[J_E3@,=*** "BBB@ JEJO\ QYQ_]?,'_HY*NU2U7_CS
MC_Z^8/\ T<E %VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ JEK/_ " ;_P#Z]I/_ $$U=JEK/_(!O_\ KVD_]!- %VBBB@ HHHH
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M]\F@!U%-WCT;_ODT;QZ-_P!\F@#)\7?\B3KG_8.N/_1;4>$?^1)T/_L'6_\
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MJ#A'44WS!Z-_WR:/,'HW_?)H \ZTS_D2?B)_V$=3_P#18KK_  C_ ,B3H?\
MV#K?_P!%K7'Z7SX(^(?_ &$=3_\ 18KKO"+C_A"=#X;_ )!UO_"?^>:UM/8]
MS,/X<O\ $O\ TE&U13=X]&_[Y-&\>C?]\FL3PQU%-WCT;_ODT;QZ-_WR: ,G
MQ=_R).N?]@ZX_P#1;5R'A'_D=M#_ .Q-M_\ T8M==XN<'P3KG#?\@ZX['_GF
MU<AX1/\ Q6VA_P#8FV__ *,6MH_ SW,'_N53Y_D>D44TR  DAN/]DU7T_48=
M2TVVOK=9!%<Q+*@9><$9&:Q/#+5%9VMZY9>'M$NM5U(R):VJ;Y"J$GK@ #ZD
M4:'KMEXBT.UU;3#(]K=)OC+(0>N""/J#0!HT4W>/1O\ ODT;QZ-_WR: /.O%
MW_([:Y_V)MQ_Z,:NO\(_\B3H?_8.M_\ T6M<?XN/_%;:Y_V)MQ_Z,:NO\(N!
MX)T/AO\ D'6_8_\ /-:VE\"/<QG^Y4_E^1SD/@K5X_C1/XK:^C.F26WEB#>V
M[.P+MQTQD;J[RL\:H3XB?3?*^5;1;C?SDDNRXQ^%7O,'HW_?)K$\,=13?,'H
MW_?)H\P>C?\ ?)H R?%W_(DZY_V#KC_T6U<AJ?\ R)/P[_[".F?^BS76^+G!
M\$ZYPW_(.N/X3_SS:N1U3CP1\//^PCIG_HLUM#8]S+_X<?\ $_\ TEGI%%-\
MP>C?]\FCS!Z-_P!\FL3PQU%-\P>C?]\FCS!Z-_WR: '5Q_Q"_P"97_[&&T_]
MFKKO,'HW_?)KD/B V3X7X/\ R,-IU'^]5P^([LO_ -YC\_R9V-%(3CU_ 4GF
M#T;_ +Y-0<(ZBF^8/1O^^31Y@]&_[Y- #J*;Y@]&_P"^31Y@]&_[Y- #J*:'
M!.,-^(I2V/7\!0 M%-\P>C?]\FCS!Z-_WR: '44WS!Z-_P!\FCS!Z-_WR: '
M44WS!Z-_WR:4-GL?Q% '(?\ -;?^Y>_]N:W]?757\/WJ^'GB34S$?LS3#Y0_
MO7/DX^-G?_D7NP_Z>:U_%EW<VOA'4I]/O8=/N8X&:.ZN1^[B/J>*N70[L9_R
M[_PHD\+IK4?AFS7Q1)#)JH0_:&A VDY..G&<8SCO6M7/>![V\O?!.FW&J:A!
MJ=U)$2]U:C*2?,<8X'(& >!R#6_Y@]&_[Y-0<(ZBF^8/1O\ ODT>8/1O^^30
M!R/_ #6W_N7O_;FNPKCP<_&SO_R+W<?]/-=>6 /0_@*N70[L9_R[_P *%HIO
MF#T;_ODT>8/1O^^34'".HIOF#T;_ +Y-'F#T;_ODT .HIOF#T;_ODTH.1W_$
M4 +12%P.Q_(TF\>C?]\F@!U%-WCT;_ODT;QZ-_WR: '44W>/1O\ ODT;QZ-_
MWR: '44 YIN\>C?]\F@!U%-WCT;_ +Y-&\>C?]\F@!U%-WCT;_ODT;QZ-_WR
M: '44W>/1O\ ODTZ@ HHHH *I:K_ ,><?_7S!_Z.2KM4M5_X\X_^OF#_ -')
M0!=HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *I:S
M_P @&_\ ^O:3_P!!-7:I:S_R ;__ *]I/_030!=HHHH **** .&NO^2[6?\
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M*UZ@X0HHHH X_P#YK;_W+W_MS785Q_\ S6W_ +E[_P!N:["KET.[&?\ +O\
MPH****@X0HHHH **** "BBN:\;:?XHU#3[1/!VI0Z?<)<*T[2C[T?H.#W[=Z
M .EHI%R%&XY;') ZFEH **** "BBB@ HHHH **** "BBB@ HHHH *I:K_P >
M<?\ U\P?^CDJ[5+5?^/./_KY@_\ 1R4 7:*** "BBB@ HHHH **** "BBB@
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M]U-WXXJAK.H7>FZ)>7MKI[WDUO"TB6\;?-(0/NB@#1HK#\*:W?Z_X9M=2O\
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MW8S_ )=_X4/HJ/?+_P \O_'J-\O_ #R_\>J#A)**CWR_\\O_ !ZC?+_SR_\
M'J )**CWR_\ /+_QZGJ6(^9=I],YH 6O/_BYXQU;P=HNFW&B/"DEQ>"*0RQ;
M\K@G'M_/TKO2T@/$>1Z[J\E^/\-W<>'-&\FVD?&H 'RP6P2I Z>IH ];C8O$
MC'J5!.*=4$+2B",&+G:,Y;VI^^7_ )Y?^/4 2457:YV3)$X19) 2B&09;'7
M[XS4F^7_ )Y?^/4 244BDE?F&#Z9IA>3/$7_ (]0!)14>^7_ )Y?^/4;Y?\
MGE_X]0!)14>^7_GE_P"/4;Y?^>7_ (]0!)14>^7_ )Y?^/5(,XY&#0 4444
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M_P (_P#(DZ'_ -@ZW_\ 1:UM+X$>YC/]RI_+\B-/^2@3?]@N/_T:];E8:?\
M)0)O^P7'_P"C7K<K$\,**** ,?Q=_P B3KG_ &#KC_T6U<AJ?_(D_#O_ +".
MF?\ HLUU_B[_ )$G7/\ L'7'_HMJY#4_^1)^'?\ V$=,_P#19K:&Q[F7_P .
M/^)_^DLZ3QO<^*+70D?P5:P75_YZATF(P(^<D9([XK?@,IMXS<*JS%!YBJ<@
M-CD#VS4E%8GAA1110 5Q_P 0O^97_P"QAM/_ &:NPKC_ (A?\RO_ -C#:?\
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M<(ZBFX?^\/RHP_\ >'Y4 >=:9_R)/Q$_[".I_P#HL5U_A'_D2=#_ .P=;_\
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M_P"BUH\7?\B3KG_8.N/_ $6U'A'_ )$G0_\ L'6__HM:O[!W?\P7_;WZ&/\
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MZP_^BEJAIG_(PZ1_V$+?_P!&"OSJO_R./^WU^A]!1_Y%'_;K_4]4\>:2^N>
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M]6O_ *41ULT <?\ \UM_[E[_ -N:["N/_P":V_\ <O?^W-=A5RZ'=C/^7?\
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MP*Z:@ HHHH **** "BBB@ JEJO\ QYQ_]?,'_HY*NU2U7_CSC_Z^8/\ T<E
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M6BHO(']^3_OLT>0/[\G_ 'V: ,SQ=_R).N?]@ZX_]%M7/7__ "0N+_L#P?\
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M@>><I_S6W_N7O_;FNPKCD39\;, L?^*>_B.?^7BNM:(,V=[CZ,15RZ'=C/\
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M4 %%%% !1110 4444 %%%% !1110 52UG_D W_\ U[2?^@FKM4M9_P"0#?\
M_7M)_P"@F@"[7%^([;Q#<Z\E[HFG7-M<6\;6ZW<=Q RS1,0V"CYQRH(/!KM*
M* ,GPQI[:9X=M[:6*6*;+R2K-(LCEW=F9BR_+DDD\<#.*UJ** .&NO\ DNUG
M_P!@0_\ HUZ\T\0Z'9WWB[6IY_.WM?R@[)F4<-Z UZ7=?\EVL_\ L"'_ -&O
M7"ZM_P C+K/_ &$)O_0J\3B"I.GA8N#L[K\F?5Y?3A4Q4%-77LU^9SW_  B^
MG?\ 3S_X$O\ XUZA\'[2*QTC5H(-VQ;T$;W+'F).YKAZ[_X5_P#'CK'_ %^+
M_P"BDKQ,AQ%6IBFIR;5GU\T=&>4*5/"IPBD[K\F==KM_+I?A[4+^WC$LMK;2
M3(ASABJD@<?2L+X:>*;[QCX+AU;4X(X+AI7C(B!"L%/! -='J-[%INEW5[<*
M[Q6T+2NJ+EB%!) '<\5E^#?$MCXL\-0ZII=M+;6[LR"*5 I4@\XQQCZ5]L?&
M&9_S6W_N7O\ VYK2\<D+X!UPGH+*4G_ODUF_\UM_[E[_ -N:TO''_(AZW_UY
M2_\ H)JJFWR._%;TO\*/"?\ A*=)_P"?A_\ OR_^%=IX-\0M:>"?$NKZ0RN\
M4\(0RQG&2%4Y!P>]86*U]/\ ^2>^*O\ KO;?S2O@LFG25>3IQ:?*]VGV\D?4
M9Q"JZ$54DFN9;*WZL67QAXAEU.WOFNK3S;>.2-1]EXPY4G^+_8%=]X$UV^U_
M2+N;4S$TL%V80T2;05V(W3)Y^8UY57HGPL_Y 6I?]A!O_14==V2X_$XG$.%6
M5U:_3NCCSG X;#8=3I1L[^?9FZW_ "/R?]@QO_1JUMUB-_R/R?\ 8,;_ -&K
M6W7UI\H1W$Z6UM+/,<1Q(78XS@ 9-<>_Q/T"6 [$OR&7@_9&YR*Z;6_^1?U'
M_KUE_P#0#7A=I_QYP?\ 7-?Y5XN;9C4P*@X).]]_*Q[.59?3QKFIMJUMCT+0
M/B'HUAX<TVSN(K\36]K'%(!:L<,J@']17;:;J%OJVFV]_9EF@N$#H67!P?;M
M7AM>N>!/^1#T?_KV6HRG,JF.<U-)6ML7FN6T\$H.#;O?<Z"BBBO=/#,?Q=_R
M).N?]@ZX_P#1;5SU_P#\D+B_[ \'_H"5T/B[_D2=<_[!UQ_Z+:N<U)MGP(1L
M%L:- <#J?W:T3_A,]"'^Z+_'^AY]4%Y_QXW'_7)OY5G?V^W_ $"-2_[\?_7J
M*YUUGM)E_LK45S&PR8>!Q]:_+886MS+3\4?>SQ5'E>OX,^C=(_Y EC_U[Q_^
M@BKE4](_Y EC_P!>\?\ Z"*N5^I'YD8_B[_D2=<_[!UQ_P"BVH\(_P#(DZ'_
M -@ZW_\ 1:T>+O\ D2=<_P"P=<?^BVH\(_\ (DZ'_P!@ZW_]%K5_8.[_ )@O
M^WOT,?X>_P#,T?\ 8PW?_LM:WBS_ ) :?]?MI_Z41UYY=.Z>#O%/ENZ;O%<J
MDHQ4D%TR,BN:>V21=LCS,N0<-,YY!R#U]:\C,LUI8*JH3BW=7T/5EE=3&UIS
MA)*S2U]$?05%?/S;X6CDBGN%=94P?/?^^/>OH&M,#CH8V#G!-6=M3R\=@9X*
M:A-IW5] HHR,X]:*] X#SC3/^1)^(G_81U/_ -%BNO\ "/\ R).A_P#8.M__
M $6M<AIG_(D_$3_L(ZG_ .BQ77^$?^1)T/\ [!UO_P"BUK:>Q[F8?PY?XE_Z
M2CS3XWS&/Q3X+PS#;>%N#C^..O8Z\R^*_A;4-?\ $/A&>P2-DAOBDA>0KC.'
M_E&W3GI7IM8GAA1110!C^+O^1)US_L'7'_HMJY#PC_R.VA_]B;;_ /HQ:Z_Q
M=_R).N?]@ZX_]%M7(>$?^1VT/_L3;?\ ]&+6T?@9[F#_ -RJ?/\ (]%D_P!6
MWT-9'@__ )$K1O\ KRB_] %:\G^K;Z&LCP?_ ,B5HW_7E%_Z *Q/#+FM?\@#
M4/\ KUD_]!-)H?\ R+VG?]>L7_H I=:_Y &H?]>LG_H)I-#_ .1>T[_KUB_]
M % %7Q=_R)>L_P#7C-_Z :UHO]2G^Z*R?%W_ ")>L_\ 7C-_Z :UHO\ 4I_N
MB@#SKQ=_R.VN?]B;<?\ HQJX_7+RVM7T3[5<10[M LMOF.%S\K>M=AXN_P"1
MVUS_ +$VX_\ 1C5Q^MVEM=/HGVFWBFVZ!98\Q V/E;UKS\ZY?[/ES[:;>J/L
M<)S?N.3?S_PLS?[7TW_G_MO^_J_XUUOPON[>Z\:W'V:>.;;I[[O+<-C]XGI7
M)_V3IW_/A;?]^E_PKK?AA:6]KXVN/LT$<.[3WSY:!<_O$]*^1R?V'UV')>^N
M]NS.K-_;?4I\]K:;7[HX_P 5_P#(ZZW_ -?LG]*R:M^,Y[V/QWKBV]FLJ?;7
MPQE"^G:L3[5J7_0.3_O^/\*_H/ XF$<+333V7V9=O0_GW'8><L54::W?VH]_
M4]0\#?\ ),O&?_7*;_TFK:U/_D2?AW_V$=,_]%FL#X?/+)\+/&;7$0B?RYLJ
M&W?\NWK6_J?_ ")/P[_[".F?^BS7QF+:EB:C7\S/U?(8N.!HI]__ &PZWQ9_
MR+Y_Z^K7_P!*(ZVJQ?%G_(OG_KZM?_2B.MJO-//.;\::;9:C:Z8+^TAN0FIV
M^T2H&QEP#U]JZ2L3Q/\ \>VG?]A.V_\ 1@K;H P_$'C#1O#-[IUKJ]PT4NHR
M^5 %0L,Y R<=!DC\ZR_B%_S*_P#V,-I_[-7/_%G3Y+SQ)X0>/1KW4!%>DN]L
MY 093@X!QTSGCH:Z#XA?\RO_ -C#:?\ LU7#XCNR_P#WF/S_ "9V%>$7W_(;
MU7_L(7/_ *-:O=Z\(OO^0WJO_80N?_1K5\SQ%_NL?\2_)GJ</_[U+_"_S1%7
MH7PJ_P"0+JG_ &$#_P"BHZ\]KT+X5?\ (%U3_L('_P!%1UX_#O\ O<O\+_-'
MK<0?[K'_ !+\F=Q)_JG_ -TUD>$/^1*T;_KRB_\ 0!6O)_JG_P!TUD>$/^1*
MT;_KRB_] %?=GPYLT44'I0 WS$_O+^=8G@]U'A>VRR_?F[_]-7KQ*RM8)+*)
MY(U9F7))Y)-3+86JC"P1@>@%?,SXAI0FX\CT\SZ2'#]6<5+G6I]" @C(Y%%<
MM\.!CP+: =!+. /0><]=37T=.7/!2[GSTX\DW'L%%%%60>=^)_\ D?\ 6/\
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MZV>?^@(?_1KUPFJ_\C+K/_80F_\ 0J\#B3_=(^J_)GUV5_[W#_KVOS17KO\
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M]2_["#?^BHZ\[KN/A_J5CI'A35;W5)X[>W342&D<< F.(#]36'#O^]R_PO\
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MT]#ZCBNGR/6LV^O&MM9TNT2.,QW;R*Y(Y&U"PQ^(K1V+_='Y5]*?.'G.F?\
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M/#.:\2^/S!<ZKHT.DM,8PUN9C<!02R YQC_:I/#7C\RSZ5HT^DM$9%6W$PN
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MX?/\F=^<_P"XS^7YHXKQ7_R.NM_]?LG]*R:U?%8QXUUO'_/[)_2LJOZ4R_\
MW2E_A7Y'\W9A_O=7_$_S._\  W_),_&?_7*;_P!)JVM3_P"1(^'?_81TS_T6
M:Q? X!^&?C/('^JF_P#2:MK4_P#D2/AW_P!A'3/_ $6:^$QG^]5/\3/UWA__
M '"AZ_\ MAUWBS_D7S_U]6O_ *41UM=*^>Q']KC9KF6>4M(S'=.YY#$@XS75
M?#HLOC8QF:9HVL)699)689#QX."?<_G7R5#.*5;$_5U%WNUTZ'56RFK1PWUA
MR5K)_>=_XG(^S:=S_P Q.V_]&"MO(]:Y3Q)KFBO;V CU2P8KJ-LS!;A#@"09
M/6N@M-0TZ_9EL+NUN2@RPAE5]OUP:]H\<BU.^DM+C38XMI%U=^2^>R^6[<?B
MHKG_ (@G_D5_^QAM/_9JU]=1?MVA_*/^0B.W_3&6L?X@J!_PB^ !_P 5#:=!
M_O5</B.[+_\ >8_/\F=CFO"+[_D-ZK_V$+G_ -&M7NY /49KYVUC6!:>)-7A
M^P7TNW4+CYXH-RG]ZW0U\YG].=3#145]K]&>AD52-/$R<GT_5%VO0?A:ZIH>
MJL[!56_8DDX 'DQUY-_PD*_] O4O_ ?_ .O7I/PVG%WX#U^;R9(MUS+\DJ;6
M'[A.HKRLAH5*>*DY+[+_ #1ZF>UZ=3#147U_1G7R>,?#1C;&OZ;T/_+TG^-9
M?A7Q9X>M_"&DPSZWI\<D=G$KHUR@*D*,@C->$6ZI]EBX7[B]O:I=J^B_E7[#
M'AU-)^U_#_@GY!+B-IM>R_'_ (!].V]S!=V\<]K-'-#(-R21L&5AZ@CK4A/%
M<W\.U4?#S1< ?\>P[>YKI& (Y -?*R5FT?61=TF?/>GG_B7P?[@JQD5AVOAS
M2[BUCEEMMSN-S'S&&2?QJ;_A%M(_Y]3_ -_7_P :_+Z\</[65Y/=_97_ ,D?
MI="6(]E&T5LOM/\ ^1/3M,O)['X(WMU9S-#/%'=-'(AY4^:_(KS6?Q'K]Q;R
M03:[J+QR*4=3.>01@BO0+*WC@_9^OXH$"JEO=*@/./WKXKQWR]6_Y^+7_OVW
M^-?MG#M.C.@^>GSZ1Z+MYGXMQ%4K0KKDJ<FLNK[^2.BD\5^(X[=BNOZB-JG'
M[\]A7T'I$SSZ)8RRMODDMXV9CU)*@DU\KS1ZKY$FZXM2-IS^[/I]:^I=" 'A
M_3B!_P NL7_H JL[ITX2A[.GR;]$K[=B<DJ59QG[2IS[=6[;]SBO$_\ R/\
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M ->TG_H)J[5+6?\ D W_ /U[2?\ H)H NT444 %%%% '#77_ "7:S_[ A_\
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MU7)L;1PDINL[7M^IS->F:#K5KX>^%6G:G?"1H(;:/<(EW,<L%&!QW(KD],\
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M!P<%JK'P5/A^E3FIJ;T=SD/^:V_]R]_[<U0^*Z*]GHP=0P^V-P1G_ED]7_\
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M&L74\,]QY<D<FTAAM8]E]A7DT<[PM:I&G&]V[;?\$]2MDN*HTW4E:RUW_P"
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M_(DZ'_V#K?\ ]%K5_8.[_F"_[>_0Q?A^ZJ?$X)_YF&[[?[M:OBR5/[#3D_\
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MM#48VN)GF9$==H9F+'&4/&37:T5PU*5.JN6I%->>I-.K4I/FIR:?EH>::/X
MTZ^^W>?J>I#R+V2!,,@^5<8S\G7FNQ\.:#9>&;*:VLIKB99IC,[SD%BVT+V
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JEK/\ R ;_ /Z]I/\
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M][NH8>V:)_$&8?[S+Y?DCJ**Y:ST71=1:1=/\1ZE=-$<2"#6Y7V'WP_%6O\
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M&('+K][C(SSVJ:/PYILT[PQ:YJSRHH9HUUB8LH/0D;N >U '25Q_Q"_YE?\
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MZA\9VCDN;V$-H0EW6]T\3 B?;@%2,+WQTSSUK<F\'PM!(L.K:TDA4A&.J3D
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MV/LTRB1;B.4%EMP&(\OY54MD@=<'FI/"/_([:'_V)MO_ .C%K9O%O%^'.O\
M]H?;#)]BN,?:YHI&QY1Z&, 8_6L;PC_R.VA_]B;;_P#HQ:VC\#/<P?\ N53Y
M_D>CUYI)<,OB(:]_96A'3]YT_P _?)@/YF=Y;R,#GY=V=N>-U>EUYC)]L336
MTLIJ*^&3)M+^1;9\LR?<\[S\;.V=F[''7FL3PSTQQF-AG;P>?2O)_!MW=V.L
MVL>F&&=&M+:VD6+1YXR\"N^R<L6V_-N;YC_=/%>L2 &-@>F#FO+]#AO=*NM,
MO$N-02QN!;V<+OJ-FZ2Q*QV( (]S?>;H<]>>* /42 RD, 01@@]Z\P(G7XB1
M0+JELS_V@?\ 18;J!!&BMD H 'R4(&,D[EYX->H5PV@Q7Z^)+[R9+U[3^TYB
MPBN8! N6R08R/,!R>>>3SWH H^+O^1VUS_L3;C_T8U=?X1_Y$G0_^P=;_P#H
MM:Y#Q=_R.VN?]B;<?^C&KK_"/_(DZ'_V#K?_ -%K6TO@1[F,_P!RI_+\C'\9
M:-:>(M5L=,>\NDNC#+(L C\VV*<#=,AP#S@+SG)..]7/ <TG_"+QV4\,5O-I
MS?9)(HXS&5*JN-R]B00>"1R"#S2>*&TJVO;:[N]?_L*_$;1Q3J\8,D9()4JX
M(89P>F1Z\FD\$36L]CJ3V5P;U/M[AKUI [73>6A+D@ =]N%  "@5B>&=-7#?
M$3,#V4PO;:RC8.7W2PQ23,K(=H,@.1L#CC&"RD\5W-<AXOCNF\1:.U@]PLHA
MN5VVL\44C#,?>4$$<<@<]#VH &61?@W=">02O_8\Q+B02;OW3<[AP?PX].*Q
M]3_Y$GX=_P#81TS_ -%FNFUT2CX;:H+CS?-_LN??YS*SY\INI7Y2?IQ7,ZG_
M ,B3\._^PCIG_HLUM#8]S+_X<?\ $_\ TEG9^)K"?5?"^HV-I(D4UQ T:O(Q
M51D=R.0,5R&DWR:EXXTV*UCT6-M/643'299)MJ,A C=A$J*-P!P6ZKP*[;6+
M--0T6[LYK2.]2>)HVMI'*+*",;2P!P#ZUQGAW3K_ ,->*;:*>&6SLM14P)";
MM;M0T:,RJ&**Z@+N_O9QCCBL3PSI/&-O%<>%KE9YX841XI<SJ6C<K(K!& Y(
M8@+@9)ST/2L31M1_MKQZLEW'9V-UI]M+ 8K=WD:<DIN'F&-5(3Y<J,D%N<5T
M?B2RDO\ 09HK=)7G5HY81"Z*PD1PRD%_EX(!P>#C%<UX<LY+#Q#86VK6U[;S
M+;W#VQFDBD6:1W#SR,4YW$L,#  &<4 ==JD;RZ3=+$85E\ES&TZ@HKX."V>P
M->*EWE\1Z"5U*.]C75[0MLNX9 "QR,+&!T^8$D8^[CJ:]GUM!)H&H(2H#6L@
M)==R_=/4=Q[5YC=)J"V?A(WCW[Q?VQ8^6UQ=03(>&Y7RP#T[GM5P^([LO_WF
M/S_)GKE%%%0<)YSK&L1>'M=U:Q\BPO#J\P<F[28$'RU&PA8F$J@+D 'ID<=:
M[;0+9;+PWIMK',UPL-K$BRLI4N H&<'D9]#7*>)I=>?Q)!)9)?&&PE,L!ATI
M)5):)D/SF=2>'/8<UV>GS/<:9:S2MN>2%&8[0N20"> 2!],GZF@"Q7EWBQ9H
MO%SPPZE:PEY8D@M([J"$J&"$%@1O^\'S@Y(==O2O4:X9XK\>.]5-E)>&)IX&
MD2UN8(U7]TH^='!8G Z@\C [4 =S1110 5Y7KP;3;34]&N1H$MYJ5Q.\+_:)
M'O&:1V:-O+2)FW(-N,'C9U&*]4KR[4CHH\3G_A"_[1.K_P!I/YOV4*;7[5L?
M?YAE^7.W?G9S^- 'I\>1&NXY.!DTX@$$$9!Z@T@SM&[KCFEH \OD\]?B'% N
MIVI;^T !:PW4""-%8, 4 #Y*'&,D[EYX->H5PVB17Z^)[_R9+U[3^TY2PAN8
M!"N2"08R/,!]>>>HZUW- ''_ /-;?^Y>_P#;FNP)QUKC_P#FMO\ W+W_ +<U
MV!Z<]*N70[L9_P N_P#"CRNTTJ#1]6TSQ7I\LM_93S-";C4[?=*$E= )/.!W
M;<@!<KT;G .:]4KRS18]2U:ZM-.@MKD:*J17T-G/?Q^6EN9#Y8)$7F$@H3Y9
M; PHW$<5ZG4'"(Z+(A210ZGJK#(->8^$VN&\<0))JMO=.HD:9(+N HI"LI4(
M@#?> (SD $@\@5Z?7#>!(K^.*W#R7LEFJN$;[3 T'WCC:BC>H] 3QT/2@"S_
M ,UM_P"Y>_\ ;FNPKC_^:V_]R]_[<UV%7+H=V,_Y=_X4<#XLELK3Q@L=_:Q:
MFVI0010VPG2.6)HYBX'SX78[;>X)*8P>W3^%]-GTK08[:ZCBA<RRRB"$Y2!7
MD9A&IP,A00.G:N?\1:3-K'BB\M],O[F&86=M-<(EM&Z Q2O)"-SL,,S;N.F!
MR1Q71>&KZ34=!AFN)9)9PSQS>;"(G5U<JRE5) ((QP2#C/>H.$Y_49[G3/$^
MLS:;96FK//;1R7,4C.LENH7:%^6-]RG&X(,-DL<'-;GA"WBM?"&G16US'=1"
M'<LL0(0@DG"@\A1G !Y &*Y?Q1KBZ#X@O_[#U*4ZA.D3W=C'8?:-F<1I)N+H
MJ9^4?,Q' XZYZ[PY8MIOAVSM9(GBD1,R+)(';<22Q+  $DDGCCGB@#E/B&3;
MWEK,;^WLXC&69!-!%-,P=,@&4<_)NQR #C/6NL\.)*GA?3%N'6246D6]UDWA
MCM'.[O\ 6N>\4QWC>+]/;3Y+D2&RF#+:3PQ2$;TY)E!#*/0<@GWKK;+>+"W\
M[?YGE+N\QE+9QSDKP3].* )JR/%6GS:KX8N[.V>%7E"Y\]RL;*'!96(!P"H(
M/'>M>L#QQ);Q^#;W[;9+?V[F*.2V.?WBM*JD#!!SSQSUQ0!S^@7RZIXYMFM5
MT=!8VTL4QTF629<-LVH[B-4&"N0-V?05W]<9X3LS8:W.MDFMPV<Z O#J5NI5
M64!5VR9W#@8P<UV= &3XH1V\,7[0/!%,D+,DMP5"H0.N6! XSR>!7-?#HLU[
MJQ6_6^A7RT5Q<Q2Y^:0@@1@!04*=1G(;MBN@\9IYG@K5E#K&?LS8=B!M/KD\
M#ZGIUIGAA;]8Y_[1-^<[=GVRX@E]<X,0&/QH WJ*** .?\8V,M[I=J\9LC':
MW:7$T=_*8X9$4-PQP>C%6Y&/EK)\&W@U7Q/J6H6XTX0_9HX'.FM))#)(KN<[
MS&JLP#8XS[]JU/&L6GW.C06NI:;)J1N+I$MK>*3RV,V"P8/D;< ,<Y[50^'_
M -I:UGGB%_\ V3=$SVQU Q&4LS$MRAS@]?FYH [&N=\;1Y\/^8+JWLPLT8DN
M)FC4I&6 ;:S@@'^?3K715S?CI)'T&#R)&CE6^MRAC=4?/F#A6?*J3TR?IWH
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M: /,=,BCCT36S:P1(YT.Z^W?Z+;1".7:/EB,0RR?>SG(X7G->C^$?^1)T/\
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MT5B>&!Z<=:XW3?!6H:?XHDUD:GI[-*1OB&G, F22YC)E.POGYB!R0"17944
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MZ@(KHR/\KB5 I:1>?FW$<G'%=-\(=;TFSL?$%C=:G907<GB6]V6\EPBR-F0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %4M5_P"/./\ Z^8/_1R5=JEJ
MO_'G'_U\P?\ HY* +M%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:V?47:X5U0Q*><LRKUZ<;USSQD4G_";VFS>=8(&XKR&!X .<8SC# YZ8.<T
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M'_HY* +M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(G#7*F+.-JQ@$G?D@;,#/F-D# /'I6OI7A6XTBP%K"LLBABV7P,9/0   #V
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M+$_]Z/\ [Y/^-&)_[T?_ 'R?\:EHH BQ/_>C_P"^3_C1B?\ O1_]\G_&I:*
M$^;;SC=].*CQ/_>C_P"^3_C4M% $6)_[T?\ WR?\:S-?\-6'BC3UL==M8;NW
M602*C;EPP[Y!![FMBB@""**2&%(HO*2-%"JH4X '0=:=B?\ O1_]\G_&I:*
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M]FKL*N7PH[\0^;#T9/>S7R3_ ."18G_O1_\ ?)_QHQ/_ 'H_^^3_ (U+14'
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M^OF#_P!')0!=HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MNP/\5_X9_P#I$C9NFD7Q5IL2S2"-[:X+(&X8@Q8)'MD_G6KL_P!MOSK*O/\
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M!?\ V_?^B1789KC_ !(?^+F^"_\ M^_]$BKAO]_Y'=@?XK_PS_\ 2)&S>?\
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M"/SFR#C:?O<@=*ZK(]: "BC(]:,CUH **,CUHS0 449%&1ZT 8GBS_D#0_\
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MFB2![R$2-&C[@IZ<'\* -FBC(]:,CUH **,CUHR/6@ HHR/6C(]: "BC(HH
M*I:K_P ><?\ U\P?^CDJ[5+5?^/./_KY@_\ 1R4 7:*** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "J6L_\@&__ .O:3_T$U=JEK/\
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M?04ZB@!NQ?04;%]!3J* &[%]!1L7T%.HH 0(HZ 4M%% !5+5?^/./_KY@_\
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M\BZW_7S;?^E$=7=*=1HUED_\N\?;_9%4/%KJ?#K<_P#+S;=O^F\= &Y2%@"
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MU_2@!U%-\Q?7]*/,7U_2@!U%('4G@_I2T %4M5_X\X_^OF#_ -')5VJ6J_\
M'G'_ -?,'_HY* +M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !5+6?^0#?_\ 7M)_Z":NU2UG_D W_P#U[2?^@F@"[1110 5Y-X6.
MGG7E$Q\.?;!J<PQ.7:^!\YL9;H7],<=*]3NY9H;222UM_M,RC*1;PF\^F3P*
M\LTW7;^[^(4>G:E<,;..Z!M[9;^,%)MQ++(ZC][M_A3.>H(.* /6:*** .?\
M'_\ 'CJ?_87O/_1S5-?_ /(YZ-_U[W7_ +2J'P?_ ,>.I_\ 87O/_1S5-?\
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M +"#?^D\U;58NN_\A;P__P!A!O\ TGFH VJQ9_\ D>['_L&W'_HR&MJL6?\
MY'NQ_P"P;<?^C(: -JLBR\+:-IWB"\UNRL4BU&]&V>8$Y<<=N@S@9K7K,L[V
M>;Q)J=G(P,-O% T8QR"V_//_  $4 :=>4?&JVAO-0\-P7*"2)VN-RGO_ *NO
M5Z\M^,/_ "&/#'^_<?RCK#$MQP]1K^67Y,]?)4GCHI]I?^DL\_\ ^$8T;_GQ
M3_OIO\:]"^$%A:Z=?ZU%91")&CMV(!)R<R>M<G79?#&18M0UN20[42"!F)[
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M "BBB@ HHHH *Q_"DTD_AR&2>1I',LP+.<DXE<#]!6Q6)X/_ .18@_ZZS_\
MHYZ -NBBB@ HHHH **** "BBB@ K$C_Y'ZY_[!D7_HV2MNL2/_D?KG_L&1?^
MC9* -NBBB@ K*\374UGH,DUK(8Y!-"H8>AE0']"16K6)XO\ ^1:E_P"N]O\
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M&;!FV2S,XR)$&>2>>37<:[_R%O#_ /V$&_\ 2>:N"^'!(\;3;5S_ ,2]^_\
MTT2NZUUG_M;P_P#)_P Q!N__ $[RUZ643E/!0E)W>OYL\[-H1AC9QBK+3\D;
MM8L__(]V/_8-N/\ T9#6QN?^Y^M8L[-_PG5C\G_,.N.__32&O4/,-RL33O\
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M+_PQXQ\-Z7:Z?;SQ:C,%D>7)8 NJ_+Z'G.:[_<_]S]: '44W<_\ <_6C<_\
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M93]WN"#7;6US%>6D5S;.)(9D$D;CHRD9!_*O!9?]2_\ NFO:?"G_ ")NC?\
M7A!_Z+%;Y7F4L=S\T;<MOQO_ )'CYGET<#R<LKWO^%B*/_D?9_\ L&1_^C7K
M;K$C_P"1]G_[!D?_ *->MNO:/'..\ _ZOQ5_V,%W_P"RUXM9WNL+8PK%I,;H
M$ 5C= ;ACKC%>T^ ?]7XJ_[&"[_]EKRK3O\ D%VW_7)?Y5\[Q'-0A"\4]>M^
MWDT?8X"#GC:MI-:+:WZIBZ#=:I+XKT5;O34@B.H09D%P&Q\X[8KZ%KPK3/\
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M,;[P]JMM9V%I;S>; 96:9F&/FQ@8K*K5A1@ZE1V2-*5*=::ITU=L[&L3P?\
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MZFL\1EF*P]-U*D;)>:-,/FF%Q%14Z<KM^3/0J***\T](S?$?_(K:K_UY3?\
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M;=T>7Y'J*,CU%9/_  B^C_\ /I_Y$;_&C_A%]'_Y]/\ R(W^-?F'+AOYY?\
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M)5VJ6J_\><?_ %\P?^CDH NT444 %%%% !1110 4444 %%%% !1110 4444
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M "!;+_KWC_\ 017AG_+>Y_Z^I_\ T:U>YZ3_ ,@6R_Z]X_\ T$5X9_RWN?\
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M03B3MVKE*ZW7?/A^#MJZ6[EVUMF1) 4+ B3GFN"^UZE_T#1_W_%?LG#-94\
ME-.^FT7V79?@?CO$U%U,>W%JWG)+J^[/I#P#_P D]T+_ *\8O_015#Q'_P E
M-\%_]OW_ *)%7_ &3\/-!R,'[#%D?\!%4/$?_)3?!?\ V_?^B17RZ^-_,^YR
M_P#B/_!/_P!(D;5VC'Q9ICA256UN06QP,F+'\JNZC&TNEW4<:EG>%U4#N2IK
M+O?&.C:?XML_#=U<,NI7B;XD$9*XYQD]B<&MVLSC/ AI^JZ?IJ/>:-J,21(J
MNS6S8!X'\ZVO#ND:N/%FE22Z/?PQ17.^226 JJC:W)/XUZ/XR_Y%.\_[9_\
MHQ:W*\2EDF&I555BW=.^Z_R/:JYSB:M)TI)6:ML_\SQ;Q5_R/6M_]=X__1,=
M9$__ ![R?[I_E5CQOJ%Q:_$#6D@TVXNE,T9WQLH _<Q\<FL"76+TPN#H=X,J
M>=R<?K7RV88>I+&3DK;]U_F?38#$4XX.$7?;L_\ ([/XA_\ (H^#?^O7_P!I
M1UP5=Q\3(7F\&^#5BG>!OLN=R 9_U4?'->;_ -G77_04N/\ OE?\*_>\DJ3C
MA+1@WJ^WZL_!\\IPEB[RFEHN_P"B.]\-_P#(N:5_V.-K_P"BA7NE>#>$XWA\
M+:2DDK3,/&-KEV R?W8]*]YKY;'-O$3;5O>?YGW=!)99ADG?W7^@45YW\1M5
MU*SUO3[>PU"XM(WMY'80/MW$,H&?SKD_[<US_H.ZC_W^_P#K5\UBLWP^%JNE
M43NNR_X)Z>&RG$8JDJM.UGW?_ /5?"'_ "+B?]?-S_Z/DK;KPJVU+5K.#R;;
M6=0CCW,VT3=V)8GIW))J[INO:VNN:8K:S?2))>P1NDDF596D ((QZ&L:6>X6
MK4C3BG=NVW?YFM7),52INI)JR5]_^ >T4445[IXAQ-YJGAA/B_9:?/I$C^('
MM28K_P KY57#'&<^@/..,XS7;5R5U=^*5^)]I;P:5;OX>-L?-O2!O5L'C.<C
MG'&.0:ZV@ HHHH \S^*'_(P:3_UZS_\ H<=<?73?%[3X-1UO1X[GS-JV\[#R
MY"ASNC]*X'_A&-.];K_P)?\ QKX3.HT7C)<\FG9=+]/5'W&32K+!KDBFKOK;
MKZ,W]-_Y#^D_]A&W_P#1JUZ!X\\3:KH=]I]OI4D$8N(Y7D:6+?\ =*  <C^\
M:\NT+0K.R\4:-/ 9]ZZA;XWSLP_UBCH379_%^]%CJNC2&WN)]T,XVP)N(YCY
M/M7?E\G3RRI+#R=[Z:6[>;.''Q53,J<<0E:W>_?R1F7/B_Q'=75I/)>6N^TD
M,D>+7N49.?F]&-:.G>._$<FL6$-Q<6DD,]U%"ZBVVDJSA3@[N.M<!_PD*_\
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M,EC*3J2CRV=OR"OG35-!M+O7M3GE>Y#O?7!(2X91_K6[ U]%UX/=?\A34/\
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M_P (IX>_Z 6G?^ J?X4?\(IX>_Z 6G?^ J?X5]__ *R?].OQ_P" ? ?ZM_\
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M?_G]U#_P*:OR_P!G0_G?W?\ !/TOVE?^1??_ , ]T\!_\B%H_P#U[+6AK_\
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MM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5+6?\
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M;3Z+_(]$HK!\7W5QI'@W5=0LKB1+BWMGDC;AL$#K@]:\-_X6SXD_Z#%[_P"
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M+&?\_&<_]F8/_GVBYX9T)?#?AVVTI+AKD0;SYK*%+%G+=!_O5JUSW]K^)/\
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MT?VOXD_Z%9?_  9)_P#$T =#534]/CU2P:UF=D1G1\KU^5PP_5:R?[7\2?\
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M2L2*@)ZD 8J6N;@U[Q%<VT4\?A8;)4#KNU% <$9_NT_^U_$G_0K+_P"#)/\
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M)Y(1<I]K2V"F5H<'(4-UR=H(ZXS6-X(M=2M+Z5;@3+!);+-<H=ODQW+MNV1
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M_P!1?S5VWD:[4"C8KAF#)LSD;0>"&ZFNZTRWGM-)M+>\F^T7$,")+-_ST<*
M6_$\US<_@[4?[;-_8:W';J+V2\CC>Q$A5WC\M@6WC(Q761!UA197#N% 9@N
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MD*6P3QQZ(QPIY"\=3VKR?3[BUUWQO;75AKFCW<*W2M//*HC%RZ\ 11"7YWX
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M_P"!LW_Q5 %?6/#.BZ^!_:^FP73*,!V7#@>@88/ZUB_\*J\&?] ;_P FIO\
MXNNB_LJW_P">EW_X&S?_ !5']E6__/2[_P# V;_XJJ4I+9G53QF)I1Y:=227
MDVCG/^%4^#/^@-_Y-3?_ !='_"J?!G_0&_\ )J;_ .+KH_[*M_\ GI=_^!LW
M_P 51_95O_STN_\ P-F_^*I^TGW-/[1QO_/Z7_@3_P SG/\ A5/@S_H#?^34
MW_Q='_"J?!G_ $!O_)J;_P"+KH_[*M_^>EW_ .!LW_Q5']E6_P#STN__  -F
M_P#BJ/:3[A_:.-_Y_2_\"?\ F<Y_PJGP9_T!O_)J;_XNK5E\.?"6GS"6WT2
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M?V5;_P#/2[_\#9O_ (JC^RK?_GI=_P#@;-_\50!=HJE_95O_ ,]+O_P-F_\
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M5;_\]+O_ ,#9O_BJ +M%4O[*M_\ GI=_^!LW_P 51_95O_STN_\ P-F_^*H
MNTC*KJ5=0RD8((R#5/\ LJW_ .>EW_X&S?\ Q5']E6__ #TN_P#P-F_^*H F
MBLK2"3?#;0QO_>2, _G4]4O[*M_^>EW_ .!LW_Q5']E6_P#STN__  -F_P#B
MJ +M%4O[*M_^>EW_ .!LW_Q5']E6_P#STN__  -F_P#BJ +M%4O[*M_^>EW_
M .!LW_Q5']E6_P#STN__  -F_P#BJ +M%4O[*M_^>EW_ .!LW_Q5']E6_P#S
MTN__  -F_P#BJ +M%4O[*M_^>EW_ .!LW_Q5']E6_P#STN__  -F_P#BJ +M
M5UT^R20.EI KJ<AA$ 0?RJ+^RK?_ )Z7?_@;-_\ %4?V5;_\]+O_ ,#9O_BJ
M +M%4O[*M_\ GI=_^!LW_P 51_95O_STN_\ P-F_^*H NU2U7_CSC_Z^8/\
MT<E']E6__/2[_P# V;_XJC^R;;<I8W#[6#@/=2L,@Y'!;!Y H NT444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MMNCZ0E@CW9E,VY2N3N.1@[_3O7IGQ5D2W\'VLEQ(J1QZE:%Y'("@>8,DD]*
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M&,,3. >^!FO"=3^*7B;7=-CC.GZ= AD28,CR9^4YQU[U[EJZE]%OE4%F-O(
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT&'1E^SQ&.X@\K?MEBE#C9]_D%3RHYQQ7:T4 </_ ,(YK.E7UUXEN+ZSU+Q
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M-\RY!))ZYP:V];T'^VK[1IGN?*BTR^^V-%Y>[SB(W11G/RX9PV<'[N/<:]%
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M,D*/]IG;)/., :%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>img30600998_12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img30600998_12.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#X17AI9@  34T *@    @ ! $[  (
M   /   (2H=I  0    !   (6IR=  $    >   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $YI8V]L92!3
M96ET=&5R    !9 #  (    4   0J) $  (    4   0O)*1  (    #.#0
M )*2  (    #.#0  .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                         #(P,C,Z,#,Z,30@,38Z-3(Z,S8 ,C R,SHP
M,SHQ-" Q-CHU,CHS-@   $X :0!C &\ ; !E "  4P!E &D = !T &4 <@
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" *;!0(# 2(  A$! Q$!_\0 'P
M 04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0
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M,$=.01UP #U6BO%/C!\:]1\,>(H?"/@BT2[UR38)9&C\SRF?&R-$'5R"#SP
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M\<-7UOQ<W@[Q_:);:J6:."9(C$3(@):.1>@;@X(P,C&.17NM !1110 4444
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MYS_US;D 'TP?O5](>#?&$/Q'^'(U71Y%M[N>!X94#D&VN-N",CD8)!!ZX(-
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M=CT[H<=*W/VFO&/AGQ)::!9Z!J5IJEW"\DKRVD@E6)&"C:6'&21G'4;><<4
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M!Z9",.,9!'H*](_9?_Y)%)_V$IO_ $%*\V\*?\GIS_\ 82O_ /T1-0 _XO\
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M>\:7UA,S*]JGFB.(Y)W ,ZLB!>,+@=3SUKV'X=?"O6/"OC!=3\*>.XK[PKN
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M#>*OA3\*/"WA"#5)4>Z-P]_>6LSX<AU*Q(Y *J W(XSCTSG3_9'12_BUR!N
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MO/#L;M<S 8,T2QEU<_[6%8'_ '<]Z\TTKX>? Z^\*V^L7GCB_M&>$--:R7T
MFC?'S+Y7E%S@YZ Y[9KT7P5X!\'6OPY\96WPSUVXUDZUI[VLAGF1_+D\J0(,
M*BE2?,/7VH \@\,>'/%G[0WBW4;_ %76VL[2S(=I&5I$MRV=D<4>0.BGN.F2
M23SSWQ<\.^(_"7B:TT+Q-JK:LEK:@V%TV<M 6;CG)&&##!)QVXQ7>_LT^-]#
M\*WFN:1XEOH=+DNVBDAENW\M-R;PRLQX4\C&?>N=_:(\9:1XO^(5N= N4O+7
M3[,6[7,9RDC[V8[3W R!GN<T ?9=%%% 'A/[5W_)/]'_ .PH/_13UZ#\'?\
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M\#7>J6.OV-[-+;-]GLXI09G<K\JM']Y.>I(&*\X_9/T&[BCU[7IHV2TF$=K
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M7DAL)U6)B>3\K*VT>RX'I7>^%/"&B>"=$72O#EDMK;!B[\EFD<]69CR3P/R
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MY#74>P^V1&&_6O4](\-:/H7AY-#TK3X;?340Q_9@N58-][=G[V<G).<UJ44
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MW_VW=GY"R'R_+'WOE&-W&[O7J]?+'[04+^$OCEH7BNW0@2I!=$CC=) ^"/\
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M]T45Y)\7_C*_PWL++3;"WBN_$%Y")"LO,<"]-[!2,DL" !QP?H?.;KQQ\?\
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M'!X!'?'2N(\7^)-<\2_%[1I?%FF#3=8LI+:SNH0" S+*3N /0$,.A(/4'!H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6V(OX(S#\*U/VN?^91_[??\ VA7?_ _X5:A\,].U;^VY[*XO;^6/#6;NRB-
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M<VP?ZHBD?K7:_"SX!0>"->7Q#K^I#5=7CW>2(U(BA9A@OD\NV">3C&3P3@@
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M0W+C@Y))_/)K-^-OPZU;XD^%[#3=#N+*WFMKSSW:\=U4KL9<#:K'.6':NI\
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M"W_9STZYFF1(8O#^7D+<+B$YR?;%:'Q1^'5M\2O"7]DS7)L[F&43VMSLW!'
M(P1D9!!(_(]J\@T/]F[QAY:Z1XB\9+'X<67S&L;&XF=9.<_ZM@J*3Z\X]Z ,
M_P#9-_Y&;Q#_ -><7_H9JG\%9%LOVF-8@U+Y+EVOHD$OWO-\S)'UPK?K7I/P
M0^$&O_#36-5N]=N]-N([R!(XQ9RR,00V3G<B\5%\3_@"?%?B1O$WA'5%TC5Y
M"'E63<L;R#I(&7YD;CD@')YX.<@'H/BOQ'X*T#5=._X3"YTVVO)E?[')>0AF
M4#&[#D'8.1U(S^%>7?M37$-W\-M"N+65)H9M15XY(VW*ZF%R"".H([UG:/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,W?]35_Y3O\ [;7N5%'UFKW_ "#ZM2[?F>&_\,W?]35_Y3O_ +;1_P ,W?\
M4U?^4[_[;7N5%'UFKW_(/JU+M^9X;_PS=_U-7_E._P#MM'_#-W_4U?\ E._^
MVU[E11]9J]_R#ZM2[?F>&_\ #-W_ %-7_E._^VT?\,W?]35_Y3O_ +;7N5%'
MUFKW_(/JU+M^9X;_ ,,W?]35_P"4[_[;1_PS=_U-7_E._P#MM>Y44?6:O?\
M(/JU+M^9X;_PS=_U-7_E._\ MM'_  S=_P!35_Y3O_MM>Y44?6:O?\@^K4NW
MYGAO_#-W_4U?^4[_ .VT?\,W?]35_P"4[_[;7N5%'UFKW_(/JU+M^9X;_P ,
MW?\ 4U?^4[_[;1_PS=_U-7_E._\ MM>Y44?6:O?\@^K4NWYGAO\ PS=_U-7_
M )3O_MM'_#-W_4U?^4[_ .VU[E11]9J]_P @^K4NWYGAO_#-W_4U?^4[_P"V
MT?\ #-W_ %-7_E._^VU[E11]9J]_R#ZM2[?F>&_\,W?]35_Y3O\ [;1_PS=_
MU-7_ )3O_MM>Y44?6:O?\@^K4NWYGAO_  S=_P!35_Y3O_MM'_#-W_4U?^4[
M_P"VU[E11]9J]_R#ZM2[?F>&_P##-W_4U?\ E._^VT?\,W?]35_Y3O\ [;7N
M5%'UFKW_ "#ZM2[?F>&_\,W?]35_Y3O_ +;1_P ,W?\ 4U?^4[_[;7N5%'UF
MKW_(/JU+M^9X;_PS=_U-7_E._P#MM'_#-W_4U?\ E._^VU[E11]9J]_R#ZM2
M[?F>&_\ #-W_ %-7_E._^VT?\,W?]35_Y3O_ +;7N5%'UFKW_(/JU+M^9X;_
M ,,W?]35_P"4[_[;1_PS=_U-7_E._P#MM>Y44?6:O?\ (/JU+M^9X;_PS=_U
M-7_E._\ MM'_  S=_P!35_Y3O_MM>Y44?6:O?\@^K4NWYGAO_#-W_4U?^4[_
M .VT?\,W?]35_P"4[_[;7N5%'UFKW_(/JU+M^9X;_P ,W?\ 4U?^4[_[;1_P
MS=_U-7_E._\ MM>Y44?6:O?\@^K4NWYGAO\ PS=_U-7_ )3O_MM'_#-W_4U?
M^4[_ .VU[E11]9J]_P @^K4NWYGAO_#-W_4U?^4[_P"VT?\ #-W_ %-7_E._
M^VU[E11]9J]_R#ZM2[?F>&_\,W?]35_Y3O\ [;1_PS=_U-7_ )3O_MM>Y44?
M6:O?\@^K4NWYGAO_  S=_P!35_Y3O_MM'_#-W_4U?^4[_P"VU[E11]9J]_R#
MZM2[?F>&_P##-W_4U?\ E._^VT?\,W?]35_Y3O\ [;7N5%'UFKW_ "#ZM2[?
MF>&_\,W?]35_Y3O_ +;1_P ,W?\ 4U?^4[_[;7N5%'UFKW_(/JU+M^9X;_PS
M=_U-7_E._P#MM'_#-W_4U?\ E._^VU[E11]9J]_R#ZM2[?F>&_\ #-W_ %-7
M_E._^VT?\,W?]35_Y3O_ +;7N5%'UFKW_(/JU+M^9X;_ ,,W?]35_P"4[_[;
M1_PS=_U-7_E._P#MM>Y44?6:O?\ (/JU+M^9X;_PS=_U-7_E._\ MM'_  S=
M_P!35_Y3O_MM>Y44?6:O?\@^K4NWYGAO_#-W_4U?^4[_ .VT?\,W?]35_P"4
M[_[;7N5%'UFKW_(/JU+M^9X;_P ,W?\ 4U?^4[_[;1_PS=_U-7_E._\ MM>Y
M44?6:O?\@^K4NWYGAO\ PS=_U-7_ )3O_MM'_#-W_4U?^4[_ .VU[E11]9J]
M_P @^K4NWYGAO_#-W_4U?^4[_P"VT?\ #-W_ %-7_E._^VU[E11]9J]_R#ZM
M2[?F>&_\,W?]35_Y3O\ [;1_PS=_U-7_ )3O_MM>Y44?6:O?\@^K4NWYGAO_
M  S=_P!35_Y3O_MM'_#-W_4U?^4[_P"VU[E11]9J]_R#ZM2[?F>&_P##-W_4
MU?\ E._^VT?\,W?]35_Y3O\ [;7N5%'UFKW_ "#ZM2[?F>&_\,W?]35_Y3O_
M +;1_P ,W?\ 4U?^4[_[;7N5%'UFKW_(/JU+M^9X;_PS=_U-7_E._P#MM'_#
M-W_4U?\ E._^VU[E11]9J]_R#ZM2[?F>&_\ #-W_ %-7_E._^VT?\,W?]35_
MY3O_ +;7N5%'UFKW_(/JU+M^9X;_ ,,W?]35_P"4[_[;1_PS=_U-7_E._P#M
MM>Y44?6:O?\ (/JU+M^9X;_PS=_U-7_E._\ MM'_  S=_P!35_Y3O_MM>Y44
M?6:O?\@^K4NWYGAO_#-W_4U?^4[_ .VT?\,W?]35_P"4[_[;7N5%'UFKW_(/
MJU+M^9X;_P ,W?\ 4U?^4[_[;1_PS=_U-7_E._\ MM>Y44?6:O?\@^K4NWYG
MAO\ PS=_U-7_ )3O_MM'_#-W_4U?^4[_ .VU[E11]9J]_P @^K4NWYGAO_#-
MW_4U?^4[_P"VT?\ #-W_ %-7_E._^VU[E11]9J]_R#ZM2[?F>&_\,W?]35_Y
M3O\ [;1_PS=_U-7_ )3O_MM>Y44?6:O?\@^K4NWYGAO_  S=_P!35_Y3O_MM
M'_#-W_4U?^4[_P"VU[E11]9J]_R#ZM2[?F>&_P##-W_4U?\ E._^VT?\,W?]
M35_Y3O\ [;7N5%'UFKW_ "#ZM2[?F>&_\,W?]35_Y3O_ +;1_P ,W?\ 4U?^
M4[_[;7N5%'UFKW_(/JU+M^9X;_PS=_U-7_E._P#MM'_#-W_4U?\ E._^VU[E
M11]9J]_R#ZM2[?F>&_\ #-W_ %-7_E._^VT?\,W?]35_Y3O_ +;7N5%'UFKW
M_(/JU+M^9X;_ ,,W?]35_P"4[_[;1_PS=_U-7_E._P#MM>Y44?6:O?\ (/JU
M+M^9X;_PS=_U-7_E._\ MM'_  S=_P!35_Y3O_MM>Y44?6:O?\@^K4NWYGAO
M_#-W_4U?^4[_ .VT?\,W?]35_P"4[_[;7N5%'UFKW_(/JU+M^9X;_P ,W?\
M4U?^4[_[;1_PS=_U-7_E._\ MM>Y44?6:O?\@^K4NWYGAO\ PS=_U-7_ )3O
M_MM'_#-W_4U?^4[_ .VU[E11]9J]_P @^K4NWYGAO_#-W_4U?^4[_P"VT?\
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M .WK_P!HUM0KU)U%&3T,:]"G"FY16I[E1117"=P4444 %%%% !1110 4444
M%>&_$[_DX/P?_P!N7_I4]>Y5X;\3O^3@_!__ &Y?^E3UT8?XWZ,Y\1\"]4>Y
M4445SG0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?\)./$KM:2/J\9BA7^SI$"[6!B5=H9F*['W-C!SP<@'H-%%% !1110 4444
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MJEDSQN (SQFH--\=^'=7U&&RT^_>1[@NMM*UM*D%T4^\(9F41RXP3\C'@$]
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M)$78R-P""05ZD'@ ] HKRSP_XKU/4+S0;AO%0DNM2E!N=/N+ Q:>RD$M%:W
MA_>2IT \U]Q5L@?P^IT %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5X;^TC_S+?_;U_P"T:]RKPW]I
M'_F6_P#MZ_\ :-=&&_BK^NASXG^$_P"NI[E1117.= 4444 %%%% !1110 44
M44 %>&_$[_DX/P?_ -N7_I4]>Y5X;\3O^3@_!_\ VY?^E3UT8?XWZ,Y\1\"]
M4>Y4445SG0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!QGQ!_YA_P#VT_\ 9:XRO9J* .9\!_\ ("F_Z^6_]!6LN[\(7'B;
MXE7>J:_%>6NFZ;:):Z2UKJ$D#RL_S3R9A=64<(F">=I..E=U10!Y#XC^'^M6
M-CXRT7PM8SWFE^(-.6>)I[[S'2^!VNI:9]QWH%.XDC*XXXKL]4T6_N/'OA+4
M88-UIIUO>)=2;U'EF1(P@QG)R5/0'IS75T4 >3Z)X2\0PZ'X%TZZTB6!_#^J
MNUW(T\15HO*E E3:Y)4EU&" W^R.M=/KWPXT[5O"6KZ-!>:FC:C;^4LMWJ=S
M=B)P0R,%ED8##!3Q@D#&:[&B@#A[G5O'=UH/]F6OAQK'7)$,#:L]S;O90MR#
M.@W&5A_$J-$.2 W )J"6SUW1?BE<:U'H>H:W:3Z);V?VBTEM48RI+(S%EDEC
MQD,#P,<UW]% '"V&B^(KWQ%K7BZ2VM],U.?3ET_2;&]<2B%$=WW3^4Q&7<@X
M1FVKW)X#);/7_%7BOPS?7_A^705T222YN+B>YAD:5GB,9AB\IV)0DY)?9D*O
MRYZ=[10 4444 %%%% !1110 4444 %%%% !1110 5YM\1?\ D8H/^O5?_0WK
MTFBKA+E=SLP>*^JU?:6N>$UZSX*_Y$^R_P"VG_HQJW:*J=3F5K'9CLS^MTU3
MY+6=][]_(\X\5V6DZQK5_IWQ%\(-J6GL%.EZE8:7/<R>4 I:-GAW21.'SR-J
MLOXBL2+0M=3PMH$+6NJ2VD?C&VNK""[W2W%IIX.5$O5E"_,<.<JI4-@C%>Q4
M5D>.>&>);F?PW\$_%/A?5-(U&2_66]99ULW-O-'),TRSF?'EC"OC#,'W+M S
MC-WQ/X5UW5]6\:_8+*Z DCT2:+$87[4(&=Y$C,@*,XP.#D9V@]:]#_X0'PY]
MJ:;['/Y;S_:&L_ML_P!D,F[=N-MO\K.[YON?>^;KS71T >3IH][XJ\0)+;7G
MB>Z\C2;N'[=K=I'8);O.@01B,6T;RG(W$@[5V#DDXK5\/:E)+H/AGP[)X3OA
MJ-@D4-R;NR,<.FM%'L,T<S(8I"#PGEDY#9X&<>AT4 9>DZ3>:;)*UYX@U'5@
MX 5;R.V41^X\J)#S[YKF?"VGWMOJGCYI],:1;O5"]O%<J8X[M?LT:X#$$%20
M5)P1UKNJ* /+[QG\4'PCIVB^&;_1;K2=2AN[E9K![>'3H8N)8DE*A)-V=@$1
M(8'/ !K7\9>'=5'P_P#%")KFKZW)<Z3<Q0V,L%N079#C8(85<MV R>O0G!KN
M:* .8\*^"_#NCV&FWMGX:TNQU*.V0-/%81QS*Q3#?,%# G)!_&N8L9Y_#.E>
M(M!U+PS?:U>7NIW5Q;0+9/);:@EQ(60/-M:.,#=M;S",!<X(QGTZB@!L0*PH
MI14(4 HARJ^PX''X4ZBB@ HHHH **** "BBB@ HHHH **** "O+/C5I&I:K_
M &)_9>GW5[Y7G^9]G@:39GR\9V@XS@_E7J=%7"7+*YV8'%RP>(C7BKM7_%-?
MJ?+'_"(^)/\ H7M5_P# *3_XFO5/@KI&I:5_;?\ :FGW5EYOD>7]H@:/?CS,
MXW 9QD?G7J=%:SK.4;6/9QW$%7&8>5"4$D[?@T_T.0UC1-2N?BOX>UJVMA)8
MV6GWD,TID50KOY>P8SNYVGD XKFM.\+ZI:>(-+D\->&M1\*;-1-QJ@35DDTV
M:(@B14@60Y+<;3Y49'4X(Q7JE%<Y\T>5'PUXFL? FM> [71C<17TUU':ZQ]I
MB$"07$C.6E4L)=ZB1AA48$@?, >.@T/0+W1OB%J[2Z?)<:5J.F6-O'=J\91#
M LRLDBE@^2'7&%8<\D5VM1W-M!>6LMK>0QSV\R&.6*5 R2*1@JP/!!!P0: /
M)OA_HEQ;P^)IKN03V^APW&@:5+US;QN[MR>_,<9]X:9X8M->\7?#'P5HK:*V
MGV=NEA=7&HM/$T4D,&QT$:AC)O?:N=R*%.[EL#=ZO:Z=96.GI865G;VUFBE$
MMH8E2-5/4!0, <]*DM;6WL;2*ULH([>WA0)%#$@1(U P%"C@ #L* /(I/ 6K
M:?8ZWHT>B:GJS7UU<26EXOB":WL-D[EB+B%9T8;=QW".-MX'7)./2KS0$NO!
M-QX=601)-IS6(= <(#'LR Q)X]R3ZD]:V** .(T63Q8VFZ3X?NO#ZV$=M%]G
MU+4);B.2&6-$*9MPC^9N<[6!D1=HSD$X%<]'X7\37'PYL/AY=:-Y<=O+!!-K
M/VB+[,UM%(LF]$#^;YC! NTH "2=V!D^L44 >>0>%]83P_\ $BV:SQ-K=S=/
MIZ^:G[Y7M4C4YS\N6!'S8_*GV&@ZQIWB[1[Q],DFMSX;32YWBEB_T:96#?.&
M<$J>F4W<^W->@44 >76O@K7HO@UX5L$M8QKGAZ>VOA8RS*%F>)B6BWC*@E2<
M'D;L9QU#_$GA[7_&$VMZHVBS::5\-WNE6%G=3PF:YFG4'<3&[(BC:%&6R223
M@ 9].HH S] M9K+PUIEK=)LF@M(HY%R#M94 (R..HK0HHH **** "BBB@ HH
MHH **** "BBB@ KD?B1_R+D'_7VO_H#UUU%73GR34NQAB*7MJ4J=[7/!:Z[X
M;_\ (QS_ /7HW_H:5Z91794QG/!QY=_,\K#Y3[&K&ISWMY?\$XWX@^%Y?%%U
MX7B.G0ZA96FL+<7T4X1D$(BD4DJ_WAN9> "?:M[2?#.@Z!)*^A:)IVF/, )&
ML[2.$N!T!V@9K4HK@/<.2O\ 0;R?XO:/KJ6JM96VE7-O)<;ERLC21E5QG=T#
M\@8'/K47BS1M6\7ZU:Z%-;/:^&(R+C4;CS4SJ&/NVR@,65">7) R!M'4UV5%
M '">&O#&I:#/J7A.>*ZF\+.//TR]@O##):!F):U+(ZR@*>59?X3M)XQ76Z5I
M-MHUJUO9R7DB,Y<F\O9KI\X X>5F8#CH#CJ<<FKU% 'F6F^!M8D^!D'ARXBC
MM-8MYVNH4ED#*)$NS/&"RY&&  )&<!O45:U#P]JGC_6(YM=TF?0;"WTF[LO+
MN)HI999;I0CD>4[#8BKP2026Z#&3Z'10!YC!H7B34_#_ (7\,:CH*Z>-$NK2
M6YU)+B)K=UM6!7R &\S+[5^^B;06Y.!GTZBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O#?VD?^
M9;_[>O\ VC7N5>&_M(_\RW_V]?\ M&NC#?Q5_70Y\3_"?]=3W*BBBN<Z HHH
MH **** "BBB@ HHHH *\-^)W_)P?@_\ [<O_ $J>O<J\#^,E_'H_QH\.:I<I
M(T%G!;3N(P"S*EQ(Q S@9P/6NG#:S^3.;$:0^:/?**\I_P"&AO"G_0/UG_OQ
M%_\ '*/^&AO"G_0/UG_OQ%_\<J/85>Q?MZ7<]6HKRG_AH;PI_P! _6?^_$7_
M ,<H_P"&AO"G_0/UG_OQ%_\ '*/85>P>WI=SU:BO*?\ AH;PI_T#]9_[\1?_
M !RC_AH;PI_T#]9_[\1?_'*/85>P>WI=SU:BO*?^&AO"G_0/UG_OQ%_\<H_X
M:&\*?] _6?\ OQ%_\<H]A5[![>EW/5J*\I_X:&\*?] _6?\ OQ%_\<H_X:&\
M*?\ 0/UG_OQ%_P#'*/85>P>WI=SU:BO*?^&AO"G_ $#]9_[\1?\ QRC_ (:&
M\*?] _6?^_$7_P <H]A5[![>EW/5J*\I_P"&AO"G_0/UG_OQ%_\ '*/^&AO"
MG_0/UG_OQ%_\<H]A5[![>EW/5J*\I_X:&\*?] _6?^_$7_QRC_AH;PI_T#]9
M_P"_$7_QRCV%7L'MZ7<]6HKRG_AH;PI_T#]9_P"_$7_QRC_AH;PI_P! _6?^
M_$7_ ,<H]A5[![>EW/5J*\I_X:&\*?\ 0/UG_OQ%_P#'*/\ AH;PI_T#]9_[
M\1?_ !RCV%7L'MZ7<]6HKRG_ (:&\*?] _6?^_$7_P <H_X:&\*?] _6?^_$
M7_QRCV%7L'MZ7<]6HKRG_AH;PI_T#]9_[\1?_'*/^&AO"G_0/UG_ +\1?_'*
M/85>P>WI=SU:BO*?^&AO"G_0/UG_ +\1?_'*/^&AO"G_ $#]9_[\1?\ QRCV
M%7L'MZ7<]6HKRG_AH;PI_P! _6?^_$7_ ,<H_P"&AO"G_0/UG_OQ%_\ '*/8
M5>P>WI=SU:BO*?\ AH;PI_T#]9_[\1?_ !RC_AH;PI_T#]9_[\1?_'*/85>P
M>WI=SU:BO*?^&AO"G_0/UG_OQ%_\<H_X:&\*?] _6?\ OQ%_\<H]A5[![>EW
M/5J*\I_X:&\*?] _6?\ OQ%_\<H_X:&\*?\ 0/UG_OQ%_P#'*/85>P>WI=SU
M:BO*?^&AO"G_ $#]9_[\1?\ QRC_ (:&\*?] _6?^_$7_P <H]A5[![>EW/5
MJ*\I_P"&AO"G_0/UG_OQ%_\ '*/^&AO"G_0/UG_OQ%_\<H]A5[![>EW/5J*\
MI_X:&\*?] _6?^_$7_QRC_AH;PI_T#]9_P"_$7_QRCV%7L'MZ7<]6HKRG_AH
M;PI_T#]9_P"_$7_QRC_AH;PI_P! _6?^_$7_ ,<H]A5[![>EW/5J*\I_X:&\
M*?\ 0/UG_OQ%_P#'*/\ AH;PI_T#]9_[\1?_ !RCV%7L'MZ7<]6HKRG_ (:&
M\*?] _6?^_$7_P <H_X:&\*?] _6?^_$7_QRCV%7L'MZ7<]6HKRG_AH;PI_T
M#]9_[\1?_'*/^&AO"G_0/UG_ +\1?_'*/85>P>WI=SU:BO*?^&AO"G_0/UG_
M +\1?_'*/^&AO"G_ $#]9_[\1?\ QRCV%7L'MZ7<]6HKRG_AH;PI_P! _6?^
M_$7_ ,<H_P"&AO"G_0/UG_OQ%_\ '*/85>P>WI=SU:BO*?\ AH;PI_T#]9_[
M\1?_ !RC_AH;PI_T#]9_[\1?_'*/85>P>WI=SU:BO*?^&AO"G_0/UG_OQ%_\
M<H_X:&\*?] _6?\ OQ%_\<H]A5[![>EW/5J*\I_X:&\*?] _6?\ OQ%_\<H_
MX:&\*?\ 0/UG_OQ%_P#'*/85>P>WI=SU:BO*?^&AO"G_ $#]9_[\1?\ QRC_
M (:&\*?] _6?^_$7_P <H]A5[![>EW/5J*\I_P"&AO"G_0/UG_OQ%_\ '*/^
M&AO"G_0/UG_OQ%_\<H]A5[![>EW/5J*\I_X:&\*?] _6?^_$7_QRC_AH;PI_
MT#]9_P"_$7_QRCV%7L'MZ7<]6HKRG_AH;PI_T#]9_P"_$7_QRC_AH;PI_P!
M_6?^_$7_ ,<H]A5[![>EW/5J*\I_X:&\*?\ 0/UG_OQ%_P#'*/\ AH;PI_T#
M]9_[\1?_ !RCV%7L'MZ7<]6HKRG_ (:&\*?] _6?^_$7_P <H_X:&\*?] _6
M?^_$7_QRCV%7L'MZ7<]6HKRG_AH;PI_T#]9_[\1?_'*/^&AO"G_0/UG_ +\1
M?_'*/85>P>WI=SU:BO*?^&AO"G_0/UG_ +\1?_'*/^&AO"G_ $#]9_[\1?\
MQRCV%7L'MZ7<]6HKRG_AH;PI_P! _6?^_$7_ ,<H_P"&AO"G_0/UG_OQ%_\
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M/UG_ +\1?_'*/^&AO"G_ $#]9_[\1?\ QRCV%7L'MZ7<]6HKRG_AH;PI_P!
M_6?^_$7_ ,<H_P"&AO"G_0/UG_OQ%_\ '*/85>P>WI=SU:BO*?\ AH;PI_T#
M]9_[\1?_ !RC_AH;PI_T#]9_[\1?_'*/85>P>WI=SU:BO*?^&AO"G_0/UG_O
MQ%_\<H_X:&\*?] _6?\ OQ%_\<H]A5[![>EW/5J*\I_X:&\*?] _6?\ OQ%_
M\<H_X:&\*?\ 0/UG_OQ%_P#'*/85>P>WI=SU:BO*?^&AO"G_ $#]9_[\1?\
MQRC_ (:&\*?] _6?^_$7_P <H]A5[![>EW/5J*\I_P"&AO"G_0/UG_OQ%_\
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M?LQMVLV?N']*WP]*<:B;1AB*L)4VDSZ<HHHKB.T**** "BBB@ HHHH ****
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M+&C?^"^+_P")K<HHYI=PY8]C#_X0CPI_T+&C?^"^+_XFC_A"/"G_ $+&C?\
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M^+_XFMRBCFEW#ECV,/\ X0CPI_T+&C?^"^+_ .)H_P"$(\*?]"QHW_@OB_\
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MOB_^)H_X0CPI_P!"QHW_ (+XO_B:W**.:7<.6/8P_P#A"/"G_0L:-_X+XO\
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M/\+?M#Z9=O978_X2&!/+F3[R_,@SCU&1[UZ[7EWP8_Y"GQ#_ .QMO?\ T(4
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M"[7_ *XI_P"@BO/_ (VRR2^&]!TCSGAM-<\0V>FWI1RI,$A8N,@C .T ^V:
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MF:-.0+M="BG::= <E-TOW0?4?D1D'U6B@#A_%G@&XO3H&H^#KN#2M6\. QV
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M\::W9QQ6\#0V^D:,THMF+8S)(7P7;' !&!U&.<]M10!Y/_PJW6_^%<?\(_\
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M:#]J^U_8(!#Y_E[/,QWVY./S-:,6G64&H3W\-G;QWERJK/<)$HDE"_=#-C)
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MV%DS8K9QPS3(A!5))P=S#CG@$_7FO3J* &HBQQJD:A54 *!T IU%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9D'AW2;?
M3;S3X[*/[)?2227$+?,LC/\ >)SZU4TOP5H.D6EY;6MCOCO8A#<?:9&F:2,
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M@ HHHH **** "BBB@ HHHH Y[Q3K&NZ-:S7FDZ19WMI:V[7%PUQ>F%B%R2B
M(PS@9R2!S65>>/+N?4]*L?#UC8S2:CIR:@HU*^-J0KG"* $<LQYX[8IGCRV\
M2:O>6^DV6BM>^'W3??F&\CADN3GB#YC\L9Q\Q'+ [>!FHO&6E:AXBT1]+C\%
MVLTMW8B**\GN80MA(P/7'S_(3D%,Y(XQUH M:UXVU*QO=3ATK1HKY=#M$NM4
M+71C(W*7\N(;3O8(-W.T<J._$&H?$6<)J-[H6E)J&EZ/;175_.]QY;E7C$I6
M)=I#,L9#')7K@<U3O_#7B72YM=@T>VCU5=?T^&W:[EN%C-M.D/DM)(#RRE0K
M?+DY!&.<U6G\&:_HNG:[H&@V<5Y9:[9Q6ZWDDZI]C86ZV\C.IY8;4##;GG(.
M.M &KJ/Q%FM_[2U#3]+CN]"T>6.*^NS<;9,LJLQC3:0P174G)&>0.G/=*P9
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !16/K7BW0/#L\<.MZK;64DJ[E65\';G&X^BYXR<"EU;Q7H.A/
MNKZK:VC7"[HQ(_5>!N]EY'S'CGK0!KT5D:KXKT+0[J"WU;5;6TEN &C623&5
M)P&/HN>,G S2ZEXJT+1]0@L=4U6VM;F?!2.1\'!.%)] 3P"<9/% &M6)XO\
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M/_Z^$_G43BN1Z&M&<O:QUZH]FHHHKY\^^"BBB@ HHHH **** "BBB@ HHHH
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M !_3_P#71OYU[I7A=Y_Q_3_]=&_G7HX'>1\]G?PP^?Z$-%%%>H?-!7=?#/\
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MH **** *.M_\@&^_ZX/_ "->,'J:]GUO_D WW_7!_P"1KQ@]3731V9]9D/\
M"GZB4445N?1!7IOP^_Y%MO\ KNW\A7F5>F_#[_D6V_Z[M_(5E5^$\;.O]T^:
M.IHHHKD/B@HHHH **** "BBB@ HHHH **** "BBB@ KPN\_X_I_^NC?SKW2O
M"[S_ (_I_P#KHW\Z]' [R/GL[^&'S_0AHHHKU#YH*[KX9_\ 'QJ'^ZG\S7"U
MW7PS_P"/C4/]U/YFN;%?P6>CEO\ O</G^3/0****\,^U"BBB@ HHHH ****
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M'W_(PM_UQ:O3*Y*OQ'Q6=?[U\D%%%%9'C!1110 4444 %%%% !1110 4444
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M%%%>&?:A1110 4444 %%%% !1110 4444 %%%1/=6\=S%;23Q)/,"8XF<!G
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MZUS8K^"ST<L_WN'S_)G?T445X9]J%%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !7+?$V738/AEKLFN6<][IXM2)X;<@2%20-RD\
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M^$\;.O\ =/FCJ:***Y#XH**** "BBB@ HHHH **** "BBB@ HHHH *\+O/\
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MN#\N3E3QS0 EW\1Y9X;FZ\-:0-3LM/T^+4;V5[CRF$<B&14C7:=S[!NP2HY
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M444 %>6^.](\<6_Q0T_Q1X'TBRU(0Z4UE(MW<"-06EW=-P/85ZE7%>-OB/\
M\(9J=O9_\(QKNL>=#YOFZ9:^:B<D;2<\'C/XT <-\/;+XN>$-/L=#D\,:0VF
MB[:2>X:\!D5))2SD /@X#''':O;J\NT_XV_VAJ=K9_\ "!^++?[1,D7G36&U
M(]S ;F.> ,Y)KU&@ HHHH **** "L/QK_P B7JG_ %P-;E8?C7_D2]4_ZX&@
M#;7[H^E+2+]T?2EH **** "BBB@ HHHH HZW_P @&^_ZX/\ R->,'J:]GUO_
M ) -]_UP?^1KQ@]3731V9]9D/\*?J)1116Y]$%>F_#[_ )%MO^N[?R%>95Z;
M\/O^1;;_ *[M_(5E5^$\;.O]T^:.IHHHKD/B@HHHH **** "BBB@ HHHH **
M** "BBB@ KPN\_X_I_\ KHW\Z]TKPN\_X_I_^NC?SKT<#O(^>SOX8?/]"&BB
MBO4/F@KNOAG_ ,?&H?[J?S-<+7=?#/\ X^-0_P!U/YFN;%?P6>CEO^]P^?Y,
M] HHHKPS[4**** "BBB@ HHHH **** "BBB@ HHHH *1ON-]*6D;[C?2@##\
M&_\ (JV__76?_P!'/6[6%X-_Y%6W_P"NL_\ Z.>MV@ HHHH **** "BBB@!&
M^Z?I7B-[_P ?T_\ UT;^=>W-]T_2O$;W_C^G_P"NC?SKHH]3Z7(=ZGR_4@HH
MHKH/J0KOOAO_ *F]_P!Y:X&N^^&_^IO?]Y:SJ?"SR\V_W.?R_-'<4445QGPH
M4444 %%%% !1110 4444 %%%% !1110 'H:\.U+_ )"UY_U\2?\ H1KW$]#7
MAVI?\A:\_P"OB3_T(UZ.!WD?/YW\,/F5J***]0^9"N[^&G^MO_\ =3^M<)7=
M_#3_ %M__NI_6N;%?P6>CEG^]P^?Y,[^BBBO#/M0HHHH **** "BBB@ HHHH
M **** "BBB@ K$\7_P#(LS?]=H/_ $<E;=8GB_\ Y%F;_KM!_P"CDH VA]T?
M2EI!]T?2EH **** "BBB@ HHHH \W^(O_(<M_P#KA_6N1KKOB+_R'+?_ *X?
MUKD:[:?PH^_R[_=*?H%%%%6=YU7P^_Y&%O\ KBU>F5YG\/O^1A;_ *XM7IE<
ME7XCXK.O]Z^2"BBBLCQ@HHHH **** "BBB@ HHHH **** "N-^)7_(%M/^OC
M_P!E-=E7&_$K_D"VG_7Q_P"RFNC#?Q8G#F'^ZS]#S>BBBO=/APK4\-?\C-I_
M_7PG\ZRZU/#7_(S:?_U\)_.HJ? S:A_%CZK\SV:BBBOG3] "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "N&\?:#XMU"Z2_P##OCE/#-A;
M6Y^TK):)*I())<LQX '\J[FN<^('AZ?Q7\/]8T.SN%M[B^MS'$['"[L@@$^A
MQ@^Q- 'E/A.]\0:UK-BUI\:[?4H3>^2;<Z4(OM1CVN\2LP&258<KGKQTKWFO
MF[PQ\//'5UX@MM.U7PU8Z'91>($UM[U;F-FC$84>5"JDG!P.>G(SC'/TC0 4
M444 %%5[]KM;"8Z:D,EWL/E+.Q5"W;) ) _"N'D\=ZKX=?7K7Q1:VMQ<:98Q
M7T+V#MMF$CM&L9##Y6WJ!]#GM0!Z!6'XU_Y$O5/^N!K,T'Q'K(\4#0?%$%FE
MQ<68O;:6S9BNW.&C;<!R/7N*T_&G_(EZI_UP- &VOW1]*6D7[H^E+0 4444
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MA]_R,+?]<6KTRO,_A]_R,+?]<6KTRN2K\1\5G7^]?)!11161XP4444 %%%%
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M_6W_ /NI_6N$KN_AI_K;_P#W4_K7-BOX+/1RS_>X?/\ )G?T445X9]J%%%%
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MK(\8**** "BBB@ HHHH **** "BBB@ KC?B5_P @6T_Z^/\ V4UV5<;\2O\
MD"VG_7Q_[*:Z,-_%B<.8?[K/T/-Z***]T^'"M3PU_P C-I__ %\)_.LNM3PU
M_P C-I__ %\)_.HJ? S:A_%CZK\SV:BBBOG3] "BBB@ HHHH **** "BBB@
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MU"BBB@ HHHH **** "BBB@ HHHH **** "D;[C?2EI&^XWTH P_!O_(JV_\
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M )&%O^N+5Z97F?P^_P"1A;_KBU>F5R5?B/BLZ_WKY(****R/&"BBB@ HHHH
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M0=H]ZM_\)!HW_06L?_ E/\:\I[GXO4^-^I\X?M ,P^)G#$?Z''T/UKS#>_\
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MAME'B;3\L!_I"=_>IJ? S6A_%CZK\SVBBF>='_ST3_OH4HEC)P'4GZU\Z?H
MZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "L2#PCI,.AZGI#1-+9ZI---<QR-G<TIR^/3V]*VZ* .?\/\ @^ST"]EO
M?M=Y?WCQ+ )[R7>R1*<A%]!GGWK4N='TZ\+FZL;>4R?>+Q@D_C5RB@"E_8VF
M?] ^U_[\K_A1_8VF?] ^U_[\K_A5VB@#"E\%>&IYFEET2S9W.6/ECDTW_A!?
M# Z:'9_]^ZWZ* .-T_P+HHUS53<Z';?9BT7V?<G&-OS8_&M,^!?"YZZ'9_\
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M?3?^@?:_]^5_PJY10!2_L;3/^@?:_P#?E?\ "C^QM,_Z!]K_ -^5_P *NT4
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M[\K_ (5;HH Y^[T*!_%.FSQZ? ;:."=92(EP"=FW/Y&M7^R=._Y\+;_ORO\
MA5NB@"I_9.G?\^%M_P!^5_PI/[(TW_GPMO\ OTO^%7** *?]D:;_ ,^%M_WZ
M7_"E_LG3O^?"V_[\K_A5NB@"I_9.G?\ /A;?]^5_PK)T/0;>"34S=Z? !)?.
M\6Z)3E"!C'MUKH:* *G]DZ=_SX6W_?E?\*3^R-._Y\+;_OTO^%7** *?]D:;
M_P ^%M_WZ7_"K$%M!:QE+:%(E)R510H)]>*DHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7<0>W8":0A3*7+$@83&."N.@H ]6HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ***JZE>MIVFSW:6=S>M"NX6]JJM+)[*&(&?J10!
M:HKBO^%B7G_1/_%__@-;?_'ZZO3;UM1TV"[>SN;)IEW&WNE598_9@I(S]":
M+5%%% !1110 57BO[.>^N+."[@ENK4(9X$D!>$."5W*.5R <9ZX-1:R-5.D7
M \/M9KJ.T>0;Y6:$'(SN"D-C&>AZUX]X93XD?\+:\8^3/X6^W"/3OMY>&X\H
MKLDV>4-V0<;L[L\XQ0![=1110 4444 %%%9'B4>)&TV/_A#WTI+WSAYAU1)&
MC\O!S@1D'=G;[8S0!?M+^SOQ,;"[@N1!,T$IAD#^7(IPR-CHP/4'D58KQOX1
MKXY^W:X9)?#W]FCQ+??VB%BG\XR[_P!YY1W;0N<8W G'6O9* "BBB@ HHHH
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M** ,CQ-X;L_%>CC3=1DGCA$\4^Z!@&W1N'4<@C&5&>.E:]%% !1110 4444
M9'B'PU9^)8].2_DGC&G:C!J,7DL!NDB;<H;(/RYZ@8/N*UZ** "BBB@ HHHH
M *R)O#=G/XQM?$CR3B\M;.2S2,,/+*.RL21C.<J._P"%:]% !1110 4444 %
M%%% !61X5\-6?A'PW;Z+ILD\MM;O*ZO<,&<F21I#D@ =7...F*UZ* "BBB@
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M,$$9!%0V=E:Z=9Q6FGVT-K;0KMCA@C"(@] HX I_VB'_ )ZQ_P#?0H^T0_\
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M+10 FQ?[H_*C8O\ ='Y4M% ";%_NC\J-B_W1^5+10 FQ?[H_*C8O]T?E2T4
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MW^-2T4 1?9E_OR_]_&_QH^S+_?E_[^-_C4M% $7V9?[\O_?QO\:/LR_WY?\
MOXW^-2T4 1?9E_OR_P#?QO\ &C[,O]^7_OXW^-2T4 1?9E_OR_\ ?QO\:/LR
M_P!^7_OXW^-2T4 1?9E_OR_]_&_QH^S+_?E_[^-_C4M% $7V9?[\O_?QO\:/
MLR_WY?\ OXW^-2T4 1?9E_OR_P#?QO\ &C[,O]^7_OXW^-2T4 1?9E_OR_\
M?QO\:/LR_P!^7_OXW^-2U7LK^SU*W\_3KJ"[AWLGF02!UW*<,,CC(((([$4
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M^_+_ -_&_P :5(0C9#.?]YR:DHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\AF\F)74[@PPN[AQD\8ZVSLO$VA7$%YJ>OOK5B+=VU&*2S421R!<AK9((MS
MG(V,6;&,$D?-)!X$TYY;^?7+J[UZYO[0V,L^H&,$6YY,2K$B*JD\D@9)QD\#
M!I?@BWL-3L;Z\U?5-7?38FBL$OY(V%J&7:2"B*78K\NYRS8)YY.0"R;JV\8Z
M)>6EC<ZUI8<"-[@6<UC.H/)\LS1@\@$;E&1G@@X(X?P%HUP_PF\4Z'X=,<$[
M:EJEG9M<2/MC_>,BEF^9CCCGD\5ZK7/6G@C1[?P[JFASI+>6&JW%Q<74<[\D
MS,6=05 (&3QW'KGF@#!L=1UOP1?>&M UQ].O=.O8S90/I]K+#);/%"64$-(_
MFJ50C("G..#GC/\ BGXAM=:^$VN+80:@CQ-:G%]IMS:*<W,>,&6-<_AG%=5I
M?@J&QU6SU'4M9U37+JPB,5D^I/$?LX8;68>7&FYV7@LVYL9YY.=#Q/X=M/%?
MAVXT;49)H[>X,9=H& <;'5Q@D$=5';I0 W2KGQ)-=E=;TK2[.WV$B2TU.2X<
MMD8&UK>,8QGG=^'IRGAJZ\6^*-"LO%ECK:1_:[KS%T6:"-;46H<H4,@0R^;L
M!?=NV[^-NWBO0JY#_A7&F[C;C4=2&BF[^V?V)YD?V7S-V_\ N>9L\SY]F_;G
MMCB@#KZ*** "N<UW5?%=EJ(BT#PO::I:^6"9YM6%LP;G*[/*;VYSWKHZ* .9
MT75_%]WJB0ZYX4L]-LR#ON8M8%PRG' V>4N<GCKQ73444 %%%% !1110!R-[
MKGCJ&_N(['P587-LDK+#.^NB,R(#\K%?).TD8.,G'K6IX=U#Q#?_ &C_ (23
M0;?1]FWR?(U'[5YN<[L_NUVXP/7.>V*VJ* "BBB@ HHHH \9^+.@>)_MFAW'
M_":3?9+GQ/9):6G]FP8LW:0['#XR^ST;@]Z]1\.Z=JNEZ6;?7M<?7+KS"PNG
MM8X"%.,+M3CCGGWK5HH **** "BBB@".=))+>1(9?)D9"$D"AMAQP<'@X]*\
M4O?"_C)?C-I5H_Q!G>^?1KB2.^_LBV!C02Q@Q[,;3DD')Y&*]OHH KV$-Q;:
M;;07MT;RYBA1)KDQA#,X #/M7A<G)P.!FK%%% !1110 4444 87B?2-=U:*W
M7P[XGD\/M&S&5TLHKCS@<8&) <8YZ>M>?? G1O$$?@S2]1F\4R2Z5YEVO]DF
MQA"[OM$JEO- W\L"V/?'2O7J* "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ JKJ0OVTV<:.]M'?%?W+72,\0;_:"D$CZ$5:HH XK
M[/\ %'_H)>$/_!?=?_'JZO31?KIL UA[:2^"_OFM49(BW^R&)('U)JU10 44
M44 %%%% &?K:ZR^FL/#<MC#?;AM:_B>2+;WX1E.?QKFOL_Q1_P"@EX0_\%]U
M_P#'J[6B@!D/FB"/[04,NT;R@(4MCG&>V:?110 4444 %9'B7P\OB738[-]4
MU73 DPE\[2[MK>1L C:6'5?FSCU ]*UZ* /(_A=\.[C3=0U>_OM5\46[6WB"
M\,-M<7TBPWD0;"RR(1B3>.2_\76O7*** "BBB@ HHHH YCQEX0'B>V5_[:US
M3FMXI L>E7[6ZRDC^,+][IQ]37-?!OP1/H'A'1]0O]1\0)=M9;)=+OKM_(@)
M/00,!L(QQZ9/K7IE% !1110 4444 %>8_&+P-/KOA/6M1L-2\0R7?V/;%I5E
M>.;>8CL8%'S$]_6O3J* .:\&>$QX7LG_ .)QK>I-<QQ;DU6^:X\DJ#P@;[N=
MW/T'I72T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M<OK'C.YTG5IK*+P?XCU)8MN+JR@A:*3*@_*6E4\9P<@<@UU%% '/:!XJN-<O
MWMIO"^NZ0J1&3S]1AB2-B"!M!21CNYSTQ@'FNAHHH **** "H+VY-G87%REO
M-=-#$T@@@ ,DI SM4$@%CC R0,]ZGHH XK_A8EY_T3_Q?_X#6W_Q^NHT?47U
M;28;V73[S36EW9M;U566/#$?,%9ASC(P3P15VB@ HHHH **** ,3Q,OBEK6#
M_A#9-'2?>?..JQRLI7'&WRR#G/K7G7P37QG_ &+$;B70?["_M"]\]8XYOM1?
MS9,[26V8\SU&=OO7L%5[*PL]-M_(TZT@M(=[/Y<$81=S'+' XR222>Y- %BB
MBB@ HHHH *\<^,*^.?L]J5E\/?V3_;=G]C4Q3_: _FKL\P[MI&[K@ XZ5['5
M>\L+/4(DCU"T@NHXY%E19XPX5U.58 ]"#R#VH H>&AXD739/^$P?2GO?./EG
M2TD6/R\#&1(2=V=WMC%:]%% !1110 52UD:J=(N!X?:S74=H\@WRLT(.1G<%
M(;&,]#UJ[10!XCX93XD?\+:\8^3/X6^W"/3OMY>&X\HKLDV>4-V0<;L[L\XQ
M7MU5XK"S@OKB\@M((KJZ"">=(P'F" A=S#EL G&>F35B@ HHHH **** "BBB
M@ HHHH **** "BBB@"-YE1L,'S[(Q_D*3[3'Z2?]^F_PJ6B@"+[3'Z2?]^F_
MPH^TQ^DG_?IO\*EHH B^TQ^DG_?IO\*/M,?I)_WZ;_"I:* (OM,?I)_WZ;_"
MC[3'Z2?]^F_PJ6B@"+[3'Z2?]^F_PH^TQ^DG_?IO\*EHH B^TQ^DG_?IO\*/
MM,?I)_WZ;_"I:* (OM,?I)_WZ;_"C[3'Z2?]^F_PJ6B@"+[3'Z2?]^F_PH^T
MQ^DG_?IO\*EHH B^TQ^DG_?IO\*/M,?I)_WZ;_"I:* (OM,?I)_WZ;_"C[3'
MZ2?]^F_PJ6B@"+[3'Z2?]^F_PH^TQ^DG_?IO\*EHH B^TQ^DG_?IO\*/M,?I
M)_WZ;_"I:* (OM,?I)_WZ;_"C[3'Z2?]^F_PJ6B@"+[3'Z2?]^F_PH^TQ^DG
M_?IO\*EHH B^TQ^DG_?IO\*/M,?I)_WZ;_"I:* (OM,?I)_WZ;_"C[3'Z2?]
M^F_PJ6B@"+[3'Z2?]^F_PH^TQ^DG_?IO\*EHH B^TQ^DG_?IO\*/M,?I)_WZ
M;_"I:* (OM,?I)_WZ;_"C[3'Z2?]^F_PJ6B@"+[3'Z2?]^F_PH^TQ^DG_?IO
M\*EHH B^TQ^DG_?IO\*/M,?I)_WZ;_"I:* (OM,?I)_WZ;_"C[3'Z2?]^F_P
MJ6B@"+[3'Z2?]^F_PH^TQ^DG_?IO\*EHH B^TQ^DG_?IO\*/M,?I)_WZ;_"I
M:* (OM,?I)_WZ;_"C[3'Z2?]^F_PJ6B@"+[3'Z2?]^F_PH^TQ^DG_?IO\*EH
MH 8DJR9VAN/[R$?SI]%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M$9F#$>3(<=QCG]:EHH B\]O^>$OZ?XT>>W_/"7]/\:EHH B\]O\ GA+^G^-'
MGM_SPE_3_&I:* (O/;_GA+^G^-'GM_SPE_3_ !J6B@"+SV_YX2_I_C1Y[?\
M/"7]/\:EHH B\]O^>$OZ?XT>>W_/"7]/\:EHH B\]O\ GA+^G^-'GM_SPE_3
M_&I:* (O/;_GA+^G^-'GM_SPE_3_ !J6B@"+SV_YX2_I_C1Y[?\ /"7]/\:E
MHH B\]O^>$OZ?XT>>W_/"7]/\:EHH B\]O\ GA+^G^-(;A@/^/>4_0#_ !J:
MB@"O]J;_ )]9_P A_C1]J;_GUG_(?XU8HH K_:F_Y]9_R'^-'VIO^?6?\A_C
M5BB@"O\ :F_Y]9_R'^-'VIO^?6?\A_C5BB@"O]J;_GUG_(?XT?:F_P"?6?\
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M_OL4Y)XI&VQRHQ] P-/Q10 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ]<*HR<X #8 ]JV_#_AV+P[;S0PZCJE^)6#%M2OI+EEXQA2Y) ]J ->BBB@
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M*** "BBB@ HHJKJ5BNIZ;/923W-NLR[3+:S-%*GNKKRI]Q0!:HKBO^%8V?\
MT,_B_P#\*"Y_^*KJ]-L5TS38+*.>YN%A7:);J9I97]V=N6/N: +5%%% !111
M0 45GZWH\>NZ:UE+>7UFK,&\VPNGMY1CMO4@X]JYK_A6-G_T,_B__P *"Y_^
M*H [6BF0Q"&".(,[A%"AG;<QP,9)[GWI] !1110 445C>(?#4/B..!)]2U:P
M$))!TV_DMB^<?>*$;NG&: -FBN/M?AQ:6MY#<+XC\52&*17"2Z[<.C8.<,I;
M!'J#UKL* "BBB@ HHHH R-?\4:+X;@SK&L:=ITLD;- E[=)$92H[!B,\D=/6
ML3X=?$'3_&GAG39IM4TIM;GMO.N;"TN%+Q'.#^[W%E R.OK70:SH&FZY;,NH
MZ;9WDJQLL37,"R;"1V)!QVZ5A_#SP/;>#O"6EV=S9:=_:UM;"&XO+6(9D.>?
MG*AB.G6@#KJ*** "BBB@ HHKE]8\"6VLZM-?RZ[XCM&FVYALM8F@B7"A?E16
M '3)QU))[T =117/:!X.M_#U^]W#K&NWS/$8S'J.J2W,8!(.0KD@-QUZX)]:
MZ&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKE]8A\
M>MJTQT"]\.1:?\ODI>V<[RCY1NW,LJ@_-G& .,4 =117/:!%XS2_<^*;O0IK
M3RCL73K6:.029&"2\C#;C=QC.<<UT- !1110 445!>BZ-A<#3FA2[,3>0TZE
MHQ)CY2P!!*YQD @X[T 3T5Q7V?XH_P#02\(?^"^Z_P#CU=1HZZHNDPC7Y+.7
M4/F\Y[*-DB/S';M5F8CY<9R3SF@"[1110 4444 %%8?B&/Q6\D'_  BESHT"
M -Y_]I6TLI)XQMV.N.^<Y[5G:?#\1%U& ZK?^&'L@X\];:QN%D*=]I:4@'Z@
MT =;1110 4444 %9'B3Q)9^%[&VN]0CGDCN+R&S00*"0\KA5)R1QD\_R-:]>
M2?%7X=W&I)!J%AJWBBYEN-7M3)9V]](\-NAD :1(P/DVCY@W\)YH ];HK(\-
M>'E\-:;)9IJFJZF'F,OG:I=M<2+D ;0QZ+\N<>I/K6O0 4444 %%%9^MKK+Z
M:P\-RV,-]N&UK^)Y(MO?A&4Y_&@#0HKBOL_Q1_Z"7A#_ ,%]U_\ 'J[*'S1!
M']H*&7:-Y0$*6QSC/;- #Z*** "BBB@ HHHH **** "BBB@ HHHH **8_F[O
MW93'^T#3?](]8OR- $M%1?Z1ZQ?D:/\ 2/6+\C0!+147^D>L7Y&C_2/6+\C0
M!+6?KFE/K6E2V*:E>:<LH*R2V?E^8RD$%<NC  YZ@ CL15O_ $CUB_(T?Z1Z
MQ?D: ,C4_".EZEX8MM "R6FGVKV[0I;$ H('5T49!XR@![XSSWK<J+_2/6+\
MC1_I'K%^1H EHJ+_ $CUB_(T?Z1ZQ?D: ):*B_TCUB_(T?Z1ZQ?D: ):*B_T
MCUB_(T?Z1ZQ?D: ):*B_TCUB_(T?Z1ZQ?D: ):*B_P!(]8OR-'^D>L7Y&@"6
MBHO](]8OR-'^D>L7Y&@"6BHO](]8OR-'^D>L7Y&@"6BHO](]8OR-'^D>L7Y&
M@"6BHO\ 2/6+\C1_I'K%^1H EHJ+_2/6+\C1_I'K%^1H EHJ+_2/6+\C1_I'
MK%^1H EHJ+_2/6+\C1_I'K%^1H EHJ+_ $CUB_(T?Z1ZQ?D: ):*B_TCUB_(
MT?Z1ZQ?D: ):*B_TCUB_(T?Z1ZQ?D: ):*B_TCUB_(T?Z1ZQ?D: ):*B_P!(
M]8OR-'^D>L7Y&@"6BHO](]8OR-'^D>L7Y&@"6BHO](]8OR-'^D>L7Y&@"6BH
MO](]8OR-'^D>L7Y&@"6BHO\ 2/6+\C1_I'K%^1H EHID?F<^;M]MN:?0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%1$7&3AX\=LH?\: ):*BQ<?W
MXO\ O@_XT8N/[\7_ 'P?\: ):*BQ<?WXO^^#_C1BX_OQ?]\'_&@"6BHL7']^
M+_O@_P"-&+C^_%_WP?\ &@"6BHL7']^+_O@_XT8N/[\7_?!_QH EHJ+%Q_?B
M_P"^#_C1BX_OQ?\ ?!_QH EHJ+%Q_?B_[X/^-&+C^_%_WP?\: ):*BQ<?WXO
M^^#_ (T8N/[\7_?!_P : ):*BQ<?WXO^^#_C1BX_OQ?]\'_&@"6BHL7']^+_
M +X/^-&+C^_%_P!\'_&@"6BHL7']^+_O@_XTA%SCAXL_[A_QH FHJOMN_P#G
MI#_WP?\ &C;=_P#/2'_O@_XT 6**K[;O_GI#_P!\'_&C;=_\](?^^#_C0!8H
MJOMN_P#GI#_WP?\ &C;=_P#/2'_O@_XT 6**K[;O_GI#_P!\'_&C;=_\](?^
M^#_C0!8HJOMN_P#GI#_WP?\ &C;=_P#/2'_O@_XT 6**K[;O_GI#_P!\'_&C
M;=_\](?^^#_C0!8HJOMN_P#GI#_WP?\ &IHQ(%_>E2V?X1@4 .HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **:[%5RJ%SZ C^M,\V3_GW?\ [Z7_ !H
MEHJ+S9/^?=_^^E_QH\V3_GW?_OI?\: ):*B\V3_GW?\ [Z7_ !H\V3_GW?\
M[Z7_ !H EHJ+S9/^?=_^^E_QH\V3_GW?_OI?\: ):*B\V3_GW?\ [Z7_ !H\
MV3_GW?\ [Z7_ !H EHJ+S9/^?=_^^E_QH\V3_GW?_OI?\: ):*B\V3_GW?\
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MY]J -BBL73?&?A?6;Y;/2/$FD7]TX)6"UOHI78 9.%5B>!6U0 4444 %%%%
M!17/W/C[P?9W4MK>>+-#@N(7,<L4NI0J\; X*L"V001@@U>TCQ'H?B#SO[!U
MG3]3\C;YOV*Z2;R]V<;MI.,X.,^AH TJ*** "BBB@ HKG9?B%X+@F>*;Q?H,
M<D;%71]3A!4C@@C=P:TM)U_1]?ADET+5K'4XXFVR/9W*3!#UP2I.#0!H4444
M %%%% !145W=V]A9RW5]<16UM"I>6:9PB1J.I+'@#W-8'_"Q_!'_ $.7A_\
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MX>M=+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-'V&#^ZW_?QO\:L44 5_L,']UO\ OXW^-'V&#^ZW_?QO\:L44 5_L,']UO\
MOXW^-'V&#^ZW_?QO\:L44 5_L,']UO\ OXW^-'V&#^ZW_?QO\:L44 5_L,']
MUO\ OXW^-'V*#^ZW_?QO\:L44 5_L4']UO\ OXW^-'V*#^ZW_?QO\:L44 5_
ML4']UO\ OXW^-'V*#^ZW_?QO\:L44 5_L4']UO\ OXW^-'V*#^ZW_?QO\:L4
M4 5_L4']UO\ OXW^-'V*#^ZW_?QO\:L44 5_L4']UO\ OXW^-'V*#^ZW_?QO
M\:L44 5_L4']UO\ OXW^-'V*#^ZW_?QO\:L44 5_L4']UO\ OXW^-'V*#^ZW
M_?QO\:L44 5_L4']UO\ OXW^-'V*#^ZW_?QO\:L44 5_L4']UO\ OXW^-'V*
M#^ZW_?QO\:L44 5_L4']UO\ OXW^-'V*#^ZW_?QO\:L44 5_L4']UO\ OXW^
M-'V*#^ZW_?QO\:L44 5_L4']UO\ OXW^-'V*#^ZW_?QO\:L44 5_L4']UO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
L@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>img30600998_13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img30600998_13.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#X17AI9@  34T *@    @ ! $[  (
M   /   (2H=I  0    !   (6IR=  $    >   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $YI8V]L92!3
M96ET=&5R    !9 #  (    4   0J) $  (    4   0O)*1  (    #,3$
M )*2  (    #,3$  .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                         #(P,C,Z,#,Z,30@,3(Z-38Z,3, ,C R,SHP
M,SHQ-" Q,CHU-CHQ,P   $X :0!C &\ ; !E "  4P!E &D = !T &4 <@
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" 'Z!2P# 2(  A$! Q$!_\0 'P
M 04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0
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M7"7=E+%YT<T)W!UQGBO*K;]IWP)/I]U=/#JT!MR@6"6"/S)RV?N 2$<;>22
M,CGF@#V*BO(KK]I+PA:Z'8ZLVF:\]K>R211LMK&-KQ[2RG,@!.'4Y&1SUR"*
M]6M+VWOM.@OK:57MKB)9HY,\,C#(/Y&@">LJS\5>']1U1],T_7=,NK^,L'M(
M+R-Y5*G#90'(P>O'%<MX$^,.@_$37KS2] L=44V<1EDN;B&-8B-P48(<G)SD
M9'0&O/?AK_PK[_A?6J?\(_\ \)-_;WF7GG?;OL_V7.\^9MV_/UZ9[=: /H"B
MN-\=?%7PM\/!''K]X[7<J[X[.V3S)67UQD #CJ2,UE>"_CKX+\;ZI'IEC<75
MC?2G$-O?Q",RGT5E9ES[9R>U 'H]%<%X_P#B_H7PXU>RL-?L=3D^VQ>9'/:Q
M1M& &P02S@Y'!. >"*W?&GC33/ OA6;7]76>:UB9$"6JJSN78 ;02 >N>O0&
M@#H**Y7X?_$+1_B1H<^J:%'=0Q07!MY([M%5PP56SA688(8=^QK,\)_&#0/&
M?C2^\-:-9ZD;FQ$K2W$L48A*HX0D,')P21CC\J .]HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** .*^,7_)'/$W_7BW\Q7S1\*/'GQ"\*>'[RU\#>
M%?[:LY;KS)IO[.N+C9)L4;=T; #@ X//-?2_QB_Y(YXF_P"O%OYBO/OV4?\
MDG^L?]A0_P#HI* //]1\)?%CXU^)[*7Q1I4NDVD V![FV-M%;(3\Q5&^9F./
M<G Y YKZKTG3;?1M&LM+LE*VUE EO$#U"HH4?H*MT4 ?(/[1GA"'PA\0(]7T
M>4V\6O12R211G;LD^[+T_A</DCU+=J]\^"?@FT\&?#:P\K;)>:G$EY=S@?>+
MKE5^BJ0/KD]Z\G_:V_Y"GA?_ *XW/_H4=?0'@S_D0] _[!MM_P"BEH UKFXA
ML[66YNI5A@A0R22.<*B@9))[  5\">/M8L?$OC[6]:T.Q^S:?<7)D1%4XP<#
M>?0L<MCL6Q7O?[2_Q)-I9IX'T6;-S= 2:BT9Y2/^&+ZMU/L!V:NC^&7P6T_3
M/A-=Z5XEM@U_X@A#7Q(&Z#C,:*>Q0_-_O9[ 4 =M\,M?T;Q'\.M)O/#D2VUG
M' L'V4'_ (]W0 -&?7'KW!![U!XF^+/@GP=K)TKQ'K7V.]5%D,7V2:3Y6Z'*
M(1^M?/OPV\0W_P $/BW>^%/%$A32KJ8132-PBD_ZJX7/12",^QYY7%?07B7X
M3>"?&6L'5O$6B_;;UHUC,OVN:/*CH,(X'Z4 7?#/C;PK\1+&^3P]>IJEM"!%
M=));2(N'!^4B11N! /K7FO[4\:0_"?2XXD5$768@JJ, #R)N *]-\)> O#?@
M6&ZB\*Z;]@2[96F'GR2[RN<??8XZGI7FG[5?_)+--_[#47_HB>@#KO@;_P D
M3\-_]<'_ /1KUXG\'>/VI-;S_P ]M0_]&&O;/@;_ ,D3\-_]<'_]&O7C?Q#T
M+Q%\)OC6_P 0-#TUK_2[J=[ERJDHID!$L<A'W<EF()XY'7!% %G]K;_D*>%_
M^N-S_P"A1U!^TRK#PQ\/LJ1BTG!XZ'9;UD3R^(OVCOB5ID_]C/I^AV@6.5U8
MO'#%NW2$R8&YVZ  #MZ$U[5\=/AW<^// *1:+$K:GIDOGVT7 \Q=N&C![$C!
M'NH% 'C,/P5\5^)?AQ!XXN?$QDOH[$7%I8LC$K B_(JR!L(=JC"A<=.>M>B_
ML^_$Z[U_P9J]MXJNWFDT!%E-Y("SO;E6/S8R6*[#SU((ZFO-=.^-OBOP_P"
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M20J>@)"@>O/8C(![S%:6T-Q-<0V\4<UP09I$0!I"  "QZG  '/85\L_LH?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KGI_B!X-MKB2"Y\6Z%#-$Q22.34H59&!P006R"#VK4UK
M4XM%T&_U2XQY5E;27#Y/9%+'^5?(WPRD^$ESHM_>?%>X,NL7%ZSQKMN^(RH.
M<PC;DL6Z\\"@#ZOM/%OAR_L+J^L?$&EW-I9@&YN(;V-XX >[L#A>G>M"QO[3
M4[**\TVZ@O+689CGMY!(CCID,.#7@_C"X^'?AKX"3R^"K"ZET7Q'?) %M+J6
M&6=E8[B&G20@#RBI&W!_&NGU_P"(FF?!RW\(>%?[+EN();0)*QN09+=$"KG
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M_=/.>*S;;XUWNK>,=?\ #OAKP9=ZQ=:3,T*/!>(B2[6*LSLZA8QE<#EB>PH
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M)4=/7GBNX0L8U,@"O@;@IR ?8\9H Q]3\8>&=%O#::SXBTG3[D*&,-W?1Q.
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M2GJ) C $*6\K&0"0,]Q6EX( \5?M0^,-=/[R#0X%L(>X1^$//_;.7\Z]OHH
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MK@*I PH:1@>H8GC'->\_"OQ)X&\:VFL'P5X5&C0QJD-VQL(+?SPP;"_NV.[
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M!VP^WYB6(/'H!7=UX)I>K7&A>-?B=J=EC[1;Q2M$2,[6\W /X9S^%<_:6O\
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M'@[_ *YK_P"AO6SBIQ5DE=-_<8J3A)W;=FE]YZ_17D'B_P#Y.5\*_P#7BO\
MZ%/6!\/?"&G^,/$OC2WUEYVMH+L[8(Y612[O+AR%(R5V\ \<FL_8KEYF^ES3
MVSYN5+K8]^HKYN\&>'[?Q/\ "KQ'J.MW-Y<R:/!*;!#<,$MRD9DR%S@Y/'/:
MMJ3QGK5A^SC8W4-W-]LGNS8BZW'S(XP7/WO7";<^_K5/#ZV3ZV$L1I=KI<]W
MHKPWQAX)L_!'@&S\4>'[R\M];@:%I;S[0Q-P7QG<"<8R>GIP<U!X[:3Q1XP^
M'KW+O;-JMG 9C"2K*)2-X![<,125%2U3TU_ ;K..C6NGXGO-<!XSUWXBZ5JM
MPWAC0=.O-(AA$AN+AP&R!EN/-4\?2NK\/^'-*\+Z;]@T.U%K;ES(5WLY+'J2
M6)/:I-?_ .1;U+_KTE_] -91:4MK^II)-QWMZ'E?A;X@_$[Q7!%>Z9X>T>?3
M_/\ *EF4E"N,;L!I@> ?2O9*\/\ AYX='BGX ZMI87,TEU*\''2151E_,C'T
M)K)U#QE/KGP5T3PW:LTFK7MV--=,_,5C*E<]^=T0_.NF=)3E:.EG;_@G-"JX
M1O+6ZO\ \ ^AJ*\)^)>A)IWB/X?Z#8W#VJ(%M%N(SM9,O&I<'L>2<^M6?%&C
MP?#'XA^%KOPK)<P1:I.8+RV>=G68!HP22222?,_ @$5DJ*:5GO<U=9INZVM^
M)[;17SY?ZC!XH^)_B&/Q5I&O:Y9:?*]M:6>DQ,ZP;6*[V 88SMSGN3[5H^'X
M/'-W\,_$NB6EKJUM);R1G3FOXVAF>!F.^-6;&2%7H#_%CN*;H66K[?B)5[O1
M=_P/<J*^7K2[T_0M1THW-AK'@W5;:0?:;XI).MR>Y>-F4@$]0N1@G@U]/QR)
M+&LD;!D<!E8'@@]ZBK2]G8NE5]I<=1116)L%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %>7>-/B!XLTSXC0>%_">FZ=?2W%N)8TN0P9CA
MF;YO,50 %)KU&O"_'EQK5K^T)ITWA>TAO=56Q_<03D!'^24-DEEZ+N/4=/PK
M>A%.3OV,*\FHJW<VK+XG>+=&\6:=I'Q!\/VMA'J,@CBFM2< D@9SO<, 2,@$
M$9S]?6J\=3PIX_\ ''B_2;_QS;V>EV&ERB98+>13O(() "LQR=HY)X&<50\4
MIIOB3XD:I;3VVJ^+YK=/)CTZT4V\%BPX),N_ELYYV@9)ZXQ6DJ<9-6^=C.-2
M44[_ "N>XU'<7$=K:RW$YVQPH7<XS@ 9-?/7AK4+N\_9V\4Q7=Q),EO.BQ"1
ML[%+1G ]L]JZ;PG\//#^H?"9-6U.TDO=0N-/=C-)/)\H7)15 8  ;%__ %'%
M3*BHWYGUL5&LY6Y5TN>B>#O%UIXTTF?4M.AEBMH[EH$\W&YPH!W8'3.>E:>J
MZO8:'ILE_JUU':VL6-\LAX&>@]S["O*O@#X>TL^')-?-K_Q,Q<2VXG\QO]7A
M#MVYV]>^,UZIJVCZ?KMB;+5[5+JV+JYB?.TE3D9QUY[5%2,8U&NA=.4I4T^I
MP7@?XIS>-OB%J&EVEK%%I$%HT]O(R,)G(=%RWS8P=Q.,9Z<UZ57CW@N*.#]H
M_P 3Q0HL<:6!5$08"@-!@ =A7?7'@?3;GQ]:^+GGNAJ%K$8DB#KY1!5EY&W.
M<.>_I3JQ@I:::$TI3<===3BO$/Q"\:I\3-0\*^$M)TR^-JB2()P5<J8T9B6,
MBKU>G:/\4O$&G>+;70?B)H4.EO>D)!<0$A Q.!G+,",\9!XJMI7_ "=-K?\
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M^9LGON((Z'TI*ALF]7?\!NONTM%;\3W:BBBN8Z0HHHH **** "BBB@ HHHH
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ME:XLH)G #21JQ Z9(S4U>.:LG_"&?%SPWXA0^78ZY;)9W9' W[57)Q_VS/\
MP$TO@A)_&/Q+\4^+K9AMM4:RTUW^Z&V[0WY+D_\ 72LG1TYKZ6_I&JK:\MM;
M_P!,]BKG_&5YXGLM'BD\%:=;:C?FX"R17+!5$6ULMRZ<Y"CKW/%?/-Y92Z-;
MW47C;0-9M]8:;?'K\<SN4Y[*2$<=>0P//6NS^*&HQZK\"O#]U%J3:H&OXU-V
M\7EM(5CF4[ER<-Q@\GGGO6GL.62UO<S=>\7I:Q[A 9&MXS.H64J"ZCH&QR*?
M7AOQ&TW67\0Z7J.H:'>>(/#<=C&OV.VF=%5L?,6V<@YYSWX&>*TO@MJNG-JN
MJZ=IVI7T<3#SHM'O8N;8 X)23<=PY (PIZ'M4.C[G.F6JWO\C1[!1117.= 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 8GBWPGIWC+07TO558(6#QRQG#Q..C#\R/H37GW_"C;JXCCLM
M3\;ZG=:5&?ELMA 4>@RY4?\ ?->N45I&K."LF9RI0F[M'&^(OAKI>M:)I=C9
M2RZ7-H^/L%U!RT.,=<]>0#USD9S46@?#J2R\5+XD\2:Y-KVJQ1>5!*]NL*Q+
M@CA03S@G\SWYKMZ*/:3M:X>SA>]CB=)^&UO8>)O$>IWMZ+VWUY726T,&S8K,
M21NW'/7'05B_\*<N?[,_L/\ X2^]_P"$<\WS/[.^S)N^]NQYF>F>>F,\XKU"
MBG[::ZB]C#L<AXH^'.E^(M&TZSMY)-,FTG;]@N;?EH,8P.>H^4'J#D YJGI/
MPWN$\66_B+Q5XAFU^^LTV6H:V6!(O?:I()Y/X\UW=%)5)I6N-TX-WL<+:?#J
MZTOQ]=^(M(\12VL%_.);RQ-JK^< VXKO)^4$^@SR17=445,I.6Y48J.QR'BO
MP'_PD_BO0-:_M+[+_8TZS>3Y&_SL.KXW;AM^[CH>M,\;?#Y?%FHZ=JEGJLND
MZGIQS#<QQ"08SD94D=#[]SG-=E15*I)6L]A.G%WNMSSJT^%=TGCK3_%.H^)I
M]1O+8YF$UJJB4X( 7:P"  ],'OZUK>"? ?\ PAVK:]>_VE]L_M>=9MGD>7Y.
M&<XSN.[_ %GMTKKZ*'5FU9L2I03ND<#X6^&/_"->"-;\/?VO]I_M9)$^T?9M
MGE;X]GW=YW8Z]14^F?#'3[?X;_\ "(:M<M?0;VD%PD?E,K%BP91EL$9]\UV]
M%#JS?4%2@NAYI_PJ6\OK:STWQ!XOO=2T2S8&*P^SK&2!T#2 DL ..G Z8K9U
M_P"'T>M>,- UN&^6SCT7:$M5M]P<*V0 =PV],=#7944_:SO>XO90M:P57O[7
M[=IMS:;]GGPO%OQG;N!&<=^M6**R-3DO!?ABV^&_A&:SOM6CFMUG:=[J5! J
M!@HYRQ Z=<]Z\R\!Z#I^N_'75]6TD";1].F>XCD RC2OP,>V2[#_ '17NMS:
MP7MK);7D$=Q!*NV2*5 RN/0@\$5%8:98:5;_ &?2[*WLH<[O+MXEC7/KA0!6
M\:K2D^K,)4DW%=$>1?&:S34?B)X*LI7DC2YN!"SQ-M=0TL8)4]CSP:ZFQ^&<
M[^++/7?%'B.YUV33_P#CRBDMUB6,CH6VGYB.#G R0"<UV5WI&FW]W;W5]I]K
M<W%JVZ"::!7>(Y!RI(RIR >/2KE)UGRJ*&J2YG)G":M\-YW\4W.O^%?$,^@7
MMZFVZ"6ZSI+[[21@_P!>1BBR^$NAV_@F[\/7$DUR;V3SI[UB!*91]UAV&/3G
MJ<YR:[NBI]K.UKE>RA>]CS.;X3:CJ=G9:7XA\8W6HZ+9.K1V0LTC8A1@ R D
MG@D<_ABO2HHDAA2*)0B(H55'0 =!3J*4IREN.,(QV"BBBH+"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "N0N_ ?VKXIV7C+^TMOV2 P_8
M_(SORCKG?NX^_GIVKKZ*J,G'8F45+<*\[N/A7<1>*-3U;P_XHNM(CU8L;V".
MW5R^XDMM<GY>22#@D9ZUZ)11&<H[!*$9;GFVF?"+^R_!.N^&HM;+P:K(KQRM
M:?-!@@X/S_/PH'\-=AX<\/+H/A&TT*2X^U);PF%I=FS>#GG&3CKZULT54JDI
M;LF-.,=D</X&^'M[X(NI8K?Q'+=Z2S.Z6#VJKM=L#<7R2<!>F /:NXHHJ92<
MG=E1BHJR.0TCP'_97Q*U7Q;_ &EYO]HP&'[)Y&WR\F,YW[CG_5^@Z^U7+CPU
MJ4WCZUU]/$5U%I\,11]( ;RI3M8;C\^,Y8'[I^Z*Z.BGSR;O\A<D4K?,\S\2
M?"6_UGQQ>^)-+\6W&C3W2HNVVMVW*%C5"-ZR*2#MSTJ;PW\(8=+\1Q:[XAUV
M\\07]N0T#W((",.A.68DCMSP>:]&HJO;3M:Y/L87O8XSQ+\/%U?Q)#XCT/5I
M]#UJ-=C7,48E61<8&Y"0#QQZ8ZBE\-?#JVT?4K[5M:OY==U>_C,4]U<QA1L(
MP55!G ( '7H,# KLJ*7M)VM<?LXWO8\SC^$VHZ;8WNE>'O&-UI^BWK-YMD]H
MDQ 88(#D@C(XX_'-:EW\*=#N? =MX9C>:%;5_.ANP09%E/5SV.<]/3'H*[BB
MG[6;ZB5*"Z'!:9\-+C_A)K+6_%?B.XU^?3ABS1[=85C(Y#'!.X@\Y]0,YKO:
M**B4G+<N,5'8\@M/@CK&FR3G2/']]IZ3R%W2UMWC#'WVS#-=!H7PUO[2/4;;
MQ/XLO_$5C?6IMVMKG> A)!W@M(V",<'%=_16CK5'NS-4::V1Y@?A'JAT/_A'
MO^$VN_\ A']V?L362%]N[=M\W.<9YQC'M6YXA^&>DZUX?TS3K26;3I=( ^P7
M4/+Q8QUSUR0#U!R,YKLZ*7M9WO<?LH6M8X32?AO<)XLM_$7BKQ#-K]]9ILM0
MULL"1>^U203R?QYK*@^#4MC'J.GZ9XKO+/0]08M-8);J6/MYA.<8X. ,C@UZ
MA11[:?</8P['FY^$KM\,1X/?7 0MU]H2Z%GC SG;LW\\D\Y_"K.N?"XZE/H5
M_IFN2Z9JVC6L=K'=K;B175!P=A(QR6[GKCFN_HH]M.][A[&%K6. \/?#*?0O
M'9\3S>(9M0N)H62Z6XMP&E9AU#!L*!A<#!P!CZ2Z9\.KO1/'-_KND^(I;>TU
M*Y^T7E@;56\T[F;'F$Y RQZ#OBNZHI.K-]1JE!;(X7PQ\,+30['Q!9:C>C4[
M76WW21F'RM@^;C.XY/S=>.E98^$-\-*_L(>,[\>'2^38?9TW[<YV^;GIGG&,
M>U>G44_;3O>XO8PM:QPOBSX86GB'0]%TK3KP:7:Z0^Z-1!YNX8 Q]X<\9SSG
M-6_'?@/_ (36?2)/[1^Q?V;.9L>1YGF9*\?>&/N^_6NOHI*I-6UV&Z<'?3<*
M***S- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X
MWPE\/_\ A&_%6M:_>:G_ &C>:HQ.?L_E")2Q8K]YL_P^F-M'Q ^'R^./[-EA
MU(Z9=Z?*7CN!!YIP<'&-P[J#_P#KKLJ*T]I+FYKZF?LX\O+;0XZ#P$\7Q/;Q
MC)J@=WMQ"UJ+?:,[ N[=N/IG&/QIJ?#R/_A96I>*YM0\R/4+7[,]EY&-H\M$
M)W[N?N>G>NSHH]I+OTL'LX]NMSRR'X,7-MI%]HEMXOO(M#NG:3[$MLF0^/EW
M/G)&0N0  <?C5S4?A/)J7PSTWPC)K@7^S[KSUNQ9_?'[SY2F_P#Z:=<]NE>C
MT57MJG<GV-/L>4?&RZT6'X>C2;J]A?58'A:U@5AYN1P6V]0NW=STSQ72_#GP
MI%HOPSM-*OX 6O(6EO(G'WC(.5/T7"_A7276AZ3>ZA'?7FEV5Q>1 ".XEMT:
M1 "2 &(R.I_.KU#J>XH+U&J?ON;/,D^$FHV6F7>C:-XSN[/0[LMYEB]FDIVM
MP5$A((!'H*O>(/A39:I\/M.\*:9?MI]O8W G$SP^:TAVN#D;EY)<G/MC%=_1
M2]M.][A[&%K6.&UKX;&\UZUU[0=;FT76((%@>YC@65)E"[1N0G!X&.N.!Z58
M\)_#]?#^OWNOZIJLNL:S>ILDNI(5B"KQP$!./NC\!78T4O:3M:X_9PO>P444
M5F:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4$X&3145P<1?4TU
MJQ/1#'N"3\G ]:9Y\G][]*CHK6R,KLD\^3^]^E'GR?WOTJ.BBR"[)//D_O?I
M1Y\G][]*CHHL@NR3SY/[WZ4>?)_>_2HZ*+(+LD\^3^]^E'GR?WOTJ.BBR"[)
M//D_O?I1Y\G][]*CHHL@NR3SY/[WZ4>?)_>_2HZ*+(+LD\^3^]^E'GR?WOTJ
M.BBR"[)//D_O?I1Y\G][]*CHHL@NR3SY/[WZ4>?)_>_2HZ*+(+LD\^3^]^E'
MGR?WOTJ.BBR"[)//D_O?I1Y\G][]*CHHL@NR3SY/[WZ4>?)_>_2HZ*+(+LD\
M^3^]^E'GR?WOTJ.BBR"[)//D_O?I1Y\G][]*CHHL@NR3SY/[WZ4>?)_>_2HZ
M*+(+LD\^3^]^E'GR?WOTJ.BBR"[)//D_O?I1Y\G][]*CHHL@NR3SY/[WZ4>?
M)_>_2HZ*+(+LD\^3^]^E'GR?WOTJ.BBR"[)//D_O?I1Y\G][]*CHHL@NR3SY
M/[WZ4>?)_>_2HZ*+(+LD\^3^]^E'GR?WOTJ.BBR"[)//D_O?I4T4V_AN#_.J
MM*#A@1VI.*8U)HO4445D:A2,P523TI:@N3\JCUII78F[(:UPQ/R\"F^?)_>_
M2HZ*ULC*[)//D_O?I1Y\G][]*CHHL@NR3SY/[WZ4>?)_>_2HZ*+(+LD\^3^]
M^E'GR?WOTJ.BBR"[)//D_O?I1Y\G][]*CHHL@NR3SY/[WZ4>?)_>_2HZ*+(+
MLD\^3^]^E'GR?WOTJ.BBR"[)//D_O?I1Y\G][]*CHHL@NR3SY/[WZ4>?)_>_
M2HZ*+(+LD\^3^]^E'GR?WOTJ.BBR"[)//D_O?I1Y\G][]*CHHL@NR3SY/[WZ
M4>?)_>_2HZ*+(+LD\^3^]^E'GR?WOTJ.BBR"[)//D_O?I1Y\G][]*CHHL@NR
M3SY/[WZ4>?)_>_2HZ*+(+LD\^3^]^E'GR?WOTJ.BBR"[)//D_O?I1Y\G][]*
MCHHL@NR3SY/[WZ4>?)_>_2HZ*+(+LD\^3^]^E'GR?WOTJ.BBR"[)//D_O?I1
MY\G][]*CHHL@NR3SY/[WZ4>?)_>_2HZ*+(+LD\^3^]^E'GR?WOTJ.BBR"[)1
M.XZG/X5/'()%R.#W%4ZE@.)1[U,HJQ49.Y:HHHK,T"BBB@ JN]P<X3\ZDG.(
MOJ<54JXKJ1)]"3SY/[WZ4>?)_>_2HZ*NR(NR3SY/[WZ4>?)_>_2HZ*+(+LD\
M^3^]^E'GR?WOTJ.BBR"[)//D_O?I1Y\G][]*CHHL@NR3SY/[WZ4>?)_>_2HZ
M*+(+LD\^3^]^E'GR?WOTJ.BBR"[)//D_O?I1Y\G][]*CHHL@NR3SY/[WZ4>?
M)_>_2HZ*+(+LD\^3^]^E'GR?WOTJ.BBR"[)//D_O?I1Y\G][]*CHHL@NR3SY
M/[WZ4>?)_>_2HZ*+(+LD\^3^]^E'GR?WOTJ.BBR"[)//D_O?I1Y\G][]*CHH
ML@NR3SY/[WZ4>?)_>_2HZ*+(+LLQW&3A^/>IJH5<B.Z)2?2HDK%Q=Q]%%%06
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5%<_ZL?6I:BN?]6/K3CN*6Q5HHJ&:=ED$4"!Y2,\G 4>I
MK78RW)J*K[+P_P#+:$>WE$_^S4;+S_GO#_WY/_Q5+F0^5EBBJ^R\_P">\/\
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M_P#Z!FG?D_\ \51_PO\ U_\ Z!FG?D__ ,51]7J!]9@?0%%?/_\ PO\ U_\
MZ!FG?D__ ,51_P +_P!?_P"@9IWY/_\ %4?5Z@?68'T!17S_ /\ "_\ 7_\
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MW749./P!_(5Y#7>?!C_DJ%A_USF_]%M655)P=RZ;:FFNY],U)!_KEJ.I(/\
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M 33O^$;DU6W&J/+;0;8H&EFG;S%(ER"-A*D K\V O/6B53E2:6X1I\S:;V/
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MN_B]X+TMM:U/6M,U.SMV7SHHH4. 2!D_NT.,D#@]ZM?M%?\ (IZ5_P!?Q_\
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M1"  J%CECQU))ZG)P .@ JK75CX=:Z/ ;>*9+686Y<>5"L+,[1;2S3''W4
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M]*N6M]2TXP;6MRIPQ#;CN X.< 8SZ$5*K0>S*=&:W1Q%"G:P(QD'/(S7;O\
M#^STWPEHVM>(]=.FOJ\JB&U6T$K+$3_K2?,'RA2&X'\0'4UJGX)ZI_PG2Z(+
MX'3FMOM7]K>0?+V=.F[&[=QC=TYH]K#N'LIOH<WXG\?:EXHTJSTN6ST[3=/L
MW:2.TTZW,4>XY^;&3SRW3'WC7+U:U2WM;/5KFVT^[-[;12%([DQ^7YH'&X+D
MX![<]/RKL_ GPFU;QI;O?32'3--"GR[J2+>9F'95R,C_ &LXR,<G.'>%.-]D
M*TZDK;LX*BNH\&^"V\4QZC>7>H1Z7I>F0^;=WCQ&38"#@*@QN/!XS^9P#<U?
MX:7UKKFBV>BWD6JVNO('T^["&+>, L70Y*[0<GKQ[Y ;J13Y6Q*G)KFL<717
M<>(O .D:/IM])I_C+3[_ %#3I1'=6#Q_9WST81EF_>$'L!V/?@\/3C)25T*4
M7%V844451(5WGP8_Y*A8?]<YO_1;5P==Y\&/^2H6'_7.;_T6U9U/@94/C7JO
MS/IFI(/]<M1U)!_KEKR'L>RMRW7F_P 7?^9<_P"PB/Z5Z17F_P 7?^9<_P"P
MB/Z5-+XT>WD_^_0^?Y,](HHHK,\HBN?]6/K5*096KMS_ *L?6JA&:UCL92W.
M8\1:'9:Y9-:ZE )HCR,]5/J#7!/\(O#^XD?:Q[>:/\*]<E@#56:R!/2M(SE'
M9F4J<).[1Y5_PJ+0/6\_[^C_  H_X5%H'K>?]_1_A7J?V$>E'V$>E5[6IW)]
MA3['EG_"HM ];S_OZ/\ "C_A46@>MY_W]'^%>I_81Z4?81Z4>UJ=P]A3['EG
M_"HM ];S_OZ/\*/^%1:!ZWG_ ']'^%>I_81Z4?81Z4>UJ=P]A3['EG_"HM ]
M;S_OZ/\ "C_A46@>MY_W]'^%>I_81Z4?81Z4>UJ=P]A3['EG_"HM ];S_OZ/
M\*/^%1:!ZWG_ ']'^%>I_81Z4?81Z4>UJ=P]A3['EG_"HM ];S_OZ/\ "LOQ
M)\-=%T;P]<W]N+AI(=F!))D<N!V'O7L_V$>E<Q\1K01> -2?'3RO_1J4XU:C
MDM3LP&%HSQE*,HW3E'\T<3I?PLT*]TBSNI/M0>>!)&"RC +*#QQ[U:_X5%H'
MK>?]_1_A7H'AFS#>$](;'6QA/_D,5I_81Z4.K4ON8XC#THUII+J_S/+/^%1:
M!ZWG_?T?X4?\*BT#UO/^_H_PKU/["/2C["/2E[6IW,?84^QY9_PJ+0/6\_[^
MC_"C_A46@>MY_P!_1_A7J?V$>E'V$>E'M:G</84^QY9_PJ+0/6\_[^C_  H_
MX5%H'K>?]_1_A7J?V$>E'V$>E'M:G</84^QY9_PJ+0/6\_[^C_"C_A46@>MY
M_P!_1_A7J?V$>E'V$>E'M:G</84^QY<OPA\/D\F\_P"_H_PJY;_!;PU+]][X
M?28?_$UZ.MD >E68H M'M:G</84^QY_!\#O"B2*[-?OC^%IEP?\ QVN_TW3+
M/2+".RTVW2WMXAA43_/)JR!BEJ93E+=E1IP@[Q05;@_U*U4JW!_J5K*6QM'<
MDHHHK,T"J>JZM9:)ILM_J<ZP6T(RSM_(>I]JMDXKYM^-OC*;6/$SZ+;2,++3
MV*,H/#R?Q$_3I_\ K-;4:3J2L85ZOLHWZE_Q7\>]4N[AX/"\2V5N"0)I%#R/
M[\\#\/SKA)?B-XOF<LWB+4%]EN& _+-<U17K1I0BK)'D2J3D[R9T7_"P?%W_
M $,>I?\ @2W^-'_"P?%W_0QZE_X$M_C7.T5?)'L3=G1?\+!\7?\ 0QZE_P"!
M+?XT?\+!\7?]#'J7_@2W^-<[11R1[!=G1?\ "P?%W_0QZE_X$M_C1_PL'Q=_
MT,>I?^!+?XUDZ=H^IZQ*\>D:==W[QC<ZVL#2E1ZD*#BIM0\-ZYI-L+C5=%U"
MR@+!1+<VKQKD]!E@!G@TN6%[:#]ZUS0_X6#XN_Z&/4O_  );_&C_ (6#XN_Z
M&/4O_ EO\:Q[O3+^P@MY[ZQN;:*Z3?;R30LBS+P<J2/F'(Y'J*JT<L.PKM'1
M?\+!\7?]#'J7_@2W^-'_  L'Q=_T,>I?^!+?XUSM%/DCV"[.B_X6#XN_Z&/4
MO_ EO\:/^%@^+O\ H8]2_P# EO\ &N=HHY(]@NSHO^%@^+O^ACU+_P "6_QH
M_P"%@^+O^ACU+_P);_&L:TTV^OXKB2QLKBYCMHS).T,3.(D'5F('RC@\FJU+
MECV"[.B_X6#XN_Z&/4O_  );_&C_ (6#XN_Z&/4O_ EO\:YVBGR1[!=G1?\
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M9@'I5F.(+4V**! **** +]%%%8&X5!<_P_C4]07/\/XU4=R9;%9NE>6?&_\
MY$E/^OM/Y-7J;=*\L^-__(DI_P!?:?R:NFE_$1R5_P"&SY^HHHKUCRPHHHH
M]E^%=QJ%I\(/%]QHQ9;V,EHF099<1C)'N!G%:%I=76K?"_P9?^(99)[]?$,
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MJR-<QD,#U!&:^0LT9H^JKN/ZU-:H^P/^$I\/_P#0;T[_ ,"D_P :/^$I\/\
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M_.O0P7VCS<;O'Y_H0T45U_A[X:ZMXAT>'5/MNEZ9:7,WDVLFHW/E?:7R1M0
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MCZIIEDD<&I?VL ;&>PE\R*?.#PQ Z @Y.!CG.*N:Q\)]=TG3;V[CO-+U$Z>
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MR3^;58K6.QE+<OT5C_\ "7>&_P#H8=*_\#8__BJ/^$N\-_\ 0PZ5_P"!L?\
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M6L=C*6YSW_"J?!G_ $!O_)J;_P"+H_X53X,_Z W_ )-3?_%UV%%3[2?<]/\
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M&'4?_ AO\:/JLNX?6O(^M:*^2O\ A/?%?_0PZC_X$-_C1_PGOBO_ *&'4?\
MP(;_ !H^JR[A]:\CZUHKY*_X3WQ7_P!##J/_ ($-_C1_PGOBO_H8=1_\"&_Q
MH^JR[A]:\CZUHKY*_P"$]\5_]##J/_@0W^-'_">^*_\ H8=1_P# AO\ &CZK
M+N'UKR/K6BODK_A/?%?_ $,.H_\ @0W^-'_">^*_^AAU'_P(;_&CZK+N'UKR
M/K6BODK_ (3WQ7_T,.H_^!#?XT?\)[XK_P"AAU'_ ,"&_P :/JLNX?6O(^M:
M*^2O^$]\5_\ 0PZC_P"!#?XT?\)[XK_Z&'4?_ AO\:/JLNX?6O(^M:*^2O\
MA/?%?_0PZC_X$-_C1_PGOBO_ *&'4?\ P(;_ !H^JR[A]:\CZUHKY*_X3WQ7
M_P!##J/_ ($-_C1_PGOBO_H8=1_\"&_QH^JR[A]:\CZUHKY*_P"$]\5_]##J
M/_@0W^-'_">^*_\ H8=1_P# AO\ &CZK+N'UKR/K6BODK_A/?%?_ $,.H_\
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M ]6/K7,ZS3:MW_ Z5132=^WXGS/170>/+&WTWX@:W:6<20P17CB.-%PJ G.
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M'THY4',RW_;]O_SQF_(?XT?V_;_\\9OR'^-5/L!]*/L!]*.5!S,M_P!OV_\
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M2(@SP/F(QSD4S3M UC5XGETG2;Z^CC.UWMK9Y I]"5!Q7OL]U%XVEURV\/\
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M"R+,N =RDCYAR.1ZBCDA:UD'/.][L-3U*[UC4[C4-1E\ZZN'+RR;0NYO7
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M=[W)KR\N=0O);N^GDN+B9MTDLK%F8^I)KMO@Q_R5"P_ZYS?^BVK@Z[SX,?\
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MP/FH?.!VXZ'Y?OK]['6NN\)_"R34-4U[2_$T5W:ZAIMFL\4%K+&Q9F!*@X#
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M\-FM#^*OZZ'LE6X/]2M5*MP?ZE:\F6Q[$=R2@T45F:%*\_U9^E?%U[Q?S_\
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M-<ZK8ZK"]E:_Z^5@4\OZA@",]N.>U9DGQ1\*G0+[5;+4/M<=D!OC2)U<EN%
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MV@7L$,:)XBTMH[V(+PY*L<Y_X"@_X#[U@:S\1?A9X@UI-5UGPUJ]W>*% =P
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MUYQ\7?\ F7/^PB/Z5-+XT>WD_P#OT/G^3/1Z***S/*(KG_5CZU1E^Z:O7/\
MJQ]:HR_=-:QV,I;GSY\<_P#D:K'_ *]/_9VKS&O3OCG_ ,C58_\ 7I_[.U>8
MUZ]'^&CQZOQL*Z7X=W&J6GC[3+C0;.*^OHW8I;2S+$)04(90S$ ':3CW['I7
M-4*Q5@RD@@Y!!Z5I)731$79IGO>O:38:KX,\3WRZ5K_A"]@1KF]CEN'2UOIF
MW9498I*I88RH7[R^N*-=T?4M>G^%MYI-C/<V\,,$DTJ)E85'DL=[=%X!Z]<8
M&:\5U'Q'K>KVZP:MK&H7T*OO6.YNGD4-@C.&)&<$\^YI;;Q'KEE8K96>LZA;
MVJMN6"*Z=8P<[LA0<9SS]:YE1DNO]6.EUHOI_5SZ!M8;VY\>?$^#26*WTEE;
M);D-M(D-NP7![<XYKD]'MM9\._ ]X=5MGMM0DUR!M*M;\^6=PDC.,,1M4E7/
M..YZ'->4_P#"1:WYUW+_ &QJ'F7JA;I_M3[IP!@!SGY@!QSVJ/4M:U766C;5
M]2O+\Q B,W4[2[,]<;B<=!0J#6E^WX ZZ?3O^)]#QZ=%XIUJ_P#[:\/:]X1U
MY[;_ $G5K*[(@9%"X7S5;8^1C(VG 4C.1QCVQL[KX1>%/[-\+3^)D@FV&*RO
M);=K>X!.9#L&>NX[CC&0>]>+/XEUV33?[.DUK46L0@C^RM=N8M@Z+LSC P.*
MCTW7=7T99%TC5;VP$I!D%K</%OQTSM(SU-+V#MO^?_#C]O&^WY?\,>^^'-6O
M-6^*OB-=3T==)U'^Q522TCNDN"2",$LG?#J,?2O ([=M-UN*'6;66+R9E^T6
M\R%&"Y!((/(XIMKJVHV6H-?65_=6]XQ8M<13,DA)ZY8'//>HKN\N;^ZDNKZX
MEN;B0Y>69R[L>G)/)K6%/D;,IU.=(^@=<TO7]1^.7AW6-&2:;1OL\3QW<&3
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M .)H_P"%%^&_^>E__P!_E_\ B:?UND'U6KV/GJBOH7_A1?AO_GI?_P#?Y?\
MXFC_ (47X;_YZ7__ '^7_P")H^MT@^JU>Q\]45]"_P#"B_#?_/2__P"_R_\
MQ-'_  HOPW_STO\ _O\ +_\ $T?6Z0?5:O8^>J*^AA\"O#7_ #TO_P#O\O\
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MJ4MTJ?9@YY#H?F;9U&.G49/%/N/AWJUQ>:O8JX6WFT&WL(+UW&))8]OW@"6
M.WDXZ'O7J5%/VTA>QB>8V?A_Q/K>KZ+<:OH=OHD6A64D*&*Z21KIFBV!5V_<
M7C.#V)&?2"3P'K4WP6TS18X/LVJV5S]J>W2=4:0AW.!(,J&PP()X! KTC6-2
M_LC29K[[%>7WE;?]'LHO,E?+ ?*N1G&<GV!JXK;D5L$9&<$<BCVTM&E_7],/
M91U3?]?TCR&#X=:UJ/A3Q +J&_M-4O\ R0BZEJR7AG\I@PW,D8P,?*,D\]@
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MJTGX8ZYJOAV'6?M&G6,-TY2SAOKD0R7C=EC!&"6(P,D9Z].:O+\&_$3>*9=
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M>W)J77E:Z7]7L4J$;V;_ *M<^:Z*GOKVXU+4+B^O9/,N;F5II7V@;G8DDX'
MY)Z5!76<@5[C^SU_QX:[_P!=(?Y/7AU>Z_L^P.FD:Q,0=DDL04^N V?YBL,1
M_#9K0_BK^NA[!5N#_4K52K<'^I6O)EL>Q'<DHHHK,T"C%%% #2@-)Y8]*?10
M!'Y0]*/*'I4E% $?E#TH\H>E244 1^4/2CRAZ5)10!'Y0]*/*'I4E% $?E#T
MH\H>E244 1^4/2CRAZ5)10!'Y0]*/*'I4E% $?E#TH\H>E244 ,\L>E*$ IU
M% !BBBB@ HHHH **** "HKG_ %8^M2U%<_ZL?6G'<4MC/G^[4&F?=N/^NO\
M[*M3S_=JC:7*6UU)',0B2$,K'H#TY_2KEL1'<U**0,",@@CVI<UF:!11FC-
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M[;6&ELIPQX8NWRG'J6 '_ C7GF*,5:HI)KNB'6;:?9GM'C#^PD^(GA/P1?S
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M_P#0*L__  '7_"C_ (1/2?\ H%6?_@.O^%=7Y0H\H47?<.2'8Y3_ (1/2?\
MH%6?_@.O^%'_  B>D_\ 0*L__ =?\*ZORA1Y0HN^X<D.QRG_  B>D_\ 0*L_
M_ =?\*/^$3TG_H%6?_@.O^%=7Y0H\H47?<.2'8Y3_A$])_Z!5G_X#K_A1_PB
M>D_] JS_ / =?\*ZORA1Y0HN^X<D.QRG_")Z3_T"K/\ \!U_PH_X1/2?^@59
M_P#@.O\ A75^4*/*%%WW#DAV.4_X1/2?^@59_P#@.O\ A1_PB>D_] JS_P#
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M)_Z!5G_X#K_A1_PB>D_] JS_ / =?\*ZORA1Y0HN^X<D.QRG_")Z3_T"K/\
M\!U_PH_X1/2?^@59_P#@.O\ A75^4*/*%%WW#DAV.4_X1/2?^@59_P#@.O\
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M^R#TJ]BC% %'[(/2C[(/2KV*,4 4?L@]*/L@]*O8HQ0!1^R#TH^R#TJ]BC%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH K:C%<S:9<QV$Q@N7B812
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M'G9NV;W+CG=G W%?EJYK>E0:]H&H:1>-(EOJ%K):RM$0'574J2I((S@\9!H
MX?7;*]T'3?"Z^&K^\6ZU#5X$E?4-1N;I"#;S$[@\A)48W; 5#%0,CJ(Y_B)J
MMI:OILZV\FL)K,NF-=6NFW$\05(5G,OV:-FD)V.J[0_4[MP Q7;7V@6NH#2O
M.DF7^RKE;F#8P&YEC9 &XY&'/3'.*R[CP#ILSW<\-W?6M[/JG]JQ7D#H);6<
MQ+$?+RI7:43:5<,#N;/; !-X-UZ_UW3[LZK9S036MR85G>PFLUNTVJPD2*;Y
MU'S%2"3RIP2*Y;3/%/B&]N]+TS1S80/?WVL++<7JSW/E+;7.U"JF4%LYQMW
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M'4V?@32K*Q\.VBR7$L/AZ)HK9965O-5HC$1)\N&^5CTQS^5-TKP/;Z4(K?\
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MRWBDTVWL[BXF2*21$+37",([=SN8JKH0=HP6SQWUG#>QWU_)=W(EMY9E-K$
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MH!RQ[<_7F@#HJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"AY,#<0!P!G/%<1JFFZIJ/Q=U4:5KTFC&/P[:$R1012,[^?=;,^8K#8/FW
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MMRZW86[:CK&H:5JNFWI:?4M/M[6&9TB5@]NBA9T4$L,2@Y5A@M]XP'7M4MO
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
+%%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>img30600998_14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img30600998_14.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2<64&AO=&]S:&]P(#,N,  X0DE-! 0
M    )OJ^F7@X0DE-! 0      !<< 5H  QLE1QP!6@ #&R5'' (   )@   X
M0DE-!"4      !"H<CR.\+B]1))=K(K5'*#I.$))300Z      $9    $
M  $       MP<FEN=$]U='!U=     8     0VQR4V5N=6T     0VQR4P
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M;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/
M8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R9%15
M;G1&(U)L=                $)L9"!5;G1&(U)L=                %)S
M;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !09U!S
M96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M    5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M       08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M
M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12
M:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M   0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@             _@
M.$))30/R       *  #_______\  #A"24T$#0      !    !XX0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              -*   #6          !
M      $              U@   -*                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     8X0DE-! P     '$(    !    H
M )T   '@  $F8   '"8 &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( )T H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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MM>+Q3D_LUHPWMKVY%[[K,9KZ:OYM^1_QGIJ_Z[].(QFX=5]]U]M%=K'4VL]
M6Y/[->W,<:]N/D-NKRF5T6?SUF/_ ,5ZA[?J=T.VV^US+@^\N>(R+@*K++FY
M]M^&/4_5+K,RJF][Z/\ 0L3U?4_H=5M%S67;Z"UQG(NBVRNYV?3?F-]7];NK
MS+;KVOOW_P ]8DIM]+Z[TSJQ=]@M]8,JIN<0T@!N0UUM EP_G-C?TE?TZO\
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M^'J/;_WU5Y[/0?&81."$R/5&8B#_ %91EQ1_YK__T?54DDDE*22224I<9_C
MPB'XG46C2#CV'PG]+1_Z.79JGU;IU?4^G7X5ACU6^UW[KQ[J[/[#PB#1ML<G
MG]C/#(?E!J7]R7ID^:]&]/\ ;/3_ %/H?::Y^,_H_P#P78N<S'Y%F;DV98(R
MGW6G(!T(L+W>JV/Y+UM74VTVV47M-=U3BRQHY:YI_-/_ $ZW*'7\?[94>NTC
M](2UG5:V@ ,M/LISF[?\!F[?TOM_1Y7_ !BLXR!+S;WQ_EYSACSP]4(>F5=I
M?+-PDB 1!U!T(224SS;ZQ]0.O.ZKT?[/D.+\SIY%-KCJ7L(_5KG?UF-]-_\
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MK>(LHOJ=[;J+6_28N_=U/JIR&46Y73NG9>0W?C=,O)NR'-U^F^O(QO?[7;\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0'_P  1" $- 1(# 1$  A$! Q$!_\0 'P !  (" P # 0
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MCE%UB$W]M&!T]L=!.>2V!Q:VNQJJVQJ;+P$Y /ZN_M3&,L<=8:!8HZ>=%G8
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MWCS W!.JO57,%4[$[UU44#*"=!G 4IPM#]VQ?8$R2<JC)S2I0#R]>24 QC"
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M>Q=] ]KE<R9N),K ZE7M[C)QPK9VKJ=.LEOBK:PBF1_P7"S*1L;,#\N%;#@
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MI8;R[(4H@J9!Q&1S6NN1)V*!+$ ', & A\Z\/<8+_/I/(O-%CHS='?;SB1'
M.HUL,S2 'UCZ UA''V2-C@WMT;4N0D%L #IO) YYF'N.4",_^H*\^L1[CW'\
M\V% T-#TJ!J^,YI3%*8I7]VS=5VNDV;I*KN'"A$4$$$S*K++*G*FDDDD0!.H
MHH<P$(0A1,<P@4H"(@&?+-RC>P .I)Z   DDGT KD D@ $DD  #9)/0  =22
M>PK:9TUK)'I2\.'9YI-)GSPYB59,LFW#L2<T)HM[Y"E%J& 3*Q]FL!TO6>
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M8VR&.9SUWYUW"HWKMVQ'L+H:<>=_Q,A:NF_R^K5XEDVZL@32FWWK:/M":!0
MXMVTXS8QLTR4 3%0;A.TI-H)Q(5U/I@)U0OUCXA75LRQ9[&M$NPIO;+;1@[(
MVT+,P([$\DQ;7:,]CH[XD_9@\0_#MY#FN'\QB(@Y2.?(VQFQ4[C>EMLY9+-8
M2LVB5C\SFUU)T*H W_QEWOQ;NCC7^^M96C6]F2%4S5&=8'+&S39(_@,A79QN
M*\-88T3>P/H=\\;@8? ZA% ,F62,?E;#*PBXL+F*YB.@3&PYD8[/+*AT\;ZU
M\+J#[#74ZYW^-OL9,;>^MI+>0$Z#CX7 _>C<;21?\R$CT/4$5WG@?97=/YK\
M3;*R$_KQ/(?4+@2ICXF6;GO,(@[;]^X=BN6BJ[<_N'<BI@[A]0ZL_$LV$RT3
M:T^.NQU[ ^0Y!_(@$?.N_"2&+,8N1=[2_M#T[D>>@8?F"1^=>IQFJM;.4Q2F
M*4Q2O-EZU5A>63J=<KG+HRAQC;?6ZZ@!_<Q6E>U_48EN0.PF[$ K413 !#]&
M)>X /< V4X)C6/AG$@ #FADD/S:2XF<^O4CFZ^H)UTUUUUXQD:3B3*%M_#,D
M8W_AC@B4#Z:'3Z[JO_4>E]K;YND;KO3FO[3L>Z2I@!I7ZI$.Y5Z"7D4BCQW\
M.048^.;B<HNI*06:L&A! [EPF3WS(;R^M,?"UQ>7$5O"OXI)9%1>GH-]68Z(
M"J"QZZ&ZL5I9W5],MO9P2W$S=HXD+$#U9M=%4;ZLQ"CN2*V!M3=!6H:O@(R_
M]1WE-2^/\>\1*^0U32)2+G-@/6Y>QE6B\T]*Y9)/R@!TSMZO7KDF4PE'X\AP
M,0L<9#Q$,CM!@,?)?%3RFZN5,=OO?0K&.5RO8@RO"3U^#MN>?#S[.O'OB#<K
M!AL'E\O('59HL-9O/#;<VM"^RDJKC[+UV99"NNH:L_%D>B%H! 6.J>'EKY'6
M%B $):=L3,N$))*I^Q5SH626=H$\S@"@@WUZQ((&$  H 5(,<ER_%]Z=S95+
M%"?]W9Q(K+VWIE0-T!Z?WANH/MNMY>"?_#>XHO%AFXGO.&^'(F"&2*:>[XBR
MJ#IOFMK7[OB@VM[Y,@P#>FJZQ.=3&VUM@[A.+N@^/_$R*=)';GD-6:]K@W(R
M)P$IBGLJT.R:^H<@AY.4H%%X!P!1-RF< $*-K&2X(;(7U[D"/2YN)7C&O9"Y
MUHDD DKKN".AVYX"^P?X/<(RQ7><:_XNN8B&\B9(,)BG8:T7L<:?O<HWL^7/
MDIHG!(=&!JNJSVJRW:=D;/<)^8L]CEW!G4G.3TB[E91^X/\ 55T]>JK.%C '
M8I?,X@0@%(0"E*4 KDC2-0J*$51H*HY5'T4: _(5N3B\5B\)86V+PV/L\5C;
M.-8;6QQ]M%:6EO&O0+%!"J1H#W)502=EMDDG@<^ST!]:N(&]GT'^OH!\_P"(
M]Q5_'22Z>*]SEH3E+NF#,G3H9T5_J>J2C<P?>F9:*E%"YR#58H >O1*Y##"(
MJD,67DTP?"'P#)+YAC>9R?EJ;2!OVC B9E/^[4C7E@Z!#L-\W^%3[GX?/K[7
MOVC(\-:7WA1P1?!LQ>Q-!Q?E[23?]E64R?'@[>5"-9&[1A]^D4@V=JWW<?M[
MA_NVSQF)UY=4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2L$;MY,:2X\(00;5N
MZ$/.6Y9VUH]$@XF=NVSM@/6*0+O6.O\ 5])C+#?[L[9I"11\G6JY)@P2.19\
M9LB8%,4J/YNH-KYB4KZX\?>:U#J)P$5[O:N)&WUJXP:"'XG\\TK$%9;56XQ,
MG<[M_9*S$M&"(&5D%&J1#F*[5R"0002"#L$="".Q!]"*IYYT=/6C[8JI^8_
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ML@5-5VUC'K+X5%62<!QY)B\3!BACQ=743-%:2M,(XB)9&9%F7E))1G(^%E#
M*-J=DX;)X87?&7%EE;8NXW=9V^L;""RU&DDU_=216D$4,\\L=O&+B1HP7F*J
MCL221T'49#G-K3C+2'>C>F[JIAHZDB4K:>W/8&3.:W1L1PDGZ*LO(23])Y\M
M^(, J-OBE7RS,AB_*FE=  :)]%Q%>Y:<7>;NFNY#U2V4E+6 'LJ(I4$@'J=?
M%UYS)W/K=X'?8)X0X-M;3)^([0YW)<J2MP[82RIB87&B/[2OU:&\S$H.N>)/
MNM@K!DY+J+1:M>SVRT7::>V.XV*;M,_(JBL_FK#*/9B4=JF'W.X?/UEW"@A]
M"@900*7L4H 4  *Q$5%"HJJH&@J@*OY*- ?D*W]Q>)Q.#L8,9AL;8XK'VR".
MWLL=:P65K"@'X8X+>..->IV2%V>Y.R2>OY]57TQ2GT^N*^AH;)T  =D]!T[]
M>@! V=GH-;.NXN0Z5?3UKW*DZ>_=C3$),Z5JMG?P;6JPTNVD'URM< 9N=_$S
MYHYPH>#@XT[AN:0:+J(2LJ"B2*2*,>N+Q7'\IF%A4P6KAISL-(I#)%W!T>QD
M!Z@=0O0GXN@T6^TG]K#'<(6U[P3X:W]OD>+)T>WR7$%I)%=6'#:-M)([613)
M#=9O0*@+SP8\GGE9[A1"FVLQ8LHMDTC8UHVCXZ/;(,F+%D@DV:,V;9(J+9JU
M;(E(B@W01(1)%%(A4TTRE(0H%  S$"2Q+,26))))))).R23U[UY1SSSW4\US
M<S2W%Q<2R33SS2-+---*Q>2661RSR22.S.[NQ9F)9B22:_5G%=5,4IBE,4IB
ME,4IBE,4J$UIYGQ-8Y^ZLX'*4*1>3&S^.MUY!M]D$GFR,9#LZ;;4ZJ>KK5LT
M8=T\<R!C*/2RJ<N@DV*1-N+!<5#+)*5R58Y@UU?='*+6>RX^C:BIO'&;TM -
M-IVG>VI'+.[2.YX!M(P[.8IC2?):=3OQFWT?6ZU';!0CW=_=/VCNJINDER(F
M4KHV[^H5HZM<2^6?)/CGLG3O)60XKZYNULL=9H&SZ[9(YM9*M!2,NSK-IE*D
MZGEZ\,F>.73(JJV,HJF@Z,T(L+=7P4K*.K.8.E[=J37M^O\ L[4NL[78N.&O
MN2MYHD]LRJL9/7>O[I7(66=VJ<;S$A&2C"B1<I+A"ENDM'1T,NZ(FD=PDY5!
M %*[-2.7O%/96O'^W*!R4T3<-6Q-@CJG+;$@-KT:2I<3:9=^PBXBMRME;SAX
MB-GI>2E8IC%1#UVA(23N3CD&3==1\U*JI7'6SEQHV'XR;,Y94V^5?;FH=;4O
M8=N6L6K[%$7&,LCC6Z4NC,UFNR\&Z?QTC/K3T.XJ[=FW75/\].FR,7U1\<4K
M'W&'0,OJBJ3V^]R1R6Q>8>U:X6S[EM;$B;Y^P7^%4F(O0&I59-8I*UJ;7(G3
MJE.KS%>,9V"3:N[];/C;G:+!,N5*A9Q\ZK>ZK=SEH'!GECP.MG$:\;LU59MN
M:1F5MWTG<Y;#7JLA-R#]E=HZFP$8THDH$;6IX5&@SDZY9RK-K&.VJ:<FT?BI
M4C-RU!CQ$WA2.3^KVJ-;UGNW:]#U!R[H$=Z;"H3$MMN?C==ZIY&LX=(I&$7L
MRM;.F:32+_/M4VOWSUI:GS^VJ2,CK^J.&:E1>ZG?3JT%/ZZV?RDA;!!:+L]#
MJ\Y>;U).4#(T.V,X5DL^=JR\>S**D38WPIE;MI.&;+GE7ZR2+R*?/G8.R7S'
MYF6VY8K@&:#L#WEC'7\)) =?\K'8'X6  6MQO G[7/$WAK':\-<81W7%O!L7
M+%:[E5L[@XN@5+">X94OK*,#28^\EC,(TMK=P1((&TM./>PMH;.=6ZR342!-
M<I2CAE"2QHQ9$C>7,*+DE=:R:1$V;Y1C%K).GY%O5>H_$-%#&*FZ(&7;$W]S
M>RW!D*"!3M.@#KS'X$WZ@+^(L-[T >M;;_9B\:_$'Q?XFX]FS0Q*\'V$YN,1
M"8H8<OCI+VX;[ABXV@9!=V<-C%*]S<W,,DHN6C5+@K)R))[+]6YA!'<4Q3E/
MMZ;_ "K//&[CQ?\ D]MBMZJU]'K+O)=VBI-S1FZRD55*\FJ0)2Q32Z1#$;LF
M"!A%,IS%4>O#MH]J"CIRBF:ENKN.TB>:0_"O0 $<SMZ(H([D_P !MNP)&!>)
M?B-P]X6\(Y/BOB&XCCBLX76QL_,1+K+9%D/W7&643'<L\\@TS %8(1)<2\L4
M3L-XM'7U>U1Q[6UI5&_PM<HVJWU9B$C=A4%G$UM=J5=P8  %'3HR9G3M40\E
MG*RJIA$QQ$8]FE:>629_Q2.SGV!)WH>P Z >@ KP0XGXAR/%O$6;XFR\GFY+
M/9.\REXX_")KR=YFCC'3EBA#"*%  $B1$  4"H6],42EHNT.X@'>V0P^X@'_
M %.I^OM_'M] [9U_P^6OH/KW.ZL56>>9/^T7_P 0?[\4IYD_[1?_ !!_OQ2J
MR>IP8HZ\UMV[&_Z9/_IV'_J-Q^_\P^G[_P!8<'T^O]#^NOK2IXT2,836HJ=#
M2C5%]%RVNH",D63@H'0>,']::-7C58@^QT7#=51%0H^QB','YY] E2&4D%2"
M".X(.P1\P>M=]K=7%E=6U[:2O!=6D\-U;3QGEDAN+>19898V'X7CD174^C*#
M6DYS>XEV[B/NRPTN2CWJM%EGKR8UI:C(J&83U7<KG4:MQ=@0$0FH8#A'33(3
M%62<HE=E3%D\9KK2#C[U+V!9%(#@!94'=9 /B/\ PL>JGU!ZG8('N[X&>+N(
M\8.!\?FK6XMTS]G!!9\38D.HN,?E8T"32"(_']ROBINK*<#D>.0QEA/!/&D.
M<KJF37Z/2F*YT?;Y_K]=^G>LCZNU!LW=5G:TW5=(L-XL3LQ !A QZSL&J1SE
M3%W).P*5E%L$S'+ZS^1<-6:(#W56*&=,T\4"%Y75%'<L=#Z>Y/\ E +'T%8Y
MQ5QCPMP/BYLSQ9G,=@\="K$W%_<I"974%O(M823-=W# 'D@MHY9W/1$)K8JX
ML]$.@,*G*R/+A=.[S]HKTK#%U_6Y-\RKU41FF"S%1ZZGF*C-]-61DDX,HT,U
M%O#QCPA54_FQR(N$\6R.;:=6@M04B8%6D8#G<'H0HZ\BGJ-[+$?X#L'S&\>O
MMCY'C.UR'"'AM#<87AJZCDL\AG[I%CS.8MI%:.:&S@VXQ5E,I(,G,V0FC(VU
MGMXVINX$;9OW0ZZF5^X,<@IMV/&C=U@C"5RXR8_"0"!IQ86NL=Q-5%P!!LT>
MHD-2-A%05308O&RZ[E18E7;@KCP[#UK19OB',-D^O7ZD]^Y_.MX\IBF*4Q3
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MDGU:./VQ>DKS^UEU.^+$49CJW8UU,O?ZLQ!1K76%[E$W"E\HTP@T("2%3VS
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M4Q2@B  (B(  !W$1]@  ^HB/Y &*=N]:R74%W;6]U;[6<5 Y75?HT$C24)8
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M*K#MU]/3K[5-OK!VA:V=2KEM)KG,J#;9"4"W$QC")6M9K4#7VY $Q0'L1*.
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M,E(:8B[#$QD]"/FTG#S+!I*14BS4!5J^CWR!'+1VW4#V.BX04(JF;V[E,'<
M'VS![FVN+*YGM+J%[>YM9I(+B"52LD,T3E)(W4]F1U*D>XJ3;*]M,E9VN0L+
MB*ZLKZWAN[2YA;GBN+:XC66&:-AW22-E93T.CU /2L1[OY*: XUUPULWWN'7
MNIH+P.=NYNUGC(9S(BF!A,C#1:Z_S6<==B'$&<.Q?.C 0WBB;Q'MT55:)[#=
M:\'*'[4+QMI#EY4^)NJ;KR'MPN#Q\?9+ FO0: L[,8R+=:-;*-Y"[V$BBPI@
MFT^0U\SDI_T3PH^/FK["$]^GZ]MUJ<<J3\A[=MRT[VY$Z.E]%V#D1-S6V(6
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MXMX:<6=V.E/G1B%,5%FUF26*-,LJ)2_%SK!$HB=8I<L7ACD@DM_B7;7FA;V
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M= ,HY"#\4<"LRJW9G9B-JJDS?P+PW)C('R5['R7MTG+%&PT\%L2&^,'JLDK
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M.[L=*JJ-LS,3H*H!+$]AU)Z5]*CR,L<:-))(RI&B@LSNY"JJ@=2S,0% ZDD
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M8VO*6C\Y9I_800?M)-GTY@O(/FP%>G:4I2E*4H 4I0 I2@  !2@'8   ]@
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MA"&C?7821.&C?7IS*=>FJMV0Q..RL8BR%I%<JOX"X(=-]^21"LB;]>5AOUK
M7'WI7<"^,-N0OVHN/=:B[LR4%6+M%CD['>)6%4[=@6@E+C,3:$*Y*'?Q>QB#
M5Z &,7XGQ$ "X9#BK/9.$V]WD)&@8:>*)(H%D'M)Y*(7'0?"Q*^NM[JAL.&,
M'C91/:6$:S DK+(\D[H3ZH9G<(?FH#>FZL'S'JO],4IBE,4IBE,4IBE,4IBE
&,4IBE?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>img30600998_15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img30600998_15.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1N24&AO=&]S:&]P(#,N,  X0DE-! 0
M    &W:^<# X0DE-! 0      !<< 5H  QLE1QP!6@ #&R5'' (   )@   X
M0DE-!"4      !"H<CR.\+B]1))=K(K5'*#I.$))300Z      $9    $
M  $       MP<FEN=$]U='!U=     8     0VQR4V5N=6T     0VQR4P
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M;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/
M8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R9%15
M;G1&(U)L=                $)L9"!5;G1&(U)L=                %)S
M;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !09U!S
M96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M    5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M       08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M
M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12
M:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M   0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@             _@
M.$))30/R       *  #_______\  #A"24T$#0      !    !XX0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              /9   &_          !
M      $             !OP   /9                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     8X0DE-! P     $+X    !    H
M %@   '@  "E    $*( &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( %@ H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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M=:_;E_6:JZBS%@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M13=_*0EIZL>XBVY+.:JGI+:8H.)'T82#(3QO[D[WU#:B]TPZFEHN*TD72C?
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MD@8!Q,YWI[V=@ !%T<?Z\I"^./\ E<<6'K<1[7%Z%N20&&?\D@QG?^#G>1Q
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MF<GW,^V8J+C>V1$![YR(!81#';K@>O35@1. "/&, F8.?/&1QS5@1. "/&,
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MFE*:4II2FE*:4II2OXJ"H#TYY,9AI4!Q)I49I)T:<XN R"*"(PI05% 80;
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MU)Q$!G\W7&%O<*"E)8>4E"$N+(:60EM0E*U$)A*%#*5&$D9!(KDE]A)2%/-
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M6^0'GGC.M(C$<9VWF9P!Q&"-MM\5I$8CC.V\S. .(P1MMOBG' !>UPR/ ]
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M !NU^/ORZO\ ;7Z>&T=!Z=CQ_K]U%S]W^@K,SQ(__F_=Z?YL-:_W?ONG3?\
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MM#R2#[?^[.8\21OCDQ(F'DD'V_\ =G,>)(WQR8D2"X"'>W A8.;Y&_ <]\"
M@&A@@^)W!D[1@1N=O&9!-#!!\3N#)VC C<[>,R":<B-N;W'.!"X=[AVQG/P
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M-VS:ZFU<H67$OHM[D.APSW+[^SN*E2>XDGN!(5()G)NZGTZ^PJU>U'1G+=:
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MN"<0/KN#4@8C?[SF>"-YVQGG<&HN. Y#K< [VL/Q&_2X!WXTP)V'TB,9D8S
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M3(DG>*$#&)^\QG.\GWF)Q)\4&**W8<CTX[6'/:W40_2$3C8B-O/N!!YGB?U
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M +B.,"%QQTXXM>^,]Q[B(AH8 SD&!GG?>8C./ \  T, 9R# SSOO,1G'@>
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M]:#ZV+HH3FEX&7V5*@?EXF/]AJ>=]<#7O[\0/_X='ZUN?YJ^*?EU#_SK]/\
M\P].'/&O=1>?_'S6J.JX!_*E4J]K??\ 3C?RO,+@'GGL AYW[>@F@3^8=$&9
M_-.FQ[_ZC:/,8V!(/M'G^;7J@G]TW4<3/Y^UB!YC4;H^V/)!]H\T"%KV[V 0
M&W(=,>86OZ/F ]\L9B?$D$3L><^QF.[V(\8$S$^)((G8\Y]C,=WL1X %QP&+
MCT#(#QC%[CD+A8+!;@=4F-SF!R<$;YS$#!@R9,[BA,;G,#DX(WSF(&#!DR9W
M%>>F.@#?@,CVQ?ZY$ 'X:O.>2(W.!YS'X8!(^M:N<\D1N<#SF/PP"1]:FW'
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MQ!X@"8WB8!QY&_(P2*O7MN#_ (PU#>?Z6Z>=;A_UK:1_1<0SG(#UUU?K4_\
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M A?J/.<ZGXGR-YC!\@D&.!MC%/Q/D;S&#Y!(,<#;&*D;7$1'I>U^1^?8!L&
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M IC&\9&<1[P1$#(V@2!4C;T;@%\V"X<XZVMQG/?N.=!/=!,8DP=L\3.^,>/
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M/&\08/(&!$;1QYJP<<\;Q!@\@8$1M''FI$.0QS<0N 6#RZ>7%^,9MJ ['.T
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MR["EOI2Z5)LK5+BY9;%9F>!G]E2H/Y>)C[?_ *#4\[8^FN#KO]^(_P 71_\
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MU]_'ORJ<G4R"3I8,F!$,V&DP??*? )P"VMX&N#?:(OU4 G&%>V'E^T)P*0J
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MXZ9^? ]1'7H'H$C0=%Y'YHTW$QO9-'WQ!C;<3@"OYM.J?XS=1^/S]K B8_\
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M[PZIZFA0RL2>8'3< !HN*5J2$') <'*6XC$J,\"A5)D!0*3224L!PP%)A$D
M&"X#VUU^XM/C1I&GHNKMRS8Z0[?0<N'%H=+3%\ XX@J[%NJ*$K4X4]RE_:,'
M;H+%K:WOY.W4&JO6-@C4+CX@=WS+-HRAQE-PYIBE-6[B4%UJW3ZJT(92OM2V
M2@#M,5>C<K5U%LQ?9!H/32E=,GB3(9 :WJ<QG"6(71=/*A>O=6A:+DN@/(&,
M]06S1J3U2@I7%[2KA)@*@0I2D@]8Z'Z<=^)MGJ_5NN:_KMMJ?YW?M=+&FWQM
MV=*0RU;W#(MVBA<)0JY#:&TJ;'IM]Y677%.UW;XD=6,_!N_T'H+IKI;IB\T8
M=/VE]K1UG2Q=OZ\Y<7%U9O&[?"V^Y3@M"ZMU:'2''0A*1;M(8K3L8= >OC/@
M(*2P'K(CH4I "!*> T[TX2"?3&*("R81A@@]*X^C"'I1#%K])!)2R$E164-!
M/J*_A**405*B 2HS,&).!!-?D,*[W2L-I;"G5+2AN>QM*G"H(3M]E(/:F3,
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M<K2S"PRG2:3&GU+J>UHTKC.[R]HRSU\S*' B#USBG$(!3!$9%# 6]POP 7#
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MQX,=4_QFZBVC\^ZR3YC\XW.9&?;WV^EO[\V&UQ'FX@.>M_(;\#]1L&8C:1,
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MW<^865I#KJ$W++*WU..-ML%Q4:_%:PQ4O4.!D!,!BI6<L,*)@]61 8>=&='
M26 Q# 5#%&,!<-Q]"$  > '7V%II*&D- J*4-H;2I1E12A*4@J,"28"CY),<
MU\!4XIUQQY24A;CJW2E [6PI:_4*4@]T("C@9A.TY%9L39O:>)JW%4TW!&2
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M<Y4HG+,,HF2R-(9*+E(U;$] Z@_&PMS WBO@(!K;O=A=F,#031'+H@%4,'M
M@2$9G1>D.C#TKJ'5-]^<4WW[I-55J0:%M\O\HDO7CWH=WS#_ *Y_U64^H$-
M]DE [H'TKKOXA?NUTKHG3!I(T[]R&@HT8O?/?-_G$HM["W5<);%I;_*A7R(6
M&2NX(]0I+I[95_&H^XF"?=O]':'PRG$UF4K6.*HR91>H59;V"T5_JBX&GW6G
M%N$N%=_/BB<EOIB5B& (_P";=%Z+.D]8=2=5'41<#7VF6Q8_*ELVI:]$+)N/
MF%_,=WI8AAJ.Z))$G3U'U_\ G[H#I#H=.E?*JZ5N+I]6IF^]87_KKN2$IM/D
MVS;EOUP"KYA\+*<!,P*NJ+N_>YJF+;U-DJ2U#*4P4"EAI8D*A6[ ]I7]4VE(
M$YRD]-"W-4:1 X)T1B94@ Y2:*=8:7"L"*&$R+&Z-\-[73[/K'3[^^5J-GU?
M?7%VZVW;FU<LVWR\M#:5^M<!UYE;J5H?[6D]S:5>E!(K+:_\6M0U.^^'NJ:5
MIJ-*U#H#2K+3V''+LW[6H.VC=NA;KC2;6U+#%PAE3;EOZCJO3=6D/DYJNYPW
M4[;)Z=G.?9FVBM[E5!Y@%0ZN)E2I@(E9:\BG F)U4L"1(0D4"9'#"<:0:E$U
M1&'I*5AQT4:B/%Z;T!UOI5LQI%C\1GF=!MB$V[*=#LU7[=KW]PMT7CCJW$!*
M24I6EP)0,(:2B$#.ZQ\3OASKMU<Z_J/PDMKGJ>]3ZEU<*ZGU)K2GKU3?8J\<
MTYEAMISN4 MQM2 MTR77EN%3BK+$;AX"MK2W;A]Z<8G+)^@G.&;@>H82RRH(
MT9ON[W&+6,<4?IIO1!5[U"'T(\IQBA_G]F<Z,[NO6NM?SC"6M(.F?F[Y4J*E
M$/)]<W8N, !S+7R\R/[I&!TMGK_T?AA<?#@Z5W%[7AK?YW%Z>U"0&1\K\C\I
M)/<R?W[YM,),>F2":N#3_=/(::A;)0BL]&X:HRW)<PK)GDM0WSDYR>>F6K%#
MLMC3.\3<E-/6% H?78OUI2B"&-$L!.8BB.2DJ@P^L] ZLYU9==6],=2JT&^U
M2S;L-30]IC&II<:;1;-!RV#[J4-*[+2V/:I!AUOO2ZE+BT'/=/\ Q/T1KH6Q
MZ$ZRZ,'5&G:-J3VJ:*Y;ZU=:,XT^\Y=/*;NS;,K<>1ZE]> N)<2"R\&RT5H;
M=3>J0]R!>XC=?M04%R.BD2&0RPE7W>VND2]L4>BA7F%"UIC$*0UL0)B2RTZ5
M$:>O,@+"&&)5'Z(#%UG5NBCT9\/OB$@ZJ[JQU>=0]9^W#3Z)=:2H/K2ZXE]Y
M:BI;CJ4,@JDAL9KN>A_$4?$+XJ_"=T:);:$-!#6DBWL[I3]HX$MOJ2JU:7;M
M+M+=M"0TU;J=N%(0D2\J,7&JQO,D:CE=*QKVG;[*ZBM3.\/DG-U32WA2E3+&
MXJ(HA*N>&+V,X#'. @DE.XJ4*Q*J=24\)!BU*FB%.&$Z>^&>J]2]*=-,W'6.
MH(Z7N;:UU-_0E6S;CC3Y"E.-6UV74E+!6I2V&W6G&[=2^\-.+'?79.J_C%HO
M2'776-Q9?#[2G.M;2\U#1[;J=-\ZTT[;H*&FG[S3O16%780VVW<N,/,NW:$A
M"GVFRINL.Z-;L@DV5ZATWJW(:.L5-:FOY\VS$S+'A2PNY,SJSDJE6\('9,0H
MB@B5*4"!7&3 6F.*6)"52-:FBC40J/I/4OP]_.=_HVM].ZN[TWKFAVB-.LKE
MNU;N[95BVE;;=L];.*0"&T.O-A1+B"VXI#C2X1V?'NC?BFO1M+ZAZ;ZMT%CK
M+IKJ?4%ZMJ-D_>O6%XC5'7&7';QB]9;<4DN.6[#JTA*%I>80MI]I2G0Y0M4J
MKTG=3Y/BHC1-/2$R4WD7XQX53:[SB^/*XJ-(<@+4J':#T4J%O/3 >4F@-4!&
M;''&,15XH(\MH&@=0VZ=2'5/5*NHTZA;"S3;-Z=;:9:6K2@ZEXMHMU2XZ^E?
M:IPI1"4@ *_A#!=4=2]*7CFD'HGHQKI Z5=F]5=NZS>:U?7KZ5-+MTN.7J8:
M9MULA:&DESN6M2I [DJR]7^(E):R;I8JK#MKEDRL#<0U-;].BN8SCAB8DT8P
M.B67$XM,7NQQ<$1JM A=U@+E;0C4QI3(G-/#ZJ+YPU\&M3:TZ_Z?/6]^.FWU
MW#]GI;=DE!%VL3;N7JQ<)^889=2V\[:M>BU=.H"P&%GNKZ_<_E!Z0]J^D]5'
MX;Z4KK"V1:VM]K3NHNN%5DR2+MK363:=MK<W+*W;=B\>^8?M&7?3FZ;2$FQ]
M--XAE/-Q53ZUQ2(2[L%5QF5._P EGO(0GI6R8'8AW++2O7NX23E2,Y(629&<
MUPIUB4Y45ZA.884>1VK7/ALG6>B]"Z7&K*M[SI[Y%=GJB;7[*W[.W7;%3EKZ
M_<EMU+A4 E\K:6EM7>X$J2OI'3/Q<<Z>^(G5'6QT)J]L>JU:HUJ&B.WA2INU
MU&\;O0AJ]^5*5NL.-H;4IRT]-YE3R"VVI2'$?KDG=G(5,ITK"]4]HE!+<HU,
MIY!(S7*B:<51@R^I!)&2H>U+BO:5YCE&L4''*3$)<".$J'U94"F,0C.BV]4^
M'FK:[I?35IK75*KW4=#UDZJ_J"],;'SB/4"D6J&6KED,);0E*$O*+A4946Q(
M2-[1/BGH?3&M]7WG3W13>F:3U+T\="M=);UIY9T]9:*7-0=N7[.Y7=%YU2W%
M6X2PE [6TNGM*U>*2[N)68*/)J%5LH^AK)(#([G/<I01ORF7G1B5'GJU<:;V
MM.D/--)@5N#E&G4IE"-40G<5B$X5:*,L@IU%\.[^[ZD<ZKZ6ZD=Z9U>ZMDVN
MHD6C=ZQ=MH2V@.>FMQ*4K+;-N%H<0XVM;#3R0TZ%+5IZ2^*VF:?T@CH7K;I&
MWZRZ?L+Q=_I*5:B[IMW8.K6\ZI =99<6ML.W%RIMQ"V'4-W+S"R\P4-HQAJO
M.C)4&>WF:9<DAEIRPK2VM(TR=+X^L;F="T-*%H)@%0!"6)8L5%H@6N2V).3&
MK<%*E1'!Z9D0CWSI_3+K2-)M;"]U2YUJ[:+[ESJ5X.U^Z=N;EZY*@CO<#;;:
MG?18:[U!MAMM ,)%?->I]8LM>UR^U33=%LNG;!\6K=IHU@>ZVLF+2S8LV@AP
MMM>J\]\O\Q<OJ;2I^Y==>4 5U=^<]QY<V[;:4;?X92C0G4RFA7,)DU1/<*DM
MXA/-F@TM+ S>ZR(D,4/WQC#&=$YJP'V/T@*A \0(ZUIG1/YNZVZ@ZP_./K)U
MVP;LTZ?\J4&V[$Z>"LW7S"_5DV0(2&&X#D=RBD=W:]:^(AU;X;]*?#\:1Z!Z
M;U%[4%:J;[U1>AUS4UI9%D+-!MRG\Y *7\T]W>C]E +D(J6LN[ JK%?Z95P+
MD:-C@IXCDE/%+<<Q0N$3M%*4S.4R&1@[ R(@10KA<(D<$(MZH4P$@HB]<)GJ
M8.%TS\/E=.](:[TL=5%V=9=U1SYWY$L_+_G"Q8L0/E_FGO5](-!R0^WZA44?
M9 [JR?6?Q5_=;U[TWUL-#^0'3K.BM?FTZC\TJ[.D:H_J*C\V+%@,"X-SZ*0+
M=WT^WO)<[BD5BR[Z')BW*U#KFED-,IE>J#4VL$U4[<'D%7KVIM9&9H*,(>P:
MBB?;H36B,^&)0S&I8DC@M;S"(Q,A6%XZZ^%+%WT/HW2:]7<1?Z!</WFGZTS:
M^GV7#US<W"DKM3<*5Z13<!)"+E+@<9:>"Q!;5F++XW7EC\2NH>N6]"9<TSJ>
MTM]/U;IQ^^+H7:V]E96J2B^^30@OA5H7$J79*:]%]ZW4V>\.CZ+QO5I^CIO5
M2DE,=OC-3N3*B2\I0%Q(9F4*WHF8%XQEJWMY6*VPX71$4E$E.ULQ,:2%O L_
MT%L9*F E+LVWPPU=W6^G^HM>ZQNM9U31;Q#Q#M@ANU7:-0INTMFFWT?+N*<[
MUW%TH.EXE$M!2"I?(O/C'H;'3G5/273'P^L.G=%ZBT];"2QJCS]\C4'BH.WM
M[</6KANV$LA#=K9)+";:'"FX6ET(;IV4-V4@NE)I0I#N#HF15QGIV)I4C/C?
M-KG*#XUH(PA+A;51S<6)J@HHB$E)#&G6)2#D:)O*5(5*E) KBYFI?#W5[?J'
M4NH^C>J5].W6L]JM6M'M.8U*TN'A*O7;0\KM;4I94X0MMQ:777E-NMMN%NL;
MI/Q3T*ZZ3TCI#X@]%-=76?3A6G0[ZVUB[T:^M+=>/EG7+="EN(2A+;(*'FFU
M,L6X>8<6T'C\Z0]SU+*:5D658DO;TW,9+5)9LN2!+!4YK525A?3Q5%J9Q>7%
MQ9EBU[=52)68W1P01((2D41L$!\9XEJ2M[5NA=?USIEOI[4^LG[M5QJ:;W6+
M]6F-(<O+1'8IO3+9EFZ;:M+=#C8?!A\ET))0$=S:N-H/Q)Z8Z:ZR=ZLT3X?6
MMDBUT=>G:#I:=;N'FM.OW$NH<UB[N+BQ>?O[IQEQ3"FTFW[65*[5^IV.)^:\
M;M5\\[?)BHK5.654]OBB;ULY2?4,Y_@2.,L.3BX&.JR U":T+HG$F-2O?R/1
M@7HH0;7HUO*A(+1I(X-^V^'C.E]8V?4^@7R-(M$Z:UIFHZ,FS4XS?L,LBV:(
M=%RT&%)0U9JRT]+UJEY1477 >/>?%6YUOX?W_1?5&FN:Y?.:P]K6D=0NZAZ%
MUI=S<W)N7TKMS8O_ #2''7[]! N&.VWOE,H"$LLJ3AT&.N<CBX@/8,"'GTM;
MRMKZ0<\8P,P"/)R#[<S/O-?)3GC&!F 1Y.0?;F9]YH/&;9 !P%N!&P_/RZ7
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M6%NPY=K0Y=W#CW4O4]U=75TMMMEM5Q=7=P_<.^FTVTE3A0TVAM*4C235B_\
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MF)Y' IUM>+SZB X^MA#H ?'B\XF$^W (S^$@\D_3>'$PGVX!&?PD'DGZ;QZ
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MZ7L(!>X][WL/?GL(@/EG2.8D$Q \1$CQMY (]\4CF)!,0/$1(\;>0"/?%/1
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M0[V&"3YXYVW@<\XSL#XD8)/GCG;>!SSC.P/B0@(CC/(AU^(#?'4+].PB-[I
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M>UP ,_$1\QP \@ ZI/W1O!)Q] /89(V)%4G[HW@DX^@'L,D;$BI[9S>V!XP
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MM<<?&W C:WQMCN-\:3M,#/TG<"9^DY\",TG:8&?I.X$S])SX$9H%P !Z= #
MB/(_$,9$<6'';0P21SR3D ;#Z'. ,R,^:&"2.>2<@#8?0YP!F1GS3%K^=\^8
M!8!"W2XVMT ;>3,Q[1CV)D@SS F>2)]V9CVC'L3)!GF!,\D3[LCT#.>_ ?4<
MWN ]1"_.6!R<8\;G\!B((X!C;# Y.,>-S^ Q$$< QMA?KR \A?.<<#D,7 ,W
MQR(<HXV(V,8QG<8.8)Q&=@=D<;$;&,8SN,',$XC.P.P,W#_1#Z\#D0&X7[<W
MM<!T.(/_ "C^&XP"(,>=HF"*'$'_ )1_#<8!$&/.T3!%2'/ !P( .+CCL'E@
M;=1#KB';<G<$C,#/D^^1/ /&8=MR=P2,P,^3[Y$\ \9@.F;7#BXWSS:V.0P
MC\>;:IYQ,'>!&-IG.QR0/IM-4\XF#O C&TSG8Y('TVFIO:PCR-[C@0Z<Y[6'
MZ6#.I$R!L-AD'G;'F1^,G%2)D#8;#(/.V/,C\9.*CD0M:]^0$>O(6O< Y'I?
MN'6[ S,1L0.-C,03L.8\'B[ S,1L0.-C,03L.8\'B<C?(6XZAQBW2W.1L(9#
MMB8$8,[\'?,\SM@2#@^<S C!G?@[YGF=L"0<'SF!OQQ\.! 0O?.!''(B'&,W
M'5QOO]=P08C&0,[ '?.(%7&^_P!=P08C&0,[ '?.(%+"/4 L(@'3&;XZ"%_T
M]+:$@<$R 3SG$9Y!C]7,T) X)D GG.(SR#'ZN9I?BX8#H/.!&_.. SYA8+<@
MC>#D\C;($;9W./8R9V*-X.3R-L@1MG<X]C)G8AQGJ-^,6MY6N'^KGF^@SC@1
MOF9]Y@_Y]MHH,XX$;YF?>8/^?;:*8[8"XV&X -[V$/I8+WQCD,L^<F!(@D1$
M@_C)B,YV.&?.3 D02(B0?QDQ&<[' 1N(^>>+B%L#QY7M<<6OB]] ( ]L;P#.
M1O[Q,#,QF(H! 'MC> 9R-_>)@9F,Q%!OUO?BUPS@ [@(WYOD/CH(XB-Y@XR3
MX($;1@[[4$<1&\P<9)\$"-HP=]J=L?$ S>U^H=0P.+7$;C;3SGZ$XB8X/!R,
MS $":><_0G$3'!X.1F8 @32W%[WXR'<?/J-QZAQ\])WB(WP? ]N! X._W4G>
M(C?!\#VX$#@[_=4@("/E;C^S-N!OD,!Y  ZA! ]YW_KQ.XC!R<[DBH00/>=_
MZ\3N(P<G.Y(J+@-LV[YO?BU^]NH#8.;==6")Q/C$1O,>)X(D[3Q5@B<3XQ$;
MS'B>").T\5(!TOB^ &^0Y#X=[V'K; #>$\QF,D1@['Z^(D<3DB(3S&8R1&#L
M?KXB1Q.2(!SD.P@(7'@0_P!HCUO<+W"]&X@XG(.//_@![1N# [8.,R-N#_X
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M=YC_ &&IYK"Z[_?B/\71_P#&[7X\_+I$?%;I[^8>G#\->ZBK5)5C^E*I.?\
MM]. ]["$PN.;7OP'80^&O03I_P#V!T7'_HC31R)FS9Q)$?PB9@C;FOYM>J/X
MS=1X_P#3VL#Q(.HW$"8C<YR#CF*M_:V1'(<@-_CSC-[C@<\AYYB9P!@[$1]-
MLXB!D8V/M@YG &#L1'TVSB(&1C8^TP\_IQYA;.0 +7Z9O@-16WZL[X,XP29C
MG$9-16WZL[X,XP29CG$9-3<0N AVYOGYAY .>1' <6U(!@@^=HQ]Q]R,; 9.
M\U(!@@^=HQ]Q]R,; 9.\UYY$1Z9Y^@<<CQ>W7GF^M>T#G&WXG?8;Q/W;16K:
M!SC;\3OL-XG[MHJ1ZCWN(WP ABW;K>PX$?F.M/@>,",D',^>(D9 ^X5/ \8$
M9(.9\\1(R!]PJ.+<"/E8<],VYN(8 >G6^KO.X'O(QSB=H!R1SQ%7>=P/>1CG
M$[0#DCGB*D0O:P6Y#KC@+#@,Y$!\K7OH#$R9V.8SN9&3C (]YB*@,3)G8YC.
MYD9., CWF(I?/:^1$+ /PO<>1R. \[!Q(QYC !DCZQ V&!D^TG=&/,8 ,D?6
M(&PP,GVD[P. MQUZ!Y#],@ <Y\M49,[\<GW'XX).V/>J,F=^.3[C\<$G;'O3
M@0[9$,9QW"_00^G7%@;@^< YQGP8Y!_'C,EN#YP#G&?!CD'\>,R?0"'6]K7L
M/3ISU#I#Y\VYU"#Q$S$CGG(X/*O;:=JTD'B)F)'/.1P>5>VT[5'\W.;?#/>P
M\#:U^@CGM;3[6,3]<>)&XF8Y QYFK]K&)^N/$C<3,<@8\S4=+7L(_(! ?@(@
M&+=L7#.KS,2!]Y!'U )S/G,'%7F8D#[R"/J 3F?.8.*FU[#R&0&]PM?CF_<+
M<W'B_.I,2-C@B(,QOM'@SM WC:I,2-C@B(,QOM'@SM WC:EQZ -NENP]! +A
MD0&]_D%L"@<D3S/D<@F#@$1'WF<A Y(GF?(Y!,' (B/O,Y"W6XB'(_6W7 \!
M:_-L@&D\0 =A^$\9&YF-IP32>( .P_">,C<S&TX)H AR(\CGXCBV< '/?C/0
M $'8#88^@S.,D[>-\<DB#L!L,?09G&2=O&^.25AP( -L"'81S;KUQ?S$0[!I
M(R"1.0?(&)XXS]PGR:2,@D3D'R!B>.,_<)\FI'BP9 .OER("/E8 P/Z;6#>3
M@GCWV! ]Y)R/U3,&\G!/'OL"![R3D?JF7I<6 ,6SWMT"^>.H^8!<;7G;O).9
MQXGDQC?@>Q,"8=N\DYG'B>3&-^![$P)CSBUL>0\<B%[W'CY=+]!UJS,Y]QOM
M,1 W^_F.16K,SGW&^TQ$#?[^8Y%3?RZ6XO?T0X$._ WS; =!U(]^9WB.X[@^
M-Q&)R>14CWYG>([CN#XW$8G)Y%!\[_/%^ X' 6N-N@!\QU1[1]V8W.XR9@3R
M3]PH/:/NS&YW&3,">2?N%,A<.<6&P_YP]>>PV'H,6.;:F#!VS(D?X(XV\B1R
M$YVFF#!VS(D?X(XV\B1R$YVFIN. OT$1"UL!BW4.@XQ;.0OJ0,F.0 9G)S/!
MY&<SC!BI R8Y !F<G,\'D9S.,&*"&+VZ@/3T<V^(@ ]KV\]4',3P1SW8GZ D
M>8GVH#F)X(Y[L3] 2/,3[5%N;WZ"(WZ6QR "-QQY#;FVD[1'( CF<[$@0,^X
MG::L[1'( CF<[$@0,^XG::O5MM$/PA:&@ ?^=NGF1 +XFMJMD![<_P!P#K'6
MP/[CNJR3_P#1W6< F,Z?<3B/)Q_H3W3X< _I!Z()/_TMZ>P"8SJUI."/?_0Y
M/6GKSQKU?II2FE*:4II2FE*:4II2FE*YR/$U^U"Y#T"290'_ #O_ $=9;@;9
MXOTU^U/@;_$.W'G4]2'^#_OC<S(G&\<UYT?E*?[:-X,S^9]''^#']P43N)@3
M,<UKYZ@%K\"%\#;XAG]-@[=OL7!,QN#R)^AQ^J3Y\_ ^"9C<'D3]#C]4GSY#
M;M; A\[VOD;!QSSSY#J"?,Y!^Z)C D[[;;>XH)\SD'[HF,"3OMMM[B@Y' A>
M(+V[=0L(6S;CCSO?(8&0828GSP9!G$[[^T1@,#(,),3YX,@SB=]_:(PN(6#-
MPO</TW#D./+%Q[WT@$DX@Q!_5!V._OF!XBD DG$&(/ZH.QW]\P/$4'N%N+W^
M8V .;"%NENN=!X,[Q'W"2=I!GF>,4'@SO$?<))VD&>9XQ01N%[#P'7IP%QX$
M;_K$! !"^@$$B1N>.=S W C]@()!B@$$B1N>.=S W C]@()!BIO>UA  Z<6#
M AUL-^H7L/(YMI$3()/.\G(/$B.#$C88FI$3()/.\G(/$B.#$C88FO/ X$<7
ML'%ASTN/7D!L/'.KN,@9B3O(^L#C8B1OM6K<9 S$G>1]8'&Q$C?:IO;(7 <W
M#GJ%L]L?$?@-]2)P8(Q!V\SCSGZ#ZB*D3@P1B#MYG'G/T'U$4O:P]K@']@@%
M@"P^>>>;81,CS!/]8)DF1[8VVG*)D>8)_K!,DR/;&VTYFX7R%[!?-N?.X!WM
M8.W'%D'@Q)C$[>T$^)D^=]YD'@Q)C$[>T$^)D^=]Y!W'%K  " ?#KU^E[<A;
M ^!F9)()^O''XQ.QG(^!F9)()^O''XQ.QG,?.]N^+\#;(Y'@!N''P#3[HGQF
M-Q.!@;D0=_J:OW1/C,;B<# W(@[_ %-18/KP(A;_ %\W#H'Q[V3^&X!G_-M!
MY/T\63^&X!G_ #;0>3]/$\?' 8R ].!YQ<.@= #G4W^F3G!'.XVS!Y/).U3?
MZ9.<$<[C;,'D\D[4M\>;?JOYW$+8#I>PVTGZ;3^V/: 9R>8D32?IM/[8]H!G
M)YB1- [<9ZX\A !N.,6OUSR-@&GSOCC/N"1 SF8X,;"2!\[XXS[@D0,YF.#&
MPDA<,Y ,XL&?T8M\!Y ![B*#C!.,R<?KS/U&Q(\ (.,$XS)Q^O,_4;$CP!-_
M[;YO<./*W.+?.UM:8_JC$0=_>=LS]TS4C^J,1!W]YVS/W3-1TOC/?(7ZB//4
M; .?/F^J=XSCQ@QP!MP)(Q[;15.\9QXP8X VX$D8]MHH&..<@-KAD?,;6L 7
MR Y 1'-AT.=]L$3!P/83,DQ@C! &)%#G?;!$P<#V$S),8(P0!B13F_.>.W6W
MGTQBXV_]:VFT;8W\\3[<YS G_@S3:-L;^>)]N<Y@3_P9J..;=QX$0YP(#S<;
M#:^+7$+ZN^T^!N ?<$;0)$QF8!BKOM/@;@'W!&T"1,9F 8J;#C(A>P"/ <7S
MD;X'%[=O@D9P#$D#<[QC C(S$^?K)&< Q) W.\8P(R,Q/GZL!D,@ !TP \C8
M1$!OU /,<<ZF3@X))YR1D"0 1'!/L,[4R<'!)/.2,@2 "(X)]AG:@W !#]73
M&>W(C8>V;YY""0?V\YQYV D><1C8()!_;SG'G8"1YQ&-EQ#D+VL'%N,W'%_(
M+VN CUOI )P8F3O.^(&8]S$P1XBD G!B9.\[X@9CW,3!'B*FXW"_40Y'/8,8
M$>X\A?(!H )QQ.PQG)SD#P-C&)J0(,< [#'DYR!X&QC!-=<% /Z":+_DII[^
MR;3KSLZO_C9U/_.#6?Z1N*]9OA__ !$Z,_FKT_\ T5:5SD^,M*+W4#?%1>1)
M:3@LF.=*54\E1@2Q1^KA4O,PU-GQI;"(S/1B]7 :L5DP1F>B(00B,0A8-<K1
M5I;T]YQ1A*'G5J/A*6FU$_@*]?/R,=7L>G_@9UIKVIN%G3=$ZLZCU:_=2)4U
M9Z=TQT_>73@3([BAAEQ0$B2 )$U4DX4N\)_9JO(I%75MJ9N"K&UHV[[_ %PE
ME4^I6^7G58C3JS4I21KG"16=O(C@/+4D-OMTROB)*85 XK0/C& =M#VKWH+]
MN6K=DD^F%A)*D@F/X2%DY$=T(!,QBL=H_5?Y6GQFMU]8=!W73'P\Z-NG[@Z!
M;ZHW8.W&I6C+ZV4NK>N]'UZ]N7$J0IMRY+&F6+[B5JMF2TD*K&[=KM8VV+:#
M(=W.RR:']SI:GFU+)E19$F4Q<H=9 >'& H4!D)KL6#PG3EJ53:WK$CDM>P41
MO#8X-;PK0FG 7R;.[NA<&SOD .]A<:<2(#B4X4(3]DX!(*0D?94"D&)^E?"3
MXJ_$UCKVX^$'QLTO3[7JIS2'=;Z;U_30PW:=06=JI0N$J1:*-DZXIIJZN67;
M5BR+:;*ZMKRR:N$-]^UWP,OLIU Q;_AWF/';_>+3S6(UW^_$?XNC_P"-VOR9
M^75_MK]/8C_R#T['C_7[J+]?G]@K86X[.=LCNX+W5RH]*ZMQ<UBIP7JS8G7U
MJE8M.,4*E!GHN,,/IG'FF&1^C###Z40V  L&L^S\2NNK=EFW9ZEOVV6&FV66
MT_+]J&FDA#:!+),)2D $DG&237G!<?!WX9W5P_=7'2&F.W%R\[</NJ5=]SCS
MSBG77"!<@ K<4I1@ 23 %6(JI3;PXJ'S!3J5:N-%(Z>3!5E[-EVG#9-#LY-I
M\V/1*AL2&H6R(UQ]3ZR!6\M*43%)A!/M#@D) T3#H(1R-KU]\3;YNY=M-=U>
MX;M&_4N5-(84&D0M0*X8F.U"S !,)48Q6.N?A+\(+-QAJZZ5T5ARZ7Z;"77+
MQ)=5*1VIFZC=:1D@2H#FKON&SG:2TH%SJZTBDEN;&Q&I<'%P7*7)*B0H41,:
MA6M6*CW6 E.E2IRS#U!YT<!1),$9AD4,$(B'#3\3?B M24(ZFU)2E$)0E(8*
ME*40 E(#$DJ,  9)BN4KX+_"M"2I71NE)2D%2E%=X E($J))NH  $D[8DUC
M6I\*=10I\W,HCJ1.E"):?D\KOM26<R:GAD;7]4\L[ 0TJ"FR)6Y^U1NK^S)Q
M@+01PP%."989%"BB%1#E/W:?%47[>F'6M73?NMEUNV6+5+BF^Q;A6.YH) [$
M+,E0,I(_A8K'?HO^#)LEZB.F=&59-N!M=PA5^M"7%+0@)(1<%4E3B!_!V4"<
M&:RJ_ HVK_B5E/\ TG;^)ZQ7Z4.OOY4:CY_^;_C_ '"LG^A;X6_R,TO_ )5Y
M_:JMA62B&PG;[3Q[JO6.0Y&D>GLNG,Z9ZF9Q(FA8E0'3 ]M\O-$!B=I.<%YG
MMKRZH$<(DI#82HE ''B4G+-.+Y-G\0_B1J%PW:6?46I/W#@66VDFU25!MM3B
MR"MI*1VMH4<J$@0)) /%N_A%\)+"W7=7?2.DL6[90%N*-\0DK4EM&$7"E94I
M*< Q.8 )%S_P*=JX\T6E,?\ XG;^)ZXWZ4.OAMU/J(_YO_V%<K]"WPM&W1FE
MC_WKS^U5/X%.U?\ $M*?^D[?Q/3])_7W\I]1_P"C_P#85/T+?"W^1FE?\J\_
MM5/P*=J_XEI4_P!)W_B>I^D_K[^4^H?]'_["GZ%?A;_(S2O^5>?VJGX%.UC\
M2TJ?Z3O_ !/3])_7W\I]0_"W_P"PI^A7X6?R,TK_ )5Y_:J?@4[5_P 2TJ?Z
M3O\ Q/3])_7W\I]0_P"C_P#84_0K\+?Y&:5_RKS^U5'X%&U?\2LI_P"D[?Q/
M5_2AU_\ RHU'_H__ &%7]"WPM_D9I?\ RKS^U59BN-,?#JVU2LVSK7>7J84Q
ME5W?TLK-3S,JE])3+YA6(7%S2M*2%,K4GG+#4#4Y*X8("1 "4AT<44-@OS+'
MK_XF:FZIBPU[5;IU#9=6AH6Q*6PI*"HRR!'<I*=Y)( !KAWOPE^$.GMI>O>E
M-'MFEK#25N+O0%.*2I00(N222E"CMLFJ I.;X5-=$,]N5)E-'IX;Z92\,US\
MK:54RP$2M+D)*X^-Y=(UQJ0"T)9+8N,,-+];ZN!-&,80_P WTN1=]:?%.P4P
MF[UG5V%7+GHVX4+677) [$=K1^T2L  Q,XYK8M?A=\&;Q+R[7IG1'DVS?JOJ
M0N]AIN%$K5-P(3"5'' -6W9JA>&:[4,F[<>MH=.,J4BEF*4HF:99SH[5:6C*
MGIJ@. -,AKJ1M3@3 YU 33<Z&)T33[F2Q*"XU:10Z$-R)06J'DKZM^)Z+YK3
MD]4.NW;H>]1IB\T]SY7Y=/?<)O%);[;<M(!4OO,$ A!4H17'1\-/@ZJR=U ]
M%VC5JWZ78X];:FW\R'U=K)M4E_N?#JH2GL$R05!((-954IVY;2*MR,T3XV[;
MG23$SL:YD#+54),G&GT[M2AJ<UC2I*>95F!6F<D'K3T1BA$=% 8F<&\U*O1G
MGI5)1D6*N_B-\0+1]=NKJRY>* C]\M7[.X86%(2M/8ZVR4*@*@C=*@4D @UD
M[;X/?"NZ92\GHBQ:"^X>G<MW[#R2A120MI=R%)R"4S@I(4)!!JXOX%.U?\2T
MI_Z3M_$]<?\ 2?U]_*?4?^C_ /85O_H6^%O\C-*_Y5Y_:J_,LV:[3&Y(J7KZ
M026A0(4YRM8M6*7)*D1I4Y<1RA2J4'.L!*=.05!&:<<;' 647#%''%##"(A1
M\3OB I02GJ;4E*40E( 8*E$X"0 P2228 &3M4/P7^%8!4KHW20 "5**[L  #
M))-U  &Y. *M?52CGA_42DQNJ)4^3:?2I)3N^RM++7,9P3(XMZ]ZG5P3M<KH
MTL3*H<C3H7=8J(@(5P%"B+)C%6H4$I(##X>3:_$+XDWSRK:VZAU-YY#;KJFO
M]2I4E#"2MU1"VD@%"021/<3@ D@5Q[KX1?".T92_<]):0VRMQMM+A5>J2I;R
M@EL#LN5?PB1"H[0,D@2:NS^!3M7_ !+2G_I.W\3UQ?TG]??RGU'_ */_ -A7
M)_0M\+?Y&:5_RKS^U4_ IVK_ (EI4_TG?^)ZGZ3^OOY3ZA_T?_L*?H5^%O\
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M-^V7;+I71+EL&"IEZZ6$F(A0%U*3'"@#%7<_ HVK_B5E/_2=OXGKB?I0Z_\
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M6^-\9#H ?(1'GOS?['XS/TC.#R3]X V\;1\$\9GZ1G!Y)^\ ;>-H".;"'0.
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MY'@;8Y\\W&^IQ$G(]H(C8;B<[>V($5.(DY'M!$;#<3G;VQ BEL" 9'GN-N
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M4/M B5K.HZ4S=Z?=:?I=Q;*L[MFY=2]J7S0?2TXAP-)_U&SZ1)2?WS[>_P#
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MP<;"(_ $@;_X,#G(*XC<1#H/>W&?J 6L&>1N%M( @ \CQ.^/P)F3C809I $
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M..UK7'(XZ\9#SN'P&9P=_,S P,\;X/M!^HF<'?S,P,#/&^#[0?J('Y\?, N
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MN-!Z*ZB;TC2[K4'=5?MEZ+H6HE=\_;VUJZ]Z^IZ;>7"0IBSMT>FAU+0+?<E
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M28SQ0C !((D$?3;&YY&28SQ47O@ N%NPW#FV0_1Q\KCJQ&28,^1!VG!_7O\
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MO;0?YQO(&^(D2,;B9@^)H/\ .-Y WQ$B1C<3,'Q-3;I;/]Q' A80N(YN$(B
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M&^/><^VV8KSH_*4'_G0O,$G\S:1&?_S"A@>#.=O;,5KYM\P$;=LWZXQR/2X
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M\QM 'ZH/D$8J<];Q6"X9$!SCH&<?'K<1OJ8XA,F#@$8SR<9^G$ 14QQ"9,'
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M8^MLA\ '4QG$@P9)\\Y_"<'ZD5,9Q(,&2?/.?PG!^I%3C(B/E8!L @ 7P%N
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M1L B&._&<@(XX'. N&K&?& )(!SXWQ@@9W&,F#5C/C $D Y\;XP0,[C&3!H
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MPI:<W3$I,()*5;=SH]N+!_4=-U%&HL6;S+-XDVSMH\Q\P5I8>"'%+#C#JT%
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M]PS14%D3I'KWB>UM!DW2JD<#V8'92B.A6PI$R\M$)XQ0YUO6=-3K6FNKN/\
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M%$@E'C&7.CW*]/Z9=<L57B])MDM7FGAU+3JT/6;3+I:7ZK:%.V[C25!'J +
M(2K@WKI]M4IS5NEN[*3)$V3U"V;N59*!S!15#4JKTRRJZS9-1<VM<PIXFR!@
MEJI]5G%HEN574UL=3E*]<@]ZF+XX&Y&9&E/,#A7&J7%G=:2\_K=MK*;._;O5
M6UFTZEEKT5MGN]1VUM4+<=3W) 2E7;VCN4)%<RWTRWNK75&6-'N-(5=V3EFF
MXNW&E/.^JA8*>QNYN5(;:5VJE2D]T_9&":NEL^JYNP;)8H)MWJ;LIGZ1'*F\
MG,=/ZM5D=Y_I5_)$0WR')T3*W3/3D)?FA^F^=5,X.30TPD2]%*\OE,!#PI.7
MNT134,"GBZQ::2MV_P!1MM:MWTW+SEQ:62+>[^;*KA[O4U<>HTAE@,I6LESU
MG"X4 )1*I'*TFZU1#5C87.D/LKMVD,75VM^U^5"6&NQ+K'INK>>+RD(AOTD=
M@62I?V3-JMM<A5]I@V[\-MTT;?)\+0U.J]NZK/3BM2-YI\HI?-;#5\(%DD2Z
M0 3@$XHIR7*%YZ56V+)6*;FV%$8>M>"?3A*#EZG<:?=*T+4F=08[K6STFRN;
M(MW NF7+,D/.G]Y]%3*0D$*#I4HJ 2D[UQ=.8OK4:UI[EB_%U>:K>V]X%L&V
M<1=_:9;'[\'@Z2H@I+02()4L;51<V;8=P<O^'1L)>Z=TY4+]W^R!%0*?9?ID
M<ZLR%>_K&67T,C5>I8L?!<0:4Z9^DQZ?(5T9#E&0I5LJ(H@TZ,2H8]YK5-/<
MZCUY%Q<)&D:XJ_MW+KM<4EM*W%/VETE 2%DMOH;[04X"R5")K9<TV_;Z?T15
MO;SJVC)LGV[<J0"M2&PS=6Q65=@"V5K"H402D!))BOASKX>55YG\,JF]-#Y=
M;)MW-MM993WF54DM[F,IA1U5K*\3ROGVJ%/GN;T:V%$A4JV69W:1VA\*7EMI
M2IA8C/>25+"+H3N,=0VC74]S=!U3.F+LW=&M'T-%9M+)#";>UN$,J'<H!;2'
MUH*>XAQP=I/V*T/:#=.].V]N6TN:BF[:U:Y96X$"YNUO*?N6%O)( )2XII+@
M4 %(0>X =U7NVJTBI/%6Z3IR8O#3K!MWF.2629U)-7ZOSI)"]/*+L^,ILON+
M#)C:SUJJ0\OQLQMS@X-JEW)8FA 4VA$:I/@--)3:X.JW=W\D^RYU+9Z@V^MH
M?)V;+P+R$+#B7'UKLK9#?IJ2E007%J[A $"3S-,M+47K+S?3MW8.,H<(N[IY
MA0:4M!0I#*47EPM?J!2DE0;0GMDD@P*N1XHU*ZL55H'3E/1NG;M5*:J?[G*
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H4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4K__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>img30600998_16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img30600998_16.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /8";\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJI_*K/AWQ=H?BR.XDT2^^U+;E5E/E.FTG./O*,]#TKPK]H#_ )'RQ_[!D?\
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M)_ /2=1M)=:N+T74$<6R!;>7<H#GYF)0]P-O.,\U[90 4444 %%%% !1110
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MJ[21 S;EEP,DHW?UP><>N#0!Z!1110 4444 %%%% !1110 445A>,M9G\/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4&D:O8Z[I<&I:;<+/:SKN1UX_ CL1W!J'Q!KMGX:T.YU>_$IMK< N(DW,<D
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M!<&2:!9)#[ER,Y_&@#AO"OQXL-2NX[/7[(:>SD*+J-]T6?\ :!Y4>^3[XKV
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MQA\!D@#722?2SG_^(K-^.&N?V7X":RC?$VHS+#QUV#YF/Z ?\"KQCX5>'?\
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MOBCP=J.E8!EDCW0$]I%^9?U&/H37R)8WEQI.JV]Y#F.YM)EE3<,893D9_$4
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M/%7@^^T."=+=[CR]LCJ2J[9%;H/]W%?,'CGP;<>!];ATRXNXKIY;=;@/&I4
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M?YB@#[>KB[KXL^"+.[FM;C6]DT,C1R+]EF.U@<$9"8ZBNTKXU\: #QWXA &
M-3N>!_UU:@#ZPUKQ;H7A[38K_5-1B@@F7=$#DO(,9^51R>H[<9YKBQ\>/!YN
M?**:D$_Y[&W7;_Z%N_2O*O#O@_Q+\5;Y]1N+M8;2W5+<W,H)50J@!$7O@8)Z
M=<YR:E\<?!_4_"&E-JD%]'J-C&0)F6(QO'DX!*Y.1GC.>_2@#Z-T77M+\1:>
MM]I-[%=6Y."R'E3Z,#RI]B*T:^2?AGXIG\+^,[*59"+.ZD6WND[%&.,X]5)S
M^?K7UM0!#=7=O8VLEU=SQP6\2[GEE8*JCU)/2O/=1^./@ZPF,<4E[?8."UK
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MPR!Q^8J>OG[X;_#OQ/X?^(]J^J6D]M:PQ22M+%)F.7 VA2RGU8'!]#Q7T#0
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M*S-?UVQ\-Z)<ZKJ$FRW@7.!U<]E'J2>*^7/&/Q)U[Q?<R":Y>UT\GY+*%R$
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M)!*I#$VUY1ZNPY.?[O3Z]:Q]#^''BSQ';+=Z?I$K6S\K-,ZQ*P]1N(W#W&:
M/K"RU?3=2_X\=0M+KO\ N)E?^1JY7S%H'PK\6:?XRT<:CI<T-K]K1I+B*175
M4!R<E2=N0".?6OIV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP,)^?)^C"N7_ &B_^9:_[>O_ &E0!E?L^?\ (V:I_P!>/_M1:^B*^=_V?/\
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MC_\ 1LM '2_L[_\ (/U__KK#_)Z]KKQ3]G?_ )!^O_\ 76'^3U[70!\>_$
M?$+Q!@8_TZ7_ -"-?1'P=_Y)5HO_ &W_ /1\E?._Q!_Y*'X@_P"OZ7_T(U]$
M?!W_ ))5HO\ VW_]'R4 <-^T7_S+7_;U_P"TJH_L\_\ (<UK_KV3_P!"-:7[
M14+M;^'9P/D1[A"?<B,C_P!!-<[\!]9L]-\67EI=S)";RW"PL[ !G5@=OU()
M_*@#Z1KPS]HO_F6O^WK_ -I5[B)$+E ZEP,E<\BO#OVB_P#F6O\ MZ_]I4 9
M7[/G_(V:I_UX_P#M1:9^T%-(?&>FPG_5IIZNOU,C@_\ H(I_[/G_ "-FJ?\
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M@?\ CGY5[3XF\1V/A;0KC4[^9$6-#Y:$\ROCA5'<D_XT ?&-?;.C?\@/3_\
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MEFGBMXFEGE2*-1EG=@H'U)HM[B&[MX[BWE2:&10R21L&5@>A!'!% B2BBB@
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M\,];30/B!I5W+*([=Y#!,QZ;7&WGV!(/X4 =-\=];_M#QK#IB,#%IL 4\_\
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M'X&O$_C'K7]L?$6^16+0V*K:)SW7EO\ QXL/PK7^"?BE-!U#6K:Y?%L]D]T
M3_'$">/JI;\A7 Z;97?BKQ3!:AMUUJ-U\[^A9LLWX9)_"@#Z&^"/A_\ LCP,
MM_*F+C4Y#.?7RQ\J#^;?\"KLO%'ARS\5>'[K2+T?NYERD@',;C[K#W!_,9'>
MM*TM8;&S@M+= D$$:Q1J/X548 _(5#JFIVFC:7<ZE?2B*VMHS)(Q]!V'J3T
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M;I)$X89]#Z'V/-7*^0? 7BR\\)>)[6ZAF86DLBI=P[L+)&3@DCU&20>U?7U
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M* "BBB@ HHHH **** /C;QK_ ,CYXB_["=S_ .C6KZ7^%/\ R3'0_P#KD_\
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M<@WP"\)-+O%WJZKG.P3QX^GW,_K0!STW[0DDUY;Q6FAQV\#2J)99YRY"9&[
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X]\6_AQK'BSQ'IM_HM
MO&Y: PW+O*J!-K94G/)SN(X!Z5K> /A#8>$YDU+4I4O]57E&"_NH#ZJ#U/\
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MT_>(W)1XW^]&XZJ?T_ B@#:HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HJ.>>&VA::>5(HD&6>1@JJ/<FN5O?BCX*L'*3>(;5
MB#@^0K3#\T!H ZZBN-M?BMX'NVVQ>((%.<?O8Y(Q^;**ZFQU"RU.W%Q87D%U
M">DD$@=?S% %FBBB@ HHHH **** "BBB@ HHHH **Q?$'BW0?"R1MK6I16GF
MYV*0S,V.I"J"<>^*N:3K&G:[8)?:7>175LQ($D9SR.H/<'V- %ZBBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BL7Q!XMT'PLD;:UJ45KYN
M=BD,S-CN%4$X]\5=TG6-/UVP2^TN[BNK9R0)(SD9'4'N#[&@"[1110 4444
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M1G!//O0![]117@/QP\0ZWI/C6S@TW6-0LH6TY':.VN7C4MYD@R0I S@#GVH
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M^HXKZKT75K77M%M-4LV+6]U&)$SU'J#[@Y'X4 7Z*** "BBB@ HHHH ****
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MJ,?T!H ^5K2WFU/4X+9&+3W4RQAF.<LQQD_B:^R]!T2R\.Z+;:781"."! O
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M/!GBQ[2VW&PN$\^V+')522"I/?!!_#%?6E>$?M%>7]H\.XQYNRXW>NW,>/\
MV:@#7^ GB674-$O-"N9&=K!A) 6Y_=MG*_@1_P"/5:_: _Y$.Q_["<?_ **E
MKB?V?1)_PFNHD9\H:<P;Z^9'C^M=M^T!_P B'8_]A./_ -%2T >$^$?#TOBK
MQ38:-$YC%P_[R0#.Q "S'ZX!Q[XKZAL_AIX.LM.%DN@64R;<-+/&'E;WWGD'
MZ8KP7X*_\E.L/^N4W_HLU]2T ?)7Q-\)0^#O&,MC:;OL4T:W%N&.2JDD%<]\
M%2/IBO5/V?=4DN/#NJ::[[EM+A9$']T2 \?3*$_B:YC]H/\ Y&S2_P#KQ_\
M:C5J_LZ?\S+_ -NO_M6@#W.BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,3QC=M8^"M<N4^
M_'83%?\ >V''ZXKXTK[.\663:EX/UFR0$O-93(@']XH<?KBOC&@#[>T^T2PT
MVULX\!+>%(EQZ* !_*K%9V@:DFL>'].U*-MRW-NDN?<J,_KFM&@ HHK)\4W+
MV7A'6KN/[\%A/(O..5C8C^5 'S+\3O&L_B_Q/,(YB=+M':.TC!^4@<%_JW7Z
M8%=9\./@Y!K^D1:UX@EGCMI_FMK:%@I=?[S'' /8#ZYKQVOM^RM8[&PM[.$
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M3C_]%2UQ7[/MPZ^,=2MA]R33S(?JLB ?^A&NU_: _P"1#L?^PG'_ .BI: /
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M/_HL5Z?^S_\ \B'??]A.3_T5%6QXH^$>@>+-=FU>_N]2CN)5566"2,)A0 ,
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M7V<K"R2TU"/^%HI@A/U#XP?Q- 'LWCGXB:3X3T6=X[N"?4W4K;VT;AFW'HS
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MUVWBKX)_:= T?3?#<EI%):-*]Q/>.RM,7"<_*I_N].P_&@"O^SO_ ,@_7_\
MKK#_ ">JWQ_\,S-)8^)8$+1*@M;G ^[R2C'ZY(_+UKKOA3X"U?P,FK)JES93
M+=F(Q"V=FVE=^[.Y5_O+Z]*[^\L[>_LYK2[A2:WF4I)&XRK ]C0!\N?"_P ?
MCP1K,RWB/)IEX%6<)RT;#HX'?&2".X/L*]VF^+/@B*Q^U_V[$ZXR(TC<R'VV
MXR/QQ7!^(/V?EEN7F\/:JD,39(MKP$A/8.,G'U&?<UGZ5^SWJ;W"G5]9M(H0
M>1:*TC,/0%@H'UYH X#Q]XN?QKXIEU3RC# J"&WC;[RQ@DC/N22?QQ7IG[.G
M_,R_]NO_ +5KEOC'I.E>'-3T;0=)A6.*ULS(_.69G<_,Q[L=O\NV*[']G>V9
M-/U^[YVR2PQCTRH<G_T,4#,G]H:&<:[HTS ^0ULZ(<?Q!LM^A6J_P%UW2]*U
MC5;._N(K>:\CC\B25@H.PMN7)[G<#[XKV;QKX.L?&NA-IUVQBD5O,@N%&3$^
M,9QW'J._ZUX#J'P2\:6=RT=M9V]]&#\LL-RB@CZ.5(H$>Z^,?'VC>%-&GG>]
M@EO2A%O;1N&=WQQD#HO3)/\ ]:OD6O9O"WP%U":[2?Q+<Q6]JIR;:W??))[%
MNBCZ9/TZU%JGP#U^;5KR73[S28[)YW:W2260,L98[0<1GD#'<T >[Z-_R ]/
M_P"O:/\ ]!%>!_M!VSKXOTRZ/W)+ 1CZK(Y/_H8KWW2+:>RT6PM;ED:XAMXX
MY60DJ6"@$@D#(R/05SWQ!\"VWCK1$M7E^SWENQ>VGQD*3U4C^Z<#\@>V* /*
M?@=XPTG0_P"T]+U:\ALQ<,DL,LS;4) (8%CP.V,^]>[:9K.F:S'))IFH6U['
M$VQWMY Z@XSC(XKYINO@IXXM[CRHM.@N4SCS8KJ,+]?F*G]*]?\ A%X.U?P?
MHU_!J\<4<MQ.LB+'('P N.<<4 >+_&+_ )*KK7_;#_T1'7KWP'_Y)X__ %_2
M_P#H*5A>/?@_X@\4^-=0UFQO-,CMKGR]BSRR!QMC53D!".JGO7=_#3PG?^#?
M"K:7J,MM+.;EY=UNS,N"% ^\ <\>E 'FGQ]\,S)J-GXD@C9H)(Q;7! R$<$E
M2?3(./\ @/O7/_![QU:^$]:N++5)?+TZ_"YE.2(I%S@GV.2#^'85]*7]A:ZI
M836-[ D]M.I22-QPPKPKQ-\ KV.Y>?PW>Q36Y.1;73;73V#8PWXXH ]JG\1:
M+;6!OIM6L5M0N[SO/7:1['//X5\N_$OQBOC/Q6]Y;[UL+=/(M@W!*@DEB.V2
M<_3%7H_@OXZ>;RVTJ)%_YZ-=Q;?T8G]*[WPC\!H;2XCO/$]W'<E"&6SM\^63
M_ML0"1[ #ZF@"]\!_#$NF>'[K7+E"LFHLJP@CD1+GG_@1)_!0>]3?M ?\B'8
M_P#83C_]%2UZI'&D4:QQHJ(@"JJC  '0 5Q?Q0\'ZAXV\,VVFZ;-:Q317BSL
MURS*NT(ZX&U2<Y8=J /$/@K_ ,E.L/\ KE-_Z+-?4M>,?#SX1Z_X2\8VNKW]
MWILEO$DBLL$DA?+*0, H!W]:]GH ^=_V@_\ D;-+_P"O'_VHU:O[.G_,R_\
M;K_[5K>^*7PSUGQOKEE>Z;<V$4<%MY3"YD=23N)XVH>.:N_"CX?ZMX%_M?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5A:YXS\.
M^&]ZZKJ]K!,B[C!OW2X[?(/FY^E;M>(_%3X;>(O%'C=+_1[-);9[6-9)GF1
MK@L",$YZ;3P* /*?'/B<^+_%MYJZQM%"Y"01MU6-1@9]SU/N:][^"&B2:3X!
M6ZG0I+J$S7 R.?+P%7\\$_\  JYGPE\!?L]W%>>)KR*9$(86=MDJQ]'<@<>P
M'XU[:B)&BI&JJB@!548  ["@!U%%% !1110 5%<W$=I:37,S;8H4:1V]% R3
M4M9GB+26U[P[?Z2MTUJ;N%H3,J[BH/!XR,\<?C0!SVB?%;P?K<*L-6BLI2/F
MAO2(2I],GY3^!-:]YXT\,6$!FN=?TU4']VY5B?H 23^%>"ZE\"?%EI(WV-K*
M_C_A,<VQOQ#8 _,UFP_!GQU+(%?1TA']][N(@?DQ/Z4 ,^*/CI/&^OPM:(Z:
M=9H4MPXPS$D;G([9P!CT KTKX ^'Y;/1=0UR="OVUUB@R.J)G+#V)./^ UF^
M%O@$ZW"7/B:^C:)>?LEH2=WLSD#'T _&O;[:VAL[:*VMHDA@B4)'&@PJJ.@
MH EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHIDTT<$+RRNJ1H-S,QP * 'T5E_\)'HO_04M
M?^_HH_X2/1?^@I:_]_12YEW-/95/Y7]QJ45E_P#"1Z+_ -!2U_[^BC_A(]%_
MZ"EK_P!_11S+N'LJG\K^XU****9F%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !114<\\5M"\TTBQQH,L['  H#<DHK+_ .$CT7_H*6O_ ']%'_"1Z+_T
M%+7_ +^BES+N:>RJ?RO[C4HK+_X2/1?^@I:_]_12CQ%HS$ :G:DG@#S!1S+N
M'LJG\K^XTZ***9F%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 445F-XAT='*-J=J&4X(,@X-)M+<J,92V5S
M3HK+_P"$CT7_ *"EK_W]%'_"1Z+_ -!2U_[^BCF7<KV53^5_<:E%9?\ PD>B
M_P#04M?^_HJ_;W$-U"LT$BR1/]UU.0:$T]B90E'5HEHHHIDA1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !67XC_P"1;U'_
M *]W_E6I67XC_P"1;U'_ *]W_E2ELS2E_$CZH\5HHHK@/JPHHHH ]^HHHKT#
MY **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "L?Q3_P BOJ'_ %R/\ZV*
MQ_%/_(KZA_UR/\Z4MF:4?XD?5'C-%%%<!]6%20?\?$7^^/YU'4D'_'Q%_OC^
M= GL>]4445Z!\B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5X3?_\ (0N?^NK?S->[5X3?_P#(0N?^NK?S
M-<]?H>ME6\OD5Z***YSV0KV+P?\ \BI8?[C?^A&O':]B\'_\BI8?[C?^A&MJ
M'Q'FYI_"7K^C-RBBBNH\(**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *R_$?\ R+>H_P#7N_\ *M2LOQ'_ ,BWJ/\ U[O_
M "I2V9I2_B1]4>*T445P'U84444 >_4445Z!\@%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !6/XI_P"17U#_ *Y'^=;%8_BG_D5]0_ZY'^=*6S-*/\2/
MJCQFBBBN ^K"I(/^/B+_ 'Q_.HZD@_X^(O\ ?'\Z!/8]ZHHHKT#Y$**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ KPF__P"0A<_]=6_F:]VKPF__ .0A<_\ 75OYFN>OT/6RK>7R*]%%%<Y[
M(5[%X/\ ^14L/]QO_0C7CM>Q>#_^14L/]QO_ $(UM0^(\W-/X2]?T9N4445U
M'A!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !67XC_ .1;U'_KW?\ E6I67XC_ .1;U'_KW?\ E2ELS2E_$CZH\5HHHK@/
MJPHHHH ]^HHHKT#Y **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L?Q3_
M ,BOJ'_7(_SK8K'\4_\ (KZA_P!<C_.E+9FE'^)'U1XS1117 ?5A4D'_ !\1
M?[X_G4=20?\ 'Q%_OC^= GL>]4445Z!\B%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X3?_P#(0N?^NK?S
M->[5X3?_ /(0N?\ KJW\S7/7Z'K95O+Y%>BBBN<]D*]B\'_\BI8?[C?^A&O'
M:]B\'_\ (J6'^XW_ *$:VH?$>;FG\)>OZ,W****ZCP@HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K+\1_\BWJ/_7N_P#*
MM2LOQ'_R+>H_]>[_ ,J4MF:4OXD?5'BM%%%<!]6%%%% 'OU%%%>@?(!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5C^*?^17U#_KD?YUL5C^*?\ D5]0
M_P"N1_G2ELS2C_$CZH\9HHHK@/JPJ2#_ (^(O]\?SJ.I(/\ CXB_WQ_.@3V/
M>J***] ^1"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *\)O_P#D(7/_ %U;^9KW:O";_P#Y"%S_ -=6_F:Y
MZ_0];*MY?(KT445SGLA7L7@__D5+#_<;_P!"->.U[%X/_P"14L/]QO\ T(UM
M0^(\W-/X2]?T9N4445U'A!1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !67XC_Y%O4?^O=_Y5J5E^(_^1;U'_KW?^5*6S-*
M7\2/JCQ6BBBN ^K"BBB@#WZBBBO0/D HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *Q_%/_(KZA_UR/\ .MBL?Q3_ ,BOJ'_7(_SI2V9I1_B1]4>,T445
MP'U85)!_Q\1?[X_G4=20?\?$7^^/YT">Q[U1117H'R(4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7A-_\
M\A"Y_P"NK?S->[5X3?\ _(0N?^NK?S-<]?H>ME6\OD5Z***YSV0KV+P?_P B
MI8?[C?\ H1KQVO8O!_\ R*EA_N-_Z$:VH?$>;FG\)>OZ,W****ZCP@HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K+\1_\
MBWJ/_7N_\JU*R_$?_(MZC_U[O_*E+9FE+^)'U1XK1117 ?5A1110![]1117H
M'R 4444 %<KXE\7R:!J,=JMFLP>$2;C)MQDD8Z>U=57F'Q&_Y&&W_P"O1?\
MT-ZSJR:C='7@J<:E7EFKHN?\++F_Z!D?_?X_X4?\++F_Z!D?_?X_X5PE%<_M
M9]SV?J.'_E_,[O\ X67-_P! R/\ [_'_  K?\+^*'\0R7*/:K!Y(4\/NSG/M
M[5Y+7=_#3_CXU'_<3^;5=.I)R2;.?%X2C3HRE&.IZ'11172>&%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5C^*?^17U#_KD?YUL5C^*?\ D5]0_P"N1_G2ELS2C_$CZH\9HHHK@/JPJ2#_
M (^(O]\?SJ.I(/\ CXB_WQ_.@3V/>J***] ^1"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\)O_P#D(7/_
M %U;^9KW:O";_P#Y"%S_ -=6_F:YZ_0];*MY?(KT445SGLA7L7@__D5+#_<;
M_P!"->.U[%X/_P"14L/]QO\ T(UM0^(\W-/X2]?T9N4445U'A!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !67XC_Y%O4?
M^O=_Y5J5E^(_^1;U'_KW?^5*6S-*7\2/JCQ6BBBN ^K"BBB@#WZBBBO0/D H
MHHH *\P^(W_(PV__ %Z+_P"AO7I]>8?$;_D8;?\ Z]%_]#>LJWPG?EW\?Y'(
M4445R'T 5W?PT_X^-1_W$_FU<)7=_#3_ (^-1_W$_FU:4OC1R8[_ '>7]=3T
M.BBBNP^;"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *Q_%/_(KZA_UR/\ZV*Q_%/_(KZA_UR/\ .E+9FE'^
M)'U1XS1117 ?5A4D'_'Q%_OC^=1U)!_Q\1?[X_G0)['O5%%%>@?(A1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *\)O_\ D(7/_75OYFO=J\)O_P#D(7/_ %U;^9KG
MK]#ULJWE\BO1117.>R%>Q>#_ /D5+#_<;_T(UX[7L7@__D5+#_<;_P!"-;4/
MB/-S3^$O7]&;E%%%=1X04444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **9++'#$TDKJD:C+,QP /4FJ7]NZ1_T%;'_P(3_&E=%*,GLC0HK/_MW1
M_P#H*V/_ ($)_C1_;NC_ /05L?\ P(3_ !HNA^SGV9H45G_V[H__ $%;'_P(
M3_&KX((R#D'N*+IB<91W0M%%%,D**** "BBB@ HHHH **** "BBB@ K'\4_\
MBOJ'_7(_SK8K'\4_\BOJ'_7(_P Z4MF:4?XD?5'C-%%%<!]6%20?\?$7^^/Y
MU'4D'_'Q%_OC^= GL>]4445Z!\B%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5X3?_P#(0N?^NK?S->[5X3?_ /(0N?\ KJW\S7/7Z'K95O+Y%>BBBN<]
MD*]B\'_\BI8?[C?^A&O':]B\'_\ (J6'^XW_ *$:VH?$>;FG\)>OZ,W****Z
MCP@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#XC?\C#;_P#7HO\ Z&]>GUYA\1O^1AM_^O1?_0WK*M\)WY=_'^1R%%%%<A]
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5X3?\ _(0N?^NK?S->[5X3?_\ (0N?
M^NK?S-<]?H>ME6\OD5Z***YSV0KV+P?_ ,BI8?[C?^A&O':]B\'_ /(J6'^X
MW_H1K:A\1YN:?PEZ_HS<HHHKJ/""BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH \D\=?\C7<_[B?^@BN<KH_'7_(UW/\ N)_Z"*YRN&?Q,^IPW\&'H@HH
MHJ38]#^&G_'OJ/\ OQ_R:N[KA/AI_P >^H_[\?\ )J[NNRE\"/F\=_O$OZZ!
M1116AR!67XC_ .1;U'_KW?\ E6I67XC_ .1;U'_KW?\ E2ELS2E_$CZH\5HH
MHK@/JPHHHH ]^HHHKT#Y **** "O,/B-_P C#;_]>B_^AO7I]>8?$;_D8;?_
M *]%_P#0WK*M\)WY=_'^1R%%%%<A] %=W\-/^/C4?]Q/YM7"5W?PT_X^-1_W
M$_FU:4OC1R8[_=Y?UU/0Z***[#YL**** "BJNI2/%I=W)&Q5TA=E([$*<5Y'
M_P )3KG_ $$Y_P Q6<ZBCN=>&PDJZ;B]CV:BO&?^$IUS_H)S_F*/^$IUS_H)
MS_F*CV\3H_LNIW1[-17C/_"4ZY_T$Y_S%>N:;(\NEVDDC%G>%&8GN2HS5PJ*
M6QS8C"2H).3W+5%%%:'*%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ KPF__ .0A<_\ 75OYFO=J\)O_ /D(7/\ UU;^9KGK
M]#ULJWE\BO1117.>R%>Q>#_^14L/]QO_ $(UX[7L7@__ )%2P_W&_P#0C6U#
MXCS<T_A+U_1FY11174>$%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% &7XC_Y%O4?^O=_Y5XK7M7B/_D6]1_Z]W_E7BM<U
M?='MY7_#EZA1116!Z@5[U!_Q[Q?[@_E7@M>]0?\ 'O%_N#^5=%#J>1FNT/G^
MA)11170>.%%%% !1110 4444 %%%% !1110 5C^*?^17U#_KD?YUL5C^*?\
MD5]0_P"N1_G2ELS2C_$CZH\9HHHK@/JPJ2#_ (^(O]\?SJ.I(/\ CXB_WQ_.
M@3V/>J***] ^1"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *\)O_P#D(7/_ %U;^9KW:O";_P#Y"%S_ -=6
M_F:YZ_0];*MY?(KT445SGLA7L7@__D5+#_<;_P!"->.U[%X/_P"14L/]QO\
MT(UM0^(\W-/X2]?T9N4445U'A!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M ->\?_H(KPVO<M)_Y UC_P!>\?\ Z"*WH;L\K-?AB7****Z3Q0HHHH ****
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M "BBB@ K'\4_\BOJ'_7(_P ZV*Q_%/\ R*^H?]<C_.E+9FE'^)'U1XS1117
M?5A4D'_'Q%_OC^=1U)!_Q\1?[X_G0)['O5%%%>@?(A1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M ,@:Q_Z]X_\ T$5O0W9Y6:_#$N4445TGBA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% &7XC_Y%O4?^O=_Y5XK7M7B/_D6]1_Z]
MW_E7BM<U?='MY7_#EZA1116!Z@5[U!_Q[Q?[@_E7@M>]0?\ 'O%_N#^5=%#J
M>1FNT/G^A)11170>.%%%% !1110 4444 %%%% !1110 5C^*?^17U#_KD?YU
ML5C^*?\ D5]0_P"N1_G2ELS2C_$CZH\9HHHK@/JPJ2#_ (^(O]\?SJ.I(/\
MCXB_WQ_.@3V/>J***] ^1"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *\)O_P#D(7/_ %U;^9KW:O";_P#Y
M"%S_ -=6_F:YZ_0];*MY?(KT445SGLA7L7@__D5+#_<;_P!"->.U[%X/_P"1
M4L/]QO\ T(UM0^(\W-/X2]?T9N4445U'A!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &!XV_Y%"^_[9_\
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M_75?YBO=JVI3<KW/.QV'A1<>3J%%%%:G %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7A-__ ,A"
MY_ZZM_,U[M7A-_\ \A"Y_P"NK?S-<]?H>ME6\OD5Z***YSV0KV+P?_R*EA_N
M-_Z$:\=KV+P?_P BI8?[C?\ H1K:A\1YN:?PEZ_HS<HHHKJ/""BBB@ HHHH
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MK2E\:.3'?[O+^NIZ'11178?-A1110!3U;_D#7W_7O)_Z":\-KW+5O^0-??\
M7O)_Z":\-KFK[H]K*OAD%%%%8'JA7N6D_P#(&L?^O>/_ -!%>&U[EI/_ "!K
M'_KWC_\ 016]#=GE9K\,2Y11172>*%%%% 'G'Q)_Y"-C_P!<F_G7$5V_Q)_Y
M"-C_ -<F_G7$5QU?C9]+@O\ =XA11169U'7_  Y_Y&&X_P"O1O\ T-*]/KS#
MX<_\C#<?]>C?^AI7I]=='X3Y_,?X_P @HHHK4X HHHH **** "BBB@ HHHH
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M )"%M_UU7^8KW:NBAU/&S7>/S"BBBN@\D**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O";__ )"%
MS_UU;^9KW:O";_\ Y"%S_P!=6_F:YZ_0];*MY?(KT445SGLA7L7@_P#Y%2P_
MW&_]"->.U[%X/_Y%2P_W&_\ 0C6U#XCS<T_A+U_1FY11174>$%%%% !1110
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MKP6O>H/^/>+_ '!_*NBAU/(S7:'S_0DHHHKH/'"BBB@ HHHH **** "BBB@
MHHHH *Q_%/\ R*^H?]<C_.MBL?Q3_P BOJ'_ %R/\Z4MF:4?XD?5'C-%%%<!
M]6%20?\ 'Q%_OC^=1U)!_P ?$7^^/YT">Q[U1117H'R(4444 %%%% !1110
M4444 %%%% !1110!@>-O^10OO^V?_HQ:\@KU_P ;?\BA??\ ;/\ ]&+7D%<M
M?XCW<K_@OU_1!1116)Z18L/^0A;?]=5_F*]VKPFP_P"0A;?]=5_F*]VKHH=3
MQLUWC\PHHHKH/)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KPF__P"0A<_]=6_F:]VKPF__ .0A
M<_\ 75OYFN>OT/6RK>7R*]%%%<Y[(5[%X/\ ^14L/]QO_0C7CM>Q>#_^14L/
M]QO_ $(UM0^(\W-/X2]?T9N4445U'A!1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^8_Q_D%%%%:G %1S_P#'O+_N'^525'/_ ,>\O^X?Y4#6YX+1117GGUP4444
M>U>'/^1;T[_KW3^5:E9?AS_D6]._Z]T_E6I7?'9'RE7^)+U84444S,**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BO+/B%_R,B_]>Z_S-<I6$JUG:QZE++?:04^;?R_X)[]17@-%+V_D:?V5
M_?\ P_X)[]17GGPT_P"/C4?]Q/YM7H=;0ES*YYN(H^QJ.%[V"BBBJ,0HHHH
M**** "BBB@ HHHH **** "BBB@#+\1_\BWJ/_7N_\J\5KVKQ'_R+>H_]>[_R
MKQ6N:ONCV\K_ (<O4****P/4"O>H/^/>+_<'\J\%KWJ#_CWB_P!P?RKHH=3R
M,UVA\_T)****Z#QPHHHH **** "BBB@ HHHH **** "L?Q3_ ,BOJ'_7(_SK
M8K'\4_\ (KZA_P!<C_.E+9FE'^)'U1XS1117 ?5A4D'_ !\1?[X_G4=20?\
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MW/,.EHKFO^$\\/\ _/U)_P!^6_PH_P"$\\/_ //U)_WY;_"@#B?'7_(UW/\
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M3SP__P _4G_?EO\ "N@\DZ6BN:_X3SP__P _4G_?EO\ "C_A//#_ /S]2?\
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M2T5S7_">>'_^?J3_ +\M_A1_PGGA_P#Y^I/^_+?X4 =+17-?\)YX?_Y^I/\
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MYX?_ .?J3_ORW^% '2T5S7_">>'_ /GZD_[\M_A1_P )YX?_ .?J3_ORW^%
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MWY;_  H_X3SP_P#\_4G_ 'Y;_"@#I:*YK_A//#__ #]2?]^6_P */^$\\/\
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M7_&C_A#?$'_0-D_[[7_&O9J* /&?^$.\0?\ 0-D_[[7_ !H_X0WQ!_T#9/\
MOM?\:]FHH \9_P"$-\0?] V3_OM?\:/^$-\0?] V3_OM?\:]FHH \9_X0WQ!
M_P! V3_OM?\ &C_A#?$'_0-D_P"^U_QKV:B@#QG_ (0WQ!_T#9/^^U_QH_X0
MWQ!_T#9/^^U_QKV:B@#QG_A#?$'_ $#9/^^U_P :/^$-\0?] V3_ +[7_&O9
MJ* /&?\ A#?$'_0-D_[[7_&C_A#?$'_0-D_[[7_&O9J* /&?^$-\0?\ 0-D_
M[[7_ !H_X0WQ!_T#9/\ OM?\:]FHH \9_P"$-\0?] V3_OM?\:/^$-\0?] V
M3_OM?\:]FHH \9_X0WQ!_P! V3_OM?\ &C_A#?$'_0-D_P"^U_QKV:B@#QG_
M (0WQ!_T#9/^^U_QH_X0WQ!_T#9/^^U_QKV:B@#QG_A#?$'_ $#9/^^U_P :
M/^$-\0?] V3_ +[7_&O9J* /&?\ A#?$'_0-D_[[7_&C_A#?$'_0-D_[[7_&
MO9J* /&?^$-\0?\ 0-D_[[7_ !H_X0WQ!_T#9/\ OM?\:]FHH \9_P"$-\0?
M] V3_OM?\:/^$-\0?] V3_OM?\:]FHH \9_X0WQ!_P! V3_OM?\ &C_A#?$'
M_0-D_P"^U_QKV:B@#QG_ (0[Q!_T#9/^^U_QH_X0WQ!_T#9/^^U_QKV:B@#Q
MG_A#?$'_ $#9/^^U_P :/^$-\0?] V3_ +[7_&O9J* /&?\ A#?$'_0-D_[[
M7_&C_A#?$'_0-D_[[7_&O9J* /&?^$-\0?\ 0-D_[[7_ !H_X0WQ!_T#9/\
MOM?\:]FHH \9_P"$-\0?] V3_OM?\:/^$-\0?] V3_OM?\:]FHH \9_X0WQ!
M_P! V3_OM?\ &C_A#?$'_0-D_P"^U_QKV:B@#QG_ (0WQ!_T#9/^^U_QH_X0
MWQ!_T#9/^^U_QKV:B@#QG_A#?$'_ $#9/^^U_P :/^$-\0?] V3_ +[7_&O9
MJ* /&?\ A#?$'_0-D_[[7_&C_A#?$'_0-D_[[7_&O9J* /&?^$-\0?\ 0-D_
M[[7_ !H_X0WQ!_T#9/\ OM?\:]FHH \9_P"$-\0?] V3_OM?\:/^$-\0?] V
M3_OM?\:]FHH \9_X0WQ!_P! V3_OM?\ &C_A#O$'_0-D_P"^U_QKV:B@#QG_
M (0WQ!_T#9/^^U_QH_X0WQ!_T#9/^^U_QKV:B@#QG_A#?$'_ $#9/^^U_P :
M/^$-\0?] V3_ +[7_&O9J* /&?\ A#?$'_0-D_[[7_&C_A#?$'_0-D_[[7_&
MO9J* /&?^$-\0?\ 0-D_[[7_ !H_X0WQ!_T#9/\ OM?\:]FHH \9_P"$-\0?
M] V3_OM?\:/^$-\0?] V3_OM?\:]FHH \9_X0WQ!_P! V3_OM?\ &C_A#?$'
M_0-D_P"^U_QKV:B@#QG_ (0WQ!_T#9/^^U_QH_X0WQ!_T#9/^^U_QKV:B@#Q
MG_A#?$'_ $#9/^^U_P :/^$-\0?] V3_ +[7_&O9J* /&?\ A#?$'_0-D_[[
M7_&C_A#?$'_0-D_[[7_&O9J* /&?^$.\0?\ 0-D_[[7_ !H_X0WQ!_T#9/\
MOM?\:]FHH \9_P"$-\0?] V3_OM?\:/^$-\0?] V3_OM?\:]FHH \9_X0[Q!
M_P! V3_OM?\ &M/P[X7UJS\065Q<6#QPQR LQ9>!^=>IT4 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% '">.]!U#5;^UEL+,S!8B
MKLI YSQU-<I_PAOB#_H&R?\ ?:_XU[-10!XS_P (;X@_Z!LG_?:_XT?\(;X@
M_P"@;)_WVO\ C7LU% 'C/_"&^(/^@;)_WVO^-'_"&^(/^@;)_P!]K_C7LU%
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M_P"@;)_WVO\ C7LU% 'C/_"&^(/^@;)_WVO^-'_"&^(/^@;)_P!]K_C7LU%
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M_P"@;)_WVO\ C7LU% 'C/_"&^(/^@;)_WVO^-'_"&^(/^@;)_P!]K_C7LU%
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M_&O9J* /&?\ A#?$'_0-D_[[7_&C_A#?$'_0-D_[[7_&O9J* /&?^$-\0?\
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M_&O9J* /&?\ A#?$'_0-D_[[7_&C_A#?$'_0-D_[[7_&O9J* /&?^$-\0?\
M0-D_[[7_ !H_X0WQ!_T#9/\ OM?\:]FHH \9_P"$-\0?] V3_OM?\:/^$-\0
M?] V3_OM?\:]FHH \9_X0WQ!_P! V3_OM?\ &C_A#?$'_0-D_P"^U_QKV:B@
M#QG_ (0WQ!_T#9/^^U_QH_X0WQ!_T#9/^^U_QKV:B@#QG_A#?$'_ $#9/^^U
M_P :/^$-\0?] V3_ +[7_&O9J* /&?\ A#?$'_0-D_[[7_&C_A#?$'_0-D_[
M[7_&O9J* /&?^$-\0?\ 0-D_[[7_ !H_X0WQ!_T#9/\ OM?\:]FHH \9_P"$
M-\0?] V3_OM?\:/^$-\0?] V3_OM?\:]FHH \9_X0WQ!_P! V3_OM?\ &C_A
M#?$'_0-D_P"^U_QKV:B@#QG_ (0WQ!_T#9/^^U_QH_X0WQ!_T#9/^^U_QKV:
MB@#QG_A#?$'_ $#9/^^U_P :/^$-\0?] V3_ +[7_&O9J* /)='\*:Y;:W83
MS:>ZQ1W,;NQ9> &!)ZUZU110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%>3_ !=^)<WAI!H6C2A=4F3=-..3;H>@'^T?T'/<
M&@#OM9\7>'_#S!-5U>UM9",^4[Y?'KM&3C\*R+;XJ^![N7RX_$$"MG&98Y(Q
M^;*!7RU8:=JOB/5?L]E!<7]].2Q RS-ZLQ/ZDULZ]\.?%?ANQ^VZGI3I:@#=
M+'(L@3_>VDX^IXH ^N+>Y@N[=+BVFCFA<922)PRL/4$<&I:^0_!'CO5/!6II
M+;2-+8NP^T6C'Y9!W(]&]#^>17UCI>I6NL:7;:C92"2VN8Q)&WL?7T/8CUH
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M7_Q5?'$<;ROLC1G8] HR:F^PW?\ SZS_ /?LT ?8/_":^%/^AGT7_P #XO\
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M/^$U\*?]#/HO_@?%_P#%5Y;^T-!--_PCGE1/)C[3G8I./]57B'V&[_Y]9_\
MOV: /L'_ (37PI_T,^B_^!\7_P 51_PFOA3_ *&?1?\ P/B_^*KX^^PW?_/K
M/_W[-->TN8T+R6\J*.K,A % 'V'_ ,)KX4_Z&?1?_ ^+_P"*K9@GBN8(YX)4
MEAE4/')&P974C(((X(([U\.U]G>$K>:T\&:%;7$9CFAT^WCD1NJL(U!!_&@#
M8HHHH **** "LG6/%&A: /\ B:ZM:6C'D))(-Y^B]3^5><_%_P")=SX=9= T
M241ZA(F^XN!U@4]%7T8CG/88]<CPK2M(UGQ7J_V:P@GO[Z4[W);)]V9CT'N3
M0!]-CXN^!#+Y8U]-W3)MI@/SV8KI-)\0:1KL9DTK4K6\"_>$,H8K]1U'XU\Y
M7/P0\9V]FUPL%G,RC/DQ3Y<_3( )_&N$MKG4-#U,2V\L]E?6SD94E'1@>0?Z
M@T ?;5%<)\+?';>-?#[_ &S:-4LB$N=HP'!SM<#MG!R/4'MBN[H **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *R]8\1Z-H$8?5M3M;,-R
MHED 9OHO4_A7)_%+XA#P5I*6]D4;5[P'R0PR(E'!D(_0 ]3]#7S.SZIXBUC+
M&YU#4;I\#J\DC4 ?4L?Q9\#2S&)?$$(8=VAD5?S*XKJK'4++4[9;FPNX+J!N
MDD$@=3^(KY2U+X7>,M)TPZA=:-((%7=)Y<B2,@]2JDG'\N^*R?#'BO5O"6J+
M?:7<%#D>;$3E)5_NL._\QVH ^S**Q_"WB.T\5^'K75[/Y4F7#QDY,;CAE/T/
MYC![UL4 %%%% !1110 52U#6-,TA$?4M1L[)7.%-S.L8;Z;B,UXAXP^.]Z\L
MUCX<LS:!24:ZN5#29''RIR!^.?H*\?U#4;W5;Q[O4+J:ZN'^]),Y9C^)[>U
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M/0*,F@#['_X37PI_T,^B_P#@?%_\51_PFOA3_H9]%_\  ^+_ .*KX^^PW?\
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M10 4444 %>-'X%Q:CXNU/4M3O_+TV:Z>:&VMA\[*QW8+$849)& #QW%>RT4
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M_HU:]S_: _Y$.Q_["<?_ **EKPSP5_R/GAW_ +"=M_Z-6@9]DT444""BBB@
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M:^?OA9\*]0O]6MM<URU>VT^W<2Q0S+M>=QRORGHN>>>O2OHF@ HHHH ****
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MY5OS&W\J]TH$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M8GC&-I? ^OQH,LVFW"@>YC:OC2OM^\MEO+&XM7^Y-&T;<9X(Q_6OB2X@DM;F
M6WF7;+$Y1QZ$'!H ^N/AIS\-]!_Z]1_,UU5>?_!>_6]^&=C&#E[626!_KO+#
M]&%>@4 >%_M%D;O#:Y&1]I)'_?JO._A>A?XEZ$%Z_:,_DI-=?^T#J"S^*]-L
M5.3;6F]O8NQX_)0?QK(^".GF]^)%O/MRMG!+,3CCE=@_5Z!GU!1110(****
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MW:RK+;S()(Y%/#*1D$?A4U>:_ S4);[X=B*5F86=W);H2?X<*^/_ !\UZ50
M4444 %><_%WQS_PBOA_[!928U6_4K&0>8H^C/]>P]\GM7HU?*OQEEDD^*>K*
M[LRQK J G.T>2AP/09)/XT 9?@+P?/XT\30Z>NY+1/WEU,!]R,=OJ>@_/L:^
MN+2T@L;.&TM8EAMX4$<<:# 50, "OB.*>:'/E2O'GKL8C-2?;KO_ )^I_P#O
MX:!GIW[0'_(^6/\ V#(__1LM6/V?/^1LU3_KQ_\ :BUY))+),P:61W8#&68D
MT1S2PL3%(\9/!*L10!]QT5XO^SW/+-I^O>;*\F)8<;F)QPU>T4""BBB@ KGO
M$W@G0_%\EHVM6\DXM-_E(LK(!NVYSM()^Z.]=#10!PC?!OP&RD#1"I/\0NYL
MC\WKE_$/P"TJXMWD\/WT]I<@?+%<-YD;'TSC<OUY^E>QT4 ?$FIZ;=Z/J=QI
MU_"8;JW<I(A['^H[@]Z]M^ GBN>X2\\,W<I=((_M%IN/W5SAU^F2"![FN6^/
M,<"?$*-HL;WL(FFQ_>W./_00M5O@>)#\2K<I]T6\V_\ W=O^.*!GU!1110(*
M*** /(/V@YV7PII=N/NR7N\_\!1@/_0J^>X89+B>."%"\LC!$4=6). *^B_C
M_9-/X+LKM1G[/>KN]E96&?S _.O!O#%U'8^+-&NYB!%!?02ODX&%D4G^5 SZ
M&\&?!S0=#T^&;6;2+4M38!I/.&Z*,_W54\$#U.<^W2M?7_A9X2UVQ>%=)MK"
M?;^[GLHA$4/8D+@-]#7:44"/BK7M&N?#VNWFDWF//M9"C$=&'4,/8@@_C7M_
MP \0RW.EZAH,\A86C">W![(Q.X#V#8/_  (UP?QN\K_A9EWY>-WD0^9C^]M[
M_AMK7_9]20^,]2D!/E+I[*W^\9$Q_(T#/HNBBB@04444 %%%9OB#6K;P[H-[
MJUV?W-K$7(S@L>RCW)P/QH \7^/?BSS;JV\+VLGRPXN+O!ZL1\BGZ [OQ7TK
MAOA?X4/BOQG;0RINL;7_ $BZXX*J>%_X$<#Z9]*Y?5-2N=8U6ZU&\??<7,K2
MR'W)Z#V["OI;X-^%!X=\&QWLZ8O=3Q<29'*QX_=K^1S]6- ST6BBB@04444
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M/YD1AT+G^(CT''N:]DH **** "BBB@ HHHH \,_:+_YEK_MZ_P#:5<+\'?\
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M[D,MQ<2-)(Y_B8G)-?2OP7\)3>'/"CWUY&8[S4V64HPP4C .P'WY)_X$*SO
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MYV#X?^+[B8Q)X;U,,#C,ENR+^; "@"EXGU^X\3^)+W6+D;7N9,JF?N*!A5_
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M(+!GMH KD="YY;'MDFN6\ _"C3/!KK?W,@OM6Q@3%<)%GKL'KVW'GZ<UZ%0
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MA!$5U DZ ]=K*&'\Z +5%?-'Q6\4>(-.^)6KVECKNIVMM'Y.R&"[D1%S"A.
M#@<DG\:] ^!6KZGJ^AZM)J>HW=ZZ7*JC7,[2%1MZ L3B@#U>BBB@ HHHH **
M** "BBB@ HHHH **8TL:2(C2*KOD(I."V!DX]:?0 45Q'Q0\;3^"?#<=Q91)
M)>W4ODPF095."2Q'?'I[UYKX ^,7B&[\5V6FZ[-'>6M],L"L(EC:)V.%QM R
M,D#GUZT ?0-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%17,Z6MI-<.&*1(SL%ZD 9XKR&X_:%T92WV;1+^0=O-=$SSWQNQ0!['17
MAS_M%('(C\+LR^K7^#^7EFK5M^T/IS$?:M NHA@9\J=7_F%H ]GHKBM ^*WA
M'Q#,D$&H_9;E_NPWB^42?0'[I/MFNUH **** "BLOQ'K</ASP[?ZQ.N]+2(R
M;-VW>W15SVR2!^->0?\ #1?_ %*O_E0_^U4 >YT5P_P[^(T/CZ.^'V#[#/:%
M,Q>?YFY6S\V=J]P1^7K7<4 %%%<7XX^).F^!9[6WO+*[N9;E"Z>3M"@ XY)/
M]* .THKQ.;]HFU7/D>&YGYXWW87C\$-1Q?M%1%OWOAAU7'5+X,?R\L4 >X45
MYKH?QO\ "FJS+!=FYTR1C@-<H#'G_>4G'X@5Z1')'-$DL3J\;@,K*<A@>A!H
M =1110 45GZYK%OH&B7>JW22O!:QF1UB +$>P) _6O*I_P!H;2E_X]]"O).?
M^6DJIQ^&: /9:*\-;]HM0QV^%B5[$W^#_P"BZO6O[0ND.X%WH=[$N>L4B2''
MT.V@#V2BN5\.?$;POXHD6#3]21;INEO.#'(?8 \-^!-=50 445X1\2_BYKNE
M>*;G1M!ECM(K,A))C$KO(^ 3]X$ #..GXT >[T5Y[\)_'EUXVT>[744C%_8N
MJR/&,+(K9VG'8_*P/TKT*@ HHHH **** "BD9@BEF("@9))X I$=9$5T961@
M"K*<@CU% #J*** "BBB@ HKS/XM_$.^\&V]E9Z2L8O;L,YFD7<(T&!P#P22>
M_I7/_"KXJZUKWB1-"UV2.Z:X1F@N%C5&#*I8@A0 00#V[4 >V45C>+YY;;P5
MKT\$KQ31:=</')&Q5D81L001R"#WKY/_ .$U\5_]#/K7_@?+_P#%4 ?9-%4]
M)=Y-&L9)&9G:WC+,QR22HY-7* "BBB@ HHHH **** "BBB@ HHID<L<R!XI%
M="2 RG(X.#^M #Z**\(^)?Q<UW2O%-SHV@RQVD5F0DDQB5WD? )^\" !G'3\
M: /=Z*\]^$_CRZ\;:/=KJ*1B_L759'C&%D5L[3CL?E8'Z5Z%0 4444 %%%%
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MEX ^(=OX%\'ZF$A%SJ5S=#R(6.%4!.7;V]N] SZ;HKY'U/XG>,M4F:237KJ
M-T2U;R54>@VX/YG-6=#^+7C#1;A7;5)+^$8W0WI\P,/]X_,/SH$?5]%<YX+\
M8V'C70QJ%F#'(AV3V['+1-Z>X/8]ZN^*+RXT[PEK-]:R>7<VUC/-$^ =KK&Q
M!P>#R!UH UJ*^4O^%Q>/?^@]_P"2<'_Q%?4>F327&E6<TK;I)($=CC&25!-
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MUDN0;B^F!\BT1L%_<G^%??\ +- '6T5\K:U\8?&.KS,8]1_L^#/RQ6:A<?\
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MYW[F-]VWR]OWE.,;CT]:Y_X4_$/Q5XE\;1Z?J^J?:;4V\CF/[/$G(Q@Y50:
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MYBNJKE?B5_R3?7O^O5OYB@#Y#KZ-C_9^\,","34M79_59(@/RV'^=?.5?<U
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M;3)I+C2K.:5MTDD".QQC)*@FOGG]H#_D?+'_ +!D?_HV6@"_^SS_ ,AS6O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY+;S.N);2W@D$B ]G9AP2.P!([YKVNOG/X'>,+C3_$(\.7,S-8WP8P*QXBE
M)X] P!&/7%?1E !1110!\B_$W_DI.O?]?)_D*]D_9_\ ^1#OO^PG)_Z*BKQO
MXF_\E)U[_KY/\A7LG[/_ /R(=]_V$Y/_ $5%0,]6HHHH$?-OQ^C5/'UHRC!?
M38V;W/F2#^0%3?L^LX\::B@'[LZ>Q8^XD3'\S7/_ !@UB+5_B/?F%@T5H%M0
MP[E1\W_CQ8?A7;?L\Z8_FZUJS+B,*ELC8ZGEF'X?)^= '>_&+_DE6M?]L/\
MT?'7S#H?_(P:;_U]1?\ H8KZ>^,7_)*M:_[8?^CXZ^8=#_Y&#3?^OJ+_ -#%
M S[7KXAU":XN-2NIKO/VF29WESUWDDG]<U]O5X;\3/@[>7FIW&N^&HUE,[&2
MXLLA6#GDLA/!SR2/7IG. ".Z^%%]H5QX$TZ#1W@$T,*B\B7 <38^<L.O)S@^
MF*ZA]"TJ358=4;3K;^T(<^7<B,"09!!^;J>"?SKXV_XF>@ZC_P O>GWT)_VH
MI$/Z$5ZW\/OC3?1WT&E^*)1/;2D(E\0 \1/3?CAE]^HZG- 'NM]I]EJEL;;4
M+.WN[<D$Q7$2R*2.AP017S/\:=-L-*\=);Z=96UG!]CC;R[>)8UR2V3A0!FO
MJ&OF?X\?\E#3_KQB_P#0GH U_@+HFE:Q_P )!_:>F65]Y7V;R_M-NLNS/FYQ
MN!QG _(5[?I_A[1-)N&GTW1]/LIF78TEM;)&Q7(."5 .,@<>U>/?LZ?\S+_V
MZ_\ M6O<Z /#/VB_^9:_[>O_ &E7CVA:5>Z_J]KHMB3YMW*JA23M! /S'Z L
M?IFO8?VB_P#F6O\ MZ_]I5R?P/C1_B5;LR@E+:5E/H<8_D30,]<T?X+^#].L
M4BO+)M1N=N))YI77<>^%4@ ?K[UO^*+.WT[X::S8VD?EVUMH\\,29)VHL+ #
M)Y/ '6NDK"\:_P#(A^(O^P9<_P#HIJ!'QM7VSHW_ " ]/_Z]H_\ T$5\35]L
MZ-_R ]/_ .O:/_T$4 ?+_P 8O^2JZU_VP_\ 1$=6_A)X$M_&.MSW&HJ6TVP"
MM)&#CS7;.U<^G!)Q[>M5/C%_R576O^V'_HB.O2?V>O\ D7]9_P"OI/\ T"@9
MZFF@Z/'9BS32K$6P&/)%NFS'TQBOGSXQ_#^T\+7EMJVDQ>5IUXQC>$9(BEQG
MCV(SQVP?:OI2O-?CFL9^'#E\;A=Q%,GOST_#- CR?X+Z[)I'C^WM-Y%MJ*FW
MD7MNP2A^N1C_ ($:^A?&O_(A^(O^P9<_^BFKY6\"B0^/_#WE?>_M&#/TWC/Z
M9KZI\:_\B'XB_P"P9<_^BFH ^-J^V=&_Y >G_P#7M'_Z"*^)J^V=&_Y >G_]
M>T?_ *"* ,_QK_R(?B+_ +!ES_Z*:OC:OLGQK_R(?B+_ +!ES_Z*:OC:@9]K
MZ2B2>'[%'4,C6L896&004'!KQ_XYZ!HVD>&=-ETW2+"RD>\VL]M;)&6&QC@E
M0.*]BT;_ ) >G_\ 7M'_ .@BO+OV@_\ D4]+_P"O[_VFU CRGX4V5IJ/Q*TB
MTOK6&ZMI/.WPSQAT;$+D9!X/(!_"OIN#PAX9MKB.>#P[I,4T3!XY([*-61@<
M@@A<@@]Z^:_@[_R571?^V_\ Z(DKZMH \I_: _Y$.Q_["<?_ **EKQOX9?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"RD>\VL]M;)&6&QC@E0.*\Z^%-E::C\2M(M+ZUANK:3SM\,\8=&Q"Y&0>#R
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M^V__ *(DH ^K:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?X1Q_=K0^!O@_4M-UC4M6U;3+NR>.%8(%NH6C+;CEB P'3:!G_:H ]QHHHH
M^0_B1HG]@>/]6M%3;"\WGP@=-C_, /IDC\*];^ &N_:O#]_HDCY>SE$T0/\
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ME//B.Z*#WW=&;T R/7T/@2P:WK3(%BU"_/\ #A7E_+K75:%\'_&&M2*9-/\
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M3KA(XXU+,[&-@  .22>U 'QE7VSHW_(#T_\ Z]H__017R'_PA7BO_H6-:_\
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M^(-1^)6KW=CH6IW5M)Y.R:"TD=&Q"@.& P>01^% CL_V>O\ D7]9_P"OI/\
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M1D -Q_M4 >&Z/ILNL:U9:;#GS+J=(5QVW$#-?:EM;Q6EK#;0KMBA01HOHH&
M/RKYY^#W@C5XO'4>H:MI%]9P64+RHUU;O&&D/R@#<!DX8G\*^BZ "OF#XVZ)
M_97C^6[1-L.HQ+<#'3>/E;]1G_@5?3]>7_&[PO=:]X:L[O3K.:ZO;*? C@C+
MN8W&&P!R>0I_.@#D?V?==\G4]3T&1_EGC%S"#_>7A@/<@@_\!KU3XE?\DWU[
M_KU;^8KY]\%Z+XK\.>,=+U4^&M:6.&<"4_8)?]6WRO\ P_W2:^A_B#:W%[X
MUJVM8)9YY+8JD42%F8Y'  Y- 'Q]7W-7QM_PA7BO_H6-:_\  "7_ .)K[)H
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MVMM'YV^:>TD1%S"X&21@<D#\: /I>BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
0@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>img30600998_17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img30600998_17.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2/"4&AO=&]S:&]P(#,N,  X0DE-! 0
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M;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M  !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$
M8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'0D,
M   #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M  !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!Y
M    "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G
M4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M            4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN
M=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E
M8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R
M;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU  (
M 3A"24T$)@      #@             _@   .$))30/R       *  #_____
M__\  #A"24T$#0      !    !XX0DE-!!D       0    >.$))30/S
M   )           ! #A"24TG$       "@ !          (X0DE- _4
M $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $
M6@    8       $ -0    $ +0    8       $X0DE- _@      '   /__
M__________________________\#Z     #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z   .$))300(       0     0   D    )
M #A"24T$'@      !      X0DE-!!H      S4    &              =-
M   )V@         !                          $             "=H
M  =-                      $                         $     $
M      !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
M  =-     %)G:'1L;VYG   )V@    9S;&EC97-6;$QS     4]B:F,    !
M       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$
M;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T
M;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
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M!"@       P    "/_         X0DE-!!$       $! #A"24T$%
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M&O\ +_!74*&KH_5ZZ<9^/=DV96=06C+?:-IW1L8]E.^RJJM[:_\  _X3U?\
M"^HM98?U?Z5U''RLSJ?57UG,SM@]*F2QC& [6[C&Y_N6XFR !H&T&KT4DDD@
MA__1]09BXS,BS)92QN1: VVX- >X-^@VRR-[]GYJ*DDDI2SL0/ORL@W8[7X]
MCB1<XAWNI>:&4>BX;O9Z7K[_ -^Q6\JO(MQWUXUOV>YP]EI:'[3X^F[VN0NG
MN?&14^I]?I7V!KG@ /#S]H]2J"[=7^F]/^PB--?Y1_K(.NFH^SU?U6VDDD@E
M2'D7LQZ7W63M8)@:DG\UC!^<][O8QJ(
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                      #_X443
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X]
M(N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M
M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!8
M35 @0V]R92 U+C8M8S V-R W.2XQ-3<W-#<L(#(P,34O,#,O,S M,C,Z-# Z
M-#(@(" @(" @("(^"B @(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W
M=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS
M.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @
M(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(*(" @(" @(" @(" @>&UL;G,Z<W1%
M=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C
M945V96YT(R(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R
M9R]D8R]E;&5M96YT<R\Q+C$O(@H@(" @(" @(" @("!X;6QN<SIX;7 ](FAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B"B @(" @(" @(" @('AM;&YS
M.FEL;'5S=')A=&]R/2)H='1P.B\O;G,N861O8F4N8V]M+VEL;'5S=')A=&]R
M+S$N,"\B"B @(" @(" @(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]P9&8O,2XS+R(*(" @(" @(" @(" @>&UL;G,Z<&AO=&]S:&]P/2)H
M='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q+C O(CX*(" @(" @(" @
M/'AM<$U-.D1O8W5M96YT240^861O8F4Z9&]C:60Z<&AO=&]S:&]P.C$X-&0R
M.35C+6-C8S M,3%E8BTX939A+60Y.64X-#DS,S@S8CPO>&UP34TZ1&]C=6UE
M;G1)1#X*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#IE,S)D
M-F,Y-2TT-#!E+3AD-#(M.&$U."UA-F5A,C-B8V(U.6(\+WAM<$U-.DEN<W1A
M;F-E240^"B @(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT240^>&UP
M+F1I9#HR,V1C-3%F,BTT,#%C+30Q,C M.6(X8BTU,S(Y,S@Y-F)E,S@\+WAM
M<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.E)E;F1I
M=&EO;D-L87-S/F1E9F%U;'0\+WAM<$U-.E)E;F1I=&EO;D-L87-S/@H@(" @
M(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.C$U
M9C$Y.3 R+60U8V0M.3<T-BTY931B+3%A.60V,#4Q.&8W,3PO<W12968Z:6YS
M=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^>&UP+F1I
M9#IE.&$S.#!A-BTQ,30T+31D,C M8F5F.2TW8C5F9#@P,C!A8CD\+W-T4F5F
M.F1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M
M96YT240^>&UP+F1I9#HR,V1C-3%F,BTT,#%C+30Q,C M.6(X8BTU,S(Y,S@Y
M-F)E,S@\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @(" @
M/'-T4F5F.G)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+W-T4F5F.G)E;F1I=&EO
M;D-L87-S/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" @
M(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA
M8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM
M<"YI:60Z,C-D8S4Q9C(M-# Q8RTT,3(P+3EB.&(M-3,R.3,X.39B93,X/"]S
M=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE
M;CXR,#(Q+3 S+3(V5#$T.C(Y.C$S+3 T.C P/"]S=$5V=#IW:&5N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU
M<W1R871O<B R-"XS("A-86-I;G1O<V@I/"]S=$5V=#IS;V9T=V%R94%G96YT
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC
M:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#I"
M04-$1CA#04)#0T-%0C$Q034Y1#E#-#(P14-",48T,SPO<W1%=G0Z:6YS=&%N
M8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,2TP-BTQ
M-%0P.#HS-3HR-BLP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYC;VYV97)T960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.G!A<F%M971E<G,^9G)O;2!I;6%G92]J<&5G('1O(&%P
M<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W \+W-T179T.G!A<F%M971E
M<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.F%C=&EO;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F-O;G9E<G1E9"!F
M<F]M(&EM86=E+VIP96<@=&\@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O
M<VAO<#PO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D
M/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T
M86YC94E$/GAM<"YI:60Z0D)#1$8X0T%"0T-#14(Q,4$U.40Y0S0R,$5#0C%&
M-#,\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IW:&5N/C(P,C$M,#8M,314,#@Z,S4Z,C8K,#4Z,S \+W-T179T.G=H96X^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E
M(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC
M:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HQ
M-68Q.3DP,BUD-6-D+3DW-#8M.64T8BTQ83ED-C U,3AF-S$\+W-T179T.FEN
M<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C$M
M,#8M,314,#@Z-30Z-3<K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#
M0R R,#$U("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&%P<&QI8V%T
M:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z
M<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F1E<FEV960\+W-T179T.F%C
M=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^8V]N
M=F5R=&5D(&9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T
M;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I
M;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.FEN<W1A;F-E240^>&UP+FEI9#IE,S)D-F,Y-2TT-#!E+3AD-#(M.&$U
M."UA-F5A,C-B8V(U.6(\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IW:&5N/C(P,C$M,#8M,314,#@Z-30Z-3<K,#4Z,S \
M+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R
M94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#0R R,#$U("A7:6YD;W=S*3PO<W1%
M=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H
M86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(
M:7-T;W)Y/@H@(" @(" @(" \9&,Z9F]R;6%T/FEM86=E+V5P<V8\+V1C.F9O
M<FUA=#X*(" @(" @(" @/&1C.G1I=&QE/@H@(" @(" @(" @(" \<F1F.D%L
M=#X*(" @(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT
M(CY&:6YA;"!W;W)K:6YG(&9I9W5R92 R0F=V('1W;SPO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @
M(" @(#QX;7 Z0W)E871O<E1O;VP^061O8F4@4&AO=&]S:&]P($-3-B H5VEN
M9&]W<RD\+WAM<#I#<F5A=&]R5&]O;#X*(" @(" @(" @/'AM<#I#<F5A=&5$
M871E/C(P,C$M,#8M,#E4,3(Z,S@Z,#0M,#0Z,# \+WAM<#I#<F5A=&5$871E
M/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T93XR,#(Q+3 V+3$T5# X.C4T
M.C4W*S U.C,P/"]X;7 Z365T861A=&%$871E/@H@(" @(" @(" \>&UP.DUO
M9&EF>41A=&4^,C R,2TP-BTQ-%0P.#HU-#HU-RLP-3HS,#PO>&UP.DUO9&EF
M>41A=&4^"B @(" @(" @(#QI;&QU<W1R871O<CI#<F5A=&]R4W5B5&]O;#Y!
M9&]B92!);&QU<W1R871O<CPO:6QL=7-T<F%T;W(Z0W)E871O<E-U8E1O;VP^
M"B @(" @(" @(#QP9&8Z4')O9'5C97(^061O8F4@4$1&(&QI8G)A<GD@,34N
M,# \+W!D9CI0<F]D=6-E<CX*(" @(" @(" @/'!H;W1O<VAO<#I#;VQO<DUO
M9&4^-#PO<&AO=&]S:&]P.D-O;&]R36]D93X*(" @(" @/"]R9&8Z1&5S8W)I
M<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_VP!#
M  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MP  1" '! ET# 1$  A$! Q$!_\0 'P !  (" P$! 0$           <(!@D$
M!0H# 0(+_\0 1!   00" @$# P(#!@,%!P0#!0(#! 8!!P ($0D2$Q05(18Q
M%R)!"B,R0E%A)'&!&%*1H? 9)3,T0W*24V+!X8*RL__$ !X! 0 !!0$! 0$
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MNDAWW;(:'57LTH$.$4.")K0]*3=]T/[;W;LE;>T%.V(3UU+LVD]F-!8<'4L
M0<H,"DV$I</T(_ V_7-Q[/%;$.E:U7H4VUB#%7TQ>:'8<SQUAUO%%%*R1EHF
MQGB(XB.(CB)JX]07<'8BK;LZ"Z"Z_P"VX6DY':3<6U:3=+\[KJJ;+)"PU#TK
M9]ECT"0-P2H3AZ62KR(4EU66W$QY2G$+\M8;<1\C^[^9 _SE?:[ZDFS>J.QN
MS>B>[OT^Y4]<;;U4>;[&:;HXNC0W]1]M#LZF@;KM_7I.XRAM2<UC>(+8NXD:
M@8)-E@!@<:$U5E0\EAY*\<^WX^_U'R'[>?'\/VRY;O40KUP[ :>UOKPGMBE
MAW?ZZ=-;<4:UYK.S4S==RHFC+5>+G68QPW<VK33:93K F#$(7:O!'+'(NE9D
M5=@.^$>+D8R4_K^?]']DX6@O6+T[O&PZ*:)Z+[!:8UKV8IFV[5I'<^UAVM(M
M&NDS0P$E:-N 5PJCLFV7"NNU<"&,S8!:R5L4)M209=ZN22 UF"1(I4CCYC_U
M]OZ_<?,RG0_JJ4S>>T.M5 3UK[':WKO<87LNU]9MJ7^%JABF;+H>KJ?*N9JV
MOC:YM*Q7JG-DA30Z2!#6RHBRI0;9*Z7885!D%%"$<>_D>/'S]_/CV_#]DVH\
M2D<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1
M'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q
M$<1'$1Q$<1&<8SC.,X\XS^,XS^V<?Z9XB?Y^_?;T%O47Z(]N;AW"]("19C-'
MMY"SE M?U89 !MR:09O"GU6BC#@1YZ(W;Z'\LEV'5YU7^XV&$"=8#'0V,B%V
M0TB5TU5Z+WK:^K%N_7)[U'S&T]=:KH/@(6VCO\E7\W\937R*2IRM:SH$1Q1^
M>;*N>[,$@?%C*K"DNYF2RLI47[5+1/<%CLAU]Z9V31W1BNZ>WU"B J$&I^FF
M*AJ"PV:C2:+K*M5* 3FC[FRM,.;!U\&.5_-[,NYRL2_)?D$G%.Y><4B7'/7C
M5&!4V:9O]*$P9U9@$'3_ .L@P5]FKV*.4<"'89]LE%D01Q%N 8E@#<68RRZX
M.GS!DK+D%]UI$CS1<3K1J36T76>E+7K^/1M: 46T@U#V'!MTX8+NBR5R?V'=
MK.5/F3Q"7?)) S<25]MA65-MTL@4L,LN0<DR92D20H&Q].DQ=<F"[YK0@%O$
MK$FHRH%HJTL7<)BC0\7A^N/QYSD2P2LV,D*'8=&+ENY-3Q\3W?72HS;B)#4_
MMAJO.]YFA:M3MH;+O%3+U>K['L.NM7FK+0-.$[I#&6 "(V1L'X8E?!3GP9 /
M:R04;-+E0-?G"3Q\<,@D!DB2B?FW^Y.A]1PJ;/('&[[&O6SK%IMIS6LNLW!(
M.\5+5FQ]OF0UM4T?BH#O0JQK*Q1G(3JGR4<U+$Q)(^/&F2)L5$D+4.^M2[IJ
MNL+)4;"&C$=LZCI>[ZQ031(!#V-'U]>0XNQABY:H1"D^?%98P9B1B$R-F8*C
MEU.1V24A?L=<1)H8BQ8N'$Q8S$;#SSDA[##+;.'9#N<9=?<PVE.%O.9QC+CJ
MO*UYQC*E9XB??B(XB.(CB)1WN#TW+=GK7URV-3=YVC06S.L=[MU\U_<*W3*7
M?$KGW6CDM>FXQ*NWN$0!26U5TP2:BN/Q)&(\F1B3AE;K+*D(^OX_Z@_Y2J>Y
M>AK>I^HW=<34Z?M3OEV8[K@(E+VK;-D7#6U1N%[)%@JM=4>7*)Q1=$U]K75N
MDHIJ19@X6GUO,RO#XLZ0.AFBGPN(2O/D'P./\OYG^/[P)GVD_3%J] T[T(IU
MMV%82NP.G6S#78.TVL;F/,;W%OC8U;O<?;)^RS345TNZ*/VW9=I.#WLN-&6X
MS(B'*DK0PZE2">>?;S[?A]/X#Q_I.7K_ -*O3E&IO1NB2+M=+57.CD7?XZM0
M#4<$VWLL7V'H]SH5N&W?Z&%&5'CPA%V(J'9 K'N*=88Q)<<1ESW)3Z_C_J#_
M )2@/3+I+V0!]P.GIXK3NV>O^L_12A=@JS1 O;2_]3[/@(QM&HC]?U+66FF^
MMTDS;+>!!BOJ2)#8FXS;\]-?"U6K!(PUV"2042I//[_)_'W]_P#IX\STA\2D
M<1'$1Q$QVW6^J4"L';K>K, IE.JXR4:LEKM1@> K@ 1!;R],*&3161%'#!\5
MI.7)$N9)98:1CW+<3CB)J8A>O_Z/!"^XUS'[SZQ0?5-^WI)2P.R1]$S)PK"?
M/\3I](C:XQ#SG./!+-JP,5CSE,S.,9XB;=09P)9PPJQUHP*L->.CH9<&>!D(
MA8,9$D&&Y4 F**0'I$$B.G176I,.;#?>C26'&WF75MK2K*)VG$1Q$<1'$1Q$
M<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$
M1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$2H.]>LA#<N^
MM$;3_4T,/7=6:O[1:YL G,5]XT6_[0==UT @D [^/,%C]/IIDY^6W-QGZG,V
M(EG'AM[B)K*USZ2VZ_J-.HW?LG1%S"Z>JOIXZN@@*_1[7D39]<=#;IN<VR_9
M8-LGF8DRT;&&;/AOR([3#(((1A/C<-$(T9HO/2O^'G@?3^OYSBM^BV2%:Y#U
M"IW3459(BM27"GE$P]=2$5;85CQWLUWW"H C8P8<X)?L>M5UVAOZ?N(F3*<G
M(K]E*8#M.P/<.D(Y_F>?Y'_7F3WH#TS"U"[+4GLML^?IXT0$6_MOM!_6E2IT
MS-)UKL#L0YU='5:1J%T^QAR$JIA>OALD?M3HROF35NV.>)CQHMB1);=2G_23
M2*ZM]@]9;A[%R=17_6"M"=M-DXVKL@=:Q]S%[DU9<#NMZ?JR^D-66BOS9E?L
M+)<+105AJ\.T#@SE2LJYR/KBXA46)&1*&ZK]&R]T6GZX!3+QKN)9M>6>@-$+
M<&-;2,0=@TG6'63LYH*HNN4BT/2!&N#S<WL$DV^)KD\Y!;$#7PKM@(L#J\W"
M2O/O]#_J#^'T$M)U-Z ;1ZV[VUQL&-=Z' I5:ZLZGT;M(?756<R7WC<M6:=U
M7J^M7(@'M<%8K6"ZOFBEDPR-"--NW*LR*\)MX%1$4X8<2DVS\1'$1Q$HGZB)
MSLG0>M&S-S=;=ST[4IO1FM=I[<LL&XZ=C[;C;#%T2B%[/#J$-<B\4W%,>ES!
M"FG+$EFQY:;D^<AGOA]KB!Y('UD%],.T^T6/^RGK;M1MF/N3<?=W1$WLKJR5
M0-&AM44K6U-JU$UO9+E2;5.3L^UD+$8;G;'&I!'8@2"R2:C34RX G#;&'DK_
M )>#YY\_A^'@_P!&='+]9WK[(H^I[I2-(]J-H.[DT'L?LI5JG0-=4PM9A^K=
M2WA='OQ.TMR=E00X*2%E-/%6T.%Y$(E"^D&#2$FU%A%=GI3^O\?])D^N?6#Z
MJWMVW3C83<^I*.!ZQDNXE4V3MK7J:U4ML=>0,^"(L5[UPU -&K//4'+DQD)-
M>.UVOV,VV3&$ZX+,"B,.:\E>#[?CQ^_Z3B-^K[HD15-K6/:&F>R^DRFLNO#?
M; =1=G4:E#KCM'KZLK#".7S7+(39!ZOOR1I,F*B':?;K#4KB!=*P4DPC'O?S
M'1Q[>WD\?O\ Z_<?ES,K[ ^H@[K?H?8.X%)TM?X-@/GZO0](ZUW<'5KLM<K5
MLW8076^K[+8!L>>2)U^B6"381]V^(FL19UU%MR-.'@#K^(L5 ')^G_3S/GG8
MV_\ H]K2Y=@N_7:JG;JJTB%4@ ?5NF^MT+7DV!MJZVD37ZY2]8EI6RCIN\MG
MBY5BLAHUSP*<3A?ZI/G@(B&4Q!2G[/Q_A_7O*^;']38AL6S]1@FC5VO4ED(>
MI!K3JQV@U=L /K"P6>%5;=IF_P"RV Z#M5.[/I$H+;($2K'P-VUM=I;SK,:4
M.07AR&2P["5X_P .?W<\?XS'.E_JI'#>E^L]8W, V5V$[.=AK[VX4'&:PK^H
M*LY%UIHKLU<M7MGB+5FMVHZI+Q6J[^EX*0-/Q8+Z>C#2AI0$@ZQ-GOHX_K_*
M;W^)2.(G@!_MA7=+9;VYM)=#ZV=* ]4"M9"M\;($P)+L2+?KA9K39Z_389]#
M:L9(BJ,.ILLJ*@N*^A6:LSL^5&?G!0TF$B:DJ;ISTW;SZ5G8GMH:ZK;KU%L'
M5$76?7K5&S"G9]ZW5[?/;ZX5]$^S(K>MOX9UQ@)7:/7XLO:UI#2+,6Q K\\9
M7X<F=*=5+;1-U']DN[E]CK?1^U/1NOV0"8SKRDB-V]>'=I8L)NG:^DD+=$K.
MPZO+B!",$Y^DC<PZ#L0X*&(CF1MAS8B32%N'YZN(GHVUCZ@V^QWIQV7OCO&B
M:B/$BJ0D'4^L-2OW"KL3K/9]N)T56 =XM%T(VA Z 7V$5KC\ZPBASK=?K4@G
M.=%E)4-MAU$D/<O?YWH-3*P0]0&TZF(7;9,BXEJ%7NO<%FDPFZAK:L"3^R),
MHCV&W!7QMJG55TP-BP(8 Q NMY?,A1E+UF5.RGAC")6.'ZMEC'[WNJ;#'J)7
MK)3-A=MIC]BIE*MI;8);2>@NC?63M96# .%BPN9)6HN0W!;$2V, &$$@S5>%
ML#1$^+/)S42[.X^_-9IO0DIW3J0H,.;L(^OB=4A=BWC6T^ME+SL38@W4VL\V
M2\:BV%L.@/4TG;3P8R:,U._&$CJ8J?/E21TZ!/BP42K5 ]8";;ZQU1GC.L]Q
MV82WUU8[/[PNI;4=PHD^JT[8W4>QU+7^U-;5QRQV0<[9!#>P3)07FUN$8J1X
M^71)8N#<&['89-+1)8H'JSZ<)UGI#.V]KZY:4M/=^H:C-TJOG;CI(RJOG]R2
M7A5,&2 $#:C.W;#5[":1!2&V!7M2S:Y!$6:JSK^[024TP% HD8;A]8"ETJK=
M4M]"Z5=:9U5W7O$_3Y.U-G5 4B3N;6..L_8W:E(LG7:N5K89"ZY+WC8NJZ'7
M:C V12JX;N$*YBX->JLEZR#3$!$GWN'V.[7ZI?ZK$])U?3 <+V,VOK?2).L[
M]#7.5>Z)=MC!KA9&IQ->M;Q^FG(->'UA HP)@3RKKAEV0Y!-R(+;2EHG4R/5
M?ZX5O68*_P!NB;&<;E:C[(;8*YKM'9DXR(ZD[ZJ'6K<RA@E5GEDEOO;.N(^5
M2!"7I\XU5$OS)+\4JTV,DHG7BO5XZY(.E0^QM=]A=(#ZV;WQ3;=;=K4&M0JG
M4]B]<=6&-Z[*UP4(T^^7*5-L\?20.?M$)+K@\[430%M0B-:,71B95HJ)RG/5
MCTE#F ZL9TOV?![8M-LU+5ZII*=KNH2MFV2+OG7FU=DZ=N V,$V.6J3=1NPC
M2VQA+DPE;H!:D62NSAFRPU*:B39<5$VD<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$
M<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$C;<NPFM2ZBVCM)Z']Q
M;USKVXWA0_WY;^OS5:\0-IA9<3C*F\2UPDQ\N8QG*,.95C&?'/2JOU;:ZN>/
M4L1.?IWL%Y_=S)+T;T\_5O5W2_2R7?9VZCZATVC&1P#]G_.NPQ\$W]I\-Z(O
M-G:?![>/G/%<2[/]H>U)/;E(O6\=F24;2U1MW(X$"M9JO5P-;JM2SFR]<_I^
MOAIT$6$CPK]3*O%??AQT37 3A.%(DR$3I?SSW65XFOSM=>,>EDIS<86"VM;.
M^JVQ<>\/W*W=S3:Y ((#A6 ':./TM_*?^ /PYT7Y-/6]'2'2VITVWZ<UFNV>
MOWU.-7^?[;<+88=>0<O=E3LLDY>+;DBVM\CT7N:LBI5K1%P#TR?[01NSKR?
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M9DA>/"G'7%YPAMO"&([.&X\9IIAEMI'4N/C48F/5BXU24445K7556 JHB
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MM2V10V.H[;:&=@I'ET=N[E?;N[69@1]"I^9,O;8/45UPQ57)6;./RGZ52O\
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MA>[M^EP=3?75YD0B"<B.RUMPTE'C9:7!9%QWWVXKD,;'(O.-R2<@J:/?1=R
M"S$ < %B0!] "> /P$\Q54K%EKK5B2Q8(H8M]20.2?J3Y_&75AP80]G$>!#B
MP8^%*7AB'':C,X6O/E2L-,H0C"E9_*E>WSG/YSG//F>DY7$1Q$<1'$1Q$<1'
M$1Q$<1'$3&KG3JUL.H6BA7,1&/U&YU\O5K,$F87]*6 GH#XPJ/?RTMMU#<J%
M)>9RXRXV\U[\.,N-NI0M/TCM6ZNC%'1E=&4D,K*0592/(*D @CR".1*@E2&4
MD,I!!!X((/((/R(/D&>/CNAU^W9TL(R:CL:%9KQH7)G$C4'8$0CXY0E4AS+
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MDO,DSIJ21BP[#E.QCC\<BL2HC+!MX<0$%H<--B94T9Q'[9:#55&:$59-<L8
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M5C*/<2K4!+OC#D=3S"D.JOZM+L;1R*57D<@675(Q_ JS\J?EPP7SXETFMRW
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MF9CQV_+LJ4IEA:(L1G"GY4A34=A"W74)S55+,JJ"68A5 ]R2> !^))XE0"2
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MD)QA*5-6($+0AW*4^Q3ZF<9Q\_M5D?BGB5T]-ZLGCOHV[TTGW(IMHRRR@\^
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M[%7S8?=_M'(VM8%638'9?50[;5D)X2\R+C%M*72'6H%?K4)^0^H571%;W;%
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M[L\3U!:XRQ;<^*1K>\7?U*:1\Z);=H'/LI?2,_X'*)8RH=D=EV^U=\>Q-_[
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M[E=4*32*N,U?H.9WL[']9K<N?L-,G;NRBFB^I&\[59A=ZT\]0&HU&I\;9 P
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MZ$SH7NUU>PP\J/5#2Y.&U9C-O2X+3#CO^5+[R,NN,MY_S+;COJQ^V&\^?./
M]4X_:W&+<6 ^Z"]84G\6!/ _$!C]!,BGP=V9L06;C!6HL/59*,A[%3YFNMNQ
M;&^BM;6#_?'L:ZW/=%\NBW6I19P4+<SG"1 53L&+EOSGPF2ZAS,N;YQX]^)4
MA;&5X]S;#7G"<1[,W.?F<AK334?^ZI)1>/HS ]]GXAB1R.0HFS='T)T[H@CU
M8:YF6H!.;GA,BT-\VJ1E%./YY[356M@4]K6/Y)BC^O\ 7\_OG_S\Y_WSG/[_
M -?Z\Q/[_P#4\_U\Y,?;VCB)_2%K;6EQM2D+0K"T+0K*5H6G/E*DJQG&4J3G
M\X5C.,XS^<9Y4$@\@D$>Q!X(_>)1E5E*LH96!#*P!5@?!!!Y!!'@@^#)QH_8
M"\5'+<8@_FU"$XPGZ(O(<^M93C'C&(A?V/RF_P#+CV2T3F4HQ[6F6LY]W,WA
M;_-Q.%L;[52!QV6L>\#Y=EW#,/D.&#J!X"@^9K[?_#?0;D/;BUC3YK<GU\.M
M?L[L3R3=A<UU-SR26I;'L9CR[L!Q,UF]K;2XK.1U8 1$9_PIF/D2"DX_TRME
MX:E7X\?G#:?Z_C_2]?JK))_1XM"CY=[6.>?GY4U\_P !,%1\'M2H'VG;[&YO
MF:*\;'!_8+$RB/WL9PF>U-Z2OR^#J;J/ZI:BEV5?]%J,OXQ_^&>?"]4YO/WJ
M,4CZ*MRG^)N;_">[_"#I\C]'L=PC?5[<*P?^5<&L_P#W3.P7:T<ZXAJR527"
M1GQA4L/.:(8\Y_=684MJ IM&,^/.$S'U^/.<)5G&$YOJ.JJB0,C%=!\WI<6>
M?^1PA ^?Z['\#(]L/@]EHK/J]O1D'W6G-H?&/'T]>ELA68_+FFM>?!('D6,J
ME\J=VCY?K9J*04VA*WX?E3!"+A7C\R8#Z6Y32?=GVX=RUEE:L9PVZOQYY(<7
M.Q<U>[&N6S@<E/*V+_S(P# <^.>.TGV)FLMQT]N-#:*]I@W8P9BM=W LQK2.
M?]UD5EJG/ [NP/ZBC@LBS+N7<PL<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1
MQ$<1'$1Q$<1'$1Q$<1'$1Q$<1.J.A1MD"&*Z98S*$'Q1 *5BI>?CJDC2L1Z#
M.83(C.,R6,O17W6\/1W6GVLJ][3B'$I5BH)4A@>"""#]"#R#_&/:></U%?3M
MT+TMZK2=]]9Z[::I/U6=JR+W%FW:U6^-8JA93$:JNE)$*RS3*H182?,5Z3\M
M?6#%,ALFGIHZ2MN,]$W'T;UEN^H>I,?5[W.KRZMF+::F?%Q,<TY2UO;1V'%I
MQQQ:4] (P8%[$(X/),RTV[S=ALJ\78Y"W5Y0:L-952@KM"L]; U5H/OD=G#>
M.6!\$>=,^H^\'8TZ4GU/KG6[KL6YE1:Y+U5H^OI^S#JH@S"TX*M !P4[.;9'
M*FYR],3%3$1\Z$S<K1EI.-L;3IK1X259&_S<3 Q_4[*K<O-3#6QF^\U:,;$-
MC%5#%*^Y@!W  <F2K-T^IJ5+-A;116&^XUF1Z18GCE5X?EN0.2J@GCDCM/)D
M?=*.WM_T#ZF>M]M]@(-C&3R5QFZ^VU#O0T@$LE>$[(A?IB88*C"<:'-#N5-X
M@)/NCUP6LH#!UBHL:.T\S\7WUCH==O/A[F4Z"_$RJL!$V>'9@VUY%%QP%=[J
M4LI=U=WQGR H)[FR&4OY),\]WBXN;H7HUK5/1B\9-!I971VH#!P"I/WO2:T
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M6<YSG/GSE2E9SY\_G.<YS_7D%\L?FS$_B22?YDDSH?[J+\E51Q\E55 \#Y
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MEQ24I2IQ6$X4O.,>,K5A"4HPI6?SG"$I3C.<^U.,>,<Q'U^7X?Y>3S_C)J/
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ML3YFGO:O6-K/8:U]A-%]G+]T]VEM417:]MAJ5K^F7[7FQD52$@16R\T!<D+
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M.9GPW\K5Y1. (ZH]7J^S!C@NN.B@L<9K YI,:P*U-0Q[,#35G(RS%DU/":B
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ML+;O4*TIKY(U5^J.]J4N543^P3<6R::MX\E2]>UFQ!JN7O-P$_3.%A=8C%K
M*;S/8A3EX9DJ>6PA+$CXL&FKOMY].S'L =:U*7(PLL=6<(AYX+D(?'/R_9->
MW]6ZS$[/M5&SQBU%F58MVOO1Z,6JZNBS)O3@NE*V6H.X*W@\\>#Q*FR.W&D=
M2[5":=O=@FAK78-77'<$"2L8^[7DTNB#+ ;L,F4:;5EB-.8"U6QEF(*T>^3
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MXZZM*$*5A$\)W8O^TE^H;W%[$V_0OHU=>Y=EJ=/9+D8=SBZF)[>V[=*R"*1
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M5>JN'QS64C<82EM.$X2QX2E.$XQA*<>,)2G&/QC&,8Q^,>/QXSB=W;Y@W:K
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MTG/E6<Z9WG0?6]5OJ[K P]42H:G%V6]T6OL6MO;TL?,V=-K<\$LW868@\^W
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M81$V2B4[[$Z%[@7CM+WV"TC7^XDZC[^[6)Z-V=9X@>UPQE.UEU3T!U7NU0M
M62IN,W'K.]:VYVFT-"L8'/TY2\&@(J.^2),88BHG> -[>HE/F]7>ONN:KVHU
MI6Y?5;6&J]G,F-22?IPQNT>G*?V,.VM2;(0ZLKBZ_L%)["#JOJHG-V3V9*&T
M[/B6>H3=%#X+8^R(1_7]?U_C.YI_:[OEK#1>C*76D]L-C'+ATFZ//42PW3J5
M<SEPB]B!7: W4NZU;V>33I(5^EIE'T=@(-@D-M1Q6;)7Q$>[UL[<KD9EV@ZB
M=YV&[(^IQ0=)[#MM9G]F"6W+KV#[UA=* ZKUTKCM'U]1.MFQ=I"NO-4LP )U
M*WQL:^O=CJ[BIS:D:*.:TJUS 5]HBWNB@)^I-WA$_BMD^XK^X+ZNQB][;9M)
M#U/NM^TJYKC;NC%%M5:QTM<>D<.PQ+/JN_$-2,0:4#KVXHAO51HJ$N\@AK.1
M58TFSQ@5]OEOL^P$3@:_[+^J5;PVNA0@YV-F$;TQT>%]C;-=NG8:C$NL6\]M
M=C0]#[-ZTTP--:9KXB]ZMUMJ8C9+1(N]B@;B$T2/5ZW;#6US0FV.Q,HFYSHA
M9]]V/25B@=CY5I-;#H'8#LOJH==+I21NO[-LG6FL][WZG:DV44KH&OU2L*=N
MVMA-8.H-U&NB*K96I2+ !A,CR3..(ENC8,)91,\#8PXL^#*1UQ"88T/B%!1&
M*Y_\2-.'SFGXDMA?C'O9?9<;5XQY3GB)1XET'I]3)3+'UAV=LKJM89<K,^0*
MUX52=U04G*_"GSFH+9DC5)*,(\(:8$9!,L8QCXDI\JPI'\YJ:[ =@/4&H?<B
MF5NLNM[XMNA!20Q9K3FM+G'KUU#;%; V4L$V57H+IR% +3A$.MO/OBGV!P)<
M881'NM$(LAW*?0"D$D\>?'SX_=]/QGHHUY:2-VI%8M9BH6"@ECHB+/)4RU-Q
MVC];G.)\2A1+$5U^.MV,^E:6WVEXQ(CY:?4TPMQ3#:?,ZO:FWM8:.IA'86WK
MY6-=TP6MEF58+45C"X;DV6OXH D>E]>)!8X5D>V&& BF9IDS.<:@"X,R8\TP
MOZ56<A44LQY\*"3P!R3X^0 ))]@ 2?$J 2> .3_IY/\  >3]!->#_K(=-P.S
M:]K793.^='M7)SVTG8&^.O\ LO3^O[<PIZ.PV4%S[R&#V*" 4N4PJ19K%6 =
M=%-.H?-%!K*DK5G<;IG<YN'D9N%CT9U6(AMRJ\+/P,O+HI'O=9@X^39F"D#R
MU@H*)P>\KP>+ZK6YE]5EU%:7K4I>U:;Z+;40>2[45V-=V@>2P0@ $GC@\>;N
MLD6]J[_W)L,B2CFWKQN79EJ;)QY+4V')@GKR<(C/MTQE3C,D7'&/Q(PEUAQ;
M"AC,3X%*9]BL[\UM7V#IC1XU:^F/S9BVNI5E/JY-0R;BP/![FMNL)_$GZ2?U
M#[-IL*M/N_\ 9:F8<%2&M'K/R.002SMS_P!)N7U1J\!)K_ULAIE2(S+3BFLI
M3Y<]RDIPC&,_GPO*O:K./VQ^?'XY$L_.M6T*O(+$CGZ#\/V?Y?,R#Y658;E4
M<\L3Q^ \D_7CYGY^//UDF;'C!9.O;K%/MQU@W*J<;(-R$I^'Z7[;(]WC&<?A
MQ&<)5'RC&'4OI:RSX=PCECB-8N5CM42+!=64(]^[O'\O[W/CCGGQS*XQ=<FA
MJ^?4%U93CW[@XX_Z_+CGGQ/'KV"AB05@BE)@F&;@"S,&?."394R!"-08<UN1
M+#S9XUV.2A0RL9IP?)F#I$8A&8?6_"DL2D-.HW[A)D9NKSL7'S&P+\C!R*:,
MU>WNQ+;*F6O('=P.:G/J<@J>0""& 8;=J6R["RJ4M:E[,>U$N !-;E"5L'/]
MUN#S[CCQ[">^;I+M_JIVEZS4BW]>:G01.M<BHH,KJ@=7*T/QJVPQ(;'W;7ED
MJHZ&V/%D0RG<(:4U$P-.BGH-A!R" (L.(2N-MSJ]CIMGEZ_:U659U%KB[U"S
M>J68D9"6-_OJ[Q^D2X$BP-W<\\@:4S,;(Q,FVC*5EN1CWEB3W\DD6*Q\NK_K
M*_\ :!Y/GF3VGKWH)"'&TZ/U EMUQ3KJ$ZTI>$.NK5A2W'$X"X2MQ:L84I:L
M94I6,9SG.<>>8N6TD0!6JY4QS8BK5\)6A+2E*:%@!4 ,.:4K_$IN$.8C1D*5
M_FREK&<_USGB)W?$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$2M_:/W?P['^//C]6
M#?=_]OVLWX\_[>[V_P#7QR.]3_\ Y<G_ /55?_X[IM#X2<?[3Y//_P#!\KC]
MOVK!_P N9K_Y 9TA'$3M():1!1EI.$.M?G*4.>?[M6?SGVY3G&?;G.<Y4G/G
MSG\IRG.<^;BK)>I>T ,/D&)\?L_#\/$L,K7TY+!^379X#,H![@/'D'QW > W
MT\$, .*&=P>O3F\=@]3;/'UG4[RF@]BQ%BV:2-CZD](@ZICZTVP-E19>;$MJ
M6;!(MUAKJ_TP.23<7-D-%$BU(A29<>[P\UJDSN^YT:[&85 %P#=ZU+#CM\*>
MQ6 8\>/N\^P.%W>D3,OZ?-6#1D)A;6M\M[$H9EP!AYRL'-O#6UG)MJ9JE#\N
MW?V>"10 SU!W>GK/OKKQGK$&,;EL]S,6=GMF/L&F)G\9X!WM#4MFX<..V6R#
MMF03[-';\%Z_:1*JHG%#8%C3$]$@$/5DDSL?[7CY7VQEH6M4.&RWCT"N*]?W
M0JFDKW^S*>X]_<1SW&1>W0;/\S[/4_F2NS877W7#>I;KV.P2W;592BPW7+F+
M:,?COJN4T#[,$5R#6LSHETAVR?ZC[)ZPV&I0I:]@]YQMNN%C%/T.NBKCI*5N
M2EW0GL\;3A!9BOT_Z:H"&A\G7XZ+$)++5^;+A I+I=IZ7Y#84+FU9:VD"K7L
MB*?49DO]%T%1<COLY<\]Y/ # =P"\"Z?IK/LT&7I;*%8Y74Z9&1:GV:I,C7-
MGX^0^8E%;BFCBBL*<9%#=];%:R7[C60?T)[KDYK=IM@9V%M#:#O3FP[4O]=M
M^MRDFJW#1'9RP-NFA#%H*D(1R?2NO@C7EJ83/"F!!@K%D V8!B=B2&7=G98"
MCLK;FFH9JU5,EB]Z9&*OW3VJ"H?(:Q"00P'#<JOD89>ENHW;U[ZBN;FG06YF
M55D8CFF_6[BS](@N9EM?&UE>+< Z6([*:^RQNY),XSIKV*I&QV]AWS6KW;NI
M5CM7V(OQ&@W UI,39-FBMH:ATG4:!O&)7Y;U2TWFQ4\G2KH"37;"BGDAL ]*
M+A8#,IQMV5;MGXME0JJM&%8V'C5K:@O9*6JNO>S'[OOWA7#HW<I<$J%)XF13
MI[;XV9]KRL,[_'HW>URGQ<BS75W9M>9K];CXVR6EO1P#;COC7U^C8,=E2PV(
MO=QS9S3-PU_HO:/;(_M272];B=S7C4!/66K1U@I]UN9,36.MFJ]?V&H5[6&K
MB5ML9:;5;+6CM36 K]?F9DMAG)86+. NPIK_ (6TY&75A?9EMM;%KM]?([7J
MJJ9\FVU+;,BX)76&4APSNON02&!$RV$^!B9'4*[6O$IQ=M;AK3K';%S6R,==
M3BXF3B# Q6R&N5'2W&LH%+*ZJW:K5$,:B[CFZUJ>U*N@".VWH*#=C",TH_NW
M7I[7]!<.H?2]%C +C\A Q7'D+]DQ,&\ :TY7XV,2BA"#$2C#&P]'5L]IJ\ZY
M:\/;MK,=KMCCZW+HR-C5AJ.VS)MU[FM\O'K!_3WZXY==:L#<M:\M/SJ^*OY&
M%]?5-?4_P6W#=*BS.398FEZC.PU%.GS:KEOJOZ<WF)1F9=%--P6['Q<_&HLU
MH0/^<O3]*JGK=912&_-K6G9EN=%$C5J,1\+GBHZ&A\P8#@PJW7I49OXFLXS*
M !QLF2I:,97-?DN8]J%I0CH/I;7U=-](:K"QA8@RL<;2\6D^HMNQ R36X)(1
ML>MZL<JOW2:BY)9F8]<C/WR:;66=2Y.%E]2'5ZY-[EZX,N!E;6C QZ,_(PE>
MJAACWY%;V4AZ:V]-P376?NKM="]5J_,##7R4=#0V2I*'EM8;Q(<;0GW.-LY4
ME>$K6G^3Y%)6EOWX7E*\XPE5G;NW6QUKY+J/'/MSSX8^Q/'OX/D\#D?**G<7
M&Y@K$LO/@\D#Y<D\\D\GCCGY>#Q-7GJ-]6ZGK: &L57R]]FLS11AP?-6A^0.
M(C$Q'7,M2$M-*>B2V9B5,I<PX^P]'?PXZM#C.$SCHS>9&5:]-W'J4FM@Z\A7
M1BP'(Y/#(5\D< AO '!XF/3>UNRF>NX?I*>P]R@@.C<\<CD@,"I!(\$,/ ()
MG1]&.Y?9"!JX-J[5'2J'M.EZE99KIVVT2S,Z^Q*?;2B0_-((-!B 0]?B$5YH
MU8VX)7[L:(3OO$@?!:+,JQH;XJ?#OI;7=19^?M/B37A;'=VW;*G6[+5['99%
M*Y-CFM+\O7-E6TXJ$>CCO;B!O1K"I79V'C:FKVFPHJ^R8FK3,JQP.^VDO0Q[
MP'YM;LMKLR2&!LX(>P_?],!O&S0%WUT?[,1]K#]G=<CK><8E!]^:TM=%A1T8
M4AO,Q-V^WD==O#E.J]K,Q-M3\B/[Q;+./=A.CLOI;8T_?PK];NL<DBN[3;#'
MS++!X^\=?W5[6D'GP,G H;@$]O ,S:=2:\>,U<K66#W388MU"\>!W>MVM2$Y
M/ 9G7ZD 2QU+W)J'9"TMZ[VIK>^K4WEY**7>*Q:5J:QC*LN)2#*3LY0E.,Y4
MK&/:G&,YSG&,9YA<G!S<-RF7B9.*X\E,BBVE@/'DK8JGCR//$RF/GX.6>,7,
MQ<D\<\49%5K<?4A'8@?M$DCEK+N.(CB(XB/_ ./_ #_?_P!?^''^?\O;^OXQ
M'$1Q$VM:W-O6.AU4S)SE4F6&BXE+SC.,N2XJ<PY3OY_/AV1'<<Q_3PK'CSCQ
MS:>NO.1@XMS<]STKW$^Y=?N,?WLI/[YQ[U1@)K.H=Q@U "JC.N]%1[)3:1=4
MGC^Y78J?NF;<O9@8XB.(CB(XB.(CB(XB.(CB(XB.(CB(_?\ ?B)Y'O4#_LF?
M7;LUM>R;GZM[IE=4C%U+3[!;]9RM?L["U0^>)OKE$)])@PK/3#&OHT^8Z]-E
M!&9%D 1GG<QZ\*KPU#,!I$EOTPO[+[UNZ*;9KG8;=FTR':K<5%(QS>MH<NDQ
M:#JVA6**M+T"THJ;M@N)2V6T')0F37"Y<]#$!IGL*QZODY"$EAR)ZAN(CB(X
MB.(CB(XB.(CB(XB.(CB)^82E/GVXQCSG*L^,8QY5G]\Y\?OG/]<Y_.>(G +0
M7R0R</BE2(*3,BNQV#(E(U9,8ZXG*438*# XL*5*85G#C22 R?$RO&,/Q7F\
MY1E$JW0^F6IZML2'N2[%;_O[<@C,K%7V7ONSM7@I0FIGE,EO6-4@BZ]K'5CT
MEG*HT\IKFB58T6BJ5&,$R#&?9ST]5^STP0J>.0JJO>0>1WL &?@^5#E@I\J!
MR>:]QX[?8?/@ <_/R?<\?+GP/E)![%];]/\ :K5I[4&ZZE#M52-(^:,XM+;)
MRL&V6G6QMKJ!GXG)5?LXA;RW!Y2'^<H<D0)S,T5-GP)5QK]AFZO+HS]?D6XN
M7CN'JNJ8JP(]U8>SUN.5LK<-78A*.K*2#ZX^1=BW5Y&/8U5U;!D=#P01\C\B
MI'AE(*L"58$$B>/S;?6O9'I];LQK&_/+-U,Q]<6U7LIF-]*+O]5AR6&G'7&D
M9<:%VROYFP(5PKRG,J'3)<(C"5) F0L^9T5H^IL?K' 9B$HVV,B_;L1>>UO9
M1E8W)Y;'L;]9"6:BP^E86#56V['PME5O,5@0M>76H]>H<\'V NJ'N:V/@CRU
M9X4\@JS70UWV4BCA326YJ$^&D?RY6G.,^,8_"DY\ISC/CS_-C/G/]/Z8L,S4
MEW/<I]_<\CR/QX]Q_P"HF!RM0_J]P''DD'@_3SP1[@CY<^ "//$B;L)VGG'Z
M_+"_<VF!CB/<]#B80PB6IO/N;^J4G*G'DH7A*\,K7EA+B4N?%EQ"%8OM5I%K
MN5Q6Q<'PS<DKSQ[#P!R.1R "02 >"1,EK-1Z=BVNOW@002"3Y^2@_7V)\<CP
M) OI?=;9'<+O'7;$9$1RVH.N\B#M'9#A&*Q+%$C65$V]74YQF2A]B3)-VT>N
MQ2HC\5Z')K-+L<.6Y'?G#\2?/XF[JO3]-+I*VXSMV4#(I(-.OQ[4LNL)'MZU
MM=>.@/AT;((X-?F\ZIS5P]8,%3^GSBH(!\ICUN'=R?\ C=5J4?-?4//W?/H
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M<Z[[)L6J;YEABR4@ND7,?C84F 5BN1H\\0=%^YQ[/VT\&F#R\)IQY4J&U-Q
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M$$'D'C@\SYVB/D:S848[J+[\'+KH/</]X]%BH??R Q'/R\'DB2!7X=;J58$
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MOZYG]HP[/A+5V:ZX:(%2^NM5+65LLWKKKE'N.L@,>I#8QP\+.W&R235MD/A
M4N)..3(UD&YPF0J2RQ ;6W&81-X_I$>JCU"]8ND[$K/:?KSH*@]G]-U55ZV,
M@A6P*Z3;==15-1"^TJ=8K.F38*N-KD]^-%N0,Y89ZZTV3#$6+(7A$)?VA$VG
M4WIQZ=FRYA9[0YH(R8%ICR#$GKSV-M;<@.W.6^F&Y,&TW8,\4+:E.1Y*8BGA
M;"'E,/I9RKXEX2B<JH=9]07B?9 &G^_/: B2I,MH=; - [9BKU)IQ!YR2VQ
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MV!OY3.5?$CHZT#G;&HG^S;@[ $?M9<5T_@YG!QHS:^<^,4V9Y\^/R0"IQ_\
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M3Z]EU62K-JG":ZY5K/7I=8?0[]53A,]EZ$/@RH?TB$2&ME0^P+W6_2]&Z?\
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MI3C*E*5G"4I2G'G*E9SXQC&,8SG.<YQC&,><\J 20 "23P /))/L /F3*$@
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M;?$H4B5. H#M$C VI7QR#SY(_A_C]?V?OXIS[?+G^7X2YEZW=3JOIT]N:N%
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M"9F%Z?SGZV;6&FSD;8Y36=K=OV'[3Z_VKNXX[&I_58^#817P'Y6=9U&ZF;Y
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MW[S$@D S3/Q:ZOV_3]>JP=/D'#NS_M-^1EHB-:*,=JJZZ:C8KJHM>QWM<#U
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MH9%]49'VD<^F:4)U&:R]*7;-LM^P0E[M,;7M<II90<%:,5U\_B^K<:^JC%0
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MZHEH1RFBH UPN3>98%UZ&E3\^4^]\CSRUJO\+;[#7+8F'D>DEK=]B^E38'8
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M"W-6;BY:SD&OU?=NLJ!+A;3!2-?! FI=@6L+=XEFJ-9&6K:$ I5U'D3[ 'L
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M*[ $8,&0+LU5:LH>W!LH+5^>,+Q?I3P$7,5B).9Q(3'5%D?+%>?9<1*P[_\
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M6RX/:P;=M=+.0^ZK5*;[%,O6FW,8N3NNJ6#H-(FC%1#C"Z61K=>K8+ Z?2U
M92"PR,><=<,I5-4B8'0O35ZE:\*C;&*J5Z/6V!NZA]CY%TOVY]O[$N)W=>MM
M;G=2U2]V:R72[&RA^;#H=D+ WA9*0_7Y#3D1:Q&%BQ?T:)D,;T]>HS$:K0'M
M4,%!=/*]I# @.<LUN-AW9/<^>:)=CXY@64.RH)X9L*18C"5BC+,T=7XTU<.L
MQ@\5#32$2-0WI1=)Q=(O%!GT*\W(-?ZOJO7Y4AL3=NY=@6L1K#1]Y'[)U-JJ
MFW&VWDM9Z7K:E707#.0:E6"@P:3E(4JP(,>[\(EOMFZ*UCN&QZ=M.Q +]@*:
M%V/C;>L4*-FX L)L-JJ66EPK+.##2$05898H#;C[8=FPQ"<05/FI+08[!2+$
MEL(D/Q>B/6&%NU786%0)D3:*MUR^Q."L>Y75D*WN,CI.5UX+79JHH/IJC4XU
MJ>6Y7S49L.D>5FMQ[).B/V2,R50B8R+].CJK7G]$2ZO4;;5)?7$IN\AK*76M
MI[*#RF878ZY/;"W15K5(BVE+MXIEXN;C!Z=5+:HN&A21X^.*BP($;$12)KJ[
M@^BN"W%6*CI'KP&U5I;3K/7&E=6;)>R.Q.S+^UQ>I:A8B4R #D4>M[ &:LW[
MBLA"#KNM'M\K+R:/<I4ZR?4&6U11\9$V@C.DNC:_O$AV"J2MHTB\6*=7S-[#
M4;=6UJ?K+9MBJM:A4ZOV?9.J*_;1^O+C88%8&# SY,M7773,(6*:/8*X%C\Q
MD3%*]Z='5.G5/3-/IE0N-,']>]3;=TGIHI4MN[7KMKH5 WB0JY;8L0/<!5RB
MV7)HF2IM<F#;1+*2;%7G1_M!$Q[4J8W(1)MZ]=<-6=8:47HVJ1QYB#9KO:MF
M7([;K=9[[=+SL6[S&YULNUQN-P*&#YZP&GV8R9$J7.RTQ$B0X$%B+!B1X[:)
M.W$2K&].EO73LB>.V7<%'EV<S9>OVS^KQF5'MMO )E:4W&1KQ78533'KYP9&
M8D&YU6".M6*.TU9!6(BFQ)6$U)DH>1,;N?0'JML M9CEJUW-(DK@)ZS!+ ^B
M[7F#B:-Z?W^=L[K_ !T,P;%&9BYI=U(S"TEZ(AAZTMNX'VMPT-;;B)1,'O7I
M@=.M@G)]F,4:YB;(6VGN+;QFP4S<>W:*;+V7L%4ZQ2-UB9Q6I74//S2-D5FE
MU0;8Z/&D1ZTXD'$>ACX;ZY+CZ)V$7TS^FL+7ELU9'U<012+OI7KIU[L@E6P=
MB..SM3]499*=HJMH)KM"B<-^GR2TY<@Y#EL';)AU+=G(EVVFDH1,^>Z.]:9&
MV,[N=H<Q6R5;^A=GLG?UA<DLYW2/T?CKG$M?V=)[ ;Z=K4*<5G->^@_3BW__
M '\X*58,Y)\1,"D>F=TNFU&IT,AJ)9*HTJC=I-;@ 9"[WZ5%9IO<VP)L_8H1
M+4[9LR"/ZY-)Q+BS9[T@A4L8PS3Y0)G&&\(F&1O2=Z9QZ/L&D.US:Q-S9I#0
MIVT7PWV"W><VJW9^L$^40T-:ZULHK?)=LIMAUJ]*RP G5,D&0@?&A#)+$@?$
M9C)1,X%>FWU)$;DA[OC4BU/V>!LYO>D>L$=J[/)ZG_C\BOXJZ]^OZ?G6U_6T
MG<TD-[DR[_(K3IN07=?M+CV;7(>..(D.]F?3-IVV.G6NO3ZU)BJ:UZL_Q)K!
M3;4"QIN%VOC>L &Q']SE06IK 2/N20]YMNP8T(0[;;*0),U:J&[!*#P)1"&)
M'J1+VWW0>J-E0=1C+956I S1>QJ;M;5PT80)@8%7NNOQ94-4)S,,','QYH\*
M.-3X\<$1;EA%X4PMX>XN)%4RB0+6?3EZ8TX;0P=;T@#&U[7%A[#6>LUS[O9I
ME?\ NG:D8=";U0<#D#4J#9A5U#6,H(P#L#)(-7Q2H0RM00\ 6-C1$3%6?3'Z
MLXTV8T&03O&Q:PD$M=EZ8%M?9;?EIGZ6):B)O&-7SM#6([L*?8=.SZ//>2H.
M1HY,21>A11X<M+)!1\(<PB<FK>F)TSJ<$=!B:VL)I,#=UL[&OS;GM7:UX+G]
MS7W2[^@+O=[8:MMS,%K5-MFL)4P0=AGYD\7.)S9=D7"Q87UDN(F& ?2+Z.@*
M!?-;(HNQ3E;V'IFD=?#2[=OG=UO,C-0:NLR[?JJE4TU8[Z2(48;K ]]/-HRJ
MD\'D!5PHRL//N?4.2$3,)GIC]12FP1>R3=5V ?.QRVIK3:!AW=6W2E,VML'1
M@H4&U1M+=%%E71=1VSLVGPP89R/=+R',F"Q 2)*6!XL1#B94)$S8ST.Z_D=1
M671X=.U:#0+EM?9^YK7%UCO#;FO35BN>Z#=ML&T6C-DJUP&G"%4N!*\V5Z=2
MI4YRK0LRX;@<4.?#!'AR)9R@4.HZLHE*UEK\'$K%$UU4Z[1:56X*GUPJ_4ZD
M(A@:Z%B+E/2)2XPL1 AP6%R9#\A;;"5/O.NY4M2)EW$1Q$<1(QW#I?4_8+7I
M_4^[M>U3:.N+.W'0<IUS#Q306<N%):FCY>(TI"LQ20R<PP0%%(:XY(40CQYX
MZ5&EL-/(1*P2_3+Z+$-?@=8$>O-:)5&KV>QW"O-DS]X(V(.=N (55[>[!O,V
MTOWAD;:ZT##5^S $V/[ ?"BAXLL,F0HC#"$23R?2WJF7!WBLS=#Z\Q6]D:?I
M>@+K7X0; L(<TMKG)K-%UHL2+=AP(53JN+$:2&&#8\)N&V1?:1GX_8A")6^D
M^F3J(J.[&N=J70'9RR]E>QP#L;9I\NGRM< J6=UU3:SKC3HK7 L/;C=BK$K7
M5&JD$7FVLW-RQ6.<2L4N:_$&&% XZ)AO:#TL-;;5U5K+3W7^N]7-&4[71[;!
MT=!OO5IS>+-9G;C>^MMY?54>%N34D>A%IY.68(F!95N[:^M3DZ%$LE$GCPT.
M*I$D2B>E%T;J5*TE5SVDJYL0UHW46F]/@;U;L3<V*P"-%*BS=>G[3&$3!H$O
M:@)YF6>#G) E<X!**E((%\<)FOP%HDKVCT_>FMS5MI5DT!2B*]X[ K>V-EK2
MHW!<,[4J+,R. V:*6.+1%TW8<-HA.P]=:2JNV4DJ7(<*$YKCJUY1+(ZZUY3]
M3TJO:[H(E0*GU:&N #%+)%C#D6,Y)?F._,5.SB9@@^]*DR)#\LD0ERWWGEN/
M/K4KSQ$S3B(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(
MXB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(
MCB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(X
MB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(C
MB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB
?.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(G__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>img30600998_18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img30600998_18.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1SZ4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '-Z^<Y X0DE-! 0      !<< 5H  QLE1QP!6@ #&R5'' (   )@   X
M0DE-!"4      !"H<CR.\+B]1))=K(K5'*#I.$))300Z      $9    $
M  $       MP<FEN=$]U='!U=     8     0VQR4V5N=6T     0VQR4P
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M;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/
M8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R9%15
M;G1&(U)L=                $)L9"!5;G1&(U)L=                %)S
M;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !09U!S
M96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M    5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M       08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M
M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12
M:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M   0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@             _@
M.$))30/R       *  #_______\  #A"24T$#0      !    !XX0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              ,X   &(@         !
M      $             !B(   ,X                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     8X0DE-! P     $B4    !    H
M %0   '@  "=@   $@D &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( %0 H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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MBRRS[+?2\%C]MP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MTHF1<-"%3,"-PN+,>H&CT%A@H9R4"R[AZZ0<0H;)X5X"GU,17^K![;3VP\4
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M4Q2F*4Q2F*4Q2F*4Q2F*4Q2HA\Z..3?E)QHV%J])!N:T>9%LU!=KE+U976O
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MKU^VJ/;\O;YN_P _S]<^ /5[/D]'K^7T>P/F^TH1W/SYSZ_B[YSU\<'Y9U\
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M<G%X2R:[U*X9;(M>M[6E&'JFSHFGR<1+N:%-6 A)>,0%=XC7Z8_+O87Y<4I
MD 266& 9:)T#)-< PQS1[N9"SJRB54]%NQDSC,3#<R]5ZJK-V8'#*F&*G&&
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M5CMN;?.4AU.RW-)9SE2&!DMI<PSOC2;V]J*_:-O]AUGLRONZW;ZV[,V?,'(
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M)I<8C=72[#.A&&40AGD#@C(VJK9SC'4'N:].0AR*$(HF<JB:A2G(<A@,0Y#
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MH86<1[?6QE#,0?LB5C/=>:,BMV>23ZF[C_RJ:@EIHNA7]_L*&X6 1P06:/\
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M'/;PQ_YK;**D:+'&BQHH"JB *BJ.RJH "@=.@Z=!TK\.HCU'K\_CT_W=<]8
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MM@/IV)NI*#*NRA#2,I%S#ZN/G4,PE'*<MI+<W5VVHRP31MK6G/E989MUE_\
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M'O\ #1KC^TF/,;W^!W7]7E^A3G0_=8_PU_33XV_%+ZYOCW^&C7']I,>8WO\
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MX/K!]1R,]>XK(>&N*.(^$=275N%]:U'0M1$4L!N]-N9+:5[>92DL$NPA9H9
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M3W'AUK%>)_*YY,N#('GXDXXX=TWE@DVYU&"ZO7P<%8M/LC<WTC=1TCMW/7J
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M_'OVUC[2R_$2?X]/<FU]<OX8^C3XL6W_ +(7S@_G3C#^J_CW[:Q]I9?B)/\
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MNCOE,8DQM$&Z)#U19)E0._P>@8K,-P=Z(8F#N"VTM&,+NQW+X8CN54L0._7
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M+:=/4M12T42[7Z8?6>ZQ\7>IC7S_ &'$4FR7&3D;B]@6-A3EFD[(/4H>RQD
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M,!WDG*/EG$A*R+AU(R#AP]=+KJ*57V*4Q2F*4Q2H*=IW)K1/9Z\QGB'>!0=
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M4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE8T@_A(^1_\
M(ZX<?[7>:F:ZX][Z9\5W^>WJ^:-_M_\ A_\ VJ0]J9.9.KV2.9)^6>2$!,,F
MB/?33\JY=QSA!!/RBIB))]]50A>^H<B9>O>.8I0$0U\I 92>P8$_%GKX'\Q^
M*KVP)4@=R.E8C>+_ &:$^'&KC;4.46W=OS%DUIPQ<Z$B=9DDM9Q:6@[%MW34
M)KG<"M6O>NJZ1]:++4HHDM1-<61]8K%'5NM'7%LO9'KDM@4OU[K*^>7DEE!;
MJDVH^=--MF8W207#2VXDBF?"([;99D5$9WQ\ #;5'#:L(HEE=\I#RPH*CEED
M"L591U(&54DG .#GN;HZQ[-G7VF87=;I_+2VZD-F\7FG&N5UHTH.D=2U^;H%
M9:V\[" BHZ@5.A5U*PVDMKDH^4L%K>.$3OGI%S/H>#:LXZ,DSZQ+<-;!56VY
M-Z;Q9C+<SNLLG+#,S2R2N40Q@JJ ':,89B2WM+54$F27WQ<LKM1 57.  H5=
MQ!P2<_&!7\<6^!<C4>+7#BE[GLTT?=.GMKQ/*O;<TB]B9M]==^3]9OK6Y1%D
MG$T5&DO%Q:NR'==:2L3Y$%HNHP"4<HE'$(GB^U027M_);HHMIX&L;=2&41VJ
MO%RV52<JS"$.5;(#2.2"<DPAMRL,*R$[T82OU!S(0VX$]B 7(R.X \*J;7?9
MQU2BAIRIR&[-LW'2/&^>L5EX^:7EDJ-%Q.NI>9K5MIT&L[N5<J<3>K:EK6K7
MFSPFLTYB<*>!;O6CR75L<O$1,DSES:M)+YPZV\$=Q=HB7=PIE9IE5XY&Q&\C
M1)SGB1IMJ'<00NQ693Z6V5=@+LR1%C&AV@)D$#J%W-M!(7)& ?$@&K3:W['K
M25*@YBGS^PK?=:3*\4MB\.R5\E,U%071-7[#DZ1)O+%*V+7-"K4W:]K(+TAB
MN[OMI<R[B6DEU)A6.;22LDO*5$VOW,C+(D4<<JWT6H%S)<2YGB$@"*DTKJD'
MUP@1(%"KZ()7 7PMD@!!9F7E-#@*B^@VW))502_0>D>IZ'OU,H]+\1)K6NZD
M]]WWD/L_>=]1TFGH=L>[0FNJ_$,J@VM,/:VSUK&T*I5DAK"YDHI1Q.RKY1\K
M+NY%PH0K!@UBHN/H;B_6:W\UBM8;:+SCSG$;3.QD*,A!:61_0PWHJ,!0/$EF
M,U(2DG,:1W;9R\,% P"#G"@=>G4^.? 8 [)'B<[@-]7K<^N]Y[-US"[>N>O]
MA[CU7!1NOI*K7RXZZ@*[4F4BA-62GS%LJ;6V5"GU6JW]A79AJ6?AH1N$:O7Y
M%S(2+L;X/:Q6\UK!,UO%+#;SL95>*.5GD(*I(J2%))))(F=3M9SN#@* $.)&
M=)&4.RO(@"D,R@ =2N0"  V#U \.N8E67LA=7SU4I]5:;?O46E7-&7KCX_D7
MM(T[=7CRBWR_V38DG(5D+_0;0EKVZC*6A_$.[742LGLE7D(ULX3+*PT%,Q=<
MFO3H\DAMXB7N8KI0)+B,"6*)(E$@BE3G1[4#"-R0'W$':S*91LT*JH=AB,Q9
M*QME"Q;[)3M.3U(QD#!ZX(D+.\&8ZT[&T7<;'N2[R=:X\2M)LNM:4%1U0T=P
M5CI%!-04 C]D-J,393.I6%!5S8K94"651">G7;IFYD0J*QZL-(NI%(;J-+>,
M27:R)-+S)SN227FG,)EY)D4@*DFS*J,A>9]<J:8,LA+L5C*E5VKD%5V_"QNV
MGN5SU/CMZ5;>0[,>F6X=O3>RMU[)N&QMJQVF&A=FQ56TWK^PUV9X_;#7VIJ_
M8*L12=;Q5/N6RX^Z*I.INSW2N33&7A&J560@8NO+/H]Y-&L21^;K#;PI% ;G
MZRSW$J,MW#R)XMTDQDC@,8PJ1.I5CS"[. R^/-0=Y>1F9MF& 12IC;<C850&
M<-U+,#D=, 9!O:]XN[$D]9S%%D>3-H>RL_949>9EW.E>.:]7E*V2NO:^YU[)
MZY7U<K7Y.J2"STMH>.)%=U:#6ABP%"Q(59-Q5'5.+V$3+*+- J)M51<78=7W
MAQ*)1/O#C&P >@$)]'?B03.2Q4J9&))!/H1D8"D%=NS!7[(D]<CN!TKK9S@G
MK67X0QG!5*V7=IKJ%J-*JL=:USUF6M1RT.U05SAUI:-DJZM2):'>S5?9LYVE
MKU4E,DZHN^IQ81K7ER,T8KJ<RZDVIE(C,TDDC( ZQYE1HVVD/S%8*Y*R<PR*
MX$F\N,U P*8!!EMH"+NZ$^B0PR"-I!*X*XVE<KC'2K=T#LWJ1232+QQLNS3<
MO,\HM0<JI1RSIVMJ1#A;]/5"$ID)58>J4*K5RN0E/=14"Q(LDV8*3@G(9R^F
MI.36>23N=+J\DF (455LKBQ4%Y9&Y=Q(\C.TDKN[R!G)R2%\ H& /*6P7.6)
M)E24X"J-R # "J  <>K/MR352W/@)5[%;+;LFN;4OE!VE*\J(SEK3+Q!,:I(
MK4.]-N/-;XRS592A;!"R<18Z1:]90LHRGXN70\^.[L"[IA)L5HZ.42EQ:FZ)
M'"\$4L LFL98G,@$L1NWO5?<C*R2I,P*,IP @!4@MDUN"Q<.5;G"96 !VD1B
M(C!Z%2H.0>O7H1TQ>GC+QP:<;8#9,4GL6[;3E]J;>M.Z+7;K\E6D9YY:[A$5
MF+F$RH5&"K4 VCN_6DG+%E'0K!K'INA8-4$V;9N0M/>79NVA;E1PK!;I;I'%
MOV!(V=E_;&=B?3P26))&2<DU,BB$0<;F8NYD);&<L #V 'AGM5NNT/\ WIMY
M_P!.- _TA]59<>&OW\T[^F;^ZDJ3?_N.?^8/R,M3SWYH&C<BZ4QIEW=VV%4@
M+1"WRE7"@VF4IMWH5_K/G0UNZ56<C%.XE+PQGKKR3.79S%?D47"[&<A)6.77
M9J;LK$JB]\)/+CBN(-]XU>0Y=:.9F(D3?.DZD@SY"4N*2)^Z2FZ./,&5)ALA
MLW* #(7#C>W/8'2G4Z/'R-8I.9,BE3"U)N756^*6PV'IR_5G8M-D5%VR,[5Y
M-&00;OVA_)/XB4;E$KV$G8Q?JVEH&8;,)F)=D4:23%JY3.D52J:BN1FI9K<L
MQH:.LGEMCP; [UY&BT7(R.H@@F[>1K22,4&SJ58,U4W;UDF(F10\J(&.HU=I
MH97<<%<16O#-MQ=-9!=%NI1%',)$,RJ[M'%/) #OCMYI5,<4I^$VW("R1L^!
M6?E+X0ON-;SR?VVI%^)+*!YI8#"ZVTDD4:S7%I!='ZW->6T#":>!,E(Q)AF>
M"X2*^.8I6>TQ2F*5T5IB8N?K-B@9OR(PTW!RT/+ Y.5-N:-DV#AB^*NH82E(
MD9LNJ50QC  %$1$0SW%(T4D<JG#1NDBGU,C!@?G KQ+&LL<D3#*R(\;#UJZE
M2/F)KR:-JTI;6^S]C:\<NF;YQ1+S:Z>X>Q[M!\S=+5N<?1!UVKQH=1LX;K"T
M!5)=!0Z2J9P.F(E, CUAI][!J-E;WEO(DD<\4;Y1@VUF169&P3AU)PRG!4]"
M :Y:U&RGT^[FM;A'CDAE>/$BE<JKLJR $>DCA=RL 0P(()&*H+]O3[?F]G^[
MQ]/2MJ@Z?J/5\?@?T]*>/7Y/#Y_M^/S?FZ8ITQ[>OC\788]I]GM[BLV/T/YI
MIWM;M(]9V#S45X72]9NNTYI0Q!,DB=M"JU.O]X_3H58+):HMR@4![YO-#F !
M(102X1Y0;T6G#5S'G#WLL-H@SU.7YTG3Q'+B<'U9'7L#FO -DUSQ%;28REI'
M-=/ZAM0Q1Y_XDR$>T=>@-?K]$#Z8<:H[2'8UB*V,C#;KJE*VK$* 3HDHLYB2
MT^P%*<  IE!L=1DW:H>)R^>)][J!B&&'D]O1=\-VT9.7L9I[1QZ@&YT9[?<Y
MD7OCT3\51X^M#:<0W3X.R]BAND]7I+R9,8_E(F)!/V0\" <)/Y>@?;\?\/R9
MG%83^3)^3IG]/Y:?M[.OVO3X?\.OIQ3]?61CMUZ#K[.GCC.*J*HQD;,VNMQ,
MS*MH*&DIV*8R\V],8C.&BG+Y!*1EG9R)K'*UC61UWC@Q4E# D@80(80Z#2WM
MREG9W5U(0$MX)9FSVQ&C.1X=\8^6JJQMFO+NVM8P3)<3Q0H!U.Z1U0=/9G/L
MP2>G;U6^/VV]#;2UU5UM ;0U]LNDPU?AX>)>T*T0]@:M8V*8-X]D@LE'.UUV
M!DF[=-/S=XD@NGW0*=,HATSDV61I99)7)+RR/(Q/<L[%F)]I))KJJ.-8HXXE
M&U8T2-1ZE10JCX@ ,5?3)=>Z8I3%*@CRTYO0/&2RT>J(P"-OF9Y0)2SLR27F
M:U>JP+E;D=$*1);RDI(*><'CFSCR2)DF2IE3 59$^;;\G?DLNN.K'5=1DO'T
MVUM0;>PE,',6\U#879&+,F+:$<L3.FYMTJA 2C"M!^5SRY67DRU31-'@TZ/6
MKZ](O-6@%UR'T[2N8(D=0J/NN[EN<UNDNV,) QDZ2QFIJ5RQ0MN@8>SUV0;2
ML'/1[64BI%HH55N[9/$2+H*D.41#Q(< .0>ATS@9,X%.4P!JZ^LKK3;RYL+V
M%[>[M)I+>XAD4J\<L3%'4@X\0<$=&&&!((-;NTS4['6=.LM5TRYCN[#4+:&[
MM+F%@T<T$Z"2-P1V.T@,IPR,"K ,"!W64M5U,4IBE,4IBE,4IBE,4IBE,4IB
ME,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE8T@_A(^1_\CKAQ_M=YJ9KKCWOIGQ7
M?Y[>KYHW^W_X?_VJ4N:\J^5';D5R)BN/L7KM,M)MVS[[N#8\=JC56M:.K6VD
M_;[B]K]CM[LAY:X3M:K$!!5^H5"SV>PSDS,MD&47#KD:HR$FX81SNKM+1KII
M?KL<,4$)GGFEWE8XPZ1@[8U>1V:21$554DLPSA02)<L@C"^BSL[!$5<99B">
MI8J  H+$DCH,#)K&UK/M(S:TKF]K#OB!O;:YVKGQL?1>GM.7RWZ9I<S3&%5T
M?K.]2U;GK]9=C1.GH"I5,A;3-'GD]A3#::7FHUK5!L4C/Q3!:[S:1SGMDM6C
MY<>EPW-Q<1QW,BR&2YFC5UB2%KAGDRBA3"I4*3)L5&(I5NMBR&0-N-P\:(S(
MI7:BD@L6" +UZ[B"3TR34@(+M,*7?H/2"^HM*;5VS<]Y3F\ZA$T*HSFH%EZO
M;N.TK$1>R(^RWQ;91=5J0#<DDI)0-TKUYG:U9(Y*.]Q7KR0GX=@YI7T>6)[D
M7%Q!!';+;.TLBW #I=JS0E(A#S]W0*\;1*Z,3N "L1,%TK"/8CNTA<!5*94Q
MD!MS%MN.N0P8@CL3D"JEU=S)@C[//K2TK[$F??\ \M.1/'RIVNS0]!B:]3KK
MJ.E,MA,-9IJU/S)P]A9NJQES>4>>GDI.S2;FM2S&Q/Q77AO+>)M/;D\Z,0KR
MK&TNGC1I6>6.>0PF;$F0&5S&)50A%WJ4&-V(K.-VUMWI2R1@D* K(H;9E>X(
MW;2>O0Y/:NDM/:.PL)H>#Y*07'[:UQU#,1>R;>%F:6[1%2!37VOK18H=E8X*
M+V-MJG35ME=A5JO'V%1*M7(U^]D*J_8$DW<3.O&40[]1Z0[736;W4$=PK0Q[
M#'=2?7940E&:&"146%WY4LC$!9%;:&4%J@UR!&)1&S)AVW;HU]%2<'TF!)8#
M<JC)P1G!.*I^)YJ[5M6X.7%13U9.PVDM2\?:%MND[B@I'7:]@C&-VUULZXL[
M&[K$_9WSF87L_O5CRTV$=5,B<$^C7R=Z;E82+<P>VTZ!+>PDYZM<SW4L$ENX
ME",8Y88R@=$&T)S#S6$GI!ARB2IH)G9Y5V$1K&KJX*9&Y7.<$]<[1M&TX.=P
MQBJ@KG:$4F+U)=IR>K6RK!<]65;BHLVA)!C3&-UW@ORLK]):ZBL%3C8)\SK*
M#BZ["L4O19)JBE$1<-;:K:$VK5*#9LEE);Z5*T\:J\*1S/>Y8&1H[86+R&X6
M0L"_UN%%E4DL6CDC).XD"(N5"$D,618L [0S\T#85 Z9+$@C  8''3K7PH]J
M9H5SR 3T<VB95=BIO=;C*&P$KUI4P!NAO+N*PM$#J8-GCO;WHIW9LI0CWD=9
MA$!:0\MY,:@ VX/7N+="U\Y+*#YJ+SE&.X'['*APW/Y/FN_ED2\OG[MG3]L^
MMU#SN/F;,9',Y6X,GP\X^!NYF-WH[MN,^SK5^N+O+./Y4A<IFHZQM]9H-:GI
M^MQ5ULEGU6\/.S-7LTK59N*DZ15+]8M@:_FD7D0M(H0M^K5?DO<==JK((1DH
M=2(2I;VQ-ERU>:-Y757:)$G&Q70.K"22)(I5PP4M$S+N!VEEPQF0S<W<0A"@
MD!B5ZD':1M#%E.03APN!CQZ5%J([1.U42;[06R<B=125-TEQ%VY%T6KW:$G-
M?NG\X:>H6@GU+H[V-7OWE7-QV-9-N)SE>L$A[UJ1!0$] P%PEX*<B9M8E<VD
MQR+I26EPLES?P-(\;)* FV6Z$DF>5TCA6 HR#?*S*SQJR,M21<LIN&D3;'$P
M56!7KE8]JGTN[E\ACM4 @-@@D_9'=K!IQY0-DV5>C3I;CK.YZ;I,I1H39_'N
MXQ#QWOR8=P.M9T=QU';DSI>O5AS+1<Y'V1_<+S7I"MOH-TU6B7:DM4_?) Z'
M<"6%.:O+FCGD65H;N-@+50TR^;O;K<NX4J4$<3JX8$,,/LCYXFUCM.Y61=H>
M-@>8<*=ZN4 R#DLPQCMU&:P<<O-]&Y@<>=(I\;YB-U]M;C9L?;]U7D;MJ5Y8
MZ3*57:FE:8K-&F(+94I 2U4I<)L!V^GX^NEG9FU&M-6=58QS0=FCD)8L+7S"
M[N?/%::"[A@C"Q3A)%>&YDV[6A#*\C1 (7V*FQP^-R$Q,\@FBCY>%>-G;+IE
M<.BYZ-@@!B3C).1CL<4?J3M=.,^V+G$035)_7Z=<Z[LZU:WV&[N^G+(C:H+4
ME;E[K:9":UW0]DVK;6M$I"CUVPW.K!L:C5P\I!0SIO*$@;,XC:Z^F7&@WD$3
M.2'DC:%)H1%<(8VG<1(%EEA2"8B5DC?DR/AG!7<@+B"7D;M@= 0Y1MR'<$&X
MG:K%TRH+#<J]!UP<"OQUCS"V3O3EKQ,CT=2;IT;J+:G&?DIMR)CMD.-;+1NU
MH9.9XQJ:RLJC.BWBZ2%=LU;AK38'4A5;,6$E81G=F)5BOG+IXWBD]A#:V-\3
M/;W-Q!>V<#&$39@;9>\Y,RQ1AT=D4!TW*QC."  22=Y)H?0DC1XI7&\J-PS%
MM.%9B" 3Z)Z@-DUE7RR55U"?M#_WIMY_TXT#_2'U5E\X:_?S3OZ9O[J2J2_'
M[$G_ )H_(R_K[*RP9NRL2JW^UI^T576MYLM*B&T];(&KS$O 0SSRHMI&18,U
M7*+54J"B2ZA3^3'HBDJDHL8 2(HF8X'"\</V=AJ&N:38ZI<O::=>:A;6UY=1
ME0\$,TJQM(I=612"P!9E94!+E6"X..<7ZCJND<+Z_JNAV<5_J^G:5>WMA9SA
MVBN+BVA>5(W2)XY) 0I(C21'D($:NI8$:OVS>3EDNUO+N'7]<A.._(EPXCRV
M#>&C7$C6IB^Q$<K])7MITF87L&NMKQHM>\R:+;&K%GEJ^D(+U.3@'J:;D.KD
M^IZX3CN1*VJ:Z\"E6%LTMCU((.'E%D&9&P0RA4;#$!@<$<*O]5EQ_)9&#W%X
M7BNG1E:[CM]3!7>"-T<#:DZ))'D,A9Y$WJ"R$94V=@]CWFN7YKM")LDBA?&L
MTK82V,ZWG#]:6<JJ*NW#HZY5".@>^673>)+$.BY175153%(YBCN>ZT72KW2)
M-"N;*%])DM5LFL0NV%;=%"Q1QA"ICY6Q#$R$-&Z*ZD,HKG6QXAUO3=<BXEL]
M2N8M>AO7U%=3+F2Y:]D=GEGE>3<)C,7D6X64,LZ2.DJLCLIR3L.U?WJ[;1,.
MUUQKN0L3EPU9>=D1L0A*.%E$T$DD(M&9("#ETJ<I0!-RHGY0X FD4.A<TC+]
M3YPC')/</K.MPV:))+RN98CD(BEV+3O:.6CC4$Y9 <#+-724/U6/E DAM+2+
MA_AJXU!WBA,_F^IL;F1B%4):Q:@@625NF$<J68!$0=*R8;_Y^<3N)58CY?DU
MO'7^L)Y>(;/G%,4EC3MS5>&:IJNVD538!*4M4@1)P*B":Z<4*(B4!.J4!$0Y
M&N4ACN+B.WD,T"32I!*PVM+"LC+'(5\"Z!6(\"<5WY8O<SV=I+=0K!=26T#W
M,"-O2&X>-6FB5_LECD+(&/<+DUKQ<A/HH-&QS9M=< ^,5MVG;9!R+"%M.S(Z
M1%&07,;N)K06L*.[>6:635ZE,C[I3T$X*(CYQ&@!>AI-5@3[8X^;]?54=4^#
MG;[=J:H$ARIVS)<;=-3"A5SU"VRAJ)%FCU#@H+9II/7@!,R*S<ABBA\)!XU9
M0>[WI,YDS"14<JO89/K^+]<]/96/7M2>R2F>S)<ZC7@KM.;6UML>#<MI"]RD
M*UA2Q^SXE==69@"QK%5Z2-C7T(K&R< 1Y(/7CL4)P#.#^8F[N[O)=>0-IU]8
M<US<177G/*=@5$,L:('A7 (&^,B4>D Q4C;OP=*^4VSF.H65]RT%O+;"WYJ@
M[N;%)(Y24YP3LD!C( ) <=0N1B+\?D_+XCT]7R>CT=?7Z\VE6KCC]<=![?;W
MSG'A7)>GKZ].@>@>OV_F^7TCBO0&<],]?41C.>^.WA[!UZ@UO6?0WO#M_IGC
M7;N2URB%8ZV\CI!@E4$W:8$<M]2U,SDD.^*F<H*M@M5A>3$CW1$"/(F-KSXO
M>352$-$>4G65O=2ATR!PT.FJQF*G(-W+C>N02#RHU1>V5=I%\#6\?)YI#6>G
M2ZE,I$NH,HAR.HM(L['&>HYTA=OXR+&W7I7[_1'W#M_NGC-5>25,B?/KAQO?
MOC6M-JB91\_U1:U&2,POW4R'47)4YUM&S/<^E(TBGMA>G,!4C9#R;ZRMCJDN
MFSOMAU)5Y)8X5;N+<4&20!SHRR9[LZQ*.IIY1-':]TV+485S-IQ;FX'5K64K
MN)QU/)D57'@JM(QK1*\>O@ >OQ]G7U?;'Q$?$?D#J&;XK1N!USGH0/C]OS=N
MPQZ^M<C_ (?<]/H'I[/VZ8J '_G\^._JZ^OI[,UG#[%3LPJOV@>PMHS>[8ZR
MDX_Z]JCF#D'U>DUH!_,[$M"((PD3%RY$U1!2"B@?6&3*1)=)(_N(V>HJ-I3N
M*:X\I&L+9Z2-,C<><ZF<.H/I):1D-(YQVYCA8@#T93)C.TUL;R>:.UWJGNG(
MIY&FC*%AT>ZD4K&@\#RD+2D]PW+.1N%9'=M?0Q6T]46$VP^S]YD62F6*.,+J
M(A]B/IBGV)NHF8QR(LMG:Q00,8XAW2(D=U!JD)P_YP\*0YC$T-6]-^?A 'XN
MGY.OY_946-2]I3V]O#ZJ/K+MK5,UR3U%4+C>==6>6O-2+?%*W:=96^7HUTA)
M78VL'3:RPTC%S\#(((N+R#U-_'^:S+)!W%/F3Q53"GL<'U'/?/3V?-U/CVK*
M1QN^BB.'6Q%6,%R,UYLCCE8E#)MWLTDS'9>OT7(]"*"H_KS9M<V)"J]X#%6I
M;A- G=.J[Z>5%)0H?#K^3U^WPKX-E\]MAV;9=[M/'KE,IL#4MDF'#VG3=+EF
MLC7FL.]32=MX1)F\9"K!2T$DX+&2+)1JRDT'+<5'!2F5 Y^SO)WPCP#Q1P7H
M6H3<-:=-<Q0>:WTDD;B>2_M&,5S)-)'(&E69P)E60LH255VC!4?./RM\>^5/
M@KRC\4Z3#QEK%O9SW37NG0Q7 -M%I6H*+BRAMH)(V2W-K$_FKR0JCF6"1M[%
MMYAY/S\[:IA_8;-,24_.RBYG,C+2SQ=^_>+F  %1PZ<G465,  !2=XW=(0"D
M(4I2E -U6EI::?;0V=C;06=I;QB.&WMXDAAB0?8QQQJJJ.I)P,DDDDDFN<KZ
M^O=4N[B_U*[N+^^NI#+<W=W-)<7$\C="\LLK,[L1TRQ.% 4=  +B4G?>ZM;Q
M#BOT3:%SJT(Y,H<\3$S;QNP(HJ(BJHW;>4,DT55$1%19J1%0XCWC&$?'+-JG
M"7#&MW"7>KZ#I>H7484+<W%I#),57&U7<KNE1<=$D+*.HQUK(=%XZXSX<M)+
M#0>)];TFQD+,UI8ZC<P6X9\[W2%7Y<3O]E)&$=CU+9 K8G[/X+\[XVUNR[#M
MTU<)6Y2\W8XQU.R+J5?QT"HX3BV,>9Z].JX.4ZT6ZDBD,J9-() $TP+W3=>,
MO+$=(CXWO;'1M.M=-@TVUM+.XCM(([>&:[V-<RS"*(*@(2XBMRVT,Q@R2<C'
MT5^IY&OS>373]3XAUB^UFYUF_P!0U"TEU"ZGO+BVL!*MC#;-/<O)*RM+93W2
MJ7*(+G:H'6IKYJVMX4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2
MF*4Q2F*4Q2L:0?PD?(_^1UPX_P!KO-3-=<>]],^*[_/;U?-&_P!O_P /_P"U
M2ES7E7RHX\C..K+?S/5[]I>;-K#86E-G1^V]6;"JK.!E'U?M3:M6BDR;62@[
M-&RD)/URRTRZ6BMSL0[;HJK-),'+%^P?M&SI.KM+LVIF!B2:*Y@-O-$Y90T9
M>.4$,A5E=)(D=&!P"N"&4D&7+&)-A#%6C8.C  X."IZ'H00Q!'J/0@]:BTV[
M-2O,XXDJGOG:+_<$?R8M_*6$W)8(#5\W,HW;8>K8?4M\K$W35:4AKZ:H5EK$
M8J0\&VKD,[AE5(T]?E(I>$9.!K3J[%BIM81;M9QV36Z/,B\N*9IXG63F&594
M=@=Q=@V#O5@Q%2?-1T(D?>)3*'(4G<RA&!7;M*E<C&!WR""!4BZYQA2C;GH7
M8-FV79KK;M%QFZ8]K)O:[1*RVM([K4KQI07\+2*W6X2*:5AO7&4=6V\7'D='
M8%*:?D)J4\XDW5(UX3'=1)"D<=RUN2 \KE/-@^W#2.[$N7+.6.,YV*JX43!#
MAHV+%C&) #A1GF8SD*J@;<87'7&,DGK5H=D]GM2-A:>W+JQ'9-[J$MM/DI)\
MIH#9M;2@T[IJG9<C,PDD*]).\8.HT6Q(Z+D:RL,HT=*O*_99QDX,8')3%J(=
M5DAN+>;DQ2+#9BR>%RW+GA"L,28(;.6#C:1AT4CM7EK=61U#LI:4S!AC<C$C
M.T^K&1\1(JD-Z]E]J;<)Z<W@KG.:R@Z=QI'B='0$;1]47IA$:E1.06 TCX3*
M1:SZ]N:+<A8A[;:QYL]DH-)DU613D(>!EHKW;:S/;F1FC29Y+P7S.TD\9>X\
M>;R98^;'GT@CDA7R0=I96\R6B28PQ4"/E8"HV$SGT=RG:?#(\.^3@U=)'A+'
M1UFNTM [<NT/7=G\;J?QTV/2PAJ<_B[*RU]3[S3*9=F\J]A5;! ST;'7Z47?
ML(N33B)9U'0WEFZ*",BC)R?=%C'&K01L\-X]W#(6D#(97CDDC*A@C*S1)@E<
MJ"^,DJ5]\@!F(=@&B$;+T((4,%(R"00&.>O7 ^7H7W9X:OD-N<3MN.+=<@?<
M6=?56@%K2)HE*N;<;ZWA)1CJ68V*@5B+I:0U?8+!9+K54XMRS:HV27,X<)*I
M,VR9?0U6<6]] $CQ>RO+O.[= 9G5KA8?2P!.B)&Y8$[%QXFH>;)OA?<V8E5,
M#&'" A"W?.TDL.O>JEH'#$NK-H6:WT+<UQ@]>6[;]KWE,ZE5I6HYAH6\WN7=
MV:ZL8B_S-$?WZ&I=GM\A(6Y_!LY@LPTFI!^G"6>)A7)H@/$NH<^%(Y;:-IHX
M$MEG$DZGE1*$C+1+*(FD1 $#%=I4#?&S#=45@V.65V"ERY3:A])CD@.5+[2>
MN,Y!)P0,"NTTOQ!0U9O2Z<A[+M>T[1V/;M?,-6JR<M4-84@'%1C+*M9V+NW$
MUI3:F6]W1NZ438-[7/D$8Z'368PL7%>ZDTK)>;B_,UK':)!'!#'*9MJR328D
M*;"(^=))RHR.I1/A-@NS;4"Q2'9(TA=G<J$.55?1!SZ6U1N;/B>W8 >-%[%X
M 4W9;_E.QFMG[ 9:]Y82=(O5PHD4SI:8T_=.N(S4L52]MT:SOZT_FFLI HZ4
MHCYM6)XT]5'$RS>/GT8[;NB,&\V'5)(19%8(C+8B2*.1C)Z=M,UPTEO*BNJE
M6-S*-Z;'"D $')/EK<,9<NP68JS* O210@#J2">FQ3@DC(]72JR0XP[)#7UC
MJ;WDU97T]8I6%<N)PVE./"%;4@8J.DHR0J,K0$M:^X\]"6HDHJ_L:LF]4E@E
M&D<>O2-?B474,]E>>0\U)!9($16 7SB[WAB0PD67G95H\80*H7:3O5VPPCRF
MVE>:<DC)V18( (VE=F"#G)\<@8('2J(UIV?]5TTXXQ/-9[5OD"\XXTC96K7!
MWD10Y5GLW6&WM@4W9]]I<Y$&J[2(J#!>VT2 +5QUZRK2-,K::U:@6B#!..&/
MFS:H]P+T3P1.+R2&;HTJF&:"*2&*16WEI"$E8OS2YD?#NQ;=N\K;*G*VNPY2
MNO4*=RR,&8'H-O51C;@*.@';'.F> L!INK#J1KMNXVCCU'4^ZZ^K6G9JG:G:
MGC:-=(V0A1JDOLN(HS'8U@B*I"RCR'J1C3T;*IQX-4[/)VE5HBL"YU1[F3S@
MP1I=F2.5[A))SNDC8-S%A:4Q(TC -)Z++G]K6,5%+<(-F]C%M*A"%P%8$8+!
M=Y !P.N?$[C7TZ.X-NM0[$TS?[#R,VWM\./^FKEH75E<N\7KJ.BX77]L7UP;
MR\HXI]0K\G8;FBSUC7(Z3M,H[5&:;,VB@QL>Z2>+R4+G4A<17$2VD%OYU<1W
M4[Q-,Q:6,3#"B1W"1DSNRQ@>B2?288"H[<QLC&1WY<9C0,%Z*VWU $MA0-Q[
M^H&I[Y;*J/R5"?M#_P!Z;>/].- _TA]5Y?.&_P!_-._IF_NI*I+_ /<D_P#,
M']I?U_/66#-V5B56'Y$[UH^@]<3-JN$DW2=.6+]E68(#%/(V6;.U.5M',&WB
M91,JBB9WSDX V9-1,JX4* D*?+N"^$]5XOUNUT_38':..6&6_NST@L;02 R3
M2OTPQ56$,:YDEDPJ*>I&O_*3Q]H?D^X:O=5U>XC%Q-;W$&DZ>"&N=3OC$1';
MPQ8)Y:LZ-<SL.3;Q$O(>JJVI&JJ9=55<X%*=9514Y2% I"F4.8Y@(4.H%* B
M(  >@.F?1(*% 49(4  DDD@ 8))ZD^T]_;WKY(%BQ+=,L2W0 #).>@'0#U =
M!X5^>*A706EA+RE=G(ZOSCZLSK^(D6<-8HQVY8R$'*N&BJ4?+,GC,Q7;5RP=
M&2<I.&IBN$CI@=$0.!1"AU6S.HZ7J6G!^6;^PN[,2]?K9N8)(1)T\$+ACXG&
M!@FKIHFHC2-:TC5FB$ZZ7JFGZ@8#C$PLKN&Y,?7IZ8CVY/09R>U7_P"#_P!#
M>\==E0$+N_DUR4LW(]]8#ED9*O:Z>/JO6C2@@FH]B[1:)PKR_P L];J'%-\4
MI*@^ _=$P"F8#*?.37-"U3AS4KC2=7M9+6\MS@HX]&6,DA)X7ZK+!*!NCD4E
M6&1G<"!]?^&.*]$XPT:UUWAZ]BO=/NE&'0CFP3!5,EK=1'#6]U 6"S0R ,IP
M1E&5CLS\>^'_ !BXIP98#CUH_7NK&@HIH.GM;@&Q+#*$3*!2FF[2\!W99M7P
MZF5EI5XH)A,83=3"(VBK\23W)/QU)'%0J-W+/BSJSF3HRXZ&V[&F=UNTMB*L
M)5H5(LU4[(R[RL):Z^Y5(<&TM$.3=\G4!0>M%'<:](JQ>N45+EI.JW6C7\-_
M9MB6(^DC9V31MT>*0>*./E5@'7#*"+=JNEVNL6,UC=KNBE&588WQ2#.R6,GL
MZ'Y""5/HL17FO\W^(DSPIWS9])S&Q]<[.&&6.=E/Z_L;"6.1F<YO-V=L@4'"
MTE3K.DEW!DJ_*@)T#F [1T]:F3<GZ6T+6$UO3XKY+:YM=XPT=S$R98=VB<@+
M-$3\&1._8JK @<XZWI+Z-?2V;7%O<[&Z26\BL=O@)$!+02@#K&PR,^B67!K(
MQV.G9+M^=5N0VOM"[TYGHC7\Z@:ST.#M<7([.N+QJH"S>#D("-<.)"DUF043
M CZ:G2,9"28^50KS505_=9CC?&7%QT&$VEK!,U_<(>5/)"RVL*D8,BR, )Y5
MSE4CW*K &1@!L;(N#^%!K<HN[F>$6,#CFPI(K7,I'41M&I+0Q,<;GD"LRYY8
MZ[AZ T)"Q%;AHFO0$:RAH*"C64/#1$:W29Q\7%QK9-FPCV+5 I$6S1FU12;M
MT$B%3223(0A0*4 SGUW>5WDD9GDD9G=V)+,[$EF8GJ2Q)))ZDFM]HB1(D<:J
MD<:JB(H 544 *J@= %   '0 5S-0T38HB4@)Z.9R\)-Q[R)EXJ1;I.V$E&2#
M=1H^8O6JQ3HN&KMLJH@NBJ4Q%$CF(8! 1#".\;I)&S(Z,KHZDAE92"K*1U!!
M (([&CHLB,CJKHZE71@"K*PPRL#T(()!!Z$5Y\W;)=EO6>".R/?QJ[8M)=ZC
MV1).I&LZME[7'MMKTCSA8YW,>UKCM<DC::2Q<&%O%6-@5=VS0 C";1%9K[J/
M^A>#.*9=>MN1=6TXO+90LMTD3-:3D  ,9 -L4[@Y:-L*QRR'!VC0?&'#$>B7
M'.MKB$VMRQ:*V:51=09/4",D-+"",+(N2H]%QTW-!+@;PCNW/'=\5INFW:@4
M0#$+(SDU=;+&1[Y*&3,/GIJK5E'1+!=IE-!-4R<7!M%4D!\FM+OHID<'67[7
M]<@T&Q>\F@N+C!VHD$3,I<_!YLN.7 A/3>[=^B!V&VK'H6B3:W>BTAFMX,^D
M[SR(A" Y/+B)$DS]"=L2D# +E5.1Z0O$OBMJKAGHRH:&U!&*-*U6$#KR$J]!
M$\Y;;*^!,\W;+$Y132(ZF)=PF4Z@D(1NS:I-(UDD@Q9-D$^;=7U6[UJ^FO[Q
MLR2D!4&=D,2](XHP>R(/E9BS-EF)KHG2M+M='LHK&T7$<8)9VQS)I6^'+(0!
MEV/R*H5!A5 J2>6RKC6/ZF%+H/G?L;7ATT66M^:M/'?%) Q^ZV0Y%:AC*YK_
M 'G HIF.*2"MZU0&G+W$QJ"2)G\C2-MV%07*ZC]1-2J7YI=GQV=NY*3<MC\D
MN.M"=FA(AS*S%^J<,K4-A 5$O<2.G8Z6I#3$H\.LHFBV0E5WK0RJB8.$_) (
MEN6CZ3>Z[JECH^GHKWNH3K;VZNX1-[9)9W.0J(@9W."0JG"L< V;B+B#3N%M
M#U/B'5I'BT[2;5[RZ:.,RR%$PJQQ1CX<LLC)%&"5&]UW.BY8:SE'U-JK2["6
MIFEH^S1>N0LD[,5YE<9=I.V5%G*/#+()R\HR8QS5TY0;%0;@9)J3N)())G5=
M*$.Y6^@7!/"\?!W#=AH2RB>6W$DMW<*"JSWEPYEG= 0&Y:L1'#N&[E1INZYK
MY1>4GC>X\H7&.K<3S0FUANVB@L+,D,UKI]I&(+2.1@6#3,BF6X*'EFXEEY8V
M;<5IF65@M.H>W%*S>=F?RP*\:PG&6T1[Q5ZT)-.Z%/M2"LW]SDRNIQ]!S! ^
MG;&;F%\XCGY>\@<A_,5P14(W.ORWY<O)]L>ZX[L)HEC?S2/6+.0A',I,=G#=
MVS?!?<.3'/"2'! F3<"X7MOZF7RLATL?)?JEM,\JF_FX>U"$!T6!5FU&ZL+U
M1@QA'\YEMK@94AC;R!2L;/F<SF.NU:8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*
M8I3%*8I3%*8I3%*8I3%*8I6-[<NA.6J/*FY[]X].^.LA 7_1FG=53<'N:8V7
M#S$9*ZHNV[[063BSTBL3K)S'RS7;B+82NUT7*+B)5$$A35(8;!K>@Q:WYMS+
MB2#S?FXV(K[N;LSG<1C&P>OO5;:7C6F_:@??MSDD8VY]0]M=;[T>TX_BC@A]
M^O('^[S+#[P[;[X3_B8_IU6>[,GW!/PF_13WH]IQ_%'!#[]>0/\ =YCWAVWW
MPG_$Q_3I[LR?<$_";]%/>CVG'\4<$/OUY _W>8]X=M]\)_Q,?TZ>[,GW!/PF
M_13WH]IQ_%'!#[]>0/\ =YCWAVWWPG_$Q_3I[LR?<$_";]%/>CVG'\4<$/OU
MY _W>8]X=M]\)_Q,?TZ>[,GW!/PF_13WH]IQ_%'!#[]>0/\ =YCWAVWWPG_$
MQ_3I[LR?<$_";]%/>CVG'\4<$/OUY _W>8]X=K]\)_Q,?TJ>[,GW!/PF_13W
MH]IQ_%'!#[]>0/\ =YCWAVWWPG_$Q_3I[LR?<$_";]%/>CVG'\4<$/OUY _W
M>8]X=M]\)_Q,?TZ>[,GW!/PF_13WH]IQ_%'!#[]>0/\ =YCWAVWWPG_$Q_3I
M[LR?<$_";]%/>CVG'\4<$/OUY _W>8]X=M]\)_Q,?TZ>[,GW!/PF_13WH]IQ
M_%'!#[]>0/\ =YCWAVWWPG_$Q_3I[LR?<$_";]%/>CVG'\4<$/OUY _W>8]X
M=M]\)_Q,?TZ>[,GW!/PF_13WH]IQ_%'!#[]>0/\ =YCWAVWWPG_$Q_3I[LR?
M<$_";]%/>CVG'\4<$/OUY _W>8]X=M]\)_Q,?TZ>[,GW!/PF_13WH]IQ_%'!
M#[]>0/\ =YCWAVWWPG_$Q_3I[LR?<4_#;]%6QW!QR[1+?%'4UA=%>%U<JDU:
M]<R\_,UBS[QDK"UC*1L:J7IRG#LI6B-(UP_>)UH6*!7KI!N4SD#J*E G7*S3
M^#[?3[RWO%O9I&MWWA&B158E2N"0Q(Z,>P[U*GU1YXGB,**'&,AB2.H.<$>R
MLP.9C5KJ,_(OBEK#DTS@TKZ:?825:+($@YFNR2;-VT3D@;B[16;NVSZ/=H**
M-6Z@E6:^6**8E273*<X&SK@KRA:]P+)=G25LYX+XPM=6M[ TD;O!O$;I)%)#
M-&ZK(Z^C(4(;+(Q (U?Y2/)+POY3XK#W=?4;6[TQ;A+&]TRY2&6-+GEF6*2.
M>&XMY8V>*)R#$L@*82559@=<OE#QUG.-&SEZ+)2)9J)?1Z4[5YXB(MQE8-RN
MNV(+IOWCE;2#-RU<-'J)#G3$Z95D3"BLD.=I\"<9VG'.A)J\$)M;B*9[2_M&
M</YO=QJDC!' !DADCD22)RJMAMK@.K"OG%Y3O)WJ'DSXHFX?N[A+VVEMX[_2
MM01.5YY83/+&CR0Y;DW$4L,L,\>]UWQ[XV,<BFHY=0]H?=S,ZUY4QN'?$J4Y
M2VR80<S"M:HU129K6:;;($<2"SE^=8&$/$)*_P#-_/7)&SE=1RY Z#-LB90Z
M2RJK=%36WE(\HEMP#I]LZVPOM5U%I4L+1Y#'"$A53/<W+KZ?*C,D:"./TY'<
M+E5#NNX/(]Y);SRIZQ>0M>-I>B:1'#+JM^D:S3LUR9%MK.SC8\OSB?E32&27
MZW!'"SLLC-%%+L/: X\4'C?47M/H!IIPTE)4\U*/Y^0(_D'TB=LW9@J<6[9D
MR;ID;MDDR(M&:!/ 3*>4.83YQKQAQGK'&^HPZCK M$DM[<6MO#9PF&&*$2/*
M0-\DLKLSR,S-)*Q[!=HZ5]$_)[Y.>'_)KI-QI'#[7\L5Y=F^N[C4;E;BXGN#
M%' I^M1001HD42*J10)G!9R[DM5]<Q*L]IBE:_/;Q]I=,\/=2P^A],3QHC?V
M[8MXX7GX];N2NM]9D56CGUC8*$,!V=ALKY)S"5MX "=DDSG9- Z#YC'JCL+@
M+AE-8O'U"]C#Z?8NH$;#*7-S@,L3 C#1Q*5DD7[(M&IRK,*P+CGB1](M$L;2
M39?7J$F0'#6]MDJTBGPDD8%(SW4!W&&536@V[=.GSIR]>N%WCQVLJY=NG2JC
MARZ<+J&577<+JF,JLLJ<YCJ*G.8ZAS&,83&'-^@!0%4  #     '8 #H /4*
MT.S%SN8DL2269LG/K)]9/4D]>W4=ZD)Q7Y2;<X?;FJN[=-V)S"62NO$_=".%
M9;W$MD HJ092K6=@FH1*3A)9 @IK-U@$[9<J#]FHW?M&KE*WZKI=IK%E-8WL
M8>*53M; WPR '9+$Q!V2(>H([C*D%20;CI6IW>DWD5Y:2E)(B/1R0DJ'X<4@
M'PT8'!!SCHRX*@CTW.)W)2B\N^/NM.06NU1" V! I/G,6JJFJ^K=A:*'862K
MR0ICW0?P$TV>1RIP ".DT4GJ'>;.4#FYBU;3+C1]0N=.N>LEO(5#@>C+&1NB
ME7^+(A5L?8DE3U!%=)Z5J4&K6%M?VY]"=,E,@M%(IVR1-C[*-P5/K ##H15M
MNT!YCU/@MQAON^;$FWDIB.11K^O*PLKY(UMV#.%51KT/X&(IYFB9)Q,S2B1@
M50@HN262[RQ$R'J>'M&EU[5+>PC)5&)DN)0,\FWCP9']6XY")GH7=0>F35/K
M^L1:)ID]\X#NN([>(G'-N),B-?7M&"[D=D5B.N!7F>;QWCM#D;M"V;AW#:I&
MXWRY22LC+2TBJ(E2(8W=:Q<8U ?(1L-%M@39146T329L6:*2"*92EZYTS8V-
MKIMK#9V<2PV\*!41 .OK=CW9W.6=R268DDY)SS??WUSJ%S+=W<S37$S%G=OF
M"*/@JBC"JBX"+@ 8JW,%/357FHNQ5R7D8*>A'[24AIF)>+Q\E&23)8B[-\P?
M-CI.6SMLNF55%9%0JB9R@8I@'*F2-)4>*5%DCD4HZ. RNK##*RG(((."#WJF
MBEDA99(V9'1MRLA*NC*<AE((VX.,$8QUKT1.Q7[1AUSQXZ.HG8T@W6Y Z44B
MZWL@X DBK;H=ZW4]Z^Q$VR8%334G",WL?.IHE*DE/QCQR1)LTD6*(<Z\:\.#
M0-2#VRD:??!I;8=3R74CFVQ)\$+!HR>\;J.I5C70/!O$)US3REPP-_9;([@]
M!SD8'E7  Z L%*2 =!(A. &45F8S#*S&H4<]*79I/2;7<&MX92;W#Q6N4+R2
MUC&-0_Z1GW%!;2378]!8"!TN^YVII><V3K)NB=0J/GUL9.C]%&B)R*5**L6.
MD;?UY7+?7W,5<M=[+J$-9H)Z9%%_#6:HVV(;2T2\\@X(=%RPE8E\W<%363,4
MZ*P <GI#)L$\UM-'<6\LD$\+K)#-"[1RQ2(<J\<B%71U(!5E((/4&I%U:VU[
M;S6=Y;P7=I<QO#<6US$D]O/"XVO%-#(K1RQNI(9'5E8$@@BL6//_ (7:IA=3
M36X=8UJ-HTY3%&+F=BX1/S*#G(1[(-XY8P191\T92+%=ZBY169)H$6;E<(.$
ME#"@HCT=Y'_*?Q#=<0VO#6NWLVJVNIK,EG<W1$EW:74,$EPH,Y',E@E2%XV2
M5G*.49&"[U?CWZH'R*\)Z;PG><9\+:;;Z%=Z-);/J%G9*8K"^L[NZALV=;7)
MBM[FWEN(I%>!8HWA$R2QNQC>/!BU:/'IC$9,W3LZ1.^H1JW67,1, ZF.8J1#
MF*4H=1$Q@ H  B)LZL=XTZO(B G +LB@D]AZ149/3MXG &>E<-(COD1J\A R
M0BLQZ#J2%#$ =23C &2<#-73T3K,-Q;AH&LE7:D<C;+"WCW[L@%!PUCD$EG\
MH=$IP$OG18]FZ\W*H42><>3[Y1+U#,?XLUWWM<-ZQKHC$[:?9/-%&<E))W98
MK=6Q@B-II(]Y&"$W$$&LIX&X:/&/%_#_  SSFMUU?48;:>90-\5JNZ:[= W3
MF+;13&,,,&0*#T)K:KUGI/5>GHQM&:[H]?K8(-$V:LDSCVXS<@1,H *DI-*$
M/)R"RI@%14[IRIWCB/0I2@4H< :[Q5Q#Q+.\^M:M>7VZ1I5@DF<6D+,>UO:*
M1;P*H]%1'&I [DDDGZL<+\"\)\&6T=OPYH>GZ<R0K!)>1V\;:A=*O=KN_=6N
MKEG;+,996&3Z(50 +IYC]9;3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%
M*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%
M*8I3%*@IROX5M>4-WUS8WUU6K$55&+Z(GV+:-*\?R<8Y>IOTPBG1UB(LG@J>
M7045=(N4DR*)K$2.=,R2NV?)[Y4'X#TG6K&+2UO[B_FBN;*5YS'#!.L1A;SF
M,*7EBVA'58VC9B&4N P9=">5GR(Q^5'7^'-5EUQM*M-+MI;'48([437-Q:M<
M><Q^9R,ZQPS%GEC=IDE159)%C<HT;_W,]G-Q6DZD>LLJ*YA'I6ODFMLCYV8/
M8T70)@4KY99Z\<L'IQ.'?5;.F"C,W4Q4D$>I1)"U\M7'\&HB^EU6*[AYF^33
MIK.V6R:,G)B011QSQ #HLD<PE& 7=^H/J^^IN\E5UI#:9;Z+<6%SRML6L6VI
M7SZDDVT#GOYQ/-:3%BH+126IAP6$21$@BI^'G%I?BU5[G7G5M1MRUHM!)A!X
MA&GC"-HYHP28LD%D5'#HQG9^BRKD2*B@03D(D)NZ8YJ'RE<?1\?7^EWD6G/I
MJV%@UN\<DZSEYI93+*R,J1CE+A53<H=L%F R +IY&O)5-Y*],URPGU>+5Y-5
MU1+N.:&U>U6.U@@$,"NDDLS<]R9'FVN8URH4L0S&8.:UK<M,4K^3&*0ICG,!
M2$*)C&,/0I2E 1,81'P   !$1'T!COVIV[UY@W:;<E7G*_F]OS;/NDL_K8W-
M_3=?D.<QD6= I"RM=K16A#&.5!*109JSSA(@]P9"8>K!XJFSJ'AC3%TG0]/M
M-H640+-<=,$W$X$DN?7M)"#/7:BCPKF?B;4FU36;ZZ)+1F=HH,GX,$!,<8 \
M P&\X^R=CW-0)](>'0?G_P !R_U8.QZY'Q?ZBGM](?M]OV]/9U#%.W;\YZ^P
M]NG3./4:V\/H7ODJ\%YOWB7-/Q.Q\T8[OH314YA%NX(O'U*_MD.^;H";@J]-
M?)MTB%[JB4BX,!A5.8-0>5'3!MT_5T7KEK&X(\00TUN3\6)E)]JCPK;ODSU$
MYOM*=LKM6\@![@@B*X ZGH086&/$,<G-6%^B;.2SVY<B]6\8HF1[U9TY2TKO
M9F2)A %-@;"$YFR;P@")53Q-,80J[ 3@)D/?'(%*  L83U_DPTQ8=.N]4=?K
MMY/R(F(__GM^Y7(Z;YF<-@]>6N>PJ@\I6HM-J%MIJ-F.S@$TJ@]#<7!/1NOV
M$"H03@@2MVSFM8GJ(]/3]OU?('7TA\W]>;0K61Z^/Q=NOMP.Q/MZX]9'5Z>@
MAZ/9Z/:'R>CY?N=>F*AVR#\8\?4?:.H\1U[=<5EO[$CDL\XV]H1IPZ\F=E2]
MQ/5-+W=$QNZU<M+L9-O6%URB/0#1EV0KCTJP *B:!'21![KA4I\0XXTP:GP]
M>@+NFLU%[ ?$&#)E _G0&5?#J0>N!67<%ZD=.UZR]+;%=$V<XW##+,0(R0.G
MHS",Y)S\(#N2?2"SFZNB:" " @( ("'00'Q 0'T@(>L!Q2L?_"/_ ,D,_OWA
M8_\ (M$./%W2N>E&11$OEN*^^'D_<-4MF9#]WI&ZUN<=M?1,:W2*8&<#JF 4
M74,>03.HI4S=AT*M[0I5CH%N:JO*Y:8X\9*(-USM7 HF43635;N"=3(N&[A%
M%P@H & JJ1!,4Y>I1N>BZQ?:!JEEK&FR+'>V$PG@9T$B;MK(RNAP&1T=D=<@
ME6(!!P19.).'M,XKT/4N'M8B>;3=5MS;721R&*4+O22.2*09*2Q2QQRQMA@'
M1=RLN5--:DTCK32%71J>NJTTAX\HBH\=J%!W+R[HP !WDO*+%%T^7,  4H*&
M!%!,"HMD442E3+7\1\5:[Q7?MJ.M7TES,?1BB7,=M;1@Y$=M;J=D2 ]21EW;
M+2.[$L;9P?P+PQP+I:Z3PYID5I!G=<7$F)KZ]EQ@S7MVXYL[XZ*I*Q1+Z$,<
M<8"BG5N,NE5-N1.\$:8SC]B1 .3HRL8LO'M';IRT78FD9&*:G38/)(C5TND5
MZJAY<X'*9<ZQDD13K5X[XH7ARYX4;4Y)M&N=@:"X1)I8HTD27D07$@::*!I(
MT8Q*^T8(38&<-;&\EO!!XPM..H]%BMN(K3FLMQ:226UO/-+"\'G5U9Q%;>:Z
M2*20+.R!V+;I3(RH5OUF(5L&F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F
M*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F
M*4Q2F*4Q2F*4Q2F*4Q2F*5'#F%L=74'%/D;LYLL+=[1]*[(L,<L4>Z=.48U2
M4/%BF/A^Z^Z M@2ZB "H) $0 <N6C6PO-6TVU(RL][;1L/6AE7?_ /YS5NUB
MY-II6HW(.&@LKB13XAQ$VS'MW8Q[<5Y3ZASJ'.J<1,=0YCG$?$3&./>,(^TP
MF$?7T\>OCG5W:N6V;<?CZ?E]?3IXG(SGYZ_GU>G[8_G]6*\^/;Y!^;QIU]/0
M.H_.'IZ>@/M]/4'M^=3'K.!\1[9[GY,^)]7Q9<>PRV0YUQVFW'0Q' HL;P\M
MVNI8@&$H.6UJITXE'HG^F HE+/M89Q],!@$4  H 80$,1XZMA<\,:ED9:!8;
ME#]J8IXRQ^5"X^6LNX'N6M^)-/(/HS-+;/U[B6"0*.N!TD$9QW[ 9Z$6&[4?
M8Z^U>T*Y<V]9P=TD&ZK;5H]4QP. Q-"=%HT2!!Z^"01U=;"B7_YJ0E*/0P"&
M5W"ML+3AW2(0,?L**5OY\XY[Y]NZ0Y/K^.J'B>Y-UKNK3$[AYY-$ISTV0,($
MQ_\ &)0.N.V<CM ?\OC]SP]?S^GT>OI[,R"L?[]>WRGKU[C/?U=_;ZZ?=]G[
M=/Z_9]U4/F]?ZY_[>OYN]JT_(52S5ZT12QFTI6YR)GHY<IS$,B^B'Z$@T5 Y
M! Y1(NW(;J4P"'=^E$!Z9+FC6:*2)P"DL;QL#URKJ5(Z].Q\:GP2-%*DB'#1
MLLBG&,,C*1U]A /RY/7MZTU M#:\4.DW1F8#L[?4:W:&AP]!VU@AF4L@8/D,
MD[*(?/G)-Q$8)YX#WAFDB/QQNR'\HKJRWE$\$,P[311RCXI$5Q^0U5V2:FUC
M_P"6/32F[>-7,!J*#*O0=D^+'R!=B D*?37(&=@XJC61\8H"4_P<<A66LW)'
MKGHC 4R[;-? HBD[=F.I60#%*QS\O)O=4SR+XT:5U;R!OG'^ O&K^2U_N$UK
MJJZ<LE@G9'64[QUAZK'*J;CUEL^*81C='9EE<.2Q,6P>NW!F?EGID6Q4C6'B
M+59](L4NK=(9)&N8X2LP=D"O'*Y($;QMNS& /2Q@GH>F*RQMDNIC&[,H$;/E
M<9R&48Z@C'I'PJDO@$Y0_9*^5WX,>"WA_P"Z'^?KF$^_G5/X-I_XNY_S/K_1
M[:NWN/;_ '6;YT_PZ? )RA^R5\K?P8\%_P!43(^_G5/X+8?B[C_,T]Q[?[I-
M\Z?0I\ G*'[)7RM^?X,>"WZH?3\F0]_.J?P73_Q=Q_F:>X]O]TF^=/H4^ 3E
M#]DKY6_@QX+_ *H>1]_.J?P6P_%W'^9I[CV_W2;YT^A3X!.4/V2OE=^#'@MX
M?^Z'^?KD/?SJG\%T_P#%W'^9I[CV_P!TF^=/H5Q\ G*'[)7RN_!CP6_5#R/O
MYU3^"V'XNX^3_P#I_P!?93W'M_NDWSI]"N?@$Y0_9*^5WX,>"WZH>0]_.J_P
M;3_Q=Q_FJ>X]O]TF^=/H4^ 3E#]DKY7?@QX+?JAX]_.J?P;3_P 7<_YFGN/;
M_=)OG3Z%<? )RA^R6<KOP8\%OU0\C[^=4_@MA^+N/\S3W'M_NDWSI]"N?@$Y
M0_9*^5WX,>"WZH>0]_.J?P;3_9];N?\ ,_HI[CV_W2;YT^A3X!.4/V2OE;^#
M'@O^J)CW\ZI_!M/_ !=S_F?5^GV4]Q[?[I-\Z?0I\ G*'[)7RN_!CP6_5#Q[
M^=4_@NG_ (NX_P S3W'M_NDWSI]"N/@$Y0_9*^5P_P#]8\%OZN(89'W\ZI_!
M;#\7<?YFGN/;_=)OG3Z%<_ )RA^R5\K?P8\%_P!43'OYU3^"V'XNX_S-/<>W
M^Z3?.GT*? )RAZ?PE?*[Y_@QX+=?Z(?3\F/?SJGA:V'XNX_S(I[CV_W2;YT^
MA7'P"<H?LE?*[\&/!;]4/(>_G5/&UT_\7<#_ /Z33W'M_NDWSI]"KB\(K)M]
M2Z<MM8;8W5<-[%T_MRA0%-N%[K6K:U9D(&V:&UAL)]%/4=24#7%:>I-K#:)8
M[-TK7O= K55-NN[7*B00SS0M1FU338KR=(TDD>92L08(!'(R+@.[MD@#.6/7
M.,#I5GO(%MYVB0L54*06QGT@#X #Q]59 <O%4M,4IBE,4IBE,4IBE,4IBE,4
MIBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4K&SVP
M3QPQ[,_F"X;*"DJ.JS-A.'I\B]LD R<D^95NX52'Y#CF2\'J&XFT<'J/.P?E
M$<A'Y0*QSBTD<-ZL1_!<?(TL8/Y":\S7^K.FZYJZ]?R_KZNU<> ![ #%.I/K
M)I^P_P"\?N?L&*CU_1^3M\_6IM]FR]<1W/SA^[:'%-<O(+620'#KU%-U9F+1
M<O@(#T.@NH0?5T,/4!ZCEDXE ;A_601D>YUV?FA8CYB,_HJ^<-,5UW22#C&H
M6@'_ ,I@#\^<58/D(_7E=][NDW1A,XD-O;)>KFZB;JJZN4TL?Q-],(=XX].H
MB/HZB/CE?IRA=/L%'9;.U ^(0(*H-1D,E_?,?LKNY8]>Y,[D_'U]?Q]ZM!Z1
M /D'J ^S[?[?+X" UE478$^T8/M^3]?9U!#Y_E^3P]H^CQ\/5[<4^+V>WKZA
MWZ=?'U4#IUZ_( _:$?3T]'B/Y@]N/^]>ER/5TSG/K'3&>IZ#U8\:]4#@=*+3
M7";B5*N!,*[[CIIU=03F YN\:A00>)@*0##T /'NA\V<JZ^H37-74=AJ5Z!\
M7G$GQUU!H3E]%TISW;3[,G/4_M"=SXU+'+35UJVVX]55/>6J-CZ;O;0SRG[/
MI=CH]A12$".21ECBW,8N[8K" BVDF'G /HQXGT692#=L[0,19$ARJ59'A%M6
MV;1T! M-GO6[S=^H9NQZ$WX9NF9!-?<&H)(]2L]B;MC%+Y")V(U:16T:P0.I
M5*E>(!P AY;NE4JU7(/]_=P__DY\V/\ QKPRS#N-_P!Z(?\ ?X?[BYJZ:1^Z
MF_H7_MQU(3-45DE,4[_EJ'G/S=5PX[<0]S[FH4I%0EKI,56W$7,SD62;BHDL
MO=ZQ7I"2=Q2BJ*;XK*+EWKE-%10$Q733,<IRE$AKAI=LEW?V]O(K.DC.&56V
MLVV)W"AO#)4#/JJ3<.T<+NI 90""1D#+ $D>P$]*ACJ+M'XZL1/,NW;'V8QY
M(Z5XR2?'AI";0U'KM""V'.2^[7ON%.U![K1*P$"="E2TE3Y&/M$ QBV]CCK'
M)P4.QGK-4Y%LO<)]'9VT^.&(VES>+=EX;B;=$BVPW+()BGH\Q1("C$E&0.Q6
M-P13QW0 F+N)4B,8#(F&8N<$% W4 [2&& <D#+#%2GL'.=G!R,)4&W&#E%9M
MNN]?/=M6W2-7A-+2&Q-8:Q3M$W4X6X7ITYWBQUX);C)5V94IU2IU]N&PIQO'
M/R)U!)_'2+%I1)II8-(;VR2W$HMX[EVN1#//L5VCB MC+];#KS))(HX5)'UP
MAE)GFXQZ/*E+[=[(!&61<E0S'F;,$@D ,6('0=#7QWKM"]54[5=*W_#ZXW7L
MGCM;=;U;;DEO:AURF!0Z+0+:MY-E,VJ/NNP*7L!^[BV_61M%>H-(N]FJL>7S
MB>AV F33/&/2II)Y+5IK:&\CFD@%K*\G-DEC[JC1Q21 ,?11I9(T<]$8]<0:
MY1460*[1,JMS%"[0K>)#,K=!U(4,1UR!TS8?G7S^DM?ZZY$UC0E1W*^N&EY[
M6=(N.^ZG4*/-ZGU;L.YS>OYHE(L![%936N3F%Z/;HI69DJ[K2U5*IEM40G9K
M) /U# TJ=,TM99K1[J2W6.X2:6.VDDD2>>&-95YJ;$V*HEC;:'FC>38Q1'7O
M+N+C:L@C5\QE%:0!=B,2IP<MGX)ZD*0,]2/#(QM[9LIJVO,IF$U+M'<\K(RR
M<4UJ&J&U%&=*!F;Q\M)R$KLR]ZUHL)$MDF1DE'D[<8SSAZX9Q[!-X_=H-SVF
MWA6=RK3PVZA2QDG,NWN!M"PQ32,QSV6,X ). ":J7?8,A'?KC";<_*695 ^,
MCU#K@5%EMVAVM)UMQ\3H>I-_[(L_)*N;9L5)HU3J5,:V6O\ P%VZK4G;$/L)
MQ<=AU2JU"3IL]9E&KIP[LR\!)N:_*Q4#-RL])4Z(M-:=*F4W1EGM84LW@262
M1Y"K><QO) T2QPO)()%3( 0.H92RJHD9)/G2$1[4D<R*[* %!'+8*X;<P"E2
M>O4CH<$G -34KFS#;(6W<:@<?N2%LB-&7K8>JYJQ1M6UVA%7+:&M-CEUM/T?
M7J,IM*/FYMRH[4)94+9)P\'KEA6"OC6.Z0-AA9ZNQ?B33FA%OS;JSC:YBBG5
M&>4M'!-"9DDE*P,JC *&,,TQ?&V-D9';T)PQDVQRL(V9"0JX+JVTJN6!/7KG
M 4#N000.NH_/O6%NGZA4IK7NX-:6VR<@ISB_.UZ_0]$!;6^XXW4(;Q@Z]=YF
ME[$N=6497^@*-'E$G:3/W.'F9.080[IW&OG )%C+I<T:R.LUO,B6JWJ-$TOU
MZW:X\V9XUDBC<&*4$2K*L;*JLP#*,T6X0D JZDR&(A@OHN$W@,59@=Z]5*E@
M<@'!-72KW*_4DUI3:7(B1>3%0T[J2<W+&6&Z6E@W182D/HNQ6&K76[5A*&?S
M3N9J#F7JTZE67@(-Y6PI,BK,H?N/6'G4E[&=;F&T 62XG6W9(T)RK7*))'&Y
M8*%D"NN\9*H3@MT./0F0QO*<A%+@L1W",06&,]"0<'H3ZNM1*V]VC+ROZ=WZ
M[@^._(76^\:?Q;V+R.U'1MLUW4D8\V!2JDU91TGL&'-';DF:ZC$ZQEK)59[9
ME#N4]4MKQM=?I)1VOY>=?1T(\KH-(#7%J'N[26VDO8K2>6%[@B*23++$V;=7
M+3JDBPRQ+) SJ29E4%A)>ZPDF(Y%D6)I$5@F6"X!88D(] E2ZDA@#T4D@5*[
MARZV%)<<M93>TY7;TM>;#!(SLZXW@EI-&_D<20 MT<(\?!5UDC!.P_Z3JS>.
M=O9=I7G\<TLBZ<Z@^:-:'4!$MW,L*VZQHVU1:^<\KIWP;OZ^7!]&0L I=6*#
M9M)G0[C$I;>6(R3)R]W?QY?H@?:^.",]:DYE'4VF*583B!^^&[0?_7CIC^B;
MH[]O]_IS</!_[Q6_]+<_W[UB^I_NR3^;'_8%9 \R>K?3%*8I3%*8I3%*8I3%
M*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%
M*Q]=JS6G%M[.7F'#-B&.L72MEF0*7KWA3K!FMF7Z=/'P0B%!$ Z]0 0Z#Z!R
M'A241<1Z.Y[>>Q)\LF8P/#N7 JP<4QF7A[5T R?,Y'_%D29^39GY*\Q(?E'Y
MNGI\ ]0>(^ ^/R9T_7- ]@^//;J?$]!U'3VUSZQ^?J/H\/#PZ]?FZATQ4/ ?
M%@=^O7KC'QX.:=>GVOG\ ^4?'Q]?W/;BF,_+\77P&!TZ=A\_JP)^]E?65K=V
MB?#Z&0*<Y@W=4I@_< 3"5O7%U;&Y./=\0(1"+4,<WH*0HB/@ YC_ !5*(>'-
M9<_P&9.OKE'+_P#O_IWK(.%HS+Q!I* =?/8&..AQ&2Y]?8(2>GKJPW+.LK4W
ME+R0JCA,45Z[O;;$.=$0$!3,PO<ZW[@@/TP=T"  =?'H'B(CXY7Z1*)M*TV4
M=1)86C@^QH$(Z_G\<]P*H-6A,.I:C&PPT=]=+@=,8G<#IZNAQU]51[]GKZ?G
M]'M'Y>O7KEQJW>OPS^;OZA[,8Q3U^O\ J]GL ?N^'CX=<4\/#_OZ_61\W7IU
MQ7(!U'H =1'H'3PZCU\.GV_FQVKTF<^S!\>@Q^?&?RYKU9^(=85I?%/C74ET
MQ17KNB-3Q+A$2E(*+AG1H-%=(2%*0I125*<@E H  E$.F<H:Q*)]6U.8'(EO
M[MP<YR&GD(.>N>GCFNI=)B,.E:;$1@QV-JA'J(@0$?(:D3ENJX4Q2L?Y1^ '
MGZ=,3I,M;\[J/Y=%(J?<;->5G'RN 1VH<Y2$*,MMSC>V: 7RAU0\TXS* 'D%
MW90>*5\?(/\ ?W</_P"3GS8_\:\,LP[C?]Z(?]_A_N+FKII'[J;^A?\ MQU(
M3-45DE,5'_3K^3-1^Y3Z)#DQH/86D/?4>D'O+2$2;VHD*2Q^XSR!L\):63E2
M#/)PI9- [N#0;N6@2T>=1NLKY-TBH!3!5V-R+.ZBN3'S1&6RF[9N#HR'#8;!
M 8D':1D=JE31\V)H]V-V,'&<$$-U!QX@>([>-11N_9\SVXG.VK=NG>R-EVCM
M*HZ,URG8J3JII0:=5:!HS=J6](R+84MU>+A,3$Y9+.=\TE[!.WQ\1BP7:IP4
M1&D0?(RM=%JJ6X@CM[8I#!)<S;)9S*[RW-MYJS&01QJJJ@!54B7)'IEL@K):
MV,F\R."SJB95-H"H^\ #+9)/<EC[,8P;Q;8XN7BP[QD>0FD]YKZ5V%:].Q&C
M+\,CKN)V;!3M,J]HM5NIDU"1C^>K"M<OU/E[U<AAYQR]L-<<-9TZ$Y39?S1J
M8E-!>QI;"TN+87$27#7,6)6A99'2..168*^^*18H]R@(X*Y21<G/MX6,ADC?
M8S((VRN\%025(&Y<,"QP>HZ]0:@QMSL4-4["J$1KF!V(QCZ/!\;M=\<Z^7:&
MG:;NZZ:^9ZV5L[MGL#3MNLTC$M]67B\/[,JZVA+P5>7?V4[!DK OZ@]:LWK2
MY6_$4\,C3-$3(UW-=MR;B2WCF,P0&*Y1 3/'$$Q &<!,D,)%)!D/8HRA P"B
M)8AN0.RA<G<C$^BS$^GT]+P(.*OWN3L[)S9"W(RO5'D7-ZVU-RCV#3-N[0H*
M.MJY:I4NR*C$Z_@W+RL723F&:T-4KC'ZPIQ[76UH.1E3R#)XYKUKKS>1=,34
MUOJR0BT>2T6:>RADMX)><\:\F0RMAXPK!I(VGDY;AE7:0'C8J#4Q[8MS0)"B
M3,'90H)W#:,JV1@-L&X8)R#A@.E7QYA\18_EI%:O825DKK!#6-X?70*?L?6T
M5N;3E]-(U.=J1H[9&J)J:KL;:RPJ<Z>>J;AS+I$@+*R9R9F<@0IVIZ;3[\V+
M3D(Y,T8CYD,S6]Q%AU?=#.JNT>XKMD 7TT)7(SFO<T/.V=0-C%MKIO1L@C#)
ME<XSD=>A&:HKC?P+K_')UQR6A[^XG&O'777*+74.P3I=>JC&=8<E]R47;KAT
M$76E6<#6$J2I1T*[&0M>AFT*[9OA79LX%LR;Q8S+S4WNQ=AH@INYK*9B9&D*
MFSMY;<#<X+N9.:79G8L",$L26J$=N(S&0V1&LJ@;0,B1P_AT&W&, 8/L[5^-
MJX%1=FXX[LX]EV?+1[7<G(V^<BG4^-;:O(]N\NV_2[X<:YL]4/,(M[MKQVY(
M-&N$,YEH<;C4G<FU65BC/A\B34V2[MKKD*3;VD5H$WD$B*U\V$R/MS',!]<C
M8*W+D"D;L4:W#1/'N/IR-)G (RTG,VE<^DOV+#(W#/;-12V5V=$_I?A+RJU]
MH,T9.[FVENC7W(;3C'36KJ'HBK:HWA53:6K]'DJ)2HB0<5BN4NJ36MV5QLXN
M'3R5D*PZMC>8<V>9?/'\S70ZLEQJ5C-=;EMX+:2TN#<32W3SVS><O*)9& =Y
M9%F,:8 4.(R@10 LEK8I!,L>&D=ED38BQA77:%*J#@*",GQ(+9R>^0$>'FK'
M/"\.#LB,LMJE?1!=#2,@U<D;V1U#J50*T]M /E4W*0VMXZ%6RK/W2+M->?54
M=O$715%DU+7Y_.-1]TEVB<77G0!R4#!]X3 (/+ PFT$>AT!'>JCDIR.0<[.7
MRR?$C&"?C)ZGUGO5E9C@G<]E-]@2&^^1;[:-TG^*NW.)=#L<7J^%HD=1ZANQ
MC#-[_>I6O-++.#<-E6)U5*<YE9)&7JU9!M7O,(*J5\DI(+*U U**(Q+:V@@B
M6]@OI4:=I6DDMRW*B5RB\N%!)(%!5W]++N^ !XY#-N,DNYC$\*D*%"J^,L0"
M=S' )Z@=.@%3YJ<"2J56LU=)R=XE6Z_#0";Q1,J)W:</'-HXCDZ)3J%2.N5N
M"IDRG."9C"4#F  ,-K=M[NY&-[,V/5N)./DS50!@ >H ?-509YJ-,4JPG#_]
M\+V@_P#KQTS_ $3='9N'@_\ >*W_ *6Y_OWK%]4_=DG\V/\ L"L@>9/5OIBE
M,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE
M,4IBE,4IBE,4IBE4)M*CL=FZTV%KF3 !CK[2;33GO4I3]UM98-]#K' IA IA
M3(\$Y0,(!WBAU'IE1:3M:W5M<K\*WGBF7PZQ2*XZCK]C4BZ@6YMKBV;JL\$L
M+?%(C(?SUY-USJDO1+?::586BS&?J%CFZO-,EB&(JSE8*1<Q<@V5*8"F*=%T
MT43.!B@8# (" >C.LX)DGABGC(:.:..5&'8I(H=3\H-<K7$+PRR1/Z+PR/$Z
MGH0\;,I'AV((QT/3Q-4UT$/1Z/3T]?H] =?0'R>KYO1-J3D?+Z\]._?IW/MZ
MY[T\.OY/7T]?YN@_L(8J'7'KZY]O@/RDX^,>PUGF^AT=-.=D]H?#WL[4ZD/H
MS7%VO3MR8@F03EIU@&OX-J8P@8@.%O?3(/FY3=!$L8X5()3HAUP+RCWHM>''
M@! >_N8;=1G!*QMYQ(>G7 $2J3U^&!@@FL\\GMD;G7X[C&4LK>:X8X& SKYN
MB]L9)F8CU;3CX.:L-VXFG'>G>TIY!)F9F:Q&RI"$VY7U0*($>M+Q#M74RX3Z
MAX@2W-;&T/T$W51L<_4!-T"OX&O1>\,Z<=V7M5>SD'BI@<A ?^"8B/8<>%4/
M&]H;3B+4!M 2Y>.[BZXR)T!=L>R82KWZXR<=JQ)>/7Y/V_8?M=/7F75B/3X^
M_P"OQ?,>X/@:>D/#U^OV?E]7H\/7]O%.Q&1V^3/Y/'OU^+U5>_C5JF1WGR#T
MMIZ*;'=.]C[,IU2%(A1.)6DO.,FTBX.  8?(M(\SITN;H(D11.?H/3IE#J=V
MMAIU[>.<+;6LTV?:D;%1\9; 'K)%5VEVK7VH6EH@RUS<0PXQX/(JL?B"DGX@
M:]7ADS0CV31@U(";9BU;LVZ8   1!LD1%(@ 4 * %3(4H     '0  ,Y.9BS
M,S=2Q+$^LDY/Y375"J%55'90%'Q 8'Y*^K(5&F*5$7F_JZW;+T#-R.KFJ3C=
MNG)VM[[T7WP IW.T=2R);/%5@%^XH9LRV5"H3^J; H0HF/6+U-MAZ%7-BE1H
ML>TJCO#DSV?&Y*$]/(4K:7#SEC?JL[53%%PI!VN=X3S4<5XW'J=J^1;O"(/V
M:@ LS>)+M5BE52.4,.XW_>B'_?X?[BYJZ:1^ZF_H7_MQU,G-45DE0YYT[/O.
MH]'0-MUY.J5RP/.1G$6D.9%-E&2!E:OLKE+J#7UVBA0EF3]J4DY3[+-PRCDB
M!7S--\9W&N6;]%L[1K]-ACGN6CE7>@M+^0#)&'AL;B:-O1(/HR(K8.5.,,""
M14FX9E0%25)EB7/0G:TJJPZCQ!(SCXJM1\?6LTZ>G:I(US<NZ;A9.6FW^.6N
M:?KC6=,C9E.QZTURPV,]K!',IM%I"OZ\T@T))PWV9:I6GM%%E%C6:+JT1'#+
M*S_<QY$1P]O;QI8V]W-)--*R[)IC"'(6$L'+%088UD/0;&=FVUX\X"D@AW8S
M/$JJJYRJ[\?"QC'9B1_&"U:C8?:,U)C=N(.R4K):M:Z7N#_F%4=T:ZMU6BC[
M#2V?HY**I++5CZ!AAM4FZV-#[63DJM!UW7TY*EN<Z^CF<*YL;21BSK3X=(D,
M=_#L2:X1=/DMI8W/*Y-R6D,X9M@$+0;7=Y57EH"6"8>O#7(#0MEE0F974@;M
M\>%"8&<MNR $)R<8SFKT[5[2#56GG+&(MFK=V'MD?J.O[QVO2H]GJ7WT:'UW
M93SB<8^V4UE=O13"9L!S5>TB>D:=D=K78Z5=D7+:ON&RL:L_IX-(GN 6CFM]
MC3O;02$S[+F9-A81%;=BJXD3ZY<"WCRX&_(8#V]RJ="DF0@=U 3,:G.-WI@$
M]"<(7. >G:JL>\]=5);!V%2H:D;=ME?U)K>$V]M+;U:K->=:II&N+/K62VC5
MK*[F']OC;)8C6."B7S&-K](JEIMA)-(B\A L:^LC/'EC3)^5%(TD$;SRM!!;
MN[">65)EA= HC*)L9@6:62-,9 8N"E>O.$W, KD(H=W &Q5*EPQZAB" <!5)
MR.HQ@U>WC]N_XP%":[$;:NV3J^$EP8O:PALE;63EY;*W+1+"9B+= N-6;)V?
M"&@Y)K($310E)B,L+5VW=-Y."8'33%6GNK?S64Q<^&=ER',(F C=6*M&PGAA
M;>I'7:K(0058U[CDYB[@CJ#@C=M])2 0PVLPP<^)!]8[59Q/F]4X^]3=#O6F
MM]ZM>H:VVKMBD2]^KE#:1.UZ?I@84U\5I;: V18K)"3#!M8H.09U_:M>UK,R
M,?(INVS(R3=Z9K4>YTAB66*XMIQS8()5B>4M!)<;N4)"T*(ZDHX+V[S*&4@G
M)&?'G"[BK)(I".X+!?35,;MH#%@>H(#!20:HFC=I1I&T0[ZTW"D;JTC2S<<;
M!RQJ=RW'3Z_!0VP]$U!.N*7&WU)I6;E;K$W<UCWX5(9"LW""J=G>(6:#D(*(
MEXR1;O3S)='N8V"1RVUS)YVMC)';R.S17,A<1QR%XXT(D,<FUXVD0<MP[*5(
MKRMU&1EE>->690SJ &C4 L1AF(P&'1@I.1@&J7TKRVV)N?F_&ZY=ZYW5I37*
MW#F5VNEKG=%2HL+*S<^[VY3H:NWN/E*99KV0B:E9DY&+>5=[:HZ>K[HQD;?3
M824,Q,I[N+&*WTYI1-;7,HOU@YUN\K*JB"1GB82)$?AJK!Q&R..L<C#-029G
MN-NUT7D%]CA02=X 8%2W@2,9R/%1TKXT^3MX@=Q<EJ[9[S)MJ[6.>G%G0&NV
M3&C5RS#'5W;>D]"S\E4EA5F*@X91D_;KE8'S^YNWUGG:RG)JJ1<)+H-&42E'
MS.)K>S=(E+/IE]=3$R,F7@N;I!(/1D!98XT C 17*C+*26,.:P>4%C@7$4:#
M:#@.D9QW7H222V20/ ] ;CT'M#=7W^^TNGMM6[ZK5;V'N3:?'NF[?MU.J\5J
MV>W1J)[L9M9**Q?-[U(7%561:ZLN,A6K.%+]X\P$<I!A:&]N;25<829=*FBB
MDD,]J[Q6\%W);I([3I;W B*2$&(1^B9XPZ<WFKD-L*%7;VMRC,%V2 -(\0=E
M 0NF[*CTMW78<';M/;.<@65X@]H36+%Q]+8=R66QVN:U5KG;.T>2&XF-?@T=
M>ZFA:G?+F2MUN[2$2M$E^$"<I$0E*05%I=<L5B" CFTY9F<,WL=8>6.IO]*=
M+K9;HL:SS006ENSMSIVDBCWO&&W?6EE;:TLCHF]MD98I($\0W*F/+EF*([R/
M@%4 8X#$8](J,A5!.!D@ C-<I=J3H=G3-NVZXT/<] <Z=UM ;BEZ9/1.MY^X
MV;5UCLZ5096ZIL];;0O<.H=I.KH,YFGV2<K6PX0[EF64J#5608).99T2Z,D"
M1R6\@N)FMUD5IE1)D0R&.0RPQ-U4961%>)L'#]"1'SN/:[,KJ402$$*24)QN
M&UV'?NI(8>(ZC,Y]7WJ2V/3F%ME=;;"U.YD%GA4Z;M!M5&5Q;,T5SILI%^RI
MMNNL4Q1EVH)2#-BYFDYQB@N1I8(F%ET7D8VMDT2PR&-9HIP /KD)D,9..J@R
M1QL2IZ$A2A(RC,I#&H1BR[BK)_%? ;X_1+#K\>?6 >E7"R57JK"</_WPO:#_
M .O'3/\ 1-T=FX>#_P!XK?\ I;G^_>L7U3]V2?S8_P"P*R!YD]6^F*4Q2F*4
MQ2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4
MQ2F*4Q2F*4Q2O/L^B!N'TAQWYJ36WH2*52UGR:(OL&,?I(@5BQV$B*3;8D *
MA2]TCI>0%I;2@H)163LQR(]\&:WD^A/)]K"ZCH<=H[YNM,/F[J3EC;GTK:3^
M;MS#[#%U[BM!\?:0^GZP]U&A\VU+-PC ':L^-MQ&2/'=B7KW$F #@U@A^YZ?
M]_S?/]W,\K!,'MU^+YO#KWZ ?)0>OY/M=?'UAXAZ/'YP]>*BHS\_ZY';!\/S
M$9QOM_0ZG#U]H7B7,;XN,4,?>>3<HPL$4FY2,F]9:IK:3EK2B*D4(!T1GG[Z
M?LQ.Z/<<Q,A!+"'>*'307E&UE=0U=+"%]UOI:M&Y!RK7<I!GQZ^6JQQ>QUD]
M9K>_D]TAK'2GOIEVSZBRNF1@BTB!$/0]N8QDE!'0HR>H&K"?1,'#Y_?=3ZUY
M?T^(4>R^G3GH&SCM2=]<NNK))"[K4RN4I1-YG6[>\>,ES )A(6W@N8I4&RRA
M;AY,M86WN[G1YGVI>_LBU!.!YS&F)4'\:6%58>V(CJ2!5!Y2-(:XM+;5H5):
MT/F]T1U/F\CAHG('A',2I_I@3T&1I/\ [>T?Z_V]O7-VUI8C!P?_  ?EZ=/S
M#IGI0/'KXCT]'J\? /$.@!^?%1P>F!^0]#D]#DD>K\GR[+7T-GP^?[-Y(6;E
M?98I7WC:"C'D%3WBZ71K*;6MT8HQ$C8QR&(N-6J+Z1?/>X8JC1]-U]4IA[Y@
M#6?E*UA;738M)B<<_4'$DP'=;2%MW7Q'-E"J/!E20&ME>3K2#<ZC)JCI]8L$
M:.(D=&NY5P ">_*B9V/B"\9S@]=Y?-%UNRF*4Q2F*5CNWXBBVYT\.F[=%)!!
M'CAS521013(DBDF2Y\,BD323(!2)D(4 *4A"@4H     &8=QO^]$/^_P_P!Q
M<U=-(_=3?T+_ -N.I$YJBLDJPW(_1C3D1KJ-UZ]L;BK(1VUM&[2+)M8U.555
M7TGN6B[@:PPM57C$I$K"YI"4$N]\N8\<A(*/TVSP[8K5:IM+DVLIE"!R8+F#
M:3M&+FWEMRV<-DH)2X&,,5VD@'(ERQ\Q0N<8='SC/P'5\=QWVXSX9S5A*SP8
MBJWN&L[=)L:0=N:WRNWMRE)!FK;9)!V_WAI1_IEU33/PF%%$6==;/AGV\T#5
M1:272"/4C6:9Q=EJGU-GMY+<PJ ]C:V6[>20+:Y6Y$F-HZN1M*YP =V3VKP+
M?#A]Y]&5Y<8^WCY>W).>F<Y[G.,#N+46SLL-7[#&(9W^\SDY!Q6Z.96[$&L=
M$IP$Y&VCEG>E=A1<C5K.TEUGU7L^D[*$;+TFVLD%GKN8B&4DHSC>Z9L,]-;F
MBW&*-59K?3[8DMN5H[&(1,LB%0'2Y3*R1G "L1EN]>#:*V S$@232#I@@RG<
M,'.04."&'4D9Z5]MF[.^>LE\C-OR6X=>6S;DUIC7NF]P6O:W%^@[/B;Z&LGU
MI=UK9=3J\M9H]OK'9"Z5QFF]@592-DHDWUCSK4-(D8R02@FK(D36XMYHX%N)
M;BWC@O986B,PC#Q2.$;G1#E*4R$E3TOKIW$U!K8E@_,5G*+&[/"KAMI8JZ@D
M;6](Y[J?M*E%5^.1Z7<N1=XJUZ6B)O?%5UO7HQ1&IP*K;7;S66OY"BP<PPBU
M1-!3I3'>I3)H1U$1\.D+0L4#91BH/<HGN^9':1/%N2VDF=@9&S*)I5D92P]-
M>@V[@Q;KNR#4X1E3(P;!D"@>B/0*IMSZCZ\8P!@=>M4]Q,XIH\84=KKA9JW*
MO]NWEK>I>OZXUNRTWJ2LR36OQT Y5I.KX^Q6QM R=F.P&=N\P,^\<6BPN#R2
MR+/N$1#W?WQO3!Z#J((C$KS3&XN'!=G'-G*1[E3=LB4(!&@VC/>H0P\K?U!+
ML&(5=B#  ]%<M@G&6)8Y/7I4,=0=D56-4W,ER#:=?F)=IJ'?6G3VUGHFH5[;
MFPH[>:$8DYNF_-OMK ]M>YM@UPT80S>8DO<&&>E</#H5V)>/';UQ<+C77GBY
M1A=4-Q;7'+-U(UO$;;=];M;<H$MXGW=5&]A@>FP  DI9JI)+ ^@Z9Y8#L'QE
MI'R2[# Z^B,Y. 35^KAV=E#V'0=7ZSNEVFY*I4#@OMC@W)HQ\4UC)*R5S:T9
MH>,>W]L^.^?I0,]!AHUD[C(HS.98J.YTQG+DZ,65&0I8]6DBEFGCB422ZG;Z
MDN6)5'@:Z81$  NK&Y(+;E.$[>ED>VME=55F.U8'@Z 9(<(-V3D C9T&".M5
MGIGBGLJE;X8\A-N\B'&YKA&Z#6X_,XYIJZ"UQ!)P'OQKMQ3M*B$=8;$^7MLD
M^@UO?.NH_&%DEWB"L!"U-FQ-&O/%Q?0R6IM+>T\WC:Z%T29VF??RWCV9*(.6
MH<<L8W* =[2%MP]1PLL@D>3>PCY71 @QN#9P"3DD=>N.O0 =*^>Q<)(NP7;8
MET/L*0;*[!Y<<?N5ZT>6NMU4XN0T)2=8TQG2DG RZ9W3.RIZU0?N9LZ2"T8>
M65;I1CTK,JS@FHLD44?*!$5A=6(.\Y874DTAD(V]"AFP%[';DL,]!@!9FW'T
MIHYL8'0QJJ[?:#MSGPSC'B?XA.$45"U30=6)L.073T3S"VIRX:/1KC9(]CD=
MH6#D1/+T=P@$N<L8RAC<@7;9*=24>+O2UALJ>,;#*JD8Q;4F9[I^4!YUI\%@
M1O/H"%+1>:/1ZEO-0=F !O(R=N2$  C&_P"!,\W;N7,A*GV?7#UR3T\/"QE-
M[*375.UY>]3L]EV(-=[RT[LO4O(^L,(%E&,=JO+?+6"0I>V(Q,)1TC2=M:[C
M[$YJWOG(A8FEUJK"!B[+$J'K=><Q=3)KDTDL4YA7FVUQ#/:.SDF 1J@D@. O
M,@E9!)LRAC<L48!G#2Q:*%9-YVR(R2@* '))PX[[64,5SURN >PQ4Q^SP?36
MDML::MFS-8HCLFF5FD(6_5O%Z@:AF$&==LD78E9VWA 6.0<7&QS"L0T1?%CY
M*G5%!457L?4&:YB>3E^ZH%S!<)#.>3(\ACGO9;A<LC(%CWH!&B[B1N65SV,A
M&:CYMF-XV9,,H7*1*AP&!RV#Z1./#:N>NWPK)MEGJJIBE6$X?_OA>T'_ ->.
MF/Z)NCOV_/FX>#_WBM_Z6Y_OWK%]4_=DG\V/^P*R!YD]6^F*4Q2F*4Q2F*4Q
M2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q
M2F*4Q2H?\X>%^K.=NA+#H[:"2K,KE5.;IEO8(HJ3=%N3%)8D78HD5@$JA0(N
MNPE6!S%2E(EV\9'.D=1)PC>-#UJZT'4([ZU.<>A/"20D\+$;XWQ\09&[HX#=
M1D&T:WH]KKEC)97.5R0\,R@%X)E!"R)GXRKKTWH64D9R-!GD;V-W: \>+Q)5
ME30EUVQ7"/%4X#86H(*2O5:GV0#U;.A1AF[B9@7)TPZK1L_&Q[E)8% 1\Z0*
M1RIO[3>,^']1MUE]T(+23:#);7DB6\L;?9#ZX5211]M&S*1WP>E:)U'@_7K"
M=HS8S7*!L1W%HC7$<B=0&(0,Z$],I*JD>T=:R%=F=V!&[]K[ @-G\SZ9*:CT
MM77S:5^#F>438[#V4X;'(NWB'D,B95W4ZPLH4I9IU+^83;QKWV46Q3\Y&5:8
M]Q/Q_8VEO):Z+.EY>RJR><Q^E;VP(P9%?M+*!G8J;D!PS,<;&R#AK@2]N9TN
M=8A>ULT*L8)#MN+DJ<A"F28HC]F7VN0,(HSN&\?&QL?#1S"(B636-BHIDUCH
MV.8H)M63!@R0(V9LFC9$I$F[5JW230002(5-)(A"$*!2@ :,=F=F=V+.[%G9
MB2S,Q)9F)ZDDDDD]23FMUJJHJHH"JJA54# 55&  !T    '@*Z:Z4VK[$J-D
MH=VA&%DJ%OA9&NV2 E$".8^7AI9JHS?L7:)P$#I+MU3D$0Z'((@=,Q3E*8/<
M$\MM-%<02-%-#(LL4B'#(Z$,K ^L$?$>QR*\3PQ7,,L$R+)#,C1R(P!5T<89
M2#ZP?C'<8.#6AKV@_8)<FN/E^GK1QEI5BW[H>7?.7\ A5$AF]D4EJNH90D!9
MJR@4LI,I1Y3>19V&!;2"+QJ0BTFA&NA.13?7#O'VEZA;QQ:G/%I]^BA9#,1'
M;3E1CF12GT$+8W-%(RD-D)N&*T;Q!P+J=A-))IL,E_8NV8^4"]S""2=DL0])
MPO821A@P +!3FH[\3>Q.YV<E[O&1%@U%:M#Z\(]3"S[%VY!O:JA&L$SAYT$%
M6Y,C2P6:4,F!DV;9@R)'^<"0K^48(]Y8+CJ_&^@Z9 SQWD5_<%<Q6UG(LVYB
M.G,E3=%$GVQ9BV/@HQP*MVD\%Z[J,ZK):RV4&?KMQ=H\05>A)1'"O(Y[ *I!
M/1F4=:W\^+/&75_$+1])T+J.+&/J=-8"15ZY!$TO99UV(+SEIGW"*:1'4U./
MA4=NU"D(DB04631-%DU;()Z U75+K6+^?4+Q@TTS=%7.R*->D<48).$C7H!G
M).6)+$D[XTO3;;2;*&QM%Q%"#Z1QOD=CEY9"  7<]6. .P    D+ENJX4Q2F
M*4Q2L>?(+]_?P_\ Y.?-?_QKPRS#N-_WHA_W^'^XN:NFD?NIOZ%_[<=2$S5%
M9)3%*LY<=XTZB;>U!IJQMYQI/[OCMD.:-/%:,35)66UA$P]BFJG)21Y).09V
M:4K$C+66O-$XERP?P].MRSF28.8YFUD:B.VDEM[BX3:4MFA$JY._;,S(LBC&
M"BN%1SN!#2Q@*0Q(\-(JNB'(,@8@]-IVX)!Z]"1D@ 8PI[8ZQ@F^T/H4;I&!
MY'PNC.25VTE*4FS[1F=@5.G4,\13M4UF<G8T=CS2-@V;7Y*;@IR!@%]A0L/K
MUE=[N;7[Z*G96IQ*S]./+6KI,K7+V;7-G'<K(D*Q/)+NDG=5;DJ5@8*ZLXB9
MIC%$)0R"1@,U*-RH02".4H5+E@JX5 2-QRXR"!N 7<VT@E03BJFMW-.JI;$V
MYIVG4/<4[.ZEURVOE\VE 4ZI2>L-=PEHUQ,WVDSTF]L>P:F^LR\TG$.HYA5:
MXPD9P\JW 9IM!UA?WSDEQZ<YB@N));=5GF,44#2.)Y6298I%4)%($"[@Q=R%
MVGT2[^@8M. SH$D)5-S.%!105+*3Z8)SC&T#.>^!Z54NOSK@:!J?2VR;IK/?
M%NUS=M9Z.MUOY!PM!H,%KZJ&W"A7V,+*VVM.MK*6]LHM*3K!W98G6$'M2/H[
M>233D9I9JV4>C,&F/+/<PQS6T<T4US&EJTDKROYN7+*CB#E]%0A&G> RE<JN
M3BH><!4C9DD962,M(%4*-^T D%\X!(R$#A<]20*_>Q=HGJJL["OU+?ZOWTK6
MM4;RH_'K:.YFM,K)M14386RF^O#48DK-.+PVL\I#SDAM&H0SI_5*C85:J^D4
M'-U9UN%?1$M)P329WABD$UKOGMI;J"W,C^<2Q0F;F[5$116402,!)(G, Q$7
M8,JC<H&92DF$D6-WPNQ6;;MR2V2"6 R%.#\+ ZU:RH]I'(QR7,BP;LX_;/I-
M&XV<C&6CJE8XH-4/2722LC71D-1Z2X23W?*N6^Q;3;MOM91&:E&52U3%424K
MR]CN,%8F-FBV$Z32%/N>MO=P227EH;F1&YXY2H;EI).MLHY21VY!53).95<)
M&R&-F\"Y(YQDC=5CDY:D;#N)$85?VP^D2^<G:@7!9@0<2[V!O6VUCB[L#?K#
M26QH^X5.@7.UM=,6H^N"7IO(UDDHFFWF58;9[K7B\>!6 6%RO";-=D>U815A
MW;J87:QBM#%:QO>Q6IN83')+'&;A.=RB'V_!#0B4-UV -",2?" 4%JGM(1$T
M@1@0K,$.W=T[ X;;CQZ.<KV.:B]6.TDB4-.\=K-L/1>VFFZ=[:N2V:RTO67.
MD"3JU1B(*GO+1LUA)V'?+.AP^N74M<8AI3X^S;&9[*F@?H1Y*6K,,Y5JSK7T
M@FXNTBN8#;6TY@-PXN2O,9Y!'"52U,S3!8V,A2$PKC)D"E29(NALC+1N))$W
M\L;,[<*2X)<*$RP"Y8,?M>AQ<ZI=H!J79EMU%4=.4K:^WU]M:MHF[!E:?$4N
M*CM=ZLV':92F05MOS/8=]HUD,DSL,#865EA:% 7NRUCW#?*SD*R35CC/I$FE
MSPI</<206X@GEML2-(QFGB19&CB,44J E'1D:5HHW##:YZX]BX1BJHKOO17]
M$ ;48D L&92>JG(4,01U Z5975_:4.EZ5R.ON^]#[*U; Z?Y(3^AJ09$FKI1
M[L2?5MT)3:5KB,CX#=5O=+;5<RLRV&R2$@2LZM8L72<LE<$XR-G74;4S:..9
M:16MU#.]Q:+=29YRB).6\DDQ+6\8Y 52$"[YV(V\LLR@RTN21*TD;*$E,:XV
M>D=P4)TD;T\_"/1,==V,XN8R[1_3K^GK2K6@[@<[.+NB)X^LN.["-UQ,;AF=
MJSE,^$J+A(5Y![-D].2,0OK=)]>U[HEMOWDQU?B9@).Q,I6,=Q:<DZ1<"0*9
M8!#YNUV;MC,L"P+((6=@T(N PF*Q<OS?FEV7"%6#5[\Y3&=K[]XC$0"ERQ7>
M ,,4(V@L6W[0 <G((KM>"&^KWR 8\J)V\MK?#DI'+J_ZWI]/OE<AJQ;*#48'
M76I91&F3+*#!9F\<Q5@GK"L$R26L:$LD]3>15CF8%2)=F\ZG:Q6ILEB,;<RQ
MBFDDB=GCED:6=>8I;! 9$0;=J%2,,BON%+>1I.<6W>C.R@,,,H"(=I]H+'KD
M@^!(P:GCELJH_7YOU_44Q2K"</\ ]\+V@_\ KQTS_1-T=FX>#_WBM_Z6Y_OW
MK%]4_=DG\V/^P*R!YD]6^F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q
M2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q
M2F*4Q2F*4Q2L>?(/]_=P_P#Y.?-C_P :\,LP[C?]Z(?]_A_N+FKII'[J;^A?
M^W'4A,U1624Q2HD<S^*B/+G4[*A,=BS>G;M6[9'W&@[9K$0RFK%1Y?W*FJC9
M%8J/?.V+58UFUW;;I2W)E71"-6]B/(%2<+,D4#UVGWOF$YE:%;B)XS'+;NQ5
M)5RLB!B 3Z$R1RC ZE .@)J3/#SD"ABC!MRN!DKT(.!T[JS#.>F<XR!43.5?
M9/:\Y(ECH:/M-.JU$B>,L;Q@K-+O6CZKNZ/U37( )]*"OFA???.1T=JC:!(^
M;;04Q<T8>PRKZ#K=91B%J[*0S28)76.N36>6*2/*UXUZ\L5R]LT[OM+177+4
MF>$E2PC+(H9W)#*Q6I,MFLN!E0HC$05HQ)L ! :/) 1AD M@D@#&",B6T-Q4
M81$ER9DBW1XN;DAKJ@:^>I&A$4PJ:-#UC*ZU1E&QPDS^ZZDDC*&EU&JI8\K9
M5$K,JZY#BX+0M>EELUY8'F<LLH.[X9EF64@^CZ.TKM!]+.<X\*G\K]M](_7%
M"]!U7"%<]^N<Y\,>VH&;+['&L;):52-E-L5F4;UG4/'+5T=.WS0%4V-?Z.IQ
MTCHQC'RVC+E8+40VEHW8BL6F_P!A0\'$2TM)/'+Q:-MD6HX,<+I#Q \)D98'
M4O/>3%(KJ2&*07C%F6ZC1/V2T6<1,S*J@#=&V*IGL@V,N#A(T!:,,RF(  QD
MMZ ;'I  DYZ,*EG;^"\7;:/R=I2FQW[%+DKREU=R<>R!*TW<*5)]K-QQS<HT
M]LW&:2+,-9@>/;0BDRJM'*L@M+@2QKD8E/W0H(]2:.2SDY()L[*>S WD;Q.+
MP&3.WT2OG9POI [!U&XXG&#*RKN_;)4E[?!*&,[>_7/+'7IW]@K]E>(%UB9;
ME-[R]P5!O2N3M]9[4EJ%LC14-M*%BKNXJ&LJ!;F$\60NT$TNFN+;4=9LV:U.
M4C:_,QDC,R,BVNJJ*;./1"_B9;+F6\ADLXC )8;IH&:/F32QE"(F,4T<DS$2
M9=6554QYRQ&%@9=KJ%E8/M:/> =JJP.6 965 ",*1D^EVQ76CN)T%IWC#*\9
M'%LDK'7YYEM1B_?L(QO5XFOQVUY>RRK^K:UJ1'<TRH= IJ%E6@==TU.0F6U8
MK\=&QQGTAY ZRLJYOFN+T7@C".IA(!8NSF!4423284RS2; TTF$+N6;"YP/4
M<(CB,6<@[^H& -Y)(5>H55SA5R0  *B\OV;,NZB..LE*[:UE<=G\=-2R>@(>
MQ;'XQU^^:\N6G5T:62%CK1JZ7V*5PTOU==T:.E65]JEZKJ:[^5L;9Q61@)-*
M#95HU=0UVJP3QP7<ZW3)#>O%+'<#F;BDZPX,3B5E,4D3D!4(?>N\RO-3B(EU
M9XD,8+1!D9.F,H6^$-H.X,.N>F#@7!VEP->[35T-'R6S:;"5S2+G64W&/:YQ
M^I%=VC"6K7UJ:VF8E-,[*K,S!$TI$;+*Q:UB]5F-JEG8.Z@9]#1JT<>3>O%9
M4&IB 73"&1GN1,K![J1X&29"BBXA=&\Y:')>)V=")-KD': /36Y?EY=<)M(Q
M&H<%2"=C C8&Z!A@@KT'B3T5X[.A&\U[>M)D-N(>\G9_(Z(Y8T&+D-60%AD=
M:[G96&N6:3"=7G9U]6MHZXFGU>48.:1+T^"=D@K!.QREG=+GBG\3ZCU8Q/:R
M" \R&S>QE83L@FMV5T79M0203('R)%D<%E4[ -RM!K;<)%+^B\@E4; 2K@@G
M.25=21\':.A/7L1W+[@A,NJIKIS%;+UM0-RZAWJAOC7%UU3QOJ^OM:Q<P.NY
M_5,Q5[!J*-N3B2M==LE)M]L92[N0V>E:$WTJT=0]AB6D0RC<\C4U$DP:&>6W
MGM3:RQSWCRS%><DZNMP8P$=)8XRH$)C(4AD8L6J/(.%]-%='$BLD050=I0@I
MN)(*L0?2R/ C%7WXM\=9;CO%;@)8=GR&V;-NC>%GWG9;*_JT13P:3EKJU)KC
MZ"C8:$=.F24)'&II#PG?4._;QCIM'R;N7D&3F<E*:]NUNV@V0B!+>V2V1 [2
M96-Y'#,S $LW,]+P+ E0H(59D47+#Y;>9)#(QP%ZE5!  \!MZ>..^3DF4.45
M3:8I5A.'_P"^%[0?_7CIG^B;H[-P\'_O%;_TMS_?O6+ZI^[)/YL?]@5D#S)Z
MM],4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4I
MBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE0*Y5ZAY&
MV+=W'_=G'J TW;GFL:!OS7]HK.W]CW+6;9=MMR7T=,14O!S%0U5M95XO&*ZG
M?-GS!]%QI#)RC99!XH9)5(+/K>D^[-HEH9_-]DZ3\SE\W.Q)4V[=Z8SS,YW>
M&,=:JK2Y\UE,FS?E"F,[>Y4YS@]MO;%4'Y#M+/J!<*OQM]U?J:9BGO"'WS/]
M4'^8JY>[/\A_S/\ UIY#M+/J!<*OQM]U?J:X]X0^^9_J@_S%/=G^0_YG_I3R
M':6_4"X5?C;[J_4TQ[PA]\S_ %0?YBGNS_(?\S_TIY'M+/J!<*OQM]U>G\33
M'O"'WS/]4'^8I[L_R'_,_P#6GD.TL^H%PJ_&WW5^IKCWA#[YG^J#_,4]V?Y#
M_F?^M/(=I9]0+A5^-ONK]33'O"'WS/\ 5!_F*>[/\A_S/_2GD.TM^H%PJ_&W
MW5^IICWA#[YG^J#_ #%/=G^0_P"9_P"M/(=I9Z]!<*OQM]U?J:?D_+CWA#[Y
MG^J#_,4]V?Y#_F?^M/(=I;]0+A5^-ONK]33'O"'WS/\ 5!_F*>[/\A_S/_6G
MD.TM^H%PJ_&WW5^IICWA#[YG^J#_ #%/=G^0_P"9_P"M/(=I9]0+A5^-ONK]
M33'O"'WS/]4'^8I[L_R'_,_]:>0[2WZ@7"K\;?=7ZFF/>$/OF?ZH/\Q3W9_D
M/^9_ZT\AVEGU N%7XV^ZOU-,>\(??,_U0?YBGNS_ "'_ #/_ %IY#M+?J!<*
MOQM]U?J:8]X0^^9_J@_S%/=G^0_YG_I3R':6?4"X5?C;[J_4TQ[PA]\S_5!_
MF*>[/\A_S/\ TIY#M+?J!<*OQM]U?J:8]X0^^9_J@_S%/=G^0_YG_K5TN'>H
MM[T"Q\E=A;_B=5URS[QV=3[=$UO4MZM6Q(.'A*CIS7NLB$D+%;=<:P?*2;][
M3W<D9JWKQVK9LZ;I@^75!0"YAI&F^Y5C'9";GB-I&YFSEYYCL^-N]\8SCX77
J&?'%6NZG\YF:7;LW!1MSGX( [X'?'JJ;^7.J>F*4Q2F*4Q2F*4Q2O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>img30600998_19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img30600998_19.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2#D4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (,B^@Y(X0DE-! 0       << @   @   #A"24T$)0      $.CQ7/,O
MP1BAHGMGK<5DU;HX0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q =#KQL         IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-
M!"8       X             /X   #A"24T$#0      !    !XX0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M T$    &              4=   ( @    8 9P X #8 >0 T #<    !
M                      $             " (   4=
M      $                         $     $       !N=6QL     @
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M      !,969T;&]N9P          0G1O;6QO;F<   4=     %)G:'1L;VYG
M   ( @    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I
M9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4
M>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P
M  $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M         $)T;VUL;VYG   %'0    !29VAT;&]N9P  " (    #=7)L5$58
M5     $       !N=6QL5$585     $       !-<V=E5$585     $
M  9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (
M8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E
M2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI
M8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    1
M15-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M      IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M       +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M       X0DE-!!$       $! #A"24T$%       !     <X0DE-! P
M%J@    !    H    &8   '@  "_0   %HP &  !_]C_[0 ,061O8F5?0TT
M O_N  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3
M$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+
M#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,
M# P,# P,# P,# P,# P,#/_  !$( &8 H ,!(@ "$0$#$0'_W0 $  K_Q $_
M   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
M  $  @,$!08'" D*"Q   00! P($ @4'!@@% PPS 0 "$0,$(1(Q!4%181,B
M<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V
M%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G
M=X>7I[?'U^?W$0 " @$"! 0#! 4&!P<&!34!  (1 R$Q$@1!46%Q(A,%,H&1
M%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1E
MXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>G
MM\?_V@ , P$  A$#$0 _ /54$9>,<IV&+6G)8QMKJ9&\,<7,99L_<<^MZ,LA
MS67]7R[1?92RO&I#G5PWZ-F:'[M['.]FU(^&JA5ZFG7262VS!+=W[5L ,QNL
M8W@[7?3K;^<G:<1U@K;U*YSW;0 '-/TM6:^E^<E4_P!PKO1_G ZJSNI=<Q.G
M6MH<R[)R7,-OV?&K=:\5@[3=9L]M5>[V_I'_ *3_  :,.G5[FO==<][=HDV$
M3M,ZL9MK]WY_L6=U]N3EYW3^ES<SIV7ZIZA92US996W?719F,_HU5S_;;_-V
MW?S==J:2:/1($; N][Z;.IT_/QNHX=6;B.WT7MW,<00?#5KOW7)OVAA?M =,
M]4?;32<GT-=WI!WH^K^[M]4[$:FFG'I910QM5530RNM@AK6C1K6M"PNIFF_J
MC;7.L#,?$O>!79942ZNZICI]%U>_W,_/3EA,;/0?L>@27/,PR]QHR;LBQ[0V
MQKAD7,F?98W]'8S^;M_\#LJ46T.;6ZZF[(]!A.VD7VN+ZVF+;&O=8ZSU'.WV
M4>[9L_XU-LUMJJX=Y5Y>K3PXGHTE@U8>,"QF]]E'K,V"RU]@BUGN_26O=8YK
M_8YGO_XM6<S.S>FN;75@^M@L:QHR#D5LVDGT]EC<HU_1]GO]2SU-_P!!.UOP
M3I6A-_A]KJI+#Q^O]2R8]#I+WP8LC)QG%HDL_P '=9^<U;B2%))+.ZIUW Z3
M;0S-+V-R \BQK=S6BO9NWM;^E]WJLV^E79_VVDIT4EA-^N_U:< ?M1#2)#C7
M9'W[/\U*[ZY=&JQ'93/6N:RWT'ULK(L:_8^UFZFWTG[+75?9Z[?YO[1_UWTT
MIW4E@O\ KO\ 5MC"]V2[0D%HJL)[]FU_G;?;_P"H[%O)*?_0]57-76BGJ62X
M7>G:REIK!L@']8RZW775^QKZ:7V>_=^CK72K&>['I^L#V/?714W'IM.YS6R[
M?FM:T-)'YUK['N_J(:]%LA_#[48RZLA[:+,W>Z/4QWLM:PVU$;O5_0;6W^BZ
MM^ZRMO\ PB$SJ;?LU5WVT.Q\@EE;/4:7%GT=U%P_36Y5+?TM^U[_ /"?Z-:=
M]O1\@M-F15[06Z6@2TQNJ?M=[ZW;?H(W[0Z=_P!R:?\ /;_>CKM>VRN$_P /
M_0F'2WA]#PVUUS66/8U[CN^B=KF>K_A-C]S5F6YF:\/K>]Q8Z6N&T1''[JUL
M&W!?2685S+JJ'&IWIO%@8YNKJ7$%VQU>[^:_P:/8QMC'5OU:X0X>157G>6R<
MP!P998J!L1NLG%^_P\+/@RQQ_- 2NO\ !_NM/I5N192?5$L;I78>3_Y+;^^L
M;*<T9[:G. -E-[1+@2YOVR@6OX;]'=NL_P!&NF #0 ! &@ 6-D^A5]8,:F6U
M,..^PB0T0RQCMW_;SZE)AQ''BC"4CD,1PF1ZL>8B<I2 X0;%#^LP?D8.1Z+V
MY3/U@O&*^JULVS[;J\=P+O7_ .$]'^;_ )#TXS<!E8>W(H94QXH#A8P,%@T;
MC;MVWUV_Z#^=6M]KQ/\ 35_YP_O2^UXG^FK_ ,X?WJ9%:VY=%>]UM&(3-=S0
MYPAPI=Z;G[2UW^C]1EGV?^7_ *-+(Z-UF\/K?U1EN.3[:+L6JQI =ZC6W&6^
MIM]C-S6U?]N_I%JU96-=8^NFYEEE6TV,8X.<W<-U>]K3[-[?H(J2MGG\;ZM]
M1PG..%U&K'WN,EN%0UQ8"[TJ7.H]'<VIKOW5L85&537MRLDY3SMEY8U@D- ?
ML8SZ+'/][6>_9_I'JPDDI2Y3ZR=7Q<EQQ\/.9C9&#<ZN]SJGVZFL;6[&59#/
M2]2YGO?_ -J:/0_TU2ZM976>C59.+:["Q\<=0<0:K[*V:'<U[]SW57.]S?I;
M?TG^CMIL_35I3R]%UV2;<>GJV*7%@=4]M 86"LMRKGT6,PZV9-7V9OI?HW_S
M-W_%JN.J!N.+SU2@#(IKRJ+'8S8%9?Z)I<VG#?\ I/4JNJ?B-_3_ /"+1/U;
M^LN\V^ETMSQN=6QU+-C7;0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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ML\'A&"4U-U.4E;+Q-D566&)R=':UU0D91E=UA(:7ML/6*$-(8V2'HL7B_]H
M# ,!  (1 Q$ /P#W\<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4I
MQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%
M*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4I
MQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%
M*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4I
MQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%
M*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4I
MQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2M7
M79OS$=&NL!\S!B]A%[>M"/NUAYRLJ#!:V-(0))MMG1T)E,AP0#UK"S37?'JN
M 4SGD?-)YSZ?A^<8VSC5:EKFD:.H;4M0MK0D96.1\S./6D"!IG'M6,@>)%=E
MPIY/>-N.)6BX4X:U76@C;9;FVM]EC"^,[)]1N&AL('(.0DURC-_5!JD3'_)'
M/714CHF3ZI=NQ83=;738KHUZ\%'K5';;&,NG80=V 6<;:):Y]HL@,<E'GJXV
MU;-G2OJ)[\\GE#X2>01^Z;+DX#O97JI\I8V_HCUE@ /'I7I\_P"2]Y;(+9KD
M\)12[5+M!!KV@2W& ,X6)=3_ $C'P2)G8]@,UN>ZS=IJ-[?5DUMJ@YLVF444
M(.0A9%5B0!R2)R5BDW7(1:914TV8GHO(F*+MHY4&EF+?=R/>,"P_=Z((CW[K
ML+>X@NX8[BVFCN()5#QS1.LD;J?%64D'KD'KD$$'!!%>&:EIFHZ-?W6EZM8W
M6FZC92F&[L;V"2VNK>50"4EAE570D$,N1AD974E6!-A.9J@TXI3BE.*5C[J6
M1=E)PT)>2((UF,B#'I$!BS@FS1D!H#%G8%A)3(L0HMJ_?C #V4QMJ8?-D%6X
MYP>$I.E$MW[;"BE9!Q2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G
M%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4
MIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2O'Y:/DU\A@GSUP^.QWJ]V?>]0
MHQ#S=3.*J95+8.Q.=4TO-@H&P.WHR+[AMW3YL LQ6,K Y$W9817K\,-BZ:@T
MG,BRZRE>P/BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5K+\M@KMU*>H!.
MO^EX:0%;0L^R*YKB2.XH=3BTCC]8RTSN.EQEC)\K).HN-W6V$!9?*Q>JQB)0
M8Q)Y.*U1>B$7C6)?)=R6D\=C*D%U(H2*>1=ZP%V57F$?:1XHRTD<;81Y%5'(
M1F(W7#L^BVNM:?=<165SJ6C6TS7%[IUK,+>74!!%)+#8&XSNMX+RY2&VNKB/
M,T%K+-+ K3(BFLG3OP+=/:-@PK^$-#HUVAM%=BW^+[304HI3$35V3QLO'ZVJ
M1PKM'$Q#57.=?F69LY'-C*VJKU<H+9N4@(_7:9P]INF*SK"+J]E.^ZU&\ N+
MVZE/ZSR32!F4$YVQ1[8T'0+G)/5<7^4_BOB^5(9KTZ/H-FO)TCA;0B^F</Z1
M:+TBM[:PMF2.5U4>G=77.N96+,T@4A%J+YK>@O3+KQULBM[T35%?]?;/&7%7
M,$'!*M$,8/'K6"SHKN+D\9-0L)HSCI<G&XVD4L@<>1%IR(2WA1%'0E@(_,LW
M6FXZTK3;KAW4KBXAA2>SMWN+:Y"(LJ3(1LC$@ 8K.V(2A)5BX.-X4CN_R=>,
MN*M&\J/"FEZ7J&H3Z=KNIQ:9JVDF>::SN+&=7\XNGMF9HUETZ,-?)<HJRQ+!
M(I?DR3(^$_Y'/&2]2[>XIT?J03K9*OJ1 2%7^RZA'UFI&K$*B&R&=L^[*R$)
M"GRBYK"&/>VP>2Q3)#.6[L/C&E\E272Z%=O+O\VDU!S:!LX(6*)9WC!Z[#(-
MN1TYB2#]8-7??EESZ1)Y1=%ALN2=5MN&8%UIH@-X,E[=2Z?%<D?_ +];5C*
MWIBVFMR3L,8'J_YZ?7R%3BE.*4XI7BN[J0#R[EO/YUOMZ!-*G:NA06S"/5:K
MBEF:-(R7ZS58J)#W"'GSQN$=)!99;PZ=.2)!7V15Z+<E1C1@^]6$A=]%*]IC
M?=55!%19'+991)/=5OMOHKL@KOIKLHCLHEG9-3*6V<Z9W3VSIOG7UM,YUSC/
M%*^O%*<4IQ2G%*<4IQ2G%*<4IQ2G%*_GK:_7_*Q]6?5S]>/JV^KZL_[?UX^K
M\OUXXJN#ZCVS\WK^2OSA1//I]"FF?1]>?1OKGT8_V<_7RF0>Q!IM;U'KVZ'K
M7[_+^3E:I3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE
M.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5H<[7=CH%U
MB\RM(3NQ&$Q(A2WC<N*+-D83&7,J*ZDGO9.K"B*CA@U52518X;!W6JCO.V=-
M%]VZ6<>LMKG&GUK6[30;6.\O4NGBDG6W M(&N) [I)("R*00FV)@6\&*C'I=
M.VX#X!UORBZO<:+H,^E07=MI\NI2/K&HQZ;;&WAN+:V94GE5E>8R7496(#+(
M)&SA#5F/XWGJW^:W8/\ J:-?]]YS'YR- ^#ZS_T7+^*O6_\ <M>4CXQX&_SL
ML_X5/XWGJW^:W8/^IHU_WWC\Y&@?!]9_Z+E_%3_<M>4CXQX&_P [+/\ A4_C
M>>K?YK=@_P"IHU_WWC\Y&@?!]9_Z+E_%3_<M>4CXQX&_SLL_X5/XWGJW^:W8
M/^IHU_WWC\Y&@?!]9_Z+E_%3_<L^4CXQX&_SLM/X-/XWGJW^:W8/^IHU_P!]
MX_.1H'P?6?\ HN7\5/\ <M>4CXQX&_SLL_X5/XWGJW^:W8/^IHU_WWC\Y&@?
M!]9_Z+E_%3_<L^4CXQX&_P [+3^#3^-YZM_FMV#_ *FC7_?>/SD:!\'UG_HN
M7\5/]RUY2/C'@;_.RS_A4_C>>K?YK=@_ZFC7_?>/SD:!\'UG_HN7\5/]RSY2
M/C'@;_.RT_@T_C>>K?YK=@_ZFC7_ 'WC\Y&@?!]9_P"BY?Q4_P!RUY2/C'@;
M_.RS_A5_<>7GJWG.,?*_8/Z\XQ]=-FO1]?\ ^]X_.1H'P?6?^BY?Q4_W+7E(
M'_?'@;_.RT_A5F/;&\[JK"WZ[7JY$@>B[6MY"ZE4&0$MW24@DUBF6=>U ^6>
M>XKD&/PBR'@!,AA!XV:Z 21IR^35PW1W2S\1ZQJFGZG9-IX>:W6QE:YLQ$K"
M6>^E6QTV0OL9UY=\\(< A.2\K,#@$:KR8\&<(\1\*Z\G$;0V6I2<06,>F:RU
MS)&UCIV@VDNN\50+")T@F\ZX?BO6MR\4DIO;>TCA9>8X:,:VDE\%U:2<22^;
M/=/UX)VS?3EJT&UXR!GY5ULM:+P>-KKM-Z^5>L1\G:/2RQ]BU(-E'Z:B&XI<
M5[';;>!87&KR^Y33ZO?L[67$DEV!'9)%-<Z%J-M:0,4-D61+A'E:9%<%P08S
M&%Z]%Q!I_!5JO&*:?P5P['#'K7DP@T:26XUV:\LM-\H/#.IZSJ")(NNK!-/I
MTL-JEC-)!(L#*XN4N=PQ(_3BXYE84@@#1K<!&](I(.M<:GUJEWK6&/6M778^
M5B6J,-'R:#QV/LM'$A:$IFX+08WN7.1;>),U]G U CLU=SN&-4NKV>S1=3?6
M+:70K>\U&5UM76PU60V^+5)[2&%<S(]RTEI+S);?S=6+H'*MH/*QPGI.A6.N
M2R<*P<&:G8^4'4=$X:M(I-7BEXDX/@75"^K3Z=K-_?3&.PEM])CMM9LQ:V6I
M#5)8Q'</;B6+9!SN:\ IQ2J%]Y/(MUZZ&1@>YLTB2E5F2IB]=5U24&T9D;$F
MNK+;""Q39N\=,Q<3AK)WMH@6G$K?"H^T4]9BR7*'=V85Y U+5+#2+9KO4+F.
MV@7H"Y)>1\$B.*-07ED;'1$5F/4XP"1TO"G"'$?&^KPZ'PQI5SJNH2C>R0J%
MAMH P5[J]N9"MO9VL98;[BXDCC!*H"9'1&\VX.IN_OG>MP+>,RP,HCJS%7)(
M57,D7T>F(##@[IUJPE.U( 7Z(LE?-JEM&6PF17+(6<5K89LU5#QG55N/-PLM
MR%QIVH\9&!]12;2>'4=9H]-8[=2U,KUCDO2I*V<&,,D"EY>K,Q5^4\?N&F<4
M\+>0<:A%PM/8\:^5":VDL+GBE%YO"G"0E&VZM= #@2ZYJ ]*.XU%U@LLJD40
MEA\[MI_5GU9ZM4_TZIN/4A2@-R*BH55T4)E2[O!663:6%?9;GYQ-CN44%#DJ
M/KHI;OGOL&S-HU08A@K 4 %BA3'N+>W@M((K:VB2"W@01Q11J%1$7L% _>2<
MEB2S$DDU\\ZIJFHZWJ-YJ^KWEQJ&I:A<275[>W4ADGN)Y#EY)'/S!5 "(@5$
M5455%B>9J@4XI3BE.*5YG_+X^[$C_)EX\W'5U=XUM;/7;M^FT<,7L88+IA-B
MU.9,^A>7?YC^KNCJFGMIO_EC;&WI0^O&>3=/UNVX?N!J-UPD.-(@C0^XAU1=
M'WM+C;<^>,D@!M]I/*VYDW=QBI5GPS9\6SKI%]Y0OS96[!K@\4>]ZZXFV- ,
MK8^YEI+#,?/"V.>'VP\OT@=U8%\U>;?T?Z/R;T^C\YJ$]'IYO?SJZ)_XN:8_
M]?XNW_-?]7S5MQY".&/_ !S"?_[-:_\ 9_3_ !^?]]7K,>03O) HRF7FO2N#
M#!PULT;/SQGL=!V"3EW[/5+VF=?9XTRZ?+:;*)M&V%%-U-\Z(I[>KZ,>)7G$
M_&<)FN'X+M;6W,C,HDU^RVQH[DI%N+ L5!"CIDD=LD ^MW_"?Y,^@:;Y]KOY
M1<UE;6Z1)<7MUP#K5O"\Q 7T0PR7F?)CB3>[9P@;!K[Q?R']V9L*2-Q'I- )
M&)5VSIJ^$=E80]1U4U].-T5O8Z[;MU],X]&[=?5-?3/^?3QC..8H.)N-;J,2
MV_!]I-&<^G'KUBXR.X.'.&'BIPWLJ_2>%_R8==M%OM&_**EU.T<E1/9\":S,
MBN.Z2; 3'(O]:.0(ZY!90",X)=?:/R?V/#=8[7'61A24AU,,2&TT 7/6LF?;
MCVR3O1R&^&G=-66$'RBZ"JCGT^V2RTTU3^I3?G5<*\8Z_I.J&ZXB\ED7$6GF
MUFB&GCB>UL2)W:,QW'/193^C5'7E[1NYF<] #K.+/)7Y&-5TH6O#/Y2UWP_J
M0NH93?S>3'7;Y#;*LHEM^2)(,&1GB<2!R%Y9!4[CBI&)5YM_MZ3?\9J#_P"S
MT_\ 9STC\ZNB>'Y.<?\ G_#[/7;#YOY->9_F)X8'_P#&8?\ [F=?^;M??OQ]
ME?WYJ\VWV_)O^,U"?]G*?G5T3_Q<T_S_ (O]=M5?S$<,_P#CF'YO(UKW]_)J
MV52=L_)?5-?J"[5ZV!;:*LGY(H\L*5WA6,052&+^QR@P<M16-13=J-PFIZKM
M137=3"VV5LX]7'/->*^,M>U+4VO=!\E\'#>F"WA0V,G%%I>!)8PYFG-PXB($
MF5]$J0FWN2<#T?ASR:>0_0=#=>+ORFYM7NX9KB>?5V\FVM:9;1VAV<M)%EED
M2,0X8M*\H5@V< #)[N)>3_MC.R#@3#^H57R$HUQOE0>.[.0=5YMHGZ?:+-V^
MVFBCMOIC&<[.6NJR&N/1G*F,9QG/)6_%W%UV[1VW"EC,ZYRB<06); \5&_+*
M/%E!7VBLFCV'Y)FOW,EGHWY3,>HW46XM;6W!&LM,57.YXXR%>:-<',L(DC'3
MTNHK/W?=SR#KM7*"'0V,-%EFZR2+K3L+#%-VRJB>VB;C1/=/&N^R.^<*:Z;^
MC7;.N-=O1C.>;"/7^.EDC=^!X)$5T9T]W+1=ZA@63.21N&1N .,],GI712^3
MS\GIHY$C\OFH1R-&ZQR?F]UPA'*D(^,8.UB&VY&<8Z9S6O+YI\VWI_T?D_\
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M<L,T;+)')&S(Z,&4D$&O%I8I8)9(9HWBFA=XI8I%9)(Y(V*O'(C ,CHP*LK
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M=GOU&@DDI6UGJ%Y$;'[$]Q+FZTSB!P"O8_6@F1E(5*AY,\<7NIZ%<P5G-HU
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MD977]#TS63Q$UJ=0MEN/-QI8FY6YF79S?="+?C;G=RT[]JQ'^&^K_P"+9/\
MXU[?WN\XG_XP9_\ YJE_SR/_ .F*W7Y@4_\ "EO^AA_[TI_#?5_\6R?_ !KV
M_O=X_P#C!G_^:I?\\C_^F*?F!3_PI;_H8?\ O2JDV?.<V1.#4SV&8#Y,8&XR
M.P[R^PW^'"6(O_PK+9IE7VN&7M__  =/U/:>S_E^IZ^WQ-Y7?*$?*IY0^(./
M#I0T0ZZ-)'N6+WW0\V]R]$TW1_\ '/-;+G<[W/\ ./\ %H^7S>5Z>SF-[/PE
MP^.%N'[#0A=F]%B;H^=&'S<R><WMQ>?X'FS;-GG'+_PK;MF[T=VT3MUX["+0
M)=O#I>X47ACI?U63[?.ZJT9<+;^G;;7&/6W4#K*;9W<M],9W:*;;NFVN<;+H
MK?17Y,'Y3D_DWN+;@;C>YFN> [RXV:?J#EYI^$;FXD)9U W22Z%-*YDO+5 S
MV4C/>VB'=<P7'GOE,\FB<11RZYHD21Z[%'FXMUVHFK1QK@ DX5;Y% 6&5B%F
M4"&4C$;ILV;.6[QN@[:+HNFKE%-PV<MU-%D'""VF%$ED5D]MDU4E=-M=TU--
MMM-]=L;:YSC.,\_6VUNK6^MK>]LKF"\L[N"*YM;NUECGMKFWG19(9[>>)GBF
MAEC99(Y8V9'1@RL5(-?*$L4L$LD,T;PS1.T<L4J-')'(C%7CD1@&1T8%65@&
M4@@@$5]N2*QU@UGS/%<UM8-@Y8[$\0:$RF7_  W7?*6S_P"6P;XQAE[7&N^4
ML.LL_8Y5]3;V6-\J>KGU?1G!=3BVMKBY*[A;P33%<XW<J-GVYP<9VXS@X[UJ
M=>U/W$T/6=9Y7/\ <G2M0U+D!MG.\QM)KGE;\-MYG*V;MIVYS@XQ6MKJ(YA3
M'L&^*-9C0ECRNUH;+9&1?5$H?:OZ_+:%8V8- E +V4G +<!(5'JCE4P-&!R;
MPR'QJ0U6T=8]7FM'-NNHNZSZ=<S7<$TK-9<P-;N)(GDB*&:2,1R%BQD5(W:2
M/T\[ACP[R</I</&<MPFI<'ZWJ/$6EZC?3S<-M=I-H]R+BQN;JT:SEU"ZM$L[
MTREVNH+>UN);FV F5E?I />#^W">.G_>M]U__B-+\ZL^'R_ZC_/C7T/4W=G#
M*8*@+6>JYQC5Q$7X;7TY]'I4D6R0!+7'^SG*A/7ZOY^:O7)1%I&H,>QMGB\.
M\V(0.OK+BO/_ "JWRZ?Y.^+IV/231Y[$>UM29-.0?2NA64TL+R$J"KQ6R?L5
M&4 B22Z>=?5VU<Y!,5'7KZYQC.-]G&ZNRGIQZ?7SMZ?KYGTR/E:=8QXP5M+<
M$>IN4A;/MSG/K-;;@:T\QX,X4M-NQH>'='61<$$2FP@:7(/4,96<MGKN)J3>
M3JZJH)["5!O<,&U&BGF@F91LFVD\)-;>C3W(^.QOE)!9;77*B3-^GMLBKMKG
M.J#G5D_V27V8II;:K6-..HVFR-A'<PR+/:RG^I,G8$]2%<=">N#M?!V@'S_R
MD<&'C30!:VDPM-:TRZBU70KW.WD:A; [8W<#>L-PI*,5($<H@N"KF!4,"Y['
MWJK&-8:VZ_6#K<_N:8I4NX ^I DR?IPT4D>"6<Z,,LMLXV>I([K:A]5\ZI9)
MJL]<[;ZDZSJI@%L-'O!J>T1F0Q#S/>,*9A+G9M[L%SRP2!S"O6O/CY3./GTH
M:)%Y.^(AQOR%M&O)-/(T!;K(A;4A<G$!@/6=%9ULA)A?.7@&6GV@*@^B&&*,
MBCM,Q-I,0<22=R#'K;[E3S[?=7=--937551F/T4V00SMC3"R^[Q_A%!1\JEK
MMM(T[W.M2DC"2ZG=I[N;N9)G.3@D E5'09[G<^ 7(KT/R=\&>\W1'@NYEO-=
MU6YDU/7]1&6:ZOYV9BBR, [0VRL8XR<!Y&GN D;7#()SYM:[ZG%*<4JL]_TR
M=FB\<LBLG[8#<%?*;KQT@MJAJV.CML*[.(V446UV1RDME5?+'=WC=GIL[?-'
M.J3<BL[;:35]-EN3#>V+K%J5F28'(7;,A!W02$],')V%LJ-SJ0!(67RWRB\$
M:AKDFF\3\+7$>G\:<.,TFFW#A!%J%L0QDTRZ9P4VOOD\W:;= #+/#,%BN7FB
MD#IE.IA.[]DCN=5Z9KJ2":2:B2(TGHIAF3<)3A!98L!64TUV7$+K+*)H;84=
M:I;I*(8>._9^\*=;IUU<W?!9:ZLY+.>/B7EO'(#M=AI2DR1$CK$Q8A3EL$%=
MS8R=MP7K^L\0123:_P .7O#>J6D?F=S:W2.(;J2,Q/)>:>SJ"]E+([+&=TH4
MHR">8+S&M/W/_P!09S_==ZS_ /67J+FMKO*Y78GLVQH-U'@C*N9W;<TDL&N>
MQ!,!K=FW)2\G'*5A[4V8P&%KJ);%2IZ7R2NJX CD-]-U9%8 ARY50&LR"Z2E
M5B:>2\<X[&4AU?=]<;8 6?<HZ32O+"82JGH'F-5U'[7E]5(SAB)G=@QB36;H
M1^2BMAJQ2J 4RF(*L7T=EAX(P2/L6NRE<CL'Y5NL]-!@2<.-M[BL60WE45!M
MJT"$=XH<!RJY]33V('IEM)AB+V.PI\"C4A,C9)J&(M9"D+50CVI+;5=1LI6:
MV#Y/^D]>#@)1Q<PB6-S]LUA3Z&D%07DB[4W;L@D<:ATH621]W]\KIV2ALR3Q
M.0FQ<&_WB4B8@5S)86X':J5EDJ[[]=V=1VK:E8R]A>[FJJ+G'89_7M7OV)";
M':\@)R:Q0V[$L2:XYJB[WF-=3>'LFY9T/V<26,&1>/568.O9*51EEYSNL,GT
MFK* U]8DT)0X]6XIH,3=P$"TD(:==:[4[-O)L.*R"5,1+&%UU&*5L2,SPZ47
M:-@$HCKI/;*@Y)1\FI5X(YY%>F!L^,@Y'L14\9LES%W$G,0$U. .A6-(BZO9
MW+)&98H@\5CGMHW6KO::$7#4NNS4B[)_(F2[D.R<O$E*C&)>5WIG)CMMI.[7
MC4=@M9FJPCP:QBI%7 BRB]EUD:MA%K#0NC#$C=? (;'RIXHM@<JWS'6B\H36
MUCZ>7_%*F#^,*Z/Y3]MKVEI=1#8.?D*+A*;"UFSJ/Q>H!M_GSK%PDKN@_##*
M6,"[,<%&2CACF)$&A5)=1%;3TJ5@AGONR"RR2LG= 74UK.,3BKHBK=I<(@!K
MPT.MBUX'34?EL:=%]VKLV':2Z8%7Y5)LCAXUAD.)S#*6P@U%5#:E; N*4XI3
MBE.*4XI3BE.*4XI7G4\HGDT[2>.#LF]A^HZ.6C77<*C'<:Z,AL"HZ+*UUW(C
MTAB<(=@I^24=CE357%])_'IX]+'G&F4G2.\7'.F#71V\RI4[W!Y=(/T@<,*)
MO^/VUV2N:AZ3JZP.ZEKTA$:Y%06K%)JP]&\C?Q^13B$E'V"ZC,K*A\-@(*2&
M1T%12+/$]MTW.NJE=]??FWZZ49*;I#)4QV<M.(];%:,)=@+>K:!10A5E:P/L
M1"H/.JSL!R<-3T*5."BPN>C6Z@00"7E3=P(D3M8)H%9,"I52LB[$^8JDNOT^
MM^-H4AV1N2O>M*%?..TEZU!#8L<JZA-;-&CCL<0D2QR:QZ42IZPC9<7)I<U@
M<<DF\5"/T%2.V7^CD<W4JW_;_M5%.L?3.[.VB;P>:"5_3Q:?PO&%,[L9A("@
MI-*L0;3?7;397$WEI:,@F'J9UV44,(>KZ,[8XI6JGIYY0[BJ+KAWH<^3Q+8I
MV!\?QJ!RNVF%20X"*+':=NV#1"95@5 19P4C8)X2:OB\ECQ)74DP:?YA)^W<
M;/\ *F%E*_G9/SMC:VI/M<=K_JCV&C]YT'5-=77#(1>T#" P4VIRT9'O'(U=
M9-M'+(VD(*NVC]OLRD0\ML%G(0B4"L'4;P0TD#$$I5BX;Y"7DK[+=4!4]*3C
MK/";CZA71>,PI"\JEKZ-N1#JNYV$BVDUF-R8N8EO7['9N[P8B<;:1^2"Y)$S
M+ Q()!'BRJ8EHI77WCY5G<![Z],NKE14W(^PM0]F8G91HQ<-0)1B=C\D(L0'
MA45*_D#"RAD?(!JR>[/B]^[DV*KZ,1IX#<1I(V4W?C$%*EZ,^5KKA*X)U_L(
M;&;@3"=D.YIOHQ!6[R-1-(F.M\";G@%V;E*"4[7:L*^5=UZ95;&!;PT?W;.Q
M6ZT6056>(L%*KY(_.IU\C\IP+1ZX=RC\+T[,3_IIM:,?J>+E8D1[1PPC)AH:
MGHNU9V(M))4:L):+J[Q,F*"[ VNAH&C*R$<>8D#6/*5DXWS34:4JYK(FM$]D
MUKY?]I)ATT']/VT5A+F_'E^00(A*)2$TU2GN:[2B@&*NV<B,SI>=)Q\:/<8P
MJONY]1!52N,1\W/7,14<8L%[2G:1>PY!V;F'3(CUP"UQ'3EXQ+LW#XH3E>U:
M'H^PG&X=UB1H,A[&,R*,')"(=N)$'<DE1(U ^\!J5MIKZ4NYS H1-G\3DT"?
M3"(1J4O8--&C9A,88[D 9D6<Q.6,6;I\S92:.K.]PYYHT>O&S<HS=(H.G"6F
MJVZE9?Q2G%*<4IQ2G%*<4IQ2M:_8R:UW6MT-@H[K;U_FTO,#X/*D3DT) 8E.
M)-*9G.#$7;(19LK7LC(2P@(="V!8P08D%'PY)]HJNVURFENOS>HS6]M>JBZ;
MIL\SK;RB2=HX;B26>=X@(1YK*\S(45W96+(&!*CH3X;QMJNC:%Q1':P\"\':
MKJ-U#I&H+=ZI-9Z=JU_J&J:M=:?&FGQMHM]/J4UK);Q7-S-#,TL"S!G0;5+T
MML&:HV/Y8>LL];C70=&7>+"T#^HIXHDLY'9)=CJ@<;LU'"/]A<^[[[[)Z.D<
M82=)ZZN$L:Z*:XQO;>87,%O<!2@FC238W4KO3.TD=#@G&1T/<=#7KNAZJFN:
M-IFL1P26R:E96]X+>5E:2'GQJYB9U]%]A)42+Z+@!U #"K[OWS48Q>DGRVC=
MD/:.7SQPIG&J:#5HCNNX6WVSZ,8T223WWVSG.,8UUSG/,KLJ*SL0%12S$]@J
M@DD^P $U/N+B&TMY[JX=8H+:&6XGE8X6.&%&DD=CX*B*S$^ !JGW4<.XDZ$_
M[ 'T-]I!;,H)9$*.-,95'PL,ZV8C![?;.<Y32RX;J-E-=?Y*S<2-WSMOZF-N
M<[P]&9UN]7E'Z;4+AS&3W2UC;9$@]0RI!]81#UKQ;R-V4NJIQ%Y1M10G4N+]
M5NO,VD&6MM$LIC!;6\9/54,L30L!T>*RM&RV,UUW9 :I4D^@G9F.M]DDQI)G
M$+5;--/5P8B1A31HW(.D],>JLY8;YU:)*[Z[JJ.O@&OIPFPTQBS6D.GW=IK<
M(P$=;;4%4=)+:4A0[ =S&< $]2W*&<**C>4ZU?@_B+A_RI:9&46UNH=&XMBA
M7 O=(O"(8[B95Z/)!_@%=@S&;W.QTMUJZS9RW>-F[QJLFX:ND$G+9=+;&Z2[
M==/55%9/?'U;)J)[:[Z;8^K;7;&<?5GG3*0P# Y# $$=B",@_.*]TBECGBBG
MA=9(9HTEBD0Y62.10Z.I\592&4^((-??E:R5TDDD(N)Q\U)S;C#40 &/2Q%Q
MGZ\IM&+?=PMZFOIQE17;5/.B*6O\I57;1/3&=ML8SBFE2"&6>5@L<4;R.Q\%
M12Q^? Z#Q/2H&J:E::/IM]JM_((K/3K6>\N9#W6&WC:1]H_K.0NU%'5W*J.I
M%5-ZOQ<E-",F[*SIIC,HL1TX0A;1QC*GRM VBF[5BV88WQC".Q#1+739?37&
M[EBV2=Z[XR5>X5T&A027+SZU=+^GO"5ME;KR+-3A%7/ZN_&21W4!L^FPKQ_R
M4:3=:Y<ZIY4-?ASJW$DTL>AQ2#=[D\/PLT,$=N&_P9N @3>!NDMX4E#?TR??
M,E[4Z+N6$N0BF^H^3"]MBT*D:>VZ+P%(6^,*-5='*/\ 9TV3M1--N033SG.4
M<Z.DM</6;-9'9:IIT>I6K1$[)D/,MIAT:&9>JL&'4*Q 5P.Z]0-RJ1VWE X*
MM.-]"EL6(MM5M";S0M37*3:?J,8#1,LJ?I%@G9%BN57/H%94 GA@=,=ZV6P1
ML>'O0TO3RRLRO"&\4GHY;&B;G8BRV5;MS&R6F?4QH5U;+>WV2QA#XDV(:M]=
M6V&_K8=%U![VV:.X&V^LW-O=H1@\Q20),>J0*22 !O#A1@"M9Y,.,+GB?19[
M'65,'%/#=P=(X@MG 65KB O''>E%.T"[$4G,*8C\ZBN!&JQ<L&Q?-Q7IE2MU
M%_U+Y!_=DNW_ *3I+S>Z_P#XQI__ -!:%_[+MJC6OZDO_I-S_IWJT7-%4FG%
M*TU7Q_JPV#_^87/_ #://PC_ "C_ /CR\IG_ *S7/^A@K[D\G7_<1PU_]&Q_
M]>2HDYXG7:4XI3BE.*5;3KMV!<05RVADL67=0]ZXU38.\^T77C3IPIZ/2GIK
MZRBHA=7?UG+9/7;=JIMLZ:Z;9W716^U/R7ORF;GR=7=IP)QI/<7G U_<K%IM
MZ>;<W/"EW<R8S%&N^2;1+B9R]W9Q(TEI*S7EFC%[FWN/&?*=Y-H^(8I==T:.
M.+7((RUS -D<>JQ1KV=CM5+V-%VQ3,0LJ 0S, (GCV=XSC;&-L9].,XQG&<?
MDSC./3C./_+CGZY@A@&!R" 01V((R"/E%?)Q!!(/0@X(]1%?E1--5/=)7315
M)739-1-377=-1/?7.N^F^FV,Z[Z;ZYSKMKMC.NVN<XSC.,\K5I 8%6 96!#*
M0""",$$'H01T(/0BM7$3[0W:K:"0!&O:N=#6$S> Y?'0L$M"/V)$XSM:T<K@
M:[(DGR#F)+%"3*2-Y<W1'/" UP'$DU%73+1/573EH=5U!KL1<BU9!.T<T:07
M<=S#%YY%:JSLVZ NRRB<!2R&.-R64 &O =-X_P"*GU];-=%X?>WBU26TU.RM
M=(X@L];TVP/$-EHD$D\\R/IKW%Q%?1ZE&D$L\#VUM<,\D0"L*V]X/[<+XZ/]
MZUW7^K_^XTO_ .S_ +>=0?#Y?W]#7O\ 60]W7"J]0AXFVWS[U/K'AL322USG
M&RGMG+HKKGT8SCTZZN!3?&?RX]?=/'H].<9YSO%#,=.CMEZM>7EM; >)RQE&
M.A_K1K^^O%O+O+(_!MEI$)_2\0<2Z+I"("<MODFNQT'<"6TB![]67IG%6];-
MT6;=!HWUQHW:HI-T-,8QC&B*&FJ26N,8^K&-=-=<8QCZL>CG1* H"CH%   Z
M  # Q7LL420Q1PQC;'%&D4:_LI&H11TZ=% %?;E:R4XI3BE.*4XI3BE.*4XI
M7]I/_70G/[@C;_I#VYT7_P DO_M$?E_X,'\CYZA_]\/_ *G_ /GU)W<__4&<
M_P!UWK/_ -9>HN<[4RLUF]-J2>\Z+O 6>2$%JD$6W"S(UP,W?IRJO[=%1=R9
M"M'*;]ED*693NMJRD;8LL@6;[BPAP)L,T<&VQ<2I4']D.B\3[0W11EJV':MD
MM8Y0<TKZRXI4((/4&D3<V/64N=S..2_::&*N,W3''+\@H+&R\7"+/BX.61^/
MB0Y0=LWV*9)*532C?!EUQHZ6C9NQN/L#-I*/N3KK=BQ28OJG]^.RGK,K:>T'
MUE3^,U3'2,J6D"5LG/I D\A>$IQ*WC 807E#9QAUERI79PGPE=?*T@6T$KVT
M[2A^X"S*/LRJ9N$AW7%E8E7..ODWD$[KJ,IS)"BTC%GQM@4D3EJLA=*]B/MF
M;1KN@^0?NCKXRI4P=&^@37KY(NX5I6:+ABDY[>6K+RQ2#0\B7D%>5Y32LCFI
MJ.UQ''4B&"7N<2N1V%8ULV&V9BQ(#,[LPX,$CE!X=J3(J5!-6>!WJ!430*VB
M\ONQ=0-U:NKJGEZ7D4/>NRL8NLS:I!_/B^^D&;IO+,A(>Y[ AD$.^R3&BH<9
M4"O@I/3*JBRE9N4\+?5L^-=@Y#+KB, B<XFTX+BUC\2:Z$EY]TG9=$CP91TQ
MA3=XW%?10RUD+/9HNB1;SQ50EL^5!X3C^BE="T\,-=M,,I#CMEVM6MX.2C"\
M>NI9Q0.9D  1J@)AUAQ#6 1*B$J^6CY:FYF\"$7!&'/I)DX-&2IN?1-8(KD%
M*Z"3^ OHY(V<8&I.[=!#HG3-44<+;"I8"SNI%:YU8!9.3?.7T3>+N)-=]="1
M=2W&3TV1;'ZZ9) @K"/9]+CBE;/^PE+*WE78:LT#K2+Q_6S:9F$G_P Q]R2I
M:)51:,1LU[#1FB1(:B*WEJD-91AT66T(I#@A(GN@,6>9:*MU*GGBE.*4XI3B
ME.*4XI3BE.*5YEN\W6N*]DNR/<,[V#ZM^0.^&$XHD?U<Z^/JYZ_5*XK_ *\"
M!)1&8&[6JF0F^Q3$C.9=)K1&QZ:LI41B\#?-1 36%.VI *Z5WT4JE\[ZK74=
MM5&\F'7#L]95L3:DZ:J6^I+VP\5/5WLDQF\CI.-YA<>N* ")9W':KUA,S\53
M9-IF);F#X"3&&29@BDIKH.8"E*L3<]-/+>BODJB^O5#R3Q)#R*QWJW'GGPCJ
M51WPVFD>LE>Q6 L/@09KVO&-)(RE"483?ZB]-XJVC23K48TV(HM-%U5*C:^:
M'O"R)5VB 5;57DLJ'K?WFTK/?M95"W2^A)M,2KZ!1,#!3[VH;*?=L1:=?;69
M%8ZP8R5,W$YKJ->;NGXC.$5$!S92KJ]SR#3N11U+=9C?13R90NA*ZMFG9G8D
M 'T/5A+:X:RIW"BXVEB)YMVECY2*A39)K'WA*3#]R)EOJ"1U'HMWJVA%JI5"
M+6Z(523(]@T.MW2KR=]:(+V8ZJ.>MEHP%&@81;PXF;;66 L.,6ZB7GG=/!A$
M]'D F\5^7\./ACL.^54:NQ3C+O+Y2IJ[+TLOV/D?8R1$>J?DZC?T^>/Z$=&=
M![7K#2K_ !%%(!8#RQ@MI;/5.U+;8W[P748-"$*]T%848M7.$)4DL[TW:*5F
MD1#6!(K6ZV7-VHZ?]Z>PDEI7JY;/6&?0]3I!1 "LK@ V/,A)T26)10YVTFC$
M0WC,< !XX_ O&TC:RA\@O(%'0;V_PE-2NWN(:;?7_P!)+WZH]$>[/57'4 C;
MPI2M([TEZ_$JXF==7S\NIV8%$QN-=GH /A,J?)!'C@=*&S8LBF6,JE2(A^HV
MV1>*54V =9;FAT^J=)Y6?DQ)]>.O7>\QWGI>DT>D] -##:3RB1R22'XG.[,S
MVV5*2-)DI*# V+&AH<&D.;ES3HR"/JN J$>4J86-*/V4,B,/QU<\FRFD4\LC
MKRF:O\]5J5UW?%',BD![%*[-L=L\ZMV">#ONF9[A99QO[K[Q\HZ>W]@DI6#S
M/KU8.LUEEX4Y0WDKKKL3IW\L_O;4\Y,]/:1E\2A3JWJ[!UI.:<E<*5[<C59Q
M&#( *GA:2LST1+HJ;Z8:L$,)J[.%*[VNZ'DL;<4K-YMUP\FTVNB(>060^1.Z
M9VEU/H\$&MNSY)"R4&<0F-1)KVM63K&%B0RPA$-M\3F3U+ QUE=-3XHGJ,4K
MU3P64+3:&1:8.(K*X,O)@0PVM#9TP8BYG&%"31)UN#E(T83-#F)T;E3+4FU9
M%R35!VFJFB]<::X5V4K*^*4XI3BE.*4XI3BE.*5K][&)RJ07["X_#9.]CI4.
M!K\ZY7>7L0KN/-QKV?GTB&^U=:1I?6;KE!PEZ(?+AY,T(.$U1XQXBP3:,G+W
M0:BLLM_ D,KQNB6[DG4'MHPAN) ^;41$7!=%9&*2JQ!5&"@*6\<XV34+WC#2
M[32[^>RN;6ST:\D:3BZ?1;%8)=9O5F+:(MBPU5YX;:6VF>VU"*9U>&"1(ECB
MDEI]V+_MT-+?\&E<O_69J7F^/A[3_J->QUF7;Z6JQ.A)GJTWVP3E.K&%C$],
M>G=PK(G6C8@AIC'U^TV!Z%MD_5QG;U]-?1Z/RXTO$5P;?2;G;GF3A;9 /$SL
M%8?5[\>W%>6>6?6'T?R>ZV(6*W6K"WT.U [R-J4HCN8QXY;3UO"N 3N Z8R1
M,U=15&#P*'1!#3336.QL.)4]GCT:J.FC%%-XXSZ<8SG=R[PNX4VSC&=E%=ML
MXQG/HYLK. 6MI;6X&!#!'&?:RH Q^5FR2?$FNWX9TE-!X>T31D55]S-+LK-]
MO9IH8$6>3VF6?F2L?%G)\:^E@0]A8$)E,+)XU]SDH5\*V4VU];W99PCMAH]T
MU_G58O,(/$?]A5#3/\W*W=LEW;3VS_JSQ/&3WP6'HM\JMAA[0*NXCT2WXCT+
M5M"NL<G5+&>T+D;N5)(AY$X'B]O.(YT_\N-34%]1):].5*WB9W.Z<JJHN2KB
M0-%ML>W0VCZV4A?ITS_+PBD,V;CM%-L>A1P-=8QG.4]O1JN'KAY=/6WEZ7&G
MR/93*?U@8#M3([@<O:HSW*-ZJX'R-:Q/?\'QZ/J 9-7X1O;KAG489".9&=/?
M;:97N$2U:.U5B/2DM9@,[35H^;VO6*I?VH(/IX=K7K>!<*).[',(')FNA_GQ
MT%C[C9XNHIZ<>KCWIRQ<NV_IVU]HX":-<YS[WKKMS>NNUW+9:+$2&O91+=%>
MZ6<)+-GU;V4E>O4Q[>NX5X=Y6[F?B#4.%_)CI\K)-Q->QW^MO'^M;Z#ITC3N
MS9&,226\T\?52TE@L77G &X8T<R#CF D:W3:#A;)J.8-$L>JDU9,D$VS5NEK
M_,FB@DFGIC^;77&.=$B+&B1H J(JHBCLJJ J@>P  "O:K6V@LK:VL[6-8;:T
M@AMK:%.B1001K%#&H\%CC157V 5S>75GJD-V([45<<3[$#$=](G*-V\"M]JW
MUSZF&[O">@63;(IXS[19I[LCA=3.OIVV&,VB>?:%%=^<QJ8]RM1M]80'S>X(
MM-249Z*V!#/\J%0#T[(JCJY(\&X[C;@#C;1_*3:(PT?56CX?XSAB!V\J;:+/
M5"B@[GB$2;V(ZO:00J=UX[5=E%=%R@BY;*IKMW"2:Z"R.^JB2R*NF%$E4E-<
MYTW34TVUWTWUSG7;7;&V,^C/IYTP(8 @@@@$$'((/4$$9R".H([CM7NT<B2Q
MI+$ZR12(LD<B,&1T=0R.C D,K*0RL"0000<&NRZ!6@&LJLK%T#A96)^5+UMT
M04S)P:@3TEG\U+G51S359911RX%,R;%(OG735%H^7RRU5670<:H]CQEI4VEW
M6D+-/:3&XX?T>6(VDXG!BCL88%E)"@!)GC=H3G+QKOP%92T/3YTG2X*+(NR[
MN%;F(4](R,Q SW*A@&]1Z>%7KYQ]3Z<4K35?'^K#8/\ ^87/_-H\_"/\H_\
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M:,VC9'71%NV;-TTT4$$M-4TDM-=--===<8QT:JJ*J(H544*JJ %55&%50.@
M   '0#H*]N@@AMH8;:WBC@M[>*.""&)%CBAAB01Q11QJ J1QHJHB* JJ
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M8A7FMA-C]P_H-KJ@;XL>CB_3B'=J8==$&JV3E74@:REF7D>KG84ZV8,V%>;
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ME) C+9%25U^SEGMH+:*[NS<P6]SS+>$-'!!<OLBEN"[HZKG_  FQ)#& 3(%
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MV<(:MU76=<9^K97=7*.-ML?DSG31/.-<Y_)A3?T?ESSC.*I6YMI!GT CRE?
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MF241U>M5PN[W/(:0M<1+#'!%<\\B3:T<SHL8";.8)&#$[-N<J1V(:J&/JV6
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MI3BE.*5!5K?Z+C?_ #;G_P!Z6_Q_+_Z/Y^'XI_QNV_\ 1S_I'J!=YWKCH2F
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M,8\Y7BI<4.E1'9CLY.,W;9,)N)0T.+I]),$=R1=1236J12RP*D@(BFV[6#L
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M9[#23J>1$U[:E0@;K=,YCV;Z[0F?-8A)I$69!F%>UR4E#B7VY*58@S#3]Z%
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M*;N5W43C3V.NCSE3^P:+2)DV3]"B:GIUDUJ\$-O+(P#7'-(B((=%B?E[FST
M=@P4=_1-8F0JJMT&[<=H_6PI )Z>L@@>/M':K4\BU;W!\#UST^TY []_^PBG
M%#T(P!C]W7Y?#I@#H<]O&G%5^3UGKWZG)S]OLZ'OGI3BJ#V=CX=\^&#ZB.@[
MXP#T%.*=B!ZQCUD$>.3T[$YZ9/M\'%,8Z8'7]V >Q^7/MZD],"G%,]?;G'7)
M!P,CV#P-9[6W^FA#_<CS_FN;[AO_ (33_(S?V"I%MCG#'[+?V9[8]O4^OO5B
M^>A5LJ<4IQ2G%*<4IQ2G%*TE>7^W;FBM32"KW=3B2%-64M&&X^W1D@?JO 1L
M(<%R3>/R*.["?8,'KU4*JF,=9)[,2+%395!7#]JZ'H[C2XH6D602,)HPV8B!
MAE92NY6\0,]1W!';!!K[?_([X0X+U7B[3^*8>+;NWXTX935)+C@^ZTZ!(;^Q
MOK&ZTP:AINI"[WW$,"7JM=1>:B>VG4+(AMY8KA_.Q2\V(UK;]7V$'![2<M")
M_$94,C>BBZ2A\@".L23,,FHU;NW.FY)PW39Z;-VKE;&RV/9(*[^KIMO94$D4
MB,=H>-T+=/1#*03UZ=,YZU^C7&VAVW$W!W%/#MY?C2[37.']7TJZU)EC==/M
M[ZPGMIKUEEDAC9;:.1IF$DL2$(=TB+EA[?*+E-KS6N@TJN. "*OEQO7+[$'&
M'',A= Q:VB>S%$\^78#DT3BNN=UG@ULDLF.UW1;+N=GNKI!OR$ZQ)(5A=I$7
MIO( #'QV@?U1V!\>XZ8S^&_'>E<)Z)Q'>:5P9Q!><4Z/8D0>[MU81Z=%?W2,
MPG>PMTN+EGL$.U(;F5T:Y(>5(A 8GDF#F&N.IQ2G%*<4IQ2G%*<4IQ2G%*<4
MIQ2H)M;_ $7&_P#FW_\ VE^</Q3_ (W;?^CG_2/4"[_74?\ D'YQDYZ8/;I\
MO;UU%O.7J)^\^(\<XQ@9.?9U^4]*<4QCMG(\._?Q^3OV'KZ9& XH2,X/RCIX
M]<D$=<^/L^4TXICJ<GIZB>PQZOE/CV&,8Z4XJOR?V''R=>G3U CKZNM.*IVZ
M8P.W[_D_DY[^MQ0CO\GJ_=ZLXQV]HSZZ@/L-4UB6[$0HNJ^P4^ZWS6.2AI)Q
M<Z@H2&2M(AHB++B',:F$.GH4W'95%7R!C9^H-729.4#0P*4:D$5!_LUL]O+'
M"[&6W2X1E*E'9T(]($,CH0R,-N,]05+ CK55(!.X @@@@Y&1T]+*X'A[<9QT
MSBJ2TCXGZJIJP:0M]2U;-G-L59>W8_LG,YG($HDR^F.WNS]?MJ\L U) H4"R
M&QP2P$L6"T:!1/0<W8+-O5=K$,+*[;39M5EFCGBY4:12P6]LB+O/)AMI.9&J
MLS$L22=S/G.>@':LC3,P* *%*(H ST5#E0IS\N2<GM469\-$>:0O:& ^S]HB
M4(!V,/\ 9+K"_5@E4FU:!DTT(3$C/XRZ:&XR]9VW$ILI,-M# V<I9PCH"#:#
M=F26QA(ME]V&W[S;1'F6ZVUR!)*HG5%18VRK Q/&$]$QX_6;.>F+N<=Q.P=5
M"M^MZ0& #G=T(P#T\/ GML7HGKZXK.OQ,6M.:C[^EPH\7/HS^0U15D!6:+%%
M62FC0'%*\C06. FS' ]IA)=JV4)N%$DU7I!SLBWPCKIYQ)(SQ(8$8 <M999,
MX!&6>1BS9R>YP <  5B9LL2JX'8@,3_:>O@<^T>K%:H^XOB>L*Q8[VTN85<$
MS[#WW->N5RTW1$%+Q.CJOW8#;.(C2>D8EUBA D->V1N$1%- 4-*65($6D<'>
MWVW5W<N-G>NUM-4CC:TA,*6\"7$$T\@::7+1 @ND9+B/=DLZQJ2Q]G2LR2@%
M%*A0&5F(+-VR <'.,Y.=H[^P5G4#\.<7F<+F&W;.\;BO&66%U$BG4H2C(OD
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M$.N=ZWBP3KUM :\E%@;Q5K#RK9B\FNDOEPU\_E;-$JB#CVSN/-M&[DGHFL:
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MG 4849#,3Z)4 %'0 DDX8Y/4DDD=/9WQT[9Q:GB>"3IY;DQB%]RNN[9FO=&
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M]OJ,MM:W%JJ*1,2RR9P\+,G+D*8[[T 4]1Z^M8TD949!_6.0?%<C!P" !E<
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MB-Y&Q=5NP?C1R>P\HX>.\,D=C:\.03I#)-K%O;Q7U[-8Z4YMKF07[PND9E(
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ME/!<V]S8W,>BC4H+@26\\D\2*J/+M(:..;>0PCE+Y#$MM(P9#F_E1>58$F+
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M+(2")2H9/..>ZDK)7]BM9V/*.R\LD\>A_:&%VU*_(,K9DEEIQ*TX-1<?ZOU
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M5HD@@)+L6K<U81;8@7G9_9F0-:I=^>O*SW<UX(!,2YAVVT2QI%AUM).8&C*
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MJF$,K>U]..6CA'4N6'W1Y.M^XI3#Y#\SE>=DXQYOS,KG];QQBKO?18;RFV3
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M*4XI3BE.*4XI3BE.*5PR'UL'V,?7GW-S_P SOS)#_A8O\HG_ %A6&X_Q>?\
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M1L69OV"GO ]ZZ;;>V:J9TU5VW3SHIKIOK,L(TFNHXY%W(P?*DD9PC$=00>A
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MN<8U323]??V;9JWT2:,FJ:+-F@@U011T^C[>WAM8(K:WC6*"!%CBC085$48
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MD4&$WB#Z-B2C92K;S'IK"IK0O87K^1ETO8QWL3-K(G,B-C?@6# 4A9$E2E)
M8Q:$A!, 7CS=ZCH/> I*(+BY( 6?@I$T(#B+M%12HSH/QVP"A9%#Y2)G1PP4
MB=UV1>>C1I"ZPK^,N))9U$1FAC 1A#ZSB$1B\?C(P'&&Q@,T#BD".22ZRATF
M<=JNR+Q2H2D'A[J$\M5.^]J3C1"KXO3\61U(0NG903>-*1NF27C$UH[)Y97Y
MN4UBL=DTJ?#;$VK4U&59N#%1AH_6;[!-MWRE9%:?CG8R:;=7-(^7*.XE7_<B
M_NSEO&"19BP=F(=;ME2/LRYIKX(U';)R.*%.R8RDB:S9RJVQK&:PQ@LX(.'F
M[=XI6>RSQRQ*=VQ8-O2VVYL2D$X/54211'P^HHGJS#U+V/J_LI%P,F)PR QT
MU9NX4]5(2!Q&0V"0.R"'UR2D(L:_6-GS<@)*5+U!=1Q5&VW=%TK6-)9[,[J:
M1<7(%'\3J^"C<CX>4EA0.4-#*KA$)9S2P%\2]V),6+*T24B(@ \=$)[LVXYQ
ME^I42,?'QK&FT;7@78RUH7):UN6];7IR2M8Y5)A>OQ'9$]+)3;57/AAN#/1D
MXAAB1S%Z7%NY*W6E01T!B'NI_=(223.OY_G^?"E2\PZ<5^(Z^U=UW%R.7XCE
M86O45RIR<FX%$)=+IQ5W8*-]DR)B4N41; 0H[L:Q@3U[+M@X@0T1TD)/6/L1
M"2;%!JI5:"_BGKF4M-87,KMN&3TD('=E04'IATWK9D!@\>[3")<.GPP?)AT$
M;3,VK'5YB^WKQY*#9GY;&,AHETW,8T>/7BE276WC\B$!:0-)Q.$B+N 7=#KL
M'.XK3%"4ZF6*0F%SB$C!,C84]7,*:&]'C2>E21$F0T7=)$$DM 20,<L[8.%*
MR"(]'0,!FM.3V&VG.@9VI9[W DZNN!D-),9M$NZG8-+L?:=>G6Y6/O5!P]A-
M149'QF0QYP+D;$"&<-UGKAX67>H*5A8_Q\5["*4E5;,'$AL]BY\?->=#THI(
MGP0&E+894(&S&<=).S3<9E()*96M8KQJ3*Z-]Q091LP(L!Z6[=7"BE8^6Z;6
M6S\4TXZ<,Y(A,+XFW6VQHQ+9L5*:L4)IV MT;()-9LT>&=V>?=DI3:TNDQ_#
MY9EMLBD_TW51SG3;7BE=X\\=S8H6>64;[(W(<[&(676UDQ'L _"U(A(8FI4M
M?V55D/BB<)$UX,K@O%W<&N:W6$P;/XS\0/E;(D1I@0C[AK&$HZI7=QGQ]Q**
M2*K)F/MFQG\SAY+L6[L^1'1T (J7V/[6RN"S6ZP\U&HQ!D)C34P<K6%-(VM7
MK.+N(G%Q.T?';[X<>_I*5'58^*^K*MK,C402=/=X9HM2*$8<LJCH&(S@6"HF
MV(1:T6%RFPX)6,7EED/'SR @H^8-3 B\=/QVK@N]2=RQ=:0**5,4NZ.@3\U+
M6/'[3G4(G+ON&&[DB#8@9#2R028LNIH'IL9A^HJ2Q\P.(Q0_4XTLY44>(9,#
M94;P59$,-Q;9@HI5:;;\/%06TELB2M:>#M'3F]%'WMH?3\PW;-[R[(33LX5^
M3G,]K^3O:W,CYG-'$<>2F!NP,CDT)$A!98E@D'$&!ZE7->]/ZW.5+VAI:3DI
M(9A7:^46M))]A)VV%%P_TMQ\?'C3*+DF;;UF.XEN/2> B#E%VZ:O_477]XU2
MU3RI55+8\?ED29CI*VW8VRY_?9NRNI*#ZZ)$,J.,&8%4/7&WR-D-&T,B@"N&
MM?/CR1&5S&4&U9+&#>9F9()"W"3&/, X0<I4LP3H.+K^=UE;(N[[+?6S$["N
MF?6/."@>N5]KG^GYQ6ZMB1N1 4(>W"Q0-JQI^M(Y$UH.V"%XW&HOHS^(D2;]
MZ944K'1/C2K,16L[K)&PITJ+GG62G>K[\BJB ]_8Q>FK*NNS DC::Z#=6^Q\
ML3NXX.*:+);C\, XK+1L@XV=JK*5^;U\:=<WI,YC.RMAR@.7F%W-+M<CG4-J
MBQ(@T+Z=;(-UB<L,0>UX-.(@0<MX?!FDBC$D*!79R*2TB1<,%U@KMZ%>*5./
M6;J)#NL.$](M)I'(DTNOW63KSKI($Q6OIC?5^,2^+18WO\-9,]<F9&SF#M>0
M::Z:L-'#1M@<V:I;*I[*5!XGQW* 8!7%<A.T%T#P77B61.4]3\:1VF55J Q#
M0<SA8D&@LK6N75DAW%8SV05.41L!R67=03=KLW7931)>9NE*SF#]#X7#3C"6
MNK%GLMF:U>=I8;-95($HLB0G9WMI.*MG=@S8DS @ P40^!/:I! H6" C!X(/
M&,IBUVKY9DB]W4JO4&\><F57G(LK+S=6,Z_)].1G6NP8T1BDOG&=NG<!+P\3
M8DM '(J[AB;>?LY09!%84Z8OED1:A%V@_$D%Q3A@I55^PWBPN]O+*[)5"59W
MIK%&'867C99<JG7M8NEV!OR^-KR+2FR(O8G7&R80I6.IWW'+]"CHY7D]7U&I
ML=LO&3",:@5*O+%_&O$V':R(]Q9)8Y8G9H:PBMP&P+.$UE@40L&5]:SW6V4C
M&MBO86O=VM7LP4@=GX17;VQ7 *,E_:YW;$&VPQN$4KCL_%_7RE25G3,DN.UI
M%&:8I*PZ"J@OAO @DKA,(DTSZX3FOG[,F)B"(TI+*>/=8H"0C)P\%*)'W[DL
MM+AYAHHV'H*5)\0Z-"Q=A KDGUQV#:MQ,+>A]K&IP?$P6/)&6]>TU;M+PBOV
MD9AD9 @P</!";JF\HSELW<'R,N+/WKTTH-<-Q3%2L[']56$?Z[S/KY%+!.!6
M4QL*Y+!<2LC$Z[FR^BUV7Y-;ZEL6)Q"=Q:20>0Q)T]G1F"O!Y4"H]=0]7?+<
MD.D64#C52J^ /&#6<8K:3UT%M&RFNI^D*=IP?(MFT(V?Q=6D;XMKL5"I1'PJ
M460B3!L/GMLO!P^!M@"$' P:-1R&@ XT6SXI60,?'7"6'87?L?K.\D9O)#]9
MSFS%Y'2O7:4E9A8U9PN(P1K,X[,Y#59&:5:M)0T&C2I\/ C@L0.*#]C$';PX
MP^)$'JE2SUEZD">M\IN:<ZV))+#EUX$HF_F!$I$ZP@(Q=Q#$)"V''UXM4D)@
ML8(6!(4Y(ZS/[!>"=S\R^&QMH[V:"HT$&LE*MWQ2G%*<4IQ2G%*<4IQ2M)/F
M M:[8I4YRMG%9 2M)V4M&FS6TQA0IL7C9T&;%R/(&1!=FV[-HX(+A]]1;[#O
MW,@RW5PGE)^U6:XW&E10M()!(PFC#9B(&&5E*[D.<D#/I#&5/K!S7W!^1UPI
MP/JO%UAQ+'Q/J%IQQPS'J<LO"MU:VHL]3L+ZQN],\_TV]$JS2QV\=ZINX#%S
MK:<)NW6\R2GSL4Q-2M;V[6%@ @>9,;A4^B4I$1S&7&-CQ,&=8D6(?7W1)=WZ
MQ)TW2::X;(K.,Y6QA%/=3.NN=[(@DCDC)P'C="1X!E()Z].@.?FK]&>-=$M.
M)>#^*.'K^^]S+'6] U;2KS4CR\6%K?6,]M/>'G/'%BVBD:8\UTC 3+LJY(]O
ME%22VY?7(63W3"@5=3,WIE_O"0A-Z74CXU?1/9DT-OG:2&OQW;7.ZK]FU3V0
M'YW39[+K.4E\Z\A.L*2%(7:5%Z;R  S>.T#NOJ)[]P,8S^&_'FF\(:/Q)>Z7
MP3K=_P 1Z+8MYNNN7UM#9KJ-RC,)YK&"%G/F .$MYY6#W(5IEC2)H]TP\PUQ
MU.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3\OY>*5YPN]O0>-VUVZB-6=2&$<B=D
MFZZE%VWX+*[.&-:1*&I/OEB K,D@[-PO&IO;4WR9;A1R;9<$Z#P6:&MA[%=F
MHX>[:UU22,)'-Z: X+XW2!,'I^LH8YQU8Y S^MTQ]E^2'\KOB?A"#1^'.-U?
MB+ARTNUCEUDQO><36NE"TN42RB:6^LX;\Q7ALGCN;R5[BWLX[J K=F2U%MQ.
MI_B>[ "K'23[ _*@ND-'2+F<U]N9%S@1;35CMNHRCY6+82? %Q"SCU5'! \D
MF3&)?V8*W0*91?,ILNL)"!)9R2I<@?HIHR\3PD]V60%6! \%RK9PV5R#Z!^4
M%^45Y&/*!P!?\.Z9P^O&.M:E;M;Z?<ZYH(MX>&GFP)=1ANKU!=+?P+GS:.P#
M0R3;3<S&!6BFVZ4W:DCC-=!(RQJ&P9.-C+R21P08'G*]U8K!0,I-B0K-GK()
MR-,8;"!3-F(1P_9(JXT8Z^I[5+V:V_.LS.Q9B69B69B<DL3DDD]22223Z\YK
M\\E 5550%4 !5 P H&%  Z  8&!T'853Z^.H<B[75M.[4K!-E .RB]D3,"]D
M1Y=FTE1ZM Q,H)0ILG.0NQ5V' #D%DUVHD.35B;\@W53*)+Z/LE6>SL=2EMT
M\UEEF:R+F40!V,23$*.<(<["Y"A2V-P RI[@^U^0'C;@;R=^4&/B/C?A6SUZ
MSEL&L8=2;3K74-3T"Y$R3V^I6$-UA'*%9(9N6R74<4QFM7+QF">A])^%F]Y-
M(&JUX2*-5I#V[C78BW E&TMF)-#3?&V[<6FRT4CP_P!YTQLG@D_)NMV6VVJW
MP5_C79',^;5H%4\D-*_AD%$'M).&./4!U]8[U]P<;_EL<!:7ITJ<#:=J?$VL
M21D6TE_:2Z1HUJY!"R733E=0N.4<,;:WM8EF *>>P9#C:OT%2:=?3%K=$94U
M',YU3I1Q9<"ER0H>#<7S0-CFGJD0LEVDR2;H$IG!"R3JG;,4:H^Q;E(Q&C2:
M0\;,0HUMH99I;B0R2,68_,  ,X51T51Z@!XD]22?SAXTXVXEX_UVYXEXLU27
M4]3NML>^3$=O:6Z$\FRL;9,0VEI%O)C@A507>260R3RRROLNYBKE*J%*'UCM
M*#L.V&5P3=F?!0:S9:*') JF5!-7T9:2-X(9>P=UFY)+CD=AK5%71P55>KHZ
M[^T?;+;Y6Y,58_.8X3$I5I(D)+2;B'*@]1(!GJ<=,>RO8-*@X;FX_P"'.$I^
M#M#FT^_U[AC2+NY:_P"+4OY8-4FTV"\FYD/$T=M'<N+F5U,=HD$;D;8 BA*F
M^DI>5L*F:CGQW5IH;G%8P*7F=&"6Z#'0K)8J)-$-6:"BJRB+35V]6PW2W65W
M31QIILJIMKG?."9!'-+&N<)+(@SWPK%1GVX%</QOH]IP]QIQ?P_8&9K'0^*-
M?T>R:X=9)VM-,U:[LK<SR*D:O,88$,CJB*S[F"*#@:TZ9["725MWN3.)Q,NR
M)VO^O%C]CAL=@C:!=<@G6DG%JL L7(.,ZV"UKA2_%ITGL[7>96<S'86H];^E
MYH['([C7.*N7KAZ>4>R6 \@<EG30_'(]'J6H;L]+R25Y04TO'NO5_2>0Q&.E
MOA[,$FL5MD03B$L(EJU'**1G,> .7;>U-S3X-'2:E2PEWYD;Z<NP!.A3<7JE
MYV*NGJ:*N-M9,7)&5+7K"/V*>'F&M=_+KI=K"I*A7A *U/%">Y4--73-@]AA
M.(^M,%E*K^T\@\\D?5RSY  KZS-8_37C[K3L;/NP+NTJH86S@K9W65_;<81B
MX#-*EJ\.6AAZ&<Z2DV_K6/5D+)$!YP1"2HQ=S"12E6\$=QY.=4O:6!Z<'8H2
MA'MMQ W<DNN>&0=<G/J5";N9BD]C,B%#PL8KU.3-"<,S8AN;M=VI46^-D(@Q
MAV$)"JI5<:U\@YWL7.^M@^%MQD'21[TS7K?<XV)RIA9L(G85AT&MOLH!4B<X
M*0N'F7(7)-U7))RZTBT3+MI#&R8?UR,?4V=&7\_S_/\ M5(TT\F<+BW;1[U@
M'5\\D>L:MRIJ+FDE9R;?25C+"N0%"I#''L>K=M%R/S%74:8V/"M[#FC^8QIS
M&D7Y=^.C<B&1LN]14K$Q?E'4D<9L<I%^M\M-22GKNI[JK9,24G<>#*CNT]HW
M:UIPE5$=.&!;,1(@D*;EXG8+NR%U H Y%9S%4AC74OM)&,:4KHI[Y91E=ZC8
M-)J:'A.P&ECWA7DJKL];: ZOPN]" JDE,G,![99U^6>21&3Q^^J@<P-AO7(5
MV1?2IZTDWRBVCA@@BI7837R(R&;U%V:E]?4U8T0KZG>DJ79N1VHO-H;"[2BW
MTA]=9;<L(C$.KZ6U[9 G%G E(^H+.JS<00AL9)+"22HR=MLE(TBI63'_ "$V
M<+L=Q 8IU2+SD)MV,;]28S.'%TPN.+2.XWE&,[V8DRL=<QO*H&MFL9R3;R^5
M(+D)&+(#\8BM=3+#Q)NBI453?S(1"&@HHZ4I(LYEB<#GL^M>!N)\Q0/1EO6E
MSV50TEB-59&Q4VG<T\(SVG+*Q#@ZNE=A3X8(*<O9("*206&V4J??X?DF7N4I
M7['KT0WKUIV0QU1&VN0LP,/R4MXM1K*[HGG:!)QM\?'0E^T?LXE(I"Z=?%XZ
M=?L7#"+R47@L[$*5"M.^1F[]J)ZS3R]Z:JB.R&_YS/HUB8Z780B%-A!<3EK"
M-"6IB92"KEF("TYN^)/!5;5J571%3K:(''B=AA2CME&L*5;OM)V;FE4R0%4M
M0U2ZM>U974%S7.HUS-04"812N:>6@H&0&VI.0C"S _,WDGL^'CH;#G*8@095
M^+.9#+HL+'9=N5*HC47EC0:ANK]:2B*.K,L(]2G2EU=TSQ(6X&3JV/VA@4%*
M-2D/K@%"B366"PN\N%S>SGB92#LHQ&"[A6'BY>0$/P#12H[K'O-V&K6LI#V,
M[)KS&2.E'GE L@/44)L.JWU:YA72Q[.FS& IN-^M,,G8S+1.&;QF.%G$U-/R
MA1DK8$H=KMI'F Q]2K53KR>;U&&G[&XZ(<5U:,=E%  H="7EI@S4:D@_LHQG
MQ* %Y3886-NF\*5CK.J;+WLH<-CLX^";Q7"<,?6'\;"[/5*F$1WP#$^F;[N*
MM6IIB BDF=A[$BZQG776.QR)7#I65F6,!DKD(T1ED%C$;:F[:CI; <(K+X0/
M::KM8R5?.&@Q2J]2OR?C)I%+PB55PH^%LN*2_MQ7H(J\*B5<#X5U\H636./[
M1#&;@0^:&8!(ICK"(3&A;A';5R=E+91Z\4:L';5=2NZKOR'S(144G<7;54=@
M%F5[175:W4',^O2#1V&3R,]EB4KA<5,R>:M8[D; YA\WUW+=)' HR!L)QLNX
M!C*^<SDD8;#4E*XU/>0*X^P5V=/QM9U)7:--7K6?<8S8[LU:!1631^5]5.QU
M;4#*R$&=LJYW82>,C7QLJ5BZ1-"-/K'&2=BZ)_1HZB"H^4*5+-Z]U74%MBXJ
M(WB.8GK#:"FMF#)\2L8+"["FBHJL)9-EWW7N"RNO)3&K.;PY4&D)E9O<R^6A
M,C62<2"NC,8;JNWRE0.U\B-FU?GL3,[:KH 3Z_TE0?5"<Q&3,["1<7#+9IV$
M8I!HR%E85.NXK!4%IA,7B#$N='DP(2%88Y)I""@XYNTC"E<]MY6TW<#8R;6E
M@HY\E=KZFI1+9)<#F,]:P.R%< K*%2=/L07JE!MAE*FTA;0B,H2J PMFXLL5
M((H6,!D6H@N>4J;NU-@]B&W;#HW3=2E$HW6UD2"RYC;9L7+(T$DQL#5@^+/E
M8KAE*J:M)HZC2K.1JDR;(&0ALDDRR#8(QF<,2T6+N5*C@IY10P^CZ?NAO2,C
M+ZV[T@:=TA\/'3(+H79,G<OH.)(UF@0)BQPI\:7<7LS7;R%XN%%;;Q]5!TW9
MI$\/!ZE9"V[_ %ANIF[H=/K0DEVF1MQ[6R-8.+H%:UWL!847'>P;BP'5PMX(
MZ7;#DH?*!$:5!MZZ?%\6$XP)1PXBFN\WT4J/#'<3LAF<=MXW8-<B:UKREI]T
M\C<6.UQ9P4G;0PK><@I/1W&) /D]3RJ $Q[W$X-:2@N,>+*C [9U&XLLZ)D1
MMA!E*R^7^2QQ#D"L^>T"87Z_+6CV#HF#VHE88;$ADUN==P]ON)$T,5I@ H[B
MU?2B4T;8$)B4UTDQ\PJ6;""9N#!8\80*Z*5R!'D:,)1"R#5E4<"IV01>F^O=
M]PX9/[^A Z)2*N^R,RE<#AFDQL' /X;!IF%D,-+HR.(A1EB.7^'0)A7[R=R(
MPB!34JHEN>2"S[(K6-6U2IAU5PTKU4[Y'2<>;;1J:L&UO=:.VG6&A&<F"R0M
M%T%CH%KJ?LG,8<N X-(T!E35_((LR,-6C42I6QF"=V1LYN !1+:NR+*R]KL[
M&UA8('>1-7&U=PN@H\(D[.V7JFHE+<J&L819O7-V""ZI#G ]*\AFRY)YF..]
M"2E1O)_); (-= BE)I!"X S_  DYQ0\Y,JGV*@BO(P$@M8RV!7$<W4'ME%8O
M9AB_.OT'&CT_8J"Y)9NZ&Q,GB,OM':E1\EY1R9"NBMRA^L\B=U56-1U#=W80
MR^L<*(E%:P>ZPN\ZC2,3AKJ-[+V+*(U4ZX:R;!!OBL"1"L#*$<CQ.72MH]$(
MJ5A/8KR22VOHZ\MLI#7]14!2_=PA1EA3] ^*G,DLZ-5GK92-B("Z_:Q%=S'X
MR23CPAPP-*R)I(=#+,P.69C0#%M*#ZE;::QDLHF5?1"632&I5[)I&#9FBD)3
MDXV9[1C8CI[TV$.Y,&;MPI8DU9*-M2JP3+X(D2R[;!S!T:@U-/U*SOBE.*4X
MI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5C,RAL6L*+FX5-@(V3161L%AAH&6;Z
M.F+]FOC^5HHGM_*T53WQHLV<H[)N6CE-%TU61<HI*Z7([QNKHQ5U.58=""/Y
MZ@]".AZ5L]&UG5>'M4L=;T2_N=,U73;A+JQOK20Q3V\T9Z,K#HRL"4EB<-%-
M$SQ2H\3NC:].KWC"IGK7;,JM5-^[G;[!17>JF,B9(;Z5R(<))**J94SNKJ9E
M"*^[ABSD.R+7=H+32W0;)$';I?6?<ZE+<1+%M$>1^E*D_I",]!^RA&"5ZY;I
MG: *^B/*E^5%QIY3.$=)X3>"+08/-%7BR?3IY%/$EY&[*J[0$-EI3QK'//IP
M>8373,LDK6\,4;;,>:ZOF2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2M=O>3M
M_(>O>X&'0'6./)9*X^;=.W+[99R4ANOMV30&<3'>C<>ZP]VV,>YMR.FR6SD;
MJLLBX:Z*-U_9_)5Y.++C%;O4]8\]CT_3[RTCC2+;';ZF=LLEW:F;I,G* MN8
M\!#;)RB.DA#I\[^7#RO:CY/VL=&T :=-JFJZ=?2S2SEY+K1O3ABL;U(.MM)S
MOZ;R8[E67FVRR.DD(:.7$/&87S.!78NVI6Z'FKBM*Y-SM@2+#G70BL '@& N
MLHH-!9T44C<!@,223C<79_$B6I4\C-I0ONW*'B26>?\ *5P/!P/JMI:6MS=W
M=K?VTEY#)<6RQ+"!<21"T%PLC+=3PHJ/.PB@VK+"VS])@=5Y'O*7<>4K0[Z]
MO;.QL+W2KJ&PN(;6\:>2X8VL4S:@]J\2-9V]S*TB6R\VX#-!.@D_0Y:Q_=+N
M14_1FCC%X6TH1=CT"#2.Q:+ ]4%)#-9>31=N!L<#:NE46J.^[5B_(D"#M71J
M-$CWSS?"ZJ2+1SQVC:/=ZY?)8VFT,5,DLKYY<$*D!I'P"3U9550,L[*O0$D>
MEZMJMMH]F]Y<[B P2.),;YI6!*QIG '0%F8]%52>N #KY\<G;?I?W.HJRK"-
M5Q#(E,*:>2B3W0RL,'&BK\)&"Y&2RT9,<R/W'.34:2"-GS!<@J@T>,'@!ZV=
M#T&VPMP_V&N\+7^B7=M;,1=K>L$M)H59>=+N5#"8V)*2AG3"[F5E=2K$[@L'
M1N([+5[2XN #;-9J6NHI64F.,*S"4.,!HRJ-EL*596! ]$M&_CM\QG6.[[U.
M]5(U"9'6J$LG=A%Z1D1;X0UCDN:."1$XPC"@9CA)2&%U@B"BH(<JJ19O]V^P
MK#MD66'CWT_5^!]1TC31J+SPW C"&[AB5@]N'(7<K'(F1&(61E"E<[PI0,RP
MM+XQL-3O_,%AF@,A86TLA4K.5R=K*.L3NH+(I+ XVE@Y53Z .<5775I;\JX8
MQ\V4I.10N2-U(6(EC/2:BQ+H>R!*2IZ(Q\$^=1J3=RK\P;Q]N_(1,B16%^]Q
MN+GD!VA5FS>I_0WD)TKAZ]GU*ZU&#3+C6+:3;I<<]T7O3;2VKQ:@PTQI3%);
M*DL:+<FV<[IIX]XV@+\G?E-Z[Q5IMOI%CI-SK%KH%Y"'UJ6WL0FG"\@O8Y])
M4:RL EBO6DMYI7LUO(]J6]K,(_TC%K/^.J>VG/ZA/%;&<DI"VUE[[4#,SDF<
MF3!?71FQ;D!>X]WA94:Q"K-]/=EL.]$GBKYSC1BDH@L[>\WY:-(X?T?B.SM]
M$C@LW.FQ&[TRTL4M;:W)EE>&X$T>U9Y;I7(=>66C6%"965TCB[#\G;7>*=>X
M1U"ZXCENM0B]UY_,-9O]3EOKR[ A@CN+1H)N8]O!9M&IB?FJDSSRA8%:-Y9L
MZEG07K+-#$A-&XQ,L+RAZ1?F6 NW+7" 7"Y=158GHA'A$S9A&31ZJNONLP9,
M4&7I65UU;ZZ;9TYY0E[<(%"LOHXP3%&S=.Q+%"Q(]9)/MK[HTCR_^4[1+/3K
M&QU31=FE06UO97%WPAPE?7\<=FJ):E]1O-%FOIY8$CC5)Y[B2?"(3(6&:M7$
MHN$@\5C,+C339A'(A'PT7 ,=W#EYNS"1\<V$BFF[MXJN[=;-V+1!'9PZ76<K
MYTRJNJHKMMOF,[,[L['+.S,QP!EF)).!T&23T'2O*-7U2^US5=3UO4YA<:EK
M&H7NJ:A.(XH1-?:A<RW=W,(84CAB$D\TCB.*-(D#;8T5 %%>1O3JF!$ELV1C
ME+0:HW"2GIBQ(=I=-L9K60%[,"J 9D4WK;>8;0ED_*,%<[INAX1JJ.?:(DAN
MS1\@DXTMK7UR2_3KKX="R2/$X6Z<"9;1U8]<CS?$IE:.SRHJ=,2X]7L:U71,
MIKM7 0I.9,X5/-5$3Q3#_1$L2>H,V2;=2HCJ?Q^U7!Y[-[.F3Z23R6R&_KRO
M.-M%YQ9+*OXD6N;YG#;D&-5J35Y7.)X'@4M-PC-@-HRU.+C"#U1MNR5<[;84
MJ31/2CK@$JZPZ:&P5TA7EJ4O"^OLX";2V7K*EZIKZNG-412.IE5CFY8<N-@K
MM<1N<&O6AU\IO@D_(N2>FCO"E<,YT<ZYR%_:;@G')I\(NE&2YLF#C[@MT/6D
M@+S $VCDEENM:")PQ@PJ;E1K-JHK,@X%A(T#27S.T(MY,HL744KF0/I90-='
M!DH!A)D4E0NYWG8+253>U;/L.3/K;?T>[ZY.928/3F6R H7U^AYXM$6P,@Z7
MCX]'1J]'"FA!DS<H*5E#GK#56]LE;J&YL2+3>2%H^?F"4(N"UX1#9V?BP<='
M 1R=UY%9D)@DP+-(X&"QUT^/QY\L9CP0*".[$Q(@:S:J562SO&704GA8V)5P
MP(U>HO,^M1B<F!$LL'0K/([U\[ LKYPL=+C)B*-N+9D)9U,M-+Q7)K6:U,2Y
MX:>2$BHDFCA2I:TZ']<6PF.,A8:PP)^+R:>S$?9D=NVY0-R/9':>1&+(?R*W
MQ4Z:6+*D9KI'(PB>&261E1#A&)P])%@AI$8UJ*4K/"G56DS<7NV(&H\:,!^Q
M=7C:=N/<Q.)N6-32!BH&7K5LQ?R4E('<B2+J1 Z58OY2U*(R<H]=[FB1=V:Q
MJ_PI7+1ZPTLW,,SR,4<:%!]YZ]CVKCYAD>VJ=OZU>I3>)/E'8KE#=#Z/%E F
M0.Z>P#*NWQ7X9\6QA[A2H_VZ,=>4'8PE'A=CP(R,5G_K'JQN^YZQ/F&%FVC*
MKHEH.2&H%.X\2D8):RYM*Y.#%FG+UO$7)XJVB6 C%^[;+*5(6_62EU"[@[O%
M5\DW5^,>S:[CY@D6,;W..@X^N6DJ]C@K['5!.(C&0W,?UTQ'5%$LOU!>S]11
MSNI46.N@?6QY"<5FN*M#-9YDLPD;BN$K_O9O B",[,L)!)X>4B#>Q4@).MWQ
M@<D\;UR_8N(:+PZ,,Q09D//G&A%2I/NGK#3U_$XP<L8/)=SL1#R^,"3L-L.P
M:T-K0VP, OGJ"F2U=2>+D#\'F"D7C3F01,TX? R#R/AWBK+WI@@KHI6'1;I1
M04$-P4_ AMAP)Y HC54%9M8-=-PP\)*8M20UL&K$994=CLX' K.^6PK1('N[
MG8X^].Q_UX[)'!<#OL-RI7XD/1[K3*H/FN3D"=NXAD+V9C^1FLOF+93X3V_>
M2-_?[;W]L>1?^F9NI8=4;+^\^WB^'>FD55#:-FNJ*E=_/>HM#646E,@E44*[
MR26MJB2>28'-IO%)*'=T01F96JC<0D,7D(<Q"Y%%7E@2[V9Z+/1)0JS,N1AM
MR2%YPSXI6>8I2!N*>.T2?2DTXKJ4Q>70R4,['G,TL6022-SI,NA)Q9V9S4\<
MEY-N^:'"(]MHZ-J:B!6S40&U'BQP]FU4J#(KX_NI\*(;%HW6&1Y3?JXVZ:*$
M-I9,G;Q;KZV4RLI%%UWI]QNN:(JZMU#4\6SO.S>S ;DM(WGPYE[!2N^EO2?K
MK-<9W-1$VB02B%%0D:= 3^?Q>21\1UKDTPE]+.8U(HY)19F/'H9()Y*GFDB$
MO6ADRB44''WI0:DBTT4K]1'I90$$4I]S$PDU$$J-/6_(8$<3MNUW,BW=7[8&
MMJ7&QFLB?3-R:LH%85A(,97) 5AOI.*?E18M11K[-BBGJI79V3U$I"WIHK.;
M'%S65D,L#S1F )6Q:6U?!GLEKB15$:DD=K1.8)P&/2YY6\ND\4S*0L<8FDF9
MXJ[1>)E7SA^HI75F^D_7.1J2'XQ#SCEA+:CA%)R8$C8EBCHZ;A5:/%G]=.W@
M$9*F8O$\@KM=5>(V>W;(6+'U?8JBY.V5:,]VZE<62]*:8FM>NJNF9N_I;#2;
MB1_,#"1=I>R!1U*PTO!C(Y)H;*RCBTMB,A@)@.):MG,')N7$7367+D6HMN3D
M!]X34J<BU40,U-JWL)^$QM*JD'2T3 'K=Z_9M00Z<#A(F2-=1;1RB,>IO!X,
M8W0^(-'61^K;UF&6VZJNVZE56!^-CJ''FCL</@DM5%+5N\IT<',7%<,A#1:J
M'4VAUA(UU!Q)^=$QT'B B4P.,O 06*-A#0*S8["!^B APLRW4J29WTTH.PY6
M=GID!*A,_/S@18J\^@UFV37<V&RP-6C>GDGL>E,&E4?-1UF0K9LG%3H8.\9A
MC[/.SDNP>$,:/-%*_A'IG014_))$] RY9[,0]2!Y8T4M2T%@DFWHT_&9'6$A
M/@G$O6$&)M''L.CS7>=$&;B7F0['8*<-$ACQ\V<J5CQ#H/U?*R*12(C"9$\3
MDIJS94O$7%GV@K6@::W+'Y+%[0GT2J[>8;5[#IW,PTTF:)671F-BSFKR82TL
MS>-2TG.OB"E=Y,>E77:=I:8/Q SJ\:PBDX )- Y[/(Q(8\"ZZS(]8%-.8W(8
MY)!9F/R*%2Z2F"S63BGK4\1]ZRQ,OR(W31GA2L7;^/CJJWB3>$[00^^!-XS>
M,2SDS9EF'C3T1V/M>+7=<FQ:3G):0DAHM,;-AD?DSD\7*O3;)9JX:#B#1@1(
M-G*E9% >JT=AO;N_^W"RXQS*[D@54UL,8,1KMGO'P-?M'^Y\H1=KDW;<I)9T
M_4BX\R09,!*>8M6-<B5TG3@)N\64KIKBZ =3[[D%Q2FTJOQ(#U]5U#*LL\DW
ME<R!+FXE7\K'3:+:L?@)\;I'#S"1@XT^5E<<U%R9_I$XDS?E7+.,A4&:E=Q.
MND/6VQ91O*9)"3":K\'!8S*8W'+"L2'U]8<>K%XL^KX+9U<125!H+8XV)*N%
MFPQK,X^:2W$;_+[[5X T3&:*5E;OJK1+\5H#(0A,@'UO&0=BU!C\P<>L75LR
MET>=GSKYJZ(JHOAI)63&]5XL[T6B^4'N6^HC5!)%--2I&JJKX=2U>Q>K*]9$
M!<&A0_8/% Y$Z<D>X(%HZ<+CH^Q)R(@4*Z @+=?0/&Q.[U1G'X^R& 1*342-
M9-$%*D'BE.*4XI3BE.*4XI3BE.*4XI3BE:D/)UV5[,5PYKRH.FQD4*NAY KK
M[%S9T0C0:7^[4[1$,6?JQ[(<VQ?MT7MFS4J$BH B@DD\3?,7:*#E#U]\[=;P
MSINF7(N+O6$9[(3V6G0!97AS>7TP42;T925M85>612=I5@2#BN8XAU#4(#!:
MZ4ZK=F&[OYBT:2XM+.(DIM=6 :XF9(XV SN!&1XR"6\E43^!]6]*YI>U+PG_
M &VI8O;]8PVM-H8BWTUC(V,$).!DLAF4KC8V.+!L'W>CI^\RLU26!/AV<J&'
M(P<^CKPW+OU0W%[:65OI-ZMG<S7/.)/,>18I(HX8I&D#[ 0HPV'5L; S+G;B
M"+9IO(M+F[GU.T:ZMXK?DX_1JC2)(\LL:QE-YR3D>@R_KE5;% _E>KR<1OKZ
MXJ.A;TM:P.R,4MDY"*QC[2"B#84[2<B:1JP(K."TIF00+&EQ3U0@Z2+[N'0Q
MXP&ZY;[[D2H@:]ROPI<02:@+N_L;2WTV6T2>YD,[(Z7L9EMY8$BA=Y0XV@I@
M.K,<C:CLN)>)8)H[$VUE>7,]_'<O#;QB%71[1Q'/',\DJ(A0Y(;)5E7H=S(K
M1*;[\DKNL7QSV'2TGFE>U?>$2[YKV3"3 8.X.-9/1U8M<,1DF".%U&CTG!)H
MP+/AK9 NS8%\;(*KN-6;W&$YD>@+96_$5M>Q0W%U93:"+:9'=4,5]='<T;@!
ME6>%D5B4+)U &X=8TFM-=S:%<6DDT%O=Q:R;B%D0N)+.W&%="2K-#*&90&"O
MT.<&L\JGR,D7-1]5P<8KVY^X=[W)13V\SC2*Q>IZGD;:M )[Y<*V!*@#Z?HP
M*/O2!Q7 6/Q",R8RJ9(M56S9PBNLVT<Q[OAU1=ZK)+<66CV-G?+8QF66[NXC
M<R1\U+>*40><2*L?IR32Q($4@D$ D9[;76-KIR1P7>JWMU9M>.(H[:VD%NC[
M&FE0S\F,LY")%'(Y=A@') ,L3GR)L:TO.!5'/>NUNQ6.V99,<IZ&V,5/U#C)
M>PY>U55C+/6MFEBN[*9Q<N^14#H30E'603!'&FNV_NZJ+A2)!PZUS8SW=OJ-
MG+);6TMY-;HEWA+:$_I6-RUL+8RHN',"R-)M\,Y%29M=6WO(;6>QNHH[BXCM
M8IW>U].>528P+<7!N!&S#8)B@3=XXP33B'>3.ZK2I.R9O,(%.^N#B!]VHE10
MN9@*YKV=#C,=(W.&@V]7&P,IM]]LWL)D.>_#K0E@I1(($]^T*P) NZ1U8\W,
MW#-E:WMM##/!J0GT26_>&2YN('21;-IO.D>*T&;=F&ZUA<%Y,%)R@]*M3%Q!
M>7-I<2RPS6!AU>*S6:.W@F5D:Z6'S=TENFQ.JG;<2*0B9#0AR-M6DL/RBP.!
M32R$TJ1N"4T32%O!**N_LL%Q"DZ\KFRC!$&(=C5 !"4-9Y(A,4*R,0/F)P)'
M%VP9TXPFDD_]N/R_U=OPO<7$-MF]LXK^^LWO['3'YYN+FV17=6YBQ&"-YDC=
MH4>0%P.I7#[=E/Q'!#+<8L[J6RL[I+.[U!.3R(+AV1678T@FD6)I$65TC(4G
M !RN[CSSRG0*#SF?1[-#7B:@U.]@8YUWN2WV36"H0>"RN9/8\+BI)!!U,])-
M)QA$E(FB3Y,.#V>@VV$7!1!%8L#:$T'"T\\%O)Y_8I/>6$FH6=FQG,\\4*R/
M*I(AY43*L9*EWVN<A2=KE:3<1PPS3IYE>/#:7J6-U=*(1##+*R+$P!E$DBLT
MBAMJ908+ ;D#9[Y$.X-E]/8C1\@K6I'EIN[,O^NZN.):M63MLQ"R8NW9NPHO
M1:;0U=*P):DLJPKURZ4?QA NS<[RG#5E[#9?!P]H]MK$U]'<W:VHM=/N+I#E
M@6>-"0[8AF!MX2 UP!ME*$<K)SC/KNJ7&EQ6;V]J;DW%]!;., @)(P!1<S1$
M3RY*P$[HPP/,P,9C*P_*O$H ^L0EMUOOH_5]"O8,"[,6F*TKS(BCI;-AP$@O
M$R +>;9/S<M!<R)@RL%6#-#(Z/N\+>P>DFV6SAS)M^%9KA;=?=&PCNK]9Y--
MM7-QOO88&D43+)R.7"D_+9K<3E'D7&55LJ(T_$D4!G;W/OGMK)H4U"Y40;;2
M6948Q,G.YDS0\Q1.80ZH<X++M+;4FCIL^:MGS-=-RS>-T735RCMC=%PV<)ZK
M(+I;X^K=-5+?533;'U;:[8SCZL\Y8@J2K @J2"#W!!P0?:#TKI 0P# Y! ((
M[$$9!'RBN1RE5IQ2G%*<4IQ2G%*<4J$+LZ]5IV 8QX=8PYZ];1LHL49;#'F!
M;M79=@Z8JL7)%%'8A@;OLX2?*-6CIIA9\Q8J+[JHI;H*]5PMQEKG!\MY-HD\
M43WUNMO*)XC/&H2:.594A9Q"9P$:(221R;8I954*S!UX?C;R><->4"'3[?B*
MWFECTVZ>ZA:UE6VF?F6\L#V\ERL;7 MF,B3M%#+"6GMX&=F1&1NVIJEH+1<-
M90N##L(M6V5]GAAX@PS(#BJKQT[T<'23)DRR27;8=[-6NZJ6-6[1-)!+3333
MT<C\3<4:MQ9J<NJ:K-ND?8(K:)YO,[15CCC*6D$LLO(1S&)) K$O(S.Q)-2^
M#."M"X%T:#1=#MPL<9D,U[-';^Z%\[S2S+)?W,$$'G,D0E,43,@$<*I&@51B
MO+G_ )*&EIC!'I]!-%UDP&S*X):Y;8VSA!X8T7@09BNIKZ?5W6&LE"*:.V<9
MRGH5<8U]&%=O3W'DQB39J\^ 9-UG$#XA,3NP'L9MI/KVCU5SWE#E??I<&2$V
MW4I'@7S"@/RJ-V/_ #CVR<^=SKG;4PK" ]O1\6?.VK:R.MOR%(4T%-]4-A!V
M\*78OU5]=?JSLH)=%@^F^WH]")IRCG.=7&VNWH6HVD-S<:0TJ@FVU'GQD]]Z
M6-ZR@?(P5\>M ?"N&L+F6W@U18V($]AR9!X%'O+16^?:67Y'(\:CGKQ+3$"O
MVD9O'UU6QR)6W74B%+([;:J:OA$N$/F^-<Z_7G"BB&J>VGY%--MD]L9UVSC,
MC48DGT^^@D *2VES&X/;:\+J?L-8+&5H+VTF0X>*Y@D4@X]))58?:/D]8(Z5
M_JG<^6Z^CJZ@V !R5C@7(0XTX-P[8/\ W LR;OV?OHIZ@2&NLMW2:J65V3]J
MW=ME,Z9V27134USC.N.2;6\N[&4SV5S/:3F*:'G6\KPR<JXB>">/>A5MDL4C
MQN,X96(-0[[3[#4X!:ZC9VU];":WN/-[N&.>'GVLR7%M*8Y59"\,\<<L;$95
MT!':N:T8,1^BJ;!FT9)KKJ.EM&C=%MHLY6]&5G"NJ.FFJBZN==<J+;XRIOZ,
M>MMGT8YBDEEF*M++)*518U,CLY5%_512Q)"+_548 \ *SPV\%N'6WAB@5Y&E
M=88TB#ROC?(X15#2/@;G.6; R3BM=$WL2FV-#VD5<=@E!ELC87;+EHPU[.2X
M6?'3(8A*,B&;:*HV0VT9D&9%NS09!$1*6B:B:+-)CC7U4<SEBE-S$OF^83)$
M"?-U*E"4W$OR^V"<G/K.:^F-"X<XSGX]X4M$\GJW7"-SK?"44UPWDPTBZT^X
MT:YDTL7DTNJOPW(TUO-;23//?/=LS*SS-/G+U<+KW(3,MH.CY7(WZI20R:H*
MTD)TFOJEHN1,FH6%)%'ZVB*:2.JKQ\Y7<*:HI)I:[J9PFGIIC&N(=PH2XG51
MA5FD50.P =@!\P&*\<\H>G66D<?\<Z3IL"6NG:7QAQ-IUA:QEBEM966M7MM:
MP(79G*0P11QJ79F(4%F)R3K+ZV"[MDMT=V;67)%=&T%O+LQ$:OLNS>Y'9F15
M9$WT?$B&,6CDFZ6-S,=HM&N8QEZ[?O) .E(Z0(HME'@[40650,#\-<?6#4UY
M(^Q79*"43)8**Z^4V9OSLXAUS9!K6#SN8/:Z^ ]19Y?DBEQP0)L"N'<KWL24
M10<6HB/H/8=\VTA)(7,2!IL4G*3:+J5AN/*%V_F:4/CM-T%$[!L6/5#.;-L1
MC&(B7D\2MXA!NR]U=<$1-5'BEV5WM44/F;BBBTX&61)$[R;QT38D"8$8N41U
M<'":E6)D/8J_9?([((R9I4[2HJR\A'7;K-"XL$96X$LP@]+6WUW6=3R6SR-V
M^ !+M1C"Q#@K6N/DTM%I,^'#'\M<%XPX,0(FI4<1ON1WZG9FOV\=WZ@A!=TK
M]XM(7L:K>YC!"OV/3JUW$'&OY3AC= =O8;JT1R:39Z($_1NE7[[=20H&YXAK
MK$]E*X%?^2KM-=UAUXG3_7AF7@FD3Z222T@&D6<GBJS#M= J^LN7R$1;+JXH
M,)KX/5,3GRVP%F5IZS-K-.PJ1@M3,-751<-%*Y*?=+N7)HFN2=/^O47%W-%O
M(.$J!S&*ZL<G+*QE/4:42T'$Y;+GA:W$ T_;30+%2BY",!P\&4BT@P*>-Y)*
M!KEX*:*5B<W\A'8^AJ)ZY%2$MJZ[+%;]=J#O6_&0GKS8C'4E!;CF*,1CI9_.
M-NP[>)4^1*),#PA@<W:7,0G$Y '"S.J83&-VH]%2L9)]@+YK.7#+!@3XK816
MOA_G2GY"O)*5E!L;-(A17DCZX(JQP>(9'AV74OC],;3F&TINNJX91(N8',&X
MUU'EB0(@_G^?Y_V*V"A^UMK6IU=[1]EZ!!0"P!$.D-H+]5A^K&0.D;AA=)B1
M@66:EG+.1M<OC4_M2(V_':Y,!/@X9 "I 2KU@:TU)N"ZE5@G?DPG$J@QRP^N
MA.NB,9ET\G0[K<N[I:P;E*6U7M*5!#I1=,T>,P%TTQ&HZ C-J2"0P$A+BTW%
ML8TWB?I1 38V:1&L%*Q&#=I958]ST;8Y :]P-O64]!Y2E"\36PDA4 VM3I-V
MFMTXC&F4;E,9&'%=R0)B*<C9B*D,2-)XT+DXJO(AD<+@U*C\'WJOA[*Z)[)V
M-9-(QZ,W%X^+/N*KZT@\+MN5?(\@N#LET:@E71"T8")LX@0NRPQQ&?)0.,2.
M,Z4\F6FAJ:1/5C"P^A*1;J5)U4]NNXM[65U8&YF58U3ECVO[.4)>,=*4/)D]
M;+85'5JT]'+H1K3LL<<5894!;N1N@-2>6?J"F[=I*710^#&O8&34J:.B7=;M
M!VHFX603*CT(WU[L>#6-,(G*&L-6BSVNBT3G "/Q:#GI:0N:;ZV^3DX,B?7D
M14-6%/9@4IBJ\?= CJ!/0F/4J%>YW<3MA"07=B&B9G7%$R*'5?.Y[U?<[4O*
MIT3FT&J^35*(GECL;E&7FC7S\R(7G#Z,22KCM;0*8UR<*@#>R5B1E@^=$U*E
M2V^\EVT_V'J6GL%JPM0<WM;K)1O8)Q%: L>(#P\T[&%F H:;$60?[!FP,'>:
M,C8R7A*J:Q&]2;F.IY2D5B1M<HS=-E*H+OVR[+Q;I/O'9#84 EL;NNC?('O!
M3L)=SY"_JJDO7^42A\UDDPLI]8!=C*1SMLLK&WC0-"8$^K.1K0X"F?EB;S*Z
M:E;#X1W7[06)V^EM<Q&CD2G7J!=CC_769E,0Q9N?CS>.P-,X[ME];+NYFPG7
M1>4/!2+&I4J%5(OH*68RQG9*[Q;0%LI4UO\ L/<YGLI><)B;ZH8[4W6!*K$I
M]&I3$Y9(KBMQU94(<SOWBMCXRQHK&X.T:MEA\7BR!B!V,I.)D-DXC#J-:CTE
MMU*HV]\D?::-55&[#(B>M$X(7ITC3[FTZ%B BPPXZJ\;63U]AZ-76\=7L.6K
M6&T,#NP#34+:46#5=JY.0"8)Z5LNWT30;J5(9?M9>XRZHC5MI"JME=B5-VZL
M:K\2VMV5OU]$)"&=>+NR.VD:?IUQM;\BU>&&)=\A "XV=';#C!)DS4FL< 1&
M9K1UW#U*QN8^4*S U9PB4!A-4$#\RZ7]&[Y<ZBXY.)QM';$[;WE'JC,N&D B
M,QWF,YB<5%''4JB=9Q]XUGLW=AE(X-F.[LBBY;*5A]C^1'N%576MK84D;U0]
MNAR![9W@#@J'42]HWM+.LW7J1A8_$9O(H=+NSXLS0J$U:& ,ADDAL67%Y5$\
M3Z-QP=1LF(QZ2/5%*[J6=V>T=3&^]5JN#\%L:#161=+(E1U-:U@;:F(&>[5M
MZ8CX4V6F&+C:-95&(DO81(E, 'P*(N9Y(&R*X>;5B,V5%ZJ5G!KNOW2@]9@Y
MS;]<0VG(I$;2L(5<]PR>CI-(6[6GHQ'*R/Q>SM>N</[1E+#K6+FR,UED/F4O
MTLF[=:V(0%K)RL-)Q2;-GL=4J8.\/;SL73MM5[2'6BK&4]F\FIJU;N>*%X$0
ML%L99US(8+%Q\$',&%Q4QM%M#A.:I;R2SERLV1@+?(+.U9RO$@RJ*4KO>WW<
MB;TQ7-$.H2VCT4LFWIV+ATO&FZNL7M$6I]=Q1D\N1TP(4CU]E,8L6=DU'D3$
M1%1T!D(L8"8R+,](;/8\,W0=*59CKY8\]*T-5$A[,N(!![X+U5!IS<4.!:ZQ
M0+!#\Q:Z[N B88U.9V08#@QO+R()%7DM+-3AD*0<,G".5?AK-2J[=Q.P?9"M
M[3AE9=?OH18;$>L/:CL3)CEQQ2>3#'M>O1BB1X.*@AD*G\ RCI+U+7?CRQ<@
M1<[ -$69]F/-[#%HR=4JMAKR*WF7#SZY(.$I8'55(NNFXZ<U',A4O-7-:;GM
M3"J9GSAQ6\Z%3J-QR%IA&%U#XE 6A>KK&VLN>PN4A=GL42V26:*58;LU&-;/
M[K]6ZGDE@W)$*X(=:>X]BG!537W<M#:$Y9!9_P!.PL4/R(K3D\@3\^G&14[F
M*0X;)'A,"A@Z066&*[[XWT4K4U9O<WL/*J0I&)P2Q^P\GLJF4.RO99K-J6J6
MYK+*]BX90'9&PJCZ5PRY%* KN5CAM:]P(/")=(I7)98TCT$E>T,V-^\;LWF=
M4U*S>YNP-A6/V3*7/4LWN813!DUXOB\.NT3V0L8!2M'P+L,>:E2SZ;=7QDC4
MKJU!=RBWXVOR1B00PDG%R<O%2(L>C(@&\D0I2KT]\>Q\PZS]@JYGT=VP6:B>
MFO:1^A$SIXH)KMS,RG8[H/740F4]18;Y3U P/:PRI8V;U0R3#P]:6:#7;+#]
MTINI6'V)W([CUSK;\"6;T7-930]@5\ZM*\:]I:PI'$8U2,XIB9620/->L&.R
M3:R9;-('(8V!%3(/#+Q/F&E?3<+9HZ$D\(.8ILI5A:.[56)/^SYRM)N3KP76
M<O@3F==9\1NN9:[=79"P0"IWTHLT==6EHFHB/R&/3Y\$.4=**IA5A1]JM'#[
M.1RT(H_>\4K8AQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2M>]G^-OK_ ']V)GG8#L2.
M4N50]!H)7L @YW8J%!U;'HGN<?FTQ+N.G![LVXF)\ZY,OU2>B>K#.FK1LFKI
MMLKCH;7B34-/TZ#3].?S+ESSW%Q/'M>2ZDEV*F\2(P00QH$4+G=W)&,5I+C0
M;*]OIKV^4W1>&&"&%]R);1Q;V<*8W4N97<NV[]7&!GO5!]_&I?M,7KT]B'6B
MY9;$J[IN*]P=P%SE8-"YNRJ,?;1Z-R&,588ADC.(+3(.LNYD38>12=#R.JGL
MG>7@_1AHW5WWOEL+VQU>;4[.&:YO)M(YEDL\T!NVM(Y(Y;I)HHR(7 $992&3
M'H[6W9K2G0+VTO-+BT^[EA@M8M5V7;0Q3+:K=21R1VSQ.X,JDEPK95LX;*[<
M5SG?C:NVG[AZ*1'K3:<JB(RF*L[5?/'9LM#(3-\?2-;9P#)7BDIKHX58MR#*
M:$GIU 8+$NTE0C9B.SDZHL/5</K1Q)97EGKDVI6L4S7EWI7(TQ)YX/Z-:1R1
MKRKB-6*F%50LSJ0[,WZ/#!14Z!=VMUH\6GW,D*VEMJ7-U!H8IOT]R\<C<R!V
M4$2LS[%4C8%7TR5):UU=^+V!UP"ZI"!UGRLBZZRANSZ#PP0#C-GMG2?M6!6%
MSJ4&-4W6J0+860=.2(,6QP]3T:8:#';M?9ON_<:JXXHN+B35':UB4:D^EE45
MVVVT6E2!X(DZ9?>H"N[;>N6"C(4;*#AV&"/346YE)T]-0!=D7,\FI)MFD89P
MFUB61!N&,*2<;CT #QERBJ&?7<OUU[2':BLZC:$(]:C$])U/$['8V+53^5:S
M=)J[AITTP&QZ1")3C8J(--WI5!/;.K8B+)M-=D%,DG$T5V=134=+CN[6^OTU
M)(%NYK8VUTL7()$T:,TD;Q>@Z$(>I*NK'(LCX?DMA8M8ZB]K<6=BVGO,UM'.
M)[9I.: 8G<+'(DOIHX+8_5967I6'Z>(D>MV%Q>!;L [--4.UD/[=MA;^E:YW
ML5Q/8V2%D'<4,W;[3,Q>5DMHP<-H[!A+4 %B^KM-;V!E5BWSS*>+G&G^8I8+
M&3I4VD%EO;@6XMY%=1*EE_@5N1N!DG<R22X(W(K,*P^]=3?>>/?,X&I1:H%:
MTMS.9XV5C&UY_AC;D*0D*!$C!& VT5FZ/C&=X"W+ 778<PYJ:S.V 'MQ&89K
M6H! Q YNULX99LG#+3+!Y1U+ \A>"&@ACEP+#[@&6%%_9%7*F=N83Q,-]I.-
M/07=OI+Z1+,;ERD\!MFMHG$/+"PO&&9VPS\QB!E *S#AX[;J$WSFVN-335(X
MO-T#PS"X6XD0R[R94<J%&50H.OI&N'./%RZEDDN2,C^R4FCW5;L1>S'L/=77
M).N8P2?RB=Y,1N1R5B$MY<FA((K%)@?B0-Z8$-8^]>(H--F(TLS17<;*U@XH
M$4=G*VFQ2:KIU@VG6.HFYE58K?9)'$SV84QRRPQRR*CF15);<R,0,4FX<,LE
MW&+^1--OKT7UW8B"-FDFWI)(L=T6#Q1RO&A=1&3@85ER<R%,/'!%)?#NSL07
MLZ0LD>S/9R"=ERSU( -65BI6"G*^-MXJ.1W?::$1Y!6 HH+$G.[=R@F35VT;
M*;-M,+1X>(Y89M,F%M&QTS3)]-13(P$JSI<(96(7T643YV@$$H,GKTSRZ#'+
M%J,1N'4:AJ$.H,VQ28FA>!Q&H+>DK&  L<$!C@=!4Z]R>L"W:^K(_!QEB.ZJ
MED(M6N;D@<Z;QEE,VX2:UF<U- U2D3($@S8^+4WV72<#]BX[&RFR*VZZB2*C
M5Q T?4QI5U).UN+J*>UN;.> RM"7@N8RCA)55S&XZ$-L;ID8!((F:KIQU*VC
MA6<VTL-S!=PS",2A)K=]Z%HBR!U[@KN7P.>F#3*<^+*531Q<D93[:RD#2W:*
M01";=H:P'5-#=R-BSH.,CC&:'83.UBWO]6L;)<QED0.A6@>3:#MU%F8E\@P]
M1OKNH.*(H19R'28I+W2XYH-+NFNYMMO [2-"D\ 3;=-;"1EC<O%NP&=2W6M5
M-PY+*;N,:G)'::B\4VH6ZVT6Z>9%C69XIB^ZW6X,8:1 DF,E58+TK;HQ8M!C
M)F-8(:-F(]JW8LFR?I]FW:-$=$&Z"?K9SMZB2*>B>OISG/JZX].<Y^OG(LQ=
MF9CEF)9B>Y).23\I.:Z< * H& H  ]0 P!\PKE<I5:<4IQ2G%*<4IQ2G%*@/
MLC>C3KQ6CFQ'05"2;(EA@EN"W.) 73]4DINEZ6*ZK EERLUUURZ7;)M<[X8I
M.G.=]=6^==^OX)X3EXSUQ-&CNFL0UO/</=BT:[CA6!0V)46:#8LA/+1VDQS6
MC3!+Y' ^4CCJ'R><-2<0RV4>I%;NVM([%K]+"6=K@L,P2/!<F5X@O->)8BW)
M663<!&0=?54^4"02'*$5,=>;(M"Q"63&T>!T2-;&7IQSAWJX&,7J$G? (I"
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M3=#$VJVFN^%*ZR(=<.G&A&R'L"HGK7J6E#(C6]NNXC6E98(R >KEL\+P.Q7
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M[089=CY&F\.27]M:73ZA96<=]=O86JS\]I9;M=@2,)%"X"R%P!(SA$(PY!9
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M\[MUE4]^AX8XEU'A35[;5M.ED!AD4W%J)I(H+Z $[K:Z6,XDB;.0&5MCA9$
M=5(Y/C3@[2..-!O-"U:&(K<1.+2]:WBGN=,N2!LO+)I!F*=,8)1TYD9:*0F-
MV4Q%U_Z;53UW.')#&</I&7):L4Q1B6MA#\[&446;MH20#%&8]C[JD9P\4]^R
MW:MEE4-=&BRSA#7&N.CXP\I?$'&=K:V=\8K*V@,K7%MISW,-I?,TL<D#7-O)
M--S#:\I>4'D=5?,JJCG-<EP!Y'.%?)Y?7VH::)M1N[D0+:7FK16D]_IB)#-%
M<I9W44$/+6\$S"<QQ1.T8$+O)'TK2#_DECLE+8'4-(=<HF8>B!]T%Y9*[$V'
MN56JI:+P#4 U#1E]LEMKE<,7/23<J]:;9RFNYC##"N-DM=T]Y'DVTV&>[O=1
ME17:S6**WW $)+/S"\JY[.D<813W E;'6MOQ_?RPVMG81.R+=O++/M)!:.'8
M$C;'='>3>1XF-<].^F3QG^1&R.IO77O;7XB0/=&JM(8L"I4UG.ZJ<-MDO/(+
M3VQH V4SLFBZ<M;*&R5^EKIE%=6!L554_1ASLIV7$G#UMJNHZ%</&I(O3;W?
M3'.M$@GO DA'4@-;-$OCBX89'3'*:!KMQIEAK$".<&T$]KDYY5RT\-J609Z$
MK<"0C&"8 ?7FKOC6[-S;KCWEH^S!Y\GEI++'!PFT$W#]PKI*X78AUJ#E6IW*
MJNWQ1=KL2Q)V*K[979*1"AQ+.WMT,;\VG$>F0:CHE]:M&F8K9YK7"@<F:WC+
MPF/ ] ';RV"XS&[)V)%:_0-0FL-8L[A9&Q+<)#<@L<2PSN$EWYSN(W<Q<YQ(
MJMW&:_THB0P<98.A9=@R*#'R6R#T>1:H/63M#?\ SR+EJYT4073V]&/3HIIM
MKG.,9]'IQSYR@GFMI8Y[::6WGB8/%-#(\4L;CLR2(5=&'@5(->[7-K;7MO+:
MWEO!=6LZ&.>WN8DG@F0]TEBD5HW4X&592.@Z55&H>DE(TM,F,[BK,V]D#$87
M':*2!ZR*-/:E7K5UJ5;M,C4=!Q,<W;J"QZXS9IIJ.>.TW*3EPIAQKZ#Q'Y4N
M*>)],ETF_DM(;.6>VF9;**6WD*V\4D9MWDY[&>"9W6>5)Q(>=%&8V1 4/E/"
M/D3X)X+UB#7=+BOKB_@M;NW5M1F@NH@]U-%*+N.+S5!;W5O'&UK!);&(>;S2
MB599&YHMYSSFO7:U 6IV3Z>QJGKBJ:4*,!]UMXG;<5<"7M(6 H8UFI%O)VXM
M/YCUKQ48HLZ>O&2K4WH9W'[IK(O]"/NV<..;>.WN6N(9E!,!DA?(E3;L!0L=
MN_., Y7;GN,9K["X3\F?EBU/C+@SB[2TGN."9-7X0U:.\@XXX>6T.B6TFERW
M3>YIXB2Z5(8(9DEL39"X5D>W-MS08ZV(]9EGKGK?U^<$E72Y%Q2-4+/UWNZJ
MKU9ZK P*CI5VHOG9=1THOLINXW6VRKNKG?93.=\YSS77( N)P, ":4 #L ';
M&/9BOG7RG)!'Y2?*%';)%';1\<<6);QP*BP) NO7ZQ)"L8$:Q+&%$:H @0 *
M H%:3G%E6DW[Y-^_6U/63BE,=B''0]U;?QR!;P'^"YN:Q2;-ZE#TYJI9F76O
M?I+$SUE^*\^75JP>[O\ 4S@3A,GOAKAZP]7NU>K.C['(DNX:Q635M<$,<SFT
M(J:Z\!8!9<6D4#N0OFENJDNE'5A\!K^[6IR,1DG):![%0^:3D-LT$5JA<.2T
M_93/"E3"[[<]LS7=;2&H6="J;@ ^7]?T8+3MY2*,PF:V_2<WJ*O9E:$U;4\C
MULDECV198R1R>P8XR4K+L17\2ADUKIM&);#DF*!=])%*BEOW3O5OU5D<B)=O
MER<RK:[XN-LJX@!WKNE!KG#/*<DLH+5AT\L,AU:Q (Q.7$H:AB7T27U6AV=A
MC#-Y3+FT/C$C#31%_/[_ +:5>GN_V$F$/A'721Q 03V795IV [92@/.:^C9:
M6[ :#ZO2DU& S\&3"$48C8'TZ632^VZD8T$G6A5B^CPMWHP(/V3E2L\Z6D.S
M(VY+VJ^^[P.7FA7-0=452AXU!JYAC 1?LT#6H>N<-"$:^A\45U@^L:3IXD,%
MRQ[,3P]\4(*YD>$7F6>JE4.;]DNU]S5)*8V^,O5&<)G(KQ_V&]E%4P9^,NGL
MA:?=,'1L_EJ\<D4+<Q\E"Z-Z\ WDI):" VM?2UY;LB8%1Q=: >ZCE*YQ+N;V
M];0"Z#H<V]#!>I5BVWU^MNQ3U8B5XV_F5A=W4:AK2R\BF8!AL[A/4KJ(DAV&
ML+6.X&@9!B<0YI("SEJ!F&C=2KH=6)]9-AUAV^=EK=E786E@\D+@.N=Y3.-0
M  >LV+HTO%G<\*!G-70:N(7,("+M5]+8["9F(B3=,XF*)I-BTB%LAAIXI6H"
M%=2[?@O1OKU=\-C-"T5*;+$>%2!P6"5<-DD@BTCG,9[?4!+1/8?L6S2B-59,
MSW=>2L6<A"!Q3TB) M)(Q=VA)]7HYR'4K9Q5,^F%3^-#L!+:,KR3..WM2Q>Z
MR%PPR>H.9C81WN4$ J&YW(Y6X#"VZMG8E)!<1-Z_<182B)F-6D8 '@80+'U0
M$:%*549AV\[K"J",3:IKRK;MG;:5VPD31E5029UM=Y2XTWM:RHK<E3VM+H#U
MOZO@8 R@\>8.[JB[L1&PTP!&HJV@<T/FFT@81\DI7"DW=RW-):Y%UUW5ETUE
MH:JNA,KZ]U:K355CUNWTKN8T^86RPE@K>K%Y4+V+C&/O1Z+5U((*9I))<A)Y
M$Z3!!54T5*E<1VS[#D+8]Q:]AGJ%J+W9W,@]T]6I!5L/(PKJW0%51>_G5&=@
MWK2.P1A=CE@5<P:ASVDGD%BR.(7%I;A4'! +-=8*E&U*^5 ][YH":4D=N2]S
MTCK-"P[^JJW+I,[U).JALFRQ],55/JM84A:%04G5#*41 B4(S<1#1F(2$GKZ
MR6$NJ@PG)SL=#-55*XE,=A^\5BU64MQA8\UE,SJ_Q"=9NT$>H]K65=L1]\]K
M;6K_ +4.B;":JXK_ .=6;<K(JY@NFD#KLE!E6IKW%-/=JQ</@Q-2K)^->X+V
MO 1<F+'[&UK<D<1CE:;Q4_7]CP&R+.KJ<2,=,])\-EV(EU>Z[0^(-F_N44(P
MZ!RN"RN:Q@PA*V$V*$F.PABFI5 : D,HZV41UKA\G[5S_K35EQ .X=MSCL>Z
MKCKXM*3M]QFV8H&KFF'QHO0[V&[_ #F#+V99: ^1Q8K:]FR ,\CL0F[48/2C
M7%*V">/^QNV5ZS67S3L9.Y9"]X56W6/W_KTR@,%C$7:3ZT^L-=3ZS7,C?E(B
M0LQ-V)G9I^N&C+29BM8F04,ACV\B:^X, BE1/'>T5ZE.TX>*8N^0.;/6[MV1
M3<OZ/;P& :1R)]0X[K.4(GV"4*)P)&XF&AR%A8/;C.UBEF.:Q.2"89J@9'_B
MKABQ8J5KOQV:[(]ENB\ZQ'^W5K764F7BB/\ 8&_GL.K>J8J<Z^=B@:M0$8O7
M$=6B%."GXI.XH@<N1P9C4A^8I<^CT":3VN#<3$R 0\=/Y_G/_;2KVR6W[75G
M,U"4/V'?' \RL3QH0()V5$5_0\IF,R@MNGK.#6!*UI #JX;!)<\>B&R&0)!Q
M&W<6B:WJ.0 -HP>DF)-2NO!W[VSJ+(J<3J^K@NZ-ZVSY&Z2)P1I35**R-[$^
MJT2OJ553/8RPAE<0\A(+P-K4V.&*-]RPVM9HI)]1S. !G.K4ELI42T9V&MWL
M!)J?93VP\6_'8-Y!NN)B!3-"35]82[<%-^L]ZOSP-[.ZEHGKY #6L>D;!=J]
M;AX48^5CSLO%GL\DJPU/0<I5V+K[!6#%>\SFI=[8?R2$RJJ)$PC=%P-G6K]Q
M##XVF;)G9>>7]"I?5!*QRU8G%1(8?$;4KZVF<)9SS<%54N@"[LJ0)$U*UU0F
MXNQ-21F^;/AMMS,C<LA\;_CELRMJ-*QNM U>#P9\2O%;OMFOX!$J4<FVPF@&
M+@M)%!L7'GXV!>&=A4NA,N'ZP>."5*D<WW [)1;K9])1SN17,NC0/L!*$!1F
MA;6HBR;OM:O M,QLTM3D)L(YTVBG7FP+R960:=%XY5@2GH')+"B;L/$V-@L)
M-')"X/*5?GOIV"G5-3GJT2CMK&H9#I)(7J,RIR%(U^SO>X'A255@)C(^OAUH
MU;8X6<-(J@8D>+$JJ*E:WLPF$-IRB+35/:&NPY12M7=@]D>WEOUUY"(E9=HU
M:U8)]:O)1')MU9?SJ-+6K P<.AEF@J;,PNH1/6N&V2!1>"AH%R4F,ZOVT(?9
M(26?-$+08>]!1C%2K1)=E^W"G>Q.HTK4JFKX/%[7HJ'0NE+'GT8BI&Z:&D-5
M5L>L"=0R /.MDFLFS)<M(I)/A48EL'['0^%1:305I%9M#$$1DA)212J^2BZY
MW<G5VF+3G??NWXC9@+L)TYF?;>N(Q&*"AXGI@3.7(@ L&('E25#D#41C==%"
M"@_=A=9R8N"2$-$RV0NR\0,%D#2E3A%>UW=0UW%L:(-+)JG1*)6?>T;CG5B9
MS^*"IQ8M.PBJ9B9J"<P*JF76H;9A([8)@9"[ <6=CLF3JUX +RJ)MHB$--6+
M &_G[J5W_CWL<C;7<-K.B78J4]CRY7H! G<Y+'H-#(DSK"T"UJX+SJHF&\"@
M,%%LEXD3<^S>P&4_,5F5_LHD/FQ]XL_8834K>OQ2G%*<4IQ2G%*<4IQ2G%*<
M4IQ2G%*<4IQ2G%*<4K4_;?C$)62?[ 1X+V4DD&ZX]J[) 6I?='LZXC9DN?E
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MW6;@A$_2AV\:(29RW&(N,HJ8>\@W.A26>EP:E<7<*/=()8+3EW)>2,S<D@7
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..*4XI3BE.*4XI3BE?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>img30600998_20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img30600998_20.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1J\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &J"^:!8X0DE-! 0      !<< 5H  QLE1QP!6@ #&R5'' (   )@   X
M0DE-!"4      !"H<CR.\+B]1))=K(K5'*#I.$))300Z      $9    $
M  $       MP<FEN=$]U='!U=     8     0VQR4V5N=6T     0VQR4P
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M;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/
M8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R9%15
M;G1&(U)L=                $)L9"!5;G1&(U)L=                %)S
M;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !09U!S
M96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M    5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M       08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M
M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12
M:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M   0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@             _@
M.$))30/R       *  #_______\  #A"24T$#0      !    %HX0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              .K   '90         !
M      $             !V4   .K                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     4X0DE-! P     #^@    !    H
M $\   '@  "4(   #\P &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( $\ H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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MUK:R_;Z?\Y;Z;/4?_P"E+$S?JXX-L8>J9[Z[6.80ZX;FDN98RRH
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M[L2B=F@;$D4,L6)$D%XP8CRZ>GR6'2#9="/'/Y?S\\?SX_SX_I(!7N!*DKW
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MHMKN0,"5[ZG5U[@""5Y4<@$$C[CWFB=G^-JAK5KWKY6AL_9XJ/=>(.UJP*L
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M0CS)ON[>'6,YC#L.U:IZ>]1PX)-RBC-%'33^ELJHMKIKK^<YQCC[@#DEB%4
M$EF8\*J@>69B0%4 DD@ $F7L?&R,NY,?%HNR<BT\5T45O;:Y]R$K0,S<#R>
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M\&R+,8DZ7^'JX=*[:-\*_!7RE"D/ZO;]7H^EZO'GTS?ZAJ#?@;!385'OPI)
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ME*LI4L&Y+8:/(RLO+O6K%;U[*6JNLR+TLJ5*ZE<&E*_3?N['7RX(!Y# \<6
M,:O[=T03K.,U7/)=,&\B&[H2QM/&VEM=>XC(&F%=DQC,K*)V.[/P2/D6B.<#
M2N\FM@,'7W08O!"F-TU=>"?9=)[RO99.TP<3#./8&Q&P6.JW^7COQS8]6-@V
M=,YV16Y_>5#&U5URAG2T>1-N*<W'-2TVV6=Z\6"T>OBULHYX#/<,ZL/Y"L;,
ME$\<I]CB,U\KD7IJ!/Y?<%0&WR0R89K[,CHR<P6UJ[+3%KAUL3!)FGQ6&RN)
M'6K4>_*;1R>PN.O]F#939DN2QC197+POA;E;C/KP]3MZ*S;B?/\ R^[PL[5[
M"K#?L]*\T5U9F+ET.UB5#(P<S(K]1@'6OR%M7;NO%I:W(H8A;/1[L6VK(J:T
M'ZJPY:IT=0"S)=56> >.3QSN%U%[>UCW(K'2RZ[3?A--#)8(1B,D>@,RT.X%
MJZ:ZK%!H0N7T:MR#=5%\PWW7QE9HLFIG77U].<EU9TELNC]F=;L#7>335=7E
MXR7_ "ERVCDBJR^FDLU;!DL 7Z6!',S<#/IV..,BD,H+,IKL*>HA4\?4$=P.
M1PP\^009M7SEIG1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<
M1'$1Q$<1'$1Q$<1'$2">T@"'RKK/V%C-A3I_5\"D-(VH%FUDBE]FQ*OXD3@Q
MQE(YHQ7TT4V2=1@0L\-([8TW_ILL8]FV,^W*)Y:>H)'J@IW&Z-QJ$WUXX9 >
MB%L$A<!5Z!=-Y)2U[V*NA1MK--LW=/9/9;\6(JP@)2>D)P+CHV4.I!+]HNRT
M;-6BS@R.?CY_U\^?8>/Z^>!P#YYX!D $,2P7M'(![N7/<H[5X4@$ E_K*KVJ
MP#%BJM[#.)$<1'$2L[MZI"\=T/&JF[L!^QGF]W63L+K5.;K-!QJ-:]<+Q^H2
MQ> 8=ZH%'0HGD>(0D^S/94>D36%:N,:$-DMD@\_;\O\ 7S_E+,>),<1'$1Q$
MT![J=1IYV@W$M(S*J?CX9&*'(T6TL&E8W8<C]32F^JKJ.2PLFL5C&-6V^-4]
M V62[=ZG@AHY47RE\OIMO9UUZ;8_2/661TMC9%-M>:F-7D>K?:X*5WUWT9>.
MU-E59*HRKWHWUA^> /8_A7U5\(NEW?-^(GPSS.O-KC;3#S]/D)O!A8&+1B]E
MC8>9JK,:W%V%=N0@LN7*-M-]1^7>@('-NOM2^+5 5%GT$N8_4\BCC.+CQD(.
MU93L>K&TXA)A#AKN*E:-E"4DSA9TS;HK)N&QS!5$LNJDY?Z[*(9^+I+M)U9U
M#K5T_7O6.9U5K\5*;-8UOS5>PU^RH'97M*<^_,R+#EK4UB&QU9K/4;U"5+*W
MHN?\>.A>F>H/^+?@O\-[>@]]L<_(/5&/G;:O:=+]1:#+%CY73V3TU7C4X>/A
M79)INJ^2?$^2%1KQ@H<&O+Q5S6#UB),:,[SMF-CT[(5] ->]FG05(C'BJ2V,
MX:1FZ!+G5\D*-:I8PC]<<:*MG>B?S#U5^EH_-(:W7]2;OHK,Q]?U3DVV8+6+
M5J>L<?OIY8^*L?<^F>[#R^!P,H,*;?=F[@[C*W7PUZ,^-NKSNL_@?C)I^JL2
MA\WJWX-Y%R-DU!>/F-GT3:RUIL-:S'U#K5 LI9O2H3'=L? LV/STRHC.N)#3
M;B6T*^*:)D&YWKQ."4%"/M%\871=J0QFH2JXVBOKMJIJH3AA%-9/.OIMLGG7
MGN%76FWOK1=BV#U%C%!V+N\2G8L4(^DU9Y[-C6./*FG-0>>1[\SY&NU8Q;KJ
M&IOU^33:]=]*>IBV4W5L4LKNQF 1;4<%;$MI[E8$, 1Q/-7_ +H9HBS) /ZS
M5_;78F7V1",*V6= MT8O&86=4(#OLQEA:<+1U+2*2]TS0(YU!/V4/C#@9AR6
MPOA_L^3W;^I] =-=,=?X.YQ[-=F:+Y7*UN1>FKV NHO=JL]*A5^T<3,RL>I
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MEHW6]$^'?5^+TIM,S,V-FQ-5NHNU^*V#7CY5N-;9F8N2&6G-MKH%7[FPLO#
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M-PB"X?+ZZK<1H'ZN=R8;$[#=1.L+RC"*+W[:)2B+A9,J!5?Y:Y+COE3C%P\
M$=E&;/0J.61:NL*-6_S"6<)H[<]3Z<ZMR&PAL.F-[E4XF<$9[=;F7XPM-?=V
MI>E;UL+:2[@UW*+*RS J.3S\N]9]#[WHO>Y?376.CLUNXU[\68N;378K5O\
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M!!!\$$>XE2.];K96S(Z,KHZ,5='4AE964@JRD JP(((!!Y$H [.RH@W[I2)
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MMC4U)3ZOHMD6TG(JOQQ9394;3'A%[1U7/X3/Q]V44Q>QN5Q64^Y6)DY*^&K
MB;<GG(I,S%,((/$-M5-4_EGK+1PLFW44=)[)IJI>Y;?X@]/[318>F&;\1Z5P
M\+,Q6N_;FN;)VHR@"!O<BZC+^?%?'I!O24BE[4(L[@1P%.W-&[WNTLZ0^&V8
MFYR<>Q<5>G=CA8&H3&J;&_\ AW&P-OA-JADIQD6@V7-\T%M!0A@WI_QZ^F/7
M/KGT_.?T]<_Y_3GBTUL<1'$1Q$<1'$1Q$<1'$1Q$<1'$2F_S5GS0'KQ6RI>J
M.J-I47O=,.5NYOVTM5>LH8,&).M$8RF)RA&I Y+/R9!V_P!%W(- K*PF&C5R
M ADLRY>ZBD3+?#BO!WO6";DZX&=5HY"RE^3AZ"AW4(_+);6D,;;1> M]@!N7
M3*(P4K)YU\5ON7+E$HL+9Z!RL?'IZKN&+EPJY/CS[>!^0Y)X']23_,F269@H
M+$A!VH"20JEF<JH/\(+,S<#@=S,?<DFV/B1'$3J3ZX5L"-.9+L/UCK<217/[
M%M$5!6H5)FLH5V)IN==V^X_#'5?+S1?39'9MA3"NNVF=L91*[_%61KDMUGF1
M*HMHOM6+WMGW+=03,):,&,3S$U^S-F*Q_P"W60Q!J/:ALB-V>1C=FW1;),LH
M:()Z)8TQA$LFXB<=1FT5<(NU&K=1VWT4T;NMT4]G*&BN,85T17SKE5+53&,8
M4PGOKC?TQ[O7TQRDJI8,54LH(#$#N /N ?< _?CWEU;KEJ>A;K5IM*M92MCB
MJQD_@9ZP0CE>3VE@2O/CB8F,37B:C0%OA9Q&\)(,(\OHF7(.08\0%PH[4F4F
M-&B3A^H[<H*:L22VJ*V^5$6SS=TYRH]WQZP<8K2>YJ  E#<6V-3754"QRLBZ
MZQK"S ]EC $^%<LW+G<9;5[A;]BI2O:%[,C9ULV%C5;#)S<XK2NCU.!@8E>,
ME-5BG(Q:S96O:]M"TU!:%T2\D/5"8=BZF2=4R+#IV\')LDW+GYUO'#,Q@6R+
M[4G!EI"HLR:N&&Q584?0%GWF@C9T)SMHHW=;I[*<%\2>E,[J32M^Q$I3<565
M@OZ@QKLS!X?UM>V3RBFIK&KO%60XH+U<\JQ!/T-_A;^,>C^&'6;5==9><_1.
M=B9#5U>A;M,'1]1!\<XG4->L5+[:\D8=>9K;<O6T'.%.:%9;:58+A?3.-]J>
MH5&A(5<U8EK+CFI,D8;YKF8#9E.ZO%O_ )?3,:?PY]]-;GP[5PW<F4<P"32=
M^@H7=,VP)?".NVV'T3B=5=(Z#&P-YK[=G4MEMJG79E>9G:RFSMXQ+,2WTER*
M:V5[0=?E95@:UJTQV50TWWQTVGP?^-?Q!V&^Z%ZLPNE-FV)BX5HZHT>5HNG>
MK<O']1OVKC[S'^:MUN==595@N.I-3J,:Q<*JZW85FPB6"5Q=-7VRD[S I@-,
MOQFWPS,?6U=!Y8 6QZ>YO((B;;CI*"7USG&,I%133;.<XSKC;&<9SZ!K]QK-
MJ'^1RZKGJ/%V.>ZG+QV_\.1B7K7DX[?_ &W5(?RGS9U1T)U;T:]'_$6DRL''
MRQW8.R0TYVFV-9Y(LUNZU]N5JMC60.>_#S+@![\'D24>;.<C'$1Q$<1'$1Q$
M<1'$2%)#UYJ<Y&3L5&QQ6O&<DDB$R+D:A+EJBD+R7-D-&R,D<GZZ>1PH\*81
M31374?N':+W1!%-^@Z323TUW./O]K1DT95F2,]\?';#JKVU56VQTQ&8LV,M&
MP3(J2HL6(%:HR%B:V0DF8[XU+(R!#4'<6,U#-0YL''UEZ2C%N  22>0.#R/$
MK#\K5,SJ:#J(2=.;XM.BM;*#-K#J"IX6TE$H&M@T.E22,V;'AHS>0NG#MRNV
M9O4).Z(#L.W'S;!5F\WPBOZ3\+MO@X=F\*KH]9O/V;<VOV^US&QL:QKLO%)P
MFQ[+1CJJJK.C8RUOV+V6*ZCN&HW>/9:N+W?-78OKJ+\?'K[[ !5=Q:&5?4([
MBH8-W#V*]I]^B\>$7F==]+Y%&;/ZI6C9P;/8V>,P=42:.15211ZL2P*.$&AM
MO&+M*PEJ1C^#FY719F*RJ^>DR1(BFQ65R4V3R/B!DX>PZQQ\G6=4:S6W?\/8
M+W;7&R,L8^1LZKLBMZ&R=+3FO7?Z JXLM[42JJNLN!Z0-&I2VK7%+L*^U?F[
M53'=4[TH;@A^S):D%.>>0/J)8D*?JXVO7Z_=,6%CR:OH*A.NNUC@([M,BSNH
M#=N4;'DH\FV9NW1IJ1$9$TU)6@_0@A@HGHD<3'N,.VY%NBHW?)Z<JN^ZPLUV
M-GYIPNH==?D##J3;4:K=Y!R"SJM#5W"W<8SV&MO2)-!L4HU;,&0G/^5P%M>N
MI7Q;57U&..U^*G;XY;E.S'L Y^KD/P>>X<\S-@-:=AF8AL=H[N@PM&-.<94%
M(7?7L)M .]2TVSIE)K/*A>5.;5TUSK\/+MVL?6UWUWRK\53;;.N%?L="]K4;
MKH^S69*D"UM+GYNLNK)'(+8&W3:T GD'L5:!QP1P/>XM64%[L?/%RGCM^9JK
MN4CVX%F.<=O;_F8N>?)YY,[C]J'<6$XQK.NLT/M-FGGW+&NO=NC$B>R&/7.R
MF8+= ^O-$UL:XSZ-64\,;[[>W73?;W[93M?LSI'-_P#DNI,O6.1XIW^IL-7=
M^'SNFLV!*\_\SX%0 YY X\SZV=6/WF'7=^>+D+W'\_3R5H5?Y"Y_YF?UCO'2
MX/9-O; NUZ#?;_C=*YJIF49#(Y_&,^Z>"QQ^M5--=LXURJWF:R6<YU]-\XVU
MSE_P5N+N6U=NKWJ <\Z?:8>3<1]O^PVV4;$$_@V&#[^/!C]H8Z_]^+L8^Q^8
MHLK0<_C<%:C^HM(_O-BH1:-:V8PT*5U8,*G@[?7WZO8?* LC;>W\9]=E1#UW
MKIG&-L>N-\ZYQZX]<8]<<Y_-UFQUKFO88&;@V \=F9BWXS<_RN1"?Z3*KNJN
M'=5;7:OXUNKC^ZDB=*2O&I ]@LJI*3Z/LK&([-]6,.7<[ZFW?S>C/=#9!KA+
M/Q$]M2+#W*Z[932V>-=%=]-UT]=KU6EVMV ^TJP,BS7U=WJ9:J#2G9W]P9N?
M!'IOXXY(1B 0ID/?2CK6]BK8_':A/U-R0HX'N?) _F0/N)(A4N*!#G9<V28"
M!3!/XSXD3=H,6+-+W:Z84<NW*B:"&F=]]-<;*;ZXSMOKKC/KMC&=?55;?8E-
M-;W6V,%KJK1GL=C[*J*"S'\@#+C,%5F8A516=F)X"JH+,S$^ JJ"6)\  D^!
M/D=/!HN%+R.1$V04" &O#!HN1<)M6 L6.;J.WS]ZY5SJFW:M&R2JZZRF<:)I
M)[;[9QC&>311=DW58^/6]U]]B4TU5J6LMML8)76BCRS.S!5 \DD"&955F8A5
M52S,3P%502Q)^P !)/V YG"D,OBT2T"JR>0B "<DD J* -RS]NQU,R4YOND&
M C<N%-,.RI-1)31DR1]Z[C*>_P /3;VY]*\?$RLLW+C8]UYQ\>[*O%5;.:<;
M'7NNOL[0>RJI?+NW"J..3Y$I=TK4,[JBED4%B "UC!$4$^Y9F55'N21.>W-B
M'1<D ;$F:YL.S&$"HM)?3=\/9&MR"8ET[;XS\1% CN))Z-%-\8U6V8N<:9S\
M+;TH:FY:J[VK=:;GMKJM*D)8](K-J(WL6K%M1<#RHL3G^(2KN7N*<CN"JQ7D
M<A6+*K$>X#%' /W*GCVG:<M28XB.(CB(XB.(CB)Y3ZTBM/3#RX0@V%$=.:M)
M0KMG>A(?:M7==NV#687O.6$4MP/*:7?WE88!OUF/6.WV)%I)/=8B<>E&4L@Y
M9.&;X<L7K;B)ZL.(GYC'IC&/7.?3&,>N?USZ?QS_ 'Y_CQ ]A]_S_&8M+H/$
M)ZR%CIG'!,F8A)+'9B):&&B;Q =*8D5;G(R>:Z*8SA(F#+M&Q$<YU_IMG2":
MNF<;:XY':OJ56\#U*'>RE^/JJ>RFW'=D/NK-1?=42/)2QU]B8/E+*SYKN54M
M0_PV*ME=RJP^X6VJNP ^SHK>X$K3[B,G>W?OQD$-55<,D[3M-INC]T0=LCLX
MWZ_W,OIO]HO(TXL BKA-/;7ZX)E3&,,=/5B2#.RKP<^:S$M6XB.(CB(XB.(C
MB(XB.(CB)IEWFIP[:-,;R.O_ (K>X*5-L;>JA^UUUR]S)8EG9XY"I^OIE5*0
M"]'3##/.VJ+A_@=LOC;1'TYQ_6^GR-KIC?KOIW.EOKW&GL '=\YA<N:/S7*J
M]2AEY 9F0GPL]T_P^]<:[I'KM=7U)V6]$=>8&1T3UEC7$BC]E;KBBK/;CD(^
MLS&IR?7 +U8QRA7PUG,FGK[<8*_J<@5M1_VIM9<#1=/6/N]R@@XUWW82 *OC
MUSG"PHRU>LLYV_*FJ.BVOKHIKG.YT.XQ]_I\#;XWBO-H6QJSSW4W*2E]#\\$
M/3<ME3<@<E>?8@SA/B3T/L/AOUQU'T9LN7NTNPLIHR..%S=?<JY&MSZ_L4S,
M&VC(''A2[(>&1@)DYMYPT<1'$1Q$<1'$2MJXL_MV[YT53:6_S4/ZYQQ]V$L!
M#7'O:[S)\IH$K<:[_775Z.473/();X]5&3U?;'KC&?3SO;_^_.NM%IP>[$Z<
MQK.H\]1Y4YMA.)JJG^P>ONMRE4^2I!]I]2]$#_V>_P"'7XA=<.OH[OXH;3'^
M&?3=A)6U=%CJVPZJRJ3X)HREK;76,I^C(QT!/) EDO/1)\M1Q$<1'$1Q$<1'
M$1Q$<1'$1Q$<1'$2IOS)DP0;JM#S#Q]8HJ9A>PE62&H"M8E:DC,A&VI&$I+)
M0+QS-+MC4M@</#)"1!_#\@Z!$2![;9O!1S NK+=@A-$D7QB6JI:E(3]5Q<-H
MWF\A=R$HB]GUJZ5#DHNX=5G5DZP% NJ4@]?1%X!!(39$<ZV= ,2!E+DI4)(O
M%T!S'1%$L?XB.(CB)HGX^<8Q5%R8QCTQCNOWFQC&,>F,?]]9:WXQCTQZ8Q_#
M&,>F/X<1-[.(CB)P"HH8=&OPQH<R+B"C1=@3%DFJ#T>08ND]D7+-ZS<Z*-W3
M9PEOLFL@LGNDJGMMIOKMKG..465UW5O5=6EM5BLEE=BJ]=B,"&1T8%65@2&4
M@@@\$3)P\S+U^5CYV!E9&%FX=U>3B9>)=9CY.-D4N'JOQ[ZF2VFZIU5Z[*V5
MT8!E((!D:3*RXU3 8K([7E3(!!F.RKS,\DKX,.:)O3)LAD;#6HP<W0?.G P?
MEHU&K:,W+PFW23^.L])ZO%M]=F[+%TU%V5M<NO&P:^7;.R;*:T#W7.*\540*
M[,B%$K(1GM ')>SN)ZG1=*;7KK.PM5T;I\C9=09 2@=.ZK'SLFYL? U^-\UO
M+LO)LLQZ:\O)%]V4C7TX^):S>FF/B&BM<H@%APBTXJ,F]=R<1+XF8U6R..!7
M.KIFOLV6W;N4=L^FJK=TU<)J(.FCE-%TV6TV27134USKC(P-AA;3$JSM=E4Y
MF)>":LBAP];]I*L.1Y#*P*NC ,K JP!!$U/4?3._Z0W&7H.IM3FZ3<X)096O
MSZC5?6+46VJP>Z64W5LME-U3/3:C!ZW92#,7L>C:MM95D_F44:.9"*QG(.9B
M'#V-3N/*?G.JH":QYR,DXG.NWIOE-F43;JYQC"Z*NGKKG'V&EUFT*/F8JO?5
MSZ&74UF-FXY/WQ\W'>K*I_'BNU0?^8$>)MNE_B!U?T>F1C:/<W5:S-__ !#1
M9M6/M>GMFOW39:'9U9>IS01RO=?B/8@/-;HW#"+=8GV6JKV[0B:"NP$0;8VV
MS$;:6;Q:SF[?7\X:@K2CPO4 <4UQZZMF\VB*3M??T^?F>FO^4UUGRO46LX^2
MS*M]BJ#SB[5EQ=D%]PM&SQZ?E[R!X1,S#5W/_>9P_BG7_MGX5=8<C?Z+,^&^
MZM(7]M=%UV;?I*RP^]VPZ0V>8=EKU)X-MF@W=E%:\_+Z)C])U$E_EIKB!W>(
MI>94[9$2=I$Q0&>DY$_BR;N"FRV[;&FF10(E(6,A$-&[QH_=%Q\A0RHQ5RLP
M9/=]=4E.,S?BYJM?U!1H<W4;/$M-M&/GW9#XH.!?D=A16KHMR$R*E6RNQ[JK
M^/3;NK6P@B>U:3_!EU3U%T!F]=Z/KCI;=4MB9FQZ<Q-7C;=Z>H<#"6WN(S-C
MB:S(UF==;1?C5863K+.W)05Y&10K%TMET4T5TT43WU434UQOIOIMC;3?3;'K
MKMKMKG.-M=L9QG&<9SC./SCGK0((Y!Y!\@CV(_&?&K*RL58%64E65@0RL#P0
M0?((/@@^0?!G]<2(XB.(CB(XB.(CB(XB?-5))=)1!=--9%9/=)9%7351)5)3
M7.BB:B>^,Z*)J:9SKOIMC.NVN<Z[8SC.<<D$J0RDA@0002""#R""/((/D$>0
M8]_>0P>Z[T^<" 8ZA$<1 3&),M,03:LC)^J<CY(ZWVW>E-%:W*1=1PH0SNI]
M11>;.&K_ !OM\V@MG/KC<4;_ &U%U^0V5\W;DXRXE[;*G'V@LQT "5%=C5E!
M17P/3*!6KX'8PEAL:EE1>SL5']112ST<.>>3^Y9">>3W \AN?J!G)7@-B,)1
M84LCUR2%UI*8VX:1.OYK'XJ;KF"2U-BS;#) /U "(I/GPO"[/+@O'GT[62?[
M$".[5X/5V9[LZ1G8%F-K\7(U&.IQ<A6RL_#ORJ-AG8I=VLQ[#?;E8"6]K]M6
M0F"&K].L,E@[P\^G8'M=;W/>O"56+6U53A0 R]BUW$$CED:X@DMVE.1QTGW'
MV!C4=KYM(JUB-JR4L9<"K*(5K)D(6$C0A8EA%A)0T>L=TLY-M$Q*F'!P/F3Z
MDF[ENLD)U,:N$M$KWR^AR<C/;'V.7J\:JE;=;7LL9LR[)N%1:S&NR-<@6AS<
M.VB[Y8ULK!K?1*DFGOR42KNJ2YRW;<:G]-44MP'1;22P"\%E[^[P>WN/ D,R
MNN>GDTFTX(6)00^)22K<MCI.U)!5)>NFCMDDX3W0.QFX@X\2U/M4G><86092
M=0@COION[':(Z_$YN,78]78>'A5Z_>V9>/L^ZBK5T;2G8.CD$&C)U%UEST,4
M_A9\85D$!;.X\2P].#;98UN,JO1PQO>AJO'OW)D!5#@?<+82#[@38@K W#Z\
MH+9FI5@DSC57V9"5 JGQ,DGSB8R>KC2!)KG&?AY9#4H4X;O?=ZJ?&)L<Z?T?
M?SGZ<Y:]+GZ[TG+Y6QUF8+AQZ=:X>/M*6K;[]]AS59./'%;\^>)ENG=90_('
MI+D @^[>MZ'''_Y?1//\Q^<TPUZ@'B\;O^#/YU7QI_849<A\ME-2I!:6G\6(
M8GHF>W"/=N7FVLE9,GPF&I+"FSS*(EAE=!QECH$CP3L!U913?H,VO!SZ4UV7
M3?R/2K3%H3 IP;\'4V(J<X][5VY;BUD[K7"LI?ULB[!?#=SFJUE?_:<?.JYX
M)L9LPL:;+AR%/R:L*Z0H'T<]GI*51?@MU'GY:==H'#NRX(GM=]06M!&<;&IY
M3="=YT79K0<Y(F;8.S,/F<0"Z/8XDX,EY,OKHJOM&%8X"(:1,34O5>#5@]-*
MFNSF_8NYU6>^3:>5M&!79\[10[7/2EF9:R9!6FK&'TJ,GYFZOYJR&P[&NO<O
M6OK8>3CJB@#@7)2E9/T!BE)J91W,P/>QK6GN9#/'9;K2=[%+1<?O8Y.!1Z&@
M9.1";QM@">&\VD108CHO)G"LECYYHS'149@W\LL$U%R?#TSNJ.-C/E\[+Z/I
MSJ.GIX9-PU]6=DY5V+78,E[UH&MK=[LK' QKZ'>S)N7&[EN-F,:Z62VBT/PN
M1E8OS2UU-8U=2BTN:POJEWJ-"%"ZNJA:K<CD]O<':IT96KYG2O\ KC.C?8B&
MW@3*P1FY&1^M6TD+"D)%K+\/86+LEO(XU'%=E&XS6%38C/&*Y),E[G&K2/I:
M+CWCW<:\"WTZBP:=!FZ6JK/9+<G9OC4VMCG$->;9K3C7Y(X:TYF%7@OZ9K^D
MV7<K8B>HMMHXMKW4W6-476K%2Q@KAE>A[[+&I^K@+<;A6P;R*P>>[D*-T^<;
M-A'$1Q$<1'$1Q$B6_;&,T]1ERVU'8>_L(_6-63^P0D#%J;I$IF6AT5*R$?%V
M*J2#I9-T==CTAB.Z#5VOKNYQL@T=+8T041*"H 4Z@N>R'C\G-,=EB5_N>P/8
M666UKU$@?8@9*Z8HNQ["I2Y['M#L%"ZM' ',Z%#@%@F)%H6 6+)FD?CI:QRQ
M%@(&2%-N+V1/2?Q$_G7V^W7VY]=?;CVYQGUQG7T_&?7^/KC^/)//)Y]^?/\
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MKS-?9D"FK(:BG/QFLQ+KJZKJVMKKN9Z^X!P#.[Y>F!-69_TJZQVC:C.YY[5
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M'KG+DG7Y!$/: KTTQG95L!"3I-'/IKJ06QGWX?M;;X)"[?2VW5 ?5L-$QV%
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MHQ!JBB=7E7$OS6KR?6LR9FNS( R^A[L)K,) VDKU^1L%T]8(%R$>?X>.D3U
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M^?36[)P P" ^;;*,VJQ"W<BT-8>PV,CUQMVLFUJMN^_CW@+Z-1C:J"-U3.2
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M%3;T"W3?"3I/9=3J''[K(ZBR:K-?T[@<GP+LC)MR+L?R"+\6L\CW&^X &,C
M(+&PK5-D'CXH>%%,TM<:I-1PMHDR9-T]<?C&J+=!-/']VO.[IIKQZ:L>E E-
M%:4U(HX"5UJ$10/P50 /Y3YTV6PR]ML,[:9]S9&=LLS)S\R]R2]V5EW/D7VL
M3R27ML9C^9G;\NS"CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB)4CYH)E((7U.A3
MH'+#L/;'>SE!1.4O1UYN^M$:*0Z0RE=E(8_9=\AGC24U;7AAIG#8M+(E\T9'
ME/HGS3)U'=SJ?$24O%TL&7ZUD503^'$66UGRGW.(-W<F_?P)A?4/%]=T\WA/
MM$S3![KIA/+B HZX' ==DBJ'JXD+K/)(XX]_(Y\CC[D>/Q'CW\>>1]N36Z\"
MMOK^M"W+IV@\6.G-;=Q]1/HX+\+Q8'K[?H[FL<Y$HCB)P"GU'Z81^D)L%BWR
M#SZ8B4471&*D?EU/DDR*K5%PY28*.?A:O%&[==?1OE39)%53&NFR)7SXP])8
MGU[L%.=,HJ.F.G;[NIK)6$(<$G<0:&\=G[0^J-XVX,,1I18*B^^83&*/V#1V
MHRU0W<-D%MMTM'Z_M('' X]N/'\I8KQ)CB(XB.(CB(XB.(CB(XB.(CB(SC&<
M9QG&,XSCTSC/YQG&?UQG'\<9XCV]IBFD39CDT$XRX<1=)JUC0ILP%>WZ"R!1
MPHH]P)&1E?"D>$X)L7+P*](C1K4ID<HSTT=XW$"<L\88J5@#'+8P5<>I4J_[
ME*<>POZ5>,W./5ZB,]+V55I84*#O_<T]FW;<7Y+6-M*Z]L]MVUS+<C,Y_:.1
ML-IB+C_.Y>VK*;/-.)D549]&+EY=V)\TM[-21G9OK_%>0%@3=TZDP=91@R92
MDR\,QI!R9:LQPHGI]#&_1&^%I:4D)0"XP[4; P1)K\^,)M$E]=UQ*3^&OLI5
MFR*F*(F3:]N.K7*E=5@]&OT5[LJV^VAN[LHHM7OJL4,"U(LN5ZW$V%M-6JS:
MUR+\C3X-&#M;:L&Z_*S<1AL,KY^WT]+B:S#V59H6[8;'$N^6R\2YZRM>:^/D
M[9\R>*/$FCMLY5'N=69!)!=-55B\V:MGVK1ZGIMG=JZRR>,W>&Z^J:WRSINO
M[/AK)[;9"NCE@CJQ1NQPK E&*J_:X!Y5NQT;M;@]K*W'# G56X]]"T/=3;4F
M34;\9[*W1,B@76XYNH9@%NI%]%]/JUED]6FVON[ZW Y7*I9CB(XB.(D86%2M
M36MHABQ*]BLL<,\XV'DR8EODZ+4U]?:L(D"&J!P0OIZY]C@80:+:9_.JF,\U
MN?I]7M O[0P,7*:L\U6VU*;Z6_\ %1D "^EOP:JQ&'V,ZSIKKOK+HYK#TQU+
MN--5>",G$Q,RT:[,5OXDSM98;-?G5MQ]5>7C7(WW4R*OV!V!#-MEZ9O^>@&R
M6N<-85:V-;H@NNNN,>QOHZD3IC9K%OKC&-$]6=CX1;Z>FJ37*>N$N:S]AYV(
M2VHWN=0O'T8>T_\ ?.".!X ;(=-FB_DNR[5'@+QP)V'_ +1NF]Z!7US\-^G-
MC:[<W;[HXGH3J$DDEK33JZ<CI+(M/)+&_I8O:WE[@Y+SZMK*[$0U=JSLJC&D
MW8+.4FZDRH24,BJ#=-531+5X7@-@KQ21#TD\[;*N$P!B:*))8SG7*F=<^LKL
M=_B,B;'2IF(SA3F:/*2T*">/4NP,\XF16H]V7'NSF \^>)3;TK\,MY7;=TK\
M0;]!D)4UBZ/XC:B_"LM9%9FIP^H^FJ]SJ\EVX"U-LL+0J[D A.?$DD+98#K,
M%59O$9NX-&1KLTQ,-18M2,[AAJP1J6**$5#:3I-J)>R$2Q>Z[#_F<N'.?E6[
ME%)5;78':UC9KJCC9GKO2^0EOIU_+&BLUK9;ZGK=X5+;JZ2#6&-C#A2@+CE,
M;H[(R>E,OJY=UH*\'"RJ<#(P;LO+7;+G929]V'B+C+@/2UN9CZS,R*&&3Z/I
M5#U;:K'2MON:NBJ@ 282%_/8QN+K]RW9S14>69E%HT\=O]!;=H8:CE7+EBY5
M(;_*:HN$D]\+IK)[8QL@MA.JW;ZRJF[(;.QFIQ\BG%R'KN2T49&1D5XM55OI
MEC6S7V)60_':>2W 5B*,'H3K#8Y^DUF/TYMES.I*K;]%7DX5^(FUHIQCEVW8
M-N2E5634F*!>7J=@:WK9>1;7W?T;N2M 8^>OE)>#)K5F"?2*:A@9-B7/@AC!
MLL[74>AFCG=Z@ILF@IJDDNFEG=;&$O7&^?3DV[77U5Y=GS5-OR)49:46)=;0
M6<UA;:T8NC=X9>& /<CKQW*P$8'1'56PR>G,==)L,2OJS88^LT.=L,3(PM;L
M,K)NKIK6C.OJ6AU#V(7=&8*A]3ROF<V>6=$*VTBBDL>KLM)G+!,,"[(-%W>,
MF#.J^[95]E#7;# 6AHW4W?E'.=&;'3*>SA73"FGK7F;'%P'PZ\EV5L[*3$H[
M49QZM@/8;.T'TZR_93ZC<(+KJ:R0;%F/T[TINNJ6W"Z?'KO;1Z;-WN>++JZ2
M,'!-8M7'%A!R<NQK57'PZNZ_(;N%2-VMQ_6MGP7]H#FKEI&+9SI 4,--XZ]>
MM&I(J.*:E]T5PS-9?5T3U;IA""C[Y5!3#1-+&ZN<:^[.L5[/!LS;M<,BL9M'
M;W8SNJVNK4UWAZD)[K*PEB]S*"%8,#_"9!Z3Z@_X;JZNKU>7?T]9F96!9M*,
M>^[%Q,K$.$'JSKTK-.(;3GXRX_K6+ZS/VH.[@'/N9\YV.(CB(XB.(CB)Q'[)
M$DQ>CG.5]6[]HY9+[-7+ADYPBZ1W05RW>,U4';1?&BFV47+59%P@I[54%4U=
M-=\(GDAZYPOK[UW\C%'TV#-=<;MV4[?7P*A8R.>2?M#V-O.G)(Z$WE,])E8O
M60Z.'5>!D0-MJ7@\FE!)O)#0&32#9]+)4>D) O-G2/U]O/\ U\?TGKIXB?SG
M33.^JF=-<[Z8VQIOG7&=]<;>GNQKMG'KKC;TQ[L8SC&?3'K^G$1[-/3T]NOI
M[O=Z>W'I[O7W>[T]/^-Z_GU_7U_/KZ\1*HNXX@4KY!O&&:4;#=C*%G6N/0=*
M5+)"974>K0-QN5D$;G0<:Q6.LOF$D55("]:[FC*^$Y V6T8AW2>Z1]_[#[?^
MO_3S+7^),<1'$1Q$<1'$1Q$<1'$1Q$<1'$30?OW7DB<0"*]AZV;8WMGJ](];
M.C^$]-LKG(>CIJE8<26V3QE7=B6C^F[Q=#3UW7P,RU2QC9UMG/"]=X&0V!B=
M0ZU.[;=+9/[5QE'ALC#5>W9X)(()3)Q.XE>?J:I5 Y,^C/\ #CU-K*^H]Q\,
MNJKBO1GQ<U;=);,LP%>OW=C%^F=W6&(1<C"V;+178?%9RQ<Y[:0)M]6-AQRV
MJ]AUE1)UAW'9J ''QBOKC*B:+Y#511HXQC_B.V#CXS)XEG\HNVZR6WYTSSK=
M;L,;:X&'LL-Q9BYN/7D4N/NEBAN#^#(>4<?9E(/D3Q3JSIG:=&=2[SI7=4FG
M::'99.MRT\]K/CV%5NK)_BIR*NS(H?V>FVMQX83.N9LYZ5MP+7-\^0FS;!4T
MU=0GJ=!VE21-7;.-VREGSC7)::$VGZZX>"1/S,;?XQGW:8RRVSZ9VU]/.L'_
M -^_$#9[#^/"Z3P$TV*?=#M=AQDY]J?;OIQQ7BO]U[A^(X^I>HB/AW_AIZ4Z
M:4FG?_&7J"[K3<H!VVITCT^1AZ#$N]F-&;F^EM<8GP2,A?L>;).>BSY:CB(X
MB.(CB(XB.(CB(XB.(CB(XB.(CB(XB5H^5VR#-1]6F]B!Y)U^!_;EGPY4@([)
MM/FZ^G+8@RD EE$D-4*_L\OJ;^O/PTGPG'8>\/$(_&9"'8$0/U%4X/?TY]_?
MG\/?P1[>X^W/N"/$E2 >2H;PPX;N !92 WTLIY0D.O)*EE =67E3BOA\D7W#
MUCF&6=VP_L+&PUWRH)%+3B==AZO5/CV\*KIV<^Y(K'ZXJX.U*I3A]+<A<-8X
MX<,H$I# Q<T3."B>R*1+6.(CB)PB3%,H.?C%EGK9$BR=,57 UZZ&$4$W:"C?
M=9@28JH/1[U+53.[5ZS71=-%]4UVZJ:R>F^$2O\ \9D9:PV@K'BK(E(C+2/]
MPNZXAL5EL@+2N3$$1W:&T6:3P[(SCIZ7-E7&B.JI H1=+O'[O=9VZ54<+*J;
M) _I^?'X\?K^DL-XDQQ$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$Z5W'Q3MTU?;-
M]F[YD07+-W+)99GML37#N .SUZDW43;%E-!3C9LDF60?-TOA-5=$<+,VBB-I
MJ*V97X*NCM:K(S)^\:IJ2[A2%M(K8J!:KJ.%/;W(A&=5L<NFF['%@MHR,:O#
MLJOKKO Q:LVO8K1CO:K6X:G,K%K-A68]C=]R%S7?<MFG/;>Y[,Z]0.#*1R10
M]LG,9Q JR7M2S!3A81 -"#,\K([!GWT)P&$.]'OTX4@,;,Q\>#LRKI[N]4RT
M69LT.0ZMW6QZ?P,%\;(PT&9GX&L?:;2IFQ]<+5R#D;'/^7>BIP_ITI4J)C4K
M?8W>0C(B^X?!?H7I3XE]1=0)M-9N[6T?3_4?5E?1_2F94F;U(V+?K4U?373G
M[1JSLVAJ/FLRS+NOR=GFW8=..M"B]+[[,AZ>]AREYU:B;G+F+ZRII(K #-34
M8T>,(M8D9@1]J#WLN(LBJRSY",D52#)MOLX74U2(ZN,:931W322R.D-_=O=4
MF3FG%^9&3L*$OQ!97B;''P,GY?\ :6$ES-8,6WN0<LS!;"P#%2LUGQM^&>'\
M/NKK-?T_7MSI[=9TWG78&W:C(W'3.UZCUMVQ7I7=WX==>/9ML:O&OM455J7Q
M366#.&=]O^=9/%(XB.(CB(XB8:[A;!W8 .P]W;S4F!B,GA[9CI\'Y!9C*"\5
M,.W2_JEEQ\VW7B3))M\-;1'X3EU\5)3?X6R>$V#6VQJV1=_5JPK\$5_3Z9KO
MOQ[V<^.[O5L=57ANWM9N03P1NZ=YD4].9_3:TTG%V&ZU6[MR#ZGS"7ZC"W&#
M337PXK]&VO<WO;W(S]]5/8RKWAH3;]78XW"2T'K+Y5NW/QS2) 5=TH_A:' 4
M9>3G#5J/RD&2P970/D]L_.2+ZDX58-&K93;*ZA%X_P!35TWCTX]N.F7E$&K6
MX^.["@MC4:C,LSL&L 4JMQ2ZUQ99<&LMKX4L'[K&[RWXL[.[.TV>=+IULUVS
M;<;%%?9E-YL+=+B=/W79/?GN<&NS78@'H:PXE29%UMJKZ:8M&-PG/5, 0+V@
M7*3V<%%;0A4_@KU!\Y&N$0(BPCB!\CD%A5COEKL,=)9:B6N/0<BQPEAPR<O_
M )H@\H'3&/W[&RS.S;FV-;5/ZKHYIJ.=;GJE7*>!79<]2+QV+2M:A X>RS)J
M^,.RQL+I'!Q.G>G\1.D=[TWU!19CU955FQS>FM>^MQAL"F0OK+ETMZV;;_\
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MNWI5LRH.?^9V"HH^[,!/ .A>E<SKCK'IGI' Y&3U#N<#5K8 2**LF]5R<E@
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M@7+]--NMOMA/9$\]?0GQH=C:C[60SL=V<ZD]5BEA,B!CY6S:EN(/7T%HH82
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M(-LWSV%J-E0<GYW/I!V=]V#;KKFLJ'JY-6 N/;6MN2&M<BNXU%W<)AZ/XO\
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M-*I:H$6B+Q#9)VV3=IZ)X6RV71WSLDBIC;"B*6VENRJNU62Q0P>MZF]PWIV
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M(J01*/Q$A$61.[V#2SG#H@].#TXRF6'UN^ANPAP*+E AOYDT.;QM$AZ$>+I
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M"Q,3 )RNVW9*KH[.(?)AVRFI((1:-Y(()!]U]_(^QX_KY_#G\?:7'J>M[*W
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MVJ+9;D# U#Z[HC'Z_7X?UE)! 4DCZAR.&!/'++]0!)4\J?I;AB"K =K*37)
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MXB.(CB(XB.(D"WEU\C%[B\,CTHLR-.6H4Z)'JP2T;#@@[;8VWT2V7/!(;)@
MZ3Z-U$DMDT#*3C_(9<M-%$T'2VNV\TN^R=);WT8NMR5:ZBZP9VLU^=8/08D"
MB[,QK[,8L"06I*_5VN064&8V1C)DJ [W)P& ]*^ZD?4./K6JRL.!^#<_< CD
MRL7J)X;0_7*2R\Y+;^GDN;R,&Q$LVU9%I_1#]FLU?Y>*+DS$(L;+LZTWT]$T
M1KW_ (,V6_X4GZ*>G/2^K/B_=U%C8E&+H<#$;&O>YFV56#O*W#)V!:Z<W7]E
M#@^38GU,/I/B:77]/5X36,^7=:+ H J:[$([23RS4Y'+@@^S>%/D&;G>0WKX
M7[)]0)?0,?C*TWTF,UZ[L#D==G&K)8K (YV&J:1V-L[-'B3+579K7@*3$'.R
MQ#8H2^64;LM7I9TV;./&F8NS.0H+,6(55106))"H@"JHY\*H"J/    G1?A_
MUY)X_P!_;WE%XGH1WWA<GELUNZJG'9\5%;MMH+&FH_2A['D$[;M.JO6#K]UT
M[DOZKN&=Q&M);*&0.EYC'9Y$)H<#R2.G;)D4HC08FS;INE*9,W7EO5;R!6;U
MV\>D2-/:FJ8_5=M=2YW*XM2-6P>.2/K6]A-/30';!O0C([0FE'V   R\VFPB
MD)@E4CV8P<]:,V:4G9#52.Z)K1U\Z#]HJM[2]4Y[:]*S2PX] G/8\=)9X)"=
M,IIN-D<_\BEJ79#K$F(^R9<+*P(64KF2!K,?R/KB&5LR,KNM8V!$-"*3R.HH
MD 4_XW>WW7GKY:D7-=)XCV)G=S]=J7AD?#J)=8-8A3LV&V;=S:<&I] Y'8\1
MCMV6M7T/GC">P>R'\LW>RC+X36CJ0Q5@!?%]T2VNV^C(:P^D71BF W7IQ)'_
M %[LWI PUC'8%&H)59\/IJL+AJ7-RH2F0-)-,(0[<DZRB!)Q.0$(EYP9+6"&
MX :V,Z[LQ.R)H&\ZV^4"3UZZ"S$?V=8"JTEO665R^%0JVJ%"*6%/:S[>-3TN
M?]-V V8- $!J,#UCT1WBL'G#RK!CF6Q^"(K1A0V'E#@LB2*C1_DYM;L"5?6;
M [%:T>$[>]9K0 1>;VA6DJ$A650=OBDC.S2"D=;0,E58^O0GVP<6$CH95:.S
MQJM&6=>&)0&<R>4OU^OY_P#I))!/(4+X4<#NXY"@%OJ+'EB"S>>WN)[0J\*)
MK[&=:^[DX\B,4[E02N(HYA77JP*3J>OQ#NQF(^P9U0$HCDF$=FY-'(]NK]DI
M"B;Z]WI1Z-FTKC$L?O>L456! 7.S\-L92)'WC^ZI]PXOU*O+K-V'CW86$5>Z
MZ+U]1(B%D+*I>43Y&[=X1:T<M<GUD+QF;D8M$H0K#B]6 8.TGTCC3+,Z#OR1
ME)IZR*1%$3O.N?5KNE3'1KN8,JT$9J2ZKDO")32@82(%4I6$IAL2 0WKW5YP
MV]B,4FE@4?!)%+&5<3:5O0+"929H\:D&Q VKO*#A(,T1(@ON+^3;K57]O3P;
M:_8X_$TU+FB$;<D;%JZ:R,,(4[_=>@'51:)MR"+E7$NEO6Z0VU@Q*I<T+*_
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M87;E( A"^;.92K[ 3KY&K+ /2Q975]DF=+890V/,2TY5$1PK/ZY_OX_KX_\
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('$1Q$<1/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>img30600998_21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img30600998_21.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1^X4&AO=&]S:&]P(#,N,  X0DE-! 0
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M<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M"7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT3W5T
M<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !2
M9W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O
M;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M      !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M    4G-L=%5N=$8C4'AL0'D            *=F5C=&]R1&%T86)O;VP!
M %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M          !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F-
M60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1"
M;W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P
M4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE-
M ^T      ! #O_XU  (  0.__C4  @ !.$))300F       .
M #^    X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             $
MVP  "=L          0                         !              G;
M   $VP                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   $VP    !29VAT;&]N9P  "=L    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P  !-L     4F=H=&QO
M;F<   G;     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    #.$))300,     !4B     0   *    !/   !X   E"   !4& !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !/ * # 2(
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M0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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M9E _P6Z!J_3KE'B37PHX!&21$%W9ABS')Q<Y/ND=$J,+@@,=^V/3XX[4+YV
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MAC\S<WP.:JW7_806RO ](ZO1WZV67Z[=9>R]<[%Z"TB<T[2Y4*H215LGVPJ
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MN8_ 9V+N:XS!3NTZY"W1*B2S.O%ZP.UC%*U].JE@,"+L9G$Q'-JL.&GO-/\
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M9W8L[N269F)+,S-DEF8Y8G))WSFHC>=:4C9%<GT_8E-K%[JA/",$:U;P(NS
M9N6E>\RJ4(,Q9<%]QE>/M&%K84MES&'&U(<3A6#^',GAS1I+&?S+(JR*?+W2
M, C;! R!TWKV!KFSE%Q9SS6TZ9Y);:5X9%SC(#H0V".H'7OM57\^S]Z@05)?
M Z%I=/G,_O1#&OOQC75A&+QX]QT/8:,4KQT,^UX\LOB2,)YG/A32TYY%.DZ3
M("IL;< ]2B<IW\BI5EZ[<K Y['&!:KQ;Q7"ZR)KE\2I!"RR+,A]&25'1AZ,#
M72SV9.VKK;-9;8TAM&VF;OL3JMN(MJC]K[5-61N5SU6=KU>V7I.VVHDZE+QL
MYF@7*%23=F?]Z59K+1#Y@@M9.5.5GF^IVGX&^N+89*1OF,G<F)P'CW[D*P!/
M<@U^C.'-5.M:)I^I.%$L\ %PJC"K<1,8IPJDGE4R(S*,G"D;GJ>E7(%7=.*4
MXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE4<B>TCZ4R+'O.M3
M-]5$$_UT.A:SM$K9%RP-=''3A(@$CC0ATE'CC[1)B'!9 ,2;K[I#,&?%<P]C
M$?*9"KH\/:R([&46,SC48WEM5C DD:.-5<LZ*2T0*,KKX@7*G/7:JL:UI9>[
M0WD2&Q=([EI#R(CN2J@.V%?W@5/*3A@0:G?<#5]C[ ]<;%KO7CM>(D;A8]-D
M([QE$,M5Y]6"[AU];K0X2@ORHT"R!)5,#F52 +LQF+:(;B@BGTM$O?Y3$$$@
M@@@D$$8((V((.X(.Q!Z5:*0<,""",@@Y!!&Q!'4'/4'ITKG-L#5'>CK%')P-
M,WFUDM#:AU68GUAL>,%7$[L:_N%VMCUNE"->@QYNPU@,5V/]XTI JE5I;HRE
M:7L M4"YSVA_W*C>5];'KU)Z^7]?/).<^>^?X_UY]I16E7.U4^[H_;_:0JLF
MK2;#V/70R<G=,70=5 U,N=_:"N%!<K16K]J,V89:Z@&AKN-MIL2KNBV[ J.3
MAD5,@X'89Z^1.<#'?&V_UK];%U3[4V^1][5XH72G7%YM)\=7ZA4KIK@2?;KQ
M^M=C*M$P)MEKCVG"-;12L[KO:[.')0:Y:)P>+9Q@6LY?C&P5R5YMM^OU^/ED
M?3IUJP-ST9W.GF=5A*#MNUZTUM5-.=<Z4=$4HWKEA3UB'#]Z"-ZS\KL],LY)
MR;&'2-'MUF?!EQH^'X<Z6-:Q,B29&%,C?;??^6.F.F_;^U=;M(]JS1<$=@$9
MRIKXBA::'A*%6&0ES#[1W8T2ZXBC(5]D!!*EZC7KODEV-&6H_BOTRET"2FJW
M$K8#5:&-SAK?M7HY?7KUVZ;_ *]/CT'KO#:?2C<FP=S:8V$1V!BPS]%==M=0
MH=^E(!![OL+?VM-A1;U[J3T<;)7K&N[1FAH8_:I2L5:4BP40[8:.U"BCIJFT
MJ\SU]>W;O^W;RK7%,HOM3V@U?C6VY'TR\A.Q$">_ ?TZ_-K+-JUOF5IX_$Q-
MO9%FX;!I>S59"!Z?:R1*C$ $I9PYLZM.UZ+ M2GN^O;J?7?H.F/+>I%4]+^T
M09<%G<6JM4(U>K_JX3MUD:2IY2;C73FHM,!-A;(0<6!(E3VU*J=UI9JQ48)<
MP>BQHNP)V?QFR ZX"EJ5[D>I\M_4_P B#VW'J:TF9UG[1JD56%O?:]T,7?;.
MEP6SRP(;4:77)_[374K)T+.&ZVH(BEF]A6(_K'?MGHI^EO3CM8HQW7@"U$"K
MM;J ^'#?%/OR_K3*^6QQT[;GKGI@$$XSG'RKLUI,+L.O:CUR'VW9/VNVE$J
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M1M?V;,T;1SQ3<LI*&)W"E1,G-&_)(H9<H 1GHW#W$O#^O?CK71-3BOWT.?\
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M$MQ*]N3)&THE;/XKEY"L7X=?>=_C0T:2[R;28Z?V('4]@7VI=8=XM=:H(P>
M)OC00RRGJ@=G:UV((A0V4* V.!++U.SK/IS!>KD*#6[*Y&::&)F=%U*+0(5U
MFWGDMXFU6Q_Q)C(Z_P 5T29%F@=FW=7"2QHAW=F9 0S :SI\FMS'29HDF<:9
M>MI[*B-[D;M$SI,BC')R%HV8C "*#@J"?MZTK=J"SL/:>D->ZGF4 =K&9$D%
M"H\%"$54J6-(:E_9LIB-,J:F28,B'.'8DI4J>*2X_%PU C15R.>\1Z?J,FCZ
M)Q+JG$=OK-QJRO EH]Z]UJ-C#;(.59@[/RHF>61%Y?">2(/EY6Y;SA/5=)BU
M[B+A'1N$[O0+;1'2YDODTY++2]1GNW(=X&2./G=\<T+GG\:**4H4C@3GLYS2
MJZ'3BE.*5B#]@ U0(5LMI-B*W7 ,"25.6 ^2AAP@87":4_,)%2I%Z/!'P(C"
M%O29DM]F.PTE3CKB$)SG"E:PTSV,T!V+$DSV@MUZKW2&"3<#C1+5U]K%YB!Y
MZOM/LXA5VN$R.!S[R6G'([<S[%4AI&7F,.-?O\4K;\F3&A1I$R9(8B1(C+LF
M5*DNML1HT=A"G'GY#[JD-,LLMI4XZZXI*&T)4M:L)QG.%?<<<DTD<,,;RRRN
MD<44:,\DDCL%2.-%!9W=B%1%!9F( !) KB[8-OTGM%2NW/3/9'9*N68KM"HV
MG_#&VT*NS9PZ -_"+$7( 1\EL6!$GY52;KHPG)%*++8/#2*X0JUD92R3 +>-
M2U7AVWO.'M1X<T:[L3I]M -4CO+CQ%O;R,CFFC)EF:-I 9.9PJ1Y,?+ I1N>
M?%[ O;UP_P (\4<1>TC3C_X>NKT2:==Q#3[:\TC3;Z06]M%?:6)(-3B03R6Z
M*+BS+QL[":X*R1E* :5]D#6=(;^TCV(B[*;L6H^GVL!>SMLCR0J2%V%:MV4T
MM?=AMP@0YU3U4'UN)*P$G9?DVJ3*@BP\00]]^DSWC<.U_P#&(UFVNM*=(K&Y
MUB]2SCNKB55T^QLKH06S274__, B02-*XB" .TONA>2N5S<-?X,T>K1BYU"#
M1;":\:QM(3)J%_=6RRW BM8>81M).Y5(8O$YF<)%DEN:OHPZ[EZI;M?,[!K.
MKLZH=NY$F4- I B(+)32$<A+B9*SEQHL)9!,U*,R(<V1&:6Y&=3]DC[O]DM>
MN\8V]_IVL/I%]KHX@72X8+>VNX[F2X@BA>&.06\0D>00F+(22-'8!U/,>?F
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M?E0G&21@G &YW \C\\8K#S(7QQE/C/\ 3/C_ %^'CUQX^?Q\YE*W<9VZCO\
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MY:(?PLAYI8U7:V<[[ =(F[=D;*[#E%?H7@#C4:M FD:K,!JL"A;>:4A3?PJ
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M?F;J>H)SDDY-5G[ :Y[/V+:FA[#I+;U7H>L*I9I$S>-+/5=@Q,V!7%RQ.<0
MY)0R;(BROPM!J$VTW. HCRID0K@BZ_#9CXMK&XL8X+I+JVDEN)(U%I*DA402
M88$NN0I&>7.5;/*1RC):J*[MY"T91PL:LQE4H&+C P W5"#@YV&XR>N=ODF,
M8PK/SQZX^'\<9^'R^/U]/'/I&R!@[]0-P=MQON!W'T%45Q'@MMD=>P[X(Z=\
M;=>I\S4%(-8RE?TQZ_GX5CS^?\?TY-B;.#YCN>_7U[[#/?IVK7[Q,<W;&_K_
M $WQD]/7T@I%OQC/G'CQY\8S\_/KC/UQZ^OY^GCD]"<@^@)QZ;D?IC]ZUZX7
M&?AD?#KM]2*A4Y'CWO3'HK__ "^7R]/7X>.3HCOC&V<?'/;U]=_*J:Y79OH!
M]X\^FWQQFJK5&E7WLCW,Q'T*2BC5=;]([-I6V=E3V77ZB$N&Z[CH6TUC4<>1
M%PI1.\*KNJYMTLL"(I>:>$D511K##]S$MJTGBVZAEEM;9#S36XD:8@[)XHCP
MAQMS^YS$;%00#UP.S^R72[ZUL]3U&X0QVNHO;+:*X(>46WC\\X!Z1$S"-&_S
ME'(]U5)^C?FGUU^G%*<4IQ2G%*CEOM]4U_5S]WO5D!TZFU03-.V:TV8I""5\
M %&L+DSRI@N1>CP1T"'';6](E2GVF6D)RI:\8XI7RR>T]W4KOF#>F=?->[ZM
MVLQ.NC%=JEJSJJRU9FYV4B?A6)JP4(?9VA=BGTLVBOU\.4L)&OAV2U9D%7:[
M@TR_%6]N7"MO=VFJ:?>26CB$SX,DD9Y%BDC:)I<D>[R+(9$8@!F4!23@5T>P
MXK]GEQ_P^>VCA6YXSTG2.,9-1X;U.VTN34[2VNM>M-.OK4P:9!#+(K:B(KAK
MZ:XM;4O-:R&VN9U2$'FCG2Z9J;5O2NL]06V]B!=U;AVM"VOVE&;1TKM35(8'
M0*NS#,R:\*MFQ:;7JO;Z_ARI4>D$E5DV;9DR[;9)F?N8LG$>=T+_ (A/:#K7
M!_L]]HG&^AVVK1<06F@_^#O9]'86UVVKS\7<8RRZ'IUYI4,"_B&U'3+*YUKB
M6V\$&6+_  2-PCO'R-PK@G2]&U2[X;X<DU#3;JROM376.)I/Q5L]K#H^CHFH
M7<%TYD:-(+F:&QTQQ(5247D@R 36!VUI+1NY=L:V1((6[=])J DQ1JR*UIDM
M,.:5<+&:^8@'6=H50,N18JE2I %X?6Z9<+S)BZYBV4^JI YZ)B!PVG_X4>,_
M;UQ?PK<Q>W#V=<0\':M8:<LMAQWQ#'IW#EIQU""B)'KG"6IW%GKL7%$D)$D7
M$.E:-)I6O0K(^J_@;Y5OM3J/;'%P=H=[ O 7%>DZM;_BR7T2W\;4[C0@0Y,5
MCK%NLUHVD\Y!_ 7%V+NPD"+:-);%HH.H5+H-;H &-6ZO 2.%1EO/_98<6ZZ_
M*DJ]^3+DO.94IQ^0Y^\KQ[C3:<(8CM,QVFF6_P!#0)%;1^%!&L2<S,%W_,QR
M3EV8XW&-]@  ,#%<IXWXVXM]H^O2<3<;:U<Z_K<MI9V)OKE((V6SL(!!:0)%
M;10PHL4:DLPC#SS22W%P\MQ/+-)&=KZ7JVW1 B(8EGZ[8ZF=B6W7>QJ44<KV
MP]974<EQL=;Z+96&W7A)>.V\_#EL/,S QT3*G ;&++@B,\;)P7UK;:A"T%RO
M,N<HP_/&V,!XV&>4^?8C(8$$BJG1M5U#0;Q;W3I0C@<LL;9:&>+.3%,A(YD)
MQ@@AD;#(RMO4,NNNNRN_ HG7G;#L^QN'2HA^'+*:QI6FQ.F$;>D"WF7Q;78$
MZ(N5H3?P+,AI$TG2*>&UA0K-.0UBSU<N';0%3K]IPS:P3B6><W**>9(3'R+D
M=/%/,WB ;9 "!B,,"I(K?-5]I>I7MDUM96<>G32KR2W:W#32*I&'_#J8H_!8
M]%<M(R#=2KX86";@,L-MLLMI99:0AIEEI&&FFFT)PEMIM",82A"$8PE"$IPE
M*<82G&,8QS:Q)CH>@V&P'H #L/3 P*Y<T19B6W9B2S9)8DY)8YQDDG))R3UW
MK^9B_3/G\O3_ (^7I_IS[$F0,X([]/ZX[XV\ZQM",[CIZ9&/3R\]_P"E:-O&
MA 5GN<+:57MFQ],;@'B,5UG;>D[?)HMVGUE,A<MNK6C&(Q*L7RLQYSBI\$#?
M:W9Q8J>IR:*C0I+\AUVNOM+T_4^5KB(B11A9HCR2!<GW2<$, <X#*V"3C&36
MPZ'Q/K?#?/'I]PK6SMS-9W"^+;\Y&[JN5>-CMS&*1>? YPV!B")KO:F+98=D
MV=LA/;1VJ9)Q->$]GFJ[KJT4\.3=<S*^Y!]<:D$:\+VJ7$6V-G6V6+$FI@V.
MT.R0CPW)+;W%O;S[!9O;/P+9\":![3]8]F^DF4WO$EI#PQ;<0V_&>H02++IL
M>NW\.OZ#?V^C:8ZB6STFV@N[07F-2NX+Z\@LWMNF\%>V@<-Z^^OZYPI;<07D
M:"#3&CU&2P718G0I=2V%M+:W\+WMT#_&NY9%G\'%M"\$#2B2HG:=DB8@G&-V
M=>SC'6.09 [4V]:(I"O3=BZ2LE>0-J9S>.G35>,V,(;%C:&V/);9UW=JR-1=
M:73"#P8F*M@T'B?F]A?LTXZ]AWLILN$]?XOX7XOEX0UC5K?AVZT8ZW#/<<$:
MU)_BATS5+'5],L#;7.BZ_+J]W:FROM2B_":NL22QK9<DUQKOM X1X]XQEFM=
M.U+24XBBLY;J*]%H5M>)+)?PJW-M-;7$HECU.Q2SMY?$A@;Q[->>-O'9H_IG
MZN]=:1URHYH-2;"4ML>]6HAL$C92C\)]9.0;BPFH>8.1Z$Q/PUH;$B9CN(4\
MJ4X[(F*?4F0AMJ:[F0@D 8  QZ5^B?:3[2-5]I>K:;J>IV=EIR:3HUGH=A96
M D\&*UM6EE+LTK,[RRS3R,<<J)&(HE7W"[V6Y\5SJG%*<4IQ2G%*<4IQ2G%*
M<4IQ2G%*<4IQ2G%*X?=K2C=N]I8)'0\_>&M&]+6F#+B<^6X1CL7NAV>,A9SX
M\?>5".NCTQY&,Y4B-+@K7A*7VLJV_A"(FYO)@-DMUB^<L@88/PB.:Y%[7KE4
MTO2;/FP]QJ$DX7;=+:!HV[$_FND QCJ?*IA'BLR65QWVFW6)"%M/M.8PIMQE
MQ.4.-N)SZ*0M&<I4GX9QG.,XYN\V#D;8.Q&-B/+<=-MQ_;/%[7*\I!P0000<
M$,IVQ\P,'KGI577.BM$/ ->U.P;%V;8:KJIAP%KZOG,Z^G005$DC8H>;K^:O
M- ;F6D"^,&@(22%LDFK0PQ7AV$GU.2[ LW02:?$R1H\TS);KB)6\(A8RO*8C
M_"RZD!0"Y9_=&&.6YM]M>([E);J>*SLXI[]EENY8OQ*M+=!FD6Y4&Y*PR!Y)
M&*PK'$3*W\/W8^3:X/I;KP71MAT<1:KV.8V1FI.SS.)5:E%@TRE7L]L0)+#-
MRZPZ*RY@_8)*)+)4<3C2(#$:/EE#F'GGHLEI&B3('D DY#G*E@4=I%Y<KR_F
M;?((P*MH-:N9[BTG>*WYK42X3$@5Q-;I;.&Q)S#$<8QRLI#$DGM61:]G]K M
M<QNRBUWV@7ORK!+M5LM<XA3_ +[=['B=2I]=,DH<2EQ0U?)4->NZ;'HTBCC*
MOD)& #W7DSRL.&4C07M8BWB%W:3)+L2A+,W(<G"A05")R<@'+CN0*O[?5;D1
M?AU@@CM^14CB59.6),2!E4EV9Q*97:4RL_,6., D'*5#V9NJ! E\4K9.WRWX
MM%O\"U$#,^A32-LA['':"C'VC3_[ -I^\X)]<-?6)LK#1$+S3+]H<.SS$8Z[
M'9@/:H!CGDP>;F.V6#&/(_+G<Q*<C<DG)(-7T.I3R,&\&%0/#**/$ 0Q^/R\
MN7S@+<2+RDD#"@ 8&>@VH-,U_4M:*UBMR"DL<9V+MK9LAPL[$>D,G-R;0M^V
M;+!BY@PH#+8D?8;F4A XZF7)48/'@QYLR?,;?G2?@NL0903@L[8Z;NQ8@8[;
MX&1TZ@9S4@1-<,KN,,(XD&/],4:QJQ+9P2%!/SK4NJ]*]D:AO_?MZV9OB#L+
M2=Y?$OZ<U<FKMBI^MDLM,XG1W2+'V;"F([;:AF,(646?RA%CE+"D9)&!+GS7
M]A-9V<,%FT%W"&%U<^+SBX.3RD*<X.#S'IR?D =0&K -/N%FN)))Q)"_+X$0
MC ,("@,"P.6YCTVR?S;$D5OTF.2G&<X3G&<8]?IGZXSZ_7_OPSS'&^?3S\CT
M^^^/GO!N( ,[8(_WP?,$;_7(.=]>D8R<>]Z?S\?#/GTSC^?T^/PY81.3]CKV
M/?\ -TV^?85K]U&![W?OOG;.3Y="01GOG;&*@<]GQE6/'P\ISX^&<9]<?'^W
MY^?7SGQ+B/4#T(] <XQZ _ CZ517<>QV.VV-@/[^6?3MUK55TL5<I@,K9K<=
M$5FN!H^91<\>(1!(@;&^T0REZ:0G.LQ8[:WG&6&\NNI^T?<:9;]YQQ",V4(:
M0A$5F8D<JKEF.1D@ ;[#F^63BM=FB9VY$4NQ) 55W)Z@ #.PQO\ 'XU&$SAY
M:%$*"IL(H,(QVI< B.E,3H$^)):2\Q+ARXRW8\J,^VI+C#[#BVG6U)6A2DJQ
MG,Q,J<$$$9##!!!ZX(.X(VR.W0#M5+<1E25(Y2I(((P5(/0YW&!D=-M_.JB]
MTRE<@=7=YA;'F6_C8.M;CJ>O 1,59&QW*Y[1 $J)4*14A#/_ )DU:K8?.P H
M,9'QE3\R4AQY;$1F3)9^-3FABTZ\:=N6-K:6/?J[RH\81=\EF)  SZD@ D??
M#=G=W?$FCQV,9DFBU"UN3M[L<5M/'+)+(>@6-$+9/4D* 2P![^:>'VL1J35H
MJ^,QX]X&:YI ^YL1)")<5BUPJR,C6)F-*;SEN3';+M3$,R$9RAYM*7$YRE6,
M\Y#7ZXK8BUH;2I:U)0A"5+6M:L)2A"<9RI2E9SC"4IQC.5*SG&,8QG.<^.*5
MPP[-]T#_ '!JVQ-&=4M:#KAIN9,_9BU]I+O>9%*HUA)5BPPY9@9H*O":E;S>
MW($4J(< DKP3>H>O);Z"#=3L=N:8=DLWFF:'?7P%Q&B1PC)5YF9!(0",1A58
MG!Q[Q 7/0G!Q8\$>V3A+V4>TKA;7M>2\U*#2;]Y-1L]*AAN;JVMKJSN;-IRL
M\]O"9K=;G\5';F82R&)1_##J]<N.M^K]I>S\W_MON5<.O5#VVU.K9I-8FUC>
M2:Z0U?+L#F6;?:)].LVN&H5A+6G&4);9KMV;=$QC1\ +$D\D8+\3HDMAK&O0
M:!PU"8UCDFM(+^?Q,R%4D" A.7WHK6 "9VR6D>,'E 3F?DO$G'GL_?COCWB7
MAR/4(=*O]:UN^X9MKNS$/AV-W<37%M%(JS2M!)*7$01]H8B%9R2V-L[ ;UA<
M]!1JW<JM:[1ED._FT;9)PQFM*>BV7F<F3<I12Y[5G5$&>K=SMA:2R;KS#-G#
MV=J>T+?'3UNQ<I_!?!_LJ_XLT]O_ ![[99]2X,]G7!7&?$KG4^!O:!K_ /CD
M.O<"Z=*NG<*Z3><-<(KK<MEJNCZ!;V%MI=_>7G#VIZ7=1N\5Q%'-=6]QOFK<
M;^R9N!M!X-M8]=XDXETG37:UUKA>P>TN;/7+J-KK5[J'4M0-J9[6[O9;F6[@
MBAOK2YAV:,E8I4NGIFB2*I5&WC]#UG2KL7>7-MW^&(V-#$G":D,M?C$YQH*'
M?64EL,,8FLO+*HCK90TP6FL(:4C^@^H/9&[<V,MQ);!56%KI5$R#&6B#([\\
M2.2(Y&6)G0@M#&V17Y.>>\E@6VFN;A[=93*+=[B9X5EY2@F$3,8UF,9*%@"P
M&5YV6MQXB^,8\(SX_AG^/P^'Z<@EP-\''H-CY=<;]?U^-81#_P!.?7EP?3%5
MJL'4C6I@W<# (WMW5T79DA<K;E7TSNC96I:5MR0\VEB7+V!5*'90H<H6)Q4Y
MA'+% C"[+8!ZUCSIDC"REA-1<:-IUU-X\L'\0GFD*NT0D_[PC $]<L K-W)%
M;=I_%_$>F6?X&UO?X"IR0B:**=[<;C$+R!F"@;*C%T0#W%%;UJ=(J]"K(.F4
MJMAZI4ZR.CB %= 0(PP0(&Q$>XQ#@0(C;;$=E&/.<X0C&5N*6XXI3BUK5:1B
M.)%BC0)&@Y41 JJBCH% V_J<FM9N&GNII;BYDDGGF8O++*Q=W=CDLQSD^@Z
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MS3$<D4,:*J1**U/[39\O%]G'WVD 5/(+,]..RCD1<;*L26\IT]<,O.QLH_\
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MYE#MB=<JM 4KSE6*Y ZGZAM$)I&<X\XCHL-TMKB,8S]GB0_*SC&'%.^>@<(
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MPRTVEIEAEI.$----MI2VVVVA*4(0A*4H3C"4)QC'+ MC8;8Z 8 P!L/(#K@
M=,8Q6OJG,23EF;+,6))+$DEF8G).3N222<^=9=J-X\9\><^?CGQGQX^6/'SS
M\/3U^><X^',+-^GR S\!^PSW/G4A(^FQ)_;^6?G^]9-J)G/KG'C'USX_M\,?
MUSG'SYB9^W7[\O+_ +LCX5(6//K^WS\_A^]5A[4=(M!=RZP+K6[ZZ8)KKN2#
MU4/@+&6KYRK32;3+,V>*Q&?<#2WWFX["5-'PIJ K[%O*X:LH3G$"]L;?4$"7
M*DA"2C*Y5D)QDC!Y>V,,&&<;;#.Q:'K>IZ#+))I\D868()XI(DDBE"$E58D"
M10I8D>%)&=]R153M&UOK=['K4]BU;LWL8T8"[#VD1O6K*L4 R"6X2JSH&K59
MZK5Z@4A-@LM]<P3K33N#5=JH\>W++YCD(8_W4R9$"V%IH<$D,MT&1Y3+&&7^
M+AE52O(N2X!3/,H W.PP35]J+:EQM>V]S:Z84F@M5M;AT;-ME9990YFE"+'D
M2D>&S.Y R"P( WT,[4]F+TC[_J+V7?>:UUY6,JC'-A@-6Z#619QZIECZ_MK9
M "S*B/HRAV*Y.#CWGVEX7B.GUQR._$MHK82"9P!CF]Q,_ $DX^./A4^'V<:D
MZ S7MI"QZHOBRXV[D(HZ^1/Q-8@UWY7J1"I';;J%W$ZFUUA2,3]FW_4#E^TR
M*^T<PTW^,;/TJ6V*("86YG.<O&XPV(VRE<EV2B.A;B?N'B*SD;$@DAS@9=>9
M?JC,1\2M1[OV?:Q I>![:\ &>2.0QR'SPLRHA] ),GL,XJ[M$N]%VG4Q%[UK
M<:Q?J6?C_>@MKIYP?8:^48PK+;BH947(EPWELNI6Q(:2[ER,^VY'D):?;6VF
MYCN(I55T(=#N&0\ZGX$ C/GOD=#@[5IUQ93VLCPW$4D$J'#QS+R,OQ5@IP>Q
MZ'J"15,.V&VMPEKJ ZC]8($T=NC8E<39KIN$D%ENTSKWJ*61EA95^=EO--#[
M#?#$R 3$:]JD.0ZZHQ#?*E\PH$%I4F'>7,SNMG9Y6>5>:2=@?#MH<E3)D[-(
M2"$0'KNQ&*NM&TNQC@DUO5RCV%K(8K>R5U$VI7H4.MOR[E($#*\\C#!0X7(+
M8WKHSK1K#KWJH=J2DAOO81MQ\I9R]CPV:L.P;:2=;E6"[7DG+;6X?LQ^>VF7
M-FRTJ;CI;BCQS,,6/@0XLNUMH[6 01KE,\SLV&:5SNTDA.S,S;[[ 8    JI
MU34KW4[Y[Z>0I)@1P1Q$QQ6T" K';VX4CPXHT/*%'YLLS$L[$[F>BYQY]/3U
M]<>OQ\>GY?+X>GUQR8L@\\8V]!\>X\N_PJD:+KMCT/3RZ_/]:QCL;YXQXSZ^
MF/AG/\,?KG/IC/IZ_7.56\OC@_O\?4'(Z5':/KV/<=OO]ZK]-UEM"E;*M&W>
MM>]CV@KML&"#A;2%?L;5=EZSV8]5X>!E9L5EHMJ:CO0;H$#(:KS%MJ%DK!0E
M7(HT)8%F8(4&V,I]1T.UU&3\1XCP3<JAV4!@X48!=6ZL!@!@P)& 0<"MOX>X
MWU+AVU-B((KZT5F>**5GCD@+L6=8I$YAX;L2Y5D;#DLI',P/D)N]Z[)[T>T^
MT'V.&@N^<28FH-$];J"XZC_Y&"MRUQMDY!\9\?\ B0RK3_R^VQC.4\C1<(VG
M62ZN)/,((X_/&"5EZU:77M9U;&+;2K"([X,TEQ/WVV1K<'U&?A6(@W7NMUX(
MP=A:Z[";3[5AA,I$B\=>^P#^I,KOU=2E:2#6LMEU?6E#,4'8\-E69=;Q8");
M7YR8R@+8APEF:BQA\5_PI$(&DT^24S)OX4S(1(!G*A@B<DG^GF/*QV/+D&L^
MA^U>Y>]2'7K>UCLI3R_BK..5'M6)&'EC:6;Q8.S\@$B#WOXF"I[+=<NR6I^U
M&LX&T=1'7R(E<V8!LE>,P'P-XUW=1"D,V/7VQJC/P@M3[O6I:\1BX,FRA?N+
MC$A[T\,0&DIFCNCQNR2*R.A*LC JRL#@@@[@@]0:[;%+%/%'-!(DT,J+)%+$
MZO'(C#*NCJ2K*P((9201N#6^.?-9*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4KA)OD
M1G7OM*]M0\X]P;V(ZUZ>VR+RK/N?;6W3MFN&H]A9:][_ /6RU5CFD_M,-YSE
MC&49<PG#[><[KP?-[U[;'JRQSH,]T+(V/_='OZ;UQ?VOV1,.C:BHVCEN;*4_
M_>1)H1]89?F>_;9D%SQ[OK_E5C/KCY9_]_U^G-RE!.XZ;'ZCT'KOOV[FN06S
MC W_ )GUSV\^@^>=JF@]W'C&/IG'I]?YX^OC/Z?U@,,$CS&,]3Z=.V,]<=NF
M:NH&Z9[?9_0CZ5.1S^/=3Z_#Y8^F<>OC/CSY_P#;\N0)5.X/<8/3?&Q[_,;C
MMY&KZUE QY XQ\=^N >FV-\U.1LG"?=QYSYQZ?3SCSZ*QY\_'X?'SCT^O(;K
MD$'&0=\_/OCT&_3;KD5L,$@4@@D@#'F=R,;'&<>@\^N]5XVIM#I^4[":*T/N
MN'3+#O94N-M;1PRS4J6>G5XV(FS<C;!7+5D-+'U8[)D5PHY#1^+P'YN *TOI
M5E0UN7A;2KB>UDOEMP]O:R!9)24!C<\ISREA(<<R<W*I&6'7!Q?VFHF!A$D[
M1M.C QJ6(D10 V< J<*21S$'&2, D59O>&YRNE].7[:(&@67:Q>E@G#$'7U0
M;=<L5F<;DL,JACTLPR+^,L-/.3I*V!\U],2)(4Q$DO82TJ';V27=S#;R31VZ
M2R<C32D!(@?\S$D9 .P]X#)&2!N+07QAB>15:0HC,(T_.Y49Y$WW)Q@#I\>E
M9[4&W7]MZGH&S)52L= ?O-7%V5RF6Z,N%8ZY^*1TR$C#$=QF.M$ME"TYRK[%
MM#B%(>;3EM:59Q7%DMK<S0+)',(96C$T9#))R$J60@G8XVVSUR<UF_'-)&CE
M6C+HK<DFSIS#/*RG ##H0>X[[5GB)+"\*\+],_\ ?3S\<_3_ $^./M(]QMZ=
M_,[#?/7M\,U6W%QG._J=]_7RW!^GH.M(KEI/8QGM-2-]C^P%W!:XJM+(U@WH
M"&B0NE6TE-CFVVK!/4LNF U,8>(#)*\K S);CH0=F%/&*;?<F7L$\,=C+:FT
MB:9Y5D2\)Q+&HY0R*.7=<!A^8 <QRK;8H+F3+YYVY0I5H]N0DD%6/<'KMG?.
M=B-]SSGO.59S]<JS\/G\,>,8]?'Q\><_/S^7S&IW)&Y.WP[?+OY=\ BJ.ZDV
MQG ZG?Z#H0>@& /CWJ#SW?.5Y\X^&?7'GY_7X^?CY_A_*PC&VW?&!UV'P/?^
MF>N*UVX;KZY].NWQR-\BH3.<]<^OPQG.?'\L9^7Q^./7T]?')D:YQ]2?V_0#
MUJFG88._7)WZ8]?EG'8=]JYU]6ZC5+3?^X6SC=8KI"YG^V%UK,LL0"#)1^$
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ML*SGDQ+B*=/$B<2*3[KKN"< [9 Z @@C;<8.,BJF?3KO3Y? O()+>8+S&.0
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MQ#J/CZ?Z^OSQ_'_GY<SCKZ')!SW[C^?QS\JZ1#G8C&^/+['F.OUK0M.VG-Z
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M"Y!SMR@KAA@>\0R^]MG>S[1'SX]?3./CC.//CX?+SC&/G\O]H)C(]?U_??\
MI^_J7!'?;Z^G;8_,?.O=22QG_P!>?X>OP_G_ %QGGP8QW4;]<Y'Z;_'&W:LJ
MW'?/[?V-?M1+'_SJ_/T^7]/3SC^?//#'4+Y]SOW.^YV\NF/E7T;G/?\ 4?\
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M0A*E+6I24H0E&/.5J4K.$I3C'G*LYSC&,8SZ\D$[@YQE3\!C?)^&]5LBEFP
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M9/F>Y/<_&M9N@TCM(Y+%COGL1M@>0'3]-ZD,]G&/.<8^'Y?G\/'I\?.<>/\
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MH%-N!2P!"VI*QM(X[7ZM6ZC2K5L?=[>D/P.<)QM:U'LDR!N!8" =BG3]E@Q
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M*LT"OD0AU;WUBY4<^^ZE@K"=;6=HES+>I;Q)=RQB&6X1 DDL:E65967'B<I
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M3K33MI;2-PZ!^RUI@#-V7,":,U2<.(&Q[='(ZN-@:I,''G94G*DTZ9/*S'E
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MD%')8%2V0J<^_0D\O4[9RP;=Z(M#:/LI5%U :LTQ>F(^$@JU0RYJAQ-P[UK
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MKB('FYE 5T?D."%96Q@@UYP76W3%98G8_88#8)4W9<G;BB5G#ARTV+>_LQ<
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MO^5BOXL?<&DZ2@;^CW("(#4#KONBIZA'CJ%$A1I=9UX4Z^Z6OP&Q%ZTHBWA
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MV[\\@66=K:1G'2-895 <Y=E$L!D2,RA1GMJ![==NS/0N@Z_L8VGW>7OO:=Y
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MQAZ;J3V0&_#=,EMN,M3-][YZZ=>#Y".ZG*5)DZ]L5FN%AAM/L+Q[S)1B*O\
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MHNP &YWV]<D^6_GY[;U7RGKN.G^V?KL-_P!:V1[)09]YZ[[6V>OW</[J[?\
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M%ST'4$D^C'/4YJMEN9R"OCR\IRO+XCXY>18B,9(P8T2,CIR*J_E4"H="U_0
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M:;9]YQ26UR;*X-I=V]R,GP9DD('5E##G7_U)S+\ZKM7T]-5TO4-.DQRWEI/
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M8+$4M?\ ?5-S>CZH=2'E]5AW;.<#.JEP++A$MZ&C5HU_-[S%),%66)N7"\Y
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M.%YD-8?4[G"D)4XB)E_,9+CB&<R<,Y?RIG"VUVVCQZ:VHVPU<W":;S'\4UL
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M,(>/B<U=VD9G=F=W8LS,269B<DDG<DG<DU^DHHHX(XX88TBBB18XXXU"I&B
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M\JHI8G?LJ@D_(5U'VSS:7;^U#V@RVLT$-BO%6LLTA=(X5G-W(;W#LP0*+PW
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MDH#NL8,,<*LPR S2,%)YBC;J>NO3KK,/ZH:0$:S_ &B>O-U*G+%L7;NQY4%
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M["UP;-ZV=L]CWI7-1W*K@X%;N=>N4JP1'9QF"%)DH8<'@BS&/M?M!6V'U/\
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MZ0R\PXMEQ"L\ENKA[JYGN9/S32O(1_I#'(4'N%&%'H!7ZPTNPBTO3K+3H/\
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MM3K-73MFBPXO5S7\@:5J^T-$6N1#V=+$VZZ9M6O<!:YMB=KXIJ:;4KF\8)A
M5YIPT5#@EVE>;>6/J?/^H^G?.*L7?M;=]V]Z[8L.J;,[4=93]D2;_6AP;&E,
M,[!P/K?0ZKAJ_=E6:N%[0@%.$USMJQ/=A$*[9\9@@$MV&+'738[R@QMD>63\
MSD]?+';Y5%K_ **[6QNU'939.L A\*K95CT!!UKMF G19-JJZ[@,]>J]NJ./
ME7ZV%;6#*IKM:VL\/K+FIC%9)D7F#;4]PS-BL+5[D8&PVS\3GIGIL/CFM7[
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M)+#I&6E*_O$AN(A[,.&AZ=+RQ"8??;SP6MQ<^*;>"680QM+,8T9EBB4$L\C
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M_:<A0=OJM]:CM4PE#ZNU@#G7]?L=/6P,M$X:3D)D%R<I2M8[!T+[4?8U3VK
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1N*4XI3BE.*4XI3BE.*5__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>img30600998_22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img30600998_22.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#X17AI9@  34T *@    @ ! $[  (
M   /   (2H=I  0    !   (6IR=  $    >   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $YI8V]L92!3
M96ET=&5R    !9 #  (    4   0J) $  (    4   0O)*1  (    #-#8
M )*2  (    #-#8  .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                         #(P,C,Z,#,Z,C$@,C(Z-38Z,3  ,C R,SHP
M,SHR,2 R,CHU-CHQ,    $X :0!C &\ ; !E "  4P!E &D = !T &4 <@
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" $3!0<# 2(  A$! Q$!_\0 'P
M 04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0
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M]?\ UZNT4 4O[2_Z<KS_ +]?_7H_M+_IRO/^_7_UZNT4 4O[2_Z<KS_OU_\
M7H_M+_IRO/\ OU_]>KM% %+^TO\ IRO/^_7_ ->C^TO^G*\_[]?_ %ZNT4 4
MO[2_Z<KS_OU_]>C^TO\ IRO/^_7_ ->KM% %+^TO^G*\_P"_7_UZ/[2_Z<KS
M_OU_]>KM% %+^TO^G*\_[]?_ %Z/[2_Z<KS_ +]?_7J[10!2_M+_ *<KS_OU
M_P#7H_M+_IRO/^_7_P!>KM% %+^TO^G*\_[]?_7H_M+_ *<KS_OU_P#7J[10
M!2_M+_IRO/\ OU_]>C^TO^G*\_[]?_7J[10!2_M+_IRO/^_7_P!>C^TO^G*\
M_P"_7_UZNT4 4O[2_P"G*\_[]?\ UZ/[2_Z<KS_OU_\ 7J[10!2_M+_IRO/^
M_7_UZ/[2_P"G*\_[]?\ UZNT4 4O[2_Z<KS_ +]?_7H_M+_IRO/^_7_UZNT4
M 4O[2_Z<KS_OU_\ 7H_M+_IRO/\ OU_]>KM&: *7]I?].5Y_WZ_^O1_:7_3E
M>?\ ?K_Z]7:* *7]I?\ 3E>?]^O_ *]']I?].5Y_WZ_^O5VB@"E_:7_3E>?]
M^O\ Z]']I?\ 3E>?]^O_ *]7:* *7]I?].5Y_P!^O_KT?VE_TY7G_?K_ .O5
MVB@"E_:7_3E>?]^O_KT?VE_TY7G_ 'Z_^O5VB@"E_:7_ $Y7G_?K_P"O1_:7
M_3E>?]^O_KU=HH I?VE_TY7G_?K_ .O1_:7_ $Y7G_?K_P"O5VB@"E_:7_3E
M>?\ ?K_Z]']I?].5Y_WZ_P#KU=HH I?VE_TY7G_?K_Z]']I?].5Y_P!^O_KU
M=HH I?VE_P!.5Y_WZ_\ KT?VE_TY7G_?K_Z]7:* *7]I?].5Y_WZ_P#KT?VE
M_P!.5Y_WZ_\ KU=HH I?VE_TY7G_ 'Z_^O1_:7_3E>?]^O\ Z]7:* *7]I?]
M.5Y_WZ_^O1_:7_3E>?\ ?K_Z]7:* *7]I?\ 3E>?]^O_ *]']I?].5Y_WZ_^
MO5VB@"E_:7_3E>?]^O\ Z]']I?\ 3E>?]^O_ *]7:* *7]I?].5Y_P!^O_KT
M?VE_TY7G_?K_ .O5VB@"E_:7_3E>?]^O_KT?VE_TY7G_ 'Z_^O5VB@"E_:7_
M $Y7G_?K_P"O1_:7_3E>?]^O_KU=HH I?VE_TY7G_?K_ .O1_:7_ $Y7G_?K
M_P"O5VB@"E_:7_3E>?\ ?K_Z]']I?].5Y_WZ_P#KU=HH I?VE_TY7G_?K_Z]
M']I?].5Y_P!^O_KU=HH I?VE_P!.5Y_WZ_\ KT?VE_TY7G_?K_Z]7:* *7]I
M?].5Y_WZ_P#KT?VE_P!.5Y_WZ_\ KU=HH I?VE_TY7G_ 'Z_^O1_:7_3E>?]
M^O\ Z]7:* *7]I?].5Y_WZ_^O1_:7_3E>?\ ?K_Z]7:* *7]I?\ 3E>?]^O_
M *]']I?].5Y_WZ_^O5VB@"E_:7_3E>?]^O\ Z]']I?\ 3E>?]^O_ *]7:* *
M7]I?].5Y_P!^O_KT?VE_TY7G_?K_ .O5VB@"E_:7_3E>?]^O_KT?VE_TY7G_
M 'Z_^O5VB@"E_:7_ $Y7G_?K_P"O1_:7_3E>?]^O_KU=HH I?VE_TY7G_?K_
M .O1_:7_ $Y7G_?K_P"O5VL[Q!K5OX;\.W^LWR2R6UA \\JP@%RJC) !(&?J
M10!)_:7_ $Y7G_?K_P"O1_:7_3E>?]^O_KURWAWXK^'?$O@'4O%UFMW#I^F>
M9]ICG11*NQ0QPJL1R",<\U=^'_Q TKXCZ!/J^AV]Y!;PW36K+>(JN6"JQ("L
MPQAQW]: -S^TO^G*\_[]?_7H_M+_ *<KS_OU_P#7J[10!2_M+_IRO/\ OU_]
M>C^TO^G*\_[]?_7JAI'B[2M=\2ZUH>G/+)=:(8EO&:/:@:3?A03R2-ASQCD8
M)YQE^-OB3I_@?4M+T^[TG6-4N]5$GV:#2K99G;R]I8;2P/1L\9Z&@#H_[2_Z
M<KS_ +]?_7H_M+_IRO/^_7_UZY7PQ\4]*\2>)#H$VD:YH.J-!]HAMM:LOL[7
M" D$I\QSC!ZX[XS@X[>@"E_:7_3E>?\ ?K_Z]']I?].5Y_WZ_P#KU=HH I?V
ME_TY7G_?K_Z]']I?].5Y_P!^O_KU=J*ZNH;*SFNKI]D,$;22-@G:JC).!ST%
M %?^TO\ IRO/^_7_ ->C^TO^G*\_[]?_ %ZK>%_$MAXO\-VVN:1YOV*Z+^49
M4VLP5V3..P)4D=\$9QTK6H I?VE_TY7G_?K_ .O1_:7_ $Y7G_?K_P"O5VB@
M"E_:7_3E>?\ ?K_Z]']I?].5Y_WZ_P#KU=HH I?VE_TY7G_?K_Z]']I?].5Y
M_P!^O_KU=HH I?VE_P!.5Y_WZ_\ KT?VE_TY7G_?K_Z]7:* *7]I?].5Y_WZ
M_P#KT?VE_P!.5Y_WZ_\ KU=HH I?VE_TY7G_ 'Z_^O1_:7_3E>?]^O\ Z]7:
M* *7]I?].5Y_WZ_^O1_:7_3E>?\ ?K_Z]7:* *7]I?\ 3E>?]^O_ *]']I?]
M.5Y_WZ_^O5VB@"E_:7_3E>?]^O\ Z]']I?\ 3E>?]^O_ *]7:* *7]I?].5Y
M_P!^O_KT?VE_TY7G_?K_ .O5VB@"E_:7_3E>?]^O_KT?VE_TY7G_ 'Z_^O5V
MB@"E_:7_ $Y7G_?K_P"O1_:7_3E>?]^O_KU=HH I?VE_TY7G_?K_ .O1_:7_
M $Y7G_?K_P"O5VB@"*UN$N[9)HPP5LX##!ZXHJOH_P#R"H?^!?\ H1HH -2_
MY=/^OE/ZU=JEJ7_+I_U\I_6KM !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ",<"D!I)3A
M1]::IH DI::*<* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y+XJ_\DC\
M4?\ 8+G_ /0#76U%=VEO?V<MK?6\5S;3*4EAF0.DBGJ"IX(]C0!\H65C?6]K
MHG@RSC<V'CZQTJ>1D/$/E<3X[Y*QAC[&K9O+K3?@[XBAM+B>PTJX\=S6NJ3V
M@PT-FR(& QT!^48P<YQT.*^FH]!TB&6QDBTJR1]-1H[)EMD!M58;2L9Q\@(X
M(&.*6WT/2;2SNK.UTNR@MKQW>Z@CMT5)V<8<NH&&+#@D]>] 'B'A^/P]X=^,
M"Z;\+-38Z!-HT\^KI87+WL%NX!V2CELR9"C .>PZX/$>!Y--\+^,O#.H+?6.
MMW6I:CY(U/0M7E6ZE\QR"+RUG4L0<@_*J?=Y))!KZDTG0-'T"&2+0M)L=,CE
M;=(EG;)"'/3)"@9-16WA7P]9ZP^K6>A:9!J4C,[WL5G&LS,V=Q+@;B3DY.><
MT >-_"O0/#6E?'[QQ#L@M[^SGC&EQ/=-O*2)(TVU2WS\;2<@[>.F:T_C!9ZC
M?_%WX=6NB:I_9%](;T0WOV=9_).Q"3L;ALC(Y]:]6_L'1_[;_MG^RK'^U-NW
M[=]F3S\8QCS,;L8XZ]*EN-*T^\O[6^N["VGN[/=]FN)85:2#<,-L8C*Y'7'6
M@#Q#P<-5A^-6I6WQ$U2?4/%^GZ>ZZ$_EQQ6US;L&)9411\_7OTW#G;D>9^%!
MJ=WJ6B^(O^$B\/6GB6XU<)))-=WS:I,^\J8984#H$88'W ,;02.17US<Z+I=
M[J5MJ%YIMG<7MI_Q[W,L"M)#_N,1E?PJ&+PUH4&M-K$.BZ='JCDEKY+1!.V1
M@YDQNY''6@#P?4K3P=K_ ,1/'DGQ;UB2QN]-F1=*\R]>%[:W"$J]N@X=CPV
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M<TC$%^I&0, GC QTH ^B]4\2Z-H]REIJ&JV-O?3)NM[2>Z2.6?L JDY.2,<
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M0HV_*W3/\.1Z=\ +U[WP'>NNC6NF6G]I3?9GLO/%O=+A<R1+,Q8+G(P,#@C
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M_P#LXER&Y<;3DC''U- '40_&^WN?"NC:M#H4RSWVNIH=W9S3[&LYB,L<[3O
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M_P#Q%?*E%'U.GW8?7*G9'U7_ ,+F\ _]![_R3G_^(H_X7-X!_P"@]_Y)S_\
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M7/U?_P!%25\JU]5?&#_DGUS]7_\ 14E?*JC<P QDG')Q7J8/X&>7C/C1Z?\
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M]:QJ2;:MM_7Y&4J<4D[[_P!?F6?#'PQ\1Z__ &=?MI5P-&N;B-9;A)$5Q$7
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MW?\ 4U?^4[_[;1]9I=_S#ZM5[?D>&T5[E_PS=_U-7_E._P#MM'_#-W_4U?\
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M ,0:I+J6KSBXNY@HDE\M4W8  R% '0"J->Y?\,W?]35_Y3O_ +;1_P ,W?\
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M >JFLOQ'X/NOB#KFCJ-)OO"]C=6NJ/(]O$%+%WB,;7 V84RD;VC;YC@@G.<
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M^.4?\+S\2?\ /CI7_?J3_P".4?V5B?+[P_M;#>?W'O5%>"_\+S\2?\^.E?\
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M?4@R31%"\4DK .,CD%3D'Z8H [.;5[&WUFUTJ6;%]=QR2PPA&;*1[=S$@84
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M<><:I8:S?_#];>[T_P 4-KT-VGF:1::>]MI]BJ7@=WC$4:QW"X4;?FE;Y@P
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MM97A:X\6^(_#^D>*[?6X_P#B82)<2:1-#&MJEJQP45U0R^8%PVXL5+ C !X
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 9'B/_D'Q?]=A_P"@FJ-GT%7O$?\ R#XO^NP_]!-4;/H*
M ->'I5M:J0]*MK0 \44"B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MWZD_^.5YO11[*'8/['R__GTCTC_A>'B3_GRTK_OU)_\ '*/^%X>)/^?+2O\
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M)'I/_"\/$G_/EI7_ 'ZD_P#CE'_"\/$G_/EI7_?J3_XY7F]%/V4.Q7]CY?\
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MWZD_^.5YO11[*'8/['R__GTCTC_A>'B3_GRTK_OU)_\ '*/^%X>)/^?+2O\
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MCTC_ (7AXD_Y\M*_[]2?_'*/^%X>)/\ GRTK_OU)_P#'*\WHH]E#L']CY?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-'UE=@_UKH_\^W]Z/EBBOJ?_ (1'PW_T+VE?^ 4?_P 31_PB/AO_ *%[2O\
MP"C_ /B:/K*[!_K71_Y]O[T?+%%?4_\ PB/AO_H7M*_\ H__ (FC_A$?#?\
MT+VE?^ 4?_Q-'UE=@_UKH_\ /M_>CY8HKZG_ .$1\-_]"]I7_@%'_P#$T?\
M"(^&_P#H7M*_\ H__B:/K*[!_K71_P"?;^]'RQ17U/\ \(CX;_Z%[2O_  "C
M_P#B:/\ A$?#?_0O:5_X!1__ !-'UE=@_P!:Z/\ S[?WH^6**^I_^$1\-_\
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M -"]I7_@%'_\31_PB/AO_H7M*_\  */_ .)H^LKL'^M='_GV_O1\L45]3_\
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M-'UE=@_UKH_\^W]Z/EBBOJ?_ (1'PW_T+VE?^ 4?_P 31_PB/AO_ *%[2O\
MP"C_ /B:/K*[!_K71_Y]O[T?+%%?4_\ PB/AO_H7M*_\ H__ (FC_A$?#?\
MT+VE?^ 4?_Q-'UE=@_UKH_\ /M_>CY8HKZG_ .$1\-_]"]I7_@%'_P#$T?\
M"(^&_P#H7M*_\ H__B:/K*[!_K71_P"?;^]'RQ17U/\ \(CX;_Z%[2O_  "C
M_P#B:/\ A$?#?_0O:5_X!1__ !-'UE=@_P!:Z/\ S[?WH^6**^I_^$1\-_\
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M -"]I7_@%'_\31_PB/AO_H7M*_\  */_ .)H^LKL'^M='_GV_O1\L45]3_\
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MP\2?\^6E?]^I/_CE'L)C_P!6\P[+[SW>BO"/^%X>)/\ GRTK_OU)_P#'*/\
MA>'B3_GRTK_OU)_\<H]A,/\ 5O,.R^\]WHKPC_A>'B3_ )\M*_[]2?\ QRC_
M (7AXD_Y\M*_[]2?_'*/83#_ %;S#LOO/=Z*\(_X7AXD_P"?+2O^_4G_ ,<H
M_P"%X>)/^?+2O^_4G_QRCV$P_P!6\P[+[SW>BO"/^%X>)/\ GRTK_OU)_P#'
M*/\ A>'B3_GRTK_OU)_\<H]A,/\ 5O,.R^\]WHKPC_A>'B3_ )\M*_[]2?\
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M+2O^_4G_ ,<H_P"%X>)/^?+2O^_4G_QRCV$P_P!6\P[+[SW>BO"/^%X>)/\
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M.!CH.!T'H_PIUBXU[X4^'M0O69[B2S5)'8Y+LA*%C[G;G\: .NHHHH ****
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M-(&VE I.2P;C'7/%>;>*;_P_JD]G?>&86DCF\7Z2;C4(GW6UY*' )B(8ABH
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M1T)WJX_X=P:)!IEZVD^([3Q'J%U<?:=4O[>X23S)F '1"0B@* J=@O?DUV%
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M!_A'JWJ?P'<GT2BBN.4G)W9\#B,14Q-1U*KNV%%%%2<X4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** ,CQ'_P @^+_KL/\ T$U1L^@HHH U
MX>E6UHHH >**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>39
<FILENAME>pyxs-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-22T07:17:53.2550+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1" xlink:href="pyxs-20221231.xsd#StatementConsolidatedBalanceSheets1" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails2" xlink:href="pyxs-20221231.xsd#DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails2" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows2" xlink:href="pyxs-20221231.xsd#StatementConsolidatedStatementsOfCashFlows2" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="pyxs-20221231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="pyxs-20221231.xsd#StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="pyxs-20221231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:href="pyxs-20221231.xsd#DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails" xlink:href="pyxs-20221231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails" xlink:href="pyxs-20221231.xsd#DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails" xlink:href="pyxs-20221231.xsd#DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" xlink:href="pyxs-20221231.xsd#DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" xlink:href="pyxs-20221231.xsd#DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" xlink:type="simple"/>
  <link:calculationLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="pyxs_TenantImprovementAllowanceReceivable" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_TenantImprovementAllowanceReceivable" xlink:label="pyxs_TenantImprovementAllowanceReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCash" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="pyxs_ServiceFeeIncomeFromRelatedParty" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_ServiceFeeIncomeFromRelatedParty" xlink:label="pyxs_ServiceFeeIncomeFromRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireInterestInJointVenture" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="pyxs_NonCashResearchAndDevelopmentExpense" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseExpense" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="pyxs_NonCashGainLossFromEquityMethodInvestmentInJointVenture" order="6" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" order="7" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="8" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="9" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="10" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="11" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:label="us-gaap_PaymentsToAcquireInterestInJointVenture"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_NonCashResearchAndDevelopmentExpense" xlink:label="pyxs_NonCashResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_NonCashGainLossFromEquityMethodInvestmentInJointVenture" xlink:label="pyxs_NonCashGainLossFromEquityMethodInvestmentInJointVenture"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="pyxs_PrepaidResearchAndDevelopmentCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_InterestReceivableCurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="4" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_PrepaidResearchAndDevelopmentCurrent" xlink:label="pyxs_PrepaidResearchAndDevelopmentCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="pyxs_AccruedResearchAndDevelopmentExpensesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="pyxs_AccruedResearchAndDevelopmentExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_ShortTermLeaseCost" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="pyxs_EffectiveIncomeTaxRateReconciliationPermanentDifferences" order="4" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="pyxs_EffectiveIncomeTaxRateReconciliationPermanentDifferences"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="pyxs_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="pyxs_DeferredTaxAssetsLicenseFee" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDerivativeInstruments" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="pyxs_DeferredTaxAssetsOperatingLeaseLiabilities" order="7" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="8" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:label="pyxs_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_DeferredTaxAssetsLicenseFee" xlink:label="pyxs_DeferredTaxAssetsLicenseFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="pyxs_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>40
<FILENAME>pyxs-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-22T07:17:54.1606+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_RestrictedStockSharesUnvestedAndOutstanding" xlink:label="pyxs_RestrictedStockSharesUnvestedAndOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock" xlink:label="pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_PrepaidResearchAndDevelopmentCurrent" xlink:label="pyxs_PrepaidResearchAndDevelopmentCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_FurnitureAndOfficeEquipmentMember" xlink:label="pyxs_FurnitureAndOfficeEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="pyxs_EffectiveIncomeTaxRateReconciliationPermanentDifferences"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_NumberOfFinanceLease" xlink:label="pyxs_NumberOfFinanceLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_TaxCutsAndJobsActDeferredTaxAsset" xlink:label="pyxs_TaxCutsAndJobsActDeferredTaxAsset"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_StockOptionsTwoThousandTwentyTwoTwoThousandTwentyOneAndTwoThousandNineteenPlanMember" xlink:label="pyxs_StockOptionsTwoThousandTwentyTwoTwoThousandTwentyOneAndTwoThousandNineteenPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_NonCashGainLossFromEquityMethodInvestmentInJointVenture" xlink:label="pyxs_NonCashGainLossFromEquityMethodInvestmentInJointVenture"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:label="pyxs_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_LiquidityPolicyTextBlock" xlink:label="pyxs_LiquidityPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_ProceedsFromTenantImprovementAllowance" xlink:label="pyxs_ProceedsFromTenantImprovementAllowance"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_TaxCreditCarryforwardExpirationYear" xlink:label="pyxs_TaxCreditCarryforwardExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202001Member" xlink:label="us-gaap_AccountingStandardsUpdate202001Member"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized" xlink:label="pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_CommonStockIssuedToUniversity" xlink:label="pyxs_CommonStockIssuedToUniversity"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_LaboratoryEquipmentMember" xlink:label="pyxs_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_PfizerLicenseAgreementMember" xlink:label="pyxs_PfizerLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_RelatedPartyTransactionServiceFeeOtherIncomeFromTransactionsWithRelatedParty" xlink:label="pyxs_RelatedPartyTransactionServiceFeeOtherIncomeFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:label="pyxs_TwoThousandTwentyOneEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_ProceedsFromPromissoryNoteIssued" xlink:label="pyxs_ProceedsFromPromissoryNoteIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:label="pyxs_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_UniversityLicenseAgreementMember" xlink:label="pyxs_UniversityLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities" xlink:label="us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_ConvertiblePreferredStockSharesIssuedValue" xlink:label="pyxs_ConvertiblePreferredStockSharesIssuedValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:label="pyxs_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_AlloyTherapeuticsIncMember" xlink:label="pyxs_AlloyTherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_EstimatedCostToPurchaseLicensedProducts" xlink:label="pyxs_EstimatedCostToPurchaseLicensedProducts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_LicensingAgreementsTextBlock" xlink:label="pyxs_LicensingAgreementsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_AgreementsWithPfizerIncAndLegochemBiosciencesIncMember" xlink:label="pyxs_AgreementsWithPfizerIncAndLegochemBiosciencesIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_NatureOfBusinessPolicyTextBlock" xlink:label="pyxs_NatureOfBusinessPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_TemporaryEquityIssuanceCosts" xlink:label="pyxs_TemporaryEquityIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:label="us-gaap_PaymentsToAcquireInterestInJointVenture"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses" xlink:label="pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_GrossProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="pyxs_GrossProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_TenantImprovementAllowance" xlink:label="pyxs_TenantImprovementAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:label="pyxs_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_RentIncreasePercentage" xlink:label="pyxs_RentIncreasePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseMember" xlink:label="us-gaap_NonoperatingIncomeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesReservedAndAvailableForIssuancePercentage" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesReservedAndAvailableForIssuancePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_PotentialDevelopmentAndCommercialMilestonePayment" xlink:label="pyxs_PotentialDevelopmentAndCommercialMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_LegoChemLicenseAgreementMember" xlink:label="pyxs_LegoChemLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_InitialPublicOfferingPolicyTextBlock" xlink:label="pyxs_InitialPublicOfferingPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_TenantImprovementAllowanceReceivable" xlink:label="pyxs_TenantImprovementAllowanceReceivable"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_SecuritiesPurchaseAgreementMember" xlink:label="pyxs_SecuritiesPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_OperatingLossCarryforwardsExpirationYear" xlink:label="pyxs_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock" xlink:label="pyxs_ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_StockOptionsAvailableForIssuanceMember" xlink:label="pyxs_StockOptionsAvailableForIssuanceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="pyxs_TwoThousandNineteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_UpfrontPayments" xlink:label="pyxs_UpfrontPayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_LicenseAgreementsAbstract" xlink:label="pyxs_LicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_UpfrontFee" xlink:label="pyxs_UpfrontFee"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_RelatedPartyTransactionOwnership" xlink:label="pyxs_RelatedPartyTransactionOwnership"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_NonCashResearchAndDevelopmentExpense" xlink:label="pyxs_NonCashResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_NumberOfDaysCommonStockIssuedFromEffectiveDate" xlink:label="pyxs_NumberOfDaysCommonStockIssuedFromEffectiveDate"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_RisksAndUncertaintiesPolicyTextBlock" xlink:label="pyxs_RisksAndUncertaintiesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_SubleaseExpirationDate" xlink:label="pyxs_SubleaseExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:label="pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoSharesOfCommonStock" xlink:label="pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoSharesOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_DeferredTaxAssetsCapitalizedResearchExpenditures" xlink:label="pyxs_DeferredTaxAssetsCapitalizedResearchExpenditures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_UnvestedRestrictedStockAwardsMember" xlink:label="pyxs_UnvestedRestrictedStockAwardsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_SubleaseAgreementMember" xlink:label="pyxs_SubleaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_GrossProceedsFromIssuanceInitialPublicOffering" xlink:label="pyxs_GrossProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_ContributedAmountToJointVentureByEachEntity" xlink:label="pyxs_ContributedAmountToJointVentureByEachEntity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_StockIssuanceExpenses" xlink:label="pyxs_StockIssuanceExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_CashReceivedForInterest" xlink:label="pyxs_CashReceivedForInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_SeriesAConvertiblePreferredStocksMember" xlink:label="pyxs_SeriesAConvertiblePreferredStocksMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_IncrementalBorrowingRate" xlink:label="pyxs_IncrementalBorrowingRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="pyxs_SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="pyxs_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_OfficeAndLaboratorySpaceMember" xlink:label="pyxs_OfficeAndLaboratorySpaceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_UnderwritingDiscountsAndCommissions" xlink:label="pyxs_UnderwritingDiscountsAndCommissions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="pyxs_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale" xlink:label="pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_IssuanceOfConvertiblePreferredStockShares" xlink:label="pyxs_IssuanceOfConvertiblePreferredStockShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_TwothousandtwentytwoequityinducementplanMember" xlink:label="pyxs_TwothousandtwentytwoequityinducementplanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval" xlink:label="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_DeferredTaxAssetsLicenseFee" xlink:label="pyxs_DeferredTaxAssetsLicenseFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="pyxs_AccruedResearchAndDevelopmentExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_MaximumPercentageOfOwnershipInterest" xlink:label="pyxs_MaximumPercentageOfOwnershipInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_AggregateMilestonePayments" xlink:label="pyxs_AggregateMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions" xlink:label="pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_FairValueOfCommonStockPerShare" xlink:label="pyxs_FairValueOfCommonStockPerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_BiosionLicenseAgreementMember" xlink:label="pyxs_BiosionLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_VoxallMember" xlink:label="pyxs_VoxallMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_OptionUpfrontPayment" xlink:label="pyxs_OptionUpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_ServiceFeeIncomeFromRelatedParty" xlink:label="pyxs_ServiceFeeIncomeFromRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MA" xlink:label="stpr_MA"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_OperatingLossCarryforwardsBeforeTax" xlink:label="pyxs_OperatingLossCarryforwardsBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_MilestoneAndRoyaltiesIncurred" xlink:label="pyxs_MilestoneAndRoyaltiesIncurred"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_LesseeFinanceSubleaseTermOfContract" xlink:label="pyxs_LesseeFinanceSubleaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_PaymentForLicenseFee" xlink:label="pyxs_PaymentForLicenseFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_ExtraMilestonePayment" xlink:label="pyxs_ExtraMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoCommonStockValue" xlink:label="pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoCommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_MinimumAnnualRoyaltyFees" xlink:label="pyxs_MinimumAnnualRoyaltyFees"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_SeriesBConvertiblePreferredStocksMember" xlink:label="pyxs_SeriesBConvertiblePreferredStocksMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_SubleaseTerm" xlink:label="pyxs_SubleaseTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval" xlink:label="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RestrictedStockSharesUnvestedAndOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSAs unvested and outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RestrictedStockSharesUnvestedAndOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Shares Unvested and Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RestrictedStockSharesUnvestedAndOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted stock shares unvested and outstanding.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Other Current Assets [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Prepaid Expenses and Other Current Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred tax liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of common shares issued upon conversion of preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Common Shares Issued Upon Conversion of Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common shares issued upon conversion of preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PrepaidResearchAndDevelopmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PrepaidResearchAndDevelopmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Research And Development Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PrepaidResearchAndDevelopmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid Research And Development Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment in accounts payable and accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of restricted stock vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common shares authorized for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: present value adjustment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Less: present value adjustment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: amount representing imputed interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating lease liabilities, net of current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, net of current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in accounting principle, accounting standards update, immaterial effect [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included in the measurement of lease liabilities, included in operating cash flows</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of common shares reserved and autorized for future issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock reserved for future issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common stock issuable upon conversion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Grant Date Fair Value, Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Grant Date Fair Value, Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Credit Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax credit carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_FurnitureAndOfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Furniture and office equipment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_FurnitureAndOfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Office Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_FurnitureAndOfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Office Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">ESPP Withholdings</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation permanent differences.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Permanent differences</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee compensation and benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for (Proceeds from) Tenant Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in accounting principle, accounting standards update, adopted [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Reverse Stock Split</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Derivative liability related to extra milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Derivative Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NumberOfFinanceLease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of finance lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NumberOfFinanceLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of finance lease.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NumberOfFinanceLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of finance lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating loss carryforward</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TaxCutsAndJobsActDeferredTaxAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TaxCutsAndJobsActDeferredTaxAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Cuts and Jobs Act, Deferred Tax Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TaxCutsAndJobsActDeferredTaxAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax cuts and jobs act, deferred tax asset.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_StockOptionsTwoThousandTwentyTwoTwoThousandTwentyOneAndTwoThousandNineteenPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options 2022 Plan, 2021 Plan and 2019 Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_StockOptionsTwoThousandTwentyTwoTwoThousandTwentyOneAndTwoThousandNineteenPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Options Two Thousand Twenty Two, Two Thousand Twenty One and Two Thousand Nineteen Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_StockOptionsTwoThousandTwentyTwoTwoThousandTwentyOneAndTwoThousandNineteenPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock options two thousand twenty two, two thousand twenty one and two thousand nineteen plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Recurring</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NonCashGainLossFromEquityMethodInvestmentInJointVenture_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Non-cash loss from equity method investment in joint venture</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NonCashGainLossFromEquityMethodInvestmentInJointVenture_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-cash Gain (Loss) from Equity Method Investment in Joint Venture</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NonCashGainLossFromEquityMethodInvestmentInJointVenture_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-cash gain (loss) from equity method investment in joint venture.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability Statement Of Financial Position Extensible Enumeration Not Disclosed Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Derivative liability statement of financial position extensible enumeration not disclosed flag.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_LiquidityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_LiquidityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liquidity Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_LiquidityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Liquidity.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ProceedsFromTenantImprovementAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from tenant improvement allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ProceedsFromTenantImprovementAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Tenant Improvement Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ProceedsFromTenantImprovementAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from Tenant Improvement Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carryforward expiration year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit carryovers expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash at end of year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash, cash equivalents and restricted cash shown in the statement of cash flows</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202001Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2020-01 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202001Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2020-01</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Basis of presentation and summary of significant accounting policies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfLand_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease agreement, square feet space area in building</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfLand_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area of Land</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Extra milestone payment for which derivative liability recognized.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Extra Milestone Payment for Which Derivative Liability Recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Extra milestone payment for which derivative liability recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_CommonStockIssuedToUniversity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued to university</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_CommonStockIssuedToUniversity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Issued To University</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_CommonStockIssuedToUniversity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock issued to university.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average shares of common stock outstanding - basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Aggregate Intrinsic Value, Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Aggregate Intrinsic Value, Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PfizerLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pfizer License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PfizerLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pfizer License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PfizerLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pfizer license agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RelatedPartyTransactionServiceFeeOtherIncomeFromTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recognized service fee as other income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RelatedPartyTransactionServiceFeeOtherIncomeFromTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Service Fee Other Income From Transactions With Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RelatedPartyTransactionServiceFeeOtherIncomeFromTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Related Party Transaction Service Fee Other Income From Transactions With Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TwoThousandTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TwoThousandTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TwoThousandTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty one equity incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of deferred offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested Restricted Stock Awards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted Stock Awards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Joint Venture</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis Of Presentation And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Basis of presentation and summary of significant accounting policies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in process</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction in Progress [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average fair value of options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, renewal term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Renewal Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Real Estate [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ProceedsFromPromissoryNoteIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Promissory note issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ProceedsFromPromissoryNoteIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Promissory Note Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ProceedsFromPromissoryNoteIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from promissory note issued.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of Series A and Series B convertible preferred stock into shares of common stock (Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of estimated useful lives of property and equipment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Estimated Useful Lives of Property and Equipment [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Estimated Useful Lives of Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per common share - diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_UniversityLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">University License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_UniversityLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">University License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_UniversityLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">University license agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-Dilutive Effect Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse Stock Split</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of derivative liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrealized Gain (Loss) on Derivatives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Changes in fair value of derivative liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity method investment, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment, Description of Principal Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Real Estate, Type of Property [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ConvertiblePreferredStockSharesIssuedValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible preferred stock value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ConvertiblePreferredStockSharesIssuedValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Shares Issued Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ConvertiblePreferredStockSharesIssuedValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock shares issued value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of preferred shares conversion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock automatically converted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Shares Converted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value $0.001 per share, 10,000,000 shares authorized; zero shares issued and outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Present value of future payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Present value of future payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxContingencyLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Contingency [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Long-Lived Assets to be Disposed of</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating lease ROU assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Liabilities, Operating Lease Right-of-Use Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Operating Lease Right-of-Use Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series B convertible preferred stock, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AlloyTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Alloy Therapeutics, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AlloyTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Alloy Therapeutics Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AlloyTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Alloy Therapeutics, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_EstimatedCostToPurchaseLicensedProducts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated cost to purchase licensed products</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_EstimatedCostToPurchaseLicensedProducts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Estimated Cost To Purchase Licensed Products</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_EstimatedCostToPurchaseLicensedProducts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Estimated cost to purchase licensed products.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Base rent payments to receive over sublease term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_LicensingAgreementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Licensing Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_LicensingAgreementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Licensing Agreements [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_LicensingAgreementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Licensing agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Lease Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AgreementsWithPfizerIncAndLegochemBiosciencesIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Agreements with Pfizer, Inc. and LegoChem</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AgreementsWithPfizerIncAndLegochemBiosciencesIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreements with Pfizer, Inc. and LegoChem Biosciences Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AgreementsWithPfizerIncAndLegochemBiosciencesIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreements with Pfizer, Inc. and LegoChem Biosciences Inc. [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AgreementsWithPfizerIncAndLegochemBiosciencesIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreements with Pfizer, Inc. and LegoChem Biosciences Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of voting membership units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment, Ownership Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Expired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NatureOfBusinessPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NatureOfBusinessPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nature Of Business Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NatureOfBusinessPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nature of Business.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term, Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from stock options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock in initial public offering, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible preferred stock value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of Series B convertible preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Income Tax Expense (Benefit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Estimated Useful Lives of Related Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Related party transaction expenses incurred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TemporaryEquityIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TemporaryEquityIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TemporaryEquityIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity issuance costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par or stated value per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInterestInJointVenture_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Interest in Joint Venture</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInterestInJointVenture_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Investment in joint venture</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative liability offset to research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability Offset to Research and Development Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Derivative liability offset to research and development expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average shares of common stock outstanding - diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount payable related to licensed products</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Due to Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Due to Related Parties, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross unrecognized stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_GrossProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross cash proceeds from issuance of convertible preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_GrossProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross Proceeds from Issuance of Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_GrossProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross proceeds from issuance of convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross unrecognized stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureTextBlockAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Text Block [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TenantImprovementAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvement allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TenantImprovementAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tenant Improvement Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TenantImprovementAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tenant improvement allowance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash at beginning of year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets, noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Recently issued accounting pronouncements not yet adopted policy.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Recently Issued Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Receivable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RentIncreasePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent increase percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RentIncreasePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rent Increase Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RentIncreasePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Rent increase percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransactionTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransactionTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transaction Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental cash flow information:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment in Joint Venture</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Expense (Benefit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current income tax expenses (benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase in deferred tax assets valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other (Expense) Income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in accounting principle, accounting standards update, adoption date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock (Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesReservedAndAvailableForIssuancePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares of common stock outstanding percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesReservedAndAvailableForIssuancePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Increase In Number Of Shares Reserved And Available For Issuance Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesReservedAndAvailableForIssuancePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award increase in number of shares reserved and available for issuance percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reserves and accruals</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PotentialDevelopmentAndCommercialMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential development and commercial milestone payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PotentialDevelopmentAndCommercialMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Potential Development and Commercial Milestone Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PotentialDevelopmentAndCommercialMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential development and commercial milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_LegoChemLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LegoChem License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_LegoChemLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lego Chem License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_LegoChemLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">LegoChem license agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of restricted stock units issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock, Shares Issued Net of Shares for Tax Withholdings</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, option to extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_InitialPublicOfferingPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_InitialPublicOfferingPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Public Offering Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_InitialPublicOfferingPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial public offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal and professional fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock voting rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, authorized (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Voting Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Equity Method Investments [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TenantImprovementAllowanceReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: tenant improvement allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TenantImprovementAllowanceReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvement allowance receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TenantImprovementAllowanceReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tenant Improvement Allowance Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TenantImprovementAllowanceReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tenant improvement allowance receivable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Securities Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Securities purchase agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercisable at December 31, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Shares, Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value per share; 190,000,000 shares; 35,110,016 and 32,792,867 shares issued as of December 31, 2022 and 2021, respectively, and 34,958,730 and 32,222,881 shares outstanding as of December 31, 2022 and 2021, respectively</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, issued value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating loss carryforwards expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Derivative, Gain (Loss) on Derivative, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of derivative liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in the fair value of derivative liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Classification and Accretion of Convertible Preferred Stock [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Classification and Accretion of Convertible Preferred Stock [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Classification and Accretion of Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Prepaid Expense, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Current Assets [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses and Other Current Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Common Stock Reserved For Future Issuance [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Common Stock Reserved For Future Issuance [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of common stock reserved for future issuance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transaction [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Derivative Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_StockOptionsAvailableForIssuanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options Available for Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_StockOptionsAvailableForIssuanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Options Available For Issuance [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_StockOptionsAvailableForIssuanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock options available for issuance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Assets, Fair Value Disclosure, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets measured at fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Outstanding, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income (expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation and amortization expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen equity incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research And Development Arrangement Contract To Perform For Others [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss and comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: current portion of operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liabilities, current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_UpfrontPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_UpfrontPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_UpfrontPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Vested and settled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Vested and Settled in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, equity instruments other than options, vested and settled in period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_LicenseAgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_LicenseAgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net operating losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Liabilities, Fair Value Disclosure, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities measured at fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Common Stock Reserved For Future Issuance Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of common stock reserved for future issuance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Reserved for Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchase Program, Number of Shares Authorized to be Repurchased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares authorized to be repurchased under a stock repurchase plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Estimated Fair Value Assumptions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_UpfrontFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront fee.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_UpfrontFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_UpfrontFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RelatedPartyTransactionOwnership_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RelatedPartyTransactionOwnership_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Ownership</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RelatedPartyTransactionOwnership_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Related Party Transaction Ownership</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Non-cash lease expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, rent expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Non-cash lease expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity By Class Of Stock [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, by Class of Stock [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OwnershipDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ownership [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award expiration period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NonCashResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NonCashResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NonCashResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non Cash Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (decrease) increase in cash, cash equivalents, and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NumberOfDaysCommonStockIssuedFromEffectiveDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of days common stock issued from effective date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NumberOfDaysCommonStockIssuedFromEffectiveDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Days Common Stock Issued From Effective Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NumberOfDaysCommonStockIssuedFromEffectiveDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of days common stock issued from effective date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Risks and Uncertainties [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Risks and Uncertainties [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risks and Uncertainties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SubleaseExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease expire date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SubleaseExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Expiration Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SubleaseExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublease expiration date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty one employee stock purchase plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity convertible preferred stock converted into shares of common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Convertible Preferred Stock Converted into Shares of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, Conversion of Series A and Series B convertible preferred stock into shares of common stock (Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation expense weighted average amortized period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units ('RSU')</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities of Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and development credit carryovers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 16)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_DeferredTaxAssetsCapitalizedResearchExpenditures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized research expenditures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_DeferredTaxAssetsCapitalizedResearchExpenditures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Capitalized Research Expenditures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_DeferredTaxAssetsCapitalizedResearchExpenditures_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets capitalized research expenditures.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercisable at December 31, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_UnvestedRestrictedStockAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested restricted stock awards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_UnvestedRestrictedStockAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Restricted Stock Awards [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_UnvestedRestrictedStockAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested restricted stock awards.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Accrued expenses and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State taxes, net of federal benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Losses incurred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SubleaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SubleaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SubleaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublease agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Outstanding, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_GrossProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Gross proceeds from issuance of initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_GrossProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross proceeds from issuance initial public offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_GrossProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross Proceeds from Issuance Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_GrossProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from issuance of initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Total gross deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total gross deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets before valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intrinsic value of options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ContributedAmountToJointVentureByEachEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contributed amount to joint venture by each entity.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ContributedAmountToJointVentureByEachEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contributed Amount to Joint Venture by Each Entity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ContributedAmountToJointVentureByEachEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contributed amount to joint venture by each member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amended license agreement amount incurred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total undiscounted payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Future undiscounted operating lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future minimum lease obligations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed period of sublease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Finance Lease, Term of Contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, term of contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangibles</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_StockIssuanceExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock issuance expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_StockIssuanceExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issuance expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_StockIssuanceExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issuance Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_StockIssuanceExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issuance expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_CashReceivedForInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash received for interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_CashReceivedForInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Received For Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_CashReceivedForInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash received for interest.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SeriesAConvertiblePreferredStocksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series A</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SeriesAConvertiblePreferredStocksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SeriesAConvertiblePreferredStocksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Convertible Preferred Stocks [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SeriesAConvertiblePreferredStocksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A convertible preferred stocks.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_IncrementalBorrowingRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incremental borrowing rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_IncrementalBorrowingRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Borrowing Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_IncrementalBorrowingRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Incremental borrowing rate.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accumulated depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of accrued expenses and other current liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Accrued Expenses and Other Current Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Accrued Expenses and Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_OfficeAndLaboratorySpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office and Laboratory Space</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_OfficeAndLaboratorySpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office And Laboratory Space [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_OfficeAndLaboratorySpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Office and laboratory space.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common shares reserved for future issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_UnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Underwriting discounts and commissions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_UnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriting discounts and commissions.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_UnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwriting discounts and commissions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_UnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting discounts and commissions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Insurance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Insurance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Equity Method Investments [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Equity Method Investments [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and Development Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period shares new issues.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series B convertible preferred stock, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Nonrecurring</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Nonrecurring [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Issuance Costs, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Issuance Costs, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting commission and issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty obligation period for licensed products upon first commercial sale.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Obligation Period For Licensed Products Upon First Commercial Sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty obligation period for licensed products upon first commercial sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total lease costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease right-of-use asset obtained in exchange for new operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use asset obtained in exchange for operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted, Other Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss from equity method investment in joint venture</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income (Loss) from Equity Method Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Equity Method Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss from equity method investment in joint venture</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_IssuanceOfConvertiblePreferredStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of convertible preferred stock shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_IssuanceOfConvertiblePreferredStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series B convertible preferred stock, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_IssuanceOfConvertiblePreferredStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Convertible Preferred Stock Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_IssuanceOfConvertiblePreferredStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of convertible preferred stock shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money market funds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TwothousandtwentytwoequityinducementplanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022 Equity Inducement Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TwothousandtwentytwoequityinducementplanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">TwoThousandTwentyTwoEquityInducementPlan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TwothousandtwentytwoequityinducementplanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty two equity inducement plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effective tax rate from continuing operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective income tax rate%</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective income tax rate%</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Effective tax rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common Stock Issuable Upon Conversion (pre-reverse stock split)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock shares issued upon conversion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Convertible, Shares Issuable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit carryovers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncash investing and financing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Common Stock Reserved For Future Issuance [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Common Stock Reserved For Future Issuance [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of common stock reserved for future issuance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from issuance initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of common stock in initial public offering, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income tax computed at federal statutory rate%</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Basic and Diluted Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options vesting period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate maximum obligation to pay future contingent milestone payments for normal approval</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate maximum obligation to pay future contingent milestone payments for normal approval.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate maximum obligation to pay future contingent milestone payments for normal approval</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_DeferredTaxAssetsLicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_DeferredTaxAssetsLicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets license fees.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Exercisable at December 31, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">IPO</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds from issuance of convertible preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of Series B convertible preferred stock, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expenses Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expenses current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Changes in Level 3 Fair Value Measurements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split, conversion ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MaximumPercentageOfOwnershipInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum percentage of ownership interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MaximumPercentageOfOwnershipInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Percentage Of Ownership Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MaximumPercentageOfOwnershipInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">MaximumPercentageofOwnershipInterest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Expired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AggregateMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate milestone payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AggregateMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AggregateMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate milestone payments for first four licensed products</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of option to purchase restricted stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares, Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares, Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum number of common shares issuable under exercise of options.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Number of Common Shares Issuable Under Exercise of Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum number of common shares issuable under exercise of options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options to purchase common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Options, Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Options, Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_FairValueOfCommonStockPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of common stock per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_FairValueOfCommonStockPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Common Stock Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_FairValueOfCommonStockPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of common stock per share.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Financial Instruments Carried at Fair Value on Recurring Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per common share - basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_BiosionLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Biosion License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_BiosionLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Biosion license agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_BiosionLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Biosion License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxContingencyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Contingency [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_VoxallMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Voxall</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_VoxallMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Voxall [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_VoxallMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Voxall.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of cash, cash equivalents and restricted cash:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share sale price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock public offering price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_OptionUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock option upfront payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_OptionUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option Upfront Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_OptionUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Option Upfront Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ServiceFeeIncomeFromRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Service fee income from related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ServiceFeeIncomeFromRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Service Fee Income From Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ServiceFeeIncomeFromRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Service fee income from related party.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Stockholders' Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_MA_lbl" xlink:role="http://www.xbrl.org/2003/role/label">MASSACHUSETTS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Net Deferred Tax Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_OperatingLossCarryforwardsBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards before tax.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_OperatingLossCarryforwardsBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_OperatingLossCarryforwardsBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards before tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Outstanding, Vested and settled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options Vested and Settled in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, equity instruments other than options vested and settled in period, weighted average grant date fair value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MilestoneAndRoyaltiesIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone and Royalties Incurred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MilestoneAndRoyaltiesIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone and royalties incurred.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MilestoneAndRoyaltiesIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone and royalties required</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_LesseeFinanceSubleaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease fixed period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_LesseeFinanceSubleaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Finance Sublease Term Of Contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_LesseeFinanceSubleaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee Finance Sublease Term of Contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PaymentForLicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment for license fee.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PaymentForLicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment for License Fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PaymentForLicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment for license fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-Based Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Office Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options exercised (Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ExtraMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Extra milestone payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ExtraMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Extra Milestone Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ExtraMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Extra milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoCommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity convertible preferred stock converted into common stock value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoCommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Convertible Preferred Stock Converted into Common Stock Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoCommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, Conversion of Series A and Series B convertible preferred stock into shares of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted common stock (Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MinimumAnnualRoyaltyFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Annual Royalty Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MinimumAnnualRoyaltyFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum annual royalty fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MinimumAnnualRoyaltyFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum annual royalty fees.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SeriesBConvertiblePreferredStocksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series B</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SeriesBConvertiblePreferredStocksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SeriesBConvertiblePreferredStocksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Convertible Preferred Stocks [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SeriesBConvertiblePreferredStocksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B convertible preferred stocks.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SubleaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SubleaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SubleaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublease term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful lives of related assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred tax assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OwnershipAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ownership [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate maximum obligation to pay future contingent milestone payments for accelerated approval</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate maximum obligation to pay future contingent milestone payments for accelerated approval.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate maximum obligation to pay future contingent milestone payments for accelerated approval</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Stock Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of Series A and Series B convertible preferred stock into shares of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Shares, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Estimated Useful Lives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful lives of related assets, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of additional shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-dilutive effect excluded from computation of diluted net loss per share attributable to common stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_RestrictedStockSharesUnvestedAndOutstanding" xlink:to="pyxs_RestrictedStockSharesUnvestedAndOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock" xlink:to="pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_PrepaidResearchAndDevelopmentCurrent" xlink:to="pyxs_PrepaidResearchAndDevelopmentCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_FurnitureAndOfficeEquipmentMember" xlink:to="pyxs_FurnitureAndOfficeEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:to="pyxs_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_NumberOfFinanceLease" xlink:to="pyxs_NumberOfFinanceLease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_TaxCutsAndJobsActDeferredTaxAsset" xlink:to="pyxs_TaxCutsAndJobsActDeferredTaxAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_StockOptionsTwoThousandTwentyTwoTwoThousandTwentyOneAndTwoThousandNineteenPlanMember" xlink:to="pyxs_StockOptionsTwoThousandTwentyTwoTwoThousandTwentyOneAndTwoThousandNineteenPlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_NonCashGainLossFromEquityMethodInvestmentInJointVenture" xlink:to="pyxs_NonCashGainLossFromEquityMethodInvestmentInJointVenture_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:to="pyxs_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_LiquidityPolicyTextBlock" xlink:to="pyxs_LiquidityPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ProceedsFromTenantImprovementAllowance" xlink:to="pyxs_ProceedsFromTenantImprovementAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_TaxCreditCarryforwardExpirationYear" xlink:to="pyxs_TaxCreditCarryforwardExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate202001Member" xlink:to="us-gaap_AccountingStandardsUpdate202001Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized" xlink:to="pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_CommonStockIssuedToUniversity" xlink:to="pyxs_CommonStockIssuedToUniversity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_LaboratoryEquipmentMember" xlink:to="pyxs_LaboratoryEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_PfizerLicenseAgreementMember" xlink:to="pyxs_PfizerLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_RelatedPartyTransactionServiceFeeOtherIncomeFromTransactionsWithRelatedParty" xlink:to="pyxs_RelatedPartyTransactionServiceFeeOtherIncomeFromTransactionsWithRelatedParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:to="pyxs_TwoThousandTwentyOneEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ProceedsFromPromissoryNoteIssued" xlink:to="pyxs_ProceedsFromPromissoryNoteIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:to="pyxs_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_UniversityLicenseAgreementMember" xlink:to="pyxs_UniversityLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities" xlink:to="us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ConvertiblePreferredStockSharesIssuedValue" xlink:to="pyxs_ConvertiblePreferredStockSharesIssuedValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:to="pyxs_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_AlloyTherapeuticsIncMember" xlink:to="pyxs_AlloyTherapeuticsIncMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_EstimatedCostToPurchaseLicensedProducts" xlink:to="pyxs_EstimatedCostToPurchaseLicensedProducts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_LicensingAgreementsTextBlock" xlink:to="pyxs_LicensingAgreementsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_AgreementsWithPfizerIncAndLegochemBiosciencesIncMember" xlink:to="pyxs_AgreementsWithPfizerIncAndLegochemBiosciencesIncMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_NatureOfBusinessPolicyTextBlock" xlink:to="pyxs_NatureOfBusinessPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_TemporaryEquityIssuanceCosts" xlink:to="pyxs_TemporaryEquityIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:to="us-gaap_PaymentsToAcquireInterestInJointVenture_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses" xlink:to="pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_GrossProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="pyxs_GrossProceedsFromIssuanceOfConvertiblePreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_TenantImprovementAllowance" xlink:to="pyxs_TenantImprovementAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:to="pyxs_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivableCurrent" xlink:to="us-gaap_InterestReceivableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_RentIncreasePercentage" xlink:to="pyxs_RentIncreasePercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseMember" xlink:to="us-gaap_NonoperatingIncomeExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesReservedAndAvailableForIssuancePercentage" xlink:to="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesReservedAndAvailableForIssuancePercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_PotentialDevelopmentAndCommercialMilestonePayment" xlink:to="pyxs_PotentialDevelopmentAndCommercialMilestonePayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_LegoChemLicenseAgreementMember" xlink:to="pyxs_LegoChemLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_InitialPublicOfferingPolicyTextBlock" xlink:to="pyxs_InitialPublicOfferingPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_TenantImprovementAllowanceReceivable" xlink:to="pyxs_TenantImprovementAllowanceReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_SecuritiesPurchaseAgreementMember" xlink:to="pyxs_SecuritiesPurchaseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_OperatingLossCarryforwardsExpirationYear" xlink:to="pyxs_OperatingLossCarryforwardsExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock" xlink:to="pyxs_ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable" xlink:to="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionDomain" xlink:to="us-gaap_TransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:to="us-gaap_DeferredTaxAssetsDerivativeInstruments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_StockOptionsAvailableForIssuanceMember" xlink:to="pyxs_StockOptionsAvailableForIssuanceMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_TwoThousandNineteenEquityIncentivePlanMember" xlink:to="pyxs_TwoThousandNineteenEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_UpfrontPayments" xlink:to="pyxs_UpfrontPayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod" xlink:to="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_LicenseAgreementsAbstract" xlink:to="pyxs_LicenseAgreementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:to="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_UpfrontFee" xlink:to="pyxs_UpfrontFee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_RelatedPartyTransactionOwnership" xlink:to="pyxs_RelatedPartyTransactionOwnership_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_NonCashResearchAndDevelopmentExpense" xlink:to="pyxs_NonCashResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_NumberOfDaysCommonStockIssuedFromEffectiveDate" xlink:to="pyxs_NumberOfDaysCommonStockIssuedFromEffectiveDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_RisksAndUncertaintiesPolicyTextBlock" xlink:to="pyxs_RisksAndUncertaintiesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_SubleaseExpirationDate" xlink:to="pyxs_SubleaseExpirationDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:to="pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoSharesOfCommonStock" xlink:to="pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoSharesOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_DeferredTaxAssetsCapitalizedResearchExpenditures" xlink:to="pyxs_DeferredTaxAssetsCapitalizedResearchExpenditures_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_UnvestedRestrictedStockAwardsMember" xlink:to="pyxs_UnvestedRestrictedStockAwardsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_SubleaseAgreementMember" xlink:to="pyxs_SubleaseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_GrossProceedsFromIssuanceInitialPublicOffering" xlink:to="pyxs_GrossProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ContributedAmountToJointVentureByEachEntity" xlink:to="pyxs_ContributedAmountToJointVentureByEachEntity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:to="us-gaap_LesseeFinanceLeaseTermOfContract1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_StockIssuanceExpenses" xlink:to="pyxs_StockIssuanceExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_CashReceivedForInterest" xlink:to="pyxs_CashReceivedForInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_SeriesAConvertiblePreferredStocksMember" xlink:to="pyxs_SeriesAConvertiblePreferredStocksMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_IncrementalBorrowingRate" xlink:to="pyxs_IncrementalBorrowingRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="pyxs_SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="pyxs_DeferredTaxAssetsOperatingLeaseLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_OfficeAndLaboratorySpaceMember" xlink:to="pyxs_OfficeAndLaboratorySpaceMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_UnderwritingDiscountsAndCommissions" xlink:to="pyxs_UnderwritingDiscountsAndCommissions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="pyxs_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsNonrecurringMember" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale" xlink:to="pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_IssuanceOfConvertiblePreferredStockShares" xlink:to="pyxs_IssuanceOfConvertiblePreferredStockShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_TwothousandtwentytwoequityinducementplanMember" xlink:to="pyxs_TwothousandtwentytwoequityinducementplanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems" xlink:to="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval" xlink:to="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_DeferredTaxAssetsLicenseFee" xlink:to="pyxs_DeferredTaxAssetsLicenseFee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_AccruedResearchAndDevelopmentExpensesCurrent" xlink:to="pyxs_AccruedResearchAndDevelopmentExpensesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_MaximumPercentageOfOwnershipInterest" xlink:to="pyxs_MaximumPercentageOfOwnershipInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_AggregateMilestonePayments" xlink:to="pyxs_AggregateMilestonePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions" xlink:to="pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_FairValueOfCommonStockPerShare" xlink:to="pyxs_FairValueOfCommonStockPerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_BiosionLicenseAgreementMember" xlink:to="pyxs_BiosionLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxContingencyTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_VoxallMember" xlink:to="pyxs_VoxallMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_OptionUpfrontPayment" xlink:to="pyxs_OptionUpfrontPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ServiceFeeIncomeFromRelatedParty" xlink:to="pyxs_ServiceFeeIncomeFromRelatedParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_MA" xlink:to="stpr_MA_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_OperatingLossCarryforwardsBeforeTax" xlink:to="pyxs_OperatingLossCarryforwardsBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue" xlink:to="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_MilestoneAndRoyaltiesIncurred" xlink:to="pyxs_MilestoneAndRoyaltiesIncurred_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_LesseeFinanceSubleaseTermOfContract" xlink:to="pyxs_LesseeFinanceSubleaseTermOfContract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_PaymentForLicenseFee" xlink:to="pyxs_PaymentForLicenseFee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ExtraMilestonePayment" xlink:to="pyxs_ExtraMilestonePayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoCommonStockValue" xlink:to="pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoCommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_MinimumAnnualRoyaltyFees" xlink:to="pyxs_MinimumAnnualRoyaltyFees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_SeriesBConvertiblePreferredStocksMember" xlink:to="pyxs_SeriesBConvertiblePreferredStocksMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_SubleaseTerm" xlink:to="pyxs_SubleaseTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval" xlink:to="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>41
<FILENAME>pyxs-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-22T07:17:52.0279+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="pyxs-20221231.xsd#DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1" xlink:href="pyxs-20221231.xsd#StatementConsolidatedBalanceSheets1" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="pyxs-20221231.xsd#StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="pyxs-20221231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="pyxs-20221231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="pyxs-20221231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="pyxs-20221231.xsd#StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOrganizationAndNatureOfBusiness" xlink:href="pyxs-20221231.xsd#DisclosureOrganizationAndNatureOfBusiness" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureDescriptionOfBusiness" xlink:href="pyxs-20221231.xsd#DisclosureDescriptionOfBusiness" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="pyxs-20221231.xsd#Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureLicensingAgreements" xlink:href="pyxs-20221231.xsd#Role_DisclosureLicensingAgreements" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureJointVenture" xlink:href="pyxs-20221231.xsd#Role_DisclosureJointVenture" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="pyxs-20221231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:href="pyxs-20221231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNet" xlink:href="pyxs-20221231.xsd#DisclosurePropertyAndEquipmentNet" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:href="pyxs-20221231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeases" xlink:href="pyxs-20221231.xsd#DisclosureOperatingLeases" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStock" xlink:href="pyxs-20221231.xsd#Role_DisclosureConvertiblePreferredStock" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquity" xlink:href="pyxs-20221231.xsd#DisclosureStockholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:href="pyxs-20221231.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="pyxs-20221231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureNetLossPerShare" xlink:href="pyxs-20221231.xsd#DisclosureNetLossPerShare" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureRelatedParties" xlink:href="pyxs-20221231.xsd#Role_DisclosureRelatedParties" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="pyxs-20221231.xsd#DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureSubsequentEvents" xlink:href="pyxs-20221231.xsd#DisclosureSubsequentEvents" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="pyxs-20221231.xsd#Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="pyxs-20221231.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:href="pyxs-20221231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="pyxs-20221231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" xlink:href="pyxs-20221231.xsd#DisclosurePropertyAndEquipmentNetTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="pyxs-20221231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesTables" xlink:href="pyxs-20221231.xsd#DisclosureOperatingLeasesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:href="pyxs-20221231.xsd#DisclosureCommitmentsAndContingenciesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityTables" xlink:href="pyxs-20221231.xsd#DisclosureStockholdersEquityTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:href="pyxs-20221231.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="pyxs-20221231.xsd#DisclosureIncomeTaxesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureNetLossPerShareTables" xlink:href="pyxs-20221231.xsd#DisclosureNetLossPerShareTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails" xlink:href="pyxs-20221231.xsd#DisclosureDescriptionOfBusinessAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="pyxs-20221231.xsd#Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfRelatedAssetsDetails" xlink:href="pyxs-20221231.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfRelatedAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:href="pyxs-20221231.xsd#DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails" xlink:href="pyxs-20221231.xsd#DisclosureJointVentureAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails" xlink:href="pyxs-20221231.xsd#DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="pyxs-20221231.xsd#DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="pyxs-20221231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:href="pyxs-20221231.xsd#DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:href="pyxs-20221231.xsd#DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails" xlink:href="pyxs-20221231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails" xlink:href="pyxs-20221231.xsd#DisclosureOperatingLeasesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails" xlink:href="pyxs-20221231.xsd#DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails" xlink:href="pyxs-20221231.xsd#DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:href="pyxs-20221231.xsd#Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:href="pyxs-20221231.xsd#DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails" xlink:href="pyxs-20221231.xsd#DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="pyxs-20221231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xlink:href="pyxs-20221231.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails" xlink:href="pyxs-20221231.xsd#DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails" xlink:href="pyxs-20221231.xsd#DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails" xlink:href="pyxs-20221231.xsd#Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="pyxs-20221231.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" xlink:href="pyxs-20221231.xsd#DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" xlink:href="pyxs-20221231.xsd#DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails" xlink:href="pyxs-20221231.xsd#DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureNetLossPerShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="pyxs-20221231.xsd#DisclosureNetLossPerShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" xlink:href="pyxs-20221231.xsd#DisclosureRelatedPartiesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="pyxs-20221231.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_ServiceFeeIncomeFromRelatedParty" xlink:label="pyxs_ServiceFeeIncomeFromRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="pyxs_ServiceFeeIncomeFromRelatedParty" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_PfizerLicenseAgreementMember" xlink:label="pyxs_PfizerLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="pyxs_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoCommonStockValue" xlink:label="pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoCommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoSharesOfCommonStock" xlink:label="pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoSharesOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_18"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_19"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_20"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_21"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="pyxs_PfizerLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TransactionTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pyxs_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoCommonStockValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoSharesOfCommonStock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_18" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_19" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_20" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_21" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_SeriesBConvertiblePreferredStocksMember" xlink:label="pyxs_SeriesBConvertiblePreferredStocksMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_TemporaryEquityIssuanceCosts" xlink:label="pyxs_TemporaryEquityIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pyxs_SeriesBConvertiblePreferredStocksMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pyxs_TemporaryEquityIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_CashReceivedForInterest" xlink:label="pyxs_CashReceivedForInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:label="us-gaap_PaymentsToAcquireInterestInJointVenture"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_NonCashResearchAndDevelopmentExpense" xlink:label="pyxs_NonCashResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_NonCashGainLossFromEquityMethodInvestmentInJointVenture" xlink:label="pyxs_NonCashGainLossFromEquityMethodInvestmentInJointVenture"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="pyxs_CashReceivedForInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInterestInJointVenture" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCash" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="pyxs_NonCashResearchAndDevelopmentExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="pyxs_NonCashGainLossFromEquityMethodInvestmentInJointVenture" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOrganizationAndNatureOfBusiness" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureDescriptionOfBusiness" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureLicensingAgreements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_LicenseAgreementsAbstract" xlink:label="pyxs_LicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_LicensingAgreementsTextBlock" xlink:label="pyxs_LicensingAgreementsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_LicenseAgreementsAbstract" xlink:to="pyxs_LicensingAgreementsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureJointVenture" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_OtherCurrentAssetsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNet" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeases" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStock" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_PreferredStockTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureNetLossPerShare" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureRelatedParties" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_NatureOfBusinessPolicyTextBlock" xlink:label="pyxs_NatureOfBusinessPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_InitialPublicOfferingPolicyTextBlock" xlink:label="pyxs_InitialPublicOfferingPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_LiquidityPolicyTextBlock" xlink:label="pyxs_LiquidityPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_RisksAndUncertaintiesPolicyTextBlock" xlink:label="pyxs_RisksAndUncertaintiesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock" xlink:label="pyxs_ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:label="pyxs_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pyxs_NatureOfBusinessPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pyxs_InitialPublicOfferingPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pyxs_LiquidityPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pyxs_RisksAndUncertaintiesPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pyxs_ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pyxs_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:label="pyxs_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pyxs_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="pyxs_SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="pyxs_SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:title="presentationLink" xlink:type="extended"/>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureNetLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202001Member" xlink:label="us-gaap_AccountingStandardsUpdate202001Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_NumberOfFinanceLease" xlink:label="pyxs_NumberOfFinanceLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202001Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="pyxs_NumberOfFinanceLease" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfRelatedAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_SeriesBConvertiblePreferredStocksMember" xlink:label="pyxs_SeriesBConvertiblePreferredStocksMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_UniversityLicenseAgreementMember" xlink:label="pyxs_UniversityLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_PfizerLicenseAgreementMember" xlink:label="pyxs_PfizerLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_CommonStockIssuedToUniversity" xlink:label="pyxs_CommonStockIssuedToUniversity"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_LicenseAgreementsAbstract" xlink:label="pyxs_LicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_LegoChemLicenseAgreementMember" xlink:label="pyxs_LegoChemLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_UpfrontFee" xlink:label="pyxs_UpfrontFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseMember" xlink:label="us-gaap_NonoperatingIncomeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_BiosionLicenseAgreementMember" xlink:label="pyxs_BiosionLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval" xlink:label="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval" xlink:label="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_EstimatedCostToPurchaseLicensedProducts" xlink:label="pyxs_EstimatedCostToPurchaseLicensedProducts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_PaymentForLicenseFee" xlink:label="pyxs_PaymentForLicenseFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_MaximumPercentageOfOwnershipInterest" xlink:label="pyxs_MaximumPercentageOfOwnershipInterest"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock" xlink:label="pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_PotentialDevelopmentAndCommercialMilestonePayment" xlink:label="pyxs_PotentialDevelopmentAndCommercialMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_MinimumAnnualRoyaltyFees" xlink:label="pyxs_MinimumAnnualRoyaltyFees"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale" xlink:label="pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_MilestoneAndRoyaltiesIncurred" xlink:label="pyxs_MilestoneAndRoyaltiesIncurred"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_IssuanceOfConvertiblePreferredStockShares" xlink:label="pyxs_IssuanceOfConvertiblePreferredStockShares"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_ConvertiblePreferredStockSharesIssuedValue" xlink:label="pyxs_ConvertiblePreferredStockSharesIssuedValue"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_UpfrontPayments" xlink:label="pyxs_UpfrontPayments"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_AggregateMilestonePayments" xlink:label="pyxs_AggregateMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_NumberOfDaysCommonStockIssuedFromEffectiveDate" xlink:label="pyxs_NumberOfDaysCommonStockIssuedFromEffectiveDate"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_OptionUpfrontPayment" xlink:label="pyxs_OptionUpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_ExtraMilestonePayment" xlink:label="pyxs_ExtraMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses" xlink:label="pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized" xlink:label="pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:label="pyxs_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pyxs_SeriesBConvertiblePreferredStocksMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="pyxs_UniversityLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="pyxs_PfizerLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_CommonStockIssuedToUniversity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_LicenseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_TransactionTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="pyxs_LegoChemLicenseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_UpfrontFee" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_NonoperatingIncomeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="pyxs_BiosionLicenseAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_EstimatedCostToPurchaseLicensedProducts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_PaymentForLicenseFee" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_CommonStockValue" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_MaximumPercentageOfOwnershipInterest" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_PotentialDevelopmentAndCommercialMilestonePayment" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_MinimumAnnualRoyaltyFees" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_MilestoneAndRoyaltiesIncurred" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_IssuanceOfConvertiblePreferredStockShares" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_ConvertiblePreferredStockSharesIssuedValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_UpfrontPayments" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_AggregateMilestonePayments" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_NumberOfDaysCommonStockIssuedFromEffectiveDate" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_OptionUpfrontPayment" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_ExtraMilestonePayment" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_DerivativeLiabilities" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_VoxallMember" xlink:label="pyxs_VoxallMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_AlloyTherapeuticsIncMember" xlink:label="pyxs_AlloyTherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_ProceedsFromPromissoryNoteIssued" xlink:label="pyxs_ProceedsFromPromissoryNoteIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities" xlink:label="us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="pyxs_VoxallMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="pyxs_AlloyTherapeuticsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="dei_LegalEntityAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="pyxs_ProceedsFromPromissoryNoteIssued" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_DerivativeLiabilities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_LegoChemLicenseAgreementMember" xlink:label="pyxs_LegoChemLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseMember" xlink:label="us-gaap_NonoperatingIncomeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses" xlink:label="pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:label="pyxs_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized" xlink:label="pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="pyxs_LegoChemLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_NonoperatingIncomeExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_TransactionTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="pyxs_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_PrepaidResearchAndDevelopmentCurrent" xlink:label="pyxs_PrepaidResearchAndDevelopmentCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="pyxs_PrepaidResearchAndDevelopmentCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidInsurance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_InterestReceivableCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_LaboratoryEquipmentMember" xlink:label="pyxs_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_FurnitureAndOfficeEquipmentMember" xlink:label="pyxs_FurnitureAndOfficeEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pyxs_LaboratoryEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pyxs_FurnitureAndOfficeEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="pyxs_AccruedResearchAndDevelopmentExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="pyxs_AccruedResearchAndDevelopmentExpensesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_RentIncreasePercentage" xlink:label="pyxs_RentIncreasePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_IncrementalBorrowingRate" xlink:label="pyxs_IncrementalBorrowingRate"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_TenantImprovementAllowance" xlink:label="pyxs_TenantImprovementAllowance"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_TenantImprovementAllowanceReceivable" xlink:label="pyxs_TenantImprovementAllowanceReceivable"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_ProceedsFromTenantImprovementAllowance" xlink:label="pyxs_ProceedsFromTenantImprovementAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseExpirationDate1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="pyxs_RentIncreasePercentage" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="pyxs_IncrementalBorrowingRate" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="pyxs_TenantImprovementAllowance" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="pyxs_TenantImprovementAllowanceReceivable" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="pyxs_ProceedsFromTenantImprovementAllowance" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_VariableLeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_TenantImprovementAllowanceReceivable" xlink:label="pyxs_TenantImprovementAllowanceReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="pyxs_TenantImprovementAllowanceReceivable" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_SeriesAConvertiblePreferredStocksMember" xlink:label="pyxs_SeriesAConvertiblePreferredStocksMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_SecuritiesPurchaseAgreementMember" xlink:label="pyxs_SecuritiesPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_SeriesBConvertiblePreferredStocksMember" xlink:label="pyxs_SeriesBConvertiblePreferredStocksMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_AgreementsWithPfizerIncAndLegochemBiosciencesIncMember" xlink:label="pyxs_AgreementsWithPfizerIncAndLegochemBiosciencesIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_GrossProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="pyxs_GrossProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pyxs_SeriesAConvertiblePreferredStocksMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pyxs_SecuritiesPurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pyxs_SeriesBConvertiblePreferredStocksMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pyxs_AgreementsWithPfizerIncAndLegochemBiosciencesIncMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="pyxs_GrossProceedsFromIssuanceOfConvertiblePreferredStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_GrossProceedsFromIssuanceInitialPublicOffering" xlink:label="pyxs_GrossProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_UnderwritingDiscountsAndCommissions" xlink:label="pyxs_UnderwritingDiscountsAndCommissions"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_StockIssuanceExpenses" xlink:label="pyxs_StockIssuanceExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="pyxs_GrossProceedsFromIssuanceInitialPublicOffering" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="pyxs_UnderwritingDiscountsAndCommissions" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="pyxs_StockIssuanceExpenses" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_StockOptionsAvailableForIssuanceMember" xlink:label="pyxs_StockOptionsAvailableForIssuanceMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable" xlink:to="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pyxs_StockOptionsAvailableForIssuanceMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_TwothousandtwentytwoequityinducementplanMember" xlink:label="pyxs_TwothousandtwentytwoequityinducementplanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:label="pyxs_TwoThousandTwentyOneEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="pyxs_TwoThousandNineteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:label="pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_StockOptionsTwoThousandTwentyTwoTwoThousandTwentyOneAndTwoThousandNineteenPlanMember" xlink:label="pyxs_StockOptionsTwoThousandTwentyTwoTwoThousandTwentyOneAndTwoThousandNineteenPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesReservedAndAvailableForIssuancePercentage" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesReservedAndAvailableForIssuancePercentage"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions" xlink:label="pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_FairValueOfCommonStockPerShare" xlink:label="pyxs_FairValueOfCommonStockPerShare"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_RestrictedStockSharesUnvestedAndOutstanding" xlink:label="pyxs_RestrictedStockSharesUnvestedAndOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pyxs_TwothousandtwentytwoequityinducementplanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pyxs_TwoThousandTwentyOneEquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pyxs_TwoThousandNineteenEquityIncentivePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pyxs_StockOptionsTwoThousandTwentyTwoTwoThousandTwentyOneAndTwoThousandNineteenPlanMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesReservedAndAvailableForIssuancePercentage" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_FairValueOfCommonStockPerShare" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_RestrictedStockSharesUnvestedAndOutstanding" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_12"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_12" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_OperatingLossCarryforwardsBeforeTax" xlink:label="pyxs_OperatingLossCarryforwardsBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_OperatingLossCarryforwardsExpirationYear" xlink:label="pyxs_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_TaxCreditCarryforwardExpirationYear" xlink:label="pyxs_TaxCreditCarryforwardExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_TaxCutsAndJobsActDeferredTaxAsset" xlink:label="pyxs_TaxCutsAndJobsActDeferredTaxAsset"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxContingencyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxContingencyLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="pyxs_OperatingLossCarryforwardsBeforeTax" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="pyxs_OperatingLossCarryforwardsExpirationYear" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="pyxs_TaxCreditCarryforwardExpirationYear" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="pyxs_TaxCutsAndJobsActDeferredTaxAsset" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="pyxs_EffectiveIncomeTaxRateReconciliationPermanentDifferences"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="pyxs_EffectiveIncomeTaxRateReconciliationPermanentDifferences" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:label="pyxs_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_DeferredTaxAssetsCapitalizedResearchExpenditures" xlink:label="pyxs_DeferredTaxAssetsCapitalizedResearchExpenditures"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_DeferredTaxAssetsLicenseFee" xlink:label="pyxs_DeferredTaxAssetsLicenseFee"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="pyxs_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="pyxs_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsDerivativeInstruments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="pyxs_DeferredTaxAssetsCapitalizedResearchExpenditures" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="pyxs_DeferredTaxAssetsLicenseFee" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="pyxs_DeferredTaxAssetsOperatingLeaseLiabilities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureNetLossPerShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_UnvestedRestrictedStockAwardsMember" xlink:label="pyxs_UnvestedRestrictedStockAwardsMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_StockOptionsAvailableForIssuanceMember" xlink:label="pyxs_StockOptionsAvailableForIssuanceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="pyxs_UnvestedRestrictedStockAwardsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="pyxs_StockOptionsAvailableForIssuanceMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_UniversityLicenseAgreementMember" xlink:label="pyxs_UniversityLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_PfizerLicenseAgreementMember" xlink:label="pyxs_PfizerLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_VoxallMember" xlink:label="pyxs_VoxallMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_AlloyTherapeuticsIncMember" xlink:label="pyxs_AlloyTherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_RelatedPartyTransactionOwnership" xlink:label="pyxs_RelatedPartyTransactionOwnership"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_ContributedAmountToJointVentureByEachEntity" xlink:label="pyxs_ContributedAmountToJointVentureByEachEntity"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_RelatedPartyTransactionServiceFeeOtherIncomeFromTransactionsWithRelatedParty" xlink:label="pyxs_RelatedPartyTransactionServiceFeeOtherIncomeFromTransactionsWithRelatedParty"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="pyxs_UniversityLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain" xlink:to="pyxs_PfizerLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="pyxs_VoxallMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="pyxs_AlloyTherapeuticsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TransactionTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pyxs_RelatedPartyTransactionOwnership" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_OwnershipAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pyxs_ContributedAmountToJointVentureByEachEntity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="dei_LegalEntityAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pyxs_RelatedPartyTransactionServiceFeeOtherIncomeFromTransactionsWithRelatedParty" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_OfficeAndLaboratorySpaceMember" xlink:label="pyxs_OfficeAndLaboratorySpaceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MA" xlink:label="stpr_MA"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_SubleaseAgreementMember" xlink:label="pyxs_SubleaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_LesseeFinanceSubleaseTermOfContract" xlink:label="pyxs_LesseeFinanceSubleaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_SubleaseTerm" xlink:label="pyxs_SubleaseTerm"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_SubleaseExpirationDate" xlink:label="pyxs_SubleaseExpirationDate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="pyxs_OfficeAndLaboratorySpaceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_AreaOfLand" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_MA" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pyxs_SubleaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubleaseIncome" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_StatementGeographicalAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LesseeFinanceLeaseTermOfContract1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="pyxs_LesseeFinanceSubleaseTermOfContract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="pyxs_SubleaseTerm" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="pyxs_SubleaseExpirationDate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>42
<FILENAME>pyxs-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-22T07:17:52.6342+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://pyxisoncology.com/20221231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:pyxs="http://pyxisoncology.com/20221231" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" namespace="http://xbrl.sec.gov/stpr/2022"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" namespace="http://fasb.org/us-gaap/2022"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" namespace="http://fasb.org/srt/2022"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pyxs-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pyxs-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pyxs-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pyxs-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple"/>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1" id="StatementConsolidatedBalanceSheets1">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails2" id="DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails2">
        <link:definition>100020 - Disclosure - Operating Leases - Maturities of Lease Liabilities (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100030 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows2" id="StatementConsolidatedStatementsOfCashFlows2">
        <link:definition>100040 - Statement - Consolidated Statements of Cash Flows 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100050 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" id="StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit">
        <link:definition>100060 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" id="StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
        <link:definition>100070 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100080 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOrganizationAndNatureOfBusiness" id="DisclosureOrganizationAndNatureOfBusiness">
        <link:definition>100090 - Disclosure - Organization and Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureDescriptionOfBusiness" id="DisclosureDescriptionOfBusiness">
        <link:definition>100100 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" id="Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>100110 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureLicensingAgreements" id="Role_DisclosureLicensingAgreements">
        <link:definition>100120 - Disclosure - Licensing Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureJointVenture" id="Role_DisclosureJointVenture">
        <link:definition>100130 - Disclosure - Joint Venture</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100140 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" id="DisclosurePrepaidExpensesAndOtherCurrentAssets">
        <link:definition>100150 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNet" id="DisclosurePropertyAndEquipmentNet">
        <link:definition>100160 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" id="DisclosureAccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>100170 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeases" id="DisclosureOperatingLeases">
        <link:definition>100180 - Disclosure - Operating Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStock" id="Role_DisclosureConvertiblePreferredStock">
        <link:definition>100190 - Disclosure - Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>100200 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100210 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100220 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>100230 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureRelatedParties" id="Role_DisclosureRelatedParties">
        <link:definition>100240 - Disclosure - Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>100250 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>100260 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100270 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" id="DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100280 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100290 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" id="DisclosurePrepaidExpensesAndOtherCurrentAssetsTables">
        <link:definition>100300 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" id="DisclosurePropertyAndEquipmentNetTables">
        <link:definition>100310 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>100320 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesTables" id="DisclosureOperatingLeasesTables">
        <link:definition>100330 - Disclosure - Operating Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100340 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables">
        <link:definition>100350 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100360 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>100370 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>100380 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails" id="DisclosureDescriptionOfBusinessAdditionalInformationDetails">
        <link:definition>100390 - Disclosure - Description of Business - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100400 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfRelatedAssetsDetails" id="DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfRelatedAssetsDetails">
        <link:definition>100410 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Related Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" id="DisclosureLicenseAgreementsAdditionalInformationDetails">
        <link:definition>100420 - Disclosure - License Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails" id="DisclosureJointVentureAdditionalInformationDetails">
        <link:definition>100430 - Disclosure - Joint Venture - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails" id="DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails">
        <link:definition>100440 - Disclosure - Fair Value Measurements - Summary of Financial Instruments Carried at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" id="DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>100450 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" id="DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>100460 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" id="DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
        <link:definition>100470 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" id="DisclosurePropertyAndEquipmentNetAdditionalInformationDetails">
        <link:definition>100480 - Disclosure - Property and Equipment, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails">
        <link:definition>100490 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails" id="DisclosureOperatingLeasesAdditionalInformationDetails">
        <link:definition>100500 - Disclosure - Operating Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails" id="DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails">
        <link:definition>100510 - Disclosure - Operating Leases - Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails" id="DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails">
        <link:definition>100520 - Disclosure - Operating Leases - Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" id="Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails">
        <link:definition>100530 - Disclosure - Convertible Preferred Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" id="DisclosureStockholdersEquityAdditionalInformationDetails">
        <link:definition>100540 - Disclosure - Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails" id="DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails">
        <link:definition>100550 - Disclosure - Stockholders' Equity - Common Stock Reserved for Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
        <link:definition>100560 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" id="Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails">
        <link:definition>100570 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails" id="DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails">
        <link:definition>100580 - Disclosure - Stock-Based Compensation - Schedule of Estimated Fair Value Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails" id="DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails">
        <link:definition>100590 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails" id="Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails">
        <link:definition>100600 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100610 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" id="DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails">
        <link:definition>100620 - Disclosure - Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" id="DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails">
        <link:definition>100630 - Disclosure - Income Taxes - Components of Net Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails" id="DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails">
        <link:definition>100640 - Disclosure - Net Loss per Share - Summary of Basic and Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureNetLossPerShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" id="DisclosureNetLossPerShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
        <link:definition>100650 - Disclosure - Net Loss per Share - Anti-Dilutive Effect Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" id="DisclosureRelatedPartiesAdditionalInformationDetails">
        <link:definition>100660 - Disclosure - Related Parties - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" id="DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>100670 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="pyxs_LicenseAgreementsAbstract" name="LicenseAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_AccruedResearchAndDevelopmentExpensesCurrent" name="AccruedResearchAndDevelopmentExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval" name="AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval" name="AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_AggregateMilestonePayments" name="AggregateMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_CashReceivedForInterest" name="CashReceivedForInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_CommonStockIssuedToUniversity" name="CommonStockIssuedToUniversity" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_ContributedAmountToJointVentureByEachEntity" name="ContributedAmountToJointVentureByEachEntity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_ConvertiblePreferredStockSharesIssuedValue" name="ConvertiblePreferredStockSharesIssuedValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_DeferredTaxAssetsCapitalizedResearchExpenditures" name="DeferredTaxAssetsCapitalizedResearchExpenditures" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_DeferredTaxAssetsLicenseFee" name="DeferredTaxAssetsLicenseFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_DeferredTaxAssetsOperatingLeaseLiabilities" name="DeferredTaxAssetsOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" name="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses" name="DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" name="DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" type="enum2:enumerationSetItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" enum2:domain="us-gaap:LiabilitiesAbstract" enum2:headUsable="false" enum2:linkrole="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists"/>
  <xsd:element id="pyxs_EffectiveIncomeTaxRateReconciliationPermanentDifferences" name="EffectiveIncomeTaxRateReconciliationPermanentDifferences" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_EstimatedCostToPurchaseLicensedProducts" name="EstimatedCostToPurchaseLicensedProducts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_ExtraMilestonePayment" name="ExtraMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized" name="ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_FairValueOfCommonStockPerShare" name="FairValueOfCommonStockPerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_GrossProceedsFromIssuanceInitialPublicOffering" name="GrossProceedsFromIssuanceInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_GrossProceedsFromIssuanceOfConvertiblePreferredStock" name="GrossProceedsFromIssuanceOfConvertiblePreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_IncrementalBorrowingRate" name="IncrementalBorrowingRate" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_IssuanceOfConvertiblePreferredStockShares" name="IssuanceOfConvertiblePreferredStockShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_LesseeFinanceSubleaseTermOfContract" name="LesseeFinanceSubleaseTermOfContract" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions" name="MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_MaximumPercentageOfOwnershipInterest" name="MaximumPercentageOfOwnershipInterest" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_MilestoneAndRoyaltiesIncurred" name="MilestoneAndRoyaltiesIncurred" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_MinimumAnnualRoyaltyFees" name="MinimumAnnualRoyaltyFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_NonCashGainLossFromEquityMethodInvestmentInJointVenture" name="NonCashGainLossFromEquityMethodInvestmentInJointVenture" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_NonCashResearchAndDevelopmentExpense" name="NonCashResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock" name="NumberOfCommonSharesIssuedUponConversionOfPreferredStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_NumberOfDaysCommonStockIssuedFromEffectiveDate" name="NumberOfDaysCommonStockIssuedFromEffectiveDate" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_NumberOfFinanceLease" name="NumberOfFinanceLease" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_OperatingLossCarryforwardsBeforeTax" name="OperatingLossCarryforwardsBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_OptionUpfrontPayment" name="OptionUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_PaymentForLicenseFee" name="PaymentForLicenseFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_PotentialDevelopmentAndCommercialMilestonePayment" name="PotentialDevelopmentAndCommercialMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_PrepaidResearchAndDevelopmentCurrent" name="PrepaidResearchAndDevelopmentCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_ProceedsFromPromissoryNoteIssued" name="ProceedsFromPromissoryNoteIssued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_ProceedsFromTenantImprovementAllowance" name="ProceedsFromTenantImprovementAllowance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_RelatedPartyTransactionOwnership" name="RelatedPartyTransactionOwnership" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_RelatedPartyTransactionServiceFeeOtherIncomeFromTransactionsWithRelatedParty" name="RelatedPartyTransactionServiceFeeOtherIncomeFromTransactionsWithRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_RentIncreasePercentage" name="RentIncreasePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_RestrictedStockSharesUnvestedAndOutstanding" name="RestrictedStockSharesUnvestedAndOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale" name="RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_ServiceFeeIncomeFromRelatedParty" name="ServiceFeeIncomeFromRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesReservedAndAvailableForIssuancePercentage" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesReservedAndAvailableForIssuancePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_StockIssuanceExpenses" name="StockIssuanceExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_SubleaseExpirationDate" name="SubleaseExpirationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_SubleaseTerm" name="SubleaseTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_TaxCreditCarryforwardExpirationYear" name="TaxCreditCarryforwardExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_TaxCutsAndJobsActDeferredTaxAsset" name="TaxCutsAndJobsActDeferredTaxAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoCommonStockValue" name="TemporaryEquityConvertiblePreferredStockConvertedIntoCommonStockValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoSharesOfCommonStock" name="TemporaryEquityConvertiblePreferredStockConvertedIntoSharesOfCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_TemporaryEquityIssuanceCosts" name="TemporaryEquityIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_TenantImprovementAllowance" name="TenantImprovementAllowance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_TenantImprovementAllowanceReceivable" name="TenantImprovementAllowanceReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_UnderwritingDiscountsAndCommissions" name="UnderwritingDiscountsAndCommissions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_UpfrontFee" name="UpfrontFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_UpfrontPayments" name="UpfrontPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" name="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems" name="ScheduleOfCommonStockReservedForFutureIssuanceLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_AgreementsWithPfizerIncAndLegochemBiosciencesIncMember" name="AgreementsWithPfizerIncAndLegochemBiosciencesIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_AlloyTherapeuticsIncMember" name="AlloyTherapeuticsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_BiosionLicenseAgreementMember" name="BiosionLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_FurnitureAndOfficeEquipmentMember" name="FurnitureAndOfficeEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_LegoChemLicenseAgreementMember" name="LegoChemLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_OfficeAndLaboratorySpaceMember" name="OfficeAndLaboratorySpaceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_PfizerLicenseAgreementMember" name="PfizerLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_SeriesAConvertiblePreferredStocksMember" name="SeriesAConvertiblePreferredStocksMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_SeriesBConvertiblePreferredStocksMember" name="SeriesBConvertiblePreferredStocksMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_StockOptionsAvailableForIssuanceMember" name="StockOptionsAvailableForIssuanceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_StockOptionsTwoThousandTwentyTwoTwoThousandTwentyOneAndTwoThousandNineteenPlanMember" name="StockOptionsTwoThousandTwentyTwoTwoThousandTwentyOneAndTwoThousandNineteenPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_SubleaseAgreementMember" name="SubleaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_TwoThousandNineteenEquityIncentivePlanMember" name="TwoThousandNineteenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" name="TwoThousandTwentyOneEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_TwoThousandTwentyOneEquityIncentivePlanMember" name="TwoThousandTwentyOneEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_TwothousandtwentytwoequityinducementplanMember" name="TwothousandtwentytwoequityinducementplanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_UniversityLicenseAgreementMember" name="UniversityLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_UnvestedRestrictedStockAwardsMember" name="UnvestedRestrictedStockAwardsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_VoxallMember" name="VoxallMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_InitialPublicOfferingPolicyTextBlock" name="InitialPublicOfferingPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_LiquidityPolicyTextBlock" name="LiquidityPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_NatureOfBusinessPolicyTextBlock" name="NatureOfBusinessPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" name="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable" name="ScheduleOfCommonStockReservedForFutureIssuanceTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" name="ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock" name="ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_LicensingAgreementsTextBlock" name="LicensingAgreementsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" name="RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_RisksAndUncertaintiesPolicyTextBlock" name="RisksAndUncertaintiesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" name="ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" name="SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>43
<FILENAME>pyxs-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-22T07:17:52.1976+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="pyxs-20221231.xsd#StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="pyxs-20221231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="pyxs-20221231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="pyxs-20221231.xsd#Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfRelatedAssetsDetails" xlink:href="pyxs-20221231.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfRelatedAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:href="pyxs-20221231.xsd#DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails" xlink:href="pyxs-20221231.xsd#DisclosureJointVentureAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails" xlink:href="pyxs-20221231.xsd#DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="pyxs-20221231.xsd#DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:href="pyxs-20221231.xsd#DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:href="pyxs-20221231.xsd#Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:href="pyxs-20221231.xsd#DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails" xlink:href="pyxs-20221231.xsd#DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="pyxs-20221231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails" xlink:href="pyxs-20221231.xsd#DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails" xlink:href="pyxs-20221231.xsd#DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails" xlink:href="pyxs-20221231.xsd#Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="pyxs-20221231.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureNetLossPerShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="pyxs-20221231.xsd#DisclosureNetLossPerShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" xlink:href="pyxs-20221231.xsd#DisclosureRelatedPartiesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="pyxs-20221231.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_PfizerLicenseAgreementMember" xlink:label="pyxs_PfizerLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="pyxs_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoCommonStockValue" xlink:label="pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoCommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoSharesOfCommonStock" xlink:label="pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoSharesOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="pyxs_PfizerLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TransactionTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pyxs_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoCommonStockValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoSharesOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_SeriesBConvertiblePreferredStocksMember" xlink:label="pyxs_SeriesBConvertiblePreferredStocksMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_TemporaryEquityIssuanceCosts" xlink:label="pyxs_TemporaryEquityIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pyxs_SeriesBConvertiblePreferredStocksMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pyxs_TemporaryEquityIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202001Member" xlink:label="us-gaap_AccountingStandardsUpdate202001Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_NumberOfFinanceLease" xlink:label="pyxs_NumberOfFinanceLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202001Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="pyxs_NumberOfFinanceLease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfRelatedAssetsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_SeriesBConvertiblePreferredStocksMember" xlink:label="pyxs_SeriesBConvertiblePreferredStocksMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_UniversityLicenseAgreementMember" xlink:label="pyxs_UniversityLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_PfizerLicenseAgreementMember" xlink:label="pyxs_PfizerLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_CommonStockIssuedToUniversity" xlink:label="pyxs_CommonStockIssuedToUniversity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_LegoChemLicenseAgreementMember" xlink:label="pyxs_LegoChemLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_UpfrontFee" xlink:label="pyxs_UpfrontFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseMember" xlink:label="us-gaap_NonoperatingIncomeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_BiosionLicenseAgreementMember" xlink:label="pyxs_BiosionLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval" xlink:label="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval" xlink:label="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_EstimatedCostToPurchaseLicensedProducts" xlink:label="pyxs_EstimatedCostToPurchaseLicensedProducts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_PaymentForLicenseFee" xlink:label="pyxs_PaymentForLicenseFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_MaximumPercentageOfOwnershipInterest" xlink:label="pyxs_MaximumPercentageOfOwnershipInterest"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock" xlink:label="pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_PotentialDevelopmentAndCommercialMilestonePayment" xlink:label="pyxs_PotentialDevelopmentAndCommercialMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_MinimumAnnualRoyaltyFees" xlink:label="pyxs_MinimumAnnualRoyaltyFees"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale" xlink:label="pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_MilestoneAndRoyaltiesIncurred" xlink:label="pyxs_MilestoneAndRoyaltiesIncurred"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_IssuanceOfConvertiblePreferredStockShares" xlink:label="pyxs_IssuanceOfConvertiblePreferredStockShares"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_ConvertiblePreferredStockSharesIssuedValue" xlink:label="pyxs_ConvertiblePreferredStockSharesIssuedValue"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_UpfrontPayments" xlink:label="pyxs_UpfrontPayments"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_AggregateMilestonePayments" xlink:label="pyxs_AggregateMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_NumberOfDaysCommonStockIssuedFromEffectiveDate" xlink:label="pyxs_NumberOfDaysCommonStockIssuedFromEffectiveDate"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_OptionUpfrontPayment" xlink:label="pyxs_OptionUpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_ExtraMilestonePayment" xlink:label="pyxs_ExtraMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses" xlink:label="pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized" xlink:label="pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:label="pyxs_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pyxs_SeriesBConvertiblePreferredStocksMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="pyxs_UniversityLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="pyxs_PfizerLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_CommonStockIssuedToUniversity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_TransactionTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="pyxs_LegoChemLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_UpfrontFee" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_NonoperatingIncomeExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="pyxs_BiosionLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_EstimatedCostToPurchaseLicensedProducts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_PaymentForLicenseFee" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_MaximumPercentageOfOwnershipInterest" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_PotentialDevelopmentAndCommercialMilestonePayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_MinimumAnnualRoyaltyFees" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_MilestoneAndRoyaltiesIncurred" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_IssuanceOfConvertiblePreferredStockShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_ConvertiblePreferredStockSharesIssuedValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_UpfrontPayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_AggregateMilestonePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_NumberOfDaysCommonStockIssuedFromEffectiveDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_OptionUpfrontPayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_ExtraMilestonePayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_DerivativeLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_VoxallMember" xlink:label="pyxs_VoxallMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_AlloyTherapeuticsIncMember" xlink:label="pyxs_AlloyTherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_ProceedsFromPromissoryNoteIssued" xlink:label="pyxs_ProceedsFromPromissoryNoteIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities" xlink:label="us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="pyxs_VoxallMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="pyxs_AlloyTherapeuticsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="pyxs_ProceedsFromPromissoryNoteIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_DerivativeLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_LegoChemLicenseAgreementMember" xlink:label="pyxs_LegoChemLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseMember" xlink:label="us-gaap_NonoperatingIncomeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses" xlink:label="pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:label="pyxs_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized" xlink:label="pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="pyxs_LegoChemLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_NonoperatingIncomeExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_TransactionTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="pyxs_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_LaboratoryEquipmentMember" xlink:label="pyxs_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_FurnitureAndOfficeEquipmentMember" xlink:label="pyxs_FurnitureAndOfficeEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pyxs_LaboratoryEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pyxs_FurnitureAndOfficeEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_SeriesAConvertiblePreferredStocksMember" xlink:label="pyxs_SeriesAConvertiblePreferredStocksMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_SecuritiesPurchaseAgreementMember" xlink:label="pyxs_SecuritiesPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_SeriesBConvertiblePreferredStocksMember" xlink:label="pyxs_SeriesBConvertiblePreferredStocksMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_AgreementsWithPfizerIncAndLegochemBiosciencesIncMember" xlink:label="pyxs_AgreementsWithPfizerIncAndLegochemBiosciencesIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_GrossProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="pyxs_GrossProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pyxs_SeriesAConvertiblePreferredStocksMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pyxs_SecuritiesPurchaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pyxs_SeriesBConvertiblePreferredStocksMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pyxs_AgreementsWithPfizerIncAndLegochemBiosciencesIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="pyxs_GrossProceedsFromIssuanceOfConvertiblePreferredStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_GrossProceedsFromIssuanceInitialPublicOffering" xlink:label="pyxs_GrossProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_UnderwritingDiscountsAndCommissions" xlink:label="pyxs_UnderwritingDiscountsAndCommissions"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_StockIssuanceExpenses" xlink:label="pyxs_StockIssuanceExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="pyxs_GrossProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="pyxs_UnderwritingDiscountsAndCommissions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="pyxs_StockIssuanceExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails">
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_StockOptionsAvailableForIssuanceMember" xlink:label="pyxs_StockOptionsAvailableForIssuanceMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems" xlink:to="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pyxs_StockOptionsAvailableForIssuanceMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_TwothousandtwentytwoequityinducementplanMember" xlink:label="pyxs_TwothousandtwentytwoequityinducementplanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:label="pyxs_TwoThousandTwentyOneEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="pyxs_TwoThousandNineteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:label="pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_StockOptionsTwoThousandTwentyTwoTwoThousandTwentyOneAndTwoThousandNineteenPlanMember" xlink:label="pyxs_StockOptionsTwoThousandTwentyTwoTwoThousandTwentyOneAndTwoThousandNineteenPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesReservedAndAvailableForIssuancePercentage" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesReservedAndAvailableForIssuancePercentage"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions" xlink:label="pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_FairValueOfCommonStockPerShare" xlink:label="pyxs_FairValueOfCommonStockPerShare"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_RestrictedStockSharesUnvestedAndOutstanding" xlink:label="pyxs_RestrictedStockSharesUnvestedAndOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pyxs_TwothousandtwentytwoequityinducementplanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pyxs_TwoThousandTwentyOneEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pyxs_TwoThousandNineteenEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pyxs_StockOptionsTwoThousandTwentyTwoTwoThousandTwentyOneAndTwoThousandNineteenPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesReservedAndAvailableForIssuancePercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_FairValueOfCommonStockPerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_RestrictedStockSharesUnvestedAndOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_OperatingLossCarryforwardsBeforeTax" xlink:label="pyxs_OperatingLossCarryforwardsBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_OperatingLossCarryforwardsExpirationYear" xlink:label="pyxs_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_TaxCreditCarryforwardExpirationYear" xlink:label="pyxs_TaxCreditCarryforwardExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_TaxCutsAndJobsActDeferredTaxAsset" xlink:label="pyxs_TaxCutsAndJobsActDeferredTaxAsset"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="pyxs_OperatingLossCarryforwardsBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="pyxs_OperatingLossCarryforwardsExpirationYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="pyxs_TaxCreditCarryforwardExpirationYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="pyxs_TaxCutsAndJobsActDeferredTaxAsset" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureNetLossPerShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_UnvestedRestrictedStockAwardsMember" xlink:label="pyxs_UnvestedRestrictedStockAwardsMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_StockOptionsAvailableForIssuanceMember" xlink:label="pyxs_StockOptionsAvailableForIssuanceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="pyxs_UnvestedRestrictedStockAwardsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="pyxs_StockOptionsAvailableForIssuanceMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_UniversityLicenseAgreementMember" xlink:label="pyxs_UniversityLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_PfizerLicenseAgreementMember" xlink:label="pyxs_PfizerLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_VoxallMember" xlink:label="pyxs_VoxallMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_AlloyTherapeuticsIncMember" xlink:label="pyxs_AlloyTherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_RelatedPartyTransactionOwnership" xlink:label="pyxs_RelatedPartyTransactionOwnership"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_ContributedAmountToJointVentureByEachEntity" xlink:label="pyxs_ContributedAmountToJointVentureByEachEntity"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_RelatedPartyTransactionServiceFeeOtherIncomeFromTransactionsWithRelatedParty" xlink:label="pyxs_RelatedPartyTransactionServiceFeeOtherIncomeFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="pyxs_UniversityLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="pyxs_PfizerLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="pyxs_VoxallMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="pyxs_AlloyTherapeuticsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TransactionTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pyxs_RelatedPartyTransactionOwnership" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_OwnershipAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pyxs_ContributedAmountToJointVentureByEachEntity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pyxs_RelatedPartyTransactionServiceFeeOtherIncomeFromTransactionsWithRelatedParty" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_OfficeAndLaboratorySpaceMember" xlink:label="pyxs_OfficeAndLaboratorySpaceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MA" xlink:label="stpr_MA"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_SubleaseAgreementMember" xlink:label="pyxs_SubleaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_LesseeFinanceSubleaseTermOfContract" xlink:label="pyxs_LesseeFinanceSubleaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_SubleaseTerm" xlink:label="pyxs_SubleaseTerm"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20221231.xsd#pyxs_SubleaseExpirationDate" xlink:label="pyxs_SubleaseExpirationDate"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="pyxs_OfficeAndLaboratorySpaceMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_AreaOfLand" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_MA" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pyxs_SubleaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubleaseIncome" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LesseeFinanceLeaseTermOfContract1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="pyxs_LesseeFinanceSubleaseTermOfContract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="pyxs_SubleaseTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="pyxs_SubleaseExpirationDate" priority="2" use="optional"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079010802352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 21, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Pyxis Oncology, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001782223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">83-1160910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">150 Cambridgepark Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">221-9059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PYXS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,980,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Portions of the Registrant&#8217;s Proxy Statement for its 2023 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein. Such Proxy Statement will be filed with the Securities and Exchange Commission within 120 days of the registrant&#8217;s fiscal year ended December 31, 2022.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079010422464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 179,293<span></span>
</td>
<td class="nump">$ 274,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">1,472<span></span>
</td>
<td class="nump">1,472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5,847<span></span>
</td>
<td class="nump">2,466<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">186,612<span></span>
</td>
<td class="nump">278,673<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">11,165<span></span>
</td>
<td class="nump">1,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">13,602<span></span>
</td>
<td class="nump">232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">211,379<span></span>
</td>
<td class="nump">280,021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">7,097<span></span>
</td>
<td class="nump">11,951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">24,537<span></span>
</td>
<td class="nump">6,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">31,634<span></span>
</td>
<td class="nump">18,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">18,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">50,555<span></span>
</td>
<td class="nump">18,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 16)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.001 per share, 10,000,000 shares authorized; zero shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value per share; 190,000,000 shares; 35,110,016 and 32,792,867 shares issued as of December 31, 2022 and 2021, respectively, and 34,958,730 and 32,222,881 shares outstanding as of December 31, 2022 and 2021, respectively</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">373,225<span></span>
</td>
<td class="nump">352,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(212,435)<span></span>
</td>
<td class="num">(91,718)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">160,824<span></span>
</td>
<td class="nump">261,313<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 211,379<span></span>
</td>
<td class="nump">$ 280,021<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079015677856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par or stated value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">190,000,000<span></span>
</td>
<td class="nump">190,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">35,110,016<span></span>
</td>
<td class="nump">32,792,867<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">34,958,730<span></span>
</td>
<td class="nump">32,222,881<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079010483200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 86,129<span></span>
</td>
<td class="nump">$ 51,054<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">37,352<span></span>
</td>
<td class="nump">18,663<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">123,481<span></span>
</td>
<td class="nump">69,717<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(123,481)<span></span>
</td>
<td class="num">(69,717)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">2,764<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_ServiceFeeIncomeFromRelatedParty', window );">Service fee income from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,231)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="nump">2,764<span></span>
</td>
<td class="num">(6,027)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from equity method investment in joint venture</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(231)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (120,717)<span></span>
</td>
<td class="num">$ (75,975)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share - basic</a></td>
<td class="num">$ (3.65)<span></span>
</td>
<td class="num">$ (8.95)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share - diluted</a></td>
<td class="num">$ (3.65)<span></span>
</td>
<td class="num">$ (8.95)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of common stock outstanding - basic</a></td>
<td class="nump">33,033,081<span></span>
</td>
<td class="nump">8,493,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted Average Number of Shares Outstanding, Diluted</a></td>
<td class="nump">33,033,081<span></span>
</td>
<td class="nump">8,493,273<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_ServiceFeeIncomeFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Service fee income from related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_ServiceFeeIncomeFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079008926944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Pfizer License Agreement</div></th>
<th class="th"><div>Convertible Preferred Stock</div></th>
<th class="th">
<div>Convertible Preferred Stock </div>
<div>Pfizer License Agreement</div>
</th>
<th class="th"><div>Initial Public Offering</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>Pfizer License Agreement</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Initial Public Offering</div>
</th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th">
<div>Additional paid-in capital </div>
<div>Pfizer License Agreement</div>
</th>
<th class="th">
<div>Additional paid-in capital </div>
<div>Initial Public Offering</div>
</th>
<th class="th"><div>Accumulated deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning Balance, Shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,724,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="num">$ (15,645)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (15,743)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, Shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,289,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series B convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152,081<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series B convertible preferred stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,660,103<span></span>
</td>
<td class="nump">12,152,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoCommonStockValue', window );">Temporary equity, Conversion of Series A and Series B convertible preferred stock into shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (194,023)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoSharesOfCommonStock', window );">Temporary equity, Conversion of Series A and Series B convertible preferred stock into shares of common stock (Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(127,537,173)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Series A and Series B convertible preferred stock into shares of common stock</a></td>
<td class="nump">194,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Series A and Series B convertible preferred stock into shares of common stock (Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,056,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock options exercised</a></td>
<td class="nump">170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised (Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted common stock</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted common stock (Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">306,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">6,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(75,975)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75,975)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">261,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">352,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(91,718)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,222,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,229,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock options exercised</a></td>
<td class="nump">$ 183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised (Shares)</a></td>
<td class="nump">73,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted common stock (Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">432,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 15,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(120,717)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(120,717)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 160,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 373,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (212,435)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,958,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoCommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity convertible preferred stock converted into common stock value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoCommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity convertible preferred stock converted into shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issued during period shares new issues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079015668896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pyxs_SeriesBConvertiblePreferredStocksMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_TemporaryEquityIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 419<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Underwriting commission and issuance costs</a></td>
<td class="nump">$ 15,704<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_TemporaryEquityIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_TemporaryEquityIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pyxs_SeriesBConvertiblePreferredStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pyxs_SeriesBConvertiblePreferredStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079015663280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (120,717)<span></span>
</td>
<td class="num">$ (75,975)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">709<span></span>
</td>
<td class="nump">647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">15,764<span></span>
</td>
<td class="nump">6,441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_NonCashResearchAndDevelopmentExpense', window );">Non-cash research and development expenses</a></td>
<td class="nump">9,281<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">1,127<span></span>
</td>
<td class="nump">604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_NonCashGainLossFromEquityMethodInvestmentInJointVenture', window );">Non-cash loss from equity method investment in joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Changes in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(3,381)<span></span>
</td>
<td class="num">(2,444)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(8,328)<span></span>
</td>
<td class="nump">4,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">11,951<span></span>
</td>
<td class="nump">5,092<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">4,259<span></span>
</td>
<td class="num">(615)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(89,335)<span></span>
</td>
<td class="num">(35,326)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(6,399)<span></span>
</td>
<td class="num">(540)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInJointVenture', window );">Investment in joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(6,399)<span></span>
</td>
<td class="num">(590)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of Series B convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of common stock in initial public offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="nump">183<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">183<span></span>
</td>
<td class="nump">304,044<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(95,551)<span></span>
</td>
<td class="nump">268,128<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at beginning of year</a></td>
<td class="nump">276,316<span></span>
</td>
<td class="nump">8,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">180,765<span></span>
</td>
<td class="nump">276,316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_CashReceivedForInterest', window );">Cash received for interest</a></td>
<td class="nump">2,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for taxes</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment in accounts payable and accrued expenses</a></td>
<td class="nump">4,479<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use asset obtained in exchange for operating lease liabilities</a></td>
<td class="nump">14,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">179,293<span></span>
</td>
<td class="nump">274,735<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">1,472<span></span>
</td>
<td class="nump">1,581<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash shown in the statement of cash flows</a></td>
<td class="nump">$ 180,765<span></span>
</td>
<td class="nump">$ 276,316<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_CashReceivedForInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received for interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_CashReceivedForInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_NonCashGainLossFromEquityMethodInvestmentInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash gain (loss) from equity method investment in joint venture.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_NonCashGainLossFromEquityMethodInvestmentInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_NonCashResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Cash Research and Development Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_NonCashResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079021349632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Disclosure Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of Business</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. Description </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Nature of Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pyxis Oncology, Inc. (the &#8220;Company&#8221;), a Delaware corporation, was founded in June 2018 and launched its operations in July 2019. The Company is a clinical stage company focused on defeating difficult-to-treat cancers. The company is efficiently building next-generation therapeutics that hold the potential for mono and combination therapies. The Company's therapeutic candidates are designed to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. The Company's antibody-drug conjugates ("ADCs") and immuno-oncology ("IO") programs employ novel and emerging strategies to target a broad range of solid tumors resistant to current standards of care.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> operating segment. The Company&#8217;s chief operating decision maker, its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for the purposes of assessing performance and allocating resources.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079017755920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2. Basis of Presentation and Summary of Significant Accounting Policies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s fiscal year ends on December 31 and its first three quarters end on March 31, June 30 and September 30. The accompanying consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). The consolidated financial statements include the Company and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated upon consolidation.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Section 107(b) of the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company has irrevocably elected not to avail itself of this extended transition period, and, as a result, the Company will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liquidity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the Company had an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">212.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The Company has incurred losses and negative cash flows from operations since inception, including net losses of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended December 31, 2022 and 2021, respectively.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has not generated any revenue to date and does not anticipate generating any revenues unless and until it successfully completes development and obtains regulatory approval for its current or any future product candidates. The Company expects that its operating losses and negative cash flows will continue for the foreseeable future as the Company continues to expand its research and development programs and develop its product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company currently expects that its existing cash and cash equivalents of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">179.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of December 31, 2022 will fund its operating expenses and capital requirements at least twelve months from the date these audited consolidated financial statements are issued. Additional funding may be necessary to fund future clinical and preclinical activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company plans to continue to fund its losses from operations and capital funding needs through public or private equity, convertible or debt financing or other sources. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, or suspend or curtail planned programs. Any of these actions could materially harm the Company&#8217;s business, results of operations and future prospects.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expense, and related disclosures. The Company regularly evaluates estimates and assumptions related to assets, liabilities, stock-based compensation, operating leases, assessment of the useful lives of property and equipment, valuation of deferred tax assets and liabilities, impairment of investment in joint venture, and research and development costs. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Actual results could differ from those estimates and there may be changes to management&#8217;s estimates in future periods.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is subject to risks common to early-stage companies in the biopharmaceutical industry including, but not limited to, uncertainties related to commercialization of products, regulatory approvals, dependence on key suppliers for active ingredients and third-party service providers such as contract research and manufacturing organizations, protection of intellectual property rights and the ability to make milestone, royalty or other payments due under any license, collaboration or supply agreements.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risks</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company&#8217;s cash and cash equivalents are held at an accredited financial institution and the Company has not experienced any losses in such accounts. The Company maintains its cash in bank deposit accounts, which at times may exceed federally insured limits. The Company&#8217;s cash equivalents consist primarily of short-term money market funds held in accredited financial institutions. The Company believes it is not exposed to any significant risk in cash and cash equivalents.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers all short term, highly liquid investments with original maturities of 90 days or less to be cash equivalents. Cash equivalents consist primarily of money market funds as of December 31, 2022 and 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value Measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principle or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, the first two are considered observable and the last is considered unobservable:</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> 1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> 2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;Quoted prices in markets that are not considered to be active or financial instrument valuations for which all significant inputs are observable, either directly or indirectly; and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> 3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment, net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment are recorded at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful lives of the related assets as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:73.0%;"/>
          <td style="width:2.037%;"/>
          <td style="width:24.963%;"/>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated Useful<br/>Life (Years)</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and office equipment</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shorter of remaining life<br/>of lease or useful life</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Construction in process</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">N/A</span></p></td>
         </tr>
        </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and amortization expense is included in research and development and general and administrative expenses. Major additions and upgrades are capitalized; maintenance and repairs, which do not improve or extend the life of the respective assets, are expensed as incurred. Upon retirement or sale, the cost of assets disposed of, and the related accumulated depreciation and amortization are removed from the respective accounts and any resulting gain or loss is included in income (loss) from operations.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company evaluates the long-lived assets, which consist of property and equipment and operating lease right-of-use assets, for impairment at least annually and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. Management then determines whether the remaining useful life continues to be appropriate, or whether there has been an impairment of long-lived assets based primarily upon whether expected future undiscounted cash flows are sufficient to support the assets&#8217; recovery. Recoverability of these assets is measured by comparison of the carrying amount of the asset to the future undiscounted cash flows the asset is expected to generate. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. The Company recognized </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> impairment losses for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">lease right-of-use (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset during the lease term, and operating lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease ROU assets and lease liabilities are initially recognized and measured based on the present value of the future fixed lease payments over the expected lease term at the commencement date calculated using the Company&#8217;s incremental borrowing rate applicable to the lease asset, unless the implicit rate is readily determinable. The Company determines the lease term as the non-cancelable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease ROU assets also include any initial direct costs incurred and any lease payments made on or before the lease commencement date, less lease incentives received. Operating lease ROU assets are subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Leases with a term of 12 months or less are not recognized on the consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Variable lease costs such as common area costs and other operating costs are expensed as incurred. The Company accounts for lease and non-lease components as a single lease component for all its facilities leases. The Company had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> finance leases as of December 31, 2022 and 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Investment in Joint Venture</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investment in the Company&#8217;s joint venture is accounted for using the equity method of accounting. The Company applies the equity method of accounting to investments when the Company has significant influence, but not controlling interest in the investee. Judgment regarding the level of influence over equity method investment includes considering key factors such as ownership interest, representation on the board of directors, participation in policy-making decisions and material intercompany transactions. Under the equity method, investments are initially recorded at cost and are adjusted for dividends, distributed and undistributed earnings and losses, and additional investments. In the event the Company&#8217;s share of a joint venture&#8217;s cumulative losses exceeds the Company&#8217;s investment balance, the balance is reported at zero value until proportionate income exceeds the losses. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company assesses investments for impairment whenever events or changes in circumstances indicate that the carrying value of an investment may not be recoverable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Contingencies</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company, from time to time, may be a party to various disputes and claims arising from normal business activities. The Company continually assesses disputes and claims including resulting litigation to determine if an unfavorable outcome would lead to a probable loss or reasonably possible loss which could be estimated. The Company accrues for all contingencies at the earliest date at which the Company deems it probable that a liability has been incurred and the amount of such liability can be reasonably estimated. If the estimate of a probable loss is a range and no amount within the range is more likely than another, the Company accrues the minimum of the range. In the cases where the Company believes that a reasonably possible loss exists, the Company discloses the facts and circumstances of the contingencies, including an estimable range, if possible.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company expenses research and development costs as incurred. The Company&#8217;s research and development expenses consist primarily of license fees to acquire intellectual property which does not meet the definition of intangible assets and costs incurred in performing research and development activities, including personnel-related expenses such as salaries, stock-based compensation and benefits, facilities costs, depreciation as well as external costs from third parties who conduct research and development activities (including manufacturing) on behalf of the Company. The Company accrues expenses related to development activities performed by third parties based on an evaluation of services received and efforts expended pursuant to the terms of the contractual arrangements. Payments under some of these contracts depend on preclinical and/or clinical trial milestones. There may be instances in which payments made to the Company&#8217;s vendors will exceed the level of services provided and result in a prepayment of expenses. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company adjusts the accrual or prepaid expense accordingly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company maintains an equity incentive plan as a long-term incentive for employees, consultants, and directors. The Company accounts for all stock-based awards granted to employees and non-employees based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. The grant date fair value of the stock-based awards with graded vesting is recognized on a straight-line basis over the requisite service period. The Company recognizes forfeitures related to stock-based compensation awards as they occur and reverses any previously recognized compensation cost associated with forfeited awards in the period the forfeiture occurs. The Company classifies stock-based compensation expense in the statement of operations in the same manner in which the award recipients&#8217; payroll costs are classified or in which the award recipients&#8217; service payments are classified.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company values its stock options with service conditions using the Black-Scholes option-pricing model. The Company uses certain assumptions to determine fair value of the stock options pursuant to the Black-Scholes option-pricing model, including the expected life of the award, volatility of the underlying shares, the risk-free interest rate, expected dividend yield and the fair value of the Company&#8217;s common stock. Since the Company lacks sufficient historical option exercise data to provide a reasonable basis upon which to estimate the expected term, the Company uses the simplified method described in the SEC&#8217;s Staff Accounting Bulletin No. 107, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Share-Based Payment </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(&#8220;SAB 107&#8221;), to determine the expected life of the option grants. The Company lacks sufficient company-specific historical and implied volatility information. Therefore, the Company estimates the expected stock volatility based on the historical volatility of a publicly traded set of peer companies. The risk-free interest rate is based on the rates paid on securities issued by the U.S. Treasury with a term approximating the expected life of the equity award. As the Company has never paid and does not anticipate paying cash dividends on its common stock, the expected dividend yield is considered as zero.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to the completion of the Company&#8217;s initial public offering ("IPO") of common stock, the fair value of the Company's common stock which is one of the key inputs in Black-Scholes option-pricing model, was determined by the board of directors with input from management and based on certain assumptions including probability weighting of events, business and market conditions, volatility, time to liquidation, a risk-free interest rate and an assumption for a discount for lack of marketability. The Company used 409A valuations to determine the fair value of the shares of common stock. The 409A valuations were performed using methodologies, approaches, and assumptions consistent with the American Institute of Certified Public Accountants </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. After completion of the IPO on October 8, 2021, the Company uses the fair value of its publicly traded common stock to determine grant date fair value.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for income taxes in accordance with FASB ASC 740, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (&#8220;ASC 740&#8221;), which requires the use of the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between amounts in the consolidated financial statements and the tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income tax (benefit) expense in the consolidated statements of operations and comprehensive loss in the period that includes the enactment date.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes deferred tax assets to the extent that it believes these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Loss per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net income (loss) per share attributable to common stockholders is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the diluted weighted average number of common shares outstanding for the period, including potential dilutive common shares.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In periods in which the Company reports a net loss, all common stock equivalents are deemed anti-dilutive such that basic net loss per common share and diluted net loss per common share are equivalent. Potentially dilutive common stock has been excluded from the diluted net loss per common share computations in all periods presented because such securities have an anti-dilutive effect on net loss per common share due to the Company&#8217;s net loss. There are no reconciling items used to calculate the weighted-average number of total common stock outstanding for basic and diluted net loss per common share data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recently Issued Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2016, the FASB issued ASU 2016-13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (&#8220;ASU 2016-13&#8221;), which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss model that requires the use of forward-looking information to calculate credit loss estimates. It also eliminates the concept of other-than-temporary impairment and requires credit losses on available-for-sale debt securities to be recorded through an allowance for credit losses instead of as a reduction in the amortized cost basis of the securities. For "emerging growth companies", ASU 2016-13 is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. The Company is currently evaluating the new standard and expects it to have no material impact on the Company's consolidated financial statements and related disclosures.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2020, the FASB issued ASU 2020-06, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(&#8220;ASU 2020-06&#8221;). ASU 2020-06 revises the guidance on calculating earnings per share, requiring use of the if-converted method for all convertible instruments and rescinding an entity&#8217;s ability to rebut the presumption of share settlement for instruments that may be settled in cash or other assets. As an "emerging growth company", ASU 2020-06 will become effective for the Company for fiscal years beginning after December 15, 2023, and early adoption is permitted. The Company is currently evaluating the new standard and expects it to have no material impact on the Company's consolidated financial statements and related disclosures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recent authoritative guidance issued by the FASB (including technical corrections to the ASC), the American Institute of Certified Public Accountants, and the SEC did not, or are not expected to, have a material impact on the Company&#8217;s audited consolidated financial statements and related disclosures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079017712912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_LicenseAgreementsAbstract', window );"><strong>License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_LicensingAgreementsTextBlock', window );">Licensing Agreements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3. Licensing Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The University of Chicago Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2020, the Company entered into a license agreement (the &#8220;University License Agreement&#8221;), as well as a sponsored research agreement, with the University of Chicago (the &#8220;University&#8221;). Under the terms of the license, the Company has the global right to develop and commercialize products that are covered by a valid claim of a licensed patent, incorporate or use the licensed know-how and materials or are known to assess, modulate or utilize the activity of certain specified biological targets. In partial consideration for the license from the University, the Company issued to the University </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48,919</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock in 2020.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursua</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">nt to the University License Agreement, the Company is obligated to pay potential development and commercial milestones of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as well as running royalties on net sales of licensed products at varying rates ranging from less than a percent to the low single digits, subject to a minimum annual royalty of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during certain years following the effective date. The Company is also obligated to pay the University a percentage of certain sublicensing revenue ranging from low- to mid-teens based on the date of entering into the applicable sublicense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company assessed the milestone and royalty events under University License Agreement as of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and 2021, and determined that </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> such amounts were required.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Pfizer Inc. Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2020, the Company entered into a license agreement (as amended, the &#8220;Pfizer License Agreement&#8221;) with Pfizer Inc. (&#8220;Pfizer&#8221;) for worldwide development and commercialization rights to ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates. The Company&#8217;s rights are exclusive with respect to certain patents owned or controlled by Pfizer covering the licensed ADCs. Pfizer has also granted the Company a non-exclusive license to use Pfizer&#8217;s ADC technology (&#8220;FACT&#8221;) platform. The initial licensed targets include CD123 and extra domain B (EDB of fibronectin) and the Company has the option to expand the scope of its license to add additional licensed targets that have not been licensed to a third party or are not the subject of a Pfizer ADC development program. The Pfizer License Agreement became effective in March 2021 and the Company paid a combined $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the license fee, consisting of an upfront cash payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,152,145</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Series B convertible preferred stock, which was converted into </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,911,015</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock upon the IPO in October 2021, with a value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to Pfizer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On October 6, 2022, the Company entered into an amended and restated license agreement (the &#8220;A&amp;R License Agreement&#8221;) with Pfizer, which amends and restates the Pfizer License Agreement. Pursuant to the A&amp;R License Agreement, Pfizer granted to the Company exclusive worldwide rights under Pfizer&#8217;s FACT Platform technology to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates. Additional ADC targets may be licensed for a nominal upfront payment and milestones. Further, the Company granted the right of first negotiation to Pfizer, on an exclusive basis, to purchase or to develop, manufacture and commercialize licensed ADCs and licensed products in one or more countries directed to EDB and CD123. In accordance with the terms of the A&amp;R License Agreement, the Company agreed to pay $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to Pfizer (which was paid in January 2023) and issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,229,654</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock. Additionally, the Company will issue such number of shares of common stock </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">180</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> days following the effective date (the &#8220;Issuance Date&#8221;), equivalent to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million at a per share price equal to the closing price of the Company&#8217;s common stock on the business day prior to the Issuance Date, such that Pfizer&#8217;s ownership interest in the Company shall not exceed nineteen and a half percent (</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%) with any difference in value between the value of shares and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million being payable in cash. The Company recorded $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as research and development expenses for the A&amp;R License Agreement during fourth quarter of the calendar year 2022.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is also obligated to pay future contingent payments including development, regulatory and commercial milestones up to an aggregate of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">665</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the first four licensed ADCs. In addition, the Company is required to pay future contingent payments including development, regulatory and commercial milestones for ADCs to each additional licensed target beyond the first four licensed ADC targets developed and commercialized via the FACT Platform. Additionally, if ADC licensed products are launched, the Company will pay Pfizer tiered royalties on net sales of licensed products in varying royalty rates ranging from low single digits to mid-teens. The Company&#8217;s royalty obligations apply on a licensed product-by-licensed product and country-by-country basis from first commercial sale until the latest to occur of: (1) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years from first commercial sale; (2) the expiration of all regulatory or data exclusivity; and (3) the expiration of the last valid claim of a licensed patent covering the licensed product in a country. The Company is also obligated to pay Pfizer a percentage of certain sublicensing revenue ranging from twenty percent to low-double digits based on the stage of development of the licensed product at the time of entering into the applicable sublicense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company assessed the milestone and royalty events under A&amp;R License Agreement as of December 31, 2022 and 2021, and determined that </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> such amounts were required.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">LegoChem Biosciences, Inc. Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2020, the Company entered into a license agreement (the &#8220;LegoChem License Agreement&#8221;) and an opt-in, investment and additional consideration agreement (the &#8220;Opt-In Agreement&#8221;) with LegoChem Biosciences, Inc. (&#8220;LegoChem&#8221;). Pursuant to the LegoChem License Agreement, the Company obtained worldwide (other than Korea) license for development and commercialization rights for LCB67, an ADC product candidate targeting DLK-1, and products containing the licensed compound. The Company paid $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in March 2021 to LegoChem, which was recorded as research and development expenses. Additionally, the Company may purchase certain initial quantities of licensed products from LegoChem for an estimated cost of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is obligated to make future contingent payments including development, regulatory and commercial milestones as well as running royalties on net sales of licensed products at varying rates. During the year ended December 31, 2022, the Company stopped the continued development of LCB67, based on review and analysis of data from the toxicity studies, and anticipated clinical use and commercial prospects of anti-DLK1 ADC. Due to stoppage of clinical development of LCB67, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> amounts were due and payable related to the manufacturing of the initial quantities of licensed product as well as the milestones and royalties related to LCB67 ADC of December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, as part of the Opt-in Agreement, LegoChem had an option to pay $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to the Company, in exchange for the right to receive a milestone payment (the &#8220;Extra Milestone Payment&#8221;) of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million upon the earliest to occur of certain events, including the date of pricing or offer of the first public offering of its common stock or if the Company is the subject of a change in control transaction. The Company determined that the Extra Milestone Payment met the definition and recognition condition of derivative under ASC 815, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#8220;Derivatives and Hedging&#8221; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for which there was a binding contract and firm commitment in January 2021. An initial derivative liability was recognized for $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million with an offset to research and development expenses in January 2021. The derivative liability was re-measured at each reporting date, and as a result, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was recorded in &#8220;Other income (expense)&#8221; in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2021. The liability was realized upon the IPO of the Company and Extra Milestone Payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was paid to LegoChem in January 2022. The Company has no further obligations under the Opt-In Agreement as of December 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">License Agreement with Biosion USA, Inc.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 28, 2022, the Company entered into a license agreement (the &#8220;Biosion License Agreement&#8221;) with Biosion USA, Inc. ("Biosion"), pursuant to which the Company obtained an exclusive, worldwide (other than Greater China (mainland China, Hong Kong, Macau and Taiwan)) license for development, manufacture and commercialization rights for BSI-060T, a Siglec-15 targeting antibody, an IO product candidate (now referred to as PYX-106), and products containing the licensed compound. Under the terms of the Biosion License Agreement, each party granted to the other party a right of first offer to obtain an exclusive license in the other party&#8217;s territory (Greater China for Biosion, and the rest of the world for Pyxis) to develop, manufacture and commercialize any bi-specific or multi-specific antibody any antibody-drug conjugate controlled by a party or its affiliate that inhibits, modulates or binds to Siglec-15 as an intended mechanism of action.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the Biosion License Agreement, the Company paid an upfront license fee of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which was recorded as research and development expenses. The Company is also obligated to pay future contingent payments including development, regulatory and commercial milestones up to an aggregate of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">217.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in case of normal approval and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">222.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in case of accelerated approval. Additionally, if products are launched, the Company will pay Biosion tiered royalties on net sales of licensed products in varying royalty rates ranging from low single digits to low teens. The Company&#8217;s royalty obligations apply on a licensed product-by-licensed product and country-by-country basis from first commercial sale until the latest to occur of: (1) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years from first commercial sale; (2) the expiration of all regulatory or data exclusivity; and (3) the expiration of the last valid claim of a licensed patent covering the licensed product in a country. The Company is also obligated to pay Biosion a percentage of certain sublicensing revenue ranging from mid-double to low-double digits based on the stage of development of the licensed product at the time of entering into the applicable sublicense.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company assessed the milestone and royalty events involving Biosion as of December 31, 2022 and determined that </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> such amounts were required.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_LicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_LicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_LicensingAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Licensing agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_LicensingAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079017852400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Joint Venture<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Joint Venture</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4. Joint Venture</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2021, the Company entered into definitive transaction agreements with Alloy Therapeutics, Inc. (&#8220;Alloy&#8221;) and Voxall Therapeutics, LLC (&#8220;Voxall&#8221;), to finance and operate Voxall, a joint venture company formed in collaboration with Alloy to leverage the Company&#8217;s technology and Alloy&#8217;s ATX-Gx</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:5.025pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#153; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">platform and antibody discovery services. Voxall granted to the Company and Alloy, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the voting membership units of Voxall in exchange for certain initial contributions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounted for investment in Voxall under the equity method of accounting. Voxall has incurred losses since inception and the Company&#8217;s share in the losses of Voxall aggregated to</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">million for the years ended December 31, 2022 and 2021, respectively. The Company recognized its share of losses of Voxall only to the extent of the carrying value of its</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">investment in Voxall and the promissory note issued by Voxall, which aggregated to</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">million for the year ended December 31, 2021. The remaining unabsorbed loss will be offset against future income, if any. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As the Company has no commitment to fund the losses of the equity method investment, the carrying value of the equity method investment has not been reduced below zero</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI https://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079017816064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5. Fair Value Measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:4.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables present the financial instruments carried at fair value on a recurring basis as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, respectively, in accordance with the FASB ASC 820 hierarchy (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:4.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.699%;"/>
        <td style="width:1.23%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.995000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.23%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.995000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.23%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.995000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.23%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.395000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements at<br/>December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">177,279</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">177,279</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements at<br/>December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">272,210</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">272,210</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s cash equivalents represent deposits in a short-term United States Treasury money market fund quoted in an active market and classified as a Level 1 asset. There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> assets or liabilities measured at fair value on a nonrecurring basis at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021. There were no transfers between Level 1 and Level 2 of the fair value hierarchy during the years ended December 31, 2022 and 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recorded the derivative liability of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in January 2021 for Extra Milestone Payment due under the Opt-in Agreement with LegoChem. The fair value of the derivative liability was initially determined using a probability-weighted income approach and revalued at each reporting date. Changes in the fair value of the derivative liability of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million were recorded as expense within other (expense) income in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2021. The significant unobservable inputs used in the fair value measurement of the derivative liability include probability of payment factors and the discount rate. The liability was realized upon the IPO of the Company and Extra Milestone Payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was paid to LegoChem in January 2022. Refer to Note 3, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Licensing Agreements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, for additional information on the derivative liability.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Level 3 assets or liabilities as of December 31, 2022 and 2021.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079014165856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6. Prepaid Expenses and Other Current Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.065%;"/>
        <td style="width:1.622%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.645999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.622%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.043999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,560</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">619</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Insurance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,308</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,763</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued interest receivable</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">598</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">381</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,847</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,466</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079017567280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7. Property and Equipment, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net, consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.932%;"/>
        <td style="width:1.619%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.818%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.619%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.012%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,247</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,804</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and office equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,036</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">530</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">225</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Construction in process</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,177</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,990</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,123</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: accumulated depreciation and amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,825</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,116</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,165</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,007</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation and amortization expense for the years ended December 31, 2022 and 2021 was</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">million, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079017714576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8. Accrued Expenses and Other Current Liabilities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses and other current liabilities consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.065%;"/>
        <td style="width:1.622%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.645999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.622%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.043999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,414</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,381</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee compensation and benefits</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,238</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,963</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Legal and professional fees</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,794</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">982</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,091</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">266</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,537</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,592</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079014103648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Operating Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9. Operating Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2021, the Company entered into an operating lease agreement, with a lease term commencement date of April 1, 2022, the date the Company took control of the property, for an office and laboratory space in Boston, Massachusetts. The lease payments began on December 21, 2022 and will continue through </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2032</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and with scheduled rent increases each year of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%. In addition to the rent, the Company bears the costs of certain insurance, property taxes and maintenance, which represent the Company&#8217;s proportionate share of the actual expenses incurred by the landlord. There is an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">option to extend the lease beyond December 31, 2032.</span></span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At the lease commencement date, the operating lease ROU assets of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and lease liabilities of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million were recognized based on the present value of remaining fixed lease payments over the expected lease term using an incremental borrowing rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%. As the Company&#8217;s operating lease does not provide an implicit rate, an estimated incremental borrowing rate based on the information available at the time of lease commencement date was used in determining the present value of lease payments. Under the lease agreement the landlord provided for a tenant improvement allowance of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to be applied to the costs of the construction of the leasehold improvements, of which $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was received by the Company during the year ended December 31, 2022. The tenant improvement allowance is recognized as a reduction in operating lease ROU assets and lease liabilities on the lease commencement date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of lease expense were as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.492%;"/>
        <td style="width:1.608%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.151%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.608%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.142%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,978</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">650</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,681</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Variable lease cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">121</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,780</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">730</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other information</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease right-of-use asset obtained in exchange for new operating<br/>&#160;&#160;&#160;lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,497</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities, included<br/>&#160;&#160;&#160;in operating cash flows</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">663</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average remaining lease term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.00</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.25</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.40</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.00</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Variable lease costs primarily relate to common area costs and other operating costs</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which are assessed based on the Company&#8217;s proportionate share of such costs for the leased premises. Total lease costs are included as operating expenses in the Company&#8217;s consolidated statements of operations and comprehensive loss.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturities of lease liabilities as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, were as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:75.252%;"/>
        <td style="width:2.082%;"/>
        <td style="width:1.0%;"/>
        <td style="width:20.667%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ending December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating Leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,557</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,208</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,302</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,399</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,499</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,750</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total undiscounted payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34,715</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: tenant improvement allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: present value adjustment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,768</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Present value of future payments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,921</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: current portion of operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, net of current portion</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,921</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079014103648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Convertible Preferred Stock</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10. Convertible Preferred Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Series A Convertible Preferred Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2019, the Company entered into a securities purchase agreement (as amended, &#8220;Series A Agreement&#8221;) with certain investors to sell shares of Series A convertible preferred stock (&#8220;Series A&#8221;) at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.9681</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. In June and July 2019, the Company issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,724,925</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Series A to institutional investors at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.9681</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share for gross cash proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, less issuance costs of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, resulting in net proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. On October 1, 2021, the Company effected a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_21fd044a-b819-46e1-b788-a6db20d760e8;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1-for-6.359</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> reverse stock split</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Upon completion of the IPO, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,724,925</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Series A were converted to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,573,659</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Series B Convertible Preferred Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 5, 2021, the Company entered into a securities purchase agreement (as amended, &#8220;Series B Agreement&#8221;) with certain investors to sell shares of Series B convertible preferred stock (&#8220;Series B&#8221;) at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.6458</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. In March 2021, the Company issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92,356,299</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Series B to institutional investors at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.6458</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share for gross cash proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">152.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, less issuance costs of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, resulting in net proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">151.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. In addition, the Company granted </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,455,949</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares, or $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, of Series B convertible preferred stock through separate agreements with Pfizer and LegoChem. On October 1, 2021, the Company effected a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_2c1f21b5-66b1-456a-be0d-8b2e18d9a8f1;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1-for-6.359</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> reverse stock split</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Upon completion of the IPO, the entire outstanding shares of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104,812,248</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of Series B were converted to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,482,486</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079017722672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stockholders&#8217; Equity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Preferred Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the closing of the IPO, the Company filed an Amended Certificate of Incorporation and authorized </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of preferred stock, with a par value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. The board of directors has the authority, without further action by the stockholders to issue such shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, and to fix the dividend, dividend rights, conversion rights, voting, redemption terms, liquidation preference and other rights, preferences and privileges of the shares. There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> issued and outstanding shares of preferred stock as of December 31, 2022 and 2021, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Initial Public Offering</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On October 8, 2021, the Company completed an IPO in which the Company issued and sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,500,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock at a public offering price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, for aggregate gross proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">168.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The Company raised approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">152.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in net proceeds after deducting underwriting discounts and commissions of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and offering expenses of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company was authorized to issue up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">190,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock as of December 31, 2022 and 2021, respectively, of which </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,110,016</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,792,867</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares were issued as of December 31, 2022 and 2021, respectively, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34,958,730</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,222,881</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares were outstanding at December 31, 2022 and 2021, respectively.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Voting, dividend and liquidation rights of the holders of the common stock are subject to and qualified by the rights, powers and preferences of the holders of the preferred stock.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Voting</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;Each holder of outstanding shares of common stock shall be entitled to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> vote in respect of each share.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Reserved Shares</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company reserved the following shares of common stock for issuance:</span></span></p><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:94.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60.207%;"/>
        <td style="width:1.205%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.502%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.215%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.871%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,720,415</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,926,969</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted stock awards</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,015,387</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">618,494</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options available for issuance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,697,166</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,289,259</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee stock purchase plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">752,524</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">424,595</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,185,492</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,259,317</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079017592912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12. Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2022 Equity Inducement Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On July 1, 2022, the Company&#8217;s board of directors approved the 2022 Equity Inducement Plan (the &#8220;2022 Plan&#8221;), which became effective on that date. The 2022 Plan allows the Company to make equity-based incentive awards to its officers and employees without stockholder approval pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules, or any successor rule relating to inducement awards. Unless earlier terminated by the Board, 2022 Plan will terminate on the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_2078513f-c53f-43d5-970f-e0c43d587906;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ten</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">th anniversary of the effective date. The Company has initially reserved </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,400,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock for the issuance of awards under the 2022 Plan. As of December 31, 2022, options to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">400,692</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">320,550</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> restricted stock units were outstanding under the 2022 Plan and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">678,758</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares remained available for future issuance under the 2022 Plan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2021 Equity Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On September 27, 2021, the Company&#8217;s board of directors and stockholders approved the 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;), which became effective on October 7, 2021, when the Company&#8217;s registration statement was declared effective by the SEC. The 2021 Plan allows the Company to make equity-based and cash-based incentive awards to its officers, employees, directors and consultants. The Company has initially reserved </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,852,807</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock for the issuance of awards under the 2021 Plan. The number of shares of common stock reserved for issuance under the 2021 Plan will automatically increase annually on the first day of each fiscal year, beginning with the fiscal year ending December 31, 2022, and continuing until (and including) the fiscal year ending December 31, 2031 by the lesser of (i) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the total number of shares of common stock outstanding on December 31st of the immediately preceding fiscal year and (ii) the number of shares as may be determined by the board of directors. As a result of the evergreen provision of the 2021 Plan, the Company added an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,639,643</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock to the 2021 Plan as of January 1, 2022. The maximum number of shares of common stock that may be issued pursuant to the exercise of incentive options under the 2021 Plan is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,705,614</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unless earlier terminated by the Board, 2021 Plan will terminate on the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_41e41108-0a2f-4aeb-862b-b3c3f3023412;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ten</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">th anniversary of the effective date. As of December 31, 2022, options to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,668,700</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,449,172</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> restricted stock units were outstanding under the 2021 plan and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">360,924</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares remained available for future issuance under the 2021 plan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2019 Equity Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2019, the Company established the 2019 Equity Incentive Plan (the "2019 Plan"), under which the Company is allowed to grant options and restricted stock to its employees and non-employees. The maximum number of shares of common stock reserved for issuance under the 2019 Plan is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,042,408</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares. Options granted under the 2019 Plan include incentive stock options that can be granted only to the Company&#8217;s employees and non-statutory stock options that can be granted to the Company&#8217;s employees, consultants, advisors and directors. The 2019 Plan also permits the Company to issue restricted stock awards. Unless earlier terminated by the Board, the 2019 Plan will terminate on the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_41c663ee-99b7-4ec5-8325-a97c8245ffa8;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ten</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">th anniversary of the effective date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to the IPO, the exercise prices, vesting and other restrictions of the awards granted under the 2019 Plan were determined by the board of directors, except that no stock option may be issued with an exercise price less than the fair market value of the common stock at the date of the grant or have a term in excess of ten years. Options granted under the 2019 Plan are exercisable in whole or in part at any time subsequent to vesting. As of December 31, 2022, options to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,651,023</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94,379</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> restricted stock units were outstanding under the 2019 Plan and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">657,484</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares remained available for future issuance under the 2019 Plan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2021 Employee Stock Purchase Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On September 27, 2021, the Company&#8217;s board of directors and stockholders approved the 2021 Employee Stock Purchase Plan (the &#8220;2021 ESPP&#8221;), which became effective on October 7, 2021, when the Company&#8217;s registration statement was declared effective by the SEC. The 2021 ESPP initially reserved and authorized the issuance of up to a total of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">424,595</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock to participating employees. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The number of shares of common stock reserved for issuance under the ESPP will automatically increase annually on the first day of each fiscal year, beginning with the fiscal year ending December 31, 2022, and continuing until (and including) the fiscal year ending December 31, 2031 by the lesser</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of (1) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the total number of shares of common stock outstanding on December 31st of the immediately preceding fiscal year and (ii) the number of shares as may be determined by the board of directors.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> As a result of the evergreen provision of the 2021 ESPP, the Company added an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">327,929</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock to the 2021 ESPP as of January 1, 2022. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares are issued under 2021 ESPP plan as of the date of issuance of these consolidated financial statements.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the authorized number of shares and shares available for issuance under the 2021 ESPP is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">752,524</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock Options</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options granted under the 2022 Plan, 2021 Plan and 2019 Plan (together, the &#8220;Plans&#8221;) to employees generally vest over </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and expire after </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10 years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes stock option activity for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 (in thousands, except share and per share amounts):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.137%;"/>
        <td style="width:0.069%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.744000000000002%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.069%;"/>
        <td style="width:1.0%;"/>
        <td style="width:5.943%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.069%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.295%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.208%;"/>
        <td style="width:1.0%;"/>
        <td style="width:7.465%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br/>Options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at January 1, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,926,969</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.03</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.5</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,414</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,178,280</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.06</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73,841</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.48</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">834,095</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.24</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expired</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">476,898</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.51</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,720,415</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.68</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.8</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercisable at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,037,934</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.34</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.5</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted-average grant-date fair value of options granted during the years ended December 31, 2022 and 2021, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.06</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.57</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">per share, respectively. The aggregate intrinsic value is calculated as the difference between the exercise price of all </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">outstanding and exercisable stock options and the fair value of the Company&#8217;s common stock of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.34</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share as of December 31, 2022. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2022 and 2021 was less than $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company estimated the fair value of each option on the date of grant using the Black-Scholes option-pricing model applying the range of assumptions in the following table:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.065%;"/>
        <td style="width:2.019%;"/>
        <td style="width:27.843%;"/>
        <td style="width:2.019%;"/>
        <td style="width:19.037%;"/>
        <td style="width:2.019%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96.09</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.66</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72.88</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">103.41</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.60</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.02</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.81</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.36</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.00</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.11</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.25</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.00</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense related to stock options recorded in the statements of operations is as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.847%;"/>
        <td style="width:2.298%;"/>
        <td style="width:1.0%;"/>
        <td style="width:21.929%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.298%;"/>
        <td style="width:1.0%;"/>
        <td style="width:22.328%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.298%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,330</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,396</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,617</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,976</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,947</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,372</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has an aggregate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">million of gross unrecognized stock-based compensation expense as of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, remaining to be amortized over a weighted average period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.29</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years. The Company has not recognized and does not expect to recognize in the near future, any tax benefit related to employee stock-based compensation expense as a result of the full valuation allowance related to its net deferred tax assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Stock Awards</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the 2019 Plan, 2021 Plan and 2022 Inducement Plan, the Company issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,174,656</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> restricted stock units ("RSU") to employees and non-employees. Compensation costs related to these RSUs were recorded based on the Company's stock price on the date of issuance and amortized over the service period.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, the Company issued certain shares of restricted common stock ("RSA") to the employee co-founders and certain non-employee consultants in 2019. The shares of restricted common stock were issued pursuant to standalone restricted stock purchase agreements that are independent of the 2019 Plan, 2021 Plan and 2022 Inducement Plan. The shares of restricted common stock pursuant to standalone restricted stock purchase agreements carried a purchase price equivalent of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.01</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. As of December 31, 2022, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">151,286</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> RSAs were unvested and outstanding</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of the restricted stock purchase agreements, the Company has a repurchase option whereby it has the right to repurchase any unvested shares upon termination at a price per share equal to the lesser of (i) the fair market value of the Company&#8217;s common stock on the date of repurchase and (ii) the original purchase price. The shares of restricted common stock issued to the Company&#8217;s co-founders and non-employee consultants vest based on a predefined number of shares.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognized an associated deposit liability for restricted stock awards issued pursuant to standalone restricted stock purchase agreements upon issuance based on the purchase price of the awards as the unvested shares are subject to repurchase upon termination. As the awards of restricted stock vest, the Company reclassifies the deposit liability to additional paid-in capital. The compensation cost was measured based on the fair value of the underlying common stock less the purchase price of the restricted common stock and the Company recognizes compensation costs over the requisite service period.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes restricted stock activity for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:70.57%;"/>
        <td style="width:1.081%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.265%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.724%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.359%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br/>Average<br/>Grant Date Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-vested at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">618,494</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.04</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,174,656</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.69</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and settled</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">432,354</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.55</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">345,409</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.74</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-vested and unsettled at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,015,387</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.64</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has recorded stock-based compensation expense related to the restricted stock of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended December 31, 2022, and 2021, respectively. The Company has an aggregate $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of gross unrecognized restricted stock-based compensation expense as of December 31, 2022, remaining to be amortized over a weighted average period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.26</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079017775712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13. Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company recorded </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> current or deferred income tax expenses or benefits as the Company has incurred losses since inception and has provided a full valuation allowance against its deferred tax assets.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation of the expected income tax benefit computed using the federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.205%;"/>
        <td style="width:1.161%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.241%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.161%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.232%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax computed at federal statutory rate %</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State taxes, net of federal benefit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.6</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26.6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27.7</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development credit carryovers</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.9</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Permanent differences</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.7</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.9</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective income tax rate %</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company's effective tax rate was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% for the years ended December 31, 2022 and 2021, as a result of the valuation allowance that eliminates the company's net deferred tax assets.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Significant components of the Company&#8217;s net deferred tax assets as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 are as follows (in thousands): </span></span><span style=""/></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.458%;"/>
        <td style="width:1.526%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.049%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.517%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.449%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,108</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,918</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangibles</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax credit carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,674</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,648</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Derivative</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,455</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,577</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,645</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,003</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reserves and accruals</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,105</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">804</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capitalized research expenditures</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,059</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">License fees</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,235</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,716</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liability</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,107</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets before valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61,486</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,811</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57,812</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,748</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,674</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease ROU assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,674</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the Company's federal and state net operating losses ("NOL") in the United States were $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million ($</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million before tax) and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million ($</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million before tax) respectively. The federal net operating loss carryforwards in the United States can be carried forward indefinitely but may be subject to annual usage limitations to the extent certain substantial changes in the entity's ownership occur. The state net operating loss carryforwards begin expiring in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2039</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In addition, as of December 31, 2022, the Company had $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of federal and state credit carryovers which begin to expire in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2039</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. These loss and credit </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">carryforwards are subject to review and possible adjustment by the appropriate taxing authorities.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company assesses the realizability of the deferred tax assets at each balance sheet date based on the available positive and negative evidence in order to determine the amount which is more likely than not to be realized and records a valuation allowance as necessary. Due to the Company's cumulative loss position which provides significant negative evidence, which is difficult to overcome, the Company has recorded a valuation allowance of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of December 31, 2022, representing the portion of the deferred tax asset that is not more likely than not to be realized. For the years ended December 31, 2022 and 2021, the valuation allowance for deferred tax assets increased by $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. The amount of the deferred tax asset considered realizable, could be adjusted for future factors that would impact the assessment of the objective and subjective evidence. The Company will continue to assess the realizability of deferred tax assets at each balance sheet date in order to determine the proper amount, if any, required for a valuation allowance.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Tax Cuts and Jobs Act contained a provision which requires the capitalization of Section 174 costs incurred in the years beginning on or after January 1, 2022. Section 174 costs are expenditures which represent research and development costs that are incident to the development or improvement of a product, process, formula, invention, computer software or technique. This provision changes the treatment of Section 174 costs such that the expenditures are no longer allowed as an immediate deduction but rather must be capitalized and amortized. We have included the impact of this provision, which results in a deferred tax asset of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of December 31, 2022.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The U.S. tax attributes may be subject to an annual limitation under Section 382 of the Internal Revenue Code of 1986 (the &#8220;Code&#8221;), and similar state provisions if the Company experiences one or more ownership changes, which would limit the amount of the tax attributes that can be utilized to offset future taxable income. In general, an ownership change as defined by Section 382, results from the transactions increasing ownership of certain stockholders or public groups in the stock of the corporation of more than fifty percentage points over a three-year period. If a change in ownership occurs in the future, the net operating loss and research and development credit carryforwards could be eliminated or restricted. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. Due to the existence of the valuation allowance, limitations created by future ownership changes, if any, will not impact the Company&#8217;s effective tax rate.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is subject to tax and will continue to file federal income tax returns in the United States as well as in certain state and local jurisdictions. The Company is subject to tax examinations for tax years ended December 31, 2019 and forward in all applicable income tax jurisdictions. Tax audits and examinations can involve complex issues, interpretations and judgements. The resolution of matters may span multiple years particularly if subject to litigation or negotiation. The Company believes that it has appropriately recorded its tax position using reasonable estimates and assumptions, however the potential tax benefits may impact the results of operations or cashflows in the period of resolution, settlement, or when the statutes of limitations expire. The Company does not currently have any reserves related to unrecognized tax benefits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079017672912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14. Net Loss per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic and diluted net loss per share was calculated as follows (in thousands, except share and per share amounts):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:45.492%;"/>
        <td style="width:2.562%;"/>
        <td style="width:1.0%;"/>
        <td style="width:21.324%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.552%;"/>
        <td style="width:1.0%;"/>
        <td style="width:21.518%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.552%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Numerator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120,717</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75,975</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Denominator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average common shares outstanding, basic and diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,033,081</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,493,273</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.65</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.95</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s potentially dilutive securities, which include restricted stock, and stock options, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following potentially dilutive securities have been excluded from the calculation of diluted net loss per common share due to their anti-dilutive effect:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.822%;"/>
        <td style="width:1.434%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.953%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.434%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.356%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options outstanding</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,720,415</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,929,969</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted stock awards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,015,387</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">618,494</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options available for issuance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,697,166</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,289,259</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee stock purchase plan</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">752,524</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">424,595</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,185,492</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,262,317</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079015016224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Parties</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15. Related Parties</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company was founded out of Dr. Thomas Gajewski&#8217;s laboratory at the University of Chicago. In 2020, the Company entered into the License Agreement with the University of Chicago, as well as a sponsored research agreement. The Company incurred $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for the years ended December 31, 2022 and 2021, respectively, with regards to the University License Agreement. Refer to Note 3 for additional discussion.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pfizer owns more than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the Company and is considered the principal owner of the Company. On October 6, 2022, the Company entered into the A&amp;R License Agreement with Pfizer, which amends and restates the previously executed license agreement between Pfizer and the Company. During the year ended December 31, 2022, the Company incurred $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of research and development expenses for the A&amp;R License Agreement. During the year ended December 31, 2021, the Company incurred $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of research and development expenses towards license fee. Refer to Note 3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for additional discussion.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company and Alloy formed a joint venture company, Voxall Therapeutics, LLC (&#8220;Voxall&#8221;) to leverage the Company&#8217;s technology and Alloy&#8217;s ATX-Gx&#153; platform and antibody discovery services. The Company and Alloy contributed $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> thousand each to Voxall along with certain license in 2021. During the year ended December 31, 2022, the Company has not incurred expenses related to Voxall. During the year ended December 31, 2021, the Company provided services to Voxall for which it recognized service fee other income of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">181</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> thousand. Refer to Note 4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for additional discussion.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079017852400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16. Commitments and Contingencies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Legal Proceedings</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, the Company may become involved in various legal proceedings that arise in the ordinary course of business. The Company is not currently a party to any material legal proceedings and is not aware of any pending or threatened legal proceeding against it that the Company believes could have an adverse effect on its business, operating results or financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Commitments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the normal course of business, the Company enters into agreements with various third parties for clinical trials, preclinical research studies and testing, manufacturing and other services and products for operating purposes, which are generally cancellable by the Company at any time, subject to payment of remaining obligations under binding purchase orders and, in certain cases, nominal early-termination fees. These commitments are not deemed significant.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079017809968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17. Subsequent Event</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On February 2, 2023, the Company entered into a sublease agreement for approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,729</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet of office and laboratory space in the building located at 321 Harrison Avenue, Boston, Massachusetts. The sublease is for the fixed period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> months and will expire on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 1, 2025</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company will receive approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in base rent payments over the sublease term. The subtenant will also be responsible for certain other costs under the sublease, such as operating expenses, taxes, insurance, property management fee and utilities.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079016556832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_NatureOfBusinessPolicyTextBlock', window );">Nature of Business</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Nature of Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pyxis Oncology, Inc. (the &#8220;Company&#8221;), a Delaware corporation, was founded in June 2018 and launched its operations in July 2019. The Company is a clinical stage company focused on defeating difficult-to-treat cancers. The company is efficiently building next-generation therapeutics that hold the potential for mono and combination therapies. The Company's therapeutic candidates are designed to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. The Company's antibody-drug conjugates ("ADCs") and immuno-oncology ("IO") programs employ novel and emerging strategies to target a broad range of solid tumors resistant to current standards of care.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> operating segment. The Company&#8217;s chief operating decision maker, its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for the purposes of assessing performance and allocating resources.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s fiscal year ends on December 31 and its first three quarters end on March 31, June 30 and September 30. The accompanying consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). The consolidated financial statements include the Company and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated upon consolidation.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Section 107(b) of the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company has irrevocably elected not to avail itself of this extended transition period, and, as a result, the Company will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_LiquidityPolicyTextBlock', window );">Liquidity</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liquidity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the Company had an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">212.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The Company has incurred losses and negative cash flows from operations since inception, including net losses of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended December 31, 2022 and 2021, respectively.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has not generated any revenue to date and does not anticipate generating any revenues unless and until it successfully completes development and obtains regulatory approval for its current or any future product candidates. The Company expects that its operating losses and negative cash flows will continue for the foreseeable future as the Company continues to expand its research and development programs and develop its product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company currently expects that its existing cash and cash equivalents of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">179.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of December 31, 2022 will fund its operating expenses and capital requirements at least twelve months from the date these audited consolidated financial statements are issued. Additional funding may be necessary to fund future clinical and preclinical activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company plans to continue to fund its losses from operations and capital funding needs through public or private equity, convertible or debt financing or other sources. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, or suspend or curtail planned programs. Any of these actions could materially harm the Company&#8217;s business, results of operations and future prospects.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expense, and related disclosures. The Company regularly evaluates estimates and assumptions related to assets, liabilities, stock-based compensation, operating leases, assessment of the useful lives of property and equipment, valuation of deferred tax assets and liabilities, impairment of investment in joint venture, and research and development costs. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Actual results could differ from those estimates and there may be changes to management&#8217;s estimates in future periods.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_RisksAndUncertaintiesPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is subject to risks common to early-stage companies in the biopharmaceutical industry including, but not limited to, uncertainties related to commercialization of products, regulatory approvals, dependence on key suppliers for active ingredients and third-party service providers such as contract research and manufacturing organizations, protection of intellectual property rights and the ability to make milestone, royalty or other payments due under any license, collaboration or supply agreements.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risks</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company&#8217;s cash and cash equivalents are held at an accredited financial institution and the Company has not experienced any losses in such accounts. The Company maintains its cash in bank deposit accounts, which at times may exceed federally insured limits. The Company&#8217;s cash equivalents consist primarily of short-term money market funds held in accredited financial institutions. The Company believes it is not exposed to any significant risk in cash and cash equivalents.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers all short term, highly liquid investments with original maturities of 90 days or less to be cash equivalents. Cash equivalents consist primarily of money market funds as of December 31, 2022 and 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value Measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principle or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, the first two are considered observable and the last is considered unobservable:</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> 1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> 2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;Quoted prices in markets that are not considered to be active or financial instrument valuations for which all significant inputs are observable, either directly or indirectly; and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> 3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, net</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment, net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment are recorded at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful lives of the related assets as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:73.0%;"/>
          <td style="width:2.037%;"/>
          <td style="width:24.963%;"/>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated Useful<br/>Life (Years)</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and office equipment</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shorter of remaining life<br/>of lease or useful life</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Construction in process</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">N/A</span></p></td>
         </tr>
        </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and amortization expense is included in research and development and general and administrative expenses. Major additions and upgrades are capitalized; maintenance and repairs, which do not improve or extend the life of the respective assets, are expensed as incurred. Upon retirement or sale, the cost of assets disposed of, and the related accumulated depreciation and amortization are removed from the respective accounts and any resulting gain or loss is included in income (loss) from operations.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company evaluates the long-lived assets, which consist of property and equipment and operating lease right-of-use assets, for impairment at least annually and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. Management then determines whether the remaining useful life continues to be appropriate, or whether there has been an impairment of long-lived assets based primarily upon whether expected future undiscounted cash flows are sufficient to support the assets&#8217; recovery. Recoverability of these assets is measured by comparison of the carrying amount of the asset to the future undiscounted cash flows the asset is expected to generate. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. The Company recognized </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> impairment losses for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">lease right-of-use (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset during the lease term, and operating lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease ROU assets and lease liabilities are initially recognized and measured based on the present value of the future fixed lease payments over the expected lease term at the commencement date calculated using the Company&#8217;s incremental borrowing rate applicable to the lease asset, unless the implicit rate is readily determinable. The Company determines the lease term as the non-cancelable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease ROU assets also include any initial direct costs incurred and any lease payments made on or before the lease commencement date, less lease incentives received. Operating lease ROU assets are subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Leases with a term of 12 months or less are not recognized on the consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Variable lease costs such as common area costs and other operating costs are expensed as incurred. The Company accounts for lease and non-lease components as a single lease component for all its facilities leases. The Company had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> finance leases as of December 31, 2022 and 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investment in Joint Venture</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Investment in Joint Venture</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investment in the Company&#8217;s joint venture is accounted for using the equity method of accounting. The Company applies the equity method of accounting to investments when the Company has significant influence, but not controlling interest in the investee. Judgment regarding the level of influence over equity method investment includes considering key factors such as ownership interest, representation on the board of directors, participation in policy-making decisions and material intercompany transactions. Under the equity method, investments are initially recorded at cost and are adjusted for dividends, distributed and undistributed earnings and losses, and additional investments. In the event the Company&#8217;s share of a joint venture&#8217;s cumulative losses exceeds the Company&#8217;s investment balance, the balance is reported at zero value until proportionate income exceeds the losses. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company assesses investments for impairment whenever events or changes in circumstances indicate that the carrying value of an investment may not be recoverable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingencies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Contingencies</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company, from time to time, may be a party to various disputes and claims arising from normal business activities. The Company continually assesses disputes and claims including resulting litigation to determine if an unfavorable outcome would lead to a probable loss or reasonably possible loss which could be estimated. The Company accrues for all contingencies at the earliest date at which the Company deems it probable that a liability has been incurred and the amount of such liability can be reasonably estimated. If the estimate of a probable loss is a range and no amount within the range is more likely than another, the Company accrues the minimum of the range. In the cases where the Company believes that a reasonably possible loss exists, the Company discloses the facts and circumstances of the contingencies, including an estimable range, if possible.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company expenses research and development costs as incurred. The Company&#8217;s research and development expenses consist primarily of license fees to acquire intellectual property which does not meet the definition of intangible assets and costs incurred in performing research and development activities, including personnel-related expenses such as salaries, stock-based compensation and benefits, facilities costs, depreciation as well as external costs from third parties who conduct research and development activities (including manufacturing) on behalf of the Company. The Company accrues expenses related to development activities performed by third parties based on an evaluation of services received and efforts expended pursuant to the terms of the contractual arrangements. Payments under some of these contracts depend on preclinical and/or clinical trial milestones. There may be instances in which payments made to the Company&#8217;s vendors will exceed the level of services provided and result in a prepayment of expenses. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company adjusts the accrual or prepaid expense accordingly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company maintains an equity incentive plan as a long-term incentive for employees, consultants, and directors. The Company accounts for all stock-based awards granted to employees and non-employees based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. The grant date fair value of the stock-based awards with graded vesting is recognized on a straight-line basis over the requisite service period. The Company recognizes forfeitures related to stock-based compensation awards as they occur and reverses any previously recognized compensation cost associated with forfeited awards in the period the forfeiture occurs. The Company classifies stock-based compensation expense in the statement of operations in the same manner in which the award recipients&#8217; payroll costs are classified or in which the award recipients&#8217; service payments are classified.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company values its stock options with service conditions using the Black-Scholes option-pricing model. The Company uses certain assumptions to determine fair value of the stock options pursuant to the Black-Scholes option-pricing model, including the expected life of the award, volatility of the underlying shares, the risk-free interest rate, expected dividend yield and the fair value of the Company&#8217;s common stock. Since the Company lacks sufficient historical option exercise data to provide a reasonable basis upon which to estimate the expected term, the Company uses the simplified method described in the SEC&#8217;s Staff Accounting Bulletin No. 107, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Share-Based Payment </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(&#8220;SAB 107&#8221;), to determine the expected life of the option grants. The Company lacks sufficient company-specific historical and implied volatility information. Therefore, the Company estimates the expected stock volatility based on the historical volatility of a publicly traded set of peer companies. The risk-free interest rate is based on the rates paid on securities issued by the U.S. Treasury with a term approximating the expected life of the equity award. As the Company has never paid and does not anticipate paying cash dividends on its common stock, the expected dividend yield is considered as zero.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to the completion of the Company&#8217;s initial public offering ("IPO") of common stock, the fair value of the Company's common stock which is one of the key inputs in Black-Scholes option-pricing model, was determined by the board of directors with input from management and based on certain assumptions including probability weighting of events, business and market conditions, volatility, time to liquidation, a risk-free interest rate and an assumption for a discount for lack of marketability. The Company used 409A valuations to determine the fair value of the shares of common stock. The 409A valuations were performed using methodologies, approaches, and assumptions consistent with the American Institute of Certified Public Accountants </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. After completion of the IPO on October 8, 2021, the Company uses the fair value of its publicly traded common stock to determine grant date fair value.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for income taxes in accordance with FASB ASC 740, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (&#8220;ASC 740&#8221;), which requires the use of the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between amounts in the consolidated financial statements and the tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income tax (benefit) expense in the consolidated statements of operations and comprehensive loss in the period that includes the enactment date.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes deferred tax assets to the extent that it believes these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Loss per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net income (loss) per share attributable to common stockholders is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the diluted weighted average number of common shares outstanding for the period, including potential dilutive common shares.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In periods in which the Company reports a net loss, all common stock equivalents are deemed anti-dilutive such that basic net loss per common share and diluted net loss per common share are equivalent. Potentially dilutive common stock has been excluded from the diluted net loss per common share computations in all periods presented because such securities have an anti-dilutive effect on net loss per common share due to the Company&#8217;s net loss. There are no reconciling items used to calculate the weighted-average number of total common stock outstanding for basic and diluted net loss per common share data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recently Issued Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2016, the FASB issued ASU 2016-13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (&#8220;ASU 2016-13&#8221;), which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss model that requires the use of forward-looking information to calculate credit loss estimates. It also eliminates the concept of other-than-temporary impairment and requires credit losses on available-for-sale debt securities to be recorded through an allowance for credit losses instead of as a reduction in the amortized cost basis of the securities. For "emerging growth companies", ASU 2016-13 is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. The Company is currently evaluating the new standard and expects it to have no material impact on the Company's consolidated financial statements and related disclosures.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2020, the FASB issued ASU 2020-06, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(&#8220;ASU 2020-06&#8221;). ASU 2020-06 revises the guidance on calculating earnings per share, requiring use of the if-converted method for all convertible instruments and rescinding an entity&#8217;s ability to rebut the presumption of share settlement for instruments that may be settled in cash or other assets. As an "emerging growth company", ASU 2020-06 will become effective for the Company for fiscal years beginning after December 15, 2023, and early adoption is permitted. The Company is currently evaluating the new standard and expects it to have no material impact on the Company's consolidated financial statements and related disclosures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recent authoritative guidance issued by the FASB (including technical corrections to the ASC), the American Institute of Certified Public Accountants, and the SEC did not, or are not expected to, have a material impact on the Company&#8217;s audited consolidated financial statements and related disclosures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_LiquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_LiquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_NatureOfBusinessPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nature of Business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_NatureOfBusinessPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recently issued accounting pronouncements not yet adopted policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_RisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risks and Uncertainties [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_RisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079017552832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock', window );">Schedule of Estimated Useful Lives of Property and Equipment</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment are recorded at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful lives of the related assets as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:73.0%;"/>
          <td style="width:2.037%;"/>
          <td style="width:24.963%;"/>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated Useful<br/>Life (Years)</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and office equipment</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shorter of remaining life<br/>of lease or useful life</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Construction in process</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">N/A</span></p></td>
         </tr>
        </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of estimated useful lives of property and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079017629456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Financial Instruments Carried at Fair Value on Recurring Basis</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:4.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables present the financial instruments carried at fair value on a recurring basis as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, respectively, in accordance with the FASB ASC 820 hierarchy (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:4.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.699%;"/>
        <td style="width:1.23%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.995000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.23%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.995000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.23%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.995000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.23%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.395000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements at<br/>December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">177,279</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">177,279</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements at<br/>December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">272,210</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">272,210</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079017852400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.065%;"/>
        <td style="width:1.622%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.645999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.622%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.043999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,560</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">619</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Insurance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,308</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,763</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued interest receivable</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">598</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">381</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,847</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,466</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079016838704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net, consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.932%;"/>
        <td style="width:1.619%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.818%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.619%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.012%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,247</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,804</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and office equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,036</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">530</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">225</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Construction in process</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,177</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,990</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,123</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: accumulated depreciation and amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,825</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,116</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,165</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,007</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079017552832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock', window );">Summary of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses and other current liabilities consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.065%;"/>
        <td style="width:1.622%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.645999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.622%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.043999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,414</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,381</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee compensation and benefits</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,238</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,963</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Legal and professional fees</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,794</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">982</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,091</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">266</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,537</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,592</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079016521744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Components of Lease Expense</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of lease expense were as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.492%;"/>
        <td style="width:1.608%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.151%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.608%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.142%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,978</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">650</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,681</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Variable lease cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">121</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,780</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">730</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other information</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease right-of-use asset obtained in exchange for new operating<br/>&#160;&#160;&#160;lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,497</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities, included<br/>&#160;&#160;&#160;in operating cash flows</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">663</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average remaining lease term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.00</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.25</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.40</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.00</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Variable lease costs primarily relate to common area costs and other operating costs</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which are assessed based on the Company&#8217;s proportionate share of such costs for the leased premises. Total lease costs are included as operating expenses in the Company&#8217;s consolidated statements of operations and comprehensive loss.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturities of Lease Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturities of lease liabilities as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, were as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:75.252%;"/>
        <td style="width:2.082%;"/>
        <td style="width:1.0%;"/>
        <td style="width:20.667%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ending December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating Leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,557</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,208</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,302</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,399</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,499</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,750</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total undiscounted payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34,715</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: tenant improvement allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: present value adjustment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,768</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Present value of future payments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,921</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: current portion of operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, net of current portion</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,921</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079017631888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock', window );">Common Stock Reserved for Issuance</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company reserved the following shares of common stock for issuance:</span><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:94.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60.207%;"/>
        <td style="width:1.205%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.502%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.215%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.871%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,720,415</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,926,969</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted stock awards</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,015,387</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">618,494</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options available for issuance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,697,166</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,289,259</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee stock purchase plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">752,524</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">424,595</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,185,492</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,259,317</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of common stock reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079008848800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes stock option activity for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 (in thousands, except share and per share amounts):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.137%;"/>
        <td style="width:0.069%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.744000000000002%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.069%;"/>
        <td style="width:1.0%;"/>
        <td style="width:5.943%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.069%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.295%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.208%;"/>
        <td style="width:1.0%;"/>
        <td style="width:7.465%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br/>Options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at January 1, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,926,969</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.03</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.5</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,414</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,178,280</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.06</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73,841</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.48</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">834,095</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.24</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expired</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">476,898</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.51</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,720,415</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.68</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.8</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercisable at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,037,934</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.34</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.5</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Estimated Fair Value Assumptions</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company estimated the fair value of each option on the date of grant using the Black-Scholes option-pricing model applying the range of assumptions in the following table:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.065%;"/>
        <td style="width:2.019%;"/>
        <td style="width:27.843%;"/>
        <td style="width:2.019%;"/>
        <td style="width:19.037%;"/>
        <td style="width:2.019%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96.09</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.66</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72.88</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">103.41</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.60</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.02</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.81</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.36</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.00</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.11</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.25</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.00</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-Based Compensation Expense</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense related to stock options recorded in the statements of operations is as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.847%;"/>
        <td style="width:2.298%;"/>
        <td style="width:1.0%;"/>
        <td style="width:21.929%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.298%;"/>
        <td style="width:1.0%;"/>
        <td style="width:22.328%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.298%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,330</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,396</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,617</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,976</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,947</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,372</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Restricted Stock Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes restricted stock activity for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:70.57%;"/>
        <td style="width:1.081%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.265%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.724%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.359%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br/>Average<br/>Grant Date Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-vested at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">618,494</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.04</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,174,656</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.69</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and settled</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">432,354</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.55</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">345,409</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.74</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-vested and unsettled at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,015,387</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.64</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079017877488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation of the expected income tax benefit computed using the federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.205%;"/>
        <td style="width:1.161%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.241%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.161%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.232%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax computed at federal statutory rate %</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State taxes, net of federal benefit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.6</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26.6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27.7</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development credit carryovers</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.9</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Permanent differences</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.7</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.9</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective income tax rate %</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of Net Deferred Tax Assets</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Significant components of the Company&#8217;s net deferred tax assets as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 are as follows (in thousands): </span><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.458%;"/>
        <td style="width:1.526%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.049%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.517%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.449%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,108</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,918</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangibles</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax credit carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,674</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,648</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Derivative</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,455</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,577</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,645</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,003</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reserves and accruals</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,105</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">804</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capitalized research expenditures</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,059</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">License fees</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,235</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,716</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liability</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,107</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets before valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61,486</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,811</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57,812</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,748</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,674</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease ROU assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,674</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079032321248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic and diluted net loss per share was calculated as follows (in thousands, except share and per share amounts):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:45.492%;"/>
        <td style="width:2.562%;"/>
        <td style="width:1.0%;"/>
        <td style="width:21.324%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.552%;"/>
        <td style="width:1.0%;"/>
        <td style="width:21.518%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.552%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Numerator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120,717</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75,975</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Denominator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average common shares outstanding, basic and diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,033,081</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,493,273</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.65</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.95</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Anti-Dilutive Effect Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following potentially dilutive securities have been excluded from the calculation of diluted net loss per common share due to their anti-dilutive effect:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.822%;"/>
        <td style="width:1.434%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.953%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.434%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.356%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options outstanding</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,720,415</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,929,969</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted stock awards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,015,387</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">618,494</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options available for issuance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,697,166</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,289,259</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee stock purchase plan</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">752,524</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">424,595</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,185,492</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,262,317</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079018054080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Disclosure Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of Operating Segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079010616944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Lease</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Lease</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (212,435,000)<span></span>
</td>
<td class="num">$ (91,718,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(120,717,000)<span></span>
</td>
<td class="num">(75,975,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">179,293,000<span></span>
</td>
<td class="nump">274,735,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_NumberOfFinanceLease', window );">Number of finance lease | Lease</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,724,925<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basis of presentation and summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_NumberOfFinanceLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_NumberOfFinanceLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079008871696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Related Assets (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of related assets</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Office Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of related assets</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Estimated useful lives of related assets, description</a></td>
<td class="text">Shorter of remaining lifeof lease or useful life<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905813&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140078940861936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 06, 2022 </div>
<div>USD ($) </div>
<div>Days </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 28, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86,129,000<span></span>
</td>
<td class="nump">$ 51,054,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,110,016<span></span>
</td>
<td class="nump">32,792,867<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, Value, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,000<span></span>
</td>
<td class="nump">$ 32,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=pyxs_PfizerLicenseAgreementMember', window );">Pfizer License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_PaymentForLicenseFee', window );">Payment for license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued | shares</a></td>
<td class="nump">2,229,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, Value, Issued</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_MaximumPercentageOfOwnershipInterest', window );">Maximum percentage of ownership interest</a></td>
<td class="nump">19.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale', window );">Royalty obligation period for licensed products upon first commercial sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_MilestoneAndRoyaltiesIncurred', window );">Milestone and royalties required</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_UpfrontPayments', window );">Upfront payments</a></td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_NumberOfDaysCommonStockIssuedFromEffectiveDate', window );">Number of days common stock issued from effective date | Days</a></td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=pyxs_PfizerLicenseAgreementMember', window );">Pfizer License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_AggregateMilestonePayments', window );">Aggregate milestone payments for first four licensed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 665,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=pyxs_PfizerLicenseAgreementMember', window );">Pfizer License Agreement | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock', window );">Number of common shares issued upon conversion of preferred stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,911,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=pyxs_PfizerLicenseAgreementMember', window );">Pfizer License Agreement | Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_IssuanceOfConvertiblePreferredStockShares', window );">Issuance of convertible preferred stock shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,152,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_ConvertiblePreferredStockSharesIssuedValue', window );">Convertible Preferred Stock Shares Issued Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=pyxs_LegoChemLicenseAgreementMember', window );">LegoChem License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_EstimatedCostToPurchaseLicensedProducts', window );">Estimated cost to purchase licensed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Amount payable related to licensed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_OptionUpfrontPayment', window );">Stock option upfront payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_ExtraMilestonePayment', window );">Extra milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses', window );">Derivative liability offset to research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized', window );">Extra milestone payment for which derivative liability recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=pyxs_LegoChemLicenseAgreementMember', window );">LegoChem License Agreement | Research and Development Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_UpfrontFee', window );">Upfront fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=pyxs_LegoChemLicenseAgreementMember', window );">LegoChem License Agreement | Other (Expense) Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Changes in the fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=pyxs_BiosionLicenseAgreementMember', window );">Biosion License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval', window );">Aggregate maximum obligation to pay future contingent milestone payments for normal approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 217,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval', window );">Aggregate maximum obligation to pay future contingent milestone payments for accelerated approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 222,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale', window );">Royalty obligation period for licensed products upon first commercial sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_MilestoneAndRoyaltiesIncurred', window );">Milestone and royalties required</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=pyxs_BiosionLicenseAgreementMember', window );">Biosion License Agreement | Research and Development Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_UpfrontFee', window );">Upfront fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pyxs_UniversityLicenseAgreementMember', window );">University License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_CommonStockIssuedToUniversity', window );">Common stock issued to university | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_MilestoneAndRoyaltiesIncurred', window );">Milestone and royalties required</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pyxs_UniversityLicenseAgreementMember', window );">University License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_PotentialDevelopmentAndCommercialMilestonePayment', window );">Potential development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_MinimumAnnualRoyaltyFees', window );">Minimum annual royalty fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate maximum obligation to pay future contingent milestone payments for accelerated approval.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate maximum obligation to pay future contingent milestone payments for normal approval.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_AggregateMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_AggregateMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_CommonStockIssuedToUniversity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock issued to university.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_CommonStockIssuedToUniversity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_ConvertiblePreferredStockSharesIssuedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock shares issued value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_ConvertiblePreferredStockSharesIssuedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative liability offset to research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_EstimatedCostToPurchaseLicensedProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated cost to purchase licensed products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_EstimatedCostToPurchaseLicensedProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_ExtraMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Extra milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_ExtraMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Extra milestone payment for which derivative liability recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_IssuanceOfConvertiblePreferredStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of convertible preferred stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_IssuanceOfConvertiblePreferredStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_MaximumPercentageOfOwnershipInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>MaximumPercentageofOwnershipInterest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_MaximumPercentageOfOwnershipInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_MilestoneAndRoyaltiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone and royalties incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_MilestoneAndRoyaltiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_MinimumAnnualRoyaltyFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum annual royalty fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_MinimumAnnualRoyaltyFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issued upon conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_NumberOfDaysCommonStockIssuedFromEffectiveDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of days common stock issued from effective date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_NumberOfDaysCommonStockIssuedFromEffectiveDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_OptionUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_OptionUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_PaymentForLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment for license fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_PaymentForLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_PotentialDevelopmentAndCommercialMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential development and commercial milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_PotentialDevelopmentAndCommercialMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty obligation period for licensed products upon first commercial sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_UpfrontFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_UpfrontFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_UpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_UpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=pyxs_PfizerLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=pyxs_PfizerLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pyxs_SeriesBConvertiblePreferredStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pyxs_SeriesBConvertiblePreferredStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=pyxs_LegoChemLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=pyxs_LegoChemLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_NonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_NonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=pyxs_BiosionLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=pyxs_BiosionLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pyxs_UniversityLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pyxs_UniversityLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079010339776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Joint Venture - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from equity method investment in joint venture</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pyxs_VoxallMember', window );">Voxall</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from equity method investment in joint venture</a></td>
<td class="num">$ (500)<span></span>
</td>
<td class="num">(1,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_ProceedsFromPromissoryNoteIssued', window );">Promissory note issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities', window );">Equity method investment, description</a></td>
<td class="text">As the Company has no commitment to fund the losses of the equity method investment, the carrying value of the equity method investment has not been reduced below zero<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pyxs_VoxallMember', window );">Voxall | Alloy Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of voting membership units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_ProceedsFromPromissoryNoteIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from promissory note issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_ProceedsFromPromissoryNoteIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the principal activities of an investee accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pyxs_VoxallMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pyxs_VoxallMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pyxs_AlloyTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pyxs_AlloyTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079010703424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Financial Instruments Carried at Fair Value on Recurring Basis (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">177,279,000<span></span>
</td>
<td class="nump">272,210,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">$ 177,279,000<span></span>
</td>
<td class="nump">$ 272,210,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079010646512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=pyxs_LegoChemLicenseAgreementMember', window );">LegoChem License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses', window );">Derivative liability offset to research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized', window );">Extra milestone payment for which derivative liability recognized</a></td>
<td class="nump">$ 9,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_NonoperatingIncomeExpenseMember', window );">Other (Expense) Income | LegoChem License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Changes in the fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Fair Value, Nonrecurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative liability offset to research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Extra milestone payment for which derivative liability recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=pyxs_LegoChemLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=pyxs_LegoChemLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_NonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_NonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079008879952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_PrepaidResearchAndDevelopmentCurrent', window );">Research and development</a></td>
<td class="nump">$ 3,560<span></span>
</td>
<td class="nump">$ 619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Insurance</a></td>
<td class="nump">1,308<span></span>
</td>
<td class="nump">1,763<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Accrued interest receivable</a></td>
<td class="nump">598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">381<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total Prepaid expenses and other current assets</a></td>
<td class="nump">$ 5,847<span></span>
</td>
<td class="nump">$ 2,466<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_PrepaidResearchAndDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Research And Development Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_PrepaidResearchAndDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079010622896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment gross</a></td>
<td class="nump">$ 12,990<span></span>
</td>
<td class="nump">$ 2,123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(1,825)<span></span>
</td>
<td class="num">(1,116)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total Property and equipment, net</a></td>
<td class="nump">11,165<span></span>
</td>
<td class="nump">1,007<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pyxs_LaboratoryEquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment gross</a></td>
<td class="nump">2,247<span></span>
</td>
<td class="nump">1,804<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pyxs_FurnitureAndOfficeEquipmentMember', window );">Furniture and Office Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment gross</a></td>
<td class="nump">1,036<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment gross</a></td>
<td class="nump">530<span></span>
</td>
<td class="nump">$ 225<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment gross</a></td>
<td class="nump">$ 9,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pyxs_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pyxs_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pyxs_FurnitureAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pyxs_FurnitureAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079009473552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 709<span></span>
</td>
<td class="nump">$ 647<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079010473440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_AccruedResearchAndDevelopmentExpensesCurrent', window );">Research and development expenses</a></td>
<td class="nump">$ 17,414<span></span>
</td>
<td class="nump">$ 2,381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation and benefits</a></td>
<td class="nump">4,238<span></span>
</td>
<td class="nump">2,963<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Legal and professional fees</a></td>
<td class="nump">1,794<span></span>
</td>
<td class="nump">982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">1,091<span></span>
</td>
<td class="nump">266<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 24,537<span></span>
</td>
<td class="nump">$ 6,592<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_AccruedResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_AccruedResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079008796128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">Dec. 31,  2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_RentIncreasePercentage', window );">Rent Increase Percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Operating lease, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">option to extend the lease beyond December 31, 2032.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,602<span></span>
</td>
<td class="nump">$ 15,300<span></span>
</td>
<td class="nump">$ 232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,921<span></span>
</td>
<td class="nump">15,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_IncrementalBorrowingRate', window );">Incremental borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_TenantImprovementAllowance', window );">Tenant improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_TenantImprovementAllowanceReceivable', window );">Tenant improvement allowance receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_ProceedsFromTenantImprovementAllowance', window );">Proceeds from tenant improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_IncrementalBorrowingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incremental borrowing rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_IncrementalBorrowingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_ProceedsFromTenantImprovementAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Tenant Improvement Allowance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_ProceedsFromTenantImprovementAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_RentIncreasePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rent increase percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_RentIncreasePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_TenantImprovementAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tenant improvement allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_TenantImprovementAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_TenantImprovementAllowanceReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tenant improvement allowance receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_TenantImprovementAllowanceReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079016567200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases - Components of Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 1,978<span></span>
</td>
<td class="nump">$ 650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">1,681<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable Lease, Cost</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">3,780<span></span>
</td>
<td class="nump">730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use asset obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">$ 14,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities, included in operating cash flows</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 663<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">3 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">9.40%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079008761568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Maturities of Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Apr. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 2,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">3,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">3,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">3,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">3,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">18,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted payments</a></td>
<td class="nump">34,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_TenantImprovementAllowanceReceivable', window );">Less: tenant improvement allowance</a></td>
<td class="num">(3,026)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: present value adjustment</a></td>
<td class="num">(12,768)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of future payments</a></td>
<td class="nump">18,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion of operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (165)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">$ 18,921<span></span>
</td>
<td class="nump">$ 15,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_TenantImprovementAllowanceReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tenant improvement allowance receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_TenantImprovementAllowanceReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140078940129344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 01, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 08, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 05, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Net proceeds from issuance of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 151,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share sale price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pyxs_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement | Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share sale price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,724,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,724,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_GrossProceedsFromIssuanceOfConvertiblePreferredStock', window );">Gross cash proceeds from issuance of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Net proceeds from issuance of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split description</a></td>
<td class="text">1-for-6.359 reverse stock split<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split, conversion ratio</a></td>
<td class="nump">0.15725743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pyxs_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement | Series A Convertible Preferred Stock | Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of preferred shares conversion | shares</a></td>
<td class="nump">22,724,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pyxs_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement | Series A Convertible Preferred Stock | Initial Public Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Convertible preferred stock shares issued upon conversion | shares</a></td>
<td class="nump">3,573,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pyxs_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement | Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share sale price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.6458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.6458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,356,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_GrossProceedsFromIssuanceOfConvertiblePreferredStock', window );">Gross cash proceeds from issuance of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Net proceeds from issuance of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 151,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split description</a></td>
<td class="text">1-for-6.359 reverse stock split<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split, conversion ratio</a></td>
<td class="nump">0.15725743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pyxs_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement | Series B Convertible Preferred Stock | Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of preferred shares conversion | shares</a></td>
<td class="nump">104,812,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pyxs_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement | Series B Convertible Preferred Stock | Initial Public Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Convertible preferred stock shares issued upon conversion | shares</a></td>
<td class="nump">16,482,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pyxs_AgreementsWithPfizerIncAndLegochemBiosciencesIncMember', window );">Agreements with Pfizer, Inc. and LegoChem | Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,455,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Net proceeds from issuance of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_GrossProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from issuance of convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_GrossProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pyxs_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pyxs_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pyxs_SeriesAConvertiblePreferredStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pyxs_SeriesAConvertiblePreferredStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pyxs_SeriesBConvertiblePreferredStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pyxs_SeriesBConvertiblePreferredStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pyxs_AgreementsWithPfizerIncAndLegochemBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pyxs_AgreementsWithPfizerIncAndLegochemBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079009494672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 08, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par or stated value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from issuance initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152,296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190,000,000<span></span>
</td>
<td class="nump">190,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,110,016<span></span>
</td>
<td class="nump">32,792,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,958,730<span></span>
</td>
<td class="nump">32,222,881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_GrossProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds from issuance of initial public offering</a></td>
<td class="nump">$ 168,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from issuance initial public offering</a></td>
<td class="nump">$ 152,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued</a></td>
<td class="nump">10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock public offering price per share</a></td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_UnderwritingDiscountsAndCommissions', window );">Underwriting discounts and commissions</a></td>
<td class="nump">$ 11,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_StockIssuanceExpenses', window );">Stock issuance expenses</a></td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_GrossProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from issuance initial public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_GrossProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_StockIssuanceExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issuance expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_StockIssuanceExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_UnderwritingDiscountsAndCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Underwriting discounts and commissions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_UnderwritingDiscountsAndCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079016564368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Common Stock Reserved for Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems', window );"><strong>Schedule Of Common Stock Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">11,185,492<span></span>
</td>
<td class="nump">8,259,317<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems', window );"><strong>Schedule Of Common Stock Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">5,720,415<span></span>
</td>
<td class="nump">5,926,969<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Unvested Restricted Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems', window );"><strong>Schedule Of Common Stock Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">3,015,387<span></span>
</td>
<td class="nump">618,494<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pyxs_StockOptionsAvailableForIssuanceMember', window );">Stock Options Available for Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems', window );"><strong>Schedule Of Common Stock Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">1,697,166<span></span>
</td>
<td class="nump">1,289,259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems', window );"><strong>Schedule Of Common Stock Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">752,524<span></span>
</td>
<td class="nump">424,595<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of common stock reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pyxs_StockOptionsAvailableForIssuanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pyxs_StockOptionsAvailableForIssuanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140078940421104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Sep. 27, 2021</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of common shares reserved and autorized for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,185,492<span></span>
</td>
<td class="nump">8,259,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,720,415<span></span>
</td>
<td class="nump">5,926,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of option to purchase restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,015,387<span></span>
</td>
<td class="nump">618,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.06<span></span>
</td>
<td class="nump">$ 7.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Gross unrecognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation expense weighted average amortized period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,947<span></span>
</td>
<td class="nump">$ 6,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_FairValueOfCommonStockPerShare', window );">Fair value of common stock per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of common shares reserved and autorized for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,015,387<span></span>
</td>
<td class="nump">618,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation expense weighted average amortized period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock public offering price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Gross unrecognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_RestrictedStockSharesUnvestedAndOutstanding', window );">RSAs unvested and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units ('RSU')</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Number of restricted stock units issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,174,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pyxs_TwothousandtwentytwoequityinducementplanMember', window );">2022 Equity Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of common shares reserved and autorized for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of common shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">678,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pyxs_TwothousandtwentytwoequityinducementplanMember', window );">2022 Equity Inducement Plan | Restricted Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of option to purchase restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pyxs_TwothousandtwentytwoequityinducementplanMember', window );">2022 Equity Inducement Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pyxs_TwoThousandTwentyOneEquityIncentivePlanMember', window );">2021 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of common shares reserved and autorized for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,852,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized</a></td>
<td class="nump">1,639,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of common shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,668,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesReservedAndAvailableForIssuancePercentage', window );">Number of shares of common stock outstanding percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions', window );">Maximum number of common shares issuable under exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,705,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pyxs_TwoThousandTwentyOneEquityIncentivePlanMember', window );">2021 Equity Incentive Plan | Restricted Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of option to purchase restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,449,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pyxs_TwoThousandTwentyOneEquityIncentivePlanMember', window );">2021 Equity Incentive Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pyxs_TwoThousandNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of common shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">657,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,651,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pyxs_TwoThousandNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan | Restricted Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of option to purchase restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pyxs_TwoThousandNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of common shares reserved and autorized for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,042,408<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember', window );">2021 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of common shares reserved and autorized for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">752,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">424,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized</a></td>
<td class="nump">327,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesReservedAndAvailableForIssuancePercentage', window );">Number of shares of common stock outstanding percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pyxs_StockOptionsTwoThousandTwentyTwoTwoThousandTwentyOneAndTwoThousandNineteenPlanMember', window );">Stock Options 2022 Plan, 2021 Plan and 2019 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_FairValueOfCommonStockPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of common stock per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_FairValueOfCommonStockPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of common shares issuable under exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_RestrictedStockSharesUnvestedAndOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted stock shares unvested and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_RestrictedStockSharesUnvestedAndOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesReservedAndAvailableForIssuancePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award increase in number of shares reserved and available for issuance percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesReservedAndAvailableForIssuancePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pyxs_TwothousandtwentytwoequityinducementplanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pyxs_TwothousandtwentytwoequityinducementplanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pyxs_TwoThousandTwentyOneEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pyxs_TwoThousandTwentyOneEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pyxs_TwoThousandNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pyxs_TwoThousandNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pyxs_StockOptionsTwoThousandTwentyTwoTwoThousandTwentyOneAndTwoThousandNineteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pyxs_StockOptionsTwoThousandTwentyTwoTwoThousandTwentyOneAndTwoThousandNineteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079010647776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding, Beginning Balance</a></td>
<td class="nump">5,926,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="nump">1,178,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
<td class="num">(73,841)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Forfeited</a></td>
<td class="num">(834,095)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of Options, Expired</a></td>
<td class="num">(476,898)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding, Ending Balance</a></td>
<td class="nump">5,720,415<span></span>
</td>
<td class="nump">5,926,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable at December 31, 2022</a></td>
<td class="nump">2,037,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning Balance</a></td>
<td class="nump">$ 10.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">4.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">2.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited</a></td>
<td class="nump">7.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Expired</a></td>
<td class="nump">5.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance</a></td>
<td class="nump">9.68<span></span>
</td>
<td class="nump">$ 10.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable at December 31, 2022</a></td>
<td class="nump">$ 9.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term, Outstanding</a></td>
<td class="text">8 years 9 months 18 days<span></span>
</td>
<td class="text">9 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Exercisable</a></td>
<td class="text">8 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 72<span></span>
</td>
<td class="nump">$ 16,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable at December 31, 2022</a></td>
<td class="nump">$ 59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079016776448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Estimated Fair Value Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">96.09%<span></span>
</td>
<td class="nump">72.88%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">101.66%<span></span>
</td>
<td class="nump">103.41%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">0.81%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.02%<span></span>
</td>
<td class="nump">1.36%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">5 years 3 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 1 month 9 days<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079016520064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 11,947<span></span>
</td>
<td class="nump">$ 6,372<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">4,330<span></span>
</td>
<td class="nump">2,396<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 7,617<span></span>
</td>
<td class="nump">$ 3,976<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079010446224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Restricted Stock Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Outstanding, Beginning Balance | shares</a></td>
<td class="nump">618,494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Shares, Granted | shares</a></td>
<td class="nump">3,174,656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod', window );">Number of Shares, Vested and settled | shares</a></td>
<td class="num">(432,354)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Shares, Forfeited | shares</a></td>
<td class="num">(345,409)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Outstanding, Ending Balance | shares</a></td>
<td class="nump">3,015,387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Outstanding, Beginning Balance | $ / shares</a></td>
<td class="nump">$ 3.04<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Outstanding, Granted | $ / shares</a></td>
<td class="nump">3.69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Outstanding, Vested and settled | $ / shares</a></td>
<td class="nump">0.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Outstanding, Forfeited | $ / shares</a></td>
<td class="nump">3.74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Outstanding, Ending Balance | $ / shares</a></td>
<td class="nump">$ 3.64<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, equity instruments other than options, vested and settled in period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, equity instruments other than options vested and settled in period, weighted average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079015618576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Increase in deferred tax assets valuation allowance</a></td>
<td class="nump">$ 32,200,000<span></span>
</td>
<td class="nump">$ 21,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">57,812,000<span></span>
</td>
<td class="nump">25,748,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_TaxCutsAndJobsActDeferredTaxAsset', window );">Deferred tax asset</a></td>
<td class="nump">20,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Current income tax expenses (benefit)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred Income Tax Expense (Benefit)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforward</a></td>
<td class="nump">10,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_OperatingLossCarryforwardsBeforeTax', window );">Operating loss carryforwards before tax</a></td>
<td class="nump">48,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Credit carryovers</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_TaxCreditCarryforwardExpirationYear', window );">Credit carryovers expiration year</a></td>
<td class="text">2039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforward</a></td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_OperatingLossCarryforwardsBeforeTax', window );">Operating loss carryforwards before tax</a></td>
<td class="nump">$ 48,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">2039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Credit carryovers</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_TaxCreditCarryforwardExpirationYear', window );">Credit carryovers expiration year</a></td>
<td class="text">2039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_OperatingLossCarryforwardsBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards before tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_OperatingLossCarryforwardsBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_TaxCreditCarryforwardExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_TaxCreditCarryforwardExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_TaxCutsAndJobsActDeferredTaxAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax cuts and jobs act, deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_TaxCutsAndJobsActDeferredTaxAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079018079232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax computed at federal statutory rate%</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="nump">5.60%<span></span>
</td>
<td class="nump">5.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(26.60%)<span></span>
</td>
<td class="num">(27.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development credit carryovers</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_EffectiveIncomeTaxRateReconciliationPermanentDifferences', window );">Permanent differences</a></td>
<td class="num">(1.70%)<span></span>
</td>
<td class="num">(0.90%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate%</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_EffectiveIncomeTaxRateReconciliationPermanentDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation permanent differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_EffectiveIncomeTaxRateReconciliationPermanentDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079015621088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of Net Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 13,108<span></span>
</td>
<td class="nump">$ 12,918<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangibles</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">3,674<span></span>
</td>
<td class="nump">1,648<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDerivativeInstruments', window );">Derivative</a></td>
<td class="nump">1,455<span></span>
</td>
<td class="nump">1,577<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Stock based compensation</a></td>
<td class="nump">2,645<span></span>
</td>
<td class="nump">1,003<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Reserves and accruals</a></td>
<td class="nump">1,105<span></span>
</td>
<td class="nump">804<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_DeferredTaxAssetsCapitalizedResearchExpenditures', window );">Capitalized research expenditures</a></td>
<td class="nump">20,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_DeferredTaxAssetsLicenseFee', window );">License fees</a></td>
<td class="nump">14,235<span></span>
</td>
<td class="nump">7,716<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liability</a></td>
<td class="nump">5,107<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets before valuation allowance</a></td>
<td class="nump">61,486<span></span>
</td>
<td class="nump">25,811<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(57,812)<span></span>
</td>
<td class="num">(25,748)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">3,674<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets', window );">Operating lease ROU assets</a></td>
<td class="num">$ (3,674)<span></span>
</td>
<td class="num">$ (63)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_DeferredTaxAssetsCapitalizedResearchExpenditures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets capitalized research expenditures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_DeferredTaxAssetsCapitalizedResearchExpenditures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_DeferredTaxAssetsLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets license fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_DeferredTaxAssetsLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating lease liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Operating Lease Right-of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDerivativeInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from derivative instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDerivativeInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079014883632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Summary of Basic and Diluted Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (120,717)<span></span>
</td>
<td class="num">$ (75,975)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of common stock outstanding - basic</a></td>
<td class="nump">33,033,081<span></span>
</td>
<td class="nump">8,493,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares of common stock outstanding - diluted</a></td>
<td class="nump">33,033,081<span></span>
</td>
<td class="nump">8,493,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share - basic</a></td>
<td class="num">$ (3.65)<span></span>
</td>
<td class="num">$ (8.95)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share - diluted</a></td>
<td class="num">$ (3.65)<span></span>
</td>
<td class="num">$ (8.95)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079013537040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Anti-Dilutive Effect Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive effect excluded from computation of diluted net loss per share attributable to common stockholders</a></td>
<td class="nump">11,185,492<span></span>
</td>
<td class="nump">8,262,317<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive effect excluded from computation of diluted net loss per share attributable to common stockholders</a></td>
<td class="nump">5,720,415<span></span>
</td>
<td class="nump">5,929,969<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pyxs_UnvestedRestrictedStockAwardsMember', window );">Unvested restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive effect excluded from computation of diluted net loss per share attributable to common stockholders</a></td>
<td class="nump">3,015,387<span></span>
</td>
<td class="nump">618,494<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pyxs_StockOptionsAvailableForIssuanceMember', window );">Stock Options Available for Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive effect excluded from computation of diluted net loss per share attributable to common stockholders</a></td>
<td class="nump">1,697,166<span></span>
</td>
<td class="nump">1,289,259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive effect excluded from computation of diluted net loss per share attributable to common stockholders</a></td>
<td class="nump">752,524<span></span>
</td>
<td class="nump">424,595<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pyxs_UnvestedRestrictedStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pyxs_UnvestedRestrictedStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pyxs_StockOptionsAvailableForIssuanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pyxs_StockOptionsAvailableForIssuanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079009483312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 86,129,000<span></span>
</td>
<td class="nump">$ 51,054,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=pyxs_PfizerLicenseAgreementMember', window );">Pfizer License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 17,300,000<span></span>
</td>
<td class="nump">25,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_RelatedPartyTransactionOwnership', window );">Ownership percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pyxs_UniversityLicenseAgreementMember', window );">University License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related party transaction expenses incurred</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=pyxs_VoxallMember', window );">Voxall</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_ContributedAmountToJointVentureByEachEntity', window );">Contributed amount to joint venture by each member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_RelatedPartyTransactionServiceFeeOtherIncomeFromTransactionsWithRelatedParty', window );">Recognized service fee as other income</a></td>
<td class="nump">$ 181,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_ContributedAmountToJointVentureByEachEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contributed amount to joint venture by each entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_ContributedAmountToJointVentureByEachEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_RelatedPartyTransactionOwnership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction Ownership</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_RelatedPartyTransactionOwnership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_RelatedPartyTransactionServiceFeeOtherIncomeFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction Service Fee Other Income From Transactions With Related Party</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_RelatedPartyTransactionServiceFeeOtherIncomeFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=pyxs_PfizerLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=pyxs_PfizerLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pyxs_UniversityLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pyxs_UniversityLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=pyxs_VoxallMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=pyxs_VoxallMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140079014817424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Details) - MASSACHUSETTS - Sublease Agreement<br> $ in Millions</strong></div></th>
<th class="th">
<div>Feb. 02, 2023 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MA', window );">Office and Laboratory Space</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Sublease agreement, square feet space area in building | ft&#178;</a></td>
<td class="nump">17,729<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Base rent payments to receive over sublease term | $</a></td>
<td class="nump">$ 5.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_SubleaseTerm', window );">Sublease term</a></td>
<td class="text">36 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_SubleaseExpirationDate', window );">Sublease expire date</a></td>
<td class="text">Feb.  01,  2025<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_SubleaseExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sublease expiration date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_SubleaseExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_SubleaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sublease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_SubleaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pyxs_SubleaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pyxs_SubleaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=pyxs_OfficeAndLaboratorySpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=pyxs_OfficeAndLaboratorySpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>pyxs-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:pyxs="http://pyxisoncology.com/20221231"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="pyxs-20221231.xsd" xlink:type="simple"/>
    <context id="C_bbf8f5ff-a294-4a9f-8e73-2626887266b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pyxs:StockOptionsAvailableForIssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a4a72a0d-ee7f-4589-88fb-129aff57c90e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_580efdd7-1697-4746-bb08-330be421f077">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_47830253-f4d4-4397-a12e-e52eed550ec3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_d17eff6a-c465-4999-9b00-c89ab59f6085">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_1f74468d-690d-401f-99d9-cb0dfb69f6d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_63b19c56-1b8a-44d0-841a-bbbe8b23192a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pyxs:UniversityLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="C_08e26df7-c143-4cfe-8ad0-f01a4ebe0f85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesAConvertiblePreferredStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="C_47b0f4dc-1f2b-43a4-82d0-e3339f869c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e7d9bbba-b0b8-45c6-b0a7-dd4392b30f05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pyxs:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a299bf89-0287-4625-8850-fb9123db63e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_7dd94bc0-72fc-44a2-b88d-da7188b1ce64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_97a1de80-f534-45ad-9ae5-0bf704ac27f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_dd3f048c-500a-44b0-97cc-8865eadc0230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesAConvertiblePreferredStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="C_7f69dc96-1c3c-4d15-bee7-ceb32b6a4546">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:BiosionLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-28</instant>
        </period>
    </context>
    <context id="C_3ade2bd0-ad16-4bf4-a99d-4a51299354f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_57e97640-061e-4d91-86fa-37e25ab50455">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2af509fb-9702-480c-8cbd-911f991087fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-06</instant>
        </period>
    </context>
    <context id="C_38547283-6d39-4795-b0d3-95f75e72293e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="C_606b0303-5274-48c3-af42-6ee3a9b3c452">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SubleaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-02</instant>
        </period>
    </context>
    <context id="C_5e6b169a-61c1-4460-b0cf-4abc20516158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_98625906-14f2-47a1-9eb9-724228999619">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ea786617-a1e9-4846-aa80-4f080345af40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_056d4eec-ac13-4d48-b518-557aadce6575">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:LegoChemLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3f691b8c-c469-4e4a-96b6-9103063b1982">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ab715df4-cb33-446f-9bc3-90688e948155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pyxs:VoxallMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_52660871-d822-4029-a359-773d492fbb93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-27</instant>
        </period>
    </context>
    <context id="C_aae7c872-143d-4e13-980e-a4b7733afaf6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-08</startDate>
            <endDate>2021-10-08</endDate>
        </period>
    </context>
    <context id="C_3437eb60-7ead-49e1-af88-52c11bcf8430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-08</instant>
        </period>
    </context>
    <context id="C_93a31468-e176-4adc-8cfc-d60e8d2102f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4e8c269f-db1b-4dbe-9107-8e90b43b9fa4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_878945eb-02c9-42de-ab14-20785d15bab1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwothousandtwentytwoequityinducementplanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="C_23f0eeb1-4ec3-40f7-8427-0bbf70cd0d1c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-06</startDate>
            <endDate>2022-10-06</endDate>
        </period>
    </context>
    <context id="C_c0ed8f27-3a4c-4474-9fee-718c5b4c9f5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_dadd6f97-7a5c-4e8e-b808-bf02287c4b0a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_de8208ab-bcfc-47b0-b387-5579dfad9705">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_21e45814-d1c9-49d0-b212-624324f81c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_570474f3-f0f4-4608-961a-97edb7e8318e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pyxs:UnvestedRestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6eb028fe-0dfc-4fcc-8cfd-de5ca6f2a851">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pyxs:VoxallMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a1592c2f-78e9-4a1b-b7a3-b5e832dfc0e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pyxs:StockOptionsAvailableForIssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_afca8c75-429e-4247-b930-08b342481fcc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:LegoChemLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="C_915e850b-ae03-438e-afb7-244101692549">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5fa06219-1252-449b-973f-3a4c942c0ae4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
        </entity>
        <period>
            <instant>2021-10-08</instant>
        </period>
    </context>
    <context id="C_d9e659d3-c4ff-4e05-bb19-5b5effadffa3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2b2bc485-3a60-4ce8-850d-05c0692602e2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6c431810-e959-4b5a-b476-c39c7b79b09c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pyxs:UniversityLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="C_22898140-752b-4c56-a019-59406d30b9a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_f2ddafed-be8d-4bfb-afe6-eafef4a6d2bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pyxs:UniversityLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_382dcedb-c053-467b-83f2-217ce9a3521e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f891bb1b-8647-4939-8740-f3d10c242ed2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1f7d801f-7c91-43b6-b20d-6c5b26ad7c1b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4595b0e9-9dcf-4916-9f78-cc4f6d5b5648">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pyxs:UniversityLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4f7769e8-70e6-4d06-bdc0-89e5d970d334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:StockOptionsTwoThousandTwentyTwoTwoThousandTwentyOneAndTwoThousandNineteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e31029d2-1718-44fb-bbfe-596a8f71bb1d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9d0748e3-ecbb-419d-b1da-43ca99f6d64d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_72ee8eff-e4a6-4e5c-8e34-b16da25e910f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="C_b7d0661d-e805-4887-84a1-6ba122628999">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_18591516-6c3d-465a-804c-40424d183530">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_772490ef-27c8-4a53-a78c-52e1650134c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pyxs:UniversityLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="C_7df0d474-6f80-47b5-b237-25bf19a5fb4c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6d15f333-7588-4ef5-8888-a6b87820dd75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-27</instant>
        </period>
    </context>
    <context id="C_07d0bbc1-f9a2-43f9-8983-bf7982db0cbd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_dbf80555-08a0-4969-b239-4e3694866a9d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9188f657-2f90-466d-b42f-29e1c97321d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:BiosionLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-28</startDate>
            <endDate>2022-03-28</endDate>
        </period>
    </context>
    <context id="C_d4e409b9-f87d-4dfd-8ff7-0b2a843ec39f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:LegoChemLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5c8d1870-c7a8-4c74-97ca-d9e6a13f9efc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ffecffd1-fb25-4239-b101-0b9e9224e3c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0ca7fd08-59a5-40fc-a0ec-73b51bc9fbd9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_fa5ee9fe-cc4b-4842-b6f4-396be31d8300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_3bcaea08-ed4d-45f4-8fc4-c0510f776740">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ac6c23d7-b491-43cb-a347-d0c5845136d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-08</startDate>
            <endDate>2021-10-08</endDate>
        </period>
    </context>
    <context id="C_375ab7b5-f3d4-409a-a33f-662272797faf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesAConvertiblePreferredStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="C_d753a366-cbec-4a3f-8e6d-a172249fde7b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_4311203d-759e-4680-a158-b189b0b27135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e79d7fea-f750-4f59-be70-803b9b5030d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SubleaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-02</startDate>
            <endDate>2023-02-02</endDate>
        </period>
    </context>
    <context id="C_d2032e34-dd12-44a0-9706-073c354f8dbb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5f32f318-d7b3-49c5-87d5-d8693945f998">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d6d15861-ed2b-4844-b8f3-06bd9a409de9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_10356595-90e4-4664-b68b-60f5a32b9285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_403332e3-9bcb-4fd2-8dda-17c8ccb33760">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pyxs:VoxallMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_83982012-10a6-4487-8dce-be863732bf86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b7382cca-33a6-4f4e-9ad5-9ec9267d027f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_5e0e5fda-24f4-4956-a238-9aa47842953a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="C_1bfa7a44-4da1-4bfe-8679-1f28fa3b517b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_cf314be8-48e6-4158-ba0a-296598f0c1fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9ea37f53-ac68-4a4e-aac4-357a7fa13f64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_163b85b6-849f-484c-908c-c506a40b598b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5c8c8e6c-dc1c-4e3b-9625-ec421e4f99d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:AgreementsWithPfizerIncAndLegochemBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_a7460a4a-43b1-45a4-98f8-5736508db488">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:LegoChemLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_38e9b9ce-48eb-4a5a-a998-eeab38167e13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
        </entity>
        <period>
            <instant>2023-03-21</instant>
        </period>
    </context>
    <context id="C_f0dc477c-0a31-42e2-b84e-32a6047229aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c48b4d06-4690-4a44-ad08-1d47a45d7069">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_3389ea65-f351-4b62-b0ce-6e94188e7981">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_466cd526-a6e1-4fea-9b6a-9ed2473eda8d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">pyxs:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SubleaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-02</instant>
        </period>
    </context>
    <context id="C_a1de02fe-e0e6-413a-b471-0f1518c7ea8a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b0e457cc-4ee1-4962-882e-7cdda5c5a1d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwothousandtwentytwoequityinducementplanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3d815e67-ceab-4431-bce9-20d33a91f2dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pyxs:UniversityLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0aaf1ee4-befe-4b18-b335-1a09ea9d6b96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5e26e7a4-9894-40ab-9e05-0b5c0cf9ee51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_fe914f5c-2d5d-4dbc-9ba9-aab3f109118d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="C_da4afd79-994b-493e-8986-8748cbb9b1f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="C_4fe8a1ab-50a0-48b5-951b-24bf559a7115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c0722afc-490f-4a94-9fc9-f07e63c7ee4d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_db0b438d-a530-4514-b2e4-b58d0c1167a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pyxs:UniversityLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_85b71da5-c5ad-4ef2-b3fa-15ed03b03ade">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5478d9a9-32de-4b14-a7d9-c5a5e108dfa0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_967897c5-c155-4f05-933c-68db3867f01a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_84cf517c-82fd-437e-b63e-4d987372dee8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:LegoChemLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_53e9aeb6-174d-402f-8c2f-b1df11873669">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a5dd394e-5224-4d6a-bf00-62f63373e448">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_f6a77c26-5d28-4ad5-be66-8947787249a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4460d945-b64a-45f5-af82-5ed6de882504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_e407da6f-df2b-430d-8ab8-23f237d727f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6f4aa2e1-b13f-4cc9-a66d-bd0c94991ce0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_adc6355e-17ce-4144-a867-ae971f7735e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesAConvertiblePreferredStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="C_53f21008-ad1c-494d-bca3-09d4d9bb06f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_671ff9d5-4324-4bce-bc54-ecdc38e8840f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_43213977-374c-49b1-8370-aa4e647874fe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:BiosionLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_00119c4b-52cf-4804-ac21-c9c54ee69b67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_39ee5c29-3e12-49e2-946c-de8d95e7af1a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1d6dfd74-4dd3-4d8d-ade5-27835ecdb4ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="C_6da87304-fe59-4975-99b3-27f5fd2ceb69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_4a91be42-9646-464e-a10b-8cf7d387c4f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pyxs:VoxallMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pyxs:AlloyTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_6adee125-dbcb-4f6a-b664-d9891421fd72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-05</instant>
        </period>
    </context>
    <context id="C_706b851a-18a8-416b-8796-5d143cc0bd07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9194297f-b13d-4587-9fe5-fcc007d82f0e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2caa6904-2924-4060-8a2d-3b3cec935236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:LegoChemLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-31</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="C_fb9e3219-0355-4d5e-8d21-c73eefcac6c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_09c28f97-719c-42ef-a251-1140fcd23e11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pyxs:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_efd5ca4b-dd20-4280-870e-b98268ab08eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_3722df37-e565-465f-bb4b-034fdf13c6ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pyxs:UnvestedRestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_6378744b-423a-4a6b-972a-85f28e55d021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_2e52bce4-48fd-4d5c-8c03-b3c7a4ce8258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesAConvertiblePreferredStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="C_39d48607-26ba-431a-ac8a-d3b4ffb3641d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_48de2a5c-eadc-4299-a519-18facbfa1720">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a7b2c38b-0a9d-45f4-9d96-7571430846e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="C_e311d53d-fcab-422f-9f96-6793c81e2f3c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_08a1f0a8-28d8-47d4-a0dd-966a0c736ac3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_f4712df5-2590-48af-9284-6195c97975a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pyxs:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e54e83a0-b25b-418c-b85c-d5c2ca67e4c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7f8a7acb-6ab0-451e-8b00-67975a1ecf54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pyxs:StockOptionsAvailableForIssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_bae164c2-2642-4b70-85fd-0d414f578d75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5f97b551-d4c5-4d8c-95ef-8c2b79aac91a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:AgreementsWithPfizerIncAndLegochemBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_1c996d2e-def1-46a6-a4e5-dd50cc8ddbfa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e41e2b33-e797-4eaf-ab2c-e21d506eef7d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="C_df8cfd51-bc03-4a95-b0a5-24677e60cdc1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="C_4673806d-5b9d-43ee-aed1-9c1f8ab9e297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:BiosionLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-28</startDate>
            <endDate>2022-03-28</endDate>
        </period>
    </context>
    <context id="C_5779ffa7-ef54-4318-b0b8-ed0b0cb8c6b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ccb57e6f-0f25-4bfd-96c2-4d333afebc0b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesAConvertiblePreferredStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_96ed1430-e72f-4da1-9065-31aa0a3ed55e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f1ffa94f-ab1a-4b1c-85bc-689829d80a9f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwothousandtwentytwoequityinducementplanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_98ff73fd-5dca-4046-abbc-fee18b4eea2d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2c0f07bf-9ab0-42b4-921b-a98e8aea7faf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:NonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:LegoChemLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_de5078e1-9398-411e-9b9d-a3b0e59ba4db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_453b4504-5d6b-406e-8878-c49bf593ff1e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pyxs:StockOptionsAvailableForIssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_8e2d7745-07cf-4ad1-90b5-7d195c47708c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_622e53e6-f8fa-4c10-a051-8ba806014c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f4ce7ade-74e0-45ba-8c22-a5ba47efa398">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2ae41d03-8671-4c50-80d0-d05659459fdb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwothousandtwentytwoequityinducementplanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a8379558-2ae3-4803-896a-b59ad651d3b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pyxs:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4881d8cf-3758-45cf-9629-35b8395ed61a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pyxs:VoxallMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_Days">
        <measure>pyxs:Days</measure>
    </unit>
    <unit id="U_Segment">
        <measure>pyxs:Segment</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_Lease">
        <measure>pyxs:Lease</measure>
    </unit>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_26aa710e-2ffa-4cd0-bc6a-fe75f8ecd043">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_375ab7b5-f3d4-409a-a33f-662272797faf"
      decimals="8"
      id="F_21fd044a-b819-46e1-b788-a6db20d760e8"
      unitRef="U_pure">0.15725743</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      id="F_75a80392-2b27-400f-a0cf-7ce4dabe8391"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_75c9cf87-9bea-4479-b9a0-51fd354b8283">0001782223</dei:EntityCentralIndexKey>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_e41e2b33-e797-4eaf-ab2c-e21d506eef7d"
      decimals="8"
      id="F_2c1f21b5-66b1-456a-be0d-8b2e18d9a8f1"
      unitRef="U_pure">0.15725743</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:PreferredStockValue
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      id="F_00af17d6-813e-4e14-882a-ed1d6e7ac76a"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_39ee5c29-3e12-49e2-946c-de8d95e7af1a"
      id="F_41c663ee-99b7-4ec5-8325-a97c8245ffa8">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_f1ffa94f-ab1a-4b1c-85bc-689829d80a9f"
      id="F_2078513f-c53f-43d5-970f-e0c43d587906">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      id="F_b428182c-65cb-436d-ad3d-3dafc7163ff1"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_f4ce7ade-74e0-45ba-8c22-a5ba47efa398"
      id="F_41e41108-0a2f-4aeb-862b-b3c3f3023412">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <dei:AmendmentFlag
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_d611e941-4710-44ff-876f-7ae06b2a44a8">false</dei:AmendmentFlag>
    <us-gaap:PreferredStockValue
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      id="F_a2ce678e-6dad-403a-8b9e-c365b9d6f501"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:DocumentType
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_d7b842f6-e1d7-477d-97b9-5e30a063be5b">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_9c1a1456-6ebe-4eba-9c89-267e70c63d60">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_360eebb6-513d-4d44-bec4-c939bc0c3121">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_f6475505-b154-4299-82a5-f715333ebd74">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_5acbaa35-3dcb-4be4-84b7-6748dda7b920">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_e7ea0f11-893b-49c0-b35d-91bf41d5ee55">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_edd1796a-1b47-4d70-95e7-065988a8776f">001-40881</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_1f7d7b59-516d-41bc-aeaf-f9ebf8a36ff0">Pyxis Oncology, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_f4dafdad-484e-4eb1-92fa-c3516392de48">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_6c9a37b6-b0ca-42fd-9b27-ef039ebbae76">83-1160910</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_ba20a7c7-9153-4b68-adc3-c8f4fb687441">150 Cambridgepark Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_7614f85d-6c19-4937-a711-13e6d224b397">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_3bc8a45c-a599-49fe-8249-b7cae1b03917">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_b65f61f9-0831-4e9b-a440-0017ab3b3a54">02140</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_4db554cc-355e-4938-81d9-829216b65297">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_037e4f96-c311-47a0-946a-d74c99314a57">221-9059</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_9e3c39af-ce9d-4cdd-a03b-f2ed9c0173a4">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_f704e9a6-7819-4d68-b5cf-ad59cd80d16d">PYXS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_dc1aaf07-d223-4c48-9beb-d29b612f0e76">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_c270360d-a487-4912-80e4-cc73b58764da">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_6517539a-9ccd-485b-8221-99608b8c518e">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_de3b6bdf-3935-4558-ba46-82fc308ad0d3">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_ed7e0fda-3e9c-48e6-b77e-a989e37cee0f">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_4e024beb-4ab2-4a2d-a681-0770e5b30231">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_1befa643-62db-4a92-96aa-df6020cebece">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_51d04845-666d-494f-8d63-1529e72e6c0d">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_7ed8902f-d741-47e9-8012-fac4f641f011">true</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_1318667a-6179-48b6-8eb5-6bff4565b345">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_35f2d4c4-ba93-4c29-a03f-df1d54919bfd">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_00119c4b-52cf-4804-ac21-c9c54ee69b67"
      decimals="-5"
      id="F_9b2b6008-003a-404d-99d4-d37086b35aef"
      unitRef="U_USD">76900000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_38e9b9ce-48eb-4a5a-a998-eeab38167e13"
      decimals="INF"
      id="F_def12a5a-5a9d-4c92-af9a-d19a50b9c542"
      unitRef="U_shares">36980621</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_079d766f-af96-40dd-bea5-f0e0a8165165">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Portions of the Registrant&#x2019;s Proxy Statement for its 2023 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein. Such Proxy Statement will be filed with the Securities and Exchange Commission within 120 days of the registrant&#x2019;s fiscal year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_d4aa8cb6-3198-4dcc-a420-320c219c7d99">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_6e6db33c-c670-49b0-bea4-9b92995a52e4">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_9ab248d6-8a29-4ffe-a80f-0da91cddb6cb">Boston, Massachusetts</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_f77df0be-b36e-4eb0-9fb4-304a93701b1a"
      unitRef="U_USD">179293000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_dbb1fae5-7206-482c-a0e1-56ba5d943102"
      unitRef="U_USD">274735000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_1ba6b95b-dc5f-4cb1-8be9-97964a23973b"
      unitRef="U_USD">1472000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_f0b04946-033d-4bbb-ab58-147e170c9c0f"
      unitRef="U_USD">1472000</us-gaap:RestrictedCashCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_6e2a0a02-281f-48ba-ac2d-fd5156df618e"
      unitRef="U_USD">5847000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_c47c72ca-15a2-473a-acd3-90e23967329c"
      unitRef="U_USD">2466000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_91efea23-c023-4aad-ad13-7a8002959032"
      unitRef="U_USD">186612000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_067a4cf7-fa5a-4a96-8c5a-595e20e547b1"
      unitRef="U_USD">278673000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_8ee0e6f7-5949-4918-8a99-4f1db4d40866"
      unitRef="U_USD">11165000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_7346dd59-6309-480f-9978-9a8f5f3ed2e1"
      unitRef="U_USD">1007000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_000c0ab5-975f-43f5-8387-6283b2ea1cd4"
      unitRef="U_USD">13602000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_2518903d-d9a1-4aad-a07f-911f272a5943"
      unitRef="U_USD">232000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_61a35903-aabb-4792-ac29-31e8f2180739"
      unitRef="U_USD">109000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_6320e7bb-d155-426d-9b36-66c065376b78"
      unitRef="U_USD">211379000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_ac6a8f46-7e40-4abe-8876-ffca2b22ec1d"
      unitRef="U_USD">280021000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_1613405a-b409-4fb5-84aa-d543b051d547"
      unitRef="U_USD">7097000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_560a1372-d552-4ddb-856b-67adc92f0b95"
      unitRef="U_USD">11951000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_c5835064-a2ea-4fa0-afd7-f63062813d3f"
      unitRef="U_USD">24537000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_25720e36-8501-4bd7-a2a1-690474ddab7d"
      unitRef="U_USD">6592000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_f09da2fa-1f70-4a80-bece-e7c8344a6738"
      unitRef="U_USD">165000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_9df3f90c-9499-4087-b0eb-b7d1fc34e2f0"
      unitRef="U_USD">31634000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_ebc7d8b5-0cd8-4739-abc0-d0571402fb9b"
      unitRef="U_USD">18708000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_cc8a478f-53e2-4d87-ad4f-7e7a4e81121d"
      unitRef="U_USD">18921000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_34033721-78db-4b26-b55e-f55d7361997d"
      unitRef="U_USD">50555000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_c22c6d56-0d96-4469-b964-6efb7bfe4081"
      unitRef="U_USD">18708000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="INF"
      id="F_7a979be3-8efb-4609-919a-518da8b737bc"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="INF"
      id="F_b3aef1db-1617-4d6d-b134-82b5083860c6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="INF"
      id="F_d45a208a-1379-42b0-8f1a-c56dc23ee2ab"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="INF"
      id="F_73ecc630-75b1-4301-b905-de9a610d1ca7"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="INF"
      id="F_4bf55630-1a02-48ac-81c6-afd188116887"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="INF"
      id="F_61fac355-b3c5-41c7-b4da-0dcbc9ebd90f"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="INF"
      id="F_9c3570cb-3cc7-49f2-b9c6-3e5113d24ffe"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="INF"
      id="F_df515620-3083-48b7-8a65-c7752d9e5670"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="INF"
      id="F_0bf11c4b-0180-4565-85de-fcbe3603bd56"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="INF"
      id="F_07110ba9-1b37-40f2-a960-0cb7839adce8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="INF"
      id="F_eb3fda72-3c51-468f-8ce1-5a3f47268989"
      unitRef="U_shares">190000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="INF"
      id="F_3877c111-9db1-476d-aed0-31774bfd3f70"
      unitRef="U_shares">190000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="INF"
      id="F_3c5c4569-3958-466f-bfa6-c8ca800f2b8e"
      unitRef="U_shares">35110016</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="INF"
      id="F_31d31057-244f-45ee-9098-9b165f395234"
      unitRef="U_shares">32792867</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="INF"
      id="F_757c2f76-716a-4e51-84b4-6a73302815e9"
      unitRef="U_shares">34958730</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="INF"
      id="F_1ee4b183-a2ce-4eed-b58d-14e337eaa4c1"
      unitRef="U_shares">32222881</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_00b6712f-b0e8-4b5d-b47a-da5bc07db260"
      unitRef="U_USD">34000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_e911c4ef-0914-4927-a9c1-69f4c908a164"
      unitRef="U_USD">32000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_be0a2518-572b-4447-8622-1ab450dd40ef"
      unitRef="U_USD">373225000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_fa6706dc-a97b-4f3f-8bb5-ed77b0591495"
      unitRef="U_USD">352999000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_4d89fb4c-2d90-4053-a2f0-56ce921f2437"
      unitRef="U_USD">-212435000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_fd18533d-89f6-4f66-b36e-44a1da9f21bd"
      unitRef="U_USD">-91718000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_d4408e7e-7efb-4edc-8dd2-3db29d8ee514"
      unitRef="U_USD">160824000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_c223880a-0234-4a73-b3b2-82e4d00152a9"
      unitRef="U_USD">261313000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_e88f6638-d0a4-4c78-8bc2-e96b3c23194b"
      unitRef="U_USD">211379000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_ca3c5581-4f3c-4e6f-b299-7441c9b0cb03"
      unitRef="U_USD">280021000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="-3"
      id="F_f7b6b5a8-cf1e-4d39-a327-0f29c879c2c3"
      unitRef="U_USD">86129000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="-3"
      id="F_31224bd2-40bf-49a8-8a6e-ca56fd15bbb1"
      unitRef="U_USD">51054000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="-3"
      id="F_7905669c-da59-4b80-b0d8-df93757d75a8"
      unitRef="U_USD">37352000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="-3"
      id="F_14915534-ca76-47b7-9317-ca7ed7dc04c7"
      unitRef="U_USD">18663000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="-3"
      id="F_88421dfa-26e5-48be-8ea2-f9a5a1e80e02"
      unitRef="U_USD">123481000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="-3"
      id="F_0930ef4d-0412-4e4f-8bfb-233c4ea53a8b"
      unitRef="U_USD">69717000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="-3"
      id="F_9ef3833f-ced3-4c96-9960-95939a769b6f"
      unitRef="U_USD">-123481000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="-3"
      id="F_15262f68-6ed6-42bb-8576-a02a4070f953"
      unitRef="U_USD">-69717000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="-3"
      id="F_d896adde-1cbe-46b9-84a2-20b322b836fe"
      unitRef="U_USD">2764000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="-3"
      id="F_ac6634bb-7bb9-4889-8cda-b72aa846959f"
      unitRef="U_USD">23000</us-gaap:InvestmentIncomeInterest>
    <pyxs:ServiceFeeIncomeFromRelatedParty
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="-3"
      id="F_84868a23-e73a-43ab-9752-dfa257eb3063"
      unitRef="U_USD">181000</pyxs:ServiceFeeIncomeFromRelatedParty>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="-3"
      id="F_a9dd97b3-c268-40e4-a145-86b59246727c"
      unitRef="U_USD">-6231000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="-3"
      id="F_07f0bb50-dbe7-4b26-a6a6-9714df9485e5"
      unitRef="U_USD">2764000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="-3"
      id="F_69af4052-7e13-4e60-b865-904799839d6e"
      unitRef="U_USD">-6027000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="-3"
      id="F_ccab80d8-e272-443d-8ef0-311d4bfe32c4"
      unitRef="U_USD">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="-3"
      id="F_99e7cca8-cf16-49c9-b934-c164a6045630"
      unitRef="U_USD">-231000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="-3"
      id="F_24dafaa2-2f1b-417f-af82-7d232995c71c"
      unitRef="U_USD">-120717000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="-3"
      id="F_26d6ba2e-a116-401c-9a47-8b24f72f92a1"
      unitRef="U_USD">-75975000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="2"
      id="F_23217c58-cbb3-4d24-9ad3-ba93769a2e14"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.65</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="2"
      id="F_04b142d3-ff0f-4f68-a740-7a5309aa1ee5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.65</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="2"
      id="F_ee7d5069-e7bd-441c-8817-99723d5db99f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-8.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="2"
      id="F_51c23966-0d91-4af0-80c3-75840b587608"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-8.95</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="0"
      id="F_a4772deb-5f59-45e1-8704-0d0a0a3af0b6"
      unitRef="U_shares">33033081</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="0"
      id="F_181f5ba5-dbe3-4201-8895-d5339e769ac9"
      unitRef="U_shares">33033081</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="0"
      id="F_e3faed05-1937-4115-bf7a-d6066eda6057"
      unitRef="U_shares">8493273</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="0"
      id="F_f978ad06-40af-4bb2-9b2e-c12c544f7a03"
      unitRef="U_shares">8493273</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_b7382cca-33a6-4f4e-9ad5-9ec9267d027f"
      decimals="INF"
      id="F_6c4aabeb-608b-4ff6-aaa9-553c3bca4682"
      unitRef="U_shares">22724925</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_b7382cca-33a6-4f4e-9ad5-9ec9267d027f"
      decimals="-3"
      id="F_2a61c7f9-433c-4e9e-ab1b-a897d5ebc573"
      unitRef="U_USD">21942000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="C_d17eff6a-c465-4999-9b00-c89ab59f6085"
      decimals="INF"
      id="F_d92d99de-b8ec-4ac9-a361-363d1089de16"
      unitRef="U_shares">1289342</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_d17eff6a-c465-4999-9b00-c89ab59f6085"
      decimals="-3"
      id="F_b8ffdb6b-6d87-4a27-8b15-76e583264d3b"
      unitRef="U_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_07d0bbc1-f9a2-43f9-8983-bf7982db0cbd"
      decimals="-3"
      id="F_2cab8aa7-0788-4300-a8d5-c1e756f3fcbe"
      unitRef="U_USD">97000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_21e45814-d1c9-49d0-b212-624324f81c19"
      decimals="-3"
      id="F_bffb2274-d1b4-4683-9d6d-bfdea5529262"
      unitRef="U_USD">-15743000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4460d945-b64a-45f5-af82-5ed6de882504"
      decimals="-3"
      id="F_5240999c-2c45-448e-9bfd-3d1f048fa882"
      unitRef="U_USD">-15645000</us-gaap:StockholdersEquity>
    <pyxs:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_a5dd394e-5224-4d6a-bf00-62f63373e448"
      decimals="INF"
      id="F_e1d2f84e-4568-4626-879d-32674fb2ab11"
      unitRef="U_shares">12152145</pyxs:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="C_a5dd394e-5224-4d6a-bf00-62f63373e448"
      decimals="-3"
      id="F_0db3b881-54b5-4968-b16f-2da5ff54abd2"
      unitRef="U_USD">20000000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <pyxs:TemporaryEquityIssuanceCosts
      contextRef="C_83982012-10a6-4487-8dce-be863732bf86"
      decimals="-3"
      id="F_3fe2b1c5-1148-41a6-82d5-4db19fa98202"
      unitRef="U_USD">419000</pyxs:TemporaryEquityIssuanceCosts>
    <pyxs:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_ffecffd1-fb25-4239-b101-0b9e9224e3c5"
      decimals="INF"
      id="F_60525367-a49f-435c-b5cb-e03b95201efc"
      unitRef="U_shares">92660103</pyxs:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="C_ffecffd1-fb25-4239-b101-0b9e9224e3c5"
      decimals="-3"
      id="F_3879eb03-832e-479b-8a67-bc1ce67ad9b7"
      unitRef="U_USD">152081000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="C_2b2bc485-3a60-4ce8-850d-05c0692602e2"
      decimals="-3"
      id="F_35a314d6-9e3a-4b7e-9122-cfd17d94eccc"
      unitRef="U_USD">15704000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_de8208ab-bcfc-47b0-b387-5579dfad9705"
      decimals="INF"
      id="F_53b0a928-b8b0-471d-b6aa-525e974242b6"
      unitRef="U_shares">10500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_de8208ab-bcfc-47b0-b387-5579dfad9705"
      decimals="-3"
      id="F_013767bc-9dc7-4f20-b7d4-40262e501a23"
      unitRef="U_USD">11000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_d753a366-cbec-4a3f-8e6d-a172249fde7b"
      decimals="-3"
      id="F_d2ce6306-5850-402c-bac3-ccf3a7bf4ec3"
      unitRef="U_USD">152285000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_22898140-752b-4c56-a019-59406d30b9a2"
      decimals="-3"
      id="F_5571f57e-467f-490e-aa36-b5f424c53796"
      unitRef="U_USD">152296000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <pyxs:TemporaryEquityConvertiblePreferredStockConvertedIntoSharesOfCommonStock
      contextRef="C_ffecffd1-fb25-4239-b101-0b9e9224e3c5"
      decimals="INF"
      id="F_4f2eaccc-b84a-4205-9a49-89bd2cb2c918"
      unitRef="U_shares">-127537173</pyxs:TemporaryEquityConvertiblePreferredStockConvertedIntoSharesOfCommonStock>
    <pyxs:TemporaryEquityConvertiblePreferredStockConvertedIntoCommonStockValue
      contextRef="C_ffecffd1-fb25-4239-b101-0b9e9224e3c5"
      decimals="-3"
      id="F_40952fb5-4595-4bc2-9f51-d6680d666f02"
      unitRef="U_USD">-194023000</pyxs:TemporaryEquityConvertiblePreferredStockConvertedIntoCommonStockValue>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_5e26e7a4-9894-40ab-9e05-0b5c0cf9ee51"
      decimals="INF"
      id="F_07f97213-13d6-460c-ba28-2ac865be3033"
      unitRef="U_shares">20056145</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_5e26e7a4-9894-40ab-9e05-0b5c0cf9ee51"
      decimals="-3"
      id="F_9d19b788-04bb-4885-a4b6-3e929099a9d2"
      unitRef="U_USD">20000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_8e2d7745-07cf-4ad1-90b5-7d195c47708c"
      decimals="-3"
      id="F_02fd240b-ac24-4638-b5bb-1421c368370d"
      unitRef="U_USD">194003000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="-3"
      id="F_48507914-14d2-47ee-ae93-0766fe65c8ee"
      unitRef="U_USD">194023000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_5e26e7a4-9894-40ab-9e05-0b5c0cf9ee51"
      decimals="INF"
      id="F_3402c8f5-d786-41e1-b821-c19293beec91"
      unitRef="U_shares">70396</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_8e2d7745-07cf-4ad1-90b5-7d195c47708c"
      decimals="-3"
      id="F_44c08c25-1674-4888-bc8f-6878aa239d34"
      unitRef="U_USD">170000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="-3"
      id="F_3795117f-ce3d-453d-b244-de7e86ca82b4"
      unitRef="U_USD">170000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_5e26e7a4-9894-40ab-9e05-0b5c0cf9ee51"
      decimals="INF"
      id="F_04ec58c0-c989-494c-8569-84e1b2245828"
      unitRef="U_shares">306998</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_8e2d7745-07cf-4ad1-90b5-7d195c47708c"
      decimals="-3"
      id="F_a5374442-f165-4f0d-90a8-3f8e3b0ce6aa"
      unitRef="U_USD">3000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="-3"
      id="F_ab159ef6-c2e0-47c8-8569-2ebf31c34bc4"
      unitRef="U_USD">3000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_8e2d7745-07cf-4ad1-90b5-7d195c47708c"
      decimals="-3"
      id="F_7bf31454-b931-46cd-a985-1c3390b4df04"
      unitRef="U_USD">6441000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="-3"
      id="F_5119ebf4-719a-4322-aef0-f0e0d9bba694"
      unitRef="U_USD">6441000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_e311d53d-fcab-422f-9f96-6793c81e2f3c"
      decimals="-3"
      id="F_ec8d38ac-a3e6-4c7b-aded-3380c9e33e5f"
      unitRef="U_USD">-75975000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="-3"
      id="F_a2dd9dae-4fee-4090-8ada-97d17b7b9a6c"
      unitRef="U_USD">-75975000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_85b71da5-c5ad-4ef2-b3fa-15ed03b03ade"
      decimals="INF"
      id="F_c414eb1a-7bac-4dda-b744-555edb91c2b7"
      unitRef="U_shares">32222881</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_85b71da5-c5ad-4ef2-b3fa-15ed03b03ade"
      decimals="-3"
      id="F_9f2933d7-fdf8-4682-abda-f38832df364d"
      unitRef="U_USD">32000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_1f7d801f-7c91-43b6-b20d-6c5b26ad7c1b"
      decimals="-3"
      id="F_84aff777-7ed7-48bb-b1a0-8a1d293cbdec"
      unitRef="U_USD">352999000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4fe8a1ab-50a0-48b5-951b-24bf559a7115"
      decimals="-3"
      id="F_089fb919-036c-4a93-8bae-c362cf50c8f5"
      unitRef="U_USD">-91718000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_4d3284a3-e624-4189-98d7-4236e18f0689"
      unitRef="U_USD">261313000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_e31029d2-1718-44fb-bbfe-596a8f71bb1d"
      decimals="INF"
      id="F_7153999a-5f65-409a-bf59-0624740ae63b"
      unitRef="U_shares">2229654</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_e31029d2-1718-44fb-bbfe-596a8f71bb1d"
      decimals="-3"
      id="F_dd06894d-7177-49a9-9820-1db2126f3c13"
      unitRef="U_USD">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_706b851a-18a8-416b-8796-5d143cc0bd07"
      decimals="-3"
      id="F_59172ff2-bcb9-48ba-a212-0e89a67cc4b5"
      unitRef="U_USD">4279000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_f891bb1b-8647-4939-8740-f3d10c242ed2"
      decimals="-3"
      id="F_4a9a9421-1635-4017-9563-e9cbaf488e24"
      unitRef="U_USD">4281000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_c0ed8f27-3a4c-4474-9fee-718c5b4c9f5f"
      decimals="INF"
      id="F_01817c59-0a4f-4d92-9453-018244aafcbc"
      unitRef="U_shares">73841</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_3f691b8c-c469-4e4a-96b6-9103063b1982"
      decimals="-3"
      id="F_c36ec260-17eb-4790-890e-74098b59da4b"
      unitRef="U_USD">183000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="-3"
      id="F_8e834ee1-0430-4747-bb35-9a278bbd87be"
      unitRef="U_USD">183000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_c0ed8f27-3a4c-4474-9fee-718c5b4c9f5f"
      decimals="INF"
      id="F_adb11212-427d-47e4-bb81-84b325e72b63"
      unitRef="U_shares">432354</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_3f691b8c-c469-4e4a-96b6-9103063b1982"
      decimals="-3"
      id="F_1f161f04-25f1-47b3-8eeb-270eefc8bd56"
      unitRef="U_USD">15764000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="-3"
      id="F_fba64715-7849-4893-9178-4191729043bb"
      unitRef="U_USD">15764000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_dadd6f97-7a5c-4e8e-b808-bf02287c4b0a"
      decimals="-3"
      id="F_ed8900dd-92f4-4fd1-b744-8bfa93ccf4c3"
      unitRef="U_USD">-120717000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="-3"
      id="F_8e41995a-d1ea-4bb4-9863-f1a22c91b086"
      unitRef="U_USD">-120717000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_39d48607-26ba-431a-ac8a-d3b4ffb3641d"
      decimals="INF"
      id="F_5d0f120c-b367-415f-8735-9e3c503abf9e"
      unitRef="U_shares">34958730</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_39d48607-26ba-431a-ac8a-d3b4ffb3641d"
      decimals="-3"
      id="F_98701ff7-3fef-48b5-8665-277a9db21428"
      unitRef="U_USD">34000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_93a31468-e176-4adc-8cfc-d60e8d2102f2"
      decimals="-3"
      id="F_4c6db28e-adeb-4d2b-ac8b-c6deff5c39af"
      unitRef="U_USD">373225000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c0722afc-490f-4a94-9fc9-f07e63c7ee4d"
      decimals="-3"
      id="F_6ab88177-cfb9-435f-b67a-495f2081ca54"
      unitRef="U_USD">-212435000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_8eec8cb5-9415-4140-a67b-508b64ffa862"
      unitRef="U_USD">160824000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="-3"
      id="F_799e58b5-d38f-4308-9547-73e2ec379197"
      unitRef="U_USD">-120717000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="-3"
      id="F_50c7e9b8-58db-4c5e-9f16-5c2439a285c0"
      unitRef="U_USD">-75975000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="-3"
      id="F_fb80a35b-b99f-4aa5-b153-e99c28c6c49e"
      unitRef="U_USD">709000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="-3"
      id="F_b8d3b1a1-8823-4c5a-81e0-de4ef880a3df"
      unitRef="U_USD">647000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="-3"
      id="F_1f7c07db-4462-4c00-acbe-7d603f44b597"
      unitRef="U_USD">15764000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="-3"
      id="F_abe1f05b-f91d-4f43-b15c-f153f4e3ca69"
      unitRef="U_USD">6441000</us-gaap:ShareBasedCompensation>
    <pyxs:NonCashResearchAndDevelopmentExpense
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="-3"
      id="F_ddead4c3-99a8-4162-80f7-376eafd4203e"
      unitRef="U_USD">9281000</pyxs:NonCashResearchAndDevelopmentExpense>
    <pyxs:NonCashResearchAndDevelopmentExpense
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="-3"
      id="F_e30ef7b1-2b66-462e-b71e-02583e060888"
      unitRef="U_USD">20000000</pyxs:NonCashResearchAndDevelopmentExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="-3"
      id="F_7806ad03-9173-4dde-ad97-383a3ad00144"
      unitRef="U_USD">1127000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="-3"
      id="F_c8cd4cfa-474a-41fd-923f-2e8b8bb538fd"
      unitRef="U_USD">604000</us-gaap:OperatingLeaseExpense>
    <pyxs:NonCashGainLossFromEquityMethodInvestmentInJointVenture
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="-3"
      id="F_36468cc6-2548-4375-9df8-22f5650de6e2"
      unitRef="U_USD">-50000</pyxs:NonCashGainLossFromEquityMethodInvestmentInJointVenture>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="-3"
      id="F_0079618c-53cc-4bd8-8c31-f0639449dc5e"
      unitRef="U_USD">-6231000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="-3"
      id="F_fd608f0b-fc5f-4cd3-99a1-08a7e585e86e"
      unitRef="U_USD">3381000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="-3"
      id="F_71169218-f757-4b92-9f79-a8dfb3ef6879"
      unitRef="U_USD">2444000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="-3"
      id="F_97977d15-710e-44b9-9dad-68f51372eceb"
      unitRef="U_USD">-8328000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="-3"
      id="F_233544e3-ebc7-43ed-abec-4be57c8fb6e6"
      unitRef="U_USD">4643000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="-3"
      id="F_e8a2024f-9806-488d-b3ad-8c7309e17da7"
      unitRef="U_USD">11951000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="-3"
      id="F_c9aff77c-87a1-4a20-ab05-04e9cc6749ea"
      unitRef="U_USD">5092000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="-3"
      id="F_bd7a31a5-63d0-418b-8500-f647ec6acbb7"
      unitRef="U_USD">4259000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="-3"
      id="F_10bc9711-d718-4b5d-a6bb-af68eae1fb45"
      unitRef="U_USD">-615000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="-3"
      id="F_c8128bbd-153d-4981-bb32-01addd217a36"
      unitRef="U_USD">-89335000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="-3"
      id="F_ae2158a3-935a-4e81-bbc6-661f8f8ed226"
      unitRef="U_USD">-35326000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="-3"
      id="F_214a1fd1-f1fe-4c0f-9f07-f7faa4ee0140"
      unitRef="U_USD">6399000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="-3"
      id="F_204cfee0-d3a2-4a98-ac8d-65b8391169f0"
      unitRef="U_USD">540000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInterestInJointVenture
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="-3"
      id="F_c5118153-11a6-4f00-b317-77f84be8a44f"
      unitRef="U_USD">50000</us-gaap:PaymentsToAcquireInterestInJointVenture>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="-3"
      id="F_509acf03-ff2c-4f03-bdbd-050ccde011cc"
      unitRef="U_USD">-6399000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="-3"
      id="F_48a70272-5807-43ca-b2e9-80822fbaa70c"
      unitRef="U_USD">-590000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="-3"
      id="F_495ba30e-6f9a-4931-ada7-5f1fc3e78b98"
      unitRef="U_USD">151581000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="-3"
      id="F_12ece6f4-7f91-4e22-bf89-81ccc9746041"
      unitRef="U_USD">152296000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="-3"
      id="F_682597bd-2f81-439c-a5cd-1c4fa8d9f325"
      unitRef="U_USD">183000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="-3"
      id="F_a219fb88-cd97-41b6-be63-124e7917a4a3"
      unitRef="U_USD">167000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="-3"
      id="F_665d2a55-d2db-4ca7-9626-518239c01f14"
      unitRef="U_USD">183000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="-3"
      id="F_1d9e0471-aa12-40f9-999f-7a879c1e59a3"
      unitRef="U_USD">304044000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="-3"
      id="F_e2f4e1ce-56c4-4b37-b2ad-8fd45fe7fe38"
      unitRef="U_USD">-95551000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="-3"
      id="F_14d2e1f2-4b81-4903-b3de-f063500aec52"
      unitRef="U_USD">268128000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_788e0265-ce73-48ec-979a-d2a6f07aad2f"
      unitRef="U_USD">276316000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_4460d945-b64a-45f5-af82-5ed6de882504"
      decimals="-3"
      id="F_2c4d5beb-2c48-4f6c-a658-eb14dd6ee645"
      unitRef="U_USD">8188000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_b0bbeaaa-31e7-4a0a-b5f5-dda27211b565"
      unitRef="U_USD">180765000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_9165d944-712f-4f9d-b47c-7c3a78b31767"
      unitRef="U_USD">276316000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <pyxs:CashReceivedForInterest
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="-3"
      id="F_0260926a-bc3e-4c86-bc83-ac30085e03b9"
      unitRef="U_USD">2166000</pyxs:CashReceivedForInterest>
    <us-gaap:IncomeTaxesPaid
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="-3"
      id="F_b0ae8ce8-3936-41f7-b899-3ca8ab78003b"
      unitRef="U_USD">17000</us-gaap:IncomeTaxesPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="-3"
      id="F_c32c81ca-d8e7-4787-bb34-032d9face39a"
      unitRef="U_USD">4479000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="-3"
      id="F_84f3342b-320b-4b17-8869-81df75339eed"
      unitRef="U_USD">11000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="-3"
      id="F_cf12b3ea-5117-4009-9b97-50302b3c878a"
      unitRef="U_USD">14497000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_f6c654ad-e66f-4e73-9cbe-721f064cfbd5"
      unitRef="U_USD">179293000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_a48ee119-1b49-492e-8ffc-297f0c86960c"
      unitRef="U_USD">274735000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_074f6ec1-a2db-4aec-a994-dd4d8f1846c6"
      unitRef="U_USD">1472000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_2a9410a3-aa7d-482e-88c7-692e2ab4e80e"
      unitRef="U_USD">1581000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_22340cd5-8536-47c2-ada7-a462e10eec2a"
      unitRef="U_USD">180765000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_4431c01d-1775-47ea-8df5-e332cdeb9576"
      unitRef="U_USD">276316000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_2f0147dd-67d9-455d-90af-56590913ee7c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1. Description &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;of Business&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Nature of Business&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Pyxis Oncology, Inc. (the &#x201c;Company&#x201d;), a Delaware corporation, was founded in June 2018 and launched its operations in July 2019. The Company is a clinical stage company focused on defeating difficult-to-treat cancers. The company is efficiently building next-generation therapeutics that hold the potential for mono and combination therapies. The Company's therapeutic candidates are designed to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. The Company's antibody-drug conjugates ("ADCs") and immuno-oncology ("IO") programs employ novel and emerging strategies to target a broad range of solid tumors resistant to current standards of care.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; operating segment. The Company&#x2019;s chief operating decision maker, its Chief Executive Officer, manages the Company&#x2019;s operations on a consolidated basis for the purposes of assessing performance and allocating resources.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <pyxs:NatureOfBusinessPolicyTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_7f15c21e-ce1a-472c-a32e-e659514af919">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Nature of Business&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Pyxis Oncology, Inc. (the &#x201c;Company&#x201d;), a Delaware corporation, was founded in June 2018 and launched its operations in July 2019. The Company is a clinical stage company focused on defeating difficult-to-treat cancers. The company is efficiently building next-generation therapeutics that hold the potential for mono and combination therapies. The Company's therapeutic candidates are designed to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. The Company's antibody-drug conjugates ("ADCs") and immuno-oncology ("IO") programs employ novel and emerging strategies to target a broad range of solid tumors resistant to current standards of care.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; operating segment. The Company&#x2019;s chief operating decision maker, its Chief Executive Officer, manages the Company&#x2019;s operations on a consolidated basis for the purposes of assessing performance and allocating resources.&lt;/span&gt;&lt;/p&gt;</pyxs:NatureOfBusinessPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="INF"
      id="F_30698667-058f-4f1a-82bb-630824ebf859"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_72a18483-4508-4611-afbc-d74d75300057">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2. Basis of Presentation and Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s fiscal year ends on December 31 and its first three quarters end on March 31, June 30 and September 30. The accompanying consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). The consolidated financial statements include the Company and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated upon consolidation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is an &#x201c;emerging growth company,&#x201d; as defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). Section 107(b) of the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company has irrevocably elected not to avail itself of this extended transition period, and, as a result, the Company will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Liquidity&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, the Company had an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;212.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. The Company has incurred losses and negative cash flows from operations since inception, including net losses of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;120.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;76.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the years ended December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has not generated any revenue to date and does not anticipate generating any revenues unless and until it successfully completes development and obtains regulatory approval for its current or any future product candidates. The Company expects that its operating losses and negative cash flows will continue for the foreseeable future as the Company continues to expand its research and development programs and develop its product candidates.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company currently expects that its existing cash and cash equivalents of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;179.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million as of December 31, 2022 will fund its operating expenses and capital requirements at least twelve months from the date these audited consolidated financial statements are issued. Additional funding may be necessary to fund future clinical and preclinical activities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company plans to continue to fund its losses from operations and capital funding needs through public or private equity, convertible or debt financing or other sources. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, or suspend or curtail planned programs. Any of these actions could materially harm the Company&#x2019;s business, results of operations and future prospects.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expense, and related disclosures. The Company regularly evaluates estimates and assumptions related to assets, liabilities, stock-based compensation, operating leases, assessment of the useful lives of property and equipment, valuation of deferred tax assets and liabilities, impairment of investment in joint venture, and research and development costs. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Actual results could differ from those estimates and there may be changes to management&#x2019;s estimates in future periods.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is subject to risks common to early-stage companies in the biopharmaceutical industry including, but not limited to, uncertainties related to commercialization of products, regulatory approvals, dependence on key suppliers for active ingredients and third-party service providers such as contract research and manufacturing organizations, protection of intellectual property rights and the ability to make milestone, royalty or other payments due under any license, collaboration or supply agreements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risks&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial instruments that subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company&#x2019;s cash and cash equivalents are held at an accredited financial institution and the Company has not experienced any losses in such accounts. The Company maintains its cash in bank deposit accounts, which at times may exceed federally insured limits. The Company&#x2019;s cash equivalents consist primarily of short-term money market funds held in accredited financial institutions. The Company believes it is not exposed to any significant risk in cash and cash equivalents.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company considers all short term, highly liquid investments with original maturities of 90 days or less to be cash equivalents. Cash equivalents consist primarily of money market funds as of December 31, 2022 and 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principle or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, the first two are considered observable and the last is considered unobservable:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Level&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; 1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Level&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; 2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;Quoted prices in markets that are not considered to be active or financial instrument valuations for which all significant inputs are observable, either directly or indirectly; and&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Level&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; 3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Property and Equipment, net&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment are recorded at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful lives of the related assets as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:73.0%;"/&gt;
          &lt;td style="width:2.037%;"/&gt;
          &lt;td style="width:24.963%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Estimated Useful&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Furniture and office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shorter of remaining life&lt;br/&gt;of lease or useful life&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Construction in process&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;N/A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;and amortization expense is included in research and development and general and administrative expenses. Major additions and upgrades are capitalized; maintenance and repairs, which do not improve or extend the life of the respective assets, are expensed as incurred. Upon retirement or sale, the cost of assets disposed of, and the related accumulated depreciation and amortization are removed from the respective accounts and any resulting gain or loss is included in income (loss) from operations.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company evaluates the long-lived assets, which consist of property and equipment and operating lease right-of-use assets, for impairment at least annually and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. Management then determines whether the remaining useful life continues to be appropriate, or whether there has been an impairment of long-lived assets based primarily upon whether expected future undiscounted cash flows are sufficient to support the assets&#x2019; recovery. Recoverability of these assets is measured by comparison of the carrying amount of the asset to the future undiscounted cash flows the asset is expected to generate. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. The Company recognized &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; impairment losses for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;lease right-of-use (&#x201c;ROU&#x201d;) assets represent the Company&#x2019;s right to use an underlying asset during the lease term, and operating lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease ROU assets and lease liabilities are initially recognized and measured based on the present value of the future fixed lease payments over the expected lease term at the commencement date calculated using the Company&#x2019;s incremental borrowing rate applicable to the lease asset, unless the implicit rate is readily determinable. The Company determines the lease term as the non-cancelable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease ROU assets also include any initial direct costs incurred and any lease payments made on or before the lease commencement date, less lease incentives received. Operating lease ROU assets are subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Leases with a term of 12 months or less are not recognized on the consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Variable lease costs such as common area costs and other operating costs are expensed as incurred. The Company accounts for lease and non-lease components as a single lease component for all its facilities leases. The Company had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; finance leases as of December 31, 2022 and 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Investment in Joint Venture&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Investment in the Company&#x2019;s joint venture is accounted for using the equity method of accounting. The Company applies the equity method of accounting to investments when the Company has significant influence, but not controlling interest in the investee. Judgment regarding the level of influence over equity method investment includes considering key factors such as ownership interest, representation on the board of directors, participation in policy-making decisions and material intercompany transactions. Under the equity method, investments are initially recorded at cost and are adjusted for dividends, distributed and undistributed earnings and losses, and additional investments. In the event the Company&#x2019;s share of a joint venture&#x2019;s cumulative losses exceeds the Company&#x2019;s investment balance, the balance is reported at zero value until proportionate income exceeds the losses. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company assesses investments for impairment whenever events or changes in circumstances indicate that the carrying value of an investment may not be recoverable.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company, from time to time, may be a party to various disputes and claims arising from normal business activities. The Company continually assesses disputes and claims including resulting litigation to determine if an unfavorable outcome would lead to a probable loss or reasonably possible loss which could be estimated. The Company accrues for all contingencies at the earliest date at which the Company deems it probable that a liability has been incurred and the amount of such liability can be reasonably estimated. If the estimate of a probable loss is a range and no amount within the range is more likely than another, the Company accrues the minimum of the range. In the cases where the Company believes that a reasonably possible loss exists, the Company discloses the facts and circumstances of the contingencies, including an estimable range, if possible.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company expenses research and development costs as incurred. The Company&#x2019;s research and development expenses consist primarily of license fees to acquire intellectual property which does not meet the definition of intangible assets and costs incurred in performing research and development activities, including personnel-related expenses such as salaries, stock-based compensation and benefits, facilities costs, depreciation as well as external costs from third parties who conduct research and development activities (including manufacturing) on behalf of the Company. The Company accrues expenses related to development activities performed by third parties based on an evaluation of services received and efforts expended pursuant to the terms of the contractual arrangements. Payments under some of these contracts depend on preclinical and/or clinical trial milestones. There may be instances in which payments made to the Company&#x2019;s vendors will exceed the level of services provided and result in a prepayment of expenses. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company adjusts the accrual or prepaid expense accordingly.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company maintains an equity incentive plan as a long-term incentive for employees, consultants, and directors. The Company accounts for all stock-based awards granted to employees and non-employees based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. The grant date fair value of the stock-based awards with graded vesting is recognized on a straight-line basis over the requisite service period. The Company recognizes forfeitures related to stock-based compensation awards as they occur and reverses any previously recognized compensation cost associated with forfeited awards in the period the forfeiture occurs. The Company classifies stock-based compensation expense in the statement of operations in the same manner in which the award recipients&#x2019; payroll costs are classified or in which the award recipients&#x2019; service payments are classified.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company values its stock options with service conditions using the Black-Scholes option-pricing model. The Company uses certain assumptions to determine fair value of the stock options pursuant to the Black-Scholes option-pricing model, including the expected life of the award, volatility of the underlying shares, the risk-free interest rate, expected dividend yield and the fair value of the Company&#x2019;s common stock. Since the Company lacks sufficient historical option exercise data to provide a reasonable basis upon which to estimate the expected term, the Company uses the simplified method described in the SEC&#x2019;s Staff Accounting Bulletin No. 107, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Share-Based Payment &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&#x201c;SAB 107&#x201d;), to determine the expected life of the option grants. The Company lacks sufficient company-specific historical and implied volatility information. Therefore, the Company estimates the expected stock volatility based on the historical volatility of a publicly traded set of peer companies. The risk-free interest rate is based on the rates paid on securities issued by the U.S. Treasury with a term approximating the expected life of the equity award. As the Company has never paid and does not anticipate paying cash dividends on its common stock, the expected dividend yield is considered as zero.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prior to the completion of the Company&#x2019;s initial public offering ("IPO") of common stock, the fair value of the Company's common stock which is one of the key inputs in Black-Scholes option-pricing model, was determined by the board of directors with input from management and based on certain assumptions including probability weighting of events, business and market conditions, volatility, time to liquidation, a risk-free interest rate and an assumption for a discount for lack of marketability. The Company used 409A valuations to determine the fair value of the shares of common stock. The 409A valuations were performed using methodologies, approaches, and assumptions consistent with the American Institute of Certified Public Accountants &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. After completion of the IPO on October 8, 2021, the Company uses the fair value of its publicly traded common stock to determine grant date fair value.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounts for income taxes in accordance with FASB ASC 740, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (&#x201c;ASC 740&#x201d;), which requires the use of the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between amounts in the consolidated financial statements and the tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income tax (benefit) expense in the consolidated statements of operations and comprehensive loss in the period that includes the enactment date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes deferred tax assets to the extent that it believes these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Net Loss per Share&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic net income (loss) per share attributable to common stockholders is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the diluted weighted average number of common shares outstanding for the period, including potential dilutive common shares.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In periods in which the Company reports a net loss, all common stock equivalents are deemed anti-dilutive such that basic net loss per common share and diluted net loss per common share are equivalent. Potentially dilutive common stock has been excluded from the diluted net loss per common share computations in all periods presented because such securities have an anti-dilutive effect on net loss per common share due to the Company&#x2019;s net loss. There are no reconciling items used to calculate the weighted-average number of total common stock outstanding for basic and diluted net loss per common share data.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (&#x201c;ASU 2016-13&#x201d;), which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss model that requires the use of forward-looking information to calculate credit loss estimates. It also eliminates the concept of other-than-temporary impairment and requires credit losses on available-for-sale debt securities to be recorded through an allowance for credit losses instead of as a reduction in the amortized cost basis of the securities. For "emerging growth companies", ASU 2016-13 is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. The Company is currently evaluating the new standard and expects it to have no material impact on the Company's consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Debt &#x2013; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40) &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&#x201c;ASU 2020-06&#x201d;). ASU 2020-06 revises the guidance on calculating earnings per share, requiring use of the if-converted method for all convertible instruments and rescinding an entity&#x2019;s ability to rebut the presumption of share settlement for instruments that may be settled in cash or other assets. As an "emerging growth company", ASU 2020-06 will become effective for the Company for fiscal years beginning after December 15, 2023, and early adoption is permitted. The Company is currently evaluating the new standard and expects it to have no material impact on the Company's consolidated financial statements and related disclosures.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Recent authoritative guidance issued by the FASB (including technical corrections to the ASC), the American Institute of Certified Public Accountants, and the SEC did not, or are not expected to, have a material impact on the Company&#x2019;s audited consolidated financial statements and related disclosures.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_b1be25a6-d5da-44ee-a06e-429adee7993f">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s fiscal year ends on December 31 and its first three quarters end on March 31, June 30 and September 30. The accompanying consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). The consolidated financial statements include the Company and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated upon consolidation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is an &#x201c;emerging growth company,&#x201d; as defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). Section 107(b) of the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company has irrevocably elected not to avail itself of this extended transition period, and, as a result, the Company will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <pyxs:LiquidityPolicyTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_1d992552-0430-4b69-9e79-32fa234bebed">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Liquidity&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, the Company had an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;212.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. The Company has incurred losses and negative cash flows from operations since inception, including net losses of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;120.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;76.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the years ended December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has not generated any revenue to date and does not anticipate generating any revenues unless and until it successfully completes development and obtains regulatory approval for its current or any future product candidates. The Company expects that its operating losses and negative cash flows will continue for the foreseeable future as the Company continues to expand its research and development programs and develop its product candidates.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company currently expects that its existing cash and cash equivalents of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;179.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million as of December 31, 2022 will fund its operating expenses and capital requirements at least twelve months from the date these audited consolidated financial statements are issued. Additional funding may be necessary to fund future clinical and preclinical activities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company plans to continue to fund its losses from operations and capital funding needs through public or private equity, convertible or debt financing or other sources. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, or suspend or curtail planned programs. Any of these actions could materially harm the Company&#x2019;s business, results of operations and future prospects.&lt;/span&gt;&lt;/p&gt;</pyxs:LiquidityPolicyTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-5"
      id="F_b3ef92ad-08ee-4c5e-a6ff-d5ab7c9dacb3"
      unitRef="U_USD">-212400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetIncomeLoss
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="-5"
      id="F_78a4f0e6-903d-43af-ba0b-fb7b707bedc2"
      unitRef="U_USD">-120700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="-5"
      id="F_7bd00b07-6887-47e6-ae8d-136c1f8fadfc"
      unitRef="U_USD">-76000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-5"
      id="F_6b2bf50b-2930-45c3-b77d-8564896a8060"
      unitRef="U_USD">179300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:UseOfEstimates
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_d4a2545b-86ff-482a-ac89-4bff2e556fc8">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expense, and related disclosures. The Company regularly evaluates estimates and assumptions related to assets, liabilities, stock-based compensation, operating leases, assessment of the useful lives of property and equipment, valuation of deferred tax assets and liabilities, impairment of investment in joint venture, and research and development costs. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Actual results could differ from those estimates and there may be changes to management&#x2019;s estimates in future periods.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <pyxs:RisksAndUncertaintiesPolicyTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_99478180-13b6-4157-8e59-95e9f6d4f209">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is subject to risks common to early-stage companies in the biopharmaceutical industry including, but not limited to, uncertainties related to commercialization of products, regulatory approvals, dependence on key suppliers for active ingredients and third-party service providers such as contract research and manufacturing organizations, protection of intellectual property rights and the ability to make milestone, royalty or other payments due under any license, collaboration or supply agreements.&lt;/span&gt;&lt;/p&gt;</pyxs:RisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_3c8d2bc5-76e9-4726-88a0-f461f2446bb7">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risks&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial instruments that subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company&#x2019;s cash and cash equivalents are held at an accredited financial institution and the Company has not experienced any losses in such accounts. The Company maintains its cash in bank deposit accounts, which at times may exceed federally insured limits. The Company&#x2019;s cash equivalents consist primarily of short-term money market funds held in accredited financial institutions. The Company believes it is not exposed to any significant risk in cash and cash equivalents.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_966977eb-49e0-47a6-8b69-66a0a7ebd866">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company considers all short term, highly liquid investments with original maturities of 90 days or less to be cash equivalents. Cash equivalents consist primarily of money market funds as of December 31, 2022 and 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_9c457ab0-1eb2-4044-b4b8-9ce4f83cf489">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principle or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, the first two are considered observable and the last is considered unobservable:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Level&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; 1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Level&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; 2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;Quoted prices in markets that are not considered to be active or financial instrument valuations for which all significant inputs are observable, either directly or indirectly; and&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Level&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; 3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_111182bd-d681-4cb2-8da9-031ccf676799">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Property and Equipment, net&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment are recorded at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful lives of the related assets as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:73.0%;"/&gt;
          &lt;td style="width:2.037%;"/&gt;
          &lt;td style="width:24.963%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Estimated Useful&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Furniture and office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shorter of remaining life&lt;br/&gt;of lease or useful life&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Construction in process&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;N/A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;and amortization expense is included in research and development and general and administrative expenses. Major additions and upgrades are capitalized; maintenance and repairs, which do not improve or extend the life of the respective assets, are expensed as incurred. Upon retirement or sale, the cost of assets disposed of, and the related accumulated depreciation and amortization are removed from the respective accounts and any resulting gain or loss is included in income (loss) from operations.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <pyxs:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_9562f89a-1b00-4343-b82a-a4b6cb36878d">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment are recorded at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful lives of the related assets as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:73.0%;"/&gt;
          &lt;td style="width:2.037%;"/&gt;
          &lt;td style="width:24.963%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Estimated Useful&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Furniture and office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shorter of remaining life&lt;br/&gt;of lease or useful life&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Construction in process&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;N/A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</pyxs:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_cf314be8-48e6-4158-ba0a-296598f0c1fa"
      id="F_f99bc6e4-dde6-4783-b40a-747263583873">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_98ff73fd-5dca-4046-abbc-fee18b4eea2d"
      id="F_7b054131-23b0-4568-8a5b-e44bacd03e3c">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="C_915e850b-ae03-438e-afb7-244101692549"
      id="F_265cfcd7-4e38-4e59-ad89-9f1914edd5dc">Shorter of remaining lifeof lease or useful life</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_8e9770fa-8077-4908-bd79-c300d55ba66d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company evaluates the long-lived assets, which consist of property and equipment and operating lease right-of-use assets, for impairment at least annually and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. Management then determines whether the remaining useful life continues to be appropriate, or whether there has been an impairment of long-lived assets based primarily upon whether expected future undiscounted cash flows are sufficient to support the assets&#x2019; recovery. Recoverability of these assets is measured by comparison of the carrying amount of the asset to the future undiscounted cash flows the asset is expected to generate. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. The Company recognized &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; impairment losses for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="INF"
      id="F_196f33b4-994a-4b12-8c6a-4fa5b5611a7e"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="INF"
      id="F_9d7355fb-8f33-4041-af31-e5ddfde587a9"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_c0411a81-dbb0-4dc9-bdfc-f0e6c49cdf7e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;lease right-of-use (&#x201c;ROU&#x201d;) assets represent the Company&#x2019;s right to use an underlying asset during the lease term, and operating lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease ROU assets and lease liabilities are initially recognized and measured based on the present value of the future fixed lease payments over the expected lease term at the commencement date calculated using the Company&#x2019;s incremental borrowing rate applicable to the lease asset, unless the implicit rate is readily determinable. The Company determines the lease term as the non-cancelable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease ROU assets also include any initial direct costs incurred and any lease payments made on or before the lease commencement date, less lease incentives received. Operating lease ROU assets are subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Leases with a term of 12 months or less are not recognized on the consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Variable lease costs such as common area costs and other operating costs are expensed as incurred. The Company accounts for lease and non-lease components as a single lease component for all its facilities leases. The Company had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; finance leases as of December 31, 2022 and 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <pyxs:NumberOfFinanceLease
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="INF"
      id="F_d4d9cdc4-f0b0-470e-89b8-7c5a2408706b"
      unitRef="U_Lease">0</pyxs:NumberOfFinanceLease>
    <pyxs:NumberOfFinanceLease
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="INF"
      id="F_12d369cc-4250-4257-8746-326d0e03ef02"
      unitRef="U_Lease">0</pyxs:NumberOfFinanceLease>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_13832a71-ea80-4758-ba3e-cdb2814b492d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Investment in Joint Venture&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Investment in the Company&#x2019;s joint venture is accounted for using the equity method of accounting. The Company applies the equity method of accounting to investments when the Company has significant influence, but not controlling interest in the investee. Judgment regarding the level of influence over equity method investment includes considering key factors such as ownership interest, representation on the board of directors, participation in policy-making decisions and material intercompany transactions. Under the equity method, investments are initially recorded at cost and are adjusted for dividends, distributed and undistributed earnings and losses, and additional investments. In the event the Company&#x2019;s share of a joint venture&#x2019;s cumulative losses exceeds the Company&#x2019;s investment balance, the balance is reported at zero value until proportionate income exceeds the losses. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company assesses investments for impairment whenever events or changes in circumstances indicate that the carrying value of an investment may not be recoverable.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_5029a56d-0cd6-43f1-8395-387cab3e93c4">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company, from time to time, may be a party to various disputes and claims arising from normal business activities. The Company continually assesses disputes and claims including resulting litigation to determine if an unfavorable outcome would lead to a probable loss or reasonably possible loss which could be estimated. The Company accrues for all contingencies at the earliest date at which the Company deems it probable that a liability has been incurred and the amount of such liability can be reasonably estimated. If the estimate of a probable loss is a range and no amount within the range is more likely than another, the Company accrues the minimum of the range. In the cases where the Company believes that a reasonably possible loss exists, the Company discloses the facts and circumstances of the contingencies, including an estimable range, if possible.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_fbfa1981-5160-4aea-83bb-33ee39b4d520">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company expenses research and development costs as incurred. The Company&#x2019;s research and development expenses consist primarily of license fees to acquire intellectual property which does not meet the definition of intangible assets and costs incurred in performing research and development activities, including personnel-related expenses such as salaries, stock-based compensation and benefits, facilities costs, depreciation as well as external costs from third parties who conduct research and development activities (including manufacturing) on behalf of the Company. The Company accrues expenses related to development activities performed by third parties based on an evaluation of services received and efforts expended pursuant to the terms of the contractual arrangements. Payments under some of these contracts depend on preclinical and/or clinical trial milestones. There may be instances in which payments made to the Company&#x2019;s vendors will exceed the level of services provided and result in a prepayment of expenses. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company adjusts the accrual or prepaid expense accordingly.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_1e653a7f-06c6-4c64-a08c-a2784045e811">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company maintains an equity incentive plan as a long-term incentive for employees, consultants, and directors. The Company accounts for all stock-based awards granted to employees and non-employees based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. The grant date fair value of the stock-based awards with graded vesting is recognized on a straight-line basis over the requisite service period. The Company recognizes forfeitures related to stock-based compensation awards as they occur and reverses any previously recognized compensation cost associated with forfeited awards in the period the forfeiture occurs. The Company classifies stock-based compensation expense in the statement of operations in the same manner in which the award recipients&#x2019; payroll costs are classified or in which the award recipients&#x2019; service payments are classified.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company values its stock options with service conditions using the Black-Scholes option-pricing model. The Company uses certain assumptions to determine fair value of the stock options pursuant to the Black-Scholes option-pricing model, including the expected life of the award, volatility of the underlying shares, the risk-free interest rate, expected dividend yield and the fair value of the Company&#x2019;s common stock. Since the Company lacks sufficient historical option exercise data to provide a reasonable basis upon which to estimate the expected term, the Company uses the simplified method described in the SEC&#x2019;s Staff Accounting Bulletin No. 107, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Share-Based Payment &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&#x201c;SAB 107&#x201d;), to determine the expected life of the option grants. The Company lacks sufficient company-specific historical and implied volatility information. Therefore, the Company estimates the expected stock volatility based on the historical volatility of a publicly traded set of peer companies. The risk-free interest rate is based on the rates paid on securities issued by the U.S. Treasury with a term approximating the expected life of the equity award. As the Company has never paid and does not anticipate paying cash dividends on its common stock, the expected dividend yield is considered as zero.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prior to the completion of the Company&#x2019;s initial public offering ("IPO") of common stock, the fair value of the Company's common stock which is one of the key inputs in Black-Scholes option-pricing model, was determined by the board of directors with input from management and based on certain assumptions including probability weighting of events, business and market conditions, volatility, time to liquidation, a risk-free interest rate and an assumption for a discount for lack of marketability. The Company used 409A valuations to determine the fair value of the shares of common stock. The 409A valuations were performed using methodologies, approaches, and assumptions consistent with the American Institute of Certified Public Accountants &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. After completion of the IPO on October 8, 2021, the Company uses the fair value of its publicly traded common stock to determine grant date fair value.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_da88ec1f-82e2-4d39-830a-e2ff267bbf32">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounts for income taxes in accordance with FASB ASC 740, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (&#x201c;ASC 740&#x201d;), which requires the use of the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between amounts in the consolidated financial statements and the tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income tax (benefit) expense in the consolidated statements of operations and comprehensive loss in the period that includes the enactment date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes deferred tax assets to the extent that it believes these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_51ea7f9f-b80b-4e67-9da4-b5c43bcb1de1">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Net Loss per Share&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic net income (loss) per share attributable to common stockholders is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the diluted weighted average number of common shares outstanding for the period, including potential dilutive common shares.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In periods in which the Company reports a net loss, all common stock equivalents are deemed anti-dilutive such that basic net loss per common share and diluted net loss per common share are equivalent. Potentially dilutive common stock has been excluded from the diluted net loss per common share computations in all periods presented because such securities have an anti-dilutive effect on net loss per common share due to the Company&#x2019;s net loss. There are no reconciling items used to calculate the weighted-average number of total common stock outstanding for basic and diluted net loss per common share data.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <pyxs:RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_daaef799-6e7f-4f40-af72-7cb486393590">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (&#x201c;ASU 2016-13&#x201d;), which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss model that requires the use of forward-looking information to calculate credit loss estimates. It also eliminates the concept of other-than-temporary impairment and requires credit losses on available-for-sale debt securities to be recorded through an allowance for credit losses instead of as a reduction in the amortized cost basis of the securities. For "emerging growth companies", ASU 2016-13 is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. The Company is currently evaluating the new standard and expects it to have no material impact on the Company's consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Debt &#x2013; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40) &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&#x201c;ASU 2020-06&#x201d;). ASU 2020-06 revises the guidance on calculating earnings per share, requiring use of the if-converted method for all convertible instruments and rescinding an entity&#x2019;s ability to rebut the presumption of share settlement for instruments that may be settled in cash or other assets. As an "emerging growth company", ASU 2020-06 will become effective for the Company for fiscal years beginning after December 15, 2023, and early adoption is permitted. The Company is currently evaluating the new standard and expects it to have no material impact on the Company's consolidated financial statements and related disclosures.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Recent authoritative guidance issued by the FASB (including technical corrections to the ASC), the American Institute of Certified Public Accountants, and the SEC did not, or are not expected to, have a material impact on the Company&#x2019;s audited consolidated financial statements and related disclosures.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</pyxs:RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock>
    <pyxs:LicensingAgreementsTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_5dc4c4ae-ddca-4502-a93d-0b06fad33284">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3. Licensing Agreements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;The University of Chicago Agreement&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In April 2020, the Company entered into a license agreement (the &#x201c;University License Agreement&#x201d;), as well as a sponsored research agreement, with the University of Chicago (the &#x201c;University&#x201d;). Under the terms of the license, the Company has the global right to develop and commercialize products that are covered by a valid claim of a licensed patent, incorporate or use the licensed know-how and materials or are known to assess, modulate or utilize the activity of certain specified biological targets. In partial consideration for the license from the University, the Company issued to the University &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;48,919&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of its common stock in 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Pursua&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;nt to the University License Agreement, the Company is obligated to pay potential development and commercial milestones of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million as well as running royalties on net sales of licensed products at varying rates ranging from less than a percent to the low single digits, subject to a minimum annual royalty of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million during certain years following the effective date. The Company is also obligated to pay the University a percentage of certain sublicensing revenue ranging from low- to mid-teens based on the date of entering into the applicable sublicense.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company assessed the milestone and royalty events under University License Agreement as of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and 2021, and determined that &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; such amounts were required.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Pfizer Inc. Agreement&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In December 2020, the Company entered into a license agreement (as amended, the &#x201c;Pfizer License Agreement&#x201d;) with Pfizer Inc. (&#x201c;Pfizer&#x201d;) for worldwide development and commercialization rights to ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates. The Company&#x2019;s rights are exclusive with respect to certain patents owned or controlled by Pfizer covering the licensed ADCs. Pfizer has also granted the Company a non-exclusive license to use Pfizer&#x2019;s ADC technology (&#x201c;FACT&#x201d;) platform. The initial licensed targets include CD123 and extra domain B (EDB of fibronectin) and the Company has the option to expand the scope of its license to add additional licensed targets that have not been licensed to a third party or are not the subject of a Pfizer ADC development program. The Pfizer License Agreement became effective in March 2021 and the Company paid a combined $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the license fee, consisting of an upfront cash payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,152,145&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of Series B convertible preferred stock, which was converted into &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,911,015&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of its common stock upon the IPO in October 2021, with a value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to Pfizer.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On October 6, 2022, the Company entered into an amended and restated license agreement (the &#x201c;A&amp;amp;R License Agreement&#x201d;) with Pfizer, which amends and restates the Pfizer License Agreement. Pursuant to the A&amp;amp;R License Agreement, Pfizer granted to the Company exclusive worldwide rights under Pfizer&#x2019;s FACT Platform technology to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates. Additional ADC targets may be licensed for a nominal upfront payment and milestones. Further, the Company granted the right of first negotiation to Pfizer, on an exclusive basis, to purchase or to develop, manufacture and commercialize licensed ADCs and licensed products in one or more countries directed to EDB and CD123. In accordance with the terms of the A&amp;amp;R License Agreement, the Company agreed to pay $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to Pfizer (which was paid in January 2023) and issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,229,654&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of its common stock. Additionally, the Company will issue such number of shares of common stock &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;180&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; days following the effective date (the &#x201c;Issuance Date&#x201d;), equivalent to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million at a per share price equal to the closing price of the Company&#x2019;s common stock on the business day prior to the Issuance Date, such that Pfizer&#x2019;s ownership interest in the Company shall not exceed nineteen and a half percent (&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%) with any difference in value between the value of shares and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million being payable in cash. The Company recorded $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million as research and development expenses for the A&amp;amp;R License Agreement during fourth quarter of the calendar year 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is also obligated to pay future contingent payments including development, regulatory and commercial milestones up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;665&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the first four licensed ADCs. In addition, the Company is required to pay future contingent payments including development, regulatory and commercial milestones for ADCs to each additional licensed target beyond the first four licensed ADC targets developed and commercialized via the FACT Platform. Additionally, if ADC licensed products are launched, the Company will pay Pfizer tiered royalties on net sales of licensed products in varying royalty rates ranging from low single digits to mid-teens. The Company&#x2019;s royalty obligations apply on a licensed product-by-licensed product and country-by-country basis from first commercial sale until the latest to occur of: (1) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years from first commercial sale; (2) the expiration of all regulatory or data exclusivity; and (3) the expiration of the last valid claim of a licensed patent covering the licensed product in a country. The Company is also obligated to pay Pfizer a percentage of certain sublicensing revenue ranging from twenty percent to low-double digits based on the stage of development of the licensed product at the time of entering into the applicable sublicense.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company assessed the milestone and royalty events under A&amp;amp;R License Agreement as of December 31, 2022 and 2021, and determined that &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; such amounts were required.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;LegoChem Biosciences, Inc. Agreements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In December 2020, the Company entered into a license agreement (the &#x201c;LegoChem License Agreement&#x201d;) and an opt-in, investment and additional consideration agreement (the &#x201c;Opt-In Agreement&#x201d;) with LegoChem Biosciences, Inc. (&#x201c;LegoChem&#x201d;). Pursuant to the LegoChem License Agreement, the Company obtained worldwide (other than Korea) license for development and commercialization rights for LCB67, an ADC product candidate targeting DLK-1, and products containing the licensed compound. The Company paid $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in March 2021 to LegoChem, which was recorded as research and development expenses. Additionally, the Company may purchase certain initial quantities of licensed products from LegoChem for an estimated cost of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is obligated to make future contingent payments including development, regulatory and commercial milestones as well as running royalties on net sales of licensed products at varying rates. During the year ended December 31, 2022, the Company stopped the continued development of LCB67, based on review and analysis of data from the toxicity studies, and anticipated clinical use and commercial prospects of anti-DLK1 ADC. Due to stoppage of clinical development of LCB67, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; amounts were due and payable related to the manufacturing of the initial quantities of licensed product as well as the milestones and royalties related to LCB67 ADC of December 31, 2022.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In addition, as part of the Opt-in Agreement, LegoChem had an option to pay $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to the Company, in exchange for the right to receive a milestone payment (the &#x201c;Extra Milestone Payment&#x201d;) of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million upon the earliest to occur of certain events, including the date of pricing or offer of the first public offering of its common stock or if the Company is the subject of a change in control transaction. The Company determined that the Extra Milestone Payment met the definition and recognition condition of derivative under ASC 815, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;&#x201c;Derivatives and Hedging&#x201d; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;for which there was a binding contract and firm commitment in January 2021. An initial derivative liability was recognized for $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million with an offset to research and development expenses in January 2021. The derivative liability was re-measured at each reporting date, and as a result, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million was recorded in &#x201c;Other income (expense)&#x201d; in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2021. The liability was realized upon the IPO of the Company and Extra Milestone Payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million was paid to LegoChem in January 2022. The Company has no further obligations under the Opt-In Agreement as of December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;License Agreement with Biosion USA, Inc.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On March 28, 2022, the Company entered into a license agreement (the &#x201c;Biosion License Agreement&#x201d;) with Biosion USA, Inc. ("Biosion"), pursuant to which the Company obtained an exclusive, worldwide (other than Greater China (mainland China, Hong Kong, Macau and Taiwan)) license for development, manufacture and commercialization rights for BSI-060T, a Siglec-15 targeting antibody, an IO product candidate (now referred to as PYX-106), and products containing the licensed compound. Under the terms of the Biosion License Agreement, each party granted to the other party a right of first offer to obtain an exclusive license in the other party&#x2019;s territory (Greater China for Biosion, and the rest of the world for Pyxis) to develop, manufacture and commercialize any bi-specific or multi-specific antibody any antibody-drug conjugate controlled by a party or its affiliate that inhibits, modulates or binds to Siglec-15 as an intended mechanism of action.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Pursuant to the Biosion License Agreement, the Company paid an upfront license fee of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, which was recorded as research and development expenses. The Company is also obligated to pay future contingent payments including development, regulatory and commercial milestones up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;217.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in case of normal approval and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;222.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in case of accelerated approval. Additionally, if products are launched, the Company will pay Biosion tiered royalties on net sales of licensed products in varying royalty rates ranging from low single digits to low teens. The Company&#x2019;s royalty obligations apply on a licensed product-by-licensed product and country-by-country basis from first commercial sale until the latest to occur of: (1) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years from first commercial sale; (2) the expiration of all regulatory or data exclusivity; and (3) the expiration of the last valid claim of a licensed patent covering the licensed product in a country. The Company is also obligated to pay Biosion a percentage of certain sublicensing revenue ranging from mid-double to low-double digits based on the stage of development of the licensed product at the time of entering into the applicable sublicense.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company assessed the milestone and royalty events involving Biosion as of December 31, 2022 and determined that &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; such amounts were required.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</pyxs:LicensingAgreementsTextBlock>
    <pyxs:CommonStockIssuedToUniversity
      contextRef="C_6c431810-e959-4b5a-b476-c39c7b79b09c"
      decimals="INF"
      id="F_90cdbb3b-93c9-463b-b0a8-70143f163c1f"
      unitRef="U_shares">48919</pyxs:CommonStockIssuedToUniversity>
    <pyxs:PotentialDevelopmentAndCommercialMilestonePayment
      contextRef="C_772490ef-27c8-4a53-a78c-52e1650134c4"
      decimals="INF"
      id="F_03d80a2c-f84e-40e2-90dc-0e1e49081153"
      unitRef="U_USD">7700000</pyxs:PotentialDevelopmentAndCommercialMilestonePayment>
    <pyxs:MinimumAnnualRoyaltyFees
      contextRef="C_63b19c56-1b8a-44d0-841a-bbbe8b23192a"
      decimals="INF"
      id="F_02503f1c-a5ec-443c-8ebb-fca26d412de0"
      unitRef="U_USD">3000000.0</pyxs:MinimumAnnualRoyaltyFees>
    <pyxs:MilestoneAndRoyaltiesIncurred
      contextRef="C_3d815e67-ceab-4431-bce9-20d33a91f2dd"
      decimals="INF"
      id="F_31b10035-1daa-42a2-b71a-376724b96eb0"
      unitRef="U_USD">0</pyxs:MilestoneAndRoyaltiesIncurred>
    <pyxs:MilestoneAndRoyaltiesIncurred
      contextRef="C_4595b0e9-9dcf-4916-9f78-cc4f6d5b5648"
      decimals="INF"
      id="F_44a58517-2f85-48d4-b3c6-5f0b07b7091d"
      unitRef="U_USD">0</pyxs:MilestoneAndRoyaltiesIncurred>
    <pyxs:PaymentForLicenseFee
      contextRef="C_9ea37f53-ac68-4a4e-aac4-357a7fa13f64"
      decimals="-5"
      id="F_fff135e4-9536-431b-8b18-f63e32877ccb"
      unitRef="U_USD">25000000.0</pyxs:PaymentForLicenseFee>
    <pyxs:UpfrontPayments
      contextRef="C_9ea37f53-ac68-4a4e-aac4-357a7fa13f64"
      decimals="-5"
      id="F_2faa6396-e30b-4f62-b531-f28b0fd7838f"
      unitRef="U_USD">5000000.0</pyxs:UpfrontPayments>
    <pyxs:IssuanceOfConvertiblePreferredStockShares
      contextRef="C_1d6dfd74-4dd3-4d8d-ade5-27835ecdb4ee"
      decimals="INF"
      id="F_75d54e83-b35d-4ad6-a779-46b902f0586e"
      unitRef="U_shares">12152145</pyxs:IssuanceOfConvertiblePreferredStockShares>
    <pyxs:NumberOfCommonSharesIssuedUponConversionOfPreferredStock
      contextRef="C_72ee8eff-e4a6-4e5c-8e34-b16da25e910f"
      decimals="INF"
      id="F_48d8e0da-a21a-4d0f-ad00-8a13396dbeaf"
      unitRef="U_shares">1911015</pyxs:NumberOfCommonSharesIssuedUponConversionOfPreferredStock>
    <pyxs:ConvertiblePreferredStockSharesIssuedValue
      contextRef="C_5e0e5fda-24f4-4956-a238-9aa47842953a"
      decimals="-5"
      id="F_21cb963d-0e16-4ae5-8e6a-e3fbf8511938"
      unitRef="U_USD">20000000.0</pyxs:ConvertiblePreferredStockSharesIssuedValue>
    <pyxs:UpfrontPayments
      contextRef="C_23f0eeb1-4ec3-40f7-8427-0bbf70cd0d1c"
      decimals="-5"
      id="F_5ebe9d37-5467-4b41-8469-3cf2473e16da"
      unitRef="U_USD">8000000.0</pyxs:UpfrontPayments>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_2af509fb-9702-480c-8cbd-911f991087fa"
      decimals="INF"
      id="F_c79ecf32-274f-4f12-884c-0b6ad026c4a6"
      unitRef="U_shares">2229654</us-gaap:CommonStockSharesIssued>
    <pyxs:NumberOfDaysCommonStockIssuedFromEffectiveDate
      contextRef="C_23f0eeb1-4ec3-40f7-8427-0bbf70cd0d1c"
      decimals="INF"
      id="F_21e26427-7937-4fcb-8ecf-96d45031d438"
      unitRef="U_Days">180</pyxs:NumberOfDaysCommonStockIssuedFromEffectiveDate>
    <us-gaap:CommonStockValue
      contextRef="C_2af509fb-9702-480c-8cbd-911f991087fa"
      decimals="-5"
      id="F_37527caf-f176-4693-ab3a-fd8ef5a87e16"
      unitRef="U_USD">5000000.0</us-gaap:CommonStockValue>
    <pyxs:MaximumPercentageOfOwnershipInterest
      contextRef="C_23f0eeb1-4ec3-40f7-8427-0bbf70cd0d1c"
      decimals="3"
      id="F_fb3a160e-7be8-428e-91eb-59d45e084214"
      unitRef="U_pure">0.195</pyxs:MaximumPercentageOfOwnershipInterest>
    <us-gaap:CommonStockValue
      contextRef="C_2af509fb-9702-480c-8cbd-911f991087fa"
      decimals="-5"
      id="F_81c29a35-b828-4b25-b159-9d87ac746d87"
      unitRef="U_USD">5000000.0</us-gaap:CommonStockValue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_f891bb1b-8647-4939-8740-f3d10c242ed2"
      decimals="-5"
      id="F_3eb106b7-faae-4353-88ce-a4189496b95c"
      unitRef="U_USD">17300000</us-gaap:ResearchAndDevelopmentExpense>
    <pyxs:AggregateMilestonePayments
      contextRef="C_18591516-6c3d-465a-804c-40424d183530"
      decimals="INF"
      id="F_35b0c421-a735-4630-9348-c772618523c4"
      unitRef="U_USD">665000000</pyxs:AggregateMilestonePayments>
    <pyxs:RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale
      contextRef="C_6da87304-fe59-4975-99b3-27f5fd2ceb69"
      id="F_82920f91-cb9e-4c6f-a396-d7bf5782b842">P12Y</pyxs:RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale>
    <pyxs:MilestoneAndRoyaltiesIncurred
      contextRef="C_e54e83a0-b25b-418c-b85c-d5c2ca67e4c7"
      decimals="INF"
      id="F_f057a6eb-0551-48fa-9b2a-811e1f82fcff"
      unitRef="U_USD">0</pyxs:MilestoneAndRoyaltiesIncurred>
    <pyxs:MilestoneAndRoyaltiesIncurred
      contextRef="C_fa5ee9fe-cc4b-4842-b6f4-396be31d8300"
      decimals="INF"
      id="F_4d98d585-c37d-4b0d-8e4e-dc51e0600f7c"
      unitRef="U_USD">0</pyxs:MilestoneAndRoyaltiesIncurred>
    <pyxs:UpfrontFee
      contextRef="C_84cf517c-82fd-437e-b63e-4d987372dee8"
      decimals="-5"
      id="F_77c3f490-131b-4e2b-80cf-2b411b2d20d1"
      unitRef="U_USD">9000000.0</pyxs:UpfrontFee>
    <pyxs:EstimatedCostToPurchaseLicensedProducts
      contextRef="C_d4e409b9-f87d-4dfd-8ff7-0b2a843ec39f"
      decimals="-5"
      id="F_416f443d-3f4f-435a-9c2c-100f2207a78a"
      unitRef="U_USD">7000000.0</pyxs:EstimatedCostToPurchaseLicensedProducts>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="C_056d4eec-ac13-4d48-b518-557aadce6575"
      decimals="INF"
      id="F_700cfb69-c305-4eb6-b0f7-b1aea0c8873d"
      unitRef="U_USD">0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <pyxs:OptionUpfrontPayment
      contextRef="C_a7460a4a-43b1-45a4-98f8-5736508db488"
      decimals="-5"
      id="F_3803ab40-4267-4f68-809a-7ffb74182694"
      unitRef="U_USD">8000000.0</pyxs:OptionUpfrontPayment>
    <pyxs:ExtraMilestonePayment
      contextRef="C_a7460a4a-43b1-45a4-98f8-5736508db488"
      decimals="-5"
      id="F_8a90ae72-7c52-40ef-a4b4-652243a29a43"
      unitRef="U_USD">9600000</pyxs:ExtraMilestonePayment>
    <pyxs:DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses
      contextRef="C_afca8c75-429e-4247-b930-08b342481fcc"
      decimals="-5"
      id="F_40868468-6926-4235-9c8c-0090b5581a84"
      unitRef="U_USD">3400000</pyxs:DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="C_2c0f07bf-9ab0-42b4-921b-a98e8aea7faf"
      decimals="-5"
      id="F_835e9cda-d1bf-4086-b784-ff8621fbc2c2"
      unitRef="U_USD">6200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <pyxs:ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized
      contextRef="C_2caa6904-2924-4060-8a2d-3b3cec935236"
      decimals="-5"
      id="F_8899686a-6911-4007-998b-1c69dd75f290"
      unitRef="U_USD">9600000</pyxs:ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized>
    <pyxs:UpfrontFee
      contextRef="C_9188f657-2f90-466d-b42f-29e1c97321d0"
      decimals="-5"
      id="F_d115b6b8-b967-4530-aed9-d2414a145984"
      unitRef="U_USD">10000000.0</pyxs:UpfrontFee>
    <pyxs:AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval
      contextRef="C_7f69dc96-1c3c-4d15-bee7-ceb32b6a4546"
      decimals="-5"
      id="F_489505e1-f0c2-4526-a244-a9efbe78bcec"
      unitRef="U_USD">217500000</pyxs:AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval>
    <pyxs:AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval
      contextRef="C_7f69dc96-1c3c-4d15-bee7-ceb32b6a4546"
      decimals="-5"
      id="F_632989bd-0f53-4666-b8f7-5bce7ea254d0"
      unitRef="U_USD">222500000</pyxs:AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval>
    <pyxs:RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale
      contextRef="C_4673806d-5b9d-43ee-aed1-9c1f8ab9e297"
      id="F_ba94c6ed-e590-4e5e-9ada-851012eb0876">P12Y</pyxs:RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale>
    <pyxs:MilestoneAndRoyaltiesIncurred
      contextRef="C_43213977-374c-49b1-8370-aa4e647874fe"
      decimals="INF"
      id="F_15adc3c5-ef55-4237-b833-370e05e67d88"
      unitRef="U_USD">0</pyxs:MilestoneAndRoyaltiesIncurred>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_b8370498-dd90-4576-aaab-022ffa37f120">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4. Joint Venture&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In March 2021, the Company entered into definitive transaction agreements with Alloy Therapeutics, Inc. (&#x201c;Alloy&#x201d;) and Voxall Therapeutics, LLC (&#x201c;Voxall&#x201d;), to finance and operate Voxall, a joint venture company formed in collaboration with Alloy to leverage the Company&#x2019;s technology and Alloy&#x2019;s ATX-Gx&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:5.025pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x99; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;platform and antibody discovery services. Voxall granted to the Company and Alloy, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the voting membership units of Voxall in exchange for certain initial contributions.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounted for investment in Voxall under the equity method of accounting. Voxall has incurred losses since inception and the Company&#x2019;s share in the losses of Voxall aggregated to&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;million for the years ended December 31, 2022 and 2021, respectively. The Company recognized its share of losses of Voxall only to the extent of the carrying value of its&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;investment in Voxall and the promissory note issued by Voxall, which aggregated to&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;million for the year ended December 31, 2021. The remaining unabsorbed loss will be offset against future income, if any. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As the Company has no commitment to fund the losses of the equity method investment, the carrying value of the equity method investment has not been reduced below zero&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_4a91be42-9646-464e-a10b-8cf7d387c4f2"
      decimals="2"
      id="F_72352eb9-fd04-4e60-aa64-a362674ab6ab"
      unitRef="U_pure">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_6eb028fe-0dfc-4fcc-8cfd-de5ca6f2a851"
      decimals="-5"
      id="F_8eb431cb-b2db-4da9-8d85-3c826cb56fda"
      unitRef="U_USD">500000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_403332e3-9bcb-4fd2-8dda-17c8ccb33760"
      decimals="-5"
      id="F_ce1efa4e-1b22-42ec-a629-9a6581bf0020"
      unitRef="U_USD">1200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <pyxs:ProceedsFromPromissoryNoteIssued
      contextRef="C_403332e3-9bcb-4fd2-8dda-17c8ccb33760"
      decimals="-5"
      id="F_b41d1a03-6d6d-463f-959a-c952cd3f4c65"
      unitRef="U_USD">200000</pyxs:ProceedsFromPromissoryNoteIssued>
    <us-gaap:EquityMethodInvestmentDescriptionOfPrincipalActivities
      contextRef="C_6eb028fe-0dfc-4fcc-8cfd-de5ca6f2a851"
      id="F_79f58cea-d603-412a-ae07-d0cdf8f935ad">As the Company has no commitment to fund the losses of the equity method investment, the carrying value of the equity method investment has not been reduced below zero</us-gaap:EquityMethodInvestmentDescriptionOfPrincipalActivities>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_f38e5861-0152-42e8-a598-e670d91b79df">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5. Fair Value Measurements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:4.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following tables present the financial instruments carried at fair value on a recurring basis as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021, respectively, in accordance with the FASB ASC 820 hierarchy (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:4.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.699%;"/&gt;
        &lt;td style="width:1.23%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.995000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.23%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.995000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.23%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.995000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.23%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.395000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value Measurements at&lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;177,279&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;177,279&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value Measurements at&lt;br/&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;272,210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;272,210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s cash equivalents represent deposits in a short-term United States Treasury money market fund quoted in an active market and classified as a Level 1 asset. There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; assets or liabilities measured at fair value on a nonrecurring basis at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021. There were no transfers between Level 1 and Level 2 of the fair value hierarchy during the years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recorded the derivative liability of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in January 2021 for Extra Milestone Payment due under the Opt-in Agreement with LegoChem. The fair value of the derivative liability was initially determined using a probability-weighted income approach and revalued at each reporting date. Changes in the fair value of the derivative liability of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million were recorded as expense within other (expense) income in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2021. The significant unobservable inputs used in the fair value measurement of the derivative liability include probability of payment factors and the discount rate. The liability was realized upon the IPO of the Company and Extra Milestone Payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million was paid to LegoChem in January 2022. Refer to Note 3, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Licensing Agreements&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, for additional information on the derivative liability.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; Level 3 assets or liabilities as of December 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_0a351edc-586b-4e4c-a7f6-bbf94e990db7">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:4.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following tables present the financial instruments carried at fair value on a recurring basis as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021, respectively, in accordance with the FASB ASC 820 hierarchy (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:4.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.699%;"/&gt;
        &lt;td style="width:1.23%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.995000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.23%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.995000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.23%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.995000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.23%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.395000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value Measurements at&lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;177,279&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;177,279&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value Measurements at&lt;br/&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;272,210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;272,210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_671ff9d5-4324-4bce-bc54-ecdc38e8840f"
      decimals="-3"
      id="F_c45fa535-d680-45fb-8844-e5a7ac64d38d"
      unitRef="U_USD">177279000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_3bcaea08-ed4d-45f4-8fc4-c0510f776740"
      decimals="-3"
      id="F_34ad4de3-eedd-426f-8839-bf82a3e013ba"
      unitRef="U_USD">177279000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_f6a77c26-5d28-4ad5-be66-8947787249a5"
      decimals="-3"
      id="F_f4acd167-83ce-4a01-b57f-450474b01d3e"
      unitRef="U_USD">272210000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_47b0f4dc-1f2b-43a4-82d0-e3339f869c87"
      decimals="-3"
      id="F_c6ca1977-8979-423b-a8a8-b52c95b60a28"
      unitRef="U_USD">272210000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d6d15861-ed2b-4844-b8f3-06bd9a409de9"
      decimals="INF"
      id="F_66ea34cc-c061-49ad-a85e-6553cb651550"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a1de02fe-e0e6-413a-b471-0f1518c7ea8a"
      decimals="INF"
      id="F_49827f0d-1e04-40b2-8cdf-e439235c6660"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_d6d15861-ed2b-4844-b8f3-06bd9a409de9"
      decimals="INF"
      id="F_642d07c8-5d5a-4b10-91c4-cac82285f2ac"
      unitRef="U_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_a1de02fe-e0e6-413a-b471-0f1518c7ea8a"
      decimals="INF"
      id="F_31e13251-461f-4f3d-a9b5-f8178131ec0d"
      unitRef="U_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <pyxs:DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses
      contextRef="C_afca8c75-429e-4247-b930-08b342481fcc"
      decimals="-5"
      id="F_0c8ffba3-bc10-4779-b668-96fdd00c15ac"
      unitRef="U_USD">3400000</pyxs:DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="C_2c0f07bf-9ab0-42b4-921b-a98e8aea7faf"
      decimals="-5"
      id="F_4428407c-c57f-4148-b507-73add8808e8e"
      unitRef="U_USD">6200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <pyxs:ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized
      contextRef="C_2caa6904-2924-4060-8a2d-3b3cec935236"
      decimals="-5"
      id="F_c1fab83d-f681-40a0-a715-5ca6d1af734a"
      unitRef="U_USD">9600000</pyxs:ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0ca7fd08-59a5-40fc-a0ec-73b51bc9fbd9"
      decimals="INF"
      id="F_2a217c20-88a3-4414-9885-05a7fe771d3c"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_0ca7fd08-59a5-40fc-a0ec-73b51bc9fbd9"
      decimals="INF"
      id="F_7beeddea-aa1e-4e48-8f53-72e775271b46"
      unitRef="U_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_6378744b-423a-4a6b-972a-85f28e55d021"
      decimals="INF"
      id="F_16f52d25-9d41-4442-96e5-00bfbd32f533"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_6378744b-423a-4a6b-972a-85f28e55d021"
      decimals="INF"
      id="F_739ab674-e945-4a5b-a92c-84b2819b5d88"
      unitRef="U_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:OtherCurrentAssetsTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_f8b52a7a-f591-41b3-8546-b38730f850f2">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6. Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.065%;"/&gt;
        &lt;td style="width:1.622%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.645999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.622%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.043999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,560&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;619&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,308&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,763&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued interest receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;598&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;381&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,466&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_bcb14799-b364-4006-9932-f80606195e78">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.065%;"/&gt;
        &lt;td style="width:1.622%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.645999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.622%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.043999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,560&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;619&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,308&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,763&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued interest receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;598&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;381&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,466&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <pyxs:PrepaidResearchAndDevelopmentCurrent
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_a88e8313-c1cb-4351-a3d9-682c7a27d2b0"
      unitRef="U_USD">3560000</pyxs:PrepaidResearchAndDevelopmentCurrent>
    <pyxs:PrepaidResearchAndDevelopmentCurrent
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_2b47c7ff-6abc-4ded-bf6d-75dde3b9a689"
      unitRef="U_USD">619000</pyxs:PrepaidResearchAndDevelopmentCurrent>
    <us-gaap:PrepaidInsurance
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_c86c2478-04df-4483-9b52-e386aee72c5d"
      unitRef="U_USD">1308000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_ab7f79f3-fa87-4f2f-8707-6c2ee1b9c936"
      unitRef="U_USD">1763000</us-gaap:PrepaidInsurance>
    <us-gaap:InterestReceivableCurrent
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_de3ef799-1102-4f56-a4f7-87b4d2f2fd4a"
      unitRef="U_USD">598000</us-gaap:InterestReceivableCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_b9654815-bf92-4895-8fa8-10acf1aa0af9"
      unitRef="U_USD">381000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_46d77d70-7f36-4a39-8b6b-27921fdd174b"
      unitRef="U_USD">84000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_de03580e-f838-4a3b-80cf-82ca4a1732e9"
      unitRef="U_USD">5847000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_82401c02-298e-4b01-aa2f-b05b4d5a9a21"
      unitRef="U_USD">2466000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_bed7a128-98ff-4bce-9cfe-6129b4410f1e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7. Property and Equipment, Net&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, net, consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.932%;"/&gt;
        &lt;td style="width:1.619%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.818%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.619%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.012%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,247&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,804&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Furniture and office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;530&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Construction in process&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,990&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,825&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation and amortization expense for the years ended December 31, 2022 and 2021 was&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;million, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_9e21224c-9c55-40cb-81e4-9d8ed8dd498c">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, net, consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.932%;"/&gt;
        &lt;td style="width:1.619%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.818%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.619%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.012%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,247&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,804&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Furniture and office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;530&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Construction in process&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,990&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,825&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_a8379558-2ae3-4803-896a-b59ad651d3b9"
      decimals="-3"
      id="F_5320ffbd-e53c-4aea-9f1a-c290ccdc7da8"
      unitRef="U_USD">2247000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_f4712df5-2590-48af-9284-6195c97975a9"
      decimals="-3"
      id="F_3d17b76e-e578-4ae5-b5d5-245c10b0f20a"
      unitRef="U_USD">1804000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_e7d9bbba-b0b8-45c6-b0a7-dd4392b30f05"
      decimals="-3"
      id="F_b76a0ab0-ba16-4a1a-9f11-751c05b5ad65"
      unitRef="U_USD">1036000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_09c28f97-719c-42ef-a251-1140fcd23e11"
      decimals="-3"
      id="F_bc52b881-2db2-478a-adec-f484339cc2e9"
      unitRef="U_USD">94000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_622e53e6-f8fa-4c10-a051-8ba806014c88"
      decimals="-3"
      id="F_f58576d5-d5db-4257-8a3c-383c44b0ba48"
      unitRef="U_USD">530000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_5478d9a9-32de-4b14-a7d9-c5a5e108dfa0"
      decimals="-3"
      id="F_14197e04-2fcf-407b-936e-f339783d5801"
      unitRef="U_USD">225000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_163b85b6-849f-484c-908c-c506a40b598b"
      decimals="-3"
      id="F_ff417fdb-58db-4b19-a856-ecb6fee75fc9"
      unitRef="U_USD">9177000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_1db3e7aa-c581-4a05-8d2a-c94dfc433bbe"
      unitRef="U_USD">12990000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_02edc6e8-21ee-47bb-8cb0-2dfb353403b9"
      unitRef="U_USD">2123000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_ebd741cd-4279-46b9-9e05-3cdeb729e5f8"
      unitRef="U_USD">1825000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_01fee292-1d77-448d-a036-b082ba7668ae"
      unitRef="U_USD">1116000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_5c234500-45da-474b-8e3e-fb6ca3b54d0c"
      unitRef="U_USD">11165000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_94092326-d9ca-4e35-8406-789f16d78e7a"
      unitRef="U_USD">1007000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="-5"
      id="F_89ece6b3-740b-414c-8bb8-3e843f1bea47"
      unitRef="U_USD">700000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="-5"
      id="F_de99a5a9-86d7-400f-afae-3ba0c9bcd0dc"
      unitRef="U_USD">600000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_c5107091-45ea-441b-8752-d295c92ad6cc">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8. Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.065%;"/&gt;
        &lt;td style="width:1.622%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.645999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.622%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.043999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,414&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,381&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,963&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Legal and professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,091&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,592&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <pyxs:SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_57987ba0-39ce-4c1d-bae6-24143faa9795">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.065%;"/&gt;
        &lt;td style="width:1.622%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.645999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.622%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.043999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,414&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,381&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,963&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Legal and professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,091&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,592&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</pyxs:SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock>
    <pyxs:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_6ae336ab-434f-481d-942f-57ed0f71b22c"
      unitRef="U_USD">17414000</pyxs:AccruedResearchAndDevelopmentExpensesCurrent>
    <pyxs:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_0a52ac59-3107-4848-949d-cee8f082274f"
      unitRef="U_USD">2381000</pyxs:AccruedResearchAndDevelopmentExpensesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_424f155e-5d38-4ba5-b135-bc28a69f7c47"
      unitRef="U_USD">4238000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_b0215c36-69a9-4b04-9eb5-564fca6ad77d"
      unitRef="U_USD">2963000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_095d8a5f-f7d6-4ca4-80a5-71e45654efc5"
      unitRef="U_USD">1794000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_f68b1d17-4164-428f-bdde-81df1a992765"
      unitRef="U_USD">982000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_08b279ee-689f-489c-86e3-7beacf232fc3"
      unitRef="U_USD">1091000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_d826441d-33d9-40c8-a9c4-941bf62a0072"
      unitRef="U_USD">266000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_ee18e940-e1a0-403e-81ba-3a73bd96f1de"
      unitRef="U_USD">24537000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_0d99c4dd-9ee0-43ee-b49f-70643ce709e9"
      unitRef="U_USD">6592000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_caa98c84-a6c7-40d5-9723-99e88d6b0754">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9. Operating Leases&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In September 2021, the Company entered into an operating lease agreement, with a lease term commencement date of April 1, 2022, the date the Company took control of the property, for an office and laboratory space in Boston, Massachusetts. The lease payments began on December 21, 2022 and will continue through &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2032&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and with scheduled rent increases each year of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%. In addition to the rent, the Company bears the costs of certain insurance, property taxes and maintenance, which represent the Company&#x2019;s proportionate share of the actual expenses incurred by the landlord. There is an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;option to extend the lease beyond December 31, 2032.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At the lease commencement date, the operating lease ROU assets of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and lease liabilities of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million were recognized based on the present value of remaining fixed lease payments over the expected lease term using an incremental borrowing rate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%. As the Company&#x2019;s operating lease does not provide an implicit rate, an estimated incremental borrowing rate based on the information available at the time of lease commencement date was used in determining the present value of lease payments. Under the lease agreement the landlord provided for a tenant improvement allowance of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to be applied to the costs of the construction of the leasehold improvements, of which $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million was received by the Company during the year ended December 31, 2022. The tenant improvement allowance is recognized as a reduction in operating lease ROU assets and lease liabilities on the lease commencement date.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The components of lease expense were as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.492%;"/&gt;
        &lt;td style="width:1.608%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.151%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.608%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.142%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,978&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;650&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Short-term lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,681&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,780&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;730&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other information&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease right-of-use asset obtained in exchange for new operating&lt;br/&gt;&#160;&#160;&#160;lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,497&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of lease liabilities, included&lt;br/&gt;&#160;&#160;&#160;in operating cash flows&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.00&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.25&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Variable lease costs primarily relate to common area costs and other operating costs&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, which are assessed based on the Company&#x2019;s proportionate share of such costs for the leased premises. Total lease costs are included as operating expenses in the Company&#x2019;s consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Maturities of lease liabilities as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, were as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:75.252%;"/&gt;
        &lt;td style="width:2.082%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:20.667%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Years Ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,208&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,399&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,499&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total undiscounted payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;34,715&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: tenant improvement allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: present value adjustment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Present value of future payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: current portion of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease liabilities, net of current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_53f21008-ad1c-494d-bca3-09d4d9bb06f6"
      id="F_46c43839-b12c-4f18-9ad8-c2d3ee1c6d88">2032-12-31</us-gaap:LeaseExpirationDate1>
    <pyxs:RentIncreasePercentage
      contextRef="C_53f21008-ad1c-494d-bca3-09d4d9bb06f6"
      decimals="2"
      id="F_570c7dc8-1bb7-4502-ad22-b8c5406d589e"
      unitRef="U_pure">0.03</pyxs:RentIncreasePercentage>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_47830253-f4d4-4397-a12e-e52eed550ec3"
      id="F_78d12bde-cc34-416f-9024-0eeaf30c048d">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_81fa43d3-b564-417f-965e-a15f574ab549">option to extend the lease beyond December 31, 2032.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_fe914f5c-2d5d-4dbc-9ba9-aab3f109118d"
      decimals="-5"
      id="F_1c2c8412-02c3-4b94-bb3d-d582ab4619f5"
      unitRef="U_USD">15300000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_fe914f5c-2d5d-4dbc-9ba9-aab3f109118d"
      decimals="-5"
      id="F_112ec353-49c3-47d1-acc5-fcc846f69820"
      unitRef="U_USD">15300000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <pyxs:IncrementalBorrowingRate
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="3"
      id="F_406290d7-48c3-47c3-9b39-1eeba5e37354"
      unitRef="U_pure">0.094</pyxs:IncrementalBorrowingRate>
    <pyxs:TenantImprovementAllowance
      contextRef="C_fe914f5c-2d5d-4dbc-9ba9-aab3f109118d"
      decimals="-5"
      id="F_867f7bba-9c89-4ec7-b987-5e0d2b054c51"
      unitRef="U_USD">6400000</pyxs:TenantImprovementAllowance>
    <pyxs:ProceedsFromTenantImprovementAllowance
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-5"
      id="F_a9c173f6-c331-4d18-ab26-d82eb2d865ba"
      unitRef="U_USD">3000000.0</pyxs:ProceedsFromTenantImprovementAllowance>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_c9610c48-f326-403d-9de1-810ff34e1ff6">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The components of lease expense were as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.492%;"/&gt;
        &lt;td style="width:1.608%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.151%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.608%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.142%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,978&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;650&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Short-term lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,681&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,780&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;730&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other information&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease right-of-use asset obtained in exchange for new operating&lt;br/&gt;&#160;&#160;&#160;lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,497&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of lease liabilities, included&lt;br/&gt;&#160;&#160;&#160;in operating cash flows&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.00&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.25&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Variable lease costs primarily relate to common area costs and other operating costs&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, which are assessed based on the Company&#x2019;s proportionate share of such costs for the leased premises. Total lease costs are included as operating expenses in the Company&#x2019;s consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="-3"
      id="F_216dd1c6-97fb-42e5-a174-ebaa4bc91f73"
      unitRef="U_USD">1978000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="-3"
      id="F_f25d87b2-f1ab-462d-9630-6089ac657747"
      unitRef="U_USD">650000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="-3"
      id="F_b7505076-2bd5-4908-a03d-74af7cb58b94"
      unitRef="U_USD">1681000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="-3"
      id="F_cda23bb6-58f8-4c38-9cc5-269a04354278"
      unitRef="U_USD">5000</us-gaap:ShortTermLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="-3"
      id="F_c1d26570-04e3-4422-9ee3-7c477d1e6ae8"
      unitRef="U_USD">121000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="-3"
      id="F_91ec74d0-bdef-4da2-8f41-5796ae9a1fa5"
      unitRef="U_USD">75000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="-3"
      id="F_46eced01-add7-4219-97c4-f28057553fd4"
      unitRef="U_USD">3780000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="-3"
      id="F_a79724cf-3dde-415f-892c-16ef1df8dd8e"
      unitRef="U_USD">730000</us-gaap:LeaseCost>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="-3"
      id="F_26e088aa-8d6a-4f95-97e6-e012955e2617"
      unitRef="U_USD">14497000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeasePayments
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="-3"
      id="F_70efcbf0-305f-4b2f-a9fc-64a1dd155fda"
      unitRef="U_USD">663000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      id="F_40e15558-cfa1-4c7a-bae0-06bb727c4e94">P10Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      id="F_e4a81cd7-53e2-40e4-a896-851a5d21c8af">P0Y3M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="4"
      id="F_912e2c9f-adaf-4dfb-a81d-e2f85e433fd8"
      unitRef="U_pure">0.0940</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="4"
      id="F_97968d3a-e253-4de2-81f2-830f9d1ca27b"
      unitRef="U_pure">0.1000</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_428a292a-e24c-4709-91d6-4d258be86e01">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Maturities of lease liabilities as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, were as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:75.252%;"/&gt;
        &lt;td style="width:2.082%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:20.667%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Years Ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,208&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,399&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,499&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total undiscounted payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;34,715&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: tenant improvement allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: present value adjustment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Present value of future payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: current portion of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease liabilities, net of current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_0f454f63-2617-43c9-a899-283209abcf06"
      unitRef="U_USD">2557000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_629f4c84-2879-4a3d-9ca9-9f3f6e3b5a0a"
      unitRef="U_USD">3208000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_3e37d128-b423-492f-b20a-86a40897838e"
      unitRef="U_USD">3302000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_38c2e3d5-081d-4b01-8745-b5b799ea0f43"
      unitRef="U_USD">3399000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_18f4baf0-3339-4af0-9fd7-70a872166a6d"
      unitRef="U_USD">3499000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_18d93da9-a51b-43e3-9d8e-5a973081692f"
      unitRef="U_USD">18750000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_01dbae9e-1be6-4c36-a8b2-e6891c8477f7"
      unitRef="U_USD">34715000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <pyxs:TenantImprovementAllowanceReceivable
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_f4461769-bbdd-49e5-8905-9caa6cc6405f"
      unitRef="U_USD">3026000</pyxs:TenantImprovementAllowanceReceivable>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_2e12b9ee-705a-4ae0-8f7c-f51ec8f7766f"
      unitRef="U_USD">12768000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_7b1c5ef6-2b35-4591-938b-b05a55dd21ad"
      unitRef="U_USD">18921000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_5179b652-1a0d-4699-a7ff-fafccdf09ad7"
      unitRef="U_USD">18921000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:PreferredStockTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_e4c7d106-be07-49eb-a7f7-9a0b084551c8">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10. Convertible Preferred Stock&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Series A Convertible Preferred Stock&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2019, the Company entered into a securities purchase agreement (as amended, &#x201c;Series A Agreement&#x201d;) with certain investors to sell shares of Series A convertible preferred stock (&#x201c;Series A&#x201d;) at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.9681&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share. In June and July 2019, the Company issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,724,925&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of Series A to institutional investors at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.9681&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share for gross cash proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, less issuance costs of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, resulting in net proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. On October 1, 2021, the Company effected a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_21fd044a-b819-46e1-b788-a6db20d760e8;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1-for-6.359&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; reverse stock split&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Upon completion of the IPO, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,724,925&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of Series A were converted to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,573,659&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Series B Convertible Preferred Stock&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On March 5, 2021, the Company entered into a securities purchase agreement (as amended, &#x201c;Series B Agreement&#x201d;) with certain investors to sell shares of Series B convertible preferred stock (&#x201c;Series B&#x201d;) at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.6458&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share. In March 2021, the Company issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;92,356,299&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of Series B to institutional investors at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.6458&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share for gross cash proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;152.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, less issuance costs of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, resulting in net proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;151.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. In addition, the Company granted &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,455,949&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares, or $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, of Series B convertible preferred stock through separate agreements with Pfizer and LegoChem. On October 1, 2021, the Company effected a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_2c1f21b5-66b1-456a-be0d-8b2e18d9a8f1;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1-for-6.359&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; reverse stock split&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Upon completion of the IPO, the entire outstanding shares of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;104,812,248&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of Series B were converted to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,482,486&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:PreferredStockTextBlock>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_ccb57e6f-0f25-4bfd-96c2-4d333afebc0b"
      decimals="INF"
      id="F_86d6e817-eb50-4951-b088-d1c965203ab1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.9681</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_ccb57e6f-0f25-4bfd-96c2-4d333afebc0b"
      decimals="INF"
      id="F_fe4a647f-9320-417b-af88-e81b57d2a981"
      unitRef="U_shares">22724925</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_2e52bce4-48fd-4d5c-8c03-b3c7a4ce8258"
      decimals="INF"
      id="F_63d9bea8-8731-4dd3-a755-8e14c31ec3fa"
      unitRef="U_shares">22724925</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_ccb57e6f-0f25-4bfd-96c2-4d333afebc0b"
      decimals="INF"
      id="F_24eb2f9c-790f-4578-baa4-81c48314cf4c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.9681</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_2e52bce4-48fd-4d5c-8c03-b3c7a4ce8258"
      decimals="INF"
      id="F_c2a292c4-3ea4-48d2-af11-31fcfd525bc5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.9681</us-gaap:SharesIssuedPricePerShare>
    <pyxs:GrossProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_08e26df7-c143-4cfe-8ad0-f01a4ebe0f85"
      decimals="-5"
      id="F_8437c418-74b7-45d5-9552-55f8df00eaa4"
      unitRef="U_USD">22000000.0</pyxs:GrossProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_08e26df7-c143-4cfe-8ad0-f01a4ebe0f85"
      decimals="-5"
      id="F_f624d656-9d43-4579-b66b-f35e7ce20e91"
      unitRef="U_USD">100000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_08e26df7-c143-4cfe-8ad0-f01a4ebe0f85"
      decimals="-5"
      id="F_d0113c2d-2f45-43c2-9737-d841b1172736"
      unitRef="U_USD">21900000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="C_375ab7b5-f3d4-409a-a33f-662272797faf"
      id="F_4407aca1-3d5e-44ea-a1d0-74473f5cb1a1">1-for-6.359 reverse stock split</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_dd3f048c-500a-44b0-97cc-8865eadc0230"
      decimals="INF"
      id="F_80d780cd-8cea-4154-a9d6-7b460d269854"
      unitRef="U_shares">22724925</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="C_adc6355e-17ce-4144-a867-ae971f7735e9"
      decimals="INF"
      id="F_1aebff4f-06de-4f93-8b2b-a1cc847b1349"
      unitRef="U_shares">3573659</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_6adee125-dbcb-4f6a-b664-d9891421fd72"
      decimals="INF"
      id="F_d920fa75-2f62-425e-9b27-a18dcfbc5359"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.6458</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_4e8c269f-db1b-4dbe-9107-8e90b43b9fa4"
      decimals="INF"
      id="F_058abee8-ea0f-4125-aded-a9c4060cd11c"
      unitRef="U_shares">92356299</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_4e8c269f-db1b-4dbe-9107-8e90b43b9fa4"
      decimals="INF"
      id="F_231c7c1b-7917-445d-a95e-20aded6d2f13"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.6458</us-gaap:SharesIssuedPricePerShare>
    <pyxs:GrossProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_08a1f0a8-28d8-47d4-a0dd-966a0c736ac3"
      decimals="-5"
      id="F_78717fea-6647-4784-b1d6-1b635dade365"
      unitRef="U_USD">152000000.0</pyxs:GrossProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_08a1f0a8-28d8-47d4-a0dd-966a0c736ac3"
      decimals="-5"
      id="F_8f4f4498-8e02-4b44-9b8c-18be5440f0e8"
      unitRef="U_USD">400000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_08a1f0a8-28d8-47d4-a0dd-966a0c736ac3"
      decimals="-5"
      id="F_483cfa52-6e0e-4113-9a19-4c80ea0f5ee0"
      unitRef="U_USD">151600000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_5c8c8e6c-dc1c-4e3b-9625-ec421e4f99d1"
      decimals="INF"
      id="F_04304815-ef0a-4e66-aa17-06c7bf80bb7f"
      unitRef="U_shares">12455949</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_5f97b551-d4c5-4d8c-95ef-8c2b79aac91a"
      decimals="-5"
      id="F_9106f9d2-1c9a-43bd-9f70-5370cde1e33a"
      unitRef="U_USD">20500000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="C_e41e2b33-e797-4eaf-ab2c-e21d506eef7d"
      id="F_20a3ebc9-d486-479c-b78a-4c6c6088528d">1-for-6.359 reverse stock split</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_38547283-6d39-4795-b0d3-95f75e72293e"
      decimals="INF"
      id="F_5fc76690-cd8d-446c-94c0-fb711f6cc6a3"
      unitRef="U_shares">104812248</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="C_a7b2c38b-0a9d-45f4-9d96-7571430846e6"
      decimals="INF"
      id="F_95195a4c-e8ea-4c5e-bf7a-54641d952712"
      unitRef="U_shares">16482486</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_567f3fb5-f824-4076-8bbb-e7774016837a">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Preferred Stock&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In connection with the closing of the IPO, the Company filed an Amended Certificate of Incorporation and authorized &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of preferred stock, with a par value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share. The board of directors has the authority, without further action by the stockholders to issue such shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, and to fix the dividend, dividend rights, conversion rights, voting, redemption terms, liquidation preference and other rights, preferences and privileges of the shares. There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; issued and outstanding shares of preferred stock as of December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Common Stock&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Initial Public Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On October 8, 2021, the Company completed an IPO in which the Company issued and sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,500,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of its common stock at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share, for aggregate gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;168.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. The Company raised approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;152.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in net proceeds after deducting underwriting discounts and commissions of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and offering expenses of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company was authorized to issue up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;190,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock as of December 31, 2022 and 2021, respectively, of which &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35,110,016&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32,792,867&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares were issued as of December 31, 2022 and 2021, respectively, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;34,958,730&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32,222,881&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares were outstanding at December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Voting, dividend and liquidation rights of the holders of the common stock are subject to and qualified by the rights, powers and preferences of the holders of the preferred stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Voting&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;Each holder of outstanding shares of common stock shall be entitled to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; vote in respect of each share.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Reserved Shares&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company reserved the following shares of common stock for issuance:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:94.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:60.207%;"/&gt;
        &lt;td style="width:1.205%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.502%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.215%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.871%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,720,415&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,926,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested restricted stock awards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,015,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;618,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options available for issuance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,697,166&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,289,259&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;752,524&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;424,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,185,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,259,317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_5fa06219-1252-449b-973f-3a4c942c0ae4"
      decimals="INF"
      id="F_b9386fc4-c5e2-4e0f-96bb-2ddb45f9383a"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_5fa06219-1252-449b-973f-3a4c942c0ae4"
      decimals="INF"
      id="F_5653226b-dbd6-4295-9fd9-4fd9b486d2a5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="INF"
      id="F_9f58c56b-c86e-4089-8925-9a97aa2f30b6"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="INF"
      id="F_c879b3e0-18bf-4541-9e83-d44149ba821b"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_aae7c872-143d-4e13-980e-a4b7733afaf6"
      decimals="INF"
      id="F_3fe88f82-5993-4cf4-a782-9165f44a4082"
      unitRef="U_shares">10500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_3437eb60-7ead-49e1-af88-52c11bcf8430"
      decimals="2"
      id="F_6a503739-712e-4640-a776-7b9c6d9a88a1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">16.00</us-gaap:SharesIssuedPricePerShare>
    <pyxs:GrossProceedsFromIssuanceInitialPublicOffering
      contextRef="C_ac6c23d7-b491-43cb-a347-d0c5845136d5"
      decimals="-5"
      id="F_7849ef11-b876-496b-ad0a-f1e06db66ec3"
      unitRef="U_USD">168000000.0</pyxs:GrossProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_ac6c23d7-b491-43cb-a347-d0c5845136d5"
      decimals="-5"
      id="F_8c142ee5-b3bf-4388-b26a-e8d259a728a9"
      unitRef="U_USD">152300000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <pyxs:UnderwritingDiscountsAndCommissions
      contextRef="C_aae7c872-143d-4e13-980e-a4b7733afaf6"
      decimals="-5"
      id="F_3f89a586-2e6e-424c-8239-35f80fd08061"
      unitRef="U_USD">11800000</pyxs:UnderwritingDiscountsAndCommissions>
    <pyxs:StockIssuanceExpenses
      contextRef="C_aae7c872-143d-4e13-980e-a4b7733afaf6"
      decimals="-5"
      id="F_d06ff37d-05af-4490-ae47-ee9d162b9a97"
      unitRef="U_USD">3900000</pyxs:StockIssuanceExpenses>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="INF"
      id="F_b28c0699-97ba-4a4e-b755-61b75da58696"
      unitRef="U_shares">190000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="INF"
      id="F_fb9dcda7-b505-4e47-bf45-780f17ed2faf"
      unitRef="U_shares">190000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="INF"
      id="F_3ace31da-96a1-4b63-8ba6-0788368d4b32"
      unitRef="U_shares">35110016</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="INF"
      id="F_b36bb458-50ea-4140-b877-454be93d7e0d"
      unitRef="U_shares">32792867</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="INF"
      id="F_3a301ad4-37fc-4bfb-a425-105c779cc22e"
      unitRef="U_shares">34958730</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="INF"
      id="F_bbe73c82-3fbb-48a0-8c96-d7ee65d5190e"
      unitRef="U_shares">32222881</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockVotingRights
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_cd9b3ae9-aa07-4256-9a02-ab10dea60d5c">one</us-gaap:CommonStockVotingRights>
    <pyxs:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_938201ee-0af4-4453-9634-ad747fc1e1fa">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company reserved the following shares of common stock for issuance:&lt;/span&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:94.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:60.207%;"/&gt;
        &lt;td style="width:1.205%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.502%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.215%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.871%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,720,415&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,926,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested restricted stock awards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,015,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;618,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options available for issuance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,697,166&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,289,259&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;752,524&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;424,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,185,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,259,317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</pyxs:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_dbf80555-08a0-4969-b239-4e3694866a9d"
      decimals="INF"
      id="F_d26db75c-8849-48be-a778-a0644290d274"
      unitRef="U_shares">5720415</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_de5078e1-9398-411e-9b9d-a3b0e59ba4db"
      decimals="INF"
      id="F_31a62249-2fde-4e5d-8399-edda3c4f270a"
      unitRef="U_shares">5926969</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_9194297f-b13d-4587-9fe5-fcc007d82f0e"
      decimals="INF"
      id="F_7ab4590a-19ac-4dde-979a-9b1035a20184"
      unitRef="U_shares">3015387</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_382dcedb-c053-467b-83f2-217ce9a3521e"
      decimals="INF"
      id="F_0d0d20e5-dcac-4d7c-906c-d0d456929b9e"
      unitRef="U_shares">618494</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_7f8a7acb-6ab0-451e-8b00-67975a1ecf54"
      decimals="INF"
      id="F_b2c76ba4-3c85-4a74-90b6-c07d366b376d"
      unitRef="U_shares">1697166</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_bbf8f5ff-a294-4a9f-8e73-2626887266b2"
      decimals="INF"
      id="F_146959d5-dcf6-467f-8ea2-99852a205ffa"
      unitRef="U_shares">1289259</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_a4a72a0d-ee7f-4589-88fb-129aff57c90e"
      decimals="INF"
      id="F_0563b703-8cb2-47bf-bd99-adafd38db950"
      unitRef="U_shares">752524</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_97a1de80-f534-45ad-9ae5-0bf704ac27f6"
      decimals="INF"
      id="F_1cdf87e8-883d-47d6-b5d7-44e27fb5747e"
      unitRef="U_shares">424595</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="INF"
      id="F_7658e2ff-9f8e-4952-81d6-4c5287fc9598"
      unitRef="U_shares">11185492</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="INF"
      id="F_06ab3faf-f754-4cd8-b011-39a1f90c97e8"
      unitRef="U_shares">8259317</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_505d1ee4-8c28-4056-96d5-67ae0f3684ce">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12. Stock-Based Compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;2022 Equity Inducement Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On July 1, 2022, the Company&#x2019;s board of directors approved the 2022 Equity Inducement Plan (the &#x201c;2022 Plan&#x201d;), which became effective on that date. The 2022 Plan allows the Company to make equity-based incentive awards to its officers and employees without stockholder approval pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules, or any successor rule relating to inducement awards. Unless earlier terminated by the Board, 2022 Plan will terminate on the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_2078513f-c53f-43d5-970f-e0c43d587906;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ten&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;th anniversary of the effective date. The Company has initially reserved &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,400,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of its common stock for the issuance of awards under the 2022 Plan. As of December 31, 2022, options to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;400,692&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;320,550&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; restricted stock units were outstanding under the 2022 Plan and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;678,758&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares remained available for future issuance under the 2022 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;2021 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On September 27, 2021, the Company&#x2019;s board of directors and stockholders approved the 2021 Equity Incentive Plan (the &#x201c;2021 Plan&#x201d;), which became effective on October 7, 2021, when the Company&#x2019;s registration statement was declared effective by the SEC. The 2021 Plan allows the Company to make equity-based and cash-based incentive awards to its officers, employees, directors and consultants. The Company has initially reserved &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,852,807&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of its common stock for the issuance of awards under the 2021 Plan. The number of shares of common stock reserved for issuance under the 2021 Plan will automatically increase annually on the first day of each fiscal year, beginning with the fiscal year ending December 31, 2022, and continuing until (and including) the fiscal year ending December 31, 2031 by the lesser of (i) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the total number of shares of common stock outstanding on December 31st of the immediately preceding fiscal year and (ii) the number of shares as may be determined by the board of directors. As a result of the evergreen provision of the 2021 Plan, the Company added an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,639,643&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock to the 2021 Plan as of January 1, 2022. The maximum number of shares of common stock that may be issued pursuant to the exercise of incentive options under the 2021 Plan is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,705,614&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unless earlier terminated by the Board, 2021 Plan will terminate on the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_41e41108-0a2f-4aeb-862b-b3c3f3023412;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ten&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;th anniversary of the effective date. As of December 31, 2022, options to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,668,700&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,449,172&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; restricted stock units were outstanding under the 2021 plan and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;360,924&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares remained available for future issuance under the 2021 plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;2019 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In 2019, the Company established the 2019 Equity Incentive Plan (the "2019 Plan"), under which the Company is allowed to grant options and restricted stock to its employees and non-employees. The maximum number of shares of common stock reserved for issuance under the 2019 Plan is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,042,408&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares. Options granted under the 2019 Plan include incentive stock options that can be granted only to the Company&#x2019;s employees and non-statutory stock options that can be granted to the Company&#x2019;s employees, consultants, advisors and directors. The 2019 Plan also permits the Company to issue restricted stock awards. Unless earlier terminated by the Board, the 2019 Plan will terminate on the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_41c663ee-99b7-4ec5-8325-a97c8245ffa8;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ten&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;th anniversary of the effective date.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prior to the IPO, the exercise prices, vesting and other restrictions of the awards granted under the 2019 Plan were determined by the board of directors, except that no stock option may be issued with an exercise price less than the fair market value of the common stock at the date of the grant or have a term in excess of ten years. Options granted under the 2019 Plan are exercisable in whole or in part at any time subsequent to vesting. As of December 31, 2022, options to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,651,023&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;94,379&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; restricted stock units were outstanding under the 2019 Plan and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;657,484&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares remained available for future issuance under the 2019 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;2021 Employee Stock Purchase Plan&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On September 27, 2021, the Company&#x2019;s board of directors and stockholders approved the 2021 Employee Stock Purchase Plan (the &#x201c;2021 ESPP&#x201d;), which became effective on October 7, 2021, when the Company&#x2019;s registration statement was declared effective by the SEC. The 2021 ESPP initially reserved and authorized the issuance of up to a total of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;424,595&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock to participating employees. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The number of shares of common stock reserved for issuance under the ESPP will automatically increase annually on the first day of each fiscal year, beginning with the fiscal year ending December 31, 2022, and continuing until (and including) the fiscal year ending December 31, 2031 by the lesser&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of (1) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the total number of shares of common stock outstanding on December 31st of the immediately preceding fiscal year and (ii) the number of shares as may be determined by the board of directors.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; As a result of the evergreen provision of the 2021 ESPP, the Company added an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;327,929&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock to the 2021 ESPP as of January 1, 2022. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares are issued under 2021 ESPP plan as of the date of issuance of these consolidated financial statements.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, the authorized number of shares and shares available for issuance under the 2021 ESPP is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;752,524&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock Options&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options granted under the 2022 Plan, 2021 Plan and 2019 Plan (together, the &#x201c;Plans&#x201d;) to employees generally vest over &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and expire after &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10 years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes stock option activity for the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 (in thousands, except share and per share amounts):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.137%;"/&gt;
        &lt;td style="width:0.069%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.744000000000002%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.069%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:5.943%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.069%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.295%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.208%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:7.465%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding at January 1, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,926,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.03&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,414&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,178,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;73,841&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;834,095&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;476,898&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,720,415&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;72&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options exercisable at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,037,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The weighted-average grant-date fair value of options granted during the years ended December 31, 2022 and 2021, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.06&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.57&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;per share, respectively. The aggregate intrinsic value is calculated as the difference between the exercise price of all &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;outstanding and exercisable stock options and the fair value of the Company&#x2019;s common stock of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.34&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share as of December 31, 2022. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2022 and 2021 was less than $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Company estimated the fair value of each option on the date of grant using the Black-Scholes option-pricing model applying the range of assumptions in the following table:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:47.065%;"/&gt;
        &lt;td style="width:2.019%;"/&gt;
        &lt;td style="width:27.843%;"/&gt;
        &lt;td style="width:2.019%;"/&gt;
        &lt;td style="width:19.037%;"/&gt;
        &lt;td style="width:2.019%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;96.09&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;101.66&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;72.88&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;103.41&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.60&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.02&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.81&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.36&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.00&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.11&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.25&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.00&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation expense related to stock options recorded in the statements of operations is as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.847%;"/&gt;
        &lt;td style="width:2.298%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:21.929%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.298%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:22.328%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.298%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has an aggregate&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;million of gross unrecognized stock-based compensation expense as of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, remaining to be amortized over a weighted average period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.29&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years. The Company has not recognized and does not expect to recognize in the near future, any tax benefit related to employee stock-based compensation expense as a result of the full valuation allowance related to its net deferred tax assets.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Restricted Stock Awards&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under the 2019 Plan, 2021 Plan and 2022 Inducement Plan, the Company issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,174,656&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; restricted stock units ("RSU") to employees and non-employees. Compensation costs related to these RSUs were recorded based on the Company's stock price on the date of issuance and amortized over the service period.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Additionally, the Company issued certain shares of restricted common stock ("RSA") to the employee co-founders and certain non-employee consultants in 2019. The shares of restricted common stock were issued pursuant to standalone restricted stock purchase agreements that are independent of the 2019 Plan, 2021 Plan and 2022 Inducement Plan. The shares of restricted common stock pursuant to standalone restricted stock purchase agreements carried a purchase price equivalent of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.01&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share. As of December 31, 2022, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;151,286&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; RSAs were unvested and outstanding&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under the terms of the restricted stock purchase agreements, the Company has a repurchase option whereby it has the right to repurchase any unvested shares upon termination at a price per share equal to the lesser of (i) the fair market value of the Company&#x2019;s common stock on the date of repurchase and (ii) the original purchase price. The shares of restricted common stock issued to the Company&#x2019;s co-founders and non-employee consultants vest based on a predefined number of shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognized an associated deposit liability for restricted stock awards issued pursuant to standalone restricted stock purchase agreements upon issuance based on the purchase price of the awards as the unvested shares are subject to repurchase upon termination. As the awards of restricted stock vest, the Company reclassifies the deposit liability to additional paid-in capital. The compensation cost was measured based on the fair value of the underlying common stock less the purchase price of the restricted common stock and the Company recognizes compensation costs over the requisite service period.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes restricted stock activity for the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:70.57%;"/&gt;
        &lt;td style="width:1.081%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.265%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.724%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.359%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Non-vested at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;618,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,174,656&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested and settled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;432,354&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;345,409&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Non-vested and unsettled at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,015,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has recorded stock-based compensation expense related to the restricted stock of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the years ended December 31, 2022, and 2021, respectively. The Company has an aggregate $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of gross unrecognized restricted stock-based compensation expense as of December 31, 2022, remaining to be amortized over a weighted average period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.26&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_878945eb-02c9-42de-ab14-20785d15bab1"
      decimals="INF"
      id="F_f822de35-f504-42c1-9e9c-f43cb1bb50ff"
      unitRef="U_shares">1400000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_2ae41d03-8671-4c50-80d0-d05659459fdb"
      decimals="INF"
      id="F_2fcc706e-a2dd-4df5-b3ea-1436f5adeecc"
      unitRef="U_shares">400692</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_b0e457cc-4ee1-4962-882e-7cdda5c5a1d8"
      decimals="INF"
      id="F_c76a5c38-a92c-40af-85df-edcb448167aa"
      unitRef="U_shares">320550</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_2ae41d03-8671-4c50-80d0-d05659459fdb"
      decimals="INF"
      id="F_4e4cf2fa-3b1e-40f9-bde2-088d4776efc2"
      unitRef="U_shares">678758</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_52660871-d822-4029-a359-773d492fbb93"
      decimals="INF"
      id="F_1c000a38-c2b9-4f10-bff9-c35a88235629"
      unitRef="U_shares">3852807</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <pyxs:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesReservedAndAvailableForIssuancePercentage
      contextRef="C_10356595-90e4-4664-b68b-60f5a32b9285"
      decimals="2"
      id="F_51127572-821c-4e2b-98e1-ccb599a22da1"
      unitRef="U_pure">0.05</pyxs:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesReservedAndAvailableForIssuancePercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_da4afd79-994b-493e-8986-8748cbb9b1f6"
      decimals="INF"
      id="F_cd7d0022-b59d-44b3-95af-db9defa40649"
      unitRef="U_shares">1639643</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <pyxs:MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions
      contextRef="C_57e97640-061e-4d91-86fa-37e25ab50455"
      decimals="INF"
      id="F_16b945ea-5d31-462c-9ab8-43beda251a87"
      unitRef="U_shares">7705614</pyxs:MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_57e97640-061e-4d91-86fa-37e25ab50455"
      decimals="INF"
      id="F_0206ba68-98a0-4c2a-a28e-e79da52166e1"
      unitRef="U_shares">2668700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_1f74468d-690d-401f-99d9-cb0dfb69f6d0"
      decimals="INF"
      id="F_87e22e1e-c2dc-4b9c-ab50-1120877dea07"
      unitRef="U_shares">2449172</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_57e97640-061e-4d91-86fa-37e25ab50455"
      decimals="INF"
      id="F_bb107d6c-2c22-42bf-85dc-7358bd31170c"
      unitRef="U_shares">360924</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_fb9e3219-0355-4d5e-8d21-c73eefcac6c3"
      decimals="INF"
      id="F_db50b4e7-7dcd-45e3-80ee-7ff0668dd1cf"
      unitRef="U_shares">4042408</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_9d0748e3-ecbb-419d-b1da-43ca99f6d64d"
      decimals="INF"
      id="F_cd067478-d2ad-40a2-8880-651025a9ba35"
      unitRef="U_shares">2651023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_3389ea65-f351-4b62-b0ce-6e94188e7981"
      decimals="INF"
      id="F_fa085fab-fba1-4587-be5a-faccd9d4d21e"
      unitRef="U_shares">94379</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_9d0748e3-ecbb-419d-b1da-43ca99f6d64d"
      decimals="INF"
      id="F_76dc511c-a214-4045-8f3a-a3afd75a16a1"
      unitRef="U_shares">657484</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_6d15f333-7588-4ef5-8888-a6b87820dd75"
      decimals="INF"
      id="F_4939c241-f372-428a-b63f-36dca40a4471"
      unitRef="U_shares">424595</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <pyxs:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesReservedAndAvailableForIssuancePercentage
      contextRef="C_0aaf1ee4-befe-4b18-b335-1a09ea9d6b96"
      decimals="2"
      id="F_77a4ff6b-04a0-42b6-b235-e1600341d6bc"
      unitRef="U_pure">0.01</pyxs:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesReservedAndAvailableForIssuancePercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_df8cfd51-bc03-4a95-b0a5-24677e60cdc1"
      decimals="INF"
      id="F_fb773912-192f-432c-b363-8190251614f0"
      unitRef="U_shares">327929</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="C_0aaf1ee4-befe-4b18-b335-1a09ea9d6b96"
      decimals="INF"
      id="F_29e3d1d2-e3f9-43d7-8462-b2a5ab27db65"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_1bfa7a44-4da1-4bfe-8679-1f28fa3b517b"
      decimals="INF"
      id="F_80c0e824-2827-4835-8563-bc5b0bd2a1f3"
      unitRef="U_shares">752524</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_4f7769e8-70e6-4d06-bdc0-89e5d970d334"
      id="F_4e94d74e-d773-4d95-b932-5dafdd5edfd2">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_4f7769e8-70e6-4d06-bdc0-89e5d970d334"
      id="F_1e90e4ba-e229-47c7-a2d1-4b805217420d">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_ac7f8dca-c384-4e6f-8288-64f433252c62">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes stock option activity for the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 (in thousands, except share and per share amounts):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.137%;"/&gt;
        &lt;td style="width:0.069%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.744000000000002%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.069%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:5.943%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.069%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.295%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.208%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:7.465%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding at January 1, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,926,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.03&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,414&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,178,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;73,841&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;834,095&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;476,898&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,720,415&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;72&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options exercisable at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,037,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="INF"
      id="F_c2d594d3-937c-4721-b63b-ad4a5aadc22c"
      unitRef="U_shares">5926969</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="2"
      id="F_318c00cc-1f37-493c-aeeb-19acf16317e6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      id="F_97bc0266-cae7-4cdd-846a-bf42b735fe6e">P9Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_7a1bee7a-a17b-4a9e-8d3a-f661dc34e86e"
      unitRef="U_USD">16414000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="INF"
      id="F_cd364b96-cec9-4be6-9cc3-70c9c9f6d574"
      unitRef="U_shares">1178280</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="2"
      id="F_7a62e176-cdc5-4f5b-8e83-430ce5620b79"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.06</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="INF"
      id="F_11807cf3-e992-46fa-b644-0a2d28b35495"
      unitRef="U_shares">73841</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="2"
      id="F_3e7321fc-6149-4839-a385-10ebff1db88f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.48</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="INF"
      id="F_64b2549c-a21d-42ed-a7ce-81c29131b247"
      unitRef="U_shares">834095</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="2"
      id="F_e7d79e48-c5f0-4e48-9bcc-f21c2c11e49a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="INF"
      id="F_d96e0a08-3262-47f6-a2d1-be62e99db932"
      unitRef="U_shares">476898</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="2"
      id="F_8492f507-2bde-4092-8add-8ba7d333bd78"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.51</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="INF"
      id="F_1fd0560e-a276-4823-b7f6-ec2ca45f92e0"
      unitRef="U_shares">5720415</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="2"
      id="F_1018a87b-9e35-4443-a7c6-c76902bcc061"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_421d5667-55dc-4691-9c77-5db7a1e835dc">P8Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_6837add3-1b72-42cc-8d54-2a1bbacd1218"
      unitRef="U_USD">72000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="INF"
      id="F_8010e802-f645-496d-bf74-a872ccf11246"
      unitRef="U_shares">2037934</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="2"
      id="F_6c5dd3c2-1cb4-4476-a1d8-e39fb4d33a24"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_0d92c3aa-9b4e-4d03-9bf5-994da8bfea2d">P8Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_87800b2b-ba1a-428f-bfdc-941c2c717976"
      unitRef="U_USD">59000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="2"
      id="F_1b18feb7-9aeb-4ad9-880e-2141cb6d4e22"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="2"
      id="F_5b2027af-cb5a-4c9e-8797-ba4ba6a5a917"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <pyxs:FairValueOfCommonStockPerShare
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="2"
      id="F_0f774c72-da39-459d-999b-480afebe885b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.34</pyxs:FairValueOfCommonStockPerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="-5"
      id="F_c3335331-251c-4cd0-8bc0-f2785e52cdd8"
      unitRef="U_USD">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="-5"
      id="F_cf99a92e-78b9-4511-a98f-177cb9a90edb"
      unitRef="U_USD">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_d33eae78-9df5-45bf-8181-bcd0f6944a9c">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Company estimated the fair value of each option on the date of grant using the Black-Scholes option-pricing model applying the range of assumptions in the following table:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:47.065%;"/&gt;
        &lt;td style="width:2.019%;"/&gt;
        &lt;td style="width:27.843%;"/&gt;
        &lt;td style="width:2.019%;"/&gt;
        &lt;td style="width:19.037%;"/&gt;
        &lt;td style="width:2.019%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;96.09&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;101.66&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;72.88&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;103.41&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.60&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.02&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.81&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.36&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.00&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.11&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.25&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.00&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="4"
      id="F_41a85512-88ef-48a1-bd22-285603bafbf7"
      unitRef="U_pure">0.9609</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="4"
      id="F_18b033f8-a929-4fc4-82e4-e610b2552a58"
      unitRef="U_pure">1.0166</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="4"
      id="F_c48b76c6-663b-4c69-94b4-6f4a57690bec"
      unitRef="U_pure">0.7288</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="4"
      id="F_ec57d48d-1db9-4e0b-b703-f54af0561377"
      unitRef="U_pure">1.0341</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="4"
      id="F_440b066e-fe2a-4a49-9ad9-0bd6dde1ac70"
      unitRef="U_pure">0.0160</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="4"
      id="F_f44cb382-3369-4fb4-8bcf-ce63c633f710"
      unitRef="U_pure">0.0402</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="4"
      id="F_bef07b45-9a3c-425d-8a9d-751afeb3d193"
      unitRef="U_pure">0.0081</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="4"
      id="F_a08cf75c-e63f-4456-9b3d-1316809f4b3d"
      unitRef="U_pure">0.0136</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="4"
      id="F_bbf97932-aabb-4cf4-887c-9e76fd68b045"
      unitRef="U_pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="4"
      id="F_38a12b4d-0b6e-48d0-8d48-f36057a8abd7"
      unitRef="U_pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_48de2a5c-eadc-4299-a519-18facbfa1720"
      id="F_2a32dc7c-d293-4a11-aaa7-b524c14481c3">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_7dd94bc0-72fc-44a2-b88d-da7188b1ce64"
      id="F_3ad0758b-c516-4462-967a-c221df4a4681">P6Y1M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_3ade2bd0-ad16-4bf4-a99d-4a51299354f9"
      id="F_49fe1eb9-88eb-42c9-99a9-be5a4a386802">P5Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_5779ffa7-ef54-4318-b0b8-ed0b0cb8c6b5"
      id="F_3bc8634e-9103-4c1e-be1c-772e02ecbeca">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_3cae245e-411e-4fe0-a0f0-0c0ccf8b4ce8">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation expense related to stock options recorded in the statements of operations is as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.847%;"/&gt;
        &lt;td style="width:2.298%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:21.929%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.298%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:22.328%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.298%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_98625906-14f2-47a1-9eb9-724228999619"
      decimals="-3"
      id="F_e1b9bc96-1af2-4d12-a4ef-8c13e4553ec4"
      unitRef="U_USD">4330000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_efd5ca4b-dd20-4280-870e-b98268ab08eb"
      decimals="-3"
      id="F_10ebe9e6-cad4-415c-b43f-eba8e048fc3a"
      unitRef="U_USD">2396000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_e407da6f-df2b-430d-8ab8-23f237d727f3"
      decimals="-3"
      id="F_262077bd-3dab-429f-a138-720d7f5c89c0"
      unitRef="U_USD">7617000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_d2032e34-dd12-44a0-9706-073c354f8dbb"
      decimals="-3"
      id="F_99bc3e9a-2cc3-4776-a680-d081d83fdced"
      unitRef="U_USD">3976000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="-3"
      id="F_0daa00a2-1ba7-42a4-bfb2-3f546bdf82b5"
      unitRef="U_USD">11947000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="-3"
      id="F_c4680745-9c6b-410c-86cd-0d4a63332bde"
      unitRef="U_USD">6372000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-5"
      id="F_47831aea-524e-407b-a41f-2778f1614456"
      unitRef="U_USD">25200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_4ee6c8a5-5099-45e2-80c0-35e5c147a41d">P2Y3M14D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="C_5e6b169a-61c1-4460-b0cf-4abc20516158"
      decimals="INF"
      id="F_9a4929af-7b2d-4602-88c0-a0927df92829"
      unitRef="U_shares">3174656</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_9194297f-b13d-4587-9fe5-fcc007d82f0e"
      decimals="2"
      id="F_4a030434-bf67-4090-9f9f-5c7a4a99e89a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:SharesIssuedPricePerShare>
    <pyxs:RestrictedStockSharesUnvestedAndOutstanding
      contextRef="C_9194297f-b13d-4587-9fe5-fcc007d82f0e"
      decimals="INF"
      id="F_7322e7c2-d27f-4c51-90e6-05f192ecb683"
      unitRef="U_shares">151286</pyxs:RestrictedStockSharesUnvestedAndOutstanding>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_d9ddb626-2b89-4813-a6c8-c19e4a7cd660">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes restricted stock activity for the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:70.57%;"/&gt;
        &lt;td style="width:1.081%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.265%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.724%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.359%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Non-vested at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;618,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,174,656&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested and settled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;432,354&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;345,409&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Non-vested and unsettled at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,015,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="INF"
      id="F_cfc96860-824c-4929-8c2d-ccbcd7b066bd"
      unitRef="U_shares">618494</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="2"
      id="F_bfbd468c-ed38-4582-b72d-acd39e02a1c0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="INF"
      id="F_a83427ab-f39f-4a2d-9fdd-85fd895ae802"
      unitRef="U_shares">3174656</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="2"
      id="F_3603034a-ef03-4e41-b25c-f30593b540d1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <pyxs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="INF"
      id="F_b5508971-c9f4-4bf5-998c-e66cad952cb5"
      unitRef="U_shares">432354</pyxs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod>
    <pyxs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="2"
      id="F_8af3a2c0-f7ca-4cd3-9e3a-32c55d036455"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.55</pyxs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="INF"
      id="F_8b492ed3-003c-410c-91f9-515a5f1f7d77"
      unitRef="U_shares">345409</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="2"
      id="F_bd69e674-4d0c-4ffe-9b2e-3e2702871238"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="INF"
      id="F_105ebe99-5d0d-48c9-aabf-700934eda7c8"
      unitRef="U_shares">3015387</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="2"
      id="F_12289d2b-57ad-42f2-9c33-1702f76687ed"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_ea786617-a1e9-4846-aa80-4f080345af40"
      decimals="-5"
      id="F_c3962b90-14ad-49a2-bf79-f2a6b918e0ee"
      unitRef="U_USD">3800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_5f32f318-d7b3-49c5-87d5-d8693945f998"
      decimals="-5"
      id="F_0b204ce6-4937-4ecd-acd8-24474d53915f"
      unitRef="U_USD">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="C_9194297f-b13d-4587-9fe5-fcc007d82f0e"
      decimals="-5"
      id="F_c590b1a7-932f-4685-ac31-0c5f9f662b8b"
      unitRef="U_USD">7400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_ea786617-a1e9-4846-aa80-4f080345af40"
      id="F_21e0edbb-c723-42af-81fc-29240529adb8">P2Y3M3D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_5e2f8ec2-e86b-4db8-9b11-53e0082e27aa">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13. Income Taxes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the years ended December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company recorded &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; current or deferred income tax expenses or benefits as the Company has incurred losses since inception and has provided a full valuation allowance against its deferred tax assets.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A reconciliation of the expected income tax benefit computed using the federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.205%;"/&gt;
        &lt;td style="width:1.161%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.241%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.161%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.232%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income tax computed at federal statutory rate %&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development credit carryovers&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Effective income tax rate %&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company's effective tax rate was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% for the years ended December 31, 2022 and 2021, as a result of the valuation allowance that eliminates the company's net deferred tax assets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; Significant components of the Company&#x2019;s net deferred tax assets as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021 are as follows (in thousands): &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68.458%;"/&gt;
        &lt;td style="width:1.526%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.049%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.517%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.449%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net operating losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,108&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Intangibles&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Derivative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,455&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,577&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,645&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,003&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Reserves and accruals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;804&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Capitalized research expenditures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;License fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,235&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,107&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax assets before valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;61,486&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;57,812&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease ROU assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred tax asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, the Company's federal and state net operating losses ("NOL") in the United States were $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million ($&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;48.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million before tax) and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million ($&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;48.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million before tax) respectively. The federal net operating loss carryforwards in the United States can be carried forward indefinitely but may be subject to annual usage limitations to the extent certain substantial changes in the entity's ownership occur. The state net operating loss carryforwards begin expiring in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2039&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. In addition, as of December 31, 2022, the Company had $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of federal and state credit carryovers which begin to expire in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2039&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. These loss and credit &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;carryforwards are subject to review and possible adjustment by the appropriate taxing authorities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company assesses the realizability of the deferred tax assets at each balance sheet date based on the available positive and negative evidence in order to determine the amount which is more likely than not to be realized and records a valuation allowance as necessary. Due to the Company's cumulative loss position which provides significant negative evidence, which is difficult to overcome, the Company has recorded a valuation allowance of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;57.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million as of December 31, 2022, representing the portion of the deferred tax asset that is not more likely than not to be realized. For the years ended December 31, 2022 and 2021, the valuation allowance for deferred tax assets increased by $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively. The amount of the deferred tax asset considered realizable, could be adjusted for future factors that would impact the assessment of the objective and subjective evidence. The Company will continue to assess the realizability of deferred tax assets at each balance sheet date in order to determine the proper amount, if any, required for a valuation allowance.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Tax Cuts and Jobs Act contained a provision which requires the capitalization of Section 174 costs incurred in the years beginning on or after January 1, 2022. Section 174 costs are expenditures which represent research and development costs that are incident to the development or improvement of a product, process, formula, invention, computer software or technique. This provision changes the treatment of Section 174 costs such that the expenditures are no longer allowed as an immediate deduction but rather must be capitalized and amortized. We have included the impact of this provision, which results in a deferred tax asset of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million as of December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The U.S. tax attributes may be subject to an annual limitation under Section 382 of the Internal Revenue Code of 1986 (the &#x201c;Code&#x201d;), and similar state provisions if the Company experiences one or more ownership changes, which would limit the amount of the tax attributes that can be utilized to offset future taxable income. In general, an ownership change as defined by Section 382, results from the transactions increasing ownership of certain stockholders or public groups in the stock of the corporation of more than fifty percentage points over a three-year period. If a change in ownership occurs in the future, the net operating loss and research and development credit carryforwards could be eliminated or restricted. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. Due to the existence of the valuation allowance, limitations created by future ownership changes, if any, will not impact the Company&#x2019;s effective tax rate.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is subject to tax and will continue to file federal income tax returns in the United States as well as in certain state and local jurisdictions. The Company is subject to tax examinations for tax years ended December 31, 2019 and forward in all applicable income tax jurisdictions. Tax audits and examinations can involve complex issues, interpretations and judgements. The resolution of matters may span multiple years particularly if subject to litigation or negotiation. The Company believes that it has appropriately recorded its tax position using reasonable estimates and assumptions, however the potential tax benefits may impact the results of operations or cashflows in the period of resolution, settlement, or when the statutes of limitations expire. The Company does not currently have any reserves related to unrecognized tax benefits.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_c48b4d06-4690-4a44-ad08-1d47a45d7069"
      decimals="INF"
      id="F_f28ee4a4-cf70-479a-8689-15f7287e2d44"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_a299bf89-0287-4625-8850-fb9123db63e0"
      decimals="INF"
      id="F_b84d8acb-2c7f-41fc-aa85-e9088fcf12d1"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_c48b4d06-4690-4a44-ad08-1d47a45d7069"
      decimals="INF"
      id="F_a4eb101b-f682-41d7-ad6d-6fe2e711474a"
      unitRef="U_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_a299bf89-0287-4625-8850-fb9123db63e0"
      decimals="INF"
      id="F_03e3127e-bb9e-46b5-a4db-67b668bc02f7"
      unitRef="U_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_d730a093-f729-4575-ac61-3127becabe42">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A reconciliation of the expected income tax benefit computed using the federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.205%;"/&gt;
        &lt;td style="width:1.161%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.241%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.161%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.232%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income tax computed at federal statutory rate %&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development credit carryovers&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Effective income tax rate %&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="3"
      id="F_fb9ca2ab-c5cd-4bca-832a-a3ea57a950a7"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="3"
      id="F_5c03ec70-227c-4ca7-a334-3f042b6ed85e"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="3"
      id="F_588bc660-a999-4c6a-8aa8-63620db29a53"
      unitRef="U_pure">0.056</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="3"
      id="F_48155b6f-5a4c-414d-904c-b4aecc0b6cf2"
      unitRef="U_pure">0.057</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="3"
      id="F_94f4cf33-f554-4cae-9051-69edad7308be"
      unitRef="U_pure">-0.266</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="3"
      id="F_b87b8c51-968a-48b4-b65d-0f75ba6e97be"
      unitRef="U_pure">-0.277</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="3"
      id="F_c5410b17-494a-46d5-aff1-aa0f9f6480c4"
      unitRef="U_pure">0.017</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="3"
      id="F_c8b76a7e-68f1-4485-863b-ea5736e50202"
      unitRef="U_pure">0.019</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <pyxs:EffectiveIncomeTaxRateReconciliationPermanentDifferences
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="3"
      id="F_bc4bd1f5-dcf2-45ea-8a26-459720803dfa"
      unitRef="U_pure">-0.017</pyxs:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
    <pyxs:EffectiveIncomeTaxRateReconciliationPermanentDifferences
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="3"
      id="F_75049c6d-c405-4cfc-9a2e-fed4ca949035"
      unitRef="U_pure">-0.009</pyxs:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="3"
      id="F_a91c9ca4-2a36-4865-a8aa-2944100a9cc6"
      unitRef="U_pure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="3"
      id="F_f9e5bae3-03d1-4b08-b28a-c56739eafd45"
      unitRef="U_pure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="2"
      id="F_9bd92f94-7c40-4e8a-a5b7-b933801e05a0"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="2"
      id="F_69d4a0ca-62be-4060-8ade-4a1277831108"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_9e5a41fe-1854-4fa5-82d2-40cc74978bca">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; Significant components of the Company&#x2019;s net deferred tax assets as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021 are as follows (in thousands): &lt;/span&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68.458%;"/&gt;
        &lt;td style="width:1.526%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.049%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.517%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.449%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net operating losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,108&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Intangibles&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Derivative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,455&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,577&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,645&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,003&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Reserves and accruals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;804&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Capitalized research expenditures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;License fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,235&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,107&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax assets before valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;61,486&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;57,812&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease ROU assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred tax asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_34a20ddd-ef8a-4fc9-bbd8-842a91454658"
      unitRef="U_USD">13108000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_bddd8984-a00f-4ed1-9cfc-603dc88503ee"
      unitRef="U_USD">12918000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_fd0dfd93-d996-4c06-8fc6-e418921ed9f2"
      unitRef="U_USD">69000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_d9f0ce8d-006b-4a31-ae80-a8b2a89cec27"
      unitRef="U_USD">75000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_f5e31051-3781-4279-9cab-2616aecfc5a0"
      unitRef="U_USD">3674000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_cb9a678b-89f0-4f77-9b43-58532a48b6c2"
      unitRef="U_USD">1648000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsDerivativeInstruments
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_6e3ff422-d70a-4c2c-a9bd-51ef96f04eca"
      unitRef="U_USD">1455000</us-gaap:DeferredTaxAssetsDerivativeInstruments>
    <us-gaap:DeferredTaxAssetsDerivativeInstruments
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_e089720e-1e5a-4496-9f2d-fd0e4a6753d2"
      unitRef="U_USD">1577000</us-gaap:DeferredTaxAssetsDerivativeInstruments>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_bd3bcccb-51ec-43e0-b673-b24f264402fd"
      unitRef="U_USD">2645000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_e4e846c3-955c-431d-9e6b-4aa334d176be"
      unitRef="U_USD">1003000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_c3e87f63-3f46-4612-b062-5cec0749ab5b"
      unitRef="U_USD">1105000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_6ab8c8d0-477d-4c9a-9eec-c80bcf8d808f"
      unitRef="U_USD">804000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <pyxs:DeferredTaxAssetsCapitalizedResearchExpenditures
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_50b51b0a-2179-42e6-842f-c720b088fdfc"
      unitRef="U_USD">20059000</pyxs:DeferredTaxAssetsCapitalizedResearchExpenditures>
    <pyxs:DeferredTaxAssetsLicenseFee
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_c70cae85-64bd-4c07-9d9b-c4ce9eef5dac"
      unitRef="U_USD">14235000</pyxs:DeferredTaxAssetsLicenseFee>
    <pyxs:DeferredTaxAssetsLicenseFee
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_948619c6-2b01-4f02-9525-3f87501575c9"
      unitRef="U_USD">7716000</pyxs:DeferredTaxAssetsLicenseFee>
    <pyxs:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_d669f803-3118-4835-8997-2ba61bd46d1d"
      unitRef="U_USD">5107000</pyxs:DeferredTaxAssetsOperatingLeaseLiabilities>
    <pyxs:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_f3963af9-fd00-4382-bb35-ea8bd5c4a9f4"
      unitRef="U_USD">45000</pyxs:DeferredTaxAssetsOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_0af0a78f-854d-477f-bb7c-634edc65a0f5"
      unitRef="U_USD">29000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_4cd73d7e-dbbc-49eb-877b-5d724bf36428"
      unitRef="U_USD">25000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_99addee9-e777-4dc0-b09c-348f3c0f0069"
      unitRef="U_USD">61486000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_2e319832-350c-4d67-ad3f-26b97acc51dd"
      unitRef="U_USD">25811000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_f4fff1b1-4cdd-46f3-8d8d-0afbb74e07a9"
      unitRef="U_USD">57812000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_1e18345c-043e-49f7-8de1-345d37347375"
      unitRef="U_USD">25748000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_64ceaeb5-73a5-4418-8a5d-fcb188cbf3bf"
      unitRef="U_USD">3674000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_259e0526-f3f4-44b3-a67c-4a44b97a970c"
      unitRef="U_USD">63000</us-gaap:DeferredTaxAssetsNet>
    <pyxs:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-3"
      id="F_edfbae06-9691-4886-a151-68c932ae1509"
      unitRef="U_USD">3674000</pyxs:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets>
    <pyxs:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
      contextRef="C_4311203d-759e-4680-a158-b189b0b27135"
      decimals="-3"
      id="F_e8aa8390-ba09-4f9c-9ffe-aa5fe9cb4f8a"
      unitRef="U_USD">63000</pyxs:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_d9e659d3-c4ff-4e05-bb19-5b5effadffa3"
      decimals="-5"
      id="F_d34e19ec-cb64-47b3-9a3c-147ff4696790"
      unitRef="U_USD">10100000</us-gaap:OperatingLossCarryforwards>
    <pyxs:OperatingLossCarryforwardsBeforeTax
      contextRef="C_d9e659d3-c4ff-4e05-bb19-5b5effadffa3"
      decimals="-5"
      id="F_9a0ef27d-a439-4414-b597-6ba4d814c901"
      unitRef="U_USD">48000000.0</pyxs:OperatingLossCarryforwardsBeforeTax>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_96ed1430-e72f-4da1-9065-31aa0a3ed55e"
      decimals="-5"
      id="F_f610826a-b100-4722-a209-ad3ec73a1859"
      unitRef="U_USD">3000000.0</us-gaap:OperatingLossCarryforwards>
    <pyxs:OperatingLossCarryforwardsBeforeTax
      contextRef="C_96ed1430-e72f-4da1-9065-31aa0a3ed55e"
      decimals="-5"
      id="F_a59e1615-ea07-4ae4-b328-900eeb41ae4f"
      unitRef="U_USD">48100000</pyxs:OperatingLossCarryforwardsBeforeTax>
    <pyxs:OperatingLossCarryforwardsExpirationYear
      contextRef="C_bae164c2-2642-4b70-85fd-0d414f578d75"
      id="F_0220035b-df26-4708-af71-fd505575d02d">2039</pyxs:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_d9e659d3-c4ff-4e05-bb19-5b5effadffa3"
      decimals="-5"
      id="F_51ce342e-2b34-4fd5-94a4-a24fb795feb5"
      unitRef="U_USD">2500000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_96ed1430-e72f-4da1-9065-31aa0a3ed55e"
      decimals="-5"
      id="F_9acb2f25-7174-4996-aa59-17368ad39618"
      unitRef="U_USD">1200000</us-gaap:TaxCreditCarryforwardAmount>
    <pyxs:TaxCreditCarryforwardExpirationYear
      contextRef="C_a299bf89-0287-4625-8850-fb9123db63e0"
      id="F_2398856f-241c-441c-968f-3562c8628276">2039</pyxs:TaxCreditCarryforwardExpirationYear>
    <pyxs:TaxCreditCarryforwardExpirationYear
      contextRef="C_bae164c2-2642-4b70-85fd-0d414f578d75"
      id="F_62d88d67-ee5a-4f6a-a06a-09e51e958d12">2039</pyxs:TaxCreditCarryforwardExpirationYear>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-5"
      id="F_0ae6feed-e39b-49a3-92ff-515d9c706581"
      unitRef="U_USD">57800000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="-5"
      id="F_ddcd673b-f043-4fcb-a605-05d3d2da096d"
      unitRef="U_USD">32200000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="-5"
      id="F_f908fca8-848e-47c4-8524-c59f7517713a"
      unitRef="U_USD">21400000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <pyxs:TaxCutsAndJobsActDeferredTaxAsset
      contextRef="C_b7d0661d-e805-4887-84a1-6ba122628999"
      decimals="-5"
      id="F_b52f6b90-6c32-4b09-91eb-3badaccd9e3d"
      unitRef="U_USD">20100000</pyxs:TaxCutsAndJobsActDeferredTaxAsset>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_d25bae70-0f3f-43de-92f4-bb39f1dc4d4c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14. Net Loss per Share&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic and diluted net loss per share was calculated as follows (in thousands, except share and per share amounts):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:45.492%;"/&gt;
        &lt;td style="width:2.562%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:21.324%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.552%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:21.518%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.552%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;120,717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average common shares outstanding, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33,033,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,493,273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s potentially dilutive securities, which include restricted stock, and stock options, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following potentially dilutive securities have been excluded from the calculation of diluted net loss per common share due to their anti-dilutive effect:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68.822%;"/&gt;
        &lt;td style="width:1.434%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.953%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.434%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.356%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,720,415&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,929,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested restricted stock awards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,015,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;618,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options available for issuance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,697,166&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,289,259&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;752,524&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;424,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,185,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,262,317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_3414c14e-e6a6-48ee-8d91-35278061a044">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic and diluted net loss per share was calculated as follows (in thousands, except share and per share amounts):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:45.492%;"/&gt;
        &lt;td style="width:2.562%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:21.324%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.552%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:21.518%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.552%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;120,717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average common shares outstanding, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33,033,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,493,273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="-3"
      id="F_384cd0f3-44fd-4765-84af-18a7235eb100"
      unitRef="U_USD">-120717000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="-3"
      id="F_9a79e128-0693-46ce-8bc5-4f7852d0fe98"
      unitRef="U_USD">-75975000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="0"
      id="F_e41927a8-1681-401a-ad28-05fd5cbaaab1"
      unitRef="U_shares">33033081</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="0"
      id="F_1ef819f1-61cc-4647-95f8-6ed0d0c9c45b"
      unitRef="U_shares">33033081</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="0"
      id="F_67ee1d1b-7a7f-4d68-8247-a244f868913d"
      unitRef="U_shares">8493273</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="0"
      id="F_51e1154f-47a2-492f-a801-a1cc6c8b9ddb"
      unitRef="U_shares">8493273</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="2"
      id="F_9bfde924-78dc-496e-971f-ddca67a981c0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.65</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="2"
      id="F_35bd5c57-886e-44b3-9322-26e5660a6583"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.65</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="2"
      id="F_e9a3db6b-f35b-4f33-b6cd-a803c80e6a20"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-8.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="2"
      id="F_7880aa09-b153-4e66-86ac-b1f3473b7b49"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-8.95</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_9aa801ee-cb59-45fd-9320-fb4f098bad86">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following potentially dilutive securities have been excluded from the calculation of diluted net loss per common share due to their anti-dilutive effect:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68.822%;"/&gt;
        &lt;td style="width:1.434%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.953%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.434%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.356%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,720,415&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,929,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested restricted stock awards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,015,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;618,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options available for issuance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,697,166&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,289,259&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;752,524&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;424,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,185,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,262,317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_5c8d1870-c7a8-4c74-97ca-d9e6a13f9efc"
      decimals="0"
      id="F_fab05c60-a73a-4589-86a4-9de8965ec47a"
      unitRef="U_shares">5720415</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_967897c5-c155-4f05-933c-68db3867f01a"
      decimals="0"
      id="F_981d11b6-be4d-4fc1-814d-06b4986f60c3"
      unitRef="U_shares">5929969</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_570474f3-f0f4-4608-961a-97edb7e8318e"
      decimals="0"
      id="F_a052e83d-f3d8-4eb9-96a5-1b9e831ccf47"
      unitRef="U_shares">3015387</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_3722df37-e565-465f-bb4b-034fdf13c6ee"
      decimals="0"
      id="F_674345b7-3414-4e2b-8c1b-b867a1370021"
      unitRef="U_shares">618494</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_a1592c2f-78e9-4a1b-b7a3-b5e832dfc0e6"
      decimals="0"
      id="F_b5b6cad9-a7e3-42c5-aaf3-696d7a152f29"
      unitRef="U_shares">1697166</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_453b4504-5d6b-406e-8878-c49bf593ff1e"
      decimals="0"
      id="F_1364f5c2-a632-4260-af89-d781e6ba0f4e"
      unitRef="U_shares">1289259</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_6f4aa2e1-b13f-4cc9-a66d-bd0c94991ce0"
      decimals="0"
      id="F_0f4bb719-366a-45b5-ade3-0c85d39f48f4"
      unitRef="U_shares">752524</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_580efdd7-1697-4746-bb08-330be421f077"
      decimals="0"
      id="F_d1ab0541-d6d7-4b6d-8bc8-e60bd663671d"
      unitRef="U_shares">424595</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      decimals="0"
      id="F_59f55c86-bee6-4fdf-a0dc-8c7e9ec68e68"
      unitRef="U_shares">11185492</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_f0dc477c-0a31-42e2-b84e-32a6047229aa"
      decimals="0"
      id="F_d780bf48-b5df-42d5-90f4-9a23cafd4997"
      unitRef="U_shares">8262317</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_02584dfb-fa7c-4a9e-89bf-96e5bace1cf5">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15. Related Parties&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company was founded out of Dr. Thomas Gajewski&#x2019;s laboratory at the University of Chicago. In 2020, the Company entered into the License Agreement with the University of Chicago, as well as a sponsored research agreement. The Company incurred $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for the years ended December 31, 2022 and 2021, respectively, with regards to the University License Agreement. Refer to Note 3 for additional discussion.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Pfizer owns more than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the Company and is considered the principal owner of the Company. On October 6, 2022, the Company entered into the A&amp;amp;R License Agreement with Pfizer, which amends and restates the previously executed license agreement between Pfizer and the Company. During the year ended December 31, 2022, the Company incurred $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of research and development expenses for the A&amp;amp;R License Agreement. During the year ended December 31, 2021, the Company incurred $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of research and development expenses towards license fee. Refer to Note 3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;for additional discussion.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company and Alloy formed a joint venture company, Voxall Therapeutics, LLC (&#x201c;Voxall&#x201d;) to leverage the Company&#x2019;s technology and Alloy&#x2019;s ATX-Gx&#x99; platform and antibody discovery services. The Company and Alloy contributed $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; thousand each to Voxall along with certain license in 2021. During the year ended December 31, 2022, the Company has not incurred expenses related to Voxall. During the year ended December 31, 2021, the Company provided services to Voxall for which it recognized service fee other income of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;181&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; thousand. Refer to Note 4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;for additional discussion.&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_f2ddafed-be8d-4bfb-afe6-eafef4a6d2bd"
      decimals="-5"
      id="F_96ab4562-bdd5-424c-a50e-621696007943"
      unitRef="U_USD">300000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_db0b438d-a530-4514-b2e4-b58d0c1167a0"
      decimals="0"
      id="F_6e3f4de5-d809-4eae-a17d-161687abcc85"
      unitRef="U_USD">0</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <pyxs:RelatedPartyTransactionOwnership
      contextRef="C_53e9aeb6-174d-402f-8c2f-b1df11873669"
      decimals="2"
      id="F_bd30312c-429d-4768-ae0b-42a0b4750610"
      unitRef="U_pure">0.10</pyxs:RelatedPartyTransactionOwnership>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_7df0d474-6f80-47b5-b237-25bf19a5fb4c"
      decimals="-5"
      id="F_819939f4-430b-4adf-b871-ce7fafd75ba7"
      unitRef="U_USD">17300000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_1c996d2e-def1-46a6-a4e5-dd50cc8ddbfa"
      decimals="-5"
      id="F_46957378-6fa2-4993-b9aa-b61df41a83b4"
      unitRef="U_USD">25000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <pyxs:ContributedAmountToJointVentureByEachEntity
      contextRef="C_ab715df4-cb33-446f-9bc3-90688e948155"
      decimals="-3"
      id="F_4f70e6d4-215b-437d-a1f6-b7de093bdd77"
      unitRef="U_USD">50000</pyxs:ContributedAmountToJointVentureByEachEntity>
    <pyxs:RelatedPartyTransactionServiceFeeOtherIncomeFromTransactionsWithRelatedParty
      contextRef="C_4881d8cf-3758-45cf-9629-35b8395ed61a"
      decimals="-3"
      id="F_90273f4b-57bc-433e-ade1-964c93937249"
      unitRef="U_USD">181000</pyxs:RelatedPartyTransactionServiceFeeOtherIncomeFromTransactionsWithRelatedParty>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_e6145700-e6e9-499a-8d3e-a5f34e2f7883">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16. Commitments and Contingencies&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Legal Proceedings&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;From time to time, the Company may become involved in various legal proceedings that arise in the ordinary course of business. The Company is not currently a party to any material legal proceedings and is not aware of any pending or threatened legal proceeding against it that the Company believes could have an adverse effect on its business, operating results or financial condition.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Commitments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In the normal course of business, the Company enters into agreements with various third parties for clinical trials, preclinical research studies and testing, manufacturing and other services and products for operating purposes, which are generally cancellable by the Company at any time, subject to payment of remaining obligations under binding purchase orders and, in certain cases, nominal early-termination fees. These commitments are not deemed significant.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3"
      id="F_fde93abe-3dcb-43d8-8134-d5f43756c314">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17. Subsequent Event&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On February 2, 2023, the Company entered into a sublease agreement for approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,729&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; square feet of office and laboratory space in the building located at 321 Harrison Avenue, Boston, Massachusetts. The sublease is for the fixed period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; months and will expire on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;February 1, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The Company will receive approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in base rent payments over the sublease term. The subtenant will also be responsible for certain other costs under the sublease, such as operating expenses, taxes, insurance, property management fee and utilities.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:AreaOfLand
      contextRef="C_466cd526-a6e1-4fea-9b6a-9ed2473eda8d"
      decimals="INF"
      id="F_c29fbc97-ef5a-4c8e-abab-e84faf2a781c"
      unitRef="U_sqft">17729</us-gaap:AreaOfLand>
    <pyxs:SubleaseTerm
      contextRef="C_606b0303-5274-48c3-af42-6ee3a9b3c452"
      id="F_7171b917-5c36-4e61-8a11-cf4488f36df4">P36M</pyxs:SubleaseTerm>
    <pyxs:SubleaseExpirationDate
      contextRef="C_e79d7fea-f750-4f59-be70-803b9b5030d4"
      id="F_59f706a8-4070-45e6-9b2e-e5fdfb2964e1">2025-02-01</pyxs:SubleaseExpirationDate>
    <us-gaap:SubleaseIncome
      contextRef="C_e79d7fea-f750-4f59-be70-803b9b5030d4"
      decimals="-5"
      id="F_108b8b03-f924-4b27-8394-cf99fe12f524"
      unitRef="U_USD">5200000</us-gaap:SubleaseIncome>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>109
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
MFSIV5C+[<C22"   W30  !@   !X;"]W;W)K<VAE971S+W-H965T,2YX;6RU
MFVMSXC@:A?^*BNGJFJEJ@B^$D.XD583++#N=A GIF<UN[0=A"U"U;;&2G(1_
MOZ]L8^,>6<"4TA\Z7/P>RX]E^1PL7;TR_EVL"9'H+8X2<=U:2[GYW.F(8$UB
M+,[8AB3PS9+Q&$MXRU<=L>$$AUE1''4\Q^EU8DR3ULU5]MF,WURQ5$8T(3..
M1!K'F&]O2<1>KUMN:_?!(UVMI?J@<W.UP2LR)_+;9L;A7:=4"6E,$D%9@CA9
M7K<&[N=1-RO(MOB#DE>Q]QJI0UDP]EV]F8;7+4>UB$0DD$H"PY\7,B11I)2@
M'?\K1%OE/E7A_NN=^B0[>#B8!19DR*(_:2C7UZU^"X5DB=-(/K+7?Y#B@,Z5
M7L BD?V/7O-MSWLM%*1"LK@HAA;$-,G_XK<"Q%Y!WVDH\(H"[X<"M]M0X!<%
M_K$%W:*@FY')#R7C,,(2WUQQ]HJXVAK4U(L,9E8-AT\3==[GDL.W%.KDS8@%
M*9Q&B7 2HG$BJ=RB:9+W)W5>VNC;?(1^_O +^H!H@NYH%,''XJHC8>=*HA,4
M.[K-=^0U[,CUT!U+Y%K 7D(2U@4ZT.JRZ=ZNZ;>>47%$@C/DNY^0YWB>ID%#
M<_D=YF?(R\M]3?G(7/[/-(&].[J]UX[&+T^$G^GY#7I#]D(X^L]@(22'B^&_
M.L*Y0E>OH$:(SV*# W+=@B% $/Y"6C<??W)[SA<='9MB(TMB-7+=DES7I%YU
MX:?MANBPF<M=I_V;CH^QZE0^EL1J?,Y+/N?& QP G# #-(GP2@?(7+_$D=!Q
M'1K+3B5D2:Q&J%<2ZAW7@V:$4Z;&P1#!:*KM3 >4=F-2XZ!DK#\5FB6Q&K2+
M$MK%<= F5 0X0L\$<S2!#[4W![-6$RQCU:FP+(G58/5+6/V38!4=K1&766WR
MK(-EK#D5EB6Q&JS+$M;ED0,ZQV P,Q_R2#:,2QTJLU;CX&4L.Y66);$:+=>I
M+)QS'*]!DJ30N9I9'1"2/-6R,I>="LN66IW6GN%UC0=9F-Q'LJ+*:@&V>QQK
MA_H#0K/M&Q7H(0$+SE;;3V";@S,M/:/,R?0LJ=7I>14][QAZ0^AN'+K:%+S\
M&_J-;+7\S%*.X[@7?<_3NN^AN?AD:I;4ZM0J;^\:#?#-,.7\QUNER60<D&NW
M7:_MNUIL5FV]+;4ZMLK8NV9K7G2V"8T@&@V!U8IQ?4\SZ]RSI(V#@( ,B(2Y
MH):>5=-O2ZU.K[+]KMFW%_3F,8XB=)L*^%KH@[M9I_&N8-7_VU*KPZH2@&LV
M[@6L<4SXBB8K]"LHR#4:LGB#$WV?,PLV4K,: &RIU:E5$< U^_8=M;=]JY9[
M6RTRLUHC,JLQP)9:'5D5!%RS=Y\.)X]HD(94,HX&4A(A\U_:FL+Y ;U&@VNN
M.YG:>P0"MTH$KMG&[\:R-8&QS'11_LTT8*X[&=9[Y &OR@.>V<87L/X$5NWO
M"7M-T)Q@P1*X\TV%2+6WOENSIK[-]PQI?W>U&A=LJ=5A5G'!.RHN_,&B-)&8
M%VY$>Q\]H'3/M+"LI@-;:G5853KPCDL'A=W-@ZBZG<YAD-/_TG% \9GHJH;F
MJI.IO4<Z\*ITX)GM?/G811*>/P=3P0#O,&JIF16;J%D-![;4ZM2J<. ='0[0
M?1HO&H8ULPA$T';7Z?>U6<I<>S*N]T@#7I4&O*/2P!-^0],0>A5=TB W'@9X
M9LF^WW:A?9>NHZ5G-1[84JO3J^*!=U0\&(0AJ(M/NQ?H*VR''A)MB#\@Z9X[
MD&GC!:?ABFPP_XY&'"Y]+4JKF<&66AUEE1F\HS)#B7*HWH$7?@*CHL5HEBL1
M:L%930ZVU.K@JN3@F9W^C^#4/94H<C/.7F@2Z#NA6?-NH,5F-3K84JMCJZ*#
M=U1T*+'-&"2N"/V;;B!(A'IH9D7'<[OZ(<]JBK"E5I^.4*4(_Z@4,4T"QL'&
M9?>*O4XW9."'P0XW,3R@/AIKYR1830ZVU.H J^3@F_U^-K -.,'-C,P"/?="
M"\EJ8K"E5H=4)0;?[.^_LNQQZ!K2J<&('!#Q/+=]Z9Q?:FE930JVU.JT]N8(
MF7W]$Y7@=MD2N=[/BU\@U@<IAUZF17;@B02+8_!^<\F"[Y\0V _T@J.4H _.
M&7ABM"$<B37FVKNJ6?IDI.\1(_PJ1OCF!/#$<9@EU&V\8)&6I%E@]ORON9:2
MU?1@2ZU.J4H/OMGJ[WH:&K\%:YRL2.-#TP-"]X/Y:/"[EI?5O&!+K<ZKR@O^
M47EAEBXB&J!)Q+ VQIM53I[19S4F%&KGF9J:/OQR<]$[NW3V_D%J?M%AJK*
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M$W@)8#S,X"7P? ?JQ,+ I,M#CMHH.FHW,,RET NBVL"3_$XA'LX C)/>S3M
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M= !\O^9<'6[T"YK_)2S^ U!+ P04    " ";.G96 ]8YOM()  #>=@  &
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M51N4K]^E:?'\I+KAY>&6MI?_ 5!+ P04    " ";.G961HB=+HX"   M!@
M&    'AL+W=O<FMS:&5E=',O<VAE970V+GAM;)U5VV[30!#]E9&IH)50?6DN
M4!)+35-$'RJBAL+SQA['JZYWT]UUTOX]LVO'!$B-Q$N\ESEGSAQGQI.=TH^F
M1+3P7 EIID%I[>8R#$U68L7,N=J@I)M"Z8I9VNIU:#8:6>Y!E0B3*!J%%>,R
M2"?^;*'3B:JMX!(7&DQ=54R_S%"HW32(@_W!/5^7UAV$Z63#UKA$^[!9:-J%
M'4O.*Y2&*PD:BVEP%5_.1B[>!WSGN#,':W"5K)1Z=)O;?!I$3A *S*QC8/38
MXC4*X8A(QE/+&70I'?!PO6?_[&NG6E;,X+42/WANRVGP(8 <"U8+>Z]V7["M
M9^CX,B6,_X5=&QL%D-7&JJH%DX**R^;)GEL?#@!)\@H@:0&)U]TD\BKGS+)T
MHM4.M(LF-K?PI7HTB>/2O92EU73+"6?3:R6-$CQG%G-86GJ0X]: *H"NMJ@M
M7PF$!7F%6OL8E3T"D^VJ5")';=[!S5/-[0N<SK'@&;=G<+I@FJA*M#QCX@Q.
M@$OX5JK:$-A,0DOJG88P:Y7.&J7)*TKC!.X4\1FXD3GFOQ.$5'97>[*O?9;T
M,LXQ.X>+^#TD41+#PW(.IR=G/;P7G:<7GG?P"N\2-4<#LSX'C]7?R^JZ\])L
M6(;3@-K/H-YBD+Y]$X^B3SV:!YWF0:_F6V-J)C.$3!E[].TT^+''NU;?IH/X
MXR3<'DDZ[)(.^Y-*;CD3L*A7@F?PM2"'N%P?R]Y+])_>C#J9HUZ9#_1_TSM-
M6N6:_*DJ;OQ,<DW _^G;Z"_?XN$X&OSA7'C0PA7JM1]4AEAK:9MN[DZ[67C5
MC(!?X<T@O6-ZS:4!@05!H_,Q>:>;X=1LK-KX@;!2EL:+7Y8TSU&[ +HOE++[
MC4O0?2'2GU!+ P04    " ";.G96L\BNM9$'  #U(@  &    'AL+W=O<FMS
M:&5E=',O<VAE970W+GAM;+5:6V_CMA+^*X1;'+3 >BV2NE@YB8&-MXON0_<$
MFUZ>:8F.V95%EZ*=I+_^#"E;LB6*L0OW)9:4X6AF.#/?1U*WSU)]JU:<:_2R
M+LKJ;K32>G,SF539BJ]9]5YN> G_64JU9AINU=.DVBC.<CMH74Q($,23-1/E
M:'9KGSVHV:W<ZD*4_$&A:KM>,_5ZSPOY?#?"H\.#K^)II<V#R>QVPY[X(]>_
M;1X4W$T:+;E8\[(2LD2*+^]&'_#-G*9F@)7X7?#GZN@:&5<64GXS-Y_SNU%@
M+.(%S[11P>!GQ^>\*(PFL..OO=)1\TXS\/CZH/V3=1Z<6;"*SV7QA\CUZFXT
M':&<+]FVT%_E\\]\[U!D]&6RJ.Q?]+R7#48HVU9:KO>#P8*U*.M?]K(/Q-$
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MCC*Y!B2K!DU,>J_'41*''2/[4G$88K>5T\;*J;\>9#FV"64FBJEL94.:\QU
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M/(\ 9Y%<C4"K :AX!FA:B$_.QB:(C[:D\C% #J]VKA4/KJV*%Q$O21V)V?1
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M.,T/8?M)RWM;@''L0S!>$P30%M:=V?;I Q[QJ;TI1NHCN[0?7<^;Y UA8OX
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M'5Z@YZN6O&3]@@7"U?_?_2]02P,$%     @ FSIV5H036K9S#@  1#   !D
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MH3 /1TM$&)T-G%(6)SNZE0ZCJP5)*)U3S@U%#G&R9J]*LXRT'^-CL%RB; 5
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M)6[<WC,PD\28K_SR,9M'8P:$"E//$03]K?$6E>) !.-;%S/J4[+C_O,N^H?
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M+"@IYE))+\EX48?P58EIH_^A,K]!8B\M4KEKEZ%U,$>_1-2/!&E'FR12;2B
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M9HY'OS T >-KK5W[00MT_T:X^!]02P,$%     @ FSIV5N*2#R,:!   -0L
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MYM, /%\41=7\H 7:;[-?_!=02P,$%     @ FSIV5M1=GT-T"P  T!T  !D
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M=1M\QI*&UR)!).[PA:)OU38T+RPAN:TU-YJVEJ)HRE+<R+*10:($ODA:)=?
M(N<%;=791,9(J :"B5?L09WI4H>UIF"#R-C,'SH0C1;X8MO0;XUK8U>H7%E9
M"N>E;[RQ=_UU5GH\F+ZCWWUS,4N7SQ#NHE ,1@\6: Y.8<@7^FN_(DE7H_]
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M"=#Y1E&EM!MGH/M^6OT'4$L#!!0    ( )LZ=E:+CLK9<@0  !0+   9
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M/1U$8)L[6+/PI@KWGIGQ=(L*KP5=6]&R >W/#46P6? ![45X\B]02P,$%
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M^9 "=@WLTOK>][U)4#E%4JZA>^^2<1MVVG!<E@DNY&"I#W!W$USU%;A%1>^
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M.*X>.^CMU#B^')_:[SL5-DA<)'0+T_GL^^N"PM32IDGR0VXCM4]H2OFSP[\
M#G( ^ZWWZ6DB#H[_*]:? 5!+ P04    " ";.G96[=^0KBT#  #9!@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6R-5=N.TS 0_9510#Q539ON!9:V
MTG8!@<2*%<OE ?'@))/&PK&#[6S;O^?8:4-!2X44);[,G#DS]IS,-\;^<#6S
MIVVCM%LDM??M59JZHN9&N+%I66.G,K81'E.[3EUK6931J5%I-IE<I(V0.EG.
MX]J=7<Y-YY74?&?)=4TC[&[%RFP6R30Y+'R4Z]J'A70Y;\6:[]E_;N\L9NF
M4LJ&M9-&D^5JD5Q/KU9GP3X:?)&\<4=C"IGDQOP(DW?E(ID$0JRX\ %!X//
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M";+FJ![]A3NG'O=0D&AMN6"HQU]Y/Z7S<8:N5"H(#'(*^@!;%*D5NR;>-//
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MU(-AWQ5,CYG*QLBK<!3)\N%WYV'3'J)AD*T*&@K#1,P(M\19I%&[]0 =S(K
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M:'?3YJ7W23@_#M(\DU##U+[U!;E-V_JPHFQ8E2HV(.J:>69[0A@(U'%E+Y\
MQ%H*%CLTKIIWFKW?<0MKKP4+#G5SJ%'.+X$M0U*)#*9$ LUZX2V9YX7[,JXR
M_[9A?\G506*@-9Z2D9S_1 Z*:^#P\6"1*'0;DXL^-UN3/<"SA^-JQ&P<$KHM
MSV?;(Y^_3E*4;YKZ9OF&W;Y+1M"D[O@3#9>?6"8M[_F,,+,!WJWX74=Z81X7
M,1S-V(H8I@E@2; LF_42;IF;D#5U@- 7N/*Z'J0=B&:ZVY!\0)F@-BI>A$L'
M(ER,,Z%LG0LI@^53>4UMLA!'%S$UQ$"<;N@K,:BOXH1L/QFTL2$J+!>B !_W
M-TB[&>:/]H2V G/GNVIB0\_Q0MRDID+G"BNB."KUEQLM3+JL5CR3+[GZA!]$
MFL!MMK8@KQU-8B)F22)&L8C80HM#$6(C%]K'!JR'0E$#&W?VV' =BMTED4&G
M4+W27YNTG+LRDC0D?X\HQF6K: 8D:DB[<*-0BE$"Z( WU<$)02PW%+GI!''&
MEZ-0J.M8,9@RKE)#FW2#ZX;EO-6PVW%H[C&@B17',?O3["?'.Q(QA8J:0";M
M99*H64G=GD#LQ&%*.%0J/0G"O3,X#WAXGYMB=+<TUC4E^+*F?^O C18,FU+4
M=8"%_:Z _7@[&LY*)I_SO2XHG) \I^0CITUWZE86X,;U*N]OU$T,AZL4_Z$^
MCFS>Z0O-Y^?SG>/L4$SKZ-F!TSI:9LO>SFE,U]'WT]O0$:@,UIJ=-(Q.5FEY
M%I"8]6X=-T<++Y22,V>5S^M*&FI*A\<!\ORJS:JR-UYQ<0I=IO#)<L@ ^_#.
M:O/STP,LT(:3&/T $&Y@(/]/JM41OW!"P$N>"X D*R*0)URH(K:V'TTY!C;X
MLDZV JI<0,RE$I*!$!%3'%RH%Q-\Y3&FR#"(NT0.('FWK60+6B[OAV9550.R
M*J-CX5J$5((J;K_B<>RF2UG.1V@2*4:"%>GME/1.JNNF7G*?O#;#2P^B(DL!
MX<K+WANWQM6R&^=/0CHU1#310#:9DA7VY<V];S8\L+O<,N."0GDL2\VS2]4U
M'C2)'IE+-)R7XFYH1G,>XHCTV[SD,A;M9&70L!1MXX#D"PF\Y*GE,@?'.BZG
M-P\O6Q\*N'\;I!'),Z\VN;A2[03O39N05%@HWMY50S>)!GWT@"@U= \9#]P/
M8<OL ;+^@RD?CC"C>V4WH5:GG 6M<K[,#!I4Y4E+N&R%!IQ?N)XFE\8.968O
MUBK#H], LB@?$.MT>A^+<>4;F<%A.Z9N&M'R,8,TF)7:N9?_@'KD,LEQ@6@X
M9@ [A3(EEVP)_ER?L$)E=R2H57UR-***!=:',FM&CI,_B*GG1G)Z1+FB[14J
M)X).'TI:N:KD@$!>.#4J;1KCUD:VNI)6TYG^MY6 <*CB?/XXQ.ND:^-[[MKX
M1;HV)@WO[&Q'@J/C2V3ILRG-G322<(=ZX5PSX#BH?.E$\WF1==1B/"(Q5\F[
M3PV"?DWJ0AN30,B.<YK=7).A(Q*&ZK\[Z(3IN'$?B3/=J,QMR&!\[S)R+048
MG+53*4 &C6OI.K%(2 ISTG;#6CAXG9@)C0&N]\6)#4X6M-W&[CQ0B^!I:)I1
MFQWXH ,:@EB--4AN^!J$S]O@(.-^J6TO[F22U@JTQ2T]MQ ?53C-WON&FV1K
MBP3]APY(DHICN\(M@YIT!W.4%FT-')65R/98HHO:(/;Q_2_DUB**4N>'?=Z%
M)HI\XV$$#/GY@AZ.E2?9MMOD<N@Q3SDX5(PE]X)P4IUL*3Q/G]**J*Q:>*%-
M1Y4[71-:V?KL=],VOER&OF8$@+ =#;L(FGB)%Q081H+"O62F2^@P2B;\!](&
MT5Z/Y0[F5%]HY#^?;\>_XC"98K?B2)O1'QD?(VZA[K;=BDM)_R]<BU6>2>M-
MW_C^-"3I!M>/552YW8[\]AJ9BRHD+(XU_6K<+RD=1[NIV4-'?TC4P4"%6,+[
MK9E=2SRSSF^;5DH60\_L([54,E?2:  >6XFE1JZ/SWIXI].US<HSE^'26JQ/
M71^8XG;0X#/WC>T.W\I!:-6RT*K2JMOKW+&>+HW9<G>$!U"J,5']U>= $C\U
MC=!9>88A.,T3]PWNXVUH&L#](GH@Q0\?-9;CI.)@N*7@K:F)D,=6JSN5_6!0
M'=X@M5:SDY-V03N$<0%)/3&78<9,7FT5XA9R^B>>(/1$"H*.$I![];MT=5><
M[33_4*@WENH EXV):1D?,4&!G;&&M1CJ!5C0+3^;%0ZMS>?SG<D_Q76"[Z(Z
MP4LM!$QJ@]DYIUV?3RYT</"#?YSOE#WJO(9LQ+'Q?H7)?A3MI<O61H]Q%JZ6
M.M7+YVH<>MIFBUL_I-*X9COM^P")B%+2#OF%45!H:Y?659UTI(KC]5[,,322
MF+0VU=(5-OPNG;_3D95L9UNI>:T5F;*UY8QY\-@U<$L+)"0\!B?;Y&Q<"_=
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M1Y?3XZY5\_WI-<W;<NEJGQ1XN-GC([8Y*VOJ7*B]NTSO ^#S-YS58T".W:I
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M8'E)#['@#6G]R'OI+G&B&?M!."3%YQLDXSGH?<D<%[E[]M)Y[S.;AA/BZ4.
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MFISUSB,PS8QL-DXOPUR::T=3+I@E?5;0^ #R%UJ[S<87:#]4X[]02P,$%
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MG)CAK1$T*>#WI5)V>R '[3UT_A]02P,$%     @ FSIV5K3EQMK6 @  ]04
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MZ%ME*BI6AX@H$DX$WR-AK#6:>;!B6F]-GS*3]Y42^BW5?BJ<$TDEXBE:"I#
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MO7;5,G=^ZJ=EOB9:5*,=G18XP/TQ'C1-I9+0/1@2<A ;.VQ)9*NNND0WN\U
M-[-CS,G^W+]=5&/9#YAJ2OQ Q(8RJ9MDJB&]FT"?SJ(:O*J%XH4=1=9<Z<'&
M/F[UL K"&.CW*>?J86$^T(R_X?]02P,$%     @ FSIV5EOV_&<$ P  '@H
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M0_.#4W4S4D]0EJX!6$@T[80;YJ:! V4-S'XF):XG]H"V)9S\!5!+ P04
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MU(#@4$!8 T)KM%)F;<VQPDDL^!8)$ZW9S(/-C45K-X29,BZ4T+M$XU1RA8E
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MUON>]CUK-]U(=:=+ $,>*B[T*"B-J<_"4.<E5%2?R!H$?EE*55&#6[4*=:V
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M,CH9G@9$^6GB-T;6KB$7TF![NV6) QB43<#O2RG-=F,/Z$9Z]@M02P,$%
M  @ FSIV5K]R\AOB @  \0<  !D   !X;"]W;W)K<VAE971S+W-H965T-#8N
M>&ULK95=;YLP%(;_BL6JJ96V\AEHN@2I33IM4J=%3;M=3+MPX!"L&LQLD[3_
M?K8A+ TTZL5N$G^<]^4Y!W,\V3+^*'( B9X*6HJIE4M97=JV2'(HL#AG%91J
M)V.\P%)-^=H6%0><&E%!;<]Q0KO I+3BB5E;\'C":DE)"0N.1%T4F#]? V7;
MJ>5:NX4[LLZE7K#C2877L 3Y4"VXFMF=2TH** 5A)>*03:TK]W(6Z7@3\(/
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MWP[CTBQV9-;B?]7PO^K#'PFS1K[DJ\NMOB%2@NI<JUE-^W:9RFQR--Z%T3C
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ML?$.+./X\#$EOJOW?)MI7N7,F:-ZW' M5SLML;R1[8U<1]^QW)H;T5EJ4)L
M2J-0&H/2.(JF2ZWQ"JPS9@%@1%=M=L)R/:I1J,D I?E06@"E42B-06D<1=-%
MW+@2UA@[Z&M!#0<HS8?2 BB-0FD,2N,HFJ[!QG>PC&/+TY_6R:/(RU.4G=.2
MS5C>3N4VCN=-6HZ9W9J;TEEP4*,!2J-0&H/2.(JF3P)NS ;[C-GPII6[Q60I
M<_NZ[D2A-!]*"Z T"J4Q*(VC:+JF&_/#MK"%W(9Z(%":#Z4%4!J%TAB4QE$T
M78.-EV*;O93;TR.,VZM3-N;<>J5VCRV+>YUTM[@[WL@9>I.]VFYN76<-(FD!
ME$:A- :E<11-UV#CI]AF/Z5E;;_I.L_*G+;S[A+JPD!I 91&H30&I7$439=J
M8]?8+KAD0RT9*,V'T@(HC4)I#$KC*)JNP<:YL<T^R]^8=V4F=U:C=S@MR+H8
MNMY8K_(^-&T I5$HC;7M$HY*JVNH\5QLL^?2?MZ5&=19,L.# \.)[7A#>S+9
MUPS488'2*)3&H#2.HNG":AP6V^RPO,7<+'/*SA(\<@F#=SB=RH=F#: T"J4Q
M*(VC:+H &W?$-E^T<7YREAG064[C@SV:>Z@EJ,L!I5$HC4%I'$73M=2X'/89
MEP,Y.<N<J[/L)D?V8FKC ^5![0XHC4)I#$KC*)J^?$5C=SAFN^,K9F>=(7[%
M["PSL>O9)I060&D42F-0&D?1="4V)H5COD+CJV=GU=QVL[/,C>@L-:@7 :51
M*(U!:1Q%TZ76>!&.V8M C -WFYUE;E#7F@RE^5!: *51*(U!:1Q%TT6\L_(4
M>NDI[-I3V,6GL*M/89>?PJX_A5V ZBU<"J=Q*1SC"#1@=E:=0+](R!U;MNV.
M]TLWU). T@(HC4)I#$KC*)JNN,:3<,YX$F]:NEM,SS*WK_->%'I="I060&D4
M2F-0&D?1=$TW'HD#7M3*@5HE4)H/I050&H72&)3&431=@XV=XICME+>9GE4G
MU:K[T!VKVC[<+^[0"TZ@M !*HU :@](XBJ:+L+%4'+.ELBWDDKS$Q8+<S^/_
MB?R=JM;1!0G3&?E1/&6W"Y'\C;E:YB9TWG="KU&!T@(HC4)I#$KC*)HNV\:]
M<<"+8SE0AP9*\Z&T $JC4!J#TCB*IJ\%W?@X;HLULEK-LS&#NHJOIFD5WG8]
M;^+NS[.!Y@V@- JE,2B-HVBZL!I;QC7;,MAEQJ'7E=0T;:6/@7?@3$.3!E :
MA=(8E,91M(WP^COW/TE$_E3="Z<<)ERGQ>96*-M7M_?;N:[N,M-O-M_<K.=C
MF#_%J21+,5>A@XN1.GW/-_>_V3PILE5U-Y7'K"BRI'JX$.%,Y.4&ZOUYEA6O
M3\H$V[L03?\/4$L#!!0    ( )LZ=E;19TU%  4  #P;   9    >&PO=V]R
M:W-H965T<R]S:&5E=#4Q+GAM;+5976_;-A3]*X16;"V062+])6>V@23JM@#K
M&C3+]C#L@9%HFXA$JB1EI\-^_*B/2)8M,U;!^B&1Z'L/>8[(JT-SON/B26X(
M4> YB9E<.!NETDO7E>&&)%@.>$J8_F;%18*5OA5K5Z:"X*A(2F(7>=[$33!E
MSG)>M-V)Y9QG*J:,W D@LR3!XLLUB?ENX4#GI>$376]4WN NYRE>DWNB'M([
MH>_<&B6B"6&2<@8$62V<*W@9()0G%!%_4K*3>]<@I_+(^5-^<QLM'"\?$8E)
MJ'((K/]MR0V)XQQ)C^-S!>K4?>:)^]<OZ#\7Y#691RS)#8__HI':+!S? 1%9
MX2Q6G_CN5U(1&N=X(8]E\1?LJEC/ 6$F%4^J9#V"A++R/WZNA-A+@*,3":A*
M0(<)DQ,)PRIA>&X/HRIA5"A34BET"+#"R[G@.R#R:(V67Q1B%MF:/F7Y<[]7
M0G]+=9Y:WBL>/FUX'!$A?P#O/V=4?0$_@JLHHOESP3&X9>7LRI_2VX H3&/Y
M3H<\W ?@[9MWX UP@=Q@022@##PPJN2%;M37?VQX)C&+Y-Q5>JAYAVY8#>NF
M'!8Z,2R(P ?.U$:"]RPB41O U1QKHNB%Z#4R(GX,U0!X_@5 'H)= S*G!R0<
M@"$LTE%'>G!^.C2P&=:/;5C@#4\]MNQ1THCJE7H![G%, %^!XE&"OW_3H>!6
MD43^TS'.ZQ)WU(V;5YE+F>*0+!Q=1B016^(LO_\.3KR?NC2S"198 FOI.:KU
M')G0EW>ZVA A2 1DKN(%2+$ 7-='A95NW.(X(R EHISI7;J6^'Z!GQ?;[=(;
M>)Y^UMM]P<Z*"EZ+:E$<UQ3'_2A6BQ9G:L,%_?=PE96T2LS)WE"@5WX.F)T;
M&)P1V.(WJ?E-OHH?E3+KYF;$Z[L4)D>T#HF;(EJ,IS7CJ9'Q[]H6I(*'A$02
MK 1/"JZ8A4177UV^=?%.L\>8AKHZ:&DH6W>I8.RCKPHVP8(2;+H_4\8(S2;=
MJOFU:OY7S1-MBO1J9]$)F8R@?67R7YTLIH@6[5E->V:D?<.31+_!^ZQ](V!?
MRK/C93_K+A#G1+8D@%YC=KS^(IPN$&:TO@I4:/O$AF.HBQ^<'"C0%8FF,^1/
MIB<4V+-[L+\"KTQ],V1O&> QN=%L[$^'AQ.A*Q+IC^^?>!5"U,B SI8!;+G2
MS('(MPA=7O7:#-9; //0..OR%X&M,;0%:_PF--JO%\$*C]DID55?:14ML(76
MEJZQEG#TC;PZ-)K6WJ+:1 MLH;5%;<PL-+O97P27\I3[T0+W,$!53RV?,?&/
M':YY1+WULX36UJ\QR]#LENUXQZJ3 XLV/);.IM4.;*&UI6M<-S3;[OU2"/X#
MMY5<=Z5<'TUR6?7:5M$"6VAM41M3#OUO522M.G.K:($MM+:HC>6'9L]?"FCP
MMQU6VQMW[>[-'?66Y8Q^VS_R-0X?G>_P#RN8+G@T?.5GG J^_3(X$,,\A+YB
MV$)K"]9L")!Y0_# (B)V@A86.*(RY!E3>F?((A!J+?7DH9QUNN(*N"45](^F
MCKG_WFI90FNKU>P;D-F<-RNJ>%62YY0P2;KE04?R#&?'ZMC<6@2VT$IUW+UC
MA82(=7$\(T$Q0\H?WNO6^@CHJCCX.&B_@9=!>9#3P)3G2A^P6%,F04Q6&M(;
M3+4K$N5137FC>%H<7CQRI7A27&X(UE,V#]#?KSA7+S=Y!_6!V?)_4$L#!!0
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MY\G>N7%*@2_U19Q $=MDLKB%J7JKR[ZQON)J]$_PU;2XLJO5%#>(GRE79:!
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M13DVB2\0?8VH[K9U8-O=CM\SUW55+Z,\UW>JH!VVEQ7;RZ-LIU(_9F&,Y-\
MC6$MK\Y<7H2BB>51I-<>44M@.Z*]2K3WIFK;:].XEL!VC/,KX_S6:[M ]&I5
MVW%=:Z^T7P8Y;M=K+NVKBNS54;*?(0.&$UW9@TA^G@@7#*L/<Q/-HUBO/:.6
MP'9D=RO9W3=5W-TVC6L);,<XVWIN-ZS6R[N$K-_*OF?O7]T-46[7WR]PL]8J
MI<"6NH/DDLHJ$T4C4:U67>I ]V9[ZT/5O>H6[!FF:'WO,%N2C*,$%A+2NO#E
M/<R*;K*8")KKAFQ.A6SO]#"6'3@P%2#?+R@5VXG:H.KI@W]02P,$%     @
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MDLFIL5'36%1>A\9+='5<M77L[^MCG6>ILMKX&H1TJFG66U[+*<8;[%0QU2"
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M1RWYN!?P3I.*HK]5\7)02]<(:+Q)2F&J>M"L-KW&I2NQ>^M7V(-4+<,K3-7
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MMP(]9XIF$\!6LM3:D(,VCZ03\0G">S3 OR'B$-)":/[_W7$'G4&=JH'!&WR
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M!GI":P9_'$ZQ=QN-T^MDVQ=:4[3C;(L[)\';:!S_HA^&'O&(>]XWEW8N<;W
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M)'])C@][/*YV"LCZD0##NR2#; VJ59+.1=XL24LU=/IVH<=:B'870[<0R:W
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M0 .&A&'U'-QY'GG-<\K;_&,]_@M02P,$%     @ FSIV5I>*NQS     $P(
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M(9\-?[N:O0%02P$"% ,4    " ";.G96!T%-8H$   "Q    $
M    @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( )LZ=E;J16>
M[0   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+
M 0(4 Q0    ( )LZ=E:97)PC$ 8  )PG   3              "  <L!  !X
M;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ FSIV5C+[<C22"   W30
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M965T-2YX;6Q02P$"% ,4    " ";.G961HB=+HX"   M!@  &
M    @($G*   >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @
MFSIV5K/(KK61!P  ]2(  !@              ("!ZRH  'AL+W=O<FMS:&5E
M=',O<VAE970W+GAM;%!+ 0(4 Q0    ( )LZ=E9+=G&Q( 0  +T(   8
M          " @;(R  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M    " ";.G969W_IW7P?   &8   &               @($(-P  >&PO=V]R
M:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ FSIV5H036K9S#@  1#
M !D              ("!NE8  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q0
M2P$"% ,4    " ";.G96)_R9XD $  "]"0  &0              @(%D90
M>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( )LZ=E:+9RKP
M^@0  !(,   9              " @=MI  !X;"]W;W)K<VAE971S+W-H965T
M,3(N>&UL4$L! A0#%     @ FSIV5N"(3W;- @  308  !D
M ("!#&\  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " ";
M.G968<3A.1$#  #(!@  &0              @($0<@  >&PO=V]R:W-H965T
M<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( )LZ=E;?.GK0R (  &$&   9
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M970Q.2YX;6Q02P$"% ,4    " ";.G96U%V?0W0+  #0'0  &0
M    @($]EP  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    (
M )LZ=E;(4((@&P0  $L)   9              " @>BB  !X;"]W;W)K<VAE
M971S+W-H965T,C$N>&UL4$L! A0#%     @ FSIV5HN.RMER!   % L  !D
M             ("!.J<  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"
M% ,4    " ";.G96)LC:=;X#  !C"   &0              @('CJP  >&PO
M=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( )LZ=E;MWY"N+0,
M -D&   9              " @=BO  !X;"]W;W)K<VAE971S+W-H965T,C0N
M>&UL4$L! A0#%     @ FSIV5G/<5L=V(@  JVT  !D              ("!
M/+,  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " ";.G96
M(=P+MOX"  "2!@  &0              @('IU0  >&PO=V]R:W-H965T<R]S
M:&5E=#(V+GAM;%!+ 0(4 Q0    ( )LZ=E:/*U/@Y0(  +0&   9
M      " @1[9  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%
M  @ FSIV5I5"> '7 @  -08  !D              ("!.MP  'AL+W=O<FMS
M:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " ";.G96H[EHINL"  !,!@
M&0              @(%(WP  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+
M 0(4 Q0    ( )LZ=E9"\E'CT0(  $,&   9              " @6KB  !X
M;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ FSIV5D/9Q>B/
M!   DPH  !D              ("!<N4  'AL+W=O<FMS:&5E=',O<VAE970S
M,2YX;6Q02P$"% ,4    " ";.G96M.7&VM8"  #U!0  &0
M@($XZ@  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( )LZ
M=E8+T)4D-04  (D,   9              " @47M  !X;"]W;W)K<VAE971S
M+W-H965T,S,N>&UL4$L! A0#%     @ FSIV5O1'8"^*!   J@H  !D
M         ("!L?(  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4
M    " ";.G96F]WB%>D#  "\"   &0              @(%R]P  >&PO=V]R
M:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( )LZ=E:0$ZR,.0(  +T$
M   9              " @9+[  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL
M4$L! A0#%     @ FSIV5B,S=>ZZ P  "@\  !D              ("! OX
M 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " ";.G966_;\
M9P0#   >"@  &0              @('S 0$ >&PO=V]R:W-H965T<R]S:&5E
M=#,X+GAM;%!+ 0(4 Q0    ( )LZ=E9@_*Z9$ \   W9   9
M  " @2X% 0!X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @
MFSIV5C7?;OCY P  6A$  !D              ("!=10! 'AL+W=O<FMS:&5E
M=',O<VAE970T,"YX;6Q02P$"% ,4    " ";.G96)'*B>MD"  !:"P  &0
M            @(&E& $ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4
M Q0    ( )LZ=E;'99ZJE00  *D<   9              " @;4; 0!X;"]W
M;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ FSIV5F#[-!'/ @
M%@@  !D              ("!@2 ! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX
M;6Q02P$"% ,4    " ";.G96!KAZ+ZT#  "+$0  &0              @(&'
M(P$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( )LZ=E;_
M+6!I=P(  -X%   9              " @6LG 0!X;"]W;W)K<VAE971S+W-H
M965T-#4N>&UL4$L! A0#%     @ FSIV5K]R\AOB @  \0<  !D
M     ("!&2H! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )LZ=E;19TU%  4  #P;   9              "
M@<5" 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ FSIV
M5N3CNFZ& P  Q!   !D              ("!_$<! 'AL+W=O<FMS:&5E=',O
M<VAE970U,BYX;6Q02P$"% ,4    " ";.G96#PN',,8,  #WF   &0
M        @(&Y2P$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0
M   ( )LZ=E:[GNKULP0  "85   9              " @;98 0!X;"]W;W)K
M<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ FSIV5MW3M8&5 P  E@X
M !D              ("!H%T! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q0
M2P$"% ,4    " ";.G960\A[X2D#  #?"P  &0              @(%L80$
M>&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( )LZ=E9\$4J2
M7 ,  !X+   9              " @<QD 0!X;"]W;W)K<VAE971S+W-H965T
M-3<N>&UL4$L! A0#%     @ FSIV5N4;[A<^!   [10  !D
M ("!7V@! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"% ,4    " ";
M.G96KKC2/SH#  "E"0  &0              @('4; $ >&PO=V]R:W-H965T
M<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( )LZ=E9DJC H_P,  * .   9
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M970V-"YX;6Q02P$"% ,4    " ";.G966<87 &$#  "^%@  #0
M    @ $>@P$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( )LZ=E:7BKL<P
M !,"   +              "  :J& 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M )LZ=E9P6=,4!P4  )4J   /              "  9.' 0!X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    " ";.G96TDF\;1$"   7)@  &@
M@ ''C $ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " ";
M.G96P(AM=.D!  !^)0  $P              @ $0CP$ 6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     2 !( *\3   JD0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>162</ContextCount>
  <ElementCount>341</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>54</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100070 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100080 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/DisclosureDescriptionOfBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Licensing Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureLicensingAgreements</Role>
      <ShortName>Licensing Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Joint Venture</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureJointVenture</Role>
      <ShortName>Joint Venture</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Operating Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeases</Role>
      <ShortName>Operating Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStock</Role>
      <ShortName>Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureRelatedParties</Role>
      <ShortName>Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pyxisoncology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Operating Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesTables</Role>
      <ShortName>Operating Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeases</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquity</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pyxisoncology.com/20221231/taxonomy/role/DisclosureNetLossPerShare</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Description of Business - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails</Role>
      <ShortName>Description of Business - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Related Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfRelatedAssetsDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Related Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100420 - Disclosure - License Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails</Role>
      <ShortName>License Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Joint Venture - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails</Role>
      <ShortName>Joint Venture - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Fair Value Measurements - Summary of Financial Instruments Carried at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Financial Instruments Carried at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Property and Equipment, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Operating Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails</Role>
      <ShortName>Operating Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Operating Leases - Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails</Role>
      <ShortName>Operating Leases - Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Operating Leases - Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails</Role>
      <ShortName>Operating Leases - Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Convertible Preferred Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails</Role>
      <ShortName>Convertible Preferred Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Stockholders' Equity - Common Stock Reserved for Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails</Role>
      <ShortName>Stockholders' Equity - Common Stock Reserved for Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Stock-Based Compensation - Schedule of Estimated Fair Value Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Estimated Fair Value Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100630 - Disclosure - Income Taxes - Components of Net Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Components of Net Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100640 - Disclosure - Net Loss per Share - Summary of Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss per Share - Summary of Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100650 - Disclosure - Net Loss per Share - Anti-Dilutive Effect Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/DisclosureNetLossPerShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Net Loss per Share - Anti-Dilutive Effect Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100660 - Disclosure - Related Parties - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails</Role>
      <ShortName>Related Parties - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="pyxs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>100670 - Disclosure - Subsequent Events - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept PropertyPlantAndEquipmentEstimatedUsefulLives in us-gaap/2022 used in 1 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. pyxs-20221231.htm 5276</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept DueToRelatedPartiesCurrentAndNoncurrent in us-gaap/2022 used in 1 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. pyxs-20221231.htm 5291</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. pyxs-20221231.htm 6951</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 5 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod, us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 -  pyxs-20221231.htm 8</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="pyxs-20221231.htm">pyxs-20221231.htm</File>
    <File>pyxs-20221231.xsd</File>
    <File>pyxs-20221231_cal.xml</File>
    <File>pyxs-20221231_def.xml</File>
    <File>pyxs-20221231_lab.xml</File>
    <File>pyxs-20221231_pre.xml</File>
    <File>pyxs-ex10_21.htm</File>
    <File>pyxs-ex10_22.htm</File>
    <File>pyxs-ex10_23.htm</File>
    <File>pyxs-ex10_24.htm</File>
    <File>pyxs-ex10_25.htm</File>
    <File>pyxs-ex10_26.htm</File>
    <File>pyxs-ex10_27.htm</File>
    <File>pyxs-ex21_1.htm</File>
    <File>pyxs-ex23_1.htm</File>
    <File>pyxs-ex31_1.htm</File>
    <File>pyxs-ex31_2.htm</File>
    <File>pyxs-ex32_1.htm</File>
    <File>pyxs-ex32_2.htm</File>
    <File>pyxs-ex4_1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img30600998_0.jpg</File>
    <File>img30600998_1.jpg</File>
    <File>img30600998_10.jpg</File>
    <File>img30600998_11.jpg</File>
    <File>img30600998_12.jpg</File>
    <File>img30600998_13.jpg</File>
    <File>img30600998_14.jpg</File>
    <File>img30600998_15.jpg</File>
    <File>img30600998_16.jpg</File>
    <File>img30600998_17.jpg</File>
    <File>img30600998_18.jpg</File>
    <File>img30600998_19.jpg</File>
    <File>img30600998_2.jpg</File>
    <File>img30600998_20.jpg</File>
    <File>img30600998_21.jpg</File>
    <File>img30600998_22.jpg</File>
    <File>img30600998_3.jpg</File>
    <File>img30600998_4.jpg</File>
    <File>img30600998_5.jpg</File>
    <File>img30600998_6.jpg</File>
    <File>img30600998_7.jpg</File>
    <File>img30600998_8.jpg</File>
    <File>img30600998_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="508">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>115
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "pyxs-20221231.htm": {
   "axisCustom": 0,
   "axisStandard": 23,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 508,
    "http://xbrl.sec.gov/dei/2022": 38
   },
   "contextCount": 162,
   "dts": {
    "calculationLink": {
     "local": [
      "pyxs-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "pyxs-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "pyxs-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "pyxs-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pyxs-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "pyxs-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 537,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 9,
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 12
   },
   "keyCustom": 70,
   "keyStandard": 271,
   "memberCustom": 21,
   "memberStandard": 27,
   "nsprefix": "pyxs",
   "nsuri": "http://pyxisoncology.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pyxs:LicensingAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Licensing Agreements",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureLicensingAgreements",
     "shortName": "Licensing Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pyxs:LicensingAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Joint Venture",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureJointVenture",
     "shortName": "Joint Venture",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Prepaid Expenses and Other Current Assets",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Property and Equipment, Net",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Operating Leases",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeases",
     "shortName": "Operating Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Convertible Preferred Stock",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStock",
     "shortName": "Convertible Preferred Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_b7d0661d-e805-4887-84a1-6ba122628999",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_b7d0661d-e805-4887-84a1-6ba122628999",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RestrictedCashCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Net Loss per Share",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureNetLossPerShare",
     "shortName": "Net Loss per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Related Parties",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureRelatedParties",
     "shortName": "Related Parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pyxs:NatureOfBusinessPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "25",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pyxs:NatureOfBusinessPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pyxs:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pyxs:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Property and Equipment, Net (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_b7d0661d-e805-4887-84a1-6ba122628999",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_b7d0661d-e805-4887-84a1-6ba122628999",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pyxs:SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pyxs:SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Operating Leases (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesTables",
     "shortName": "Operating Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pyxs:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Stockholders' Equity (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pyxs:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Net Loss per Share (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureNetLossPerShareTables",
     "shortName": "Net Loss per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "pyxs:NatureOfBusinessPolicyTextBlock",
       "div",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Description of Business - Additional Information (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails",
     "shortName": "Description of Business - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "pyxs:NatureOfBusinessPolicyTextBlock",
       "div",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Segment",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_b7d0661d-e805-4887-84a1-6ba122628999",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "pyxs:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_cf314be8-48e6-4158-ba0a-296598f0c1fa",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Related Assets (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfRelatedAssetsDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Related Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "pyxs:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_cf314be8-48e6-4158-ba0a-296598f0c1fa",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - License Agreements - Additional Information (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
     "shortName": "License Agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "pyxs:LicensingAgreementsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_f891bb1b-8647-4939-8740-f3d10c242ed2",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Joint Venture - Additional Information (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails",
     "shortName": "Joint Venture - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_6eb028fe-0dfc-4fcc-8cfd-de5ca6f2a851",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_0ca7fd08-59a5-40fc-a0ec-73b51bc9fbd9",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Fair Value Measurements - Summary of Financial Instruments Carried at Fair Value on Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Summary of Financial Instruments Carried at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_3bcaea08-ed4d-45f4-8fc4-c0510f776740",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LiabilitiesFairValueDisclosure",
       "us-gaap:AssetsFairValueDisclosure",
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_6378744b-423a-4a6b-972a-85f28e55d021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AssetsFairValueDisclosure",
       "us-gaap:LiabilitiesFairValueDisclosure",
       "us-gaap:AssetsFairValueDisclosure",
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_6378744b-423a-4a6b-972a-85f28e55d021",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "div",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_b7d0661d-e805-4887-84a1-6ba122628999",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pyxs:PrepaidResearchAndDevelopmentCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
     "shortName": "Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "div",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_b7d0661d-e805-4887-84a1-6ba122628999",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pyxs:PrepaidResearchAndDevelopmentCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_b7d0661d-e805-4887-84a1-6ba122628999",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
     "shortName": "Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_b7d0661d-e805-4887-84a1-6ba122628999",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Property and Equipment, Net - Additional Information (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
     "shortName": "Property and Equipment, Net - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "pyxs:SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_b7d0661d-e805-4887-84a1-6ba122628999",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pyxs:AccruedResearchAndDevelopmentExpensesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails",
     "shortName": "Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "pyxs:SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_b7d0661d-e805-4887-84a1-6ba122628999",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pyxs:AccruedResearchAndDevelopmentExpensesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_53f21008-ad1c-494d-bca3-09d4d9bb06f6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseExpirationDate1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Operating Leases - Additional Information (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails",
     "shortName": "Operating Leases - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_53f21008-ad1c-494d-bca3-09d4d9bb06f6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseExpirationDate1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Operating Leases - Components of Lease Expense (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails",
     "shortName": "Operating Leases - Components of Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_b7d0661d-e805-4887-84a1-6ba122628999",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Operating Leases - Maturities of Lease Liabilities (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails",
     "shortName": "Operating Leases - Maturities of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_b7d0661d-e805-4887-84a1-6ba122628999",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_b7382cca-33a6-4f4e-9ad5-9ec9267d027f",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
     "shortName": "Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_b7382cca-33a6-4f4e-9ad5-9ec9267d027f",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_f0dc477c-0a31-42e2-b84e-32a6047229aa",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Convertible Preferred Stock - Additional Information (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
     "shortName": "Convertible Preferred Stock - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SharesIssuedPricePerShare",
       "span",
       "p",
       "us-gaap:PreferredStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_2e52bce4-48fd-4d5c-8c03-b3c7a4ce8258",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:SharesIssuedPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_5fa06219-1252-449b-973f-3a4c942c0ae4",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Stockholders' Equity - Additional Information (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
     "shortName": "Stockholders' Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_5fa06219-1252-449b-973f-3a4c942c0ae4",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_b7d0661d-e805-4887-84a1-6ba122628999",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Stockholders' Equity - Common Stock Reserved for Issuance (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails",
     "shortName": "Stockholders' Equity - Common Stock Reserved for Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_dbf80555-08a0-4969-b239-4e3694866a9d",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_b7d0661d-e805-4887-84a1-6ba122628999",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_4311203d-759e-4680-a158-b189b0b27135",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - Stock-Based Compensation - Schedule of Estimated Fair Value Assumptions (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails",
     "shortName": "Stock-Based Compensation - Schedule of Estimated Fair Value Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100590 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_98625906-14f2-47a1-9eb9-724228999619",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_4311203d-759e-4680-a158-b189b0b27135",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100600 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails",
     "shortName": "Stock-Based Compensation - Summary of Restricted Stock Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100610 - Disclosure - Income Taxes - Additional Information (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100620 - Disclosure - Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails",
     "shortName": "Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_83982012-10a6-4487-8dce-be863732bf86",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pyxs:TemporaryEquityIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100070 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical",
     "shortName": "Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_83982012-10a6-4487-8dce-be863732bf86",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pyxs:TemporaryEquityIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_b7d0661d-e805-4887-84a1-6ba122628999",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100630 - Disclosure - Income Taxes - Components of Net Deferred Tax Assets (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails",
     "shortName": "Income Taxes - Components of Net Deferred Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_b7d0661d-e805-4887-84a1-6ba122628999",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100640 - Disclosure - Net Loss per Share - Summary of Basic and Diluted Net Loss Per Share (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails",
     "shortName": "Net Loss per Share - Summary of Basic and Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100650 - Disclosure - Net Loss per Share - Anti-Dilutive Effect Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureNetLossPerShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
     "shortName": "Net Loss per Share - Anti-Dilutive Effect Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100660 - Disclosure - Related Parties - Additional Information (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails",
     "shortName": "Related Parties - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_7df0d474-6f80-47b5-b237-25bf19a5fb4c",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_466cd526-a6e1-4fea-9b6a-9ed2473eda8d",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AreaOfLand",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_sqft",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100670 - Disclosure - Subsequent Events - Additional Information (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
     "shortName": "Subsequent Events - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_466cd526-a6e1-4fea-9b6a-9ed2473eda8d",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AreaOfLand",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_sqft",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100080 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Description of Business",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureDescriptionOfBusiness",
     "shortName": "Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20221231.htm",
      "contextRef": "C_c6a707b3-70eb-43ea-b88c-c63a408fd4c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 54,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r510",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r510",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r510",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r510",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Securities Act File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r510",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "pyxs_AccruedResearchAndDevelopmentExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expenses current.",
        "label": "Accrued Research And Development Expenses Current",
        "terseLabel": "Accrued research and development expenses",
        "verboseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpensesCurrent",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate maximum obligation to pay future contingent milestone payments for accelerated approval.",
        "label": "Aggregate maximum obligation to pay future contingent milestone payments for accelerated approval",
        "terseLabel": "Aggregate maximum obligation to pay future contingent milestone payments for accelerated approval"
       }
      }
     },
     "localname": "AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate maximum obligation to pay future contingent milestone payments for normal approval.",
        "label": "Aggregate maximum obligation to pay future contingent milestone payments for normal approval",
        "terseLabel": "Aggregate maximum obligation to pay future contingent milestone payments for normal approval"
       }
      }
     },
     "localname": "AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_AggregateMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate milestone payments.",
        "label": "Aggregate Milestone Payments",
        "terseLabel": "Aggregate milestone payments for first four licensed products"
       }
      }
     },
     "localname": "AggregateMilestonePayments",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_AgreementsWithPfizerIncAndLegochemBiosciencesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreements with Pfizer, Inc. and LegoChem Biosciences Inc.",
        "label": "Agreements with Pfizer, Inc. and LegoChem Biosciences Inc. [Member]",
        "terseLabel": "Agreements with Pfizer, Inc. and LegoChem Biosciences Inc.",
        "verboseLabel": "Agreements with Pfizer, Inc. and LegoChem"
       }
      }
     },
     "localname": "AgreementsWithPfizerIncAndLegochemBiosciencesIncMember",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pyxs_AlloyTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alloy Therapeutics, Inc.",
        "label": "Alloy Therapeutics Inc [Member]",
        "terseLabel": "Alloy Therapeutics, Inc."
       }
      }
     },
     "localname": "AlloyTherapeuticsIncMember",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basis of presentation and summary of significant accounting policies.",
        "label": "Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basis of presentation and summary of significant accounting policies.",
        "label": "Basis Of Presentation And Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Basis Of Presentation And Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pyxs_BiosionLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biosion license agreement.",
        "label": "Biosion License Agreement",
        "terseLabel": "Biosion License Agreement"
       }
      }
     },
     "localname": "BiosionLicenseAgreementMember",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pyxs_CashReceivedForInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received for interest.",
        "label": "Cash Received For Interest",
        "terseLabel": "Cash received for interest"
       }
      }
     },
     "localname": "CashReceivedForInterest",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification and Accretion of Convertible Preferred Stock [Policy Text Block]",
        "label": "Classification and Accretion of Convertible Preferred Stock [Policy Text Block]",
        "terseLabel": "Classification and Accretion of Convertible Preferred Stock"
       }
      }
     },
     "localname": "ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pyxs_CommonStockIssuedToUniversity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock issued to university.",
        "label": "Common Stock Issued To University",
        "terseLabel": "Common stock issued to university"
       }
      }
     },
     "localname": "CommonStockIssuedToUniversity",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pyxs_ContributedAmountToJointVentureByEachEntity": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contributed amount to joint venture by each entity.",
        "label": "Contributed Amount to Joint Venture by Each Entity",
        "terseLabel": "Contributed amount to joint venture by each member"
       }
      }
     },
     "localname": "ContributedAmountToJointVentureByEachEntity",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_ConvertiblePreferredStockSharesIssuedValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible preferred stock shares issued value.",
        "label": "Convertible Preferred Stock Shares Issued Value",
        "terseLabel": "Issuance of convertible preferred stock value"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedValue",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_DeferredTaxAssetsCapitalizedResearchExpenditures": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets capitalized research expenditures.",
        "label": "Deferred Tax Assets Capitalized Research Expenditures",
        "terseLabel": "Capitalized research expenditures"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalizedResearchExpenditures",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_DeferredTaxAssetsLicenseFee": {
     "auth_ref": [],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets license fees.",
        "label": "License fees"
       }
      }
     },
     "localname": "DeferredTaxAssetsLicenseFee",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets operating lease liabilities",
        "label": "Deferred Tax Assets Operating Lease Liabilities",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Operating Lease Right-of-Use Assets",
        "label": "Deferred Tax Liabilities, Operating Lease Right-of-Use Assets",
        "negatedLabel": "Operating lease ROU assets",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative liability offset to research and development expenses.",
        "label": "Derivative Liability Offset to Research and Development Expenses",
        "terseLabel": "Derivative liability offset to research and development expenses"
       }
      }
     },
     "localname": "DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative liability statement of financial position extensible enumeration not disclosed flag.",
        "label": "Derivative Liability Statement Of Financial Position Extensible Enumeration Not Disclosed Flag"
       }
      }
     },
     "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "pyxs_EffectiveIncomeTaxRateReconciliationPermanentDifferences": {
     "auth_ref": [],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation permanent differences.",
        "label": "Permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferences",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pyxs_EstimatedCostToPurchaseLicensedProducts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated cost to purchase licensed products.",
        "label": "Estimated Cost To Purchase Licensed Products",
        "terseLabel": "Estimated cost to purchase licensed products"
       }
      }
     },
     "localname": "EstimatedCostToPurchaseLicensedProducts",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_ExtraMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extra milestone payment.",
        "label": "Extra Milestone Payment",
        "terseLabel": "Extra milestone payment"
       }
      }
     },
     "localname": "ExtraMilestonePayment",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extra milestone payment for which derivative liability recognized.",
        "label": "Extra Milestone Payment for Which Derivative Liability Recognized",
        "terseLabel": "Extra milestone payment for which derivative liability recognized"
       }
      }
     },
     "localname": "ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_FairValueOfCommonStockPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of common stock per share.",
        "label": "Fair Value Of Common Stock Per Share",
        "terseLabel": "Fair value of common stock per share"
       }
      }
     },
     "localname": "FairValueOfCommonStockPerShare",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "pyxs_FurnitureAndOfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Furniture and office equipment.",
        "label": "Furniture and Office Equipment [Member]",
        "terseLabel": "Furniture and Office Equipment"
       }
      }
     },
     "localname": "FurnitureAndOfficeEquipmentMember",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pyxs_GrossProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross proceeds from issuance initial public offering.",
        "label": "Gross Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Gross proceeds from issuance of initial public offering",
        "verboseLabel": "Gross proceeds from issuance of initial public offering"
       }
      }
     },
     "localname": "GrossProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_GrossProceedsFromIssuanceOfConvertiblePreferredStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross proceeds from issuance of convertible preferred stock.",
        "label": "Gross Proceeds from Issuance of Convertible Preferred Stock",
        "terseLabel": "Gross cash proceeds from issuance of convertible preferred stock"
       }
      }
     },
     "localname": "GrossProceedsFromIssuanceOfConvertiblePreferredStock",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_IncrementalBorrowingRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental borrowing rate.",
        "label": "Incremental Borrowing Rate",
        "terseLabel": "Incremental borrowing rate"
       }
      }
     },
     "localname": "IncrementalBorrowingRate",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "pyxs_InitialPublicOfferingPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial public offering.",
        "label": "Initial Public Offering Policy [Text Block]",
        "terseLabel": "Initial Public Offering"
       }
      }
     },
     "localname": "InitialPublicOfferingPolicyTextBlock",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pyxs_IssuanceOfConvertiblePreferredStockShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of convertible preferred stock shares.",
        "label": "Issuance Of Convertible Preferred Stock Shares",
        "terseLabel": "Issuance of Series B convertible preferred stock, Shares",
        "verboseLabel": "Issuance of convertible preferred stock shares"
       }
      }
     },
     "localname": "IssuanceOfConvertiblePreferredStockShares",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pyxs_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory Equipment [Member]",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory Equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pyxs_LegoChemLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "LegoChem license agreement.",
        "label": "Lego Chem License Agreement [Member]",
        "terseLabel": "LegoChem License Agreement"
       }
      }
     },
     "localname": "LegoChemLicenseAgreementMember",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pyxs_LesseeFinanceSubleaseTermOfContract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Finance Sublease Term of Contract",
        "label": "Lessee Finance Sublease Term Of Contract",
        "terseLabel": "Sublease fixed period"
       }
      }
     },
     "localname": "LesseeFinanceSubleaseTermOfContract",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pyxs_LicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreements.",
        "label": "License Agreements [Abstract]"
       }
      }
     },
     "localname": "LicenseAgreementsAbstract",
     "nsuri": "http://pyxisoncology.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pyxs_LicensingAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing agreements.",
        "label": "Licensing Agreements [Text Block]",
        "terseLabel": "Licensing Agreements"
       }
      }
     },
     "localname": "LicensingAgreementsTextBlock",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureLicensingAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pyxs_LiquidityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity.",
        "label": "Liquidity Policy [Text Block]",
        "terseLabel": "Liquidity"
       }
      }
     },
     "localname": "LiquidityPolicyTextBlock",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of common shares issuable under exercise of options.",
        "label": "Maximum Number of Common Shares Issuable Under Exercise of Options",
        "terseLabel": "Maximum number of common shares issuable under exercise of options"
       }
      }
     },
     "localname": "MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pyxs_MaximumPercentageOfOwnershipInterest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MaximumPercentageofOwnershipInterest",
        "label": "Maximum Percentage Of Ownership Interest",
        "terseLabel": "Maximum percentage of ownership interest"
       }
      }
     },
     "localname": "MaximumPercentageOfOwnershipInterest",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pyxs_MilestoneAndRoyaltiesIncurred": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone and royalties incurred.",
        "label": "Milestone and Royalties Incurred",
        "terseLabel": "Milestone and royalties required"
       }
      }
     },
     "localname": "MilestoneAndRoyaltiesIncurred",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_MinimumAnnualRoyaltyFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum annual royalty fees.",
        "label": "Minimum Annual Royalty Fees",
        "terseLabel": "Minimum annual royalty fees"
       }
      }
     },
     "localname": "MinimumAnnualRoyaltyFees",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_NatureOfBusinessPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature of Business.",
        "label": "Nature Of Business Policy [Text Block]",
        "terseLabel": "Nature of Business"
       }
      }
     },
     "localname": "NatureOfBusinessPolicyTextBlock",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pyxs_NonCashGainLossFromEquityMethodInvestmentInJointVenture": {
     "auth_ref": [],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash gain (loss) from equity method investment in joint venture.",
        "label": "Non-cash Gain (Loss) from Equity Method Investment in Joint Venture",
        "negatedLabel": "Non-cash loss from equity method investment in joint venture"
       }
      }
     },
     "localname": "NonCashGainLossFromEquityMethodInvestmentInJointVenture",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_NonCashResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Cash Research and Development Expense",
        "label": "Non Cash Research and Development Expense",
        "terseLabel": "Non-cash research and development expenses"
       }
      }
     },
     "localname": "NonCashResearchAndDevelopmentExpense",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common shares issued upon conversion of preferred stock.",
        "label": "Number of Common Shares Issued Upon Conversion of Preferred Stock",
        "terseLabel": "Number of common shares issued upon conversion of preferred stock"
       }
      }
     },
     "localname": "NumberOfCommonSharesIssuedUponConversionOfPreferredStock",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pyxs_NumberOfDaysCommonStockIssuedFromEffectiveDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of days common stock issued from effective date.",
        "label": "Number of Days Common Stock Issued From Effective Date",
        "terseLabel": "Number of days common stock issued from effective date"
       }
      }
     },
     "localname": "NumberOfDaysCommonStockIssuedFromEffectiveDate",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pyxs_NumberOfFinanceLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of finance lease.",
        "label": "Number of finance lease",
        "terseLabel": "Number of finance lease"
       }
      }
     },
     "localname": "NumberOfFinanceLease",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pyxs_OfficeAndLaboratorySpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office and laboratory space.",
        "label": "Office And Laboratory Space [Member]",
        "terseLabel": "Office and Laboratory Space"
       }
      }
     },
     "localname": "OfficeAndLaboratorySpaceMember",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pyxs_OperatingLossCarryforwardsBeforeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards before tax.",
        "label": "Operating Loss Carryforwards Before Tax",
        "terseLabel": "Operating loss carryforwards before tax"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsBeforeTax",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_OperatingLossCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards expiration year.",
        "label": "Operating loss carryforwards expiration year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "pyxs_OptionUpfrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option Upfront Payment",
        "label": "Option Upfront Payment",
        "terseLabel": "Stock option upfront payments"
       }
      }
     },
     "localname": "OptionUpfrontPayment",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_PaymentForLicenseFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment for license fee.",
        "label": "Payment for License Fee",
        "terseLabel": "Payment for license fee"
       }
      }
     },
     "localname": "PaymentForLicenseFee",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_PfizerLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer license agreement.",
        "label": "Pfizer License Agreement [Member]",
        "terseLabel": "Pfizer License Agreement"
       }
      }
     },
     "localname": "PfizerLicenseAgreementMember",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "pyxs_PotentialDevelopmentAndCommercialMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential development and commercial milestone payment.",
        "label": "Potential Development and Commercial Milestone Payment",
        "terseLabel": "Potential development and commercial milestones"
       }
      }
     },
     "localname": "PotentialDevelopmentAndCommercialMilestonePayment",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_PrepaidResearchAndDevelopmentCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Research And Development Current",
        "label": "Prepaid Research And Development Current",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "PrepaidResearchAndDevelopmentCurrent",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_ProceedsFromPromissoryNoteIssued": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from promissory note issued.",
        "label": "Proceeds From Promissory Note Issued",
        "terseLabel": "Promissory note issued"
       }
      }
     },
     "localname": "ProceedsFromPromissoryNoteIssued",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_ProceedsFromTenantImprovementAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Tenant Improvement Allowance",
        "label": "Proceeds From Tenant Improvement Allowance",
        "terseLabel": "Proceeds from tenant improvement allowance"
       }
      }
     },
     "localname": "ProceedsFromTenantImprovementAllowance",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recently issued accounting pronouncements not yet adopted policy.",
        "label": "Recently Issued Accounting Pronouncements Not Yet Adopted",
        "terseLabel": "Recently Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pyxs_RelatedPartyTransactionOwnership": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction Ownership",
        "label": "Related Party Transaction Ownership",
        "terseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "RelatedPartyTransactionOwnership",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pyxs_RelatedPartyTransactionServiceFeeOtherIncomeFromTransactionsWithRelatedParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction Service Fee Other Income From Transactions With Related Party",
        "label": "Related Party Transaction Service Fee Other Income From Transactions With Related Party",
        "terseLabel": "Recognized service fee as other income"
       }
      }
     },
     "localname": "RelatedPartyTransactionServiceFeeOtherIncomeFromTransactionsWithRelatedParty",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_RentIncreasePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rent increase percentage.",
        "label": "Rent Increase Percentage",
        "terseLabel": "Rent increase percentage"
       }
      }
     },
     "localname": "RentIncreasePercentage",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pyxs_RestrictedStockSharesUnvestedAndOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock shares unvested and outstanding.",
        "label": "Restricted Stock Shares Unvested and Outstanding",
        "terseLabel": "RSAs unvested and outstanding"
       }
      }
     },
     "localname": "RestrictedStockSharesUnvestedAndOutstanding",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pyxs_RisksAndUncertaintiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risks and Uncertainties [Policy Text Block]",
        "label": "Risks and Uncertainties [Policy Text Block]",
        "terseLabel": "Risks and Uncertainties"
       }
      }
     },
     "localname": "RisksAndUncertaintiesPolicyTextBlock",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty obligation period for licensed products upon first commercial sale.",
        "label": "Royalty Obligation Period For Licensed Products Upon First Commercial Sale",
        "terseLabel": "Royalty obligation period for licensed products upon first commercial sale"
       }
      }
     },
     "localname": "RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of common stock reserved for future issuance.",
        "label": "Schedule Of Common Stock Reserved For Future Issuance [Line Items]",
        "terseLabel": "Schedule Of Common Stock Reserved For Future Issuance [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfCommonStockReservedForFutureIssuanceLineItems",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of common stock reserved for future issuance.",
        "label": "Schedule Of Common Stock Reserved For Future Issuance [Table]",
        "terseLabel": "Schedule Of Common Stock Reserved For Future Issuance [Table]"
       }
      }
     },
     "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTable",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of common stock reserved for future issuance.",
        "label": "Schedule Of Common Stock Reserved For Future Issuance Table [Text Block]",
        "terseLabel": "Common Stock Reserved for Issuance"
       }
      }
     },
     "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pyxs_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of estimated useful lives of property and equipment.",
        "label": "Schedule of Estimated Useful Lives of Property and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Estimated Useful Lives of Property and Equipment"
       }
      }
     },
     "localname": "ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pyxs_SecuritiesPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities purchase agreement.",
        "label": "Securities Purchase Agreement [Member]",
        "terseLabel": "Securities Purchase Agreement"
       }
      }
     },
     "localname": "SecuritiesPurchaseAgreementMember",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pyxs_SeriesAConvertiblePreferredStocksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A convertible preferred stocks.",
        "label": "Series A Convertible Preferred Stocks [Member]",
        "terseLabel": "Series A Convertible Preferred Stock",
        "verboseLabel": "Series A"
       }
      }
     },
     "localname": "SeriesAConvertiblePreferredStocksMember",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pyxs_SeriesBConvertiblePreferredStocksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B convertible preferred stocks.",
        "label": "Series B Convertible Preferred Stocks [Member]",
        "terseLabel": "Series B Convertible Preferred Stock",
        "verboseLabel": "Series B"
       }
      }
     },
     "localname": "SeriesBConvertiblePreferredStocksMember",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "pyxs_ServiceFeeIncomeFromRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service fee income from related party.",
        "label": "Service Fee Income From Related Party",
        "terseLabel": "Service fee income from related party"
       }
      }
     },
     "localname": "ServiceFeeIncomeFromRelatedParty",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, equity instruments other than options, vested and settled in period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Vested and Settled in Period",
        "negatedLabel": "Number of Shares, Vested and settled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, equity instruments other than options vested and settled in period, weighted average grant date fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options Vested and Settled in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Outstanding, Vested and settled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesReservedAndAvailableForIssuancePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award increase in number of shares reserved and available for issuance percentage",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Increase In Number Of Shares Reserved And Available For Issuance Percentage",
        "terseLabel": "Number of shares of common stock outstanding percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesReservedAndAvailableForIssuancePercentage",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pyxs_StockIssuanceExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issuance expenses.",
        "label": "Stock Issuance Expenses",
        "terseLabel": "Stock issuance expenses",
        "verboseLabel": "Stock issuance expenses"
       }
      }
     },
     "localname": "StockIssuanceExpenses",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_StockOptionsAvailableForIssuanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock options available for issuance.",
        "label": "Stock Options Available For Issuance [Member]",
        "terseLabel": "Stock Options Available for Issuance"
       }
      }
     },
     "localname": "StockOptionsAvailableForIssuanceMember",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureNetLossPerShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pyxs_StockOptionsTwoThousandTwentyTwoTwoThousandTwentyOneAndTwoThousandNineteenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock options two thousand twenty two, two thousand twenty one and two thousand nineteen plan.",
        "label": "Stock Options Two Thousand Twenty Two, Two Thousand Twenty One and Two Thousand Nineteen Plan [Member]",
        "terseLabel": "Stock Options 2022 Plan, 2021 Plan and 2019 Plan"
       }
      }
     },
     "localname": "StockOptionsTwoThousandTwentyTwoTwoThousandTwentyOneAndTwoThousandNineteenPlanMember",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pyxs_SubleaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublease agreement.",
        "label": "Sublease Agreement [Member]",
        "terseLabel": "Sublease Agreement"
       }
      }
     },
     "localname": "SubleaseAgreementMember",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pyxs_SubleaseExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublease expiration date.",
        "label": "Sublease Expiration Date",
        "terseLabel": "Sublease expire date"
       }
      }
     },
     "localname": "SubleaseExpirationDate",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "pyxs_SubleaseTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublease term.",
        "label": "Sublease Term",
        "terseLabel": "Sublease term"
       }
      }
     },
     "localname": "SubleaseTerm",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pyxs_SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of accrued expenses and other current liabilities.",
        "label": "Summary of Accrued Expenses and Other Current Liabilities [Table Text Block]",
        "terseLabel": "Summary of Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pyxs_TaxCreditCarryforwardExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforward expiration year.",
        "label": "Credit carryovers expiration year"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpirationYear",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "pyxs_TaxCutsAndJobsActDeferredTaxAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax cuts and jobs act, deferred tax asset.",
        "label": "Tax Cuts and Jobs Act, Deferred Tax Asset",
        "terseLabel": "Deferred tax asset"
       }
      }
     },
     "localname": "TaxCutsAndJobsActDeferredTaxAsset",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoCommonStockValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity convertible preferred stock converted into common stock value.",
        "label": "Temporary Equity Convertible Preferred Stock Converted into Common Stock Value",
        "terseLabel": "Temporary equity, Conversion of Series A and Series B convertible preferred stock into shares of common stock"
       }
      }
     },
     "localname": "TemporaryEquityConvertiblePreferredStockConvertedIntoCommonStockValue",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoSharesOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity convertible preferred stock converted into shares of common stock.",
        "label": "Temporary Equity Convertible Preferred Stock Converted into Shares of Common Stock",
        "terseLabel": "Temporary equity, Conversion of Series A and Series B convertible preferred stock into shares of common stock (Shares)"
       }
      }
     },
     "localname": "TemporaryEquityConvertiblePreferredStockConvertedIntoSharesOfCommonStock",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "pyxs_TemporaryEquityIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity issuance costs.",
        "label": "Temporary Equity Issuance Costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "TemporaryEquityIssuanceCosts",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock issued during period shares new issues.",
        "label": "Temporary Equity Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of Series B convertible preferred stock, Shares"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "pyxs_TenantImprovementAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tenant improvement allowance.",
        "label": "Tenant Improvement Allowance",
        "terseLabel": "Tenant improvement allowance"
       }
      }
     },
     "localname": "TenantImprovementAllowance",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_TenantImprovementAllowanceReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tenant improvement allowance receivable.",
        "label": "Tenant Improvement Allowance Receivable",
        "negatedLabel": "Less: tenant improvement allowance",
        "terseLabel": "Tenant improvement allowance receivable"
       }
      }
     },
     "localname": "TenantImprovementAllowanceReceivable",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_TwoThousandNineteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen equity incentive plan.",
        "label": "Two Thousand Nineteen Equity Incentive Plan [Member]",
        "terseLabel": "2019 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandNineteenEquityIncentivePlanMember",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty one employee stock purchase plan.",
        "label": "Two Thousand Twenty One Employee Stock Purchase Plan [Member]",
        "terseLabel": "2021 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyOneEmployeeStockPurchasePlanMember",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pyxs_TwoThousandTwentyOneEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty one equity incentive plan.",
        "label": "Two Thousand Twenty One Equity Incentive Plan [Member]",
        "terseLabel": "2021 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyOneEquityIncentivePlanMember",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pyxs_TwothousandtwentytwoequityinducementplanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty two equity inducement plan.",
        "label": "TwoThousandTwentyTwoEquityInducementPlan [Member]",
        "terseLabel": "2022 Equity Inducement Plan"
       }
      }
     },
     "localname": "TwothousandtwentytwoequityinducementplanMember",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pyxs_UnderwritingDiscountsAndCommissions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriting discounts and commissions.",
        "label": "Underwriting discounts and commissions",
        "terseLabel": "Underwriting discounts and commissions",
        "verboseLabel": "Underwriting discounts and commissions"
       }
      }
     },
     "localname": "UnderwritingDiscountsAndCommissions",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_UniversityLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "University license agreement.",
        "label": "University License Agreement [Member]",
        "terseLabel": "University License Agreement"
       }
      }
     },
     "localname": "UniversityLicenseAgreementMember",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pyxs_UnvestedRestrictedStockAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested restricted stock awards.",
        "label": "Unvested Restricted Stock Awards [Member]",
        "terseLabel": "Unvested restricted stock awards"
       }
      }
     },
     "localname": "UnvestedRestrictedStockAwardsMember",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureNetLossPerShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pyxs_UpfrontFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront fee.",
        "label": "Upfront Fee",
        "terseLabel": "Upfront fee"
       }
      }
     },
     "localname": "UpfrontFee",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_UpfrontPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payments.",
        "label": "Upfront Payments",
        "terseLabel": "Upfront payments"
       }
      }
     },
     "localname": "UpfrontPayments",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_VoxallMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Voxall.",
        "label": "Voxall [Member]",
        "terseLabel": "Voxall"
       }
      }
     },
     "localname": "VoxallMember",
     "nsuri": "http://pyxisoncology.com/20221231",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r239",
      "r276",
      "r440",
      "r450",
      "r478",
      "r479",
      "r491",
      "r496",
      "r505",
      "r541",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r239",
      "r276",
      "r440",
      "r450",
      "r478",
      "r479",
      "r491",
      "r496",
      "r505",
      "r541",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis": {
     "auth_ref": [
      "r463",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Real Estate, Type of Property [Axis]"
       }
      }
     },
     "localname": "MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MortgageLoansOnRealEstateNamePropertyTypeDomain": {
     "auth_ref": [
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Real Estate [Domain]"
       }
      }
     },
     "localname": "MortgageLoansOnRealEstateNamePropertyTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r239",
      "r269",
      "r276",
      "r306",
      "r307",
      "r308",
      "r439",
      "r440",
      "r450",
      "r478",
      "r479",
      "r491",
      "r496",
      "r505",
      "r537",
      "r541",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r239",
      "r269",
      "r276",
      "r306",
      "r307",
      "r308",
      "r439",
      "r440",
      "r450",
      "r478",
      "r479",
      "r491",
      "r496",
      "r505",
      "r537",
      "r541",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r211",
      "r212",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r492",
      "r504",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r211",
      "r212",
      "r463",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r492",
      "r504",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_MA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MASSACHUSETTS"
       }
      }
     },
     "localname": "MA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate202001Member": {
     "auth_ref": [
      "r385",
      "r386",
      "r387",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2020-01 Investments - Equity Securities (Topic 321), Investments - Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815): Clarifying the Interactions between Topic 321, Topic 323, and Topic 815 (a consensus of the FASB Emerging Issues Task Force).",
        "label": "Accounting Standards Update 2020-01 [Member]",
        "terseLabel": "ASU 2020-01"
       }
      }
     },
     "localname": "AccountingStandardsUpdate202001Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r10",
      "r503"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Legal and professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r58",
      "r138"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r152",
      "r153",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r5",
      "r503"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "periodEndLabel": "Additional Paid in Capital, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Beginning Balance",
        "terseLabel": "Additional paid-in capital",
        "totalLabel": "Additional Paid in Capital, Total"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r528",
      "r529",
      "r530",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r166",
      "r167",
      "r168",
      "r169",
      "r179",
      "r213",
      "r214",
      "r223",
      "r224",
      "r225",
      "r226",
      "r228",
      "r229",
      "r315",
      "r316",
      "r317",
      "r333",
      "r334",
      "r335",
      "r336",
      "r348",
      "r349",
      "r350",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r382",
      "r383",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r398",
      "r399",
      "r401",
      "r402",
      "r403",
      "r404",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r442",
      "r443",
      "r444",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r83",
      "r84",
      "r278"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r310"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive effect excluded from computation of diluted net loss per share attributable to common stockholders"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureNetLossPerShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureNetLossPerShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureNetLossPerShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureNetLossPerShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfLand": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land held.",
        "label": "Area of Land",
        "terseLabel": "Sublease agreement, square feet space area in building"
       }
      }
     },
     "localname": "AreaOfLand",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r111",
      "r118",
      "r140",
      "r159",
      "r205",
      "r207",
      "r209",
      "r218",
      "r240",
      "r241",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r250",
      "r352",
      "r356",
      "r381",
      "r503",
      "r539",
      "r540",
      "r586"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r134",
      "r146",
      "r159",
      "r218",
      "r240",
      "r241",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r250",
      "r352",
      "r356",
      "r381",
      "r503",
      "r539",
      "r540",
      "r586"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r100"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Assets measured at fair value",
        "totalLabel": "Assets, Fair Value Disclosure, Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r0",
      "r43",
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Description of Business"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureDescriptionOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r39",
      "r40",
      "r41"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Property and equipment in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r36",
      "r136",
      "r481"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows2": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r30",
      "r36",
      "r42"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of year",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash shown in the statement of cash flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash:"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r30",
      "r36",
      "r42"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of year",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r30",
      "r106"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Noncash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "auth_ref": [
      "r128",
      "r129",
      "r165",
      "r213",
      "r214",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r333",
      "r348",
      "r349",
      "r358",
      "r360",
      "r361",
      "r371",
      "r382",
      "r384",
      "r385",
      "r386",
      "r389",
      "r390",
      "r398",
      "r400",
      "r401",
      "r402",
      "r403",
      "r421",
      "r422",
      "r442",
      "r443",
      "r451",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether accounting standards update was adopted.",
        "label": "Change in accounting principle, accounting standards update, adopted [true false]"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "auth_ref": [
      "r128",
      "r129",
      "r213",
      "r214",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r333",
      "r348",
      "r349",
      "r350",
      "r358",
      "r360",
      "r361",
      "r362",
      "r365",
      "r371",
      "r382",
      "r384",
      "r385",
      "r386",
      "r389",
      "r390",
      "r398",
      "r400",
      "r401",
      "r402",
      "r403",
      "r421",
      "r422",
      "r442",
      "r443",
      "r451",
      "r452",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format.",
        "label": "Change in accounting principle, accounting standards update, adoption date"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "auth_ref": [
      "r166",
      "r178",
      "r215",
      "r227",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.",
        "label": "Change in accounting principle, accounting standards update, immaterial effect [true false]"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r159",
      "r182",
      "r183",
      "r185",
      "r187",
      "r194",
      "r195",
      "r218",
      "r240",
      "r243",
      "r244",
      "r245",
      "r249",
      "r250",
      "r253",
      "r254",
      "r257",
      "r261",
      "r267",
      "r381",
      "r480",
      "r517",
      "r524",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r71",
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r14",
      "r114",
      "r122"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 16)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r62",
      "r234",
      "r235",
      "r464",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r63",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common stock issuable upon conversion",
        "terseLabel": "Common stock reserved for future issuance",
        "verboseLabel": "Number of common shares reserved and autorized for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r528",
      "r529",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value per share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "totalLabel": "Common Stock, Shares, Issued, Total"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r4",
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r4",
      "r503"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Common stock, $0.001 par value per share; 190,000,000 shares; 35,110,016 and 32,792,867 shares issued as of December 31, 2022 and 2021, respectively, and 34,958,730 and 32,222,881 shares outstanding as of December 31, 2022 and 2021, respectively",
        "totalLabel": "Common Stock, Value, Issued, Total",
        "verboseLabel": "Common stock, issued value"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockVotingRights": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.",
        "label": "Common Stock, Voting Rights",
        "terseLabel": "Common stock, authorized (in shares)",
        "verboseLabel": "Common stock voting rights"
       }
      }
     },
     "localname": "CommonStockVotingRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r117",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in process"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfRelatedAssetsDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r39",
      "r40",
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Stock automatically converted",
        "verboseLabel": "Number of preferred shares conversion"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r253",
      "r254",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r107",
      "r542"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "terseLabel": "Underwriting commission and issuance costs",
        "totalLabel": "Debt Issuance Costs, Net, Total"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r34",
      "r97",
      "r331",
      "r340",
      "r341",
      "r526"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Deferred Income Tax Expense (Benefit), Total"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDerivativeInstruments": {
     "auth_ref": [
      "r95",
      "r574"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from derivative instruments.",
        "label": "Deferred Tax Assets, Derivative Instruments",
        "terseLabel": "Derivative"
       }
      }
     },
     "localname": "DeferredTaxAssetsDerivativeInstruments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangibles"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Total gross deferred tax assets",
        "negatedTotalLabel": "Total gross deferred tax assets",
        "totalLabel": "Total deferred tax assets before valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r573"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r573"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Net deferred tax assets",
        "negatedTotalLabel": "Total deferred tax assets",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r95",
      "r574"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Net operating losses",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r95",
      "r574"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r94",
      "r95",
      "r574"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Tax credit carryforwards",
        "totalLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "auth_ref": [
      "r95",
      "r574"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "terseLabel": "Stock based compensation",
        "totalLabel": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r95",
      "r574"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Reserves and accruals",
        "totalLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r328"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Valuation allowance",
        "negatedLabel": "Less: valuation allowance",
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total",
        "verboseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r34",
      "r202"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization",
        "totalLabel": "Depreciation, Depletion and Amortization, Total",
        "verboseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r577"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "terseLabel": "Change in fair value of derivative liability",
        "totalLabel": "Derivative, Gain (Loss) on Derivative, Net, Total"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r147",
      "r148",
      "r380",
      "r484"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Derivative liability",
        "totalLabel": "Derivative Liability, Total",
        "verboseLabel": "Derivative liability related to extra milestone payment"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r280",
      "r311",
      "r312",
      "r314",
      "r319",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Text Block [Abstract]"
       }
      }
     },
     "localname": "DisclosureTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r113",
      "r123",
      "r242",
      "r243",
      "r244",
      "r248",
      "r249",
      "r250",
      "r430",
      "r527"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "terseLabel": "Amount payable related to licensed products",
        "totalLabel": "Due to Related Parties, Total"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r155",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r180",
      "r182",
      "r185",
      "r186",
      "r187",
      "r191",
      "r369",
      "r370",
      "r445",
      "r448",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per common share - basic",
        "totalLabel": "Earnings Per Share, Basic, Total"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r155",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r182",
      "r185",
      "r186",
      "r187",
      "r191",
      "r369",
      "r370",
      "r445",
      "r448",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per common share - diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted, Other Disclosure [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "EarningsPerShareDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r44",
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r188",
      "r189",
      "r190",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureNetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r323"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective income tax rate%",
        "terseLabel": "Effective tax rate from continuing operations",
        "totalLabel": "Effective income tax rate%",
        "verboseLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r160",
      "r323",
      "r342"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Income tax computed at federal statutory rate%"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r572",
      "r575"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r572",
      "r575"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "State taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r572",
      "r575"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Research and development credit carryovers"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee compensation and benefits",
        "totalLabel": "Employee-related Liabilities, Current, Total"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized stock-based compensation expense weighted average amortized period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r571"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Gross unrecognized stock-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r571"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Gross unrecognized stock-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock Purchase Plan",
        "verboseLabel": "ESPP Withholdings"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureNetLossPerShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options Outstanding"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureNetLossPerShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfRelatedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r66",
      "r130",
      "r152",
      "r153",
      "r154",
      "r162",
      "r163",
      "r164",
      "r167",
      "r175",
      "r177",
      "r193",
      "r226",
      "r268",
      "r315",
      "r316",
      "r317",
      "r335",
      "r336",
      "r368",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r426",
      "r453",
      "r454",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A description of the principal activities of an investee accounted for under the equity method.",
        "label": "Equity Method Investment, Description of Principal Activities",
        "terseLabel": "Equity method investment, description"
       }
      }
     },
     "localname": "EquityMethodInvestmentDescriptionOfPrincipalActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Percentage of voting membership units"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "terseLabel": "Joint Venture"
       }
      }
     },
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureJointVenture"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r372",
      "r373",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r104",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Summary of Financial Instruments Carried at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r251",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r373",
      "r436",
      "r437",
      "r438",
      "r489",
      "r490",
      "r493",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r372",
      "r373",
      "r374",
      "r375",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r251",
      "r270",
      "r275",
      "r373",
      "r436",
      "r493",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r251",
      "r270",
      "r275",
      "r373",
      "r437",
      "r489",
      "r490",
      "r493",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r251",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r373",
      "r438",
      "r489",
      "r490",
      "r493",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r103",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r103",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Changes in Level 3 Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)",
        "terseLabel": "Changes in the fair value of derivative liability",
        "totalLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r251",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r436",
      "r437",
      "r438",
      "r489",
      "r490",
      "r493",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsNonrecurringMember": {
     "auth_ref": [
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value.",
        "label": "Fair Value, Nonrecurring [Member]",
        "terseLabel": "Fair Value, Nonrecurring"
       }
      }
     },
     "localname": "FairValueMeasurementsNonrecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r377",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Office Equipment"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfRelatedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "Initial Public Offering",
        "verboseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "auth_ref": [
      "r34",
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.",
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "terseLabel": "Impairment losses"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r54",
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r98",
      "r159",
      "r166",
      "r205",
      "r206",
      "r208",
      "r210",
      "r218",
      "r240",
      "r241",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r250",
      "r370",
      "r381",
      "r487",
      "r539"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "negatedLabel": "Losses incurred",
        "totalLabel": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r18",
      "r34",
      "r51",
      "r115",
      "r124",
      "r203"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Loss from equity method investment in joint venture",
        "terseLabel": "Loss from equity method investment in joint venture",
        "totalLabel": "Income (Loss) from Equity Method Investments, Total"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r232",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r90",
      "r91",
      "r92",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r160",
      "r324",
      "r325",
      "r330",
      "r338",
      "r343",
      "r345",
      "r346",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r161",
      "r176",
      "r177",
      "r204",
      "r322",
      "r339",
      "r344",
      "r449"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Current income tax expenses (benefit)",
        "totalLabel": "Income Tax Expense (Benefit), Total"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r151",
      "r320",
      "r321",
      "r325",
      "r326",
      "r329",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r572"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Increase in deferred tax assets valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r31",
      "r38"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r522"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r522",
      "r582"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivableCurrent": {
     "auth_ref": [
      "r519"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Interest Receivable, Current",
        "terseLabel": "Accrued interest receivable"
       }
      }
     },
     "localname": "InterestReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r22",
      "r201"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r217",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investment in Joint Venture"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r418",
      "r502"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Total lease costs",
        "totalLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Components of Lease Expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.",
        "label": "Lease Expiration Date",
        "terseLabel": "Lease expiration date"
       }
      }
     },
     "localname": "LeaseExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfRelatedAssetsDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeaseTermOfContract1": {
     "auth_ref": [
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Finance Lease, Term of Contract",
        "terseLabel": "Fixed period of sublease"
       }
      }
     },
     "localname": "LesseeFinanceLeaseTermOfContract1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Maturities of Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r419"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Future minimum lease obligations",
        "totalLabel": "Total undiscounted payments",
        "verboseLabel": "Future undiscounted operating lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r419"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r419"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r419"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r419"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r419"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r419"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r419"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: present value adjustment",
        "negatedTerseLabel": "Less: present value adjustment",
        "terseLabel": "Less: amount representing imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee, Operating Lease, Option to Extend",
        "terseLabel": "Operating lease, option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease, renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease, term of contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r11",
      "r159",
      "r218",
      "r240",
      "r241",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r250",
      "r353",
      "r356",
      "r357",
      "r381",
      "r486",
      "r539",
      "r586",
      "r587"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r9",
      "r112",
      "r120",
      "r503",
      "r525",
      "r535",
      "r579"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r13",
      "r135",
      "r159",
      "r218",
      "r240",
      "r241",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r250",
      "r353",
      "r356",
      "r357",
      "r381",
      "r503",
      "r539",
      "r586",
      "r587"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r100"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "terseLabel": "Liabilities measured at fair value",
        "totalLabel": "Liabilities, Fair Value Disclosure, Total"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r157"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r157"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r30",
      "r32",
      "r35"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r19",
      "r35",
      "r116",
      "r125",
      "r133",
      "r149",
      "r150",
      "r154",
      "r159",
      "r166",
      "r170",
      "r171",
      "r172",
      "r173",
      "r176",
      "r177",
      "r184",
      "r205",
      "r206",
      "r208",
      "r210",
      "r218",
      "r240",
      "r241",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r250",
      "r370",
      "r381",
      "r487",
      "r539"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss)",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss and comprehensive loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing nonoperating income (expense).",
        "label": "Nonoperating Income (Expense) [Member]",
        "terseLabel": "Other (Expense) Income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segment"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r205",
      "r206",
      "r208",
      "r210",
      "r487"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r410",
      "r502"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r580"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "negatedLabel": "Non-cash lease expense",
        "terseLabel": "Operating lease, rent expense",
        "verboseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r406"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails2": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of future payments",
        "totalLabel": "Present value of future payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r406"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedLabel": "Less: current portion of operating lease liabilities",
        "terseLabel": "Current portion of Operating lease liabilities",
        "verboseLabel": "Operating lease liabilities, current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r406"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, net of current portion",
        "totalLabel": "Operating lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r407",
      "r414"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities, included in operating cash flows"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r417",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r416",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r94"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating loss carryforward",
        "totalLabel": "Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Description of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOrganizationAndNatureOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r145",
      "r503"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets, noncurrent",
        "totalLabel": "Other Assets, Noncurrent, Total"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other current assets.",
        "label": "Other Current Assets [Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForProceedsFromTenantAllowance": {
     "auth_ref": [
      "r24",
      "r27"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.",
        "label": "Payments for (Proceeds from) Tenant Allowance"
       }
      }
     },
     "localname": "PaymentsForProceedsFromTenantAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r29"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payment of deferred offering costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInterestInJointVenture": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group.",
        "label": "Payments to Acquire Interest in Joint Venture",
        "negatedLabel": "Investment in joint venture"
       }
      }
     },
     "localname": "PaymentsToAcquireInterestInJointVenture",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockConvertibleSharesIssuable": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common shares issuable upon conversion of preferred stock.",
        "label": "Preferred Stock, Convertible, Shares Issuable",
        "terseLabel": "Convertible preferred stock shares issued upon conversion",
        "verboseLabel": "Common Stock Issuable Upon Conversion (pre-reverse stock split)"
       }
      }
     },
     "localname": "PreferredStockConvertibleSharesIssuable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r3",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par or stated value per share"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r3",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "totalLabel": "Preferred Stock, Shares Issued, Total"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockTextBlock": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.",
        "label": "Preferred Stock [Text Block]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r3",
      "r503"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Preferred stock, par value $0.001 per share, 10,000,000 shares authorized; zero shares issued and outstanding",
        "totalLabel": "Preferred Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r520"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "totalLabel": "Total Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current [Abstract]"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r144",
      "r230",
      "r231",
      "r482"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Prepaid Expense, Current, Total"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r483",
      "r488",
      "r536"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Net proceeds from issuance initial public offering",
        "verboseLabel": "Proceeds from issuance of common stock in initial public offering, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock in initial public offering, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "terseLabel": "Proceeds from issuance of Series B convertible preferred stock, net of issuance costs",
        "verboseLabel": "Net proceeds from issuance of convertible preferred stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r28",
      "r81"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from the exercise of stock options",
        "verboseLabel": "Proceeds from stock options exercised"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r133",
      "r149",
      "r150",
      "r156",
      "r159",
      "r166",
      "r176",
      "r177",
      "r205",
      "r206",
      "r208",
      "r210",
      "r218",
      "r240",
      "r241",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r250",
      "r351",
      "r354",
      "r355",
      "r370",
      "r381",
      "r446",
      "r487",
      "r500",
      "r501",
      "r521",
      "r539"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfRelatedAssetsDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r61",
      "r466",
      "r467",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property, Plant and Equipment, Estimated Useful Lives",
        "terseLabel": "Estimated useful lives of related assets, description"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfRelatedAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r57",
      "r137"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "terseLabel": "Property and equipment gross",
        "totalLabel": "Property, Plant and Equipment, Gross, Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfRelatedAssetsDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r59",
      "r121",
      "r447",
      "r503"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r59",
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule of Estimated Useful Lives of Related Assets",
        "terseLabel": "Schedule of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfRelatedAssetsDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives of related assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfRelatedAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r127",
      "r429",
      "r430",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r108"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "verboseLabel": "Related party transaction expenses incurred"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r427",
      "r428",
      "r430",
      "r431",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Parties"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureRelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r86",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research And Development Arrangement Contract To Perform For Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r86",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r85",
      "r126",
      "r594"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development",
        "terseLabel": "Research and development expense",
        "totalLabel": "Research and Development Expense, Total",
        "verboseLabel": "Amended license agreement amount incurred"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development",
        "verboseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r518",
      "r523",
      "r595",
      "r596"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows2": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash",
        "totalLabel": "Restricted Cash, Total"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r518",
      "r523"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Unvested Restricted Stock Awards",
        "verboseLabel": "Restricted Stock Awards"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.",
        "label": "Restricted Stock, Shares Issued Net of Shares for Tax Withholdings",
        "terseLabel": "Number of restricted stock units issued"
       }
      }
     },
     "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units ('RSU')"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r6",
      "r68",
      "r119",
      "r457",
      "r462",
      "r503"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r130",
      "r162",
      "r163",
      "r164",
      "r167",
      "r175",
      "r177",
      "r226",
      "r315",
      "r316",
      "r317",
      "r335",
      "r336",
      "r368",
      "r453",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r415",
      "r502"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease right-of-use asset obtained in exchange for operating lease liabilities",
        "verboseLabel": "Operating lease right-of-use asset obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureNetLossPerShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Anti-Dilutive Effect Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Components of Net Deferred Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Summary of Basic and Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r79",
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule Of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r53",
      "r133",
      "r159",
      "r218",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule Of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other current assets.",
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfRelatedAssetsDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r109",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r86",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r277",
      "r279",
      "r281",
      "r282",
      "r283",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r74",
      "r75",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Estimated Fair Value Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Stock options vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Number of Shares, Cancelled",
        "negatedLabel": "Number of Shares, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Outstanding, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Number of Shares, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Outstanding, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r293",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Number of Shares, Outstanding, Beginning Balance",
        "terseLabel": "Number of option to purchase restricted stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r293",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Outstanding, Ending Balance",
        "periodStartLabel": "Weighted Average Grant Date Fair Value, Outstanding, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of common shares authorized for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of common shares reserved for future issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Options, Exercisable at December 31, 2022"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercisable at December 31, 2022"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r300"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Number of Options, Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of Options, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of Options, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average fair value of options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r80"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic Value, Outstanding, Ending Balance",
        "periodStartLabel": "Aggregate Intrinsic Value, Outstanding, Beginning Balance",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r285",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Options, Outstanding, Ending Balance",
        "periodStartLabel": "Number of Options, Outstanding, Beginning Balance",
        "terseLabel": "Number of options to purchase common stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r285",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Ending Balance",
        "periodStartLabel": "Weighted Average Exercise Price, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "terseLabel": "Number of shares issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r284",
      "r303",
      "r304",
      "r305",
      "r306",
      "r309",
      "r318",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Award expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r80"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable at December 31, 2022"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r300"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of restricted stock vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Common stock public offering price per share",
        "verboseLabel": "Share sale price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning Balance, Shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r411",
      "r502"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r159",
      "r182",
      "r183",
      "r185",
      "r187",
      "r194",
      "r195",
      "r218",
      "r240",
      "r243",
      "r244",
      "r245",
      "r249",
      "r250",
      "r253",
      "r254",
      "r257",
      "r261",
      "r267",
      "r381",
      "r480",
      "r517",
      "r524",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r17",
      "r66",
      "r130",
      "r152",
      "r153",
      "r154",
      "r162",
      "r163",
      "r164",
      "r167",
      "r175",
      "r177",
      "r193",
      "r226",
      "r268",
      "r315",
      "r316",
      "r317",
      "r335",
      "r336",
      "r368",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r426",
      "r453",
      "r454",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r193",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r16",
      "r66",
      "r67",
      "r68",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of Series A and Series B convertible preferred stock into shares of common stock (Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r3",
      "r4",
      "r66",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock (Shares)",
        "verboseLabel": "Stock issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r66",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Vesting of restricted common stock (Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r3",
      "r4",
      "r66",
      "r68",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of Options, Exercised",
        "terseLabel": "Stock options exercised (Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r17",
      "r66",
      "r68"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of Series A and Series B convertible preferred stock into shares of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r3",
      "r4",
      "r66",
      "r68"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r3",
      "r4",
      "r66",
      "r68"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Vesting of restricted common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r17",
      "r66",
      "r68"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Stock options exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.",
        "label": "Stock Repurchase Program, Number of Shares Authorized to be Repurchased",
        "terseLabel": "Number of shares authorized to be repurchased under a stock repurchase plan"
       }
      }
     },
     "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r4",
      "r7",
      "r8",
      "r50",
      "r503",
      "r525",
      "r535",
      "r579"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r72",
      "r158",
      "r254",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r268",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split, conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.",
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "terseLabel": "Reverse Stock Split"
       }
      }
     },
     "localname": "StockholdersEquityPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "terseLabel": "Reverse stock split description"
       }
      }
     },
     "localname": "StockholdersEquityReverseStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r413",
      "r502"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "terseLabel": "Base rent payments to receive over sublease term"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r397",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r397",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r397",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r397",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r433",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r94"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Credit carryovers"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "auth_ref": [
      "r1",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.",
        "label": "Temporary Equity, by Class of Stock [Table]",
        "terseLabel": "Temporary Equity By Class Of Stock [Table]"
       }
      }
     },
     "localname": "TemporaryEquityByClassOfStockTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r240",
      "r243",
      "r244",
      "r245",
      "r249",
      "r250"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Convertible Preferred Stock",
        "verboseLabel": "Carrying Value"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Disclosure [Abstract]"
       }
      }
     },
     "localname": "TemporaryEquityDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Temporary Equity [Line Items]",
        "terseLabel": "Temporary Equity [Line Items]"
       }
      }
     },
     "localname": "TemporaryEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Issuance of Series B convertible preferred stock, Shares",
        "verboseLabel": "Shares issued"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning Balance, Shares",
        "terseLabel": "Convertible preferred stock, shares outstanding",
        "verboseLabel": "Shares Outstanding"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of convertible preferred stock value",
        "verboseLabel": "Issuance of Series B convertible preferred stock"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransactionDomain": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement between buyer and seller for the exchange of financial instruments.",
        "label": "Transaction [Domain]",
        "terseLabel": "Transaction"
       }
      }
     },
     "localname": "TransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransactionTypeAxis": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments.",
        "label": "Transaction Type [Axis]",
        "terseLabel": "Transaction Type"
       }
      }
     },
     "localname": "TransactionTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r166",
      "r167",
      "r168",
      "r169",
      "r179",
      "r213",
      "r214",
      "r223",
      "r224",
      "r225",
      "r226",
      "r228",
      "r229",
      "r315",
      "r316",
      "r317",
      "r333",
      "r334",
      "r335",
      "r336",
      "r348",
      "r349",
      "r350",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r382",
      "r383",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r398",
      "r399",
      "r401",
      "r402",
      "r403",
      "r404",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r442",
      "r443",
      "r444",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrealizedGainLossOnDerivatives": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.",
        "label": "Unrealized Gain (Loss) on Derivatives",
        "negatedLabel": "Changes in fair value of derivative liability",
        "terseLabel": "Change in fair value of derivative liability"
       }
      }
     },
     "localname": "UnrealizedGainLossOnDerivatives",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r46",
      "r47",
      "r48",
      "r196",
      "r197",
      "r199",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r412",
      "r502"
     ],
     "calculation": {
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r181",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average shares of common stock outstanding - diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r180",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average shares of common stock outstanding - basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pyxisoncology.com/20221231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails",
      "http://pyxisoncology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31010-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "https://asc.fasb.org/topic&trid=2196965",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL120154346-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r506": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r507": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r508": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r509": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r511": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r512": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r513": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r514": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r515": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r516": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905813&loc=d3e1205-110223",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2611-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21459-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>116
<FILENAME>0000950170-23-009046-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-23-009046-xbrl.zip
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M7]SH&CLY/O41"6062CBY!K1D(<AN":>/CT)&I8^;>[%R/%^VX3T"W^8)WZ_
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M!KU0<#S2"6SA6X'+K\3]UN253J2RA?Y'^-+ :@9;DM#7MV9H>!QNHTJ3MX]
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MVN[> UFF2=1,*KY$L4GL=K%J]"6GX#@Y5CQ,+.*>.+<:(2D"_[J:N?^AO")
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M;DW9T>UJ8O#*YT8#]H\O>#)?C>A_.IDMWU[QYT=,1SXPW!*#?P(A0%W>GZ@
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M)QX\&SV%!W.N_6^C(5;'&3.^_\,*V$10+<]_9P5,_@E(Q'X."&=BA($PY@X
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M&O!\!-J]6$E6"0*X%3[654>ZJ37?VN85SG,]=XY&M(1+94>_UAZ-_\=>%E:
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M],'#6U[N]FY40>:HSF#OAL2'D<KFX"/;,NVZY[&:(4+&#_#/UW$H9#G3$8\
M<^>$2]F!+%@<,:&B,NUZ:$=YK%&2-?*[_RI.]OU\#=+%$+>!_J1'*4*^:$/\
M(^"F1MHXZ0FQ@3H>!E/%:*UJJ6'7!#,T<VEF#=W1?WBHKSWAH78O5><PKU$G
M?XDEBN'M%#Z@^"K_FPO,<Q_'1<-#U;UPMA*G\:YE)N.C<<;QS0LGQ9KDT4N[
M!X2-0SSVN]<Q8<L2H#-Z*"9>@/.5:X"OIR F^ UQ?LY]D>NW:T,M+/J%N8:X
M],#)JM5CC1B)(KJO#3!^;<<9[7@&5AH.5\P)%9^*U!-Y;"S,+UH4^WR(X"Q/
MU\&73]])9CAT1=2TGF'$%ZI1/A49655QG])_:FIQ>]4EME90K7N4=--7EOWT
M53W?7F+O5(&&M8[FL7QG*L@Y*#B+6- ==)[,5V;]W$=ENG9HNA4^?PQS\AY$
MJN3CJ.J+!;J9,+A3X(%N=."T?@M*^%%S\)V(GXR%0FV\8'P3DQ=?^U?F-I-E
MJ>-DYUM[YPKFH/D";04>6P.#\UUGS"=,_/;I0Z.Y'I]U]F_DC/B$?-$E'OH(
M8"/&O/&=2SES*/#.0'RKS.6[%Z%![%KAD"_TXJT<+FF\G9'JCO(7_;THE^""
ML (Z=K>90CZ;C!S=!_JTYIK0_<EZ2BW5$ X7"GU6$RL^(]MQNN\<A!_7F%+7
M ,P=/37W&ADUJFH-$WYS[^F[ERS//'0AQ')R$-)$<Y%=TS/AB"DBXJH<Z31?
MRS)??RGV-M$\*/G8@6<)!W@=T>D>$71OM7.NET:7JK<;_?.NS?[.=XEG:+L^
MPM-:>%2JQ8? =1^?XK4W<^1!;U-+XDJ(<%</>6#Y7:%2SQCB%Y76C5]XHVER
M+1YRO"4U^QG>-VDA<4YY=Y.S>C=UK_G&KHJ_-$F/NFPR\LO!%@R?1N]HGMUV
ME3<KA$ZY]F\X1?XHF*CFF;"([&R)W6V06VJP/YCV&EX8<2\9C>*"(;>6@ IX
M?67*LV,=O;TA \]*>7E9^.1B$\>*G/ _5/?M$?Q8,V#SL5RQS]G&!)5:>2EC
M]YH5?%1'N!#3-%V*\'2(F@A14@:EX21,AGQIMI'$EL!N/Z3/$R'?H;,#72$Z
ME<S3/E?@FJ%;?WM"0L'>(JGCX![84\MJE^/A@!NKLJ*\7JVL?,S:&8^*-A(V
MXJY?0XCY>NRP4=7!"58*3@$P#IBK)?7YG+]>6[>M/5BH^0A8%AC\T+KRP'5[
M!'#UWC\"/1EM3YB:K67!:$]'&_&!60"TM_\(;#O?DV@]]'HHQVUY^/F2SX-%
MNR>_RCFUJ'EE?EY@2K+U=$HUS[ZA^5'T,>M%"Z:XPF)$BK4!CX7,4_]]=5G3
M?9ERC9*AC@X*TN@HF0GG;=V+8L'4GGP$JL%A/D,;'J89+0T"=_ *!>Z)UB2:
M ;):SD;?W0XH/9UY]'_N7Y@EO_T*KB =JQ:,44@>JJZ9;UE!HHTB^6(@*X<2
M3.O2Y72WPRV'_UZQB.JV_Y?,\OFSJWIC(>[$K^"N9RQKB%/\FQ619Q^+FO8%
MPF8E*=L&.9VB?:J<Z*R)A/L0@_-"@I$%;@6$MB>C+GVCDM,P"@K;K0L;U2TK
M7N_[Z" 1Q2W]FD"WUDI2J5& O"!?"/(/D:,]DN;PW],"'P<%""N8E]S_[/6_
M?CNI55 \;Q7+E(04=JGJB>GKJ19;$Y':S9$CJ(E/*ID$FEE74!K4,O*HM"G:
MK;=)3I.?<V9^6>)NE]5]7ES1;;%*@IBHH(YKZK>?B>4P3K[ZC558SP&-BLU8
MI^>IO\^]=^?N>QJQYPWFJE0D*+4(34A8HVWCKQ-JA9C,/S,[0]4JBU#?XT0N
M/ *=%8&'NH84H&-0]4W&/=RD6_6;L4/XX#MM(;Y]VH-!KBX6NKKC:<&8O+ "
M-=M>.;[M+\5/372-VOD(Z",^!$U RSHN%\DC#QR7\3\%;[$$/O ,[-YD7$!G
MGUI)#XQ<Z[I_HN2)J9NA< P_F4;XP6H :;O$7F9XXI2EA6M[[8LQ.3LN<>2M
M8 N$M5DOSEUMTGQ"^+Z$)A*)-0I9Y.NI_#?W$\H@K'"->U?B8I?5VS 3)AO;
M<@Z*]\VKHJDHO6.'D5%Y9&M4\44FXN]L>VC*UF0XM605R )__(@BCIC/SB]@
MTH%F2-7EK6XRO!%3?H8=W3^);CA1S7Z@-P)*V#!^=K#0D._=M)M@P>#J_B7!
M4KM+HUAQ@2_S Y3P4%JD<$?-'EB-BE<=]1/]>O\TZUS_O NZ('P27K4;#AAR
M_;5O&O2/?=/EB9O%;[/#F:7_6 _]SW#\[V!P_%^+J/'FL;^G!I7GT^RVC2!?
MA#A'5O;<6I?:U+/(XY/:94M8B=COT2C6<98@M,733L^-TEJ7O))(;[>"EE31
M8_YEM$\8@A@)P<5WSF/]SXN6!XAO.Z9JGZ]N0 \^15-A*FXA(D;%P^S&:Z,>
M+:V&9!S#2C0VWG+M3 EZS'G8L5CT+:?-K$5ACG[WINDRPGY@LJJ]3(?_7C'"
M32+P6E7!@^#S6/DCX)=11(;@-8Q8IZ;]A/^['GCMHGD7B8[]HT84 W_5U+:%
MN (QG#A\;X.%<:>G:O\TZ_<B,?"/K7_PN3G<7S(E_HA]>VAWLWQ)4AH]&(]!
M[?DUO2T+H#V8-ZGS]%T] C\*.GU(K-U?LBW;\3[SQ%WPQ=95A\CQ>@K86*IV
M_LA3C!.UR2XQ@EQZFJTGUA[)P8VD<@HNAY<9^M]808HSH9&8G9Y#'\S0\XSD
M<"Y#TWJ6-(6U1/"2E1V44IEE$JWV^B_*,-Y;5M;-((8>#)2DH7=0?J/X>DX!
M]=1,N"_->5?[G !;7V*!G!X-<\.(;C(Q<I5,O?U28DVN(1;A5^:&WJX@\0\-
MW"OEE"[[>^;T"[*3Y@70,H6FJB%XQ3?"E:^-M5&*\%OJ\59FO\TYF?:U=IXD
MMQM62;GL-^EVYFU'I)NI%YEK=2?\J73O7]19=2W%^*\9P>[X" W/*4S,KA+.
M3-SU07@Y:*8*::8#->BO%)=[[VB;R6R>PU<J:;U2J7S"[;[N6VY-KMS5B$RG
M4^VL.-L/P[-IT$&H4_&<N^$ U*:@OLT4S@\K_6I^[>B.9=MJ\[W L@'#CT6J
MR?-(KH'3ZB_/Y2:EY_%#Y&8]3Y0<#+U6C3X:TDVY]+6@O7]Y=-\Q=;&>-W"P
MK_<<=Q>&G[RSA9D7?4CA6#F2&Q,!TG7:(1BA510=*_S+ S.[<'T2L=TNW-47
MAV%"K?MU7:6!J)3!*=:K\)FV"V%REI^-6.E$U7$ZDSXT<BY>:][41&STU9.8
M* 2?3/17/B@/^1L&'Z'*)4ZM]$ZR:]]S&=3'WFAU<2+_>" DNH.@G:,P,>93
M02"_)TFY>9GP?\;X1U5E39Y.8J@*<E*POY=+_K%^\A\Q8BM@ZR(Q[TQT()/T
M!84)/=!/QA,#$W8J<$^"B=7/7D:@3.,TR"[^TX)X6R;;2LRP2\[> /N;'M@6
MADF_I_:ME7_M)E)LZ(UI_N6BQ_9]6SF_P>>UTY*H BA-)7Y@65 \6)>WOGY"
M1%2;9#P9J8M+=]321ROA8L:6-\V_YMWY-E=RW]"O5OX]L0I^^2MM?%U>1VV]
M=_<@U0*\JW(*AO+#UT/&NK,^D1<+(J5!#X:<O/M#RN^'"?7IWNO?IR$MS-X_
MS^"B)55SO1D]@7CSYSJ&141!!%WNBI1%++O7Q%JCXV-&/RU'G.?,53-&?B%*
M4"(H.LN$=Y[69CA$.YY-R4CASL1MW1O6FB@+L:6/$.GXB. !:[O*I%<Q%]2Z
MZA#KT-[V<VGR4!(+T(OKI+,U<#=<Q6.W8QZ*<CV8]47IH($[/@@G/'8G54*1
MYP]U7+I9L*2$I1%V$B-ZA[$9+2^4WA73 ><DS26WEVR8(0\@(LXFT)ZDQL/F
M"^3VHK=N^D>VQJ22?O*Z52/&K28\A_*7L+EHQ1Y:M:,$#MDBB@F-/W_.XEN(
MZA+7!X=#8NNI7C%%2DZME*QZ]4">=/L(<"88CKD(G&U^FJ-]IX]VB%B[ICA>
M JJT>TUNEW(2,CBO^?J3^VIDL.<5J71THH/KV?:+T>K.CCA9 $): 9LO-\"-
M=LY_,S(/A@J$; IY>HT*;##0KU^"O<@%SK.B'/S]91T1A%! \A+/.)%)8:3(
M?_A9PB SW, H 6S\6]_S'^)QDR71L""=O*7ZRS$)^1D^EC>G8JVP$<G**VVD
M<6T%+/%HB,=HYBDW*E0C7:,_*S+[.%JSW_2K<=M$%+6UY:*-U*B6+XCC.79O
M;B3[AZ9:C.$%+OG+2(N.?\Z%V4N/)V>:H4*Y/96+LH0I $6RJRHG@+4Z7I5W
MT]Z,(>I*4A!W@6-R&>PI*,D&I)FDN60,XX$TG_B A)"Q0QDK2:SS/)9J/X:]
M\-=NN9M^>&L.- 56\IAY9#O ]RX..7'1*O//'3=J,3O*P6!(_.LY\ ,U4V[D
ME@6LL,7H)_3N/,33'"C;/-I%+@=HD#';7XQ"T^??+GR6$=TG#?H0_JNA[HV"
MDV:YJA0^#0ICMM__(\LSYL/(2>$A,3'F/G7XI3+=#Z#J(Y'(KQ]U7-#559)Z
MR\L_'+Y^V"HG(N+IV&W!>:!Q%T0ZMR.Z$NRW+&F5G^33VZ@=NJRC? 32(:'G
M*0M*?4JUZ5Y[A9E1BUPO2GXA=)"]N=5.WVXAO\,OO<IFQ1E=W:#][LN&&F8\
MAP=-!9 %B$0X609$&70@LTF=F.A[QX8M=S2&S&^H&YWY=31)R3[L5?GPS-^Y
M'&GF+F$@%&3/2-IX97$.P;83:KV9*EPK;P4% PP=F(16M1FX^W>H^7O#5X8S
M4-$)AZ(>O(8M_E?S8F0LV4>BX=R1\NMR:[?1N#+<XL\G=YV=2%QHWVX5V/ZH
ML['3O[)9I8"YLN[PQ2H!)Y1EG^2D2N_W_!2UEW=$D/'57:Y&)_@A2GELZ(_9
MILA[(73%CJ,7*057;(<G%MCKE+KNZ70H1D;13L+^S3UNU<)OBTB;LQ?'S>5M
M7\P5IX]+\2U'IS6F7S5C+!U!S"Y;$@Y,G['TL$_J@TNS,'+QK,\P0]?S9_BC
MI>^$/PZ,&L]<++_U;55YP(<N4WQP<,>X-$B>4_7Z7&U=Z4C)$:SGH[>!R"",
MQ;7/"#MXQV7*O31+T_5 BMBC:-*6%VT'V&H*D#\"'"#_KQG([SWR[KBJQ]]C
MK\7.BDRDC?6BC7:YOB[Q7/=&P)1@F5EJNZ&YZA76F/28Q*&@LA7N6GDIS;M%
M-L0_X/$(A//<.XYUU*I<9:R$7X6WF3X"82X;\0I"[_8)7_*+W+I<#  .M8OL
MM<>8!W0K(FX*-6G.=?Z5 ;\TF"Y2;=%^8@J)VW,M)=_P-H*ECZ;"WGL<L\L?
M:X=Q*U_)<'NC<Q1,<QCQ2N^_P:SGBGHI")YL2D[&?1X;_GKLCW^5!7+_8WN:
M%+UE)GQV[!__,4CF$@OW#(DIL*JX]DR()U"(\+EXZ7 F4OQQX@%CF^ V0]FC
MZAJ3DL9.N>?T9BK3/&*"25Z(JS2$"_O# ][L7?-:JTM9D _U&)](<G?A#Z$?
M]M./@/,C\'H*U\%:)+>+I= T1&HWEDD-!&NDJXFN+CG&4R@,5?M)DK!OX$$A
M.:XU4GJ3_D 2NMLM?]R2//(()*V_+Y;R(F\YTEI4&;URW?^Q\(H D>6*3_5J
ML[%;[ZBK;&7GKDGKIZP,A"/>+@<#W5G:(;%[;,6)E)?ERG&J\JD$PQ!-9U'"
MXYJ*%4A;16JOK?*0#=-/OI7IV_"MPJ\0'G.7\3R4"OO"TNA<889C5-ECM1>J
M+3-V%:=Z\AZ@7^F/P&!]_36Q #G3<]FTF/$-'24DGEU#U*LZUHJH]HZ-_ ^_
M\J:)GIK-W8W\WJ>Z3Y!WDJ%[DP@MR_.SC;9M"]LCD%&T?Q8>6M+_->OS1BAI
M!E3*V@7^H,2--S9WN(>/-M214&.B_WVQHA#7CT< PH**+L^. 2E_TTE?762$
ME/4=];8S.HOHK ^C.:%XM254>_'Y^-G0!U\,Y]SQZL\V,809=;99[CV_''II
MCPT+O')W;N(GORW-M#O0Y69;N\7 </!O__0B/K:L)E$.::G2:BAT+T^Q 75@
MP9H5RN9FQU0R*AM_DEFN"K&<>R]_/!10;<THRK)]$9:_U$,=K5HN@%6W36AZ
M?$T!]6*D\J-<)Q<GVXL]Q@A;>?+;!V3>C[Y;.Z??W4M+YG%*@_S$*:,PW,LH
MK_*.+72.'AI 0<(,1;/5R3J=[R[#D6,'NG]NI%JD@AE(O2V?;XU4:7,M>U$]
ME?.AWEE[=NLBUWX.F40E\74Q$\DWPD< B0SYP "_J8-/ZWA>3_Y;.W.('-;&
M&_(@8B#QGP'B)P"4B:@V!H&@Z>K*,\) (%550)6J%-7_W:X4BHQUXW+&02YQ
M\G'PLR;)00S/+2C[Y]=6:1\8%B,[NHJGG7.[!?!:=YV1M?;DO" "R F4?WAN
MG/X=+]M-]BR?$9>U-Z+1:*F[YU;OQ#,<U_X&7_*<N]O)=4^? 4>]H17++M#B
MMJ_XS4C=Y>?W[!==J&B7SAM][$>'U[2JQZ1SR;-=O"@Z_@+\L.4/5;QI.6\Z
M"9N\]Y<Z=.KN"*K-Y@DFJKO>#&'<:J3_%'H$=(?KJD>K0EZE$['1&<?$=5^I
M$]2^*9&F(=QI:^/!9[IC8AN16VAZ /-XDT^28'N8RJH&2#LBB3P]6)<9??6I
M1V3I6OU<"W,ER2RZ3^L5%:B>#X.IG@A1,HX4K?8D;_P,8KP]/$A0$2ZO498?
M?KE=_\[\RE>YINE69C9GJ=)VZ7.$A<#.V5>H":C*" 6^?L'CS9#-=/>&KB'^
M2FEW:;]/M7A@!C8GH&1[6OL /QGU87"\??2A_X>BN).\(I^-4>.9=Y_@0YJU
M&1K])&MP+^(F ^A+4<F9M9 UC-/7VD7@@-:O>=Y146$U NG [9GTZ2?FS?(+
M:_-(;[0XJ49PGPB&X#D>^=D1X9NU"DT/&BLK7D5=YCW7V'NT.>CSP<V.^1W6
M2W$A-QP2LKIUXJWV^JZ1(BJ]0TS=;2A/$W,OBNZ</G5=+REI1F=Q.O^+.6D$
M=_+X+Z<Z/]NJE?+)NK\4]&?YZ)U97<Q/'-U_[?M:#.JGEG@$HL7O=AZHFV,.
MDR?>A*X!6)AJTKY0OG8NI'/IB$>@3[8'<:GL:DQ8RO9H%\HF*N='^4!(<Y:3
M-9Z:U7Z9,^ESWJ!7EMBAZUHAFM+DL)E%2L.W()J=\DY=;0IK "<H^?4W-K$=
MZ2]Y<D6RMWI]&D0OI#W.BDIL'GI7^9<MM#F:.9L$U?B/]DC4"%V,=(5W6&;G
M]K9L[B*_."O2(YPRH)*Z RP_Q8:$US-.P_N_C4 /SU$#B8PAN =J&&X4X!WE
M8_4X%]L/OX(8***?/*#LRCUK1!_L^G\1]I51;:U=MZ%0K$A+<0LM7HI#BP0K
MQ8N[]T"10('B[@6*NQ9WIRW!W:%X<(?@'B00(,"EY[SO_61\W[T_,D;VV+^R
MLO=::ZXUYWQH A\?/SPXT.T)^23"YVD@HCSR7C(/-D%P;0;_0G\0WQ+12=KR
MU,FKJ-)ML2K,'UL3&X%J-\11I0H ZG0\6D019EZNWB+.7]7U<L1PQW0?&Y4E
MD,==S=-:@C 5-C+TB$_Q'>?Y!^YN>VX?I,@=6#R-/L45.:5Y\RL8\YSM7I-\
M>]_D/=(5_'KQ!M7R6',:XO;Z,&EO*"85+2$]RN.9VE)//IBH7&UAP)%C$=47
M#;]]M=7L"Q/'5DS/6;A=L;(HTL</*0GJ?N>TVZLQ!8T\:NMA8TLJ]^FY3?(9
MO@?0S@JW7J[/I'4&+'QHFED/&W^[0#Y _UK4UMO]O(*=+@F^\17Q4KX?/N_;
M/4<%LK';E/G8HQUIX5\D9 ^Y,EJPR3T]I2C7Z2/XP5Z^W@NO-XB/\ZDIY+/A
M5*S5GMQ8/.P8?*C[6'S)GC(1%8,>!&V2856PFABCSFU1W6CT_?BL786AC0P\
M45*!<N-?:O99KQ0]2\ 5K9^2TT@J>K+F(2$#1N^.^NWL5*S:0LIMCI=7#?NV
M;'!EAF0,KBG;UJ2<?Z9F?>4\W=X=YNTRP]\\3IR@OTISD9[\DF(UF\Y$/U=\
MHV3=.V^96>)K^%B1\WW ]D$= 4.]:6?R7Q'GU+YZ@S.0XO.Y=4N<TP(L0/HA
M_3U@1E6I[XY(QGR;3.8>\*XBFO0>T-=2=W.(*C5,LV W"^[YR$T42=X!M1IF
MM_&TNDYO>\?20SX,E ]<EZQCBCE;3H ZPV)Z;ED+DXF]!;/1QR[S(L[D%"8*
MT)_3V ]DQT_G1\Z3+F9[=:'/Y^V*XT300E35NW^D,+GK;Z-?6N]9/L)34Z\'
M> L6WH(!M"EY-<06?JQXW(=2F&&8+VXM1]!H(4X@'R>G7=EWSKE1O'+B/7>T
M0N,S@3*([/-L#'JL-.S=:Q5/]<W$@H\&:/X0M'G_B&SGJ^+K<5F,_0-6)6':
M!& E6 P7H"H7@6OP\6PY4-9B2JP:"Q5/(WG7170/V$FQGBOK]34G_"^\12VB
MQ:G/Q*I2LIUA_Q96_B^?N#!6/S55J4>\1XBE5UT:D D[_B=N=G9RI!?'=(0<
M:,SH._B.C8A[0,3K.SJPV!Q\_FU0A)(S1;ZS]+?S >8];/1* NM4Y,GJ?H9^
MUQ>WK'=#'LL!RUY*@5MN(:_;0HQ'*N08D_L(_4_=/Y2(+()*LQ!O61S0+OJ!
M_MGX;:&9(N'M1CCQ.F'\C0VITU0"H5>?8ALM:'[@5'(JP"UZ,N3U:2S43V"[
MT _[#-=>6AUQQ*!$ %SYYZUU:)"S7:CQ8T;X7IE8&(C&)7N^;CGQ*0F-1_HC
M,4*/ S[E^;==^VO]N=.'G&LSV=]D&+_5F9@EX-$447^*NF5!?[L^-5*U9D>+
M5.Z99L.+F>]CK(];>R)#'(),(9#!C[T[5"[;F5= 6AD3>RF>K)U0LSU+PA<=
M<:ZK26S\JF%D$.^_OV]HW%5&^!19W4D9V=>];P\2*B^H.!\L%G\JN4!/@;&]
MWUZ69MRA#-BYSEV9M^2&E"XD6K@D$E^\T(G](,->A7QW"2-LSV!UBL2D>:+J
M/[W5V>5#2K*T)][!-JJ$V+V@]+IL):R;:'X?=DFD6_XVK")FN X_\,C!6@>
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M8AGNAL/E%ZZ<=L[/N_@L\*+JZ68T/N5#1"=P(G/"H_F93_>B0CII!2>;F9U
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ML?K]QSCL[]9>3\^&_8^IYT-*?\!RF.S$JK+_W@ 1^ODD?(I'%.Q&RZM&1!O
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M^>+=)NFL3T /C P,DM8P>ZF2%VWIO 6!(I3VSY_O+L><3&<LQ]P#8K5>B.^
M"4'C,U7D!>VKG$;G: B9@X?BPC#X'[;:>O]>H&5=_\M:R*P2["4]^#];Y"5
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MW"6_P/<^1RT)(@0WG%;&NNDP& @U"H88#!%Z<,!6,I2TZA&UQ#&G;9\T^4R
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MDH8.6Q/474F%TAQGE3V^36GWKS%U"@?VA:?:;LG)(<I;%</5H#=#0;@3#?<
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MJ\M[Y+V.V6DV>']JE!;[7,5M)PS LIR+HS033?-,[W>Z/1DV#*H=C:/Z@NE
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M^.L>L$A_U\$PRY=XCLMUW@^\]?N&4 K<I0U>,.S:OJ&XI!BKW/]@DW\%OP=
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M$A'*!/%#^BL7?80G!,K5>@RR;YGC]^FIIW9>- ?-"6E/W@-*K13'?LDMM[I
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M>+T],;\(BU1JR6I# ]ENN2RLDL'-;!<=:S8;)9Q-":OL>:^5L'/9314WQ+>
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MD[R5>Z;P"J!M1^SLDNE^T6?PVQ&T9H:DZ9>BGP@JK'(K%6JP=.0,?+L6OA@
M*0/<#NR4T'\H0::93&L-3 N6RUTS.!/O'VVI^W[NG<)^GCCOFCXO'ZFWX"QA
MIYT<^X5H/ SSPCLHT8"I'E;4/?;4UN19Y(3A!,]Y%C?FBJ^GVY.0#^'.O?S1
M)/U8)DV[^,Y>DV(^U$>'8ISCBWKRXBRUU1NNX03HM&@SE4I-GNOE'EH_;8VU
M3*=X/C!\I#K>3  ]521+HL8<-77 E+F02K$6WU>VF:>O\5B+L>P%UMP#ON3_
MX=IN(6_P,'%]6K$1EA+@0Z! "04NEVLWI/5X"?<0XMNL-$_YKS'$PH\&K[Y'
M%'4?T]6T%%4=<\0VPVO=39_<\A;NBK6-%%:9.3D[R-8HDCP33Y1R"I!9724Q
M>IM>D2=4W)P\,Z/F5U'--?&V7[TG#XM5E))2=+U&P]&?7]6\7I)#>O+(=6P^
M=OU$(YF9R; MO#4LA/N3[,[/82[64!0M\@=T0[*J[6=SY(+:9,CB=72Q#D4$
MT-.?/T0\8%?2$QV+WMC)27#J5QJ%YJ# F6BBOOG'7X>JRL2>S! 7 SYDGFFV
M"FHTPVBRH'JAYK#2DS'*L7!Q@WYRT53&A;NH<I]<UT08:;EA?<M!,EJ^7L(]
M3N/4N-A/Y"R]KSC@0P ^,3J?UC4AO8.<</K(.++$;->4,J>FUL14DTJW9)9L
M$J;1QFY,ZJC&K2_8LZY.(5(L2U2L*X2J&]0YZ3^*1,O]T%/ Q'**WFX<4=:>
M=/-.<"HU73(U,K-*W;=(J=I+95XOY/5VI4F4)%G_PXH(;QEDM1_Y"H $#T6V
MT8OW@4C;6:V%ZJ<]Y@N."FI3W75+F\4KN6EKS<TMQ<.HZ-O0*C./Z\1O[A16
M5I87ETR:,!9'."2^! #$(\8  *F@B#I[I0T=L92^N\F&F^",AJQTS<[W=)L[
M#&@K=020""RI<D@7?>X&*<PQHB(NJ)5_S9;(C*5N\73OS$"1KW&A6N+!QI0P
M-Q,I*SW"-/98L^S!CGR;BGE\BMM2^TIS5AD<297Q_;+?EV/T0HW(-GU2D;ZJ
M;&6?J-\YPLWU-$0JAU>D>'WZPDK@FT!CG?CL^9ZJ>:UR&)'H@"A;)GUP@XTH
M95,<N/[W,]@]H-=*@(?@]F5,>7G%=Y[R?1/SX:V@@BV\65D&2TI)^;=PE<GJ
M=B;D8"QHW12(BA)<UZ7G@.,OQ=<VS5PH'NG2O$\\E9.)E1]2%>DLSH<3U'&F
M5:N4KK2F!V&TN#<[.Y#B/8[?V:'<P!)HR^#(HM/M6E)=7H!BR4_&W2I?W%@+
M# <8HE\&XS@=M "\' 1=UK_'$5BA:& "=KA[.H7;-[;F-!&QZX0W>44U.JP]
MD["^]MKFRBC!;X<4*ND<7[D^U%D;P$HXM3ZOB6H?3)(,'.BA7LQLP^4CZ[@L
M=AA/N*FEB[*B_NC"U+'65&>R^KS?S"/U,OPXP)\3 3<V'A4[:C"6MIU("?_2
M@_G'V^4N1<82TUY\-9V7RLQC-Z, SD:CF*910JQ(^-<M\"?%#PEYB7Q4QC2/
M%79E#FW5D:6]K)K42<C@=\('%(D-IG9)(T\RCU8R_P9;9QOB:D-3=)-L9F[Q
M#Y82:,KN2O4C"U*VFEY^L6X.>5_F(9#1_C&/(SCP5KO[5L<.;-:)XPF$Q?7%
MR716T#N2'%SBN[#T-Y0H76IX"N-=.O-^$[T"LFZ;J&'%JF@W3_)<D-:'GIZN
M']G_?NV0I#3Z3'4H(#O9FX#=##.K?\O-;*J=$^QH (\+/_?U[KZVGRXIW$]W
MQ75DJ96=?D[UF ;H0J?Z650JM 613L>TT1>:[<O5U-0$2]3KG#BC37)D1M\G
MZ)8\BRULW1ZZ[,9Z6ZU,2'M C]?+GIZ:A&,T5#TD=9/'04;3=NT$M=EJ9P%7
MK/1!>&_<$TCCK1'J\M86IJ%SP%>^3YBSA_)2VG"VE;7&6X6]-TJ-'8X-3<,@
M)+#-=%<^B>N8Z0RN5HUBX$MBCJPYX-+ R43Z5D49]PG(PE=BWF $-%<W]RE[
M*+HC.>CYL) 86L+@>J/R"1DX3*N6O#FVK<3$T)P(X])9X1N=E*9",5?=B$'_
MT/HH]%UK?5TSAI$,?@^SRZ.7KU^(V,6*EFY2\!;!;C3JQZ6>[0I?'A//T\S^
M2N0%,+#2Q'KC;=YQ_)Q&D2(S#)%=Q?."F;_U5DR'G=U>$UD18SFC+([11$ >
M3!#)@^&JZ!U8^3NX7*O G\+ZNN(LD,-8U8-FP>H@=?QK@WZV<*+M=Y+.Y/D1
M:U>S4,CJ"PD9L[5O/IZ>3L6+AFP1^40]U.+/FF(E=CZK+V[B]T"^S<-O=5_>
M\L%T$:%1UKEOW7Z>%,T_[PT@[I.A$OG8R"JQ"<GBZ*T=>WJ0+N!<&%6Z3^WC
M3#M0GZ;VU-&9-'I25VRTQ,/"GON"H^DHNG^UA_-PX),$E5!2#)1U^V!$C:EM
M:%M'LD,?QDG/>I<OV'C[^I.K'7Y)2T.X!4]#K=,;B5J_VP81";,ZNUL!Y;".
MR72>,'(4:5686BJOBX0S3000'9O^+3\>)BO@G(JI8ZP&G&W2!!GWSG+43#?D
MO$M5Y-ZT"!;!^L"ZM2MF5J#,&BVA(KCHX0(.TTG<?SI,>N3+!NZB9#1TEY,W
M>M<HKN<SM//#2BRE(@%6N3:%RB$YK$<]MTS)A$4UH?R1A,NW'!S&2,?UIG81
MI>EY^ZF^NNT?CA\GF5Z]?UH+L=A@7:*DDW-)")RT_&6JV9[V-DXU_7JK+->%
M6:><@S(A3N=))OK@IM=48ZO6.K;KV.&LVY*J.%V!WU!:(G;]M?TH[Y%:2GG(
MKS@G.-DFO7@=\EL>6*]\.6<FM8%7G@AC29ZX/Z[F9M9J%C[#1&>;\L>'OPSI
ML8H5<^(6I7CH-\<5'D03/@0Z/J;@J3U%6\1JGS!*"^!N%42WX46&J;?]<31_
M(^908[E-7O-9]?#[4[V7#'YT->G[$HKK6>0S:Z,EW_>66=OA)@6ERD]:)ATV
M4E\FO%E(%"0FAFZ/-;#",P2_TTU,0;0$QHT43'061P9%#C1VXCXLIPGH]&);
MB[LH>=W6YI@)!*C>^HGF]ULOHLT(9!M@DF8/9=U908L$ M[BY\3U)TW4O4!O
M X8PQNS "^ZLQ@3:Q-318B=+&SQ&)MK9>*$"ZOS[CG/).VN%>;'9\Z<;J-L>
M$^C_SULH5C@_^/_]%BHQ]3^!3I^.:Z:_?ON*^C2.VN!64>J9/]&MZ RG&YT$
M0T1M(;LN1]:L)*[E(OV4[OI,F(3C!Q??#2 6\OLQ(UDSDS5OKY$(K4^..4FB
M&A/\R,@_R,=CW?&+'U7#A(_AJG=/H3A-W!&NB5[:581?'DA33/WQG>U&?=-=
MH&^.K0EF1^W,\0=;<UG-/_PO%S*),ETR\>Z\9\I\A/Y42DC"9EZ-7TA$E=K*
MZK_+3&;-Z@AU0NH2/2CLT4!8EH_.^'D'=JEB'JXH2X<P^8(^K26E'?R6:=]V
M9E>ZMS(3)09.NM'J^[/W4NK]A!8>V@&'\TI\Y^W!RD66*A>-;.MD!0%374B!
MHP]!"KP_UYN[H,1H>;%^SX'%FO8ZT<5X5L]$U3B6]MT1&?TF=@S3#P:6KZMH
MBS,S?CB_9WH@^!.UOW,4:64*H!X.AA>"9_X]7"0W'NOD&0X'S93Y9UM8-R5C
M9YVWMOO[94;U$2(*)XR%#U@WQO[.+\@7Z&4AU=1Z^O>,Y)&F9B)@<%7SG[.I
MY$XVMK\N9B]*F*.&9>T[C^FP;##>$%#26F+EYBZXD$1;_OQAT+>8[A?FZXFM
MD[@\KZ@N,L#R+B';@6/H%A]N:0P7CN%TC;I1$1/WCN/W?DT31F-F0<DRL)]7
M9_1^,\,8;TN0/&G?ZRI?H#8YZJ\3U=<OWY/Q?F*L6B;M*:TR?V%;1%N]'D=+
M[B+.CU[]D%&N '4A">"?U22!M$YA6X]H)G8.;$$^*MX#+');FMP;GPE_TMX(
MCI[RKU6Y!TB:HJX%%8GGN1YJ":\.[@&Q?^Z^@G8J4>+O;J\Z=DKO 2MR<5*.
M5_OW@,L_125BU!JO4A/X22";ZS4LR2-L[B?7.B'Y'58-5INB3,&0]9J"Z#X.
MQGU\;,SQ8I8 VD0O3>T1*:[3-*8O>Q>%F%\TPO/>T;Y_EYPR@FR!BJD%ET^N
MU"B[/3N.G :U;DQ" BP[MM*3,]QEA1);Q#XHZ[433Q? *4+*+O37%4PV^2E_
M)Y)B,>!E?S#QW/"/O-X);?WDFS]KL'<JX[AU:)WG#'6U@3*+T.DA"G,6JDG2
M(ULDO3+#" CX@S.U5<36CL^'#2, A )L3(]WGP#@!CHS0(M%>CYE'<W?XT)F
M%16I;NJ1<J+;I>JJVZR%*J2)U3\7[!<?BZ6S37;^?75,,O]=D1M8*$)?V_"B
M:OC+7BPD!5!04M_ ?JWW4/V5R,28)27Z4HM6'L^>"?B>7]^/J-I;C:"'>8."
M(GI&ZQ[0P;AT_0AK37E=\.936T4J:.O:31%P#X#8GH%V>9'3 Y0 @J#8,)4K
M*^=[ '_'H#URY9B6S?HQE^(H::UFY-^K6@. P6,6L?CNQI/(&?]/2)=BEV!>
MA;!V/7]IVRJR;1!MI4\EWNP\^J]+\7"$-F@RLMGF3%Z'6&)JO74,MR)M[2@,
M$1=W_E5AJ&Q=YYIUY(XCO5(525?DF]<GG/:+K[[^1N8>8!V'1#>^H,N9.V^,
M.-5(;HT#D]8&5=T:5]P#NOE7CW0-3F][S.S.V('K#)^EOO5Y6@Y"K.'HG=3'
M61L=2!4_NGU$O5C;$$9S37."A@, 8.ZP>O<GWI<__5=VUPHIZOG2_)S/J\0Q
MQ=\?4CY!EO^DN2+WHAWN5+$*7J^I!?/ZO($MTK/!IUN*ETSWAQ')>BPX/]EN
M<BR9"D%C@B6PM;I*@,^[)J1GR;[S?K/==+;MQ-;7K>_H()X&NF8G3?YYAE!Q
M,%,HV1RM#1&I.^ ]CB]I+4 K1"A+&E>65).R5D-9>BQPC)G@Z\&)$@%-W'20
MF'V7I JK:LHA1-UC.SG>,%+Z";-''GU'%H!;FOF]K[537%J05^2YB!_EWF>P
MO!(<&.ZC3Y!F5MS7R%9M;4YL'O/CQ]R'P,1%LUA\>>'NIN_PZ:A<[E*\>;_Z
M4&4N'>S+TAQ-Q;F$,?3H2]IIOW&64X55 RV$$]%^>>;U.\MCN$F@"ZQ_WI'(
M$.G=@V(.TYE1Z8H\GK.G%SEZ5<*]K:GT4_.ETRBX!-I]Q_'.>YCG"7ATQF#:
MGBAS]BXAE^3Q3;<H[M.="5J@D<OKDJ>;"=L;6-&_/:$'QL^+UGA^@@GEX;(%
ME_/O.]*5/==Y,82J*V59G9;BG]")0&EG#-<(,4SWEI_!5(Y2.^ZR2VU+)6#K
M@Y]N.&UB0L4S\-O4T-&II)(SQW4?DR_%<4$E" MHO2SI;%LG6HDP*^\:*FW3
M%PV$8BS!TT>>S)BZZ<[.VF::3R1V%D!&KNW<XUSGV7,[R@T3@B\N;/7=X"QM
MDR]T?^E$JN+0:P=BD/WMUYTZN&Z,V<61I8R-U/*(BF46@GVD[NKH=[%G"BL5
MR)(ZG7D .X;+M=QKBRPFH,93Y]F*FWGR2VU)T)W>\] T6/=%7;G73*]8-+5@
M?0#)T<S;T/<2/3=MD2\-/30FBD_ZI, _MRQQ&YA^>USF#[*+[HVW $G!]!,*
ML*7*< G0.K;;"+=WDLUI&3Y&@A+F45FT(BU!AYJ&$2HPUP299E [[EK<F^:A
MZ6E%N4JPF;0+8+[!L5$L#<DZM'@J%BFZ0[:W BNIS1AYM2'W1\+QD^\Z)5D8
MPK,6/*ZKD?KF:SUEK+>[Y$NGC+7LT#Q]6!:BXX=M@E7]O-N9P7+Y2),9\1>L
MSUW#0NL_2*A$#^;S("S.-5^T!RS0<T:>B^'IFJW'/>K) S\P9P*<7I]Q-8Q0
M:6I2,* (57\R"Z]B-L<+SM[FG[!9P7)5P>TEVIV?B>.R.W'0\TWD_SBRS=:)
MST@87CV'SGP^]E-TG;;LU,=L83Z-BNI0+,%X.AL&U9^4,"ZU%JOKJT@C^))1
MASM'L/L]CDJ'#M>!-A!*]QF</XD"Z@N'G B.82+3>9[.[QT^/C<U\[9^K_4'
MP<M<V5%U+N+SI_%*OX<$.>$+)=MM\,<[]V7M\=*IK$3V<SR>*M/<GT8K:JT8
MU75AG%]\,82_-.Q*69&]CA5R*RD<(O'$K,@VLI)3$;]8133>A#.1P3,.Q$BU
M%#PX9A!G54$;#9=2IG[K05\W;6."A1I#%D/P4;_/A$U?6R+&F( '.#$+PNY+
M$QXB!X;U(.R^Y?+U%GV?U_CY)M3I+*G[8&Q%HJACEU"6ST]771*E!P[4("^4
MN" .BEB@T8 8)D >:[G[]67/ 8TIIG"D!,^ZPL61%&Z@HUN&?#U8;P/+EB1A
M8&?1>^/W.1WVPU)W!&L&U_3BEAA5). A--HS?S#3F"]0#'T6>O_399!IAC1S
MJD(0\UR")&?36V-FT4OWNZW4HXD+7!XR6RE:.+I-7-XBQX@] C.\>F"%_Y$A
MB&V1D#9DS&OGZ)9EVT>L'?YI"MF@X$@\-#W;D^3"2).Q/="I_<]M=#;?QRU+
MP8F"YYX5"VMTH5G%/JKCSZ:.R9GUWR3((5!6C?%$X6.7_UY'CVBM'75$M#]'
M1MVPFGRQ3G56\?AA0T%^1*S/FW)&/N[GS-M%B855P"J0]<VHO!1B'*2P,):3
M+ZE6[N%5U-/"@Y3C$;P'8")3>9XN/(SSX:N1H\) -?G9WL1V%/3W1G@D%?=S
MA5RY1'U*=O;H5.95M)-WZ1]KWOCZ7Y^[BY#M;:QQ)]G^6+"B'HOE//11_%P:
M(Z+?&D'3L!13B%_+NQ'M0>?,KZ6(U$RR$JLO79?TXR*G VIZXXY,CP@)%5]-
M8%"P?),VP@O.1)3LA%_I[X"A;3A]>GR)E,[81R:!1;="$PYE/'4M*V2REFN-
MW%)CMB6"T=&7<0$*"OPMZ)EGL]>T&G"*GKG:K[49=^B:82;C=1$^4>*->;PD
MW$Y;U;Q7-/O>]%_SOMG1EFWH?_M:0YLJD:3$[,\ZA+4YZG1BDIF-(T!Y*P,,
MX[GUM24,-TYELDCWB7N:$OK&SUUZC,'U &K"8;A6%.(Z(C4#G39AG-2<4:^N
M;JS))K?GF?N.CB\F3!,H2B/W!%URWVBJ0C-J%EXM[NV>3^M6L2./]#7SS#>U
MO89&/!MOE<2?,)A?&;0Z8=E [Q^0&5-5DW#952A:OP>@^W>+%^Q=CZ:4OB[?
M]0KD>'RN01GN-$7UA,6PDNK0E^V,8U94?Y ($AH?*UJ1T6E"X$B++!'0.Y'J
M/\%++ OEX4^APHV.;6^J2.4)\7+(LRZ17SNA,K"Y[L]PF!@K@EKM5I"<8&^Q
M$@9W,KA W_[>3*K!R)#XS4N%GGL@0TOH=70+@B&6;[HM>U$O9M9@B 3.?EQK
MZJ4*YD:GK@7J^,_83%+0\?(16#UEW0EAOA1CT$[/]2U$I:(&OXG1?)=H@Q.G
M_A"/Y&!7EG9 5'_',I(7*CBSNT)X?&$:B;\Z9RDT(>_"R6?T51E#KX?XQEF$
M$;S3N%UA#20X/!$H/7+1@S,;J(6MMM@J&^YQ&2CR4-+CO"F2%)7(? !'58%S
ME*1(0#>_9U5F;8P<"=(?K]-S*R=4G^(:Q]W]SOMT77M(C%BI 2L:(942 3=%
M*8V%WTG-KXS'FB\'UR4,N"'RIM- $9=Y& CH]-=0/'15UG(Z,42^1+U3H#1@
M[T0Q>OP255O4QD"R)X,H.)24-^ 3Z90ZQW.<#GC1!]PA!32.T5F+](D\DA^>
M*2F,LWE-4G5>()"7*WF#([HS'8^=XR%":I89R1M-Z[8G [SSPO15N>'S_U_6
M6FRK(\+L'I!H^7]"=SFKK5O 9U]\CTSX&_K^\=\/"Q<+@#3TKR:?+U"8^#6.
M%UFW$4>T2W$-#/,ALL>;GZYC^N*9]/F-.I_TW@HS!(#95 B']@-QV.X!7VJZ
MXFWKP5?;$RB$9/?.A<8=.RA*>%GH)S*DT#;=\8O)Z?";3$5'3X>W,9R?G)Z)
M12<DJA)@2EZ5'^$BPF$.1>P+-O< V]_'9W5YK5^.L":<=RX>Q=-1]*CHOH9S
M1PBU?4?:NXH^_Y;[S62)*6%H0Y1=E$KRCJ.VL'\ 'A9%8^2 @6<IN3?U2J)C
MH[WE+FNUL78V@WB?_[$=<-5$[:"^W;E2&;E7=@^P L/TF2PDI1['H=\<G0F?
MH<,J!2I-">D-K$YYB;>+QVSNL@6BAW_L'TOM&EJ-2OI9H)1-UHQ8NT;X;\37
MRI/XUHZ7=AS$-E?] G0]3'RM7=[9G;^ IJ:_MF9383&W8<%,C9_XQ_;J_9O^
M TT5I?J^'NCER1N'D.>ZK4)._1BJBS<%)QYK_')7X)I$+*_PHUY;W=X=Z)0$
M)/^;Z=U&0:*#_[*-5ZZ;\7LV]PIOO>\B_&WA\T_@#)3L@U74:G$/^(WO<P9+
M0BFE_OM"6GGF]_+S>T""FNX]H)*JXUR_$N)'[#^H.0XZ:D"%>^WGW8K2UOE'
MD,Q+,8#/4$^M.,U1(S<>\W,S]/YI-0Z@.=$#H_(3J+C>.:[GD6NG&]NEQ>)(
M$R,@'E<(4['_,];& 07T! G_?0\XR%\99'<,G,>/0^"/UG ^8=DP^JHI9_1U
M2EN-_DNB/^,;L\<JBCG.&<7KWR**?,!3Y'#_NMI24?N(38-C>704QB_"/9.9
MHN6>8NOZ])2,)US'>?K?'=4]=U;F6^4W*I)L/U7N-4S_R7=>[MZVCXKIT_.!
MKF2/MZ&OL71EK\5^+=.[XF)W=KD'<.G!K\9+*!O9WKANL0A349)WT-F?N*W4
M[%.+S1D>?V"!SE\>XCP970IFWJ <\^J>DA*W40&OS,X;E[EWWA:>N+00FJ8$
M %5M __4[EXXTNCO75(1&:UP.K]?/>(9VS-5W$<!)Y[#LJ93$"^(?TMW,>EU
M8K^"=7K%&8QK%*D4?&1B3R'Q$!T#^+P-ZQ<F_.!APWF!/?$+C8:-/7B4?X")
M*=:O;@(995(-6XX2RBT>WNK/9E_]]"U.&LO%5.J6(V, ^2T?\GGDV5-"H]Z>
MJ_5FGEBQUC1ZYIKQJ;@$6ZQTW:G9S.Q.M*MTS<*V@GBY4H3')^][0'1Z\.C*
M7+I]K9-E7"VY.Q.,B<S[%;*UQIA9["Y=.OJS ]<@>X>VJ,@UL+L9&":&#\E8
M4U;NC: ^/I*8>\YQ]OY<W1L *G?NH!"@$9>Q_&'P)GZ0_VLA=B.!4_R*">&>
M3A/-5A5AEGSZCN^ZI-NY&D%[N:T-SX9*F?:GN5-Z8?1@R/?J5IJ-@5M#-Q<'
MNW8HYPMF[;/6D8-,DDNYETY74X2A-3$NG;K4]@CS6%9O!^_^(0(0?!W$?G:$
MLVZ*Y2,=PQT[U= H= ;I>S*O-I'G1YI,7EJ\N!R7>YP>6P<,JVW)TG1;H6O]
M%(D>LU.]L[BJ*[B6'9Z(G-#S!M>J54/Q9+<RC@R[HP,PA0@4I>K"X/YZIV5V
MY^$9VUFM>_(W3"&WH_XGZ;M^!%;6GU:O'+;?JA4K-NY4IHJ8SCC=VGAJAO%S
M?&LZS>/O6R%>_RV(-7&^\*FY.>[.MN7#TVNG05"*"Z*#QNW A\/ZVE8^,YY8
M6FVC]1[ OBN8A=YI0!@AM5"Q).'QA >"6/Z0-O+1Y>SYDZZ#T<?J<&CO":'M
M,EVVXL^)YU^K TG'O^=\"<+FF$0@2I6X!Y^9;U8L2&)U+HO6P@NB*VF?SQ^O
M/++"=>CWXH-L!)]7/D4&KI\@WPH.5/CU(4 U;]XO;%]E_.S=$9<3.Z](6]4"
M(I4$R<8PQYC].V=N;2K[?86@*G#)1.MI=T0$2^&EWK-W> L+B8#-FS^D>9K=
M2<DEB[M29+>OSH *L#B$A90^Q9&_U3DAZ^+"46Q=^?I8U HL"OG]1![5>Z,[
M5^]W<^0M["#KD$$@A1";CNN^HU$VQ=BC3MRK#[H9=D'D/KKJ\$T[V9 4.1AO
M35J'WJ;@&_X3V""Y1"-Z7_!C9@&.]2+"D1RYO=/M!QR_J/OC-V?OV>!T(S?&
M%GF,?IRY P'OZ?K0;,RV^A:J@.N#A@P]?8J"1\Y>OL2V6W7;:3#3V+\6!Z>M
M.>]A;$&&A,(D\[4?^VO$Y0IN@K#<:O*0JWN7&/D&0914:I0)GJ;0XK]1!I1P
M-!Q_""9O4;'\@0QOJ)&_7ETAS%*RDAK?EHU](3&2,7NQ@T4)@(056")QH5K@
M9?'!V 0$-E=D3M(1O05"(B$F+P>ZS3'2+GRP8@_G:D_ W>; OE1 NP>DQ@5?
M<Z_\FK&FBV['0M)\9L(4[[$R3XXM96X$IH>BH]"U!Y(IW+G=MV^80'TKU+GC
M)YM5L*TRC^I7?2;;'WW:>HK511TKY#>FJVK'XL02C2H1HRFVG!BW_;^K7P)A
MSSI1*7U($KW?M<"G?[>?V"';@;SH*Z(^ZG;F@9ZGO028_M3[?HS(F^[VE[^_
MZ'C9'QHDJY;CG?90KWGQI1*H\B[029?[9FIM;5U]O5$4'!DYE>Q1F#JL6WI.
M)__VJXJ]V):>&WU.;"\]KT'J, F_)Y36*2D2[A_@E1QG6[H7JP>ED9<P^\D5
MOW*-,_-SAD[!>;#WL(C;/%_R)^W1'H3M8</!)8]\P8JC9J3.+T5ZH]HFV$5E
M:-7[! 7O$48-<2AH>XM$"ZT*KWPT1N5OEZE;BQI?X_QS (2F2IK\/3"$BX6+
M <> S1KO,=@22O=Z%,X2$YD99>N[,UMU#P!P+!YL$P+W_>>7Q:>XR1H8OO:&
MS4EIW);ZB+4>>WVS$RUU<9<7-;F#:2G= (/-VYS"VC)_CEWJ!EYOMQ*_2+=.
M?-&_XXZ3X_&\O0J&^MHL'%;FNDEKV%GL.RH*@MC:O2FGH9M+4350HAMNH"#2
MGQ]V<5X7^?#J5-Q5&YUY1J1Y+,3O&=C]1/7GU!%/^0FC519CLB/@'E#MB>$T
MJ8,H*#*TN38>S?:#?*J;5"$M?D*3'$V48,H*+EV3;>@9HW[3/#5U+D7?ED2>
MWI=[54XC\03+!WTV^H(^9:>F4]XW+RZJ _>]%'#B_(6/6H'<;$TC_B_;W<\R
MZ+,HMVD?89AE! L\Y#(6Q4"9-W6<>R-9GBG_;)I'3=KOV[ZO[;<ZV%@_(<X\
MU&WU'D!F@"QZ^PF?5)?SB?E1S,J?CNXVVRZQU+92L,[R25_Z1VNOO%3B!481
M(UKT04FO"X%0UW_<K/ZF;P+L&RBQX6DH*RHK6'9Q!5_*_5'P?2PYE-3)+GDS
MX4&?/:!;[_D*R]RGY"CRK;G794ZV@==F"6!C/IZ^:OT$SU9LI=OTD?$N0I@"
M;K"@E"1O3Y60Q[EA/2_:-2_G&U;N*F9<ULP3@2(#>V@DB14$&8^X$8E:O9DS
MUSH&,-%/=2.#^]<D*%9O3/$./-R;0[.L)72#IC:_Y%IHHGV(62)\91NN8JII
MK&ZCL;+$!;-_4._TORH1\&9=C3JM"([FLG& ^#V8(1#Y8A^I2:XUY%[%PM+;
M^E.;1XC193E)%FL^T0MQA>M,C^)V"C"_*>RR=Z!.TE\E6_GG'QUKA^/CY'RE
M=D.>H9W046\2J."6BPKS#*% HD2B.(4U783%1V=%2<4QKP[O=5\/S8D^2$&Y
MC;#['+ )<JQ($IO-)O+CLZ]88F'SN22PTT^W%Q_4YT=$V6#\:M.FV6^+*J(W
M +3QL_@6WWJON5>LX4BVL,<L\$-!VD0Y*=YCA1PW!F^'1?FJ2NJ).IJEYW"'
M\Y:6*(YD#,[ITUH'-$J1]S)[LI \[Z+E@JV02<2,E3)7+W%R@B(E\TM16I*K
M<=>+]T55^Y?U'E*<2'&/PEWR(S?_/-LS-3?;ITM,_3=P!HW!FX>U-B!;*<6U
M]/_AZBW#HHS^K>$A!$%"I1L%I$&Z2Z2%H9%6D1SI[A*0+@')H4-*NDL:) <8
M:6:((01FR $&>/5_SG.>\[P?[ODR<^VY]GWO?>VUUOW[K76,AZ% _KEC"WLK
M!!]QCN^,41Q^'-W*/4?V(\<?FOK[@#8],P":95/@:>_1>YQ'L,A0[Q;TSGVT
M@K_IUE*WQ4>$P>3BB(:-K-.;BF3_XW*++^ZFUYH0E%[GS]HJ3J[SW*4<W8I/
M))"AY8*I_YCTX,(D*4%#4_-L 3QIJ#,^1L\Q_":'".!GZ.X@]Y@T0=JHW+[G
M-VWN>7SG8P<3@V(W#8:QT- ZN@SN$?%W*BP,#WR)P3$!"N]M+WCES.8.JW^H
M)#]8^0*^'!'_GBX9?Y'IQ==X,!ZKD:"2Z\S-<GHW+5&A?U9G 3'-J]B4H5*?
M"Z(9A8-Z"&H_B]@=&ZYQ>Z[2KE;0?'C^3B NM?>.L:Q%#FFK6S][Q[4']!NE
M56<-M4D*W>XH(%3V3SVY!_16?NU:.&=P@(M"SZ7&8=3,,A/]ZN-G/%K<XB]/
M):XRI&^YKF2@E*,[ES6)^DC^D$Z=H@"3.D=+S:P%B$IF:6M/,F'?=KG<RR2D
MPC4BSX_>OAOLNRGW^4XPNU]@W(45I=]2@:N1GO4<J]>B#"O\G?L)-&W-I\B\
MLUY4".27TRR^Q%O:F5PT_+XQQTBC"-T,54.+!9:8.+@M@>*KV.:P207H5;:_
MIY,4X;0.N1N/"7:-QZ4/=5YX!U'^*U/Q1+/6=RZ(Z/MK&$,_13SF0W#YXFP/
ML[2>4Q2A@F'W@!B1GMA4C5+[%JKTZXROS'G"+\21,<52)&2X9%-662>Q$[HW
M)IVGY]7J^R?FK61F8[/-,H(#.4:V**9AJ&3B *_-\4\+YA[-%V<#^J83/ 3/
M'A<*<+BNJFYYE8VS<=?*34NDJI2@$^#\-*L89>14U!I-DR)Q\I?*>&B0 MYK
MQ@[588O2UBF</=K$SYU8FX%Z PMZ>^F7?B#[BU%OFNBRS#X 5PL[#?TF='IS
MG)>?CZ=&=V?,UQ$1MVT=/58/_B!!8:L//0]TMKV8K PL][7=NC$?'V_8:\W1
MKFBL:B;Q[\B=&OQT#_@ILH'UV^Z)*YKP+]\1[/\[[0B_JJ0Q'IY#N!C5,X($
M_C7E()M=2=H3J2[EZSMNG^-:)S[=!0'R1\)5<%8&"@4YC@L*R0.3NIG))!&I
MOE*$]^^[Z34UB4DO6V<+/\^BU-=\CE,?%CIIX(^FEBQXE8D%-V]D/.E $#_M
M+P'%OP>.]\!?XSPG5."O1LL"[+C4=TZ!-(Q@.V9H:B*%3\0G>*.YOQ[ECS0!
M>7[6WQ&J7*\0.+C8 A *$W-W@UQ^W4 MU. -MP5^ZP<^]9R*5'!.^,BDBSV'
M;-&.BC>LYTILG7;S+OCO),\^0+WN 2>NC-A3MX#">\",D%&84OFZZ=[I6R5_
M5X;</F*1>O6?$JI;E&8;R<LBK$N3%>Z^#PXG2[QY)[Y_[Y-.;9!6\-6NTM(G
MZ?4H^'D8EI8B0]=+)6@G1UU[INE'4,U[OBX'S)*8*\4MOG(,A_*&D-XH?\?H
M_EU"[FI(1.A,7R#?W*JEXZ=P=X$5A6N2O GC;M*YQD"5@4U+=#C<'R6:RRJD
M0#?(]BLCF\"9_Q?KG[Y'T'(K2+5[-P?4%B47T\3@L/7XLJ$Q%(CD5[+LDV>*
MH SH"_: HO5=4:;];?< \-R!1;1CL:7#WVF2=W(3%RV#Q"[#KF<Y,\;]1W1A
MWPY':.A=_)ZNFZ >%J?0I+\U3U']+2@I2I@\C:BKA,HR+SB+<#1Q3UA<^^_J
M\Q@)KG2,4]/T$FG);YV="V]3KO:ICPV7H.E4Y@+8-TCI]O->U+=">(^%%R"'
M*2="9)I"80"#3V1Q":X'NZZ(((8L7O8A$\V)N9 ^D#_N;/L)=F4ET[2!HY[E
M@D@7>-FDZ2+?:A38M-+9$>C:FF. [3J;E7")=U%W$"2!]H3S/\%8M]T0IPTL
MT';]U"0IH[=1I:3$X3-CZ.' #U,0I]X7M+1'VMT#L ,TRHPM'^WR=K[Y43U;
MVL?W>_HI'I"&WLV?]O1+)[#6U+Y,JP4JPE&EGB8ZLSI2]^Z<#FM(CO"[IP:J
M5#2'GX]R,$?UHI+[869O[X?,/O'CA;*T7=F/_K:1(OY#:/R21&)T,!#%L);I
M+>S=[&TX(?6383%=/C24!9=$Z)JVJ,84= V-PO 6^F2K3TMS%^\OS5(?\L!2
MUO:T"(4C17D*7-"(G+3)![Z4V97[)B)]8-4YIRHV[L91D-3K 3]KU5('VI*[
M6B^G)M/E[(,PT:L6(>'$Q#=U+S)>M#")1DW3&GYI%QLH%];$@06\-#%>?W$+
MTCM]@<?V[LW(X4DDL[4\.SZ][?.*9=,)S\WUV.:+Z4[(>.EDW2!MNBU[/L!-
M;<H!58&QA$MU>(8=#] 6(PL,5;>[DM.,M?1#M+!PL4F;7N6Q+&PN,!G$OITC
MTTYZ?TRY/?#K)3Y_3EYXCP/89OA7HM4,/W\/[/5>\S5_I/#QX_5=Z&E_^=Y2
M1"J0K<W6BX2%B,07@/2_ID5T,Z^B,X-H]K1![92AL.5'E:>NSF7&"JQ4;&DT
M&HV?5!]%(KK5H7DFH*7!R +>VX3*0$=?B1>F7VH86)-24XQ#1T<165$Z<\=-
M_N FAPRH&%1\R:8ML^2#%%'=BZR(W/YLQ1[T0U>4NK3G#<7P7:AN -X(ZA I
M=_;P[ZI?!$V>W2K?:+13F9@?#GZ%J4<[EMBMXY>/);G8_9AS;JQ8"Q2\WAFR
M>16IX6LBRN57HY] 6B)&MT)>;041R66\&6+"E69QAV6K=$IRKRQ;FICP7;'8
MNAA<<(R.T,@=!VHR<B8<_ 1C8T2*'++_G%=X&LX5M5A%O_O"#5#=+T['Q\='
MX75"-1<\99X:92O/U0I?F;W/F_6*_N;WM-BFH'N.7T2CN7VNIJRSU;E+^(3*
M_9P]RZQ*(C$ 6LO+@Q&JQ.@TV<';422QSE: !"?#O5$UU%$E;9Y<^RJW5/]2
MVOQP+P-;@!1LE7\ :F+P9S30VM<.RO_0R\:8 @=G)F1D:A<T6#PO0M XTCA:
M>V0Q1"6HY  1B!&5&,>=Q-HZP7?7@G@Z:BBWVI_%OSKZ:4/W)KVA\8U*J7ZX
M1JK":=ZXKS<\N,[G!;'W*^0](.H37Z>*\W\>'%O7Y+9CJ7)\-);+RN6HI<EI
M3RS3B:&TLMS>>4^)^Z7)0F5@Q7#YVKYW!M5,FL"JILO4\S0)7?J<.$8EHXZ.
MMI[VE/UKN&EEM*E'ZIOMU:D*JU'AN4\#VVY8D!(^U<V6TQ*]2-QWFW7Y*0,I
M4O,I8BTG17OH:;R@1M=!YL=9@$UR6[FQ#%8BK(70Z,2,&%T-K-]8,4!U;9+
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M1:O= ]@T5.\!S>O7; =[Q%I3-RIJG?6GTCV-O<CCY=R.KW&;/2:G4P0!C/>
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M?(]R>LU0*#C#>5-%LEUAS*=%"QR=O\G@;E'KOV$9M837Y0@#/P:90$!/'R2
M.O1C_R2IKY)'THW0T+"<(<@;:R-<ED%!7%&#8E3Q(%A:W 1CQF/?HX!?7SE(
MY.F4U5CB3E<@"(6Q*6%XB!3A8=,ZJ0^?.=Z4$3*OPR.6K=]T96\I6^7BVX^.
M\)!O#R2)-BL.DN01G2+%I@=Y+QHA3N=2@7Q+]H2C_FY]NFR %#56(E2(H* J
M^7')SU6B*B9U8+5?<\3&>I2LP#QB6EKD^P'*H=LL<L%_/FJD]2,N\CO.NQ"@
MN/C4;(,T[T8/T2I&N!7E'"/"\&J>UU.TT>[33Z$WW;J"W_'H97?863<?0;J
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M;D&^7U\MZ!?IS7A(V^5(;3[F 6FT(X;&FBJ^1,TS#??-B/Z6[?:H!<&0!/F
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M"(>MA+IGMN+8N2Q5=L:3@*KLV,C6@#QR#_(6[O<M9(W'J3\3PF<+2P8I7D>
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ME9$P/#CN,M;UEIG']<HH!0$.-I'O/+V:&5GN>/\K9881%HQ<UUOHYNN'Y[Z
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MCODUNB0CRQM?=5#!+6!\!K)L>D00=R$GBPW#!2J. /_@YO_M[-&VXD?9HUM
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MY@X\JCV]B,>=BKQRUCO)@8S?W2>E6P I],I_\Z;_U57ZC11TT>H6D#H:[6J
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M^8'/,@/QNJGI]' KG1#HIU<-O:IPE\$G4WXXLASWE,O8R]; J+D_[ZQB-P"
M!""!(=SEU+6JGY^FWYP!R%!G9;%-M,N0SYC.<B.;6N+/Y?%";Z4>/JE=)=XV
M.7L["66>957\K:AHP/7LKTW@][^<,I#VCK2T.2[K!WK3RU*8'%!3^\UIXFP1
MS9]"SE5XTM8\?U:"$RS-8YG<Y>A?YE&.K4UHCLJ_TLJ.R7(84,GZ3IQH%1\U
MCS7RZ)V<4\-#-'OQU.\6>6QJ>CO#=0-"7NO"5Q&)RX7?][<U='@^7?Q?1*GJ
M[ZW7'+GC6[+83+&FW,ZT]7OD.K;,$SEW;-'7RYRA4EX!'8Z:W-.0[4F+#!^O
MMH_Y<A9RQSX\INYKW0+\1=36(T(PCQ=XK18*JJ<R(-L[ZS.0)7$ AG'JAMQ5
M8%*A-"U"UT D.1_ S<U3>GYZO(H?T2C+P_5MSG&/P^8O.:M2Q_K+U/XY^-<I
M5^/%7WKR;U#0?UQT_VY ?U62Y[#YWZ&1_F$1]_XRB1 X:[!W&R@*=\/1^37)
MS*,+-6;;]F47CGX/RZM(JV\<S/?7*K;58OR^4-/Y]8N38XUX^;:9L")U*A>V
M#)3F#7OF" :?O?ET=6_M7D#\$NIEDQ)OO6LV;]3SB0^ELQLV#]47]7OT74_<
MJ?!C?:T:AC_'4DGA+DO*]QF+GY9+#KP.]1X2K6#(!J&09Z6W@/!:!@Y3DEN
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MQ//<FF3=-PDO3UFH]M'.)LG+G=9.I7[:+8WV=;.X\=0?[MUDB47^2B9X_QF
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M#/U3E+ZZU7_VCKC._K OKNF<RD L/&\G=@L(<QMSC;L%D&T>W@*44Z"1R[>
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M0=869EV[=QI_]SRP^1;W(IF6=*K%&=B)OA(2?3O0TGBB&_TA.@030S=0J8&
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M*_E-!]\^@> (+8T9KO.UL=ST4O12!&6BY5QL7D#(7EL_ %YS#S 6^M"P:S\
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MENFC@.^+*K;FZ\EN\B[G>GU!+V?$*/V=J6^DQ00U_6;G?)*/HS^=Z\+GSFG
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ML!K'J#%]B>&KM (2>*C4 A1OUZNEM;H)1>\J!]Z@B_40O)5)/#3V>/$^?UP
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M5'*[F^/!4$Y"2"7'#W#ENB-CO9=6$ )'S3^W\XYUW/OX^6[S99\KU1Y%6JY
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M5\:Q(H%D'JR#M[(($=C;*: #0J4M:,S#Y\\%[OB]4)5#7EV<HHR5@W>QNDU
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MS1#9WR54EQNLO5[V^MVJL6Y33>C^F=@;(<%[X>-/4XS<2-23GZC>99C^\0"
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M9D&+8:Z%,X?\/:[=FNSK?=*J_'%G;II(6I\6>31B809^$&KKE24<:K17S+Q
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MGAO B'WS%P]%X9PL(]EB\!S;A2PG\<AI?%F#;D(#(04NQV, +ICQ-_[^MNT
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M/"ARYU7,(HH9#:OV?Y>=]#\9#*/4FG!O^GXXE_H@,C9M?5;Q!@(XN!MT@XH
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M"SP;DH\E]9I):T_U7:S;>/F%>M!:DI?HKGR;]1" T>O]F_<D@&,8'(WD++?
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M.L&V=>?C0:UGJ>\ZE3O!F8/ S+-RF"EQVB!T5'+<\UV<!7\=A3JI*JL58TH
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M7.#R(P+X5\ OCX6]IKSL\XV]-!  5G*[Q!$M N@3NM4,E8 XN*+?O%\\9Y%
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ME-I5XVA?*M</,XSJ@UBE&&:_&0L=NIV3/$&)FQ4<Q*'#$66'_H#E'EV+O&J
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MJ C*PPFQC,%!:\-R?=HGR,,%UHY234F%'@ZL<[2>CMR<B9Q?XM0X?\S-/D4
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MU^SQ4NHP=I23RC<P]3)]FY7G7L)%AC7"W4G6\8)DR::T:)3.]:)1@.NDJB2
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M06W+>1*GQ^6C43"8NQ+;^N./%_JRSL42]NB=4@998F5X1<#[]!UA3Q/\:DG
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M]JQH]=D#\/LB1N8O9O[5#:;AW=PYB2I?DZT'X'R/XK\ N?2WD/=_ /\#^!_
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M>D1_XYH_ ![M%WHS(ZZ7=E#PDT6"GTM=9*<\G<'1[]#SL,7[1::P[JA%2!^
M;,]'!?7]4:G!4G;S-<1U^\;-B*>$VCX7#V(L93*K&CV*D4Z:M?8;PMK*.\28
M!R L%XY#B?$ _&S-]UW%\[U3M+E,G+WRG6X2/3^\W_UM''Z3^9<*E">A,'MX
MT"'3 P#D/@#KEC>#!Y2_#"A_7\$OO*HEO94? -28X =@UW"\_>2Y*/Q5#.RM
M%]\#\.;J4:_Y/8K"4VYO,S>LRXJ8NUO?CR+:.6V%#\ GZ2[?"S8K(]@3R@?@
MA?0_^2+RK1GE9D8:[MW>2OE?\8)2QR#PWN;1/)&5Y9@D^LKB!V -YV3E'FU>
M"XX@_0!TC_V3E645'7#HX]>9]L?20WA:DP_ 7QW])S.GM=X_ +J[C]*Z_CIW
M*YQIW_>?7/7]BYV_F*I\RUU\=Q9NQ\YZ\"]%_\E3T;_8^4B'Z!\V_K#QAXW_
MV6RH_+N)J"WS%"5(2)@\4DH814%]!R&Q)M)-9$INHA-.264A,:$\/2YZ4GS3
MV=;+N6[-JK\\_&C@%*/<C1WE,YC+Y4_N]D>/[QC'87^';.]?(5/^A5:=LU["
M!#=X)))E[#\G4K2LHN=_9<#^--\_;/QAXP\;?]CXP\8?-OZP\;\]&PE=1F<L
MV@_ S$M)Q5QZ ^HG*@#@!^R=DS"%P@B.CEC_L7.C96<#WGJ?N4KDPF^74]MP
MBK_IANB1AUK5+<,IB.M 2*2F+#:U._]O._ZW[B1.EF=ZC+ O1K%_S6 ;6<V;
ME<7VY"[J,L?5QJ2/<QB+;Y"!]TN<>Q#YC_V;"E+S(1$](LCC4'H>-#2TS'HK
M9PF'&B:]@:A!8HB@K(KW[#1M9:]]Z/D=QR->I[5&F!C4XYL2KL0>GR8"J0MV
M>]>QS3JW(L@"'*.9QI0[6SG[UE_%K6>BW2>($Z@,/)E*S \O<P]=XJHM4N-*
M6]U!V].)]2(]\T%9O!."+RWM](/@/V\IE^YOAF+8?&_Y;Y?.#\7(EJ8+UW\=
MSX?(RPO4/@#5Y+1TX<ONG\O<[#:&7THC.M?Z20^^*?BHN=/Q2)IEBF^70"64
M=[Q%P'*^M9NI;2\W+%/@=D*FSQ%(0YI=?3X["2=95MZX?]&C*QJZH- X499;
MU1AQP,"Y]+VRH4+[+LB?1BBNER/:XB2F\YY)[,03XJLO+XJ]D+K'IG68Q*BJ
M<_.!J*H?.?(V!=AJX[:ZAC.,WPF76KIAK!^CZPV!FH*_%AKB\_GYT;A:GNDS
M+%T[>3?%#5C-1P>:G<CW3<]SUVM-$[B_# F&-M &751-O._L,5O4<J +1F%T
M'K"]*0R'$W64#N<:0;0>V]<GK7<_K\NC>M)+A&1)[S?93_)<+\@R,&VHO(@]
M[MC6(Q2UNK^M_,IX==:S74Z;DE,4Y2]650KP$]TNIW.$ P&W?2(@DOK@%O)5
M<D%9DJC>"(I<1]:"\?N,9?+F-T7J+6F1%BR3%HUD;-W*I#:&;##1#7E?;.UY
M[>'<7PYS99KYJ42.L3^4?XB3B^G?/%^$I6=#(KK:&$\J2M>8A"V5S0H> (M%
M&Q+AE.5&2<U.GMSW% [NA-\']M]I^#Z_8YIJ,3K9Z='\V-T4',QS:'.8-&X=
M^XSUA^4<%O/["N)H)_Y-W*>H_4\KNX^C9GSP3LN6R<?,QLJ6!Y?,&AJFC1OC
MS-P1DOBGGX"P\W!_.#A'<PP7P(:*;>:Q/KWH:#+(O#H.)S%[.VEJ7S/O@8)+
MP!3\WL$QDLSYP-U+_61(=;+%2#3,Z^7Z0@SZ/N%TIFD[@V4RDT,@J?93&A.
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M3M.)>Q3U5UQ+L].#Y[NKG$W)M?TTV<A:Q;O+F'43Y7?28%]J:X)Y>#;/9M4
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MK$-5[&4\W*>]4,RGUP>V4V4V7<32;+[!WJT".OL$)GZ2524]?SH5T;N2R:J
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M*CX[QGTU(:NL];C813,"SUWO 69><27<6>*!:W\\^\\<>_[_RK-_'/LOO\9
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M:%@ +!?!_T 8J@:%#T9.#C;=@$6!P1@HLYL$ ? G%Q;57,GNQ?R+M _D%0J
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MO"5?0^V]_C]@?I4HO1/9!Q#U7XR*P-T+'9"@W1<6^PN4 .CSG)H/0#^PK7V
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MJ55E,A-33A$G]3@1L3-36;,:&EZE]L6-G54+F=19@1?&_;N'3X6M.T+IH,,
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M5113Z,_"#AD0B2NS+PS&C"/M@[$ C_LS+*'@.7IBL:X;"P[XB)%8DOC"W&=
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M/#6WZF3</#0(>=F;&7EI/57NO7]N\KPNK,TESZRT0T258B.<4=,;R$L8VT(
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MQ1"M^66BM%31  R,UYUI7E;07.!K>W*Z,@EWJJX1.D[_<_KX,^BBH"V0-FK
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MR&+F@$OI]_TV^XCLV2Q#?^V,P#5=U@^E(AN:F/-X60A5DSG"EY@/!9&/XW:
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MO/,(7RI]_%1Q$9S_EXK)Y9.*-.],H-(<2MKTV9V_TZD&T(F#J" 29X,0JIK
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MAN^//*4NL'5BS8L;N6J/NNFJ_3WJRG_*<?2PKL/<T@-_E\J8N):F=/W=%?D
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M'1D+XV;]/-D=>B"G)5PK6^*/5=]T!]$(6>%J-4]-=!LJWO.G;=0I"&[JA,X
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M;JJSH%65M&DP=(+L11CJ0#/EO 7>(CEH$P5>HF=OZ P[.9Y(+9FCPQ"W/Y&
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M&O(GN]3\$8HBUP%G[<Z6)T1@+Q!6NRG\,;T3%NF<F^9-Z%\.-<W5PKQJS.O
M/K55D9?T$[5@5\[^K$!LUSF ;G^=0URSUR+[\1_VKH["1X_3O!V#1QXPH(X&
M)=TD%@]TKDTG!&.?M%]3X>V[.L)/$S"[T@96&?G/5,<KCC I?C_;0VW^10+G
M %3@4#C2K?T67*:;QYJL9+.ISZK1?A<PBN&8Y5%T? K:*GF9WQ[),-<J 6;;
M!!+&&$@/9E)^@A>9*2/R85?4L5.Q3O5^IZW%/OT-E$)UC\MGB+C>ORN*[D0%
M_N/:7N;A.2#HV!C9^9D0HN$;^7KG\1!V,IV("3UQZ?X3:\\^IJ)Q#F#U"V9
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M.K;\K?,J&_O'HE)SRKOT+EHT^E!E6UOG3^V6;WL53ST^6+=[3J&*6!]]9^Q
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MO8'D\4J]\/32W&Q_Z)SJ>0-/>43L!P5S\PR)[KGJ!XZ?AGNXSQYB\ -)+02
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MJO&[[^F4*['9CVVQYY$KR;<BR]O%?7]9K2S2]G_T)\K*_4X*OO7Y[D<)JJ\
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MB8H_*431#^G]K!J'>A$ _*65UXY)#:ZS21#!<P8AQMZ2=I[:V+4.&VCK.A
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ML#48I?=JX!4 F>NS]Y&>1KC69CBT,""7#5U\#GS1OF(<ODS:I_2% 4YWEY(
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MJ7]4\/*-NV"_X<]"'[RN6/YDFQU ]-^-*:/4.N1]Y3RHE_EGL=!JX@'0 $T
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MFT,8P;^>0-&2 Q&@-Q,X#W?ZKM^T\TI: V[9V$:2,[@+&M0>4_R(I2:":K^
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M'[Z2O('NDE#]&2'5D=K+=84 ;T41X<0NPT=-&69* UH(@ =34N&CFY$GNY[
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MG7MD6?=0'6UJ ;3UC42DP4@R' P#W5Y$&4PV:GD-^GDV>>S<GTU*FJ&S+@!
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M':9@=1S(ZJ9KI95\O/KK XOQQS-@O>+#%:LZME&S"T#PD=^\>H>5]F1UYP5
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M;;+)>%]-K&S3+[4E[#D8CJC)IF/ZQQ\ D24Z/G"IK-2^)FR2F<]44+YASV-
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M&DND<99Q!"LLO&H[7LL['.(KPDIT :.T\8^65<:;*?L"T/G%\GVNA<C-D0N
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MCC0G]EOGQ5@!756QL^!(,WFA& ?<==5I97ZR)H$K.D"6P7YQXM#;7COX3]2
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M$Y)&^1!KR-!2>$35I.>L#H5<6[=6=25LL#9B]\J-*]%68B3IMF622DL\7.U
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M+2OE?\L*/X.PH&'X'6D!R%6%,6E6O,0+'%4XC^"4JQ!SH_E!.X=+BF5^UE[
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M:V)T0AY,]#^3J0O(0LPX^&_>BSK)+0Y\"%2@U?DOT? _&@+.=# ,\([Q.E-
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M 2_\NJJ4A_.XRZ= J<.Y6QJ"2_7>W/CH[M2@$':3GAV>"9DQ1?[V&;B\Z5:
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ML0P+I'K#A7W$<^J:CXN 8$BQT[8_T_3OQ6?H+JJ<=UH?N**JO#U2)$=1O]E
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M^-J#?723/5J!LN8;V%]WJ\N@=:#][9%YHV_-)50Y_;P_O^SZ7238&&SH;^;
MJ1$C)5'8J>V#RRC@T]^*HP<%$F;@?WR!MV6VC>%$@)(:^'OB?\$,GHM[0UD"
M!=7YAT3 QZ7 NB?K_95GU@:%$&"K2*IMG1>-]\\.$>[,V"Z];0I?<!OX\#F!
M;JN).T0OH?W'04$.J;*1Q4>+&:"\D2UMP4:$FXO6..<8ZHIQGD![ 2?C^O2Z
M'YE%W!?]>\$EAQ)0JNGNPMS>T17M>@]?R *RT065I9A5I"K$43PO'U8E.E+
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M]5K7?7^/)?7R$A[Q?DPJ[.,Q<#GJK_9U0G";;+'YSREN<UD#VNCA9>F80^A
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M7]1-XWN3^3#(LS1_U;]I.PU!D,QZ4P+9R8*<R:T YB32SVR]@]]5^S G1NO
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MM\"$5[4XRG R-7<9V+]9-%>/B9M:E*P.>?I,8U'5(X8G_=VJL);6.9^DT!/
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MKO12V[36#I)75,KR&K6AH/\T,?+=JNMJ#T:UC''D3:1_FAM<9,;;Z1V':_?
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M5MN;J.--4<):O"KPOWB<6G>-+$^R<."Y/OBVRCJBR'C];E)2*&A[X&&OTG5
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M06,J/RI+6@;68$KN^PZZ".+8?KW,?B'IS?=(4M#B2A!4%*2*_JV,-EK-&"5
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M64U@\"LN_+?5R"7J.PH!-([ST[.Q3C4KWK?ON=7R26%7C-'%ELJY/N2U#RG
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M\OTE&57(%9:+1QAW'[@NVYH_CBD]6A"X_L9@H&_YA:01^6A345M+-46[-5O
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M@X:Q(Q7Z5 R96[J8@\J"4-Q/EKD'ALLDFWD[+L%\6I)]NJ\6">9F\D]Q"2S
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MYJ?SGLE"290MG&04S-DCVFO>,XWR?%WEBDM<@C%AHARE67L;FD3:W%L+#ZJ
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M\\_;:6)V&05\,-FY^F*UYW7\XSLO*SUT<CY^[OV# OW;CQ8M:G]J2^=2!Q7
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M-.-\&2D7]K" U&?P'&^A]NB&&?NM\^>> $7/O3M^G>EQVO;<#W44+*Z9D3)
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M&<Q.%SG1V5(Y-H[P _$U1Z'UG:6(42]XYQM%_3[+=S"\<^-6J;'M%.PO,MN
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MU^OO&^C?.-;&+11_Y.?:(G^%G,@EQ;>\/_IAM^6#(X?K-IT[Z\B%(_I4E^)
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M.)RXOB*#$T<@"XT?I;[=P85U#]>MBER^SSOL,X;(,3+M8:8"3JJ1KC:Y0!^
MZL^P'F8D402C\1:4(+(U>(,61JI'$3W7O+>!EOHV0K".(1 #%3# R@5#Q5(!
M!*]_1PA4(K(\#O+4@,91 :RW2.)4@(J*U9'G<8T*Z!SZ$Z0UW ^EA-U^SBT%
MLNH95 D93_"EG!J@ K@@_[9=@7BP")F0-?TZA]_1?=ZRW=$Y1Q("DZV _[HI
M^#TH["W0<NB_NK-;43*@NJSF(Y6,RH)R4@$9@I)40!L/%8!9^A,DHB=%[VAT
M1LE_F;4P%? :VOV7!2%E#VK_?0*#]?)_W5^,V>/[]<>;4OS\?GTA/?(,7F;_
M.\+DP![DV^^7V,B1ZDC^4QW^VW>VZ=T!W5\W'=;^"I4L]11:31.?=R,%B+39
M[*$QFV0V!$42_J^;B+]R2B[_U0+._1L+&&P/:OL&+W8H26A!+R%.PG!1+UOP
MMX]>R.!_W53]/Q/N']"X#NPI(I*FA2ST/S'Z,!6 7FKY#>^]/LS/[A(FRO!<
ME7V(7,FIMH*+D8BL =MK3BFW)QO[-\C/_#I8/"V&PK-ED9<,3$!9I+M@S]/[
MIH/(7_NH:$D6N972G74>PTVK$(.R4.N7TRBY?%%'T=^Y^O6?6XQ76C89II#.
M;+K?0-E[XP3#M+ [L5,:RHY9S]<T*XU5#5_"2*<+J[2,P4LM+V3/"%V*D5&%
MX&Y#\L@KWZHNU,*?)7T/-&7%N)R4$G)_"'\5<*N68A6TVH0JIC]T^CC^2$.H
MZ%C^-NP%B*?;^YK"JW=40"FXO2X?Q!;IMDM/!4!ANX4K2K*R/B*N3C1H4DL]
M6$PM?YN5+$HXTC(N"@F(AOQ+G7.'"B +#<*>P4F0#Y2%([9T_W*- ]:. &ZW
MP39#;72I@'95NI^7J8#P -8-/5[$U7^Y!OD-WS]W'^5_LZ/\N:?^MG=_>X[_
M'<;[UX[CO^[?^-T<_^\'\@^A?7^>X]]22_\Q9MO_O^-E()_34]LZ\XN)A;E"
M^Y#;A=((XY!S\FT)"!WQ)3 )@J&@\K,'L9;0K#>[2JP,)(?[8B&U%YIHNX 2
M .*GJ1^?K10+7V1"]/<&M=^L7,:.!GL]#H!_#UWAT$]8 5__90YN./VS_O]6
MG0'T<!?XO?Z*J4KNHC49CK/B5/M\"WDY)^MY>UIOR5;IM.I2UG-A#:)?"RZ1
M8A24(;4WWY+,81S28O^2XB^UH'/ ;S-MTQLCRGR^Q3;J%T6+R W#I5&,]-49
MSQTP@;?[86*@#E;R]J^;6+[^L0HO[?@59F(K*^;X/TG_)/VGD,H[_T@ZG49;
M\9)G:V+KT^$?U=GP)FO%KZNI6]EK!-C 17)>UANZ2<P1;M#:T_^CZNO?^"?E
MGY1_! I#]9&.R@$CM$=B+N?;JFEP&%RF3OX/4$L#!!0    ( )LZ=E8 D%T%
MVL\! "$X @ 2    :6UG,S V,# Y.3A?,3$N:G!G[+IW6%/=ES]ZZ")->B]2
M1*G2>P 1$!!149 :Z244Z2T0BA2I @(*T@1$I$E'6NB]MTBO@O0$*4%"<O-^
M9^8[OYD[?]RY<Y][[_/\WL]Y=K+/SLY>9ZV]SUJ?M<_!_<"M C=TM72T  ("
M N M_@!P:S?0FOY.]@"@KP\( 0!P#2 F4 ((\34:_(ENM!- C*\3X.NF'[/_
M^@:X .#&Y"X'0(9OH\2?@_ %X-C]QW__QM_X&W_C;_R-O_&_*1XYV;B[V/$8
MVCEY>]MYXAM(WA+]@U$PX)G#E[?$_ZRWI"3_HTYT5QX 4E+^O?[O[.+:Q[]&
M_)M=_(V_\3?^QM_X&_][0_*NI)3B72E%"6D>"4E%&6E%:87_L@W/0P GP 9P
M!UP .X ',,1_.@'>^,,.^(N4X-8H;CIZ>[]2%!=W\Q*SLG6WMA.S<7<5][=Z
M)2XA=E<<4%;U?V5E ['SYK&V<W!R4Q$\:H8+\CC9J@@:R^C?U7^E8>?H]"#0
MT\XP\-$SFT"(C8*MH"J(ZKJROZ*_ZRM7.V\K'G]7%S<O17\5WG^,KHBO_]4L
MS@M2]K2U5WQZ7^M?>^#/5'C_]5K\_/S$_*3$W#T=Q"44%!3$[TJ*2TJ*XGN(
M>@6X>5OYB[IY\?WK /?MO&P\G5YY.[F[\?QU;F7M[N.MPNOCXV2K:&]E+V-M
M:RLC:FTE92LJ(6%K)6IE*R4A:BLE92LG(R$O:2]AS?NOXFUM_BG]E8^GRS]D
MV]J(V[G8N=JY>7OAK2$ASBO^_ZQ,O(G^*?2_-#]>1WP?10U/.RMON_OX OIK
MDD7O2HE*2#_[MTD6NRLGJRS^G_HIB_^G"_W_P%H@95L;19N_KLG=\U_$&]IY
M_,]FV\4)]!^)];_HB6_^EPI> '[UD9.3*XO_K[+_S\80_]?%AZ_]<ZGB_\GS
M_P+^%O*WD+^%_"WD;R%_"_E;R/^_A/P[W;5SPW-</SR9Q2T &@ 9"0DI"3$9
M*0GI-3*R:]=I*? <XSHCS0U*6A9&-E861A9F=B[!F^R< IS,++QBO *W[PB+
M"+/QB$N)"TD*"@D+_34( =FU:]?)KS-04# (<;!P"/VW@6L':*\1D1'?)"+@
M!0AI"8AH"7#= #< $) 0_ /_EAT0$!(1DY"272._3H'O4'<#("0@(B(D)B(A
M(2;&_QJ,_QT@IB6ANRFA3DK_Q(J,UX-!,BPY_QK?O:H.QJ<32'XI:\]P\NM,
MS"RL; *W!&_?$9*6D9635U#4N*^II?U 1]?PV7,CXQ<FIC:V=O8.CD[.7MX^
MOG[^ 8$1KR.CHF/>Q*:DODM+SWC_(?-306'1Y^(O)5^K:VKKZAL:OS=U=G7W
M]/;U#PQ.3DW/S")^S,VOK6]L_MS:_K6SBSK^?7)Z=HZ^^/.77@0 $<&_X;_4
MBQ:O%R$Q,1$QV5]Z$1#Z_=6!EICDI@0IG?H3,BL/>E[)L&L,]Y+SJSK(^:2>
M(AFM/2>N,_%+KPF@_E+M'YK]7U,L_/^69O]4[-_UF@<HB0CPDT=$"Z@"?[1B
M;^<1_EW^I;3@@ W!;A,0.YH?_*([U=DXE2)(\ZW=DV\ZGDJA9 9/5?;&A4>Q
M,E#%W'6YL)[/F;N9V>\ZUZ<5.OM?:=Q4J:8AFZ:>RZ/A&%>60,'7Q>*X8_)1
MK\^8SGE:*&X5B#9D?N]]?M.<H(^U!XR&H1QZ+>G0[W.NH5.EELH:*)QMWT>E
MD'-SF9%Q![,+(VH<E%\>LVEWB\?"R,H-M:>E+^@ZEZHXVXH=364&!LAYDY-3
MYV(JU9#NO95$_@L]3%5H1,>\77J-<LS;W:=F?8HU\<1#U8>/ GV(IA^3Y6,@
MM3/NRLQ.7-'K"ZK7S:G462O=96Y5ZS /I4I$6^KP1S1<I009P3M_B)>WL>V\
MVFTZA<>X(49_RRA!>IL282L*+&G?72C%J\Q]*U6OON* S70G^!E;' ZX;Z#=
MA0/HX!$XP!82[,O9YE-4-Q$-,Y"H*+P_]F6Q*_&$8$\Q-U::BFF-9]9G1,[@
M W;3S]BC>^2$4EUZR: GA',"FGN0$/1P"CN>M7;Y?-,C(.[JYZ*6=F-E>@@M
M1E"5>6L&JKU^8'K9;Q9!KT-!HQ@00]E=0P@09,1SM5:9PWMP -D*FJC[#,N1
M^S3K\11OQ &;U\@,G^_-C 7*Z+ ^*.4XV41NK5'=EU\KUS=:Q^N$2\GGL8ST
M<Z,3$D\K/+X_D)=G+$#2/X//@FAV&II:3T>NIH;DG0X_.UF$IH4.2?"O>I@C
M#KAQ #^H#PL7A9^8S8"CEF^#**]25\ )&D..8LION_B&G09O!3?<'0&"N$K7
M72G4;2V\3*=J9V%-XF*3="OZW?85<\OSNTPE7E9>5-,T@WJ483-MKU]!-BJC
M0^B08]VRTZ=';]H4XPP:@\+C.!#('@\I5^+ODML_-PG"?L3'/S\B@,"0I6U*
MFGF_FC"*8]&5AP7U3JY;- RE8N-)QRGYXV_)SZS&Q\D0\8.Q)OW/GZ3HM!-6
M6:$J(]W$VWK(WG@'N-4DW11?EW28<G1!1&"G0%(SMQ"U.(#(B:[EU0B=OG=5
M/>7A_G,^4!=K7W#7N&'=RIPE.YB4U9OSZ>%Y]Y-/J0SE;&;#<^SAFX0MMN$O
M3L[S: H=*^C7J-^LKU#[<TI7LH\03RWT&\T4O!\<HB9E3%3B" OW;S^P6 (<
M(&T\DU"I(KT2" +Y8_Z^I&U:5>Y+Q:H3(G[$(-<=]%0YNFN]]74.UXR,J+"F
MV1?7M?JHG^N_,X99 Q@?D;ODT*B'[8'O0;71AI\Q#^$3MK/N%3SUD\,]^0V
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MAC\&2D6<7?;=!*]/V6O>ZY#Z'AXEXK$S[5.9VA)4[!_4WB99G;66&VLW;<1
M%_?ZK=3"(,M)LIH1L4W>Z4A0Q@'1FAX-+534@-UBR(NKH-A4?;.+O?(==,>&
MJI%QH-TKGE:-C9LP1!#6:;!VN86*CME_5.=7VK1@JN_!X<DR_,3UQ4:_DE<C
M)?6CP(\SHGKZ*'IHB-Z7-H&=5TZY[I%)T0N6R?;"=5[<<Z@&T8&%%=!I?\@H
MC%(:3+LS@>[]LXM5T="=&51GD.2)#.=WDR-\G6-^PA=O9(F/R()IS%=1HK"3
M:[^(]G2[4WO;F&+Q]Y<D.D-;KV5C_P!V(Q64Y6??8G"6A<(66 DD14B;_ Q=
MUCB+FWW]=I)/XED,[2BY$;_?A?;#\'1P=6(.E@'<L-?@L3?"M&YSS;4 &KS4
MN-CN/;JVESA-<*)V\QVC ME;[<!!=T;_8)_*?5^$=\=7-_(S^@#NW,;XL)_;
MOAZC$F!5[&B.[,S)&/,R5 7Q.>!3O*YHVH)'0SJO1F_Q92&AQSCC1DD%^[IK
M6W[ Y4-GID"9H?F5I96%!75%B:<)_!YY"AQ)K;.AH/JL'BQ[_71OEL<ZIY#P
MNF^<<6N"G>"4E0LVK0I\!_H"35*$IED[/\.FE5HN+2X,L5F(CHZDD"EYAE)6
M#FL3YTB-!*IVY-+N^>& FO*?PR*(P/0/C--,2J-;GLF';PPJ*$BXVA^3?=G-
MN8/$1M^.,\4'446-";$COIC<CIA2-ONZHKW''[R#=<<>Q_L$F<P^YXY-!;-B
MI/#1!E;F[(4!0X:RLC*,H_P"8IGXC\1LE,[I$PTX(?-8;LQMI"U(EDL(#=M0
ML*V+[!)-^/CKTIC(VY-.CQ'TFE!2H9\T5*7IGT_*HC>V$S'@55'QAZU(^%Q!
M]7>_J*T GM]L=^Y>)TB-O\'>@$14/M<WU*V:/1FHO3*=%!Y20+A\&VY.BYX,
M53YOSV7%"*S#R$SQ@;[))ZKPV^NV!OB'FTL\+-9$+R53^_LJE(S'<MDJE(77
MQ=_(OH7*UH4;ITM'V7^+Y_=CIMQF5P/H^X>HR4$S!TW1^_!5X87/Z<L6EAWD
M8ZFNWD7:5Q@MU7)O+ 5::G6%<$44FVS%?_[KFE[S@'+?0Z1O(N,CI;!,8 WO
M(:<SQ2,R1?P,MAXUE5'PX8" R)8YU>QG2.P;CW7N'Z67H '6;4C UOTG*5O"
MB RBZ>SWE4;H,"0.T$4GY:D70C*8WYIU>3?HSKI]_1E>':HG3&DUYJZ;9#"Q
MBK9 MNY#5=U]OG85=$B/=TA'C.:*3$H>/N\-L8D7S\/G!8Q7F:";:)CZN(PJ
M#>1/=OT'X:6L?KOFMYH<8<G/H\[:B5TXZ$?]*]C/PE#U'S8,8I+;(A47YYS.
M2ET:KH%,P%Y2C"I]PZ1!J\F]PL]VP40MD/*1+Y!7D!"Z3(VM(<XJ&G=A^E'"
M@C0,8>QVBW<;*\H]H5:5&B-4;66=+/#1S>;EU. DW:@?M"]<<N17('";:%'5
M$0=<W#Q3/;UPQ0&?EK]!Y0HL(#B@*OAG5$Z47KC AR=:>M<J6CJ!PP?W2(*8
M$S!$1?[GG:A?BBT(W[/DP9124\72G^J 75J4PDFIY75D<'28LJA[GA.]^0C$
M;73P_&'99@V3@E">#^@=P?%VAXK2FF7-9[ )5#-QEO.1 J9?3%Q\LSYA38BT
M7>/KYEV;,4&_!L[M*"LT61"*<$$'B4WV_%,H!SE3F#0KX4V_?Q%QAX[C"Y_"
M2S+BDZUF<?J0T65BE%B)* Y(#2H:D<IXYS0EQ%>UZUO]C3N4L745_+J- 1W$
M-Y9OJB.P'U=5*98[G.&>)T^@70&,!0+(I'EC@^8)D(@3B/^%WH(^L3X[=Y/=
MFU%#E<9Y&-OI$1W4&YF>B\0&>VG,EHG+D$7(IE/=LI-,;O?OH,SC^MZG,:9[
MJ*RW%LS=\T<DTSC&Q::E]NTVQ);!;;A,P?!0>-CJ*J.%A/,\YS>$7OOCU8?#
MM]HG_6HKZ%, C*2)\P$GJ%)BU)E*BC4+M'V(F[R-GT@D6^3P5G10RUL,8<R/
M)27,F3&2<E>/5BYT<,#!S(EL:N$/1]-G;&[)3IQ%V4W[L2P9UPLP0=LEI>\(
MLM9&^+"T..#ZCJE<[EG2_MYM5^6#+.4Q44*WA=3X#?F!RHPV!=A O]/*&3ZY
MST?,^FSG"*-%UU98_.=I&)S]F@J-OUV8V32DR\1?./#QY*M:.A)]G_[9%*'3
MDO4HTDUL(VS^VHM5'9ZGSW5.! E;#-8:#IB98Z : 9_1.]X')+X13C?M$X@(
M_<H2#T)##A6]09]:YUL0O=P$4/H-42,+W</E/8/6]X>9KJ GW)G+128FGD%O
M)8/&R5YCW&?V0P0PUE/>.(!4T5F,)[;#(3HM78./B\;G\4I0L>7,Z8G.S\X8
MDX]?P[XGZIS+=*.9U\A>MW&;R\R^<1)!##=3_=S,L0T+"@LEW&X#1OP8"-JA
MGC@@17#=X,]J[A\9X3$<8*]R;T4';;PNJG72M# /5IY\=V]3J//UVSPZ?\[2
M>67CM5)5%G_+<_7IS1QALVEROH5OQL!=-W)B'ZZHZC9NJ,(DB/T7PM0MVB/(
M@V0:&Y35I_URX=ZJZW.63GRDV3SW6R' WH$P?T9E:+5Q*\"3>V(:!15X4NNR
M$OWB/Z)R('T8=1N;5??8>@F,.(HR<^@^2IJ9]J[-MA3M3S>#M Z647FE*K V
M.N[,"\D<(T,N3K?\6S?%:'&O^.&7>-B2W4NX&E"N2@*]@70/J^.?KETPBVM&
M=] NKNCR._Z>_@+<!J'Q&3FC%_R&])NZHVA%;(9CCEW/:*[DO?>7DRX"VNMJ
M%;&QP(7AF1LZ\I._KBOX/DITUZD3->DHV*AD0YT79>2^)M\KU4>6OS<?,LY-
M#Q4-0(X>J4W49:D\/7^:PL,T:/?!YEFRK<AP,=%A6&++R:ZVU3H."..ZADHO
M$BL(</*P"I)8DCZCBQF.GBXA\3J*SSE-*P@9X0(F*YG6UV0X#:T6^=H:GWXX
MOU::FY]'=.8X*3B)O<&/H*V%S<M-+N59A1M2L,B?@"QAEJ=K1I:"M4B_ ^TO
M>YGI1]5F>^=#4K<'-)-_QM<K;81X'( =-!E>W7O;P=;'X,Q(RWP][Q5 E%?Y
M5EFBZ,5>;MWGHL^[9U5+<^:[?[[J418(=;G@ ,3',SYI@AT<P(F]C;;<6[-;
M3LZ'^ 9F'WZQN:^GDPX6)2JM 8&.*.*Y/(-+:=9&HSV*0@:6A9N;$PH4/\H9
MTY*R#%OSA&XL%G"_TO0U@M6HAHK*A$$'2LR[RQM-]#TI^18B*;5G$@*UJM86
M.!TZ,T(XDTWG.[>FYQGKYZ/D!P\Z;6_<5?2(!9#B<^Q8^Z-+_.*</\V_?/$+
M86S)C<167F>JK\IQM.=Q<'IW\VDPJ0W?KF:@0U=EI"EWE_@!]SY[^;V-2^W!
MWR$+O* 5\1#9 TWLQ:C7?-.2]J.:F9.YDZNG\TJE>J_OB$A6_/3XA<_>EU;+
MA5=E\Y&[8X8H2J/T/]EU7\LQ]+M>A9.ZI5&V\0_DW/AX;O?)'UC .^K03[[L
M&>.I-[5T7+.H[O(*WER.3J/]BXGD#K8#PGLY-*T"B/W65>&X*65#"%/5MJI#
MU,YU&I=J*=C&S Z( >D;O9K-X93#7F6F%[RPN%G3O[)LKYR*:7Y,-F3)/KV.
M-KY\N,)-9T]A4+>HR=]-7Z_@.3$0]N,G^=E?&S3SW.ON477<T5UJXSX0?:/=
M/_Y+V(&[:=8)U/OI3]7X(UGV$)/56"$TO)WM/%',6SRFC6U&>F\$9./.55X\
M6#3,_],\G/19.#N+B^V&"OJ(=1'#-P'B6G8"TU2(U05;8A^D';FMO4)I57#$
M5_.PSI,R>.4$/B:KP(YXU*Z0N*T;M)PCKDOM/A$>@#NHTCN%T*$38-QOQ-:G
M;)JJ'9D@Q;2?'E3?F>]&MI!N)O?W!9ZKSFUK-DZT43MM'=^*U=NQ;;Z^Y"O1
MR=WSC#N?884!.V9Y#67T7:Q4$NR$H/^>XF$E^4FW+Z7'Y 5AT 8#P3JL-BFA
M%I_OUCRL1UZ=^"&=9@^K#<B76/U>/C#"BI!P)"K\07S!_(=';::!&?L+JWI7
M0KV]C-,B3".%7J*U UN/QAIN:7F[;+QL9R$23(14H6A"I>%T&-6D3N9SYN0=
M5 _EO1<6]QOCW)9UDW/?.20-ABI'K'%5!N6%#(7PSD@7Q V9N!5&UF_;N!AD
M<2T%RU>PK\XD=1W1FN^Q)?7H/[WCP^CC'U4$G1 IC?C>8.ON@HK/632>XKJ.
MAA6@F3NKT4'Z07%#K$4!_,S#B6;^!.\.GA._].[QD(/5B(>*^=CX1QC6Q]1O
M.%"-'[=]+'D)2E#CNBY>*ZI]]F[239G/E;$^X:K9.KVJAZMG/HDNG>CJ4U%K
MP%:K^UF5$>C&^ NB6K"\( ?1SURDS.PNO.8\0H;*4!]>)8>/K[8ZG$U.DUJE
M[SS7%@(E' 8V4T=)?$/$D+X)&TDT;4GKPEXJ52]W!Q<LY3A9'_P*4/W 0+!M
M23 CG<0 !:([38TJ[<1J//(6S=AE/CRLJM)Z6.W 8Q<MR#KB[][13 .8HZ,-
M)T/NF/$_ZM L;/![:L8O5O0ZIL?DU2/C(^\?VB$A24C!#FY*?(Y@9CSA)J-P
M.'\K3LZK]+91KQ8CLPJ9^:3_V"HX'.->,E "7C#_L3+L)=KS^I/4G5,[.SO!
M%59I@JT&)GA-&4C(XKJHD-E =HIT8\WWIAQF7_EK92DI?<5JVBJ!4S#G)5+O
MB*[,GA87EU43D4V^9%9Y6^X8J@OC8K3@:G0$E*)$K.#S@KDEN"]7: NKSJ>9
MLPM<IVF3.K*HJ/FTLWP3[U=/2^6/1"J87=X.RH-R5B/Z^9+5N +6N!- UV%1
M9VQ1!16FIN;S<Y_,YY1#'_%K=I$DE=HF7COE%.X*(=D5?''U:>JIQ(4]JE),
MUD')K[1>U?1,#SR7T<[TIW*!TT<IIL&-R7.)YG;0JWS4J?,\<@5O$G_COLKU
MD5O!ZF+S.MFNI@^P8RRI"L\?AT82?"/U;]]3XXJS)+I\@0/ZB_)@B-\XX%?3
M^>XFZ"949@(KX#3K&W@P<MKBF_+!1M:3-^5!GU):8QXU/=9E&[N:>RECAQU8
M.;Z#9Z.GF-P_8JUFV!N<XEC&2LQ-KN#M,X>YD*&M(["2O=?'@X5<-)4Z\GRM
M(@F)>-12,U[A7L'7_$[O9DLR2SBI_'QI#P ]1PUA'VD\P@$-XE?4;365RBAP
MASLUNJMWW+_ L'6&MS5Z<(&SI:K,84B!E83\SV_+:#4.XU[Q"[Z<6_C[D0EK
MW6*P2AJZS(LVW+B2LC]JT/K6@P,LE!N$+^@^MR6@Q,(@Z[E48,? UZG:KL&T
ML=IAH:]H\GGBL:15("X,7EFV'41Z(./(:;>?YQM;N12^&VI][,_]\VCBE"5<
M@]83@M20I?U'D%N?F.3AV[F9_?R@KFLTJY!)'."<]@Q=\%D(^-HDH@;<!7Y_
MKG1!GK<G7?>']#FM-U,DZ!SQ99JDD!?%=\:OA;5?HR;=2 Q6G*F,426%*J$$
M7]1/UPVUZBX'.8)&PT=?S.@>BHYNVGRL.E+CZ#O0<Q7! >0'_&\H1-O*&5*X
M#RLSA+9_OU1E*T$JK8-?>X,CF'Q-9YOMK+R*:M<=!=^)Q+,9OV5X5-FU\9.L
M*$BLIL )>W/BT+O<?D9LO\+0]AM<BWOX1@"Q)U6 '7R_9_6:CWC= Q^3]:7<
M:AUOY:J#M,=H/&UX3!:/X9UA-K_Z<N#CV$4,;X-_?]Q%3!9EO_V['#X/QVJ/
M,&,[X)?/]^9J#<*P3,CS;FE45(8,1LYC@*_/D4O")6OB[9?'H:%$'%1+D?HH
MBE5$=!O_[FQ38G- R<*(*]G;. <1YR(_IH'%A%%]P 8::.0^=X;\PG^[EC]L
M/"!&M?PEGIH(CA^ N!*X]HQJH@VS#%,':P)"T_4'WPME/U@]EE]OS34<K[UR
MZ)IRS"PDW.WTAWZP\3K/V%7D(NC_!1E35KA41BMU8F_7([SW$DP.107HNC@:
MA&RTN.\3)UD[$O6=B%\HE\#V)7QP0)Z.*;@N Q._S(5?1 JP$PG+5B>D<5<]
MC)Z]C]9R-]H0\D'LH;Y(R*-M8MJ$K*K?W.N5-Z_*X)OVR/.K@"$\4X\%3L7)
MH4[(9[E4^SY4&N:U-8UU-?>_5Z4\%J3C#7U.?P1ZL!HVJJV+P@%SZY/;W7!V
M'U6Z"Y%O]U(7'RRE;5DS>NV%]V$)(5/%5SDM-.M9*JK/TH67% /*/P5D&*0]
M$;".X"\5!@R"&T\KM9&Y$2<&Q+]*B]"> ZZNY^Y>*6/"L(#WQP;'O^3S:#[@
M@*W?JH<2.*!V5WQ>6 \[A$9 2IW/*CV*P)K$10QIOY\JBR1'D46$H=T8#^'(
MHA8E'$ AA:7/K=_-G8<Y71JD;O5M'O9*X/7$ 805!3TAU.,8UX)LJ>YT83_W
MYD".-/^%R\&NM[#<0 #%::Q_];&VDD:SE,)?W,BU6=3E5/B-F(+*QF]U<Q^E
MJBD$8:O<F@ \+#IRNQ7MZB!3D>VE\!NZHB3*&RK_6V=4*KZ2=<S#O+4!SUYN
MB[\^'BDS[_MXE6-62'XRF.>."6QU?S15=I(@2Z6J5Y\X.[E$J$FI5_<XD$"-
M";)-<928<P=9W/N]UIWM_<WQ@XKE.S;U]1UWOX&>?5>PZ3#BX?I06;#W#E7<
M!:;P_R.- UXG/:(;8SN(W;TE,1@Q?G=709DCR1D80 DF89F<+;F23Z\@ZC,B
MP[97'P<XCKF4M"0[6N5)6Y3.;&H:&]'E)>"=*AVF#U3OXFYM9.<O06L%OU]X
MX0 "F9W'V"%+XL35!^>9BP,?+PR\6 P/NE]BZW:Y6)&?XU8/.+W'J%]HVSFS
M>SP;$,,3+P41_UU] %KW=0G667;U]?.L3V/A);TSO:4[Q<<NSPH*@A7W]RNQ
MR98C*+D-LM>B(/;=N,*]6<6TLWPG@=9:IE21"C9-X>^AEWE$N5F<$K/-!BQH
MBJX<Y6]Z8+J=/:^?MEV253J\@A6S''\\QE=MC4F*0X9S"*JF28:WG\'5%B);
M1P8O8 ;)C#$81R*B,T/DTDQ&=%WN#0NM >H"D5<+;BS+58>+7=-N+L'/$(R7
M\CA@P',:OC>ZC0.TBH+!$(B[C1-C^3O:A87.,-Y8_NM?"D(!#@)SLO"VZVB_
M]ASAW&XVS<,2F<4)Y8<93WLG0O=95H7NC*H=J7%Q_Z_/X,Q@=8EO7LF(DIG?
MMZ]WM!Q9]-:F:E7_$^5^N8GXBHY>K8R&ZJ$(Q5G EKO)N[1ZE*4,DKV\MT1<
M5_/E+[0",*6U"&].J>YYZ3]&S0Z</]]MT#!$'/,DJG/&;#XF(_L$=4/J84#U
ML^(RS2_$;M:!%3L*"5<?,),P@8J30]7Z-#*1*W/+J#KNQ&/+IM>0K* 2W8C.
M=)Z-T\J755<?6@@<OE(,,#]MCI==<_+P5LX_./YB#2J#N'?FDD!E5H_8#=:#
MN38>7SY;=KQ43M'>Y'F[&?E<38V33)K@E_<3/+,O_D\O) 2K,+C*1:?P7XXY
M,SA,%WG ;[11^0>M/RJ'?-EKR,QNF1T/N%;OV?O5V,,ENW]Q$Q%$J4=,V_TZ
M+>%>>. JY6.R?NZ:W#>U<'*H%CRI.\/#J6K)1)I"9BIF@M^$X<#:WY+(\\&F
M3:O>Y0/T@A;*/4YZR)UF11M&FNVVQX_,GLCP)8YT7V]_TK^16Q[D$ MSJ"3V
M+S7/>/Y!O';OS>* _+</3P1L!JS+R@A44+&5)2$C;<3PR3(7*XM['2[SVI(+
M#W-L]R\];1VT1F4I"4(E_;=")4#_X6E</=R^\H)/=N7T0A4;:0%[$\*Y [J#
M9(2_KJ.(^[$O.LF@P^--EWR#P%,W>2%'5:AN%4;BM$R ' [D2I*9GJWJ/R9K
M\G$8XLAY_LP&F4>3!:+'+[E9, RQ58 #ZH0_757 MI[@Z<#*5;YE]MI1>!LG
M$M%-#K6R"?JJ\T5/9++64(\UAM6K.31T8TM^^W?I"FT(HR.,'E8#;ZBHHX#M
M'\D-7C+$9+6,?%CZSGX9P=(7"*RV!.<M0>#5]E$B3XK2^_2FCBB=%6Q?/)/;
M+#-8>P9S2'JSS#J%(516J-A-SWR^%#^I*+,Y1*?/7K\?94VJSF^S8[G]:>>N
MHR7WU$F05HI>$,6+ VNG!R+],0Q,[<!'ZE<D 6,Q< <# O_HQT'=#2V3=LD-
M\E.?GVFI'OZUWX7/,G  :XL&64]2G*)1PNKL)=2#=ZY'\LX"?WQW,\T9T*<"
M,E)1J&@^*ZDW$Z=$:\U*O0O;2M Y>18/TSV%$V%N(XN[M@)JV9D@ \P0RR75
M#W? :J\(DRSR'."Z(%[HW8F06V8ONBHMP OE<<V]+H6:_-^ ;4^Y<^TB0&[U
M"),\1HG/MF-Q@)1%N1T:HE:';(@J\U8!Z1365\5HLH^V?R>:#B6%$9B^(UA3
MK?/#I%YQ8SLC<("FBNDX?'/D)P[X)H# 1@H$DG5S1YL:=&=S+>@CQ,1=U^IS
MQ[1JO(U$:RNH?UK%2QP\-?4GTJM!.RZ3Q:XC=Q(@ B5IV="#1!U!)=_M+=4N
M-2[U2P%8/U_WRNGR"@Y0#]R$.QY=B)FZ7P4LP'XA*O-".#%X75@7P!IY2^!%
MT=\%_>ZV6CQ?>&R<Q<^3RAW\$7]Y";_U1F7UTN7=MTM==/=+("(0UFL]41I\
M')LY)P2=V)D_ CTK4=*B]@P.T0:-Z:RQ)^JWS>D/WK>/E7#5C6/NHEM7?Z(-
M"S^75\SMG)L^?^?;P(2@(WE[H<O :%GYEN#""\$)F9'A5!PSGG*8.M5S/"P7
MNU'X;; YK2^?\2?1F0TZ1$;#+^%Q5[.J]>6+XZJ=[&9\@"?,HV%"^Y47OU%U
M5M)WOCWL =[UD^J-_EK*'ZE^WBME"JL#8])4Y+#M5;!?%WL+WI5A(?03RL$T
M<=+?Q0\J7!=;C&)0<=X7UU^*C?SHP)Z;9JR3=1A00[41JS.G0TM/*6)<C6:,
M\!SQ>I0]<51"HN<VO AX!:_SC?8*6$N@,(F2]??>>V/U_DN_^NV'$F?#+QUF
MHLN]5:E XOZ*W*\#C<\JFAUL?(I>%-7U%$Y&OG^?X?@C&WQ3G=T+,=MJ^J<7
M8?@M<^AQ0^+6[!JE9Y=0E+'A] U(_Y&J/0VP!&:/L9TYX!-4=0C?>6BSL*V%
M#]&AS*M'O1;NZ^ 8\3*W$W9(D-Z#AY5^Q&6R=#_N"WFE:!WB@$Y(%X;YBR/\
M1HB8^1+&>CK>][B'CW=Q49I6)#_J1YRMBUI18_\F=7!( [(XHE:5^-?&0^12
M[+S9X?*V0(X6]K?$9N[/^<9<?/(>@D_>&\1*I?WF@X</;7/WZ85$R@+^P8R@
MUJ$@/_2<UVKJ.D14=6VI-=/$Q"PM)TC]7;J6PN45&*#VU+[5%H9N+\,!-0*_
M-$5">JQ?D?K3WS/8,70&U\##Q#$J3H7J[GXOTR<_Z(^4E6X_['YYY&?4O],.
M4,\LFJ&-#0Q(>M:"5N2>3*6,FS3,_V!.N=NLM9[G%:H >(^9 BC87'3W'Z[L
M5;-67AQ@5-,P[>:3?M=43[*L.CI6X.G7  4A;:ZTWCWX<< 3V ]K! Y02VSU
MT[C*5F9=PP$,IGOI4KN]$(79]6NVW\&BK(^T[U-J:=];/"]7@N-]7@OZ?9M\
M^ODSMLS%/D]>$YMC/QZ TF4IZ1V,$? _.M N6';"*D]@=#CLRNWK7F@DIYG8
M^+H6[[)P0[EUSX+$$Y:)FI"?]E+VSM)Q0-/RV5-=T&1"HN'09?=V?%@$0KX"
M;C9>.T;G1.\4>/#.N-XP7EDRD2:?[ M?%4?L\7=5.SS/43G/J=ZCQ;.S#VX9
M0W]L\_^:>F7$JDSD2CQ(V=E2XE*I#^(N.K+QG4,D]>CZA],N/'L,G58\PN0\
M Y^QU.$C!5_E%V6EM7+NSD#E0'!T&6]U;5)V<N*+<WN;(6Y/G0K0$?Y^=@?=
M$D\4:)TA_=P@L1B3_@*3W0\0L<O9_.3N46. .XY=\"I67ODVX(")H1>J-?6E
MD'P,.7Q&ALFVMJ:U,=/^P5#:\_O\JX0&C+L@&61P=")&U"//^;=Y%^15__!9
MV=?54E(6D4(?KC1P>QO1));;WZE6A0M2&F?T84O4?W!?#[AV\5Q+_B2/AKLQ
M:U6NAU/W])!?_SJ:<R2 /[QO3#3EA9L2RW;%6DX0(M5\W@0MO*&51=:E'Z)O
M\72+@*K;EG-TF""F&E-!<T^;3/X K+&W4@,+]1G:;HIE/Q H=!W.A.Y^,:AN
M^D;TXZ716'C(=;12>V#X+MOSPG/%\#O/FELSAKW'R!R!VX+3E%AO@I4)30;@
MR7\L!-T0,&D;]]YYI5\)VGYZC,_-+VPSPD-%YWC.$Z+=Q4VMS+<Z%[_,/EY>
MMLWGGOM;AX>SW4\@% /Y_"GT^NW_1MDL S&AE1ZB4M$5?=K'=0V9)O-[!X:R
MEH\[1CLO Y87;8B4K9OF;P.?8O]9B')1<J$8\8T;N<B47_4-AW%U C["O$EJ
MNQH$!YE=D]AK&,6)(Z;=L<ZSWF<\E?,"Z3[$L!J^NU?"+9]":9\)13X&B ""
MR?38_S#H?ZM4@'O@5"V"&UFE04D,.V"W]+GK]U><TE6^/GK0>7<,5#?]1 U/
M7/L@$,;6IOU8AFMQ*:_R7E+F.J?\#V3^3TN%X;I!HFL;E_^M/?/&>/W;O.PO
MR/NRI!P<!:?"#;[)S""BL=.^&73^@EJM-Z1G?0/?0MZV G8\] ?3#M-)ID!^
M@3_W>E\WU2U56@CXAAA&\1RR;?K#I/335R[C5]H6+8&'\GLC3A@Q=,*ZL(I&
M#Q<]"GN@@6?]M1D0:8#5C=>@I4">,L16Z)%4<^:^+7H"^8>&JJ(2!Y +),<-
M4=97-<IQ@H[>@5X&>0+G?3*=4(K)RA;#]20&C-;L@2F+3_7L;+(<ZOX+IC]?
MR-DB5JAVU+BRUU1C% 7C,,R"L2Z9$!5%>L&/[HQ//M$>]]374-KDM J+WT-W
MK;5".C*PPNE*!\):U:F#<FRO==N\ K48WS<\5O21W_?XG1,15 Z*#D:Z:_XF
M.<4!,7:)Z];4O&& \5C><%"BDC#UZ0)V/(0SNLN2 BD;5EQC@@Z9_;G>^%X;
M#EGSN&DI)T%JW^>5"1Q!E2[OH[F[0WBCM2/K*!3<^&F[5#:O5SW87*6,XK?]
M$V9!%M\F]-?+&C>GI!/\#H3%/A5U3WQE655[97GOQ0W%$V*D?R7O-%3A,WKH
MV7BMJ\'&H^2ORD_+,H/K/K]QYYIJO\8ER*ZSZB*(7*\T=YI=N0&#-,>XKYF5
MTE#/W9'H)]"^30 DHE.L/; C@)\O#N"$WA1_78SB6'&O^V96X^"^;99PG@*0
M'[^3X'^9^$ABN0SMM\$44>G_B9MZ<6=^-O+KXJW+(%?[H7ZG*/)!3-\W^5&I
M1.$,=/+ZR*/+]=&X57'JG4#:9@F*2/BL:/<G^J&0?:[7USHV^#]Z]T+>CC,_
M1\D=/+<C_5ZYL%>99]:LTE/>U,669GA\FWC;)070V0Y7>DQFLI'M9SRCZD1#
M[F^H/2->+G*PP6P\,;_8 A&C>&"D5D@HVUN0>Y2\G$0-:8*_P2<T^H'7ZO0F
M\G_Y%H'Z,\1XG-1>C&Z2.2EE:O1C:7=,5*G=>6?;E#$:J+I9_9Q4^H6"G+!G
M!Y2JJS>X+W<KL</UGLM.7 (HBW7K#9/I1)U#9K$'9TO"-)VA*L6/IT6ERQ6#
MKG37E2!ZWI)ZT@F1FIPZE4(-5Y^5"3S*!:*N=&]GG\7MB(:^#LK-\N=&LCD<
MR+M'=_P^XUG6F;YY::D8\,+%86'X& ?H_IX[R>8V0XHEKUUI;!B]E2Y)5ZWY
M075]49F25,TZJ96]RIY/>?/C,<$A2 "=]0EMT*,H%E?:X0]?N$]AMGE?=DZ$
MF7+A6")M8%Z+)6B='"O\"X)B568L-G56K"C! :(Y@_R.KO#6+2G%#<<.>;(O
MG/Z58F@<X%74MZ9*@U&MCK4 =Z=WTA,T&+8QW)\W"1T3(_7=#I6C;Q\]WT<X
MK:';.!;W?,ML9XIR-&?<;BEX"_F1D%4L%<I]%YP*I6IU/PM'.D1C-$H=YU-V
M[W@5I20.$%:/KL87^D.W4\_#$VE4I,;]B=;]HD/X3<WUUBX$=5P?_"ZO*"#G
M)?K(0:A.1O96W]^AW9W!7T?9:7V%#EWYN/K;=$61U'SK2>Q[;;\ 6?J9ZF<O
MO78^9M8@?YLD<L+6<[LYF5;VFY2-:BCNT5NWO$Y_2/WA0IVO'K6GQA4I?L"Y
M^B7E][EBP8BKW]F#U<1K\WJ?!T@*""Z>A VY7G:QJHBC^S;@$2V,7W" @[-H
MD$_(U\\0,_FT>4(MW^\B#')?B&?)]D?6E"S$UYKVCERB<,#S3"UZR80].@FU
MO#-6(] %U\Q/&"5_4_T,5-\/AF+KZ\A$S+^W+#K+(CY2'>ZI;RFC]F,B84[M
M4-@G."F.PO*B(3U<M+G=F3YH?="T1)-3;V_#O*1&XJ)7K_I!YIK!@<HJ00F%
M15-5M"\(<:9Y7+67<(EGY@0CGJ8^#1'*-,C<;F8_K$ 3ZE;R>FE2S8!/X<X0
M04,&1/;_8.\M Z):U[[QA0BHI'2#M(((TCDH4M(BG8*T@(!T#-V-@G1*AW1W
M2X>@=/? T$/-O./>[KW//L?SGO-\^,>'Y\/ZL)C[NN\K?]?OFEDS\)*TIR7Q
MT^)PAJS:5/4C@(!ID?"2#\L+V,X;[?N//U8F^<ED*\BN9=)6NI_-M8FPH&XB
M &)W16B-[SL*$7VUE@6;//9+GFI]SCT28$U*SB!"!C5:H_D6;&<16?L[EMGF
MW1=?+L3D./6?YF\8O/9_,,#EI7";BM4'EFN[](@0EB4YHE ,\CF!X-\5>7^F
MQ*9F7BNYG52#G6WPRJOU04<)&G-[*<EV?5K7!O0L!/Q96-D!K4)8C_9S@ #5
M#:PPN8+'+;R"KPG$J/2#JL"0M&GZ9]"3^*"J0J;Q#!(2+8]DY^HDH.]RBN#^
MZAL*]VK*"\ZN2 +/46ITZ% 5^\=#?0N5I^L"B>U$[\(#E>L2GO1<"I1@M ZZ
M+2N27VD>Y'P,.^/4G-4R+ZIC_!CP/=)=G.;Z1!%V=[D4<%9<DK^>+,O3>%+
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M(JX" =!2(("+TU@$\(3[SWUNL>_3E0?)\$*R5];("L#0*$WPN.+E>L(R#>Q
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MLXT\>]YACR=@;$SYKJ\7"4 :!^@5+L6BT1G.KHZ526I>NO+O4JP@93%2=<S
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MJ)*(YT<IGNQ4?_<+#S/J+/@^Z"48'D6Y6"O.#]J\].#1CQ\E^T-(2OA,U)8
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M=V"_S(Y)YE_3RG%\U"!MK!T7 LM?3"XZ]H?LHX*H-I=<%27(V4>$:.-?5-@
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M#EK!JVJ[2K)]MGFC'L5RUHJ)KIINW4R_%+XFY<?L%FI+>$;)[8H4X*+VS\O
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M*WG\W@>1_2\]A[_M1'CPCSL15H%TJX2,$'+>,"P)0+\QV(9EJ!TLR00:*6]
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M!J-'$*/[.O 0U_G6U3.^7BE%AZ7YLZ@B?Q3')8=7(#S/W"'ORDW-77H$KXG
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M!:[P1G-91^)E&-L9U,D0QMKG'=\M'N*TF 3VNR57-]P#+ND+;H64H-B.4OH
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MH-B[9:WC7$4%:)8[(.=P/M,+:4.N4'W3:1"[\DEO5QBR [ ';:D-NXI:9-)
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MT#X$?9)8*/$&BKM/@"#5L9Y!A.GA3SQ$;O@$]:/Q %<>&FH^65H[<8&3RK#
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MR>0^F\D-=I&)C54K!GD<%C4[^>W"N\%U#1Z(@ 4I86 "S8E4<KFM6Z)=HV7
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M5>CFYIL]C 8.1'Y>J+_R!M&DKD%;AH)B>L#3"#F]A@.I$MH\H%NEJ4&$JL'
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MLC9Z92:C^^P %Y8B4C&], N>8OF4R&5W/\HBQ4[( V[9BUQ_._9$0A7IV,M
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M&.F+R@,FX>?'+3P+PS0_Q)\'Z?U.AFO'UWM/F2X943LAUE0?2?M._.\H<@#
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M)]^_?%2(?VKE*10O7B,UW\48A-)TV?MMAJM(RA\S8 W:E'Z?\SJ-V)[$DNJ
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MEZR<G#M,V2\ZNT:\:8 GB%X/0ZR%[ABEIS]*8FT_C*3>=<>+'=W*<B]B=O=
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MPIU'$;1<P;\E_.^?G#5:M%-@KVXC?V'S_5.,)H?OCE6VD4&-L<9X>N J]5I
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MF+O18)$>@NV4#5+X4J@9BD0EZ3H$0SZ*FN,+9'5E5CC07/_T0\ZF5N_[TO:
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M2MB_7>C"/$!?E5.2'T\]NHSV>:_PX/;_$UWH 5J,6QYYTVMRLV;WPAW&C>9
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MZ2'\W6>YKZNQDCGV^%3"@N[A1\T=;I,O0R@%R[%($BUWS.(GK+38Y,VS;B"
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MO*[N1"J?_$?5]O]^\1+P__$8:-W0=X4PVA"S%=*(SR&.<=+H -&(@L=$^V>
M"-LSX)S7_HDI]KC,[Y\7]&O]+M3AW/[3]!IH%=K^*I4Z\7@V_J1$L-N@&7E
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M.SLZLCA^ASIPD<EO,7B:9&A6Q?)H<_N]47 NMBHK/MC]&'-#KS_\@[.GB5
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M'ES@>+1^WFPQLRCQ:0)Z^[%)+5*GI]F!6ZU>T7<S/'X8=[0K.@9]7A4K1/9
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MLSZR!_Y\^FW];HJ "_6]<QR'N)!Q3D8<RA\-5F89Z.1Q=$5N-ONHAZAS0I*
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M@+#(A-.$.=D#P(,'P T  *@!<A(5@)388B1>W(MP LB);1)BVS3CTU^? !\
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MI_X/G]GX0VV4;$4@X$NTJC!EF,LK%SLO:WZ8RTM73V68FL _9E<FMO_JEA0
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MA5]21O*&M,@-L1M_34)"14U-2T/+1D?'=H.'D^?&_S(1F@%F:M)T"E(R$@&
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MIA?Y7BV+KR;D7^FY,7TWX)=UES\16GY%:<QHSF@Z=E'2M&R/.;[P(^+2S]'
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MX7F3V<U:_Y3&5/<J]Q@EFT<:2DHS<7V^58_(KD8]#U5\FU3^]9&^.4ET(#%
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ML7)20KF):*'=W_K0Q/LH&5FA768..I)1#,YX_44X_:S#L+>B.9- 59L(+1&
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M5,V1"L+'N%O0F<V==E3>:7: TX*GQ0'[&H/S'75JK<:,]Z78M=YIA]EZ[XO
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M];. %Y2(X5W] ,-PVPSQA "4P. MH0;@(VE1OJ*!AR1"[C^L"95"3PKB @6
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MTXO/ZR1)YI5:#%"]2E/3^M)$'ONP*'(VC25W>-=TUE.:8?,1@E9*?@;!9S!
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MC ;1E0MAW5%=)J#L$$KUGF%\9:P@_)$)R>M<L2+9$6 +X/2LY^%,2AGZ]'N
MG6I9HNPJF53+R<C44Q0B9.T1")4E/Q)&NH\2_WJ/\K4Q9HBG,%10!124Q$0
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MT04PG/;7/_\/_)-%^X5\.?+>/F;$^C\)J_CK^N]=HA>C_P=02P,$%     @
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MLSOT0"[(8:NQ%@WDKE8+<DW;Q8&%!#2K>@,D^JG@J@=Y["Y0!DZRW457+^>
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M9D1:[F_I<MW&V9;4W#75FU)/\I$7+7UWC)_<8"4#/Z]S\%5$&8&[@]F'FFZ
M?2KLBMYN&A1@>F3U,HJ3GCOT]CYNZ77W2_+FZRW<A2^5^:4SCF?"@65+9L9S
M?2K^!T7&^>:9I-64!%J]_I95*+C5F,34U"E[1$9%44@J8?;!P?Z=+$]WHGK^
MYM0EF<T*:\Q8]MU80[3#RB<+[F%.2,P&_P?]YV+:E"H=^*??DU&[*FS[;AYD
MOVN,Z+X5_'SR9C5-BK2RP%:$*Y1P4Y+'WS 19>G"WQ>@&Z:@L[S;3BZXY\3V
M22+=2<8C_@L#1U<VT,$=JJY2-C?:&WT#K BT(I?>M(AZ(+(T="RF^^0+ZB)P
MKW_O$0K.L^4F:,H )P'Y1>  PYJ4MOC2V1T2DC^>M85=0UQN!W7C[D'Q[G-6
MO2/*/58D/MB*:'9^Q,8OOU-L8?:'.KKH!8]Z8*@[3L>F@L<+F ,KS27O\G[A
M<.6LCW:TZQ)7IL.K&V"U*@S]$_1ERK "D4.Q)5X@=]!<M/UMH'E<?GA@Q=Y\
ME4.4D;'"] _[6>BQ@AI*NH>&/X>K.\"EYE%">/8CF1M@8.0&@/X$_:J_J,LJ
M=,(6*B_::[]5F]LC-NP21%/?'(OB9DYX5SAH3[N03467FCI+[:R33J66ES
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M*E=(&"8';K41+!=SL-OT.>*R/T=%1GB;=3N5HV.U)@X>1(C\7M*@"0E@+>]
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M)]@[U)-A0[-,2>2PPO>@XC< $5O]LLZ#;K7&Z$]/6Z2=.!J""OJ^W;,8 W$
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M4D/P<F0F"3BGW9&N<P?? +7VT?DJ>>4*O(4"$0*V7/A#.:](DVZ )<[6N1@
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ME79EV&49]\SNABCYL),J&/'NG5<LZ=J(3$FZ/%5\:H;W@$=$"#)[O=>LM-B
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MF"&4CCQ\-,F9!''N0TBT9W$)Q%1%_20EOR3]P*KK^OZ$YS;.\08<KH;2.(M
M1F39@#TSE.+B2_@75'Y^K#H&$7:PAN?'JZN,*L8[0QR4[EV70S6^4++-=Y]Q
MCM/MUCV@U;SZ_FO_1 _T8PD$U2]RPI:U03X(V;NUT\*5=@UF6B_=GQ&V#+*D
M]?UBX/#4^,VP:Z#$AO8R1%'LH5:#'@_=33="T4Y^XRPF$\O#*SD=%(L+O)P>
M?Z<'"D%3(#9R5D8CV]B0E6&Y.TS]T5@BI-$T_CD\SY'9B\[W58'G4QA-Y@ME
MEAKM=]@M!J,%"Y>9.%*9D@0VC[ ]W#369)R'O"0?.X;+K-W'S33ZB9WTAR5E
M'7)D,T$8:F?CORKH.=%M*&;^L!(L[7QVC*_Q_:6",YKY0PB%>0HHR.W-Z U
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M7)X.C8ZX+'^=$2%BF LCN=Y;3N!?P%+1]!9\#Y? RX=+._5SV?"2.31,(^V
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M#Q+:,::(>"RSQ;TIK,PU]"Q[_WT"<.S,,<L <Q:PN.DE>4H!_(Z":=9CG'&
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M&KE?BSB=Q#L%9FXI,;CS/[,ZUO"P[<YUZ6IF:DQ;3=UU(A[I##;F<$!R,_
M>./K5=$:5=P/>_>!@K>S^0"),.^VX)@X=2;%Y.XJQQOP.+^-6S1K755S= NT
M4&%:2<BJW?JJ33T@A9]#[>13]QT5?<7?(7D8GCLUV/&S#TI7#CJ6"R8A'3E&
M_8 0>S'0H8ZV@&0UH_F_KW1,.ZU 7A^72'QZ-20OIX8H=$HXG?ICQ6'O76X(
M,'Y^*]$E[^K1=/6^:D*-1C(_*Z8_$O<<J;1;?,.;:XKB*/F:D3FK'155)4',
MW Z9M7Q<:_D4!P#YM,V]H KL7W,\.K*66/Z]>6WY8W??D$]:I$0=N6L>(*W@
M^32;2(%1^4YSB<84;?Q(S'K05=%!U-96T0C;X1$EBT[]GV/9Q_ZL;5/^KGZK
MZOP]]33"YZK1=7.+]1Q&D_>6JCB9]D=4T[L@]ZS&L4I/FU;IO8Z[*<_6A$G=
M[MWKRI&P88E;0/E %7-+YS6F&H"]E"UQ0MUMI)2&:!8@\^@IZ$3&7F1F6D"1
MU9B2BO;+%U(Z7^OB M1T5ZDCHT[K9&WIA>>BQ8T0^;FA0!CMO0Y]N8R_ /2^
M1$0/]HH+]MD=S *'Q6XA$G\+D<*9I6T+AEN(9.<N5?O4:=HE/:)Z^VDM6% <
MB1ZR-\=RCA[X$SHBOBW9&4QBMYPZ"!2^GKK/;,K("&QQ_\[-KDW?855]F-,!
MRB;FDT6P54UA#5>E8@,#Q-\-,2Q:&?6M"71(14IO3A!M-,UQ%'_-J.<3T)XY
M>J@9+-F;SK*IC+X^RTKJ,Q^?6D02!9S]$3(G"$--W8S+*,YWW_"TH2EB3TOJ
M'1PR5YZQT*_4Q 8+=/1XGQC$U2HU">F!RA,V"!$,Q1ZR&*4VA&C3+2M O *[
MIY0MG?;G_1<VJ3>I8+5.X A$5E(Y&/(&7LZ:KI&JC+='J76$MJ9WGV;!FZ"+
MV6B2Y/0S7CIGK HKMPZ]):$%]FA>K,(J]-$0=-FX<%!K:O OA<-:%?PC"(,#
M%VF(S@RL>/O2-NJ0YT1&+EK];<J.T95/Z";5R@I1'+%O&+D?Z)S4F@26GAU:
ML4RD%+)LAL\[/?=XRQB))S%?#9%.&H8\J*[PYY/\>DEQ\[U"K=!^3J3,JW*Q
M_'>"N9:+UV.!?J?-"HF*FRB9FD._B,K;F#ZASKLX3_CILY\,W1+5P\\Y[QM-
MHUUH#*PF7GSDH#(CHKL3G]]HVU7:\@0F=GF0M,KIN"_"G5UC842K[RQ\8 /[
MIO%RD"&DE;LQ-ZE4;,+^Z],^A+\ JA,N7XF^FY+G*R)E[GBN0ATQ, -T$OJ]
MAET$;QM;(XA1XVV_(F(.81%J:S,!F6+[PUX7#=M9KC%^AD7:FO,:Y[];8G@=
MZ/BC@50FX CY,8]R213(JU'^(/8U@Q/BD\!YA+2M]*:(,RP0[S8K4P'/-?<9
M*R$VPS:PA V?[]RP):JKUFL':&YBB8BC%VT188#8 X[<:N';CT__&1-?ON\O
M>^O8N<=DJLVG! >P6[*/T0@<6;_WM?)=FT\U%OAM7JF;-&(0&;\W:S41]]V[
M:,!"*H@PS<7%-;:K,00'V*T8B(+/J:6G77Z_$C\ZFI>/"VG7I.P^0\>D_?#V
M<WUH$AV0)_77P>+O2ULJ+*@$=22+,39)C=J8D.X[?6A9+9.:$)LW^)H]\"!P
ML\AW;RMO3JU-C; ZWJE>NHHQA%)T3N'LL^/J55^-5!$(V%W7_P5SX0UT4WRU
M!K@#0QJ*,(8>V5L2G2S?ZZ^X>S/2>#RU9WR-OAKY6H@#7(*F91H-\\;T]W]Z
ML\_ ]WR4>@?+GS)&Y*DTMH2=&C$\K0TR\FF@>SH_P;>X<#)",8Z50.6;\'=)
MJ7/= $R.GJ8<L3."^R1T3\SX$>:L4Q'Y2SMDRQ8@+T/*! #S[Y1%FM> 1, [
M0<GL8:C6CE_4PPG[[-:-$4'-T+38E._>>79+0DW5HP>#/BG\-HF9Y1W:SY@^
M*?TH76+"Z'[XZ0^$-W,66M9E.UN[L#^1!CHH>_V6H$U--,NXLJ98'E/[&Q=^
M5"93XHX.B,KFZ7+/?4+3=(4IIJ"W?M]6C'4^/*QQ>N4"IMJ-(RPP0F5WG:)N
MVOR@.VEEC;W5ONDLC8D4D5SH]I<:P"WL72]AG;.DV@I9VX=+M[+8P"9(@5SK
MSG^5R8E3"^L9$I(%J(N4/ADC\@O6[&\_+?0Y@OB=%&^5?XRIZ)>^D&VYU-[L
MOSX<S\N-9FIB.5Z[.=]6RF8_;U.-B^()WDL:2;I:+F#PSUZZYI+DJ'I8I0G4
M/ S\^J\^<OOX_NGB_[L+=?)YC!/I\<^:'X@@^A+Q0A&VZ EMA??VY#$=>DGC
M*3\:9+GB34#FGYN>E;MT8YL?./^K@ZF^@?]6_?@_T86V5%R1;)@F7;!"W\HY
MA4;!IU7M0UV.4@IJJ93BW*@_HW\OHG U+= A9"43W2-;BRAT*KA+'@?<_W=/
MJNB+_F_2G?\%+@8%%MXC,.<E/\/,(@\^JYP4)U:Z>C,JD.L]_9\MTRDH1BXK
M3TOLN;-/K7<UI*),*>QR<]*\C/&UF'R41]CO*)64>PDNI$5!JU XP*"=4OU7
MS9LAQ<&1BT/2ZPM9K#[?>Z"!46[I7C,.D'5[QW(2#M"C775\X]>% P1JX@ 4
M2H(D_UUN2 #G/4,D76>&N6/6)K[\87OUDFO 9<"WY*0P[1TH5Y5C6S\%= !T
M>/N9TM9%X]"%T+DW?!P_G6=,_\P",@*&'/;C *O%LSXX@ P"!VACQP&B"OY$
M# R2ZP>D9A\O,5X=03 _1?\?MV[(_>]JM$GS@Z2M,2LLCI+5+X3,HTN%X6_4
MA<GUA#0&F:+P23FIUU8X3H474R-N3%_)-.="SNPU5(@5JGHH+#]L8L\C;K#9
M-URQ__<#)+ZX_>]M"^8G?R\M"*G^50&A2_M'*YW0_2]?'E1E"&;]#.!2S54[
MT59XZT1Q=P1U(R(CYXZ5C=7S9C.EV,J-FNCC@ +1J3V+S%V4I!] C&=A.W22
M>5;,P-!SX'*YBR8:!S#G\0+Y@BUF26^!8S"6)\&=;\6C(-[$<*W@CP/@  ]Q
M $L<X(=-YH7LWV#"\E]#;H+2O-=P *R^X>3.D]-OC"^U+6_;.G& :1Q@B[KH
M;]3U:/\/OYS<(9QZ&W#G/_;*:%C,:!QT<I?B^/;;OVM M9W>"C@"T-\@1^L%
M6/P(L"$<)3<<P0'^?0OD_Q7+J6_0/\/\9YC_E6$B)2EADRGK[] $WRJ9Z7SJ
MNK%MJ,<:$ &+IJ*=IVGEH8:-_MLRS7F<SQE(+T[*BC2T%FDZR]@K;?)#KMTF
M/%D8=U.J_6C*!ST,:0(Y,?:\;IMJS2FKXZ8^2P2)=FU>QD8E'3K@OAU7C*$E
MT=C"JZJ.YVJT,:5Y?U'Y!DM..?$Z>1MT&>38&O!:.IS^S8 9:X:R.["IGY.E
M?S.9OH/1W@?>SJ@UK ]R7A8?--;/ K%KRGY.)0?#WKN"2!Y-87  J).41XLT
MR3^&/3I/HC0ORQ-!:.-W^A]D0!]B6*ST?V9.__\:IL5=2MCU1V7I?:[V0I\'
M=(S7#UI".AEXJM!QX8UAD0)?O-0>TGV;AR_X36A\7:D8#+-3GZ6M=2(]Y=;G
M6F#<,6A8KX33]W/\FTC]GS&N?U%@.A/_@N(,;_(Z+H'VGV=MPN?\RW\>8NX2
M7J8EZH:)$&2YG]UV1+WM3+\TI5O);9U<VSCMKL\^K)N1W!03S$O1_#!]%@FR
MBK^RX,\D7ZGS6O'8TG 8+8V9^.BTC.2+]TVI%LGW_5A\_I>@M0'+RM,MTEH'
MS533/*Z,*8/W2PSHZ\+"\U^[:@ZY9G-+M6E=,CM/N(NI'RA3,WUY(30_U<B_
M[RCE.!_0.OW4$GWBOWX-H[ZXN "?0I]/-#.R+D<T![CS!?',Q33FB<3$VKVI
MR'HK$8EDH<LR+"Z1MBK8>82)&E2O,8CCIYR;GU],=#%0-O:NI&_S<KV8JOC*
M<@*9"E<M6ZVUG"HJ45LU?T"HD&T"7P51F.,M,O&4GROWKS' 6I0]6SCLVV8C
M=*MIPEW/Y%VRG-67W26V1S22>[L0D7Q  ;,%BZU5AX<!7"RU*7X!8]RE1'=9
MK%T8(RO8-(GM&6?.@73.]Y=D/^=/-$],8X/6 6:RWS=Q@*:$^@D<P"_JVWC(
MCMY/=0\9-UCW<[]]&^ZUVIJZ\46YWU<>S@W*+-7%&SS6>?KFLKTI:46QZ:_@
MH6):$-OK6N<?#8^YW[T, ^#17V[.4VS.'4:(-/WV=UP#G>ORI,66W1BF])_-
M?*%'B%\T=+2?(#,>3*(^%'U'6^SJP;&\?C] B=L$PL9[V$_C]W5E.2[T,A@D
MOP@MI1>1&.  %<%G21MJESN^8>3:9C!E?3!F@AVOV0ZVF\(XJA]5T79$EG[3
MP'YL7WSPIN[QY:L47;()Q1GLSTZ.U_K:G_( ^L0JE;9B5Q$7!F$24<P?(%R4
M_K;V2?%FANRV2&@M]H4S%<3VXSQY8D#2R,A"0A+MV?E\5O*D6?!451A^8BA
M"FW!:84:Z-0,B8=X(JYR5C6?ZU T(_@0S'>OIUS/7R*=9>RW>XG]%L<H6(6O
ME_[L;6#"2M7+YD&-E&%M-9OIZM%:KM>Y7_8,88R"*RM?)(^W30/)T+J8%-JM
M@Y-MX<%KX,K\PEQS\,ORF0C 7Z072(+?XM+T/QT8^.L(-HW&GLH2S_?6IZ3G
M_F55X_/1=5CR:Y^T5[DF(5@'KHV:Q $BL.8Y"]<_:>$BBW_*7YB>]\\+#GXQ
MC<L#8C9J,D#%V]>!;*[)2KP0:/L>5F152I/"KN0G"#U$1[(79*M%R^4"QH];
MJ@TK T\;UJ)#EQA'FX6NH<*B@RZ'9R<A#S0D!9$54A.RI$"Z.0QPTLGY6=AI
M(DOLP=LT15WJCT'A[5N$3I-#X$'EZNS5V,GE2&GNLMTT=R/%!'K))<6'3#*S
MQGZV;8%?\VB<''D-3S<D5'.#G96N?>C;(OP=_SX?RYNF6V K:=:B-KE;C))+
M_P-5^V,76@GL\9Y&.CA;3HVE.<!9W=28+E?#"7GOC^2GV0[@Y-ICL(-N:KMO
M>6W6YY+Y;6_)/X)&V_#>#;O<?A+5HP%)SY-AOZF(;LW[BW.8PH%-Y?$UFI=5
M+\I,O*(IMJ+4U]//></,@DENFM^5C(<D5ZB6BM#.G#KL.ZC!F:(<U72J:Z*<
M3]W,-"I+T5GWI=$JP(;\N6VTY:)]BM;LGY=1&VJA1FLLCT4KQ:7_ I] >5/?
MM(V?D))L4V;1-DWNW0RQ\>$ 53DI1XM_TA,%*\:5'G4 4D880NFTXKO<%5 P
M.75#I6F2O*(1CP36NDSZF="FI*L^EMY3IO=D[3(7U,F*,@-GX_O7=K[AY4AG
MTJVI*4I*DZ_$3W,$>YS0RF5E#P&67BYD[HFS[9<K!GMN+)5E"8*-XD1E1<^"
MMN2@5*WC(E)0?+#7H0XJY>S7E/[MP(53L*5,!*R.\C\PBS,,@M?ZL>8Q&W>.
MO1I]%JO:W5_3*]"9,$\OH*U#%F7 E['.=J"\PR!J0$WT0D'.;FT;)>0I4"*;
M;"3#E5S9^]T9!S!+O=![V?#8! M?:(.\X%\A9]RQ']*%#P>.0[;K;P9JW0H.
M=/Y^IR7_@!M/"9V26@Y.TALM;]XZK)GJ+N7ZQ )8J7J;\<DU UE\B\ G2A""
M^,=4T*>3&R^4"+\2C?<WV>EK=3]6EMFY8)V) Y]+-G*GCTM[YN\T!A9X"IJ#
M(M0ZFD.T(@82*9B?1:VA7HH?PC22Y34Q.7G+]J(I<*.=1G_#H;KAHS/X8/ *
M.C8V*6/-.GX@WA;8L?]L86^K+/-)MU?::6\1<88[,ZC>$220_))H=Z+B?M\E
M<EO/$P>@ UV2%#&D\9P2ZVJ!L7!0X?S%^'./A2YF/-E8/A4Q!](L3HM-%87W
M&.?N1N^HFAQ(@=17(NM$3L./">([95(, 3T..J B&V&XH9P"N0ZU!5#D?OLA
MC<#E>L0)Q;O2(FQHX>U,IH*=*S.HG!DP3;TMR_HFN!YF([#VOL&;& C-W[,7
M]S0WFK9;$]&&OV1A6C<8\1>5Z5AZVQJQ)WN!3P2,?23(FO$$DWWYT%!!.&/<
MEM=F4G3L>"U1NDHX4<#6.E'3UY'<L,)'[K]R$=>B!<7<7:U0IOE#\YD=NSP/
ME^:B)[4X]@XVS(?8.YM =JW8"#(MT79B:J"OX^+-EVX/JMB$B_RM;/-*F&XA
M4[O6$F_EI%"Z)6G19'=V6?Y5C*.+^L-%ZH*85D"/"P.5'_0.&(71./).5YVX
MDZJ9,.PE)AW(\DBI@M3WY/(8$K4B5P(V.15/HW]YUVJ:6O=V>(T7'AZT%K6E
MZ"4;2],M(H5OU+D+XY5SH[B9>Y\WX  &P%KMN+NF_[A2E0\KMZ[\6B]-B%P+
M:S8N(D+Q-$+:YYHK6F21E2/1/+*[M_+(UO[XP>D6#D#,(&,9&T9N  N570./
MMNTQ_WW(Y],:IX$U5F]KAJC+4L/)0.8NI)!CGAV-8V_(YNN[$^-A258/F[.7
M0CIXL?2-##>0<G_@N+0F6JE;UX0Z=[SFMX[IC,=,_2!OA\X;5R*RW_LLIYLQ
M[@E#=*_\H+V;;W[M?[Q5>PS<"KZVD4#RW,(0;\3R/K=?@,6>L4A=)6&JJ_,S
M]HVW@+M>I8P_=MQ[IS)1L/;4&^'TSK&=2[B]J+93 V21Q^T+P6M;$%.P#Z',
MA?@0:!_A\/WJ_A(L9LQ\.E*:K'#;DN@C5LE9!FZA^5/%II^Y).9YS8]'?X5D
M+T(#-Z,.L$(KB[(=. "E-%_:^VG!Z'U)T\_ T8$9:UJ7%WGQPY\-H@PM()\4
M8]+KBU;!^A3;EYHA)[)D#FG8R^RS]?W1R??A4KPTTZQXRH$^K)Y'$XQ>5 \T
MX2I DNW[:.L;LI)#:%JGN=#^F& 53['WWAP,I-O'_DDROMOS1\W;XJ&=>(;<
M^F9#9T2ZVEH=JJPQXT8%?&#3>M39U[Y"U7E$OI+ELV8(%2TMM+.\(WR(45R;
M=.PM/IJ7J^.@,2YR%E!.98H-+0% ASXUG^;J2^B G,B*_LPY6[=O04V<PRT>
MPVMC93OGEJI+V#_S_R!BK7\M^JNO?5_GWH(/U4H,#E"=5EVX=0YDQ @A%]FN
M& (*CGI[?$6)P%9[BJ1(M7FE']<QC5D2"G[9W8P/%C"#O4"RL7V61Q=I1CXV
MW+]?AY1:,P._G3YO:(J/6'HZ=7+M*DU:8J^SX\NVF4*+"N/3=J/JU?I+DLYV
MYJTM4ZQ=3?I]K41'YC\<4/,0!$,"!$E/\O#A(#+'WE=[@L8V07J]G1JPU\XH
M':#DKN?4^G06-(89,)V%9LD\-UJ!XXOS2E<!K UH-9!7?1&#,6LG1?N(ZX#.
MLR<WK<=_."J0'1 29T]G*F-0%@?<TU%P>$WELPE!:(H>#X OW^NDY,3RSG9:
M3* D:+-)%S&S[J >E^=C*49[U'S= :??R33*U><4^I3;H@'! ].^1F5'B&0_
MMC<9$(4^2 F?'GQ'%<;::QAJMA+_+7,P+D)T_^;!/']LK1IMZ6YIIN!PO_,/
MTY=MH-]*2V0$AZDN'%TRI/1"W5=@3^X9S9PU84-+9#PI!O(ZKK]&XA3,]T''
M%NZ9KABU^BPIHD^K0$/@D^9TA<2#<4$=0T6WZ.CJ!^?\LWM)1;N?LO"_K 22
M6M!:(*]D(+#P)AS _-F-IO$[V?#!'*S^M8=,8GG'38%]@6G(M>IT$F_\.ZE$
M;06*[SF;C-18PW*P9M=<P$C$(;!?>%I1S)F3D?M7AE40O8)[*U,3IF6EA;>V
M7-,$+B(EY64IR9$C_TF96K9)/N:+N,S.]#X%#O \*_FV!(/A "_MG0I0QZNV
M44SFLCT6O/!Y=5MB+E.E_HZ11;+"@^\=XD->\'6M:*_=AA[=[\,JEH6P?% 6
M:V4S*CFN)4!:].FY%DO9].-0/1ZA6!C>5,7V7._WTCQ@4O&<Y7.7(4?)/LK=
MFK2C[,BG<^IQE0C9!W.@>M^>]7RFV>TAEP13<48.D#<GCT97KY+\[K!MUPQ?
M#0X0/U=0,)29E?ZLFLU41OH&(5CY"^^X_WR86_9=AEEJ25&=O2K_Z.D&VCF"
M0DTL4KA6/VF090G6A0-X0RWM-X3CH^8TRI&#0V1./#^JZN/)+%0\OC5^K?I4
M>1PL(2.H6>N:3> O4V _=_[Y4$3MH5^_(Y3B[=5KJVX?6Y9/O@R$P$G^8&%Z
M'JP76B%_3O][\"11RFAM(T7HX2MJ@A=%6;FELYU\*B>OKU3Z%2K*SDQW(ZKA
M%4[O@M52P]D2K&(^Y#,])O?+>-=L<MQM2?E\M *K[^)8,__0EK5F=C^XOUI\
MF-K;.JLI2$;!S^>97@H30%!EWT*^8L>WJ&=(QY(4;#Q4'UY>\+#8_KVK!*&4
MEC=]^V&'.-4?[66]\@USAWG%PS7O-,J8DVOY#A/G2!&'=',N[LF.JS<[D2QK
M%$3=M@>5]"CN7 /#EWWRW$3!)'(4(TM@RJ[+^'">9MEBH_18R>Z2<&;N'**?
M>@)<<NQ$$,GE*)%PECB!4(4'>3* LH+!,W7KH;/XYVCOR&9G=[3[#9GS?8<7
M1ODI@\]YN\F^XC^S&:2:;3)HC<WU-PXQK4XU00.378OR!YRLHEB)T)M?9%TD
M8+\KY'MI1#;:KN3YL@MWCK?.'QN7F [Z'[Y15,$C*OHB,-WB=4.-\5FE?]CM
MU1B7AUS4-*B+"+SB[$YG':"@_E,FSL(04>"IEO+"U'%F/5ZX\'RY87;.P5?_
M^F3*0#(S<VB"^OA'.,(<V=&Q\&/M+7I(GO&S!V>YDY/55,TV4PV3F6J]L@%=
M!O&FN%FV"9H_5I&4%+-*+]_EG6AJ?UZ7R'NB17IA8^ATO*6Z>7-!&#+D;+9]
M*1*Q-^)]'<24Q;F/3 %5AON\^=SFLB='!7LK=5IV';4> VTHJO,?CZV3D;IY
M'( _A&\Y[^O]W24G1[,6UJCE2T&]QFC?XNGC:/WQG'*:S/1EMJ]QQG/H1-9=
ML,OM5&-ZYB99657O^-+T8MD1^>>Q3[K7P0ELL+X(.22F-\4TZ4^XHD;\;N[*
M<)*/9(O'.M,J"NFP)R\DF*@(H+.6<%(BR*Y4W[J<L9@M^+GM/G>R[ZXR)88#
MO-_Q\IX'GL]6/%;_^UR;'"#[Z%/.-4=W=;+YME2A]-_H)^Y'E2.$(1TG4!I4
M>>U&YI6\:9=/X0SH<;_=^MX)\JJ X/E+<:3T7ZX]:BAHEXE!&]*26J5L5MXW
MI5[!.LICZ5,_2\-'!J%0NM.<L1A=Q^WWG2(%;(DFBWGSO/Q[A_MW)V,7*$7W
M!-G"7VY!5N2CBAQ7'0G.4";&N[Z>/?WBCWJ\:8&014*15>#=VB>8A[#&5SLN
M(!>?;3K!1?7U'FJ>KKOQZAVOIBCV8Y>B$?L2_FH(CB3-N@0&7O?7*<(I+P.W
MA0 [%WW,XELO%'2Z2FM=I>6KO&2Z>KQ-)H#<H\SC6*4"D%>B1N[.\-%K8V=*
MW_5W1/F)BDKX;@H>:>&E1=LO/M>:7CEP?%N1^3-(DW3ZCKLO\)F%0C$8!T 4
MK%<W?UE0QZ]L_D3P ?2.*<,U@R:Q=WB^)[N&K=9Q-3)QAU=T^9ID'+D1CV=#
M N] 1%LOR_P,2'-5/[M6/8M5*5@^D?$=N('KU)G&2N[0_J8]&,0/FKAACLK!
M >[;1@3VG(WL7_/OM5K%CUR]]Q/[=-]\MM=%#O8;*H0J4T$<SI$:CM8P+FSK
MS-__4"O_-;:.^3W)#&\\YBGWPY7EL)H AP[?ZRFH%?%:Y!"YA=O!441JHN%5
M?H:;Q(K.F8!*W0D<3>K(-JYF#L&;QBHY%&,BY,/\^4L+BK]WB+FJ/OAVK3C)
MVK;"DWUH'5):H.3W--DI+3_8M#V[U:4CR/D=V1U&%)F%\Q50C26;Y"!%B:=R
M1X?KK\"M(Z0XXV=V-%2W;(=/$3$SGKZA&M 9Q5$6^RKW'S*35\']IBP !'-5
MLP9"FK1 ;5[(FR;(7JGNR+D]L=#! F3:^3K9?KV2;*'I7W99& &9T/41_OS"
M+KN-^5YP53$>.1I%6(D>?M"![\JEP:G/<.Q/4"-E#R-%]F-STYE%LPM2D,Q"
M5+"R*/(>+.8O B5_;QC-*R[#-GF)_MZI'>\TIZ(/9:#1Y6UO@463/TV)1L-R
M9V?,.81?P")F&#]UYT<5#2S$;#\BK>.,V;S(2@#TD1J3?70K1,<[#B-0D;8'
MD$[*(CG$;KG2JZJVEN]O_504OH H)4"L+EZP##=!UZ#X5+O-'VB"6OY/;,HB
MNW6)C$]X\RE+/<8;(N,(OX<=4[8QX6T1XNDKFI8397ZHGCA7Y>[U--<U1_FW
MOH![+%KK3!B,#R_9L;6F#R?2[_W<N\\0XTLB+E-M,&^$ X3Z*4WEHV"Q!U@%
M25 PPNHWP5;[?.=W_R5]E_O7L]1;ZOSO+@6N/DPRU"N G<-J1QX]-#<C5@65
MFRIDV0CMCBX-D?\,+8M\%!'C'O-V!<DN#I7#@*Q<LLAK)YUK8]5T?D\X(A-Z
MUCL2GK=+,\E('OFP4P@5]%7,:I4.GRA9WV:#K4-_^N:5+F2:Y<;9@*L1!^A3
M=;Y<RQ[:R6L0G"DIP0%@96T'V>LFGM__]9IQW>1=1AA]<!1',0]WJN5GBT<!
M;T$.%:;IN3=&%Y:#O-L;UK:[^R9++%$;D <[8R!$[$**+L\=WU2.5\AE<:CT
MN+_"RFN,?KZ1 Z--IM:KQ.T^,?7-<-KT04+OI4%&+>5-<:E7#U0/< !FZJ&>
MV4#VGV,60FA:RTC+G7&[F^>3/,XUM9^)2R84:G@T7CP/Y01ILGMY(2?BN"9'
MSJ"1S9;%[3?/)C\^BW@5CF*-[8BA5@W)\,!+^B*0);%:HNW5].YLX$SY=("[
MIQRK$%!NC%$<M$2S+D5;>5KSP)>[W.H.A8O_!+W)=VW'WRR17EN9 #Y'BQ8W
MVD9\%,8!'IGO2/I' _=5N1,*6OIC]@$C',SK6YKH[$"[RZ:6"GZG<C^&905P
MVUE\I"<O7J>H6.-D3TVJ24:*F[F193Z41YQJD>5]J3A^3):;H*+OY4WZA^OT
MP@X;/B>^YJ_SF^8J&RKL36+NQL/9[+K*>IM;QK<UG=!+&:[8-FP(+PZPFX@#
M<#7[ZM-"+@A,<8!IUAM]E^>OMO]MK!G:IWP_=Y+=_7LAPNO?%B*D+63X#F\>
M\S\%QRN\G*N(+OV>+!1?(U]SD<!8O.87)SGV(Y/!,LB@J]M@^LA(YBHEJT?.
M3WZ#3C4 L)W!T"(!M<MME&F96HSS?+7HE\7L &Q9A>)ABN3AM1)8)2M\;5H9
M137OS^LN.X>40X-T>-/L1>_N>IY!'@OSVIPKPCV&!!VNCKDNZCIG2N#*.F6;
M+NWSF<T,H<<SYR<ZR<J#'N+PKUZVB1AK& ,]JC[2W]01:L_X(<71'D3F_YF1
M.\.6J^AW:?2JNE3G\J-:<W<3$/.XM!S(023\!Y.W&0^8LYU597C/^M>0KR>Y
M9(+3V?+(#8#+375Z?O#F?M#*OCTQ1#'Q9D0E2;T^954Q^L_+-CO\S6$ Q$]"
MXC!+TV0Y-ZJG9G&L2IW[16X4)U%%]M'C?RRB5NK#_W4X.!IP__T&:?#D[\U!
M_\-KY?0"'UL8'@Y _@HRO0IA@^HZ):]GT^( :RJ:EU>::Y-P-4SD&A0KZG^M
M0&Y8YF-E,8;R4ZYN1CVM]O47L%HE?D7[ZY><1\)?2/MU^=_/E%BFHZ<K_3E;
MX/.(UJ8",W#A?%=]JJ&J58-?<MSK.[H;6N8J6TH$O[HMD^3]91I.^<%MF@Z9
M;$M=!AC/(K#JPZL^QW"H,V_-T!V;FYV[+'1T1^(C%A$)U1A-Z5O<GFH2F]M#
M;$+4Z\4$[8D_JG[M_.)U0._M>TM))^6DM%L"'0BUZ,] ;O[/-)2*ZN(+%^&O
MC/A>'J=_H<K*O%,1TIT%''>Z>=Q:Y.SIM/1\ZB,"7K%J+)?PBG*I1R@9GW*S
M=?VL[/E:XMKN[F5ZOT+]"!Q^(A[_T!\X[B_G8#<-Y T>/[CQBIOJ?"CO*:&=
MG?9:\8__7SXK)"H5J9V!]^O&G/\O]MX[*NKEV1<=!$6)HN2H$@5)DL. H&0!
MR9D!D2P@.3,$!<E)0(8D.><AYYQS=,@,.6=&&&8>[M\YO[WW>>=WSEKWWO?N
M6O>]O[[=LWJJJZNKNS_575W=Z)EE[3+M$79EEE9/D?59;+Y[N*3!#_9)*_?U
M_&J5ETC)=N@R';Y4!J)4Z0A)JAK,UV!)S=C5IUKDXG?*+P^/2"^?L]%),AA3
MZTY[6 *NADX'J8QGD);41$>SW<<A44O5H\\UE"E^E#QG?35/?Y\A[;Q\??')
MD< %F1]4F0AL\0L-@+6<'*[9G-2.+,X[3HQJEA0?-<]('X^..A,2Z\!TB[\W
MQ*.VL;2QHLO?M0S_I,'83E-R94J0.DYHIR.8'5H%"L@GR7P+G2U99V.._['6
M_9UQSO8^P$&))SIDMP2IO)(OQKHC\'#7XX.KPU8A:4I^8SX#ET(B3_SPJ+M:
MP.0'U[9<56ME$ *KX!,X"/EXQ,Z'1%M;YH>53&<X?W"A 7M=O8V8[ ?5?AV<
M[LX8*DN,6NJ WN(T2B^N";OF)]H6AH_K Z=!E<_KJBW(<2W4P266XF$Q]A%U
MW4I"I(T&Q7/@]KIQX\9CS;22'9A/#<W";H<#>=FOOI,9__[F]WY0(R,X>>M<
M_;'8EQPOPZ#.M+FK#U<N^<8WJ92+:W*,E>OZHB%B.^NO^K93[55&U#PO.6-2
MI_?<#9N6<?7$<8=6"?$0_NR>RM#::R"<O?+5:'GW..;C.CFCET!IGF$6Q.,V
M+5K!F0]E@=LVS_Q)4]U_XL:I^+7?$:".[I8!9[ND"LU4Y2&9G2T+D#(3?)7.
MG DT@4G6>/[:'<_G3UAH=0YKDN'^[CW,1XMK,$1**AUQ)-X\]$6T@9QM11>3
M_3?OSKO4F#'W>_?L];K5G.::6V82MHQ9.F",-N*EXI/F7T7IL[0MXUT7:8Y-
M ZMH.A<5WO2SFWV]>!_Q$[=M@!JCQP2RS2Y&"+.J%@B0/+9IS@6; MPS:RH=
M;5HL&$DW1?1*C=/>"?4HPSD?(7Q.I<>INK5HZ::<OTRFFS!]?=M'4U#+01.A
MA!-/I:PJC8T5 5GJC*?OUOVRL!D!-1_;J.3:AGAI61222I*^= +XU^K'?.HA
M7]/D*%8R$"_M0(;'L7K!;JWLR%_)\='9") $@HX &KVM-3,C\345#9"W]C^-
MLSMSINB/&H"*+RPG.^JO@;'AUV\I@4O!^S9(96!Y;:0\_X$6=53.1[@@5K2_
M-*'*D-+5>7A"JS<IC&U.CH\*"!JQYA9.!.@P"+$2V$^D>>Q7V5$J%BF3EO]
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M @QT[(Z^LY@ )Q+5Y,DZNQN]T>_M!*+3J-(=,T3FBFUTL=NI1OGH^34NN];
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MPJ4+<=9QBJHN.)[O^3AQSR"X692354D]L W3<L2J9TK4=67DH9<T!+D#ZP[
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M1YI5M1+;QE)X\\LD[6.>K>IQKHJ)V4P64=&T3N6)7#2@:'K24CBF_(M'<[_
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MIU?P)%E4&"\T6/[ZY$XQ O(8G!!5+MRZ4DK/V:[Q4<S)2N+(/(EN;//GCGE
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M=:@)74W+%.^5]?A!%]\8/:<'V:-5!\DR3OEJ+\),EOY1;3XKOO]TME:5B;]
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MFS>3$.A'EW&.L&S6;4%%9L\"MV*!<S;DJ;.IXC[-N4&U20*)43JE,H!NX3L
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ME/F+,RAT"6O;ET*/9B_$=_CE:5U]U M?U[=R%)\_.*:Z4AV"\_>]I0L-P5]
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M6/VJ/=9 !2WIB6YB@C- @Z>N@*,6Z:?&!H4'-?Q+T6KZQS#_OC(\)"R<SX@
M%-M5H(\!K4@WJ_+_\$[G>0U_Y'?+(-4A%2*-[?I&AC^VF-EJG._W#CMC]SO
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M4+PNDJL2HHW)27?&4C;5 #3Z#XL!<J\(?18_^'AOW/>V;=+"R[[[C-EW@#=
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M:RSUM[R5><SY/%00_UP[E\M@/TVS-RGIYW$3>?0KYB*%)O&WRJ"\M%)1N:L
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MRBOU?(F1XI.$[MN>J^K'PPG"LG:B-YDN25]OM)XBAG\P09OH>7:$\"7!%V&
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M5B@UOFT;T0(5^@5I5^_-^@;F?O-_=LK6$<U6P19S_8F-JFFH*=G-[=MY3$A
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MC]#].C]*475CJ:=5[&\$G_@_]VYV#V7&[DK,-Z<]G/)9*^^_8,A+XX\"_7'
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MRG35/?GYGC+D@[V2SE_I4]U0L<,DY(1E?>X'_W('5U'X"*"H>00T!J78QJ6
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M92S.E':I[12S$)NU6K[;GR.\W5Q\E^8QA\)5*.0_2L#0,% :/#BMXWIKXA&
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M?7L:)02BYQK8TEI&#-)3M--:S:\+37G=_M11X>;S_S"F92ZU%++(^GN34<S
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M"T&6I"+">GW6F@4@:XWJ\##[)\=SZCSV3.^>@"!(D'RIKVKM<Z?'47"B.F%
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M/6'Y:'3]!.\:O];1Y\H1)HS$='U5^.2<RD"%[E!-)M ARK7XT!1YW38V?;C
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M.*YL'/V\Q@Q:*=2Z"6]?40+R)7,L8S21H20J_H<"HH$^%YCF?,]I__S0?FB
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MY7A 'V8SS>47>F.]5AU;R/%K3C)@@"@V!Q<]K_-.S)-N5RH#:VXQL;V[X#B
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MC$SS2LKSOI@\*895H$9ZL39R@VZI0K:_M8K/Y9= Y/)_^*IGM+9;B@_F\'S
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M;+SRU!TTPAX:Y>,K3>R%NYCHX9@<Y1U$3&ZMNZ'&@"&O,U%$[>]UNQ5P%7J
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MCU3-"YIEO+PR_P%$(<SWJ"W[&PO7<WI7V:6 =],V:\1=3?2KOFR,CH$OPGW
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M]=L"H3Y10)-6:NIUK4B]*'*1-9JKIBBM1;,L[8^IQFE2O=8?77FB[]W!_A^
MJ ?L(&*J=N]:M]2P?9;C4';W(RO)H/(3<-P$J:^E'H.JV"'9O&DP21=F&PIK
M5(4XCI$BJS_Y%0KX*8(G8_3)UH',:865PE+]_5QF,17U!VJ__^:V^D4@J5#W
M8H_UR-5"V@:6L^25_>"9(@+N_CG5YKUF\NCUUOF^&%=BAQ1I8*(,MV?U@\N+
M7^1+\Q1^]&*:QO]8_2AUOC<$WOV%+@IQ/!+_K9_JN1 O$1J=TV%_'GP'%.E8
MX/L :,^:,?&\-#;;(&'YY]BVT:!@\N+X6XZD8PTR"&>5<7>;JG6W7C]D_N&+
M[I7TZZJ,)@RPW84/(8U^O94;P$Z=UX]5R/E]_@9NQ)P)(;,PQ[)-1#7MT"9+
M$(4-0>TC1J2L1Y@&EN:ZN]\5G@/+G^)[E_6Z)Q;NARZJM/A*&L$FYA&><+J]
M\KIWLU>5?+;G6#E4[6YW.%TY@T*2A[TM9$6=^@*EV.F;S)!5?_T_;O7$TA=%
M8>_WSXQ)A=-LFP,!3"]L;U4FWB[OQ(_%"4B<IOQ"Q#NGRR) C=EAI]@II3W8
M%*E"R)C<6@.JCA.^.?2.'"JO@CA>)'V4*YZ<*Q%L"3V0 IX>2 :MCB7R#[#_
MP'^@7'_Y?/[>Q3A37P*5'*$&I06+WM>!+DH6>B1*:6AW"CR4/CX]?SZ?>U+'
M'G3%4+NI4V.FWJ;:(]_78=)&,=_9^!:?8-F&T(9C>UT0_<VQ'&&M@NHGJNH#
M%-04N*(W@A#!#Z&,[ '6-[[V65MROCKGK;/9:R'U(34-T2QWX0*OQN$@+B*#
M.L+<>T^*>'[^Q[.3IZ;T"4'N0"%\Y&$J)'+?,L$?UI[]RQ&/M.U<:"\ZU:3C
M0GJ3]X4FV-0L_]KJ>NZ0+5:YLTA"$F::NNI>&_H6PX5&Z#C C/;B)G01K!-M
M82Z8[LK^%V&<>:$I9JBV[C"RFVQEP^C*0*N3,BO1/.OE6Q'8>7YO.*.)3&P1
MSP8O5U6()W.#E<]L"3S_9LK'L$C7G&/R^S?-!6] Z/#C)R*MI4KUL[]W,TOS
M_T)SSBUL$5$K+V7I3CZM*5"71SK<=EO*08G&^KJLG,HN5WJ L-S%*SVK$C:>
MG/.S'?4$>Z@CC@;R39&)/&.3HXR2*Q0_K%VR]_E ()+Y*_]NQQJ.IT;(;:33
MM)%9_Z"GEKG.A;%&9TM"/R>[-!4'PKXN+QY58E7V6(>BBU."XA."B)J+]YS$
MLMU%8F13([F$V129Y]8V[8PM4JR+Y1W)2<@G3]V"_$(W?%,,VD^2$/"?M'_C
M1,-];^'-9'@RZ"%AYB U+\/36J_3)4QF1E:<6[.W':Q1@* D");%MXA*\\@F
MG;5/+SW)<(\L/>V93:F*&#OJ,#\@F>AT"_*[N+L3:FRB\+L?LM=SR^CHK!)T
MQ<KCR:IN<6Q@*M@E[A\DT]GEB_=O@%/4=C C:7C4T 0[$_G0?/T"3V<V./]'
M849/;@YQAT(7/]'22$U6RE4(1Z67;B4G*6)T.WP3W\4BI9EEUTMW]900D0E"
M(,OU]B=13Q2+8XK)\SHFFH#5R+0"- "6%OUCSCM9_6U<QJO0U_&DA( /3,UH
M<SYE;/[;SMU>&HGVJ/(K.=4;;1[S8RB@;'4GQ;^1':^'P<80 !_]UT#2+S7;
M\. B\T)\GCDY&1),,A95+$I&4OH=U\B-UNW4Z\>F<2[ZUJJ^0E[4.:H7]1BX
M!75)GL'4Q*5 N*EV_F?GA!QJVXYR^Q(CO))\69,>Y.Q^7'+%YART:YK5-#52
MP2B<63<FF)[L61ZY=D$JK.N%C!B #*\B4GRF%HP%@*['4!4KJ"@C0,YG>)?C
M1-AC#'+QSE9"'4*Q)"0T PZODH$VQHGMX%*JZ!"V09^\=^-\<\"X5FW\5+D]
M>9K?%=3RE&L8CZSM<P!0RX((2F^^ )'EY2.NQIJ=/3[-OW>UKD7'E^MQ;$@<
MQ;;-7E<.MG6SYT6D!M7.\(Y>UQP'(.>?6UN[2MMM100L!9@-^04R14"VTYA!
ME]<2$Q-UN,J([#-.H#B58=_,F3E"&;'87]J=(T[]<]K[NF'G<,@E[*-=D%/B
MSNC,^8V!J V5MA81=UP3F%\7:_3S@I-(V:<I>(%<']T+++$L.S;3,>8DF:6%
MN,+=PE6RT1@<&:KE0FX', -S)L0^6@;X>5HB3!9+C5Q=D3TYC X+P(%.5<\T
MD$H%EJ4"*XU2W5T:J4X)/*A/NKEQMN#B8HYRWDY2RG/.R0WNI>H2-8Y2@28N
M+@8SHBVIP'9W5MCS_^<\E:+-@;^B65Y[XX\QE2(C!?MWOG4?^$US3)\&MH2S
MX^8_)Z65U?J<)NL";F1F='\;RL?SDTP3N7?Z7%3&J8I=-4'&B]KK1 4+?BQ"
M<67EG2Y9L].?N7-*_6REF2YF^7.AFF+Y>8%FLC=Z'OS760&D^M72]EB4ZYOK
MPM87%5E%:10T:NW<ER?8A94&\OMY5(^'#>Z7U.;?:FL<%\:)+7\TGC;+'"S(
M-6'%=O!-EJ@5G?CX7HWF\KJ/5%3'%I3G'TTBUK5H]\F-\36F\QFMEW.=/W\
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M:;Y SZB791 ]5Z%>.:$=:V6<9'OQ9O^XFE/0Q[XO%Y[M?]+27KVVG^]LE2J
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M/]><.!'.V171,<1H;D:KL#MNR9E6GH."58\WWW.XWG/GVXP8_]_4KSENGML
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M,SA9/I)=8([.9CGUF77\<_)3M/;]8NS"_<"/IN:H/+8_";[RK PRI$^,A7^
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MIZ::O P?:]-FM[)&8&$[LZ5V2W_[%^# 2^6V7HW0ESN,;;0F1U>C;\B1_Q>
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M2!Q%4?LF!_Z0*S#,"IMZ"IKTZ-+<6C;H7<JF YE9^V71NO<]\9M"$7E+ZKI
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M>?I1F]V?9/VA(C[&CF1BO/AQNH3OXR>)/?N[=F!\(U0\K33R*$V!Q<,;B?F
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M@JHB),WRX)]IZFZ\N9.P]@J953D)JQ<2WD@6\S_LQD,Q-"5'M:KP+XG8^7Y
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M)TN+A%;JUX(BC:[FVKO\TE !A2W5O,@GK:L=JH3FSO[^;JBLDYW=/QOT<=\
MVB@&!W(HFJLL/2<O!3.]<^M7$DJ0SJ-2J^H]0:YVX,O\!?^]GRO=2@.-N6K5
M9#.I1KRA-_IR[.2Z4*-[52D"KY#L.**](&!^ELC5G_&'.,4UZC2C4VFVR==P
M8:M&IV9J%O:&+)SGY"]T)@%*U/1T%<-W[Q_:!X(^X'GD<@KP#I/YMD-&+C_N
M+G=GHWG&)BH86H=?7]TI(1,=?C3^T*/@&NI@"67SD"YV.]#73N-62LPM.?A6
MM\>8W'D=TLW&O2SRA9I')0>=*;/IFRBN'%&MF6-39=H%?'&6Z!+WGM:!$:/7
MMQC32,0];8@XOFMJ1\K"MF=19<O@.IEY3#]=&F%!KM?@)&5>AXCZ/6:^TB:^
M#?_CIN<(^A.%F;PX'O-8=><)JL7R/S,^]]^2PCO^Q]MG(:VU2S *W!1+2H%&
M-)TZ4!'/-AI=#+?2J@\=@;.^,&@>$6%+J0N%785)C9:'OP,LTR0F'O8%P;JM
M859\"(_2D#$-3#R':1F=.8:8TCQ%LKXZ>A&XTFO7G'+L]O[,_F.8_-![V?>H
M;T71& &*O$[+L\SK![J$K%TRCQ()WREG^63OC1<O1 H^CK=9>7?+Z^YK;>H<
MN>JZ0B>&-[1 32EI*R@JB52+YFR^YV$$9BRV;L'@H\51<K;U7QHW)C,46TWX
M;DA*HRN^9P&4=#?T\0)5/*%2(B'U3@5HMZS?ZP*8VJ.4#=?8%FL<.8JTY(>3
MPZ9OJ\AG\/&PM;I<_T2EQ8E_.C<.:U\ZHKO@CP.!@G\'^K),NM'9[)9EESZ)
MR,:5JEAG.-X63W" ([C"8MRIZMUG_--9J-,5;.4@!GDER8)O3"G0]/10*UFE
MD(.6?A$TSI![@<[IM8HGR*K>F)*CZ&F)X$@AOS^PIB<9;@@!,M^V>%L[R?/@
M\6#KJS8+L!D6^V%MBWHVQL3YSD!593-,M=/XDFF6A,%:,=&#U:*LS&S3TK!*
MAJS,$P"JEB(U0"1EH2\KC3!OC;62;7KXC2Z2=7+@?ROJ4D9XCTEG%YO91"SB
MI!5G/@ASWK&M6I U ?06OIF[<[89*:FE1T<]PY(*;Z/%-/P;B!KF=/GA6I(@
MS^R\U-I0>X&08 06$5]?=[;;)>G^IO$8L*P'/3#F$/21*2GPGE0XB<P"WY&B
M\!OGWM?,I!H7VK@K+F$,L:226=XOQ;?-B!_CGS2R?2E,0\6**SN")HVQL=L3
M]'U73KJN+3[4":F,U3L[3H>$B]ON-1+HVMO5)6E)UWY4*,6-;Y*&Q?U\E(>3
M"XC,$$WQ"E7>/>$;3(C/=$UBE;8EE=B(HXXB8+#9_=A/<1Q:@UC$[7EZ6G):
M]D P@J+BOQS"Y9I8YE$=%=C)$K>2WMJ(!R9\.64:W+9P[/.P=QQ]6%:#I+!P
M:[$NZ@5W^]C9MZ.P%#L$]NR2Y8Z@ONOUIFCPU:#E2>)84RS48CS!9VRS;?AA
M(/KL[!JU_DFH3 /D-3@<D28@2D%H<Z8Y1"-*5ALS9'/IY<N]8Y2,%,PS/!P
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M89/88WET(@ =@LKY!A(SH;">Z]>(<LU+8TZ(Z.4TY@Z=_<L1NMQJXZ/>6MT
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M+2DM(?W[9QYP)V5G#!8%PZG_G!E^X_[M3V2^+XA_\%SF>_.?GY7]:%(V0+C
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MR^B7./-]@042>L8&Q;=-Z^NX& :#2AJ-%BM+3G<]*5NSMY#0($>?WV^6[*)
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M72\B62:;U"2_3S6+8Y55;3:./E@C0)T>"@XW2(RBGK^3?-7._L6XFRZ[$N^
M<N2#-VZO#0.7^@I>B]LUGY!V)2<]<[A01@L#$GF-8Y9OT)UJ%13%WPR83Z-.
MM)QIS2*5/?6L;7$H^A140!ETQ2 ,B"E"(\2[1?0?GC"$@*E?64[Z90M9D6^H
M]Y-J6VOZR(W&,X_HIH*5RJ$E(**TZN"G#&CB6@#Y;+1#2OYP$H=U!LOQOI>
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M:X+Y4N=0L"Q2I'',C>*K9LJ/VL6R@U)$BJ(/U70H@Y<&[)\K=V$6A3/O[U.
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MVIA%J:88VPXKB'I\&(BY88SEPF%V:E--:Z(PE'!J+(.=;<6C@'K'7(O;LOR
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M(A!;&CC_;G<N@:SCJ"$#E7TM=ZX3-?TF(8+D' (HG2?PK [$39.FIA%#45C
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M4)R@7>&+:S?4O<;-SJP9&:?,NP<QQ$OXV9K*?NX2)"?,<FS3/E2H9@DR)XT
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M"KEZ.XX2ZF6.L&F\E]VZYJP\T Z,G642(J@*;=I&D,=X@;(VA9B1LJ']"\2
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MZPFVQ[K JKKNX?[53#(?FX2>V1O0YEO;GSMFT?*C_%WK!YBWH++(;TZ.*HV
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M[1=/+%[P.A;%41'1XRY/8K [^&Z$!:QL\$4[5/ ##HB;-X(<TB7YXPCM<U+
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M21KCNI?W*5@PDOB-GTR@?T&5'!DZ8Z_+16#@1PCJQJHVN_YCEBV_=,&RU0M
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M<+^Y"ZB)+FB"2N<P],'XXQKI33!H E1 B"4DPZ1OCP\KZ!3(P EPM$O2ZAZ
MYK*\U'+C@TSC=#>Y4*\)EL08<6PC*('Z1!]*:,B]IE2F0'T= F3RF8$;5& H
M -3>E3LR?K!B0.<!9&\38Y./R?&E:FP)*PCR'.=YQJ-74%'D4<X!WAFN]P_Z
M?"<7V@'Z0O(A5W(Y+LG@,E^T-X0-E>//URF*_*CH*ZFR1;0O55I" $_VB..5
M)Q0VT>E4S^F^<)[_)4[X ;]TM'Y.ZRI*@[7I'>G^*01O'J(_'EH75T,4EJKC
MNUN&.(96UK\K5-Y#L7R]S[K[XE*<<MN\Z4>85$@N[FY9J[IHL8:2E^^=\[AS
MPVN&'X>Z!.X5Q#AWHA U68S4X^Z=3UY(7LJ!A 7TOMU_C<Q*??6?]3]ZM!GL
MG+0PV 7>2U+_F4Z2W!]S,[#NR8F2@3JP^(Z^W=_ ^2P)BP?=(7IB4>L/%]\L
MI.JNMW^6VY0S45(&U#ZR!HUK'<H7&7O?'D!0PEY&3&1O724NKL@VI:LIW^$X
M41(0S2ML1J6"$R/K9412&]%;>1"HBE>3)[,M\.6S]%74J,)!.)@@*!@X$DAK
M(XH#8 / !<UHUYK%RK C.(";7C#) ]0ZZR$(UI60& =U>PLM)BE.PP@$_(9$
MH'*$1 )!TN*[5$I*PG-H<H!$I46$>X(5LD\/_#MSI.! 1V:[$LG'2%$R;,N!
M,'S8PB5%#8^1%-8-PR)G]]5,>V7ANH/CUA"4",2Z*PS7KH1'0;R4/2)02[1T
M?@I27$!3JD(O(>@6N$-K&;G8P^WAR/\.MI=9"/'!5DK@(\6_6%S(46:#$60P
M#;W)'#,DB%57!%\/8,3-R#,2,&10-]21I8PB>2<J@(;$T# KV01X9F!$K1X-
MZH.GGM6SBX\$P"QH!")N<S!W[SRK*&L=DE1KQ-%+D&J&94VFCR2:(GA>$*%Y
M8I+,\$M=;)T&JKJF0;IT*/QL.7E5:,"X$SWFI+=-N2+G$Y<7JB#F;"C>>TIS
M78@6<AR<Q(*HR8%@%7FA'/!RI!HNT3<L5[A(+@#8)M%%><B<0@%7^Z:]&[>F
MYJJ&##T3BDN3(C%I6SJE:!!AL>PW!F*,70LEZ0E0^*Y-WB$<@P-L#SMXS?KZ
M4H<AO(E 7V_A8Q&A0_\%@@2"%%@578WZ\L^? XM3P>/WD@@(/5PIER+I.$A[
M*)MG8=0A^@<_Q$Q;&55XVLKT)->>\%X> CQ)8KA@BJ,$A$%G[@+/A*449VE9
M230!DI%#>"LD-MF?:?&]PTNN0'[(:'L&SA#7CK$PE&.2U@2(^FTF@TUOFJ+6
MZ'* ,8W0C C<3R@-O,EMBO&.28MF N#R<JSRB'W9^L8F&$@.:34W7>WSU FK
M93 4<W#6LN",>Z+#OWHC1 4-]3P(E0=1%EV\4?1\%0$/Q,*S)O\/Q'K_L.=
M1^5[?K4=)TA4I.<,8GQUJ/-0#P8#=P6WZ>1EW(%"3Z?!!5W);#!/0V+M5OPQ
M8DSO94%_U*C^!FNSJ6]G7T06NRHQ['WM@H9N-#2;(7"@=&_)HQ4N@5^0G3O8
MC&8F8=,6:[&5.MV(0$5XLA(.Y<_2X \\99,Y#@NP2>)H??NYT?Y]+HPAY71P
M1(53"T4F$_(?$D*MLH)\\(QHIFIC-<.V;^^%)CHWB^4K"M9JZ\<13ADKX.+]
M99K41&>UG%IXW9PS]3[;CA%\N1?K(J,KW4WJI)WZI-FUM'HZ\S_0N8H, 7/
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M(T).1"Z ?$K_86M,>!GK9^6F#]7#^]+4S<4"LZ(%[T6Z4"".#J1F-<+8O?T
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MP:8B8#PU6=7A(7,^/&K%'TRG:A"([;$_,[D286T<<J(@6SE]7JLIQOR?*.+
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MR:^*^PKKPQ.L)XD$#J<OMDO@VBA0!\5FW#18)W!4,+"-],<P72GT!03:%+#
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M"3?BU13PFV1?N?Q?MKYR3[<N.O?GK_-,H>D?]1F&Y[J_K08JR;-U@U^$\56
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M5NA+5I(P8S&L46X/+PCXT<Q0N+E509C2GUL@;$.LU;171^[=5!>SKD79(@D
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MQY>5(3DQ?\T>^LY!VG?X?.Q?O5O^!XB>_3!4HFM-8;*1ES;NE>68\6?HQRM
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MR*EHW+1*^?Z$1JW!K>;F&RT2ID:BB3V6MO<W_=_SX6__W_/AK9=K(V]F.3[
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M+Z5C,V%A5^YV.N\[5_28V"GGWR&OJ\:Q[5VN7@+U"EF5JK\GHZ1^D\)OCO[
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MWZ7$K>00)%6P+8T9/)>BNJ?-Y$+@OQ5)I@%X2;"V#H8^A%(3UN;+):+A;&9
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MC54.Q NY=WG>*Y:#\650D2Y%)+K9*VO-9MZWO^.W[Z:F:[.(GZ&_WVL_#43
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M=8(E>N46-$_LW3C480&,\&Z^S5CH5D(-DG5"FFL:A4X@CLCNK&[1^@^#<)T
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M*,$H?7R8>,^E#Q>*/=95HS\[LT\Q#K_]:F%_1S4"?$)/<J-2'DD*<WJ62&A
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M2G_U\?*W4/OG3XY&OFN+K"C H2^&GBO<LJ-%;6V<\>[6[5;]S)@SM&YU]>_
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MQO;FE/+\X:):#I.(7>* ?6HB92UO_M^1<!]K^1(R4AUNNJDBBK^NTB1 MT4
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MLH27^M,EHS,#$VKX^9^6%7$KJ_('RXDWK5,^^&927S'0:HX^>+B72ZHI"O:
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MX&4#>DH25@5U8>'DEF/?:&!VV9AE<'XU16RL+;?.:/'B:L>-N3@E\VM<2UJ
MC%R6U_\,WRQN.]]^?3]AJC&^>5-L7=T!=;^U*^65SXR.;F_MC%JWUOSC0RN
M^(3T<#M3*KS.LX!TD$Z&?#3Q9U^TN0E"<,EQOI)3B#-P>9375-HN;4X*RR;4
M5!<%FK"^:GKZW44Y4U/.98#'G?D38[^<QF12E]D,K .CGO_$G!2AOH+9E?KK
M%>D^X48$*=T"<='KR_6@6C?G&P]31FQ=SPV+)T0C1ZI\?/ILCQ,V*G&F*)N:
M?E;LS[6VX%7/;8LV[[8:5I0$JVSG\@AT!L[##1.]*?T-"4!F(ASL[NKT.J;V
MC"OYS#;ZC-CL,^@G>Y7!L_!-0',BNI53L&-Q02Z-$4<TWY\DQJ V?3G'#]5,
ML>\BPCU5L-)9Q["[>$#&+:T+C4+32*GI9=XSR%E07M^]<'N/=SV#SK2Y'W!+
MYTY@9E?@(3O+SR?,N=K$JL/^N8X \?+H>.ED2J]/6H:XQ/5-6P,4(>\.S[\5
MYHE-+L7M>66=M<Y0IV\P)^:\!]OE%;Y7QD95KOR#^@EULZ BSUF;]9*<U89\
M@CA>[/YZ"?EB[<T2F3Z^JX;1&.&[^=+\Z?1[Y:J):.71D;]YYSRMUX_'_/#T
M#STPKQWU@E,UQO9O,0@YEIMT$D3#M*J!J.LB7\/&(E_V5(="G3.N@/O0N\"\
MC@XY75G3@9@V'E?=(:.WFTE.P6*N3VE:AUJ-^GB[&8QN#S[0 APFC;?*>IJO
M:PLGE[!GAY:]*J_.ZBDE2AV4)UL/_3)GYOBNGI$W5LJGP9R9G/JY7.%3==57
MMV<F2WQ"=M!_!+/50D0K>K@_(><S03"H$X7^UWG"R%91SY@-#F( BY&4E$SP
M;,OZ^\I_*.:+# 8%W>9_(G#-.=5]-Q,^_]$E#EHF[* P1;P:3<7Z2KG@\?;@
M;=;1F/2Z%J3*T#='U7NH(3,:7+.H<&]C1Y;-DMHN.,.C[>1X'/JD<&SD]=75
M//H(=M7_VX2U5G]#?3*KH)$,7FI]V2%*U9<U^W/A5J/G/M]L.\,J<$H?8?K:
MPW/-[9_;"E4-=V;.5TP27CK&ENV;/506/_OJ6\BFVN]=\V7R55PP76C4HT[!
M9)F ]*P:R#\ =;FB$_R4$:'N -6;7#[=P.4C!J/- B6I?&VNC3'6=JU3F-AK
M!]'7PD;&135K^(G8BVHMMAT@38CK^QQJ<G7""O>XBLF?V'9B*I+7 IT]2P4#
M7Y3&LILIR$4@O95&WUNQR9*_>.K^(!#,!%3PM+$>Z>K+,N!C'6W+KV@H9>WF
M],YKC&\=N54LBO/V]+_OJ!].E6)7C\.6GZ\L1>=B%80IQZ@A$K+[[U?.B-NF
MWKX=VF6K9CUP\5,=2*_1U]$.IY'J%T3YZE--(O$8=:J>KOA%X9\15%)=$3;.
M^B]"CKRZC3C!-P7GY87B4X^*90.+%F.'L[T7[SS<;KZX+SB[$S@IA'P]9W4Q
M9&$7L%\NV:ZN>QQW-^S?&C5;?VK1_'"KZ2?Y6*>_[_>Z"]B*5JX>WPPT?CC\
M_]K0&H'<4QRIWV]EAOL(;2S19G+U-C%X0]+Z2V-SXXV- VP-W=.#U]=M.8OT
MO:\PO\<%]Y]N!8P%JBV.!CK-L ESY\1=VO2STF'PZ?@@1D1*9JF;U_3?UU92
ME;749MJ<+R@VS]$PN8X@J,W45'_X)U%Y,0ARSN>SV!42HV'%.&6P4T*_;-JK
M&[U(BCYIWVSN.JKN5@N9+!Z(K9M%,)G6*;.]Q]XIYBS[FF/WH9.<^%V)QFG3
MOHV*$I\VGBZ.V1>EG%PUB,[D9DX^:7VBL[JS^B'SZ/Q?0#1U5K<:<7@RZE_
MI4^AHDR_SZ/!CEOH3OUAH8$>JEK*6=)O@@?;WJ.G"NLGG5Z2XEDJ<.+$+3IM
MQ.US;GUPBNB.0KY54^R^A_O0-2X HW]8)&EHW6X2B,H^]82O)OR;L=4=?X%.
MEH)(6F?'2ZT&7WZY'^:ZM7*)DU0_KGQ/BS_N(! 7FW/#S^8WF/CJHQV(8G14
M,XB"1&)'&5TI7/E'Z #1P2XESOH@V2GSBK@:*B[TBEH6+""H>4\G8*1*:)=2
MLHXR%)?N.'D1;R_6]\7='^>&Z,&J 0VH2?L9)N%N-TF?"$W5XO>-FT%VI3"$
M"HS+"5-VQJ+7PU6*N@9N-@)==@%LCFYXG:-AAOC_,0Z$NEYUVDLVT%@'C[J)
M$N&);=GE@*5_^TW>H"H"7&"]$_R>(3OG::=HL8"%'XN@R7_EG'H HK^ W<ZK
MP0\/OZ%-L4\H#!XON/A>."=#X\/,O]$B!N[XQ2:Y8S<4Q0F"H,75Z/]0[KN3
MS0/""9A'SU,&<S.2/E"6HP#H5.*VZ2- [-18(%U443K(15O4U5/OXV^A"*#S
M@V;QTNVC_X8^&E[5D6#8NVWD'O27"K-UISW?-UZ4(&B18A!L[+H<%YO?TRX#
M;?0\*?RR_<)4=C #$T.,7U/[;I5 PN,U2HI$,@!8[4FY$W2]QQQB4.Q$R?+;
M#[SAOQ>,50M# EF*\ ^I4V@\(DAWW!GHY%$I ;NKDQ^_R0\R!CEWANMT,NP4
M'H(Q+S!4!80V9-DW"#VU+PN =U$L%'D$A(CZ4;%#Z> +CW#T";GNJEA,R!=D
M^^4U&SK&<1$#;?M$.V)N,8>4X".3&$U25U]ON"PL-'O/\-F7&A=[G7TC4H &
M?B5C$3."ZAMWRY"H NKC&QPE/[^FRVY'"[PFP@^;2NM42Z$//W!D@ YB>OQ@
M]LR@DT&9@<ONA>-O#Q?8@Y&NYE[@DW$%^(_?E 6T3S.#@W/4.X]R#W'_CECZ
M8GI^G'"S)A\<8YD6PQ#$\^@0:/^W6L:SC\KFP(8FB;0.6J[,BMY/1%^4=)CT
MLP1@]_'^@IUNVR\Y."W__'"T("AD2^R/LCV?YU%Q--)U:[5#A"9%2X$P8&*9
MS98=U)J([T(1!9?^ B(2*RRWALEV_J8]106W?:3E"SOM3!&AH"XFEIV9G!.@
M7P% F(&P757*7,H#YH<=O,J .\#6W6!T$WE;R]B+S2+;MCX3*-61C0W:&S(1
M)?*01E00)28 2MH[DZ3HNSMRWY'!5][$>/)DDA*V%3T()KI>U6$2W4"9-4ZZ
M+T8+\2693+H%P R*)2XB:+QQPC%1;.@/[O<J<VZ2_F $\*MM3-*[(B07)UH]
M4D%3D=H'LH^6:P<E?/E;=[AV19+UWV05@!X2!A2QB06'D.?#5#EX2&7.J*+]
MH83'N60D/@S)CV(S\= "!>"LHO%Y<%\D8:<57^ZBL+%$D9Q3']0(@EZ"95E&
M4VU#]H(7Q_*W-F#? O>*)#\6J8A0%$ DD)-[$AYG(JNVBMHBA3?[T,*.6VHW
M 4:/HC"M2T\B?/].K!C,7>S'+P]EA+(2'FA EI!7H:>AU:.$^(@AP!2]PB\T
MM"!CZ*JBQP5R=GP7I29593<D/*7<&HF* HJ?EP/.)-X#5!;@WQA(+#R^$?QB
M2WA1=SX_S=?N11[_!>PY&OP%@(6+CZCCKXM__ 5<D)3)Y/7)/+]V-LKK.?5P
M"\K.3]5Y6U18G>\0,Q7RIB%NM.9KP*=2UC3B6W:AR3'2-H%6!GX-T[,=O]:\
M/&&]B!US1T4]Q4%+MJV7XR7T=AHL.3T3VJ0Z)"&*8'E&LS(;]Y65[)//7>GO
M"97.;X'<U?GS0CWU<IMO']__ZB;[_"[XN:^MKC'PH2@_P#.U\@WR^U'I8BM.
MR)2L_O+;:?9-.MUUNR:\/LA-T'IB#ZU0GF/MS FG%KZZI95CK+DQB1K^'-KG
M:-*7GZ 2)5)\3E69]=1*S0:&J,51_PQ2I;&!^SW=OX P^OW<OX"6AO._@)\^
M][(>CQV.?P'?W=.>[2Y)0QN/ZP\AVR- ^XRS[5_VET+SZ-H&DD<JSIEK ITC
M>K6!'.\&-+T,F$>&5_48"C(8U5Y5H<<3H%5GL*L6X*)FI.KQRYKSS5%]?+S[
M"V"9^POXHO,7P#WP%7CO_B]\WF3^"WCB6JW'1-0S(A3+]YB_!QA/J1O[A!F
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M%/\.=E3"CS+46]O;C MD.->YZ"H>P^S/_ $S.;OVKVD'L(JOA@X%[6+W,<D
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M?ZM#;DSUWPE@]6<=*OZ- *B_#F?PNQ!L?Q?":/^V^)O?CUFP[W_"K!?ZYA?
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MVLBSW-.6IW%6%#8L5E9>%MM9.&(O/)/J<30J*^ X]"]V+KQL9KVR@\^&^D)
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M:Y=-=\N6"J?O8^C_QTH#)W+_>_FWZ_[D!VHO7BDWOX^GZHUU>G:LS<.9C ?
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MEHAZS_^16_]5.]2+PHN.PB46IV6//IK-.4Y&*+;&/'QL2S+PZ?B(K 81TJB
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MW;XA?#@1S0/DUR%$?+FD?:.S;F.F7?AW8;/U^?OFXKE&X7&I_ K%U^?:-03
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M>AE!QJ''O;(^JJ[!V<\97G+K_\F-QL?FJ0OI=3'NF:T19.=JGY9K$]>A6$;
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M9UGJ>3I2<L%O!UHP?'*^K$QJ'17E-])$4F_K:E,42S7;TV_C55L4PG%F$)1
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M-W1C74V4>%',[^K%*#*,AE8B9N(4CFSB08KO#%PQ2X%*K=M#$6>1B[GMYP2
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MSFDI?*B4=O-)4/][#/F!4^[$B_K^A>(JCXSP6^;RSZG5[U2_/)H]C;MPDR
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MXO5,B?'&2J06IIG@R,$I&>-'H8_B-*Q@;N-MTJ?2 #S[;_/"._,D1(&5ID(
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M=@(&*B[=7^][\AV[+X$*X.88&Y37JQOGC X=7/0+'1[2UJ'.'8L+IL,_=V.
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MPBC^W]J^HZ@O ; #9QB.VY\'"T'G8=ETR<[33F"_?0ISJP^P^T+"FK;KUE<
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M ZM9KLRJWZ+313^X(>Q9[,5& 98C[&^]%ILPRTAY7R'I!MIIBC$9OQ**V$O
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M/*WO?J(_4!OTC=>DYA1A,[:+Y4)LR\W;I6\Z5NMW6]"E#6OE$TB1X!,JH#4
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M"A=_C)BV%S_CO\6U=@5(C;:@=1BB32>'(>1J\S&A+<.+6]6/UC;S$E\&2_4
M8P#7&MC^M>:R]84+414FZT#F)-=X5X $N/1$Z>^+7B')AA53I;<J<++4X#*<
M4 C^C7AOF$./WO &%Y3@\+-8>"RNN,3EHU#HEK/%YW3(+01Z#B)OE)!UI8-W
MJ=)LU;E,2ZP(]C[<]:B*-/UY!?!F X=P;-$7BNEM-!366]HSXU9*0\%Q/ZAP
MU*CC;TUV5<&YTH]<FC@4QM>WB  ^ TMI(:*+D7N9B>GQ0TH]3PU^U?S""QJT
M ,DK@!?P-PI.R8_N5FRS8^MM+#N<X#^/CP7L\3+]UU['Q M)6,_T#]A4+&Y<
M]_PAWE&NPJ-A!Z_A^,7Y!#GGU!ZO^ /W_D"N!XNPWRJJEY24[[&.*(&]#'%)
MUC&N!1CW \HY]4 ==I;"@#EGZ:,6R=S&,OS,]]N:A*;$Z<7+K(2>% B*_S8S
MV,!L./V^B-CTFT(V1YXZS=S5_44U-WNOKSKL/&&^\8;BI<U&82P9U&\/N4LM
M2I7,?S:4S)IM.WW<2UO,;A*Q0!ER,Y[]DXDZ!3OA;Q( )DWYDYX-U6O(? R"
MYF2)5^!D_M\IE/^;HW@&B?]D;0Y=;B:Q:N(=81ESHQ!3G*<HB$9#S(T.>^#)
MV+>H[HY4BA3YI)%]3NDS^]U/9<B)T#=8Z-&CI@H\QGDV*FZPS$@DWLBCTU 5
MYK+*DIUW>0"]Y%"!A>,$:J*R,!$[A%< \9,,[#BAT>L%J,>+<?W&D^B\>3X1
M+HD?(I>R\@X(!Y"NX+8=4#FX;DU,>!P7Z"_>OO0HI\!0NKCXK#[9 )G(;3[7
M.DC#.^>-JMP^=?^Y,#UDY1BPE"H8(2-!JV,<VS.>3J1& 0"T$%8Z-8EC(G,P
M/*IQ+^/FK$N::RNTUB62KP!US4.5^"QK^=;#5\ .ZO,WW2XS@R/V.!0P"!,%
M[FK\>@)#+?0(@.ZJ?.O%1=HJ[/#JX[SEEVRZBW8%5&F@&?>C*KNR\@>5^?8Z
M5K^<$_1*^FM/G5/%VB$N2?H4*\"UE6%RQ#2<WJ6G;"P7*8 1>!J.&UK=,4/=
M09GPLK;I9W7$C##2^&:$2]^]0,$J4M-FI?-KR9Q\JK0QEJ,*0YINU\$MP\#^
M/&1:U$!IY$ IN9SX?OFM]L629QAMO@R,BQ%ZH69Y\K&]>>KS4VKG]7=WG=_.
MH@=%STG."W&WKP!DR3Z+&'G^V&<E5X!2^;0A.YMV,BTTIUI'7%?C'0H A$"*
MPO46W6+[S*VD!%ME69O;4<_<3.=C:T4@T9Z?NR% PVU!*J^%[X2J7/$5'G?2
M^VB&'OAO.;JDG9;_GH+CLWVJ#4/F">PS+P=^[TTN-K.93JD'H1D:-R%A\(PF
M,DS66[1*[ ]]&Z'<+9T23?6()[M$+E'LU^J]X60;U%-@R_KAH]GP\K2G>@KS
MY=OQS[2+;7=MWQT4<V54QU[$R=WV>^XOGK \U3;[W7T%$R0=)K$W9Z!'&"0(
M)&O>-0T46S)-;7J6A8GM2"5I3N3D+G$]*P]/CQ-FN\PVB<+1PLN>Y)PDYEG;
M5.':)G>=HE1)>O@P>$^>JQJ-$X"><,UG"IU.3KN<K_@ESN+S:Z-P\1?+KV2V
MA80^)QWHV2L:@#[%% G3T+_YV+U=U:@"(L8X3U3K86!*P8VFY=&J&QP&FNK/
M?P2KMP",20#M?SL!??(OVP,;^) H^/_-L4,BFHGW815[XM*(65.GZRN]+E:W
M^[)2BR+GF++)I8?L4UW2H8L="[<MJL?<B.V09!ZS2@$)$C@M!G#N+=_@-SP5
M$FQO1,;YZSG*MYWLXV&\EH1KO3A!S(SE2<YN!?!B9/81#+TSE8N]-W4\X-RG
M[6NMUQ>TULTB=*]@IB60I& SH((!M*^=K@<UE2HSGJQC2B8D_/BN(EH%1J#;
M^/_R.HA_#L)_LX_Z=S[WS%.$:F E_47D=B-U?VUM8BX>M_'.[2BR$:!$V')<
MZU02S3(V':WJ7"5?90.*G/;,9XC9"N^JLIRFDU:HRP(HO\.M;MN<$YTD..%^
M;%%%I>W%"SNT+.$HL][6[=7G85P4TEZ/K]^>[1 [-IU^X\$VZB_)7QNXK33.
MS<4Z?ZN?'*5$T I,-,%V>C6W\)#3-WH=&B5#W-ZGOF0Y3>QF\:6&G [#^:<$
MQ&+O85(/U6Z_\]X.["4A^ZB#>..5&K305()B"WG=9GB[;!0E.8S_?A.L1C77
M<;?T#A&AJ.C9$%([%E+E!L';Y::+Z?LKP"9Y7K@Y8U/DV'::M)%,']T :<=%
M8%VBF$Y!ZQ'S1]].)[:E??]>EHVW;,VS>->\O'&G!7L397[&BC;8,7IB']+#
MN^4E'K1Y*C_Q(ZT;0D3/*.NC;DI]+C!"[$[AV^LM-!*Z);&]L,/)Y5I_D],V
M0\?.;EB>PF;DC>OYY2LAC3';XVA!I.KX_;>[W+>S2TN9'<]CI$\9\*:ROE0=
MT_SS.':'],PI;[%Y[VWL[7XH.,A1LN84[O)7E6^_ @2++?$-G5#C5%2O )U3
M1DYYLP:;&IO5-T=U7Q%4Q]')L7XL&26U<%?8_W8Q#.QT_Y=-]T9]<=A-<6*&
MR(>6.F;W@TYJSV,QC!Z,4'X"A#+Z9'G(L"EP73ED7T4OF6I!03\[D+?;2J3'
M7O+3%> VUKN\882[F+_XT:I]7G367?VRX%CFZTOW$G:[CTH6M?'(?<#0XLOF
M@ 7'M_*W/:;@TZ$G$(*W@E<  G%FLHR5-,T:HSUE40!L_Q/P.!U$C+((L<=J
M+WM+",X\'/D,<L0L"P><A6.%F;(#C$PG#4,1 \SM[N9C\C\C1A\ZS]YX&UO(
MMY)64*P$X!B4Y(?&;[<O@()MN=]7-]35R2H^M"OZT2QR__)Y;%<C4\&6KE9:
MD:Y ;HX9T7R]6\Q[LF=;SX;QDA@25>V&WWLK4VI-->GE#SX8^=2UOJ4=BW4O
ML8944%5*%,J;9.OJ*K4SV=1^=JBA(83HQUKO[^. F*?'TYG5#65#-MY! 4<+
M=(6S/C=0'^[:QQNHK%CL]8G^Z<?/YR<X7$V,@2\/>/=6*\(KZ6M)2[<4V9),
M?WLEC#95H6"A#U!IP3L5T"]BSY.3I"2QH4D.N5[>[_)&Q(6RH/9SK5F;P[K,
MOLM!G(O[?"NX1Y66A*L\448'FF[_.,&0R0PWQ("N "SH/XW21I=$'-F3?G08
MY0ZZHIG4O.RSTX3=0Y:+EX7UUL$,' 3#!*.51V#R34.:L>B06)L3F]<//N9]
M&3ID>+\:+A$,4$/OQ7(W+AF8JE2K/O6TZY/Y/CT>JB;1J\:Q8B=YOJXPP04O
M_MI76YEH%A4W\FGEO1\CQ^ZO97%Y5%I;*FM#_,GRI)Y>K<K[E-%7P4,%URF'
MFIYZ#P,?(U2CQS"1':+FT=S!#" WML\LV\XZA('.U Z,$J]<TZC$[[%%B3\M
M?I]1R7%M=!:./;KNTYOVVE^^AB*5"2.!B"6WKCI/+%\<<+.?15JM72<\TJ1<
M' 9VX1C13.5+T=#Y::K -?%.\7L/VJ,.8AJ8LGY'',^JSC#UMS3;#;.]+1U*
M$#:3Q/K+CS:".PROH:8B]/HG^'L6D#07,N^[V9;[IM #SK=0I&VON-$>A3_6
MQ:ZCD9NGS\Z'@1)"N\0L4TEH74NGV9;1_*2WZ]S/W]OC@PU28L [Q]'+HG61
MR*J,,_2E32UU1EWB-]BB^&.LK(=U!L43?PHR@"@)0/=/@1R5@[EPLH ;2;OD
MM'OD<?5'.K!P:TC3F%9\6Q$"*YT:5K997P& 6-K"_D-&D:)5ER0;$3)3W-FJ
M_!([81@:U%TO-G!W:TQIU%YK"SK#Q]K'KG/ JT(@(CD'4SJ WX":[W?BT<:8
M7287K>,I*(8Y#/PEK3U@2X%R;_+?M;"2TQ>HM3A$_3.KK-^R5G=$[((XNR>^
M'*B.#]_(^=];'1LX$DQ.$90<O!/9!Z[\7;#P4Z%+*-(#\KAU:5VXVX\O91@-
MZ[XE;S2Z.N9:3Y#;_G0GR93[C%95C1R@?[3GE[BUB K >'0NW!W1T_QYR['J
M-E%->(3"C=8N>?4=9XY'LTN0H*6T_OA7*@B7-&Z]8-*CLS?@27_Q%RVI9 WH
MO+"'Y>$&G,,A=37==_*<TO:9_&$!\)*,0 YOZ"Y"*DXNX Y0*MT8]*O02E<N
M+5.'-2;9BK*XS#5&H&6HX%ARK608^,OHGCC0;0GOFUYQ\I9;47,;SI@9)3X;
M2O*]N;O%Z^M4C?\I>B8O] CCNJO1;ZWU,U\A^U!0*4+TFN,+ @S8Z_SIWN ,
M;E)9KP]:PK5" \V1^M4^1W>XJ[P4&N2P:O4P\*"CM)>J'"49T/[.7V3Z"F#I
M310KB /7>AS%(]3\C.FV)6FA.&2W^WGV9ZWA646K)T0Q#U7N!'0I;CD7;QX5
M;3OXXT ! 7@!K%@()R'D$0?Y)5-2J-Q0!#15@EXE8EC1?Z?6W,>U[Z[B]K84
M#>Q> ^45@#@ON%]PZ9;<<'*Q(M*IFUW5N/WX6I-^]#&$?%MI>_WWEJ"S![VA
M(%-7T^\BT&T,3_O"8_5+>*ZLN+^).:WBG_YF1QCY)X(57>U=4@_*LNX?&TYS
M2C?()@_/O)N76,#K>KC;F"%(!-;&+.O[(WH./7^DTY>>BT JAB7RA41G5?^F
M.YXOBLY_</LM#WZY5$N;K,9"4-5MJ?2-$>>#G0L'S%_64LW?Y8V3)V/9";_^
MZ8Q[\:<S[AOL_(GN(2BP^>!U$63[T^(YY]0([CYJ,F[YZ\T=MZ^JE7KR[,FO
M^UW;_:5$-$!RD._FEFGD/FR(>0T)9:71IB$/&K.WDB,<2W>"VOD803D -P'4
M@.^ /@_V\2(!;!AX!6#[1S0FS$%U8R.\A"ZAK7B?.-F0=Q+VYPC?'Y(_<YRB
MX8"-W:W$;,&JS3(:4QVD?D(P(>#]X;"6:E@#<P:F3 QZ7 ^NY*HU#_,L^:K8
MY;=-=L1H2=CVU_,BC>U=J=1!74S4=:-F)@PQA*V/P5LK8-=+T:"=5_((O*E!
M+=JF#HPL9RRF[=^'M0VM]YP]EV8FZW!3/]-6E )3;'D9YB$:37;VTY-&3^9;
M 2AI8,CK.:\[AEGI/G[C.[;(ZDG^FN,;TM6[=_I6Q;Q_MEZ_Y#-<+,&8RJ*Y
M:H)TQC+J-2^*D.1I>S];P0$E=,@EH0^/$ER=MQS)UFT]2.3'UC0L"4&O,&A!
M^++!,Y5(V8C1R;4MX?=);_NC" 6?\@(8Y8N]#1R]5%OW@5;4?'/%45//9%KC
M2MC,6X'WEXS!'=J>_[VW:/P/#B8)M .BJW1YZ,YF]3E7@[TNX:V^AA\!@E5O
MOAVXU,00;.HN # O3! B"1KC.<J7FIYRI!?YH!]!XU> "AB 8W3COW"QRO^_
MQLT28[VO;XW?_2K+>/YFR5].6+(2?5P=A'U1:'.J:_8]>&!^7 A$-DHDIIGX
M4YEOR67+9L>:G= ?XX :G6T5+'9SW70I>EG__A,HB16W#'N]4'_^/_W]UP=L
MV*O-WOZZ0\_;<RN&F"D9'H-57K:#=<R$V]D?O%V+CN 4GBG]MN2?Y0_3O7CT
MT_4*0 1U>#EA,<'%'^G6E**5G&=L$%3:RU'SO>'\G;]X-X*Z;3N2]$N#,ESJ
M7;*<[:Z^SR]5;(73[W/R>5^.V?^NW>]_P$/_IPU\5X"'J=%7 $->V$:I;L7_
M>9OXMT-#K.@/4]J;]Z7" *_A:R.&RLO-,7@0QYF40ME\\FW+T<)\%B#978BC
M85IK6#Y%>D27?*L02JHR3J4B?7\?MNB=3[A%Q[%::!1M*!Q0_BB+J&=H/FF2
M%X(>YIC!46-F-=!=T1Z>^6_U9K]ZRCQ4(+7[B&0+^F;*,7>\*\4X\>]]$N5R
M,Y4D^[8?(_KF"+^0\FL*I4-]?J6=_CE_PFN\-\0\3DJ^(GAB>1ILLA=R<\-/
M9JFE1KOJ92+.6KM-#[XA9_PE[OZ':O68&'!7!; O12HK2]1!S6ZX8+FJII04
M'020MQ<;KP"H&Q*B0<NG8157 &I#*R^6D>G9MXJKSV@T9[3 WF(!+4.$3,D#
M7K!V(^H!I"KQHRPWDFXWB@$'P=9@<S7R);'WO%@7*4;?_^/+^D>. YC/W:D,
MJ)3="8'K>E'O]62$?L&6F//&E[2_+^"&SWWL96-#]_+T418U.N%@*3I_B<P(
MM+(1'E[-7O*T)W34;E,.?T2B->'R*%CT41K]VR&7G,C$ QK. G%OI81OSL3
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MWM747AP9'&4BA9[(':8V">E%1O7VGJ#11Y;4LE!^ILU U"+FMJ!:LQ8\LT.
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M.CN)\!&[!BY^+B("7YLP9<#2L6))I>!C%-CUL8XP]O)U\\?:8E9L8QXT$XR
M7@H2/1=>9RD>,FJ_R((F'KHEP+GFZVN3,=E^6>*ZKNB96MS^1D\?<^P'?2?%
MMMQ@C4^D8:@+AAU5%Z9!<Z3B2R1G81]M&;2G!#$X V&:5$K2SPR4L>(_Z,/(
M)\'WRHDM'CMC0)GL?@R7^+I1SM+$RN,4C/M]7]QCB9 [@7O=,$'N'O'.MV5C
MG$H?Z[9YZWZ1'7H]P'+_R--V#E!W4T=UUJP.NN_K.%^L0%"T8RA]]RH:X33
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M[\+.^9'\0\K2,5$24&=X%1.J*MU@NE:Z8SX]8<E1:5]"2+#_+9;+I\0>PVB
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M(DL4-R?!N-C4=I\Q'D62*94CE0YL:"1^=Z,6\;$M<CM7PO!;K@141<J!Y+C
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M.ZJMIZ<E9EU[FKLZTFNC.Z7U;\9;%LZ0%=;KZMC<B(J/'T^<S6B0G!!S$&I
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M_>74.JOM;O6XT20UI<\NYM$!2 OG&K0C(7VL(E]5YE>53W\#FB?!H*8XN"M
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MV!PIM#].>9X((2@1AU.DCY/8^L/(0/Z)S?O3BG7@04%OIFBM+JZX9\SP(0B
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MM<+;]@)YTR$+RV5JPJG@*]..[GNY<>@":\9#JF#7+Q,\A6?RS!5UO?D5O_*
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M6)/QCMUYGYEE3ENZ%$!_=/4G'F+T*^ZR,J8CLLZ?*8GQ^^@YP'NHT[1SXK$
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M5"-DMO\([&!(!B+,8NPA!/\,%Q?6\ 9?#.^I^\ A !#Y&/_&9K1'WD#J+6^
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MA/?65Z( /BGVNGIW:KEJC\D-?@,BB!=/F6GLK8@/6'D35N<9_6EFKXLM:)[
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MH >J)B.;)IQ3[#RB5B-C;7O+@UB._4"\0_B1L6PLTA@TU>@Q,'?'C?59 +.
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M)U#V@[/%\S[B!!B:( TIZLARRU@ VY6TG"81%-&;>^@<.X4P=\>UM)+2$/[
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M38;+DQ?M2\)S3JS>HGC6@,MQ-Y_M#7NBXM;'M,C5T<$3/=-4EJ-#U3"\%RC
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M?-&V;I9?0^B,!3C7!$IY,[H6^E:\Z? !C:AIAJFVCQ]SG/S96) ,MRD4/6F
M<,]I/[#Z'V'T$\99/9M*IH!FWQ"\L+O8/[U6X8+^^<D9KO._-S(4K[\$H/]
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MY$,U*GRDDLD2Z'<JR4PY/5=!LWDKU.2.'@67ND?9OPG_KBLIVJ>5E!X#U,?
MSN-7OOX+_GD]!Y)T8CU[#[[UN;[A[L1(X5U:?-93YXCKGG3,!F6!9K?03FV%
M[=4\5H\"KY"/_Y-"S#H[CI\(/HNPL2F=R(6/:9)14B(])M0 69?"-NJ5@OR,
M:,!&:XT%.@O[U51>4&S6+#SQV\V[7-BJ%+ZXZU\!W]T6;K911$8+D]>TO?JP
M*.^#$AZ;,'D-F:")L]<[U-H\?="E><MR3VK"\CPYZ\O41-9]#L@F,E2@UQ$=
M6&2$ E]^EZLU9=OB&Y8R&:/&U!@O>I"0)DIOP?Q1?(%CJO"%6#A<;D'UJ@.+
MKTV2,K.?"0H223+,AXF%4O94WU2\#]!D'H2>0@<3N;.T<X@,:TD%)IZL,2M@
MTD] Z @AL*SNC0D,H'/TJ9\WGN*K3.S05:MJNFSD<%@ZK%D@JY2>O3SZ+H[:
MX$J"@:1^?I3$!7J ?"!0P64GK-1!TND\25"8LO5YTH]Z%>Y]L;H\+";"&M\1
MY[%VZ\>7L;"K=QH9GED90X)XCA@) E%^\K!9%+W%\JZ=XYT&_L!'[7/)UMN0
MEYVH9 6=F5AD<V6B6OZHSGR!O+.-:K\L@>X0?#%0"1VU,@6[7Q.%F)I,122;
M,PKCTE^B7BM)(MJ[6X]XRCX/VIJL2<Y[_AQ:L-3@\QJ<H/MP?3I] @-Z[Y#6
M_FFV]W997>W$Z!;6R#J];BX(]]6'*Q?O:]A_Q/WZA^CE.HQM=<QAVO#M]RP?
MO[.8K]_@$\AL[*BBU MJV#*X>')EF""?H_)@2^(A4YR8[8P(HUWF?:9<F'/?
MK5C)G4\:T5OS;AIR,0%2VTXGXFQVV7*ZW6=>?#=)_PTW<DI&:ENFB=-H9!<[
M7!QC4%!5FOA@(1XB,;$Z,]<7AEN%11";\..&_F[(<\LCGRS&)[ EUJ$Z"G>H
MSCAQ),OV<M+[&L?E5U=67<U,$3SZ<??YM)XIE7\35/ O([CP+R/X'*<OM GA
MS$N$ S5Q]Q)*+CVYE7/^-.ZKMW&;RQEBR%UB<N'DZ++IV^&R]#M=F64)_:4T
MY&'DH.>:6.6XWM^S0(7$QT JB?Z0VY@L5?5:=N_.U>(OW.]5N/&\IM!39;%Z
M6GT$>X*BW'K7U(()TR)5S,?Q(2IRJ1^8':::]QF*L:O"4F7+-HG2RR=W87H9
MV1:\!<G0@86P?5]AIHC6I#H3+,\')U$;$HU'^O08>TXKG.<OU<I*Z/]4!%:E
M7A%>1+&26#&2\@7.D@_XA[8'M%7.3DK:]*<6^AM#5,P]2VIGX\&\I15#GA:*
M])K//]59<=NNVI-/'DD3T>.W\'5IM S"CFQAC EW;KN>.BTP*-M(Z-I&G<)_
M"X=$*FC;Y(P7,E6]$$X@G1Y^C6>50M["PZ,53/PLI^_45WF;B7L^9354*EK#
M[&'ZIND#V$T17/UYKT9P1F^]NF6YA<1W&13K]0S7!@+E7ZC'2=TDNZ\,T#>C
M97^/H!]<1NMM(I_YZ;K/6?@@%.0+=6AK8ELZ^+T,KM6\8@FF-C^KZ0/L9 0=
M UNZF2<S_@KYUD?Q*03D<3!Y'4N2'@M]VY8S.VOPL"HRV^KTS$P@#)T)3@BX
M?'(8:F,:<"?BD]>RZR_B$7Y"/*QO0+;OW5^$GE,0G)6?CF ;_OH^Z,.$69?K
MBQ3A&YP/K-RH6:16C@'R[7JUDRMBGBTY=/C%U_S:(KA$V1/C[IA'5, <S\^3
M^1O\OYK-PDL;8^Q':FGBA[Z0HV?"RVQXE[%3[>M+QOT+P2/>-CIPVA^L5@T2
M*^K HX#>DZ$K09&CU_0.V1G]>:%G.T07,Y26<]+'GM@(M;$S6EG@Y-)>JK<=
MCB5]<?&F"GA!1A"(#KB,@#>G#)P6YZMK(#]MYXQ]67EP\VD(CD@.%4>$6]9O
M2E=[%CK2LWF/RW)[,F?>7:5\XL!-YP<MEHOVIU_A=]F#N:%O!>%2VI&TF$\(
M]IGBN" %T[A:29]0TB-)5Y[#'DU,NOG!&[#S-IEXDPN%#G;MO(6-_K,.9/Z5
MT1B)?K4A\N4'6YH?=TNB9\.J#T/P!_>J-,<5-@_3N"UZFSJJ+#KP)<UU-G.Y
MZ-HBG5P''\N$_"FSFVRSQA7EB>I3 ?=9]364Z3H.[I%A:Y1>BY46FSA\7.JI
M><MK[C6A_-6_P,F%,;=(NJ]D-$N%3?S=7Q5I2S.[P5*(.D^NK$('YI&G)JI;
MV19F==8YD"OD3UEE'R)I]L4":?9"YIPC#Y/G]IS[I5OR6RO).67BDQON9A 9
M_2&6T,W:YEW3W;"B]6W<C1+4D[S&..KNZMAV=L#-FP8I!\PC[2;A74,$12K-
M/;L8\V;P;FH8^40PF$15;_BW(MB]W28?\2C2C3E.\?M*;",ILG:G#'=.(X<K
MOQP#+8<#L&5DA'0E,QH8*2ZV2O&>KQ!*N!GZ*DX3H-<%_/RA[L;MT_]H3*VF
M 3-'$C^08QETY>>9/5)"Q0SC7M]A.0:F+Q4NBG+K^PN8?1PRO%3LS/>2;!I&
M'C^ [O\G?C1:K0;/';56LEAYPA[<C9*^)"3YG6RR"OIK)WO,EPTXH!(T0!C8
MOY1TNV)KW1?2*;F_$,"AAY0)+,LGR,N_UNFV1_?R&U^5='JV=P\;J)!O"?N0
M>0K]D+CPBSY ]PG1>VS[7FA'XK2UMWCK:8&X ?BS\9L*;3')O8J;4<!RP__$
M@C'5YR\P\0-4VHJ%LU?$-CQV72G;VCZG<VBL/CMT-5+#F=9$M$"G8O#5WC?V
MW=>4N;41F-FI<.QK;>O!==ZA<E5J+6NG+E:"%X?K,GW 6]@BK+;PJ\V]E$6O
MQ-FM%8,>UQ2XS:B_K['A.Y+09ESEQ6<#E\HB""F[NT(0\I_<C6P[)]20=&F
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MHZ!_3=&QXLG4DG3\9_ $1.R/E@!^02!$! P!2H@)BP(EH,)V0 &0!$247T1
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MV#B_O+8?0$"(?P87CP@'"YOX2$#I^-7]V-A8.#C8./@X> 2X.'C8.+CX6 0
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M+%2.=E:O2:H^NK_??P@T4F,<.2O.JSF*73,)>K,%Y(EU"+ T)5XF>RG5B8T
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ML-H-LPAI83 3JX"Y4Q5V7(&Y>3BEW8]-Q89K70KPD%E2Y+5UB&(F8?K!M'M
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MNI;6@?C CV=BKI!]TZLLH.,"791^K(:?N.(G"+DW9"6HQB9->5(!:Y*.,2M
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MWBNB15O.-CW4C/WEM1B_1CR?TK<2Q+F%TH78F"$(=Q>J;^X?@NL 84^2MJB
MM8:#T.33Y9TO=->[()DAE%+E1RH_6C$UC%R'=<;UFQ,F@M*4_L(=DXSF/$M0
M2&03OV5<)]Q?/OL>J.7%3@I<_A)ZWMK V5(G\_>8_>EV9'IV<IX/3% ,/MYN
M>9F%]E$(7<^2(3S,"FS.PU!>"SCL/K<1'/H8EG9'-.?LXE*.N*<>=MM(@!-S
MC@>:C]$ ;JG' P'7WIZMH=?BW [R3LN<+B[Q&HH'*3<6?9>SP8+[4_GVMV>A
M"IKBC_=WEP_N8B_/+QU/S]/#?G G^XVA((2&(POAGPZ^:,N-)0J!:2V5%SJ4
M7/YFN.%["[ LYJOPTX(Y]K!*\(S.N;3A)5/ =X&*'C88R\2&Z>F)Z63ER%=@
MRQ4N+=<R3&/'OQ1OO_'*AQ__C_1[Q#/1H2[Q6&WJ<'+54RS?O?6)9N870$M-
M/N.W(4JJ6;GN)1SR_Q+O?DHZ2SO=$YE/J-W!7/P<WGDGX)7*JSNOPWOFSS>7
M;Q:!H]IL 2P:3,'Q13L40Y*2=?Q$['J8*^[S";,ZG(^^O%_F4IKS1^\:8Y?7
MR.ZI2]XL['.@6_6JE'R2-:7]HE=5<3/F.8I7^S+K&@\N>N#:#X*+H>C)^8.Y
M?)R;I ,@2!\_CN/ 4UTK[YMX=_0M$I14%P@Z"&.(6>'H_&+EQ.H\ZC27ND;1
M/]\/F )R3+/C*%\.S$?-T8U1QH7]$4&NR+!&7D%LH$&+0L.*^I6NZ2+&V@NG
M K&%M=5ZH]NZX4?0^.L;G7DGT<84B> LLWT_G:/1V$D:4N0N??U83IR2T60Q
M/JAO=I=CP!C8!!*C_?+%F5392L]LL0*/Y)%59V!*$B?G&UH/!<]A"C-[NXH2
MN)5&SLFY/>,RWY]9S37\'_O=8[!>C_1J$5YK*-N0,I1J/!Y(;-E5!(@^S,:6
M"\X>$\T^7>(>\AC:8M.K9YSJ1:'Q7AV*]PI)<Q=_*L_WTE/#JW=PHE;6A0C-
M?C\>X<T?Q68]F=F\!556>;5>=?Q^595>!'[7PQ4>-'4D;6=!<K\0GP4:]>$&
M6QN6(4RU'2]E!?5EF) P<K%\JFPJYIK21[/#<:*TK2.LE>X(%Z9;4DB48RMF
M*[09X?A8ZJ>-EQ+IJ,%=IQ2N8M@_Z>S)_-,XB<)2ES2(-[YU#Z]$K=G$I/+9
M($)Y=>WF1EGU@[G.9Z,3@-[[Q$A^M-(2;2VOZR]S[!GS*7@9E8W6#9G<*U_1
M17.$%QSN:5$S(_Y1I?ZJ;(X8'XE&^R5E,EH NK)]J.+*($V1)F756M0BJ^X*
MM0*+#$C?73LK;*#%"RW\ ,R-U6U9>3"F/-4217+'VR#Y]*R!I4YELU6?[D U
MH5:W3'7(2]+?P$&?IT0;\^UZ6L'1YQ>;U0 *AF)\.PT5W^^O&R^1;@<TEMG*
MTB>J;V2HT[ R/O#R-S0+N<'PU9:J'W?T 1/K+IAC1#%P\QI[XQ-:D4V6TLIV
M&0/BA#UZIP_7WE'YV<$S#_J9@B[F=WHKT'5I8?^[CLK4!I0QE$3,I".#0S.S
MHZHR:P9^S6+OH@,MHW[2YPDV )K/'X7]I)V'S$OA-.U- R>R:>L> %B!=JD(
M'UYR5+5&K4XA(FDV. -9Q1M)$>W/K?6'HJWH=M:(G!$M8AOQ&1_Z5JC]%E@O
MG38&< @" OHV!X8;L/H' W?Z[I&O9WDWJVK//OVP7>(A62O3X<L:@S%]B9\/
M"\"GC1=U&XK[](_I4QH$I];8DDM_7OP<C_/<WXZGM++#Q*..JJ6JPG;#KT&7
M,I<)L!B8@N:K$'4\Z=F9BW-M<32W M%S8T"#O+0\0\9# 3'& U&_UW*'PA ?
MQ0K< _)46@>@.V?5]JY<EPVGUASC<4J:-<?/*MCR'F[[*>,(?9<,,WJ38_]V
M.98!^ZYUN&H5*U.7&#W_YM7?$*N/;)B\G5#NE<YU/XKO9*:V?S@EI&9Q,**1
M:H&F-,>D;N:9UFK%>J(7AN@Z4?CK[I2;ZY'6=9A^+ J<O+2*K<W$]N=F@9H^
MI:[[Q7;Y'94D]CAJ4>C*V27&B@NDX^[,PVZJPILDXQZ@;MO:BN18DX=)/J&
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MG/D#7W+*F$=AF--/W8:QU9S U25KXR=J@%C!.13J%$1SGLYD40HH&%$!\ZU
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MQFMX)"RZU,>_<-T;(1>MW5]E2_7><AHRM2ZL&O[==CT)NCZ3R)H/N[<DQU-
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M%XYM.];GA]WBPS;F)W4YN92B9I=FF[SH> ^_[(4 E:S_1=E;!L7!=-VB$))
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M*"8 6G[KR^A=4-__,:!UWKA9D4J(H #P9.DN(4?RM;",@R11H;FM<&EX@/M
M2 OQ8LH@YO!P56OB*/<C5UDA#_YK^<TKJ5#2)D9@-QL]73J*6HY]F_<;N8/L
MF/*G1YAU?:8;L3MX!KTU$A2CXLXI5#NMU:COXXC?Y]RK!VHRA6JU#T6?&%H
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M\1H^+&IT;8!M&*]O/*]D_<[6=QV)+$+7_BP^_9*3>JBEMH^K/CUS.QZYJ=@
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MIXSC4%),7O(R*$]JB#!(94BO,IE 'J1:Q'4:+\LKW*8^'=&V2#C8)7!:='.
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M(9WRW^,CC]\.OT]Y%-6 D"]",[2ZM%7%W02R",W5C[(MF#]P&LJ)4%SQ:.7
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MFR(]**G+C0PH]$-0< ABR#CRG?T^2[U;[?>)M"=2PV@'\\W8KOX$%7O&+,Y
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MLK^]H7S8X@:1R+?T];%'XP0G^U7X7H=I0J_WPPL[O 5<G2$2G; E9!K_?/M
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M8$6FA841<KG==L? XO:&52I;QQN+ QJ(^M'7*MB8LV;7PF QPS\I'A2Q8)J
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M#,C]1MN#-,I1.=>SA;>L@Q:/B-ZE2YDULKLDHX@CJ4'B8GI<XD1PX?]L"EO
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M"PVFX8Z(6V9'25\#,.SV]L0!K#5 NEB2<U2QP8/.P=)^[HV#//'.6-"]OGS
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MPH[[-)58SKWU"/(:HE%X3H6A4.X1<..E 5EISS^!]V YB;"&#1L4_B[9JI;
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M856ER*.0XNR^#N4V*+CY4YA8B"<IO".*\.D<0"^[LL*7#.%P6Q(WYG*TDQW
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M@9KOM>R"\8H/MFK66CYR BUJAA!'XTER0*0,2] Y'+X%4<Q\PJ;K>QJ0#41
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M1,2ZS)<,WK9:TT]<'V'6K_!KZS[D? %\H57/MK[.[OS+S# TFW^%;.0^*')
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MRK/KY1-'Z:%[DB;5A8.A![!U6B;&,%J^;R\R-C1LG!SO%<>JC[;-,VM]]"B
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M6G;'41069"8?_1R_X/^.]P:5%6A7G#(5]P_X)7QWL[^_L=8/)"[C*'8I^&0
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ME5SE"\ ,,04LO7\\;H=^'EN]/XMTSEP@-7*\/_)S.E[X8%>Y=?:[+N\.(^)
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M^VU6D;7>%GJ/2 1\\5R>3KC /8NA%:>D:-R(O7^TS[ARM-N^#B'@><336S7
M#1LZY',! 5Y_(E1$B9AQHJV^;H(O9%?:U3_I-2L/\A>G;/3A0P5"F]L1-50'
M G-PJ7\P)UX_UZRA3_*],X#SDS/QXGY[?.+;(Y*TF=VN$GC7P7B?2D4[E*][
MQF9AO-HI0LN*V/20P$'S:\#Q-B*P17PE!)[#=<1SP:1> %W)'_Y:_]>UO&KY
M6RT?O_U2E6I7MD S4!\=7;C2OAL*H;-SWDKBY]WDVD$II<(C<Q0(&%CT]VS3
MKZ#RG"U*E,]I3D;GQ6R#-L:Y9Z87MNPNLC##O'NBQLI @U(SI:%ZS, T&L+W
M=AP/#9NZ'KLSWX[**LJF[98Z?V;[JK:$KET::K._0J%]%B-8]GM 21OXL\MS
M@</Y5BO1J?6)78[?UB/46'QYLY',(/W(OE/-3DHJ8$5T>0#)*,4]^(HU^,BE
MA<:\/.?@>;. [>/WD[9TQCF;*<K.Z_J;PQC"[0F#M@5T?<RI='+X8&\LGK,?
MPZER6K+(:T],:>(Z5QZ>D3[<%,N=:=MEMQH^ NUF3AT/O0/2X\\H@ H3*68
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MAA>I =;E@_,&.3<8L2WSAV$C4CL\T 9:JVK*6#"-;+\GN4BDY,Y'/Y6(>LJ
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MHH]5=FV^Z4'Q9<W2<BO\U7Q;/9YU[.81+I5@O463_'E;1[OJ]N%CC;>5K[R
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MFH[<A?!V/.J<:/RCDOIG*K+YX.'0EPD+CG(EAKJ!1Q'Z(Q5/&AX?2)2N>O7
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MK2,^/^)W?H3@XX+T*$'&">A1X^?6\307,Z#3Y_M_W+>JU>W3X]\=_",!)AA
M;RT5I&B  "$0KN,5URN'4KCS&QY&JID+Q%>1E24<F2"@_USN@_CCCM;.X4Z3
M]\[M#].L(Z@K94<GC9-YRFNS64WJFQW<5X*9NE"O7:T.K_W<+IZ Q@!0MT!I
M;]J@ '*<<,<1<6QL+4[?MT,75H"<JA/C(S<P\C6MS&;D&J_BY17R0I>8LX][
M/+GC8:BX@KBL$@LY0?T71O#V:=BCP[[8KGV7)Y0HI0;WE*+7R&8!DJ*VJ7:D
M,B/N^3SFD6FIGM4[U@LW*LUSH]3__V<^=3E,"15&^]>^VZOL?RO8[_PCB?PB
M=&34&I+?EXK$3D_XK]]GO]0Y_37<8+75TR4?UG=?^[ZPY .!N.8212<I8-]_
MB**8XO9/SHQ/5S1ZJNT99\7-P9@J^;7@#NOD)*"*GVN/&1CG=FPO,H+070'[
M3,<Q@7#0EG<G(W-/*W]E;@_T.\BO#Z!LE0[9B4F>&YC3ZFFN'GZP^\1=!"1I
M4&?M>RJ)7>&+H()["LM?VF-L(Q1X&==F4H4>9.HF)Q1<V"=9Q;OX;R:RZ7&^
MF0RE2/ETF3=0<$B=HN^'XC*H"6O [I_5KD$0 U4#]8'^=N"D0/-_) %+1O79
M]3;L'4%F+DHA? ;P</QLU>'WAF:O&7%@"K#:>O'LT&1R9PG(D-&6<Q\G7L._
MJRF6/456>>-<45D49M?9GR0D-IS"+,KH[N%R,IH7+S8=RE\2H'>1'6Y4/1[2
M.H,[/@N @562M;I#U]:R^R\5;9](0\1[5OX##R7-E"16MYZ30O>F6_[/J8]D
MT '!8%51/@'ER330*:,[D4%BJZ4&8'Z1.LJ33W_>^B(W@U)_G.4A2>'3@>$2
M$R5.+Z,M21GL4F!L05[S9[M&SL;$IY5@,QEIW[:$!;^Z_6YS;!Y4S0U@:T%L
M.4&LT6ZX4'<X< O"J1.*$E+R$H\M!IY9R7_10 &JSI%H[S;%ID,\2CF3N/IA
M>/*=,M'675E<)WD)*C7LZ99MJPYRRRXP?H S B0*4'=@I:/*[AK39V[?,Y9.
M=.7L='=WF3:0I9^>UG-W">7/^)]_CR,R=J;>D+ZI)ZU_P_2<A(2"A.3I?Z"(
MX@V_QL?SK[.#7OC9O"?.*L![+12:=Z$;CGSIH6]619[YV[P'.MR31BC91.B1
M,I\O+*VZQ<_VU :HY'J%&@G.'\!R>^5'QF>@CC9-  N'+J)*%W$^9FRL(_&-
M*$2K8F&@0#D5AHW]<=_XVK3@V-B]?+HQ4>G,O.?X\RAC813"KQ['W.S06W>"
M$O6.[R@PI>#'_($5ZN@1)#7V68HDU:MD;K"!K$ZS<UW&!<%K>PR9#32ET=\_
MG]Y.' R%!*_?9GCD!A/9\)>Z/>+ER"V]ZL%B43E\$%F,/NBQKB1\^6N_"!>N
M^W0PFS_T2.0J\P EY[(U8"#RJ%.9MQ?91AD[,=$S9-<:E*NPEGTL?FT\%9RN
M,+EY(O,+@&M,U1,06_.PC=1?O"<@[176*K*#D -^A-G2A$[W_6^/E1:]40<,
MEMM[6MSG:A[I76X,OJ=3_^O;)R19T@M:*=G=AJ4:-2%*NL$9([M!F=WD$G8Y
MHFO?'V&C,D-Q!D>@GUYD:7'%P=4#)V:55[*&A"6?8"=%HV#>.KM6,(IF?\DL
MJ&H:."I6'[&+TW_!N@ H<ZN4Y_H=LF F1LL+EC#FD&9 KG%GWT"PSR6S<-+B
MY>M&;Y?ABDOJ,EJ@T>?%0J#]\/A>8@?R;=J'J=R$UB@<=6-[ABS=4S)""A?7
MU<?%<K LG9)!295V\JJ,6 TBW+$U$,;4Z15<$Y*/?>EG]>#).."')4J)(-$T
MH)E]VR'Q'EG%?&9"<#69D]%;63\O44]#RMYT[Q_EP2W]@G)QT%L=F$Y)-[S*
M!]IV0/$Z#\[9.M\PZ1K:?E)?Y1+?5H:U>X(P. Q%663VR%/V*#506253F2=H
M-\S6C)*ZW!ZIXG7=ZV=3JA&ILZ\T;>**6D2]@OM)+A^_>6+IPWRG^9470RP"
M^(WIN$=]QA:5+N-VG75RX1&V99\#;)\L@+6GY(-T26=C]84PK0=?.V^>HUC<
MH%\/7>6MC95F0/@+NU^CF:@$UV,P*01Y6\CM>&&5DKSX]F\M4"=T4K"#4SYC
M-&YZ+0</?6?U.V#$&JO9QI5SP.3:BF/1.\X-+PGUY(HOBSF6RL0;QP@CWL]E
M,@2HU]'V4<M@AC#*O/1_FP3$E%WW/L3QEZ+=+::-+K.'TQ:4['T.)C W^A!$
M-KMA^(ZL_8N>'_9Y8 F'/9GY0->CIL]6!F@8<7 =8_#4A0@^[IA?&+JS+H*\
MS<):7P&8E&*^_VAA@>=M<>J&[[T69.2-=9\/X91E=AJ:[_"F$^J?[*E?-[!N
MV1P,/R<Q@MT1_N\TP__"F-[D8T6=GVK7:VM\J-.GEPD]I:#CH35^;9)T5A8N
M^^2UK_QDH]7^C0'5LHIRTWVBTS\2KQ2J6HW5BN;FW8(R<>F*K]:>:!L4]L8A
MANGPYL.1N<B'[#Y0I>[SW <+3U+^1TCN(J3#:-SH?+RC-\2!$2IP#20TA$*5
MU'*<:$56"WQD;=<:K89\J<29/<L?O[,+4M1_I\_91?\38Y/']OM$83%-;ARC
M:DJSMO38^N8C\@AXO%;VPFN@17]%F:,G'UT<S]P*J_!F>,+B<DAMG9]C1[8&
MVQR(H;,:(C!D^=QZ"0@ZSUH1J3HQ5-IBC4O_(VEW104*:.WVL8=WH]\[7.VN
M(0K46&]:\_B;P/](ZGOK^KDB#N?CVD0T=,L77%K3FG/*01[4<9>E_-^[M',9
M4WGYTN/G#WZ8&9U3!1,I= PQ9YW63L0<^ ]LC887GGN>37L%FYW0<&6QPK6+
M''V(,S*'MKF@ZZJ;R%.E%RRIZ'JU8N9G>:FB;P5P<<9CC_Z1V%T!!O =_4>&
M/K(D"0R/?-(Y*HP8<6O1_:@&$(?7S#('_#!8L*JQ>:A#2JFH47$4]:H-)"_1
M+T#.R?P:J &P*IWF#8+W$+@V8>D+[X.';3GKO>!>AQ:+FU5'#A/;;BMC-C3_
M;?&]OB%VV1D;8.]NI@C:##9Q&EL9DS#HU)3G/VWL$"S_J; C-NP9<?OZOLGS
MB$8=.GF+PQOHD7OIH5M#2U' T>B*VIJ\:%9,-6D39.-A^)V6CW%@ Y 9R+[@
M=V_CCQUMD5J%P3KG5O,"1\.)J/6)=49W,>;R<J?L?R2F+OW*52'T&4B+EEY%
MG_V6V7JF=A_E%S>N:FTGFB&TKFFDI,^>0\3=+"HLD8V\JNRDA5RV@0"SX0H)
M()O8^6* F1(XMN'9%$M'(O[0Q$#?_G AO!EZ?D,1^?JU1?V7\*/G&Q&(-&"
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MG0RNTW7][H82$'GZC^3VG[<RA>O7):L2"<<GH]X;HV[B&TJ"=8<;5%UT$DW
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MP<'Q7CBY>IROVN1.-$X;F08[*F+'MP+C8S7/^P\U58*1[4.DQSGMOLMWU;O
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M)]?54VGI>](.J#UL#Y*'K)7FR(1./[98Q7BO<*'6&K3GO@B(M]HG$OPV6HX
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M!+BX^+BX!-@8E_3]\-<$=_W:M>N8UV]@8M[ P\3$Q+OXP,3[)H+]KR@X>PO
M1CTW/@D!C@( CPV'@ UW-GX^4?2S)CB1<RN1X"[INQL1 '#PB$C(**AHZ-?@
M_M@)=WY-^-%Y P"'"(< CPB/A(*,BH2 P7'>B8V > <'B"2F8H)+X>##CHP7
MGEPD3DF%K]I@RL$)]>V50*&.4-N8VC1SY+J94OR(1C)2W5RJ,17&?:M/XPMH
MJ\3O7;_3]%=IVJBTQZ7130,SV^EES8.S.YH6SOXQK\M;AN9V>62T+%T"GF=4
MM [/[V$#X.'/K46\M D%&8GKTH0[0!S$<PL<*'"1V'W"\2XL:%#MW>"@,IV"
M^D9(J.&;.7)N4B-?&(!"P]78=VY$ZBUS*0UN&.C+3Q/^L06TOYEP-@+ 0+C$
MQ :( ';4(^2HZ:DBY.ZJ\Z^K"K&FFUMR):_GPNDI(:T[6A? O.SVCJ)WHG=2
ML0\24-CCFCX2+K&YQ@5#1D\*%+#?Y-96^G0_59KA>)*XQUNGA) P[+ZFI=A9
M.#_6671=1]Y3<;LN^0Q@WI9/_^E09&BQ O3R#/!"]PR@(=*"6U"6()(?4SX<
M-N+X\+I-X"'73-&;CMR349U#VC- @[??7*)%3^3 BGGE)P7UQ4_/C72*A[VU
M>O,+EB>:'XJ2^U*1H&J:A; '(CKUNK3P.CBFF<%3^A(K(_C?,D#8AK\7=@:X
MY:V=NZ2-M5@%8>UZBV VOIV;=&3C4>_587!(9' &P#W89:G3C)*70TDUI)*%
MY\]R\-9[4\_S^I.EPB*17;=E^7& 1T[:Z;3>*=&=^IKC09$I[P]Y6 5&VD:]
M[K(6'.7S%I&: C5%25Z)Y-[-7!/O]VT8#*41O7.S"K^@##)7 T'M[Q:)ZHP4
ME^N\\N,X2 98/0\^<=^8KQ3DKG4N2DS)?KMD;5M%R VQ=3H#C#@MD&FZER7H
MI7-0?$9:<<RN1H2?\_*0V?HXQ^<60^+?\]B?F'QZ!J3Z[JC+OK5C_ R@6S[,
M<633*YQN*D"4I+[G2Q(Q/XFR9^@M=>JD8!8)];%4S"]J#3[!?T2-!545KN]_
M7D!["_MD\EYM1%=GP?#2LZQ=W9%1Z<\CJYYF#E[C/=M&ANN0=::@K[:TMG4"
MF:6112_9V?6OU=^U=)Q4(Y1YW>7BWG-\M%)PVI\]9XQ#M_ A(UO.4<2VE<O]
M6<L2#?$NW^OE&3[?NM'RL?7MR7UDI4-6U_RERE(MV^>F.PPG-->(WSF-/G1>
M?56P3,0P,>3E?<Q@^'E%HW''BD7;LJA%^I8JEU79EQ5??3D*[4FM@X+DXO')
M],DS@('F1X2B[([[G2V%1O<\&0M*8WG46R%F>9X0V^@Z5GMM/">M:V<??LMA
M.:H(M7DR;7ZQA02%'EO# H5.K.NY$01S(H?2U\8F'47ZS.J_BDC9>J>UZH^>
M%LQ^LB)AJ^".S"%:TNQZ*-(['FRS[)$/69]V'Q@]O>Y!ZHS)XL6Q"8UERCH.
M0:5<J HY'J[8>_ZR9FG-6>%3P&MUQT(@.TFH0:N-X1Z;5Z*M,QB4FS(Y6&==
MGU">(R*=WAH6N@KS3G7<\',+C!=L0D&$GH;(G@&, CL/TR/#^]Z4F[#/"0<S
ME:Q4]&UHGU0 KNB*KNB*KNB*KNB*KNB*KNB*KNB*_GXZFY+WN@^#V?.SLMHY
MLIA</ !D,8/8LKJ:V+,"6=A8 8(BKO8F9C8@&+DIR-+*3HABO::>@MS*7(A"
MBTN!3<%> G3?2M8="E)S5U0W<[<QXS.G$!%&%W3E=[6UMP7!3,A=;<%VCORN
M0A27ROG/SR_8K!3DET-@-D(4EX\=R;45E,DE(% 0.1<+![,9&Q!(SLW- N3D
MXN8&,I&SLP'96=G._W(S SGYN;CYV7G(OQ.%,/KYIR#4W()?55+Z.]QY2XCB
M^[Q<7%Q87#A8(%!+5B ?']^%&G9VYO,1S(YN=C 35V8[1\IO2G[HD00YFD&M
M+G<:R2_:)J80)Y@0!04Z^2_T?5ZV]C^!_M*!/S5?*#\?S2\!!9G 0)+G/\+L
M;.Q 9C8N9@Z@.CL[/Y"7GYU75Y#U#X/^(*X ,;>R</M%G)N9C4,=R,'/R<,/
MY&)DX^+G8/NFXY>1?]1Q'@!S$YC)OZ3EU[%_-14(5!T" 0M_"^)OV^@2$A=!
MXR2G4S QL[*[8-+_,K7O0C^<SOH'K_^[T;#_)>R_B\9YQWDT.'X?C7,FOS(4
M8NYD!H(*VYJ8*:F1:X*@CA<X0+;SU&/A)J<3=[("FY,#>66 ;!STY"I.)E"8
M.[FRI+0$Q X&<H4)LOY.R=\]GW-_*2C\U_EE:\OZ5Y*.,"EGV'\MZ7BQC\&J
M"G*$.$'-0%+.(#L8Y5^K4@7] [?^M:KSX91_3'L%!7XY.T>8B=W%)ICP.8/%
MRLJ<7YP;")02X^+BY)#@E!(' L6X)'DE^8 <0* X!Q<'&\]EQOQ>]$]J)2%F
M3K;GMG]7:WZAEO-?4_N+Z)_4?MMU,P'_A7HV3DXS;C8^(+,)&Y";F9.7BX_9
MA)>;E]G"C).-&\0%XK9@Y_P!\1=J_@0E:^5XOB#<A'_G^\M440,Y_)[[HP-L
M=9DZ]B90Q\LM/R&*'\ZG^)/ A<QE.O";F%TFHZ.),\A<D/5WO'\L9/7GL/UK
M#OB3^#_&<+D/LONU&IZ7PO-"Q,[&S,;)S\;V0]7EJ'^LQ!%B 7,Q@8+$+,_]
M_*_5H[\2_,< 9O=-["Q!YL*L/P1_,/X4(M9O,?IOB)TY"&KU?Q*]<Q23\^OM
M>5D3-H/876R$@LS)+: 06W(3>WNPE9G)A3RKLYWY]U5M_]-A, BYE:V))8C5
MWL[R!]POVOXOSOD_SE=N$TX@#XB/D]F"AQO$S GBY&,V-0>Q,5MPF9]GJXDY
MD)V;ZRI?_V?&CHO=PMS$@A?(##(%FC!S<K&!F/DL>-B9@4!3<W-.3@X+4S[0
M?Q8[/GXN/GXV]JO8_3%V/PO&OU-M+FO,SP+R6S6QM@?]_UQ._KX2^C]R>O]Y
MM63GX06:@\[7F2F7*3.G!:<Y,R^0S^)\Q?&:L)F"S#CXN'FO5MS_S-B)<_RS
M;[[_7MQ^N3UD _ZX/?P[XJ9V?H^E965G#G%Q_%\9L;^K1E[4C8LJ\D^^E?V_
M53G_5TSZ/U^3__1N]&I-_@^+&-=_>\1^>\AV%;&_HXK^RW>S('M'B_]7JNC_
MHDG_YVORGSXJO%J3O^?^_N'ACP>2?W[8^.,YZK>TE+Y(K'\MSH*73X;_W0+Z
M!]&_TFS^[SS:_9/H7VF&_*=/=_^AFC][_!?'_NT;!.9F/Q_,VSM!P9>;7.9F
MK" PZ,(<1U8@"_#W>Q[F9OP6$*BM"4SXU\KP&_=OWY'YL2#^P;[,C^X_[Y7]
M[.*7!UF:F+G)*:M+2%I9@AQAPD!>;CXQ-FE)7@E)::GS'VX>7@D^:4Y.<0DV
M-DEQ"6Y!UO]"^"\A+O]=AP+$'"3,^:OP;^S_TB_?N*J2TL+HYT'_L?/Y5^O[
M[Z<KD"N0*Y KD"N0*Y KD"N0*Y KD"N0*Y KD"N0*Y KD"N0*Y KD"N0*Y K
MD"N0*Y KD"N0*Y KD"N0*Y KD"N0*Y KD"N0*Y KD"N0*Y KD"N0*Y KD"N0
M*Y KD+\9!/VW_TL,9&<N1.%"(2)\-@J0 ,#]AW2AY#_5 7?YJ@$X5+A=!#CL
M'Z\:: *0 >  <(@(O[U&  ! 149!0X=#NH:( '\^P/(& ( ,#P>'@(2,=0T%
M!>4Z .[R/0, %%1L-)P[N'A ,17\F[<(3!S0*;2T=7S"8Y[')A<-?MR@Y.73
M<(VN;!@:WF3G<7:IZ)TBI*+FA)65TW)Q2ZEEEG"(2TC+JFN:FD$?!T2= Y%>
MF(#RJR$ N&\O-(!'0S_OUSRW^N*=!G!(*!A8J/ 7)L,C !"QD7"0<>\ Q5#P
M*%1,\&^R._B$]Z%2BJNJ:41$)A?U;E!Q<'*IGX,X1A67] ]L2L >I98V3'WQ
M;42CEDQI^OU; B:G\5[3RZO&I@/OFD8UTP>I_;EIA)B;JX]GL_@BZR80&_N9
MI@<U/<TB,G"%L((\LR8CE#B!9O5ER@O)I=QB/_G'<+@$"!1PIOAB%E0  %6$
M!P!%5>DAOHJ5E9.G(U)T=.G>\^>J:3>'RGOEA)J;^MBTO_@31*?%R)CB8^._
M" 3 V^"/ZI5;^NM.J'1Q,C5WV@A99#_A=2A@;,O#D(ID"WO[=#!"NKK]D-R8
M-"2EZZ3X\:&YACHB_X3)!\BL01?E0])&38%Z)/P-SZ=B.SX&>HW>*I"8?)JR
MH-W#]U)3=#22$;S[H2JP.KK/;*QFK_6LM6ZNE\Y'.Y=O/>KM9>A?)QW6#'7%
M;U-4<W .VME9OMO=^]EHL#P-2FN#-S%O^OC)-;,A+CV<[+;&,BOR?65Z:FTZ
M=@S\KRGX*33L>T)$_GW+!D7]7&A!8LXE%>SCA5TF@3/8].&HFJ:IM#;NM,DH
MF7TBZDH1PER'B90E"G8&9.J1&L4\<4YKL7LEVMCX7W3&)=BJRXIB]?4<3:*G
M->@[7]W$(<NG^$(6(B*%4$0@S_5TUC @1]LFF(3S>=FB4QKC$-T7M$>UB]9U
MV:86-/9W#>MFB!2U9#Z8HOF]D3\82I^I'@\KC_9F@@)D@[:9PHLVX+5C>$*G
M@9V;Z+,) AT&'=7Y669XX8F/F5_<3S.LZU*M?;)/\C9"1%L8O_3Y+;?P5E+S
MOF"WZ;G.QS6%HD_\!NCETVS+\V=-?7P2X@K(-;]B,\+YR<8M<W.@^*K1-4R7
MNC/PEVCTEC'?]I).!6\ WS,?<K+[[*K<K9(AI3)GWP6I]95;O,BU&FD27+X6
M%0O@:=VP>)*(9@KF)\,(+ST)QAY*V]5=FO]'J<A  WT73VPYI2'(/.;[245#
MS#6HM6#P-MP<Z\VR"#@LGOS!6#<YVL?X EF,Y,6V*83QL[>VF&6%CFNL^$DS
M\KK;^U=?@;&[HJ;(GY 14H/)%P?HJ$=7U =S-(9*QV^3.IUT2(6Y.6 INLEN
MA%!W8B^;PK-^8LO3Y[NVK2Q@JFC;B<FZX&Z@F!\4H% 7X,!,:U,J1X-".IWD
MF],E*BX:.[, WRW'R.JX&-#C)X^D9+4X<2_O)MM(^G'_7??8E48I'.];#[(H
MZ[_ZMDY^WFX?T@V(JBDWY>PDH'@*PW+5U2%J2BAJOTVK6,E,JUB5VV,3,DSG
M_AZMLJYMXMX'ZA=@%C%I78,[*H,K<=<XRK)[:H.())QC<H@L50K5,#H)-N/N
MRLKE,[3AX? _\\BY9;04SU]HHQN38,(;,=$^K<(TSX01GA,;V_129]JTHXGA
MF#2).&@9DC7?5D_DJ>S,,\Q/-<(2QAELHU-&E*=[;\&6<-VR*FB(2,7&RI/R
M'H-N)Y\.-T-3>I5?M!K,B0SL@L']-$>6[][U' TY81WN;J5B<A4SS)2E)WCI
MFE[PT@VXI+'Q[@B!EL#5MX+J&L))A)!$\7J_F^B1 '9)^7O3!R&9<KLLTTOO
M]6W?L!X^/2ZS+TL;'HISCFR.^2#=U\5KJ>P1/""%6&0@HES>O[9& '=D$._"
MCF/_9'R9'FS$'FDQ),TUK8.ZU]WKW/Z5N@_6/:V%R)#)9SV+D!GL=U.^684Z
M@J]?V9_^B0G=P]EX7S3$&V+DOFQB)*CD.XBD?J2#'24-0KE]H_KOF.N:< 0Y
M&@0A>!\ZB? BZ$W#&%LIV!@6E@BU;XA2XN^8,VC\XX+X?]34?;W;\56SV6.$
M/=XXM:O:)-_IG7^FT9.&QB=(C=OJ;:O.."BRLU]CK0NBQ%)4EAZFN&V_$M0.
MRNP17/TJA**D/75+%:XG%I>0DH:WQ.?I]'7R[4 R8W6$P9*=T"76+>H,^S,
M^HB;^C!32N471>H0K:G=5UQA"R-H-'1KS-$-LX9+->;1:WB0VQX-&. <KL9V
MWV2V)SN;6!4K)P%K<[)X<"$!,R>>B5PNMB"LXI4P#X8S0$UE(I3=6NU *[E
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M1(I8G++UQ<U9'SPX[63IHZ[V)0VE"1SW[8B5! 3>:&7S$96A='$D2<AK'LC
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M(@,Y;CZ,8/6G:B6%HW$,M# (,R%REE[TNSV! -]]8E,2(YTG. [4Z4^#4!$
M:7OH4#01=%XENV?D/7C6PL!IM1>E>13Z=%TN+D61E17*'_0*6Y#%=*A)>C39
MD;67Z,Q>2! O$2@ZQK;R/:4P(V[!QB5HI* P 58_>1*J@KVYN?S2N\)Z(%>.
M;_GK?NC+<B_OD/I$K*63>IZ99K?E,X#W\-=3W:Y$XU>9$E;.SQ==L&Z@8(^T
MT*R6D>(UT;=)Y90-JQ3:$*20\*>"$AYK4.X@8*NW);O'OO!WV/E4-O7R ^;M
MQ<^E1O=C1/LPSP#0$+%IG41XW>!7%*5C:7G%W;!WA(1!%)FRPED&:"V8#I,
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M!48LL$VU/FS!O[8M6D-J4,4IBKV3*7E00P.#5D5*G>V%%*8C:FPK7]?%[RH
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M?>[)DH_4PXF_9F]Q_"H-C(VU=(CV3]OKFE \BUWQ8:!0!;2>=ZY_?[NV_<D
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ML<I#3]=IP,/C;]FQE_A-TVEK-_5ZMO>S5WI[SG?[9M5S[EU/>VV=BG2T2;U
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MNL/P"+ O,6YIF5I$ICJ0SVG:Y/M#46J];0"GI1LT_-B]'-E# "BRE?))DAS
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M04YJ4ER'MH#'6/H[A^5O\/I28WD&?.HD&;:\\,K ?>HH-J!;2SLU7HB:B8F
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M%MX.F,C3T;+*R">"8S3S5!/)TBL^7XI='R[3<W#9(9Q[-#M(/EU-VD6WTM
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M-KIZBZ?% ,_G@$W10;25C7O,JK6;N^?D8CB\7\])>V+TU=YT U%.^5^\MJY
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MS5Q_BQ'^N,)V$)O?(85$.R8C,'& UXT$"C5OX#%KT,]6G>QF606%J8T;I>=
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M?L"*0\AKWYZ@O8.![AHR,*W:&+<(QXFL"!-WM2BO><[X8] Y[?GQMU.&PT>
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M_D@JH?]\R9D9?8=QXXG3ZD]K+,'3%C'+C([ 16B8^WA^+^=X2'MKWJ,&[$I
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MT2+,E#G9D;OG@H![>Z>(IZ>I F!#0X0KF@U/8NFTTG\P)4X!AE"* :Z7BYW
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M7;)--A;?0)FTZ8C="]SFB+A>QU LF.9NB2 W(R>XO9\JPFET)O(AS!HQP44
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MZ5%Y*%V74%]X1$#BZF0*WK/9G[:1CGD*P[=,03E&1>G.)/U/P.7-CU:HSG!
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M1<<<@5#G_\)!>_+7/PY]:GS_9QAJ R"X19]D7O3_,.^U783%_U>=CSS=CK\
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MB2BK[I9XF.8VPD7MP@UMJQ#VDH@FD+O.571V8QDQ6M>V],$NB&DB998U8:T
MMY(VYAV^[FYBC2 UK*\]VW9,WWV2WAUI@$??IWS4/8S\F1S;H=T-U;U$NW\5
MK;A"4J3K_^CE*X/B8*(M!X)+"!K<)6B"!->@@P6'P=T'9W""ZR"##.[N[A;<
M"4Y@<'>"!Q*2_=Y;UWJU^VI_=E7WZ;ZWNKM.]SWWDF$;1X"Q+K)VC+($2::R
MAJ&3TRJ7P]]M0[(ZJDO-+>VPLD1\P%_7M[LRA$I6<V*1/R@1Z!=0M4-'I"WE
M&LLI),=@@S\]*%RA2*'G%R9Q5<'J$"?!RQFQ-)M)^9;U[+A>-];%G\MKW0E.
M-Q=]2KV4#EEB:K<8;5T.HTX*? YAO!FVKNV+.>,M(+TB<1IZ%96DR[6SQ&+$
MFJPMH0]*5(W_=^6$-NXI]!4&TYK)1%:*!KDV7,+1]F<WOHRO#)PLO':&STH/
M'#P". _3LIRIJW,2)3^5)FH"\J?)1#I:X<<KZQ$+4(_EVH+CF-;R36)-._L7
M:L5HQ:A$5[U:C=-D_8W4D1DN*M'4Q&KA5H%T=YL,_^O?TQ["C8;V.KQ&3@;>
MG,7-[0*$2AZW"('L[D(0*;J/)0AJ%T0D",V7!7# 6UE1)JG)Y:U@_/0CQ"NV
M&I6OD4-X_!4XLW.?D*BI[4=%W[]^/09M7"L)>&.$RT"[-$ZQ2B5=H86U@) 4
MUQ9@Q:W9*]"9:'I4Z%+QN=>"7+^55;=<;'GZO:?^"(1$#Z_D -S4/@3L?, 0
MK?^0)44=*2GO6[Y?QI#HWI0VR3($-<V#YI8M^RVEIF_G?+,2^$Y <05S;HV;
M_Q+3Y1[M(4)I7!=>**]^2M$ Y?5[.=7IGI\4%,!--??4*A-*39(SK@&A+5U]
M"*G4'6>E;6QYI1'#0+"VAD%O\/U]B5Q.B1UC&^=$M&'AS8X48["4[A<EKJL@
M]'AI_CW&KO2A'Q581&R]/$/(7MQ?6<JIA)$T#\N0%4MTFG2!XYM,!G6#DLS7
M,A/1&V5XE&N"\:K1J@4:P@=.6!D\V=L94*97Z0 <_C;PY:6<0!._F$&TX!.O
M-L 4Z13@OZ1FDQG'K5B?+?'RHR?_+^!L5/DO0&:#*BLR]"_ N^8OH*3CS\O9
MVR4)"/#W/X_?>G9:G^2EWO_[7WLMYOFBAM7.!3.'C ](\;WS8+ZC'D7-1P.0
MZ99TM0MK&):9<@+*P2L,=.^"15\KV>(+!T^P6Q_6IG>IR>L&A5KA^#X+#:Y\
M@RR'6.O3IGX.SFL%:.3M2K+G3,5[F;8U.QV26.Z\<KW#TUME.%U4E9 >ZUMN
M-]Q4UJ!2UCF/.9D9M'>D.,C(2,<S32&6N:1ET(AXV[U44@@K?:3F3:AAC2OV
M( =,HO#'V+5P;IBHXX1\I#G&J/3"T-+'6>FYX[N[^V<QI)59&I:JPSN5"B&:
M]W5B(H\GZ[]\CWI$_R6/^;/)X;%$?00;E>O969YST._BO3WJ0=#A,Q45WY'E
M0^3@YLSBJ?3QM"ND1\3-'#-15=\SR.$G?^F'X*C7)(\+M$\=*K,R#?'$M"G'
MD8;8$V+'+3NC06^H_QQ2>)+ULU/X#$66&2(15(@%DI+29GX3S5VER D4@5IQ
MU!RV6P0'S?0ZQ2+(F*T9EIKWM@^K!9R8L[W*_!1]4#(R,JKE)A+#$*GWDH4H
MOO/7KY<6)\.>(Z,(UI='9E]0-K0<W>^1!"3KMAWF_ :%73?26G2;$KTK@L<D
MOVRG1SU0>FOC4:Q1J-(OHLT2'.QUQ=;RL$@:-9RG*_8\[[%051$8BP5^1CS0
MM"RL9'B:BXF+_P74#=]2;_\D]Y4>7#E["#31+1I<>;A6';*$//$^B?K=_^S1
M]ONY5&GIE4=[UYH;X^BE^B ^5:853D^DRF3W7G"\.38T""ERK#F!MTPI*S\:
M7^;H6$S8ZG49I)7<\V(OF[.E>L%F#=:@?@W_2MTHJVL'J0DHU]>GG31<EW[-
MO7W#UO S)"F0UF%I)YF/897/=#$HRYK3H,DI'0# 1QO')XH"J"$'$?,0Y0,
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M/A85??,Y7*T&A2--TR@D\/.+F9SB&+$K4O"6/LC 08FAT!D,@[/2?GZS7I'
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MZ&O'!A[[>,V8?*734K!^D&6J/"7[) FJ>D?4F,PJG[(IFQ.!VASRGCPQ%EA
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M]5I1GJON>3/O<Z\N717)!*X<NI$]2,8NF2._W]J9<EB/I9H=99RIVE:)\5X
MIB.43DQOE#53YD!<T:@'!4\UQ-@Q1J_NP>7@GH>LCF_(\-$VRK6@/.R71&VP
MXB.2C>.9B5<X/$%1D#Q;#M_]T&V%_HH]^$3Y2Z#SRCW1,-N RU_ X\!#Z%]
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M8[&)Q27C\P=R!ML^,T> 9&6F9'1LPY*/-K1\>M^FBB*;^I9K1M\(M"9M'"P
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M9>%-!7S0?D'L;_\NJ1G,CPL]]$MM3R?!I,:M&Y7IDP*;&!<-D#DPVFM[/;R
M*A/%W'JAV0?Z88!3.J53.J53.J53.J53.J53.J53.J53.J7_ !U-R,%L4"A'
M84Y.N#.'Q?$_#CC "!BGFX4C)S<'%R= 5,+-T0)L#T4Q6$*M;>%BC&M5M8P,
MMA Q1CV0*I>JHS34QE;! PG5\KBM#?:P!PM!&"7$"47=A-U@CC HRH+!#>8
M=Q9V$V,\42Z,.3]F<S(RG#1!V8LQGOR[@D%?59U!&H&$,O!S< '!7%P\# )"
M'-S\?'S\7.P,/%P\7)Q<($YN'B WOS 7GS"W ,,?Q"A.B-F+(B%6PIHR<G_
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MZZMQ'L\1EM@AK 8ZS!B7O$&J4K=1CHJ%SWN;*!RC:(M<;^P_7F%Y9%@ON(R
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MA)#JKB_6%I 1X[U?@MX;>N<R4#5!^I1K23,E8RJ1W_ AN#UIP]8K,N KRDG
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MXP9O84/&+3\ 2"O^)8T?@+2^;K8PHQ7\ZY3Z<\8_<9J/W$\ZV_2^;8\!>'U
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ME79'C!:J+GM-IC%15L,:$?/=N?0GRB<1N4OL"X_E_&1OR]JTW#11WFSX]5G
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M6Y*,C?5-B@BGXIC!.R/;BS.$-7F*AF$O.<PBTER3SN&F/S,? !5KD4VOZ@_
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M0C,FT(N^J )+W;<'AXJ3@OJB^K24@Q9$Q"N&/3?,7C8^RQWEM!1MA;N-VR^
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M<%[>X)B [C*[G:$V '=:B/]L1]W?^FY_95/05XAOV&?Z5IQMH0AL5./CX^@
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MC13BXP )46-)\'=_ #P]?P_O=F?'-R?W6\27'5S1FWZ1^W2$M#&2T^2#D5P
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M;_!GV5>0#""6]-3=FN5#.]UU6:5,/SLX"RRPO<K^ZG2V$R_I]XA:.Y0).-/
M[!MV%_#N\A0(7+5C2)KFW&-T2]9F,S+K=_>(UX ZF&P/H<W.R&]KZ4!L =#-
M7O78K2%S2SY\LI.,H#>W1_041%!C!USD0%%%?1::L&K\FBM<==W3FO'IRG%I
M@-G29<?'N%A)!7-.P5D.Q7YH(7E"M*O!_VWKHAK+T681=6YNY'0TZE5-:1&8
M>X?P*1Y98 B?J?#:.\8AWX(1QXJ>O1V$ V=G9@=TXW".3[)6&22/7J8>/9[!
M*"-C!N$I%GO!9( P8X:M+V=7/R_Q8#IOC;8O]<[XOF@PG9ZU-L>W?1"7X&'?
M*D[_'KU!N[/C)+6\:#&G,<V^(L$*=\ TY%.^N:WQ54A+50CX6HB!+D&0+L@4
M$-=!6#ZAJT$8]ZKX6EGI6A%SETVZF\4ML;TC[.'#\BLI, #*/>IT:XI\7=RW
ML-[!'RS$UD84%8V$WRMX3R+*;,ZI/VP5$@T<@EJO-QQ*Y^;X/E5@[#3W^2*#
M0X957HB.38:L<46&;47'+M+1O#R\-!Q30;B\%$)%V4!%\/@?KZ,+<G^Z/R8*
M7L>VJMJ+AO=P+?"'-12-_F(0!F4GBF_^H= NOYSD3XGUAY4F;:*"[A^GYFK>
MO7?YD*L*AG9$ZHV&II\=0GYF ,F.("F8.-;+\E<GT'"-EG7"*RCSHV%J<I36
M+2J*)>N(TI$55\QQ3;KSPR89,'YF+3\P9B7TKL%\V::6P%&:W2>U  R$[]-_
MG/L]O[TQH[DWH+2PDU5DX>Z8&24GF\IH:Y"*T"BZI+%KU&*+)C8G748]SM:I
M#Z:'QPD?HX J.8*(F@NCB@MT%BP,<EQ4LD3Q3)[>N:B(6MCY^C ]@V_5K'1W
MK\2UP1^F.L>+(HK1P#88EZN:-0P4%J@<H%O\_21^4!T@4MLQ?YN!R/^LE*/1
MT>@KPE_FF$'/H*,1PVW"+"V21"QK8N\,KJ-H\#:MJOJ/WP\(RU#)1V@I\BC?
MHWYY7,][TP3F>W<8<.'"JA^ ..=DO%3&SD_2VTR.AQ4-DUD=BEU<\SU8'I]F
M1K&09PXJPE_J[8A:EFVN2F9C/IG%BTXVSLDF#:2SI[!7V,=73T2I;Z_*KKM!
MY"WLHFZ1\MW&-<5X< #-X?K2]6!.-B=X7!6?M[22K.JW(ZJ$;TZLC*@="'*#
M';$ L0](FA0?/AKP;LSD6OC_9]+!X8SW[/S&*;"=MOV/F\7;BCO/ A=[21R*
M;;(J8+UFYD*[*SIBE5<?".LSSKO:)4/2?3F)1CFN:;MB>U5..9VFE;.-+S;-
M7L!FNQ8VHR==LF5R E5X"RW;[?PSO/I7S@W^.5W"_M5%WJ9'T46LA1BIN48=
M'+)+U)+@8;,"8,W)9Q:P^VP.NA;ID93N[O_YF.;_1+J>3\0[';_J=38[*FA"
M&A+OI,C*Z;6:D>1&\/V#28$MOY1$-)/$FAIR78C=(@R=<0+"\H%&%+U?QD9O
MXH9R./4Y2;'ZLDZ+9%CT6-A^S#YHF_1H=.1H:->^-:EGA97N8<GIKD2VM^[5
M-J4'.;IC0P2V-F;8S=4?#.&FAJ>$!^4@HWPM2PH^*\!,Z$]2:*<Z6-M$+L70
MV!YMOA*P\6!RZRWR2A! #;O+AQY6@2X1"@LE_U)K9& TKHHZDO7=@(3DY-.E
M^>Y:F'+?67U!8(-GZ#TM'I6J(>9A,[K1 _(Q>WNN300PFF$AU,7<8.4K;E5"
MDA.1!=4W7?&*K"#NM0!VS,/>-=)/9C3NN^6M'1OXE=E-EK\-JYT4JXNXP Z5
M#VO1)?X5\./&8)X(!;G+IPFQNDT/SG/HQDTI.*UG.FF!'508&>.#^4 .JV/R
M@K8 Y@_H>K,K]"Z*%>BZ!U,](3X))H5*!Z0ZNM=#B^UY9AA*/P+"PJC,U&W#
MQ U-DOTPYZR7)5\G^9MB@L)9HNMCF7"[8Z2L$OFIVZW7J11&=U@PD^#$E=;O
MV;I:O';FJU.CKZ3;2C3;+W];B-VB[E'"E;#28,2JQZ2IGA-?0W,Y4.L:<5ES
MZ 72UI/=,7MBF,PGU=&(="JK@!9':YS(D8JD%!)0%BM#04Q,6UN$TN2W]K@?
M8"5".>C7J/NZ8R@%D_DN4N[S-4WV.BBZ+[KBPU4D+_02L(W-E9C.N@C8%!F\
MAYZ5%KTK.%,ERTF<34PS.!JP=<VG$8@!"ZX1 >(AJ@J_KLAC;%^AY;&04JEE
ML*KM.KXNEI&I)=,78(4L+)!)R:2S=O"@FMZ5,Y(EFE1 YA6SUL=W5;EICZ4?
M-MD05.E_V&, HX6YSV#-RE/FYW :5>M<AG]2%OIXTR3U 'CF;U42YN$1G>81
M4M 1=;=9C:#.-$&MJL;\<9URRI>M1(;XF5>ZF.1[^;KU%,XM$N=HKFK5YD%%
MHT2=Y:-DO3<]#PW%Q5',=.7])]MJ[9GBIG)26K4VZZ5BD ;F20-F4;#6YFK^
M5@1AA SQ$<@@@A75? *I=JG=G20YM3_)V_5_/COMT^+BJMOC]CUX]>N*W-[W
MWU6=HB+!5L=K#@O".EDE"3'AEC&EQ1/NVF8-*]OEYAX0ECD=&S*W-LUM*Z<N
M<R?+#MIM>$F2PMG,TC]"9Y'Q6U2';?TR:ME&[58PUW_:()IS+PW4\)%8>#%O
M_N@Z+./F;&CYVL>0 JUABS3A6ASKCQ*^QB%1EI\X! OP+")WS)G*B:VC?&Z_
M-7F8M/<L;*XBM,ET?_O-*@F)W;U@U;RB*-&](_V$,>U *%+O0<#/FN@CD95^
M",Y^6:N5L#'/%;5![-TO,O-,_-DU F_KE<GMWW[&7=E@H3F64KGMY=/4IH3&
MX:#?(D&<!B*2;4"1W9-I/]SKHOCO9]S_BAK75K/NY*9*HLDY-G!/2A0[YKK7
M9L##[1U%]QN61X]UD48+.6^9*G  -%D 5,(I9!D;Y^\]R\YL/J_MF/@--1?1
M VK:*9WKER)!6!V=$8OBG2/["$/HR'HY7-.EE2V'&O *_J'K=P>C1:</2#9-
M<%D.?RJ+P//7*;*(7VJA;JA15^>M Q$FBF1[V;2+UD9&6Y4769$ PK5HBXI2
M7RB_"2+<-2QN\W\D0__OZ$PZ;M3V0.J4-\XK*,I3_$, Q]R:OYOADAHGD"H_
M@D-FCK)-:BNU1:$?E_9$.6'-N&F#Y[3(C9D7LJDEQ-(,V'<?GW%IF12C<M^B
M4G" 41.C'B7G([&Y-I=OYSNNI?HA*SGN@T*4XV)T(51@@)@O)+]!MQZZ_@K2
M9D%]DAIWV[R%<%(V=^U1(I8]&$W[+J*>P-"#.. 6(I6J*3=IFT&,E'ZBV8GR
M8C%S\G .MR*>!VAUO@YCRP7QH;\5K]T85D"%Y>9M7X.@8A'.3'Z+B@[^Q,70
MBNM(A3L(> +.Y]O((?"[T%0=B1@!MK"2],.AQ]PG\Y'Y30VF;RY/-0M+6V$)
M1[S0333."AT6)6FV)G$_6!%OR'8Z,S>=/)@;H4K42.]Z\?><?K\2#AHF&?X@
M_(WR/+D>V!.%OK9C7ZE$Q1Q+OT%L_ [@;D3& RDW;=:)AW49%GN_C3P^=BS*
M[']F8CS9L>:I<LT\#HF':<J,%S1O..EDX?/!RD_ZB$[=<)"2E81N^:7*GZIT
M#IK.3<NI[YRX+[E&''+I#?R@<GFQ4::ME:MS;;')K[-/Q!T !M97\:8IO9I\
M0^L5KQ I_OC#7C.=*3U_%4&7I:H#]]-)Y3),\!/L%M<X\L\?>5CFGW1R[]!5
M),<OTKU%^.6ZN<7<=\&&.#V6[GDKW>DJU#Z0V'4Z[>\ R46%.Q$9WR?'\]#S
M*?0&+&^%O5".1Q# O7P.\8ZA0P7+MDA;=V-Z[5XM#[T[TN]/61/_Z9CJJ1E/
M:Y"\P\F>E%B2L,OUDE$85XL)? 5H(TEMJ2/F.8@7'3GR0I]NYY;C'+8O4M9<
M3M?])%XX)'U7,19XNZ/'0VG]0%FOF$:H0-S#XCS0R&[,&.@H$RNT[]U[.@Y8
MAQ4L?Q[Q)QN634?-ZP,0G70D6T\**.8_O0-*_?UGGEOH:]WO#M L\>H".KSA
MJZ\I^"0"/^ L!A.LV9IH50OAWZ\\6GU3:D#('-E?'TV29,V9(-:#F<#GX-U'
M2)SY%: QHH[K+):>,>]2\XU[;AM^76$NNSKG;$;&0C.ET+("V]@MH]6U-2T#
MR;J@NU\.;&_!;H<1!1T2_Q52Z+K/*-&SU1=IE%-DE4K+ZV<89-IB-KO[J]SJ
M4E"5LCI;A9D2W"R\/44D[\1CYK:RYF922DR,1!HY\*NW01T(^K/*=@!!AS-V
M<GB8:2#K?;CJZN__X9K-JN?\!DIT[4OQ)TD'C#4'7ZRT%4>?R-$FD@<*+7DX
M%!H,M<0ZK"[/VHW]8-PL4D#T&4X/,NN:WR^@S\B#U8DS1Z:CC \D*&)<1T$8
MS!6^[M;R(]8._O;<OF(M"O.L4^IK!)+C\',ENB.E:W3]*1(,>='J^6VH"77@
M,,J$E$DUV',R>;*O3ILE+*KC_]T3UCU:E@M\#!\KOND'08</%!R:*"K!%[>/
M?HH9"6ZC-XX?8P.Y2!8..G#0)\K4PS-TAUF54WTI=EHPH2FJHGW:.PCTK2_7
M6)0=JSF@O2,F2!.60XP7FV3=X%JA9J(E'RBVL(Q/OPQ(K*UI-M]ET^*2(9]7
MX%.N//MOE[G_XTHW,O7G[,6'>-W4B72Z1!G.$Q?W_.NNQKNNYI*#FA-!!/R6
MX;1A^](=;^5FII-;]X*':2_.8:?I&LT.=DV3S5,[2MHAK)HT)M0\X.)6#UA)
M&RMQFXB7K??IK0C=JL.#I615/^O-HXRQWF\!"FT6)_T(YU5=_6Z8QK%+JN)S
ML?N%RLJ5TKWH\ @K)9$<UXI5?.R83GL\GD5]^CZV$@)LLBT?W5O/3<?7IF&'
MZM:#==&\N@4KNE2#>:)YI-_)BB:)IH,T'5_N(11YLVQ_V?9\M'V+HKYH:ZE#
MWZ8:5KU_ C%4[Y.Y@&=L?Y:]ABXZ?ZA48U=97_AO&E#%1AKR'3-A^<+J;H;%
MQEI#$&7 $X; R0:.!YZ/"BD*P8Y](-JW%[J1AZC[.&+]6$_5I2]4$?S\)3UU
M!J-RYJ]*_?]"*I#G5S&X1PTK9.PO;L[.P9&-!IAUZ8F.&57-[X YD3T4D9MO
MS#=^,NTV!/2W 2XP09$>]9S. 58MP!FKC<L*Q\7^).1W ":-P GF3<,[@':^
M9UL/^_H=H/$VO5AS=*W8\!:G1R-P,T7S>G =<T21^$:MZC-/<V#ZIE'DT]E-
M);=79/I*TJWJ<Y"N]CRQ]_^P66_GG]H/F&[>?DF^^?PS&AK)*/H8U*_@Q8LZ
MO'"7L['"9 6B*DH#4KNQ$CN)CA )Y*0(3'U\LKK\6?"<$RZUZ( SC%9Y<5@E
MG0O(IKO=*JNV2.@-W9-$RE,OFI2KGD=$7_;<K;;&E+:$9G\PX"Y1ZH@N3HH!
M*RK1HHP&6I<2SJ!U; TZ3B:#;4VU:K_=K%E-0?*6Z>^/V:IG@:]3""ZK1@2W
MUW>:F] -[U:E9[^R%MDC5<<U>D:N9FJ7?40,:31 M[UB7AN4"<8KJ'UIV6+3
M_GY WK2!/8QSL=NF#-I'HP;ACU=EPI%:C0Y^X-"_6U]36O,CH-$J__YDW03%
MOEY5J-9\_Y"\<BW"Y*W>T1 K945#71\&98^XV<8Q^ ZH(.&^K4;^B7+Q#KCM
M<L%Z*CCA^,WFP&99]@+%X_/*H#/T5OHD\X:HK9C3*]+R#IB_V]0[C2G<^;$T
M1/4"Y?$?''+_BN._CR'^OSG> 7]G^;\:I-%WH,\EMLTE^<RE.=RE?;Z"J.[B
M#%JH0Z! \DJV=T=F9)FMP>@ZL&+])X9P.<$GM-J'V)*:;]<J0RB:C%SB3B_[
MGWIHRI/.SBU45J/UQ\:PBO$;C)<J_,&.P+@/$2U"K$DDKTRTHN$R9P>L:Q-5
MT CX J)+2JJ6FNS]5@N*;9W_-]//_[]2$SF8IU751=?:NETUTG+51X-J0]]R
MRTW<]*A)0>H;.XD],H)3V/)$K;4S+Q)MV!8^_4NF[_..&FV7"@X]%VH0@=7R
MS_L8JU*-4PXZ"_82M^^SL(T3'HV-<3^\-L^RAKF BJF?XH8%M(B":?W;HEQ4
M6NLZ:ENT0AN?M8I2QTJG+%>8"L>BE3]^C2LT^-66M=%BF*>^;/NK,](<1V6U
M:<IHZ-NL.4?YK<P*I6Y9%>BD#DOIZ! 2.VT('&V)3C(S3#:S6OC$@R>4+@L9
MIM%\"H(_^E1]!IA=OZ0A-K&B1=\Q3[FW@^](XE'=4IG',?I\?#V!%E\O(4O0
M]X'MO"VZMKE^*Z,B]-!_1K:A(W9#JZ70])M8,A7"9;TX,43<AP,UG+AHAPWD
MFX@5KT'=;^1,6N/-\V$!(I;SI+3F0ZYK9]#==9&''!#)JKGU&FO" 0?UHC@
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M52&_]F.2>S2U$%B:&7-#W$].GN[G^GDN(GV:JM=+(H]>*Z]JWG25[52ZQ<Y
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MI]^\*D&&]Q1&XHIA)Q:+;$YV^ET05-EYY)/!!E29J0:J,,4#0R&0&5+%;J#
M>F%UP]E@DU0>^]VD7]_K,@H0F_J81JP39*65I,@\DCY=?(W$D1X*^RHH6<KS
M4XRZ"K"MHD7TY5NOH=J<;B]"O)P* !_I=\7S\@Y-EURGQ9?&>1<C-66H=I"9
M')78W?G-:DW8^;?Q:BD )C&>MK1?JB*+V<CRNA::*YH:BL9H P+87\4FROZ
MS]G/H6A+B"9?G.RX3IPICB36*EQP2+ITP%'FF-/$$T6E$]I\)"SQ8GT2 &.K
M>B[$I0^M?,2U%9V;\RD@PRTFID.O72SV;+?KK#NUKJ6.@B4BNF)YG-T^)ZXN
M"D5?-US97Y45%K]K_BI+V.001^"33&W3 FEMRB5NO1K7/#8\\1%DFJO!>C&.
MFSF%3F_8]41<K)$[%13Z A&Z"CBNUAHGP1H",4;"-._<EBEN=]48?V5'CUD!
M5J1#2W?$:7C^[ PV1C7#Y7/UZF0R/!N#S3R8K&"W?V'14B(C&$4**C,3[*F(
MTA "//]C%_3?2PLW?$Q+6B_W&#A:PW]TS36DF(]&(/1)M:@!.@U4,MQ+1X&A
M9'N9"4&KXVM&A(:,O< VTM)>2F(?URD#%!]N3"%7NAMG!_FVC]PEQ$F.JQ]]
MU'22L QPUZ:L01'<E\AXR#R5$1V1(Z9?IB5AX1C#)3A$P28?))*7A"N;IAWB
M;KD"-LJEVBC<C$R3<:PFQ3"8>9@E(9DQ$!16"C!'1$0@/^2BB%SBF%!C?!D[
MMI7<KR-X33W[,NWALUJ<@BR^W\S&97'7;V>NL14>T7[VDRH+YOOPY;=:7%2>
MSRP![,%V6?O]VHD:0@8KL)T&SQI2S""0ERTL(T7QEPNZ28X:_#EM,H6-VJQX
MUW6@\4L+"?VD( YQBW^@U6T8IDQ%&"RQ__EMJ+X0+5;NO6F-R.R!>X+FZ+&<
MQ3.:H8RL1@K"2N.U?U?E#:&!RN4:?CWULV1>(F1(D2-#>#\=#+6LX%MLA-JG
M&!."Q![_^NC6]%ACS&-Q$ZA/0ALZ2:]5K1KY073JFB=SXY]&R!0KN *8.X(4
M>$;AC)$D!"7TL9=!J+;"%[RM?C.%E?"6$^@Q$G&+ID3&MZ-5RX[/7>A(^^D.
MM$%.P58$IVTEJNB?>NH/*V$_791<GK49UCY4,*BPNU7NT9,(*[MMBGWB[F-P
MGR6-Q#3'<T%DK$Z_'*)=)-TLT(' 25XSBL4>C.CT3HR*5)&\)&#JR--G4=]F
MPA[^@9='XP\[.LT2B08C\M:)^[OI*K#89%T+UZ_X:8JEL6(=UP*ZI@/5FUR_
MUQ#U:5Z*'6/R)OUC,(@@C[1V1+@OUES2'DPR!8234Z-"QC70P3V]M52@,VI-
M/R")=XR7<N6ROB#)VSCA]J]+(0I$@*7$(2W#@/T 3==82UOF#SJ++L'6CK7[
MX?[2!*N<K2E??W@+.4"@7Y>K\^VB*(VDS'UA37A!74ALX<0W<]3I8QB!)I/E
MI#X)I;FHS FJMXS+6<> (SZ_85_\1H<(;SLHBA[0%BV5H9ZLE6$BCM_(XV*5
M^(3&:K#BBMU']D'B3 G( =C-$C05R@PB@PSNQ=&.C-XOK?X(?W!0M"%PQKBB
MH]E <^K2] M/LZ:<OF'A.X28L>53A!E]/1%];NX.3P)3#)<NM;;\B0)!ZCEX
MG\,J :XUD96SW8NLCV ,2P'$5BY*6TLM 1MNU:'. R@*OB.'MBTD6.,QKT(5
MW+=/COS0"ST\#PU+F4<4%[>XOVZG;9WPB&+#8+KXJ=KP;:&IV*NAMF.1Z&,2
M.YZV6+98AI.8YJ[: #*47STV<>^#?V@]*I8]4[&>R6?@YK9]>7>6A5M)XJ\V
M>5$TS1'#*5P<;(ZL$N$JXF^C1,EC([K9BW$7M&( 65UE-'<!V;1[?^^^A2*G
MPI?IKSIJ;,K3B,+9W.8S;YC#K-&35;!LAD1D+"4W;*3W7)93QG#M:-]D;;C,
M;P@^X6_0;Y-5!"&A?Q@JEJ!3*&B-5XYW4HG4C!I#'Q^Z7'$T,OQ1SB!_*0L!
M"1$VI!8O)J0/6(NDNMPG)>TU'<F;YLG<+VCIG&DO*5TWK9V7+8E#UUU/@L6K
M6N"*^?9T 9?#%@HJ%$V#-M!=(2='(K\'%ZD',"X\Y G"X^3N,L=!9'7/2ZRN
MUG&(%H25I&]9MX PJF"IK&RO4U0^1L9_A$.[HF"<E)5L0/Y:IA_@P&PS!E4C
M:LC,DIG5JI 0>7>1O4J)$O=(?>[I?W CI<-11B:_SE/#)SZT!M%N2&;NTK!^
MXL?-/%)/RDZ,@N9FINJ >7Y0,*!68S@VE**(?U&MI5&%S6J?G[[9;M7>5R+Y
M32U][RR!#(D"C@I]!&\81Q[CP)I$G)XCN@Y-<%2,"77KA =%^0@&P3?2;\%:
M@HQ0BDOI-+'I)H F1KC<-4IJ94.\Y5Y0-F&)KZ4'F8JADCHDCOM4!\/\M<[0
MG0O$J"@E*1<L.FW8%0C_;<2+[1;.*?\3Q5:W@ -*YQ3;H&I<QEH5D4[\..Y7
M>U@8GGCR45WCP)8(9-P2&K)D_8!4%?'" =*E/:QJ."Z!]NY?,TRYZ-9LYO"5
MR5[O@)!7JNB'I=.+;RBX%X'F49ZRRMQJ:>AI7#!(=72A5#@/-BFDE60V9.2A
M%+UZY4L%]>X*K,%G1UA,6GMWE;:*('C9#QCK& @%5].'U)AB<HJ?RXGY:3%L
MF+(#LP9@<B%++>_((ETNQ;Y9[[K$FT)<)UIT\9D'6-&2.*<';M@N,T^&6*Y3
MXF:%H=G!T0Y*M0$B4VSP]#40)7UC,.UU]JNN2QNWR>(S3!&SXD%E=$F3&8"T
M/?LT\C4XG=(-60[4N31!R&ZX"D5&DX.V8?R TV,)@+X'(\L&X/9$X22'@@/E
MSH*[GV5NXY//.J27.^5:Q;=4&VMENV$G%<E^=5E<C%]A-]\*YS18_?M<63[F
MHWP_*QF:!PI!CVA'>D\]T=T@<J-/)=4H\JBT?IZ=-$B*;,! 4DL),E;O&Y#H
MI2(M%L) K5%EIL[5SVO. ;4G_$""]KB=:<1MS'L^$4\^SO<6\C)#EU0[#CIH
M![L7;%PQ6*_:R^)UA^F[VS#SN0DK4E0,*<PQZ\'9&N%:I_$B*2&[X5128FT;
M'*>UY1/9.^/?(6<:4RD2-@M>LLQ7K6X. *$O^L1#HEEN],&$"L,L<9JW88]K
M%=G+6V$9LF9%?01G=TJZND@D35TG<GJD!TY500)PVL7%">:K#:LONBZ8O$[!
MY$DO 5^P<"."QW,[!@E(NDV[P[[$;Z'I3]C1QMHDP^52T=HUIE(1(<RU1U9&
MQ$J00A+8VV/'0GK7T2SIV INNC.>Q3U5PNB.-(EY_;C1L!AM]P+KHO'7-'-;
MK%ZV+3>*)GTFS?A$:RYVT]5JZ;K ^9+H&=U!=%&H*74)BX9('7$LG2U*_2@F
M,XVY@/0@3I><A;9M-FT2?K.]!]HWF-#/ES R'%45.JF6H/X-41=?4&P=3=S-
MK,Y=I^^.>D*=X ^+ [,R2RA_HL;=?:/&R)<](US\*IFMIJ:F>?;4/"-6%[^1
M.*^>H[8\/$%,&,]7IPN"5KW;]VW[?@&^2XR6V"TT*5#38J.UF\=K!'.Q@O78
M'-M!!FUN1LR5+.YHHE&GI"K,$DB"PN$<A!\)+% C#6!M^\+D-[0*D'YCTWK"
M7B6<EEK3':XC:#:G2TK*AX3)$64E%3TMRO:46%/'7\ 3Q^KYAZ)71PE6A<[%
M-;T4=1Q <Z. HL%08*HN>\Z,PXW<!^>T'-$X8Q7TTJB+XC8T&819YDHH.,Q=
M)V9Z^ ^PB&U>1-R^-HPH8NH0=3FTE5U81,&*\$C@W\\L&MUOVJSP>JON4T]=
M E'WNCCKOREE_.ZR(M^0R;S86^DX]\VBG'(G1).U1,3%ID2=2?3+6L9, +AP
M]N'KO&O?/#A'+E6-8TS&V1K6N_:U4[>^V@X><K&@3B2K]9='5\6*<>_-?9:X
M]1,.>G#"5HC=]CN+%02275[]X.0+O-G4JC)3B:W@J.3^ZH'*$ZR>K)R>FWWO
M'5!#:MOZT8="E=XO68TL=T'=<W/R]3!5MRO$[WMF[(!CJ*5**$-PVZWJCB06
M[THXN*L=A ]B=6X8G2&MOD&@+IHE>@? GDLBI=*EEP^U9G+DXP@28X,S,ZUP
M2 FDF'JG>98>J_\7>U\9%-?SM3E(< _N,! D0' ?W"&X2Y#!+;A#<!W</;@/
M[A;<W1D<$MP]!+*_?;>V]MVM_[NUM;5;M1_V0U?=ZJ>>OMUU^]QS3E?WTT+N
M&KJODJB;VG'R\&71&BJ.*R^YXDB_P-<).Y04"?6,FT3H/&.J7J12OKFD0DYS
M \/9%LEEF$O2#COR-BR>#I9B7*BAP*^JD[K,B;/DO.(D@)U[P#(GA,J4Q 3F
MG+S4A0)"PO(3&YE\9Z/SW?_JO#KU+\!T]S6G$5&NE'=&X79[JZZ8SE"@0TM3
MJK*1$(DY[ &-M<%"H6_)^PN.DE\F0T2B16/S^%'#Q\L>3YT'WFC6K?4/FM&/
MDXXNQG?5O 0IC@QPU]3CN_+G$&UOH!@^U(E\^%5%(U#\ 6'QP(T8X.L<K=CP
M^K/<![9?U9E&9(_]@(>^WFF95<&VSME?PQQ8$2IQP?V%6]!(:^+T*45!9K%:
M+.3#)2_ SF5RNE7/D*U2D&>X<]G.C@GJCLYXKKUY;I:E:Q6G9^!)]Q$_E<[3
MD)]AGDPA!SP,J;](A'=8+4D- B>UTU$,QA4)B#1NU^BS%5.<?TI G3$5 M8Z
MGHT3(JL^K'O*SKMIN1/4H*P44R^NF<1B);6OC>]9%-\"M055*%M= M<T+733
M7BRN9%\8.C\H@8UJ:D(]'MYL\&\^VY#?J@#'Z;#9'0KQ()4QE,):K1!XKB0'
MIT@"CY!VA$9"$W''(D<4 '9RK1GSQF/K*) M;:R<'ZA0Y"MBL\K9Z(&K.:6?
M>D^%9%J-8FU&EY'<<';XF;9<4>7,/01%2FL@O'),SO:X!Z5NG.FL29$,P:NQ
M/3TM;1>=(%I^XQ8=(.4,#T.:-_HA)"/H7@6$C*)NX'\ZQ>'#3=[!=S\2S,<Z
M((7>?TJ8GE?P3=Z.MOR\N,]6>5$O:>+2UB,U7=''.>O-ISG&8)JAA)+1J([C
MX#LTFU;5MTQ4A7M?Q>-A9PW"@,:PY439LVI/#UMTJ-%/=/"",U/KF0L8$;W5
M  P!+A8@,R0H!_,(KDZ?RQKB^QP<+/9NW@>1KCOD[Y5:L$]L-]F>)4:7F(;O
MOHD]($/M?3I9P!]*A= -MB1&I<^VAE?4=,9DS@6]XOJ)QW@LKKT&H6R5;4:-
MKI3GG:TH L:D2DWSZF0P!)K;&-]DES#+UB1X4B%OLOEHM;9:U=']=A*$[SR)
M9H.)%WTZ6)R:%8A,HI6;SA <\1$5M#J*J)M,3@MISP\<7#70N+3M35O39>^>
MBI"/2K#YPOO8PZ_]M( #M4=$50[#(VF_%%>*G)&Q$T7K7Z%$3QR%%@8.C<*$
MO_5)JM?HPV_0DYU)1K,(]$RC-E/KHSAF.=D1 @3+D6MB<#9"<4Y@+^%JJ>IR
M_'"!QPD^YGG-)-.=WYQT7A,N=1MT'#IH60EO,/<K\X(Q8ODB%-3CAQW1KBSG
M1UWA"-]ST@#KF8)X7-XT+_C7ZL_)]]F&F2+0VA[:@4W1B@8?< ;UFEYEK"RW
M.O-(L$9823"F0PK#Z9UG(5H>\(FY1<+M\@(F_N\7RD_D?@S[D)L\5BA1I1F\
MH5/?$#%T"<8R.\O>W6QC$JFK(*<NVV5%#HZR&F)IY:1\]*X/4=_["WB7(=)*
MP$.)MX%2[BI+#1$"TUHU?@$+:G5"\Q(VR_,N\%Z,Z =:C^68/=ZII>"<F^GV
M$,.7\4CBY:GJ# @>VF!"[D>,V@S!CB!_)UG_PGE0783QRB=3YE& &5V@^ZUM
MN;?!9^2!34F+>0-!HMLW<&)L-E-GZJ;4O@H8&B^@\8(4(Y?)JS);:.OCGJS?
MA0.;  )6R.=IJ2.DHYY]LT$ #PQ\S[O/9N;,E9M(YR/6K_9,@+R\!A1*D;GU
M&A7:I>Z^*Y#KPKD 0N^W%Y0R?!#*#^+7S0!CK R$@IFOI,Y:SR"KVH R!M&O
MC067>2E[Y:#<^ B_)Y/?D4="^X#_O"4CDK(^7@_1Z^#N3-G'_,6/7(/X.&CE
MT81RY.=,:P6(G6F(:P66XSZ&C !<%<:T:F[];2WY.GK[9I=]0?87$+KP![*]
MRBS=(C! U;"]EK?Z<"_2<V_V?*35\-^IE]%[?VMUM*[Y3%VUN;@GIZ&M/A>^
M?SZ7A'S2A6A/T^?R>?^&\:+?/P2Y5@NM$DQAGC<I5Z]AH:J#O=Y!&;>O&$V8
M:(['GL6^%AD4KJW>F=HE-J.V@0M#)'WY=B.TBX6^Y-6ILI?AU7*Q'<MOP2//
MQB]RJAQ$TUO?4]^Q@%10>B)QZ3_(3G_2O/C%EJ$E5V(T?$L72C4]](D7J ^[
M]P\EIYQWF8WZ(Z/)R5<84UQP XBKIYODM.5Q/)_.3G+:Y/6QWZQ*K6]8?9#[
MV%M5"EM3E<>/'+'VVD1WNY-D0KP_7A X-2XR="B .?,A.ZM@;1G'LBT8[KX:
M*W0L9H+=%\XOJQE:LN[3]&ABT]8%2"WQ%/%P(MPBVTW/;V)2UF_UC[@K]P-1
MJGX.WT^<B0^3N]*X8>BO,S3BJX@8!1[,\4/;-ZU"#.@:P,V;A!/M:Q?0A*^C
MRO5T8:8>B42E-P ,/X^@5[55*LK]4JZGKR,^.JA'.;+>)4Y6.%^<E>/-I"@O
M-G5ERZ2_N4'Z/>M:%6/2?!&%U,DRC4@/(E)I<8CSY$,R[.+^E>)<^8?EOP#I
MX;^ 7]M_ >O&_^/*J=I?0$* <W)>!JC#K[O;G? VO3R_ZRF>?)^81.#!_5E%
MP5D)W.(B+/1X_2ST0-F328S%*#>-/2[H=3^&Z#X3W_B3>R_CQ,7')^J,X^19
M)=X4 B[AK_R3O^I\XWZ\L(AR>G*JS)S; 49HO7P63<Y[:\4']HZ=O&Y5[U-T
M%XET!+Y@:NBFG4DQ=M36:5RT3H&3PI.<7<L9Y<QK:$EI6=HB."I"!7WP-SRT
M"/R"8O/+>=PR!<1F?Y20)DB+OTW9/]R,H->G;;+AIE3(6DF J"6!!1@0WGV0
MN/J/N&8MZO=M\"C4(8F)"_/C.UZ^SCENT\Q)\R(,)Y6V?<6L]ZP&O*[V6NFM
MX!<&KLQ1O"C.W^#63E'CEEH6!'6Q K$&,G*\'XJ$Z#)!4G?DF\%3W3IV./WC
MYTUKS7J6<5[M:L7J?5_M(SMG/I#9""16-G*PR#.XBKCF!7I4QW*Q,\*',48#
M9J0E4]%<;PYR\I8(K0:DO(L_69N(S*S3J@9ZL/\%F'?TO^K2JSOH(WWFIN$
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M:NQ%D\?TF(UC+88.*ZA*Z1;)J$_R4MJ);IK,-"%-[,?C:)5W'Q:NN-%+0KT
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MG2 9Y!HQ+7]Z"A(6/#ALOU@\LN,O"=D2PLVYL0%K&XV%C&G6=90>2?N-DDS
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MY.KOUX#>QAK^LE41%6-3B)?YM]KZ,@+EMZ*%LHD<R@A0G3#VC-ZYPUL6SE^
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MRSADX*YR#(=8JDGW_3[\(2.6E4Z(*F'0C+?>1<OT9QA#T@#":DR880P=@8J
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M_?8MS' >;3QNA,4T F4(9_O1X5<SIF4_)2G$;L497L "42[GZS/&+\<,971
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M0-:Z_-CA/JZ7)S6B?<JT] L,O=$O^#?J+R8G,UU)0#J'S'@Y%L&^DR+O^8]
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M=DI;^/+;WXCUN[W/*MI\B5G X):'F\;Q*-3"R-?]#4P)QJ@_EOICVA1R*V\
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M.J3DR#@U:IE*NM;$\4;D<17]A+4*(B3&:D[ZY_KL[1EK.:DPB;]$2$1PK:C
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M_>*H!"%0W-A(T)OJB?OU6D\@E-&[ [#/+<>%HUZBI5A*93A16UXWA8;OJH#
M=Z?!E<\<)&/UR?=AM?Y(BF0;0UDOT1)"'$S8A-#PHJ)"&-/(UVI7?K;0#DM=
M55+#*==VY:-HKS/6X20\^0/1EO6K@4?)11UR6/R3($_E>[4-6[BZI%4!VAF
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M8V*VHKK?TQV:0/?URSE"$+FDCLXD:3#R8E;*."FD0C#<0.5)(LM]5N69$UD
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M4C5EJ.:E[8?BLPG;7(PYEI>%D*ZJ@WKAKI-3>R@CER[#5!61ICVQO'J+.;E
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MDSG[DB,S!.#.3Y!4[&QR9L1*L#:@5A6U<>MYR]K2SGJ% V:3S&2.-A9HDL!
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M&RV@*],'C8XPZ"K4F5P\BXKZC,;I:29:)QU_&@="1MFFC*OJBK%^?7A>U\D
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M^ZXJ@-H5/H1-KOC;W+NV\IQSV5=Z3*L,*-Q>#[;!CWY<2/MV*[&(,'^&1(2
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MXC%AYR2*>,PT9;OB>N\([=M2;]3U8O-Q,,Y/Y'\N8232.'F[[V1VSH1E*ON
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MU8=$%%R;W=5''+J-2R\K]O%;=.P>VWA7$+O2@XABI.O[I^%UF$58,6)RO$D
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M^YA="LZN$J)%ZG159H:'I5(X:\CPM" \"H.#/U.+46![9X<AZ_]NR<'LYN
MF7?I5"7)GR8AEW0/F*C0)]?-H#ZS+F<9^B[@$Q_876Y^E(1)JPBRXL#@9>($
M,S$P>CO-]N<#<I3$64:M>J*LCTY/$+_ +:DD7U$_@LC;ZLHE$Z]S'\D8H-2!
M4LT(JUIYV+6A)F=$RQ,M%;-6K)W?ZWFF-F=;-<AZ[46,1U=7'J+(V*U4J&#;
MBMF8H2IMN@W,>:O6E=?N8G1C?HX30$(X%E_&TPK,56>E+\V)#J/%2*="I$8[
M%3^AMG67>=S!+)Z;U\<'>6.>^;S/,?>-/9(Z%7A4/S$U*SQZXMN<G6)1RW,V
M@_&YF@K\UL4IX\S$# R B<@J)PQRP%2C4;?J'F<Q4_AA=NY('*>:&UM&2Q%'
M7I4&G0'F8Z8TU6%&_>&4J.8C\-]=P^+X7C9&,YPHOX>H=*/C/W*\>6$XN63?
ME"K$ANEX2]SQ=@S_9S+."+I7J*-J,U>YK1V@>Z0C(BP8V]%7M"(&!LO[F>Q)
MS[X]12A:IT\N .-4#KUT^0)KC6X5!L]HA#>\]P">+),4:.,SG<A\_3ZB .O&
MU0R8H.0)^O$UT=;*?5N!LGF9ND5;D5?BYNV<"1)1NN)IJ-ZUGYO4]*1T03/,
MWYHY,2G$M=JH6VXQZ7/3N/)F-_.3XR5MU:L,A&._;\T/J9V+C2$@V29HQ)&U
M/ILO1&4< Z.Q(CZ^CC$=^-WO%H.]@9&W5K175,L)#9*W.W-:PB<(]J*%)8Y3
MU-P\0!#:'ACLUUZOU>:W8=\(KCX8I9]E?/#2^1O3O#QG[ LB;5(=)XV-]*XZ
MZXB0*@A(8GFY? -YZ.B,;,%.J"PB9S<,Z(:2'9#6O<'-J39H>'((9/LM-T/5
M+@LA>\%D\#K*$WV:B%FS">DR@\(ZH[HUJI6>+[(& </^:(:(-IZ8AXRX%*-0
MI^)V=5,RUFT'.VG%CU6NS*\MC;;Y3&BKR7MR49FW4=#J=\NI32>0K:*>*;E,
MI26M1BV/UHZN69EO4@AUW %353ZA2Z<LO%!;%J?LXD])'P,#=WW/,G+!,@T.
M%1]&"4BM8.9<!"R8BXB60,EZ#]VUF-WPH OHU#;UH-%'4=\JU\1!J3;&</\'
M9^1>X7[N^[8(-J]0V TV93 2Z49R,;]&BB*ANJ9(@%\;WD>] (V 8Z81%2#(
M^]TAEL0$B6B*V/2Y=\)+*BF8_@3-9/F@?6&K#7H7DX?,(M\'86)Q,^,AY1U9
M]'UO=$U%KSBX5TE-MF\$U+\((DQ4,!(#FLL0VOTH$CC.<_#:<8'LW%FO'%[8
M4G6O-Y^LOPYP.KY@QT5LQQE9-]&EFQ;XXWATI@GPFEA]2CY:>RK55=C$S<[8
M4.9]1,]TI<WIY#&ZCT0_AWHC!I+S9,A,"@*U!ZNW$"WRKO9^89-]&2A!*-5A
MNVOF9S7#)BL?'QK\$CU486W'LWP^>42G8)1L>;C(1/1G:C=VF%97IX:QZR1\
MH9G=:*U-)=O/$(M]3>.5BIG:K=79>:BM;SUYVR\ZTH$) \!)(FU;;'+Y=6K6
M>N;;P;( LM[:>SC'Y(A!DERU*5FXOYWKV0&\7#MLLKGYI4><PLB(UC]-T*O-
M'Z.X;!AP?9-5X\S(.1W=%&G<YP-"Y:K&]I1DG[2? 0=F'_>AL6KW%DVY?L+R
M184RI<H<8/Z#0Q,=PQ'EJWYA0VU@@*=M2VQ'\J+<D[[),."V)QT0^T AE_QB
M4]S%F-=-0< <.W-#5:W]8*$]E0J+WRUY6Z#WUS<0I)+U!^'.7%&RQ,F[H'0/
MWXDE,1!$=R==]R6P).E=13>[XGK$#Z:A#T[C3=Z+^M:7+:%6&VG:]()57<ZO
M9ES+!3_DI70^=O^G7+I/./'Y4QSG:P[U&4FQW[H_ZN3]>7]/ 8Z'*7D$ZN+*
M8V0Y9K&-LQ<Q355PJDV=ZNR:XR"AN)GJ=-6&S4ZD0O;Q,KKI23DWI)O)A4^;
MLET\]C?#F8 U<%(;6Z-:/VH:1X\KY=!2E:# A\K\;ZC(_Q.V_"RN)L,)>5'J
MWY+2Y>U<B4D=R>S?Q&P^<G__-8AG[GAHU9>\+YW++VMV-Q%5)U$WD)]F98=.
MWE'4EA'YB1I0H3*\7N+(B%%#6I;:"@QCVE2I/.0&NE8$S84.N>H\Z@&\FAX"
M#F7LV(EU:,HVGDOJ!!(Z9:.W20T:#0'#%4$;KM/U>M]["OJ'Y/UKLB=SZ/HA
MDS%H@-(:H-HMK *(VM 3S7$B3K\!"E]1]:4 2.] GXM\JE6]\,=:%=/>=,K_
MIB8^T31'6D&N,B\*BM'?&*:S3N7'"W5%%)4/A<,YD7$$](^FGBY.=$>STGK8
M8(NX6TZ:Y!,2;YZ!D1MJ,X!Z#TSM]ME 6$/._S-+;-YW<O,>TQ <%B/EERR1
MJ7)\MB?N_0>8GQ%]=;,E@.S%NY\TT3VRU\Y[ZS9YT6PJ2E$S0W\(BQ>VW'J'
M!(HT'Q/UK#ZG2*9HKMQQ,B31[U#U5X!F&/>J\\JGIC_M9/_$W6%F20;C7CP.
M9.&P;Z>DOS0MM<)7JM<X=_L]M:B*!G*U>FB0UGGH8+<O^PQ4/-AV&5BX-4]>
M .C*LG#OLRWYP\P3VJ'N,;F=]>SI/NV("=A^B_&#*-^LN)KCL9 *"'6$X;^-
M@C6$21SNZ4T@$HG;6OTWT]2 S,!_<*QF."@(E^V9F1W"_J".EV4+6<:QYM'&
M,"^ S*(91V*'[G!\BCAJ\7;S\,X7Y;"U0.J'+*]3=MG^OKZ6IL:^95A)8V?T
M^GTE^#"I3E>H^*4!7["@;[:>WI1;Z(!?6@SMBVQFT\?RK;SF4J[(V*$;B_SF
M$ZI \ECIX+.T,N:ZA3J)._($@O.%GDE9_XW1 +U41)NOLX#2KP7AX<OR!$4)
M4%+9WE76E*U3*Z\NH+D_T%.F'#GM)YJDL;X>9DMS@Y0R=5:M<_NV9-Z^V2TM
MC]*1FD>N 6*=4S[\(K&]))%>82?<U8\)9K<WR]U+MNG&)$/<R8SAW$"6]#W,
M.AZOTH9A!8PT\(R"F@_#+\J352?:I"(>L_ J@8"A Y3Z ASI]N'=+YLNO9S_
ME9KOF/*2N 0-<3)%&0<NW^KQ9&^"P=&^P[= H!_;Z"T&BL*1.*?%\M$!@NNZ
ML\DEJ[%R,D_=L-8Q?!E;4N8P!&@E]:2J\%<\9-PO^:Y/XUE'$"UMO4J5&807
MI"!G>HAE"SY+1L,3&>8IMA=15K+V"Z<M+8YAJR;V^.716"=N9VQ]_%US[3>-
M]K+ 4E7OSUW488I.&P,<=\JHW3IO)CD;8@4MJ$\OJ]1L8VL_;^/JW?N0=2X"
MG;4;1Y3*O"&S"\L507?X9'FCR+:1J/[G;Z)CAN8FI@\PTHFYC/(3K2X&/SH;
MQL2GW 3\\V!:%97"V(FASW[DZ?YL[T.]H3T/>'P  Y([K\ZN$Q1'_3SAZ@^L
M$V:5PZNM9_9Z!2R^8Z/V=/<LRE_R=^JM[0W$Q2-J3FHZIFRJY)Q3[3[=3L?[
M0M\&F+_J!MT1.;6_R2>G^]29G).DQJQ#.YK0*C$FN6V+E+7KZCX9-9BH!D*#
M!7M3G$VW9QD^&(A;_HI5MN?_+9$P&/=6D=DQ#KZ1FIU7SL_AL30G:W*7LCC>
M.P0J-*&WA$INN8HO,<?W^R21EI=BB ?/O3HNB_RG>"0N'HHOPK%[T431Q[<\
MQNE6/Y5I&'V@3KU6: KUI@H$EAEIY1B;,R0TOA>T[;-N="IJ=1^)NK>A]FT4
MS0KF?6B87LTTTH6+)RB$N]ON#-DO5<>]UJ1+/$2%F0AGNEX:+UHTSV$JJ5,D
MJC7VEER0G!EA='!Z?C/C,I<W8"[%.R00LB83"*JYNFU!5M,"7AB;^WG \APT
M F4L=FFUZOJ3>=2T6WRO50DYE)[!FNW]Y\L2 Z\:2QQ/5Q14NO);4&DW#Z"7
M_S E8^A_E"#G.&=+[=XE^_Y"(WR1->;"(^6?L6I1T<YKHZ6'M/=&LUP"*_9X
MDY$A F8(5+NB@3T\:?=SD?%./1WQL)OUN<U6::I\,7,']A]J-=TU[.T[9_PM
MXBU-,^+\O(-D]H#TL$6[]$7?!I:U9]4;'_W5YSX-:Z]J%_*HV^HJ#89X/,&7
M$A_.O=UA4AT1&WQ-@62&>($X!+<D(CAM"X6GRVP\QA8[VXQ6\C)/<&%V$]VV
MN="XBS%\, _;-WMYX?J.;#<TN_<R))]N]YA(YZH?V_1*[G,TM.E)G/6AWJI/
M5PTQ,E,,HX?N^6B92VLI9BG"HQ4&R0ML;+ZCG<_!Y&N^:A4]AO#H&G;S1!)K
M<IJ$(Q]X',J7F%M,>RJQE__1M)E1!PNW5&B6IT^Y1O_M;1#9D?]!K,KV%V!R
M]IHO=$*ZYJQN82A2B!*FJC[,;R64V";2.8RCY];#:';33E@MH*DB=H /:[PH
M:314,LR$<F-<71\P+6\%36?5N%Q>S&D3)E?HV^9E4G9NLK>-NGNZK,=8LO:C
M?:$_*<P5'X:,B"[-=TU:;KNC33 5H79K@\^F(E(Z.1>?R[_U#A(XGF2:UCO2
M>XYCLKGKN0C5L/-A(T4F(2B'S"\F!/(ED&BKG$F]&4MM*"*KP$?F$$(PNO9!
M&,IZ^VLMUZ+\5VX?U'<P#2 3C@:P^5/4\QMU0*M\(Q]V5DJ*HD*#(KJC=+HP
M"ZNQ;&'CFND.HWM)5Q/]2B"=X^MKN%9"^$:DK(/#T="$(CQEP4::<6HV8+!%
MZ<"J:4,S9:*(PUX"EX6AAP"?]G\XZ=NU] (7=0*,-B&>@TD6I8^?VTCSL_$X
M&GW9)9*?'QLY&O(Y?#NG8LO<.7/0''0Y!7H-F=IR5T>[#BO!^&R 7!$=:+T8
MS0;QL&UB5'3C8%'"5&4+WHL=Z*9+:C?%#E0H9S/Y'WW'F$:N47.Y?;<B VHA
M&6,:!/>0-%\28$17KB!8!6678%TS4=NUN(DE3R'GH6GR"]@&'>^.'KD;K2XC
MLR%;M+F.O6=DA.W&T5_*84-L_NJLEO)YIYC?.J;YVS?5OK.:M0:-J KSS#[P
M*I(3T@1>;;[ /ENGW=2 _K8%9>P#7A5MNF1]/Z<0:S%)W18.\L&^$_UV&&N*
MZ=0I^^CFW<B@2F2D)K$=3$PT^.^*NL[]3V'39^NH/,=I6)RC*%T5X:V$B@*:
M"Y<;>WH$L=/,^CT)<WQ[G!4#R>T.!U3)]!F<I=43T3-F."5L>$P]!SL^0R/F
M[9L7P_[<Y<3V(L)^[2<M$CLNZT.SH::HI\TQH&6QL*H]?ZEG=%4<ZAJ(-F;?
M62LK6&C7@D81?\C^]\7C$VWB]0P:8B&U#NW^F!*:V-Y]V)2$A]F S1$Y-W8B
M/R%9ZN,/<CR=\C^5=0+/[QH\WN,XC+O7<A+]/(!KH9%&%UD765?,3Z^7Z'9M
M?LP)J5]0LEE)DD13Y>9$0C C)G_[QS?_JD!E+X7$R'=K2TMC#6D.1F]Z,J>R
M).DCV:]C^>[R_ 1GMP$$&YU'@1"JY'F43RW]INA+M,$]!<F?GZ[_VTB>HB1!
MZ!_QAGX%2%)?J=7@Y)Z<H.UT1LN\V'])RYTYX\SXK>FQK_3]^TW?1].)Y9N]
M.S1&SW6@]T] /]5%N;[6MI!+#9OA?Y*7G%A XHQ)1FV9GBG&^AI H7+87,6]
M,HN_KS19CDG5KHSL_^@#+T::O(41_IU]$,>3LDS=;!>IVQ1=X,AG5N,S5B6*
M^( ;_%!6@:/NC+'3Q2E9<6H?@28[?*7="[YSY;&"G#E-RJQT]]>2888=Q_/M
MW%BB%FWX-FH.SQ<WO2H^]N,_U3]+*8B3ULFH=;_"A"Y*(X4RU0IZ31OJ,Z:G
MY4G,+WY1P!SCNSNT5N]=[\2%6^"[.!D"?YY9#*G<0?N8K^HVR'97Y;8!^+':
M6FF54IH_[@,!(8HF)RMHH1QG@O3)RO(Y*=312LS@RERER#Y'NVE&0LK0"^EJ
M^A5Y]F>\"R \HDZ1#P&:(*Y*DJ3'I)4B0?N-/Q_GGF4[<CMT?-R%/I3?VWD:
MR=I(B1<R!6_D47Y4!"'FE"?_(\1260/9VI*4*^>\*&W)HS1;-Y#EP!&PAX,T
M.;E9(@<SP@#Z>-4 4*N&53ZR)%>@Z4SYO=JTS 1IKG+.$6PI(,=PGJ8*ZF?_
MIKDA2@ZF292=%[7FK#HDS,_&%V*,%Q-S)S*1,/[PO3G  U?8W$N$]YCK'PD%
M@R:-FIY#XTM/;B"."Z!+0V+5Y5P;%XONV@K[NPM7@;PXFEE,@#GT.DQ1IW'Y
MIRT#V-&UKBQ!U8:/%.W;D4F[#PK3Z:BY8!:7?%7[R0G*/H%.)?V:'.;J=D=C
M4>3X<DVJ;ZL:_)5_PU8;HIBGB%(.@[E\JW?L1'4O-::M[V?:I77%RYUUZ\R=
M&MA.M;X135)RR42N..5G-$X]G;6>:5]/'Q*B$3HLXAHJ]9)U?,%52N77)=[%
M@&]Q:MA\/W&-RJRQ/K78-H:]T=(-SW;HE.=\5V<1QS8 !=DA5JF]OQ_(Q_>^
M8=EO">YNNC8*.NX7*E\'Z2)#%.<4C5/K\YB)Q$C%QZU36N;G51L#9,DEEE3^
MXET4(.J]@^6>,+L<6G"?:0-MY3E5I:W ;N<K]SE4UG2?T4;[K)&9EB8:SQ_-
M?\B1=6;E8$]856+AD]X_.K 92,@6?UBRTZ<IQ0[;:1* <UN JJ-FQB_A;<5.
M]3,TX+$;M"<5V+YU6S!VP>R(.I,C)$O!UF;>^<&:DV/N6&?9IR&6U?QD FH.
M*H!6X(QB7M[7T:=_0Q/ #I9(5+(=[+[BD[32U;#U)CU)-<Y^CR?B F=SK&NP
M7NF.AEYQJ W0"ZN3':J,[?S^?5D;D!Z@L2A[%R:<N,_+<3*78T\M\*1H>Q/0
MMN?M:J+A;2*CY-@Z/A>M>#*O2<+VM,.8V^DH$J& J"3D#;73HJY5M.[K&?CC
MV7Q,.7VK1*1KBFDUZM(>/#&X<4-S&U)"XI(.VBW/]/U0ZGP$D/'@%]JL)7DS
M^A:(H/6,9<!RC\Y1=.^ZD,986VO>E7 L]5?YZEJFA"&S85SNC);3$^JEVTV_
MT>Z[%7%XTB*2/AL84JZ:Y?Q-$TD7/C5K28R2SH7L:G3+KN\0:_=6**/QY#8,
M#=GR9>]Z#S?1/3_'4-=9<+SU8S@8XBEK.7(F"P%JH_(P7?A3<E6]*-[[_QA^
M$U"SCS<PN*MI5;TW0:!#5?L6ZD&&8K-*^CXT46=NRI>E6% D]EI;RE;ZVXG1
M;OS9@N-.OO15^M;TDD$/7UY@M9J\IO9PM2V8I)9]70YIJ$3V!8<06^YBBOH@
MS/%B^+CL6GDREI"]F)9S8U'"5>-.SX$FI9D4445=+LEN"8E-^O^RB854XS";
M0Z['/,]ZJ\1<[;1J2T[0KZ[-MI90%YW^Z]%ME>-UN)QHIMPAN5D*MI]3B8S_
M1A^N+*'^2.)8?(IC&7*S_G,^K\(L(:'/FNPZ\L7$%QX8X!,8RJ/-] 1D=+,V
MS)1G=C) C(@_$XG16J7E,;G0J 59]PQDMSIQ<7(< 2HV#.!A3';)0@CB8634
M?&@>C-I?PIX]5,ZRVKC1_L&Y5=N\?-ABU0M%TW]7MV6P100<V#639<"$A$0:
M76G\RRKO^%KT,A%_@[Q+8AA0/B?W"G-]:.U:;!N;7@C7.O@(+HBDSP82L](G
MDY8[(5PCLHQ8KS4U\G.!CE#;G7H35/.ZGL45NCOBOZ>G+-4(Q#',<+B0J?\
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M.ETI=[;HW*^N$UMH=.VNG94K^/A(3Y+_.5&9[;BM%=W6+)\-;G_**"T3IX!
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M29'YS/-&:XPSNUA2">ISU>A3@29!T^9FF^ZK08MO;D]T@<"@:Y <O6Y2?*S
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M!I!$Z_K!*.J?-_Y&&?1ES08M^8'*.!5FT7H[T(3U'.>TWMDC@H-K'49K O8
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M4"75NJ&Y9U1;.S,]J+@WK$#!'R]531K=2]]S&R[%+&8]5.N,T_-@O>#C3$+
M#@4JC6A&32G1X^R?,2O8%>,4)ZR[?"-9WQ3 !K7XZK-QZ+_4_#S1FN& C(6+
MA+;B?R1CY(WHU3+&W#D&BU <%>^WQ45+%2A+VA1R:8$H<M_0I3=Q98"0*B4F
M>*!IL:"6<4M5K82G\\\&'<T;)K\>W\/"UX:KIG75S.F7@Y!?%5<HK7XEPY&&
M I666"B-!H83\&<2AW)QVG\Q("$!<.:-[]6N2_6\X+B%JN!&^9*&"FCL4#16
M-53,&Y/BI6QV"BC>JH.>!9I*MGH7CW<A%DSFIO@K_J=].(-'B=S2?PI6;??_
M;ID\W/6Q5*F>)PX!-@&-O:V1N19-6=])N"+2)QD >_P(_&P@>R$LA%MUQ=DF
MP&ZEJ0P$7HCA+_M=%Y]7Y 44+S[]D2LET@TA+I=$!3\7I(ILNS^1!W2M"XT-
MK(APZ.*\G;>^5X%C<ZZ@7S)<[Y&J>@HL/,C6-?$#DPDOOW39-(0Z;WZYWU4M
M,&06EFZB(\F_.R\Z';T7US<GN5G135+E)XL.*W8V,RU"&URS:[_AY//@PC7!
MEPKIT[0J^Z*LRU4IHFI,^#((UL1TM=30&#[0,00:R<T5=??E0'[YV=XW-TN_
M9<"F;?>/,!!-3AE\++$8-6&Z;0X3U6^V0H_5SB[I3=5L*_I(#-&*B _&5JKF
M4U PG&S;E'_Q?:US8I!^F=3ZR]+Q$4BO:ZW*L/)9'ML3[=&2T=YP,#^E8*%7
M(37%G-YH40&?E?Z 6RDQO/)1*O%W%\<.9G.>K%]R!.4UHB'"R!.M2IWU34
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M@@@E(=8PD>$@ML\?LF@-Q]UL::"_4O2&"B&S[M*56&$($I%XE9,MJJ4"UM%
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MYP\%\1O[GZ-+;(P<]%TB7"_3,/!Z\ :ONI+H+U7BBNKIG2O <??YJE.T#!.
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MOUDS:\W;\KP>#QU_!I"HJZBI (! #* WT!L .%YF:M6]@4 AD#<0+LS"? (
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M>O<S +""GA04LP : /!XZ'@90'C%%F$#M5+4 F <KP"(3UL VZ 3O>,1P&T
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MR\+S J,)\ +PVG2B&(RG0("SOT*',? "YK3JOUPVBI '&.,#-+@ /"]&K(.
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M+8R'5*P&T'.=J^4^(*/.-5C-T+^,T9Q)@>V9/!= X K2:ZO)\93#%5^!2:W
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MI(%S"'L7D8_XIS2R-?H:O4+ZSKF027@U0Z>/&\PSY]LQ"RS9829[<:[<O6;
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MLC_9<7%YM[A)+NC]'22F>2UZ)'3PZLH/>WS[IU-$&UF9S\F<;Z6HC.$UZ-#
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MX0F$"\KE&[K+3$ZG-@;<-=43^S5.Y>5.U=N%_/RS>H)]_<U7="7Y*0L(M^^
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M6UHJA=$#J>E)5=D*<(9F6/OWY'B$S&\? :XO#HM894AWBQ ]:W]W5SU@_FK
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M4')?1@\IP&MR*RM)(7&HNKD1AJIPB[D)_B!'9OG"=E][O+CIJVNJ]:%RVH.
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MTG0WCE2JHU-?GW1#\QM06!R%"TW@/A*-0O:OKBX.6K456=RB0T97Y-2-@8Q
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MX0Y_A[2*#5#MS9=7VI78\S%7X5 QGST,4X5.A0-JWRK [#I[4WJM,X5X6$0
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M+"A.@Q,_.(RS#D,R<M4W$Y?9_8&UO<!Z@=HH^04[I6D3!A<JM69-C7#@!:?
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MN'FQD5+*\&0IJ7'*C<HL\CZ'NP7$]_'7EM4>=8+74=YN=JXZ0%K/2 :&38P
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M?_'P&#6^V-9X33H/]5#C8%<5*H5M_1('QE59Q?WG84Y7_SUA3BCV_U'[5SD
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MO TI DM[\AS3.G[H*IX29NE/J Q>%:R)E6 SL-U1V[]#R4,\C\B+RR4VD^&
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MH79HDR_O2(V_ N"\'K19S)F[3[6GN\O;132 BNJ-K5IS\YO[*9OI8F,[T+%
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MW6&!M)-2A18(WZQ3A'EY>'G&C=1+W'QSJJ@A*GF6F/+KY%)^_!^3THJ0%/D
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M#OO>U#37@CT3K&/DO!S2VM;]XA+Z"JA#,2@T.,W'6OF94#]+(,ZQNF>J,YK
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M\C 0QJLV!N+Z<'VC$K7#<@#P:2X'ZDN><#<A&@@E7<2:8*=C;5B5BVE_^FB
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M"N0*Y KD"N0*Y KD"N0*Y KD"N0*Y KD/PR"^=OK<< N(#$:+QH)\6]S !D
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M+T];S=?I(Y+H=0OCEY2V@7=NS./>?8((Z5)ZQQ#9X@<P+AO_4D3E?R!"\F"
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MVND(;)785/Z8LRE7BZ#<K'F:>TX?2YM$PJ"-Q6RHAJI:QV((U"@!JO+'X!O
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M3UKU[LBF4>0FM1A6NZZ/8*$Z:VE,NRJ?.5#8".GMV3Z'(ZKKQ0H8FU\H8W6
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M:EC?/A!Q=I[TJ@I\89,@R=N"Y3B^,_O<2=L8?R3*S_ L<H.F$$DYX[DWF=L
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MK 4Z3HN3.#FPDZ]_Q*[Q2?BD8,HW4]M(L;%1.[ >78.YE493F BKWF ;9@F
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MW1T2/,@  PPP2!+<"3:#$Q@(,+@[G'Q?G?KOPZVZ]YR7KNK'WM)[K=5[=_!
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M0Q9'2N_2KU_NE,U';+>.<(SQ=85#%84_LM**J=5:VF(-/S[ZL.0>FN?J1<^
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M4?0&C>.^.Q W):H=-@ONCP2P)[VX#V.8\%:4ESH2FW#[.W,"%C1&GAP[CNY
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MH-?JD6V05&0)EE(UXO^X@.JXC5ZC"10V44.5"BA"C)"(%>@9+%69]=5*=]O
MB/4O]%JO'L/]DAQUH.?N%PE)0>:3RD6[UF*W',E/[I"8._<(*/4RG/E8TO';
M,/.S88'M27CQ?;^X_N 1ZO=$Q)FHI?_YVWME?;&[$U;4X5U979^P22/4<0$N
M<C$PCA3X'6GZ#<I?L)_?F%CD(I>WZ&^+RWA0S<D&[7#LSCL SP_DFY>L.,32
M<.OV8B??0-QYJIMNZFK#6['W1_H8W!1SR:PL5\4K4'5/:.?[>DPGF^S,Q%<8
MSYE;QK6[_O^_-WK?D]R2];/B1._4'H\](8N)">W4DEC\L@_,^ONG3\2RDJ6
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M&] W414^297\]O"]P_P%=_'%(.H& 6^DM;%F[<9TA'',R=4[UX.8$#5^X4?
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MN;UU8>0"HWWUO$\K2ZI3[([/&RY-HMRS"Y2=P'7?!A3;7]*3[9N:S5T+IJ/
M5<-/&X -99ZUOEFAM;JC=-,Z-(\ #!IL0M;8%\2I/_,)SZ?G#QO4K?$\3CYM
MO&;:F$D)X%;A\;N+MCR=_T@XJ<8MC$=;W4!/]H+/-@</G!7DK1\U$_O%*J?)
M0XTQP",@J]@G#N/U^_6-;6P_>RO_D ZV:L:&F>62^0YBOG)0?Q=F*[O.$B6E
MYG*!@1AP.B$ORC)BH?&R8Z=+T>S[!J<.3UVH:&'+Q:;W<P(Z@.>"MK[-E[9F
MGU94>6H4.#56%2,!>$(L(G!V'98US)9$9,'M>75^L6VQ0I>H[C\Y4,X$:_-3
M>8TLUA\VQ%'7<EO2_ZRDX2$^2BGC.O<(8*HM,\QLO+\2NL1_@O4GC_C=]C<R
M:,T)^A%PJ%L01_4(Z*BHKLQKCM0-V3Z)][2Y"S=<5*V:S$)U\*1^U-=G+M][
MCIJO>7H.[?G4^'[=WF#P&=V-51#V2@#*[,_P%UKB\M7?65UV$#*:SK^EXM1[
M/E SI\8.\_"?YH;QT^)EXE616'.-E+/-/*:-@>WWF\G[A\R+^?1AAT9&!XUS
M-V*@Q@OJ*JU6%Y:/B0NW@ELK?EZ'O9^]+U]^\E<]49:ZD&^)[&? WR'D,_N4
M)I@X;5'HU_M\KI1'4E;DQ0\B07[FZ!#I*M)F^NJ)#&A8%GS!)\MAM? :T07I
MI'2$NYJGQ,1$Y+4@UR.Q#KB=V,^RY^. ,Z]9"H>:>L]RYNKW6@ZQV"G8*MN"
MFA'#A6W&>[U-(X^ !;$!/8_9/JQZCH!\6AD7Z%G2G%^L:BB_V_0>IK#5)H:]
M[B06W69=/RRX_R#.V%/1HFF1[^/\/V2E*<O:Z)\=X#3(TL(,5EE9%J;S0@_O
M\)7H6X45V;E_5KXW=7A>@-;_E=R)@^B2OJ=(N249OYA<)$PP5-56M$A&"C,G
M5OR-:=#X9PAAQ]*;;>/SD?^4?O%NVCW3Z0^Y+!]+=#]8U0RQ1JEUQSXAK_1S
M<S\AGR'FJT>)'N^KI(I\.!$HV9G^GB\2M#5*/I4D1CVTV(9%+5< >]GF%;$K
M$)Z7?L]]=79G?IR'<+Y?RI:\H'8</,H,G _H&14^K7K7(%TC[\0XW@6)C+5F
M8:#Y2B/G]>9/ML+J%=O9<OK-?OCI9JS?!W-$PZRK?Z98@/VMA2&_E5+D<I=Y
M]6_'PO:9077#A9OT*U+O"B7F$ZI?D4/&/ZM "A195#6Z 7\Q!#@"FGN4*( '
M \9I\KP&^UZ4X0[  TVPM9LH5G<-,G=JH?)TB9KZ+"I=9<C[^=\(BS_@Z;WX
MXH*R6=OIV\4H1!#^A$7QZF!M'!;-;#!:>OZ5G/\[F1?O].4K6F%2CP#SA\!K
MK]2X_Y5?QM*9UL^=O+9!+';OZZ63%IM>])=OO ]W=0$+Z%-[?'8M5/NXO"+B
MF-,TZ&ECR<1LW^0A9\R;O9V>,4MB*&K=/6MFOK6&ZO4GY6.8YJ;23G&2M!0'
M_L NZZ-S%/:L@(<4>R0[W)B[UH[;UX9P"-T,09UY"*F#+%7.>6Z29P%$6E]]
M*@$8\@"E_>+NJ-U1)TM_;ZKA%E;UNA#M^@J=BE55/87]3^M$W=L?K"#0IJ4%
M<9)I_/U$+;]5HI@_/#(BL,ZKT=Q=YK*BFV:VLHHJ[K,<12U[M_#\*KUY=H.)
MJM@7@:9[$RF;.L57V@=?%'EW1SI&!J]6CY35CWD9T?R4_D?5+#[JU9P.W4EU
MNS&Y<JV4$E/$=$_Z>P=;CQS=/G]!N[JPOS:VY2#.S1)7^%?EZKH)_A?F/F]D
M#YL=X4>"S>T]$(%&UJ3G".>\]>CUR3A'FSP<@X^38,<BG1O'Z'6P/80%W<3?
MNYMM'_-OE#'];+0:)B:DX2G^FIMJ@4A\^4>[F@)+^!J#M[>RH':@<N7LD/VM
MU<2@T+Y2752-$U^K2<LGY??=G_VIY:#%:>IRX0ICO#&4.\&#]5?Z+O,J@JH<
M9XB^/7MK17&J=3O/W&"K=?.)'+ZDN!_MS;P,]^S:R U+AF2D3<./FAJ=,_QQ
MXPA3':JBH\"""W__&1;(S.2D&OQ>;=FWMJO2F=?UQORU(;3;UW%@P73%)"8A
M*;:)CX]!O+H0133APMI%H:^:0J[B)7= J2OQ?;1W,5F+N+;52$?K4(=13>G*
M[F=$,U-VI,J0UBN:8YQ&+>T'?30'!7N6^SNWW/Y2R)?-YJN0R5M5(JITJSN%
M$J>C>FZ#O_.96_UST?FOR!>BR@>OCTVHXAT5/Y4<2+,?/G=Z=S!,WG$X,1)_
M99^>E9WM2TSHXVD>&E2N8I=%_@CXX5S#?Z4*(65!R.6C7/W&#*6D203*[GQN
MS)'BK6=WVV?GH]?W0FN3AO^=B+[CJ8[?&%6[SD :1+C(5L-W\<.FP]9]0Z-N
M94'(R_=H67.6B &\BF>)H_WQ'H\ N840R<I*1C(^EZ>D[(-I\$C903_!:@S?
M&<Q6X15K8%%\7=K&Z@ZSY^>X08;&8NZF<:_7_M_(TU0*/VC6>2-['%M=-O&C
M7EOGN]0>[^ZUA7$:L6Y<G1ZL!,@D>E%/)=WU)^JG,[-_DIK[EBA=8>4"P3T*
M'AK^N>+)2^VBV"3^7@%/. D="GXUF<'9?1[;C"_G>DLT3OC"CI 1Q*QK9MN*
M]+B-ZZ;4'1PFGK3PL _] &NSS:E-5OI[K"/?RC'CG< :9=,Y';6$NN28(OB0
M&DWRYY3 I)[?K/81T*R/+55^45!'[^%-LICE9OA^D-DFV(<AAON[,N,:$Z6\
M/:%35"-9L\:\_[OQMJIQ=6MF&QAWJ)N<'SI%<UK%G$0+\R],X*RW#3E)40Q)
MQ08J,]-P/VMY=OCD$G!_=9FF@TXM*W!HM&V ZBO-KD%))8)R:Z2%OJC;?E4Z
M78^(B%;URHQYXAB:+7^4B$T_N)/A\D8J[BTQEHBF)>-'FZ0?>R(NP9FU[YO*
MJSJUY>J'%X4&XCQ[*RG,&G*W\@') D2S4TB@9.U 'QQ-]GL(US+ZB3CAH "G
M)ZG]EU7'V0JEB]#]/M3,<&B,3C>3@& 56]'4RE<SW>CD:;/L:(/AE&K0O/3D
M9P-BV?;X<VG367@&DW9?S>[\K_XZU<&\'$<*7NX@<-2!XJ_4^/)Z1A@)&&BJ
M,$;DOQ7,[\8D8E/D:5A6ETW\)S=Y9$^5+>"/DI8S,"7X(1_1QHOQX[SQ(&F
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M:?;Q^?$,T_Z0GM<\HK)OQMK8GG@=&)I46=_,\,*;]!T;L;+EN"KAI!S!,I!
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M=Y$)>Y&%)07-#UC/T\+T_-)Y,K=)YHT1A* F?J1QA[][;VF]:<GT 1:_!Z'
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M'M'Y6W:*OU7+C "KM!OE> #W22,93?DVQN?"+SPV0&@SXN^X&W%25Z 'RL9
M8O@WT W!FD<6O:$\1\:M0=.-:E,SY.P*9.E69%QX?U'VU>"V(G^Q:@^T(Q^
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M52<VIW,P^T\TCA]3AMM)&>#7YN/.@JHNXF4F#<=)_L_2>Y $KC +E)4%1#@
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M%\-%6=U3]"K-4SK>S.RDI/P3\!'=&Y8QE+XC>D-W+D!G?=4X[E2;J6J&/I@
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M&.".IH-*2*IEHO57&6\>I7KFI3W.?EBYT4%5JX'!NK.Q&1:,28@9M"77.R!
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M$3<7-OY1<^'PPZN':J)V\5Y0(#TT^29H)/]TX_KF%N##]A_F#/QC3@@H]Q;
M8W8=U!GU[T3Z7SL'*',IC/LC%&_#/AW1^&73_Y3V 'T+$/DCWSCQ/XRRL?%?
MZL;A;@%L\Q(WAIVF_SGC+>!<X9^-<9W?^D=:T\[%'A?1U?'3/^\+U!9B$CE^
MDPCZ!Z-Y01.W@.6J6T#5Z3]6SC]-F ?6,,[R8#J/G:8ZUR'_M1MOW(N58W>F
M:68*"2)WKCM=]1CK2086B(WN,*+>A]:8;1FIIY/A8LIU7A*D@"[]Z!\*L)(^
MM7SRZOLJTDN%\,C$0RO(+.CBIK.,-*CYG_QY(JS*5N^(U<3<6)>#Q5+HV)E*
M1C(S72YZM\GN&9=0%)EGQOX ]U'BO2,%)]H&AY ]14E-ME^_*C=Q<">L704>
MN=?Z5B5B2^O$P.D$]@%I2,1CC=8OCUE-=QVD2^;5,3)>)BMG$:AKO?<.7OS2
M.HWO=P-22Z"5<?D=^TY/-V)CIO*TSH5]:NBX&,KY\2>)'4'7<ZG8M@CU@L-F
M2/V$#$6Z?-YV81&!,'**B0HI\B1;@D$IYN=NFA*JU?WYUHN&3LYAAYF!H>_!
M0F:>/ .!R[BA_DZ&WF>NUAK];B=U!KKKN=[65D?G!"5*1N40SG33@,DY/UP+
ME5]):!X5.>DBS] _ 9ZY+DC(ABIHY#JGS-:!6ILX+=6FA^Q$5*S3%A^5P#>=
M<TFGG-JC<!V7OGX>:*>Z6)MT,(RAGX758:SGO@6YK,WS#Q06 ,E[]Q*J[YZE
M<M;5%L8;S'#&OU[/^/2 Y9,8BP_+7Z?/U)Z$^;!L60U!VV&G&?5<,TTF18 -
M85I::7A*5XF1K/6W^8%GR0^WC6-,8K))I1AZ%VIT!Y]%]3LG7;@OX^65)]'F
MI!0;ZF3&ZWCSQ'^25K8U;(Y3IT45?^Z8R(^::>_U:;X/YOKXI@K<E[>.]Z/N
MA6E_8WAO2:W67&IU\*A0CFK\SYV[,.M4 P-\=Z\#VM?/T4<2>,%II?KB#>A"
M[8I)V/#/@]&5V,1IUW7M=N?*#*_BP=:3^,66M[8SM)\&RITWLXFP>K0P<+E%
M4H#<B%%>>#DM'AN_-29MY]L%);&+>T#@TD-1%.<#2WVPLM/YIP?FO4?MYK:3
M"B-TYM&4BVWK_KO/BYKRU@=@V=4/..J1A%7WVQW."/L-,BZN[@S'/,CHB=E&
M3MTS#1,>%8D]=9,Z4)1BV)<B&R+2EY2C=#0I;M7C8*N5V(I!34^WR',N*HLC
M7EG5MA([5L[.>#OLP":'9KRMK&5\G!C;?7:LGN?2TRN+&Q@U>.IN^D? >ZW,
MU[PXEA*_\XO\#YO;&VD\"S!A-CX)F2$7\S#%FU:J06PN?'GX\%UV4-NW>PG_
M'W-O%15GUW4+%EJXNQ0>G. .@>!:N+N[NP1W=PON#H5K<"DLN#L$)T""0]+O
M=[K[C.^,T?W+N3I7^_(98^^YUYQSK;6?1?@%A22/=L7([,*:T]1U11<CMQHK
M];JJW;\^@<?8W]ZLGTW4TK2N]B/],<=G#&/JA^YXOPAYV6,WUHDR55/J'IS1
M5KXRB;S("H-:5[(:?2FX#W<GX16%\A=UO'SK50UQ2O?!#O4IM4P.Y"WE_D>?
M&H?]7@B;?,EM65C>2^232;4X&E#KO1D]HI/)82AK,QH\=K5M%(:$$V2-\:6T
M-Q(5Q2JE<6CW4Q,R77G7#9ECCU>@OYC:7QQJ\[#FDY2EGK4YX-(5)8>ASXDR
M;GV8>LP]6HU*-@^\GQ]R=XDO&I8[PDT>UY.T.#_2GSMD38WAW03$9>0U2Z1O
MHC3,1ACRU&%LU4^?406OJ[*KV_CVD7;9WC/\CG=W"]UVFCF0%;:")!A4_D+;
M+HJKB-N7OL91LGA<U'_4^+VV_,W6<B\TGIQ<5Z*TM)KI?BV^(;$L4AI-F-BN
MAV )HS=8@5$+P9"<J#RCNY#IOALB6,@$%7_(>62%'OX'AHY.P0NU1^O>_(@D
MYR+>V^]=\(?\00R6'Y,%UZH6RZ^' _DGD)DV*F=\3"J-E :CAFDTB7.=P\)'
MTD*Z4*=Q4XX:MZ^(SU_K:NJT& U7S4HJH^K4%Y\WFPN.0DE!F[?J.K5#5<UU
MIN8Z^ BZ"J>'BV8@XAJ#2.]?AA$=@MO:$T7[_LYZ[H7\3=YT.,5KU><<[06:
MC/^+)RYZ;)AJ8>QO!3N2Y)H21RN:;B3X\''&OL\DKV@\Y2V5[E&&!?/F#'HY
MV9FS<("0N+LKTIT$M/6=6H!ZSN?Y>8%N3\N'3"+K CY/'DMO5=UO4]J$Y"1S
MH@GV*9Y>QLZ6!?GX:X.8H(\:# >/$U;RU6/?/DQI)&TMQT;14\\I)NVRC]<L
M-Q3=9[4E>R>9-V6$$N#:G6-$0*0%C6:567!Q[U2Q&\)&MZ<@@V@%6J(<OPZ<
MB:-?$@WL!@D_;C5&;E1"8OW;9SNG)WXC/,0[_1(S:R-%8H/V"VT& ]C$O^R*
MA(0^\I&/8R3I+$31M!J(6VN0,1'0AH/ ='CAK',84!T$>)A\M^F^?TLKR >$
M;VO+& F66VUYJ%11,7K@AR)&=S;EXWWGMQGV#%1,-V%0U]1, 8UQ;D<GSQ9&
M4$!^0L1OE51,6^C;<X=R2(Z<$(A)E9Q $AA*H75;EP'*3$9"_NL-*H;9*&G]
M ^V"]8ZN&CRZ"4>;RAA.4LQ[-+H)<5XRO'R=FGHYH35IYA%UN<L;(\&O[D?P
M]\@;3MGWLT+$][8^.BYC7NE;E])6LJ0,=;NZLOR75E@J-.C#SKQ4=,!FV,TT
MJO32E+'HAAZ@#E=MRCK1^<>-S:@Y1SS-7-("J?:CBF]"7,3V++ DC,]2 IFP
ML@[Q'N(;G$9Q;+J>&<>-Z(&-T1IN_;EJ[NP,D_;\(E..<=E?-)%0AO+6\WI5
M#1_*H73_-JI0\&Y6PX(A;R3+9%DK;*=+:5+*2]+<$\NAI)M-RM&]89)=QI&]
M=-1STS#-N2;OD'^6HT"O;\;#X'RYE$Y+L&\D5J4&AV2!G[J-)HOR#@^'SI/!
MG_DS>9@@H]X +[L5(';PQB!L*&RO P -O$AR\V=UOJ=OUT;3,U^9@H*ULP0C
M6 42B\R08=/0X3#QY V<I/ LJ0NGB*4'Y'YG%1O5:%\M9EHX$*7&01 '+G11
M5MJU>3^D>.&7UL=I&4DEV24JH^/3+1V]P)TJ3M6R_050KV(;@J-7^[1T'>7\
M,3(F-K\2.*GTBU QTT1,M5_8!7CVWCF,-\9J_D*@SXM46\BBTVS1M3:HM&9E
M^Z:Z8I!W].>PR4[PW"[H;.;N>]"*)38V8LQ;G&&&L=6,J.OY+ENDEC8CW268
MR?GJT=JQN:37X6W:KZ>/B9.MIO\.U8LFP^@  '\#I,7TK1WHNF._;6SI6&I/
M][XB^^B. 0:DBKT)3^9EN[/]SQ8VV(?$"/0-MIZM?+]DDB!2?&<Q6JR,([/O
MXNL 5$);B(-2J]6%8+M?5=9+6U"DPG7N1_9=UG15$7QH[F:S81]O]:BW:EI<
MED+&3\UOJ!^^=J-6,N\:U\JC8G%F?H82RZ&Q+9W';Y^=:UL*$#T4.2TL':M:
MB0SJ1UZY:S:N;==O;/$!$S%PET =N1<>U%_&+$5MK=9YWT?Y>QW.@JO:3;%7
M%QEK3,<99CEP5(YR)BAAQ<9AT&R6+Z.G1E?LSEZC^D^"8,@B+?!5E6Q4&8F5
MCN,R._A,<R 33K)D'Z>M-MH:W]I8[4:SN7A"=HRF6+X\6([5?TGN:S,S/319
MJ$PZ<-?B7#?W0;=?T]04TO0:SCS^-T3R6Z@'-#U.HKF%4<NWN&4_)N9>/M?*
M;);VUY-U699&^O>* XF5-'-/KQIF<1<MVEPBO8>ZYTV\ZE<Z\-=4(YRF=K"A
MR0WJ&3]1MG#ZIK: 9(F^&51BIPYJI\0*14Y#$T@LQ9U."\/)I*TW8&$0?\9'
MN-MBTR^7@:T7QU?KXEY+:6UL9 4"/HB57R:;<?-8DZ)GP>RJ[PG<EES.(!4+
M10-EMF'9 +N/N E4A"@"I?2?\'LA#P?[\S+7EX-3X[/EFWG8=ZX05W>$+F1H
MW\J1A3DBM'6#_,*RHE138Z$*?3LMS7- UTB+]2ES230TW5CJ::R&S*UU64D
M@Z%.2].!U;._/G-C;KOZ,-:P#6F6)>.23G2,^^H6=/-C=\:T__ZNP_3SD;<7
MGUT>5P#."LQ#,9U9=,S*\,N"KQRN/MGV"I\CY/BG 5YU;MM0H[GVQ]$$NZLT
M!ZX82DJMGUO'NDE#*;KR^*/!GP(UUC1^\!3IN/V1>?(%@Q^L+^=2]W#>!]AJ
MB9T?[H7J&>RMU'J^+4/Q^+3];L&>UZ*V;\F&<@BH&/*22MVL%(5N(IBN-$ZZ
M[>O2EQHL<MK.-Z,(^'*9#3QVN36GB7@;[PT-4&8)0TWUI 1Y@I^6I02QM]7:
M7PC[1C7I_2-4YK8&-;!*H(_OCO91[9M._:LHV'I;<4870BJX&_D/[%)TT2IP
M7'PLU@UZ&?\3%!S/#KZ,'EH*>"Z*WS5H!]!D5CE(J9IRD-(5DUP$U,3D[7(W
MT3G'980$B/X"--+7\Y:276O\CX7M\[07NO ,)5IJMM679O2]=&K-TLT2!J],
MD*],!( 368RMBX[:3*4\6G2Q[1_=.*31X!H3CVE=IN92)C)HC'T"PE?(_:[^
M @S,^;:+/E.L6R^_/ME7^\O>=FC"Y79CPR1(D-NLN;.CT?TD36\<ZF* )!R>
MI<4G $G7X8W0/:D8 R];Y^-C[?6;>2?;*W;!I_>VT&%H26:UKE@5+[FMV<H$
M2@$S/H(J0QV3Q:;W3W3OBSQ#.^]?I@HVT)+7B+KZF3K._ MK;::WMLB%,:O&
M-Y>IE8LW/3+19Z*IIMO^M2G_\KP0O6&V(O"UW+QM-T0<JO&/$Z=])Z+?5!]J
M;C9K;?)B7[4RCVNP74PP:#<&;6BLAB@AU#0"<86 60=3+*6V6H-<.DU(<;8]
MYHY/)TWETC7VS:RJII#NNJN *5:I9LCUT,25T9'\Y4I_7],3? ]GC;U-PYX.
M*=P&U)[N\T]M/9OO@=87]P*KI^O:)Z&+]UM&@(DSR12QF&D9J0ZSKJSZ3;\.
MAZ/:LM4OM5K/ZXB;_%!D1XCM1;L[)RNA[E;UV4JU$H_V]I9:O)]:+-8W0 \=
M#W7+C5 VP9[[R'@U"N.UTZ,_6_<J7"O/.J'((V<C?9M2NX#FT4,CZN1A&M_=
M=-=_5&3B6&U&RF'$BO$EZO5]@XBN7[!S>A=+=R>'6RD8V(A7A2FT;R6OS/T>
MX_$)XV,H.S'PUUH-^,)O7-;R<6$VM,/RQJAI>Y HB26DOZ@R _T((V#P);0V
M4#[104KT<Q=Y^1(%RO&7U.%0F42?',+_Y<O*,!R?9[BGX.!T",PS-@2G.!4W
M^VVS6,BIG^/B.SQRJXZ]P/I\/O,&9[>DW>*$2%<EU;;]#4 FG[LZ<O"V(9@)
M&CC,>$?D(GZ'1D$5<D<LWR0Z7<=O:7JI&4(9MI<$[_JI53;)[7B8]^<ZO\_B
M7P")75P9OMOFKW] &DZ9F\>4]/L;Q3'WZJ^G=Y^8Z7\]*92<8-?<&%X(F)&Y
M^KTL@Y;FEGC]'>Q@F^^MV]YS;-&ZB4*?[[6KY#G+M\@_5['Q4N+V%'U ;[ W
MD%D6%>FAXFZ.,/]E3[82,X]:-L_5Q[&99[Q9U=!01-*KD<3RI3Y56SK;8Y.-
M%XQ:?BUYZ1.S*.0,2D]B('^!*3/K4#65CNA12G%]K2O W78M6V>MC7QE*.!3
M\,SI5A Z2TC;]+B]7A4(A3E,QD2K$WCE9/<P?>*$1*H)UP+$X>$HHE^QH#('
M=2B0PA'.U#K,4&3@X->H(?BTB?<8-)"$Z<=Y!F;KZ3RAB2''!5W$(YECC_0I
MO@GJ_2&&'N>;+=K4"_J2W/.*IXV@'^A_ >S7^]]^D)^K/HD>]A%G]+[+CX(I
M4VA"-K1#-OS%C413L3.6L"_]#;%7QR,U30=59,S_O>142,B:U^O4(V-#?59:
MINEP7)O>:M@3>7$&4:#L9KJ V)74^#OD5C,V;#!6;-JW=ZT*C%-E&.J22S##
MUM7!,3-CH/SK+V"T6.+P(+0,*RVTLEI&M+JR2"U@LCA('#A!,R$J.7R(7^Z.
M3*3(P@F#$AW%T_Z:@T\4!P?+W?[:,67X0#NB3I!0Z-AC<-R^*2AG<!GIENB>
M_NOJJ&,ELN/E0F1K95<-= -W5YGQ$@S3&R@&\ 7(&I>'-2X<=D09HPG),0]C
M(%W19OS:2Y6!GVY.^R"AVTHF4&H%M\8KGD? DBQ7R^M(2E_#NM'F$!E3LMWC
MX3%/JR*CA"LGPK.HY+EJ8(XS/3V:$\>%H\!!%R-ZE#9)^SZ9#%#!%].$"P8
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M<TL$ <AG8HG:GP)TF/$IN$)]*7& ?P%1B0&W3T%RPY6:/[)4ELP06(JC];L
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M)5BG;UW==8IU$QJS,B0.53>(T&[*:7.R'C7 T>W34WI-EJ4460N[)EG(I/D
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M-0MYB\,UIU.-?!O(R[L6>$,!5'@IW,=?!6PN+C6.#&]W9PP7(YJZU'961#=
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M5F)ZBE];ZIXV_^?B?*)>+K>G3&(7E$I_[[I]\G]^>#PL"/@CNO5$$5Z=GD$
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M=!(^-&$39,EBG^2 &;3LOP8I89&.* YF;Y'5UQ^XY-91QW[C?"1L36N*L'_
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M26V:*;!B)%95(_X\9#%U3O:K.&S?7OAH.C0FN5W6#[4YX!2(QF_;TI>^4B\
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M^'MIK-(P3V>)8EA"-O"LA];VL&!>,X<GLT"+"O,)(V$S$.-IC)!AKHG,NX^
M+:X#7Z=XAQN %7F28YV???PP0JV%A"PLB\R ?/Q#?_DGT&F'*J!?.V/DG+1"
M^[3Q"I]DN+\SLI1M36Q78KZ-G YB?<]X^^:Z_QW%;=*=CH)3,P63^]F8%[V6
M3/NB0&XX1\TJO(Z?@2C+'DV_I1KHL5[81I>G]I!=.K/&-,64+XSPRCL[P2L!
MSPPBRM5_GP?QQ40W-ZH@LA IH[DQJ%B"&:$WE2PIEL[RIREI"E HB[%O>R-N
MKB"/T9.@JHC\[KHO\P,X*EZ71_2BZ<V:5V,0[-5A@:44;!5H0'.Y]]FZD\ .
MF_6S^2. 6DG&0WB)KIF/1EG1I2HAYSK:(P2C]35.("Z.%\ )83K;]<9VW;Y7
M?Q+7-6M^3+4@_N?I7X!JU)YFE2Y)>O5F'*N<+VL6)T=9YGEIG+TR'&^%.<1T
MY=4^HW%)K^8006!/H?.#AY2X!*=25NX<QUS0[]!YKF8*QN<U7?*!SIK%/P)M
M83U3D=O(5Z+5RQU,DYHFN2WO_F_  OZ[]!]02P,$%     @ FSIV5@IDK&?[
M]P$ $U8" !(   !I;6<S,#8P,#DY.%\R,2YJ<&?LO =8%-NR-CSD("!1R2!!
M!"3'(2>)$B1G&(9A"!-@9LB21 $E"8@H400DYYQ%$%! %) H(B(@&90@(/ !
M;MVZM^?<<\\]__=\]W^HIF=Z5=6JMU;5"MT]31\,'[P#D&NJ:J@"L+"PL;RQ
MO & @R66&CU') :)=D2ZLHKP"P(DE32T<7$!A\22W!08^V<1P,Z(90[ 8>!4
M8\0&  [_&+'Q *>UD2@(*Q@"@[':0T 8QV_5.8_UR9?,F D<$V^LIUX%T0M<
M:V([EDD=RZ:/Y(<[UG'IE"O*"8'1=<>XNF,.BWA'/#TTQL .B80=:V@@,! (
MPAW^_?CH6QF&.BJ?/JYKX.1UI*'DA#FJ\Z=-"$H'!(<87C(U_ 'VK8(>"HET
M,(!@W%UU[9S!AVP2@!X !4 >;@X 5H !  +  -P!KL=5B%U_:'\WHP3#(/[P
MB,3.W0F&<4(<FSPL$QUK*VN;:7V+AO21/C;?+RVF_*G%NJX8)R0"?<@]>]PN
M5PSB>R,.&VF'^E'0AZ*U_Y2@$,I_%A"8/PN7[6#H'P4=*,;C1^$2'*;RHW 8
MQS]-*X%=H'\$XIN# 'TU)>7#+YSC8WM65GNDNYT"\AW@.ZFA$'_C*<'^KJ>$
MLC<T0F!4V?5A&,!/I 2S9_T=7Q\-PQSS];Q@"MX_V,0>$# &B5(!84 _>H4>
M5 _]O5<<'?_QK7P<!(@#YG?F#0^[^>_X!F#8-[X>"JQ@]H--#D8A74T<(8?)
M/<R7$P+Z/6)D1P+]0Y^4D!@,$@Y#(J!_5"'Y+CERX2<^Z7>^OA/4\6?!J>^"
M0]]^L(]Z#L[2-Q]PFO?%#@<<UO?OXUYU_EA&]F<+Y ._U<(E/2X>C5GFXS+=
MKV6<S\=EHN_UL(YK<9%_"_/W]']#P=DX/E8'"#@X'$I@AY_X?U3ZQDF_G_B#
M(WS\:7[X^9TC=OS)]R?GV.:7X^/#D73P6\+Y>"3^S\N.8T'X+:+'?@&P%;[M
M?\B8?\3I6YG^Z A'[(?WW\1CAZ$;^Q&ZO]-/O",]W+%_HO"#_IP8  AWV%$'
MPSZ"M4.Z(^S1?QF78(S0=S>/.O-/'0GPEQX'4/K1,[^YH?^CXQTW 1\-<P)#
MT,:PRT=#!^L7'+QCV>$!Y>%.<%S04/G)-@$4A71W_86%CT0Y09U^S(J7#(XJ
MZ1[S#LND('<,4@V"@*! &(C]L??>KM\G=>)ORD><(XD&',KZ?Z']..XHV"]+
MPW'P?^5HHZ&_+A_X(!C&$ 3]A4=VM  :0KPP&FAU0^W+WR<HPN_L7Y2)')$H
M'T68$_1[I$Y_:[SZ=_91=.TA#B#WXQF*R ."POQ&W?@[^U?U4W90920,B?HI
MN!3?*BBI_1 <N:&#1!Q]$V&0KH?+$!KR<^"(88>!_!N7Q.YXJOL;_Q3J:$+[
M"_MX!%WX5N^H.\NO O[D4QP?8GV;>7"ICTM'"<4Y+A_I VC8_@C8@\-=]_#P
M'0!PY[!3T. #: %8!\,'2P 217ND'<1&61N ?; ,(#LN >P#C^H=C &N T@(
M"0F)"$F(B$@H3A&?HJ Y34)RFH:6BHJ&BHJ6@N28_OCZ/6&1GCI%2D9*3D9&
M3DU&1D9]]$%&_:T*Q;]BX. Q@(+PT/D'.%AL &P*+!P*K(/QPX82'[1AR1]Z
MB8=U3'^$$0> A8V+AT] 2$1\"NNO0BP -LYW(3D "Q<+!QL7&X\ GQ /AT3D
M4$B!@WN.4@A/\0J(BLTM2!B?.B:]5(F=@T:_Q4Y$%'7ME3(!9ZS!ZN0:&"UV
MYF%9\'F5.$/[2T\R,.)G^XS>0SZ57V_M=Y_ZK,IU)_-&17S;P(?UK,JGKZ<W
MC!T\0NX^JFH?G-F44#.!>H8F9%=W#,UN40"PL0^]Q3WVB0 ?3^S8A7-"E+B'
M'KBQ4>$)!\50'WG0HO]J583#;A)U+5;9@ :,%EWCQ#]R@."\V).^0R<RSMI?
M,A+'0-[_<.$?>\#UIPL'HP 2G&-,"H \8-V_L,]E/M[(8J69X57Y:_#:6]JE
MEJ+B-UHVM4D7 TJA9AM&RU5)2:]%&%QX(&?,YGTG+&#EY_8W89ZYT/PYG[1W
M<P> &WL\$V9[GKSR5%D3 3J%U0ZBIU6K11NHY%9>";T><6F4W>4MG- FO]A7
ME*B]4PS6_5HZ "XYB[7,7];1L!\]WC@DO\W2<P!XF*O:G"=63?E&8N/B G=5
M57_%> 8MZ:6WX1Y+#@< Y<-]W6-L/\8)Y'X9=K??XNWS3XL.LV $WA*[%B\Z
MP#_;USH;:CBW8>,@>Y\$4BDX K8$NRAL,-5VC"P5KQ<A=P3Z#@#B-[B[Y8VJ
M&YI>9"?/2BI'Y^&_NUP#K!>'^WI4+N96#BV:2*EI!&AO)*(%NB WKCUZ^_X
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M.J$3.J$3.J$3.J$3.J$3.J$3.J'_970PJ7K9$8-QE1(00*#Y04<WO_G!2+B
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MG4&VI*5$7Q"BJ<E],VM@5SI)Q,VY4*,6_H3/HMYPX8W+J,[T'6$CN%&[@"Y
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M .9XTIAG="V]RA%,#;O&-L:^NO4Y:C5-?4MNMO/>6LMY\PIA[?D;SZ?[+0%
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M\D],EDKOC"Y;J(_P(1HZJ$)"GN%>WH&Q!'854R8:G@U%X>]G5TET;B_M;CZ
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M<W/S_H7)F@P7X9#+MZ%"M^>U>)>[2>*VJA-Z R)]NQ4 \(@/UQ3E=7ERXVU
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M&DKS8"U"7IC6>"PJHNJ\#(=T G-K5*&-6(5DUL\;NJ,F943H$5]\4_-'GO@
M)P_4#(WQT]#R^%01R[E"Q/THLL.3"$\*U@(-X:"GQ$(<LF11=$*+2>3=;(4*
MR=3DO*2W59;D=6L&LLD5 (]G8E5'V'0WA#8^YDF /Q)1)VXV@UH'SV]NW_LL
M$8I$,I,,"<?$,&JJ,YSV'@\SM'KVS,@Y4[K<NO]![0NHYL>F'OC$VR=NRA/F
MESHUC66F"]21#BN9E/!*Z!/&[G,N[D0=#7=X@;WB1%Z:D(X;OB2I5]=D;#'+
M]-K53&ZK[1OI8[[&I7'R87T"K)]6LT.FV/UZI<:FLA5[)OSO!R\4>@?X;Y1M
M-:V7!=>M%+:R,KJ<HR]YCYVS[DP#O%^:(Q5NH2 D[.8U\/SAK50)'F\@':]+
MW6BA\4-MI:\ZM#$69-'9Y^-/%4O<E.DF*<,*NO$U)RFNLQ:<$B[$$2A((/=^
MF3WI%I+-C4H1Y%Q05;7<DG1_[;TN-ZW!Q>2\ACQU%3WJ6+-$K0K11BXW$]K"
M<35M]](0_)$%KB!:/O-:?;YW;[MO2VCRM3=?\(M*@Q.P\V! JQSI.A R];!J
MIF!^>Y,9JU:\13Z\;A<.J%NWCE'02'Q=/ME]7.8'BVZ&HU9+FY&8A#K,S%L,
MGH8><6>$FBBJ75&#'6:?@=-$"WIM"JI\$5SL,H:7N";\-&"40766UG%,9VQL
ML^]L3X0E[>7&+S0@ JZJ-CUWP;P8SK4-G\Z7@11REGTKT5?;MC,YU$I**_J#
M_6F\S=9ZV9M%(Z,"2W&(Y?O253VE/PSLH:U?>]V8@JO:.TX> .)Q>2?'VMO(
M7U!=-%<>'[\?*).G-.WB\HRR.\0J^MQU6:;--Y!-)DUFR(R5CH5;MCF:6#E2
M,B*7%Z[QW#ABEKC=('E*7$Y L*65>R2H%2<U@X"=5GJC]W:AY^-IF85XR+GX
MH%9N2U 0PS5"7(IK0JFOC=(Q*Q:O1U%DE;6;\I<!7;V==@D9NQ8CLLK%(=*<
MTTWS"BYUS*\(U H[NKKTU_ ; (:X4#DJ.FX=H5O9+S'>]U,*O37>?-'OHL=&
MOZ)YK;IWY\)' !,O+#3J2]T@YTTQ>1IR5&Y-566JY87',_'OA8&?A:6%VF<Y
M$M\PN8[XFA0T/NA+?/2JKJI]?&$+DCFV<>]C4ONT!&2TTO\3WA6^,L>R_-WS
M[3=-<C?@P0:/8/1SM_8:-H+N5=V[,[M0?NF]VP5<L2C65X7KZR'O^Y,OL=_+
M5+7[&F581\.!!CP6/!=N&Q3<Q)NU>IIV8N'36Z>=G.OC+91O6D2%OEA?/->&
M)B)GUG$<?S]M;S1#-L+\D:M>YO7"H_Y;!G]LQB3CJ95FG1%F%UD7MN4<F%S/
MD-X-Y#U?P*'_J>,:Q<U/[/L<#BCV3D,AU_U13&;)IWL@+R=OW5$UCN2WC$@N
M-CJ6&+I:"K?NI>>G>?A53=^11"1N0U6F9]UU/ @;NL_>[[UD&7-74O)*K%M)
MP:P<[WRR_J_;PRV++!LK@T+/W=Q[\3M^S T.KYV!8EJ[#VP!!'*&M4223OS2
M=R<?1ZS?$.]'R,U071<>B^(C-#X\:7SO^. &26P/VR5* 1-/V[R,JD6%9\.>
M8E$:X!#@^9@G:I0BG1\6\P++J58!<993\\65K;GC#YD_#"[R#E!V(XR<(F$$
MSE38'/NO@&P IR?31B'1'(K=>Y^Y5!432#>VJ=5OFU).^WU\5Y4)D\HF=JX#
MXPGM7^1,F^)G?FWOM:0GDG^QR$B!M[.;\.OSHL>H# KM[#6RE)QS[G&/23%P
MD,6UL"$R&E/:A'NQ#,DDC.3J!+A!5BHSY285[^,?P\>\QJQ2%@\ ]KQPI-](
M;D6Q)3*^YYSVHX\]UTWT+U>.9[A(J3X;WMHM;$H/,S$PTV"*$H^Q+*ZTOV%^
MECY9/7QRFD9X\9'X6^97?.ZGO(L0;1&XCVAC&!_-W^K^$/E,YAW6;0)>2K(V
M5( CHTN>Z]Y>:E(6(<7;H35/*FWR>[<_/6.\PE8Z;>EU^<53#9FYYZH,@MA^
MH-S4J-;Z.+=--72?RV>VD93,E=1G<.G]O.[GN\]X 8T/X^W*]Y^-3%V+HRF+
MB<%<@\'HKIBS;V'DZ1)&AZD4^OA2(.1WA:9#PWEE;(MT-$N)6WQV1YC(\!Q1
M:[-GG 4K,ZP>>DVUR@=7J6>[SB;$<.CU\8J[DE@6^7!_KFI-C!87]7:S=KBL
M<;&2333L1?J73^P-HU9VRJ<KLD0_\U=EUHQ%%FK7W !I&+LE0\7A%Z2#;RNP
M$[ &3\@*JB4@;XH5<-;STD!LYY^:F8*"<:X1SM-2*MKTI$1?-E: E:#+N 7#
MPQ,SKHV+4PAQM<;$89D^7FRR-*9S#P@[!5USLW%68F:^]9:8;%>M]&9ITZ"(
MYFF!AAI;,S6)F2O73$]_QHJ)%:=C=K>M0A7+B^H+7'\/Q%+"15$.JW4^ 4Y?
MY?5MRR>7[==_% J57%?K8-&5GTOV3Y4-$+"^2D?MR>4V 8#Y$P2PF\4.3X%6
MQUC7OQRNDMX%IAEB:$ADX&EP<8*L&4K:6#"#A#39O&FQ0?I>(0/#&:VRIT N
MDL9['Y.[W>5#4KJ<3$:*)=OXKX3SE,7>F]%[TRW2?\^= +%W=>>]A5/_0S7V
M%C:.!_?&IWABL08R:*9=A84-D^T=\E4[J:H]R,9>XU8P?QT".TFMI@/'>BW%
M7[IPYZL_3>(S#25"MFEP*_E]IF'84^Z^2;/YU$PAT??T61&SVX*7ZUVZV&F>
M:]'>13U0FN-_62W"?;&695:5(3@V(@D4Z?#U=##=UTL5>9RT4<81@6AZ=2 1
M /N,>A8'FHHQ3)4F"(BH,JO>6+Z#B;;;4"C40@6["8I*VD+,^0"55ZK2-<B0
M9!SI)J:W*S7BL#;?>A<TU$@FA;U,X&XI05N=<LRZX@2\3^+\-$63!GV[JRXH
M*%"Q92$B&4TK87P[XS3A9^SZE6X4$5TOCSN ^4K-9V#A['F""*C<2C)X-EK.
M;79R>VK79T^H6^L<+G1Z=@?F@;LEYV[!P>0QM@+?TUB(V'GM4>*\%&\]RE&M
M:R,1'ZT(L]!6X#L%:I!*UQRFWHLTSZ<4-$^L%Y.;%[9T6*P8\9!F,!I3-WNO
M4<7_^#+0,I[A'L4[XWDIL:IL-LT^&1&>Z[,*!4SXFB'&'0U$DJS!382L)+ W
MTNWFH:2*? \M6KU=.$(@MTQBQ4.,&8O ,<J^131:JGK+M?I924G4VJE;DP+)
M-Y:HQ_)KE90F<.7\X^?[?=)'PG0;VG@O"1K?98$)DBG7[-)]9"E]DMIFPOA5
M\N-VF)V!6\!JY/W(4G?T>XKK=FRKKZM;O+:!M];GV+8^^IA+5!::\5.D:96(
MIW>$TS,$2ZO%]$QV0U9?KZ7JORR;M6ORHY[+]@!Y<$/=Y5X5J@Y8Y0\^L:,<
M'LW@."O#&57W-8(LM'J]98ZO9&GJBBDAF&(L:9-OV'$FY:G<%]$K%4]<JQ)\
M(6X@:8LWZ6H,^21W8D0"/PZW<F^3HPAQR:7Y(POF=C8B/'<P3TQMQC%RBR6:
M  &2M0T-*NG(UT%D$9W/VW=0G.9_KD &MTQ$]HH8/OMNI&4.I30/Q5[ \2P>
MS:%0-QL@E(UT3ZP-ESEW_9GH^<<R.=!R?OL@6VL/KQ''</+NFQ?M9*HRNB-+
M5[-N1&456HS,$UL3L2<7^+.KO=>,$6'[?,YD&-^5)HA3 8B;^_"]=%<]Z7G?
M?#;<5PUR:PI?P_IX#J_'V6DE.8(#-<9RIA+*M9J8GKRQ[A/2&LLL(G-&]#AV
MK&CWSVI=6"[)4<Q\U7]]HO+CR(O.(!/"^G'5+OWDCUNFSFY4O:6V5]/#;F=5
M5Z^="<X<7?W,%ZN*Q"RLP=^S&KA+Z[H%X7ZM<;)?A=RZ1,N!NT]K>)'7XI5[
MBN:4!2GF197)(/9'W@\63TJ>9&5%I+F3:\:RQZIZ!Z'4<??D%PHSE,;.V0]7
M3L<R)8L*QSYYGD2:"^.\YEK2-W%KP0#\]/:-R82I3KBF"Z&/:-@G,_T1[\I\
MY4$,GT7H<FRO:5EL^XPZ>VT4M[FX &Y#"X?QS7'"&1-5K+*BJ @<7JRRCXQ:
MZ6O:R0D[^.ED64ZDW56H'N+GZ?R@:6&5+E&WFG-6' 9=(5$J[IQ6&FFH1\4_
M/826A63:*EF'W(FLV*QH8:XR^)C%S\!@3\K#0,!+H:S$+E.Q3L!M2YE;TM8>
MSK35H10I\TK<Y!R6W>74>R\A2W>E=(*\6_M>B%E$?S7<B1"ODN*QB,-=U>:X
MP.D]@IV+-6WW5OCZ!SVPOYV!5M/K+X^&POD*AE0J$*0' )+$!;VA#W6GT'!/
M:G3SM;L+YSQP,R]0/_X_5+SS=QULT/>[D\:VG1W;5F,WMFTUR8YMI[%M8\>V
M;35N;"?MN9^SSGK>]USS!UP_S)I9W\]H^R\E:RJ?\QX":^=_S,B#K&:46/;,
M72-\MZFTLW5^N>SA8:Z>5S9O^TJ>J,=BDFPSN/**(2/@Z:)F"AP&&Z7SLW9V
M'RZ9Z/3!GS?9NFG+NCK:$^G9\ NJ]@PC-5'.L-!$00ENQXWWPGS#QH,S%(TV
M.UE<4HI^YH7NN<]L-=#40%>H)8PD9W>=HN8+,C6G 5S/HLL:?_;9Z%&_GL7G
MIQ7][#V1>_!9=>/_JAJ=+)^@0SKXSM7<NB,\P&=%OE*;'!:16W^H4YK:'5:[
ML0Z)7+2JK7)2H=4URU-GG;6:\KSFW1J:9E<CM?9L/T,H+:CF.BF'ESN8BDG#
MZ31!$:Y? &55[/R"<?NWY_7" %,M^NN1[Q]@J!5*,A4(;H_((ZNCDID*MS9*
MTYX:/=9F2(;#EDO=#+!^(A.TC?+O)ER'.GM/MR"BXK^HY\Y>S0Z;[!;_66+]
M_G6>K8$IU3Q2F5(Y3U<DE5J[Z.ASDJ,DO%E+*T;8JEOR/2:@K^_L]$R/!#:/
MW3_$86+NK)<?4X]Y:?OO1E3;>NL5IM[*\]'D<TJ-DY>6RZ;X3Y5(J0K=R]D+
M*#B:M:$V]FQOXDOB HMZF\$RNN7T]??>0N%F10N<RAFB\#(1W_\\G<?JVVN<
M@_#$L!-Z/8^\@-,#:Y#1:Y>;NT[PC-O$K"ONKW[1T'K?TJ=(@4$L6[4/JVPC
M!IS=XND!PS/E-:<V>O+G!E<:TV#HRY.S)?1ME>\]/X9MS1%#S+[96[4I_!P5
M>ZQ<G;], (5=.X15V/;8J?!S\AT-K7C*G-?U)Q+XVI"1VX^S4_8!TG0_AA7M
MV2_$7 >'9J+GC$F+@^)(=R@_^(0,'3X<'@;VGOYX5-62>GPHC"G16-HVV@N)
M: ;UZ$O:??\";3%%M*\>NE/6?R#TU8^O0ZV/F5Z!FJ]L?(1#]-A>@CWDRL:"
M;":B]\,MH(J^^7W=G+[L9IM[D:J _P&6II%6'RY77GIT7UI6?< Y9?9Q017T
M/]>]X*70B8+H>\ZWX[N?E780<BG:5WO]P"$Z'K5Z&J$\K<.7D65G.+(M[SZI
M?/OUH5%(#P&]?_,#;OZ,HG@(^V>2])&L[)NU^YU(F@QB_I20GI5>]OAH527S
M;_-P-/<;L(^PVS IUDS%"AD8M\;H?*_4*=U%6N&&9+)H\W>@J[(YL$_V!AY]
M*""_O!\ZE;GE9?^\4-'L:MP5("[C;JBW(TCS@&QM%1X0!/7V/4,?L^4FFC4;
MC^S)XX'QZR"7%^@.6_[VM?/5@O7YJ#RP+G2JN-A7V%1"-\KI@F*?\/_(P-I[
MG_:I'#]^15V+M& 'HE,.7'Q6[[]N;G9P[+*LUCZ(^6;R\?OH;)7:)Y=0X=IC
M@K);+]<4!40D8 D132/255(;'YBB\XA1AFXF,_ O]J9_SBF7O9UM=O'C%UW"
M84V\%4^0F-OCQ"6AL8NJ2""V89=@9+%R#I9;1)'26Y+XHTU((XT'X8\6]:K'
MU-+K3;[5I/]OLZ,*]PKZTG!D/FM-!V*)&1#6_H'8R? N'&3: N\ZC! 7A<W0
M.]V]5[ZJF\.F*6W[OJ6[#?R&=$=+>;)YI+7)1'E;JFBQX8$3Y^<%7=1&GODF
M?RA8566PCG*LHAV4" _ @'E2JSMO_.,M^5P-M-1HCL@U19XT3]JA"!>V)_EQ
M/QZM!Q4H"T@*F;-,WST5_ ?XE.8A[7TI7E<*/9O;:$TU>_D'0/W>^;=TY,4M
MYRMACYCJ&33H?&UNA3#9IC:((R[RUI7;0[']ANIV<?PTAJ]LYSV5VU++^5^(
MS;GZ$U.].H%](,#NW!%M[KL%#(YZ#VU4A"U"'8CJ//Y7>SAB0\S9F'90I-AE
M1 SF[#/.G+?3$!\M3+[L18(:6 ZV! 6+(8.D.'J@_/)<[M%=[:L<"N 5TJ+"
M (EL(O+&'*U+2,:;J+YY!>%)MI$AU>K-E>5R@==Q>V/\_>SF)$\:@X^L7M$(
M7E*1\2'F:^@T44%2XSATFM12<5&'75L;M\3D"/L,3)WU(UY5%@\&D+XS<\1X
MPL3.T=T7LD;17UB3IW?\$UXHEFH%R0UQ=LW%52"<RLQ1RI@=]G@*"3/5T ET
M:$HHQ%.3(-W)H=>OHFF7H0LZ-)M\)6&A9R6#2C.">I5QG9G#D4%MB?LJKHB@
M)AAW(':#!A)AK3\I=*V:EKG.3O/R$I!7WEL/I^*1:S>+X:2YUB1F&PK@4).
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MF4I^E/C[GI#66J=S$'%Z/(G^9!FNR9*#5GN7JZ,39XG0)6>:TC2#$&=6A%8
MY[/@*B>ZVL%)1OZNM+?4LC/&&)'#!2^?D;UR8B;QDE63(\)8#$$,_RRCJ&@V
MELB>G!;F&UX06D'PP8DT&6O!(/I6.B#R[([(FW&=P[1S.2/YD/_2BVW'X41?
MSTZN&:>6P<"Q9TAYOG-VKN5&>=RV3SMZ*EXZ>).40LEW@[$?A\P.A7?)<9;Z
MNP0HUJ^Z9LSJ"IM:;5K2XC3[79)Y0%KM)6L3Q!+*%2]X8, 1UD)[Z">NEKI
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M8H2FAEEY/UC1("AUN.\C@Y&<QNM)!2C$D )L9/TAR"G240A8,G\<(ALIQAS
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M%G/Q_ _X@Q<HX/DQRX[N%X]]'PF7A&^/CX;G![-->E.#)B7/N6R;Z4@-J['
M60H(>B82Y;"ZKDF"XIVB-^)C!@=5:"K+CK;=D,DK:IMN?S@):.$C]4=2\JQ8
MVM^MMF)4C!A=_3F;J7%SMK&YK:1J=:PO]);R?@($:V%/ (8$Q9>B_O;:>'@Y
M.#_[^!?_I]7TDT:8-&MZRAG9VBBH&3@"NG-4 TGWQSO,SJ05J*K60<8^E?=B
MDB;U8Y($K$:TL#@G+@,.=)M)T]B4-SF5&4'DC.=B2Q;67Y&AXF6=TQPF87^7
MMRC@66XHBSWCQ-(:C)?DULZ^7'F3 -58K2+=[X)/@"QA1RB#!. M?_))FHR
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M@H/_37C=A-:4@FOZSS8;&;\)SA!UM0=+MOE?5OEL5VOVAU9[@&6-.OY[I4^
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M)46_C%RWG/R:DL>PZM)J0$+)SC!*SRBY>O->Q.=0\3S_>C1NUB;_WO,)D&O
M]YG17N74'N^:H'6WBHH220GCFDW,^UQ$XV;O&-)WL  E-.YPXUS,%@QPAAN'
MQ?HZO>0!=>_FYOH'M_SD;RB=(&/?9EW(TK)SZ4NG\=AZO'+5'N*(!5)O(]A
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MEHV6Z/2WWCH^?NA2I>EZ17'%TB(:F M;>LT@="(K5[STD_KAQE?;3DS&&G&
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M%-(COM_SM:#Q]WWP1MX?7P=Z;YNZK%F<G>W<4)W_LR.+F7.*?@AZ%:4R$QH
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MD_F36N"#%8^?@>U%-+@N=?I!HS+@[U,(J/7G$\B+VBS(KQG:MTA"6\%Q>A=
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M%(\-/_>$QS!8*0IA"[:B"'$H@EW"0@5PBK)JWLZY]X.+>MIJ$P%!^V4I77X
M';,1H=$[2.^2$\BC+Y<48E:?M]9[LJJYUES^-_?]G8(8X('(8@AY'7HQ1$TH
M.NN5R_WZ[JD_1YS4PA#U:7;\\YT_G;P)\?8VC4H() J%@,(NX2#N\TTWX %_
M;$W-R5JAUR/ =[ )U^GK_"- >FO'&/X<!>=-L::E_=X>5"DND0L[A,%>!8S3
MWH-HHP\OE[@WHO_)WSX"&KO86:#0['NQZU.H:A$">7IUUWZ-_LW_$(_KY!6
M1)X# F=.YI@@Z,,YLZ71AYD=,26)YE-($&W5U.V-][6_N'] ]-!NH+$/Y9X
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MVVQO6;<?G-32=HT R,;NN^L\7-Q-'1#;G'>K]!L"^S$\W#NN8Z_#C<\3J$>
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M<K/&:TM[W3.3#X3;0N D;I;R%0+.YND>GT:%=B0U4ZJF56EG=]D@INR2Z?)
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M)J[&M_UY$/P>53/E=7!"W..=7XV_C_>TG9F?I7&RW]V3]]G9HTA6@ C)=M'
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M08ZC3&JE!(@&FYU92O;,>==QP1\+T]^M(?AT944G.8 OLACDO;&M;JR8#LF
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MJ *L=W8\<+EOR?W<GZX8@Q'P*]C-+B8_+C0!235W/Q,E G\&M.2["'I+]VR
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MH(CR]&4+WL5;A6WG@=R'WUC(*T,E:4+A[._#6*;INVH]/>PD-\S*S5L*4O=
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M'3<B%@V>IWB*Q0[125]Q"AS?+6D?KE3Z*5;)])\O))<L#GV4_)&J+AN+\ZI
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M3$CL=R(=W1?>%\=?3&(IWB:.CH>5IFQ\(T<EBGY=Q$:<UH]L6[X3LF'EHX*
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MY./NRTLG' ;:@7EJXJ<MW/'(1!!XC!"&&2Y[;#8N"3Z14K#_X6-'N:GV+#2
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M)^UY>FMKYK</+#6\?-E*$D^M04]3"+['D%)J\,,$;3Y^-[F+>!"#!EC1IT/
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ML 83,@Y>S)T65J-8"AG5T?#*<\#C\ALSA"R23QI+\#CP[/&,<XVI*Y#I2Q.
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MX-1@1U.[^7?[-S1\%(JN@X)MNP6D"MHYF4P:E.MX"JA_"!!FOQN(_,07].(
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M3E0?0)E3_@IL,1TL<#8M7+C]ND0$-G+2:LF4-G_KE:D$Z,@6_%8M%+6/,(C
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M#@H"R28=:H@)$@1 ,'/(.'O?;2*:Q&CO[ZJU2+)8_(6I?X#X2!F^&]EV,[[
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MU74^AT,[L; !C?1-KB3))')=]\Z%':S\W='PT&KK]-(R/5'B$G##H*6WOV
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MX/MOL*]OZ([' ]Q90&+_XBW50SKD_GQ(.LXW5I^!86GVYIKX:T!8@.(U]!%
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MN;#QRF<?BXY/"W1/S9*['@'K[:YP^(1-]W,1?$BV"*>:B<R(V_2VUF5)Q.B
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M.\C'M3<YG?[$(#B"!#>F1/M-Q\=9UM\ S-+$<B*,I]K,AA#& U)S0T6_?KN
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M0".6-$ 1 %BR!QS$])FO]?U!]4 A'#5VF=1+:^2@C]E)<$W0/?D_!%UBQID
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M"L\IA*6;=J2]=UTHYH<I /EE=W@TB>I2(Z*A7/78W6M8@Q[R@0WO?/9'7J-
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M>Y5ED2"W07?QIA(1.;;;WIXB5YH>.4$7W4EPM@3@U0(PEV'F?03(Z[ <UD[
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MR;VF=#%R\NJ9[,1%9:NZ7S.N7O2J?(S7;PL:HU%T76I:YD.TK,_9X&AR_#!
MD%D2M2*157C";'<9*_"]FCTSUYL&;W5;@-RE2L2TB!Q(E/1R5)W-Z<8322X/
M4?MR<U'N:YGO@N_&_V<L09;R4'W4N9%,9__)-=2]ASR]<!Y$)IE VQ5,;+]+
MW,?";JQ)Y[@I2Y/T=C*HVO&32)8?N 1<"TD\$U_*\HYZ[G8^?U@@2OI]@F;<
M[=\F=/5'I511)_'M,Q@&N8(*TS['^8E#D#HKXQZ7B*A'GP>4ND-18L)=Y$#C
M]FWCHS!X]7Q<;%:F+Q;Q$/\ 6\J=?WP2I37/LM[./K@- 5^R/(![R0I+67Q=
MQ&I8-BC;Q%IKP<:YQMTL]^F8YUE>.C5<5W>^3WZ^WKY_ 1M1+YY-RHF>H,<F
MH@(BG')]?=/[HVX;I1-B)+6\-9"%I=92=3O3$>3;7OI2HJ!B[L.PY4^#3EO/
M_05PLMD2#HVYJYLB2_Y,QV6KRD+\%7)[?2P"!5K*\MY%>[==X0NZA)M !GQY
M920O#BVY.)N,B1O'TK$^&CJP2YPFC=5X<:9NOZ=+)N*UA(NB>(!/*"(D'"\+
MS0(MHTI):/D4CAW'Q5N]"V_HP!_F*1K'+N]HE%]($>SFD%?I&2)-&=\07'QT
MM4N,#?G6X()8\%-^ 7/:5OTJ&,PI-\6V'\$C9\&*]1-$)'ID2^;@#,_>D?[D
M.QZ,]L2SXO878-7%8^M TQ5H).]A*.<L?#EX:@[&9+$UUX4)4''$ATGLOVQZ
M'H9ECQ^FKDRNN%W=]"H,WR9U+\.\]8B$7$JQB=6366S=:[@1+VAG"EN*G@YA
MA8KZ%@(W*A.IE2R2,^48S7-M=19292/OR'OQ7F8YKLLV9K?>%HBA(Q>+AXS'
M16!MFQ-!DYS*V=__XU5+6?]SA,.+X<2WP17@!=2!GECK;B,:?-BM=@N6!]Y*
MI-EHF?7Q#X]6_P0JVKS[YI9V(69G8?]RF"P&UYW>3+]!U$X!Y1U/N\*$[8J!
MYMSB6DW(/#9^N7U1N&[.^ ?AU2,/]"\.YH&O7?[<Z833S9O-D<IW1QS*:8MM
MP4?KJ4:Q653&S<YP?::8VY75DLWC<^I\^*^,.J6OP]][!#2%K@FE++L<41P0
MAK$C\QSA]AW05EEO"=<D6>V:DJWBBDR_Y+;!\P.LKL%(RR$6X93#S9,:Z_;$
M2R6649D'2;(0M#:U$(H '00VVP#K9^6&N;R_@&1+$'9'EFE[],NF8'"%])['
MI15#K2>[YH.S?$TGLKS;[^A(U79UY;=[U*[<+?VOTP'9S&*0DH_ )'(BM]:C
MF2K;TTQMMZV+VK%=MR%*<;(E>.IKZ%SPOX<5KS+K>.B>!K5\%(7 ^C6,([0O
MEJZ?FQPAO_FBOC'9L4)M;1K@)':J68P8'A!G,2:]$>VK,.W6=\W,)3>G2]%&
MI_0T72B-3Y-'-W\:M6K<(PGM%^I)_)NU*M'L^HA]T+6 1H>LWZKZ1EC<B[ZR
MZD6;<1XL]X4KD@ Q<F::(S.*/2*2%2L0$>X:)FI?8BIGRZ[[FDF2;20Q(CZ^
MMNL0Y(_[$2:CDL6%;K,47R#M..V2DJ[,66P][5(L=_<_.I_B_X;V.L2=\LM-
M'=$O@XRP=V,1*SOR!?;LKM;S+2V-+-1,M]% OW2#.-Y=1=I4TF]C_%AZX?3J
M@\[8 XPH;%]=C^F^9UM$K_!I)+N9515Y8A7A^J/6*[WBXQ#^@"<CS,FD1Y/^
M7G9-1<O-2>O'!16,K@4G_[A594<T4Y74TT402:[WR.*(P&SR>HK+CY$&GVV=
ML++H1GX@E?C$.Q_:.R1"P;H]9_#-!>=0_' H*,&3E2MB/"1,7?VWZ9LRV'K?
MM+#-/(XC,A',;9Y2PS>T/CXK2;^/+5LG,"&:+A3_AFSG^;W')W/&)@T"2E7Z
M:*?DGXM^L;]\0A5_K," LZS6IN6@I/)! 7SZ5=)C<S$0_J ,79GVP]&B+\O;
M?GY<WY9WR?2+N$651*NLIY]JSA9A[!-_$G"<LY]V1MWYC\;?(@R#5'_Q5--'
M')* =FN9:(<2/K"W8#PVEMD8NO?+H=/ZQD>L???A?W@$FYPBQOAI\\7R4>9\
MR;1LDF+G6FN_]2KNU^H_;9YN/FR+]DX(.\+1H%11SYW/"]?;>*MNTQLXV1V/
ML:"6VA/*\\MG8^?G]&VTCMKCQVB?K5R.:TI8Z[H=GO>*]X8NMEIU:ITMR9DH
M?O-.]=X\3HG0FB/1^.7M]AQD!-JY3^$<QI5K:+Z=Y?JN41)]+T.7VN1:_C#
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M508=C=Y@/75:8[94I]<2M0J#7$;0I\Y11+YS6"++E-^5%SL[[VB:7A0/\[S
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M&_9*./08I/:PFT4&N<SJFGWB?]3!Q0ART@_J[O::_?OF_>>!;L?N).)>C%A
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MSY#:/6_EA$H8+>,XRP>\OXY+L]U_Y*P+&V1'K12:5ZQ>DAQT [V$Z\L9J>@
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MP)]R1PYDLPO&TS;*],0T=A^2? KS'CJ%_GT>MZ[ZP((+8Z?+:J>A>0:ZS8D
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M9R*OJ%,G:G[=C"O'[(>P"<B]O'E!6R=W8)?].PHU\G6P72MT*;!XZWE)5=/
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MF1Y#F.$_3?O-LO^88?[_5Y;]S;"_VS4#8",CW2X>,@$@ 5P\VMME9]1P=%F
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MR.*8IT0 .U#=P%7P:"QWS]@P^DL\\*5'^MV-F6IAX@&QD\8DFOF4T1V04/
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MYE/>[6%%VX:9L*\4LR"(7VWR03DJ&9D]GIK;<(QR9IS/ &]F8X&CNGI"5'C
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MQ XS"@3<K(\J1,8,_9SZ4[CF<+DER;UYX7&NRKJP,4*,FYXBO0'4 7)]+8"
MESY"+;;[:[AAR"#05\IJ0+%!IBUV4L"'A%J6TFV#,Z=L?;("V&[2JZOY<\<,
MRO!JT7)_:6R"K_OEUU4GF;/;[-&Z$?(,8/"/ )J1Q(22**=ERMUIY!/'.@B
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M[]_OGG/J/KGWW4I5SZ[5W;-6C_%]4[XQ:\RYA$\V/^;."M^&1.\<Q/!#/R^
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M<E(#2#B)9W-M:K*]CZK0/=IU(1,=AJ4S78;+P&H+-K2,?R]'@!3I)][W,SS
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M&N^P49"B_;1PW$]$%1I/-7/727T)()7*DZX,Q(7Q?2HR3L_ZQ32%#HD 1&5
MJT!5C(PO5.3%'@5UC$*\MYY^[63M+PY3'CW!%=;]=6QV3:UYB<WX/O]XY6+\
M<<LVT@DOX;4(;R293PNS>MW&40@#'0/&LONRH(1]&\UPX/QV!7D1HKQ:_@!\
M:L'"'\D6U!NR!U]]S=6Z/R?_H?>\0>7@HT7T=E/FLUT.F%$GB6$(&HH>VKM/
M#93>?K]33P5$HVS&Q)[@J?Z'A?CU3@A82)PUD78SX>5XY3@<B\%OB;JT""/6
MJ<%Y J609]3:%XU[26GT71781+MN'"J?U)RJ5)_"@?NCFXLS@=@!#:-''G]
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M7WNO^-B4/-[+0/T[[\>@JUSANN+B/<?]#JE\L DCLSN$U,F=AI/#Z'.MV3/
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M"B'N2A.'QT_6M'6G.5C\L7]'5G\9Z0;%D]J)[V1<-N;";&[I>@RIIWUFMA\
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M:L\[W<8&R[XX,1X[G&G4,(/HU=34-0<D?1R6RIL54YB.UC):2P[)S,/FUN!
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M%TJ:JP7^J)6NVYZ,'JLDVQ_,R+@$A+1PPK7.%,=K8O7ZS"J3-7PH\RM&&U7
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ML"2P5Y()*^5(2(@0C-C/<S;7X41[(H]VA(&4JM)/FUY/SZ6EV+Y"MWO3JE(
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MKCF^U]29;0CS<^LVFQR+,X3[[67$15%?$C1%-R<*'36@UU\M?7GSW=7=Y[$
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M,RYJ<&?LNP=44]VW+[H1!*3W#D% 41"0WA-4JHA1^10$ 9%.Z#5 (!0!18J
M@**  @J*B'2D]R("TGM)0A$DD%!"@)"\^#_MG?O.&^^^>\^[YXUQOU_&"FNO
MM;+FGG/-M>9OCKVA3%&6 ([KAB:&  T-#?"<^@$H* ZB =S-&0#,S  9   8
M 3H:;> 4M<9.O;@>[P;04>LTU+K5FYP_?P$Q . 8V1 !&*AM+-1K,+4 (AO_
M^.W?^!M_XV_\C;_Q-_XWQ4TW!V\/)W%S)[>  "<_:L/IY[3_8!0\5.90_)SN
M7^N-::G_J-,JJ0! 6MJ_U?^-73"^^3/CW^SB;_R-O_$W_L;?^-\;2I>5E+4N
M*VLIJH@KJFFI:FHIJOZ';50> K@!#H WX $X >* .?7;#0B@?IR /Z2$@F(^
MZQH0X*.EH.#E+V_OZ/W(2=[!VU,!;N^CH"A_60'0@<!][!U@3@'BCYQ<W+QT
MI;<;6J3%W1QUI2U4S2Z;^5QS<G4S#O5S,@^]^9=#*,Q!TU$: F9ETH%KP3U]
M/)T"[,7AGAY>_EIP78E_S*Y%K?]I5I  Z_@Y.FO=T3?\YQ'4*UV)?[Z7X.!@
M^6!E>6\_%P5%34U-A<M*"DI*<M01<OXA7@'V<#DO?\E_GD#?R=_!S\TGP,W;
M2_S/M?TC[\  78G 0#='+6=[9]5'CHZJ<H_LE1WE%!4=[>7L'945Y1R5E1W5
M514UE)P5'TG\LWA'AW^5[A/HY_$/V8X."DX>3IY.7@'^5&LH*D@H_.?*I)KH
M7X7^A^:GZD@=HW7-S\D^P$F?6L!_%EGNLK*<HLI?_[+(\DHJ*CH*_\TX'87_
MYD;_"ZP%UG%TT'+X<T_>?O\DWMS)]W]NM3W<P/^>6/^3GM3F?ZI0!5"][\R9
M,SH*_V?9_U=C*/RS\U%K_^JJU%^*_R_ WT+^%O*WD+^%_"WD;R%_"_G_EY!_
MH[M.7E2.&TPELY19X!K </HT_6DZ!OK3](P,#(Q,G,Q4CL'$R\[!PBG *R0H
MP"O +RPF?598])PHOX"$O,2Y"Q=E+\D*B2LH*\@H2<O(ROR9A(:!D9'I#!,/
M,S./C(B B,S_:U!: 4[&4WNG$VAI)(!3G#2TG#243@ $ #2G:?Z!?\D.:$[1
MTIVF9V \P\1,'5#- 9RBH:4]14=[^C0=';4WG-H/T'&>YCJK>(6>^[8]@X0O
MCU)4ZCM&R:OE;;QWAG%2RH_\HL\P\?$+" J=.R]]X:*,BJJ:NH:FUC5] T,C
M8Y/KYG_=O6=A>=_*P=')V<75S=T_(# H&!X2&O,X-B[^R=.$M/07&9E9+U]E
MYQ<4OO]05/SQ4T5E575-;=VW^O:.SJ[NGMZ^[R.C8^,3DU/3,R@T9GEE=>W7
M^@9^9W=OGW! /#SZHQ<-0$OS+_@/]>*DZG6*CHZ6CN&/7C2G@O\,X*0[?5:1
MGNO*;09[7VX)I2A&GJNI[\K;SD@JW\'Q/O(;9N*34D&=P_]1[1^:_?<I%OT_
MI-F_*O9O>LT ++0TU,6CY00@P)%APH6WI_XN_TL*FW=WL^Y/'9I"9@K .7]X
M]>H] 4F;D4&C6R4G-P',^49G#*&FTKJI)I<CUQI! 3YGDB0QD'G.U-&%NCP!
MG19>B-N[?)O!1?N46^0A _.DY^W05[5S6/\\<SM+2U<APZP"^73[#S-M19\\
MCI7TU3BWM$^@5L!RA"CI$6ZR,RC,4_-]Q5B!S;9# /"H:9I1P_XH&=VPL6,*
MFCXP'&D^Q\[G)E0Z\2;U06E74VSA]8_\M'Y>FH?"JTLTD5.BLL'HQ2YANSA;
MT80EO=K0' Q/98US^QOV5[/-PZFC:<8B@8#H/N_.?ED2!7 5]3:A (]?FU9Z
M;V;:*4HD#"["RCX5.-\3PVB672<JXG/ 4D;@5R6S76Y?K'I6E;KRY-$ZD?>O
M:-)Q*6EN,&X!#"7#=HK$8XQ+(DD27W9[U%,!/%DX/9B0[3V-%G-^9%X;T4X!
M0BHG=3_E/6V6)OG@$!.A/4\]4:.;"J #M3+8F:?)RE^77O%@*B_K@*X#1_D)
MA^T'Z+4NA2="B*Q%E@"&\M'/#O0;&,<[O3N>I\<1@P)L;7^5"T@+MOXBGR(Y
MC"/"0\+>P5\]2K]5$X.]/&\@-J1VN<U2*9GF=-8')?:;F@#AN^P:]!D%X"?=
M7?).O$?0BGB+++<W#5DKY]!'K$C+-TPSL[8ZB.-G*JI3GH#$//=:B*92HRV5
M>THZB^<\4$[&0U>_3[]@]T^Q HZB$W:W8R@ CP3Q%>J52ZX -M"4SW);/'$E
M!"3[)81I2D?L,>>0U:X"!^DO8@DZ3\3F%X1M[WX5<>G2H]W-<6?X&.:'O\;,
MVV7?J$F1;.!(*^$PM /CTIER"CZS:$C,H_/7WXP+S+Q0$)"4K-,)__J8+?Q*
MFR#O.J0*E(2XLH1D6*]=X&\Y9NT\0 N"^I+-^E;*NT6--TX#H5TAT"YD4@ON
ML^IO.74R)P7 0JNMPPM^''NGUZ[*)H9XYN;XVQHXX5^C*4!"084=DY7- [E/
MA1;FLV[/-')ML6<9[](,7:D]53^43 &X=;R7;)#ZY<.J+ZJ4W4KD?B:/2%MD
M^=/;-UE&]=SXR? S:.<D?^)B#7:70TWYC:-S89DJL1QO:!</IB]OJH[6+K6X
MW1F$OKUSD8E9FR8Q*K6U1\J"U9$"5+&5HN ZM^V_K)MY!WK5^KCUT1E:)&7Y
M1>KD*QD].L3J@:X,/U!H'^*$]]O]_  &XW;=U)]7'/I[,M8R^5. 2WV7/BL.
MPC4%OK"C6WILH/IX.Y*$&$UE\O9="\L/.1@EM.&ZB*M6K:34LDNBKYX8U@#1
MA,2#,"D=BY4;$6KEICEJ+LPU</'I(=QVS(M'RDF+J64!/W7\73"@N!%BUE7G
M)Z_=3))P5F=2;_Y%T- X2A3;HYD8MCM'5, 4=;$ZAY5*M#$\"0QKS1\*K#*N
M:74)>Y[P%F>1J2%08H8O06=U+ I2#<PG5?>TID^N\/G5HN_2P@7P2#J<;YJA
M(2L0?M? B X_-]NC(U>O>4M+O5A2?'1^0F-Z^>&3MYG.&D!H-F ENUKJC2E+
M(GFB#P- CX.8)*XNV/2DE5WZU.0(=NE]NIXZY[B\9.!&E6;44<8UN[[(NS=4
M96W6#TD7,N;7J?+DWUH4[1E-U0/I$V-L*G!#\66!I7>GY2[E*WW_R^F):.26
M2:O8:N,Y)$SX?J!J-#O#G X;ZC9Y+M]P")KNK(RMKX:XA@WQ;(#I:IIP+_HA
ML?)R+/5OBNT["E2<)=01I#4B1&C7+G*89 AK\$?QF*,RQ^V%ODG,9IQ63UF@
MGH$;0[@C_  0'JKE/]&8CB[K@1+OV<K4#+>@1,FCNYN9VX/'P>FU_O6>LRNU
M!\IO#LJL\R/!GA0@[AL%^"A- 6063SZ4NN55NQ"22UV<* "C=Q;AU8@H!9AY
M-?LM<E G-W12^M@(V><WBOP].$L!#)O";W^>,X&]LYNSKNFSKTD=_LHF<%%\
MZ?CGZ>^R;4B7O*?@2_C!AL^SQ**[QP'W)GKQ"M/Y*3 ^\3?YB?C?1EA6O'17
M+OUD  S)[-YBG[ ZO7#W6.6.U\-6VBSS9-T+M O%96>)PY@\3C@4)19?"D?>
M.C[_+C#06V0TA+-YWU4J2/B^L: 30]1,XZX1,0]?TKW ?U_G[$,I:SK9D(^7
M.+QS;V1J6-!HW"EPOZA[_)-A3,6B/Y?GI*#1J7A=[MV'%+%J-.P5G_893*+,
M5_$M^6>1QMWPUF[_1'^>/"'P19(NOE -R?G6Y&VZ1YJ5#L?'G:>2 7<,VB3I
M6#*7'_YD&.>YI_Y4Y_8'HG5[<,39L4+(HYKX@<.(O5?=XP\.'NF!K X7AM!%
MW=Y/+6K-2>!13&5%+8(W[H*E@D^I%$G9X;CNZ-:?.QJB &S-VK"/& ,<LO/X
M7'5SVFVZ8+#%B[Z+W>.IH?85ESM$C6[YR4<,@S@1=Y>L3^@A3!MY#TWK/KC%
M3Z.S0NZ\/-[P'=M[RQZ0WVR/.^BR>[:@AG=^+1_CI*,E-<G9NB/_\EPM$R/;
MCFEMV1V?[]I,1Z&13+*M8'725?Q01QG(+7T]]!VYM<G@A95JU27!@H?G4D+,
MIL0_#FXFK0F@FV)L\$Z9&;BC[:Y;=9DCVK0A9RA [ML/RR"<Q%\1*C0M!G#O
M5@5AXE 7#I:]F!A8$%@X92B1!.YG>=B7M#FMS[!R2V,0'-H^W'P> 25^0]L8
M+J+F)UZ_72=8^DS>+E%K-[;I2MWIH2-] M9SEVE_'<EV(I3+2+!A1"!]$GI
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M'N)[[=(=S[F7KJUWBB1UX9H,Y<#1AX1#ERX03X0Z/% .8?3YOE'A.G\R'=\
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M>?3(0&IR:GREA9_,;(4P2=:]!JU+[GA0"Y4['PA^L#[MV",IB(HS7H_IUID
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M(Q0IP#L7"B"]A22N!$4(X9I3EDYX _XL1W*?: YUSAO*U-5(/YJ,H@#=-RE
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M%>;V!UP?UGCT.$5]9?G"X8N80^=(F=]$ZA'6^^Q8LH@P_X&$; #EC)(9[E(
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MHH[-E/ /E8T(AG(KJ&O 6ICLJ:+M4YJM/3I &.NM9[8C\JJO IZH6E\,U+!
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MD?EN>3.ZVSL9$7/EWSM0:$ -R6]BT0V0 *S0_ B7=LLP$_1./J^Z$ON(:D/
M-,JZ5A+U1<]KD?TB!MHS)W;?, +?,HFZY1; @<EJDGE83"7:S7QT'$"H2=UK
MN[MX\A!1("* '':Q4]:+,TP)%](<L"<J^NH$TJ,%^<^P^&F_E3P9%3;,=S5<
M080<-<QJ13QR_(@8X.Q:>6<4<#%?31K1'%2D[2D_B?1"VV:; 7E5:9S4:-9@
MK@>+]2 ]I3K),Q47O!J:XV*W3L#=2Z5LJB+B!6('\G+B0_'!WL^B@0;B>\?B
M$JTXZ>LO)2BN7L]$G J^3W0".SJW6V(./#I55X6<$AZ[M"T2P8;DAN':*^SW
M7?5Y=+]^]7?*LR"V^?CV.=8:2JU"]6!'H "(@F(8?8JE]74Y'D!*?_Y=YV5M
M]N[DH5W&3H+.)XXF2.S@\A/U#Z:H^33(,>C0P,@*:G)6,KWX&AI_%O!,7Y8@
M8<BFMD/UA9QT*RKOJ)[CAT@9UP&')+ZH?5$B3_QAAC&XT(>DH8_KL1[Z; ,;
M'*4L!'**D0?>RNSAQW(@T!,?$<1W"YWBE"QMGHU2L.5;B^RGJ3LF(2@B:!LT
MFGZNP:N)'39WM]8]WR[-,F-+[J&/;9(GH:$$K3OA/TS)O@7P:%9I,V^RSJYG
MHX(1>".'+?JR:D[U=:'3.""6-X3J],G6GY8>PI%Q$FGLX',NU9M1HCA2])/+
M"?%G1K;9>TM^ MWYS*W["#;84+LW_]%F,%QZJ<^+3GK"@%F7,;S^0!V3Q:*C
MX$%,3#PCMHTK9&6R0=B.S]^;U-6;U46K,JJ_(7;YO!/WI>AQ)!]6;(OQ:IPX
M5:6T6U2[6*A.8H@3JZ4$]%L<543Q5O[&7.'SRP\IW:C)1G2UJ'@2Q6)MU*1-
M=+#CF6U/UF4EP0VMPSOD^2!9&QL,!,*DKUF@+<9'D"(4N-B)*'ZD&U!MGO50
M,$&N#[L?715=%4UV4_U,;/]1EMXM8'034RGVN&GHO*@/]TLDYGZ?U9"*0$FJ
M-^K 2C.!I^H4W)#^2N]\Z&E54WQ_82M)>4 5:8N*NNCELMWX,/JP>8DYOJ5R
MUI,"XYELR\8]Z3;2"5L<1;<YM'L"$#O-W77V>ZY9'77!2"(."VNEHD LCA>3
M+E>[&6.@XETF<^%KTA>:W?'#V!QMM%RVZ2R2[5K F'124I-F>#5*4:!KW@W9
M9[!6?Z452TY'TK/G,8R>/V) 6>2I LM(=]5$/,0V;"=['!EQ[DLZ9DUETJ3.
M6H'_DL#XVI1BE; 2*KMR,Q3@36%&17MT5M20*#@=*I?1)//F1X5NSR/ME\N?
M*#V2@#-WYI;*DDAOP:-]1%R>I3=F$*2][I,O+6>L=8X!IV3P)0Z.9-FU\5F)
M5_J=4*@-D:?9U&E4>"Q,J+V.@*Q7^GX4+<];X;@*CY;%>HOTN>S87(!O7!OF
M C7MF(%T6"FW+@B/L)S6[RHXI_$6RGT$<G%<?@AHHMO2>#B(4[5*NZIYFD,A
MX3P>IS"E94PO!<4?]E%NGG(G7N,VXESC; I&%%@K]>Q!:83I4$C@F=#^R^[M
MI*#0%SN\T_1/4(2"W(!]:UR:?*I3E"U'35\8W2IN1PGUSUN@4VQ9G],<_U36
MSKTU=F;F877QMH3+6BS!&L OD#^[JAS!H_PQE>YHRK^!R[0(;"K4^4'&:.:5
M7WGO/HUJ+19 [A S1.'C442X)$H!VU\U)'2U/F;%;!TV@/EU_IRKJXT<O>?3
M_7YAZ8#^V6Q]2O9FI=,B#H+%@NH93#?/-795(G;UU=B&I8-I+O.S.J_O,BWV
MFH?AF_P@;I0=0LU7XWO<'L2-$X=%A59&-,(7:BROBI'MZB.(?J5!5Q]6!&5O
M$Z4L_?7$G2]C=NLB$9/XW#76N"G,]AU?@I!$6^KT&2C)9O]Q857.4C/VELY;
M&S'#)GFZB!H67QF46\!7+BT>\ @LFF\\R];44.MTL.%$#S73$Y3+C9;"N2>:
MF6#YT:J-=#WR$5V TA[:A@B!:;YH/$YB;F?V-I&[TX\.7EOZ!SX<@=+WQ20,
M>=T0PE#3?5X:+C/E?%=GVEU2\YE>_B,4&MLNB4T<;Q5MV;?BU+(&NS,R7\&6
M1GD[51J)+N%$,PL> ?(,]$NHJO80>AP1BQO7HJXLRY7FF>^43RL\F&.6=\6X
M%X6&-CHD#\C%HV7;>_T?8^P.*1JU0OL@"+:ZYAJ8P[(([X52J3TEVY-%^QT!
M+#I\.GNAN]:N/9V UUUI-R0I[-0=P%VZAC5WB)+5CYT1O,488^@W[GY)L!XD
M&>TP)B*KL\:=%B9&F&N)K;K;HI$4&>C9;F2.]?[3(](>9CH?\;W>!F@GX-%)
MN)&&+TJW@R"#N@3 A9:_Z@J%S=M[E6-VSS=\[F,*0M&VFX@2F^=VG5KA+<GR
MU#FJ]G?$]""-S'N>6.1 7BY+=,SY50MPS@Z.=K\/G-8Q=WMJ0FTZ'& +NTA6
MY2F$4YOWD\W&M-93ZJ%=_'4O_R &B\ 2#K/NLF''@&R72U)3R JRH:6 96W9
MWGU,8_7M[D:-?2:;CZQKW"C;!!JX$<+ZN3#R-A?W\Z*:=FM :^SPQ=JRBD?<
M)5;JQ&HU-;GH8W,=_9+0RN8[,Q++"D&2E,:BSI#K7"'8T#LC8,T=69@(-!,\
M%6!9!:Y/V+%VKYQ2<C:#>/@DW.ACQ-+PWE 0/O)!_;9W!Y?Y4+T"''JU&8E@
MD,_R%*OXD=B>0.-5K]$0)#,_)&I *2M"0+%YMTX%O?B5 1Z2BWC:?/>4A1('
M>9(NAU$:FQ_+8Y??&=EC;%7HW5M^L?8,L!J4%6UD;P.'UJ6%5RH924*MXXGB
MB[:IN7N(U.\?S,QQT./9S?DG(PO9*P.4Y:@(0[P&6R=^3\IE?3&56/+T'WK\
M9AE^6,FD"G)\ B3+<ETD2T?,:JJPYE56CXZDH(BC@G;>NJES^0<+BWJE6DDO
M)>YA?D-[O;I!OP2-- /-;)6P'@5WF4QZ4^Y>'=3GB"1D+<_W@4T?B'$!=M7"
MQ7)TZ/QTC797+EV&H743X>[G84M60BK#"TI-^MG?+'U/C%!9 C^M.7&L-K\
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MVU%C"'OQ=8#O%)>[O*]*?#4G4M%#Y5EE APHGH0_.W#K+E[XEW_%[*^^<N8
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M+6!:A.%HZ.]N'.[[9-Q H<=UM[8JXQ9H(K0<0R(X@ON&N2T-]RS%\#FL=&E
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M>EU!/EYF(.O%#J(3\Y-%!4LW2RLL*K?8%7S?.-+5J="/K@4O/12>+NE^]??
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M>4;<Q$;"NA>RS2[O7N7Z3;R>1[Z!ZYNA6P R-K_[K_) $(YRO->"[G<2M_Q
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M"-&:DI]4&J(':=L',("9^C4&<.[9;]O8_&PYM>7@D]:_O8DU&J2(.\)2X6(
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MZ9A\YS57XQN5]+#<K]-=SP0R]<:-O'7G?DXMZJ^$49@&&0"^$$/=D:M#OK
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MT,23PLOLNEWYSIB]?3.ZW+M/FS@(7WW(OFLB+,-X)6Q#TQNKO4IIR\C8C%9
MDT74]SBN;Y8!3,QSKI./8YZ;&Q#K,XT.!<F_.X^8YR-Z2VMTI+4_Z)\3OF^Y
M.\+I:Z_R3%.3](%;PKQ7) 8+)F^]DZ[7RBR_OL( N 9Z2YXKB1F.[^71OZ/Y
MTA$*D77&]>X'E]98Z33N(4R/,9I&KJ/PH6>5I2&O5#I87Q&V$A= 6P<?3S&
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M\:J1<<2M8/W'%K+V"H*Z?P&GC22(=X*3)I5T\7&H( %46!]Z-- @#J'6-%?
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M*L]\H\&1XXAP+6)E$0$%:J\@G];*^9H?5]M&FO13A.@SC4K_^)T^&( <.,8
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M<M-DIE:FY>1M%6VUCL+^*BLCD&0X>M@P[=I[E:^V7QC 8WP!M^$T$S5PB?.
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M]:\O4GUJ1Y\ZK/.->_[D5; M-I0%WE^1$-WT"YWVHOF9CE+__(*HS7482!U
MH=(VN<5<OK:ZV_\C6R#_UMF.YP<U@T;@'ME,<'5C./!TWJGX-+A9OG:S+%$Q
M*FS@75/'6D=:;-#BQV.R]QJI@4BMY,LA-1"]<C9'(%K2_K6Y*:64YGAJ_6,X
M0$?]N3, )'0 '*4%5E\D+;.9W:<7H6FYF[!SM?(%.J?<CC?,1YW5>@4QR"^^
MU0[07Y%9R, 8=%L1B V.3B<A+$D786,7GG4A>N\*+FQ/T<YJVP5SX>/M=*[!
M4KJ;>W%SL]XZ2]E59WD62?@6BHV<I&UN=\9;M8TDWWS]S>I>5ALMDXM+MT$+
MZM;;S8""J^4X5_51PMO2)[JFP42R9P=!C!>;/8F  !FI]AOZ[<U.:]]NF*3H
MZ$./3PW\RB>YWW_. 8_&6W@,N2UU&>#B/[*57]MCP[_=5Y7:J:"OKMW".YF>
M3K!]/ZUVZA!TVP\@*!]O?+);JQ$GP![@5LHQ-T5=Q&79XTDHF8UN!K*>8:?=
M>+K+^ZJIG*=TO3;I,6J[LB")D>>+#'2V$S8]6%2IWDBF9- [/?.U=\"YL8)C
M#S[XZ1"$404P*D4!@!GOE6["A41/Q4!"W26@[$TJ%/9ZW&DU-1,6E:7^=@DN
M8DS,FV&BI_?I;A%2Q30+*';J;<#X8V*4!WMW[&@OOI=)S^RSNR]L8HC;NDCS
M0$<:"8U>T1$3]NXBA6QA 8Q*C?KTU&D33JVJ$)8L?*".>(]\F1IT]^*X88YL
M2.'&#3725H!S"'W/*\G3UX9+)D];Q96E\:,'G[4S<IP7?L\1D0D_$S'-'<;&
M:;>666M.2I"AQUGO&@F>KA4HE3=IF<?DVI"SJQ67=AF@J!>::ZFN&1)D!3U@
M?23YR3_]%3NRT$3@K:XMKD[6NRD6+?*Y?D"AM[UD(<E5S)I 1QD*1)TXF'!,
M"(.T0U^\AH71/#T$V=Z#)6Q:(+['E)KNF(BO[(=/$'\3SH%J^0RK0,,*E;<"
MMHWVE<W4<U=R'-EFD1XFJLK/,L1/V9;(N#MQ:)VV'UX62[8\R/7VC?XC:FA/
M1)8D7\*",XX:(Z:U-.11SYD1@FM..%'\]EII$7<4CZG_X'$#8(*@16 G0&,B
M #:X=M-8Y[=.'?].Y'1H^Y,7HSW#CM9]Z03_U9(CDSAY\_@;C$M*6-A1KPWG
M0]!#J/R/6^\=D<PH%\#SD*&F^R?S@WV8P-S,>E[R$HGDN_N:\J!_<*Q4!,[X
MS9%HKR[-@'=&*K_G_IRW?V_(^ ,.='46 G8$%);6[4H,#5].,J=%C>LG$+/$
M#WWPD=@XAU%O>(6!ZL:RDG1*4K4]4J1K.QW)>'XGXS$;U>;L!'/?PSBY(A</
MO>$WHY<X8U@&D<&P6;5!V$H]#$_7OT$!:\U)!X1.--T'I9S,Q4F^MT1:.IE]
M&!GM?#O*Z;R<6\$@(98+_S1C39F9\4M33C>3B&GFR9,8OR9-8XR*28WU^".5
M-^LV_%]?<BJ(ZF!KRN)WE;?)NJB6@5Q#2>"8;(&=K^S=V*!JN^E[[VZP<(I]
M-Y7[?C=H9'PAF,#IJC9-2;;B[NGNB!2P=_!X;*:C6&Y.++M6'G'?)-G(MB;+
MN&F&DO@F17L:-([^V!0-BH<N_S,X%61=Q$W,_5SNA/WD.2D,E-!\31V?5"D@
M;MQ;&OA6-._&Q%J*35'00XJ"@^F*R?^/]0FT6P!-+$G@FV1U#3!\XX) OTZ5
M7(LTU8"^6C$]M7LP>6[9!6T0D%A@8BR]6!0X]KZ*Y?1.T<@;=QUL(2^JW#K)
MUESEG&Z@(.,(=,.&$D"*%QX <4ZVP[GV (D _?;HA X,*G_#$&,Y+4-YHV9
M4,CQ"WNQ_\>'JMA[)$^%>9<]+Z"N?2CH%\V]3$HP@/E[@9%%L#E3#"6.>)Z0
MF@@3 9(CXML;Q&G'44/*8":WTI#['M8^8PL0'OC[G*_2C)M]!MW2IC8YR] R
MX9O'A3^V$J]S?69M*77W\FR636=Z\U+9M\2Q+';12\%4K49:U,QXPF#2<'>=
M=@%!3YS_[L,=]MA;@9KC%\+(;-CN^$FPS4+?:YK8&%CE26I[B"(GW._.+W6H
MVK[K2CX$E=X#Z!O4%$-^")JZ8VS5,^O:8\O8Q]QO6 N5$6FAW6%U8*+$14P
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M!.QY%L;DA/3#7>=*_ )^L4NQQLP+4.'P-&BEJSKAYA&3*<@$!'/-R<B/>_?
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MFS+["\M\XSBINQA3%9[\;!OV^M9GGY^P@-U!B/\A7)JN;N<@*? O'23^1XI
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MB$Z^=9PM_T<<44>D60;ZO@OT:TM53RL+&7O+1&K%_)"Z&LS=5%0<I&>!\Y?
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M'BPZ$41]P,'1%Z9-;7B_T%'?T?J#D+E>O?YH"XU*\J+&Z!_7+'B#-\#!VHU
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M%D]:<D::HD!JV.OXA#AFRAI?P'_F4[O@&0RQ#[B=-J@Z ]@;^@)J&*1<!WH
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M]<,I:R.;0#PJ,C8.Z.#C0EQKY9X74"IXO<3XPCFD9)R=]1BC^%_O1"BG+U3
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M!SQN:9E^5-]J8"C'82'V!JU??XIY<7)SO12J"^4Y64R=]_4KMA=,)PS_Q%5
MRMDSL$?-VJ0+P)QGE":D?31)OS]9\I<FH.UJ8[Q;AM6?/;.L;JW--)XSZ?H4
MI77OZ=OBT'L&00RAI3O^E&TP%*W!*5;M'/S;?(:MX/P'EF#!-\,AF!LU.OV/
M;N0M(6<#M"H?G[4MKSWAAFX9@<!2*LW:A*O4,6A4C$_Y2-3MAVY<RENW/R23
M,!)SM2(S'?,3]1'*Y"COH!IM]XV-JW5DH(3DO["R>?O0V_LF506)$*O::Q"M
M7$B0=[$< J9PS8;HM*/3OP-<;)"XIE_2K*[?I(%L2O9T:0Y##DAG%_O)G)SL
M6&N&J:0XL#"J1&.Z-+!55P?]9"<[OEFUP85R2N3M2(S["#W[R+!$CD= +_/@
MC2HM2HX6"RQI%/(+A6HX?7T21'"57Y16ZD%EU1%,C+]^/*8!T"KG;OF.A-_'
M:$NQ;V; (T[FZMC$W?PFIXMD1\.@V]QB+C2_Q-@O>V)&6'JX)C,%^$6CI.O'
M8PR\U:N,XEU7X\YBB.Q/@-R02MHQHU<<1@=&8QR6<B]Z2_H&XLFZS>F][D+X
M5B92:\FNO$2Z0WKWX09GY!YNW>/M$B:4D?0],AT)/8V[@4DKQ'>VZ>W4V(6Y
M%Y;QM=*KBJ:_A-03Q"_"H8Q,-9O:@I]Z+PX@X]D28&.'KANL4LP+49_47$?6
M^Z#Z$QLMJ8IUB5K1%@C(@ZH'WIPA"BM2="A>7^^6=SGW;^)J8XBN@)9Z1OC!
MMBQ)Z)^FGN.+4-/OH/UIM4B^3F.2G5T_S!CNIDYMLJ?"G^TW9+$]F'DL)1KR
M!CU^#!AD.FIZC\4^Y1J%G.Q<XULS*J=.SF9F5F@E+9?M\U_Y@'8Q'V>+L4QY
M%&6)[UE8LG+N/TPY)YCF0<3GI#JSS1BM_,_[#,WI(AB%]<25>^3AI]PHOD/N
ME]EHEU\>G91/QZ]) )7&'8!-*$>6ANB"67PHPX\J[3-A8>%A@%=QJ,#U9"6L
M]7'O2I,NT=-%JXAS$MY@,F)!OP.?,]!,>2<LATRF A),__#JN_)D;FW*LYN/
M!KL_ 8CI^TZIUJ\?N*&U!$/6TZ]I_B*SQ:5+AG-S2JFFQJ%*&[..!]@Y(:PE
MH]B!H %?$6NS+J20MVEYX8WNY*C6-YWL/&[5L=%O]:\.7EU\Y9A$*'YPH]W?
M@=U CPX.K5/FGK#@&]S6G<6J+A**OC.5 U9P-J0[YA=RQW+JH@0IWL@4/ RP
M71AH+YYQ23J+#Z+:T:F39MC\,T\I[=0J]#\,5:"R,H]3+.0B0XNT6EDFV)T8
M98L),\=88%%\HD3FJ+ "50MKW#5ZT!.O4-,5\2'P:5G4/8Q<]*Q_?U3(<?<'
M:YJ?@#GNBHL6/PESXSV-:M'@''F3 27Z:O6)EN6PA/GA%0F1 RB<]@:W?CY:
M%7?D)X#G^Y?8+SX635P><\LZ-\EEA3U0\]7="O/ 3OZ4&@3JY6MVZ3-G<O7!
MD*-B 12$R* %Y?N$?ND3JR<)Y[ET@R9[5[/2AJ6!M@<^0"H:X/;GM1O+T^9D
M9VK]-\&\.%#14W$/8E#J VBTVP_BP,8Z'RJS@:^*(HYJWG<"2WNJ#^WTP'@O
M:SD)-3_%^KR#K93]!#RXH-_OLQ&M'"HR2CVEFQ#22^V(YV/LRDP'7#P+:X[Z
M!@URVV\II;#3%TU+8*89KE?0?%BR4X&U>B#O!D]=34E#"%DZ&JX6GIWT["W(
M/#(]C:'<-?R;6JZE+WA29(MD72Z*=0F]7C V5=S2#S=@A;MU-[_0/M02QFY\
MH[SVB^>/[SG?*+Z,-05_2Y]3X/Z8F<@^WO((); Y!V_+88!#'T4XWNJ 2A9,
M7SJL319\[!DG_9Y/L72?A1H[WU+O]<G$LF$M*$/U]>'=*P^/(AGOS2N3VIHT
M('"0"4O*F$0>X#GUYQE=HW36MZ<Y*BPQN#&QK&^F1#WH_U')K[6H#'[*6C%0
M;(_15+\]9D,-M9RV^ASV*ODB$E+E!& P?JU<8Q2?64\H/ P)&8DOV1_?,V6-
M;8]#$ ^^K>UVJA)W63QT>"6+-IXNZ>TX+\TPFV<ROWP3H-Y20UB/HACOQWGK
MB6F%:2-Q8G^I.>Z8VS;FP%U)3G'_,#]!(/8HY"D.QCRY]S^5Q/TOK!=D&FI8
MMAC;O3[6L*8IMP#,C[D)0WOCP^P-3S'P1'[L/VQP<'PCTGX)S64&C^63$&K3
M0>5,V;S,KX[O]ZXQKZI $#R.;$WZ#Z<*5(KA'HM,'-$M:HM+NGZ-NZ:+#U[C
M4O60E<SQ1.$"W'^_5@A8IVTB_&13OK-?;FB?XN1B'<N0@GK"Z26[FO3FD$V[
MG$A.]XZQH$'(NZJ\5-F/N]3-0CE[[\L<4S2&@_[8F?1"5\YK_3NQADG^8_I=
MO;GE<(%*]KDKZC4#IA;M4"$&74I:96I<-:\-CZIW[<2VDN ?2R'015#"X&;!
MN?&B5S?ZT5P^ .WZXT4N8?U?RJ!WK:(^85F.:OSUZ];)"O8I!F4GRP9])DRL
M^>K-M \]$DU0-2CK:05-;_BM*D.0YZJ/6!HBW"IFC4 S-YXK\I[8!],HE[/S
ML6\:V 8K,C96KI4[5T@2 U5SC[8WH.),I:J@?.<A96HMWM8/ B@4P<FH8 U(
MU 29E.[XR<9#<D(2Z6CJ-U[.&<V\'Q^([6#1D@YXF@)W!5GEVE,:1OF#"R@F
ME,5]/)VBGG#R+#,Q/#T4&&>-3I#74\#DK>YCNL0*%/<@(C#<\?:(7 /MBWWE
MK'($O__FEOXQ14R']U[]&Y[OPX53AZ,,-U#+JJ>C7^X()R]!3RSBZK#/.2LV
MVVQ"#'QZJ1U<YJO$]$!_-5Q2FSZIJ9NZ92DWL/=DM*K+GM!.]_T)*),MYKIQ
MO^48A.WO7+9Z=R>:ZO\B]WAR[MN[9[)GBW(DR3RD'14EI% -*ORM5I6NJQ2]
M.])IL+N>[4%17;*-VUXX;"/6601*57V*E28(2P3=\30T53>V!I_@\/<#$S97
MY!\$*WUA9 )&;3,DH1V[:5,((>>2HX122 N[83L,(D 1O==C$=G_S_9:/G%E
M<8\EZBGV]+FY(_Z@M-QF=Z5,3WRC0$GX1AM-M<JB%V'0.EA*MO$C(X?R^&P5
MLT>/O_DC.F!>($?=32G;.L3"2#Y#J:&Z\96J8*%S/WQZ.A47;8$72[%0)A]T
M?0H2=:,I.4GGZFI3 DON("J^*Z/I.35LI@,.W5Q+Z"DFOX/-3>0&S& ?B/JW
M@%EML^5)?[0+N.20/[2[I8COM7UF"98=4P2S@".LSU/QGAR$M7JX)Z[A@8ET
M)@LG?.786HQ&T"!L.8.<:'WBQ-ZQ$X$BH[AV0A[>>X,N*\-$BNI/PN8J"A7B
M&"2-[V%CM:1O7A 10%14IN^-! ._Z\OF@\\'S[(_/WDK]7+O[V)TXND%TL5@
M5](OZW+S^BK*1CVB/7AP^VD+X\<3RC=^LP=*%5 ,V[>&-REK9^N*2$X6)585
MI>.JAPFT[@G2QW3F(IN!XA>X]^Q\E2@F;'4UAN92YS;:HO1["VLKSEZ1?\ =
M>IYO:Z&\#D#:=![J.,(?I_@IFJ8;+0J;M!,6LSI1:ZR:V<DS\M8 ?J7_QQAC
MOV4I1_=E2ZN5@-A@*Z@K_2[1H3EDLZ!C&A QZ](\/@9F2RK9N+;N)3\D7Z,9
M*17(B:X*_>P'E?'D3QW[ZI$G&XR./1N%IC#1BY'=TH AS5"^LBQV1^Q'>JBI
MBO\3\"9L*,:3<V\>2XZT7^2RLFSH9-Y>?17,!1]O>"T83UL3DW!(^]D8F04@
M[[U5!'GQ5TH.'@@)-2=/[Q6EU]=]8(UY$]7=%1:"1GZ.8F&A0YF;>IXRO@@%
M97"D"1#X^PQFP%3%U":KM)C8M8%-*L\&T,M36->I+W-Q?P((^>$GVQ]8)P3
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MOKH?4S%X7#EPQ.6N;[02X%WY9WO1?X6@CF<(4NAL,2G$U\;NLELT K ")P*
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MNZN+\S!-/$OC.M478Y<@DT4+B%,'4I(J8L- U=V5:S(L?>W(25!A[I.VS1@
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M*@4Y#S\$K\7[9WS'2CZJ3+'R6QL2U3U:"B,, H' 0AXN_9'AR\\PWFB1I@O
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M.W 5GM\SSHN73SV5^+'$H/_95[M0K7@[=;&BX"[YA<BUZ2=L@0-LR3W&]#C
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MTXK7,%;P+:GP':>Z+;=DQ'(?FH=OF.S2<'7&,LP_)5@;_P-=L 0O/AEK$?I
M9WW&@W9^\6:YMB^NX4U?ET;N;I--I+WT;)Z)DAO /*;72X=.*Z17NCM0Z"_%
MKG1Q1\<;BGP\?8\(7?A(ON'N"I^5\^*+3-+OCH:6$TJ.I*K :%KP1<8<P%\(
M<,VY._Z/);+X@-<,$3W8E"IF,2S:NZ*T"69V?&P[NBO2!&U#VC1&*6,'6\WD
MB!RI>W)X,,C+TKAJ44RCD$%M/2X/;OPODACM_: :F:LT>@;@DKQPMIL1%IPW
MEZD 6%01;G6AT6#5G)U(HLJ2&TN&?OPHENX_S>3L8:S\=8D2W5$"@ST H@J
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M$V.YB%0>]0V..$&4C+@E"=FR;T$D):W3$^LCA@BVZNHZ53R$*HYEO0]7":1
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M,NVK4=FS?,=WX[6?>6E'O+C "MY4J9(H31K!B(<WYK>T3H8W@E863.X0[./
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M,XOT^<Y]!R;H_JYBT6H\J1)H=<@ _7.1RX_9"EE;+[*\\>F%A_AA[+J9KG'
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MV9[S.+J5+NS$F#HE[SIL4&+9H@$]#!6@L7^;XOU_\%\*AE^S_PM02P,$%
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M_*H%.!H=UL)Q6RGZCVT%X:_MW\9(?JPUY/6M\>![^@'?4!2^KF3<(.P]N"V
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MT@$N;: *_@YWU))C_3XN7U]?05]100^DHQ!02DKJV(R(B,"1A #J$@)MYR>
M0+%],_+#CBH,!44Z>Z*=/1 LQVT[>P]OM!PK*Q'+3_0-R 'Z&XZG-]+M*XH#
M5 CF!G.'(="HHQ@"A7XS?FS? 2H-]T"ZVZ'EG=WM'&%",$\47%;H=^X?1='.
M:#>8_!]POWJHY(;^(_='AYOSL6/2;G8(1SE6/P$'&-S.VPW-*@]V=O0^BBU0
MA 4!\V7Q<4;("GT3_Y-QH;]:_^K='QSY)O53E/[5Z!U-@-_"]\OI]X?0'4E+
MZQS-'0<[M)VJ'1HF+R(L A0XFA+"8D8BPM+"PM) $)^PN+2HL*S07V3_;,?#
MP1E^Z9^R\KODGVRH(&%'W#_;$ 9)BTM*"TL<71\9^V;C)\E?V?! &GEXN,E_
M6P<0-S=O%!IYS&41$1,49>'6L8,Z(XZ_W\KSD[7O.O\',J*C\X]SXNXN]"M-
M%-H !O_'FBBC2YXP(0,8RL,;"84=B;/]VI":#_J_8TC-YVBIL?UYJNCH2$,0
M*+0= @J#J,H?,02=G1VD193%U)14Q,%B0!5Q-64@4%)955Q21$I81$5234T<
M+/HUPG]4_8M950^H]_'J_F[6X=BLU#]G]B?5OYB]@'0^*K!V;C_)>'L?V197
M%1&6E!(1DQ)5!JL>V98"BBE)BDL)JXH"Q84E521_V/Z%_E\P#& (!^?C>:#B
M9H="R7\O#S\L_*GWKP.'(9U]8 Y@I(?[UWGD:8=$P8Y3(<?Z(Q>L?ZHG7V>%
MM/,O$J'T7T7L+ZJ_LNSPK^3B+ZJ_LNSQ+Z?C;_5_!8/\FXS\LO?GHOR7E/PU
M7QK.J*,Z<>D7^X<AS.MO]X]_+K._#>)HL4K;0;_6')3=D2O'KO_$^WNE7TP*
M,7L'($Q2ZFC_ASK8"8@Y., $I&#BD@+B$B)P$1!41!PH ?MA_^\FQA\P?)U@
MB._%65P *&(D I0^+LO '\7Y)ZF_-X+R@*-][9 P)<>C-/Y35?I7>G]O'^IT
MM%O#'.2%?BC^8/PE0[_<L__?2)V(Y'^]ZOZ5M/V\+XO^V)?_Y;3]_HLB*H8@
M%FY39X2#AR_J?V7&H!X('Q@2_=_(VA&.W=&]-PR)DH<?E_!O-Z NGC!'%K0'
MBYVGIYLSU.[8AI /PN'[KNOY(V _4'XR\A\<K,.W,O>O#/6W.+'\;QOT_WQ-
M_A,[X<F:_'\J8__$7='_-&.@DXS].ZOH?U%"CJO,ST_Z__^HHO^+!OT_7Y/_
MY2/CR9K\(_>/3Q<_'E7^]#3R;WMEX?S[K?BOWQK\)/#7ETH_=4H;HNV0:&]/
M/:0'W-D-)J^'/+JAEQ7Z!Q)_8^?["QI#;_M?O]?YH\T_2?^[P^/I\#=O98XZ
MCL(A^L=P'#&ECT;GX V%(7_,+%4PBYNS/=(.>8D%*"YX_-CT!ZE_N\,_9O+?
MN/VC^Z^Y_*U+6L7#S0.IX^$ DQ>3%?H5^Q\Z_8UKH J6)SJ:O#_>9/]JU?S[
MZ03D!.0$Y 3D!.0$Y 3D!.0$Y 3D!.0$Y 3D!.0$Y 3D!.0$Y 3D!.0$Y 3D
M!.0$Y 3D!.0$Y 3D!.0$Y 3D!.0$Y 3D!.0$Y 3D!.0$Y 3D!.0$Y 3D!.0$
MY 3DWPQ"]/O?AH$A'.18?5D5Y ^G "H K/\A'1OYG]K .FP$4!!BE6-;XV!1
M + IL' HL Y; >< 6 !L;)QC@1]_ H> $/\4+AX1#C86\9& -CD @(^%@XV+
MBX-+B$. C8>'A8V#BX=/ ""DH#Q_B@JH1$VC;\?J=8U6).8A'9NR06G3LVTB
M]I?T'*+V4,P.@R&GBBKRNIA#^M#\D34FK.]PO__%'3Q\7 )L'$*L4T?=ID>>
M'6/AX.$18.$2X![YB(T#P*7 .X]/"50BH-*G9K7SNG8$5+I-2'.$U?3L);NH
M/9)63,7P.F8'BDHOH^-053.*G3\E[OVH? @$-C$-OM%\. D@P3G"I<"A "@
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ME2A,$CD;I()((9[.7!;0QW*-?OO :"\Q,@&B_(YU?2D)KOWA$/ R3HA@70O
M[\'?"B2Z^H"41[EJQZ0F=[2BO7D;AR9JH$7L^H#E@U27T+=-\@[+*-?H932
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M3 2@P$WTIZ5.<813]M*#%&7SJT;OT5D21?'$1DUE(N38N+VO)-!J?1(C/-H
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M%Y:"7*O'?$4QB_P%UB;EJ2:@Q&J51PZ]IY9#,<,.=*4"!%(VMF\)8(F7DF=
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M*T[__5NMWN=X36]8JMU\&2I0+7O1!5U610)SKUCX,(%#$'WG3CRS#[CLBQV
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M0OGR''%?W<=Z*T R.C\D%6P+G--K3Z^W0(/2RDY'U;U::5?*KH*;.&FB-5/
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MF]*Z]=KWU\_AMF><4*U8$B-WWIY>%?3JD\PSNL FX3GA]F=G__'_M8W>?-=
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M()RU-I)>\ "SU>G8SWN\$W7DL9\X0FN>*2)"QI4.WT70A3:;)V@T\5H*R61
M+A*HU#J,=1N:"H/E>'N8:SQ7V[IWAV^PJ PTQ6:1UA#E&M6=V:/+B$X[5#&P
MQ_?93$7)$4UL;JZ4W\1YV\?W1]M,):714]K8L:%Q5=)\7TC6E*))UQFTU6Q:
M6^_,I;M;YN9/)JFHV!4;29V43&$"T<)+1W4)NWBOLEN*_@$TEF=GE^J[\70T
MZ(SGG6'=W/8M(\&!$II*!&XZ,&F;E0)5&W]9P&4T_>V7TQ3'ESG@M#B<:Y)L
MTV]7\+@>J%#.7@/C>N-)O,Q2#.#LH"*LW:=>K(8UZXNGDQI6-K?//$JHZSET
MG%MSNW>S. "??X #=0EWQGJWW$CA9;F4L<VG.#=4D!=?H7E&O))P)5K@:.Y[
M)6GF09+\NJGB)2RS41"XBH+1#3^-U?R9NY7U0CXWP4G&\14716KH&A%5_&N3
MJ6[SHXZ6 ^[L("/"T9'P",VE@&CJD9\'RH9Z,K<'1;52OL2**=O'U!+-T?V
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M>'Z&1]O%4A.D5^$^SQ((F>D9-$Q]) 8<5N"?*]#9F47KAOWTP?Y:F%J83#-
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MA&I7CQ6]+7G+$PM1*2FYJN<@-&3 =4D%1O],2>680[7L"D94];I]$=*U?W2
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M;3-!5JIVUYF-CVUTT[2LCH456@G15W/3S+2"*8\E_0E #H@^KKO#+_R;Z#]
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M=\YBFH!-TIPI2N#*@_$%><Z4 CJ.>*=MA/(?@"/CXE&<]*1?>+B=[-)$C_4
M^V7ZRQ%;?*D'U0/#+RS79%'H]M1Y[0,4EF+BKBU'):9YI/>9J'9>+ I/61,-
MX [[X:E=3X=$_V;G S";@R.OOLGJIHAI="C:3;909(7@29EQN0$1;X0[_+&.
M1K5YB-:),LD)834N-*EY:JHF%,]I9CJ5V@R5'M%.9CO)I&)GORU!<IZZ(VJG
M+4&E*5ZO&,D\KB@,BR5Z\[I-&W2R>=TB 0AFMN&>"&4^1GY2F7N=/Z=&?YQK
M;)QHY>^UQ:A*='?SH&4$LD?=:/ZHYB3FKY <'$"UHU&6;U]VR-[1FG;6'-<5
M#OY@$(=JYJBK+9VD8H##BV[WD2XK7"E>4N&.\I-6U(V2^HU>'=@KS4SBP_RT
MJ66R)UF_0@*7J'+)^7V*SZ&)M3L8KVC)F6-Z8:HED\2X9IBNGF1XV=8=13ZM
M."<_U<V%9HFX9U4#6?TW7J)Y=&7).':QA92.IPN^MH2E)3V @8@FN0Y@GG6:
MIK<=+U^:1!5-8TV;)H,*^A[8*-2)];\Q$C-Q (ZR+6]_.^N2:#U'^UX.DF:)
M#GKA1)5!@U4,OLEU(V=-0>/3U1_@)2W^8)@!",_K:)6-"5I7RKA$!?+]XG;&
M.+!6)$/C'LTIX]MPL/\U!OKM^=-8[-A>P9<>GML>!J>.#9XF+B,C)(>OW_5\
MLZU5BSEAW%\$_BS#;X)\1DP[ET5&KADT%61$86Q+C?M?(B>E$'/"+:)\D#KX
M)^#=^3!*P:2_=JX:@P^>7QM1>5+D0[.G*(GXR&*KCB;3)*3"2MMHX]M+8C*K
MB:7DJ\OJ.R S%J(6S0/71H;*0&8&>4*X/0C/5KIIGYDZ?WY8LQ>K?4V)5IO^
M3E=3ZR+K?N337SYA/H(;SN:F$A)AB(1PM"P'NMK^NL>JHV7G,]3X_DIO1HO[
M6X:$8%F?V=BDD$*I<6AN@AQ.T)A#?7607%6HJ>;7!@M:R9B<FE>&<5DR,^?H
M$QP!J*^PAI$>;%@0.7QW4RN+\T2K:J1_L:$%E0@A4V6*$V/H]\#2\4=I5VMA
M%Q=.>5!=QUC.A%=*N.3$('4]14)0K9A7LU)S(!O=@-=O>C=8NK3Z5!C5$TY(
M6!4?VO5DB*2^[02+*R.S4L,KLX41+V<O7XU\H5R[DS4?\3O/5PFG\]_AW0X.
M9Z\59%+:B[<M3HV&"EP1"?PL@8T^PMMX;I:R'RDL$FR./3W64D3=:!'#Q#N:
MZ=V<6SEO'31<P$X"<F:HZ&@UB)?> NVQSH7^KGA_ K\R0- W,\V7&)!5,[1B
M"VT3/XU22,]+B+__0B./T(P:>#8<H]W/Y&J7%4=Y=#5-:*L3B8)>;BQE'EZW
MSLCZDBMW^ODW:]JW,B--*.MGLV1=?]91*Z8H!P,!IY6(\IWFBHM4[FEJ4500
M4W==K>-2<<%P1ADOZL8%UMQ&_.8N!A-]<PLI;?7.<6HL ,"3 J-/1YW#<&1J
MF"J:73\S4EN;!#+E!$"HH#^T74P/%1V!=OI6ZG&-F(2YPJ5>%W/I"1XHR%-*
MF@3%1I]WM;7D?"]D;(]IWK3(&E'2H]@ G?8/]RT6D3='U?^TB%>=R7'_?^CZ
MRJ8X %[=Q=W=91=W=]?%W:&X.\4+I<4=%G>*N[L5=RGN4-S=M>=]YWPZ,_<F
MDQ^0#TF>)),\0RB#!E$TOUPV4Z'VFD%X7*/[OLLR\J@%*EKR*4%6L3"8U<"R
M)<'/"AZF_+J\1\- JX@]>%G^H^3@-K0@3/*H_+_XIGPR%3SB\_^_2466]YM@
M;*G/F\IPP1>!'JXAHBO145SE,6*]DNV]=R9I5W-_^MU.^\D(ZOR@>$EG9&BU
M4Y@U?A4*+@U?^344.T(*N40(1WRDSG?CQKOJ+[M35XW7"SI]=<NOH5U*8A7T
M.N#M8S+J&1>3-C'$[2UTD8#?HK6_UU\"?U7_8+L+$&NV16$MOQ-X.ZV\=):Q
MCMS+C%C#+QO1OQ56=W274Y=-G+9W0U]MSXSSITR$):K8*1PL(BZYD1SZ+<ES
M1U">-RVC<S_-F"JG+#B&.D9V\8>/:PA4SXS?\FFH<)L<)F_"7CL%X@MEOJ0&
MLQQ@"_\9 #5G.Y*;4ME%59J6FUI,&TZ:C8_>X!YB@Z(T9&A%5E,,&6+7F($X
M;#2&X_H:[<Y)D,#7/@\S'L+8*$\BBE"C6140T6"C^Q)'<J&F?+W]IJG<U'?:
M+25(+"EUL-XJOP'A^(Q3F3V629$JBC%1UUB1%.D88DH$!EUCUPPCD?&:+W36
MP%=U9&7#^O&<8&9K'D>8'Q.,PX:B=X1=<UKU3^.RUG?(T%SCLNOG+8K8^#F]
MQJG=;2'IU>!%!PY.UE@UVV9K404!NCG'(FI"Z*O]3QZ^6\LX)\*D,8QTVO=;
M+&P*1J<?Y*$>/(.ZF<WGC1N&_O5R+ASX,X2<R3@,K9$3[O+UX_6$A1VV7:L)
M526(1]5 UEGYRYLN7SBS-*S1JCD\?;%PTA!FE]%3Y!%VN&+)*J!RA"X1'?5'
M-"44CH KQ&)$+%0TG[.4(C!Y#@[=&2$.DM7J!-[@HFZ,/]"0&W$*6B^WB/TD
MJ]@N'6Q41#6T6M5*$$0]B/P'2'$?<?Q+UK$DE^,^Y(TC3NZL(*IAK+T)&DM"
M+,HJR<CI$+3C0Q(HIT,U_86EKXTL:S<J3\<@>%1"7(AGV2@0]]-_1FJ>E0<\
M*'\CC>>;<\!LF.@^=3! W'57ITTSZ9;^UVC"DZ6[H>O$L4O&O=<1:>6<'7V@
M'.#LZBZKVM'^C6%)9L3=,#$/12D%.B6.J&]Q,=#NQ3 K,NJ"-GN:!X<_@,YN
ME/-R7=!UCH&:Y/%GQ7\0U]YD);09%*2 +X[3?:#!B?][^"_>D^_^94U/U&+4
M3#1A_A.MB3^+=):P"BGMP)]P"]ZO81E\\E<&XN850P]=E*:)TRH X<V.OZ8<
MPR+G!<(^$T%H2CX>]$P9]612P,Y@$;>/* &+,2GDJ*I@L/Q37"%(%,H&L=FO
MR"+<<=&#&%MI[Q#3O &M%$A=HOZ=>(E-:QX^OM+$;H*]3=%7/,X1CHTTFK3^
M+I3YIXP<$E7L%JVG=1B8B@&HWFS[WLJ04Y_@1XKMZY'8?K)^S.XVF7;R_BW@
MS?M^[P/F%&:D+(!_(,][?O-<K/4U7DE;\$SHXSOP^>N(X]=J'Y]0TQ;]*R>=
M8_40?R'KD3E7_;B(::K765X\)Y_9JYDPP7KV#?DF$<B,$4U4!@:K%.ZL\WE(
MH#K#>O+0V6(U\9U*#G F#XL ?]\B71FCZQ?X>%(@P8+"@6>S7[#!]AULPSWH
M3[;U]>W!$=?!L([:@E*(<X0N#0BSBGC2#!:R&IM?]ML;?^A0KBZ94+?3\UD'
M20T(URXU?(IV2A3:#!.YHY/=@AG0'19E)FQ2Z?'#_'&,VYH:) ;'Y64YK ],
M8@FT!7-^L8:H.FO3F0)DF3&86 4]@GS3\H%.$8-I1-<-U]/EGS.4#B@WH,?$
M@YBZ"LZ7A!XY!KV,D=15YE%QLX3A&EBW7C]IH5N1Y_LG*/3OHOY^04%!3U!+
MCFUC8MBBG1:_>^/#2\V0G&4!SQCA:AQ/>RZE_46(0S )4!3Y01A_I'[<O[U]
M&O2F>+T$\J^73E @YS6;(N>TCAC=GYS%G(LV9W,RLN)P></!%)3[H4M@H8O[
M8)+G_Q4?PH3![=LH!;![ ]#DZBBS/:<# YY>XIHM(T"1$Y2'L@#.JQB*.,'8
M.'^LQ.OA0HY[3QFPC$,]FB%/>J)PYYUL/M++3(ISL$6;?L&7Q0*/HE4N9A8-
MY89HW^D%>B'W_=.=(;0N6E4&?""3+P1N5,>]HAV0JPU+3Z,%,,QH5^SDPI_6
M(VR 3^4]GIC4UP) -QPQ F#.T94G2+G8JW*2@@')0? X=[VXR-2!_N&DKM3
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M&97/#*D=)JS;^^1L-@_9=Z,:*KX<8>H^R<],"68WC,G3<-^:O<:1)9\QF-Q
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M$'8PD15<T %LW"MPR+SLDF7M#XG!AI8CB$H4#OZ28_ U7A._7XMDI"ZH1,(
ML2R1\\>W%@P\Z\$B7&-^QW*%A,>:Q/(>7^92UZ*?VKYIP#)4) TY5R1@6Y4^
M?V4X-7W#&2\'=Q09-OBG@ 84JGJ0E0XLGC6 ?1-<PVT3M:A\$K24B6\RS+R(
MOBVRVO-RQ8;%$#T:W*#A]5Z%2-@]:EYHJ8V%B85 !JV9%6R7&76YI"ON%V$)
MO$*6VS,N'\P6HX+BJ69/^D.R@A<_RA7\K$/?\L+K0L=9U!2W?[LE8KR<<8??
M=F8C5#!P(E_V2TF5UVPH&%U1^-L.9]9/-LKV%.F_=/(:_("TLM7-F@L']\*%
M/OKWI89EG;D\RX4JPMP?+BQC;R$958P#G3DQBB*(<EE-+FXAC54^BWL-H2Z4
MB^1<QGU*EO">9^-6.K(:'!8)U5!GVDD>R ^R#6SYCI/R%[0!UDC)5K]2Q#>2
M2((0:N1K'KJ:W/%8JW/B>IEO..CX>Z$BA2Y:_8I]_-9-7(P"8NH^7[Z)FE\O
M$FLKB'(W;'B0;F:Q+)XHC4=]??4_]R4,,5(^E&R$;W+RX^PC@5!_T=/CM*%B
M,"R;KGCL)A-#P/FR;D"3+Q\M^PN8,? 2%=T0 XV;  ^#E8UZ)+2(_#9@#*.Q
M6+R8:YB",VZ3.T<0O;J?\60])NNI^ZV3NDX##(.24MFLMW(?L[Z&K]=J?09O
M^N.7:*A!P2EC+%PTAS1,-/-D@->$6_5\[M26L[?0N#98P%;A?/%6[@#/"R?)
M0ZW&>(4L0SVV9[&6;8Z_Q%+/?$R^0*,\[]2Q4:@.=B<G_4%@#+1R;X(WQ\T4
MG=7)?P"YO8)VJ$S3I]U'H.5_P>;?B4E BJ.?=2W+AY-6]U_-A,Q3:;)I OD2
M'(\45KH#VP[&6^PJ0KQ[BS[;*1L\6.?BRE45!^H"&*B+*CON$ \HF$C'\.U&
M,F3VOG\I_ <H':_RI-IU2-G].[7VA_V/DO$*:NCTHEM2$D\F5DS7.J\=9PEW
M=)@.[K1U99U2(9 B?\NT:G>UP;SS!2$)6X4D1:%J/6WJG,/>P>2\8)U5M:-9
MG:'M#'.OS.N<[. MU,HA)+CM<$+OH.1'%YI>*IW*)7[(-IU^-77488;^Z0V3
MS*B7%&KC:$)_+"C.5QW7,NDCB @$ 1"!@C@Y+FLNJIP..CLSA?QM,;L:%3;*
MHG@W'D 0/"WHZ4'&GX,P*C>?H%SO1&>2'Y/S\B9W6Q(FTG&'V'>Q>L-:1U=J
M/C.XYF&LHS(%%1SYT_RTUINT^/[WR0X"0D#(B(RV0TI 4K&=FIV;!Q]SFG/A
M5#):&K^HD660)$R0BD#VVZ!%BERV3V64\W/N<0%!ZYRIQ_E2T6U3"#;<T#02
M&A=&0U!**%CZT-G;'[3$-O_SFL)$C/T?0"7@>2%80?61@B+5ZZJ]XEYG&_5#
M]/WA96_YF]-OYVSY^_ =<A&$(/)_@-I2LG^ L(ZNS==/T.,]$47J1[<'_I]7
MC,&XX'VQY9VH#V)*<83KB""$4M+7UU<_N\,C\L>7Y_AS>-'ORH]B!G^NZM[]
M K^$>JJ8/T.]4SUAHON_OKVZK?\FO17VV#:.9AC=KOV#<>[6_NX1>X9M:-*N
MAE!KEKL>*")&/+PE=W_W+"V5^ ^ X1(8V-/U\<&30IHQ+)@($?)\^6SM*VN_
M\!)R%/2+>2+/8\U#15UB/RE+D![Z;X_[#_!E8OD29IW&,*OGX^[L]1_ 2$NZ
M'H_N+/@485_NZ&G9KD[ RDYH;F.)W6QNJS;5=1BTP4$]2Z7AG*M8NUI#&$VM
M)\&)6_0\P2*12F3[H;Y_5JX+[@\^K"A?6!;6=ZZWQYJL(%@S17\F1*/F O(-
MIB E73_4RODHEBEZ#R093)X?J?9 "-OC%-8G2-T+4/\!&$>M#LA^]*Y F=!?
M_[PE!_4P&7;D;:G@C'<&UT_+;S!X(J_;ZVB-?D5KF_FNHBV8(G)I%#G4'HYD
M;._#AZ>NWJI=1#%D]$>66/].B'10>O=X#&_1H"7%4?>3L"LVG>EM=[MGV'[Y
MVBR$PF)RRCXF;;!AW."8?QVHT1#K0J+3H$+LG:#>7.]!08=D]]6'K\4+9Z2-
M_6=)5TMSK@*5!G)*U[M%&\O)'ANZ&*;RU'?E5;JO1'G8A\K3YC&Z6 GUEXPF
MG(GZZ],[K,^QI"%SM6'UJ0+)+0J_)*V)L*^(: ]U!/4?I,MT+4R!N2+F!PJ#
MI=]TQ<Y7F8(X<G&F6;I4"0]?RDG0@D6_<-:LW70I6;2].,H99?7Y'!R*5>]V
M".IC)6MO.J;'HL^!'0:9!.0C;.P4ZC.90]45=L]+?0QSNO?)AK@ZK#I%(E.X
M+/USQSR](-4%^ X$WXI<CGQ6YLK-P1@I6'A;4GOOWQ6J6B5F=:VKC% HW1<]
MT3LFRK6]X9_3KI WPVYH@@4.##<-18P;K%<J[,P)Y=^U#<-121+?11OA+4LO
M!>QT?#['+Y^773/0BSELF@8D%3751U+]NCR1.1A;SS<F_'^F;)A^(3 >VOGF
M;=1R4#[ZK:7_-#R<%/?^4:F%/29 W":M12Z6$UZ^=='MP*U  (9^TK A)Q8!
MQXV;,!HWQ\WNX"@ER -_^V]3L5'WM3/%UT[=+72O=FV/3Z,><V:AN@G6)X.+
M'/M''!MP5E[%@?R&Y15Y1TM=/R<1N$0($2[/<)\4Z&2PLF;<$9TZ'H,M&T.=
M0GX@1O:V;T&:8]/';X-ZB(POU'"YN&YH>[ .0^]?P[HV*;I0Y:!WRMF\9EPC
M:N#^1M:FG\I>YAO[EX0-BHSE+KQ:Y2 XA>DDJ<N=2Y3&S"JDW>D*=7"?V?#K
MQ@+<0@-1X&Y_9"J%T]ILV*Z!.5JS4MOP05:[S60B5H:^@BZC%SV_)8Y"+>TQ
MIM^6>/D0@Z'YJNPQ9\T)J)6+Q77X_MU7?* S<DPH()]8<%:(ZUN3V)!.1EDT
MS\\+V-=V(B0M"2\4K;G(N/"\AIJF"J_@;NUH[@+D X7N_^75KJ_,X2Q-M-=1
M(+MM17$M-C(#57I55,<)5'6AA4&;55194=/LD9<TRLU>K3%7>K.DR9]49$QJ
MPB=78WRYV>PT?7RNT-XRL=]NROHZS_B),[6$4%-\Y'J_W]G/'=0GL.N[%MWE
MC7TR/CJP<S[%60;Y^ALJWIT[TJ70J,Y2:#BXUB.DKN>[CYG3)6EVJQEJE<=O
M2X^8OTRD.W%)>S70B'<.':1"Y'8\*(AA$^]3G@Z$PZX!)[],LD:#2<>9+2UZ
M8+O?PJ$NSM8?]I;S;LX%&\=S5)>/^4[FS;VJOSBQ*5_+F712J!K] YC[:063
M4)+1T$<@R<5M#9RL?&>;.'DD,YW <KJY>_N\.=M&$!.L6]NXW?OS0'1REGCR
MVZ3P0'^ 2$(>I2\\WO3QZF'O3T!/\/9%%4+,_C[.S=7KU?%WY+KUS1A6='0$
MJ>> -Z^5 ,;N2R&4:6LX6SYDM!M'SV2.D*+D4(-^VW2!XP/BJ>%:'-9%:WQZ
M!QC$57-NUU]_G5@*R,=TE[57UWC4Y8(:];<HEECN$P,< BQYT+@TXO@OJP<;
M)2AM+;$'^^5I?NQ'U T-52J2ZB+C"M%+5K.@O99!W>H*C >I*K'W/:G(]OX#
ML#GO%@K&+17+7PRF*HPVZ""P6>E-B> [DXWJ?>F)?><88/N: K3<CR=4YV!Z
M!#'4Z].6I?_DJ0HEW@B1!K$^IV)7XN>4CD 7:4AFG];W$2M\CSS0']0;!OT#
M7&#R['=XSFX=J2:VBLR?GDV,1\G^ ]C=W !V7#GA!=#=\S%)_)HN2&1TS0TD
M!YJ50RS]3!1EBP0KD,1'!,?+*B9R=%ES!(QEC(2\3JPVN[]67.94-::D:"TV
M'FXHW"D-[2<V3(42\1-":<&IY<-IJY5%0.<CYR-/'=RX#]:#'NB<VZ?=6LMZ
MG_>AYO&2OL&?7OT#B'\(17SX?S1G$%L OJZ7+N_]Y,C-/ZKY8&ST$/7X/?-;
MZ>.OY[L(('X_^P&I\RV>['/OZ1'#1$0H?%[_AA9 )A(H]?"4<_K;DT\S>Z]T
M,._7Z[NK1(5,LCN)_7V%LGX=S^QZ)7"$7?OYB'K4AGDP7KW* S$#=X'Q9J:0
M;&)(J*';6INZL#"ST,J;AGC_MGKQYT(S8M6$T ]AL- X-*1L_L6Q'J11V]4(
ME*]E')GL*J-%;^ N\T) .R8P:'(;(N(ET-23L9^B1BI1!'J0;"A[./850J9]
M_J8RZ;0Q4(\)Z8^A_F%IJOS">V7@BV3?/#DSF:LAFR3B-O2'P]%RH^UK=XG"
M[NU=&TJ#>H(F6/_;1*Y;0FLQ_ $_.(-_O(LJU*<),S?)63X6F7W+ZQ<3<QH?
M9YNVK'4Z]$&1::)\J_CH3L.LG-LE W,(MOWV\%Q'M#+R%FVP\GRU.01L%8D]
ME0'$DL"9\G1^M6#&PG5A/-P=X!S]*;#8#_/=S?.7MX;&S1742DQT:R.J*K6X
M Z/.[-B I/#S4O[L#QD:D*;A#EG);,41[B85&QD!;6)6M65C1K%OH;/'] PC
M 6F#^\C!X,;9:%!Y A\3K,YJ2/T(=8)G3Z-U@H2=&T$R+,> @V#OMPD+T(6'
M)T$26X[ H1X1;&*&E3BJBX/(4/T=7+3E65SBOL_3A^^GF$OM]KSQ=-9'@!^F
M&'H&0@GO,9IL'YV2L]\GT<G)QC=_'<NA:UQD,N.>PD^8^_>1B^V32)#OANFW
M3K_WD8,\A?36MF&.^7D1T>]'K1L.#(YO<; (K<XPVW</]^\]A2\.:'N4YZ(Y
M\8,4%YIJQM!\HGFB.4\GRZ5_ 34-CUOV$Y(=2V=S@R&Y=5I5:G6-R$1?QPA8
M&# OHI%P&!?03Z@YO3I44!LM)W<P*<M^*-4CPJQ:7Z]OZV\825N%H53ZED3
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MFN9-T9NA/CL/H4.< JF2)$U+AL'":XPC;^4T.]]9FG#SM?!L#NX23<IDW_"
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M?T<-(>'%K.@)'C-FMW;X*8W=CGS*AB[%[3MGWS06Z+N-CDZ;'L1(<DX!6;S
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M4)I>MT0:2 ?QQ:]K5G8>@AZW!]#OD_#?VQZC?FE;XE!8-$_']!]IM4D$<W'
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M2R%,(_?=D,!#O&ZJ*.<:K.4NIN2D\4UB>DU_7.Q3V,9=RXP SO9>(]JK,=N
MIL-^)2M>L0Q6BFV7YTB"Y82K&WS&&NZ07IK?@,>6N6?B?+U46 (3DIP5[9GC
MW276,S=OO4&*/SI2$TFUA&#U8([F$NVK5K%G3\VA9TI;.5P0J[,Y_FG3N+/_
MX!B<,HZ=L_]308+19@A\6\8&T>,[.V@S!5"K?NUZ^_[=Q?FKM Z8?N0E .'B
M<V!O]7Y+;C55[V./1=N8U^-5 \VR1-S8;ZQW!*2:J&:L#.>[/E<3D?B,8O\
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M#++H_)*<>1(ZX\&V5+W@*-I@O3D/WQ"0R6=E+[\&Q<2#<(MW_1(K8TDJ"J&
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MC;^*JP5ZCLFH621V>3XA^B7\_?2L:V"(/>+_L/$"0YW25;_4X-,4CF65@=%
M/(FX-6F1OF\+S3 PHP8BJ] @;9R1P=$JA3*#44&J?0&*(J:O;G^6A=(.31NJ
M1 0F"(GI=^&MBJL>_P![E7N?LJF-.'0H9(-O<N/<2 68QV7U@31+"37FV1BW
MCM&G/%8YDX[Z8@E&BH)_D+\RZ=0*=EE>QX,_L'-O9E&VW!5Z8GL-#(G2?XL)
M'DW!G4@TJT]7N2W?84?EW;U$D:RR>7\MUE73_"D@3*V!L[;-6TC7-![=P=_M
M51%G"-B>2"<WNZB].F!+C0I?07!JM)[$@YZ)&/9Y^%S<P>A*"@NY-U(.*@?4
MX714JW >%:B93)R;B2^;0&<8D+D:"U.PK&'R5>9.IB6NL=S&O#R?F#Z'M7R<
M'N:E3:DH@@!SF+^1!V;NR?J60*!TA1DP,$FXMI8Z.$^.AK6<?4H" 'LG]4 !
M;?P'((RC$*"2IAO4Y]&6W&RIC&+2"!];+3V((HY71(%EO!JD7/+[\<]ON=LN
MS7UK<)(E;C[!6C::?FX1,K [5!BR6W^+JYKD(W,NL?/G;S^&"=)C]2-@6*J[
M'<M.23TUW(VF:TQ?<3IW:^SU4EYKYR86# >P5?_2T4_Q]?(6CBB2Q4HAM)-M
M3L3$=&@B4Z1IZKAUCI4'1G=80!BSY3S'N^C3ZLR^GHWSU.^=QNC<7WSNL5UM
MIF4CP%_@H=+2)O?"G?))&":UA\C.]:"R\DHFDHS/UXY%UTET*O"6*TYI,[:B
MQD-J!:>)4/Z\JGG4'9(IC\>I((E\,99DT9-O7*R2&>;YN903YL;K;49@$YP1
MHSWH7KGD"::TCFNW+V2K+%$@ V6#JF2[O+N""B^#""_.Y@*3XF;72L,\QDF>
M,QMD"-/K-#9;))\(/<<8UT%&N T*NB0YA79>A Z%X^79R>.%-TJ-S__KUT(V
MJ,>!XK]>I30K33V&V6.>!E>U8$(#OU1"0XN @*+O'3-S)ST>[KDVSZWK<SZQ
MN@(@&5VH#_E2E2@1L&-E\:L8;D*2C Z (=!@628+(#'(J4FF(RTFME0F!#M_
M\ /'<=AT7AXU5%02"<>%@#I_L8Y4-<;D\$>J]NQ78=SXHD,V"[]A.QL>,!'Q
MBZ8J'U^F).<DRQECD<-W\'Q<0IJ_D$?5^AAH?VC+B'TW[Z_7Y9M//+=9L_FK
M8? "U-8\(%IAVL8K-V8>*A"YV]JZF^L=YVFD9M"VCRVJO[[>\6!#?+P%4A-3
M4,%+ATF[D=S2TRXK!K1B4>F\)^9;V)?\\9*#<UDK'<(N] ^ LL5\-Y\JVD7*
M\!G-T<W-/S$WS-#7V\Q0]#6+2EYU>9N+7G^KM?BV\8SH CNBBAC&F^YY_!HT
MFN/B76*/"_ZUXKTLG/C=M?!RV9_-IK&W+8_Y.%:OU(*]&F4.MT?1*ET5!!LH
MZ54.LE$#> 1R[4W"W1,]G)",]@(9%JR<R/466OZ"=DSV?BBK=K4W=;5T-B>M
ML1?8?3[/L_O:+O.0/J)PW-SMVD4==:,R\>"?CK[AP8@3'SHM%(1GINO>]*"(
M+GCV%Y7&"LMK_O0SW7*"CMRP34KU<A%C$?UZWZ3B/-.<47BSX<:JW@[=8E15
M<Q(.IR<7]D92V6(-G$F/ODM8*X9&'?KE77?]M.?'<(9Y52X\?/J.R-TXVWD/
MZ*'6*WSY<7E0^H;'&;VQQ<E\8$43MHP-]I71_3G*?N4$26_(L&[N;C4 T]LX
M^-(H,EG'I*E_YS*FR:S<T I60IE$OFYS9$GC2A;"OH;:L!51NTA5SE">ER$=
MLU<#U)8LB:U8(3#Q TZ-$[8(BC5PZ+P8M;%,D_%:<\C74F;&MN@<%-N I4PF
M\WXR]O+Q(ZD^,[V5FG\ EP2JG1B^?P ,48.]*G';/;B!1(;\=ZV6>#0XD>47
M9?FF+BU#@_&X:262G\ESDS;NSF<U&#5.97U1PZ K7N>8-91])Q=X_$E1;D';
MQM1+VG<UF0D9N4JX"O@3YY%F'1#KF24EHGR&FE1^#L+Q1>O+Y A^VO+'7$//
M@9^CF.?Z'LH?:%'>MC\28329&HX4(>B)(/"48_3%?"PQ[(U]Y(HIS9.=YT<G
MTZ5YH;B$'++"3*&)%U+Q(T/IJP6S708_MRC'M]>ZQ6\?+&A-ZMQJS)^-TAF%
MO/I2KMLDY33-6;0>X.F(Y5"M!A[S*;*:>=.4-*CA*527-4._0*N)-6$2-]\/
MYBI.ML9Y3B::Z JM$J&65=?[GD\D\3 9G[EOR)'HMNBW?X^18$S<"@:2J/J&
MZ@+U=<F^<)8'8]0RK,JT)+MV= B?=PB/X@D->;95TQKX,Q>:2 EU\90"$R)%
M^!1)9]UZ_6[5<+?&R\\S-,?0@!F;0)_BU)<O0Y9>W)N;JFCP>.P(/52';^75
M,"H AH8K#1VBV4=/1.E-069 2-+?O8^$T@W!OAUGHZ<[ )NO/[[Z><)C!\>1
M9;J<,L3Q!4@ON7LK?OF9/LQ- R20I;_OBKZ9U/4Z2_>*K0^FC0DBN?\)>=ZH
MW<&9)_[Y6W!6 N'U'Z#C\9YR=/N(@.\V#F('3E'"&3JK$MO&=_(DDA6,L2K,
M+:-F]/S6 #-"'.WD4>T^M+#4EA]_A]:_%ZLS*7W&H^+$F;YNU9:Y,4&7F]P>
M*Q65#@K&?XW"PD4YID&L>5#9ZA:BB4=:R4H>0QW*IVFG]$4@12+=[C50:E,#
MNW%0'J7Q#X]GLR!WPZZHE("?;VT<9.I;&U-@'@]RDC]"FG2N-G\D&^P;=AFM
M3R#$RJ3I?)#O\?_+NKW7/9I,&S_-'?UC-%4)?5)B%I.OP#=G8(0H(]>< 3'%
M;'Z55/@3E"_Q0R8-0AQN(W/\DYD>=(J. PUUTYR0P#E/*@:#QO)OQR'2JOCH
M^07M_;*?JM>FQ4G]SD'O"M*"4,53M:NP*;Q'G'OQX&"GQ@Q?XP>E],+&JH00
M_#=U_=>7MQ^C I\NQ4C?AH)<YLJ5OYFUTW@(_K7(OUI-&&$53;=\=^@#0#C\
M.ACR@/=?<[.PD*LP]#IX\"R6U4_^L*EM?HL#DA,SNEOY+?>^#L0JF.)ROK%P
M03O:9G:U<48[4FSN/'1RO_/SX&2AUK[%DV3$[_D5=;3T\9>P3K? GR]UYE]&
M+Z71R/CI+9P>BMN"XJ?G63Z)J-0WZ5\:A3MGR]-ADC5DL!2W=SH7BDG3WSJI
MC&7,6L=&[TEBN1EM;C0BUC!=8;K' YB.P N O0Y.(+YI)(8QS^<CDIS>GLZN
M>8_)QV/3<?2?_'@-#-4=>1.@T:SD60LW>HJ)OD99UZA-Z%*K-KZQ3$]>R&CY
MB_NK#WSCZOQJBV5T*/$)GO+S>PS3@9Y /HY)[R_WD-/6IQG4D1+!XD$8 +7>
M57QR9Z&GL%3DX+Z>^G"IL]\M(?)K(-+5YZ[ON>[6&43&A3]+ 8J5+-$IR;NZ
M>H!]MX.="<)8$TB2+H7G>\'P"U44O>]Y"#-B(CDG94?@NSP[&,?$2*4"Y5:D
MXFB0!S/I:<IY-MP"G":540\1W__<&XSVG%1W,E-_%$!PWAMP(?(/$.!WN)C6
MK+1K^?OTCZ=8E]/&S_WV]"@H?[2=XFE;N=R0E'QG:DJR*R,RF-L\9$L(DI\<
M*9A&KRGTC";-;(:3.F81H^2<XD:A,<Y76T'(/*\(="R/%LII^(T49&C=Q6FA
MD);36,G,/C7$6AD/FQH*+I"8Y1;!'O]=8*"LRM\)SE+J9KW1YIZ8Y[2?5UF"
M1#B#^ P8]0HEI,?X78 8W?Q?R<Y)K0MN\.C52?D2#"GJ4QW7F<*/$GWN6?+3
MRMK2'Z21BZ9P2?H]$YEE(E*?=/:)+!R_ILK\E.M>*)G\80Y"A]E>8@U-3M5B
MWHYH)9?'[Q81J@=G!H6B,O>W?\#_O.>1+^P8EP@0HT6L-'U@B9?@CD4Z[U>A
M0[C:R#6T$ SP,_U>,#JYW.5L,!5!C<1%XM1E!9'SRZ&,FB@"0P#H[3BOF4@+
M"U# />X#U?;K&0C8_H0SND"=%TA"^IM?J\MH=M1LI54NB,(E,:^T8YMDG/2U
M]-6)%4'^^-LX@V]AR.87:KGURW6'8QKRI$TEVY1PQ.!K;=&Y72P+][K[$Z[*
M+<^!S)\V[A$QXE@GU.]5PWY28*-%1337 U!D\C03(BT[,I/>J Q?'>PZHZJ<
M_O>MT/]GMF9:!%J%B.JXN/]#I*GC::S"^CA6-\</30XM0P[L-?YQCI%7P9,B
M*Y/AG%W,+2.LJDXEA"..=K/J<]7G?K714U3KF"XKA!!ECD+B9[%P^XB1LW#O
M6Y.K "G&VSGJV%GI'>U5*M>YD#4O!9-8!H!%N)0Z5W(P5QTH/=>A\]4ZI]RJ
M:ORXB+5+ ];"[TG;6:NW6S1TZG#!G97%]@OK)G:Z=N6GNKQ@8XG-N4V)J7CN
M#K"6I7#;FI7IQ'ER?QBNEU%M6XD;3I9;OAM'0FE=\<[HX9:>R1!3J+8@;;!%
M:CH/TC"?%6.D+!CH =5*:''L&JK\Q"@>-RB2A+;.:,6=DAC<@H!.JCA>!4@C
M/J6Q(KQET_T@AT,8KC<^K-R!2_8\U@Z)1W(Z[WMCW'!PHH+6^>H'MGZ$CC^P
MWQ.$A.$QX6X*/$4D 9-55##1=$?$> -G/G0S4:X0N^)VK B*NJOYFZ6X5UV?
M433Q%>A^5Y\OHK:^1S(T8%P9&R??'F_]Z]1YFVO_A\/'?6G#R"E+%_'X]&OE
MZ"9A2N-1;("V7(G;4%-K!N9K0*)R?,4ZSGBM6*=2D,F+%1,X< 9EUQW?O-_8
MTYIUX9*!G3\.+@3F.*0RH'B"< FS>5LB)X+\=W?_( ?;-]1>!T8,@60%BNQ'
M]FDG.#DV^WG+;(\\4:=D1<I=E:XF).A):MD&>RIX=7R=MACUIKKB@T%6!"#N
MSQ%+-NASQX&F6K0%*'"#H99GE:D<QZXV3NJNVD-,V6Q\X>Z+\PW:'$'[;DO0
M'7C1)1A\:0!5E9(C9AA'QI<"Z.U"KPB"%4B05SB X8+^,NP/PA[FN@CZ=FN7
M#+1Z'P%34^5(@-4$378DBC22%I)),HF5]6%UUT3Q4I"I&4WV5, ;.DNUD0Z?
M](KRZ/"@A;VSL">*K;T041)4M8<K%6A3,2R<I2]F9 <#E]*=3>JW3CWN;R5R
MDHJ%9!S7^9)=L<)_A!'U-XSI/-H'ZD:/$?-5>>CUKL4.=N;Z2?D)7#&.1+F0
M*GB[  X(K+V"PAOX/C[] XQ,_@.L"YP/]Z+Y^ \$TLT_B@]2XSOOS?'_T%78
MW?[0M?3(I;FW0=KB+)!]9[+LD6NBJ_<]@N]EF^/G4>SE3\/P1;[HH10[#K[N
M9O+ ]RT_!3N=6>,TEQ_C9!+J/+ZQU;AHADX:MBQ>XL_*QGX6&SB>F2N.T^F(
M4NJ5BU65??"?D4T\3W8*PX G&"I&E^LU_" @[M*O,K8B9[-)K=>K1O@DF$^Y
M%=IWUDI$]F*5P,UW])HL'S[ID0WM!Q?WIL9@URDY^.5DCU3XEK>[<M(C$J;+
MI2O "V1#ETD9')OKB)HUY&X;.-BJ%+;O\,U_?Q7BRQ6859,B7]L?2D1EAOF2
MEK0G<ZJQCHO"A$L5)/KE^K2#J_=9+^BB10+E&CF_=<E)5@<$& @?R7'<!6*%
M17>F*N"%;/+KO1L48KFO)DB@(-&2,LQE21/LA%68*&DJ:4O.:MFAU!VS)R?H
ML\\?#X@)@ZOR4C-[&T9JQZYKK S+*[&SD?L/:,FD%<3 W6[TP"T=*F%+@Y.I
M51:-E/75H^<<H]#TOPNBN8:\=F ];T2]&/(L6E7;TH?TPP]XHV'C>!AM9'\3
M)3MOSIN^FW&KY]X!T;$ZM*I[6G(XZI/-$V5)[K/I*G_6?0<7E!&&!_["/.JP
M/=[2#$X'=>^6"-*4Z-(?5+;$R_P%7'IRD[Y+K7%7@)<*U'&)_0/8"F4S8>A2
M"]+_#B3MT2UIE)O99V"B>HH=UKX8JK9P+ A9,Z!J=VT6T4/O$@-&P+3=@@N@
M$WLHS^:#ACWUV@F45B&J/R>$@E$A>"$X/?F(6I1/;LGV9%?(O_1_)[FY86X8
M=P8[PPTFO8$7S0W)<TKR4E.A<B3O'@S-G8H_?87D4J@113;,T'4P-R8P\@XO
MB.YM1K7I']K+LU"N5MPTORSJ>(R[H]#J_,TK ;L9TP++3*%P8N$A7TG=E#LW
M2^N=1^)YCCED<ZD:1(\_86RH*>1[2HS^>2-1-GNR _:8\,X<D%VT;Y,S@_)X
MO5<"=*DP'.\AUS+#*0WB&Y'L6>](,E"]-BSOO9'ND%OTZ,__7?._0I>!9)KQ
M:L^Y?16V">1JS>PTC\W48+"NDBP0"4] X/ :1V4LRBHY5ZZV5^1N?QB/2X&1
M=A0"%R;$!S$3ZBL_"IM>&= 9X^^-5P_'V0G$87"QBKK=&K+T(?PM<1,1ZTOW
M)<^,%Y"3E=+UZBK;*";W3_<LUN!Y("1,K$[<$ZCUM[SUU#L<0V&HHM_U+6WZ
M(/Q7$D*H^M ??YE50_8K-O$";EKE9*SW;9U=L)*%TJ(W;GQF.T"F$45PZX"F
MLZY")\ /(45_T.BZ]1C-LOUG[?2>2GU#%T8*CPN4\$P&I(#P1_L@G,)QN!Z+
MP'I" 'MHIBSVX;O0._=,-PTS]WJK5?>&5@L5?L6<#[8-8Z Z<O9FHLY[8:]!
MP_[,(U0UPL9M$Z&&U77>DKD3*W)+!_VE'YWAK3XGJ2,U[UGPY1(/,E4/\:LM
MI+#8VN\HNK"&PDVO==_M['"W+Q9FSVRJT7M+R=HZ6T6B'#X(0I!&.!EQN!A(
MS)PPI,F).F"M'3$/!^A)+%!_[R%6TK_>A ,\"=F-ACFRN55QEH-1MRGSJKE#
M2QN'Y/=YUAZW*5X;F"^_)>K,@^C8Q@53) _H^6\88JSIF_ 5F>AA$,7/XR(I
M!D]X%MHRZM&QY;'_\X<#L3*D'@, P XF(6*=AG=Z!GP**@R;H%Q7'32J?R42
MNT)@3F=I!V_+ERND9]E5L3 ]L#&('V"$@16B3[@OMC^"S]=L*Y[^DX*.<ZCR
M*!T@'DPI-2949#XA1V]R+)TC>-E!!'6BB3S>MO8]T"N+E&9H>O+F#H<:CKLP
MR>0BWDF=4,#>"9%,VQ$,G@QB>O%1'NBXU]H7#9AE>_$U&< 3UF4-6%)DFGOJ
MER^6RI\OQ6)*])WB=%FQI?HLNC@:]#+&ES?"R51,NM.\'GBUKV??V3]0: CT
MEB<PCI#,[]$VSLG$. #5T,/0,66ITQS+X<PG%FRJY2KV1<#50/;'^WY1V3WL
MJ,A-+B8R-^R+.[L4D_-7K^6%L]8&NS\.@2IM#4:JSBU"UI%L$J8QCOL+A[FR
M4[ V-C^233G<FDM--,L+=+>\-IU*(>LR!L5FY3EZ"W..Z)72:)T[#K/#H[V3
MU08=55%#V79(L69:BN7-6).(;IYTL\ /G_66M(@&SE51Q%:H17GK^-H@O;D_
ME8'_YT0[7:0%#B&L-C9#3,TIT"E.82'W4@"MM@THR-G5@6S.\2"'V&T@!;,G
MS7IXR+JN6L]6A\=>.'6$W'9-DS6!'J9,2R=8F"!I QT3)&>M;$X<)Q.I:0KU
M88I^E=HG5R79<Z#]6FE4W 099S78,-#?*'>(FYS,4DC$M)5FMA&=I6^4=4%V
M-YS&XC'XDN$38O;EJKZ%*7'5H)+X6:VOSJ+0!#S(GZM*IW(.I+:(\33.KI=6
M[A?R65MX1R@GRV([:EM,H($7K3C Q125[\:9,M1ZNVD'&=N>.<O 5:-.<4,2
MM""%(@D3);,1^AQ"R=-6,H6%JW=BQ AO,B*$<_.^#2][S07>AAHD?%)?N(PX
M_E8N[SQ7\K,M9Q1YDJ-J$G]3TMW%11C=+%7NIQI6H_%7M>7V&@HKHT2XB\CC
MG#I/31CEA*KE)DN+ZW2&<J,0%PN/-W90QB1?K/.*,MD,XZ\)NMH9% *"2Z)G
MSU]R&O4/3/BWC3IZ'6E;F%!06]+_8D7]OPARS!YXE+.OTCDVC$<.>UBWZ@*!
ME(' N66NJBD%#DHPG"G"XXL/>[<I),6R-G/)\<'&B'G41B2=WKEC*O] V<9&
MM,%0S<Z)[]H%^79CF/[G2=">TJ]9JI>7^*ZKY6(X_P_[@9D[U?IE?@-*$0V
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MG6:ZD25VLMQ3"_^>8L#LT#G])SOW, 9,1W">GNE=+%W$NZ1.'HGQ/H '!LH
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M?'+1R1-LIXVK:Q3JM!O8V*BUZ0=Q21@.]=TH!P;'?^L8M,/ZENN/%NM*HE>
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M[X^^*BS^^FEBKQ6BP2HRG*J!/C$U-W%L/,4*KXO;/1P0GVC%B=.T6D5_4Q5
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MPJV9T.B9\,N@9F6K<MBHWS] GH3OQT3EY'!$@!1YY=(4G!Q"*=88W!CI$D9
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M@EQ[VRC.ZJD4'2FI5ORO80ZFE2Y0@Q4:X>#@?LBP75\G/L&S][8 Q&HVHH:
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MHF![])(_".K2V!O_ZZQ:1BGTG)F12.!C-3FI,%VQ3;U[4F:S]@_@8UR_N2C
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M,ZC FM ^)NTN0+1YL;D4]U@O3,[Q;A[\K6T^A%U+7HWR/%952J[1<&;%2OC
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MQW>MJ&H)HZG::"WJ#<_]5X\'C3>EGU@&9JH%UL+6!T<6] 'K%0V!V02(HQ_
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M?OS[R[1M0+V.YS4&%,W'><C6TZ)&3-<1=RU=2-XMI/U''[D#CID2<ID\6$5
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M\!1,\&],O( EIUU?QW-5<PA ;QI\$1^K->YI%'\48!:=8BF9Q3<).#R)7XY
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M:[US7'1[3(*-]RG)TU:W@[!=BWLE(Q3['<]9-.4<M.&'C]CHAGOWLLAAIZ*
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M_"XP/WV0+\^"0D+(GB1 !Q8PVY;T?2 2BN/VB.NMT+B]YI7?^5Y8N4VZ0?\
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MG]R>F&&[LOGJ(F;F3TS3:[YW8=S"1@Z6?)=(-65Q%]O'>89EH <6&K_(US#
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M;:@HM,E*:268Y%\WVYOY5G]&86/GH2YOBGHL"@^OBH5#%MUPS[X$&MH1B3L
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MMV0)9R6)54]57? \QFMCPA/.;M<_^?P_FOF9-T&+D*17)]R+B2<<@+$@'P#
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M*"N+#9VGB]1L5&?41[\-/RN"A!E.AZFD07@U1]K4;H&4/D+?0;R3+2UGWJ\
MQT#:$8N';F;)%W@J.*GQQ+7:!R&U9O/2/[Q!(X4R$>]Y<ELSS/_Y-N8X,%%
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M5P&D3T -OAQV7Q?0G83ZH-(9X;%N!+19DKU),Y2*+KGUN/4OU85437T1*6H
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M"')2D+^.>U#;=,V\,%_0H[DO]0JHR;R^O3>\GF"^EU-]RCC^;[?2%'AO64"
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MW(%V<X2:P?82_+:%%__F9;\V")32S7W4V3VU34R@3%S0TTE6L3.?K9MRJ?R
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M25"D!<8-^0)7N;OM_]&F<BB9]2PVT$U=HH?FJ9U6AW %P@'U4QLW@]P ;0R
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M.&,(F5I:V3\LD@0  "<A JO^ZP]+!H"2X@% *RL8TAY]"U7[EAH*EX,J10D
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M<_'S+V2;5L)2XR+-M"(RD-9W[Q;.Q5HW@=\*<)8T=N4T&[*V*"(4-:F"40"
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M7KX*O)#-.I=%*<'UN\.SLYR._(GMWFI7-9X0<()0!<N87(PL92]#&;.EG,X
M"8_I:0%-'6P,B3%UOJ).SN=ZKJ/7[+-?NZA_P-<534QA+%>0\!-P]VW3C44L
M@+DP#V1#(Z'$9TR9@H)@5*?2N45VO0->F7[I_BS[A[<Q)>'6&Y1B.R^'S-X/
M((N3+HAC'_=C.#5@M'9?W4.)BQUH9@OR27^*,'OF=)CG3U_W?"6["1>>FGE6
M4&I!9\C[,F?6?UN=UUF7X(9)/%OK?NQ+BE=C]\HM=7)LGHR[>ZR =!]UL[Z^
M7Y2@4LCGINPWUD^JK2AGD1%?WZGV-/A8.3'$LT=4[:ZP5N7^HYP'+JS0/35-
MD[(Q;5W;9OF EE/!=!]&:7#$BW<EOHGN E1"'X;5)TX^ &KD=<M,Q:(FBW&Y
M(\ED *TVLIMQ=1H=FKKB)PFB(08*2.+/7>T1Y>)O:CYB/B<;K(V4K-5YQB="
M"V*4BG@=PM[[:G+ESNTE<MMSW_:/V$B,VH "MM@^8.;V\JD,G8ZVA!9L%HD2
MC6ID;U/K,Q>X*7W^S/%N,>C'E;S>FW%N9^T 5__/*2 U&9V;B9Y(-+@0Z3_;
M62KR$S:4_IS;.#6 6XYM@ 25L=MO7/*(I[^WM+DN ?UEL0%"FQJO$KDLU'[K
M2J[]!>/_V]ML?@<7/7!TMMMM!\W2X!P._M"<P5Y8WJ#,X$'SSD(WN7>^3HY%
M;+^G';BU=+<M]L;_4%&1-P]%R*!$].J"M-.UA:-1:J.@=ZMU\+I5@?&&Z^N,
M-) Q]W9.'5+:5\]5R#R>9$M)%WO_5]0TADSS-)G[09W>?*5#\_3BIX D8.MV
M>0&.JKAA1JRQ$/=PAO2I1*[)TW>\AY>#/_N#7_*F+H@RWAYKK$N%C>\7I(06
M8B71LX)2G$?A=JBW$O+RM6I5Z[/_?V:G_"_35#Y=<G$1]GU5?=1 >/TI]!$K
MJ$P4&7O4B6'3R&J?V33^*(K%!I/L*^XURT]N-N&=IXP58)E$!15O6Y.<!EBI
M..7J/+WJ[9.3ZI<<'1UX(=H*/].?$:734[]-?T:<0"WSP4]&GF2-[UH@3\5[
MP?$KBR#A,? N Y+L-71^:7"S56=(E1\]@#OF%>E,@.P9*CDC1Z$2+(I"'*9$
MKURD]]YV*-S[TX9PQ[CA_[@.<*EF:VNE63)G$7F_.:+5$1HM.8P+_#;VQ2:"
MFIDJN:=RC\7ZRM3LH-.2]?^+%_YOAK5^M7XNMN&G?+N9VY/2M,27_PZ[<5);
MR>:2Y*83JY@907Y/R\2/4'F3GV5LI-O0WTRZ/-WA(?^Z3%B4=VRGI>Y.D(.A
MM@"=M6Z#=_ ]FDW-DB5,%*)?@&5)3Y^-Q/9N430^N9MN\"\!W6WE8$+!FBP@
M%M.\6+\?_9= ][UVYX(X7+('O9+D/=63TPZ2GO3VI>,M?NZM4. N^D%UW*1\
MR<5D[)FY(\N 5H<P 8V;61&2E)O@9?=A;9%E,U4BZ"4'_I"*O;HOH,:+$'3#
M&I"=Y]7>SCB'UW@_\3(;EN@WSLN8;LE% $_;G$7+@9:OSV"Q7\H7 VKOKBEQ
MY'_XAC6TR[,OSSXE@2A=U/GJY"]T:/\2B%!,!!28TO^_C3T'7QANOVFI3+SC
M.H;'NFG5DGNV1Z3Z,9)[QI@%V52ZC]R:*<PX)&;J5]=GSZ[AR.]P$JMU,4#F
M]FOP/TV,(_OA!3&N1?#%ZLF_!'5: VL%OB2LY6>\O,M\HL&AJ%M[.4Q:76Z>
M-:=0DX.'&'AJ."L>9CG1 .@0ZJO<<O]./@3S&+$-JD!=Y]^^;RF*,P>][6VX
M7;;=Q]*X(Q-?(#JVW>N1@\GB"E(?CEI#-)VEWWLKL&!_,P4S_GO)BK5XPH@U
MZGYBFN-C;?:76RGT&7.9!6A3IT?FU7\>C5J2&S_OQWEV%/4K-"-J;C@Z/9WR
MOZ[FIG=G5A\F3ET1[<:%_(IG$1XB48">;:9C!9PNIS!JW^0\P?.5AI-9](E:
M>LF2QDFP@S:RV]_#CJKQ'DUIS3,!-=LU2\ HFD;\YD+@[N-6%U'V3?!W5S)D
ML-_CT2T7^8*?R]*S %J+Q3I&19:X^](JGL*@[!<7]V8"/?X2$";+JZ?+7]!H
MQ:\=;"L\=V\[9WNPCT/+9.0"N& B\=]H4-' @4M_B+  RZ/=CYM+$>VTDG,[
M94$XODSS)'/L>\03;NNR"Z:QTTW'S[_8.@K-$J2*YYH%W*H15HA=8<14Y'??
MH"U>"6--F,X'*"^3ALF1S[7P\V?FE\31N" [](>-2_WEA02O'L?%^H-_OX]R
M.YZ?M8$M#]\B;*Y(, ;B38^;+1YX1>TKG(L8H>3U<'TFPL>0-<VQ(?VG#9H3
MJ^F-D'6MB9%WH&X:4?_'+?3#$WK@'I\OR?)*:7AB&<"^GF92!'?3.M6V@G 6
M?H=VF-=(P][M+J0^4CI)HV9^S0.,R/C)4/IA8A((D^"YP[G%5Y1GWFUP-"<O
M8O&"M^WPVH!A+.?Z%BD_:I^_&Q"^D.=</U'5;T.MH(J(N93W'N-+>3WR_6"-
MT77!+4F\:T;F@-<XT?3ZNO3SF%YGO<$ A]Y94TJ\.+SGZ9J11NY0YSD=B5>#
MDU)EP*-27D1]BU(XY_<(5W]W!+:6/?!AJ8CGL<125T=*;:]IS[>I'2&.GP-]
MJ 1+$0OWA(N0+;_>BG-O*39ZSQ<W^H-LEGBJ6P?=>3-AN=$JA]Y)D$3V32O+
M 5^HA ILRCS'W#X=YS,_J%.S!IVM= (*/<I@I7#4^_:*[ ZHZ!+''ZLAQLW<
M?UFN^X \3<<39*LA0"HU122<2<W%/"))3YA!=LF#08> VKI[;##=A?]TBKWY
M( DVZK-@?7(@;5A),]D^_C.D%P&0L_+*>W55\>*%3TIQO9<EC?;8R+3.3NRZ
MF5M9/-Z2AFJ?TRJS=9(O72X-5,:G:NN;V<,HDEKE<#KL6SR5.^L5S)IFDA"<
M5(8I+O"#_L/MZ,;AN!$5_^6A77)62NON"O;4V&Z*]\$()[ @\W&7+5-2&JB+
MPC(Q_$GG<TF?=^LM^VX+ ='#QI+3 H@_[%:6XD8(T5WA]F^U::@F%F6];E.K
MIAQN?MA!N3>J;1FPE)^]0(\<\MF2TQ+QQ7^/G?;S#6ZF)%[T 5O%MG14?_0(
M1H/Z_A*PEA%&[OEBK2:#!.; +4J.0>''*^(5%L-47)\*8>W95=60!/J +)TI
M7HA!&&T6R<+WWUF0L^.3'?(<_HL6COJH^:7DBYO-JJ!WP3?!=[._W\9UV+B%
M%KLT'N0> P"&\:=DQ1\M'Y@R4!JZ2A;(U8N#&\: X]6F@#?T&WG_3*^6*K""
MS3&PT+$SBB?.E:EN<0!T<MXX'C\3ZC')-6^:6)IVF3H?<.KXF#L%"2,>)#WE
M;&F1I\LV^V0M;"VW-G)6&SHZTOX@S1:SYOMA1:+%GR5>[NBW^X_G]1.#.H/
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M &K<?/#\E'\GJGI[&N\L^#7YZH=H^SGVVF:VV]X*90![&O]U^Q 112\88:-
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MRE(.D:2!5#FZ?N%-N-<Y28Y1^^7%93G&;YAI[<P(HJQKNHDGEHLJ&CS&ID/
M>^(/!'?VEZARBX7?C8OV:AD<$8U]?Q;Z!7>^#:0EOKY_2]PS]6%%8,'962@+
M3>T>^2.1%_@D2>EBU[K"!7K=XP6#K(^V"T**+\?A7ND3?3I=X2UA5>B(QTQ$
M981_A-;@PG@<':><WO!6_"SDS].L*TGW7N2Y"8A6]8NN80C\&?\C48'X"=AF
M:BT2Q_[-*U1QI_GM.)@BF!_\2:AOO!J4H( Q/37)=$P#(GUAX3VS:[&\= C!
MM"+II&3==LU/D\_Z%AC>NML7<_7UT><SANH/4XLNJ4IT!"?JRS..Z9TC9]Z)
M&/&&#DY]3+:"%A5:$D!BGP'>6]"4BLNUR&=^>:K!6^Z]P;I*SD2T_15OQI;^
M>F=N_"$VU$;5"]6G)^WN",G1>>9SX#W,62.]\'X4&SVL?'ZR@A6<L :D42)=
M(%\</O5,M(R!AJC?B-3:"/?3'$^3+Z(IXH\*0_76G:CA4H#YCX+I=>(P1\FA
M?DOVM1O0+WG=HMT:?F:VQ>&'ZJ#G)63<@ID70S'S'\+<_W]_2?\&4$L#!!0
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M5:W+0[PCG3/CKH]Z('R)5:#T%(CZJ.<Q1+[("SN2F?QY"C 'T2%$NR'$!Z=
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M.L[@T>CWM0,3JZ*>SVPF<X_O4/?2\YG:8LY(G+6'=<H(U]<S>->P?;+.+SU
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MNUH0DV%M+L#X?VU4B]"ZOFBD$0Y&:['>0A=?%TQE,3U_=7QO]MGO)V(\119
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M9"<K 62QIB283\ ED%OZ8NJ%!7NM,A)DR%!\KOAC&+-UO^9L0WOZ#7Y!1VB
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M."__UM>M<@AK;4S*B3M+I=JI>WF"Q$^!-\$Z<$.)HUVCFNB8'<E,/&!<-#3
MQGKPR"&[1.@AW?CFAL"V(P.J$)^.\@<3"N^2=/=CB4.AWE-RXL3ZG$CQB:51
M7%,*37.S<_<5ARL=7[3-+CKQOYSP[7I,BD03#_ILZ7ZI/SQZ0A$D:<_%N5?!
M\EJ;XXQ,FVAE@IP?6TC5.O'U#P*!,GS*%Q=-;GQ^RQ^6ON"P5\US$E_2W'22
M218XR$A=Y[US-<6@/$->ILCIK=LS_]18G+NZ()PTBJ_NE0?UJO;8LGD-7-7N
M)8[L6WO7>+H]#XB@QUSGE=X5(C;ELI9=I8G]\>B:C&J5'_<RM#8XKMXH.@=
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M]+L)QMZ3'Q.2>>XZ!M1_=>W^;%!#[$\.#G&'S?5@IC;#&O>!YSQCF=!*Z<[
M:IS)8MF$>3@*[O$"KY_"DU9JG_"Y*2##9_J,+)GGL/_G_>9OIQ/K%P8]"AP
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M@TVYN,L1LVY@OX=R):GA>]$;6_PNN_C:K?2/?*3E/^HR@JXHJ#@L;)EB0LX
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MH 3D.J")86K!(L.9-G@3C9.X_T'7W"G>-TIJWXU1*3#UGV[0S(@PI\$A.UJ
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MG.5#C78*X[;D59;V89\#'$XZ1@%NE6B5IGC>NHGI/KFD'.W:P=HV[O)B'RI
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M7X.D0"B(CXV!E)YZ[TM0:+,T/':E^\Z.(]0E[_<R:YB6@JDI@V%VO:&&Z)-
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MG70[YYKA#2^;_J/)W5<Q[+H4:*O;!QNT7<EV-'BD!N=$CVB66_D+3T1';"Y
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M-6T='@$^3EL5>L+Y6#JY>B],)*?,$<N)M;$O[?Z.U=2+'?1S)"H [FF(;[>
MQ<TGY<8TTRK_EG>.OM)[WP7T_XP989V+FOT@*\/ZQ4B_[RR'OY=6N#\!ER>
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M;F=_B6N9@J5I/^_ED(0$L0U6%YV<&0SU#GU%U54G,C6<O\*RL<FV;BW@O+Y
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M9*MVZ?(>.8.K?<GOE%6U]^&*;#FLD2K!O_%_)[J:^,'EHTTDI\!XQ:BTS5M
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MTC];&!X$<J6\IR( SNY7*"'">]$LJTPDU]IMDUPSWS/?3>:1EQT+ O?N%7T
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MM$U) HIY71=K@L+K$*X$!>9K)1^=U%5G:B/T.^@$9M'9SZHS4WO"<>4^$[\
MEV"(:TQKWUNQTZ?N07W^.H$$6S(VP2_'/GQ])O6#G4A(2M3#\S=:89)U?+^N
MM"7E"8[45_[]HK\*ERW<')A[@9*- =)@^>8:^U*_[_PYU]KZ_>NV22T:3[=
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M-,!672':O2H04;4CM1R5>NVZ;NO$G_K<!]Z9\-W\ ?+C@59I"]UC]Z72V>T
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M,V?P:7F/ +D^D\XS[]]62]\<B+".3,JS4*6:".=N>3R;^/R>)='FB>QH/GJ
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M2"Z6UYNMN B:[B7"B/>V:_&ZK9,)\,8TO9=V9I8?!$/Q +)<.>@6?7_/450
M91QFIX(/K7AN6 !5$YV0B9<6,P$Y=L:)=0P=2IWH&USTR+KWT\M_EI%V7-4X
MJ#9SFADLMDV)M=D4@=H2(#38K$)=)ZV7 F7M5UE^&9/VIV#>*'D$\6\T/3,L
MO=P=*_/'[.&\PR:=;B:E! L@;H'/K8]I(LX8'F>,$YH[.K.[<[#VU[IE&@7@
M4<%3(0PR9ODH3?FZ2D<T'\31WD?D%K"K$;]'$\X-6R*>NT1OF#\*6"C:,<[L
MZ8B6N@4BT"SPG\I+F'DEM0-^O[UR+7MA&7LAA4I&:??CR] &V0 3;NSQNEL
MV)[V-4FP%?TJ/E)@X!^'OQ5#,_N.';+\&A!5>8N27QGF\IX#2UHR'[4U$5JO
M/_FKBJ%^*HM5^3!I%2_>&6P&_QG@SW;C:/JJQ=Y0[X%8;56]RLD"]H\4F2?K
M)%)I?Z&HRM4#H>L>J92D,J[/E9R.DNQ!'I?LD=D-R87<63\+6-IGK^>?_Z '
M+@[PX"PA:(&R6-W7H^7[GH#[5H\>A1?.X!;. 6!Q3C4S$[CMNR[.0B\CSY]0
MNK1;[KW%6<+X.FYY>SY1XTEX3_W \Q:?)=0@765 UKVF9=HM#,<W"7F8RRW
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M E )^+"8>?JH( V?4Z?[3@S5%=B$GO\'%V.006#!Z:5(9*<0#3S.IX]%=3I
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MH)9E%O!BR\L8,/C</]9_RO1,==D9H^^%,_6[AGM%E7_@P<;(BZ8F];/H@KT
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M/JWQ?;KC=$T'ZW!Y5VMV*(6I'?U(XI8>3- QRP5;8M-]QV<:7=Z5?A0LS$P
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M#9VS9ZKS"7-VR=*#V#4:8MN9B2)!XFO02J@@O#J\@Q;5,)LUWI!OL&H$4V-
M3CPGX==_Q'7BWL51_ ZP6]X?(.3GTH(&;1P1[GS?\8!E4@=;9^_9X8OL35?H
M#^$H7=2U(XGYY]K+FE=I_9XCJ^,;*F4^S9U.>?I:/6#QCBE_CD?,DB#76_*%
M'FAE91TD07=,>!1ML S]AG$M[%TOEWCA)^H$]+1QK32NT!IAJ'P)/NAB_/9+
MY*D["T3X@+(?/;AV!PC#>#/5I_='C[?VD1J:>KM*6MNN6]O.K)WB+NYGVSYP
M"I/FZT0=!9V.N7Z8'D_P=&/(\&N<SEO045C"@NUA$\6LAWD7Q]T!;,MS\/>R
M7X><]#C6H%VX7G,SK8=*;2:-3T8^J'J7*QD/9_D]S@7%,*\S2G2M,#=,N14D
M<_,T>0.%*KF(:CBV+%0VYSR_25.CG?JIZ<!7V9E- GN--?K+_![T^9$C@S%,
M!#5+^)L,FKB!7P/$,^"BP0CAC)^5N6 [UG OD/Z?@F_]>J1[%<5Q'V.B3C08
M,7XHDE",1N4NE(D*TD#C,&4RI^I;]ZPQ85-O[5H5U$-+2$X98(:W8?+/!#S<
M-<&>_#4M!'2JTQ\8W79-]?1X;>,A64<QS)%D9'@[=HN=^@G:0.LVO-4"%;T/
M*P*'.OKZ-2>(Y:!>;!RWP2=83<C400CF+;(@/>QONMX>55,3G?\,7XL79MZ*
ML__19FD7BW1#[WXGHZ,DQX:Q#Z1?7#V+.N(T6H4W#%$XG&[H0DN.D_J2TBK#
M>SYWTS*;&#B#85EGY.V"/>Z(SS?T3QD@'WU28VUMS3TZZFW-FJBRG[YY>A3$
M] CBIU:^/U(HW']>R:+JT_0!7/-^5&XX-M(HALAY0"R7, <W@)4YFIGX](B\
MO5[D@U%]-%N%8.17[EH!!+=X)B"0[N3HFRFC^_T$>"7UI7A*TT*$N:1>CATA
M8(1UK-\3GK.R!Z;B3Q]9E'2*CJP^;P_LOB6< F/G#1;8BO#O7ODY'G/SGRZ-
MZL=O 6.;;S+]'KE7>87JY*BF^[;[!IY'I'D^4U&EE&@\['JI]2[APKD?8.='
MB8YT1<EW><#^(D+LFL+MS-*7:3MT%&$N%=C/9)8=E7S^^JFB/O1=F?:5'Q&I
MKE>R*\=^A84G>+K[6"K9UHS&#3>H$Y)3L[W9S 9.^]&OM7-TB=/9B0NWR=E6
M3==X"JBPQKB,'ZCK1^ZIN;0>W3N]M1QR>X/9F]LT;B@=6%O>]3;YJ28K0%G3
ML8<:\) K)EB6NH,8O:^-CERKGQ.6$I>2MFY.H8$]M'P\:CNO#U_"FE^N@]+N
M*'A?]#/#L#^B+>'M)H/ZR-G"@53BC%?YA4NL!R8VL0F?#%_$]F=B2A/S7%?:
M+;NRL:>E&;P"I*CEHVS=T$NM2D)C+XS6S*A8-X('[7MF.G#1O'I086.=:V5J
M3X,? O+B8USU9LIEM0+/Q!3-RE.,F' !,FL3?5PYD=F$=)6(]H;" T]!0S7<
MFB3\H3ZSBJB*RIC/RA@U;VB?#"Q?&0F-%\YY#)LWM!_)MSM>&I-8>GH'4%.*
MU5G6K5)*%Q5U((.U1W0'X$U+,^]T+OCPM,DY6'EG%204).K3_,U:CN36**W(
M<ET;# &KE*N5KJ)]QH&[N>DK^E_-]>>,G#@8]=;\EA4 \LA0..Y%WV,\[:1/
MOR/49^O;W_D+''+IO_^>QC*@3Q.S%LYX3^I$$8+K6<SPAHFOA[#1W5;C']#T
MN&+)'1R* 6S\3X^&S?!9SUD)3H^PT=2*:,_<HH0\6 90.*$0=#@MF<@_(E%'
MKA]?6D:7VF.*M[?"HN9QTCLGN!>5^"QK'<_+SW%)G%^,(1TPC*9&6=Y2<X3\
MA<;^\''E.9A;_:R?HJ.@>.E)UF6!S^I1_;:"&0]-+X\DSG&VS+5#V34V49,;
MJSQA 0QM<P-]_C,N_%^0UZN,Z.R+'FGF)*W?DTZ22N)B'RS-/JK4;_.<D/+Q
M7T$ST!3G*?&#=*\2*@)[GI7M&NA4^E,F9\UN)N#^:,3\[MXI)%8R.)<84AO+
M1+W *HC]3@%)B$(R<IR[0KFE*3$"R+[TE.R+;.JY).W6GWC'?^6V,*4#KM?=
MT,E)O*)A5&<7:<7!+=_4C"QEP1C,+[=QTN<JQM>STC?^FPEM Y3;S=L=(2VE
M?8F3,E?YI>VOMD"AHO>$D\GLR4#2-?/*@IT/(QB1.R:<&B$<^]+S^K7TY['%
M.B5>KB&CF*2)0ION:_I]%+I<O2U5!W)X>J[VXG#Y;X)UB*H0P5O99TN/:(UJ
M-S)#99D5T"-PJ?C0ADH\Y91'CF>/S;>.S;\&UXK]LF-+J,,\4X(K4VZ;D@3:
M9XD.0+-I#8\(@2;T$(Q:BY"_^J56Y6$!H"FU1076]V+ !UZ-T496Y3FC,KH,
M3JF.-<P<SACIX&_?]"QL?Z/9='#3'J[/.2\/19(<;*,>K*J@O7.]RG60&!^\
M$&O1E @5_6SXWAI+A;7:VLNRM$=/;<1R2;XTHMO7RGL#GJ+44WGG]74V"_\D
M4!F:#4^H+=D4V<_5H3AZ5IA$0[6A%0ZPJ2D.?7;Z?!OC/_C[B> -2/JE->]"
MO#XR-C6R89716-\>YG9+WSK]ZL/;$)4JMD25Y(UT,1UAPO#N^99NV@F#NO4[
MP$)QO[0(FC??9)_?()Y^3[P4ZDY1,LQ6L?L3TYRO0J8W,$(C*Z<M'@6X$H?"
MJ^*]-T <O8V'',:F:OZJ&C//W+U>?:+!4V!!!SWK"&][=SG2?0<@PBC]0F^L
M,T64C0N_\&,I,C5>M3^?Q,^USB!3>+ &4-[,?B@[_KHZW_;__:%^_S]*=:JT
ME-_;68PHBKD/N> %T9QR?RSQIA8\Z281R/-KYHC)KE=QJI8JR6-H)LP\9JLC
MOP2VPO%=>2I?N9VF9 ACB[W% SPO02FFNI</I#_,8NLC]"2%T'FH9K ')_CM
MARA.,62,\+(T22:^L.MLV/YV]@C,2&3"5)?5P-*(B"EZ)NA?FOL"RY'VQ^-M
MW. )/ ;HK(QU6-I\7U@FR!HFT#MY-4VH_$01AS^8>>D2;^3TGY.F.\@Q-BB.
M/J=(@^]MK0U-$&AO[?*K9"O]V,Q]MQV<Z]3GFF5B#)8-WJO!'5+ %<;I4X3E
M+05A-16M6_1(E@=$6XM;_./^"[W7X7Q3X3*OYL:5)-VKZZ97.!?26!2L_T:5
MX-S8X5805/VBZ>E<H5>DW]^7919 *YWGHW0Z_*1L>",J8L\[W>:HR-\>6 KT
MBE?V2@L&/7/B,\MI]2Z_ Y!*<WI%R-[\XG;KG]NJ@UBD]%,H'4.'6^L3)<);
MFRUTG?E_0KYWO7K- &V:6,NBVN^?,WF:,J12KM<U93 Z+3W_J1E4FA64T.U@
MPV#=>,CSK$6'O*^ZA8!<24)#*QV /(*9PK?:UG/"S@UR@G^UMJFIX Z>(\)*
M6Z)@2R#0/"!FN!F7(\91RMG0](DT.Q^:%B[EU.OS(V&OD5\))[&?1@ V:B+\
M9:]W\R7-9L)Q3":#1;O.A$8CY,"\KC%$C.>9',.7@=SGG#0$>&:X A"5NIIK
MC07$KVB$@! $I'4]Z%BQ4C")EW0[9DK&CO(,!E4TQ-JYFY+UV;B8*'BFX/SX
M]:>J[-=;CN"GGY9WN$;\/J.4^K(ID1-]+/!.!F.[U)2 9W$0]22EICC&Z[QE
M!OQI+ARY[Q,L-D'+@J8?!_/G>TO\6R64M8^&K\72-!^2A;99^PN.O_3FR4N5
M@"L-3XSF3C[D[;T>J92_1ZXM[9VAG]I3>JBSKV8L7FQRBHI?4R09GD;E/7D9
M5"8&('[Q?]2\L.\6_@=02P,$%     @ FSIV5O@A[BRG40  ]E4  !$   !I
M;6<S,#8P,#DY.%\W+FIP9Z2Z>3Q4[_L_?I DR]AWIBRIA,I:EB%)$MJ0=1*R
M3,B6B6&2+%E#410BV4WV;#/V-=FR9YE!=F;(.#%FOM/K\]X^[_?G]_A^?K_?
MF;G^F'/NN<^Y[ON^GM?S>=V'-D:;!;BN73&\ C P, #WZ!^ -@GH 4R,C'^^
M].,0_<M\A)GYT"'FHRPLAX^P'V5G9SO*QL;!R</%P<G-R<;&)<#%S<O'S\_/
M#A$4$N 3XN'CY_O3"0,3_3^'F%F9F5GY.-@X^/Y?'[1&@/L(,,6 86*0!!BY
M&9BX&6BM !0 &)@9_CJ OQT,C/1G/,QRA/4H&[U!)1? R,#$Q'B(Z<]3TZ\&
MT:\#A[B9>8Z?TSW,>].>1=*+[WQ(PH<C4I=*F_AO#1"EE>Y[/V,]*B H)"PB
M<T+VY*G3RBJJ:NH7+NI=UK]B<-7PVNT[9N86=RVM'!R='CB[N+KY^/H]]D<^
M"0A]'A8>$?DB*C'IU>ODE#=O4[.R/^9\RLW++R@KKZBLJOY24]O<TMK6WM'9
MU3TX]'UX9'1L? )/F)M?^+FXM+Q"VMK^M4/>!7_O_?&+ 6!B^/OQ/_K%3?>+
M\= AID,L?_QB8/3_TX#[$//Q<X=Y=&^RV'OQ2IX/.<)W*>%#:1.KE-(M(O]]
M[X&C M+*>!G2']?^\NQ_Y]BS_T^>_<.Q?_HU ; S,= GCXD;@ $'M[.B3@)_
M#"-TD!-\#'4==,;7H/1GW=E:]K[%?[K[8\:MXVYMXJF;#C<:+^=I/\P+_NC+
MO[:SB*XP>>]7A&(&PQP<W.47UMM# _E4B<?]$[Z>8<P32S1U P@XI[ZH##[M
ML\C@H38)1>)N1 6:?259SN]35\Z4D4S+N8?W+]N'"?7IW85RP5P5Q1$9(I7P
M,!K 0I'/0=2VA[F+?ZLL1(PJ\K_.]WH5>>AW-/?,J)28A?^^U-+N!,O:*'';
M]/O:XM#F^J^\083UFVY#44=B]Q.653L&KWQD*-GXH#!8&L3<(II&UIO->DH8
MN'MQ9N,+I0)5*EMURT5;ZT-2/ (<7,F9SCC9CE58!!KB&VL])^I*!49+%A*G
M*L -CK'7 Y%31W0L7^5Q#!V30$2"4_LFJF^S**=&J.)N>X]+L\#LUL_+_H)N
M6+>*,X]6E)[%06RVY%JI6K9(7-N,@+80ZGY2R[0*,2-<T+!^R-%8T2B*!MP>
MFE<Z%V=1Y70OZ\[D6-FOHK3XYU=Z\#/-OU'07&2?67D-F%C;L$B1MKI;51.M
M#E%,$@D1N[R=R(+7@=X,[H,):>J2Y C.[0<0R\#'I<3X%Q9&0Y?//;1G?:XM
M1@.XNU;-4&K[-Z0SA+"*2,_6E^,NT\)$\0I!XT*G'CY?]O5CBR'IS:5H1QK
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M 6]HN6('+&9&;$T9RK^BS4_\E#:K=;G;CC!-=@B(RGG%+2P:3-Q9MHO.I8[
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MJWU@Y)JMHU1]_#UC];&#040<"*4!,OYSF(,8U8P]CZI,B-L_:> U8)LN3V@
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M7%2^K:N*>;0LR1UN?@L\]DSW<(8GJ8Z@4ES_2)?.//CTV-VXI>+O?C$S8P(
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MM37_E7(%3,+W/:?RU9 4HW:D!WV-'EQ.7KGL?-3R65[SLR?2CS'B-" B%,5
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M"YY;4?0@"<:<V6Q\;%L</E^"V' [S'?SIJVMOI.[2NO6F1N7P@VE/:(R'9/
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M&P?\H\*.]=R,T 0Q;)#!Z(EXVUJFAU3/PEK?HM0E];\-+8#[4_\#4$L#!!0
M   ( )LZ=E9PY-A!2EX! 'K  0 1    :6UG,S V,# Y.3A?."YJ<&?LNP<T
MG.V[-_J(WGLOHT8201"]C!(M(@@B>D0G>AN"4:($48,$0:(F6O3>HD5$=,,@
M&(2H,\08#/--WKWW?^_]__;ZUOF^<]8Y9ZW]7K-N[N>9^WFN^RKW[_Y=,\_@
MYG K -U=+5TM@("  $C%OP#<*AU&$^+J! #Z^L -  #( "("1> *OD>+/[@;
MYPH0X?L$^+Y%WML__P$> *";W.8"2/'GJ/#'*O@&<&W_=>W?\K?\+7_+W_*W
M_"W_3>6^J[W74T=>8T=7?W]'7_P)XE3"OQ@%$YXYE*<2_:/?D9[V5Y_PM@P
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MDWK:N]I><@&I!TCF)[X3%"R"MU>%4'],^\NR_VN&1?T?6?8/P_[=+CA 14B
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M37G=;LER$6Z*%[CUD#/SR\9A\<7N4?2C;L(?M(RAP*S_4LCDLF'SY+XPRW
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M6SJ7;-/I!D\LP8%M!G!H;V!V%U/T #(SX5S?/^H!Z=G6VT^D,X_6G[&@*W'
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M\JCJ"?V[:R.Q<+FQT>&#A-_B<!;G%@QIR>CUD6$_M]TPW1<O"JF@L3B HT,
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M>RL+HD)8TCYB@V;]+XSOUG76)8O49<%D?@FZW/E*PAQ)2!AIV=T8*F%I WE
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M+5KM(N=VL'1! @Z FRD6Z_,/+)DG!]83,(A?'(ZFG+CG8 I6<SO!:UKUJPM
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M<=)9?[.L\#$5T7:461_QY4QG#OKR\[9><&E+:D<R[??BVG7DW.9Y(Z*;,UP
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M:C,,#B=WUT$U;'TT#,Y!V")Q_7M_?O:'#!)/9!V=/Z_:2(X3+X&_N2E^[YM
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M\X<(TV#(>K"94RZN[>AL]V1=="Z=NGH-]D]"[IA')>/_I5(8;5>G>VWUG*%
M;_;K_6EF;$S%G^?E=E-(@4!?6]*)K_KS74V]="]S#L^N\R+D9# )EX)$(Z:/
M"&XB10K_1;::1864H)E!-;=0HFS+^ >?L)D7&'Q;29;[/J\S0/&P:S3(:='F
M"AO8=I.DVFQ0K6S0&C!1])L<\#CW5N%97TMZ\3X[-I':?DUA RLB$W2D'5V\
M!4^>3+9?TW6XUE?&B%-VA%J$A8^+I#FC&<LS")>[TU\**0]=DV;= Z/%)0R=
M-#<:1_+3;<<]P;K&7^DY4]<5U_Y$1[#5C;<:%LCQB+E#D%!_SC?G"D>Y.4-E
M;3+!XV'C07?'AB*A%#4#1BV^G,B4EO&S(FFDKK\UK<#QBL8HAVNJ+UTWTDCR
M6D+!,F.>[ 77]YMU()%BCH%27& C5CO6J#E9(V)>C/]'JJU )IR\EHC%$HOI
M[8(U9=LE;URW/!\ ;WDUPG= /(WR.K]]/\'_D-/>P=R\">A)0K?;,#=GM,:B
M+-CQ8Q\5D_2W-2_J<W4X4%]8P%&FW$^?X*[;"Z<($.0TT3^F'BN#U"@>,4>X
MFN!OZ^@D>XP8VGA]XC'P?(F7&D>$.'G,M<O$C-.;$!6EH]\P7Q$NP70C.?D!
MW_X "KX<2]N;>RH*JA.C=Y*B+8]&^K(99R 701GJ+O;!_+ ):.W84X90[OX?
MLR"K;OQ'0YC%VQ)BAW?)GB[VXH._AJP:RU/ZV[WS:K>=&#JCJM)POW02<CD%
MX;V'A#&O^'_R^\GKRC<O-;]'^_1V<O#V_/);3XOMXL,YR?9TWL'>YB>JG!VW
M]P#T<FC]X,][</>Z=N\"W">3W2_.G8QTYV1=['G"(FP,110*LW&%&.8T89'+
MPJ>4-Z+D-\]?/\N79XQ[\S0Z7KQ_S<3FJ84C7N]26EH*XM\LY?T[^-O<I7SB
MI?^J./@>,![SWU17>XCXWW:R_H6B\GR;5^N) #O-AY]TW]'YT-A)D:T/_?AV
M) EOI#T+(#%#(-CSN0&;<R>%P'Y2_$*76@7\L"B/'U<$/7@NAJCM%L*8 16J
M5\G)A+(?&1)^NX9;=& NPI-BKYM9T.>*2LM 7<9T(X[F-9-N\[R@ACB9/'*=
MN,[]O"^/M)]^46"0R)J(EM<;XW-Z/ &C5B9R>AI![";2M2Z\65(7E6DF16Y3
M.DM M)E2GBT>DURZ=0%/FCG9V]N/5WS>UC;W0Y%"S&7A>PFDI .!URY=OM-@
ME<H7V<S0U!1#9OF;!YTH+FXR@-^FG %9V)D*"FTA$=RCT?&*VEN;F6EJPPUK
MC!O_$5.'%9\;M6JQTTK*"#V:"G:=Q_=EO5:8^M1JVZ1S(K"[M.OFFXOU=)7N
M*]H65-LO 8E';1*CR,>NW_-.X;,>U5_K5T%22@D1T6*@+.5R6BIV%Q5?->YW
M[^%.WX\QD6)-^[U 1OI#P$Y=S^..>9BOI!LVP=\LT+_V_"2%.K)NQ2WV>DTW
M&+Z8+^^!O ?P='41"XN0,*5:6-/#LL*4<S[%G]U*W!\$>$2\AC&[2-.9/T-U
M764GK29?,8Q./X /N@:A)P2&\\(3>HRA R8D-N2(PG/[I/J".9.]Q7/=\A5/
M]Q5W=_0TT^"Q["P\)=:D]-*ME)_?MD2B\P_A7[JX8>F6QW-NV@A5@JK\,;=H
M7KT(/;YHN=$[(0MNI<F:TFP:-PW--#IYK R;!VL:$_XKOR6O+H/O 7DFHQ_Z
M%3>>/?> "9?_YFH6#O0_$EW\-Y"2#D(%DQ+TY^6JVT3XG!E<+1DPZ(OXV4G0
M$@L@YK(C-[ST8:5\F\0*,2\^Z]6=$,6%OZ(0\+!(2-L0%OZ!X R"<A+,,_U.
MMQ<%D3Q?H.0XL&K@DK_MO9FRC_S9:VB-+O[045V*XB-*4#JXHY:*1)O:=5Y"
M=QT6_/O+I2/U@4RC^THHY6K:18X)YB8Q8EO[Q';[:#M9$MSP*S8I%1LCPN6K
M6=5'S2BBN.!!!W4IFJ5#@C#)FOW2M>JD94[F".]P#L<7*;;&SW&]\STX7B=2
M&$W3'/4-P$ /(!ZZX^6<%:5Y)^4C3W:E/?BXYW]\S+$9:1\(<#H)78E)TY&1
M!02$1BF2A.(T^-1^1'"1X ?@MZ?_7^C=:*LDA_+92[:7+#>"2:A>_YR\!RS=
MK=]16[,J/U%U]DJ9S D0/D!)W0B)219NCDSS:7N9S5NN&?;'S])Y*B9^BO!\
MNER/A1517 )AG?GC'7-MJ.P_C<P9/MXW&\__'CWR"J?&\(&%'N2AI6A_HK$0
MQ0Y+%CYZAPG^Y*+A!+^]W^]IZNMGA<W?6E+5GW2EU2B+;=/V+;]>P2X9WXCV
M!H71450W5-;'_%[7.YW2J8[?4*M++ZLM5JOZSBBJ@Q<4O"9D& QS&O_SI \/
M.<,^Q=P#[Q,(BN2++_W!J0,&7YV1LBK7FON,7[(P)2%4S<QA?-]]U,D_YU7+
M363#!.+FGSA7D<WI4/88GD0=^ZK8CDC1G)<LF1" 14*Z]LZ^MKC-@4D7XSSX
M<-PCOY3PR&U7!SRF^ @1VNHRF6B2S-])P4AYD6]3;5O-FFO P&>GI?#,[_4C
M>I:5;!HZH3)6E@?4C:+>.X]+RY%Z]H7AV4G/A2S,@EK?TN@(2=! '(2SDQ9H
M7T\JL#-4R\,F]I<<7XCMOM90K\--LW[1D,*"+BH[S#=$H-_GF#?KR?8JFF^4
M%QJO\DRL*5[XU=Y^9QH@@J9'["-X"-U[WE<X<*YG1:QH"J\I2ZTSG0&;WJD_
M#& D:1-+F_IS7Y[_R F1(M4T!;B _/^B'B,&N2!:HF>_3^[S[IF\85PB X:%
MMPX_^'!#J@H:,=EOY+"P0/*8A!L2>ON$'QWM=7@E0!OBQJ>&)>Z_Y$NL,6$^
MOD^N%G,EJE5#3H8HFVB$LG8%5<7(S@\0)\2[3)9NW9&,0)MYCMM___KL"/<M
M6_V^FK14^30Y\5LC#<T#W2]<F%QL[R. M6<HV^7/]O9[*LTWY^ZS8B5L9?K[
MWFZ/HX/[/)4(ZR@>?N029\MO@H;>=7LK)UJ%(@4BI,HU$\V"0S&(VK8?\?.3
MH!FHC)7Q^7),J8R9Z;*S/]<U"U=\1B0']*T>BF2 ,^Z!$/"RFP$_O*8!=HVC
M.CEH6VSX<\3S%YU:/B,&&]?OA>!*T@EU*4H1P9#3] ?@\-,=3[S!$3JWB8G.
M9-Y> 'B9I&V-X&[?0&=&3]"$<0(H;\V&QKH,Q#96BQ$<;%EDJ)\_A&'U)GS"
M<&DI"2.N^R-;;D[ ,VA-[=@N$EH)CYA$D#XFX<IZ(TL+J/^D5TKYSSH2&O=
MK]?47?-?8I:<$IB2R26!_CTP!5V\(M%$<_][T;UD6_(8I^$>*.?\DVJF5*G$
M\R<QQTA_=6/M&*<"4"OM'E-TCU!.R_< K6[G(%-ME;_MBP7!\+(O+WREN!.,
MR(.A#%D^5B@== XZ7V"N5W'#)VA;)O-Z5Z?)O_W'H?7-L\7#2%H26NH]>ENR
M[G4'QKOSV^M6_9',-@FZNB.!5.1CUS61@F2"F=V-)W7'N1UXC3+V8KQN6&4
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M*FC*-!I_+_?:0-Q '',2OA=9#V6%%"KR\,>\'PG8B[ZCC,B\8;P<V>"MNR_
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MI6F!;I8'@4<'$1OF'.F'B^_BQWXT#ZYR*71,#0CW#*=L-?$C&9#4PL;VK/>
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M]+!U*^7(]?3,UUV<->JSBSR7K_LJUT\J1RFW&W7E8K0>=I@@/UQ>;LQN8-@
M;SQ1&4R<V+_V_!40:B65RYP!8\ILE\1%;%Z%IG/.'IBWA(JZ)^UOY<53Y I'
M,S@N8WN2H'7!(WUT^1.6XBK@LY@-M<SZ E67+8H! Q?<->YRO#&)HQ 7I,E,
M$[IE$2J%>F<VUT,\8:!PNJG%_,UN8W^6J#-P/FA+'R*";M-J!HY^.W=;L[>(
MR 1+?C@YWUM<-R]?$#$G'=VD(HT-A8KZLBE%QR/F"!NG:[@9XW^!-!09,[V
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M[ OG0+9V#ALQ/".S8=B6ID*&&9B^=ETD:.OW ,Z!(XR>!#*ZHS5&K=3HC?)
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MH&0T9-?N2Q.LC%M:BJ/'6FR'A\(WX_4WC>:OQQ/9?^)^AT^O+ZKZ(/!Z/K9
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M5'Z0;"LGK$6VS.03KGXEHNLW<*;A# X\O_<QTR-F9+B!S;8SC*GP^\=K'/G
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M[DL3'V_OE7"/]?WS]7"H-8KKT!U6M[^_,KF?55,3I7R7@X3<ZTXE2LC:53\
MI*N1$I;]E%SZ-PE1(_$EH681R\S9/]\8?^ZQZ7G]_T<!:JZ!4,VK0K1]AF8[
M-GUNJW-*9ZV9Y*9<4WVX&#_:')1Y>E%N5,Z!S"IDBUWGD;UZ-G5&)T><RA:=
M4S4INU!EXL+.^]6:X"O]&+89?$\G21\>99"P)[A'>-S@D%]'>:RDT!D=Y\$)
M*<MO& VMF%=<69RY 6 :W+."P^ZB!> -->&A.;NYGV23L&;)OS=7!]',R/0N
M%TH(J+LPZ<DY@S/,UMVYB[29*3<-9\/-/,M4KF>DC?R?CK3GVNKJC#SY%A7_
M B 'A.[J#,EK":K*8$%<(CV_H-F075*&*0;P](3'ZIU#*6G+FKP/%S"FFP#5
M(_U EKVFH^C\\.YT(E[N<AP-A.A,L^EJ+@^*OUS]!J#9Z2B%XB %\2!DBA,;
MP[79/E2P=_Z8UWL0&0RY@*;T-/L[_6'2TB*E*AH\+<0.H@I6,4L+@=O[$B0/
MT2PO!\408A7DH^2[ I!Z0S.9 N)MRM?#GJ*!1A0O\/S>!BHRC*SOF*1S38-K
M%B5.3;!-U$!^4,%SPYCEJOE3W+:8VWCM^SKC^;H''M<HF1E/;61 (L&@<!GV
M(&[PN_4IOOL%!;P^CX)$2S-;$#$UE")^7'1ZQQWFL@., I70G6K" B153&/Y
ML^J:MUTC7";BB=0/M0HC^<EU?9U30;D["*.?_;^ZJ3L85&4&9 8.':?_]X??
M9LW&J]+?D0Q+ICXJ?O9C"U?A[E8M )$+0ZD6;4MV0>S4$&UQ,VI0%JW?,,5N
M)9I<;DLJ&ES#US&J6U&SK08CH.(=DRSXLW2Q"1OX8EM.JW^:Y&K9/)D+B0NN
M]=6""\6IS=\?,V>C8NEC(Z5-7LTD+SE9F$DD".>+$,Z@0!DC> M6KSI];#WV
MQ%%C4>W\#H+\'8QK?R1>U!B([IZ?U#= A%X2.I3'^S]@/\IN;@1Y-4E4@MQ:
M/7EI"RL<#*K"&(1YA; =2?_Z^N/WF:%OAJ!QM\4[E@TD\,?AVGF G\&[3D^/
MM^(\7S;FY0F?9)Q_.5Z6E](+$,5IT2CL+=T5J/'U)VC7J(E[57D@%6MQ&-.=
MGFM=D'FG@8_*L<HQ:?U%I8*PZ&2)N=%5O9C=IZ@;H"+D(G8?. 1E(@C+I?DH
M$W(^2^;!XDNZN<#45Y-R%?M27W%/3.CF1$HMA<MQ6)9>1C@=G*G>T[_?>0.H
M-M'< $;,E1W,OQC;13DPO=6::JNFLD1W> MXRI,I4\%,EX.- X_\\D=QFR/,
M^H-/B)Y7NUL7[DGNSFMZ)-'60'Q>O[>=5WXZ.8A]-**LY*QLRK&R$*)9!Q_2
MAH Z$8?3;!'J%PD9 IE1^#@VSEN%NBMDDYAL)<4W@$TA?/G=E$8AM*2Y)76+
MF'*/NP"9ZSRX/*<,D)H];]+EAUAW11;[[R2ZGWPP'/B='W=AY1[D8WL^4-K*
MK%HW[K%14X.O2SK*_+6E+/"D\O"V1OBJ+VU *Q>R3OG\9,G10"+E633^K('&
M6#,6@]3K5>476')H3K!UP>=,XPRSZD7^&V#<'GK4!,Q.>9H0/)H_H$U;$*VT
MP\AS%0S +CJG"+<#RT6*B)]I/*=Y,,ECX1GZ];M>GML-P+/Q\OOMRVMJMOCT
M"0L?X3ND@$=A/9J> 5%T\_6"0X%1RQY^O-BU]DOF"@5S&MX^CWKO<I@K6W<%
MR].@'\XPJ57'<''T7$;/_Q9UA08@IBXYHRIE@KYIJ]JM##^B9G,H+S_<X-9G
M6139W[!YSQ#.,$(A/]#QK<Z]M$1,EA]!;&^N<@XSJ1A4P)#CQ+H!TF-<5?8N
ME*T-3AD$-]6*1(;!;H4+^3]71Q2_2GR/@M9 N/W2)3'DB0G(M!!X./ZZ>Q19
MOSP^>/]@NMQ?O[[-<U];0I?VS.C=<@6X7;/[:8&_T[GA_GL7#&&LR+)616J2
M(5--QCW:B57SYQ;YI\MY1')<DN2EN^F?'MUE+/AJT+BCB=\D\S4Q7KI"F,,Z
M_FFBS8-7"7OFK&L\HAI^O2F72+^N] <M%5=&'UZ^G352,_&;T\5/?!^U@AB]
M382$X08:=2_!YZ;/<KY_ES5@\F8ND]3"^EN(+H>ZB92EN<F4%IL-TSN-S^=@
M"5;0<[ 'IU0J C[]75=[PVJ]C,+-4Z>-PL5%?*O+=MS%S,I7[W8'.T?-N<;W
MPN$6J$]$#+<G)(KI\L7GA?\"?T<Q-%IL#HE<W?<784^PC])9U^N3/U/Q$X+6
MCOFE!U%ZFOEJ^WNDW6%IGD(DXS$M&H>@=$@N.3:N"!T#Z.3#U1QXG5E!BTJ!
M=BV?"$;WL>&%^SG!^AZE;*-*591U)$[JA[;L/,R,)4,^+)<IWQ$9'\ H@8*^
MR"Z-YV<MQ5RN8D+U9>,#F.4[_<9 >,]E86.B&2U>EH,+O96&SFD=5@T[$@-]
MA7[EOO!2.%KJRGEMYA"D5#WN!*"'JSQAKQ^\4M^;CVTBFCJ&A'2;DR2O11[U
M/*@D]=FQ/6@63*_Z 8W1=/XPYCMKKX+)'L0!E%F=H#DMR'C3VT53\R0'/915
M"W8_7H5>]2\S?MI!*7B7/#\/)'WVZ3$7;P''$ G3N=Q63H"L1>!T:?8._W:*
MJ9>KD(IN8KS!U42CA)W+&Y],O--_E;?_7TM/GB)><#6@ O+-6=+9WDY[7$0-
MK\X''&,O?Y6">C.TTY[MGEA$?'00H\W[..5Q1+Y4U?6D+H3K&]_P^'G%[T),
MZ.I0F 7N/5"T[\KOT9.]\?V&O9WKY>>[>^%(-9L ZY5\#24\I-B2.IPW[[$/
M*GZ9#?V"4,K 39Y1=<V"&OEV="UAKBW')Q?IBU-J>3*K9I3U>:-/+U>Z3'7^
MXU<]ZD!V2"1LE^?-H3W[!-^A"![D#V8@[+GI9#K(KWJPQ&BIMW%Y-YC) $$S
M[5S0AL=2.2H3;UI1GZZ"7A?T^-Z!*DILQVN1 ZWA>$J;_HBQM=_/_5+;PL/?
M4Q+QQRAP\ J4!AE<&UJ'T-CP1IAO1Y3TGON]B@98_NCJ-;DM%4'*^U,,(CSY
M\(P,31S=GHO\9!F>?A>7?Z<=P8\I?5HVV04E\LBX;Z[A;LFSV%-..M\WZYXL
M_5XWOI+-EX.M\)\R6C264R,OGL$5X]6*%VPWG7GVUW[GI;52*(M?9!+L#<Z#
M94?4BN?B[S/3>+L'R8WF0<)[7&CVS-F:-*B>U29*87]Z-DY?O/@]<%\CQF?W
MAR3?TFG!'FWY^[-Y]U)D_IH<[C:B*%[(/<2M'OVE>^X[6G2 (:C,Y=DLWYD?
M<G-,V"^,])E5+53X6:)^S['_S/;1]*]=7[Y2P,O8OQT>LU.]4Z'J#O7N1!#6
M.Y%ST[\RZ5'%?."?R;?(N%D/7>6*<Z@TWI'4SUM=).50$+N@- *GG9>]6/9R
M^5%U<"HCN+Y?&9"]9=A23UTW>6IG[U2JZ=Z>)5O6FPIKXB(*JTMZ*3(;R1)_
MO>C*'74X@XAU?6%ZE0)L..?4(-KRP)D0E6'>5/H//@$^KM&IR7*A&SR#&#^9
M6@+"9:MS[,^;&%,2O9Y[Q28O-CI0G]G*#!0XI,BFY9A\\2@6!S-;QU?R8A3_
M]YC67]IL4JTP?8(O$DA^;%O=HO=D*,3<<L&!E)ZN4GY=)F6;\+)XGC%' G$=
MI#=*;E/\5,3ZPC>A#[3]#<Y@T--]9?00/MLC1^;H&S%%*K<_NG],D33476A-
M#&"DO_$U:-?"DK&ZNN)[UMK6=U0M?QP<M06D(**YUI;?)W51-85E^168.O9Q
M6=[["O.8*<4<?J#HM02%A,@8E)?ZF5UG+^^<P*2KG[!'9<5C<^Q\C"HF5+@H
M U!,;R\GD)"0'LF8X@ W,$,)U<0WEL3QOM5):FK;!0SN.79RC+C A\B2I5C<
M'(<,>%RT]95,>131.91OX,1_E,_+/4:@>:E)!GLM\/,-<%\QIG(=;T^#TZ<@
M<?I8)?I7Q(^Z):24^VBI@<N[[T[/VN%QYM'^CDPP=B/B_I;!ZL'^I.AF+[?(
M793 :JH<'O+-O$JM7=J#A6'NGW]KV\E4W>9Z?4@NBXD6-81?3U-82 #%6<$Y
M^&N@!SM7@W R4V'Y\S(J1:UV.I0Z.2!75=* >5T$:OJCRTVGC\"=6R20T@BN
M9=";?0/K^TGRMXY)VU;"3S)YJEH9G4'E2E"KDN=;"O&!C4H9<HP!]@KZE&XU
MNB/R!46WTOE4'C8QTJ<%JD-)=ST<F@')][]O -!5+4@=?E*ZNYMRUK5+F\G4
M#&X(FV(L)O4ZY0ZTWL6F:);'>@U)[?%*IQY_W=9B,^+UE.85?IDOWVV-5-&B
M@5!^.B:"-<']K&FIF=DI5GTR/)GMZ'ST&6.C1+_CAK]"EADR7+]Z2EJCJ$_D
MD]*5:)*-^P<S'FB,0^[5T ^![UP)09*;01R: 6R-);))1;N"L'X/_0 ]\.>4
MXS/HV[N*6!."XGA!7K]2Z2K\3+ ;)N \W-8:?KKRB5XL0$I MFLJXD(7,QY;
M_Z%/1P'2I_3T6D#X!L!PL-JWOFAJG;&.M#L\>$BW:>7S^XV4,WDBY:R!MW>B
MI,RZFCOWE^FS@TS+<%3ENS>"&!WT[T9>&!YCB%2IN;!<,H45".T27IV9V>H1
M_)*@OZ(1N'B9'66WU#74I.\OL8+4!ZUX+YJIJ^4U.E>I+YH_G>)[N9^=4^_N
M3C/F3_5!C<[VL7=1X0))>X0U^_7KW#/K.")V]L@=X5+.2:4*$PU9/EY^-0&6
M1"\9HR_'0WX)\L3;30QMT?BI#(>\970!PPO]@B^6<B\)?XACYCEHZQV5'W@,
M/N8]PWM_<+!&X\/BA"%/R?6Y\:.T9JGT&\%H(M4$SVZ!W\YVYEY7V9ZR!9B5
M!8?3+087TM=T2BYK5TD&3W]Z1A"5+\OMGWT;M',I>R',P,L:TMT$<FHZ;C!)
MQI95D9EB-+V0]A8'JO/[T!S3CV8.Q\J2G=SSY=>O'7;.PY@N@=/?S5$>IW_C
M>0&H <)/_VX@^8\R1R>7OR=OX^,\[C?)>#]< ,Y$@K2$K@HCL/J*5N_73KI#
M)A3?H)E-]'%BB/,AF)GGY=X3<<HYL$=/-SB[,I^Q+%?'I#:OS[2$]"V1I/8D
M&9>?VW7+\!ZKK2PI-<SNYGT@2C3%&FT3,F_/A0U8YQC!AJN'PNY&HRI#OVL1
MRA1BBO53B8FVW9VQJ4@4=U;\^H&\ZCFSKA4_CG5'IPRHQVJJEH'N14(W%15M
M:'J>6Y'#F,5BV;<+3O FOCO=5Q^;RI!8<ZYMDT&I@"<_0&K;I&M+'H^Y=7CU
MIL[NZF.5=[?CS-E[&\NTA=LGBD710NKLAIBSV,L96CDPOZ],B?!HZM;!/R\U
M%_;FF3A*YFHOL<YS5W/CXCO:C+Q82)C]ZFXV&HJR6Q-%NJW._X*?';UW=BYU
MEX8/T[\F=J4^8F8-ES90=H.?="69,]6-LX\=6&C66L&[J]]93X7,LK>7>E#6
M51C"%$%VI$_O<OP!O=/^3^C=?*GR']"[]LF\278_I+?QT.Y^1L.+/,A6J2^/
M*QKO!H@/7F^_O %";LNYB>9_Q235&/WD<+VGZ5V3: *7HC6>TQ1?CKC$$;[=
MU?*2R^K.;":F<T%2[T7\S@RIL*\PM\[Y 2'!(&%%'[3Y>A.%[;L#/EBKK5?A
MR3',CGZ2_:!#>YNS>*  XJ>,!:.CH]/%%3K^%M/A=^7)UG  ,IWR;'Q45?O6
M#^*<Q&_$Y>--!;K^361X6V_TIQ;01P+-:YKTJ0YRU2UB1.=A.<S4GY.^3%\%
M7V\R7/&Y_VSN"L2FM3G96WKX9=?\88.IS%"X:S!TZVM@R,Y,C;_(JKTP!VK'
MO[$\[8[P^U0=D0-Z$(I#1C*]@*U&),!V5K&&S"S1SFL.GR1Z0OWZLT$CVDR3
M'(.MH CF0$GD4ZC^*%1JG35B.].3Y1RSU)(MN1!2<'&)OI(1B+&>F*Z8(.RS
M98 NT!/^+CI=I-V] ;0T['J"-7ZX@UX7>'B]N@&V=7SK5_BYLC+O/<77A^?R
M*U7VA>"^YP?.R2__#Y/8_Y\AST%QY?DK$I2F4>E,UER)SO :B]?2L?O<Y[L(
M_OY;T_$<EP.3O3MNK\)!05K;V\$[H#4B?H*9%KS/K[I96_B/IQS? ._1;-6I
MO6VT\.-.7][5F8-\P=KJ^[C[@7?3<+;R?$-=Y2AY#_:Y42+>?I(F\T_+Y8\'
M'W9EOTN(M\=L^V9<5EE@KT_D5V+>:>,4PL,]0@X]&ZWU"2M"A.@A*+IWEG%0
M<K+5;%YU1:YA4H97K\FBE[<B?]0BR4J0==>>FI%HM@SM) E*T>@ZEAO 3B9\
M#!<H7QN%*<TH)6C"*7*3DNX>F#1:<0NA>ZP3+[_B_A(F$%O+KRUJ*\J%^!LM
MF=X )3,BBA8R[8M\"=3G6ES;4"((5W<Z19VA,,.CF3&,P9)7S7Z)TBF+F41
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M^U$L,3X\*3LM$7E1EJ\]1O"(+(R!_3^V62_"U+@&1I8?',C-6W_'ACC"-'/
M)EJUTWW,+O)XD(\.66\V?LK#2V N1:!C[U+0TG0EF&11_95;_9VE(:*9*=2W
M/4):S&8MFL>I]EXZ?WS)N(;+K:>G^0I6;#""TAN0&JN--5(:(K+SV'/F!B:%
MSLEV[GR7BZ/3]=[#@!.$SBRC9PEK0B2U1C?]>.YU',>ZM[^?F\F9@?HDV".
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ME)5]6E\./LL>KKA"Z#$&RLW*=$97D]XYB8R7&-M7] >R.K3 7ZA]W4CW&=$
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MNAM5W/,7TQXAI)@9Y_8]=$6T ^_H):26J\E1^C>G$[7;\._^!AC.R(,XS*"
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MD: .!9B39Z* ;'R]%BJ!:WD'GO9C.Y(G.6WYN@&Y3X@T)((V,3=I8_1DF.\
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MI+:<3BCS3\^OH\4.T%4WQ@XN,=U0 _I0H$_P[9(-2Z.P%&/CX\JMIY0:]5W
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MT%4\<>2O[4L^)L@ 9#<<D,T/N3$Q ,=SG[E $_A"/0+F?<Y.647 30\ ,3+
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M(9,=*'#->:-NWK5<%_H W:KP4BY" >5D]71.*?A^)F7<4*.ZWDL[NS^LNAO
M/WEU\YHP#$,P8K$K94(0#H(TQ!BV:ML]"#K2>NLX0T>0X6#@_S^4(&A0PHOU
M'W6/.G.6%@VF_C:GD7\5PV!*M+H49+#JB2U!LD.;/GF:Z4Q_1R%95[*I&?MI
M/_%1;$QC2V,&3[KMRW=U8WR;)25J'W@"(].J21VU,E;CY<3Z\RTOI.LB"B)T
M]8>2N#FJZ)I_^AY5[LL53_SO/Y'T+P[ .64(3Y=[\RQKG_@(C-JM^Z\L4"7]
M' SRL[F[FN:\IT_O""/=Y_>RQ_H]D)D:5'\7)\:Z*5\63LP3ZV;4T ,0Z8(^
MK(&26P--QI<F$*D#1_>:*N(?XDT&O]17\.#N\JHW[".37*8':T\TBYQRGJE:
M9UAI[;M]),D%K$;N8X>??/LKJ?\7!9:&49X$R;\?-$^2:4W8JOZ@6###F3.J
M_XL%I.<DP1#R]V*"]R=W8S"!>S> G?A;SJXV\H^+T\ ]'#+0P'> WYV<+.LZ
MY+QQQ3!S Z@!_[8_!2.D 580VBE8YE;5[^UD%=T>VJ2KE2!N_Q&+HM-RT'BS
MIO/4N-3RGOB*,HJE3'SB@$F!7&#377]PZ6-Q>[L0OZ%:^-C&[;*%:Z!PLS;L
MDK:-[F68759RFX41#\ZY4V,+E;\>J3'<_<(4OVY8:TVEL*ZO%Q?#TP+8S<FD
M#P(8;U[3H^[6AL)M7R^^ YL<\5=YC ]N%//%=+#^DF%7),;=>L8[[$77F-AY
MR-+V>5#RE+ =<]=>10* )0$P(O)3D7::[<US@=ZNS=<) PW/"==F5G5D?$!;
M6;LB+IFXO[?A%W4Y HG+?;*?\&S7L[L^?KH!..#)0,OQ%\6>BWRN0R8&S&XB
M'Y4:*CM6TN@Z)_3_EJ,^JO5,0#\8 _W*($%NM1_:<B;["5G<_LU9+X&#*:7+
M5[QK^\S3_+F].<Y-JD\=.4VV&1FN9LY ;P'P+,O^'"WJ62FQB4&SQGK[%KZ0
M(O$%O]WG/PL*I?.LW*BF@=M+D0T,K8';2A36#2UNURS73\:/^<^S(J_JD-"*
M@E6U$_LU"4H,9\& 679),@QUZ;Z^O@H[:'N%P<5;UN7[SQME K52^HTKQB;-
M)NWE=)W%&($]C-"JMJ+V(I=25WIFT["GD*;+:,X2!$BT8/HJD7X&^9P3'YSR
M4^Z$7N--ZOOFOK2M,Y-;:C",C)DXDJ!TUF>@IU*B1+V49^2)]U@\4'AR^=-G
M2*'(6J!1$<:YALEF,Z%A.E3*Q&X0 Q1Q<W,>7PK9'9AI&07)BT:[J^A=IUHX
M(.A?<]IKA677ANZ/EWR@*[\2B(5ZGP([Q3:Q+@S278JW2792CF4$%&UL=.-L
M"M!S4Z]!!QF)HZ/_6H,Z9HA/U0YA*XT?U!"*KZC>]PPXG)HEY@4'XKG^EAD?
M3U!#:_:,N6?(36) Q5OL#P* *O##J7>G:@EI&DH]7NP[BT3:^%Z0N05AD<W5
M24X.ZK"".IKYXH#[&SA^'H IM\XF5O@4?T.-CXC*F#?/\TZ.DA/ZY>;1ID%G
M3>9$XA\O/.,D&)+_P\DB1.G%H&5J.A8O[;IN .!2-_ZU&P"E]TN3\2V#I[SZ
M5[7\NM2O\9,.7<^7H,4_YP\]RI7_V7EN*'\(W&LQF>ZJ3&MW<"I<J7F,J82=
MS45"G?GUIT\*QI/8%<2?.'TS(*VK.U]9F!NE*@*%J,G$%.AL4I:?%M<DG2XW
MSS45:;&_NV[](8PUX\OB)\!6DAI#82E00$7;DF8Q,OB\ ,-*2R; 6?:A23RI
M0K3MXEXF47 J4QB!+5-983CO8!^ N-1(,((&737B$A$,<N;/>4V,0-_Y2NGO
M42H+%^>(8XI\.+KU,:T==C)R QB0.CGWB=$!R$P=8"1Z@?A/^R!IXL7"YB#H
M,^A:UMFRSZ5&1ER6CB4"'-HO-H$9=A.Q2U+;]R*6>(&79_GMDW+AG6^1 %P
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M,(K:7/ R?C!^#B$+^'I5!)^XJ[#L.7= U5:\O(?Q2MO#N8&:A-4:V=(^%_Q
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MV;QKI5B)$$:SU5-FP]QRF[X^<)$S9MOV>AW\]"G6Q["CN*224:V?^Q;?2-T
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M/T'ESR'X-RSXIS@$(J.]E6_QYDCA%F)X;P"H]W^@3!Q:PEL19?^IA/\[QJI
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M_%GDE7=ZH<0LUJN-S+*#Y>N(;[.+Z B]:9M;@;#/WS3YU:9Y,K8SC%JR(3E
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MUJ?9\L^.3R#:G*^?UP3HT=U5]OC^^+3<X2\&((&^N1AQ-PN48#N^3S2&5&_
MDJGKDS:6QJM5PA_/;8'=LRQMG(,Z+$40[]/2*K, Y1[B5O%TR$\[42X;7V[W
M3Y:N1TR-R4'Y3A][4GT&!F?.AZ%-_C-8VHOW.3,,*;=X?VU-"ZC<\H$8Q8G(
MJ:%[D$HV$0]L#VK3N(S68ZP]9Q5IP/L)%WEZEGOK$V79==%R&N16CQZE1U.
MBU@:!GQ,.WRQXHD)HQ2G%5.L""IU!IYQ#7%\6K68#"L!18HS!%P/2T]JS.I&
M[.CK]#]E;_AD::$Z5.,P7G1<9MI;Y&&*>GM]*2V<LY-,IL5<F["UPYPW(85U
M _ (K&'CDF-Z:(D];YGIG.W';BT<E9%0,.!3M"!M!;FWP/1_VKNNJ*B6K'T4
MI"4(@N2H!$&@$92<@PC8DA&4++F)DFER$ 0D290F2Q1H$"4V#8@T(()(DM D
M"9*S+0)-F.;.=:Y_FC5K9M::_^$^U,.N4V?M;^\Z9]=7M?:J/2A^3WM#W=UL
MG)58+:,S"%.K8#H!7<#SD'T2$#]'YX_7>/ZMXZ\ZA)WD:#40PS0G8'H>(85%
M(90)W8(2&H!X*\,G1X-$Z.P 9Y\_Q)7EXW?X7NCL-V-5[!B5N'7JN*,?.P<7
M74@C*%$=\#LJG&PZRC30UU6107U@E; T_[#B>U'%$%Z?$[9+!_=^-RE NL=9
MZP4MC",V<%!AZEF+5G%)CI,R<)(_YU8'CP]#087A_,BL+"S&?]EC=]O8OQ^E
M7B\&2CB_^+VB,/(\Q(, OJ7.BKN]S18M, X9V,!&8M=E#T94JFH&L\72>A2M
MTC.#&\3WM;*;8,)GUB0I8@ZE9F&+86T'[15Y7,B(%'/_9,(OMCL(Y Y%F!FT
M]G/Q(':D!=D'QKX'<K2K:'?:W(B)*'="W_(0?F_=-&V1/V=M;\K3APVX,Z+Y
MV=,( FE\$WDE5:O\<"[D^VR-0^?Q334'UP5H'Y0NT7X 7/U*6E_6PEZ!ZWW=
MC9!DX+ S)9?\AVK35EU$!5B:I6@:,S[1QOKPU4T;^6+P=.:.AN0L4G*+KY%T
M<*X1 <:.YZR7Q3,8V2=,//7BJ84PSN_7=P!D]9\"4S:K@7OJFO=>]7OLNWQW
MJ'=<MV XO?>])=:HPKU3+%64E05W^V6Q>I!S4F?.U5&-X44Y_G%RMXM?L')W
M@)<";[X@!)3F8#5&JDDZT5(*@;8];J6IO/FU*A\W3:ZFOQQSD'24C$AS9_E<
M^&XCVJ[W7F=))?!$(\:'[[:3WJIO8(Y3Q;2Z2PEF&3?UZ.U:MFHDEYBS.6#L
M1\XWVLQL;#]B1HZ-0BFY[#HIS%Q5/<QCZ)BK3F;S2&GE&.H#:?XG;T;_Q^O!
MFE)[9$QZG0"S J7^D'+H#T/P88Z%H.GK=OK[;5^*%6_*LZXJ^WCE;V>8#$I?
M*[17A>LEBJ9<^/H9%26<]*'GD8]"[94X)8F%NLU OA5:]Q5)=^CN-&;:OCI>
M/0S\-+("N/))8C_0<0[/:^Y$[Y1=CT)N[T4*J]L/:@ZLP[<1B7PE16I<6N*)
M$K#8*+FVSN$F_7^],-]_:XQ<,;7][*E8$-S3?XPUJB@GHEEPV\%TTG#UP.N-
MK^-&?I.GA!H1>JR1D,HUQAMQ E >WML62/.DWC5('02_'D5,)D(W9EBM=68?
MO*9A6MC7LPF6&8C>L=F+FCTSJR;-+MM]A!+I/UN7Z'44G)?T<3P[3T$GP)Z-
M^%!^FZLS'H'=I-&\D&DP^(F:MJ/]L9M3[Z>K,_?+,LG=S@&^1__$Y!,)_2Q2
M2<"\V/2SD\@]SJY#\O=9)208LHG1-O7<YL49R@IL>3UYX7!SF;ALPKC@V]OH
MCX\CQ6="6!0.EPCZ[2JY!Z5=9BG()GW*E(;3_94\\[KLAW]H;&,VHUV?+52]
MJYAP\\VYTY#K;QEFX'#&O;#\FFNY;+P,6DSQOD6&N<^'5P1N+?(^\UJ@P@0*
M+8KAX%(B@![;#M,OW*YQ*B_?</*XMW.]8B.OI@&%NMC*+C_N[8*1%W"OT2PV
MQ 90Z$KVAMN65+/9B@GQ1UP7L1I576Y0 ZWPG/W-+9>505?D9=^E1@-"<<FG
MAEE$\P"=$IL_#V!"8BRC_\.E&/^A9(+?DF))M?8D9@)T#5I:4)(AQ_T9GQKK
M(,M4#!E'!2!" S]EP%5RY)T9R6J=NZ:GDRM%CGUJ8KN3V[8*)_0' 6\F2U-I
MJ+\L"K575;SW1#NB%RRE5(T3>9*Z]DW#-7C RMQID<5WY$6_/+/OH<#6P%ZX
MIR7-H*1Q1G6-0['HJM )D!IZPRO,)/R?/.CZ.PW$V$(L329B,Q070CI1O3 3
MD_C^@Q4W5RWM>";N7I;N3.5C3X3&G/90]?TB9 /&)JG'<\I@HPH(J;>LN&FB
M3GT&O2Q+A-2,2CL6'+%]D^U5BZ-)]MJFV9F9T##.K@R+OZN?FK'UXQU2MNX(
M4;34U^K#D&5\DR8V8Y-&T>NE[%L#M7^M#O;_N..K:V_D;7'["$8&R_AQ(1Y6
MH,8W_LFNU.@&C^Z/D#4YP]73XL,97WHSW/-,#"<=)&,[BKT#+F /RML-'W!&
M7@Q^R70G6'4\1E\LNIEA:CG[W&</.7(E3X2I S+:Y*CH@<[U5SVB@3\ND\MJ
MA(W0K EK@4B]MSH84#?SH;2,[0MPI$GE6,NCDNT>DN#V_E8=]Z1LU(C*C!GY
M@SW\EDB2]KF5@P//+L>=,9LNSL2 +I'*?VNA[[_7]!0W)J9$GF=SN%5%&0)S
M/HJJ9 85Q(2VHT,U7:TG %?B"7#\EG;Z0%L&\.CV=OR1:,B%5G>GXD]49*93
MME"L,LVE0H1-@P:**OFV%_)?%C7.,D' ^KM=RLT1[ ZPZ.=WD6$%,?FY_/6@
M.'E@_IZZG\X02LIU5N:26G,CCKYQH$\]X&6/X9@ A#-G68#3YW,M[\8BU,T
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M\B9FNO12$Q->M"69S'"OT>J>^[PI4X[;7?QG$RK?W O6 EW!"IE\H)G-+U$
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M;L:7#*H_EM+;+*AR2<TI6PP+6JM7QM#X9>+H,HLY"<N/L^2A('SP)?%4?N"
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MR:J6]NTPJL3E"3C?/>"G7US78KB,<%< Q=$5G>:=I*_^Z441HH^Z\MW:0;S
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M;8FS@Y6Y!)-"I8B"9:($R#IDRG/*,5#UB9K"SV$GYQ-"W+$$UJH+D@"(1IW
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MH?P_N.G!_RK'\+"'71P5%"H>'F$V+SL<&?>=C"KB9\>9VK18QT%/ ,ESNFN
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M9/L\>L-W4TVJC]7(&]DB^W2TFL])8L]JQ_N[Z6#+O2*79AK7>[P@$*C5+0U
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M:/M/3J28*@K@M^HK48N1@N5PHZ"@4I\HHK"=Q_6Z"9)"HX94[912.V.@[![
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MYH+<E_<Z+!RP!-^["11LE;US&O7&G&"'YL$/,CIQ5?&QH$N6XR2SHEU7-<;
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M0G=>=<RN"C,O\=QVULY,YGTN=>7)#Z'^Z+NJ*82-+!S2P4EIQ=5]/;"\5QU
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M,#"!DIN;0^P ]G*##.FO3P>&=>TH$^=\"P*=10@.%QNV(VPE&["I^06"?>E
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ME0O\[4] MBA$V-KI"AL;^;2B<%AC0O83II/J%8N;DN3->\#J)T3979A=Y=7
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M#FN.V!3#O:RSVSF7STJB]<3+EDUYJIG.O=16=8IRC2;*;O3[A-PSZ!,WG'L
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M.(-4MHZ-P-8[NX_XD%]V:XYI(U<?1)/62A< RE+=^%(PB6 *O/B5&S!1EGM
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MT@;GQYDE0S,AZ=TMO%K4 "<>?.)9_*?N/K[">LL<=1!*8O@](/XBWC7=\![
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ML!RO!MXSP!D[1);EQ^Q0.VE7&HZ/N;2&5UWK9"]8@L^G4?<9.@R/\<; ^PG
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M_H:Y=^?;#8]Q(U 7-@>9?R7+X-.IY*;,S?-IC_;H?Z8=0FJ.YO^M<P9$\97
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M,@;M'(;_GV/_ESDF]H_\Y.;;5V+@X%^C1K'\HY( ^3$6&$M,<-Y=8?'X&_A
MX(/W;5?UD_@;A-W<AP9TC/TYT,&)\L4(? MZ#NBCTK%TDQEO-[[#C#.F4XA+
M-9)AD8U9RZ;Z-<;@% L5, IFE666:.UO>FKU:)#S37T ;?5X*FA9Y?%KJ[U8
M6O[ILPH"4EE_R>%=QS[0B>9( #;5C'LT,CFQ68J\M7:#*:KLKY)S<K7 GV$J
MNO\2F$+\WU/_;9B*/Z+V^NU=0-L8GEVLT;C^"K_ZB2&AQ' ).Z*X@3S;[]8
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M,SQ^^UZLOJKF%OVE.5*/H<HDT[0Z^WPL_F1]YR*N/'=JR&=.HW-4>E*<$'>
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MXD*MD\Y'5F/"H*(<X14M657>K^^$:4^#R^1]O> "0^X;2:C[JSV..I]2I%A
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M-4U',6;TMLJJ[%F<;*)6/=L0@Y#!+(!.>$?G.6+BC1%^5V83-$X*(@:V$5/
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MOCY36@91K'?_4']/F^0KW_OC.PS(/?VC-KO+YW^>=L=;@$*^JO(CG[!S![7
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M5D[VIQBU6JZY4TR_>C^H[(\[Y#NXD6+TDVF2P>0'6GZ4+WA72Y8U;'2D5H$
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M_$W>TEM /EP,N7T+&*'3 @8*,+(?!E"/\#$OSP*?S2P\P!.>1>MY"%@USR-
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M95[FEPB7O"[I&E8(./JG(%N.8K\'V5K]<U0MTL;5-EW!SA*\^N/T&(F+^5O
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MO@?CF$,X<-JLYN)B56R<87"P+FQPK=[#,4 __U5K&V4>_CXTW/+)-'_(OOW
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M> ['\X_DQXN7. UFV3?K0;Y5_/> V"X"8])FBO+59@XWZI^6NP3')6CPT4,
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MH1K=GV:2]6/P>[Q&*% WO([Y7BMAZ*FEC"&?AV/> CY7YWQ.&IHBW^NP,N)
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M>)$;*Q;D&MZ7]LIST+U(J#"O="#U"3)-5)O[R[G3VAIVBL<S,U)?;-7/(K:
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M6ON7WEUKWB/7@?=M,Q"]KM67)^"H2'%C0LC9)/,:AS&"&A"GRZN\-;AW%O5
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M[)HZL,S900.X^R7V]_N6^\0\('3%;J7:HI'?$><4GRJQ;=!<-CH1 RH[9[B
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M<@@E=O_+^1Z??X AFNZ\K+_K8;X_R7XC>Y(=(9"OD_2]ZEL<*9MG2<0S3W4
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M(L^+O9C%AIM7SB1/FP<^GXV!K;URE);I!<\ 8&%%>$BP) #GAG3\^@K(S1[
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ML224^P"_GO:(2$#*\#T>T2#V/-#X>K#Y'I@L9) (6W,GB#![!_4?CG&^K@I
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M1>R")DU E598^,\#0=QP GJ6HKZ@/E>][<W2![GM:>AD&,2)8B![^9ZRZE%
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M<V7NK=/KGBCM<<!7S16*NXP1'J(\G1@NA<&.C[V+,ERE9*3YBW4Q\EAXTD]
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M!ZJW$N =>5//4LKZB4HYAKX(0AH H8X$YDYIDB1Q0F3 A F9;XS;6UGKZ:/
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M8;W**0BNWUCSIF7'?2#_?<YBYLZH1*O8OP'KK\_21\%)>W8/@Q2[%J4E6@-
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M+\2_L SM91M2J:^Q*FT[-<STZ/?NPAE,;^P)]ZV5,]*E3O.F+"XOM9,7]>+
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M!09 "NQ2N=K\DLJFYW:)6VWB6)855S!V2./:-,(.UJU-$,E_-!'BW%DP,8.
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M-KE)$20Q'19?ON-H()S%5.MF+4572W;V^Z*SN:V\FN9+U48PG'1GN6)0.FO
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M&2JE"VH:L$. 0N4TNBFV5&Y;TK;R@*UU@UJY_G-B,]%V;!]:S+$%SFQ,9]!
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M8#P!J%U;36)GW!P40"GQ!@6BTUW@0E+I?[>V(R<_MQ,($.2.KZ3;LS& 3Z9
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MI+<PV5R+OKY-.?FL4:DYZ]676HG(O >FSO!\'..;?_RB[+/%A4\5!H:L-K'
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MN$2S,L_+"V'?J,@8 \C*0KC#W-7.!39N91CC%MXQ,M[I4,#7IF.1 C_0*31
MU0#[[YGVJPKJ[<.4*!;^DV5] 90\SODJV1H 1OLA:4P::-FK;K MM!ZP%X!/
M6>__T4,M3K)C'!@%9SCLF?[I[?L/9]*7ANR?=1V! *"ME>J,267SM;^67-O
MK$)O7IY-Y'N@O N([K1;S\9<I=!#) &0]#196W11ZS >+.??+6^8?>H<81<:
MAQ[2NEV9*C@[C_>/GUPC7NJ.4&L]#$_,=WH&]+@XY>)*];B:9MS;V[*W7+HT
M:RNAJ0X*N8(HXR.IZ@)TY +D9\/7/>;<0]R0E3%M&^-S%?_]/SX!'O"B'H(?
MURW;&'=+P8ZHTB^X2?VZE!%5NH-IZ1'?<35\QZ,1W[$3-^G^XCL>;\-W/![
M=SQ^]CSD=WLTXCMN!&RPU66*G2O7=P:]6QGZGT%[979#ITS-VJZ47-4Y?\-E
MZ^+:?;"NW89+2%X?_E*5J=!K<+7Z)J/<SMENUXSZ&)&@WWPQ=K;^Y.I'[6=R
MCD[ B,"\RD51GDM<%"&DE]J:WD*YWF(U7IG"D@GC;N^687'35^R^Q2.OOKZ_
MKDA+9/^Q1^<7SFS><8D\!K"_"'@VD.WV.6W;+<2W0UN4;1X0MOJ/!H&<"OA4
MV"DV:R+E2F0MN"R1\N>8@NT9X[J*]?(L=AA2 N62AYPZ?% _Q#.^*RN?$OK
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M%+1ES+]^Q+JMY>Y$\+R81FQ0UT,Y2A##,8N2M@2/^Z6F0N"&:P86+Q>3X[L
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M-LB:KB;T<-_"(MMNS6Q0?^JO! KX(!/.3G[;IPN=L+R<=/N?63D#U$G&L81
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MG^D1FM;ER[U)LQ^]7S"X(,B/7\GLYH N5S2QX2ZVTM\+AFF];_C+"'3FM;D
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MW7ZYK5JU$AP8-BA M;IJYF?2L&U%QQ7 WLYVDR@O  M4!4"/I0.PEY;MU!^
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MRV+*=>:X1?W#TM,VQP\(!4=X@A%A60T4_R%AQ1K0/>P_BEZ27D^]%%T"3HX
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M8GK9PK&VMR['KE((<T3WC;JIOG,\K^]?GK[X]5C^%P] 0B/6PMCZ.6R;3+:
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M]QV;;H_/S\ M,V<25.ZQFU]<P+9(>0@W^78%-D@&S^U'F*+6V]K'DG&#*UH
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M+D^<;O!G>H.#CBL[L_$]-T)9]^*77J@?2B/<*M-$E%V[UL9J(]>R*+MY[Z'
MIM7.FGK)+5>UQBKR=LSZN=;FT1M]//M%<]KP[+O$%<A\)E3N,6YAU/%#%F!P
M@R_+3G*<[&ZP0+NPR(O5(6L7JQK6FZ&V% PFH0,Q,PW/?*VW(KP25MX<^SYD
M!HC)L?W$[NF4(GA7\G\  G[VIKP0"P6VT"DI<$>.S8>N&AQ!NL9Q%L5%"J(&
M5(Y]V_5:[Q_%V3VCHPDG$KB7.8?O(DT1T71"M@6=$.%(R$HCVVII5#]H3Q8
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M40,IXL\PM\=.B[@H-9V_BL,<B(J,"UZ0P<U%0);,7MBJ,-6#Y@^.$I9?1-
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M25>2=,M1>#RK\VVOHJ*;-QLGEP$?X_L[O@@HSZ#Q]LN55#Q:WE2V3>@1T13
M"7G^J4]/8Q)\]^.L1LX238DY_5CUO=_W:.U C_^U-F3?][]*75->%&A%I GE
M&8SB%@>7?D&6HM#2J?=XY!$/T1LLV1(*N<M:^@$ \>(F3H#/6'G;\88T:3B&
M%:#/##A(@V&#1%X:"A2$=)IS#^$@;AF1TVSF7%L<,>IGIH^&29RH>Z04V#4:
M]SD0^Q#I*FU9V.A0^<6VR'[1GD1Y-+-XGHXM:&C4-W-_CP&*/$!1HF%&M^[
M6&P8X>4F:0?&" ,A@B@>IYOT,!>6NA:HVG(CC( =YPXDT= @G0$8(S&B+P*<
MJ>9H:MZVP%*%]>3,%UZV*C<0F:V<%W[K5=#JF6FC3(*3 5>7<50U\Z<F,5(&
M!RQD9T,H-2J\\Q$[GA$W&E#H2<9Y3A1+,)R%1_R/NRK5IJ9O4].WSZ'IV\M(
M'IZ297+T/^7\%>;!YE<OWH84.6Z/!%WKVT)IQ;78<-9IJSOL@6S(:S0OSCLN
M'(,'^1U)ETI4"PS+12_(-^YE);%Q6'F*4MCQ_\G%</1P#9Q+19A8_M!)ZYX1
MN!"V7X9*./SME4Z1S#8TH-)NY1<D*;^"=P%( =BMA2Q'?J+/P!^17\_UWZQ]
MYWFWDL_2<R%U23&5T '*MWR5MP+C8C@#&<"< 2(/JE2@'.0WS:P5#"DO-AVX
MLN@E:^5[TVQZ$O&T >1M.?X?XV%U\)(T*@P;DO$\(54X$2/N>"39:059[7GL
M3N$4K]E43@>+L 'I$.9NR*_I)AVR'3X8X ,#);AW=-^Y135V?1<Z6X&=Q[=6
M@]-);\!9J%RQ]/D^.V8QF%@.)+YZ63;<&ZO<)AAA?J(EWD#9)I_C*G.&>UZ*
M_N9%\7^S5UY[(])N;.$Z+)C0B0[PW[" :W+6:-;>NO#%3VON/0R[:="P6PJK
MRHWW2=(UGR4MO(]GW_MO>ZBNND5=()>/3)P]TJG:MF.5=_%2I1T"]5H'C_;:
MM0F\UE,/U4F=?M[J=*21XH*NJ>]K -MY6*0MW_F!/W8F'[/^9#^<^=9D=BDC
M5=%Y\6I*]; >#MH6C<"$9X5?@98#6K_"O3[YCTYTV@''2>?"N&Q5*C'_AY<C
M//.,9.0<0VQZB0TOVKP'K([6+AK5.G_%(^J[\8%!7<V$P1G51+JJ[*C9 #3Z
M:"W<M;T*?RYYK8R?<=D7=/=S\Z-I+JQWR1'KT$6-5M+MU,H@=;;='5X2;B4=
M)H/* I+?['ZW T,G:B::7S9BO  "X.:H9!=S961@,IB# Q@4*@_4 "N+CDZQ
M0@AR70)EV],J"):@D>W0J<+C"ADHJ_RME2:<W5(9>J[9"CY)?2M5M/ID.OK'
MLV?D?3?</F,0PTCQP1(>_'\NVMG?_GOEJH(;KI)1TP<2JK/3&?G)L':D9F1G
M<1<I&[$S[2U!E'.%!:0= *^K*-B=!O'IX,&0D=<*A'C^B#MXR _%HR&A B!7
MAQ;!2&/.%$YJ77\ 8"HOV=H)-F(N[.5<L6YO)C'1;2MWP37R800-#%[Z[!UC
M9+EY8I%,K-DV7]^U"1Z:3AZ">&C[6BV&5RV.8%658^2VOY?Q]1&H5C/K5EQ$
M4K-_ #FRS5O!1M.#=G+AMUMAWSKF+_I^Q5Q,8%V"X9M%874-847. 5R@;MON
MY$98-YO8G%<&#VV&2?X7BCGS=;[4:%O\_& S^U;$N!372G1Y<] *B:%/-^QL
MK[MQK(SW[/?4S,]"L!3M9GPO(U%=\FK6%J9?3>;%*G!TX(?%^F1:WY*+.9G6
MM\.T]O(K" 6QJ5,K^9 A//OR_E<::V>SIFDEN(/4GNA4J3A/(C(AB&$)3O;B
M00!V$R<^\>'9GE,>HS&#2W"K;+T@-W%M#.;+DZ_B;EJ2^-;  P>=<NTP 7FB
MECJ;UE\^^,J'UKS)BWC4:"2-[>BQ. \IJ)IKE;$?&GS0N _>VRD@&'!6_,SA
MFB[JJ5+6BZIGV#.^&3TL8FR23BUB.^41#XTM(DQ#WCI\2$-C5ILEM5IO6N.Q
MF2$&%J@1P3<=42,>SPY(Y5L$&9RPJW=>]GW]<,*N_I78U<FFFFRJS\ZF&J3U
MR+*I<^;7"*$3A8\^K8V@[!P8+/4/86R@15!?^U^=2LG._>^^^T8 ID_/3T]3
MJK3PWN!I+O8B92$EZ%Z[>>\CEF@B#+)BWQ!U+BG+&0IVUTYJA=G'8ELFLIS$
MQ-@&"RKX?A9DV:[*MCB"G;'3J$\FD4)@(C+8"VN7BYL]YHC2AH+ASS$-AGJ"
M1@$BD<1UR7_%R-15WX\SHI,T<B_\G; 3<SK@3;'S%FM3^;3?X4D^.KRJZPOW
MQQ\6I>RV&K'44-]U3PS/H"E>^F#R!3G__5PAI657N;SP%4Y@?!&7V.]]65\"
M@+K,@WT7O13V*2WD(Q[TH2E@"Z1C618%73.?L,4;^PTW:M:@,(*&,^^T2TA$
M_Z;/BZ+*UKNA=H/6#32=4H(GBUD4!<<9WE\WQ!@@[;/8##V>O5"0Y,#Y/Y20
MOW49U2DT<4M$^J1&/[8:/5_M.GBN]>Q<)$$W>]$#N5<[2>695LT'3*9"&#X[
M;YNMBAA6J L2) 7[IV>0(_R(E&K4L_..\FM #EE:(*(?29(FF4\10*'%!!QI
M;L5*&8S1F/ZQW]]=VS08^X<ZX-T(^@35JY<Y";Z0GS$'/(O<;\6_G*W*JFA=
M'0("^]:(*"7)GE3Y50!=')HY&PAE-Z_8$M%);VSC0@6&K:!%1W@M0"@7\CL:
MA&#IZS- 4#P.,9AYN6$^^+#4NHE*VP5\[)%4,*/_DQVB;O8E*.!J>:Q]N&A0
ME</;0.*_PY(W&Y)R;MO*3YNF*'/Y08+79,DT'!NAKWV5A>=KN\*<JY9K5$DG
M(124:5CUB_R5]45>R6L"P[(P\/!<Y7-Y3?I\Y71T^E,GAP4$/M%KPU/DJ^NR
MN"*-JN>(@<-;,!7C7*Z:;H,<4!?VF(/P[[;1L*U:@&JUL @VB)Q,Q VXT06G
M$,G2.[@_6@-? O*#,\\%&BQ1Z J05=5V4^#^MDCJ23M^+.WH^_N<__3".X!6
MLZ;,#3U;^F,:Q2K !/3"?E+97;1Y75BA5TX^U]:"U.,/F:S46W,FIGOX40J-
MR-%NEL@[AR);*VGA.HY!XZR(FE<_3]ZH8:?EV_MP-KG9:^$U-NH[K7$;U!,=
M3L<(V+1NZJ.0_F8PV3 >HVQN#&*^:)N\"'0ST,AFD\,X(&,-]M>C0Y,/5,B;
M0V5((X1^@\\:ZB'8J)=-A7A8NXOI0]$XFJ^_APL+#+QRET [##[)_T"TJ*^6
M^0@0-P*!&+_H5<FT,UH'ACF921MS6#..+MT3RZ3Y=1H[&-%:<5EL;&B9D=6W
MLF"ZVE%-\]^DQ8)11QFLO>WVSHJWQUOMX@54G+O)%NX-JXN2HG%SEXA3<,3J
MW[?V^8.I\2<?'5M#7;>P"Z&,2LF:72=@13]NOWC,N>@_SFSC1;GE515E* 1'
MT5P>165UH4"<%R8B7]*6>H$N<[\F4,B\XI#EY=LF.J?RSQM+Y7\G<*T0"N[T
M[B'(C5\*>"%X-_;'^%[B7H?"A!A -89Q&JO70^$]C52/QR7YX0RUR%((5/0T
M16QE!HNB$[QL6BE>S#12C5M<!62N1(9[:T6%.+<I'/A=RQ8!3<BT#NN?UO%'
M:%B]TAVWO&7T6UA&4AU!B#ZZ<:%%N$ C:(V1.I>8].*11_0:;.QX]CV,6HS:
MZD#3TLY8F40[&[U;=&I"_,;]$33?X:%G2?B<>4EC9& H:LVL>IX;%IA\:D@$
MQ^T+>*]SM+E#G9/O3AYI-:1=ZJU?4&!3?:GK7:WXO$6)\@FQ<>?%^M=?3XB-
MB6WLMIW6FR/ISZ _Z*!*A[R80O.VR?>)=NQCW<07["BHU3I.+#(3,MPL%!0K
M?XDR_Y(1(Q$#MJWL2\8L9.D3=GCWL1AFCXW18YEC&-E!HS9=Y(F6/H^D'/%T
M_(L$AM N\UK)JKK0GZ0"Z88P"L5,L]S0)I[5Z"Q T#8O.W6KC2<V6B$PWL9W
M49I=[K_.:O8T"96W5B=7,U:6WG5TL3OB?Z!+5MD9W]A85*7U[K8@+6@3>O8W
MDZ'LSW<ONA-5WG/F\"NQL3WP(11U+9HVBO>J$\*['T O7;_!-[N  397/%-4
MSMX8?2_-=+ : 0D88K3C*L%\!^?)RE4T-;NBR^1:"4/@O-.^(('5S$N.';#]
MSCO-4]SCH (!W_X(K$.&G0ZRH5VUX($Q)&7'< XPBEF*%'5]0.84XE=9*HP]
M1+]>$L"R[)Y.,XJK^>X<@2Z!&9Q]*VKYTYPV7 J%Y'K&U&AEQY67GY:A/XG]
M=V&?SP*W4Q"T*H>[0X*X,R@1L&*]8Z=9*L[D]G;R,KK-4F_I976"T)N[J*G)
MD/+JL)C*8C*&@)!@ZDA4IZIHX<+)(XP%%X*;^97S*)5T6C0;'SY+!J-4EX-)
MK$F4^N!='GV9VW_YX:,9,%.>"/]42C3%<L:]EIXVZ?O\X^=<8;'H6PX7<5Q'
MXWFJICDRJO-@W2,Q5:G@"XI@7U8-OSR3UK^JO*1 94^5L SCL/FEB_CW=9BL
M55PDKOK.]FRC:)C"K?40)<*25Q%Y?X&Y!4@?TT:2Y!9^2AP%GOTDJSY3617L
M"ZZ/]FW9^-Z&,"!'TD4TT(F*F/H[;X.R%9+YG,0U95UO"!1*\PE6S'.FIPR$
M=O;0T:1+W$'A^A)X7+B\FDMN/81/DWP*IR. %YK[9ARQ!$]9*4Y5FL8]GV;G
M+3< I)MY^NQ<UNZQ0^=Y%H?!:/,58D\@/9XSSY(AM;+H$VUXCS@6^@)\XL'#
M>X]G9T[*V_3W>.&_FOKH!P/+/CO7B4H^!]]+R8__#08<.LZGBT5>MJJ?ADFG
ML$V@6@B<AT(0Q=J%%MTX:R5-$RV^Q4C# ?)E94F1'->.G>UW&N\.I-S8);+=
M3_NT2?PVY$+?+!-AS3%8N__41.,4KYWBM>\6K_UFBM=.\=K;=EIO'MN,.D,\
M!PGX^K:)]2E,^Q']]6=,^D^&R;WLK8L-8#B#6S( CQ1W?V:6[?=DZ(@U]-RA
M\HJL(_F1OT]+4DFO@$J^?LI$9GFH+SS0LTZ19 7W4>\!I8:U%3=YB'K.XP%7
M>5+\5G;*J2PCIUU>S1(\F0)IE%"I8_N-7/N(+ )R/@3!2F7/4CNJ#_S.F4TL
M-*7E$JF:=DK7^DC:9M"O?^FW,/P[6BWMQO#4J+%@@#+RP<G*^A[NW-O-\U)K
M)PV.%WA\?MJFVW=ZD ;H#CNKKGB#&+.Y!M:_H!-^:OG2HQ"2 =A=RS6Z70="
MT9;%2Q>Y"#F8_86'>U-6C0_9P-2T+U_0C3%R"E>3_\^&OH?S9V^!JD(AQ)J[
M+&AK.)T0QZ-\>UMI7(Y0"AHC((JNWD_,:&[ 0Z/4YE%&4UXWA:NZ=#EBZ-T;
MBGT>6:^)G*\/1_5)LI1:YNK;RHNQ+_Y%Z*I2%H'M<Q*)[S=S5<+G FR%99 '
M*]&98._IPKG:*HT!@OJ=#OK<VLJ 9ZNKY/8!A(Z.S2L D%@61;C%J-F$BH?C
MV0^HV7R-7B2.11Q$+<D;-)=@'E8$S#8Y=YK +6_="CT-+[E]LD-HP%[.P=>K
M9D9G"4% N?SJK_OCZGU4&](V?TUC#,XY1%:8,?Q*EL<T"?)"AV$ &4+4_&7V
M3W)]@6V]GT&Y?)?95.DU2A;-A&.%XI8Z._F^ DS9:B^\9N#HK0XV9K>\6C7,
M;R/]+4N.K,IEYY)?SY%K@5\.65:55.1*E5T^V[F\];P]R/QQ-D3HER5HP!U)
MG*_?BHA_A(+,'?OZK33+0\/^9T^W_OZW6(J3^U%D_$6_0:B9]KEOT:VD P6@
MBH,U(LS@L:;%\(?,GR8+8V!=+EA"<1:Q<Y<L?;0U@:'XK)27JY?;7HJY:VN?
MZ</;(A_C,WENC4/QFV2T ?%E@=Z,/NTZUDNSQ_@?'1\Z,5V'0'X>71HK'!9:
M2<'\X5#KWJ:*V.#!C.B[+.DRBTC$N$L]JV4;@M\^2,X?ZROC-): =SY'\](4
MV1R?Y3QIE^6?Q4] /)Q4XT7>MJ4JFY!9'#XX2AG[@V>JQ/9-0+R;*N=\YU-)
MG]7<[Y[4WU7:N0*:-03SS3ZB+?<R0JBEO3+2BR,[$4,WI3I<M*@H?Q%-=K0R
M$R@,R>3A!>.LY%Q!)D$G>ETN#2WXM-PVOV+R(OZ:]90&A+'N,^L[Z ^05K \
M]UFNR+J'*.S*.IRSV <P,$*PZ*72E0]W7RS=%E> :2Z44X3DTGUU$E*"-WT$
M:/)%I"^7 %9P AX166O:XJ/.H3:BB:Q,>D6_P:].OA"JR;*#E1U4"!<8R?Q.
MR3RO,*('TGBED$(!N"KN/SU$9:*V^5I9^E.T[<F]!_=G7_JRDL SQGH+'"=-
M"T7;]23EZTYPR^HTD!$O*&.NDO[EWT^?'-W_;L8VY[J<RV#IVIOMRD/R0H+Q
MN\]R5>$G]S@$SH[# _G-B;:;0S19,W:%6@-^->D[][^01\E2Z%=)T&WIIW_V
ME3W_Y"O:Z0:$'IT3F3(ZM^LFQ%@B6J][V1LWU'!$)\<G7W_ADXB+LNUX13R=
M*C95IOG@"]_W!\JGV/O8"+GRZ1K)X1S>;S>G#3VO\CJ<TI/[L/G7['$5$?L&
M<@KS? ,-O5^MXK,(SYX\/U?7(.+'.6" G3P\)B<:ZE(;2(D1=X!P@"7]6[\:
MAE.^V>!QV]G]>_>^P..0>I$&ZY8M(WO$IW#I%<>SGYHKQWFX"[#4UI)QXS&_
MPR#@A>.*T(OB(1CM8*O]*T>'X\N(R)SLHO;D=*#Q$M $U@OE-9E4R =*QD)F
M]DNT3!0),[0I!XX(;\]3VQ:Z9WKMHUMVXGDBGCZ/&:8J!7F,A8W4X@UR8Y\*
M2A$/DB^UR(<!_]A65"&-2(]_D#]!YM4?S_Z5K[D/EXZ0N4>-P&/OX^-"(87(
M19BNE#IC=I[#V'O,PWR27 IU19O.A>?8?4BN@Q_1(R86C=;QT-KAI?0VHX>"
MTMF_ZU^;[B.Y%_.%*H,)W=*C9G&T:>9D,<.=T?KN[>R_3K)[]^Z9P\SKAK]@
MT5$R)XC(J#*(5^J:%/DCT=/@/AV.\9LLBN'%G.KK_'6Y[M?P0A4+Z%U!D7V+
M\C5S6%BD$K#!N')O."+N.3=2[)X@#@YMZZ*I*N;!$E)X$GBU6S9;#;PR@J]3
MR-#9LQ<WDF13[G3*G;Y;[O3;*7?ZT7.GDQUR<U>VGOW@+EHVG$_,R0EAE-,T
MC );)(<O6;)L-M"J,.$9])X]%02"2& W:-39P-(L61Y?.K-'X/#*;Q&BJ_*^
MGJ_$@R0]\@V[%MSFHZYI/>=1#>T@LE,WXDOD#!MG-;AL$"4-@=WP<N]+:P]C
M475 $OG&SD;QIR0LQJ00PEWS?HNXVQ&3",YEGG"V\PTK,VO,?BE-Q*5'<MM<
MP,#;E!NF.F EB9%ZJ/D>4IYF]LM\VT!]WG^8'3 -&?89XHW?^WCC+SP+>L;/
MP.X*4(P<LK841YK19V=-IX!?<]I\HC&*47(8%,A8YFU0=^FGGUY(^DPCDE<K
M)QP!C1*3BW^I*Z!Q.5*]M*EU<RG[)BE 7H6DIYM&PR4?IVR2DGJ23;YBN"QC
MDK41>=,%5IQU@UR>WZM2WT=+PI^5?3(&M@2!1AO>(COK@S2C@,6HY]RS$*[6
M#?,727?L0>97RS8I\"Y8&L 'MH?;/=S.T0#/%DQ@7:;+SLD[YT)K$IEUKJGL
M0$TK*V09"%M>KIK!KH5@ZNBF'<]>1.'US/(A3+*OO<&[?TA' 7EVO',Y;#4S
MD5]@!1H)+7M+,[(S838>"=D$SP1<:][21'<6BXR803IOCOP)DN(@;+0%VB7-
MX2'L7*(B)K78]KG?YZ-%,T=AQ_[XXV$BA&"L:1=N>X6X'ZU8-F 4C&KI_3D*
M8?[PZ$!7L$9[J2/Y2J,I<DTBY<O6J?\1SXQKXNDUF)L><\&HBWW/YOW8;A0@
M#!JX+H]GZ1JJE* S4X&>@ 9Q:CW-%+NJ2\E]J"]SBVMJ/ET'"R8"%(=%,F_2
MY>\WIN#RFKW"+.[2H9FQ./3,4>JDJ$W3K%%HUB@<?'HE1N 63J,2H@4X%GTC
MC\[B!_L%+)R<E+!46G#A.X-OA5*#/=RQ.A>/Z-:Z"-$"@@0V\ABN8HF893A\
M 68;NLH,CK"$$QL@'3#I\YR)J749!5 ,O>N1&[Q,X/X^P"%SR+?E&+'&Z3&G
MUI)XCE:]V4$(]]4K(P6BT1_/?G9+-I<T 5L,ZVTBD(E=W=%*RY /2U9QKC*!
M43?5*+H'PY=4?A9U:?>U!%92!$'6I8PF@V@QB'>&[>KCEO-B1?E3[-$Q^P69
MT@[QHBST-&G!GM!<6J-74IYHS#Q:F"LOL]I;Z9$2 N9J,II=4$HG*V]+B88]
M@-)14^'EJNS2.A]<16M)'Q?VQ+6%<W#Z%1(#0Q] 9E'OA!"I3CZIEVK*1WZF
M@O\WQ[&UN;6Q])Y$S ZV7Z2C.7;E(4O"NS[O;K=@D,%<]+!M/%V_W!T5'R(T
M+-"J)#IX@U;OE@:ZB$OH%#9H4HOGL4]%%!=.1M1D^_*-AXVBE4$E=G+C#?*6
MV0!QIVQ\:'3IN->3L_J0#%P_S)7;!MP-/9$V0[^E#/M61D\['8E[S_FL-4_2
MLMV98D42S/>*39;Y[MSKJ2[EO<=6I\68 LVC@>:_3X'FCQYH_CB+]B%.ZT53
M%1]L19_DVQS(RLN</*S_*U]O'B&FV(/<\+VIM@\Z@<E@?;_K^:^>+"3/OIPE
MEMYU-,QJ "J.M](>F!P6Z-S:%S[TZ"WLH\"9%+;,=VKTR<%C1YU;![&Y%6AP
M(YH>,1R/C!@W^M17@#*3*7>X.EV-829^!G"63,O@"QL^(_[-0EPZ#2GZ3(5'
MUX81CDZ'1_*E.UX>9]):[*MLQ( 68DLF\/'53J-ST">]T,]\[?MGZR-?MBA&
M.D/B1WJXG\ZW7VF4Q \P'I-DA:J2IE&7.1",,A 3"UP?1<MR=G9^RH56ZZ:0
M3A@6BK[FR\]Q:+OPC'/@7@3#\$"ZS?^[Q+V*OZM"R2\#\#-FGTO;B\;*Q/5)
M7X'BE;X$U4H?JYLMQ\#](@8:K.]_G?W(SD.U]YKG?I&/_?#W-C)+N<>#JQ,#
M.^#/<' L1P9BYBZ;ZE)ZC.5@V*X75<G\86!*P7@;R]$('>Q<SH.ONE=D=.8I
M3T,X.J54S23&X@I)/3321]@??+0WXTQ05)@O/8J-\'J/.C<EA]9X'B^U@C<^
MN>#&9/9_],6X<U;4]Q(6UNOR4T]?)*$HO&?/F*'OO5)2?GR#:BJ!?^>Z\5\N
M$=MR5Y/=^KX#K5R1!4N-T])LMUFV^C$9*14CNWV..OH3??"%!!Q'__QCO^UV
MHW]Y"=!Z2=9R^"L$0/2)_[?IH[]U3'C#"2(..@(=CD(G)?/DN")678L>-.[9
M]6PO6_&)SDY+P/(9N""1>9# +"?'64MW7%2<$)4E8 PR"MJ^ W3'Y>NKIGVE
M]H6KW$6K9M IKZ+6Y9\8=.+*A438MU_/T-CT"%3ML-II>K#1G$G$X]DOUBC
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M[SOVP"@([BDJ&B<-J$MZ##6>EQ)!%P7DXJI6D8WF@Z=ESRP5(%Y3]2(*S@G
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MQ9TJ "KG (<EN<6]:\,#P"*AI,$LK[ 2TG.XTC?-^^PV;TOI;S'[95\^$A5
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MC;86Y>3]T'9#+E&II6-Y\?*7^:_PL1>__67Q*YNJ_/J#*-(PE0GSJ0KA(CI
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MO1*%< H,#JSIAJ?HAAWW+DM$ 2K@*,[A)G#QLT' EK^G*PNO@@!+&?@F_GM
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MG0F4B?\HU0M8$<>D7&6/J-NMK-]":)U#RI#K(,EBSV;U)(L]E<4JD 691^T
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MZ/;PXR*%Z$/553/4] BVNU1=I3W:9WO=C+1+;F[AZXGUYYK+MC_T#*>1QLF
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M:(^E/M$X?;4K.TUS&9O""EJZ-^ &0O7-^?MAKC#"$8XR1,_N3'Q.$7P"_"7
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MEY!T;XN+]\;L^=^:%F)2Y1@XH7$C/7T+O1F."NDG(R/HX JK\'N>8YA#N]8
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M&\77!XTJZ< \X]60+/"T++9!0ASY#A6EKJT$LU@;6Z3+Y6[*VY(!R9NVI!O
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M27*\@ 4E^*;WF J&$J:""I Z\5DX XV>"5?A*(4G/6#V74K3!H&)NPPN03-
MU[N$VZM[:F?F*N_C4Y==*/WJR/D^&RMIH&0 %RTX0PM!2HP#F0N4F$EVYN'P
ME6W=#3T-#/+I%[#ZOO@B$3L333,A,6>OL:,P[0Z70)>XCB(73&DT;.306\Q[
MF2#UD7)$'6!#/;L[Y-;!VSYD[^B?UUE9L874.&W^MA@(;:C.B&@0C$#1H>JR
MBA?<]!NAWK/XELC=FIFEI<WB6":N$X_^A"\WX'-A?>,'T$%4G$E#7N!0\[[
M$?&"V@Y<YNJ;&V*;B-L2:<JP_I/]A"0/\(5L)WMD@!U_L74NN<E*9'^X3*X\
M P6N6;I\MWR($)B=,"']2<O29U8Q1^>=.6UD*\ X$EG-><5A)Q8"<]B$-KA:
MFDCOOE-8<*)CUS\I3"0MU&Z/'K04TX=6%[O6F\=P0ASK) 'WX-S@]>SSGE\
M& @B:W%?$!Z,:#GZZJ3A,>>AMF4+YHLP5XHPBF+<28XH8P 4[&XP4F1F-56F
M9AU_AND!"U'RJ,;XBC0JV6-Z0.4ID0>9'T'_:KR\5*YZ<%EM8E0]RBAM(HV;
MY.929L/F@R+(5)W\ [X(0_W3WZ]2=E_)K238678X:S;TB>ES(6G&KBHE2$XN
MPPHWC-X=">>!H$(TP7G9YL,!P7FYL:,9&H,;(5+PQA*\7J=9)^G/T!$P-C*<
M^':>A,E'YP8,>&&F"UO%G4?4+5T"7QM.* Y+SKJ2?"/-3!&K#9]M927&MAL\
M]N[? Z(/Z528N1/.MF(8.,MI$7>^]V+63PBKB\*,Z<NYR2P,#PX0G%X&W(R@
M*8N0%+]#9-#1(M1YS<E^X+&MJ\YOG+M 50V,$CTBRA7"Q,UO+SR.T E +T8=
MS/'B8XDDG+#+Y#ONP8D'2T?JS"-)XBQKXV#.LR79]TJ!V!@OOQY"#_00NG,
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MG$X/T5S=U#Z/1?V>/JDE_,74XLF\Q1MW:JCAL^E"ZX=4Z,"#H/=Z.&)LHRE
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MJJ&C&B@&H[[Q/)#41!6V>4L3Q+*Q\M-2-M!#WV[V36(JPX7')@8J;P'EE6U
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M.^YC53U@FZMCM4SF0"WKNKF6/O+>90<\M45IFST9<H-^<CE=?JV@?Z1%,9]
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M/RC,O6V@GR(,?FCG[$,J9*XP]/> H7^]PM#_FS#T#YNTGWW*__?6ZT>M@_Y
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M7+-PO^(LW!JAW=T!Y>1UA;UB)W8G"&)+ 9OQ.\0/I:9.\N0HS2\06:W,IS&
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MN5:X=U/+H_'O7'L00':/]75ZZ1TF 4G"( TP:I86> ?G%+_' *VVT._;/?H
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M4R$WTSD4)/1V2-$)N)BZ[A<&/1X^=]O11KWC5:9]U\[ABE37U(V=(D7P.-0
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M4[(P.?$<T:(Q;P*]2&6X5Q$1#230&3'A]*NU-E'JU8EHG5KD9CT\5,6G!X>
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MJ$+T<!"^I[QI9/(&IGW#UVM\^X%GJ!/8":@#]C6NX,K?LAN_)P;C(<7R<=A
MQ/1\):;G1<3T[ .F)Z;B\.E_<L7^;=:^H#39'(<M49?6"@&=W) 0SA:0;A+R
M$UO7GX4=GVGXI79>$ BXF#,NV8:F[!/05?^NV0S"=+\%)R8[!;_MPP(6H2&[
M_UU1T]PL+3M[+H:47,19%@R-^W-/(![K&$FQ.D_M9##Y)+W8 9H:31S.!=9"
M&P7(?B>@CU$:C'7;4O)W)6 J>XQO]ZA]'#.+NRG"?RQJYV8$>:+W<&L%T[KP
M;I@?V7-\D-KG^^#@S EBV)KRT!SJ>'YM!H;BN7E?9C+JS\%Q&.DP=9ZM^K5C
M+(DYP,T>IK(R&PS;BGVM"T_W=,BDS.G;B5&R* 4'A+KFO;?#!;A:[E O E&R
MM,]1CAZJ' 5#QU?&<.*IGI62*%?/QR,:=@?8T\O#D9HB0S_)%]_8U-HC3$VN
MD/DXUR[+CMP3Z21[\V_9:OWZX_B7CVV.2+VXT5=2YFWKK'$3N"+G;K2Q=?3P
MY$IBNZZ\H(6]3;XI->OH!7,W;=TZ;)RH#=PUQPLW]-1L\6J,(_=&'DB><_PT
M7F_FN8Y&5W/Z!>^!7X:'\P@8*'5'B#<=**JY4K>#.%=7H)US5"FX^^)HSS86
M_N8:VFD.K_8W-V><))9[\OFYX.!,P]+S.FEKJBH14JC$Y%Q5H1^/.,V*\'IK
M8OFB>LT#1J(_I+Q2C-*O#9CQRS!E=H[]@VTPD+YQ/!7^Q. A;U@P)D*Z2"\G
M2@G1ACX(,)U" /I%FAB:[N:YO6W0RV"^M&T74Y $69RSHBYIX/C-']F#Y)>:
M&6/IBQZTE\BE9<PW,@SU;<!6X&.+B1)"R*8%?2""<$4L+$U-IY8P-(8,B:6R
MYP)"<2+>T8:0:2BL;\XM@D$"%$+WV(G:#M#@<!9VK'O1Z!1Y9!C"-I@M3234
M0A8NEZ.%<,PT/H,$=]Y;'@=\-+M-;M]D%+UMQ*=9DEYGH*4"=]/0J6_;I?$X
MV*$WZEMU4'UBJ4[X&H3+C06F=758/5,".2+';'@1>'\:FDZ1W!M'JN@@)NA$
M>0@4+4.V(7^&P,?[CCU2X8:0TXR%Q]QKLW'L#%G'G$7PQ9GA1A)E<^%5P],,
MXHS_K+*FJ<_+C4=N1_>[X 8A?X1W,Z)%@,6#6W(U6$A!)/^8\>FWY=2@Y5.X
MIJDSB(DNN&,^Z,N4BJZ(XX@7*I4$47L!&G3 L-187IT16SR=:?FZMU53W"*I
M%)$SAOSCT^D3*#VAS]X3W$BHWAJ:8KBJJW4)RO8@^:N<.RS!9XZ?Q)7OK1'-
M*HM.Q=B-L',2ODF@UD*\@=1&&%SUH$MM<^<H6H-[RTY"A((@M7I&6$%6(M1<
M0VU0J@'U^^[*BG19(3R_&;Q'-?'BO$46A>6]$*\W[1QV,Z (S%$AS3OA3B-@
M/($&7();-@S_3% (V_/D!7(.$*B:C0G)1'OD?KL3QAI%BQ,]*!;"[>;H,N?N
M#>\1)OG,\#PW&<5%TAW@]E*00 -:-"($A"CF"9.J^?I C[?YPM1J\'8XSQ:C
M3X;Z3-"NI8R^M-?S/JW7\'G!8HQ<%?*  0E=W[6LGT='GGD+<:=*WHU0GU'_
MEO]SLNI?>/""_2;K"27?=&-ZV5K:P]%R6MHN';N'@Z-$Q@#4&C)9L0#_8RNB
MQE)D:<F&>L><HN2M+?#0(AN88P4U-A4H)XTWP BX%ER"<Y3EJ=/QHZ0L?';!
MBR84RMACUKUAGQ\-0S;"1>.2#)P&+=9,'2.5(38K@AD=VPK1GDZQ0% ?:&9A
M57$:CFE4*,#'K %:RFRX88/]FE!Y7L\[94LRFIL#3\)DF+0XIEEF:U*B%O2J
M><T1F8W UWSLZW;>N$\D2'CCUG&3^5?3OIYA%]1#RR?$0"0(H0=Y*6GL@]-:
MBH-&BC#P6=.PY4QDX[(!;*E7TJ!FQ]'8"LI>0@CO#\RA&!XB$M=S#<:"6UJR
M:5:T@^2]7[FS-AA//J8)%@-"2TY0DMPS"1D^<EX;]LOKQ8*;U[WN7"K8B[@-
M1OS,+B>50/=YZ"E;=+S/,^>G+2Z%':*?Q$^F7<8^M1S'#Q>#P36*DARQ#9I<
M1[&%Q4:=\4!UQB1OH+BI_JEB=A;\"_:,8#SIL:^0Y)/3:_EDIX^WDQ&/ -0G
MKVV%(Y*S ULZ7JT"0/P-.,?,)KC1;I;>N39$=(HT-!,.7:/A";F_<+5U/P/A
M3] 70SKUE69E&))B^UZ7)FN857A56[?4)6D:"!X'#,D>\(510.AN-=S#!%)9
M;EJ&\S"[ Z80+*,%][;HW9G<0CMW/5*![8,16!<6<V]5,8##C,/\\_V2^HAG
MC7C6K\2SOHQXUGW LT:C/7+T2?.W/7(*(][48VVP5LDEW@FHQ@TQS"A+,:>0
MO/G>JV? '&_S:/">$/5:QJ'6L@.Q#UHO+KFV\&21L0*#5E+W424]1@-OI&@L
MB91[QY!DBJX&/@(# .RHO6W=K8ZU%3WX^;RFT078<9R;=EU(K0:>#KZVM>JO
MM"DAXP:E[#SN&IZ:T0RB+*8?4X*_,2_\589@(UN?)(WHSNPJ$+A*TX9>@EN;
MWXJJMU'>.'L\&;Y<AV<I9,Y' G>-ZYB-D-/']\KYB+"'G5B.O8,]O 6%=\IL
M\/Z0A#([3X),+'^R&(THA2_YDQ%43O,";EBT2R6.[\U@O,&IJ;#<XMC'D :H
ML(A03X(M[.):4R\B%&(GS_(?@-(/!QHLLY;8W9'>(S%51G4Q@@M@ZPR&Q%0G
MRR'(S=CB:?$3*TXK3-D7;>F584A*/O5K+ PF;ZE$3_?H2VX/USJBCA[(6I8N
M?@@>>) FIB YXL*R5MC;>;TVTZEV!SW$7(<4:>9%,^]7+?47<)$&P@13Z>64
M#<)>C[MP_2NT1<>&. 0G,-?;'/.,Y#U8"[_1V4G4N2OM"YZL"N_@EC$5E T!
M@SR36AP^&GDOO$US<J_RJ=O944U3ZB1-L+U<[FWR@^1[H[,:<.5$+PE:EK;O
M;5V!+]<* "88:B-(3:_<:7/(C 4][4LI09UB%JKRAZNP[IN32L67#RIM"<9M
MG&7B[_%N;5G""@Z^/[/%)6\G1L.G81G,'_+"B &YZ&!*R2>N9:+'.7=FP-/W
MPS=&+H5+]']P*<*&T"JAH,$2RP 7>CA]'_@2D6QZOT/JF8"+,[B(X(FZC5ZB
M]9Z9GLA_9O29;VZE\1O;USK;3*]T]#2CI[D/UOF/ -B.XE?GW5W"+DU32'!V
MFY"SE(-I:IJ7+C>64S(.%MWY,W?;]269#F5!)H(6=<17SGA['6E7'P=9$!#+
MLXA3!]4-RH4K+(M9(>?4@EK1)PDS6SI%-.!4AIN%T1:7N<_-& 4J\W\ZZQ=-
M>)5>FPUGN&BD$+\C^3LIO#C5Y[C@"X];(ZVR!15[*2;[,_323-/@F[A"?&@=
MQT\RZSOYIB*&V 93O5@ K> BMAWR3]*\/YH"-%FL9V9Y^SQ,1\]9((L\L'_=
MOJ*"7972UD:G>TUB20>GQ)\ZEEZ)<3E@^K$)20*<N=QJD.X#IXDS=YKC0D!I
M=#2BH[$/2O]63>C4. *'^PF9K'5B=#\@L4['S?K^) J%A#J]SEB@Z&3LYGG[
MX^@-J1(ES:"*6ZV$$AF+#U.C!;?0FCAH-+H*>.GPA#I$>E_QK< D*75KF@P&
M@5]"ETH\G3)?PR^T^:>=L,*N<]4Y[J,'$WPJ#A0G2 K/Z:@)'.^A9*0<%$CC
MD,+/LO<M9;I!,'=BY=H91C2XS9I'O0>S"E(+M_8(<@;?4'I&?TAG$S+KIAZ#
M\/1\##?#Q3B:CM'+,IN/J6QQ4H[,)*F?]5Z\UPP>PWM S()Q$9$A/+:,Z#A[
M6A.@\*5=F1AT/.I(QO$12^]HJGUP@D)FX^!(X$RMBAQ".JQA0UAP#UCI]F+H
M)SB#>8$N$;RHY4017PT//SIPLALXW,BL[108&CM;72WH5+B[=<7&XSTNF P6
MD#Y2/;;VYID)*2-.BR GET(2:?NQ+5[TJM3@@159QY,\+.+2: ]_L0<+-&Z;
M>V+;YERJ4WL+QMT!P5L3.DX&"A<TX(E/_[;^!S+"-*]61Q\1QMV;@V3M<G!<
M'IH;&^THKZ>;O#>%]<#UQ,0^UW(T<$69+TU^:B!$!<&O<]8GEL(<,:)G62GQ
MTX1J\@-O[>UKYLO,Z3L;#H- <PO*:'0,^Y43H\I(^^3PUF?&]9WZ3&2BF$E%
M!+$^>I?:3N/'HJ/@F7M/JFE'UC:BS*B*X<_CTC['B55E/*L_Q<SK1+&CBFU'
MC1>4"N=(S7VE-*N8B&(1]ME7O'8%Z*6@N11[C0+^?!]MZX$XR #V[95?V*E-
MW/IKO.LV#^CV_/U=T%01P!H!K%\)8'T5 :P1P+H_!U9#LQ$-DY+&G38:GFW)
M%D&8GGFAW]9>D=G&QM64$EAN6N*1D!8,>SW$DQ0:#-EO4?<5!B<-Q$_ST8\"
M,^D,:+N!N ?;PBS5%9EL?<:YHB'#R2QHN4^S2KA0A426KY0.>%_M<ZQ,QB';
M@&]>2BSDH @:Q0O[1T!4AH)L74,WV?KWADI;;W&S0=./6C3YRC"1EW$0?%W8
MDD3%%5N6F1EZ,/2!*:M I$:!ZR,]5.S[>(XV)6^4=Z4UN^3TW2M7*]8V=F(Y
M]JZV\=&4!=$)4VN=#_F79LA6!IRVRTQ&SPR2LRS<@NZC<C6%-T)3M%&UZLVO
MIER8:@P+U[)D,8/H2Q)G0\WK#_N*59+=/+FWK!@_%7AP:?"+U#." XS3BTVY
MIK'N<MA2C=']<<V&QS_YC*#70FR0L>)Y:"[O+V9FT$4C"'@O73.<&SUXE("Z
MX*JSB=E-Z-N.F#K1VT"2)I+?H6S1(YJ58SXF)BCIH_JM+ICFS&0-S6?*@T23
MS#,7Z 3W[_M#N*?NR%2D3-R%@^/ES;;? U9.)OT$;#G.?=Q:0_+K"B%+&%YT
M7$JZH&Y$P!7882&,(<HSVS$$+UBUBV!6@:WL\!PCW]-E[W[\&JX6HP68U*_*
M^)S1P63LL$@C[#F4K (%0!&"75NG,05>,U5V4;2+]V3=9HVQ0[EA IP!%#PD
M#!.Y(ZQ1$]9YMKF:EQ1ZO*J3?7.IK, Z46!AYVF>(_<P3EG#:XWECZ'7E>'T
MW=3QO$+\%1HZK]$?*S'AU0*O64;/!:XQ$Z%1RUG'?C1<7<N,.1_+ <F=':!)
M6H=(C_SXI.?1ET+.Z!BZ@AT]2/Y:G!EORIE_%FQF$J*0648<2+;\*MUP-A5N
M"]'.&_ -O9N-Z2@6)C.L5BZ&I3SO$/66WF [-\ (8C$YW?O!.?[17QBA*M*1
M4'AJ#@G1FT+ /8KOEX/[N[0S6BCDY&B7G.ZQ P+IIB5WT$X7E;X?=_!> IJX
MK+W7A-(6IE.D33FD*G53?%5>!_IN(_U]U@Z,-8^KR+G!BZ=]AB1YQH0D;&2>
M50T.AY ,YT-:'X1^JDT5RRSWX!T7)CSJK1X#)="P<;AMS761!S<-+IA\1'\6
MI8\OL#4MMIT!),4#JTP>Z8N.,2)GLN;"C;:8!%Q780IN0[\OP(UL8:-G57\5
M](.[#TFW3O9T3'=CJ^--:/7/97%!XI!!PFW0K!/4!'L[8U8]UW0$%VKL".QV
M8/T#4^Y-K\VF7]+Q'B..6IX PGG7D=3IJ$Q>:>H4FWZU"[ COG9S:5$"7HP+
MP$*<S#FY":V$C,KC#OT4?W,1(?.UD24"*KD828(U=PJ/0DQ)A)'$C&',&&Y;
M4J0&M.C3=M"(82<>, FY*+()*A",*QRU![9H(NOG8*99S.OMYOFZ_6*J&Z(3
M8)7YR"$VMS)8*ZQ:YN9O\13UZ%=[*)Z)WBJV: @4QE0RCN18$/DT<K@$%#,6
MI#6F":*$DVV&VI@.!VDS/;;WC-NAV&3)@M_/S&FOQ';D9I)[M%Z7&[%&#7(&
M=.IOAS>X8E+P('DOR5)^VF ],<.)MPOOQ76XWKMKR)CL1Q>RG%-DW,1W;2ZZ
M4#!6PAN5WMLXA!Q'^\!DZO$C#67\PH&\$EKW;7KGW.-Q=X/+&S-K&'SJ,'IA
M/ZBC)U4*8_Y%8^;U:55XA$3\;3\9FINSFES8@+H*7;^BU19"=PZQA9RN+52Q
M8^2B3N0(7CN8RC[E/WLW]ZE;O:6-JNSV4@XHGWX 5V4KDDC\3$K=>-YM)G@@
MVK;A8C#:<*IID=+_OF1J</[C]V]2H=LH1=-H"*J!IVH #+T[3C.BM*J4B'K
M/U$$90\/TYG #;Q4BI02.-)""GRBV>#W=?-P<2&"_A/8<X.L',$479LM(=V'
M@4S?6GK6<''H@A0!RSN#?X+!%(M=8"+LD[@,:/A4T]-E*%C)@WDPWLA4)VD\
ME(4S-L2"0K'7 O&A. >*TC+;;B[I$-(F(,$E_DQF =I"A*=3D:PBY7$@JAY(
M27YA\QCD['TEC3IC9OQQ;A(YPKI=21]$F&>$>7X=S//P:81YWCG,\])%^]W&
M_(\[L+>+E2E:<"T_RC!W4)+HFKUE^NE/2#]]C\+5VY>DZ4.QHUH]9H>NN*0H
M$E)J9>P!U5]I_$/98^4>6YV<T\2)9)X.006,4IBZ. &@ >+"HY)W<&&?;C[E
M8I =&40D'9ERGA YO-#&XVA ^RA$9C\OB^H&.;7N7GAC@/85N:9Z\N1RWY=?
MBZFJ7H#TX),WH,)*=[:9^!!EH#(=9PD<I&1\<2W:952TXR"MZE<&EK!-%EQ]
M\\*B;_>U_I 79_JX<JKP]. Q/7KYS>N1V<F+=EUFFV\7I?DR/K._060+D9#>
MCK[UI(7@J7M-)_-)@1T&WR)V!>5Z\AR[!T=1>?'-O3O8P9K:!2TJ7)$GM*X7
MWG>H"RY8<W\I7YP<';YX^?SXU=&S%\<OCDZ^(1O[Y>CIT9&ULMY9"!]K[]?\
M3__AP8W@]FA6N#6GZW."G[W[^7M4):NB;87:4K_2(92P394BV9)_4 ]OL_+X
M30<_X9%K3#S6]FNBTY(!\3@.4&-_-Y@MJ$8[\BF=*X4EZ]=.?F&WY/]&.8YR
M_%#D^"R3+C)+.ELB)IGHA0FD8!BNQ5$@H1*JTYKF/'O894E;_OCF[2_)!_@V
M8BW2;44A)Z!3$.LHD3MS.J)$WH5$$NSQBS=U&)/X7L+=636JM#B;YO<,-,C(
MKB@SQ1-U!0U\)_;OC6 +.>._RCX;)G_FT66<>I\PJ?Z%U8('5AM'B.<4\?J/
M3^BU2RX7!7]G#F$4_+L0?")*G>;MDB(7&4JL??5%%\[7ELG<"]-0CSH6#;'5
ML93."#<,R/4HVV(?8PRKL[H\,WF4PITY$5$*[T0*Q=(*P-U@I*C,>I_-!L=[
MMC@OM8R2LC.[%B7E+B0%!U1WYK288UU!^A,I'Z.$ZD$#H%*-9O-_]@4;+?@4
MUL? 8I.$P7?6<*MZL8#_Y(9<!+W)G^S-N#QB/5!O](GMAY,O;Z*([LQQB2)Z
M%R):+"Y!"6O )U-_ZF8C :4,G?*:F&0<J/S10W$JG H=3[:9*_R?!>/AEQ.W
MC7*Y,V<DRN7=5$^LN/D#YJ4ZJOUDT[E3YHH:@_5?D_!%P=J138Z"=1>"Y7F#
M,B75&BDDPH,OUBLBK:\DRCO8)C$1;?*[)XE,PTQ^-_J)NX<0W^24(.(2&?DD
M,W09Z80E:)SQR<0#EEP0AXUSCX*/9DED?,,DIHNH02 6P7Y;PEJ-GH)O'T"N
MPKOO*Z1EIU""$32Y_Z!)'Z)8M,D9=?F7A@M5F[KWN0R((YXI!E#0-DS=JAF
MB&3<S2-TRQIJXA MX;[EQIZE@^2-H[R0/B![THJ.U+G:F0GJ&'!<2QGK%QB7
MC#O49O69;P"(KU4''^03O^-V,7%$^#<+ER-SEW<MY66/=9R<*9#13HT0DHS%
M(+1E0V#]W+3SII@Q*1:];BNSD@2=\8;AG!\-#R*LDA]Q2/?ATR?_G4 $@2.X
MF<5J_AK1_\F/?$O^+']MJ\B+NBQI[G;$:,9@* 9#.[OF 493:-(OQ6ER4_<0
MJLEIQ'1['C&]*#&AY8#+$)HQ*[@S9R?*ZQUG!1&LC.Q387I0V]\//AT$_)TR
M/CE-3 O!-)/L>9D01(PPNHNNSW+NM577 1%$%,.=.1)1#.]"#(F?D E5>+2&
M-\O*<N6$ \>BS.S,_D69N9-",U@@$@WK1"+?:5_-%2J\(*(?*S_:M]-[KN"0
M"M[12D[A2<:@9IW*XS\)\<EX#Q(%=6<.3134.X$WBF PY>YLXR,_LE-3S9EA
MMUMB[DR)Z4*>L,DX<A0SAK,>+-M;D[19*4P\C@2,0"91-G?FG$39O"/9Q 0M
MV:RNF!=K:KL+._3(8A955J&E=*3_7O8%K616%3X%Y!H,*\*\<NWQES8A8F&+
M8K<S1R"*W0[$>X.Q X17YDD!* ',AN[WX_EQ8!I$B!'XN,/['F7M+F0M2&?"
MQW/35,R"N1G7!+A%P%4\9WU'A5J:S:0-Z;5/(ZI4E"#&H?^)?!$ES[?0JNMT
ML!DE=&=.2Y30NY!002DXA*16'=9(6P]/U7=VO/*LJ/W1R69^81DO<HC^;@[1
MP\@A>DL0D4FH7]3Y4><_!)T?YNJW]7!2$YA/ AYT<KH&S:$#%[9R,C?!NNB(
MRF0%GEQ,S._6>8@R>.>1$<]:6_?8\N5%23Q,S!LBZM/I,^>]'R_)UU-O^AC.
M\NV,#+JC(8]N@IK,-9*)93(6#'\S&/ 2975WSDV4U;NBZ++#4C$OZ$E1DQ5A
M?E"-G2U8<T.U1\/#/RFZ*%<[L\=1KNXJ$]^8>=.S4\B4Y4+ $_EW=G?GHK3<
M<:\SCU1NL.^4)65ILK);SGET,7$])NVFQ:,:Q69GMC"*S>Z@+#QA,AE%6VV"
MS%0KI=WPOJ#->L(K0'WI-!EQ!8*6"U:#!\\IE8??YI=:W/X*;!M!\!UF0T(M
M.!6PFQ#5"8M!&;FL=N<,1;F]JZ!KD15ESV ,:D75?XY[SB 26QDGGM+&^NHU
M)C%^,PX=?-H7.3%7\0!",Y7WQ+;<4X3_"P,Z2WX4R)TY'%$@[T(@A]PI*!K!
M)%-GU1P <;;Q.N\9C>C9P0A(W*U-CH)UU^4XYJUR'$G$J.^2BP(%!B]3((M1
M>'9F(Z/PW DK,8B*=#E;Y%(CK2>..(@"LKXJNAA7[<[F18&YDZ1[DU&:XJPN
M^]4DIUX4D9W9KB@B=V)3J&5QBFW2ZV,NJK;(C:.[X20??6U9EWG$EN_2GD8Y
MNJOZ+L&9*@(+YDE]CCT7RV(=S<Y.;UT4ESLN\&9S8GGB5OH"(OYU&;L)=VBS
MHH#<B3TQ35,W18M8=!IT.6>JF?.LH?Y;^'&=\R?@FK7PB%F>S(NSHDSZJC%M
MK.'LSFY&";HKCZQ8P>T['=5:95V/8Q/@5;.VDWAFW<_*8BZHHL2L3"-4,6ZN
M%U[I[?O_>??]D\-7"2Q*;E;%//5I"K,2'K<CMK0XJ62'3D&4O+N0/!U/HC-)
M4H?Y\49KQ4$EMS^HI+(%M52 E [>Y4^2<9QS^C=LC G;HE/LB;Z\4QKO0)=&
M<'.!]8HF39;9&8]#:0HF?X>E;D#7>K3UC%)9@KJ=&8.U0'@'<F7*S!(B&&^
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M%]YLDQ@<+H.H0QR@*4ZX1"!530T^=%BWMN&11W]Q"X@GX/Y<F=*<X@ DKXW
MD3[BI-&JU2Y I/,ON/.!+\/B'_31;;B/<$SUQ)V3W]=Y_N1'""8^)__ F4B?
MN@:GFGXTV E)-WX+CG</+YE\:$ ]<,1A?UX6[;AC$S32SUF;9__T'MQK%?3&
M%C3$Y"XL&[#40@NW6M.4TJS!MOW!M:M1LYP_*PJ!L30*=<6XU)SUBV&5! _F
M5(O7\<));H^YCE3-U51;V=:\%#]\D50Z=FO*,R-O_0I[P7@1NB76B5.[><B0
M*PTM:?+/GA#P>-CPO@+\U(FN%"G*&#!;R]:9M[3,PS&U!\G[4.>[S> 8L3(E
M'\'*! 8@G(T"S]]79&74&##(==H<'"0NL.?O36\Q=W5:JS;99J=_IG<EH1AM
ME'T$,8MZ&6H/H,"06,#YL#&]+[P$2C\<:94L_&VYF9RJ-?WPEGQ\#%"F$X<?
ML:!2V["=W2'M2)IJX@UA]! (4F8G\L*9Q)=B-22M8@-;C3S+Z\YV;ZUKD(@-
M7&15='IN=59P(VO9!R/09,5\ VP'E"'(6AJZ]#(:T$\O"-O2JPTP$6IVN0;=
M&$Y^R>2WEV*X0Y 5TD8C'-(PL+V=F-!WD/QG?6XN/8_$G[M 8*4W:1(4$/5#
MDQ.RQH>E+Z.^0;G"5FM4Q3*KBT>4E1F7IH70=UYTFZF68_ZR*$5-XJA:D=EP
M=7FFP_0*'AN';MAI7^0L=:WVA%,J3-Z&2,/@Y5A;X=//ZERH?JW7(YXCC?HF
M>>-Q(](6V6V\MC]/QA050[V#8)I-(X>H,IA?*K0E 73T:<V*2),_J%Q"=3NI
M31]:XB;Z8+R>0=O)9 @3>DN9C2<\Q>^WK6)K2T,C84*NS$\_O!4%P"3SJ.O)
M-EZ)'/,@^;O.F5%%8K/2OG+FYK2$N"1*FC_8MCPJEZ]L?9!*TK)V+.U5>E$E
MGB,^PJMV1U_9&QV8&>DBN>L.VN07M'C+PIP%?@=OJ;=S^(&.+W(I:25^D)TR
MU2D8-)NYKBDWC@I*.@\Y L6.=TJW7V]K. \/BA8D=BF>!=OC):Y]A7M#;59$
M4\%JUJV^.F*^%P3JG3O#[%,@?KAOYGCXUC5*$$\TY?>BO#[2GI"/4W:9ME(R
MN46&I2V(O.$^YW7SF29"D56F0\KC;'4=J.:6PVG(YINO.*7V)6!OUUR96U'1
MP/Y6%M]P/L.-)$N1;Z"@:D>W!$UVBD6[5IJPLLYST&D,!<9.XD,Z)]C*6"GA
MG)/U3!^-@PL]H/(E?$+ZFAX-=%VN_-K1A#U0$X8Q-EL6YWF10VV97^CHKOJ6
M6 I6AGUBOY'/2N&U!(V$@$D\OHA;2_H[2"FH3 MG@TH3I3EH2&%)H$Q0-9F"
MI1'5S%5'51CN5=RX-7KE@^1[QRX"FKOA,7<8BLB=TF'^$3W< L]8L<!8"MX5
M7^K<9)\KU@BP-CD5^0R#SEQ7M^5YP,>5^3P2F7K/G.4T!Y)3";96/&73WU]K
MM5E/"ZN@X6'>B!; B 8G,S:-HN;PGXLFZ^,4F(>J$QS?#1X8I9$9<K=_%4\[
M>R^2T.::.S4@.8J5OM(;7CO#+BD'$31+[R6)=KDI'?&+<N[$]R.9KH:NL 0;
M;[BQ?'+<-J,E!H-<.05BL_5>>-["+=G=KY7>S08 (N]\1:.9.4O0-1[NVU(J
M$P$@M. 0)UAR+C^R%@@2!=1!U%)LV6OGR*ER:L,MW[;<,EV,GPJ?G%.J#TZ9
M/*1Z?JR.7F,&M)=0"C+VY+?G?2-3(B^UU00X8M5[P^8ZU@'WR%@+1:!G7P1-
MYW/$3Y6ZAK4?8JVT46E]M9-*"C]KZXHH+B$.Z!L9V>USDJ*EP !"+D@4+K9
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M,&W40U-M_MFC),.7%YUM\Q,D,K4APDJQT2.Z3R%*LY),[8#$6G+.*.Z1$R@
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MAF=T4S6,V@TP_3]\11_ K<@(-:Z<3::<<>:>15++P@1NVX!D"=+Q/#EBP9M
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M<\NKXBM]"W)7OYXAU7E#3PU[\NW3U_3U)V6V@:V"&WPQ^6N^V>%36FKY 2Q
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M9\AMOC<%MHG:TS2$92GF'E(8,&.4(B<EN%QCE6A^(@;P9ZHLHB G7!:66!7
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M)1/<HCA/O7$&"X7H-\8,4!US.PBSL?!^A*[YSBK)%R=5U4_@I.2S\]];>*R
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M9C\8][ B;7E&!6,7)D#3O[+U:)WY+I8VL2)_J3:4P)<;AR]E,03+78WE+O9
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M"_KSOBF[AR_&44.(ZZD<?WP_#O-U5, ,@K6+_%7ERL^"B><GH?=.7:HXG5'
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MIW'N/N3+O_[9[G=[="_^W>L>M>B#?4J11;5Q#:KM:<$7HUP5N%0^[#<O :Y
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MV$'LT_Q  D8@[23U>F]E]\?12DE%^?A63MU%<I([_YZ"DZ,#"K"M0Q,P0&H
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MHLB>49$-N@>M[L'!%K"H*#/Q:3?FK/ZHN2-X4G\9J@!6/E>OL+@?_86^;3S
MM_@8CS5;+_V8BM[JUGQ4G!H.]OA[,\#6AI'"]A@_&T5%ZY*UW^FC: W3D@H?
M-]G\^4'\]%&Y]*&1?X^:WG73WNZG_?2H-/#R]+!U>/A4B7X_QN.-MY^:S.SB
MM!=U*NI4U*FHTT=-FC\Z:?7Z)UO!XXU7I\\'1\!_L:IITVK(/J^VVH-"WQN"
M*OE^'.9MA;(_V[S\LZ7H!7>RVS$;*?O]#&4<J/'&BY/3SL#VO'"+?=]8ZQM>
ME4<Y FZZUT4";XS3G+I5O.CUNYUC\] 6-Z/RXY@:"N9PX1![/B5M&F$P@1WA
MGADO^D>=4SL6?(U/SX5+DC%A@$[_0IP*=72C"^.(&])%^DD'G:.J(PD605]Z
MWRR+@!9@G>MS>>$N1Z9BO^#>4+I]E3=2BFNB?QG!MF7>A[/SW[TO<!F64H==
M*0IJW8)=^?PYU<-&Z++6@X7^T\:.L"$UTX3GZDY1IO,FK>%AYZ1:0EJ,:0KK
M^!_;I+%:B)@P4C*$VNFH76*'+%X;>E*G5U^+>ZXGDDFU6F&IL-6*B\PN#F1Y
M,ZHEI;Z&F<K+N#"-319OQ]5EDKKR)LH/_UT"_:B,![;P:F"NF1^%U=)5W4VQ
MZZ#"YD;52@PZ!W8@U8R<7:;'S;G)SLAV)3847V3 /-ANN!S!'R7U:<'^W_S6
M,,I44*1ZG$#I0#%97O5?]68I$-&<[V@YK+ P)3\(LE+=.*7%!<8.+@M\8S!T
M_4207C!,0Y)XS\EJ.B^J-N9I"9NBO$N0 ]C<C==EQ_J)B4YY#)TR.+R?3NG=
M0:<<'U4T?@^5,CA88HT'JI2C2J6M42E+[UN6G 6WMGT!"K+6:<KV4R1)XG06
M7*=WC*:!&5S ML&/;VNM;I<:?=%KCSI]^]9J"?"GD1]EU!*2I .<_Z)+G]IP
MF668T]#@"94(C9*UNFQ#BH;;C5GIR/KYV!W DFRC/;Z7"%U-33SVW%4R:W4+
M381&:*2D5C<.Q<+C\4O@8MCE*Y4I,T$0 U?%Q"S2L,Q!Z.8Y;Y@?7J+J, J)
M^@,O=MYTFA-;V:UE-K;ZC:HVP3LIP>4,^>!3UT>;+2YGR/VEEQ\J+G#?]E!D
M'K@ZA)1*MSJM46OA&;> C.>M97TP*T'X^?J4!#(0E(K631@50DJ3E<\=+C0F
M!UVB>S*GV;RZ !L@9PDU!Z<[1]$U-0JO)#ZV9?>B*2:6Z"[,ZXXO'>\='QEN
M,X:H!:@?YRD<-4)]V#(=QXV:^".-X .(>1Q.R_M[>HWZ!:8-1*+ ;@] +7SZ
M=-ZBT<#Z5B= D:F/*H4^V*PBD:G[2R\_G(C&@K+KF.L/@.8JV0GB+>'FXD[/
M6=V7=J:Q)^Q:GN]:OW"AS<>BS4'7/>D^X)"_GCH9_NR[&$*F>R2;CLU+[97U
M,38"90TG.5#^0Y!K53ME?/6*=_0JPV/U.^YRMKZ32A5"O#,AOB4T(65#1UU'
M;',2:0[]F*!4[HJ]+/]H5X]=")_.[.ZQ>1%@P<_FT%W[80:ORLD60Q@A*-#X
M',*KD0+@SU&IGUS!&C6X(?!GJ%SYRY!-R P-RTS;B6# ,1@TBK*\\"9^/#*(
M>("QS2%P$K$3S.RPX_TYO8+!930@:CS.H MU T>S?$KMP1%@S\LIR?0<?O01
MKZ9FXY=*3^ J2Y-QRRY,-7R<,%VM89L%J'Z*7<L1^$:(6P,@P+QE\CU)KQ)\
M> DV[D<800C3)5,>AAJD)1C(8)'&0"CT0O_2CV):1;-$\ [X(8"%R],T42A)
M8"1VX:7+^:8S. >]A265+N>;,DHV&/P@D2 -# I\WBBQ<^V$+$%J?@8+9^RS
MH$=A?@[F4$0@0<.ZOXL!_QR]WL$*0//Z/XA_D;%<44[J4LYJ2ZIR*B@PH8-"
MVQ)Y"194[?;,:&EV'Y-EHDVW. )K)S2>(Z>E/-CJHY(,(K ]HC24,^>^DNP_
ME/:;^8F.F&!DM8)B:6Q(,6]3.&R!3?DK&+A^,"G1 9HSTKOH>M-G.4O42,X6
M'KF"@P%Q0Y0@H#R!!1M/%AE@H!F R#D/)BHLT=F:,0++WD@PNV$<;*(#"PU^
MYL& >>_#*91"0RJ6H_;V2P.]5'QJ!CMK:FQ_O@;/JOB%@N-WX>++Z$=,K_@0
M-!YG:HQF/S#>BT&OBA<2?MI3?EH\?=&)A;PW-H3-H"$FYL<'(K(G4J) 'B.>
MW#+VN9OC,9_N@B#-0B+ JZB8L)O:/H-]%R#9M9+0857^O(7A:^B<)O\YK!(Z
MKK468&X<TZ%;\T;+R]*Y'[-['H>;$Z"CQY_!21BYU\0NE.P%P0/K; :7X>FR
MX_U#'Y23E)@V+A&5FJ6X5 @1&15DN!']2[#7S)(4Q>8N%^RVEDJ$*M06;9UN
M':K QU@\'*,-*W-^MV]SG^?7%Z2<I59;XJP=][WPS$9XY@N0>8E25L,Q9__E
M3V=OOGJ?=.3-F=D;IG>.OUE+YS?0M"9"I"@'9T*'Y[B,6=LQI4VGB,4#,<'4
M%&H]F%0YT\$PE=2GH*2CPR4,EO&D$9M@-(?0.WMWO@*<\2M,ZK''CX/#0>!K
M2&^:@<!E=I0%QE$5P#?S5%N?Z^9B1J!C;:MWPN:$WF7DT]VUX-R.=V9?B9[E
MB+S"81EHIHO],D%-3RM#5@(NAPZW D&$:V2%$AH9J*,1*V;OL1F=?28(ADL_
MFY.\HMOF'D@/N#KSDS%^2T8**',/A4RLO# :1P4MT#0*VX6"YW6\SXA=ZMMK
MAC<(NCGA?4NO;@_G[<7O]"J5(*CF^+O^$T'$2+N#>*F=W2,<'"Z+8C9,</#$
M)6D0(' X>NV][+WR>GWM_%__E#?>R_XK/DU<SZ+,1C"CS]JA'B"1T"]\N CH
M+$=OP_P-#?SE8-7=/"AXVZ6/E5*"V(_(BG)7Q"_8S7^IK.M]:6DPBLRL#6D-
MI ;ROR\QMZ8&'P\N" ?Z8V+#0&6%C]%PJY14;;N+*[AK;FZGP/+TJJV3JS0!
M# W^3<X(\PX7FC:37]KDPL2!T2VD_?'5%FJNU&,U5B4*9;,*I2YF9@]7+_@+
MD5Z4YZ7BPW=2TC$%=C>?^!G+GD5'V-DL YZ%$\^@Y91*H5/"H1L-6S A\Y/0
M'P<V'5P/3*O'&L0ID3+_M,KMIJFT<J"0LR%"3<2/"+6FPBF@T=CB:1":P'/]
MK_]SW>_V3M_ 5*X2E>63:(8$J["H"\ZFS'& ("G0C@/1@&L"YRN% E)'])+O
MQ/#4R]YIY_#G5[R<Z+,((_0"JH3/D1SC.E3 B8H';Z->]8I22)*[4$-%B^#D
M<_CY1,Y8>\K>B_;B)S5.SR=JNLS1ZXW$-=9<_P3VP9(=7&&?'55*YB;;B\T1
MQ^PB519,(K@GI /2E0).@O\^P*"I*3(T45R[A< _6/Z:,5,W?,  RRG4VDB2
M6313,::89(ID1F2RFRHGIXHMM @SFK%4TN!-N$HG?OG7/]L@^5HFT!JF:F="
M S=+*EKO<=GB;TD$1E>.\.\:5;=P%6S@.>R9/TY;GC[)5+^N9Z7J0+_HU5]]
M$('7K.&^8R>SP.&4K$R2RHB_&ZOX167[K[#Y45.2CQM&Y-J"9-0M'@A08P[_
MT $(/HPPB:;E%(:?H*:N.(Q?P'-S4P^\4&>J:?FAC77K**B.68NV_X(MS9.[
MQ4)>V-2'6\IH%]?.0G6[V-@58N,V@MO?1F IPM;<0P<^+5#2[QT[JI5M./I%
MHYU -5EZJ7,]7_3[_=57^T$ *BECY%3?\C!@P:S8TR(+^*4@"PU$%@PY/%Q@
MHJ#40(+ "CLH<O^A28>6G]?>.!YN=]VPQ77^ZV<P)\Z_?M9.%7;&%),H"SD'
M4@.U,#V;^WZ59M^9Q\TW+LD8+Q)>1?[/7#FC"E,ZM.,72,/&=#&9.<3,.F2%
M3_*H#Q EX/C X1P/_^0!84SA"HX(L!KX4*"QCO>EYKO!Z_CNF#E9QQH#S7.0
ML=4O.$=8[,LHH$(0.MPYS:H(3M! &.$(,KO219SO:T?GRDQ]H-'/-(_,8)E9
M';D6BSM$LV1V9+@"-7^5WMBUX1M##.S$\QRRX11%#4=NV%10@EN6GD\QFYL)
MK)0P-5D,";F]->2V+R&W>QIRNW51II]'H_9;G6EQ,5%P&#G+T-14$ES:7(IX
M?.LSA*,0V@X$S(;U7&8TH\"0@:M#-BWAJ&NL/YLJ@C>VR"63 H697)Z<*,QW
M*(R ZE"-P'*U!E!6QLH4^Z=CG;&[\,<+!2_AW#2\XOVUSF"AD.@\W[F(.#%#
MGGTQMDZHGR.#X/'MC"OF(/=^P8IDAFLN8*K1""Z!(\1?RG!<'<O>Z_0R$?W-
MI)M'%DF?.7V ^A'185\G!2,$5\ 7U<F2"B5QO.E2G.A8)2JC&DN(H<X(0*TH
M$<[W\,19K"R4\;<DPFLN"G8=4D4/>GQ5__!NXW)B7<,HQY &JN"AX]YRA!C0
MS>!_5S:/DN_ZPS(!12OXE C!RDC-THQF,.7B4X@-4BFH5KVP5%4=T" +56)%
M-1B.X; P^)KJ6+KRQZTS)J!Q2'@UYL_:*<&B3:*\2#.2 CB>+%(4D:$3.$%+
MAWJPEUH-P]^7?A:EL$:,%9G\3UJ1*XRCB-&WK",)_3Q-"!NI(EN#* O**8P.
MWJ2+6G%*:5Y5PZ+2F11&PIAQFN%V(%E46^ /T[+0R;$98]\4M^&L_=**\;9I
MQ -&%V*RN3]#$H5E)M"49Z733VGE%#Z6H)K:ZA$\Y:364FHQ_'N<XE!HX RI
M:Y#&3!+S:3D Q2:8YRZA\4J9$)6B_@[:;78M2([,OHK??TRBF*DQ=S2T*SNM
M%L>B<BH/LFC(,GB:TC>%'\7X\;<4R+I/?A8DU#(D"7L'$3J;@8E/&>YQKJXF
M6+R.I#0PZQF[H;^21$2N^(#,W.NV_]IRY0.Q8E%+4%LW ^)Q8ZRLNLC4HRH>
MJA)H,%K^UQ9UC?S?+=;;G>).&[$B^?Z[%$/ZZI:0>.<X0=YKW=XL\_CN$Q.)
MO>$ X"K,C654&JA<EZ%#<46>F;M(JI5)&E6Q#[(VN-+IVO(FQNY$"SK*[5BP
M,FA\J6SI$.O"QEO);61<62I#\TSG69"7*<]3&">K#@K195>9S3\QMX*B2&P@
M'YI@<\KM4(FN2\HN-[+ KJ*<+@%!S.5_M15%]C,;_U/_#XP0G*_UM9FGHD&/
MYP\8$P<ZN;X^,YL6!S@@=8!^5-F4L":3Z8GCHM&[;K>%J,JI*MYX$U.4)4^G
M=I=,U=:JX"K:E0L'##V+Y4JU]!-ER-0!,G(?5M[ 6U2<=?:/R!%+_EO7$O><
MHBWLW\=_ ;%WO+."7\^YV5C,21=RR;*4$N!81?L8JN$'<TWE-:/6AO<M;Q*.
MA);"#_\HN:9A3B$SB4+"]#%0XOVU/YWIZ!?ST/#NI&Z<IS""%,OB5\7-J8@R
ME?(MTM?;JM3#Z-(,5XM3%)LHG_LG/[]9TO1PS)S%_OSU*%;7R\(:]R :S<WK
MZ"I0&B"]WI!(;E.FYFLD)XS472G JX&CCCC^>><D>FU-[8)&":Y(F];UQO<N
M*L$;UMQ=RN/#?N_XY.C@M#\X/CCN'_Y,J.@U)K);7-2AA?JPMG[-?_H?#%/1
MV;4)UH/%>NHH5[0,YSBH-:+ "GQ=BF*H,$6D@I-AW?2_A:.$H_:&HWY=S5'U
MCB88%)B56$!FR,8"<Q=^92-0N9*<.8C;R+ B S-$F*ZA!"!,]QQ,QPBS>TI9
MXK\%_A&.:<KN"<<\!\=P\Y*5G$(AN*OBD*OJQ!37+QS4D-T4#GI.#JIUMN-<
MCIJMUUK*F82E "4T+(U#Q3);7F*.AU,>?H&U!#/^X?BZ3&'$A$E'HC0ZV\R*
M/,IV,VTOPMH!N&[&#VM5M%W<T0'FD$0"%5UJ>%>-X&0-YCW7K-:^031;R%_G
MU)[080!N=@2^!D'%6(6<6:2A[W%&V:[IE9^%.?4(BY6;9V6FL$R+]?FX$K[J
M:P6+0< HN]%MYLD;2BTID72+6FUWSGVA@Y#3S0L&Y2>ZSQN&)[KH<X5O.R&/
M&ALEU'0]O/W&8N;V22N3.G@L-BN&VF_;8FM92=4\-9"*""97=C-> &<X5$^0
M0RKL_E*^X7 5CF^A?MYU?::S6P]C=&!@&,U(P[ZT-%5^B7X_/IP.BY7O(#=I
MW(MOPI 2E5>;8N;"[@["A0W$3)2O'Z/36XP;I>KZJ6.-,-=Q3LZ"S'$Z#+E,
MR-S#-Z!][2+/QA?.Z44U+KF[9V5;@>0&15-N:VBI9+C85>T-!I+ATOP,EZVQ
MMYXX!N*"&IERZY%SIY&IQ'1L";T\OGV.=9TICQG=_,4<S3GX#7OD4JL8[I<2
MI\FX3?6<JY\Q!$&!W9O.%0<%)Q@;ZML06]LYG&L$<,@;W85E#-P6NSY;T>/,
M3_11P#Z76QRE2;OZQLWXC[):B]]Z$17\FYZIHZ6#=)Q@NY95W>EUF =ZUO5H
M;!EKBG_(89_<Z!$P'DTQIBAWHL"I\IKN)VGL5WLBT T@^0T<_\'CHQ'7>Q5S
M.8.E->*@\\Q'6]:\)\JKR84< 0+'71_IITV%J#@ ^=8)T3Y5RP0K,E)1H</*
M[2EM76]D,T+.VI[KHA>\\E@W1Y&Y"D1^B8'7U*#>CKGV' J_<<)Q:,IZ,-5"
MF$A)<V1QQ\OOWC$35J3:?:0:\Y';"U#SCB'Y*@3=*W-S 'X;PV3;%\$DI3@=
MNJ^-92+Q@FD:JIBY]O;KT(N8VRR#*)F5^CQ\I6.F3 44-S(>"_O0@8_IN28/
M%FM4MBRB0I7D+E-,'HR=2+(;+C:%^6O+H[,8HOQ[>Y0I516KI-@H$MLU@(#J
M!%WKD^7*QR^7U9Q5?5VX"YJ^(XS0C03?SB,5:\FXLN='0<WP:#')3;N8OX"M
M9;<V!$K8_L?6\[TAI[];9N JK =OL",'3$AC8O,VJF(,CW=SAY"6HBG"P35V
MBA("@6Q=DTS!9[6,5EEB9EIWGE K4>2\L,ZSON[NB$8$Z_><NV7,5 W,,VE7
M7#FO:OF18F9RGNH"5"9 %1[T;\K[<=Y+-:/JLF99?)@QT&2H4JZHTWWGJ]]!
ML#L<99I Y,0U%.,\56!#A_5T'4IE?W]>%42^*/S1R$W8?5O&B)YC*D_'ZW6/
M6]XJ4FOPRMWC0([%F/6!7-=YVK;)KIO:2][AX,W%V5O<1?X8OGG5(N%DXM'K
MPA+HQAYW=,]F.A*)\;ZOTN8K6J ?T +]:"S0KZ# C-SY_08C-<H])^UAB$=,
M4R+=E._M7( 2QY3>,INSM8F5/"XI!X%[PBW6!>03NB91.GPR5H _ZT9OKBT,
MZKM6;'[)*K:/$0K?4PI_IT\[N:'I]ZO/04C/_U%9:CLNN5E'Y"FD[H/F)HI0
M7=,^@?"X5/<:,+8C%NA$3&;A*:;]5(H^0D6)[US4=K<(=G=\"D]NQ+S30M8F
M*'] J.+O!JHX9\HCWT/32$9<#<]66]OMGX(GS(]?/J/$^AP4*<;?G% WRUZK
M%CL1WH*"@3S,.1:BKO@I4#]%78UQ_\81H=,071^!U>X4%:(M4%+/+<8+"6W2
MI8C]Q!_K\M]N"!&^;(J@-48=44FPJAD\5:%M8][LW.,2'*;"UY)\7CUF<VRB
M:B!Y;BH:.WW&4BJC3WX%[BAH/M:JFD2%J5J &"0EW\;JTCA'V).!53U(P7"A
ML;"*97%=*LY4JREYIN7H2@>,*0B[9C5H/%4HSXHR._2D,N)OTK*(W2)J9U.%
MP$8"!B.035'RR\]5IA-OOQ"N8@Z<>+BPB^H<0G$9_FZG\R=XF6IMV<GL'L*M
MFBDL%;#F)9FN[3^#V=$^9Y#,>\\.0:<,W4?LV(2(ZZW.Y :OTKHUX4(W-;9<
MHE%3"8I=!BJB0#NLF,."P[H " :AAA^?O_Q*__6]R7R81:']#<3]I"H61&@V
M*(+O2B/K((Y4OI083V$U\)9<>SAVRR03;7JOKNBNXX,B1>.YQG,U>?C&K62K
M6#HZK,+CAGB =J(5V:O-I110R$ZXAE.9:)^5K4CI%,DWHF35\TW%&>J4Y.L:
M4I0=3P>:D(G?J5@3S]>7CK+1C*T[.,FL7EWKM#;N?U #L6Z,3>:$":MTAR+,
MMJ?,]L&Z(K7=2MX?Q^*\ R76G$#XUDK>W]J'\#<_#_U_>W^*TR'8>Q?4/<S[
ME6[>+9J4,%U9#(E9_O&8Y0.)66Y^S/*C+%IC8Y;7EY\C(,$MWYRE28K&IM3E
M;RY-/+K%E;F!-PP"Z0A:/!1;I"W2B$1%/EC=(^1(5'U$B:8SS"JT%;VJ*]([
M%A]NL2<1WVR<W+KJJ''A>!<4I$;A,V[)\15ER8U?_,ZEC_'"+UAY[^/'EO<1
MOO1.>#(W%BJ5-DC;87!MG<3^"QS'*3F=\+*WIA7;!7Y5SH D@T*DX<;!GCNL
M.@H%D"Q]VVCX+Y_?7N /+037IQ%%(%L!!K(EHS:+L!A76*Z%45\KG=!3PQ4-
MT4N@^RKZB)@4G$I;9'Z21XQ[ZKC@E#.AY[JL!<P21H(1__D:&5VUC[QU8"T[
MLN4V*F:BZ&<H*?W$6_,4[%,'=\>ZIZ\?:N36Z4FY4I>8MIYI37]<$6I4U?KD
M)J-4EX 0]2ILDR9*\%*4P8*DV%9R;ON HU\>V[NBV\BC+H=4Q=0(^?5+3IDV
M+<[1,;B::<=*<[O+)AB8P7J$0E-9GZ% =Y&H[UYU9V0[#G!4C"X+Q Z7:O(B
M#S:=WV!;KOJ6;W)X9:PRW<:!>F,O<LY4^0E#Q#K(22-0-=A*AY!,, )E.*?D
M*W\TBN*(J )VO&KT_>*X6S7D-EBK:>&MN[E2K_KJCEYWJ87W@E,1^$+74R![
M*,>096S&I.O-8E07=_)5U\H P^2H- SLM*#0Q.GVN\"%J]RSJ;=NV8AI+W2<
M.+= )C9;O\R<VP&CGZ0H)D@,$.[.K3HIJ.PJK?E/G>EQ>KZN7K_.#,3U76_R
MT1:0D %^+(-::Y!:?\TJ^!O6,"C)6^S"XEJLY!'LE)]Q0MXJ<4K=0!C'IW5=
MOSBL$=;0 0K=&M&P$"/ARL4.:J6BTR'+:?A_@2V6^8B0V?6@H,"$*ETD19;&
MG/E6+6DU.'UZT $#*(BH3 1U@!U'>4$]K+4T<R3G*,JF8EX+A/>8$-ZA0'C-
MA_ V9)!X4?C?/V%=M6_'_K=_EV""12C4+M4W$,/X1:P_;_O1D<"+X[..][]Z
MDD\5.O*HL[*Q5_];[93WSFG*=49=GMAAYV%\NQC$F]V!OU&=K(OWYZL;:K;<
M"&KJQJZC]]B>&*J[6-'&B+;=*[C]5F66Z&*H.D>UPB[M-<,Y'^>0TVVG(7Z/
M6!--!>LJV7SRS9J0WRJK?"=$\DG'^V#FMA,BF1LL5JT2+[#.(WU&C/Z=7_@B
M@C>/459'K'7R3WLO$$1( W)X#.&@E1 H@: 6PHP?VCV+?(ETW!;I>/J-@\;S
M;U%"9FL8Y?XX4SLD)4\[WCG/D1&+$(V\G1"7U49Y_T"<Q@F51[9<B)*WJL(Q
M<D6<;G9'?DN3NZVIB+WG%7O^-XTRYB3UJ!-=B*>^W1!Y<%8_3W="QO$FD0#[
M8C=)6*RI++;EU/;^TDVPJO0D<-/#"5'TYX,*6QIHQW&&!>XN5#+;.DI?UF,,
MOA*JU!OX[=[A2_6*[NH=AOI3U1;>295[?\WVL G,Z)T.#MB#."5?O@W2<"_$
M4BG&21DJS(BI0TM.+WI,B\DH'9+3.U<=N!C;TM/F UAI\_OY:%7UO!]%W"$T
M+X?3J' F59N)KC69T0QTVU7\T]9H"S7XA@_7Q1OU"VL5,W0!KC45@BH4#V<E
MS+'Q A2W,8(IZL])T(A>Q]$T*K1S>-U-C259[.HZ+;F$*36-M6T4M$<9,[B=
M[.YZ_X?S2:1&\$SC*?\\&D6!XMJF_%MU(M*_,:=C'N<LBRBK#L-[,(O(%H_!
MS#+@@7S!(6]7(I2SU2.1_^>%W;89YIB8'@71S.KMVW:_^GT%!2@V 71Z&!<7
M@@<DNFDVWGN[1M(E"]ZI0%&7DD&/RB3T=9F$Q)87UB%X <8Z.+Z&6K!(QWM;
M9:%A7)DU4EH/)70<MV[_05QYQUE1-K5=DO63U&%**X4(]=\0 UX,^$=9T%]7
M)#)7(5<?38B1-N<YQ*CBCJ_&>RBR^S%E-YNC^0S=N52GBA/$05!$^<3 E>8<
M0)]-.=35,6(HO5;$B76J_;Y#2-G:@\.H=G" 3R 0P2H9DXY88[Q0R*&VLRO[
M:CBGXT-U3U[.L*YUSGJK9;K_)*C,8B?(C\6P^;X:?\K2/#?]LC@L>6TAG59-
M?U8MIV 0.?8VC&^U .OE9S,51_[0UI]=M:XFF8=+<%@-O3)0DLC@6N_8K,QF
M::XQ^X6R,G]+*-J2G(6Y]Z>SLR]<!.0>$82L_7(=&C[3.3Z+^@YUX^L%42!M
M&Z5MXSZT;9SIL&Q=^HO$L4I,5S5&$YA#\.#EBHM0P8UQBXYO&14H8F&#I1:H
M@<2(*B'H<M5)[@=5?7E<QC2/;+DMBDS/<U5((^+&T(;PX[/PXZW(3)V9,F4A
M/S1'$H6V"(;1H(ZGO+([*>4[J=^6UO/Z)$EM/&=%5?0>>W;PL3C#0CU4:PML
M.DZP6/$&OP2]G$7_\6MRP#$@:XV*I,ERDRA5I$/CI$-EM<\H4X<9WL$S"]W6
M'!BM3 SS4=HAMYPBJ*FD;K"NAJXK:.9_IR*77W4YU36Z=>+^*D$CK9P?AS#>
MZA!JV*J(Q+DN"U<Y!JAQ\ET/3I@H1W6LF9"(((A\O&F4.[N)/M(_5&#E-^:2
MJ9ISM8ZL@E+B:M55<?9,F:JHQ@;% O*&RC1 B>,9@IJ;(C9@88)A->F@"OVJ
M>D=I+YZ&*4.%<52ZN.L,CK2U^J7V;)AF[M$07TREQ*(4;5P!C!X5,.(JNC=A
M\G<GX36H-;6XGOK?&=Q [Y.MW.OB)ESUD!IF9Q%)-VKX@ZVD)PS?*ZJD'14%
MT]0%PEPI9<Q^SL9^XEHU>#&V-0BO@)KHKCQG6#_SSC]??*:3%;)MO]L;+*.7
M;?IJG!$2]2'SI^HJS;X[[@(CG,TT%JPHK,)<=P2TUF/Z]UMD=%-8/X%31 _1
M%K-PX@207,S'S,4\DES,1TK3:+K;:EO95WQX.'HG6G])Y7T6A]U3Y05E7 0D
M2;4-;0I9W-T(N"D<;\FKMMJ3]DJC2@@E4WA-57M$%^$ BS^# 7E<:F=EQ(7/
MIHY3'-K7OC*RM,@;J8_-<S@8?5=<#6CI^GL:06+?B(!\G!A_<XC_9 _QIAC4
M^\6ST:($%4'YN%%I&XA!#%.5UWI^W3U"B^39*B&5M[BZF,%M0*IY*LM2'@I^
M&F5^&7:\,RO6\GE>J&D+%< 4*_9DWB2]\JY43 \-5'2IPS+3F:(C:(NJM!DD
MDK#]"HYLT8S\89[&)096+OHNL+N0:8%CS\;UH1 D-%5%Q_M09ABXT-+P#897
M<"_>A1NF)=5L8G\C5WLWZUF0@F,O20XKQKW%\R)#/V?>LH$+0^"D$1[!"1XR
MJ!,^=U@K2)"IF"M(,%8588A=CD"8 \!QB8%E (Y<('&\,/J<EKX.FMD1N"MM
M%G5Q3=U'4LDDII8HP4)P :\R[3H5@^)26!SW3:2K*T!5S148Z%.AZ#71:X^R
MH&=.73 3M,=<\[6JZU5O"X6"]L-=ZWJ)6KN'_;]4I=BJ)1T\M:Z2V^C^5=D<
M#]7=3Q<AMT_WG8J"512AB:6NBHQ2>-G-Q4JQ=J#))6HN6^^YC'.2>(??*'[Q
MFY.2LNTBD--WWW:\SSN1O4OAI1^K[1$QO>'31X+UR8*)USLBN&-0Y2=:[\L[
M;@^FN L=03':GPJB%^Q8RFS4_J$,NS+R)^^WM./U6L;W>L;YCV1!?B69#Q\^
MP8$%VW"=F4(4]O5G_^5/9V^^KKJ"*^:;_J&] \9IP,0LKM#*_#*"94*B"3KX
M,/Y8V>/GMFHK%SF>4O-C3E[,.2+)%)3%/D_V*+%V0-3D<OW/*]^@(YHOH[3,
ML1XTG>]@4K&^VQ;FT).UJ!1W2^VVEI)H]"[VN9OJXF(L3;Y*2,7]P9=TP##*
M<JS/A]\L[>*5'A1=3X<!K@F=E#0N+!&]N@4UYK7!$43Q<U\<=IS*P04&N2M=
M>ECWPZIU4<?3*H>=W-(J:V@*HX?^''96)?>[_89.6Y1'2'$*_A!,">]%OW-P
MY(R:*B#/Z;VV;6J==\C(X.:HG "9FV-2[Z2+-V+DNNDT9LCZR+I-Z_Q0?W3'
M^SAJW?"T]7?RT===^)$^^2_UV4633:=EWK 0],#DX72R9O05G8<T:KT<V)&4
M#JH\EV<@LIG;UWAA.#1CVFOFORJ5*+U*5)9/HAG;J=B!$7:NS'%T<-IFT";
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M#I;Q]_3:C^.%7S]].E_H4C+H"I2QYQ:M0!G[N_<"9>PY 9!1*WN_EWLO4(9
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M4VN0A8. OR8+?_?R-TC9( L'2/OJQ'=DX>^T\6-(P$'C ;P +\ +\ *\ .\
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MZ6,T@ @ N *N@"O@NC5<^\'#/<*_AQ6V5WKFGV=_U5-[E%$ZRBBF#&+ [L0
M**,,U+%_.WV>'MY+/[[:"$C/.P&SRT:$L;&6L?'GYL_9.SW5V>%\/*Z^Z@FH
M V"&)",%X#HP7(=>55MK@3595'ODK;VKJE\BZE'VU[U7/2ZJ]VB@0%@'7 '7
M@>,*=)TXJKVCZ[A[9[MFI%UJMG]4^3)[_=W;>;O@ZJ L*^NGMQ'XG<M7[]$_
MNA8HMMY1M[5NVLWUV:]W:![\X_7'[.!-]O+3IX./[U__GHI]!U)6^^_W!__(
M7KY[EWUX_?'PX/UA]MOOV:?_>GWX.OOP,?SW_:?#T6+UI]?V*#OQTZ:>9-^.
MZF;13]SVPF?ZY,3K:>PI'M??XD*S9E;-YG%-8+MT]>2DKF+S\S5907O!!WWL
MQSK;KR<3KV/#<?A;^W6+MNCCMN^Y7<.Y^/[%>E?UHLEFT[EO+Q_K;^5\G.F
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M2\?C2FH]J\K3>-/QD]HUGM/C]M=V%79<G7VW)>MI.]#.[;A8:UU-L\MC_,>
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M/S='WL^:8<N3_0L/GOVV>/#LL'WP3#=1MKSRUA\;/\T8:5L^::8G+OY 0*.
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M#Q;="Y,OF?]^XB>-;YZGL2%$8L"F% KOKW)V[N2FE& ":  :B&00R<!= !J
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M7LVGU>3+AW#CM5OTFH:G:E]J'MMI&F1:E&K="4"(2'V.2&D9'&AX^Q@,P=Q
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M6OCV1OG"<M>DS=WW3MJ^Q3G8\F6'O2DM@P.%;!^#1XKO=4:J/Z;A,\! P$#
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MDGQU6%[O/)[%L:O)OQ_8]( GP+4O<?!FJJMP$A-^]/#&P8+6E45%* ,5 B+
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MO*RE]/ZQ9O5*@M4)%^#W?V(UOX0OSXPW)/*-T);+E;V-;_#D*.'HL\E$VE<
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M:TCUX)&:D4[/CNU9-QRF"4P!#/VX,(W*= =?L-],3,O.IXYRM8/IW@Q&A?V
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M4F:["DX.17*3/X+TDS&E$QSA]O@.V0^Z!)2[Q.QO2]C'TKBN_JQU,;8$7?]
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M8O,Y$ NMT$! !E"N15HKW;W* O>O!4+= :&PURDYRY#SX)6Y4@8Y*34R,H6
ML2=BVS7;Y"TX*H$X-1%^<(6<81AA[1C\I4GR?N7!)E=?FO.?UZQ9.;*K=RF!
MI?U0_P&(.^O_ZW'X.1N)>I+[SO_R91+'36SV)A/DC62"N#.9P,YX;_T57&#4
M,G-<_:<=SRT$(]DT9G)4OWP!HUS]UW 4FQD$*-5[>W791C=@=N$EP:1FM7DW
MR5:H>OUQ&MN6_]7GX>P"#/;'^LU%O&S-_ V?E_8KVV>;(R9PF78T GL><\@T
M'(-ZSIMLV6TUF=9N>?"20&V,Y.O+6-D)?&O]16O>I[&]6^MP8_X08C,(PO)5
M H1>9]6;"SO^&-L ;7;_!RS6X"O6@'.J.2!UY-MR5L)SXA KI)@-06NLH]XJ
M;*4>)ZQ<0L8ZL"#4<60H<0"$X6@;K4HVW<:S:Q"[,6OB?T#N_AK7#I[[4TX,
MO1U/YK/F#S#Q8P_LL_DQ_U@AK9\RT%H;D_?PJG5X._8Y((^ &-I_#V(\Y!GM
MO?%H,=S:EX(2QX7Y;4T!:%@-"C6M?EA^^N-*8Y>Z!Q=L>VW9K,Q-SHPL)H>
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M@!!(QY#BV"%.N$?:.8U8U)PEXJ+EZK9/]=(JK/(Y.,(Y+%KD=.Y8(YGE6*?
M/;OM4^^S'+77M\H;OE7<Z5OQV7[/>NJB#!<8K;2\B/5=8AVB,598@S3@0L0Q
M3L@F&Q%S%GOC?,!A*_.4X#.NE$?8,I*'DE 0:P[G4"LQ5Y0::Y]1K/<OI9ZZ
M6/?D/9;:.:BFL9E$8-&G.+HZ^RH  L2X%SR_.(R8B0%$.90]6YN')<F7UL$+
M@A4VH.0"?!?GQ"&M!$6!YFG-U ;IMZS#MSB]U]Z#!,^:]_8J1P/PYW0>PV]#
MZX:CX6P8&[ 4[P"533<^^GG8^%'=S*?QS7PZ!3)]@&?X:53[?WQ713 <DRPE
M<)D[0JZ>X.:C9ACT6;5D1_7+ B(WK5MMV5$M25]M\&67D>K>:U6;YN;XBB24
MT0I<*F+&QSPO(B!GHT04@"1+UAIEMN9P/D21)E=?FO,_YY<@D5?OTI)A*WZM
ME&?)K U>?<C:]D"]N4?$R4]%<X[LZ%:*$S<5IVX5QR\59W3-C,S^9MCD'6MU
M:F/05(]&]>?A^&/UPW ,G]3S!J[0_'A^,!U[*L22M:Q#5O@KOML<VW4ODI59
M^7853-GYK%XE%_,S@@"<XU?MX6ADK^KY#&[Q)897B]L1W!)Q>0*(P<A.FGC>
MQ(F=VEE<T:=-F"^N_=VNPK)/PV;8BN+5^>H:>\K+%K>5Z@Q+\7TF[;XD[/+Y
MSB2E]SH.W^<H>B:Y,!O_'>[2AWU0=H8Y.\"#=GC'<C<7:SN(-KJV!:!C''ON
M?/MM7@#E\[=MYJ'K6S-6]'PN?EXO!9]TG+.9X^^.GCZX^+[S@M$A5>^^8^T\
M-[NGQ\75GJBKI<75OA!7FU?0NZ.?Q<7V:G-S,;?%W!9S>\O<DN[H9S&WIQ71
M'*K:O#0W/ 3[_XA-M%-_T:XDA?@ICNJVX'J]Q-2=?04=8W:'M/2%]WWM=D.&
M#NW,*?MM.FB!=Y=12AL9DS:7:? \FY($9#A-2*@8<%+$4?JH#;QM?<>RG&#E
M UZ/P\_7'F!5[+$L\CC,]ALUX(1W=O]-Q^Q:;YQ)<>S=X<4I*4!Q[,6Q]\VQ
M8RNH]<(@1K#*0Z<U.'8#;Q6C3EA3JGAZS%;:YW'L=, T*7Z]RWZ]PXO3)95S
M"/;_<CD9U5<Q@O&XS!I^O2_5Q7&$8Q^3RRF+*MV!? ?MQMDQ3O2&Z 6QG9X%
MW8W8..6)"!&1"$PC[JP X,7@AZ?:2I.4W]ZH_2V]U%;V^X_8MA'>V%5S2*3&
M!Y3ISO8&+M:HN./BCKO#B=X0O;CCOKACARD1GDDDC37@CC%')CJ!A.3)6VF#
M4N$0O<B>QAW3@9$''?!9K-$))$Y*#4R7[,QO\:,=M8F2R;1.L6E !>&#%$OU
M2T\@6LDFGP#1"T0[/=.Y9XW+B*"M2"BI(!'WEB.-K4"*1"ZDX#'YK>8DWSBT
M,B]SO=^PVK_& U>L#)0I!2O%%'69[,47=X43O2%Z\<5]\<5):D<"48@3R1&G
M.B$70D2:A$2L,53)+5_\C0,0C^V+C:;%$W?9$)42DYYG2MJN?]W)VG>,H:>%
MP\J [@[CM>??*UUP75>,[IX<BP8<9F)$4IN\0<AXI&5D2+EH?:*,IMS,]?$Y
MEM;D;_=//FR.!9N#%@^7<=4OT,9UC.P%#!0PT$U%*6"@=V @:"HY!\?.6#"(
M8Z^1-9XCPXE+DEJ,%3U$DN<)P "5^\>M=-RP%2CP//4SFY1=7NUPB:+-/NID
M@\K]RQT=M6?4AWJ6:VP>-+^@.^L='=/CT\*697CT ?:RE^'197ATYXW\;G :
M(]'1<(PBL1C *<N+C\XB9A5SP<A$0CQ@-="Q<"D?"%9&1_<-G!8L4;!$P1(%
M2Q0L<1)8 @=C/ \!F1AQ'F$8D>,F(84E9SXJ;*(Y8#73D;"$' C3W5*F B4>
MG^>"W_-TO;_O'CS<AW'$1Q]I>$*T.+*4?3LQ"'TL-9ZN9?V1%TY^13T9=D[$
M+=&X6&?4)_9C7!A^9!.P[=R./MNKYM5WU=^ZIE%=I.SVI*<G&HINK=%><V2E
M5XCC()!1E"%CHM9!.JP$/\10]-]BT\3X;A*G=C8<?_PMVB8V'^)AAYS+C@0\
MSXM>S5FUIG.U('2WQI@OSL]/<3Z< >'](T8NWV. ]\E(Q9%-S-MQ]6><S!:#
M(?,<E4$[E_M-?0GO=56USC:&:CB>U16\:+V6H5&6H<I^G,:8>W@.JL_#V45E
MEY_#69>Y[1]\Y=OOJV!G,4_]?CV9#D<5W";/R%K<K/UJ\ZZSNOY':UZF]6@U
M*7PRS?>>70UR'-,^2DI#']L%NY&%$,'.ZNE5U5(2'K?ZJ6YF]7A0_9=M&NLO
MYDV<S9JSZ@-<:O&($WN5'ZRI7/R8+S>NU@,RZ?+QVHM_'HY&[<,,Q_/\F,#?
MCQ?5+N4YDC7FTG.FF8'XD'K$$]'(V*"1IP'"3>)ET/JV-18L48*Q1C80.,=P
MB+^\90B;P(-Q#LLDMZTQD.67+Y/AM&W4^#-PA=R,&C.C+N$^%\%>744+X>?I
M*\#F5%1@.KN>VW8[).H%6%N*-*AJXR]BF(] N=ME[N'83UNW4$50ERJS-ZO>
M,>3\!,FV._DC%/8J>(V(<X"3!*:@;Y0"\/&"8QF$-EL+20_1S+9U\A_P!&^7
MS'D?ISG^ 51](^TSF4_C.N^#Z&;BA]Z9]]G?Z.?$Q?S[LPH\FPUAV+(+G%?V
M(=/646UZ&@=BWK2?>/ 7399X#U[&@@,9CIOYU(+[&JQ]3S6S7Y8U(I=P"-QK
M\3V\+:C,-,*;-EF7-N[P;__RA6)B7C7M1>II?ISL[IH+,)\KWP:TG]O1=1$*
MZ&).[H7*7;7?C^".0./0NB\X;9B?8?UV<.83>B.E Z$N1.0]XWD/9T(&4XYP
MC#8Q[#'7V]VNE&:8"H82#W .,PI90B.*@L88A,#Q?K$!J$+\;$<? %S<$&O4
M1'\>YM.<5FSZX)32\%-$V03WW!D]H=QJDBQG@2$G\K9CHD!NI8@Y\YZ$XM8)
MOI6H/U1,^VZ2]?1#_<L7>/%P^N)93U96-;9OM#!2+:IV\:J&#[90U=E7)+G$
M<H]GR^O9!B.V@J^%X[L=P/WQ[J\*(J2X\'W_6N#>'7"/>.HU)Q1AZAGBSG#D
M' L(<!ZUCDMBTE;G@A0-X4EX1(,(B ?GD7'6(&L=2P0;0K*[O%74?M/IY1=^
ME_YJXNO,I[WK??+&>I^X>X.;..LM]*O@ J/5H(&%D&^4\!8I_ZJ4 S+S#, :
M-UG*52#(>B]0\B#\$)P83?'AI7RUL'WU>SWV7UG9+I)^2](_YZ!@&GW]<0QW
M@; !"!IR1FN1.%L$)9_L:-Y&'-.8@Y?L M+P2PRWTV'U)W#;^<0<COC9^H V
MI3=O\GEVO$@7Y!,@^G#U=%I_SE],ETF^HF!WM>_'DAH<%.*Z53#X81PSB,3H
MK(A,L>W5E0=/4GQ[S9^?5NSY [ASW[S!5QK?G.UO07?B2O7]6?6ZV1W!W\9.
MH8;+C^M9#NT_#4-L]>)R,AKZX:Q5A4'^)#8S(-JL3:+OU9D;&CL<+TC?.K%/
M=CC*E1N57: [N%BK8GM07O79-J"E[=V G5EI%[J^TQ3<5/VSZB_ W-,-$+E.
M[]](0ZS>-RQ2\56;!YGE5X?/%X?;T:C^G),CQ=]^S1QHJ9)RSB+CM4$\>H6<
M ?T6$0?JL.!>D,?XV]8<?&A9]/::0Z]7##J(EY7]M0=K)PO1K@.-F(!^@^0O
M,XKKK.'BCW$SF\X7S%U^UNK113T*F^K1#/+7BZQA48Z[E,,:3Q1+$GG&" @Z
MT<@Z*E'0-#H:M!3./MI7OI_6/L;0_#JM+X^L*.P,]UY1L@<",!J'GZXSV*M\
M>YA/5\ZH76&*X^Q&;F6+*%VLT][I5X;-)N*%6UKX.RR5;[B]4KV1Z-@3&([O
MRIZ<':Q:XJERJCFC]@2E0D82[+E&B8%:\ES5;$(D2!.<$N.1I+R<=8BT*K#E
M#5C;#QD,/;!&J.00[[\M^F(QKK$>+X+!%49<KDTM0DW0ME1G36RJ'X99;>IY
M TK5_'A^DEKR;75EO(\USHOJ_C;>V-%NP,YG]:H:/S\C6-=S_*H]'(WL53V?
MG;<IA5>+VQ'<$G%Y HC!R$Z:>-[$B<U!SXH^[?:2Q;6_V]66X=.P&2YR0^>K
M:^QISK"XK00T:NCWF;3[=BTLG^],8GVOX_!]CF)G1)##7>[@#\?O1Y/MRW6X
MBVHWMS!VK_QSNY*X-$?KSGZ*;5X Y?.W;7#1]5Y<*WH^%S^?;D?(457T?W,\
M],M6/-0=E7UPLZG.RTB'M+[[/K;SW.R>2A>O>Z)>EQ:O^T*\;LXV=D<_BXOM
M56/;8FZ+N2WF]I:Y)=W1SV)N3RNB*5.JNZ/)ORW729M9=_IK=8RG'5+&!_K;
M%S>=L6NL*NPI["E6K5BUHC:%/2<*ULN@U"X5/+V[50[Y2.!>$F7=L9L'G2C4
M,4X\LK'TD97J,:VEC[<ZVU%O5_8T+$NF*9$A$"^14<DA3J- EBB.HK.6.V](
M4EN#4K^E9/KF!MM<.WV@X:A&Z<Y.1.N8_>J-TR@.O#N\."4%* Z\./"^.?!$
M1=#*492(!6<L:4!&,HPDUL9Z*93B:FO'+@Z>*^41MGDC(XVY2R"/B%$K,5>4
M&FN?R(%+L7\/8K%>'7#?9>6TY\F8/R_JZ0RU#54.DHTI"P[= 7,'G7S3,4[T
MAN@%BYV>T=R-Q9P26& E$75!(&YR8^5VM!:W27DGM#,'&571FNS<>/;0R12I
M26<';Q7S4_QO\;_=X41OB%[\;U_\KP^6,N<D$CII!(Y3(Y.[A5)I+.9,<*JV
MAI-\2R[D2/Y7%-_;9=-3RE)ZG@GY;SL=MMUF2E5*SW#80=/"]]VPU3&.]88Y
MA]]/5W!=5TSP'EQ' I5"881Y9(AS2O.$<X941FZ!1&GC%J[[EKS*R@$<.*U"
M#YI4>4I;5F:9=\2H=8SLQ?L7[]]-12G>OW?>WY#H%0\8N1 3XL%2I!,G2"@#
MCM]8DNSVI*-OR.H<Q_NK@V9UBO-_=IM6"F*>.PUTU%8"'^H\$:54PO0, QXT
M'7[3<-(SFBUGJ.<Y=]AI%/C( NBC*MYCRI\/K&GWYV^!D9TSX'OFG,GH8\ $
MV9"'G5%BD%&>HT0U%DH(EL)!2G,."Q[90.F#UD<_K1DL"+(C!JUC9"_0H4"'
M AT*=#@-Z&"5493[A%@($7$B$M*&>D1D3"0D'8*.A\@_'3COQ IPZ!MP*!5(
MO4X]O9M=Q.GFP-WN+*MTC+5= Y#/UCRZ^R"B:ZPJ["GL*5:M6+6B-H4])XK9
MRW)QEXI6;C>S; 42U0G-F[@8\EW5;F:'XQCR*/#XQ5_8\<>88_=J#+=:SP;_
M=S>M_K:4ILV?6]/!NY/MZICT=$CM7_@.K?YVVBJ[2SN0!7Z>5IDR8JVM13I(
MBW@R AD5)8J84"-$I))L==KZEB7D/_(KODM_-?%U]A[OEL[C[?B7I>OXM9[>
M[,;UV](W7!UFOP(?<*,ZFSSNF*7KC7LIKKX[O#@E!2BNOC>N_@1=];_]RQ>*
M"2_*V27O5-8I>Y[S>&.;BVIBAZ'-8MA+>/A94PW'?C0/BS3'[")6EX!-Y]-X
M">=4=:JV\AB#]1G[4A]PH75ZI/+YIFE4?WY, J2L('0'%95FO2= ] )J3A+4
M%-TZ?=WJ&-F+<^D*)_H;<K\X[U2RZ\OLNL(Q>9<P8E@DQ!U-R)KDD>26A$"$
M2,$>?H[%>WN5PY/F,+,L).OL7O^.6;#>Y"5*+4:73,O_M'>) 5D@K_T8JVF\
MM,/Q=7%&.^;BA^&XNHIVVOS8G>1PQWA_6EBO9'!/@.@O'JJMD<_O\TOXP*]V
MIN,(Z$9HY),%$..51<Y&C+!T3E'E>=P>&N%4P%*2@*+& G&M%=* DY!TEE J
MJ3;&W U\5I;R]<)0_K&RD^V7N;4UN0%U4!/]>9A/L]D\?3>1KX;7HG^#*:7,
MX66;H8Z1O?CAKG"B-T0O?GBW'X[<:N*#0H)%BL K<V2UD4@+8D6@Q&N;;OMA
MS@BA[80G82+B4F-D";AR1[1QV%%%F"A^>*_LXS,JBAONOA4J]1PO+6\2AHW/
M11T5F*K8G7Q^QSA]6NBLY)-/@.@O'IV=H/7<U[::1NI-0C;8W+8Z.<"3.65#
MDQ:1,Y;"UM"*@^=U?E[:\3_ C+^/TRPS-Y:Z)O-I7*]U(;JYV,7O7.LR9[P,
M;N_%<OWWW;%N'>-;<>]=X41OB%[<>V_<NS)2!V;!GPL&[CU2I$F"'PPG$XBW
M5+FCIXN.YMZ7*R3%O_?8OV]F=>#W//ID#UWYF6#L^Q?G@#M%BQ,TG#OFJ3;5
M9 H69@I7KJ9Q!&:KFM7PS>4E&%8+IF!YE!V'JF[;(6[L_\G?K/ASXJ095/ $
M_B*_<MLC!OX7*F?SSWJQ>>I-?0FO>+78"F!>9<+5DWJ:[7"F6G.13ZU3U<SA
M,@NBY;U8^=26W %.B)=#N/19=7NF2=/>=[U=RS8;5(Y?)G$,9ZTV<6T]![Q$
M.R0(GB(;??BGK:#,S[*\"AS0,A#8"L]P 9<;?H*GJIOF[(8MNIWQ#\-/?_]W
M^''L@@NJ+34T>V[N$5?8($."!!].A791RXC)848! %?CGDX-_V5G\RG\^R$K
MR >XT4^CVO_CNRJ"LYYDDS.=QWUN[AXF2!83U.K9DLS#V.S<@=B*?JIZ8E1^
MCCY>.K"9C PJBBD%*Q-; P.F890W3K:EC[.+>MZ ?C8_GN]Z\2Z^6?55MPRW
MZQY ,4?%)ROHUB*WU1,M7R(_[+F=S^I5K^W\C&"$SO&K]G TLE?U? :W^!(!
M>+>W([@EXO($$(.1G33QO(D3FU>!5O1IP\+%M;_;M2CX:=@,%S;N?'6-/4N#
MB]LJ<48%_3Z3=E],L3B0GF%]G^-(?HNO7PV?2:F^\7(=7A ][3&E)]>S^W]S
M'7GURSAD[+1I@+N35'KPF,?N9Z&^-3!\ ]=TT^&:M7;<H--MD_L-LVY7.O=<
MW+R6IY/6^NN>GRVJ[U!#BL<H>S>%HT.K,&7_V'/[\B/'&1 TL5**>Y)]ME]X
M86BWUR!*%[ZRQ/KP)5:<N.!),I0[ZR+.O,D5^091S2@VUOF$Y2$JJ.Y,U*XZ
M!/P\C[_#;3Y\CJ-/\;_@GA>':1I !T*49KN=K@/I<+:GP+X#P3[>G1"N^Q[J
MM&!?GTM/>D/TD]>)@MJ6J$U2D[C7'&":,HA;%I#QUB"36)*1.6'Q5B.G8Z*V
MG*'_\+D^"%AC XIU*8OKLFTJ.;K^@S51T@E]!6LE>CT!HI^\3A2PM@1K+#(5
M"-7(<<H0-S0A1[%%6N:R1J,TT_')P=K%-,8#P36&:<FM==DZE=Q:_^&:+'F$
MOL*U$K^> -%/7B<*7%O!->UI9$$@G#M)<(<)THH+Y(13QD2+$V=/#==^K>?3
M0Z$U8TIRK<O&J237^H_65$DD]!6ME?#U!(A^\CI1T-H2K1&=N+-YI UC>244
M?C,I**2PU8H2*:T,3X[6AI\.E5OCAT5KQ3B= %HKN;4NF9T/%Q'(GL )E&Q"
M7S';08/8$]T5W!OF''Y#9T=UK&# -08,A@5KD!6D;1S#D DZ(F&-8E@3:>C6
M5(%C8L#7V5L<% @2/5"BN[WB'KPAMMB^DNA[ ="Q;0D&3[SL()G[A2VM1,EU
M]!5+EA#[!(A^\CI1L-]J_RH)SD83$7%1(NZ91%8[BJ+4AGC-E4KJ*;'?8?)^
M?*"(*(F_+ENEDOCK.7K+&G]>P1]V/*N&EY-I_:GMPEK9W.;1CGV'9C9UWV&=
M%H@K52TG0/23UXD3-(H_[.IF6\#H$HPFSB51TB#G0D#<1(&T 8AIO+72>\FQ
M>%0B<G+UI3G_T'JDM]<.Z?7*'_T1?1Q^RJUG#[3ZW):5=S3GV#&KVNW>4#^6
M'.2+1K%PYR9#UT]V-(^5#?]WWLRRZ2@IE[XBV(,&_&5)N]/IROXL:9^@@2V(
M^"Y$3".ASL2(%!86<1LQTDEYE 2)'GY34AY_:?ZOC16X7[YX./3U9?[K,$OS
M=*#D0?O5/*7I[OS2?,'5)3O<17/W_@:BKE.5YK/Y-!YB@?_%Y<%."UGW.8O1
M&Z*?O$X4!+E$D,H1+V*2B#H&:% 8@@S3#CD E$*$0(D]R :?/=CQ4.6;AI*2
M2NVR$2J9T)XCMD4FU,^GTXS;EF->-R:JCC]NSZ[L3HZG^Q[KM%!<R8]V&.V5
M_&A_\J.+H=;\5'2U\PFQWJ"CDL_JDIJ^VP^"!M4XSC)0NH6=2CC?5W!TQ,V!
M](QFBQOJ>1ZHW6EXU.VEA\>,>SOJENJ[.-Q]12UYMV7>31!EG!04$8L#XM(8
M9%5*<+_D?4C8V'"0C35[\FZ_U^.ENWD)&;BO:E"!I5^%I?![+GW]^XK)O\\O
MX<H>_@[#3WL^A5-W4Y&?"<:^OY.,/(<.AR;C\^*$O>2 V]Y-C*/(U*D2@]#'
M4N/I1K@?V;?\BG:51YW@BQ!Y2S0NUC'PQ'Z,"]N/VCY1YW;TV5XUK[ZK_M8U
MC>HB9:N=F@?6^5"N98UPEK9_"7 B]RH0+)&+6.7-&BX#'(6,Q0YK+@3Q^C;
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M#%NM=#[0EA<%N-.$,TQLX(BIY/.,5 >Q&Q6(8.&5,MY3&H]BPK^]WFI+"_C
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M%4(@G*NTN9$&N=Q/@4<F#==26K,U*W*CX.&-G>2RED7)RM[JAT?68HN!HGC
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M,H?^V)YE X7%0)+]7<M.7#_/=@KW";[( \J%2-?*A3B)G!"L$;8T(6ZC W4
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MO7S[_MW@YLKG!*Q9MI8YWY)3!-D^UCD=LS9UK0U>"M2RE.PN1]$F'>Y39S&
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M<XPQ<.T)HC5Q@(T\1LHZC"*5J@XU==X_3I>8A]4XA34\>CN=F_$#]_6)6U'
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MM=/D#&-6['3.:JK4M90P#(S_]P"_7\%]J1.[<6ZV /G.)YN0F:@."]N5V/4
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M%JH_EVCZ/=%TSW@@.CCDK."(2\N0-LPAPF6,7&@A-;X;3?<ZB%I[AAR/$?&
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MW]90.IT"'T@OL;M$$YBX4UDV$W!#.JT((+P([[T%4=Z!Z\\LBI@S</Z=14:
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M:RP*BD<3J9&*N*VDEQ#.UU0@(P)!/(+^UU; _X*G7++@C=K:'_4"O./7\5?
M0[<///EWG&\FJW[Y[>>/E$Z>2;J_(=/ EW_5_GN1@!Z P YQ3F-,J=R$=S>V
M*7;C6T4_[*(9=\@3;&F7<P8@RRBI_A\SFS4ML/D%V( %8-H?I^U\.CFK_H]I
M6^/.%VV8SY<!DK44-3<5F;'Y  \#7-U,?1K*,81H#R211!*KB42U8P+Q( A2
MAA#D(N=*12;\CFX26%C,,$,UE1QQY1@RD5,D0F!&6^9X36_E8=\LY_P6L/>M
M%8?:X)[YQ>P"GG\^?(W*Q-H^W47<IR$R'9]ZG_!],QZG(HPF!>B.LZ-FSY*M
M=918&(4XEFG_7!"@$6E H8X^6JH%#^3ND@U2>YET9Y0UW!-KC6R NQ5F5ML:
M5K/G.Y?L3VF&G;?X"B3^MKKT\$U'$6^N4YU)F Q_":\105\C4Y_V@KX=L^Z6
M]"RXT*2P\"U84XIY[L,U!"NKP"2@J"D8!$LE4DQS,"):QT!HK.F6$?D4B=SP
M:SNA["MV#E++7H_V'P$[\,6]+F4']&(3XDB9F%6,K:U2"6N'/M:()(7&UB %
M'F*Z75U=55\[K6SHML"F_64II-?%'9>!MCYDZ #TK$)TF\]-(;X4'6PW0H>K
MZCUP.,R']$\S:1>S%#%,P<MTW3SEB";FW=+1"#TR6\R;<7?PWS%+4\II4S?F
MX&1.F^)WHGT//6WJ/_^2BK[_ZW_]YU_.YQ?C__K_ 5!+ P04    " ";.G96
MFCKFAIH5  "F]P  $0   '!Y>',M,C R,C$R,S$N>'-D[5W;<^NVT7_O7X'J
MI<E\E67[Y"2-)SX=7S/N^-@>6T[:IPQ$0A(F%*D H&WEK_]V =XD7D!*M$VW
MS$..3"P66/P6"V 7EY_^^;+PR!,3D@?^\>!@;W] F.\$+O=GQX/'A^')P]G5
MU>"?7_[RTU^'0W)^>75#;M@S.7$4?V+G7#I>($/!R#</7[\E_SZ]OR8/SIPM
M*#D/G'#!?$6&9*[4\F@T>GY^WG.GW)>!%RHH3NXYP6)$AL.(^9E@%+^3<ZH8
M.3K</_PTW/\T/#P<[_]P=/##T>?#O>\_?7?X?_O[1_O[F6S!<B7X;*[(-\ZW
M!'-!V;[//&]%+KE/?8=3CSS$A?Z=7/G.'CGQ/'*/N22Y9Y*))^;N&9XOTCV2
M1@9%Q8RI&[I@<DD==CR()%FN7K@,H)F\8+;24D"QAP>'GPX&A"HE^"14[#(0
MBW,VI:&GC@>A_T=(/3[ES(4&]ABVS!I!)AD0\>41E"%K%6C(726&:K5D:1YL
M[I>)\/8",1M!\@B3,=_^</]@>)CD9'ZX.$QR)3F0<,1>%/,EGWALB&1,:(#D
M\!#UQ&270B69IU1.=&;XJ&N8$*FE6"]",F=O%CR-,&6-%)I_383G3U%U]@]&
M__YZ;;0K)O:X_WNQP$#_:83)$RI93![*X8S29;Z^4<):15S&BZL,">LUAD17
M%;7@_N>12<R2\HH*0^=0H+!)A5]R D;-<?#CCS^.=.K@RU\(T4K+%\M *&)T
M]SIP-%85A>%?P[C$(7X:'AP./QWL ;,!\7-:7U'=T6Z5B'':JA()R-M6(@8)
M2_]<5FXAJK5*E*4JKW\-\5=EJ?FN4KO<#5&K>W0-T2TF8;OVB/L3_JC?&DDO
M;%9H89<?,4_)^$ME%8HMQG9X%-AD_;>LI?M%%GW+IHBMM6D&^*M>$R1&/BV6
M^GZ@=%GX*?ZX7')_&I@O\ T[[%'<:^_9E&@[=D2%(P*/55N[T5($2R849S)K
MW36#N6#3XP&.F\-X=/S-HY,],*4Q2:Z =5."R2/(PKSKM'IQ7L459K[&9$FT
MZ8U3 (;C@80V]R(K].9R+@5K*B=DD3 +T6B5BWN7H>J:T"Z;-A4:LG"?5XM\
MGM!T36"'>DT%ABQ.Z%E /DN):HN,W,>03O#'X_U5C;GJ2-&7P \6*U.U>(40
M_WOBNQ<^U&AU!=9"+'1U!H3#=+ 695R]N((IU%\.]O$_6(ED%B7)3^J[Q' C
M&78_C3:9;+ /)7-O_2_Z]V97BC)')!49-]"IG6]=C0NS11]CF-H&[P&DU:N8
MLP 7=-R%/]U3ZN%T\&'.F)('!KLZA!;H#A"ZA _!)5_*BD2\B&'6XV;I=,F2
M_7:IYV[^[)J!49!?J0H%1U-T.]5?KCF=<$]_.6>*<D\>1KUQ)Q86K ]U-TW]
M"D.2%$),*? I+8@$4_.99,HBWT2E?4L.>WW8M1_?40')<Z8X2%FW3Z]GLF#^
MJ4'_)M^LL?ZVQW<+?)./T%'/J)Q?>L%SW+N;9+#@^ETEKBE/[,3(E6BV?9_=
M&=/(9$(JS)3.@@6TT1P7[4_L.I"R)LX6)A;L/S? /BU)3\;6RB)86*\0NW;R
MP'_"=<;$8["@FS(A,#UP?@=H];_SP'.9D!=_A# /Q@60PU5=>[ 5;XOZ?-_$
M=*05($D-B"Y:ZU.V$G\CIAHX1= 5Z0>0=]&MNI.*E@NR:-T/;Z9U_33FM:8Q
M36<Q-IWXQU:3F![/VLM0,:,^_U,+ 1WY!I=V['9Z&DKNLWBR4I_<@N:/^>5E
MAJ'NN(8EPADS[<&L"^8YDX[@2ZQ,.83%1-7 '>SG@,NPZ<&J#]8]_.^WM"%/
MJ>1@#K-N?AQ.P\6"BM7M]('/? Y#%O75B>,$H8^.F#LP?PYG$;!M,K0HP4%.
M"71I"/]:G$*/OZ9$3,N42=)"25QJKS&--.::.[@T\V<G,\',V%>H"$5T%GSS
MSK^$"4FY]'@UPNM? ??5+] &\+L0J#4""T*?<@CIW"3*WD/3")I+RL4OU O9
M5T;Q[_+.5$QI >N['%C(AF@^),NHAZWN! >&F27E[L7+$LP20\_8+:SAQ%DH
M<#5W(B53N?E.K3P6*#_GH(RXDIBM'O0T8Q)Q)H9U#VY]<'4T?H7A95BO+[%O
MW#"5Q[.8S +A]P40&D8F!!VS^CL!9CUH=4&#"9T(65GORD0%-V&LG]$"[ \Y
M8"/657TSP[_'>LN0M24<;</M']90<X],H^E,J8.V<$I33FW!+>_#J?#%]A#6
M[5QY%_IF_RJ@J(;J,.^U*7*+]Q@UZF:Z"4_!/NFH+ PPF9UR]4@MJ.7=+)K/
M4#,B64X]<HV0NX(L"S:F+R6^LVRZ!:.\J\1D)CIWCTM=JP=S;=QA<,?$PYS&
M#I+R9 LJ>?<(,-!;& A,+8CFT6/3J,_<,P\C;7=4J#*7\P:)!:.\5R3*3R(&
M/4!U.P\,!0NNM M)[Q'2?G7F.P6KK2I2"V!YWT>&6;1C*,.NAZ_VC"^<2/9'
M"/)?/*6>QXIT"U!Y#T?*@1@6/3AO%IU[M2A=S6C=8=XOTD:TCGP3_^HWS=3N
MZ;O /::PK,[9AA8X6M0G[YYI1WU,Z;WRM!"JRJI& WH+\'G_3DG8JL?R5>)7
MQ1V^0<YJ?#_EG4*U8UD]XFT%M<I KB*VX)IW&U4$N'HD7R_258QMT^P6M/,.
MJ&91KUX!=@U_%<-<3&0!,^^WRIVZ[.%JT3M2#)T]@P7&O&NKTE/28]I"D*P8
MRE(Z"X)Y7U?Q.9(>N/8B9Q6KF,H,%B@+O&$E4;0>SL;],!,I*^Z >0(+7'EO
M53:@UD.T:V2M&*9B(@M4><]0/LK6 ];.X9T3U]75HU[F<ISH>HU:!WLJ&5B
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MVED@H1O?A="'M?'70Z![)P(W=%(369O\X_1W4"1!-U=PB;S%B9V1SF[T"R6
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M7B D#=$2LS7SW(7+*M)[DXMO[#<'_>,A.-<L6V?O7$.D5XM@I.)NRO_4D0P
M^9K- A!S<<H#"7#BF1Y(^,K099#>![!=[DW_@3E*]=Y- 8/1:CQG@BX9E.P4
MB%M!T4F1L/4Y'A);OT9F72H+42<%NPR%KT]F8Q1F"A:():\SK@M7@["3 E[3
M"4R#\0;2$L$J"+HI$!B$,S (U;IHH^JD:$:OT.@EF#PLJ</61;-1=5(T8]*K
M,:NFZ:18#_@8O3ZI&Y_G+)&M!F%'!11X#+G4AR(WQ:Q)WF%A3YL)6X.\F\*F
MS\+(HC#-AJPUJ3LOZO@Y&,^#4%+?'3\#U0H_;'Z[U6=A,I]O8.:M&//O8/54
MWC#M\>YF,T;1E3(35Y;<26$* (C#SQB!Y$\LCW6S/%T7.U''B\42EB/,O,<1
M#T^5TM?/^G$:H0'X=3)U57 5R:"T#.HY8%H&[KNAHZF719(WRM5)T=,+Z:HG
MH7:ZCHIG-A-N/IJC3X)L2EB#M)-"_A*\4,];EV;]6R>K77CE@W9NKL;L19UZ
MF=AE/=I-,56<]-[!JFL.=L&%SE,B7GEZ9T6ZP2>UV>WT-)0PYDM9(IF5K+,"
M[N*:'V>C<BTPVL*M[:JC^0KWC843[1SOAJ=_K6&VROK?U12Y_K(;C\YVIC./
M2JFU/%)_O)F<X>^*BU%*3$H[O#K;5&9^!7J=!G\*QHLJFLZ*AKL0?.6MS(:3
MC+43@0\_S919W@3J/TR=N,$23P!HW$HTH3U^W6TR+G_'?0R/((U0,&G3OM*2
MYJA%VUE1"][:?91L&GK7L/30 V@ 9:H52)B$9&Q&='M.W6VF>.(0/>X0;[7&
M !R>"XC.R69NRRQII)WYO'L3F9= ),;!Z9?_!U!+ P04    " ";.G96@>RZ
M1_@-  #<Q0  %0   '!Y>',M,C R,C$R,S%?8V%L+GAM;.U=67/C-A)^SZ_@
M:E^2VI7E8R>SXXJ3TOB8TI;'<DGV5/8I19.0Q0I%: %*MO+KMP&*$@^ !"E9
M )R\C$=4-]1?H]'H;AS\Z9?76>@L$:$!CBXZ)T?''0=%'O:#Z/FB\SCN]L>7
M@T'GEY^_^^EOW:YS=3.X<^[0B]/WXF")K@+JA9@N"'*^'W_]P?GU\^C6N0VB
MWY]<BIPK["UF*(J=KC.-X_EYK_?R\G+D3X*(XG 1PP_2(P_/>DZWNV[^DB"7
M/7>NW!@YYZ?'IV?=X[/NZ>G#\<?SDX_G'\Z.3C]\./['\?'Y\7&&#<]7)'B>
MQL[WW@\.XX+?CB(4ABOG)HC<R O<T!FG/_I/9Q!Y1TX_#)T1XZ+."%%$EL@_
M2MH, <%YF,)XI<$Y]:9HYMYBCXMWT<G@>7TBX1$FS[W3X^.SWH9+2L$^=5.R
M+GO4/3GMGIT<O5*_XT!O1)3_ML*/I.2O)?J7,TY]\NG3IQ[_=D-* Q$A-'O2
M^_7K[9CC[$(/Q: UU/GY.\=)U$%PB$9HXK"_CZ/!II'YZC6@&"PFQ,\KWIV@
M_].3T[.37NR^X@C/5CW&TQO'T*?,'"XQZ__ AX_^9S=DOS.>(A33$Q"2_]:4
MH,E%!UJFW;0QIIV_-V@B7LW118<&LWF(.KT]PMB:_'".")A#]'R+H"_H5S=>
MD" .$!U.^)/;P'T*0O[D"L5N$-+3.H![:?S-H O5OWD(DEVZ='H3XI=ZH"V:
MT@=KW1?P;3_R+_%L3M 4113\WRVF=&>H:LT;T*O[Z]0#CM)[@N9NX%^_SD&G
MB*EX&$\1N5P0 D+U*06OP;R>OPC1<*)"O1YOZF/YS44XB!HQF&F\ G&N_[<(
MYJQ'[U"<%5M(T$)9>_FA ZBD[WED@60=E7'0X\5LYI+5<%+@:*R;??_BX2=)
MYMYPE'@#_F0M66-5M&O7R*C@+8." P*'F!K/T(/[BN@(>< +DO!I;3BY03X(
M'K*I8!%CLMJ0CF!N>,#7DPGBZ43N>6/MO+$ AU5AUJ"Y=YL@&.0^?-=R$FK?
MM@RXYX;>(N0:9BE?CAJ]QBCRD9^VP8"^3<K Y!%(U"=>3B"7>*DL\-^<..7\
M:DW1H\R-LM:Z <B1\D\(GEUT%K3[[+KSWS)C#OSQ.,;>[U,<@KE1-CO%JXT6
ML9"GXV "Q!<=R+M?$,M&(0GO. L*\N$Y^VTW3)1N",CU9"."!9,-7H!5W;LK
M]RE$&TH;$":67P&.Q:XL/H<_K&.7;L@&4#^^= E9@4O^YH8+9 ?6G/E56J>%
M72@TS'SGV@!&S9% KI#X;DYNIPDJ>TV8MF9!S%-)GBA'+!)",,UGO.B)):"K
MO2@+V2M&H=$@:QWI"-&8!![,Y,R76H6MQG'FP_.4>'4'H8Y-*.5^-$V][R$"
MBPOYMQW8U#T-C@0^U6AL:NY%8J3%<7AJ,M):'Y.OH5F(K;[G^,K5</)($>>P
M YS:\.O[?I!(? ^=.(@NW7D0@_A60&P3V8BHUEC/3,9:8:NL+IE\+9C^C :E
MUF4C5B.)D'_MD@B&)(6H;3%CHB+_"DT"+VB!-L1YB"%;;L8D7^-A&"F Y  G
M+GWB*-=B\4)*#X4Q39_P<A O!34UT-!]0F$#N]8+I5YJS0(69BNYG"FA!G%E
M!1RAR!)B'6*+PH&BM#D:#4(JUH^$PJOQ:M-\I<IUB*7LU,QP8\(JCE!>$:4.
M6ZZJQ(@MN()#CZ.3U5ADODY"KT%X20%%*+B85H/0"K41(8!Z/BT#MJH.(AFY
M%2R:AG"^Q"$=MSDR<TRGVO!KF/1X>5%-0N;G!;3:=5^J.2BHOLBCP]O+Z@EB
M7R^AUJ%]<18MUKJ05LOT5)\92^:J6L9D]T&O6!NXA<^'W)>PVS9=W04.B6O<
M;47#[-5&!.,"2<! _LKCTJOM),A4P/;2_/: (IBN![,YP4N^$:4?AOB%;3\9
M(0]!(@:)KQTJV+W3[5JI:]'C2KR/D0^#GQ4^V*Y*#TC[,_;I_:M%:D%-J_):
MH\9FX:)!@MN9*34UN&)95)6].;3R7LD&'C\GK#J?.=9D6_+4TB<W-RII6X:$
MGDT.3NF>;7C)*5^SSM>C^I&??Y"A?.=[,/>NFSQQ\W#D<*L@.\,6K(ZT;_.O
MI:"WJ$HKE:.M\:DU)S1U^Y+-5):<\<B=&A4%\.EI,)&G[)KG*@5R"]T?@D;9
MV+A"2Q1B7EQ?<]@Q)4"DCO,]N1&_C'<0+6$L,8P)Z0 "%@)/+(&*8D5;S9+9
M@$S)6+^@B!U' UOM^[,@"L INNSX6=%<C:XE*)DKSXW&B"P##]V@]2&T&VAG
MA'AA]]XEF1*"V7CK;+9"(5;@:^)^KA"!V(/9[!<WB)A&AM'VV9TM^U%K^W3[
M+3/:9(O(5Q1/L;]UP-3X$E@9HRSASU#J%+CH/&7B;NCT!+Q5$8<L_JW@T0"B
M=M 7 ,CI-0@OCX&$LDO)=>A=Y'B*NL[1:!"R-DP1BEW'M;=2;7U842[3UO)H
M4+/"7"I4=#V?EC&I-&%*!J@*KRU%@^UE1P9$.4R8>X*7 >#^O'JD"%2ZOADO
M>N9W^4E/-0*;AY#/^V1 Z8*M:0 Z#%U"XN I1/E-J7:D:3O5#.]AD#&;] A;
M.KA"R5_X'"Y\'I1X4S=Z1NP.D>1F$6&V(.Z436B3[10;--H$C]#()D%L3YHO
M09OXJ7JTZY7+!]SWP*RVEUZ5=H=:4J+;OX<91$#NAO>+IS#PAC"*"#1C1R)M
MK&\16J<-&MW-MURA.4%><A44_#]$7'8(3V<8)K _^'.K]=#6ZZ0)T"#Z#PZB
M^!M\N2#":M6?PN6PH&:SV]V.^I6QKD;8#39H=#=7,YZZ!'T&+?)50DAW\\[%
M1N0M!A0?0$,.C%Z_(N(%E&5;:R7\RT(EU'0_+RW<X8BQJBU$OD,EB#>/%8%_
M>'_ L[V?5F+D!0S)9/NCC9.MHD4\1C"SA,$?R!<5JK83P\=WK(/R-+L^XY7>
MOKD>*.F=ONG)ZK5J_OVG4DWA:H&-%CZ]/^=1J83"F>/4-K8>5G"/Z(F-=9/6
M2JH[E'!BV/['YD%6>5%(M0$]!Z.;U8J%&)NV8ML^UM:)USXWOC87PISA4N$N
MU(:+J $]PV53]9:-A)3 '.U7E)O4M"]J0(?V&U3AQ;VCWH AOEA255?VPF)^
M+6OF*C5=R;*Y JL)YB@KSZK9HH3;$$,LU%H;A0%;/AU72TDJ?$($$F+-?2 I
MS]7V@9AO;]MYU.IG.2G5^;2?O*S>,R6FW;=JFQ>GI-INW)2&#J@M.PF[HHY+
MSYZJ5K4C(;Z6C1D!NU074D18Y#,%3*/ZCCK6)LT:H8IF=S6H\QNR5? 0;P+4
M7=C+RYIW'H*+VOE<LN81S]Q673?3$'V!;1"!;?#7[5JQ4-P2;)J0;._#*':Q
MT=>"MT0MHFJZ!JSC?L)*@)6W%8HY]Q;+JCF-<N"JQ*=/[1D?4*7C+9F6B5LZ
M@B43M8Q>[UV*-9??2(S7K#ABMY?DZG>F]1?H*KUXZ NQ9LMX4\RYZR_K2Y;U
M6\C5]W/^=8ORKA#6=MD,1,*DYSKT/9F:$/#>FC?.#^_MA=RZG5/MA?A9SW0]
MFX=XA=#ZX*2U[PM5P<QCQS5E98G9LK<T-NGO-3%;C$:4<@0WJ S8Z*2U$> D
M!*Q]#Z=A"9S5+[50\"E"$/5\>\L\FWF!<@;:B%^?_4B'>941R9BT)7H-QT(-
MDW&!1^'>>;:\C*/DW'EV"=&4\(++=(FIV-OFL"14-L0/E:#&4PAH'Q"9E4$9
M'1A4@OKFDH"5<<J8#+OYJ(2B= 5P^KWVC0$54@H(M>QX*5NR4%P!H09Q!38J
ME+9,9[J35WBYB &._HW>NY#AO0,]/[R@<(F^XBB>6E+^.X1F_@N!Y<,+MF6F
M.9!"P+%8LK)Z*)7<X 6Q8]7U8!H)EI8<SCV$1OJ3&)&26I2/[AKP2@BMKQ8Y
M&+3R3+@3U%)S!D/?3'4[(4Y;,1UH,H7M#I6W8SC89'+:&2MOQG2HW+WN#I4U
M8S#4PG2R$]Y\6\:E;,D5E@_N*Z(CY $OR,]_>3BY03Z[%Y5=$;F OEAM2-D1
MRP><'+($4+GGIN1U8NF2]W@OH+^V;\@0+A@*N?,*ZL>5"K(CR7M[-?$;1ON1
M?PLC.LQ8FQTYW]OKYY*?6AY$Z6D&($KV<K$7XR1@TQ>SV9$3OKW*X.$E:"K@
MI\?YTI0=N6$[S?"E.!6UW",R<]F:RE7 #KHBL!AJZM)O<U44EU'5&S &7L/Y
MHP'N9BT;JA#Y3-%:$](F#55!H\F@M5::_(JABA)- :WU(6AL;WLPVCON\GZ,
MUFV9G'5D=P+P#=\%FS0EH2@)EMLQF[^^MT"Y31*!@[_W<(+)BTM\2U:"2H R
MZWB%O>#<3C/T&<I\JCQB8(>31XH*%\>9?6]X2162O?!-HGG+$*O;/?RG<$:;
M^5>RY/N.^=XE-[0D#VPP!*I-Q4JPJ@CSAUOLPJANUE\P]E^"D+TP:!#%$$JQ
M&]X*7LSH#+T>>]&-IS;OL4%\DUF=-CK?WLUU)2&A>+HV>L%UKQX[>P\0&/QG
M%*%)D#%THZ]'WD$3VQM4!A&-R2+_WL0?[48M'M[BM8Q ?-^QC;#E 3K;3"VZ
MNMB$4EDUKM)=<4)B$\2NRH+4L%2T8 ) <4A8!ZK M;?"0[LDK%QT:-6."=W1
MH \T'<9M7^4SM'+7-@-4PZC6F FP*S,$1;]=T<1;^(ARA%_I"DKD)JA=%K0K
MFY>(VQ!@JF%YVZ$D:] $^))87 VJF/GMAE!%%*TPHN3<)G3$.DY6C-8X<>72
MP_HY^^<)X/[\?U!+ P04    " ";.G96+X88#9TL   *00, %0   '!Y>',M
M,C R,C$R,S%?9&5F+GAM;.T]VW;C.([O\Q79VI>9LYM*7;:GI^M,S1SGUIL^
MJ3@G257//-519-K6MBRY22F)^^N7E&Q9DGF31(F@XY<JQ^8% $$0  'P[_]\
M681'3PB3((X^OWG_]MV;(Q3Y\22(9I_??+T_'MV?75V]^><__O3W_S@^/CJ_
MO+HYND'/1R,_"9[0>4#\,"8I1D=_OO_REZ-_G=Y='UT'T6^/'D%'Y[&?+E"4
M'!T?S9-D^>GDY/GY^>UD&D0D#M.$3DC>^O'BY.CX>#W\&48>^_[HW$O0T:</
M[SY\/'[W\?C#AX=W/WYZ_^.G'SZ\??_3CW_]KW?O/KU[5^H6+U<XF,V3HS_[
M?SEBO>C<483"<'5T&41>Y =>>'2_F?2_CZXB_^W1* R/[E@O<G2'",)/:/(V
M'S.D&'P*-VB\D. 3\>=HX5W'?@;>YS<E?%X><?@VQK.3#^_>?3PI>@E;L+^.
M-\V.V5?'[S\<?WS_]H5,WAS1U8A(-K?&))OF[-=)4G0H-_[A)/^Q:+HS]//'
MK.W[GW[ZZ23[M6A* EY#.NC[DW]]N;[/2'),%S.A!$9O_O&GHZ.<<A[V<1RB
M.S0]6G_\>G>U"UT0)2>38'&R;G/BA2&=.AMACM%4B/\&)4:['QC5_K/4,UDM
MT><W)%@L0_3FI#-,]#.*V-8XGJ"IEX9)2PB%X_0';[SP@J@[N)5A3$.;#7Z\
M0(M'A-N"RAO#,)QS.ASVTT=T7!"F);22D40P;P"N0[M<O00DIJ(ZC&>K3(Y2
MP??A_8>/[T\2[R6.XL7J)(/^/J'"E,GALY@)WF!"_YR<>B';M?=SA!)RZV'Z
M\QPE@>_5]B"=A1QO!LY0:#G<L.@57Y+QE'Y/S[<D> S1+<4)8<Q^C_W?1E'^
M_SP.)_0 O/@]#9+5.9H&?I"THH*Q61TC5G?^Z0>$WLAX1__YOE5^3CT24, I
MM(0"D:D(#-9TL?#P:CR]#V910*'THF3D^W$:)52YNJ6H^P$BH\DD8!V\\"J:
MQGB1]3Y'B1>$1$7*@<'HC9QF4& *R20-T7AZ09)@P=CJ*T'3-+RFFBH=] Z%
M[+L1(51&:5+8/F0#$/TZ\.E1A$8SC/(]V(4G.PX[ +J_Q/1\_T8!HI_-8-IT
MQ &0O/0"_,T+4_0%>>SO; $*;BV,HBNJO>/,2"-G'L8!9<*DZ#J.[I"?TF^C
M6<;]C>DR !"V2&F&<5H//0#:MSBFNFJRHE*.G;1+!ML-2K:R3-"@,1$,3334
M82]63\R=Y)WF&( W=M4P,_NAW;A6$#Z+%XLXRK[?>(\N8WQ%2,H,(0.8-YI@
M*.;/P*%R&$TH>$MZO.>*D#G.;S_!4%SP6 >.H]T5<IVJ=.EBF7D=V[&$H=GL
M$:=0D+D_7[RPCRVWBYG)[&Z= F2ZQQ,<^,E&T#/_>F;>FMM%#><:@&>N:.L%
M>O!>NMG!K0<< $6JJ%S'A-PB?#_WJ'E #<-)P"XBGM#%=(K\Y.+%#],)W<4X
M7K#52G/C<CP]9\W0I#Y 0I?ND3:BNL%#7#HDUH='8Y)9!G" )5B;U[<>U:A,
M,5KS,8<0P>DC0;^G5#V^>#)GI+09583L!$V#*.O-;@DKC=%+@B+*9ILA&&[]
M.[L9:!O@PMBO0!2RZ[Z8<S%!-I<%4X\\9L[^E!S//&^9076"PH1LOLF(FA%T
M_<7W D)* 71%/Q9$"[U'%'Y^(VEX8A'<![:A5:#FC2R 6363Z!J/<0;4)%.,
M-K)) +YF9^MH96"049K,8QS\L=TJ4G1V.@%!@UDRC5!8=P "_CA-V,4WBY-H
M@$.YEP5$2J=QPRVBT],N0IJ;0]8# @+2;2%J#0%P]8:0=JF@L%431KB*C(?]
M-T<QIHKDYS?OZ3S9_?HGIJF@R><W"4[1]LLX2JA2<1%F)Q/51M",?=@ M[[<
M;Q27,J4JL/2 WL :"\_&HR4.*+LEJ\]O/KPY2@D%(%[FZE0;&KS;H<'4"PEJ
MC"0WC*(-NKH'L5DR[+("*#+LRB:SZ']P ?V-9#.+^D<74*_(1K/X_P\T_+5T
M#+,T^ $P#?K>^G\%CWL_^_Y'\'@WVO1_/^'X1VS[3;K'LQW<*_OA7BD@*.XF
MEW&4.0,I?ZF@YO:Q@83'KLTR9KWQ%O3C _8BXOF9_[(2YUS'1-W1 CI7M^,O
M%:E5@WK[NPU:IX\DF 0>7I6()V,68?O]8I3OF_A_&R9[Z!&R!D^*!J>A%0^#
MX,21<KVJEP5$2DSP0*>1[ )>2[L 2_D$A!AL#:S-K5@[$J6 \]NZ"'0'BN]>
M4+)OOM].J4V%ZY'&7 &A;F]3KRJ+7!V=:J>]6^>)S;WW@"A38JIIK'G4PWA%
M;;31@D7M5Z,7\KMBD4!I/(Y=-[WBV*RWL[\RNO<*RFX64-D&2=QZP>0J.O.6
M0>*%TC60][$BG>IVO5 L[32T .X=BT&)T.3"PQ%==B(EMJ"Q#2IKLCD(OJ[O
M-;;PN8/O/&4Y&K<(!W'N[;U!S]DO0F6WS5#&- >]V7.:BS#I,)"MW=QRK?I:
MG+Z0DJ];P\Y]\9S05%W_@.@9D)0C*#-R:_!@RX'MXKD6;],26,90Y8T-AUDS
MZN?PDBRPMH34/4M^"UB,:8N=J1X3#A'R)3),!=U!X9 A6[?LMW&>R''Q@K ?
M$&%(4/-QX"";+X\!;&4#P4$W6Y-Z[L6SAR<_XYBTV=_BL> @G2^-(:Q5@UDQ
M]/XO)4EV2?H0"RRX#.R==*0[1$\P$B14$.&GP$<YBG?(CV?Y52_ON!]L6@ND
MO$%)GK]S+6:,:IM#T*#5H$%)-2,!TI5;;B["_ MFF/CKQ(YH7R66J5&ZV@6*
MN:! 6 UYU25PA0,T* 6>&-7B;KU2HW"A0Z6*>G.(+Q"J@56*>V"@^&MM$<G=
M<)D&^[87VJ(-GNGUY*).-%69#H*;5_ TD(I#(T0 SQ!J*2C5"#1NN8$BWFPG
MB.Z_*P<!Y[@ C[S6%FB'_1[POIXUU.+&WEF*2(-L!/'F_4@"4SE5)JU$L0H-
M$_>^MD#O:44#$D";XQ4Q%3!3ZOKPD>P>%S!Q-\;]O$ 49U'6YG=1/ O,!$J#
MC,ZU#F%B;8[%7UVB:+M0HCW-'.T2D[3G":56& -<>JD=9O@;%#*8C)\R2Z*?
MW"<1-_3*L#T!SJG0,1C+,'G &9Q=P[0,TP>F2=(L?LLP2>"IL"VBO S3!)R2
MVS(4S#!9P*BY78/%#-,%G*[;?S2980J"TY-K062OL^[*H<;M7A9A.=34,%5\
M19"X0F4G55Y/A7N.GU+8J&M?23:;AT'.8I+HY*E5VQ_*UU2!.U\O7?Y&54XD
M>K((0!6U/H0G[TUX\E 7SV!#DYO)1Z!$.40M]^QOK)U"SL8D  O;!^<=%)Z/
MT.VMVD-)O3V9:TK+ZP*@R/@R.+ Q;;8+.#RKS="@ *J84-#219J]-E1[)5Q1
MT833\5#AZE QT8F*B73L\70TR<\.*?3<IC;R@ L)<L\">#P\(5^7S)M'6[Y[
M]UY>^$FKK]WDYLL8WZ#GDIS$]%1-Z=F_4)0!;C:&>\QFLY1=QXSI@:221^;T
MV&7_,2/AB:K6;+6331B_+,U=KZ\-[]5BZ068\>UX>AU'L^O@"4U&A"!V<7.*
MJ(:Y9(KZ>"KR;FGW-Z9BW:2,73?OKJ-KY!&NUL1M!Z#4F,/5 ,_F7C1#5U%9
M] 61'RQ#))3]F901OP358427",!,*OK9-!4VPSI"BJL%>^@9!UZ8/\EJD!P[
M0SODM#9O(1=^+0/VJ'-NOW[(V<2NA4DRY3V"60^&E92?0]6'X?*])?9&)19(
MSZ($2H=#^K<*^5;&=26!ALM(X$DBRXCOA29]Y<D/<"O3[Y'<,%8.:/IX?Z=O
M0VYT+B.U7^[2]/LXE]?9+]4:.):<RP_MT5[C.[><2Q;ME[>&+B(Q0'A]SR*L
MB]_.N814H+0L7(#.I;;"(^BN(Q%ZP(Z96)U[?XXF*8OINB!)P&@P^4K0- W9
M\4H'O4.9(RH_9UO'\'3V#5.MDBJ[R>HV9%A$$R:GESIY%!H=;<1^%%07PB?-
MN-#M;@$U(40;MIJ*L-+I"0FATU6]0J<N0J6>D!!B0$F#>71Z[AM"MA_#7 K?
M;12U@K0"O$.EZ5IPQ[" Y&6*Z8%.SUL*W&7PPC[)7U*3=+  ?F;YL9Q(:DCC
M^"GWSTCAE_6P$\1'$IQFH>97$667&:6G' -I%X?N<YNK096[,FUM ZB+7'UU
MU(XP6KH*3)KHIW U5#6UZ%-6?6#21^^FJ8%NIT67LL(!GBZRZZ;^"+,'M9D;
MZ)OU,NT5;0[FM=+PTI:O).X?=>3L(5,OG;M ZT@+J:[JW+U81V+(]5YWW)3U
M9QH,YPD:R"\CB*XFNYH]1T\HC+.U&6',O,GK2C0)]OSD(;Y%F %\&>-Q,D=8
MF%!H=&BK?LH.&.AY,CM/\.I+MSA8>(3@I 08_6L+%/WC^QU;>XZ#M?K;D,!P
MZ5/_%1I QEV8"L"^>"_!(ET(0:O^?J@7!3GUUJ5Z4#8U .55@YFQC2W@URC(
M"M4F*]'K6;LKI^QC(Q=._%Y>/?V-T](NP%)^ :$1=&!:Y>VHF;%MJ$E99/"V
M' R;A!F98E1E/> @(&5'>9]]0**#EB20L?+7"7?EJ[2],:A*M>SS.L,/\5:P
M\\"2=SA43MDS'<-FP ,?@8L75LR9;^HTZ6EL"UVC67PV1PO]K:WH84ZM6TXQ
M7>-+Q"U@4/K51DV..&+^3X^%'^:26&=A5;W,%=H*8I*Y07775-[!&%RC&1UY
M1B78VFP>/X;!+#NWV*.>J\N4W12PC4T)Q*8/0D22.$+TMR)!ASE7P]&2^=*]
MD(>+^4D@X3_R?10R'D*3GHG F\D8)8I[,E95D(*44GGGD8U??7*+XTGJ\VL<
MZW:U45$X10_Q.LSXUL/LD92S%+,R[526T]WOYW\(Q(-N;VB'69MCS*!FFG,L
M9=@U!P@.#&X[*Z%?A0J:Y^;DBJ@PZHO?VB[@TFI.]6;&5GHMRJBZY[/<@!D:
M3\?/$57XYL'R*DH0I4Y]:^GW,UZ!:4V'TJ)]7<91^5&EJJ^0!WGKL<SMKCBA
M- N\L*R$1^Q1D@5[WL<+ZR<'=^LU'L0<SP016_M1%*5>>!>OO#!9T8W//5B$
M;8U!LQYT>QCG#[AL95)Q>K'UO0PP2;9$8OYZ'MC=!S5([?4ZTM7-P:)GV%5^
M<-4EG$8'8W!M*E9+7EK)-Q</1OW.!OT:THER$< 3PDU[FS;6-NJCQ&(KFO2@
M5=>U6+EFO-/:^!EP[JW(CLOI$L>+/#$O>$*<NF=M1C &>?YX6W6I>/!QVYFS
M#EX2[.F<+/R&5MX2P<&3Q];C.O >@W#]0")?S^>V-4:\W>%7X^F4H(09%Q*5
MG+M;V@]F(ZO%"W FU[X@CT5I,7A^#9+YURA^) @_L=B:JVB9)H0]F1;Y%)WU
MLVKLP*&6<)9]6B":GZ/T-,(LA.\<Y?\+%G68N?O=851E^'4>^'/.HJ_?F/N#
M?XQW&*U/MB^<Y9N2$53AN8U)%JAWP2(""3LC+Z)TD3GEXN@F3M8Q?E3(AEZ]
M^FA_\SB8OV,RQ)"?X=,]3L_9L'Q@3Y,,D\G"#9-C^.U$B(''CI>/HHN>PUDE
M@E"^#9*U8#J@Z!W>CS)8Z7,O7A13$\'H37A!-W5@&U"":6TA2;A;I9Z5*WNE
M11JKJ4R$:@EF(W%N,&FLQUD:46T5M4D>?@6>$K+D5Y.D<%@Q44:L%C)7'NCF
M+.*FK36=\#N@Q#H4K58A;S14VM#9M#?E"& 3=P]DO%8TM9IPM8 ^F"G\0'1.
MKBH/DV)&E 15T*RSJ/>B)I0#>9VE3&.IH@P1AED( XA$&>Q-G $+B*CEBB)N
MVUG,>Q$K/023PRS' F5+BEW>,.GF,&-RH_QA/@5AF3MKMVHP:62+$[6S+&"^
MH0%$\$E]J# I9X'A&N? ./<,2=^44R39./?42*^BC9_VX]SK(7WSE##;R"RE
M?MHK2O7R:-E[UV][]-*O#!/-==]7^VPPPX1TW=IOD8AFF(*NFZ7B5#C#A'+=
M:C*0I6>8H@Z;!3IY@8:IY; IT#1;T3#E7#<*FN1-&B:=P[8"/X'3,'T<MA"4
M2::&[V5<-Q2:9K\:)I_K)@,_!=<PD5PW!P09PH:IY+#*KTA,-DPHUU7^#CG3
MABGIL*H_<!JV8<*[;C5TR>@V3$K7S8A^4LG=>=WFEYBNQ#>*+'O!"=;#-J4W
MOG]/*3&_H&3.A,,39?M,&]]95>$K+<H!K#Y2(X!.[P$::>>!7L[8A0$AEOW*
MK?JKT<%8H8AO\8L7AN):J)7?.Q*+(/_M+'XZF: @IQ7]L"43_8.%$GOA1910
MU#EEGWDM>@<IGXN[3CL_0P+&]O/6NSNNN!_;7IH)]JY^_X&VKTJ8B':KX(FC
M3L.Y*;',%^$?A6&\>J"ZB[=$:1+XS(4NEF.2UM;>.+B."6$>H#SZ,:6Z_GBY
M5I@8>&$ZH5_=QCA3,9,$!X]IP@ZMAYA%#C%5+@[#+*">6^ZSY\FLDTUPKFM1
M0=377*E0'/L(3;+)Z.=%0$B,5U0/1MP*MWI]P(CR<T1\'&0*.[NK#Z@%L/3"
M$7-CRFJ]M1S,P7I0S35S?M4GN>+K7%:B_L%2F)]5!14HQM)$8HEBR[#<U>O
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M96/#HBG"F.D^3?: JI<%1"ZF4\1B-;<G*TL[S<5Y2B7Z>(GR1^2%Z7;Z UA
M;SU[-+N."3GS,%Y152&KY2U 1]+!V 6L>(Y31#\Q&O(N1'6ZV11++)0^\H,P
MR);[;,Z4V*MHP_-,$!&"$L)TSB(,_SE_)EDNP-H//,"2T2T<Y S^;^35)5BS
MOA86CZENE(9!4H9KM&"JA6!59#TL"N+F[#4H_W"IIF8=G6Y&84P30@_:7^)'
M,O*3.H5$$,H[.7@YKV7+[:93<>TFF%=LVGDO8G6SC+_ ?G$?]\8,4-<#89)
M^X95Z1#@$J%F5\&D09.\2I&M*,<>>'S#%O^U0=@3 0J#T]T[]":R4&GCND\%
M7:FHM)*=O=MO3(HF=K:S-^Z-J2(SSYTM-:9-!7UG@+-Q .T5J0[>!&<OZ$UQ
M3MVP=/9>O#'[2/T9SMX^MSYX!]PF [ZKUVR;:+E>W'W*O#DQ%#X>=X(!;E#"
M1-_F>;X1Q7\2A&E6:R-3MRY>_#"E$UY2BK$(BS195WTY9\VRIWPK R0)#AYI
M(VK?/L1GVP< V>N^"%M\<JR,VCWRJ5&1!(@(T;OP<,1>(]X@ML,/]9QW4\-;
M+6S1$0N]ZA9&)K%1^J ;W*<K_@"R0@H]S@B&@,IZ'\IN^X.*S<""CLPFO?$R
M,[:-N_U-,31VAN6!@=(X"W%[8W=,F^=AZ^6B,K.%"YQV-W/YT5OTR>B)GOA,
M9E_&F+V<S#1G,9B:/6VS@CX3N%O*T[3&Q,^R-:-R@+\?D*6,]J]75)+RE$<7
M>&+*+EN 4;.OFYL!S>,^Y8 AI6//:"O/FI?H)##IT"(9V:0A:I#?Y-+!V5O)
M)ERHKX,Z>S/9F!RZZJZSMY*=Q90K%7NWGM$[%+(*U;<>SC8XK$RI$G"K!^Q%
MQ//71)$Z*97=K#H?!="1TU7E%RT?8Y.Q.B)-D/]V%C^=3%"0XTL_;-&D?WR_
M1C,OO*!;B)LEPVO1.TCY7%Q?U<[/8-X**65ULIL:3-?T(:9',]N05-IF"9R$
ME1N1^N#,C&W0G4-E*B:4W->!SR)[1C.,,CADOAQ%'QMA\-M=IB@/S&MI%V I
MO^RVL[(AN/),0F59#S@(*':JK,\^(&'<WT]P4D*$_K5%@KU[.WZ.J-R8!TLN
MR+P6QN3<[33X V%]&2=M;PRJ;_&+%X9B*"J_NW40GJX4<MC,V&"((G\73=['
M&#^QV*#5 R61MT346O+)5>2+N4O2>FB!P.&3W=^A2BF;UZ8"^;[F+,)<2F4#
MY-<@F9>[-#LUM$>U0(@O0929]IM'CXLUHL*#"O'$FZ'3%84."6^)FXQ@;,<*
M*%W,S=NWRC[&H,M$, NH0NL0S(?XESB(DF^4!BGS1UYX_CRWUGB -NG>-T77
M[XE=(I2=(7G07</M87Y\!^]E=9T__/O61EX6F/<)\FM5B<>%4637^P$42;57
MUJB7I.3;5SDD@!),Z[)=XJ:H!,'O6G<N8ZWA/JC6Y9;:N> I(8L/,$D*AR_W
M)7IV(0GD)KMS*#?RXA1$J'H(@"*M*00,^A+4CY<V/H> TK8U0TD5,H4/PSE:
MB"Z5BGTD\XP Q5:ZJX3>$X8Q5[J"QY)W;#9%$_J1V"(6J<6]M(8&X7C(4#N9
MU]%5!I-:-EC*R$GN;(!6&^9KY)Z$29GA&8UK+3L;Q=:$;31]PS!I,1RC<-0#
M9XN.-&:/1LYYF&09CE.X;EEGB[*8$B4M+T7<":.]3Q\)^CUEMNT3>V4!6"!M
M#;R=]:L'F(J:VPB<K<(BC8OE-04 LBI44]S>/O#R<NO<MC:"'.G8XVG),I#%
M97+;VLA$+[TY2$V<&RHMMM^4!:-T#9J.,E!PRY<8)S-J;%S'%()Q=(?HB4A8
MO4.637&+8WH>)ROASF@S@KD*WM,I/:M874;O,<:LV^I^Z<FRN14]K/ 6\L;3
M:R^:"-FF:&";(\X1\7&PW%A?X^EF<07!6BT'LHUF7XP_='#M?1[H\3.*9]A;
MS@/?"X6HB-L:2OT@R1+GP+)/)4#I7]^_C.H@K;\U5P BI2J&IQ7H*VHZU*HQ
M!JJOA6"#B=NZQ&)67Z_9U>@D&HFHM1W ,R[-+30QO.5&%L"\1H0@=!E$+.WT
MFL'R@/!B/-TXA-\+(%?W,R8:*E-M*%:=C2<F=+H9%U]L?)G,RGXW/NNVLB)[
M9% V?ZVE@\&,*@.\$L3(M7AAWC/J/(BILH8EN+M\<ZYEFU:*-C2U!X%211Z-
MU5(_WM8R5EAGSA&EC8@HFW= $59&E72S!S>W,HW9"3RY1.$I5N@%/<Y%(6R4
MAD1&EHVMZ!R*'3V)V\(N(C,6*$64LD5I[6ZV@X1!P.,N$A3=D8>^Z_6O<R67
M1S*5NZ<@D&$53X430H%_/]M@P-"]AB97Q>T!$VEC;*^0$C##P@PON88+"28=
MC L_@8$*,^;+$!?HN^A@DL&H*&AK6<",]3+)(54'J;-A7(WQK;MF6P9BK;]F
M_SS24?_Q_U!+ P04    " ";.G96R[7_A5FL  "+" @ %0   '!Y>',M,C R
M,C$R,S%?;&%B+GAM;.R]>7/DN+4G^O]\"KR>>>'J>%G=5=5S?6_W72926UWY
MJI0*+>7Q=+QP4$FD1!M)I+E(2G_ZP<%&<&<F 2[5_L-NE40>G . P%E_Y]_^
MU]N6H!<<Q0$-__V[CS]\^ [A<$W]('SZ]^\>[MXO[TXO+[_[7__QW_[M_WG_
M'IU=7%ZC:_R*ENLD>,%G0;PF-$XCC-[=??D>_>^3VRMT%81_??1BC,[H.MWB
M,$'OT7.2['[Y\<?7U]<?_$T0QI2D"1LP_F%-MS^B]^\E^=,(>_![=.8E&/WR
MZ<.GG]Y_^.G]IT_W'_[YEX___,L__<\?/O[^P^__OP\??OGPP7B-[O91\/2<
MH'?K[Q&\Q<8.0TS('ET$H1>N X^@.S7H EV&ZQ_0DA!T"V_%Z!;'.'K!_@^"
M)F$2_$*4&&]Q\$N\?L9;[XJN.7O__ITAS]MC1'Z@T=./GSY\^.E'_5;M$_"O
M]^JQ]_"K]Q\_O?_IXP]OL?\=8JL1QGSL#H.HQ]]*S[_^Q)_^^////__(_ZH?
MC8.J!QG9CS_^[R]7=US.]VR%$C9K^+O_^&\(B>F(*,&W>(/@OP^WE[7<_?PC
M//%CB)_8$OI7WB,F;&Q.XCG"F^KW2!3E7H-I^1FFY>/O85K^>Q6U9+_#__Y=
M'&QW!'_W8U]&[]D7@.UR6R9IF66:>,0RRR62=2P3> B^=/D<$&_8L7QLN0\%
MW2"!%S29_'CX+<&ACWV^__20=)U[B,#72*.\\+O]6\R$^_3IXR?Q2?UW^,V?
MV0>>1,&:B7B7T/5?[YZ]",</X0O[-?:7H;]*$]CQ<.HI>IPU0?"@UW\\F&>8
MM9A-&Y^R&*]_>*(O/_HX^!'D@!^X0%P8]H\_GX=L\O9+WV<\Q*?LQU5T3U_#
M M]-3_9D<>/%CWQIT_C]D^?M!)^8)+'Z3<:P_,6?X6#Q4X)7FU7RC*/3-(K8
MS;",8YS$]]XCP?=LS4_8V'\MR'$$@1'$.\,;S!CR[[VWJ\![#$B0!#B^QLGR
MD>T<;YW42-7^WN'"U'P"U^GV$4>KS2G=;FDHMO!E'*?8?]C1\)2&4@E8;6XB
MR17?[%7?P]&T1MUYYYL-YFH+N_[I%K,YOV6'WBU>4Z8@D(!?[0?NQ2-(#G0^
MG+_=1UX8!\#!#8X"ZM<>$!6/CK!.%UX0??5(:BB5<<O7T_C*""*<>U'(KH"8
M32+_)EK8KWU\S-F_#'?L,KO"+YA\_(+A,V^;_(HWQCB!V><7)\'ZE*9A$NT;
M6:]^=HRS"0Y%<7">I1';"^+SX]/*K"S^E[CN$.KTKK7K@QWD.R_PP5+RHO4S
M4WK.8,7I#BP\>1M7716=WAMAZJL9.G_;X3#&-Y0$ZWW-Q'=Y<P2!F-)PZL7/
M-Q%]"9CJ?+)_B+%_&4K[-WSB%CM7+UJ.I2,(C?'IP(EYPHQ@GRDA,/7\KEU&
M["9[PK @)_OLD1MO#[]:OGJ1K\\MICNFVQWW",#B@79_%H#(H0^7>-UGYWQ<
MYPK"DO'D U\7Q"N:.^6_C["VI]XN8(8H_Z3\((%KG>E7<%;X)VER39,_X>2&
M'2HU2]3Y];&V[6/[]GDL;I^5V#%?N<EY*?4TO:<^-NU6%\/-Z8M7UHJP4Y9I
M\DRCX.^X;OO8'V>,R4H?8_RW%"ZF%_9_]VPHIO5X0=%-T/[\",RO=CABDQX^
M76$VQ]Q'N]JP6XA;^S4"-+\S@A!7F(V,\VPI&W__P ZF> WJ)_;/W];LT>46
M_E4CW'&T)F !"76HS9YN>VL4S9Q=Q?!E<^N]5@7//33ZEZ*WQ#45]UWMAFI_
M;XQK_QE.V,MPN>:[&4P:9M>L@QW!V:_NP,_*#MOX8>>SV;_<;MG_1P&[[KDK
MIDXEL$%Z]/65ETV=15CS\!BVB+P)-4=W^*F)\_KG1V ^[[(4EWE]?*#K6R,(
MPG9VNDT)!':$SYRI,Q%^9AJ-=EA>T3AN.N$.(C'&D2$<T##E4NL7,Z\"NA<T
MNDC! @!W"(]HUIP/!]-Q;Z6ES'9APP;1]K+*=YO_^YST\?._I>RNN0SC).+Y
M 3'?6O?LB)96QS65H;4_8M#CL+]\8>?"$_[,2">0&J -$=LJO$W61E@2'860
MQD>R;U3Z:Q\?-X*F@GIOI^S?07+J1=%^0R-8G[H+I.O;UMRA%RE36>% @.CO
M9A.L,6P=[@FL=#UW?&D,E7V[(W2/,3_\&MWF54]:F] ND31F'VR]D,W66<">
M9FKJNN0=[T=KQ.F_Q?R6-:+ U4[U[N]-Q.:-VZR_EI?&_B3$P=_]P\@]/[K)
M4+BF;C&<[^J/]^P;J/,<'DQFC.V6;7IVHO+9?Z;$QU$L[O&Z#=?VVAA&A[36
MF*)Y$]$UQGY\$='M/0Z97K$DA+XV:*\=7QY#+.*%U]ZVV?=8>&@FGH>E3W=)
MK1.Y#\6!,D3@<HQV-.+7(7=ER7CX*?6+.ZWK6Z/IO-H5UQ+<K'MZK.!_[N"Y
MQ9 W):Z1NQT[H9I"_RUOCG'S1$]>&/R=[XQ3"DG>@2\,K]"_8<8TFV_^S]5&
M)V7KA8BS%)XV?<'Z,*-8.U'PXH&*:EQ&M;9-U;-C;%@/4M[X'H/C>K7A:6/L
MZV&3W1Q<:G_1>IJC6'O,%92F%,;<<^/J,,T*_S0T_$PMI''<Q3)O>&$B!HJ.
M?B@UZBS%?\)>=,_&K-.X#J=C;8.#9R--0'/] WV,E^NDZ/NHVNWM+UGCSS""
MXOM7>O],TYBI.?>O;$KV\(OB[U8A^$.,7U\'(4XP#D$OK'>F.!EGS,S++VP3
ML7N);YU;#'$XMK.ZI6 VO3J*9YA&"5B%_+LXI7&M(E-^<$RO:;=H=>WC]NXP
MIMAX\?-G=C'"J0FVG%#SON#DF?J7W 4-BWT9_H$&8?*5_<B6O_*:.Y*4-5G*
MVLM>:V.&AG9#1?[Y.53^Q,$CP>=ANL7"S+BFB=3;L%^1L^9NG(E$'UM3EEI>
MLK:85P';.SY<<8U?2O.SX]: *%<=CEZ"-:X)%!$B*SU7&_ :/X4PC2('#@ZI
MQI"IF[&FYD@\DRE'X%AGS*Z[IIIT(&,Q9;WH"[O<[B+Z(BS_&I_:(6]:U>E*
MT:KSMUT@SB70(NNTNK;7;&V<.$J,3</^E6T8]H\_ER\5C&L=?QU>&,@'=K?U
M"#E)8Z8)QD4+INZI41*BXV?X'TS:"S.FN9JG2E+A#TRQS?_">+(V2[H/S1$F
M 7)25QLCB+]\"^J$JWYVG!R<:F<O>_+#A^8*JV[O6CN$V-44Q+QB4[O0(#R2
M;K=>M%]M[@)V-6V"-804,J<VW.T!CJ_8IW')E*W*<*P=PF,L7H2]U>:*S7W=
M"F4/C,$>SW1H]AKEGQE%GZ5, 6!:(('U#7V=\5"W90YXT5[RP5L2>5\"PHX[
M&JK,R0L:_?$Y6#]76!:9HE:9?G \-6L2&0EMHD;PGCZ$ 2_++L5%.[Q@SX+P
M'B%V1*-]AWR9^H='V,@%S35?[&%D>L)IMZ[9TX?1<*X# 20$'&$U ;_<G^>4
M8"B]@L:$7H9,CV'V_MI)UF#K>"-,GE)7SW"\CH*=O'0KKN(V=]<1A.Q9<!MV
M*D97S'@.8[Q\BC!N/C :GY_A#F:7Q@:K"L9*% >7(UE;1IFC=N.QZ]P(_4F_
MR 7&/,M6^%6YR9T]$_\Q2)[-]ZN6W2K],:+!.BC-(57T\DF^N!NH5*;95L;=
MD^BXH=#V&*A%YTM%H$CE@8-#BBE!S9&HPP@XO]45[)[XBL]#_ZQ<S5[_W(BY
M;S)%0)58\!W:DO%6^<HX:!(F0%BC65_][!AIKI6!H ,R<0X@, DO197;WA+1
M46J?>)D*O\;8G1W1)X!Y:]QZC:_,4#_B53=:81F\6NA(+B:2]W*+0_SJ$0B_
M'Y#E8KXU4&SA"XV2)S:55Y2I;2NFP'CD/(;8+L0+E)NH%N'@& H#"78+&ZS"
MBYW_VQBA/]"7N[@7*QX<'^RBS;-8^[B3R"/[>1O$,8WVUS3!PK?6%G.L?&<T
M#W.C:WE"L&G"C6:B3XJ?$TCSN(.TJ";;HB?1L3 JF)YRQ:B3/S!&8C]8MQ8K
MM;UE+Q$P2X2(DP"P%/R'&&]2<L4,(JYMB7/7].TWPF_:HCH!7)2S@*3UQ2-U
M3UM;FLRSW]VWUOK.J'D]2Z:3^S!-C,GLJSQ_6Y/4QSZ<J:#;I:HRH#C#W1%?
MK0TTB8J3;AF/[>^-6##.;7X)VL!3IP3@))189\I)9I)V!&0^ENJPZ-\WC$N/
M_)]@UUBR5?GP""OV$$98S*9*1UV%63BT[EYN>VL"ISD/UQT(]IM_9S+>'R/*
M W<I+UGT2 ;Y>9 GJ)788+[0"_:E>D2B&++?5>5ZU3\[JD,1,J]:/8G\H;'-
M<6.Y1?Z5UL6J3=PC"5G,D="*?%4"M; %JAQ'A[X]!3@5X$0G'#<5DW=Y<QQO
MI[; C&F6JX#].AR#]O=&3_)O\DU6/3F&(\#_2RJ]^_>4Z1.\AH(=DDPEN@Q-
MQ*P2UNPM9E<#LQI4%KPX5V7*$SS0)+WS84>I-LI*;B @?1DFF&W(^H+UFL='
MKPC0^6N=$O^SIR>-C5XCRP$$QBQ@8Z<:3#@.U_LV)VCS.V,(L64&5B3*M:XH
MVS5,N_<EF!<]@4J1'=1EK39U G5^WV)M6U7WGD8DXLH$Z:/HC F*6U%0UV+^
M='IUC*("O 4P$Y%AFNQ-W:VNM*#A#6L["U2M_?TSVP [G";!&@#LZUUS#4\/
MY(^X"(C,9JWU0AB/V,O;5BY@<-?<TYLT6C_SNX8[*'UV7/OINOJ;Z_KJ1(*U
M5> "RPU3!:#(ZX(==0>$<-MIC1/#(\"<N)?J(W?F0P,9O!*,^#.F3^P+>P[6
M'JF---<_.V1,N?*H*/YUW ND[%/N?H,TO#M2]#GP W8C&#@W#;5I]<\/A2E\
M)2N.*\[JXA,62\?A8 55686-:H$AVY\?P_] O%BE&S:"'54\Z'Q=K_"31Z2S
MO[SQJIX8Y5J3&!^=>BS6/6U/Q=+["E+ 1>4 NU<@,HZ?*/1!/@EHO XX,FRS
M^G4<I<GX_%>O(3M(GX.=K,#WGNKNW^[OCY\%U)8?7_OXF!A 1B/+M@^D^9TI
M)G/&+7F4&7)!73+E^1O;84&,;Z*@UG\].!OV8'^\A%=KJ(JK#B K;:^,M0UZ
MM!R3DPNG?AWJ,+BLX%--11ZJJ^9GQW R3H6U3APT0='4+JT'#6I[;V1A5%6'
M[C-=T8ZZ^WL3<"[UZ/9Z%*D1XX[:O2S[HI[@$&]J 6W;WIH2;D';O=SAQ7'"
MIZ":B7OM-HC_*H"#X*?ZP&GM&V-$(/OEW9WLJPDTV.DN1QPEHZ2R2%9^:?&!
M=;>VJ(ZI;!NQ%@F@Z4,6BH3/Y#5A#R%]A Y0H /P/N?Y)B)7+4$V)T/9*WS-
MWRE-=9?MSX^>1<'VTRKB3D)Q#:KOL%-B1>W+(Y;#WM/EFDUTI$/^C6B?A[X]
M 0.]->VX]GF7Z*2KS2;&R3UM;/->$\8]EMATX&QDJ4'7KH>'4AE#(TTQS+^^
M<S+\=+88K8U2N[X]AC.O"[RH[E?'#5MV*B0>,?\.A[?HB)ZA4&64Q$O%'GAU
MSL'1^+%V''R.:!S7F9(UZ9Y5)\%1=$;80I^9?15YA&WEI;\-PB#FZOX+E@=3
M8QU9MW?'29VN.&L-MX]RVMQ3=LUO:+2]H!'?4W%M$;%=VM_486%XC@8_&,RQ
M1\7MT:I)9U">\AONX=[$727J&R#7HQX;IO91B\;'(8#,5D&8QX7CO0S!@<"4
M(9&1Z!%V6:0[.%  "QMR,5-F'.XD)+T3]-Y#61@7@:"]F7WEL\-6XLG_@)5>
M#$<T/VL19 W<=60OO,)FWSD:LA_7(O8ECE#9:4Y$BSJ$F:S1'B4Y6MB_($/
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M:1#P:3:&+KN\.>[URV9V%7$8 Z$LMN2$=GESH C?'S$A_Q72U_".:9<4&J>
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MYF0^<MKSQ!3#PEJN^<#JQ SXT"AE8[._J,'AN9T:7ARQ#H[00>=#+G<V#V)
M=56*(1&,B4YS\Z"'%7?KS*?!_,)[[XDACK@N;3.L'/%YDB"M[,6!=#,.)'A
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MF9GAL<?[V,G;@*O7QJ]YJ,]\I9\BH4[B'9!"238.LY3$^( ) BU['=J  \\
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MXA#'B>X^,)%B^.RU'X39D*?@J.&>[FLJO#9A+US8Y9:FHMR<VYV1='NP3WX
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MQ&8>K6KM:5/7TD;9R)>A@AL0/$.E3_2"?2@V>_$" B'F"QJI1;03CLQ !SK
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M[ZE$2KAUE]HBOXA4*_LK@7:X?(HPG\;^WG9%&4G22-.>A2@DDP)5B^'0U^Y
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M[YA6'[O.UK0D$,G)(EUC@B"Z=;TFQ(OCU>://-<K645\O%[(ZYPBV*22)G3
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M:XGZ9T"2KVL4R/]XQE0B/8%6NRMR\@CH(S-C;9557"_$,_.L_G<\M?849!D
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M!M<5/=?K%\5M/5J0J#9E,"X;'X=K=N!;JT8WQA#HRN8H0]>DYW-NX4"Q!=X
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M06_\I*YF4N5A5*9(?^#!-N$N/9ILYR0(I==)E.>+S6\1//C%(GN*W]Z+ 8F
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M.H3KA5+X1"7ILQA/4AO*LQB*1'&]G' H$-BPS"((=WH^;%]I,DB%)PC-!*4
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MM&XQGTJHZM$RI%.A]'6)(YTU0N$-3<%%UD+H!UX^ <+'2E@+BG8F E=9["O
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M$%F;=2\.R=^O9BC<B;#!LK/@]E@2;@Q9 _? H;D9M0'4&UJ:CFZB0ZX)3P*
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M?@%>,GG!E00($,R'Z5%) !CX$ A$! (1__8?K]OPS0N 21!'O[S]^,.'MV]
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M'S;QR_L5"'+2\0\YN#FPZ!_?SN,7 !=/2*'Q_,.SD=![ N$O;[M_?Z^;G K
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M<H.V&F)];1+WLF+>"/$@Y4K'9AL#1%;!D97E>N8E@4\AEMS6 J(O@C!+J;<
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M]0^:J<=-2<>BN!Z=*!>R<@CII,:..(Y7_^B3%A<>@CKF"9A @$@#,(FX"Z6
M_EP &H$-CCJT U*E41JM-_;2S.TX^^H,_FC&\XI$3#@.MJH8BT9Z=N%@A1F
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MKW^+@_@R.JV$^#6-XZ]\[5L#83>8CA>])U55[262XP^!+5P=R1LHQ]\ 6[A
MTG=7KK\%MG"-I"^]7'\2/%DU =]7Z7D*?%*F5=VYN?Y*6-/2C'UKY_KC8ON6
MJ===G^M/ENT3=(P;0M=?.%N]9SHWCJ,\7Q[WM57KH54'N&/6U,LD#;9X40[O
MSQ9)DFT+U$YOKB;YYDIU2MSV9;RR\56!D\"T!@SZUQ$48CFW<D+-OXU)3+,N
M29N<\J\C$=2JAM(AJ?GW*87JW+1?[ZJ*R3D./"4X2!(>)UW!C\2_QDB:!2$Z
M^NZ15"N77#5L\@2,M06:-0V[6Z#Q=T?7O)BCP34O"9@ZO/=!\OL5!%C/!$A3
M2D?>4*S/.PGM>'S+^OS4H:WVY$7P$JR0 H_G-J8L:'QW2B&MK$EIB;/F?]!!
M\_]4MIJ#_:EL=9^:CZZ!H-YD4N(1[6%YN+Y XQ4Q= W"7O7I'2Z'.=FM7BGN
MCC]HF$J%,F?QMW^#,%T&CI>@G.KRM*27JU$J$U@>LNOB5*^N[[IH\H*,4;C.
MLEOV1CK3SI_+A/<3NV2OA0Z(9)POD_ZCGY;K=G&6W!$D=M.L\EL&O(O7B)NV
MB$N09,);YJ8DDW G+=+#P 1.H16L56D6OQ5;R;*/@4FHV4N\RW757S$ E&C!
M$N+\!3L;F!8NCXD4C>=%M+H +R",=Y@O2X*(=^ R/0U,Z%<0 >B%N-SG:HO,
M)BP?TN %B$Q)K*]Q;4_GH5M7 )D'E:,.Q3&NK90NF^/K(* L";!L=28[#I:F
MPWQ W2ZE2%OE:A?2_EHE^_@GK>,,.MK1I7PG..X7E^9F035K#-ALKEW3JKQT
MJE\S98-_?F\I5 8@4DDNZ$:D(6%R%WK1K;<%3">*ED^9L;WKPH%G;1/:FO"#
M'""D^RN;;6QDQM,K$2&J+_^1H=/J.D*\E^4;JUWO]5!#5D_)$NGO.P5N,XO2
MZ-BV/B\/+:X]^:Y2HW+,\FJ4^BC^6A6T?  ITJA6%.A,4>$4<Y8YBJ@@FZ#
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MIP[OZJ3P&W#;H;:X89QZH5U&-7X:$T?Y(Y?U+>AX%Y*)V<LU^F\"[PF7I@Y
M@B;&RV//[:=,#R9_ZNBE!EX"[O&SHN7Z2P**52#IP+W&.;TP4!";*,5.W2XV
M3$$ZH%IF!!LF:#A^5/V$?HWCU?<@Q,5:KI'DC3;!4TB6#KV&L&&*MYW85&93
M&T@FWF4(+PBEMPT3NP P>/$*7>GP#E9T7N3.-DRK>;B+SJ?5RX:)X-.Q_%T9
M!-9XY!RMRI@P&5X4'-#.Z6-S$;X ?%.V\'V8>>& J9,&TZ$ %M\_]W8!,@QP
MW;+*Z,WI6!7Y 3C*G]@8^JB_"7P,V14@II-F-=='4U,+KFU?(1+IO6U@_3P9
M@;"6EC>V@>Q?(=(3A365O+%I[X*P,7GPT?2S[91ZL&U,12;IIF$;7.[Z^T4,
M329. O&H#L(VE+L8/GLUMR$V;LG!O,:T1^?R<*._/--S+=1V,$^9P6BF]>DZ
M35P]<??F;#![41P<.A!S2'*U_2=:'FZX)<1$W32.OX'1 "71Y>/NLQ=1!'LZ
MF1S/\SH,O;J3R]WG+\,P8CC=',]?.MQP+WQZ[CYZ&6YN%NY#/6]=+ G+09A@
MQ\T=@'E>VH=LN_7@?KD^\Y+ 1X?<11!F.#]^L]G$(G0N/1@A&7$@GQ-)06UN
M(I*[14NQ+G+T-_L8F 3BGL((N*'[XYMM+$"ZY/Q<3![W2Z=J( =[WB@&)MI*
M(%V4OBBK#R7++$U2#VEHT29G&\HTY<:P9Y+E<G3HE)LF=10+V):U:N2V%A!=
M BJWIXPK&+QCI1$&S);CCJ>)$SK%ZG"U3HR9P2-X]-0!DQ3J,P-49F=RP7?\
MHDD?,](/WYE!*GU0:+JY<P.A@_(PQCV*)7;Z(DJ#%9YW\ **%T:7KWZ8(?/Z
M"N&*_?U96J:L(%OPBS2%P1-J]!2"QQAUV.*'FK'_^W,<(A2G]@9GPA;^L?YK
M?5$?@)_!W)-)7=CV)%@5*!1_Q !, ^D^VY,'8-2^T/E%:P"LUWR70*'6S9JI
M"*_,#:?2C[+AIP<-,W^_FK%-N!NVNS#> Y ?<$4]-6;5&'I[9>'C7\IJ;O?H
MOS#PL5J,/Y;7@DN(Q EW4T9C;?K)X@6I UCV7\7P.DDR'+)()U.PIVE6$&<"
M$L&6J\FJ]0K'708CZ!?UU>&?QB>\I<YP/KC2A^ L5Z"K$#9L;_I)ZCA:>LPT
MA5S+ED".KXX,+XOK7XZ[):UGZ1N]]1,L6@II_A75S1WW&P\^PUHX.>D[O@<A
M?@1VY\'\/+"L7G8"_!\V\<O[%0@* P[]<+3;T#^^W8"-%UZBE2:6JB6U&&A8
M\DDJOD5TG'7^;,#*K:*M<0 ?> %AO,L+S1_+T./\8]AP?(R1K,5<@$1'?L.7
M/"*RF Y!-6,K=*2@K0\3!'<9+[W80)#3P?*B</J8**>)\$N\O!05AHGAER:U
M-$LPDU^Z[8QLB(,(W-<(8J#,ZF'/!#@[E=5'U202F-8F@/YU)![]X]OR>X2V
MVG.P(Y)*:J%,--RM@S\ %!<+S/;*J/H:OWIA2*>B\?=IG1UG>X[H4C.V/=N/
M%PW,[6;TOIE&W=F^\1>A:V69L>Q9OXX746S];DS>\)'W4/D\46K?57V4B3:<
MS&+_B':KMP/()/.3Z\BG"SI&Z['/)H+(ZO[='K8M%R[!#I3Z9OLM2)_K7>2X
M6GA4 T!\#J+<*+^.D%$-DO2P,NB8\+&)N@%G^[O<74"9M,P(RC8$!>G#MTG;
M@MM'&77Y88N#P$!99NTQ_EL<1.E7A$&&'<J7GO]<F+(D0F6ZZT;T < 7I+==
M 9!K"T7LN.3V4#^^*>\8PVF"'6%=!X:[B9J4>D)JMP<\IX/C]RT,;T6CI&/7
M4G4<& %'0QT@CEGO*%@,O\!AB[&-=T>!D?+V'*!J>A2<AT:A>Z*Y%96<%,[#
M+^8((4>B27D<YHEDQR7!Y]&#[>\H8K0+MX, 9/D=',6$ZK[ H!#/5W=U_$$>
M30%M;!815/W$T4#WE(ZH'JNJE"MD325JC^-A5'V86,JUZ'@XE3)V)?H'' =/
MAOD$O<..9X8=S&X$+<C=],/2_"7EWW<\%>Q@5B/ZU-VM<JI*F/6\F-%2"=4A
M;A1?IC&0-!78_) ])> ?&7:!O*#_6!?:W"L\ISDG;C@NO;V)V*(F,<SWM>2V
M)@)9T=C+=<V48L7>$MN:>.=_) 'G(K]%3'_\35V0,-= =I21XG(^QS#=(+OK
M)D84+*-[@$[=!.U5@!]VW,%X!["XH^V,/B,HBT]8KM?HN$-8(O$80]QM_[#S
M6&_E.3W,[^+.F<_>R#=&TU] X"W7-UY$RR59:V":F2] XL-@5]G(RW7%EY1H
MM)X#C33-![#!0N-7$&^@MWL.?"^D[DYZ6T4/=Y)T!PMB\4\U0M&_OGU>M$DJ
M?VM^J_'BB:G-S9/.#!,F-567IB1#PWE"$?ZTIF/M$;Q;VYQ/V>WTMA:L-3O*
MG];:#.'Y@A=V)YW>>B,#9-Z ) '@*HCPT]V\E,4C@-OENG+J?Z10SN^G;)<U
M/E4AUOP::<>)=%,N"?#XK.V?_UWY5R]?=P$L3$ZT=5G?;[4T[HW@F9R-8 ZR
MB>?X[2C31FQD/)"UR]R[EA]@P1V\B3PSRG%VXUE@38X[FCR.PC+<C*HNBZ3Y
MTLWMR376<KPJ8\D]#$3-+\;!IS%(T0YL>GH8CQEJ:&:9PT**:^!5<HBQ =WE
M*);'@+73V@$D,X"&$:?.T-9G@P]3(6K;_(['O/%V%4<NZ4!G>CPCX(!Q/'I-
M5#A3+&$=Z$R'C<0]9*Y'] D(H[Z6G+N1?<(LUG1PNAZRUT]=O.G$/CD8GB?-
M,6WGM-&PL/(/^#]/B+9___]02P,$%     @ FSIV5NU?))O ,0  =S," !
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M(UU;>!0X%CR@DHT+:PITI_OO[[$Q=\G$/.D.>ZN"O=[T("-HV0*_Q=(A(AS
M<N/T?"1316=EI=U9-8D.#[<GI?OL#<QA[V0PZ('O<-P_[9T>HWTY:.W+WTT@
M&VA?6@P7P?F:"PXD@:2M:7(*$+ *+JU (/L,*:\$HL[_S(&#E$T[=PG2ITY3
M-LCU_/&7"/F1%1RKLC0SR4&L,FMF)@)C%A2?57)3D9.C5JVU:JUI:NVP56OH
MX:LD;9IJV[!-OU/2;T7<&&MY>D>W!8[OD']?'SGNT[8T4WMO3^!8;IL$?,2
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M*D#.\8[;^BVUG"<'Y4"MC1P<RTDC/KI[+_>%)CM'P*]=CVCC;E<G.V+ISI<
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M8HXW*.I@9+Y5*5*N2;%S>==9&X7/NGB+$KO<SF=T?7,J]Q=0E(OUQOIJC:[
M>=?FL-CU#V-R!N.VZ4+],C6WQ^(*"BQQ#>1J=5%?8S%P<4EC)-.,+J?S =5J
MN';A%J[JG[2_ULI%O9"\XEJF!5FXK:&3]XAR6;M!E9V@\8O-*BB\*I1<NO.2
M[N/B/M.+'W$A[,JG*O.]E1VHW-NKK>J7N^(3.OP58[?Z&C'&PB1<KYR*VHST
MGPAJ]' M=>,B MR;A[_I7F^=_%;;;:_PW1YMIW9%V[T=KU!56.+/HK:>MUN(
M"W<X*U9U]5>[\H6W[MV-1<?@LZ44U%Q\+-#:A8W>[Z*5?C# .XT&>*V1WF]!
M>RUH;YM >R?;0<_M5*8M:*\%[3T?C;@])LAX5TR0%K37@O9:T%X+VFM!>RUH
MKP7MM:"]%K37@O9:T%X+VFOC^<]=L&V/,SW9%6>Z!>VUH+WGM;X6M->"]EK0
M7FOVM&;/YLV>Z:Z8/2UHKP7MM:"]ULEOM=T.:SN]*]JNF:"]%J#7 O0>B*BG
MVT'/[52<+4#OP<V-T]/UYL8# /3@B^W%3X]@</Q[5PR.%J+70O1:B%X+T6LA
M>BU$KX7HM1"]%J+70O1:B%X+T6NC]\]=L&V/,_UE5YSI%J+70O2>U_I:B%X+
MT6LA>JW9TYH]FS=[HETQ>UJ(7@O1:R%ZK9/?:KL=UG;QKFB[%J+W-'"I%HNW
M[5B\L^V@YW9JR!:+][!VQ9"!<8\'Q1MVCP];)-Z#VQ7 9%MF6#Q^WGUPVOOM
M^<66[Q\[[SX!>N+!S$,'1+DJP(A9S0]'I[8:^NV4$$A+>1FK1XP6JP4[,,L_
M'NM(4QX>([^6;$+*)SE7M2,\D*%(\KLX;W5H=L.+'^GO]3R3!_<M!,CAK2)"
MW!&!C (T/!V"0 "!$GB(T'=IYJ/YA4V*+.QC'!10QK#0 C['%J8LPOF456QG
M[^%C/I;^B(PR,E'XB(?@<C(! J#-_\$EY9IS*(KTSTJ4%X>$ DP\(,I+Q^CE
M4%ROR#J<G9U5N<?!,?''9;*5+I5581[ 2'L8GV/D262NQ5_*FGV1FO)X$HIG
M3+@O]Y7;AOU/L 5Z@E(F,$)2/> R6X8X?M=*+RH01IPM@5UH7?0XS\DDT9PQ
M-(C\TYFCLE5I'E$D#6?#26%&CDYAT^%D75(8\C/,Y)*GCRA$#SPD6NWS"O%]
M/R:GEO5:,EW#P5V,M]5GW14@).E7)"4[]]Y'E_8KPZ+&AH@)AM^37QU(E$SP
MD\5,-A YF%J3P)&8@(2)^&F&QQ*FI\ ZK?AV 2>N.//T[=S"_Z1$50HS$W(2
MI5X>QS7@868EB'C>)AI-IU62K!.,YP0RAI5,2WS7 C5K^< :KQ#PMO[N?=]#
MQ.Z?N<[F!R.)/%D#E\D@4)%RP,JOF,W5O0>]UX"$+88Q$4--JP0-R'K*QWH7
MCXOC&&0,?\"9@V"_#?+ BJVGT'U9AS!;8HD% GA-B'-FC47!F2Z&9KH"W9J3
M"]'OXD8?]#OBO_XNX]G%Y<'@:&_$0-Y@?YG51PKG6*N)*+Y_][<7 D,\A^4I
MB.H<&,)7C3&1\O>[<<;'= ?T\()0;)X6)E!CNF"7KI&#I.60-\<*N$M&\(T,
M'F X:F10K.H$U5S'*S;*]U7J<>0-II*<IN.:" =78O7DH>ND66:WS&6904/%
M$!.?(5O<.H);E6>K!)W"F?8+<M-W\W3V .E'$/(< 8"'K$.J++_$)ZQBQ<+P
MX#B#I@US&:5%H1-02B6AM"O2=WX91241ZQP$VC"=B>1+%+_'E%/._/G9E//U
M&K,R[X6/$(XW4<5^Q/)&QV FE;8'C+&2AKRPP!MZ9I1),BA(4X;%ZT45PL+B
M:!#.7M8)(U.N(&$71]9G<I<)0:BE)3A=(=P6'D3,C.#/PJ_G!*>9)' B26LA
M:U$-F[8$MI'\+X(L >'^PK_II*[A*X(:4](1_*V2S^XXHO$LG K#Y4N-M3%I
M/IL92]^LC3,R:, 8YR8B"8'?F72!23/:?28_ONH0Z#62HAJF+#A[<F.ETGK"
M?@^V-LH)0[7^H6JB&#46EPA)>"VKJ+:1L8DJEKR,T:HI9JIA04N(U^92N+-\
M!.P*&P+&%>KX6CF/ Y$[O+T4RRAO+K#Q1C^\?(7,@MXXSAKDEYH16:I\\E^"
ME*6X%'\[\6>AZJC"9L5Y-"'*L 9>Z_+B'I7GK2B48N/\SQQ/+TV.EYPJ]06)
M9]44%"#2<X:,(0L7A5B"#U(%F%:5'A[?Q<R%I@-FE8)IGE7J;E9,FC<W4+"D
M01?\D8RT3:VT:435:B1E"[5R6PU3=?Q] A38T&'F.J["L\ZH?K6=JE=6%@MI
MYBEU ZHF*\NP2N>JHG1J*TS+)2Y[E8[RQ+$YC(-A%[2G0 S@EHUPB]08T20<
M@Z$IU^?;B$S;(D;AD<+Z)]UA;[#B/B\?[:7 <YTZ=X3UB0@'L-PX/4>6I3#M
MREA_-0Q=7"JVGH;/T0)\FJ#^L'<R&/3.#H^/^Z>]TV.*Z??;F/X?.@7W-Y*)
M,GFZ::%QU$B0T<I+ 'O=LU4BXS;Z'#T$XO@Y"H0??_E<+:V7D:E&Q3Y8 R82
MV*!V+MXF&&IAH_$2K&P&V_D8/L=X1&B"G-5S40=2T_V'&.F0(W.EL.32FR1E
M88H?EZW+"3QGG?4PSE'=S_%CV@ISG;@,!3Y7%-VG^QT7$&(</_B@RGD68!9$
M>8IQ2_(V?,<)LFB*SY8K?^4L0O0F;&&;^K +D '-6U_X^+F*6,UG&'<,%2)]
M;M!@SW4ZQ9]P%E:!? N4KPZ%E6#UNU5 .K)Q7'T"FK1U6OQ,Z$C@CQ1^PW9G
MF>LQED*;XMHB8C_IT#)6!2VVE 7%=J!&&H/"Z?>V@Z#;J4-:&$ZK>;="[($P
MG[D@/G>)*4.F=7A  6,G;4MJ;TE15:(TK+E1A[!.JD _OT\<--.FW-AMK'?[
MHNUUK$_OC*Y"F,EM<T8?Z@#\:T'.5-H/U7/3:(TZ<[(0,3,3Z4"[R._,&K#M
M<^LM6Q[$8KS:)9:*\AP?A<6*(S\$MQ]Q(V " S^ 0497VU,\&$NLBT?1IMBN
M-7DF(AWKS G'-#/!%W0(P.R>ZID >SND( ],+(CD-6Y4,1Q" Z@U&(6/J8-*
M;5'^A]+LGZIPPC@# <Z$^[<K,D;*Q(BZQRFT);%MD=#6GOSM$;6C71&UU:
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M6Q5DJ!]2/[M*^VM.#8J7!OQV!):YZ>#OG3I#$WM.6@2%?!EQ\.@I3 3 %]U
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MF=PO?AZ9</[+?[SX>9K%T2__'U!+ P04    " ";.G96K%0B[ ([    @@(
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M:(1_E3IC(E1D<JYB_*UA X:E)*&>2;3OH.*56ZO,FS0OTF1OJHHLG:4Q:+O
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MZ.2&[>/^!]5)#=J5G26MF*H0T*<R3Q/B,*YFK0T77<R ^I?%),VX$$NE2&.
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M##Z3"Q.OY!1?@/8(,XSJ3@&&.'6(LLD5&,94Q"I:U:"T$2A0"W+PXJ2\@(?
M!E0MS4^:-"G27%<3?QV;]&!LP9MY;HJF96;_2YEQPZ[RL*R8!N\9<5][IN?$
M]^+$%Q+(8"?9+QD/RQ!9QCR-YYRW24; *>8G&XY3Y<VQ>9J9]DCJN,S8D\MV
M:O11ED/,XZ,\,*K?PM3?MUR;/K8S4,;T4,=<_F>-T=H0\FRI!DRC\S2.R3WU
MTEQS=AYS"KM(VY2:V#SG1>?42<ZUP(L7Z,I57.%<8W5?F] *TQT?8-*AS9B^
MR70!X,3W,4EUK.<J:<;'!91,."NL*=\:?7F5DT6.E7,)T# WALO%,7)^(ZX
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M<#V:H33$@^WIG?)]Z3HO;-"FCG%"RO;*&X+A&E)$G ;1<J0B;(P3"&J.P;D
M<1I2'B^RFL R%_+;>@E]\A9=@8;;<#,A$R[%+,)F##4Z2BVO905NV@QPZ^-L
M'AQ7R'+WJLJ#G&'/;]Z16;]9J&'*Q*1R++F?<;)R9H)EEE\R'8HJ(9)RXR-@
M=U$IX]RE2@*H%':57^& K26R5YX4C/5A0'-#DB;([['DG%VW=C75>BW7\M;=
MF$1C;Z9$N0.QB=Z5  !CK(0A;RRTTE8ZQ-QOFZ06N===]E=C<S2(\3_7(<,U
M$JR6(>M+^1P?I\BII9@^1]@:#V+ CN!IJ=44QO*,$[B3Q(\0MR@-5F<4Z2/Y
M-PJ; LC]FQHV)'4VZU%IC"S 6B->6$*]G++A7[A]J3$E,2]GU$<3FV3YXPQ3
ME")LK3>$(2"\@5V8Y@6=/Q\ OKM<-L&UULH4JU(CI?)Z[,5.52=B_4.^KQ_Y
M%3X'<('7"H^Q#=,L47XEMV:@6(TO4_H@"B2N*P8RW5DY!(R%(P$9!UE\+8G2
MI#:;A"<I0M>SDZ+*TM@D-UKA&UZ>([J$IM4JT# LN@=P\3'E?P3Q2G$N_O.E
MO0Z^JNB7E&$&O%;IQ%.JKIQK5L9"\K]*O,"T.%/,0JE/W&%V AP0 8JU(^;2
MJ0J-[JV5F.((B TO8_1"R0$]K.&D++R4QQ6+YM,-%6SI:!_T@H(X3BVM%&4U
MPT$<:[DK?]0??]>K40'[#4R:>!U3[6X#7SNJ\C2U*3Q>50]J*#D>XZGM,*^V
MN*S=>65$!)8[0=N'JVJ!:7AP1&J$84%L"*$EU]>[TBK61HE >.[Q37.*]&[Q
MUEM57[4#GIOCIVR_I[*E<.O!UKO%>[=X2]SB7B"DV0 >;JT(L0^B+XEMI7WO
M4;?I,Q0_R7/;,F?YUM8Z!@QO4RSLMW?U_ZKS4,6Q3%1:=L5]UI<Q[G+T^K:4
M,5[?Q8YL))XSQ53UM\:H6(W1E&IS16[2[),U-OX9&V5&XB.:+_,^RZ/3]V0[
M"DK>W9+8+X<6QUC1GTRFLS36H3;VX%F6ABHJ,Y4'7O'6#,W8QN/DKI(US6(J
MF1V"*T*9$?QNQGVV:X<OUW:4J+BNQ[*99M[J5H6E"6'+,7 $N(W)(\=2^S9S
M"MA6H]UFY<O$$HE)5589XXV,N=QX&-,Q.\S(8%[EQE-.I@V"R^5447Y65E)Z
M:W_?NGO?MB.[_)W2IJ)B[=XEIJ.Z"SO@ML1IO6M5%?OI+IS,<T \]@$MC)N5
MV1M>9?YV1<"JF0O9W.H)D)U2.>!AKB.-!7-M(0UJC^&^#D.5YQBE8_W?L(JI
MRL88@S8K,V"GN:I%R.Y:3@T?XNB%I-[,6(&^\J9QV!6VT,B5*<9;YH  N8FP
ML([:ZZ5V\E2^W12S'>J$$_9U4G+8&HYMB[F3<Y)" 126N@^57_:BDA+<;^Q,
M/'V=>R4PW/Y-3!B!.^_)5(?)U'9D5K]+[ZR)8\0$V]DA$#=2SUT,/5QZ( !1
MK:PY/0 TH=;3P7^<8A!P@HA#E<1-I@NNT@/W#+"V*HQ!GY0D?\!0J#[C.!EH
M 4C9<KNZ2!%I-/$L>/7?I#*+*+[#K >_, 09Y9J%;2#DR?@VB &M[-@&A$=*
ME]])1X%I6FA;L' S(<YM2+A2LZLNN[[8T) J?6#X*"^<=^K-UQ2VI-T,ABYI
M.'EI()+;O_RF$UFU&!>D16(6PLXV\<#8%4.?,?P#%]:K.]VF:Z.MH&L8@38'
M9(E(O' ]E$S2$6DAF0G>(\,!7T1I(K?6E?,9IW#]DHK.Q/(FK\)WIM,TN5$R
M+DAA^A6$! QT L&FR%V3&(P/S")7:VR2:IX11L+KF(1Z%BN3_9..GK:B]+(K
MZRE#0QX4/7[;,/<(OW^?X'$NCAXQET"WL6ET9"-)D72*82R33QL&@G4;_L?&
M!A#T(62M#R$[;0<\-R>FI_U1/2V%6P^V/H2L#R%K20A97UGEZPOVU7-<T>@3
M8G(+EQP%)0?MQ9@:%F("#-G"I5.XT!H"T, 7.6\==310W\K,Y=HYAY,Q&7F=
M9S\I->-D[S"=+:I"$>E-0HE46923<1IM(:;1+"6Z_G>9*'%T$,#_CPZKSKG4
M" G-)9S_G G*D[%&%DR;T9@E6[7HTM11U=:WX)V.E(K%")9H>JX6,BR$;VEI
M'>G:0*S["/HSZ,WQ(F@O6#]'W!XXY;;=['$#<>S]W_]V^5%<O;NX^N7JY[\'
MXO+=18LO<8]M[02&'YA^L'_JS-L&/GNPEM-7(&S,D*TDXUH$^\/#S7Q&PMC9
M"8A7+YZWQ-S^H$?R9G'6_?:4W^??BU]D)L7',H[U7";/\*?'PQ;A(1_/OCNA
M0/RZ_W8M$^F/Z"FX?*:P 33L@5/O+R9:C<2 HN6P!M05.Z1[7M<S_AX8&PR,
M#21-YQ<7@_?7@[?B_!W\_^</@\';C:J#M6Y?9^W%DO[*],!H/3!Z.;%U>MA[
M.147:9(H&2^>/>L5L;:Q4O]\NGLP/8W:;BQ_*PNU!8:O=^E<4:_AHT/RX!W=
M26][T:$'1@^,'A@],'I@= $8&RB7G,]F"N-_5'[VS/Q^*\Y->=>3U^*<RIEB
M:$]8Z+DNM,I[^#\@_)^)QH\[A#?5(7SDCJB8)^.W78W$SRJA:@$?% 4X]2?S
M34[FHCH94%Q'Y*+25"R=\Y>S=)9I56 :]P?.+'>GUHX3ZDQFP.%!.P"Z.;':
M[8_6;BG<>K#UJ0';EQKP>T3^)\H,>"1@U.R31SC'YS(G-E#6J23_MD)ZM<BR
M7=KG[P#0HP4@?'O3\OG[]Q^N_H(A%Q?7EW^YO+X<?&SK6;334+*F)+=?V,.'
MF:U&044P'K@^MX&A6WV;BHML?%7NDY.7IX>GAR?/#P]>')^^_.ZUZ?IV=.0P
MHLM%1ZCLD'AK*Q1QZ.@Y-J&BZB!82DR)BXG45)SA*@NQ8UHFQ1N=3E7T^:([
M_=WI[TY7[\YY--=87_"]RD;8]^IZHF %JBQTF*^Y&5MHPEI>?$=-6+UVW&O'
M7U=%8!-IH'/ M .N[50F6J-K=5[O_3AX?_[A_/KRZATG&OPZ>'=-:0<_#]X-
M/IS_(CX,?AF<?QRT UN-G+6M"+M<2V0-0#8N,^1_;U1^"[]_GU)][U(,S*32
MUE@PQ'88YM*PIJP)=GJ.J>")WS49M,<!]<E0JJI6777.N%=!@F]2SJ8K*'C]
M7Y<?Q7W)X;>.M7VL3>]0&53;;KFCEW I/F+##\VVPMYUW:6HE39**M3F XM>
M4\W:_U?[P3\Q;!I^VT%JT_%3'XQ&V(M[K@1&QW?NZ(<+T_*@N%$J^6;TZ%%)
M\%V%=S;\X +;\DTF6$<LPV+ZLA"_A:;'E?GL'V*GX]>2^F]TY%#=;>169+\I
M([#](Q!47(+.&PYY:P[72JQ=.]]>VGYHT/[UOP8?0) .NB)(HT"%+3VPQR V
M*^$>1;DJ4.\K)MS1L]X>Q"A\N2AGH.^93FH3M>!JE-.R*+F5DFND0CW8T""T
M^!)-T>NQV)X:J%U!XW=7?Q77B,H_77T8= :9 5FQ?88&7',HANC*.%D5<>5.
M6=S/IOX"E3_5"7<=K"-^(/R[0F.ANC)*XSB]R9LE0M;THUE"T@=M1^/WD>\2
MOGX[K_<??CQL1P^:IS*K4Z--;#6#-^2*;L@;;E;7%>$7JR<G6/$9>))KD>5Q
M-=O^SQ54\UB25P;:Z*]5@S[+RP(14;^OW_"??W#%YNTP7%1PZJSE*C#R#IYY
M4<AP @=M^[51DT? JAE>5_,Y<!'@$>?T*$,FL"B#(,I1/)K)A4,>;H7F+J'I
M$YG7!;*/BKM#G5A<705Y?' ]DK>BB=.#.'4?-.SDR9VZG8SE>3HB\#C[:"->
M//TUZ:.2OB[ZO%<3-DE-.-IJ-:&16;_ATAUK!'5# '9F87U_P18#\E?.RBPO
M)??(M5+8H9##= YB?Z4 P*=#-9'QR+=Q!2NL71.ELSPPND:*O\H(5JDQ])[_
M7MW=.R#A<K@0&1\$OAABOW)^"EO&8#->U]@X]_04\MK@O]SJ'-\)RRQ3W)2=
M>OYF5<]ULG4X8XD<C72L2;K%[/["?FO[F0/VX^) Y+U1,#S\:Y;T/8.3L@NH
M/#4\9=LEY^AU@'//84B)&A>. )0K2]0"?QTC_.D,YY)^L^X*_+!(PT\3N 2J
M#JQ P(!P)7S0V;7C"-A&F2P\N"28>F9<KJ$$+.1]C;)T6@-6&$L]A9=AD"&,
MA _!)A2@602_A+(TC>%E:#NYYK3:VYE*\MJF+ )@ZQT<0TYADSGV@H7AD@JL
MZ1"HLS3]?$8"SW0A/MF.\HDLRDSA6]BBE?[EGO6U7O>!^)1@=R'XK$SH5X03
M;5CQ.&7B_@X(9>(T=U^YOV'YF<[1,X2]8F$U,""J&  @8.Z(B(06J @Y,QMB
M9>'Z/9=A46MJS;Y^:D:-O9Y-W]FZ^QMW%<8E>J0",82),0HIUE/-<YW1P5!W
M:CX=:CK-1^+62P=YIZ79W/4O,$Z_7IH8P65G]H"1RUAF"UA[FI2$!"%FV^34
M"-N@K_E'I#,^Z1UUB]VH$#[4-#MB:^2]M+Y=AV^P"#T= KVR1X&]M9,%AW/!
M".C A>=HMZ_M)GSZ1@\K)(@QKA!;8<$0<1K*F%H"XZDBSE<H?_=9L?WT)QY1
M7.BYCETA$,*2D3@\?7%"U$/"FB/$.7SE? RX &B8:7<Z  Y_]V%AWGY9?]ML
MV:PV5F.8V'4R]EN5*T(ZB\],ZY"T(L$1_RP!D2(=&D@!V\BP0Q:#[#7L+*O^
M0* 81!R)FRQ-QJ,RKN@PWZ]J(P$@IRSQVBE@8^8C"HJ9IJ9C5X3, ,@8,"EG
M)+#=OHP-P43FY:6JW7S8#@@P1<D'QV?% 7SNBZAQB^=I7 (1SH"ALJ4;((4'
MSZ02T3$GJQA?$.XJ#XN2.C'7W' ;.98X!W=R!])L&I(YGF'8EK.1F"4LHYNU
MT<.&:[P1Z0,RAK B=HC9Y13/!]A+PB$+"WL:C0D!F._2 FTB,%,2V<9MKB=<
MP+9_\Q;&K#C8P^4$'(<][.A=FB%C'&9##N$CR5_WNZ\!#+,T#G! HLUAF)4J
MJHQ B!C^M343F0[?&(Y1D2HYF\4ZQ(YVS)29BV693,;&!;+C;BL;APP7Q 48
M-B)O)/:CHS7ZB\1'#*L:88\\7(KI.F[606B%*W8\E^;?T?/&,"%V+<=.T+P5
M;]5..G#,DCBBD1[<A^[TX<"RB)!VX3CT C&]9%/:+(61 ??6F;QZ36Q#-;'C
MK=;$W@&Y0Y)04(='NB/P44[(7M BNJ.D.1IL^!Z1M!!EVEA%R':*B>3XA"1-
M]GP8('$K,F;A>3.Z07UQO;)[>W^VPN_S>ZN];3A">CZA#.1^EF) VHL1MXP#
MU<B55:9$"O1OH23*I0G(,%F. #+R040RSRJ]PU=,=O2^V@_,D(QENW W>J[6
M+:YVLM5<[;SJ6'P!$F*"=I^.D VXJ]=>'%%HML?,C(**B(NA_5%6Y *4*)U&
M)MC(JBM-4PE9M?()6B8R!8HETB.T?4SE)ZL.&3TS19,$'&(ZIM\K*;I,1G(.
MYXP2."EAK"N 6@2J@.MO38^F66#Y9RAS53=U$F.L"-BPS %=<K1"K#+_.8.>
M@0+.V<OI':-HS[>:HC6$I.X0LP$;*Y%>H<D$3<W6SAW0)X6\%=)44,'KC9_I
MZ51%:!<0O(9@2;9WHKP"0@*S&8&J$:95"TQFRC=4: )RL [,:S#:1/&"OGQY
MXD;#R&AFL^9P(J8Z06.J"QRU9J>[ULAV52#KGF%[A:T4V$->D \CMWZ9$HW]
M'J6$L8G(FG VPS ]0,*\; TQL4E#Q"QKIR'#<FX="[]'!_(WT+0?A?6Q]M=)
MIZV*H-CDB)0-W\=1'UG31];TD36]G(BG^6*KY<1WJ3B/C(.X0T*B%4H(@.1S
MRRN-UTA[( )-4)JX(P<'A1IV8=IH'0I4(,\@@0SE&S;*&O\D^6 C].E9%],=
M;FW\LT1-&O3=,C;NV%DYC'7(_B.0&<G=2_$6SA-L_II.4XK$Z#77CE&DEUM-
MD<XK#TN'K/??K#[#HZ9Q5I2U(\?2C7H@RTY)4+ G$NVHT@76.3[88''D-Z*
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MG5<U[0GBD>5O'QE^[RG&!\)WQO2>G)XG&Q'=3%WQW1^IN,B Z\/5CBM]"20
M.;X(#+X;<U'+ODAW;*)?9 _P0>,S"4MS99V!]@+3$YEFOH"H 0,ENM)%3I@
MI-S@5Y7.:W@O$ ^O=#5E6;#K>4KTY3)UZ_GN\^<O0H5K;U'7^CMP!SV>N]T<
MCU-U#7=6FFJYJM7 P([^[70OFCF!^V0D0N\8YE FU;EZH(-N:;(GB2Z!;\^/
M=8Y3[B#<;IZWJ\G>!'D__^'NLQ?[>R^/]E\>'!T=/MM[]4< \+X__^#@V^OI
M\3$ MRA*NB\](1] .'X#^8W8@[OX1"^48?X02'7,55Z=E.+3GS]$XFRJU5B<
MQC%LN$(Q%$1&':.TB(1EOFQ4$#<+4^%?2X?E$=_J7.8QJ*ENP(V00L[>ON\)
M2H4ZRYO:(&807UG*3:(&41)U652*GV5E!&:WF@9H$2"U .Z4#GE&=0G7O"2V
M94=2U[&: 79-946C9G(.BLM$3DB_:;TD4?Z!>PR[2U09&ST"=E?DXI&/X/')
MU^EL!C*!OA:G/<$V//^J)?HP_2G@O$UXSH06B!(C0*K9S(#0B_JLD,DED!M"
MD2NCB9"!@HO8\KJ0)L'QWV@# G-A2IZL47,W@3 1%'J"+"%I\F(LR#'V?P=Q
M=N/$V8,-%V=_+F+9.W'6H T3KMQ<L'43J'9+^"!3" BC&<H;8U-D0HK4 H(D
MAU*E0/!AL+?X(\DA*';@OUY<H1'^46OK+JF,O%0I_D722"/4PE) FIV!.%N0
M.%LZ8>1U459%OI.IRA2S(@4R#,S(*(F&>N9>;DTE"N*)0JT=<"%Q_ E$QMU&
M>J?UZ&Q4HW57@*PDD$/99:EK8/LES$V[)1'+@\:H4L-%C)5?O%\I,E+^)E,*
M66,IKJ8*&&5AOH2\-5?P-.A%LD(^NH,69H D($")XP(<+\8"OH1CQ . I94J
MTSO--T9Y\,,:X/<<W=U+=80EX"S]043X3MYBT00;Y/8:3=XB!DI1$&H$<P*Z
M?D$IT8J6< EQ4?AV6<?3!GAP.B(OX)=12@^W0>Y.Q4Y,=U=HE%CY#!"89$>O
MI,X)$_'48X#?[@I>](2<^KV-V(_IR+Z-5_]>@;J_'O!<3^2:&K>6&1""G1&0
MX2\[<@PG?RS3*SDOOVU&T7(D_/8I18.PO%'"\N&&"\O(VD$2Z)G ?#=%>/]P
M]_#P\,$NMQN^;U%UW^8.OSQZ]N(9W-]71WO/]_8.GN,EEFMUB1_1CB5+)3[)
M%&3_WMQ=TG5EGM<4TP<J".ZQI#T*@\J8TPS_X_#Y0;2WOQ>)%,W?@"EY@L;-
M1"5U;%5,4$_0+C\M4@XJ@L\S.2==9Z1A2^I+.B>#:0PD-R&;:6/';Q0THR8U
M+ #?-07I7J@H@J+F='.[OG(JG=9ZJ=45A2[A1E*.+G*6V@11G2VUL/-<T6IY
M8J^@\0BKM*B!D/63D(TVE9 5>5V*#Z:8&+DT>6N-=WDC*?/42L%UT4AWV(IE
M"8, K)BH2HQH_\58'.W]T0>MH-UG)ZZ-0;M*0 :CY:8S=NT 34'[3%G 5( X
ML5%$7/#U1-2S(H>WLP)H(9OCJBE:P,C&!$1PJM4EA]K &A!FP2PS9<8(,*21
M !J%ACXB@*?YW.V&MA$)/19*FAQM5YXBSJ1.1%Z(%$@X3@L@^$4:('3[SS8F
M0*LWD93.9SA'DZ;.,I5H.%;@<F/@CL45LEK_<U4(6"X<-*'8; 9D@/AOB#)H
MN(0!5AH-!W;73W87;RB[^[6127<?.S[CH6@"^U28WCN9VSJB@$'$@9D!G2$C
ME:LQ,BHGCG>S<_"EL4J4D6DD*/0?1>CO"_8@I<#G,.XW"IU@]G=F;*6&#2'Y
MD=>*?$U6^ []6R.6]J<*5CJK35G+G *Y<.Z 4J7R"I?,2@!NX(YD:C =]H!\
M+3$='JT5]7I\T^%K>X=[0L &L^&FB1^;:C;\"2ZN0:M4?V[N4E4;6/E,HK*G
M9QS%P0&S3O1@"<"E!WO)H^#'2IFM2"H!8<)E'V7RBV)[G1]57DH0/.ST5@H!
MS:C454T)A*7*,3=+7:NXQH2E;@ FI;T$J\0 #6L$@&$P;B.N6'SA9$DEIDJF
MU10^EK4A]1S72XMB4:B1M3ADA/;JY*.89M6\#.F_A@LT461H\'&EH9EA4-0V
MBU)NJEWRW(9)]850/K%]W/Z@1!_5:!^(1ZHQ&8[I6UD6.?NP7.Z'#^<#GH"\
M@J@UOF1Y7FB\=>;EI*8X1X[I6T@W2--E?K&EX8M^F>T P$&<WC FL:G6O,\H
M)/:$_* _A\*/\:;'Z'-"L1"( =O95".81AVYUTG?$Q 63>"66I67'1C8F.8!
MFN OQE.0R#H.4 (NZ]'?0?!%L3>>RGRB\$'T;Q64B<EV1<D!SAC3/ICH!A,=
M /C96I&DQS?1?5)P&9%]]X4\#2+%1HD4FVJA>P,\-6=>^=1TMM4:VEOD[;69
M%:4S>H4ZQ_%=]86#_=T7#WBY:?C]X7+?Q^4^P&R2/_RH>W6;;T[([FWN_&D<
M&RRDU#/OGR\IF2E00X[%EMX6G/)(D6MA%/*8DCW-)65J&BQ'A087+C%HTRVQ
M5B"1.(J>LU$/8<;N"4Q@9^!0.3&J*S=9*S3*9;VBH3Y5:/H?@]H#/U-T56M6
M#L?*7;S5JKE%$<>U*6D)L(:V^08U,]IVF 6ZVLPDO?OBJUN^59SU,DL2+O1R
M&]\EQ&- U;BP2VFS7;=TJ%!N1PZHU12P<#*][9F@EKJ%4X$JR[Z3F:2?0!?U
MBB[ >XP58-J>)(8Y)5J[D$=X#YM^)=[$IGQ%VFZ(22L\1AJ#&FYF\XKM++"G
M?]2ZFB_.3YHS*<X</XM_PK^N)@T.X7U;74O?[BJFNU99@8]#3^XUM_#I=IAY
M,62F/JG,U(,.1.Y7"J;!!QGX_F3@00CN@1!\)D'^Z*7D2U;Z.D9I[;)(+S&4
MO\C)VIX51CEAKXGS9S\CR\L9YG9@D<.QU&EM. "'/8\86E*/,$>OP@>P9**5
MOT)?I"WT/2OR4H]TRH585K@AK2AE7$0OB6F+9@57N!'="ESETA?5L[Y1Y^7@
MAZ;S$I-#:,/P.D8:IRD*OU9BAYL*XJ),JWD$0E918J&8"5!&+ H3D1-D7*<B
M(\\$PC&RCHHI9LM4<U>RC0%%R8=_!TB5C7PF!?)##-X9@Z0/0VC4.0! <U_+
MQDGNM/HB!T7$ 7/K&H17,59ID9.@N#7'S[":1.'I%B8X5CA/3$"JS4Q7&$9$
M<J6LDYN7^+1N]$IC5$_N+BE&C 89G')IT0#SR^**M9N1^N<_4Z],T E3WP34
M<PCE_:UM\*YSA:P&RAH1%A2$V87T/[NB^2YPG^[;B8\VB[H7+4Z1>I9(,B*G
M!I/>%3'JA16'[""EK5$%=]_-GQ>8@<MOE#,5ZS'>6T179.OPR?8#<?1L8>B1
M2C'=C;0W> A8>%6#ADBDO:GWBJ2,R[QF*K&YN6Y(7 _L;?\9Z);S,B"*!%>C
M8J5G= KT%B]X5XAW185O4L*R2Y4"&JDF!7R*?.U%6H@GSJQ58J4F%_9'JB%F
MZ26P\<IF][%B&=.9%0XC;"P(JZCHVY5?%"F,F81QE.:RD@R=A.I"6CP**D;:
MTE7G[U=JC(-XV@OQ=)!/UY:;W4$^Y1@)($YG\)TITI[PNXZLBB2)C)E&V<@V
MXE-=&16H/,B&(*.>>IF)>@<X,@<2DC(3K/*-OQ2I3GR>FD\C,S"?9,+8B%!;
M3"U3DK7@PMI/VRT^ U0^:B7)DJ5CZ4*(3P13<5YV617Q%TRG4XO5>L-QK2T8
M6^, PTH*XA;X7B26KS,2EP45!RX5P)"E;:.XQ&%E143%N=K/."^= %Y7GG79
M]V?%%>S(_E[6YE(3>,@ .F=IX_6VC:I/?4@1@K?1"1 P^&5K?XUIF(! DDA9
MJNJNF<(#$WI23.ARX$%/GP?]5!2)^$C!RKWD/A')_T -;2N :R2<I==/D+93
M*+7S)!I7EPC9\KRI<M3R+4JR=W WHV7$O7#5@=Q8KHP'JGS!UU[6GV$A7C*V
M2-)C)IS[U3P*&AOW3O(U0;H92K8JK6GZ$KA1D(5X/V8"K#*OW0;)]<71G&QV
M8=N&5S87H6%M0&31:9N R(;")@^YH*YV2M0N:*\=193>04W4*IM;DM1@7TZW
M76?W=^B;)&PT#1NLEME1,H.[X;3(PSW6(EDZ(-53FQ(8N(2WO^3%5:J2B?)2
M DT#T!^UA0U45\NNOLI+ZLS3+M6Q)*A_F?;*FGK,( ,9A6M;8;7E2;Z\(T87
MGBM7H/+$3W:XMP-/N#W,X+R+E2EG3\>Q-A047GNO[>%ZP'/PVO;2:VMW@*=+
M$/CCR0*(G)!+ O9==!0"P@YL-BN/4: @&?DKBLL0OGR/X<LO]@[#_S8Z;=:G
M'?@H06Z[P,%4/=$&[I[@^'+WZ.%R$5[N'KYZ.5SF(5QY* ^R>%$OQC?TZR.7
MF T*50GYT'W I(N^Y:3K4-NV?D+K9+<N-GP\T.TB.PHW;)'\S-8^JVS=0&H;
M?GJP'28[VNZUL&S=A#_TOJ/?)^N"/ )5LR=(B(: XBH*C/_6OD(^6ZQ:G6I@
MFMY[\4G-),.[$\MB;R=@6*K0<&2=ZQQD4U4RG@).61^ +/N/*[[[X^N^8,HF
M=&"\+7KWY$Q]DT;:(]_^F3:-!Y)8S*5OWD46+V]?QN>-O>XCA08S?/8+6C31
MI9G#]1);K[9%!O--?3I%NV3TJAKYD:_ "80DK(D/SZ8I!]7=OA!(ITR^3> 0
M6!* 7FDOU>VS,02R W15@D9$84XJC_%1:TQ\OF!,O'D,WQ. J2:96&V21UA3
MBXH59]@%VG99O2KJ-&%C[ B#G2A1Y]:38L[*%=!D)/-RCE7 &A9/V, F^$OE
MVO_>A058P>'U-A;>1@F#.OU9BS/WJ28Q8J%.6(SG@DWBPN*G'+N$EZ(,$E?.
MO&,<%O\^R_6H+L7K.L'BY1^!W,.9@(3":^7(L_U7+Y]Q ;$,4Z1@@3TG:6?O
M7W_L2P=B3Z^BCI6^@^(=H3JR$85XN<EGI3)=9Q:-"#YB:Y;6&(%VS=&S._5L
M&RON2?\24"V-F%=AW!U>#0GR T<7H.3<(79=)X*[1ZV%(M:RI'ZPW:2"4;A<
MD[9E28NB/MT[U!<SN,!;14MY()*P&)O(E0?1:\59@GSC8BQ@XG/%VB$/5'[/
MN'*!0.Y+U2K31_H#MO8]_0KH&Y4EX;[TJR.9&^<@-7X4;W0I[:*WJ+/ F K^
MHPRI\^TFGZT"):CBG#]IHV#@F-!KV5I:HR(A"$A-LC4-\;&^"S8-,'M&"BP>
MH.N[\6X2/T0L(I[HT#B('6]ZU7\USI\UHZ"Z&<H<65;88*Q1HX2SO)11X"M.
MXKI4T%O+\![NF#9T2TB?=W('#(1K)]&($/;5'KOMK=^;! OLW-IZ:/_ BAQ)
M;;BIT!Q3)'8X'W?P50Z^RL?Q51ZM!SP'7V4O?96#X^().RXVU7-QL=A0CY37
M;C2\^-!FTT\$$%\O?CM$0V]$K<.CW6='S_8.]IX_>[7_\NCE_A'>^OU>7?J5
M5_S;>/*<L&^+*:/V$-@BJZE12FP=>JN$C]:52XB/K86*ECE\N3%U5%<J!;5C
M:__ &4AEGJ-7J)3L&%HVVB9X"U81\)[0[\#:!EM,M:J=";BQ&BG27<E\VW^?
MGO/_/ML:;6_IOKB [Q@-,$0"M#!AB 3X6B3  [@6%SC24N^B()M^*Z6%2M?)
MBFJ'3.%T#'>0C<F6OK^W]\=MVAYUOVVY(+$%33[!KGMU!MIYG;E^/,_WACZQ
M3P[5,8OC+@XD]+-0_V!J$QPU9P^T;G&L1;' 6FE5"SM;->)GV%B]J$MT3Z$+
MEWU3&T1'B:,";X'KW1,LVPY3O*;%%08?V^PN/5Z&= NE,%TPP6HY?CFZ.8I[
M YF$Z4)<#+JM<!D4P4<1)(>A6R[?^0>044PJ0WXP5E1KLU4DTJ]8D4N&LO?&
MP@?.[;TZ;5*I$TIV4[GMV! L)VC/_6!!( 9SV>,P"F11S[EC(,BRQ6S@%>[)
M_?5!,-?X1:M#+\F[-A%S-6X_;/@+QRT\2!B$_!<"(19ISA +<:^Q$/<1]S#8
M90>[[,%FV&6!="7<WLG1\])G@8W"+#!74GNC;5K O_?[PK\CRWAO9Y0/#.FK
MS+IW,MQ_+0.'!%^<[9S+I_^$E=%=A\6PPL:E*NVR,33)BA!HJO"%C:82RV!V
M0G>#*N[M&1#71X!A&1EX3(R<)55?U55\(0LCF$7&(#N7R'*IFE*WU+U("F69
M5UG6F8J8J7*9B<(T,A".7>>X233%-/57.Y7HPSW@R=S*GVJA' )KV50W@(N-
MHG0$R^&VO!A*JZ[_\I4Q ":D[.5+JVXM?7'H--77((FA>66KPW%'3.]=QS@A
MNEL,2MO@U:>:"1LG@O3D>(4<@18?-<I:[)J, NLI;-3Q%G6YJ6I#9C)711L9
M<3;#HHBD_7Y%I;2U"9$E8TDM9;  .&<+X: P[9@+0:%NF5.S9>_1H?ZI:)0P
M16Y#ELNJ0!-'\*0U8V"1*ZRFQ)'%"7%V<LDXH>FV[J"!@6T6 TLVE('UM!^9
M39GI[BZTV.O$&BS)(L<$"W"E\CGA7/?-]UA0LIIN+R5V 9TS:B)-D@9IB+$V
M<9VAG0Z-^!,N[6ITJ7PUPF"TU451UBK4^@F&^S\;POV'</]'"?<?FJ'W0$18
MT@S]^5I)"-^@4DBU\RM:F<X]M^N/K/#;C>97R?:UR(<*:&SP,R?G5F.9M194
MD"5L)Y>*C(/H_HM"J^?FZ,D]P0^G)'<LZ:X[J(L%M*G:@$KLJJ9J(:YO3JLA
MD'>7XAP8WT%#!^C':;8)=S%G)+MSN;R!#?63#;W8<#9T%IB*T"1)E3%-,3-:
M45#!1PX^\;>M)T2(F92 A?M:YEP&0(['VF0NOMVGQ10CN)62*]075QP.%/C'
MHE;4#A&I6)E*@NH; O.B8XJ[R%$GID$]@".1N/@.4'E/ZPF@MC@XC,3!WL'^
M1N37K()8WW#0)]H ,KZU+<WD9:$YC! ./RGJ$> #<K<IR4EL2/DJ?*C=&CJF
MK] NP@D>IICJD:YL0X/*Z)AK9HQ-D=GJ%XFU1U,GGQS#WN91>RB,Q*K1:%RY
MFE<1/3U6"1I[(\$&'W@G+3# 22:P=PVS2>[<8&P\9E5@<PGL4DF>95D#RS>V
MF_A,8J"[GO$<&%I)44ZP9GL!7<,[EA%Q^@F&SN4VE&K)L/:RQS+GXB!BJM)$
MQ 9;1)#]&SW3^E+CGZDF_RY'Q^'@;WEO^,PGVAWL)L%PDMBH2J3RBL0+;E97
MQFE1UMR85+8?9*=ZR4WN,,26O=E$>V/%R7EO'1AIHJB!8[-![GZA\2';*6]5
M,R6;\9=C&<;"Y&K>1":618I^:[=N(%VS@ILA&D4.<B1X)H0ZFO]!Z*9 !.QT
MKXO4F^L !"?<D2_8(>5.4+PDT, &(0&EXYIE,IV2QP$>@P'*6@</ ;+&2B74
M?U#;)@SP/.&#'9_/IU0RQ0B\DKJ-E'5:1=UF5X3D;*:D\C"48H*W&Z%C3ZQ]
MIN7BT70/!L==>3+E4M@[8"/L[P'BZ$CT[3$7-PRK*.ZT7WGWD\$J<D6.@=FV
MP]FJ$^(X*U-4O!6B.+,:&&H<7!GN1'DW,H?J)!+3Q(7GYN-4Q[[5!Z C[YR/
M(Z; 2;K@C?>U60!;F%MPH2$P1-1VT^&F8,3^;9\7WRCSCOZM09OHIS;Q<L.U
MB7<%7%6,: *FCS?T?2,V]T1H SKU&GO:8L]N=H)CH^SQF$/A77Q;THV_;SH9
M<LE/:8Q5%MBZY6N8(;EATID7;:W#<%OEBL)5(W$U5422G=&C9AG%"VM10[YT
M>"1$'$F]"4=O1;\N-EP.BHZ"^,3,R-OHE@:[.P4+1VEV1[(H"F'8]-=U!R:N
MEL/ P*7'35<OW#"%5%H(%0LO\:HH5(]7Q#_ZA;<+P]'&I8W6XQ4K,]1&&VJC
M/;BS]/EZP'-PE@[.TD&N?))RY:L-ERO?V$+E9S85D-C[&^3XJ,1]<#D\*%KU
M+O)JB)Q<S:2?/?)-_U<N]@N&W!]^E&MUF1\*<3%>D*PS/K2=++LPD&T'X[2>
M67A[?6Y>4)J@T42"!&PRLHTH*2>;5614BI8F95\@ \\I$OE28>H19FG;E@#/
MPY8 D2^@8(W4W(X8OIO4UB:/,=IU.B'=ASK;\RJW /XI9S?#ZGKNG2'PA8#N
M":%M-46);$$'+/XSCYRS+Y/7.JLS5QI@AL$J5868T\%3'Q:+%\# ;BJV4-(W
M8=DL0B(7^6!1F;Y#?/:=PJC=\=AE(&[1\Z[I,_EL2[="&TO!0Q1F>TGGYZD-
MI*'$O](GG;76CQ&\+AGO"CNTD&FCJ?<1YAHHSIMKE0.AJ\D7>=N:#5B5QY5P
M7Y.:O2LN2Q?;@<MKMH$#R##SSA8HZ*(;>Z@)$MCHP]5+L=5$<)?C)F@(*3HV
M9()-P<W,Y!?*F(0'?9%VW@X_3<?F2F%17E[J'5VX]$@05#,>H@$@ A_S[]L5
M(A977DWA2DRF8H(9H6.)#V5%0JV[F=@X/--YB&>^"#VE1I)5G/Q0;/'&]2R?
M;U=\;I6R6'+TB">81U+:A;#A'Q!?F:]N)V(PA#MH$-\Y@8*MXKE9""^_3\$^
M9T59ZE&J(G@&$$):ET!A] 1==HZQX)#8[J7(=.PPSD6A-VBRF.O9 ,!%&UG_
MBJNIZ7ZGEQ<!.XAD/1/)^M4:=V7(Z0V9%GQSK7\\03Y '(LLIU26"A/$4-FR
MOLO2,8B;^ @GE^.M\KYFV]S*<1?;U"I@&)P2 E\T]6/D#>OV1FXR<0/=@F4Z
M"2PO\J\4KO+M1%8QFSKG5F7= E 8D(H^5NDG*YM,./)PPE%<ZECY&9:7R%K*
MWJ*E@.XPG05H$W>"_5-B3!4N+61U?CU+?FR#UC^)80CZ"\=-EF'CE:]L?=>/
M\*ZH</L4PNF:E+39)R?"5P:=O0L>B A](5Y-"''E84_?%A+ A$V%SG8^ 8O!
MOE1/F.-)N,LND5853:RA%I2]M!PI+)7IAV,QD?*I"M-4''+M76 GF)!)*HBM
M4T9 &"G@$>3*QR*7($L1HZ,N,,0E\\3Z^4MDF$GKB:B3QQ7.:U&6*B"Z=5=7
M1>O]LDD67803[*<IY>0J*6#Q"(PR6*KE+:GS0""]H1-?6^X(UV^E@5:-AK!V
MU?7VDBJE5.6Q70P.$!ZC!&SX0ECI@=9V%RK@Y'@9T!4\>=?JBLH^=%!QVQ46
M69B9$NE<T1.Z"Y9Z2ZZG2O6R"AM%LV)Y%ND"8L;:A?=C*O552HDHH,>10Q@Y
M*I4-8[,"-[#2*.0!9>-0#,+Y.PK!BMEVQ?_,;/V,Q9,+!+V%%[<DEJJSY #F
MX-.-*"EZN2'"4XYVA*?>@&:V#G O>Y2AO^7\YO _\["/9A/E:#MJ+A8!IOJ_
MJ*$NU*)<CO&,8]N+U-4HG8T G1KZQ.%6ML@P6Z(X-P+U'R3\*Y"S5LMIZ(T$
M?5GE3(:[I]I(8DK1D $KOV6V#]\N!:S&J<3PRFAI)X '$2A#<6Q) 524R,+2
MI0U!B_W#L7V8TI'O*IT-X0)#N,"#APN\6 ]X#N$"O0\7&"Q3:V^9ZE<EL%5(
M^[8C!RQ1Q9M2R"A&4-6L2V5S5;PP]L/(_.A$F 5Y?8ET%!;373(XK9I79#4G
M5M8!_I7.X\9WN2O$KU,0RK"FN/1"U'+)S,I49?!@T :C,>*P#2>OLQ&KJM3E
M=>N)R>&W]RNJW4E?.N!%7NQT!]RV3UAA\]!V[FT7RO8%)!MK1]"1B10-#O9U
M#WJ#5"/"-G*[Q2P_?_@09J)@_H-13GMVD;O+['4^ 62E<-ZQXY$I("]LW1]>
M <GW-]T.3IT,1/C?8<WK*A6+MHJVR:$8CTOL^Q*C+5H9T&ITQEH:?#-S4<T-
M#-AH[35$J\%9U:11([U[&-\>?$B]Y]3]*GFVTH>$=8KSG2\Z-$-XXP*9FJ_Q
M2L+(7',_5;;,I35YW, 9O<VB6V:?K2[69F +@P25F\G$R93NQDP&3!6$&5I+
MZ=8P0Z-L@5;[LI.]2H5^J7F(),<TIK\M)W#MK?J!?8.M5)85]0]RYO306-_I
M[!#^I%U3!&OV1"B+*UEZT-@J;98^H5]_Y4$%)T(3^$/S8%[F26AL.I+:.7#%
MTNXDUH,13!4L^$:TH&Q?1V;#F6%GG]#F$XAHX7N$'IU5V*H@ 9U/]3\PD,M%
MJ*AK:Q3B0B0\J7W]SN5!!OJ\]O19;01]OA@O)ZZ8C,QTH>UC[!BS(_;@!5^M
M4):\/N3$N:[4]=F0QVPN/OIH2B\ [>^B"+1S@,T'#K#_@-Y>NU*-@VVUC[;5
ME^L!S\&VVA_;ZE)P+"1B_>L L7QB+42 >V59KW:_Z[TK_>#EWD]/S+IU>]/=
M-[3;W>OU%H\=TO%@0F!8<=N63 SU0E2RVO'\/BZ32J)41H\X>*VE@6/TP1C+
MO%!P %K.#(E]9)JWFE-3F,!''E@[63@TJX7^(P=EM^SU+MQPT<S8+G(0RS2N
MN1H!Q5  C'(;O1\6/'"2)][#L%VCS_D)@H;"])\PRV<#2J^=3B98<AW$>I=3
MV9,;T63W+ LZ8_M$3%7DY;70&6HQ9&GR)MM7KUXM:6&+'Q=AUJA,1B5U#"-M
MH;6(8V'2XDK\4YD"RW U=Y-"B\:NK\?7AOT/('M[KKVTS,/;+:O%<,M_::<G
M02PEKI9B;VA?0<8'U8&BJ!X,1-2N5@C7Y,*+R250T*W&4:Q3.'2X4Z=D%/L,
M*SGEY6-0I(N#)%AM\PZI>(@=DYUS>B68KN#*=FT_[55C9I7M/TPT,KKU05K?
M26.EHUP9<G60XAQ+)$KPR: O$$OF34V1PX68V(Z?"1F90*S+?6;1BKE];'.@
MK=/<M8%_2@(K63XIDG-9&['*2"#P0:T4W>H7MXHF'E/$,^QDVD2==<"YJOOM
M"4<!M]^][7L8/DS)9#O8%#IIA[QAQ9U4V4#/.ZSF\M:#WFI "G2&,3&@FW:)
M^5?$I9SAL7M?+,8@8K@;WJH<MNSHR9+<I$;,%E"B P#'!''-S*S(^K*+MI==
M@5K+BQ.QOXL'O;,?B?_^D\QF)Z<[!T=;(PXLCK<747V$N6ZJE:;AY__ZW!W+
M#Z]A<0DB7(.M@QE:D8CWN^-XQ?>T[SRX0Q-[QH$IOK+L"*0K2"!Q.$3+=H'1
ML  CUK;"BO"6J9$#*L@.DM?HT[!<CG,S;+ 'LR871=_IPK:XEB6XZ7)(G;.F
M>W!14'NR%0,+]]GMR*[?+M0* \0<2RR*;SC=T5A7_^)+MI9P([Q2=FT";#:I
M95KZO"L E<H3:99XDEJIL(UU&",5&-!<U+4+\ELLN60?E%M-LU['+8-U=R:A
ML.)<^0-QJ:*-X %C+(4A;RQV4EXQPNQ1E[>1^-=]1D1G<S2(=:2U(<-9UDZ[
MD>VE?$U^H+B/A8@D3]@Z#V*X@>!IJ3XM1B),<KB3Q+(0MRBG#@M54VE[^HN"
M/@!R_[0U-%OL/:#2Z")-E:N?2]I=9*'&J[#\"[<OJ19H6<]<D=+6.*,"I1=7
MPL[6'K6PBXNRHO/G \!W%Q.O?3\ZHUB%&RM5MIW(6TVF^>J'0J<E\BO.5I+P
M6A4PMA&68@T+U'7#7%I\F5)J4!#R?2N0Z7+=4C@2JA2:M/.*;%B[30*08C'H
MG/-]G- /+U\BNL2V>BO0,*PJ"' ),>6_!?%*<2K^_86[#J&*&A:E8 :\4MG%
M4VJNG$_:8N'\'S5>8%J<38=7Z@NW&9X"!T2 8O;YI?0J2J=O;R.F> +B@F,8
MO5!R0*]1/*VK( UHR:+Y=+'4K#C8!7VD(H[3RK0:4>8<$5K/6FY*J0K'WPZR
MW&&_D<TY;6.JVVT4:F5-[I)FI KJCW24JX#QM'98-EM<U"J#0@0""R:@S<7G
MQ6-J"AR1&F-\ QM@:,GM]2ZUQJVC1" "E]]3\\8,KKZUM^:^6@]X#JZ^_KCZ
M@L 1NP,\W59=Q!!&=PD HHWO4/?G8V1MY(U:,P?@QI9?!!1?I]BAQW=?_J++
M6*6IS%51]\4E,%16[%V(WZ945FP71Y%I$;H2OMXWP_D\;>DVU_FC;'*/2&/J
M?5"&4PD/M^+>U#>@YHI8Y< IW$WBFCM_6]22.M?P28]K5&:II8DVHKC*K?,=
MG_/E;<KMR'H[.,LGFZ7*FLY Z4WK$KUR9$YS%9Y(7V_*\7L,==UJN+NWL[PX
MGP*@*UIO7*$!\;F3)5#/T+&6*(Q5O4:C5*W+J;4(&057/5:N)@-L!E[11E5S
M5N)M#A/:;-K@^)YBT6V+!C:L-)$,A>W_=&4PGR>/7*(>->>Q)HY6$X1V;(4/
M2:=[1X!= $5@YN([C$O\62$D;@B-'3C54^54FU%P[N8^P&'5'[B<]G;Y*S$K
M4AUK>[&I\52";9JBH+*C00NU=2;YU!!G=<5T%S=$88(1PE;"+K'$/XF-B/DN
MJLA7ATQUIBM[F\NJB+\@C00J--4S*@Y,VAJL+$[E%1Z3'PY# :@N&=F+J8Y+
M:U?N0T,)IRJ9V&Y@L]3];3,SV<[YZJ2D3C#HLL:U#)F$?2,.FY'SW^'KM@,X
MU\UCL:3$&!I@O38Q%^N'NP05N!*ARZKE7L5*9GE3*Q9#KZP%WSH]BPGS=;+A
M-\G&E._F9.-29HK28 S)QL,EZ]LEVXQTW7>V2V@GAC:WO==]^ -W>2[:3<&:
MV%=_RV1)U2?)%S6W[E[FQ7A_^=<E ;MV+N3)RR>P;6=!) !VJ5%U=4ROZ:9)
M)5!!N"\Q6LC)YK"*3)D)QN#-:@.\OU2M".%M)U[ ESAZ):G5=3H/O7JL"&,S
M@%+9"J.@S@!+MY$>SF'\>:'Q?-A_<J1SSH#6><UA>SBV*TM-3E(*25"HE,<J
M+![0B#3^KX;9-X4$_/YM^!J!NQQH4]]HTV:DJKXK;BPG8@4"5Y@>I'&I+WWB
M -QTN/5)JR(@/0"$H%62/GR< B!P@H3CI$CGX (G<+D 59OR O1-39(&#$5&
M -MJ&<E9Z5875..U+6%?%R#)4W")70_^8*DP2C!SU_\DT$)<! 7ZX;"+ 8]4
M++Y3C"/;"-)UD&B:<'M#C2_WN+I.RXCJ): UAQ?..PWFZXI5TFT&XZ9 &TJE
MA4CI/H4U\TU@-7(18B10(>Q<#P*T<%BBC+$GN#!4R 9BUC-B-MX(8H8Q;Y>
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MX:DBSC<H?_-9L=GT+8\HSO2E3L5';L=\2E@R%ONOGA\1]9 9-1OF5TXG@ N
MAD;[TP%PA+N/*_OVB_;;=LMVM:F:P,2^%V#8X5,1TCE\9EJ'I!4)COA[#8B4
MZ-A""MB&P0XQ#+(3V)EI/B!0+"*.Q94I\LFX3ALZS/>KV4@$R"EKO'8*V)C]
MBJ)@LL)VK$F0&0 9 R;ES0.NVXVU'M@XO+)N=X2FKNZVX;L[*P[7\S\DG5M\
M6:0U$&$##)4-W  I/'@FE8B.)=G#^()P,U98E-2YO>:6V\B)Q#FX 2J09MN0
MQ_,,R[:\=<0N81'=G&D>-MSBC4@?D#'$#;%#S*XS/!]@+SG'*,S=:70FI+:U
M%5I#L$]VXKH3^<9'$9O\[5L8I.)A#Y<3<!SVL*6W:0;;4IQ-.(2/W.G[5O<U
M@F$6Q@$.2+0YCDVMDL;\@X@17EL[D>V1B?$7#:F2LUFJ8VJ]34R9N9@Q,I]8
MS\>6OZUL%K)<$!=@V8B\DMATB=88+I)["A.K\MV';=].NPY"*URQY[DT_Y:^
M[ P38]]/[*7(6PE6[:4#SRR)(UKIP7_I3Q\.S"2VJ:_CT'/$])J-:+,"1@;<
MNV/?W4$-6VLU['"CU;!W0.N0'E3:]]N%KTK"=.[(VQ\-S1-@R_2(GL4HT*8J
M09Y336T#[KS(=T(8(&6K#//OLAO.@"0K'U,_"2U3E]WYP10@)RA LKF74>[L
M]-D(=\]=H=<3A Q<0=P7&+$)1+T4<<OZ3:U0V21%%$#_YDJB4)ICC_D2 62%
M@X0$GF5*1ZB5;.E=M1O9(1G+MN%N#"RM1RSM:*-9VFG3J_,,9,,<+3X]H1EP
M43\'@4.QW1YS,HHB(A9&10@:6@'JDRX2&UWD%)6ND83L6>44;1)&@4J)Q BM
M'IG\XA0AJV%2.0,XQ&)"?S?R<YV/Y26<,\K>I'ZQE@ *$2@!OGTK/5J8R#'/
M6):J;>0DKMA0KY&ML1 M-_QY4YZ% LXY2.A](F?/-IJ<=<2C_E"R<[91(K%"
M2PE:F)UY.Z)O*GGMZZK@W<;O=):I!,T!@M<0+4CU7HA70$5@-BM*=>*R6C'(
M3/9&"BT_'M:1?0U&FRI>T-V7)ZXTC(S6-6<%)TH:]) .K4TWK9'-J4#3 WOV
M$A,I\(:R(M=%Z=PQ-=KX S()8Q.%M?%KEEL&@(1YV0AB@Y%&B%G./$/VY-+Y
M$WZ/]A-NH&LVBMMC#25P'CH$Y8GOXV (I1E":890FDV7$)]OM(3XKA"GB?4(
M]T@\=.(( 9"<;&6CZ%HY#X2?*<H1-^3:H#C#/DL7GD.1">0*))"A9,.&6.N0
M)*=K@DX\YU.ZP8^-'VM4H$'-K5/K?YW5HU3'[# ":9'\NQ1@X5V_]E.6%11Z
M,2BL?2)'+S::')TV+I4>F>L?K?S"@^9J-F2U)\?2CW(?BUY(T*NG$FVGTH?1
M>2;8X6_D**+P3X7!DA2L![P+;2-A, X^ANHVQM[%A3(Q4(/= 1^>#C[ H8^4
M+RK<BGRZ,IIJ"+,%!2L*LV5%-B:U)D32)B22O:F;E-Q@GAU')0LCL6',/C9"
M-_9$7\+_2N=H0#$*)!PERTH<[(L$5$T:1/OT_L++8B'V+JRGSE.L#@-3A8@<
M3XNBY(RWY2_"HC ,BXV %/%#?_)2W")!Z L!H9HTO//4AEW!!.=V@@\.>.?7
M,]TDA,.0;V#(LU;<]P>:8+A:ZWFUVH2TP?<7C*>-DPQ1RF*(R_[O&F2-NBR^
MJ*\]:9UV;8?;359HQ,:7<.<06\E>@U3=SV'CJG'-:/JE"\@+09Q[:P-6\1L;
M5\?*CW+31T0M !KXNHYI)<'3&0BV^'RB4@PP8*,RJ4<4?8ZF69 BQ=E4:L V
M7Q;A=2%-$L&0 N.6,98.?GMVO+<G9KO9+J8SX%,O8%>@-,&EE";8WG!1UO"B
M4);((BI?C(?C6L?C8A+0/; (20<3%B86#1W@:&J*-2*/O67JS<-&Q0J?PXOK
M X@3A<'GHW88=)/BY&D8Y3HUP<6KO%I-9-.+G42VR);ET\V$SK*#??DF -LI
MT4"%#%DUHFTP0A!S?4?[RHO=HP>TK^#HWZ8!24_L*R\WVK[R2Y'XH/E>!3:U
M*$,&U,"2K(PVS!3 I9G8!"?\QLLS35$56TP:" #<P6D0(I"SZ;<&6F%@%TDG
M;;#QC0_VV![1BU<;32]^P@09BB_Y65[UAEY\7J$\36BW=/DCF^Z4EQ5E02T6
MLN'LP%1>!<$LZ)*Y4C(%N@'?_2++4L;3NE1557HA8Z*I@JT-S\9<IHHL)N-4
M<R(AY@LVD3)#?'6_Z,G^WD83E',0VHWJ74+&H@Q"I(.R7$MK3*2-RY;IO3$H
M442>S>P)ZSM2+K<USRXF9Y1-HW$*N':Q>8W0$AJ#NPYPS-A?:<_U0SAC$:P$
MY:B"Y2@@4)FFB@.F)0=1;)_-B)2X%0Q;O*&&:T#>GC !^<./?WUKL_CE9:&9
M20 I3XIZ5$5=Q34I;-8T, IE(DX8;^=.QU/,E*4!;6(N_MRNQS"84M80#^"8
M.!Y$YSXV%<YJ8F1>^2"1=L$%GP-A\YY;.=:^!$-P_X<#7Z<#SVV#D,C^2V26
M_NK).?4C>N%OZQ4-/E29'$+CUW<?A^N!%T-H?%]"XX<V"?\23"_>B5\O/K\[
M__2)NR6\?]N;7@DM^[J+%2#/?BR-PIH&<XID<Z$VW1RRMM9JPYH2%:?2*)_/
M-P\T;2Z;%@S#P6UI2G%O:.6CZF=!5C27UNX$_;24V/4EET\.U;_['7A-,*A
MQ2HQ-?*XGLV4P=3P-=P>*X?O<US99!Z)BSQ>8^S9E&;  S#6@:X\,*?Y3GSW
M>G[\W0#3^X3I=Y]UE:H!JO<,50SS7&>@#K1PL-M\.X'S=^FK_/YMBLJ]Q1K%
MC:.NVV=^?6$_W,JG3O>_NQFJ%@RXW>,C FL(9[@7^_O[ ZAOY:]U=H>_#1@\
M2"Z;2B,W5G(9/$YKMH^C]<"+P>/4:X]3GPC+@YJISW\^/_M\\?Z=^/Q>G/_E
M_.Q_/I^+#Q\OWG_D+SY<?#S%GW\8F1_?OZ54YM/?Q-G[=Y\NWISS3^+#.3S_
M9IU/94U%@5ZY11]8WKR(Q%]SF6&+X\##1VZ_"S&5V*;E=U83"-JQB$]-F&V[
M=,9/*J=V0K8AW:X0_U5<89\LY\.$)7 %9%',9H6IZIPC_+C.0@RP+E4:N;6.
M86Q;;2,L6J!2[I;5*EJ@;KVJL*1!NXY!D -Y*R?4T7HRDV]T3P=HM,P1869(
M7]7FQ\^7^([^N_TQ[!_N'AX>MH_A\.7NT?.OV(6>#QS%&H9<L6-!?&6 ^2/
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M2Y$HB@=_X4>?:L\3@4XC#[B+,8!=Q!Q,<"!(LFNAN-[ZJ *]($;"T-F%4'(
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M0!W*83]6<P$RB1BR45K-P2_N4!SF5!=I2\K$]LQ2-+59:1@!90RB*9!#508
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M9J1Z\N:I'D,ZK![*RG.C8D;U]R2@W^G!1+C+US^='LR5[[W^/U!+ P04
M" "<.G96D";_,R(5  !+\0  $    '!Y>',M97@Q,%\R-BYH=&WM/6MSV[:6
MW^^OP*;3CMV1%#ULRY;=S*BVW'@WL3VVLMD[=^YT(!*2<$.1+ E:5G_]GG,
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MEZ@15 @_\&ZDC9P!J'VZTAHN(ZIK-\C600B%M<C.+[Y6,./EJG=Z<=6KH+B
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M)_9X$[%B0J>P,C8="W<9/@)NY8B#C;$R(LZ?][TP!&B;1!Z@85YA0^ERP.
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M*,K#97W>E,[)[NI:T_TJQ-I$"(>,*3H;U)_#+4^')53V86:SE#.2Q$-UIZ1
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MXH!*A27+^>7\19B:D@-'/U N_'W%X6 T8%/)8:!7I%"0;N57*M")3]B(+Z:
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M6L=Q:0B3&]7J WZYM@[OT!L(R,7&R.)=B59"ID=;Q"D&%)<]IJO%C!$^_AB
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MZXN8Z0G]N\7+[Z8G_M\T_@E02P,$%     @ G#IV5HJ)3>3/!P  84H   \
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ML &I-C']\R A8LFX"R17Z1\LR5*A"%=>1H* \:4+I]G:.RB49O4CBJZ5P7A
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MKM@UA6D8,I^*A]9H_-3_DG]N+V;LH2L&"S&\ZR!E#Z=RY_O6T;:6R\B2EIG
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M_-'"+8OO_P-02P$"% ,4    " ";.G96UI*/!Q?S 0"?&@( $0
M    @ $     :6UG,S V,# Y.3A?,"YJ<&=02P$"% ,4    " ";.G96[/>.
M#+:@   &# $ $0              @ %&\P$ :6UG,S V,# Y.3A?,2YJ<&=0
M2P$"% ,4    " ";.G96E.M_HX9S @!SM ( $@              @ $KE (
M:6UG,S V,# Y.3A?,3 N:G!G4$L! A0#%     @ FSIV5@"0707:SP$ (3@"
M !(              ( !X0<% &EM9S,P-C P.3DX7S$Q+FIP9U!+ 0(4 Q0
M   ( )LZ=E8QG'U*9/$  !MJ 0 2              "  >O7!@!I;6<S,#8P
M,#DY.%\Q,BYJ<&=02P$"% ,4    " ";.G96NL7JF/&" 0#QS $ $@
M        @ %_R0< :6UG,S V,# Y.3A?,3,N:G!G4$L! A0#%     @ FSIV
M5BT(?G)KN   -1L! !(              ( !H$P) &EM9S,P-C P.3DX7S$T
M+FIP9U!+ 0(4 Q0    ( )LZ=E9S&7^AL;,! *P? @ 2              "
M 3L%"@!I;6<S,#8P,#DY.%\Q-2YJ<&=02P$"% ,4    " ";.G962FI8G2MN
M 0#:) ( $@              @ $<N0L :6UG,S V,# Y.3A?,38N:G!G4$L!
M A0#%     @ FSIV5K,'+2J2!0( .6L" !(              ( !=R<- &EM
M9S,P-C P.3DX7S$W+FIP9U!+ 0(4 Q0    ( )LZ=E:E8,+L+R\! #B6 0 2
M              "  3DM#P!I;6<S,#8P,#DY.%\Q."YJ<&=02P$"% ,4
M" ";.G9619U# W#X 0"L;@( $@              @ &87!  :6UG,S V,# Y
M.3A?,3DN:G!G4$L! A0#%     @ FSIV5GBL.[N_#0$ ?(8! !$
M     ( !.%42 &EM9S,P-C P.3DX7S(N:G!G4$L! A0#%     @ FSIV5LA<
MGZR&7 $ :+P! !(              ( !)F,3 &EM9S,P-C P.3DX7S(P+FIP
M9U!+ 0(4 Q0    ( )LZ=E8*9*QG^_<! !-6 @ 2              "  =R_
M% !I;6<S,#8P,#DY.%\R,2YJ<&=02P$"% ,4    " ";.G96[/>.#+:@   &
M# $ $@              @ $'N!8 :6UG,S V,# Y.3A?,C(N:G!G4$L! A0#
M%     @ FSIV5O:5[+6/O0$ 3!D" !$              ( ![5@7 &EM9S,P
M-C P.3DX7S,N:G!G4$L! A0#%     @ FSIV5E]YV;/GC0(  /0" !$
M         ( !JQ89 &EM9S,P-C P.3DX7S0N:G!G4$L! A0#%     @ FSIV
M5F%R9E5+E@  ]YT  !$              ( !P:0; &EM9S,P-C P.3DX7S4N
M:G!G4$L! A0#%     @ FSIV5BX#IXHJ?   V8$  !$              ( !
M.SL< &EM9S,P-C P.3DX7S8N:G!G4$L! A0#%     @ FSIV5O@A[BRG40
M]E4  !$              ( !E+<< &EM9S,P-C P.3DX7S<N:G!G4$L! A0#
M%     @ FSIV5G#DV$%*7@$ >L ! !$              ( !:@D= &EM9S,P
M-C P.3DX7S@N:G!G4$L! A0#%     @ FSIV5C6Q'(,NA@$ C]<! !$
M         ( !XV<> &EM9S,P-C P.3DX7SDN:G!G4$L! A0#%     @ FSIV
M5A1D-\ZR@00 CZ W !$              ( !0.X? '!Y>',M,C R,C$R,S$N
M:'1M4$L! A0#%     @ FSIV5IHZYH::%0  IO<  !$              ( !
M(7 D '!Y>',M,C R,C$R,S$N>'-D4$L! A0#%     @ FSIV5H'LND?X#0
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M @ 0              "  7J\)0!P>7AS+65X,3!?,C$N:'1M4$L! A0#%
M  @ FSIV5JQ4(NP".P   ((" !               ( !:.XE '!Y>',M97@Q
M,%\R,BYH=&U02P$"% ,4    " "<.G96M#F'?+H[  ##5P( $
M    @ &8*28 <'EX<RUE>#$P7S(S+FAT;5!+ 0(4 Q0    ( )PZ=E:_&+81
MA@T  -Z?   0              "  8!E)@!P>7AS+65X,3!?,C0N:'1M4$L!
M A0#%     @ G#IV5@9]V]]F#@  19$  !               ( !-',F '!Y
M>',M97@Q,%\R-2YH=&U02P$"% ,4    " "<.G96D";_,R(5  !+\0  $
M            @ '(@28 <'EX<RUE>#$P7S(V+FAT;5!+ 0(4 Q0    ( )PZ
M=E;7,=4:/!$  ("Q   0              "  1B7)@!P>7AS+65X,3!?,C<N
M:'1M4$L! A0#%     @ G#IV5M(JM?Y. @  M T   \              ( !
M@J@F '!Y>',M97@R,5\Q+FAT;5!+ 0(4 Q0    ( )PZ=E:17/]RZ ,  ,H>
M   /              "  ?VJ)@!P>7AS+65X,C-?,2YH=&U02P$"% ,4
M" "<.G967[LF$1((  "M40  #P              @ $2KR8 <'EX<RUE>#,Q
M7S$N:'1M4$L! A0#%     @ G#IV5HJ)3>3/!P  84H   \
M ( !4;<F '!Y>',M97@S,5\R+FAT;5!+ 0(4 Q0    ( )PZ=E;J-4A$.P4
M -0T   /              "  4V_)@!P>7AS+65X,S)?,2YH=&U02P$"% ,4
M    " "<.G961L7DS?P$  " +   #P              @ &UQ"8 <'EX<RUE
M>#,R7S(N:'1M4$L! A0#%     @ G#IV5M@=ECG6&   _+(   X
M     ( !WLDF '!Y>',M97@T7S$N:'1M4$L%!@     K "L G H  .#B)@
!  $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
